(TOP (NP (NP (NN Induction) ) (PP (IN of)  (NP (NN NF-KB) )) (PP-TMP (IN during)  (NP (NN monocyte)  (NN differentiation) )) (PP (IN by)  (NP (NN HIV)  (NN type)  (CD 1)  (NN infection) )) (. .) ) )
(TOP (S (NP-SBJ-77 (NP (DT The)  (NN production) ) (PP (IN of)  (NP (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (NN progeny) ))) (VP (VBD was)  (VP-COOD (VP (VBN followed)  (NP (-NONE- *-77) ) (PP-104 (IN in)  (NP (DT the)  (NN U937)  (JJ promonocytic)  (NN cell)  (NN line) )) (PP-TMP (IN after)  (NP (NP (NN stimulation) ) (PP (CC either)  (IN with)  (NP-COOD (NP (JJ retinoic)  (NN acid) ) (CC or)  (NP (NN PMA) )))))) (, ,)  (CC and)  (VP (PP=104 (IN in)  (NP (VBN purified)  (JJ human)  (NP-COOD (NP (NNS monocytes) ) (CC and)  (NP (NNS macrophages) ))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD-78 (NP (JJ Electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) ) (CC and)  (NP (NN Southwestern)  (NN blotting)  (NNS experiments) )) (VP (VBD were)  (VP (VBN used)  (NP (-NONE- *-78) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB detect)  (NP (NP (DT the)  (NN binding) ) (PP (IN of)  (NP (JJ cellular)  (NN transactivation)  (NN factor)  (NN NF-KB) )) (PP (TO to)  (NP (NP (DT the)  (JJ double)  (JJ repeat-KB)  (NN enhancer)  (NN sequence) ) (ADJP (JJ located)  (PP (IN in)  (NP (DT the)  (JJ long)  (JJ terminal)  (NN repeat) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-80 (NP-COOD (NP (NN PMA)  (NN treatment) ) (, ,)  (CONJP (CC and)  (RB not) ) (NP (JJ retinoic)  (NN acid)  (NN treatment) )) (PP (IN of)  (NP (DT the)  (NN U937)  (NNS cells) ))) (VP (VBZ acts)  (PP (IN in)  (S (NP-SBJ (-NONE- *-80) ) (VP (VBG inducing)  (NP (NN NF-KB)  (NN expression) ) (PP (IN in)  (NP (DT the)  (NNS nuclei) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP-COOD (NP (NNS monocytes) ) (CC or)  (NP (NNS macrophages) ))))) (, ,)  (NP-SBJ (NP (NN induction) ) (PP (IN of)  (NP (NN NF-KB) ))) (VP (VBD occurred)  (SBAR (RB only)  (IN if)  (S (NP-SBJ-81 (DT the)  (NNS cells) ) (VP (VBD were)  (ADVP-TMP (RB previously) ) (VP (VBN infected)  (NP (-NONE- *-81) ) (PP (IN with)  (NP (NN HIV-1) ))))))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-82 (WRB When) ) (S (NP-SBJ-83 (NN U937)  (NNS cells) ) (VP (VBD were)  (VP (VBN infected)  (NP (-NONE- *-83) ) (PP (IN with)  (NP (NN HIV-1) )) (ADVP (-NONE- *T*-82) ))))) (, ,)  (S-COOD (S (NP-SBJ-84 (NP (DT no)  (NN induction) ) (PP (IN of)  (NP (NN NF-KB)  (NN factor) ))) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-84) )))) (, ,)  (IN whereas)  (S (NP-SBJ-85 (NP (JJ high)  (NN level) ) (PP (IN of)  (NP (NN progeny)  (NNS virions) ))) (VP (VBD was)  (VP (VBN produced)  (NP (-NONE- *-85) ) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ-87 (DT this)  (NN factor) ) (VP (VBD was)  (RB not)  (VP (VBN required)  (NP (-NONE- *-87) ) (PP (IN for)  (NP (JJ viral)  (NN replication) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (PP (IN in)  (NP (JJ monocytic)  (NN cell)  (NN lineage) )) (, ,)  (NP-SBJ (NN HIV-1) ) (VP (MD could)  (VP (VB mimic)  (NP (NP (DT some)  (NP (JJ differentiation/activation) ) (NNS stimuli) ) (VP (VBG allowing)  (NP (JJ nuclear)  (NN NF-KB)  (NN expression) )))))))) (. .) ) )
(TOP (NP (NP (ADJP-COOD (ADJP (JJ Positive) ) (CC and)  (ADJP (JJ negative) )) (NN regulation) ) (PP (IN of)  (NP (NN immunoglobulin)  (NN gene)  (NN expression) )) (PP (IN by)  (NP (DT a)  (JJ novel)  (JJ B-cell-specific)  (NN enhancer)  (NN element) )) (. .) ) )
(TOP (S (NP-SBJ-80 (DT A)  (JJ new)  (JJ B-cell-specific)  (NN enhancer)  (NN element) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN identified)  (NP (-NONE- *-80) ) (PP (NP (JJ 3') ) (IN of)  (NP (NP-COOD (NP (NN E4) ) (CC and)  (NP (DT the)  (JJ octamerlike)  (NNS motifs) )) (PP (IN in)  (NP (DT the)  (JJ human)  (NN immunoglobulin)  (NN heavy-chain)  (NN gene)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (NP-SBJ-82 (NP (JJ Tandem)  (NNS copies) ) (PP (IN of)  (NP (DT this)  (JJ 67-bp)  (NN MnlI-AluI)  (NN fragment) ))) (, ,)  (SBAR-TMP (WHADVP-81 (WRB when) ) (S (NP-SBJ-83 (-NONE- *-82) ) (VP (VBN fused)  (NP (-NONE- *-83) ) (PP (TO to)  (NP (NP (DT the)  (JJ chloramphenicol)  (NN acetyltransferase)  (NN gene) ) (VP (VBN driven)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT the)  (JJ conalbumin)  (NN promoter) ))))) (ADVP (-NONE- *T*-81) )))) (, ,)  (VP (VBD stimulated)  (NP (NP (NN transcription) ) (PP-COOD (PP (IN in)  (NP (NN B)  (NNS cells) )) (CC but)  (PP (RB not)  (IN in)  (NP-COOD (NP (NN Jurkat)  (NN T)  (NNS cells) ) (CC or)  (NP (NN HeLa)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (NN Footprinting)  (NN analysis) ) (VP (VBD revealed)  (SBAR (IN that)  (S (NP-SBJ-84 (NP (DT the)  (JJ identical)  (NN sequence)  (NN CCGAAACTGAAAAGG) ) (, ,)  (VP (VBN designated)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN E6) ))) (, ,) ) (VP (VBD was)  (VP (VBN protected)  (NP (-NONE- *-84) ) (PP (IN by)  (NP-LGS (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP-COOD (NP (NN B)  (NNS cells) ) (, ,)  (NP (NN T)  (NNS cells) ) (, ,)  (CC or)  (NP (NN HeLa)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Gel)  (NN mobility)  (NN shift)  (NNS assays) ) (VP (VBG using)  (NP (DT a)  (JJ synthetic)  (NN E6)  (NN motif) ))) (VP (VBD detected)  (NP (DT a)  (JJ B-cell-specific)  (NN complex) ) (PP (IN in)  (NN addition)  (TO to)  (NP (NP (DT a)  (JJ ubiquitous)  (NN band) ) (VP (VBN found)  (NP (-NONE- *) ) (PP (RB also)  (IN in)  (NP-COOD (NP (NN T)  (NNS cells) ) (CC and)  (NP (NN HeLa)  (NNS cells) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NN agreement)  (IN with)  (NP (NP (DT the)  (NNS results) ) (PP (IN of)  (NP (NN gel)  (NN retardation)  (NNS assays) )))) (, ,)  (NP-SBJ (NP (JJ tandem)  (NNS copies) ) (PP (IN of)  (NP (DT the)  (NN E6)  (NN motif) ))) (VP (VBD stimulated)  (NP (NP (NN transcription) ) (PP-COOD (PP (IN in)  (NP (NP-COOD (NP (NN ARH77) ) (CC and)  (NP (NN Raji) )) (NNS cells) )) (CC but)  (PP (RB not)  (IN in)  (NP (NP-COOD (NP (NN Jurkat) ) (CC or)  (NP (NN HeLa) )) (NNS cells) ))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (DT a)  (JJ mutant)  (NN E6)  (NN motif) ) (VP (VBD lost)  (PP-COOD (CC both)  (NP (ADJP (FW in)  (FW vitro) ) (NN binding)  (NN activity) ) (CC and)  (NP (ADJP (FW in)  (FW vivo) ) (NN enhancer)  (NN activity) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (JJ striking)  (NN contrast) ) (PP (TO to)  (NP (NP (DT the)  (NN mouse)  (NN Ig)  (JJ heavy-chain)  (NN enhancer) ) (, ,)  (SBAR (WHPP-87 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (DT the)  (NN octamer)  (NN motif) ) (VP (VBZ acts)  (PP (IN as)  (NP (DT a)  (JJ B-cell-specific)  (NN enhancer)  (NN element) )) (PP (-NONE- *T*-87) )))) (, ,) )))) (NP-SBJ (DT the)  (JJ human)  (NN enhancer) ) (VP (VBZ contains)  (NP (NP (DT an)  (JJ octamerlike)  (NN sequence) ) (PP (IN with)  (NP (CD one)  (NN base)  (NN substitution) )) (SBAR (WHNP-85 (WDT which) ) (S (NP-SBJ (-NONE- *T*-85) ) (VP-COOD (VP (VBD bound)  (NP (NP (JJ octamer-binding)  (NNS proteins) ) (PP (IN with)  (NP (ADJP (RB only)  (RB very)  (JJ low) ) (NN affinity) )))) (CC and)  (VP (VBD showed)  (NP (NP (DT no)  (NN enhancer)  (NN activity) ) (PP (IN of)  (NP (PRP$ its)  (JJ own) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Interestingly) ) (, ,)  (NP-SBJ (DT the)  (NN MnlI-AluI)  (NN fragment) ) (VP (MD could)  (VP (VB suppress)  (NP (NP (DT the)  (JJ basal-level)  (NN activity) ) (PP (IN of)  (NP (DT the)  (JJ conalbumin)  (NN promoter) )) (PP (IN in)  (NP (NP-COOD (CC both)  (NP (NN Jurkat) ) (CC and)  (NP (NN HeLa) )) (NNS cells) ))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-88 (JJ simian)  (NN virus)  (CD 40)  (NN enhancer)  (NN activity) ) (VP (VBD was)  (VP (VBN blocked)  (NP (-NONE- *-88) ) (PP (IN by)  (NP-LGS (DT the)  (NN MnlI-AluI)  (NN fragment) )) (PP-COOD (PP (IN in)  (NP (NN HeLa)  (NNS cells) )) (CC but)  (PP (RB not)  (IN in)  (NP (NN B)  (NNS cells) ))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (NP (DT the)  (JJ novel)  (NN enhancer)  (NN element) ) (VP (VBN identified)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT this)  (NN study) )))) (VP (VBZ is)  (ADVP (RB probably) ) (NP-PRD (NP (DT a)  (NN target)  (NN site) ) (PP (IN for)  (NP (ADJP-COOD (CC both)  (ADJP (JJ positive) ) (CC and)  (ADJP (JJ negative) )) (NNS factors) )))) (. .) ) )
(TOP (NP (NP (DT The)  (NN NF)  (NN kappa)  (NN B)  (JJ independent)  (JJ cis-acting)  (NNS sequences) ) (PP (IN in)  (NP (NP (NN HIV-1)  (NN LTR) ) (ADJP (NN responsive)  (PP (TO to)  (NP (NN T-cell)  (NN activation) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN rate) ) (PP (IN of)  (NP (NP (NN transcription)  (NN initiation) ) (VP (VBN directed)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (NP (DT the)  (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) )) (PP (IN of)  (NP (NN HIV-1) )))))))) (VP (VBZ increases)  (PP (IN in)  (NN response)  (TO to)  (NP (NP (JJ mitogenic)  (NNS stimuli) ) (PP (IN of)  (NP (NN T)  (NNS cells) ))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-65 (NP (DT the)  (NN response) ) (PP (IN of)  (NP (DT the)  (NN HIV-1)  (NN LTR) ))) (VP (MD may)  (VP (VB be)  (VP (VBN governed)  (NP (-NONE- *-65) ) (PP (IN by)  (NP-LGS (NP (CD two)  (JJ independent)  (NNS sequences) ) (ADJP (JJ located)  (PP (NP (JJ 5') ) (TO to)  (NP (NP (DT the)  (NN site) ) (PP (IN of)  (NP (NP (NN transcription)  (NN initiation)  (NNS sequences) ) (SBAR (WHNP-66 (WDT that) ) (S (NP-SBJ (-NONE- *T*-66) ) (VP (VBP bind)  (NP-COOD (CC either)  (NP (NN NFAT-1) ) (CC or)  (NP (NN NF)  (NN kappa)  (NN B) )))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-67 (NP (DT The)  (NN rate) ) (PP (IN of)  (NP (JJ LTR-directed)  (NN gene)  (NN expression) ))) (VP-COOD (VP (VBD increased)  (PP (IN in)  (NN response)  (TO to)  (NP (NP (NN treatment) ) (PP (IN with)  (NP-COOD (CC either)  (NP (DT a)  (NN phorbol)  (NN ester) ) (CC or)  (NP (NN tumor)  (NN necrosis)  (NN factor)  (NN alpha) ))))) (SBAR (IN if)  (S (NP-SBJ-COOD-68 (CC either)  (DT the)  (NP-COOD (NP (NN NFAT-1) ) (CC or)  (NP (NN NF)  (NN kappa)  (NN B) )) (NN binding)  (NNS sites) ) (VP (VBD were)  (VP (VBN deleted)  (NP (-NONE- *-68) )))))) (, ,)  (CC but)  (VP (VBD failed)  (S (NP-SBJ (-NONE- *-67) ) (VP (TO to)  (VP (VB respond)  (PP (TO to)  (NP (DT these)  (JJ mitogenic)  (NNS stimuli) )) (SBAR (IN if)  (S (NP-SBJ (DT both)  (NNS sequences) ) (VP (VBD were)  (ADJP-PRD (JJ absent) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-69 (NP (DT The)  (NN HIV-1)  (JJ mutant)  (NN virus) ) (VP (VBG containing)  (NP (NP-COOD (CC both)  (NP (NN NF)  (NN kappa)  (NN B) ) (CC and)  (NP (NN NFAT-1) )) (NN deletion) ))) (VP (VBD was)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-69) ) (VP (TO to)  (VP (VB replicate)  (SBAR (IN although)  (FRAG (PP (IN at)  (NP (DT a)  (ADJP (JJ much)  (VBN decreased) ) (NN growth)  (NN rate) )))))))) (, ,)  (SBAR (IN while)  (S (NP-SBJ (NP (NP (DT the)  (NN deletion) ) (PP (IN of)  (NP (NN NFAT-1) ))) (ADVP (RB alone) )) (VP (VBD increased)  (NP (NP (DT the)  (JJ viral)  (NN growth)  (NN rate) ) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (CC Neither)  (NP (NP (NN deletion) ) (PP (IN of)  (NP (NN NF)  (NN kappa)  (NN B) ))) (CC nor)  (NP (NP (NN deletion) ) (PP (IN of)  (NP (NN NFAT-1) )))) (VP (VBD decreased)  (NP (NP (NN activation) ) (PP (IN of)  (NP (JJ viral)  (NN replication) )) (PP (IN by)  (NP (NN phorbol)  (NN ester) )))) (. .) ) )
(TOP (NP (NP (JJ Specific)  (NN depletion) ) (PP (IN of)  (NP (DT the)  (NN B-cell)  (NN population) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (JJ aberrant)  (NN expression) ) (PP (IN of)  (NP (NP (JJ human)  (NN interferon)  (JJ regulatory)  (NN factor)  (CD 1)  (NN gene) ) (PP (IN in)  (NP (JJ transgenic)  (NNS mice) ))))))) (. .) ) )
(TOP (S (NP-SBJ-205 (NP (NNS Interferons) ) (PRN (-LRB- -LRB-)  (NP (NNS IFNs) ) (-RRB- -RRB-) )) (VP (VBP are)  (ADVP (RB well) ) (VP (VBN known)  (NP (-NONE- *-205) ) (PP-COOD (CC both)  (PP (IN as)  (NP (JJ antiviral)  (NNS proteins) )) (CC and)  (PP (IN as)  (NP (NP (JJ potent)  (NNS regulators) ) (PP (IN of)  (NP (NN cell)  (NP-COOD (NP (NN growth) ) (CC and)  (NP (NN differentiation) ))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN fact) )) (, ,)  (NP-SBJ (NNS IFNs) ) (VP (VBP inhibit)  (NP (NP (NN growth) ) (PP (IN of)  (NP (JJ various)  (ADJP-COOD (ADJP (JJ normal) ) (CC and)  (ADJP (VBN transformed) )) (NN cell)  (NNS types) )))) (. .) ) )
(TOP (S (ADVP-TMP (RB Previously) ) (, ,)  (NP-SBJ-86 (NP (NP (DT a)  (JJ nuclear)  (NN factor) ) (, ,)  (NP (NP (NN IRF-1) ) (PRN (-LRB- -LRB-)  (NP (NN interferon)  (JJ regulatory)  (NN factor)  (CD 1) ) (-RRB- -RRB-) )) (, ,) ) (SBAR (WHNP-87 (WDT which) ) (S (NP-SBJ (-NONE- *T*-87) ) (VP (VBZ binds)  (PP (TO to)  (NP-COOD (NP (NN type)  (CD I)  (NN IFN) ) (CC and)  (NP (DT some)  (JJ IFN-inducible)  (NN gene)  (NNS promoters) ))))))) (, ,)  (VP (VBD was)  (VP-COOD (VP (VBN identified)  (NP (-NONE- *-86) )) (CC and)  (VP (VBN cloned)  (NP (-NONE- *-86) )))) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ (DT the)  (NN IRF-1)  (NN gene) ) (VP (VBZ is)  (ADJP-PRD (NP-COOD (CC both)  (NP (NN virus) ) (CC and)  (NP (NN IFN) )) (JJ inducible) )))) (, ,)  (NP-SBJ-88 (DT an)  (JJ intriguing)  (NN issue) ) (VP (VBZ is)  (VP (VBN raised)  (NP (-NONE- *-88) ) (PP (IN as)  (TO to)  (SBAR (IN whether)  (S (NP-SBJ (DT the)  (NN IRF-1)  (NN gene) ) (VP (VBZ is)  (VP (VBG functioning)  (PP (IN in)  (NP (NP (JJ IFN-mediated)  (NN regulation) ) (PP (IN of)  (NP (NN cell)  (NP-COOD (NP (NN growth) ) (CC and)  (NP (NN differentiation) ))))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD generated)  (NP (NP (JJ transgenic)  (NNS mice) ) (VP (VBG carrying)  (NP (NP (DT the)  (JJ human)  (NN IRF-1)  (NN gene) ) (VP (VBN linked)  (NP (-NONE- *) ) (PP (TO to)  (NP (DT the)  (JJ human)  (NN immunoglobulin)  (JJ heavy-chain)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ transgenic)  (NNS mice) )) (, ,)  (NP-SBJ (NP (PDT all)  (DT the)  (JJ lymphoid)  (NNS tissues) ) (VP (VBN examined)  (NP (-NONE- *) ))) (VP (VBD showed)  (NP (NP (DT a)  (JJ dramatic)  (NN reduction) ) (PP (IN in)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NN B)  (NNS lymphocytes) ) (PRN (-LRB- -LRB-)  (NP (NN B)  (NNS cells) ) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP-COOD (NP (NN Preparation) ) (CC and)  (NP (NN analysis) )) (PP (IN of)  (NP (NP (NN bone)  (NN marrow)  (NNS cells) ) (PP (IN from)  (NP (DT the)  (JJ chimeric)  (NNS mice) ))))) (VP (VBD indicated)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN bone)  (NN marrow) ) (VP (VBZ is)  (NP-PRD (NP (DT the)  (JJ effective)  (NN site) ) (PP (IN for)  (NP (NP (JJ specific)  (NN depletion) ) (PP (IN of)  (NP (DT the)  (NN B-cell)  (NN population) ))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN fact) )) (, ,)  (NP-SBJ (NP (JJ transgenic)  (NN bone)  (NN marrow)  (NNS cells) ) (VP (VBN cocultured)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT a)  (ADJP (NN bone)  (JJ marrow-derived) ) (JJ stromal)  (NN cell)  (NN line) )))) (VP (VBD revealed)  (NP (DT an)  (JJ altered)  (NN B-cell)  (NN maturation)  (NN pattern) )) (. .) ) )
(TOP (NP (NP-COOD (NP (NN Identification) ) (CC and)  (NP (NN cloning) )) (PP (IN of)  (NP (NP (NN TCF-1) ) (, ,)  (NP (NP (DT a)  (ADJP (NN T)  (JJ lymphocyte-specific) ) (NN transcription)  (NN factor) ) (VP (VBG containing)  (NP (DT a)  (JJ sequence-specific)  (NN HMG)  (NN box) ))))) (. .) ) )
(TOP (S (NP-SBJ-62 (NN CD3-epsilon)  (NN expression) ) (VP (VBZ is)  (VP (VBN controlled)  (NP (-NONE- *-62) ) (PP (IN by)  (NP-LGS (DT a)  (JJ downstream)  (ADJP (NN T)  (JJ lymphocyte-specific) ) (NN enhancer)  (NN element) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP report)  (NP (NP (DT the)  (NN identification) ) (PP (IN of)  (NP (NP (NP (DT a)  (ADJP (NN T)  (JJ cell-specific) ) (NN transcription)  (NN factor) ) (, ,)  (NP (NN TCF-1) ) (, ,) ) (VP (VBG binding)  (PP (TO to)  (NP (DT this)  (NN element) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ multimerized)  (NN recognition)  (NN motif) ) (PP (IN of)  (NP (NN TCF-1) ))) (VP (VBD constituted)  (NP (DT a)  (ADJP (NN T)  (JJ cell-specific) ) (NN enhancer) )) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Subsequent)  (NN cloning) ) (PP (IN of)  (NP (NN TCF-1) ))) (VP (VBD identified)  (NP (CD three)  (NN splice)  (NNS alternatives) )) (. .) ) )
(TOP (S (NP-SBJ (NN TCF-1) ) (VP (VBD contained)  (NP (NP (DT a)  (JJ single)  (JJ DNA-binding)  (NN HMG)  (NN box) ) (ADJP (ADVP (RBS most)  (RB closely) ) (JJ related)  (PP (TO to)  (NP (NP (JJ similar)  (NNS boxes) ) (PP-COOD (PP (IN in)  (NP (DT the)  (JJ putative)  (JJ mammalian)  (JJ sex-determining)  (NN gene)  (NN SRY) )) (CC and)  (PP (IN in)  (NP (DT the)  (FW Schizosaccharomyces)  (FW pombe)  (NN Mc)  (NN mating)  (NN type)  (NN gene) )))))))) (. .) ) )
(TOP (S (ADVP-SBJ-63 (NN TCF-1)  (NN mRNA) ) (VP (VBD was)  (VP (VBN expressed)  (NP (-NONE- *-63) ) (ADVP (RB uniquely) ) (PP (IN in)  (NP (NN T)  (NNS lymphocytes) )))) (. .) ) )
(TOP (S (PP-TMP (IN Upon)  (NP (NP (NN cotransfection) ) (PP (IN into)  (NP (JJ non-T)  (NNS cells) )))) (, ,)  (NP-SBJ (NN TCF-1) ) (VP (MD could)  (VP (VB transactivate)  (PP (IN through)  (NP (PRP$ its)  (JJ cognate)  (NN motif) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP identify)  (NP (NN TCF-1) ) (PP (IN as)  (NP (NP (DT a)  (ADJP (NN T)  (JJ cell-specific) ) (NN transcription)  (NN factor) ) (, ,)  (SBAR (WHNP-64 (WDT which) ) (S (NP-SBJ (-NONE- *T*-64) ) (VP (MD might)  (VP (VB play)  (NP (DT a)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN establishment) ) (PP (IN of)  (NP (DT the)  (JJ mature)  (NN T)  (NN cell)  (NN phenotype) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Nuclear)  (NN factor)  (NN kappa)  (NN B) ) (VP (VBZ activates)  (NP (NP (NN proenkephalin)  (NN transcription) ) (PP (IN in)  (NP (NN T)  (NNS lymphocytes) )))) (. .) ) )
(TOP (S (PP-TMP (IN Upon)  (NP (NN activation) )) (, ,)  (NP-SBJ (NN T)  (NNS lymphocytes) ) (VP (VBP accumulate)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (DT the)  (NN neuropeptide)  (NN enkephalin) )) (SBAR (WHNP-72 (WDT which) ) (S (NP-SBJ (-NONE- *T*-72) ) (VP (VBP correlate)  (PP (IN with)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (NN proenkephalin)  (NN mRNA) )) (PP (IN in)  (NP (DT the)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBD investigated)  (NP (NP (DT the)  (JJ transcriptional)  (NN basis) ) (PP (IN for)  (NP (DT these)  (NNS changes) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN proenkephalin)  (NN promoter) ) (VP (VBZ contains)  (NP (NP (DT a)  (NN sequence)  (NN GGGGACGTCCCC) ) (, ,)  (VP (VBN named)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN B2) ))) (, ,)  (SBAR (WHNP-73 (WDT which) ) (S (NP-SBJ (-NONE- *T*-73) ) (VP (VBZ is)  (ADJP-PRD (JJ similar)  (PP (TO to)  (NP (NP (DT the)  (NN kappa)  (NN B)  (NN sequence)  (NN GGGGACTTTCC) ) (, ,)  (NP (NP (DT the)  (VBG binding)  (NN site) ) (PP (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NP (NP (JJ nuclear)  (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN NF) ) (-RRB- -RRB-) ) (NN -kappa)  (NN B) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Activation) ) (PP (IN of)  (NP (NN T)  (NNS lymphocytes) ))) (VP (VBZ induces)  (NP (DT an)  (ADJP (NN NF-kappa)  (JJ B-like) ) (NN binding)  (NN activity) ) (PP (TO to)  (NP (DT the)  (NN B2)  (NN site) )) (, ,)  (S (NP-SBJ (-NONE- *) ) (ADJP-PRD (JJ concomitant)  (PP (IN with)  (NP (NP (NN activation) ) (PP (IN of)  (NP (DT the)  (NN proenkephalin)  (NN promoter) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Mutations) ) (PP (IN at)  (NP (DT the)  (NN B2)  (NN site) ))) (VP (VBP abolish)  (NP (DT this)  (JJ transcriptional)  (NN activation) )) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (DT The)  (VBN purified)  (NN homodimer) ) (PRN (-LRB- -LRB-)  (NP (CD two)  (NNS p50s) ) (-RRB- -RRB-) )) (PP (IN of)  (NP (NP (DT the)  (JJ DNA-binding)  (NN subunit) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))) (VP (VBZ binds)  (NP (NP (DT the)  (NN B2)  (NN site) ) (PP (IN of)  (NP (NN proenkephalin) ))) (ADVP (ADVP (RB relatively)  (JJR better) ) (SBAR (IN than)  (SINV (VBZ does)  (NP-SBJ (NP (DT the)  (NP (NP (NN heterotetramer) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD two)  (NNS p65s) ) (CC plus)  (NP (CD two)  (NNS p50s) )) (-RRB- -RRB-) )) (NN form) ) (PP (IN of)  (NP (DT the)  (NN factor) ))) (VP (-NONE- *?*) ))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (PRP it) ) (VP (VBZ appears)  (SBAR (IN that)  (S (NP-SBJ-74 (NP (DT the)  (JJ T-cell-specific)  (NN activation) ) (PP (IN of)  (NP (DT the)  (NN proenkephalin)  (NN promoter) ))) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-74) ) (PP (IN by)  (NP-LGS (NN NF-kappa)  (NN B) ))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (SBAR-ADV (IN as)  (S-COOD (S (NP-SBJ (NN NF-kappa)  (NN B) ) (VP (VBZ is)  (ADJP-PRD (JJ ubiquitous) ))) (CC and)  (S (NP-SBJ (NP (DT the)  (JJ transcriptional)  (NN activation) ) (PP (IN through)  (NP (DT the)  (NN B2)  (NN site) ))) (VP (VBZ is)  (ADJP-PRD (NP (NN T)  (NN cell) ) (JJ specific) ))))) (, ,)  (NP-SBJ-75 (NP (RB yet)  (DT another)  (JJ T-cell-specific)  (NN factor) ) (SBAR (WHNP-76 (WDT which) ) (S (NP-SBJ (-NONE- *T*-76) ) (VP (VBZ synergizes)  (PP (IN with)  (NP (NN NF-kappa)  (NN B) )))))) (VP (MD should)  (VP (VB be)  (VP (VBN considered)  (NP (-NONE- *-75) )))) (. .) ) )
(TOP (NP (NP (NN Expression) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-jun) ) (, ,)  (NP (NN jun)  (NN B) ) (CC and)  (NP (NN jun)  (NN D) )) (NNS proto-oncogenes) )) (PP (IN in)  (NP (JJ human)  (JJ peripheral-blood)  (NNS granulocytes) )) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ (VBN purified)  (JJ human)  (JJ peripheral-blood)  (NNS granulocytes) ) (VP (VBP express)  (NP (NP (ADJP (RB constitutively)  (JJ significant) ) (NNS levels) ) (PP (IN of)  (NP (NP (NNS proto-oncogenes)  (NP-COOD (NP (NN c-jun) ) (, ,)  (NP (NN jun)  (NN B) ) (CC and)  (NP (NN jun)  (NN D) ))) (NN mRNA) )))))))) (. .) ) )
(TOP (S (PP (IN Upon)  (NP (NP (JJ functional)  (NN activation) ) (PP (IN of)  (NP (NNS granulocytes) )) (PP (IN by)  (NP (NP (CD 4)  (NN beta-phorbol)  (NN 12-myristate)  (NN 13-acetate) ) (PRN (-LRB- -LRB-)  (NP (NN PMA) ) (-RRB- -RRB-) ))))) (, ,)  (NP-SBJ-70 (NP (DT the)  (NNS levels) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-jun) ) (, ,)  (NP (NN jun)  (NN B) ) (CC and)  (NP (NN jun)  (NN D) )) (NNS transcripts) ))) (VP (VBD were)  (VP (VBN increased)  (NP (-NONE- *-70) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (CD three)  (NN jun)  (NNS genes) ) (VP (VBD showed)  (NP (DT a)  (JJ similar)  (NN time)  (NN course) ) (PP (IN in)  (NP (NP (PRP$ their)  (NN induction) ) (PP (IN by)  (NP (NN PMA) )))) (, ,)  (S (NP-SBJ-71 (JJ maximal)  (NN mRNA)  (NNS levels) ) (VP (VBG being)  (VP (VBN reached)  (NP (-NONE- *-71) ) (PP-TMP (IN after)  (NP (NP (CD 60)  (NN min) ) (PP (IN of)  (NP (NN induction) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-204 (NP (NN expression) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-jun) ) (, ,)  (NP (NN jun)  (NN B) ) (CC and)  (NP (NN jun)  (NN D) )) (NNS genes) ))) (VP (MD might)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-204) ) (PP-COOD (PP (IN in)  (NP (JJ terminal)  (NN granulocyte)  (NN differentiation) )) (CC or)  (PP (IN in)  (S (NP-SBJ (-NONE- *) ) (VP (VBG regulating)  (NP (NN granulocyte)  (NN functionality) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Platelet-activating)  (NN factor) ) (VP (VBZ induces)  (NP (NP-COOD (NP (JJ phospholipid)  (NN turnover) ) (, ,)  (NP (NN calcium)  (NN flux) ) (, ,)  (NP (JJ arachidonic)  (NN acid)  (NN liberation) ) (, ,)  (NP (NN eicosanoid)  (NN generation) ) (, ,)  (CC and)  (NP (JJ oncogene)  (NN expression) )) (PP (IN in)  (NP (DT a)  (JJ human)  (NN B)  (NN cell)  (NN line) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Platelet-activating)  (NN factor) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potent)  (NN mediator) ) (PP (IN of)  (NP (DT the)  (JJ inflammatory)  (NN response) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Studies) ) (PP (IN of)  (NP (NP (DT the)  (NNS actions) ) (PP (IN of)  (NP (JJ platelet-activating)  (NN factor) ))))) (VP (VBP have)  (VP (VBN centered)  (PP (RB mainly)  (IN around)  (NP-COOD (NP (NNS neutrophils) ) (, ,)  (NP (NNS monocytes) ) (, ,)  (CC and)  (NP (NNS platelets) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN report) )) (NP-SBJ-74 (PRP we) ) (VP (VBP begin)  (S (NP-SBJ (-NONE- *-74) ) (VP (TO to)  (VP (VB uncover)  (NP (NP (DT the)  (NN influence) ) (PP (IN of)  (NP (NN platelet-activating)  (NN factor) )) (PP (IN on)  (NP (NN B)  (NNS lymphocytes) ))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-73) ) (VP (VBG Employing)  (NP (DT the)  (JJ EBV-transformed)  (JJ human)  (NN B)  (NN cell)  (NN line)  (NN SKW6.4) ))) (, ,)  (NP-SBJ-73 (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (JJ platelet-activating)  (NN factor) ) (ADVP (RB significantly) ) (VP (VBZ alters)  (NP (NP (NN membrane)  (JJ phospholipid)  (NN metabolism) ) (VP (VBN indicated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN incorporation) ) (PP (IN of)  (NP (NN 32P) )) (PP-COOD (PP (IN into)  (NP-COOD (NP (NN phosphatidylcholine) ) (, ,)  (NP (NN phosphatidylinositol) ) (, ,)  (CC and)  (NP (JJ phosphatidic)  (NN acid) ))) (CC but)  (PP (ADVP (RB not)  (RB significantly) ) (IN into)  (NP (NN phosphatidylethanolamine) ))) (PP (IN at)  (NP (NP (NNS concentrations) ) (VP (VBG ranging)  (PP (PP-COOD (PP (IN from)  (NP (CD 10-LRB--9-RRB-)  (NP (-NONE- *RNR*-75) ))) (PP (TO to)  (NP (CD 10-LRB--6-RRB-)  (NP (-NONE- *RNR*-75) )))) (NP-75 (NN M) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (DT The)  (JJ inactive)  (NN precursor) ) (, ,)  (NP (JJ lyso-platelet-activating)  (NN factor) ) (, ,) ) (PP (IN at)  (NP (NP (DT a)  (NN concentration) ) (ADJP (ADJP (RB as)  (JJ high) ) (PP (IN as)  (NP (CD 10-LRB--7-RRB-)  (NN M) )))))) (VP (VBD had)  (NP (DT no)  (NN effect) ) (PP (IN on)  (NP (NP (DT any) ) (PP (IN of)  (NP (DT the)  (NN membrane)  (NNS phospholipids) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB also) ) (VP (VBP show)  (SBAR (IN that)  (S-COOD (S (NP-SBJ (NP (JJ platelet-activating)  (NN factor) ) (PP (IN from)  (NP (QP (CD 10-LRB--12-RRB-)  (TO to)  (CD 10-LRB--6-RRB-) ) (NN M) ))) (VP (VBD induced)  (NP (NP (ADJP-COOD (ADJP (JJ rapid) ) (CC and)  (ADJP (JJ significant) )) (NN elevation) ) (PP (IN in)  (NP (JJ intracellular)  (NN calcium)  (NNS levels) ))))) (, ,)  (IN whereas)  (S (NP-SBJ (JJ lyso-platelet-activating)  (NN factor) ) (VP (VBD was)  (ADVP (RB again) ) (ADJP-PRD (JJ ineffective) )))))) (. .) ) )
(TOP (S (NP-SBJ-107 (PRP We) ) (ADVP (RB further) ) (VP (VBP demonstrate)  (NP (NP (DT the)  (NN impact) ) (PP (IN of)  (NP (NP (JJ platelet-activating)  (NN factor) ) (VP (VBG binding)  (PP (TO to)  (NP (NN B)  (NNS cells) )))))) (PP (IN by)  (S (NP-SBJ (-NONE- *-107) ) (VP (VBG measuring)  (NP-COOD (NP (ADJP (NP (JJ platelet-activating)  (NN factor) ) (JJ induced) ) (JJ arachidonic)  (NN acid)  (NN release) ) (CC and)  (NP (JJ 5-hydroxyeicosatetraenoic)  (NN acid)  (NN production) )))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-76 (JJ platelet-activating)  (NN factor) ) (VP (VBD was)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-76) ) (VP (VBG inducing)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (JJ nuclear)  (NNS proto-oncogenes)  (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Finally) ) (NP-SBJ-77 (PRP we) ) (VP (VBD explored)  (NP (NP (DT the)  (JJ possible)  (NN role) ) (PP (IN of)  (NP (JJ 5-hydroxyeicosatetraenoic)  (NN acid) )) (PP (IN as)  (NP (NP (DT a)  (NN regulator) ) (PP (IN of)  (NP (JJ arachidonic)  (NN acid)  (NN liberation) ))))) (S (NP-SBJ (-NONE- *-77) ) (VP (VBG demonstrating)  (SBAR (IN that)  (S (NP-SBJ-78 (JJ endogenous)  (NN 5-lipoxygenase)  (NN activity) ) (VP (VBZ modulates)  (NP (ADJP (NP (JJ platelet-activating)  (NN factor) ) (JJ induced) ) (JJ arachidonic)  (NN acid)  (NN release) ) (S (NP-SBJ (-NONE- *-78) ) (ADVP (RB perhaps) ) (VP (VBG acting)  (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NN phospholipase)  (NN A2) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN summary) )) (, ,)  (NP-SBJ-79 (JJ platelet-activating)  (NN factor) ) (VP (VBZ is)  (VP (VBN shown)  (ADVP (RB here) ) (S (NP-SBJ (-NONE- *-79) ) (VP (TO to)  (VP (VB have)  (NP (DT a)  (ADJP-COOD (ADJP (JJ direct) ) (CC and)  (ADJP (JJ profound) )) (NN effect) ) (PP (IN on)  (NP (DT a)  (JJ pure)  (NN B)  (NN cell)  (NN line) ))))))) (. .) ) )
(TOP (NP (NP (DT A)  (JJ novel)  (NN HIV-1)  (JJ isolate) ) (VP (VBG containing)  (NP (NP (NNS alterations) ) (VP (VBG affecting)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN element) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (CD Three)  (JJ molecular)  (NNS clones) ) (PP (IN of)  (NP (NN HIV-1) ))) (, ,)  (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (DT a)  (JJ single)  (NN isolate) ) (PRN (-LRB- -LRB-)  (NP (NN AL1) ) (-RRB- -RRB-) )))) (, ,) ) (VP (VBD exhibited)  (NP (JJ distinct)  (ADJP-COOD (ADJP (JJ replicative) ) (CC and)  (ADJP (JJ cytopathic) )) (NNS properties) ) (PP-TMP (IN during)  (NP (NP (NN propagation) ) (PP (IN in)  (NP (DT a)  (JJ human)  (NN T)  (NN cell)  (NN line) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ phenotypic)  (NNS differences) ) (VP (VBN observed)  (NP (-NONE- *) ))) (VP (VBD were)  (ADJP-PRD (JJ attributable)  (PP (-NONE- *ICH*-105) )) (, ,)  (PP (IN in)  (NP (JJ large)  (NN part) )) (, ,)  (PP-105 (TO to)  (NP (NP (NNS changes) ) (VP (VBG affecting)  (NP (DT the)  (JJ viral)  (NN LTR) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN Nucleotide)  (NN sequence) ) (CC and)  (NP (NN PCR)  (NNS analyses) )) (VP (VBD demonstrated)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (JJ novel)  (NP (NP-COOD (NP (NNS duplications) ) (CC or)  (NP (NNS deletions) )) (VP (VBG involving)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN motif) ))))))) (. .) ) )
(TOP (S (NP-SBJ-54 (NP (DT These)  (NNS changes) ) (PP (IN in)  (NP (DT the)  (NN enhancer)  (NN element) ))) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-54) ) (PP (IN in)  (NP (DT the)  (JJ original)  (NN AL1)  (NN virus)  (NN stock) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Subcloning) ) (PP (IN of)  (NP (DT the)  (JJ variant)  (NN NF-kappa)  (NN B)  (NNS segments) )) (PP (IN into)  (NP (JJ LTR-driven)  (NN CAT)  (NN expression)  (NNS vectors) ))) (VP (VBD confirmed)  (NP (NP (DT a)  (NN correlation) ) (PP (IN between)  (NP-COOD (NP (JJ promoter)  (NN activity) ) (CC and)  (NP (ADJP (JJ replicative/cytopathic) ) (NN capacity) ))))) (. .) ) )
(TOP (NP (NP (NP (NN 1,25-Dihydroxyvitamin)  (NN D3)  (NN receptor)  (NN RNA) ) (: :) ) (NP (NP (NN expression) ) (PP (IN in)  (NP (JJ hematopoietic)  (NNS cells) )) (. .) )) )
(TOP (S (S (NP-SBJ (NP (NN 1,25-Dihydroxyvitamin)  (NN D3) ) (PRN (-LRB- -LCB-)  (NP (NN 1,25-LRB-OH-RRB-2D3) ) (-RRB- -RCB-) )) (VP (VP-COOD (VP (VBZ induces)  (NP (NP (NN differentiation) ) (PP (-NONE- *RNR*-55) ))) (CC and)  (VP (VBZ inhibits)  (NP (NP (NN proliferation) ) (PP (-NONE- *RNR*-55) )))) (PP-55 (IN of)  (NP (NP (JJ myeloid)  (JJ leukemic)  (NNS cells) ) (PP (IN from)  (NP (JJ various)  (NP-COOD (NP (NNS lines) ) (CC and)  (NP (NNS patients) ))))))) (: ;) ) (S (NP-SBJ-56 (DT these)  (NNS effects) ) (VP (VBP are)  (ADVP (RB probably) ) (VP (VBN mediated)  (NP (-NONE- *-56) ) (PP (IN through)  (NP (DT the)  (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor) )))) (. .) )) )
(TOP (S (NP-SBJ-58 (NP (JJ Little) ) (PP (-NONE- *ICH*-57) )) (VP (VBZ is)  (VP (VBN known)  (NP (-NONE- *-58) ) (PP-57 (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) )) (PP (IN in)  (NP (JJ hematopoietic)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD examined)  (NP (NP (DT the)  (NP-COOD (NP (NN expression) ) (CC and)  (NP (NP (NN modulation) ) (PP (IN of)  (NP (NP (NN expression) )))))) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) )) (PP (IN in)  (NP (JJ various)  (ADJP-COOD (ADJP (VBG proliferating) ) (CC and)  (ADJP (JJ nonproliferating) )) (JJ hematopoietic)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ-60 (NP (JJ Constitutive)  (NN expression) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) ))) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-60) ) (PP-COOD (PP (IN in)  (NP (NP (JJ various)  (NNS kinds) ) (PP (IN of)  (NP (NP (JJ hematopoietic)  (NNS cells) ) (, ,)  (PP (VBG including)  (NP-COOD (NP (NNS macrophages) ) (CC and)  (NP (VBN activated)  (NN T)  (NNS lymphocytes) ))) (, ,) )))) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN in)  (NP (NN cell)  (NNS lines)  (NP-COOD (NP (NP (NN KG-1) ) (PRN (-LRB- -LRB-)  (NP (NNS myeloblasts) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (NN HL-60) ) (PRN (-LRB- -LRB-)  (NP (NNS promyelocytes) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (NN ML-3) ) (PRN (-LRB- -LRB-)  (NP (NNS myelomonoblasts) ) (-RRB- -RRB-) )) (, ,)  (NP (NN U937) ) (, ,)  (NP (NP (NN THP-1) ) (PRN (-LRB- -LRB-)  (NP (NNS monoblasts) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (NN K562) ) (PRN (-LRB- -LRB-)  (NP (NNS erythroblasts) ) (-RRB- -RRB-) )) (, ,)  (CC and)  (NP (NP (NN S-LB1) ) (PRN (-LRB- -LRB-)  (NP (JJ HTLV-1-transfected)  (NN T)  (NNS lymphocytes) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NN Receptor)  (NNS transcripts) ) (VP (VBD were)  (NP-PRD (CD 4.6)  (NP (NP (NNS kilobases) ) (PRN (-LRB- -LRB-)  (NP (NN kb) ) (-RRB- -RRB-) ))))) (, ,)  (CC and)  (S (NP-SBJ-61 (DT no)  (JJ variant)  (NNS sizes) ) (VP (VBD were)  (VP (VBN observed)  (NP (-NONE- *-61) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT All)  (NN cell)  (NNS lines) ) (VP (VBN examined)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT this)  (NN group) )))) (ADVP (RB also) ) (VP (VBD expressed)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (JJS Most)  (NN B)  (NN lymphocyte)  (NNS lines) ) (VP (VBD expressed)  (NP (NP (JJ negligible)  (NNS levels) ) (PP (IN of)  (NP-COOD (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA)  (CC and)  (NN protein) ))))) (: ;)  (RB however)  (: ;)  (S (NP-SBJ (NP (NN analysis) ) (PP (IN of)  (NP (DT a) (JJ  lymphoid/myeloid)  (JJ somatic)  (NN hybrid) ))) (VP (VBD suggested)  (SBAR (IN that)  (S (NP-SBJ (NP (NN suppression) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) )))) (PP (IN in)  (NP (NN B)  (NNS lymphocytes) ))) (VP (MD may)  (VP (VB be)  (NP-PRD (DT a)  (JJ dominant)  (NN characteristic) ))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-64 (NN HL-60)  (NNS cells) ) (VP (VBD were)  (VP (VBN cultured)  (NP (-NONE- *-64) ) (PP (IN with)  (NP (NP (CD 10-LRB--7-RRB-) (NN  mol/L) ) (NP (NN 1,25-LRB-OH-RRB-2D3) ))) (PP-TMP (IN for)  (NP (QP (CD 24)  (TO to)  (CD 72) ) (NNS hours) ))))) (, ,)  (CC and)  (S (NP-SBJ-62 (NP (NNS levels) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP-COOD (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor) ) (CC and)  (NP (PRP$ its)  (NN RNA) )))))) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-62) )))) (. .) ) )
(TOP (S (NP-SBJ-63 (NP (NNS Levels) ) (PP (IN of)  (NP (NP (NN RNA) ) (VP (NN coding)  (PP (IN for)  (NP (DT the)  (NN receptor) )))))) (VP (VBD were)  (RB not)  (VP (VBN modulated)  (NP (-NONE- *-63) ) (PP (IN by)  (NP (NP (NN exposure) ) (PP (TO to)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (NN ligand) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NNS Levels) ) (PP (IN of)  (NP (VBN occupied)  (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN protein) ))) (VP (VBD increased)  (PP (IN in)  (NP (DT these)  (NN HL-60)  (NNS cells) )))) (: ;)  (CC but)  (S (NP-SBJ (NP (DT the)  (JJ total)  (NN number) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) ))) (VP-COOD (VP (VBD decreased)  (NP (QP (RB about)  (CD 50) ) (NN %) ) (PP-TMP (IN at)  (NP (CD 24)  (NNS hours) ))) (CC and)  (VP (VBD returned)  (PP (IN toward)  (NP (JJ normal) )) (PP-TMP (IN at)  (NP (CD 72)  (NNS hours) ))))) (. .) ) )
(TOP (S (NP-SBJ-65 (NP (JJ Steady-state)  (NNS levels) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) ))) (VP (VBD were)  (RB not)  (VP (VBN affected)  (NP (-NONE- *-65) ) (PP (IN by)  (NP-LGS (NP (JJ terminal)  (NN differentiation) ) (PP (IN of)  (NP (NN HL-60) )) (PP (IN toward)  (NP-COOD (CC either)  (NP (NNS granulocytes) ) (CC or)  (NP (NNS macrophages) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Nondividing)  (NNS macrophages) ) (PP (IN from)  (NP (JJ normal)  (NNS individuals) ))) (ADVP (RB also) ) (VP (VBD expressed)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) )) (. .) ) )
(TOP (S (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (JJ nondividing)  (JJ peripheral)  (NN blood)  (NNS lymphocytes) ) (PP (IN from)  (NP (JJ normal)  (NNS individuals) ))) (VP (VBD did)  (RB not)  (VP (VB express)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) ))) (: ;) ) (S (PP (IN with)  (NP (NP (NN stimulation) ) (PP (IN of)  (NP (NP (NN proliferation) ) (PP (IN of)  (NP (DT these)  (NNS cells) )))))) (, ,)  (NP-SBJ (NP (NN accumulation) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) ))) (VP (VBD increased)  (ADVP (RB markedly) )) (. .) )) )
(TOP (S (NP-SBJ (NP (NP (NN Half-life) ) (PRN (-LRB- -LRB-)  (NP (NN t1/2) ) (-RRB- -RRB-) )) (PP (IN of)  (NP (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) ) (PP (IN in)  (NP (NN T)  (NNS lymphocytes) ))))) (VP (VBD was)  (ADJP-PRD (ADJP (JJ short) ) (PRN (-LRB- -LRB-)  (NP (CD 1)  (NN hour) ) (-RRB- -RRB-) )) (SBAR (IN as)  (S (NP-SBJ-66 (-NONE- *) ) (VP (VBN determined)  (NP (-NONE- *-66) ) (PP (IN by)  (S (NP-SBJ (-NONE- *) ) (VP (VBG measuring)  (NP (NP (NN decay) ) (PP (IN of)  (NP (DT the)  (NN message) )) (PP-TMP (IN after)  (NP (NP (NN addition) ) (PP (IN of)  (NP (NN actinomycin)  (NN D) )))))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-67) ) (ADJP-PRD (JJ Consistent)  (PP (IN with)  (NP (DT this)  (JJ short) (NN  t1/2) )))) (, ,)  (NP-SBJ-67 (NP (NN accumulation) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor)  (NN RNA) ))) (VP (VBD increased)  (PP (IN in)  (NP (NNS cells) )) (SBAR (IN as)  (S (NP-SBJ-68 (PRP$ their)  (NN protein)  (NN synthesis) ) (VP (VBD was)  (VP (VBN inhibited)  (NP (-NONE- *-68) )))))) (. .) ) )
(TOP (S (NP-SBJ-69 (JJ Further)  (NNS studies) ) (VP (VBP are)  (VP (VBN required)  (NP (-NONE- *-68) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB understand)  (NP (NP (DT the)  (JJ physiologic)  (NN role) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) )) (PP (IN in)  (NP-COOD (NP (JJ myeloid)  (NNS cells) ) (CC and)  (NP (VBG proliferating)  (NN T)  (NNS lymphocytes) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-43 (NN Kappa)  (NN B)  (NN binding)  (NNS proteins) ) (VP (VBP are)  (ADVP (RB constitutively) ) (VP (VBN expressed)  (NP (-NONE- *-43) ) (PP (IN in)  (NP (DT an)  (NN IL-2)  (NN autocrine)  (JJ human)  (NN T)  (NN cell)  (NN line) )))) (. .) ) )
(TOP (S (NP-SBJ-44 (NP-COOD (NP (DT The)  (NN IL-2) ) (CC and)  (NP (DT the)  (NN IL-2-R)  (NN alpha) )) (NNS genes) ) (VP (VBP are)  (VP (DT both)  (VP (VBN expressed)  (NP (-NONE- *-44) ) (ADVP (RB transiently) ) (PP (IN in)  (NP (JJ normal)  (NN T)  (NNS lymphocytes) )) (PP-TMP (IN after)  (NP (NP-COOD (NP (NN Ag) ) (CC or)  (NP (NN mitogen) )) (NN activation) ))))) (. .) ) )
(TOP (S-COOD (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (DT the)  (JJ human)  (NN T)  (NN cell)  (NN line) ) (, ,)  (NP (NN IARC)  (CD 301) ) (, ,) ) (VP (VBZ expresses)  (NP (DT these)  (CD two)  (NNS genes) ) (ADVP (RB constitutively) ))) (CC and)  (S (NP-SBJ (PRP we) ) (VP (VBP have)  (ADVP-TMP (RB previously) ) (VP (VBN demonstrated)  (SBAR (IN that)  (S (NP-SBJ (PRP$ its)  (NN growth) ) (VP (VBZ depends)  (PP (IN on)  (NP (NP (DT the)  (JJ autocrine)  (NN production) ) (PP (IN of)  (NP-COOD (NP (DT this)  (NN T)  (NN cell)  (NN growth)  (NN factor) ) (CC and)  (NP (JJ high)  (NN affinity)  (NN IL-2R) ))))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-46 (-NONE- *-45) ) (VP (TO To)  (VP (VB dissect)  (NP (NP (DT the)  (JJ molecular)  (NN basis) ) (PP (IN for)  (NP (NP (DT the)  (JJ unusual)  (JJ persistent)  (NN expression) ) (PP (IN of)  (NP (NP (DT the)  (NP-COOD (NP (NN IL-2) ) (CC and)  (NP (NN IL-2-R)  (NN alpha) )) (NNS genes) ) (PP (IN in)  (NP (DT these)  (NN IARC)  (CD 301)  (NN T)  (NNS cells) )))))))))) (, ,)  (NP-SBJ-45 (PRP we) ) (VP (VBP have)  (VP (VBN analyzed)  (NP (NP (DT the)  (NNS interactions) ) (PP (IN of)  (NP (ADJP (RB constitutively)  (VBN expressed) ) (JJ nuclear)  (NNS proteins) )) (PP (IN with)  (NP (NP (DT the)  (JJ 5')  (JJ flanking)  (NNS regions) ) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN IL-2) ) (CC and)  (NP (NN IL-2-R)  (NN alpha) )) (NNS genes) ))))) (S (NP-SBJ (-NONE- *-46) ) (VP (VBG using)  (NP (NP-COOD (DT both)  (NP (NN DNase)  (CD I)  (NN footprinting) ) (CC and)  (NP (NN gel)  (NN retardation) )) (NNS techniques) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ-48 (NP (DT a)  (NN region) ) (PP (IN in)  (NP (DT both)  (NNS genes) )) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP-COOD (NP (CD -276) ) (TO to)  (NP (CD -250) )) (PP (IN for)  (NP (NN IL-2-R)  (NN alpha) ))) (CC and)  (NP (NP-COOD (NP (CD -203) ) (TO to)  (NP (CD -183) )) (PP (IN for)  (NP (NN IL-2) )))) (-RRB- -RRB-) ) (, ,)  (SBAR (WHNP-47 (WDT which) ) (S (NP-SBJ (-NONE- *T*-47) ) (VP (VBZ corresponds)  (PP (TO to)  (NP (DT a)  (NN kappa)  (NN B)  (NN enhancer)  (NN element) ))))) (, ,) ) (VP (VBZ is)  (ADVP (RB specifically) ) (VP (VBN protected)  (NP (-NONE- *-48) ) (PP (IN by)  (NP-LGS (NP (JJ nuclear)  (NNS proteins) ) (PP (IN from)  (NP (NN IARC)  (CD 301) )))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NN agreement)  (IN with)  (NP (DT this)  (NN finding) )) (, ,)  (NP-SBJ (CC both)  (DT the)  (NP-COOD (NP (NN IL-2) ) (CC and)  (NP (NN IL-2-R)  (NN alpha) )) (NNS promoters) ) (VP (VBP are)  (ADJP-PRD (JJ active) ) (PP (IN in)  (NP (NP (JJ transient)  (NN transfection)  (NNS assays) ) (PP (IN in)  (NP (NN IARC)  (CD 301)  (NNS cells) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (NN mutation) ) (PP (IN of)  (NP (DT the)  (NN kappa)  (NN B)  (NN enhancer) ))) (VP (VBZ results)  (PP (IN in)  (NP (NP (ADJP (RB markedly)  (VBN attenuated) ) (NNS activities) ) (PP (IN of)  (NP (DT both)  (NNS promoters) ))))) (. .) ) )
(TOP (S (NP-SBJ-49 (NP (NP (CD Two)  (NNS proteins) ) (VP (VBG binding)  (NP (DT the)  (NN kappa)  (NN B)  (NN sequence) ))) (, ,)  (NP-COOD (NP (NN NF-kappa)  (NN B) ) (CC and)  (NP (NN KBF1) )) (, ,) ) (VP (VBP are)  (ADVP (RB constitutively) ) (VP-COOD (VP (VBN expressed)  (NP-50 (-NONE- *-49) ) (PP (IN in)  (NP (NN IARC)  (CD 301)  (NNS nuclei) ))) (CC and)  (VP (VBN induced)  (NP (-NONE- *-50) ) (PP (IN by)  (NP-LGS-COOD (NP (NN PMA) ) (CC and)  (NP (NN PHA) ))) (PP (IN in)  (NP (NN Jurkat) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP They) ) (VP (VBP bind)  (PP (TO to)  (NP (NP (DT the)  (NN kappa)  (NN B)  (NNS motifs) ) (PP (IN with)  (NP (JJ different)  (JJ relative)  (NNS affinities) )) (SBAR (WHNP-51 (WDT that) ) (S (NP-SBJ (-NONE- *T*-51) ) (VP (MD may)  (VP (VB reflect)  (NP (NP (PRP$ their)  (JJ different)  (NN contribution) ) (PP (IN in)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (JJ various)  (NNS promoters) )))))))))))) (. .) ) )
(TOP (NP (NP (DT The)  (JJ functional)  (NNS domains) ) (PP (IN of)  (NP (DT the)  (JJ murine)  (NN Thy-1)  (NN gene)  (NN promoter) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN Thy-1)  (NN gene)  (NN promoter) ) (VP (VBZ resembles)  (NP (DT a)  (`` ")  (JJ housekeeping)  ('' ")  (NN promoter) ) (PP (IN in)  (SBAR (IN that)  (S (NP-SBJ-68 (PRP it) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ located)  (PP (IN within)  (NP (DT a)  (JJ methylation-free)  (NN island) )))) (, ,)  (VP (VBZ lacks)  (NP (DT a)  (JJ canonical)  (NN TATA)  (NN box) )) (, ,)  (CC and)  (VP (VBZ displays)  (NP (NN heterogeneity) ) (PP (IN in)  (NP (NP (DT the)  (JJ 5'-end)  (NNS termini) ) (PP (IN of)  (NP (DT the)  (NN mRNA) )))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-69) ) (VP (VBG Using)  (NP (JJ transgenic)  (NNS mice) ))) (, ,)  (NP-SBJ-69 (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN promoter) ) (VP-COOD (VP (VBZ does)  (RB not)  (VP (VB confer)  (NP (DT any)  (NN tissue)  (NN specificity) ))) (CC and)  (VP (VBZ is)  (ADJP-PRD (JJ active) ) (PP (RB only)  (IN in)  (NP (DT a)  (JJ position-dependent)  (NN manner) ))))))) (. .) ) )
(TOP (S (NP-SBJ-70 (PRP It) ) (VP (MD can)  (ADVP (RB only) ) (VP (VB be)  (VP (VBN activated)  (NP (-NONE- *-70) ) (PP (IN in)  (NP (DT a)  (JJ tissue-specific)  (NN manner) )) (PP (IN by)  (NP-LGS (NP (NNS elements) ) (SBAR (WHNP-71 (WDT that) ) (S (NP-SBJ (-NONE- *T*-71) ) (VP (VBP lie)  (ADJP (RB downstream)  (PP (IN of)  (NP (DT the)  (NN initiation)  (NN site) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP-COOD (VP (VBP have)  (VP (VBN analyzed)  (NP (NP (DT the)  (JJ functional)  (NNS domains) ) (PP (IN of)  (NP (DT the)  (JJ minimal)  (NN Thy-1)  (NN promoter) ))))) (CC and)  (VP (VB show)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (JJ dominant)  (NN promoter)  (NNS elements) ) (VP (VBP consist)  (PP (IN of)  (NP (NP (JJ multiple)  (VBG binding)  (NNS sites) ) (PP (IN for)  (NP-COOD (NP (DT the)  (NN transcription)  (NN factor)  (NN Sp1) ) (, ,)  (NP (DT an)  (JJ inverted)  (NN CCAAT)  (NN box) ) (, ,)  (CC and)  (NP (NP (VBZ sequences) ) (ADJP (JJ proximal)  (PP (TO to)  (NP (DT the)  (NN transcription)  (NN start)  (NN site) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN DNase)  (CD I)  (CC and)  (NN gel)  (NN mobility)  (NN shift)  (NNS assays) ) (VP (VBP show)  (NP (NP (DT the)  (NN binding) ) (PP (IN of)  (NP (NP (DT a)  (NN number) ) (PP (IN of)  (NP (JJ nuclear)  (NNS factors) )))) (PP (TO to)  (NP (NP (DT these)  (NNS elements) ) (, ,)  (PP (VBG including)  (NP-COOD (NP (NN Sp1) ) (CC and)  (NP (NN CP1) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS results) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN structure) ) (PP (IN of)  (NP (DT this)  (NN promoter) ))) (ADVP (RB only) ) (VP (VBZ permits)  (NP (NP (JJ productive)  (NNS interactions) ) (PP (IN of)  (NP (DT the)  (CD two)  (NN transcription)  (NNS factors)  (NP-COOD (NP (NN Sp1) ) (CC and)  (NP (NN CP1) )))) (PP (IN with)  (NP (DT the)  (JJ basal)  (NN transcription)  (NN machinery) ))) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN enhancer)  (NNS sequences) )))))) (. .) ) )
(TOP (NP (NP (NP (NN Comparison) ) (PP (IN of)  (NP (NP (ADJP-COOD (ADJP (JJ constitutive) ) (CC and)  (ADJP (JJ inducible) )) (JJ transcriptional)  (NN enhancement) ) (VP (VBN mediated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (ADJP (NN kappa)  (JJ B-related) ) (NNS sequences) ))))) (: :) ) (NP (NP (NN modulation) ) (PP (IN of)  (NP (NP (NN activity) ) (PP (IN in)  (NP (NN B)  (NNS cells) )))) (PP (IN by)  (NP (JJ human)  (NN T-cell)  (NN leukemia)  (NN virus)  (NN type)  (CD I)  (NN tax)  (NN gene) )) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (NN kappa)  (NN B)  (NN sequence) ) (PRN (-LRB- -LRB-)  (NP (NN GGGACTTTCC) ) (-RRB- -RRB-) )) (VP (VBZ binds)  (NP (NP (NP (DT a)  (NN factor) ) (, ,)  (NP (NN NF-kappa)  (NN B) ) (, ,) ) (SBAR (WHNP-75 (WDT that) ) (S (NP-SBJ-76 (-NONE- *T*-75) ) (VP (VBZ is)  (ADVP (RB constitutively) ) (VP (VBN found)  (NP (-NONE- *-76) ) (PP (IN in)  (NP (PRP$ its)  (ADJP-COOD (ADJP (JJ functional) ) (, ,)  (ADJP (NN DNA)  (NN binding) )) (NN form) )) (PP (RB only)  (IN in)  (NP (NN B)  (NNS lymphocytes) )))))))) (. .) ) )
(TOP (S (NP-SBJ-77 (NP (DT A)  (NN factor) ) (PP (IN with)  (NP (ADJP (RB apparently)  (JJ indistinguishable) ) (NN sequence)  (NN specificity) ))) (VP (MD can)  (VP (VB be)  (VP (VBN induced)  (NP (-NONE- *-77) ) (PP (IN in)  (NP (NP (JJ many)  (JJ other)  (NN cell)  (NNS types) ) (, ,)  (SBAR (WHADVP-78 (WRB where) ) (S (NP-SBJ-79 (PRP it) ) (VP (VBZ is)  (VP (VBN used)  (NP-80 (-NONE- *-79) ) (S (NP-SBJ (-NONE- *-80) ) (VP (TO to)  (VP (VB regulate)  (NP (JJ inducible)  (NN gene)  (NN expression) ))))))))))))) (. .) ) )
(TOP (S (PP (IN For)  (NP (NN example) )) (, ,)  (NP-SBJ-81 (ADJP (NN kappa)  (JJ B-related) ) (NNS sequences) ) (VP (VBP have)  (VP (VBN been)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-81) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ important)  (PP (IN for)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (NP (QP (DT a)  (JJ few) ) (JJ inducible)  (NNS genes) ) (, ,)  (PP (JJ such)  (IN as)  (NP-COOD (NP (DT the)  (NN interleukin)  (CD 2)  (NN receptor)  (NN alpha-chain)  (NN gene) ) (CC and)  (NP (DT the)  (NN beta-interferon)  (NN gene) )))))))))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (DT these)  (NNS genes) ) (VP (VBP are)  (RB not)  (ADJP-PRD (RB constitutively)  (JJ active)  (PP (IN in)  (NP (NN B)  (NNS lymphocytes) ))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (JJ other)  (JJ regulatory)  (NNS mechanisms) ) (VP (MD must)  (VP (VB play)  (NP (DT a)  (NN role) ) (PP (IN in)  (S (NP-SBJ (-NONE- *) ) (VP (VBG determining)  (NP (NP (DT the)  (NNS patterns) ) (PP (IN of)  (NP (NN expression) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN investigated)  (NP (NP (DT the)  (ADJP-COOD (ADJP (JJ constitutive) ) (CC and)  (ADJP (JJ inducible) )) (JJ transcriptional)  (NN activity) ) (VP (VBN mediated)  (PP (IN by)  (NP (NP (CD five)  (ADJP (NN kappa)  (JJ B-related) ) (NN sequence)  (NNS elements) ) (PP (IN in)  (NP (CD two)  (JJ different)  (NN cell)  (NNS types) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (SBAR (IN that)  (S (PP (IN in)  (NP (NN S194)  (NN plasma)  (NNS cells) )) (NP-SBJ (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (DT each)  (NN element) ))) (VP (VBZ correlates)  (ADVP (RB well) ) (PP (IN with)  (NP (NP (DT the)  (JJ relative)  (NN affinity) ) (PP (IN of)  (NP (JJ B-cell-derived)  (NN NF-kappa)  (NN B) )) (PP (IN for)  (NP (DT that)  (NN element) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ leads)  (PP (TO to)  (NP (NP (ADJP (RB significantly)  (RBR lower) ) (NN transcription)  (NN enhancement) ) (PP (IN by)  (NP (NP (NNS sites) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (DT the)  (NP-COOD (NP (NN interleukin)  (CD 2)  (NN receptor) ) (CC or)  (NP (NN T-cell)  (NN receptor) )) (NNS genes) ) (PP (IN in)  (NP (NP (NN S194) ) (NNS cells) )))))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (PP (IN in)  (NP-COOD (CC either)  (NP (NN EL-4)  (-LRB- -LRB-)  (NN T)  (-RRB- -RRB-)  (NNS cells) ) (CC or)  (NP (NN S194)  (NNS cells) ))) (, ,)  (NP-SBJ-83 (DT both)  (JJ lower-affinity)  (NNS sites) ) (VP (MD can)  (VP (VB be)  (ADVP (RB significantly) ) (VP (VBN induced)  (NP (-NONE- *-83) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN tax)  (NN gene)  (NN product) ) (PP (IN of)  (NP (JJ human)  (NN T-cell)  (NN leukemia)  (NN virus)  (NN type)  (CD I) )))) (, ,)  (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG showing)  (SBAR (IN that)  (S (NP-SBJ-84 (NN NF-kappa)  (NN B)  (NN activity) ) (VP (MD can)  (VP (VB be)  (VP (VBN modulated)  (NP (-NONE- *-84) ) (PP (RB even)  (IN in)  (NP (NP (DT a)  (NN B-cell)  (NN line) ) (SBAR (WHNP-85 (WDT that) ) (S (NP-SBJ (-NONE- *T*-85) ) (ADVP (RB constitutively) ) (VP (VBZ expresses)  (NP (DT this)  (NN factor) )))))))))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Isolation) ) (PP (IN of)  (NP (NP (DT a)  (JJ rel-related)  (JJ human)  (NN cDNA) ) (SBAR (WHNP-313 (WDT that) ) (S (NP-SBJ (-NONE- *T*-313) ) (ADVP (RB potentially) ) (VP (VBZ encodes)  (NP (NP (DT the)  (JJ 65-kD)  (NN subunit) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))))))) (S (-LRB- -LCB-)  (NP-SBJ (VBN published)  (NN erratum) ) (VP (VBZ appears)  (PP (IN in)  (NP (NNP Science)  (CD 1991)  (NNP Oct)  (CD 4)  (: ;)  (CD 254)  (-LRB- -LRB-)  (CD 5028)  (-RRB- -RRB-)  (: :)  (CD 11) ))) (-RRB- -RCB-) )) )
(TOP (S (NP-SBJ-15 (NP (DT A)  (NN DNA)  (NN probe) ) (SBAR (WHNP-314 (WDT that) ) (S (NP-SBJ (-NONE- *T*-314) ) (VP (VBD spanned)  (NP (NP (DT a)  (NN domain) ) (VP (VBN conserved)  (NP (-NONE- *) ) (PP (IN among)  (NP-COOD (NP (DT the)  (NN proto-oncogene)  (NN c-rel) ) (, ,)  (NP (DT the)  (NN Drosophila)  (NN morphogen)  (NN dorsal) ) (, ,)  (CC and)  (NP (NP (DT the)  (NN p50)  (NN DNA)  (NN binding)  (NN subunit) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))))))))) (VP (VBD was)  (VP (VBN generated)  (NP (-NONE- *-15) ) (PP (IN from)  (NP (NP (NN Jurkat)  (NN T)  (NN cell)  (JJ complementary)  (NN DNA) ) (PP (IN with)  (NP-COOD (NP (NP (DT the)  (NN polymerase)  (NN chain)  (NN reaction) ) (PRN (-LRB- -LRB-)  (NP (NN PCR) ) (-RRB- -RRB-) )) (CC and)  (NP (JJ degenerate)  (NNS oligonucleotides) ))))))) (. .) ) )
(TOP (S (NP-SBJ-316 (DT This)  (NN probe) ) (VP (VBD was)  (VP (VBN used)  (NP (-NONE- *-316) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB identify)  (NP (NP (DT a)  (JJ rel-related)  (JJ complementary)  (NN DNA) ) (SBAR (WHNP-17 (WDT that) ) (S (NP-SBJ (-NONE- *T*-17) ) (VP (VBD hybridized)  (PP (TO to)  (NP (NP (DT a)  (JJ 2.6-kilobase)  (NN messenger)  (NN RNA) ) (ADJP (JJ present)  (PP (IN in)  (NP (JJ human)  (NP-COOD (NP (NN T) ) (CC and)  (NP (NN B) )) (NNS lymphocytes) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (FW In)  (FW vitro) ) (NP-COOD (NP (NN transcription) ) (CC and)  (NP (NN translation) ))) (PP (IN of)  (NP (DT the)  (JJ complementary)  (NN DNA) ))) (VP (VBD resulted)  (PP (IN in)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NP (DT a)  (NN protein) ) (PP (IN with)  (NP (NP (DT an)  (JJ apparent)  (JJ molecular)  (NN size) ) (PP (IN of)  (NP (CD 65)  (NP (NP (NNS kilodaltons) ) (PRN (-LRB- -LRB-)  (NP (NN kD) ) (-RRB- -RRB-) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (VBN translated)  (NN protein) ) (VP (VBD showed)  (NP (NP (JJ weak)  (NN DNA)  (NN binding) ) (PP (IN with)  (NP (NP (DT a)  (NN specificity) ) (PP (IN for)  (NP (DT the)  (NN kappa)  (NN B)  (VBG binding)  (NN motif) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (DT This)  (JJ protein-DNA)  (JJ complex) ) (VP (VBN comigrated)  (PP (IN with)  (NP (NP (DT the)  (NN complex) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT the)  (VBN purified)  (JJ human)  (NN p65)  (NN NF-kappa)  (NN B)  (NN subunit) ))))))) (CC and)  (S (NP-SBJ-18 (NN binding) ) (VP (VBD was)  (VP (VBN inhibited)  (NP (-NONE- *-18) ) (PP (IN by)  (NP-LGS (NP-COOD (NP (NN I)  (NN kappa)  (NN B-alpha) ) (CC and)  (NP (NN -beta) )) (NNS proteins) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ-19 (DT the)  (JJ 65-kD)  (NN protein) ) (VP (VBN associated)  (PP (IN with)  (NP-COOD (NP (NP (DT the)  (NN p50)  (NN subunit) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))) (CC and)  (NP (DT the)  (NN kappa)  (NN B)  (NN probe) ))) (S (NP-SBJ (-NONE- *-19) ) (VP (TO to)  (VP (VB form)  (NP (NP (DT a)  (NN complex) ) (PP (IN with)  (NP (NP (DT the)  (JJ same)  (JJ electrophoretic)  (NN mobility) ) (PP (IN as)  (NP (DT the)  (ADJP (NN NF-kappa)  (JJ B-DNA) ) (NN complex) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Therefore) ) (NP-SBJ (DT the)  (JJ rel-related)  (JJ 65-kD)  (NN protein) ) (VP (MD may)  (VP (VB represent)  (NP (NP (DT the)  (NN p65)  (NN subunit) ) (PP (IN of)  (NP (DT the)  (JJ active)  (NN NF-kappa)  (NN B)  (NN transcription)  (NN factor)  (NN complex) ))))) (. .) ) )
(TOP (NP (NP (NN Lymphocyte)  (NN glucocorticoid)  (NN receptor)  (NN number) ) (PP (IN in)  (NP (JJ posttraumatic)  (NN stress)  (NN disorder) )) (. .) ) )
(TOP (NP (NP (NN OBJECTIVE) ) (: :)  (S (NP-SBJ (NP (DT The)  (NNS authors)  (POS ') ) (NN objective) ) (VP (VBD was)  (S-PRD (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB investigate)  (NP (DT the)  (NN possibility)  (SBAR (IN that)  (S (NP-SBJ-103 (NN glucocorticoid)  (NN receptor)  (NNS changes) ) (VP (MD may)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-103) ) (PP (IN in)  (NP (NP (DT the)  (NN dysregulation) ) (PP (IN of)  (NP (DT the)  (ADJP (ADJP (JJ hypothalamic-pituitary-adrenal) ) (PRN (-LRB- -LRB-)  (ADJP (JJ HPA) ) (-RRB- -RRB-) )) (NN axis) )) (PP (IN in)  (NP (NP (JJ posttraumatic)  (NN stress)  (NN disorder) ) (PRN (-LRB- -LRB-)  (NP (NN PTSD) ) (-RRB- -RRB-) ))))))))))))))) (. .) )) )
(TOP (NP (NP (NN METHOD) ) (: :)  (S (NP-SBJ (PRP They) ) (VP (VBD measured)  (NP (NP-COOD (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN lymphocyte)  (JJ cytosolic)  (NN glucocorticoid)  (NNS receptors) ))) (CC and)  (NP (NN plasma)  (NN cortisol)  (NNS concentrations) )) (PP-COOD (IN in)  (NP (NP (CD 15)  (ADJP (RB consecutively)  (VBN admitted) ) (JJ male)  (NN combat)  (NN Vietnam)  (NNS veterans) ) (PP (IN with)  (NP (NN PTSD) ))) (CC and)  (PP (IN in)  (NP (NP (DT a)  (JJ normal)  (NN comparison)  (NN group) ) (PP (IN of)  (NP (CD 11)  (NNS subjects) ))))))) (. .) )) )
(TOP (NP (NP (NNS RESULTS) ) (: :)  (S (NP-SBJ-COOD (CC Both)  (NP (DT the)  (NNS patients) ) (CC and)  (NP (DT the)  (JJ normal)  (NN comparison)  (NNS subjects) )) (VP (VBD showed)  (NP (NP (DT a)  (JJ morning-to-afternoon)  (NN decline) ) (PP (IN in)  (NP (NN glucocorticoid)  (NN receptor)  (NNS concentrations) )) (, ,)  (VP (VBG paralleling)  (NP (NP (DT the)  (JJ normal)  (JJ diurnal)  (NN decline) ) (PP (IN in)  (NP (NN cortisol)  (NNS levels) )))))) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (NN number) ) (PP (IN of)  (NP (NN glucocorticoid)  (NNS receptors) ))) (VP (VBD was)  (ADJP-PRD (ADJP-COOD (ADJP (ADJP (NP (CD 63)  (NN %) ) (JJR greater) ) (PP (-NONE- *RNR*-46) ) (PP (-NONE- *RNR*-47) ) (PP-TMP (IN in)  (NP (DT the)  (NN morning) ))) (CC and)  (ADJP (ADJP (NP (CD 26)  (NN %) ) (JJR greater) ) (PP (-NONE- *RNR*-46) ) (PP (-NONE- *RNR*-47) ) (PP-TMP (IN in)  (NP (DT the)  (NN afternoon) )))) (PP-47 (IN in)  (NP (NP (DT the)  (NNS patients) ) (PP (IN with)  (NP (NN PTSD) )))) (PP-46 (IN than)  (FRAG (PP (IN in)  (NP (DT the)  (JJ normal)  (NNS subjects) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-48 (NP (DT No)  (NN group)  (NNS differences) ) (PP (IN in)  (NP (NN cortisol)  (NNS levels) ))) (VP (VBD were)  (VP (VBN observed)  (NP (-NONE- *-48) )))) (, ,)  (CC nor)  (SINV (VBD were)  (NP-SBJ-COOD (NP (NN glucocorticoid)  (NN receptor)  (NN number) ) (CC and)  (NP (NN cortisol)  (NNS levels) )) (ADJP-PRD (VBD correlated) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN number) ) (PP (IN of)  (NP (NN morning)  (NN glucocorticoid)  (NNS receptors) ))) (VP (VBD was)  (ADJP-PRD (RB positively)  (VBN correlated)  (PP (IN with)  (NP (NP (NNS symptoms) ) (PP (IN of)  (NP-COOD (NP (NN PTSD) ) (CC and)  (NP (NN anxiety) ))))))) (. .) ) )
(TOP (NP (NP (NNS CONCLUSIONS) ) (: :)  (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP provide)  (NP (NP (JJ further)  (NN evidence) ) (PP (IN for)  (NP (NP (DT a)  (NN dysregulation) ) (PP (IN of)  (NP (DT the)  (JJ HPA)  (NN axis) )) (PP (IN in)  (NP (NN PTSD) )))))) (. .) )) )
(TOP (S (NP-SBJ (DT The)  (NN finding)  (SBAR (IN that)  (S (NP-SBJ (NP (NNS patients) ) (PP (IN with)  (NP (NN PTSD) ))) (VP (VBD had)  (NP (NP (NP (DT a)  (ADJP (RB substantially)  (JJR greater) ) (NN number) ) (PP (IN of)  (NP (NN lymphocyte)  (NN glucocorticoid)  (NNS receptors) ))) (PP (IN than)  (NP (JJ normal)  (NN comparison)  (NNS subjects) ))))))) (VP (VBZ is)  (ADJP-PRD (JJ consistent)  (PP (IN with)  (NP (NP (NP (DT the)  (NNS authors)  (POS ') ) (JJ previous)  (NNS observations) ) (PP (IN of)  (NP (NP (JJ low)  (JJ 24-hour)  (JJ urinary)  (NN cortisol)  (NN excretion) ) (PP (IN in)  (NP (NP (NNS subjects) ) (PP (IN with)  (NP (NN PTSD) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (NP (DT the)  (NN receptor)  (NNS changes) ) (VP (VBN observed)  (NP (-NONE- *) ))) (VP (VBP are)  (ADJP-PRD (JJ opposite)  (PP (IN of)  (NP (NP (DT those) ) (VP (VBN reported)  (NP (-NONE- *) ) (PP (IN in)  (NP (JJ major)  (JJ depressive)  (NN disorder) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ present)  (NNS data) ) (, ,)  (PP (IN along)  (IN with)  (NP (NP (JJ other)  (NNS findings) ) (PP (IN of)  (NP (NP (JJ HPA)  (NNS abnormalities) ) (PP (IN in)  (NP (NN PTSD) )))))) (, ,)  (VP (VBP support)  (NP (NP (DT the)  (NN possibility) ) (PP (IN of)  (NP (NP (DT a)  (JJR greater)  (JJ negative)  (NN feedback)  (NN sensitivity) ) (PP (IN at)  (NP (NP (QP (CD one)  (CC or)  (JJR more) ) (NNS levels) ) (PP (IN of)  (NP (DT the)  (JJ HPA)  (NN axis) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ thymus-specific)  (NN member) ) (PP (IN of)  (NP (DT the)  (NN HMG)  (NN protein)  (NN family) ))) (VP (VBZ regulates)  (NP (DT the)  (JJ human)  (NN T)  (NN cell)  (NN receptor)  (NN C)  (NN alpha)  (NN enhancer) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (ADJP (JJ human)  (NN T)  (JJ cell-specific) ) (NN transcription)  (NN factor) ) (NP (NN TCF-1)  (NN alpha) )) (VP-COOD (VP (VBZ plays)  (NP (DT a)  (JJ key)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (JJ tissue-specific)  (NN activation) ) (PP (IN of)  (NP (DT the)  (NN T)  (NN cell)  (NN receptor)  (-LRB- -LRB-)  (NN TCR)  (-RRB- -RRB-)  (NN C)  (NN alpha)  (NN enhancer) ))))) (CC and)  (VP (VBZ binds)  (PP (TO to)  (NP (NP (NP (JJ pyrimidine-rich)  (NNS elements) ) (PRN (-LRB- -LRB-)  (NP (NN 5'-PyCTTTG-3') ) (-RRB- -RRB-) )) (ADJP (JJ present)  (PP (IN in)  (NP (DT a)  (NN variety)  (PP (IN of)  (NP (JJ other)  (ADJP (NN T)  (JJ cell-specific) ) (NN control)  (NNS regions) ))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-43) ) (VP (VBG Using)  (NP (NP (NN amino)  (NN acid)  (NN sequence)  (NN information) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT the)  (NN DNA)  (JJ affinity-purified)  (NN protein) )))))) (, ,)  (NP-SBJ-43 (PRP we) ) (VP (VBP have)  (ADVP-TMP (RB now) ) (VP (VBN isolated)  (NP (NP (NN cDNA)  (NNS clones) ) (VP (VBG encoding)  (NP (NN TCF-1)  (NN alpha) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN TCF-1)  (NN alpha)  (NN cDNA) ) (VP (VBZ contains)  (NP (NP (DT a)  (JJ single)  (JJ 68-amino-acid)  (NN domain) ) (SBAR (WHNP-44 (WDT that) ) (S (NP-SBJ (-NONE- *T*-44) ) (VP (VBZ is)  (ADJP-PRD (JJ homologous)  (PP (TO to)  (NP (NP (DT a)  (NN region) ) (VP (VBN conserved)  (NP (-NONE- *) ) (PP (IN among)  (NP-COOD (NP (NP (JJ high-mobility)  (NN group) ) (PRN (-LRB- -LRB-)  (NP (NN HMG) ) (-RRB- -RRB-) )) (CC and)  (NP (JJ nonhistone)  (JJ chromosomal)  (NNS proteins) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Expression) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ full-length) ) (CC and)  (ADJP (JJ mutant) )) (NN cDNA)  (NNS clones) )) (PP (IN in)  (NP (NNS bacteria) ))) (VP (VBP reveal)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ single)  (NN HMG)  (NN motif) ) (, ,)  (SBAR (WHNP-45 (WDT which) ) (S (NP-SBJ-46 (-NONE- *T*-45) ) (VP (VBZ is)  (VP (VBN predicted)  (S (NP-SBJ (-NONE- *-46) ) (VP (TO to)  (VP (VB contain)  (NP (CD two)  (VBN extended)  (JJ alpha-helical)  (NNS segments) )))))))) (, ,) ) (VP (VBZ is)  (ADJP-PRD (JJ sufficient)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB direct)  (NP (NP (DT the)  (JJ sequence-specific)  (NN binding) ) (PP (IN of)  (NP (NN TCF-1)  (NN alpha) )) (PP (TO to)  (NP (NN DNA) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Northern)  (NN blot)  (NNS experiments) ) (VP (VBP demonstrate)  (ADVP (RBR further) ) (SBAR (IN that)  (S (NP-SBJ-47 (NN TCF-1)  (NN alpha)  (NN mRNA) ) (VP (VBZ is)  (UCP-PRD-COOD (ADJP-PRD (RB highly)  (NN tissue)  (JJ specific) ) (, ,)  (VP (VBN found)  (NP (-NONE- *-47) ) (ADVP (RB primarily) ) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN thymus) ) (CC or)  (NP (NN T)  (NN cell)  (NNS lines) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ immature)  (NN CEM)  (NN T)  (NN cell)  (NN line) ) (VP (VBZ expresses)  (NP (NP (RB relatively)  (JJ low)  (NNS levels) ) (PP (IN of)  (NP (NN TCF-1)  (NN alpha)  (NN mRNA) )) (, ,)  (SBAR (WHNP-48 (WDT which) ) (S (NP-SBJ-49 (-NONE- *T*-48) ) (VP (VBP are)  (VP (VBN increased)  (NP (-NONE- *-49) ) (PP-TMP (IN upon)  (NP (NP (NN activation) ) (PP (IN of)  (NP (DT these)  (NNS cells) )) (PP (IN by)  (NP (NN phorbol)  (NNS esters) )))))))))) (. .) ) )
(TOP (S-COOD (S (ADVP (RB Interestingly) ) (, ,)  (NP-SBJ (DT the)  (VBN cloned)  (NN TCF-1)  (NN alpha)  (NN protein) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potent)  (JJ transcriptional)  (NN activator) ) (PP (IN of)  (NP (NP (DT the)  (JJ human)  (NN TCR)  (NN alpha)  (NN enhancer) ) (PP (IN in)  (NP (JJ nonlymphoid)  (NN cell)  (NNS lines) ))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (NP (DT the)  (JJ endogenous)  (NN protein) ) (PP (IN in)  (NP (NN T)  (NN cell)  (NNS lines) ))))) (VP (VBZ is)  (ADJP-PRD (RB strongly)  (JJ dependent)  (PP (IN on)  (NP (NP (DT an)  (JJ additional)  (ADJP (NN T)  (JJ cell-specific) ) (NN protein) ) (SBAR (WHNP-50 (WDT that) ) (S (NP-SBJ (-NONE- *T*-50) ) (VP (VBZ interacts)  (PP (IN with)  (NP (DT the)  (NN core)  (NN enhancer) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN TCF-1)  (NN alpha) ) (VP (VBZ is)  (ADJP-PRD (RB currently)  (JJ unique) ) (PP (IN among)  (NP (NP (DT the)  (ADJP (RB newly)  (VBG emerging) ) (NN family) ) (PP (IN of)  (NP (NP (JJ DNA-binding)  (JJ regulatory)  (NNS proteins) ) (SBAR (WHNP-51 (WDT that) ) (S (NP-SBJ (-NONE- *T*-51) ) (VP (VBP share)  (NP (NP (DT the)  (NN HMG)  (NN motif) ) (SBAR (WHPP-52 (IN in)  (WHNP (IN that) )) (S (NP-SBJ (PRP it) ) (VP (VBZ is)  (NP-PRD (DT a)  (ADJP (RB highly)  (JJ tissue-specific) ) (NN RNA)  (NN polymerase)  (CD II)  (NN transcription)  (NN factor) ) (PP (-NONE- *T*-52) ))))))))))))) (. .) ) )
(TOP (NP (NP (JJ Immune)  (NN response) ) (PP (IN of)  (NP (JJ peripheral)  (NN blood)  (JJ mononuclear)  (NNS cells) )) (PP (TO to)  (NP (NP (NN HBx-antigen) ) (PP (IN of)  (NP (NN hepatitis)  (NN B)  (NN virus) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN hepatitis)  (NN B)  (NN virus)  (NN genome) ) (VP (VBZ encodes)  (NP (NP (DT a)  (JJ transcriptional)  (NN transactivator)  (NN protein) ) (VP (VBN designated)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN HBxAg) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN investigated)  (SBAR (IN whether)  (S (NP-SBJ (DT this)  (NN antigen) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN target)  (NN structure) ) (PP (IN for)  (NP (JJ human)  (NNS T-lymphocytes) )))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-58) ) (VP (VBG Using)  (NP (JJ recombinant)  (NN HBxAg)  (NN protein) ))) (, ,)  (NP-SBJ-58 (PRP we) ) (VP (VBD found)  (NP (NP (JJ HBxAg-specific)  (NN stimulation) ) (PP (IN of)  (NP (JJ peripheral)  (NN blood)  (JJ mononuclear)  (NNS cells) ))) (PP-COOD (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP-COOD (NP (JJ acute)  (NN hepatitis)  (NN B)  (NN virus)  (NN infection)  (PRN (-LRB- -LRB-)  (NP (NP (CD 6) ) (PP (IN of)  (NP (CD 6) ))) (-RRB- -RRB-) )) (CC and)  (NP (JJ chronic)  (NN hepatitis)  (NN B)  (NN virus)  (NN infection)  (PRN (-LRB- -LRB-)  (NP (NP (CD 6) ) (PP (IN of)  (NP (CD 17) ))) (-RRB- -RRB-) )))))) (CC but)  (PP (RB not)  (IN in)  (NP (JJ healthy)  (NNS individuals) )))) (. .) ) )
(TOP (S (PP (IN With)  (NP (JJ HBxAg-specific)  (JJ synthetic)  (NNS polypeptides) )) (, ,)  (NP-SBJ-59 (JJ several)  (NN T-cell)  (NNS epitopes) ) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-59) ))) (. .) ) )
(TOP (S (NP-SBJ-60 (JJS Most) ) (VP (VBD were)  (VP (JJ located)  (NP (-NONE- *-60) ) (PP (IN in)  (NP (NP (DT the)  (JJ carboxyterminal)  (NN half) ) (PP (IN of)  (NP (DT the)  (NN HBxAg)  (NN protein) )))))) (. .) ) )
(TOP (S (NP-SBJ-61 (NP (CD Five)  (NN T-cell)  (NNS clones) ) (ADJP (JJ specific)  (PP (IN for)  (NP (DT a)  (NN T-cell)  (NN epitope) ) (ADJP (JJ located)  (PP (IN at)  (NP (NP (DT the)  (JJ carboxyterminal)  (NN region) ) (PP (IN of)  (NP (NN HBxAg) )))))))) (VP (VBD were)  (VP (VP (VBN established)  (NP (-NONE- *-61) )) (CC and)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-61) ) (VP (TO to)  (VP (VB belong)  (PP (TO to)  (NP (DT the)  (ADJP-COOD (ADJP (JJ CD2/CD4-positive) ) (, ,)  (ADJP (JJ CD8-negative) )) (NN subtype) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP establish)  (PP (IN for)  (NP (DT the)  (JJ first)  (NN time) )) (NP (NN HBxAg) ) (PP (IN as)  (NP (NP (DT an)  (NN antigen) ) (PP (IN in)  (NP (DT the)  (JJ cellular)  (JJ immune)  (NN response) ))))) (. .) ) )
(TOP (NP (NP (DT A)  (NN study) ) (PP (IN on)  (NP (NP (DT the)  (JJ circadian)  (NN rhythm) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN receptor) )))) (. .) ) )
(TOP (S (NP-SBJ-71 (NP (JJ Circadian)  (NN rhythm) ) (PP (IN in)  (NP (NP (NN glucocorticoid)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN GR) ) (-RRB- -RRB-) )))) (VP (VBD was)  (VP (VBN studied)  (NP (-NONE- *-71) ) (PP (IN in)  (NP (DT the)  (UCP-COOD (NP (NN rat)  (NN liver) ) (CC and)  (ADJP (JJ human)  (JJ peripheral) )) (NNS leukocytes) )))) (. .) ) )
(TOP (S (PP (IN For)  (NP (NP (NNS rats) ) (VP (VBN exposed)  (NP (-NONE- *) ) (PP (TO to)  (NP-COOD (NP (DT a)  (ADJP (JJ natural)  (JJ environmental) ) (JJ photic)  (NN cycle) ) (CC or)  (NP (DT a)  (NN 12L)  (: :)  (NN 12D)  (JJ artificial)  (NN light)  (NN regime) )))))) (, ,)  (NP-SBJ-72 (NP (JJ peak)  (NNS values) ) (PP (IN of)  (NP (JJ hepatic)  (NN GR) ))) (VP (VBD were)  (VP (VBN detected)  (NP (-NONE- *-72) ) (PP-TMP (IN between)  (NP (QP (CD 23:00)  (CC and)  (CD 02:00) ) (NN h) )))) (. .) ) )
(TOP (S (PP (IN Except)  (IN for)  (NP (NP (DT a)  (JJ 4-hour)  (NN advancement) ) (PP (IN of)  (NP (DT the)  (NN peak) )))) (, ,)  (NP-SBJ-73 (NP (DT a)  (JJ similar)  (JJ circadian)  (NN rhythm) ) (PP (IN of)  (NP (JJ hepatic)  (NN GR) ))) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-73) ) (PP (IN in)  (NP (NP (NNS rats) ) (VP (VBN reared)  (NP (-NONE- *) ) (PP (IN under)  (NP (NP (DT a)  (VBN reversed)  (NN lighting)  (NNS regimen) ) (PRN (-LRB- -LRB-)  (NP (NN 12D)  (: :)  (NN 12L) ) (: ;)  (S (NP-SBJ (NNS lights) ) (ADVP-PRD (IN on) ) (PP-TMP (IN between)  (NP (QP (CD 18:30)  (CC and)  (CD 06:30) ) (NN h) ))) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (JJ human)  (NNS leukocytes) )) (, ,)  (NP-SBJ-74 (NP (DT the)  (JJ peak)  (NN value) ) (PP (IN of)  (NP (NN GR) ))) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-74) ) (VP (TO to)  (VP (VB parallel)  (NP (NP (DT that) ) (PP (IN of)  (NP (NP (NN plasma)  (NN cortisol) ) (PP (IN with)  (NP (NP (ADJP-COOD (ADJP (JJ high) ) (CC and)  (ADJP (JJ low) )) (NNS values) ) (VP (VBN detected)  (NP (-NONE- *) ) (PP-TMP (IN at)  (NP-COOD (NP (QP (CD 04:00-08:00) ) (NN h) ) (CC and)  (NP (QP (CD 23:00-24:00) ) (NN h) ))) (, ,)  (ADVP (RB respectively) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (NNS patients) ) (VP (VBG suffering)  (PP (IN from)  (NP (NP (NN Cushing)  (POS 's) ) (NN syndrome) ))))) (, ,)  (NP-SBJ-75 (NP (DT the)  (JJ circadian)  (NN rhythm) ) (PP (IN of)  (NP (NN plasma)  (NN cortisol) ))) (VP (VP-COOD (CC either)  (VP (VBD disappeared) ) (CC or)  (VP (VBD was)  (VP (VBN inverted)  (NP (-NONE- *-75) )))) (SBAR (IN while)  (S (NP-SBJ (NP (DT that) ) (PP (IN of)  (NP (NN GR) ))) (VP (VBD did)  (RB not)  (ADVP (RB significantly) ) (VP (VB deviate)  (PP (IN from)  (NP (DT the)  (JJ normal)  (NNS subjects) ))))))) (. .) ) )
(TOP (S (PP (IN For)  (NP (NP (JJ apoplexic)  (NNS patients) ) (PP (IN with)  (NP (NP (NNS lesions) ) (VP (JJ localized)  (NP (-NONE- *) ) (PP (TO to)  (NP (NP (DT the)  (NN base) ) (PP (IN of)  (NP (DT the)  (NN brain) )))) (SBAR (IN as)  (S (NP-SBJ-76 (-NONE- *) ) (VP (VBN indicated)  (NP (-NONE- *-76) ) (PP (IN by)  (NP-LGS (VBN computerized)  (NN tomography) )))))))))) (, ,)  (NP-SBJ-77 (NP (DT the)  (JJ diurnal)  (NN variation) ) (PP (IN of)  (NP (NN GR) ))) (VP (VBD was)  (VP (VBN abolished)  (NP (-NONE- *-77) ))) (. .) ) )
(TOP (S (ADVP (RB Conversely) ) (, ,)  (NP-SBJ (JJ diurnal)  (NN rhythmicity) ) (VP (VBD persisted)  (PP (IN in)  (NP (NP (NN apoplexy)  (NNS patients) ) (SBAR (WHNP-78 (WP$ whose)  (NNS lesions) ) (S (NP-SBJ (-NONE- *T*-78) ) (VP (VBD were)  (PP-PRD (IN in)  (NP (DT the)  (JJ cerebral)  (NN cortex) )))))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD postulated)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ circadian)  (NN modification) ) (PP (IN of)  (NP (NN GR) ))) (VP (VBD was)  (ADJP-PRD (JJ independent)  (PP (IN of)  (NP-COOD (NP (NP (DT the)  (JJ diurnal)  (NNS fluctuations) ) (PP (IN in)  (NP (NN plasma)  (NN cortisol)  (NN level) ))) (CC or)  (NP (NP (DT the)  (JJ circadian)  (NNS variations) ) (PP (IN in)  (NP (JJ environmental)  (NN lighting) ))))))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ-79 (DT the)  (NN rhythmicity) ) (VP (MD might)  (VP (VB be)  (VP (VBN regulated)  (NP (-NONE- *-79) ) (PP (IN by)  (NP-LGS (NP (DT the)  (`` ')  (JJ circadian)  (NN pacemaker)  ('' ') ) (ADJP (JJ located)  (PP (IN in)  (NP (DT the)  (JJ human)  (JJ basal)  (NN brain) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-80 (NP (DT These)  (JJ diurnal)  (NNS variations) ) (PP (IN in)  (NP (NN GR) ))) (VP (MD might)  (VP (VB serve)  (S (NP-SBJ (-NONE- *-80) ) (VP (TO to)  (VP (VB coordinate)  (NP (NP (DT the)  (NN reactivity) ) (PP (IN of)  (NP (DT the)  (NN target)  (NNS cells) )) (PP (TO to)  (NP (NN cortisol) ))) (SBAR (IN because)  (S (NP-SBJ-81 (NP (NP (DT the)  (JJ diurnal)  (NNS rhythms) ) (PP (IN of)  (NP (DT a)  (JJ GR-mediated)  (NN response) ))) (, ,)  (NP (NP (DT the)  (JJ fractional)  (NN inhibition) ) (PP (IN of)  (NP (NP (JJ chemotactic)  (NN migration)  (NN rate) ) (PP (IN of)  (NP (JJ polymorphonuclear)  (NNS leukocytes) )))) (PP (IN by)  (NP (NN cortisol) ))) (, ,) ) (VP (VBD were)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-81) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ synchronous)  (PP (IN with)  (NP (DT those)  (PP (IN of)  (NP (NN GR) ))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-55 (JJ Multiple)  (NN Oct2)  (NNS isoforms) ) (VP (VBP are)  (VP (VBN generated)  (NP (-NONE- *-55) ) (PP (IN by)  (NP (JJ alternative)  (NN splicing) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN interaction) ) (PP (IN of)  (NP (DT the)  (NN Oct2)  (NN transcription)  (NN factor) )) (PP (IN with)  (NP (DT the)  (JJ cognate)  (NN octamer)  (NN motif)  (NN ATGCAAAT) ))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ critical)  (NN determinant) ) (PP (IN of)  (NP (NP (DT the)  (JJ lymphoid-specific)  (NN expression) ) (PP (IN of)  (NP (NN immunoglobulin)  (NNS genes) )))))) (. .) ) )
(TOP (S (NP-SBJ-56 (NP (JJ Ectopic)  (NN expression) ) (PP (IN of)  (NP (VBN cloned)  (NN Oct2)  (NN cDNA) ))) (VP (VBD was)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-56) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ sufficient)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB reconstitute)  (NP (NP (QP (IN at)  (JJS least)  (DT some) ) (NNS aspects) ) (PP (IN of)  (NP (DT this)  (NN regulation) )) (PP (IN in)  (NP (JJ non-lymphoid)  (NNS cells) )))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (PRP We) ) (VP (VBP describe)  (NP (NP (DT the)  (NP-COOD (NP (NN isolation) ) (CC and)  (NP (NN characterization) ))) (PP (IN of)  (NP (NP (JJ multiple)  (NNS cDNAs) ) (VP (VBG encoding)  (NP (NP (NN mouse)  (NN Oct2) ) (PP (IN from)  (NP (DT a)  (JJ mature)  (NN B-cell)  (NN line) ))))))))) (CC and)  (S (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-57 (NP (DT a)  (NN variety) ) (PP (IN of)  (NP (NP (NNS isoforms) ) (PP (IN of)  (NP (DT this)  (NN transcription)  (NN factor) ))))) (VP (VBZ is)  (VP (VBN generated)  (NP (-NONE- *-57) ) (PP (IN from)  (NP (DT a)  (JJ single)  (NN gene) )) (PP (IN by)  (NP (DT an)  (JJ alternative)  (NN splicing)  (NN mechanism) )))))))) (. .) ) )
(TOP (S (NP-SBJ-58 (PDT All)  (DT the)  (NNS isoforms) ) (VP-COOD (VP (VBP retain)  (NP (DT the)  (ADJP (RB previously)  (VBN characterized) ) (NN POU-domain) )) (CC and)  (VP (VBP are)  (ADVP (RB therefore) ) (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-58) ) (VP (TO to)  (VP (VB bind)  (PP (TO to)  (NP (DT the)  (NN octamer)  (NN motif) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (JJ Different)  (NNS amounts) ) (PP (IN of)  (NP (DT the)  (JJ various)  (NNS isoforms) ))) (VP (VBP are)  (ADJP-PRD (JJ present)  (PP (IN within)  (NP (DT the)  (JJ same)  (NN B-cell) ))) (ADVP (RB regardless)  (PP (IN of)  (NP (NP (DT the)  (JJ developmental)  (NN stage) ) (PP (IN of)  (NP (NN B-cell)  (NN differentiation) ))))))) (CC and)  (S (NP-SBJ-106 (NP (ADVP (IN at)  (JJS least) ) (DT some) ) (PP (IN of)  (NP (DT the)  (NNS isoforms) ))) (VP (VBP are)  (VP (VBN conserved)  (NP (-NONE- *-106) ) (PP (IN between)  (NP-COOD (NP (NN mouse) ) (CC and)  (NP (NNS humans) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN cotransfection)  (NNS experiments) )) (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-59 (PDT all)  (DT the)  (NNS isoforms) ) (VP (VBP are)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-59) ) (VP (TO to)  (VP (VB activate)  (NP (NP (DT an)  (NN octamer) ) (VP (VBG containing)  (NP (NN promoter)  (NN element) ) (PP (IN in)  (NP (NNS fibroblasts) )))) (S (NP-SBJ (-NONE- *) ) (VP (VBG revealing)  (NP (DT an)  (JJ unexpected)  (JJ functional)  (NN redundancy) ))))))))))) (. .) ) )
(TOP (S (ADVP-TMP (RB Finally) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NP (CD one) ) (PP (IN of)  (NP (DT the)  (NNS isoforms) ))) (VP (VBZ encodes)  (NP (NP (DT the)  (ADJP (RB previously)  (VBN described) ) (JJ lymphoid-specific)  (NN Oct2B)  (NN protein) ) (SBAR (WHNP-60 (WDT which) ) (S (NP-SBJ-61 (-NONE- *T*-60) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN suggested)  (S (NP-SBJ-62 (-NONE- *-61) ) (VP (TO to)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-62) ) (PP (IN in)  (NP (NP (DT the)  (NN function) ) (PP (IN of)  (NP (DT the)  (NN octamer)  (NN motif) )))) (PP (IN in)  (DT the)  (NN context)  (IN of)  (NP (DT the)  (NP (NP (NN immunoglobulin)  (NN heavy-chain) ) (PRN (-LRB- -LRB-)  (NP (NN IgH) ) (-RRB- -RRB-) )) (NN enhancer) )))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (ADJP-COOD (ADJP (JJ Murine) ) (CC and)  (ADJP (JJ human) )) (NN T-lymphocyte)  (NN GATA-3)  (NNS factors) ) (VP (VBP mediate)  (NP (NN transcription) ) (PP (IN through)  (NP (NP (DT a)  (JJ cis-regulatory)  (NN element) ) (PP (IN within)  (NP (DT the)  (JJ human)  (NN T-cell)  (NN receptor)  (NN delta)  (NN gene)  (NN enhancer) ))))) (. .) ) )
(TOP (S (S (NP-SBJ-47 (NP (DT A)  (NN family) ) (PP (IN of)  (NP (JJ transcriptional)  (NNS activators) ))) (VP (VBZ has)  (ADVP (RB recently) ) (VP (VBN been)  (VP (VBN identified)  (NP (-NONE- *-47) ) (PP (IN in)  (NP (NNS chickens) ))))) (: ;) ) (S (NP-SBJ (DT these)  (JJ transcriptional)  (NNS activators) ) (VP (VBP recognize)  (NP (NP (DT a)  (JJ common)  (NN consensus)  (NN motif) ) (PRN (-LRB- -LRB-)  (NP (NN WGATAR) ) (-RRB- -RRB-) )) (PP (IN through)  (NP (DT a)  (VBN conserved)  (NN C4)  (NN zinc)  (NN finger)  (JJ DNA-binding)  (NN domain) ))) (. .) )) )
(TOP (S (NP-SBJ-48 (NP (NP (CD One) ) (PP (IN of)  (NP (NP (DT the)  (NNS members) ) (PP (IN of)  (NP (DT this)  (JJ multigene)  (NN family) ))))) (, ,)  (NP (NN cGATA-3) ) (, ,) ) (VP (VBZ is)  (ADVP (RBS most)  (RB abundantly) ) (VP (VBN expressed)  (NP (-NONE- *-48) ) (PP (IN in)  (NP (DT the)  (NN T-lymphocyte)  (NN cell)  (NN lineage) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Analysis) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ human) ) (CC and)  (ADJP (JJ murine) )) (NN GATA-3)  (NNS factors) ))) (VP (VBZ shows)  (NP (NP-COOD (NP (NP (DT a)  (JJ striking)  (NN degree) ) (PP (IN of)  (NP (NN amino)  (NN acid)  (NN sequence)  (NN identity) ))) (CC and)  (NP (NP (JJ similar)  (NNS patterns) ) (PP (IN of)  (NP (NP (NN tissue)  (NN specificity) ) (PP (IN of)  (NP (NN expression) )))))) (PP (IN in)  (NP (DT these)  (CD three)  (NNS organisms) )))) (. .) ) )
(TOP (S (NP-SBJ-49 (DT The)  (ADJP-COOD (ADJP (JJ murine) ) (CC and)  (ADJP (JJ human) )) (NNS factors) ) (VP-COOD (VP (VBP are)  (ADVP (RB abundantly) ) (VP (VBN expressed)  (NP (-NONE- *-49) ) (PP (IN in)  (NP (DT a)  (NN variety)  (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ human) ) (CC and)  (ADJP (JJ murine) )) (NN T-cell)  (NNS lines) )))))) (CC and)  (VP (MD can)  (VP (VB activate)  (NP (NN transcription) ) (PP (IN through)  (NP (NP (DT a)  (JJ tissue-specific)  (JJ GATA-binding)  (NN site) ) (VP (VBN identified)  (NP (-NONE- *) ) (PP (IN within)  (NP (DT the)  (JJ human)  (NN T-cell)  (NN receptor)  (NN delta)  (NN gene)  (NN enhancer) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP infer)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (ADJP-COOD (NP (JJ murine) ) (CC and)  (ADJP (JJ human) )) (NN GATA-3)  (NNS proteins) ) (VP (VBP play)  (NP (DT a)  (ADJP-COOD (ADJP (JJ central) ) (CC and)  (ADJP (RB highly)  (VBN conserved) )) (NN role) ) (PP (IN in)  (NP (NN vertebrate)  (JJ T-cell-specific)  (JJ transcriptional)  (NN regulation) )))))) (. .) ) )
(TOP (NP (NP (NN Processing) ) (PP (IN of)  (NP (NP (DT the)  (NN precursor) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))) (PP (IN by)  (NP (DT the)  (NN HIV-1)  (NN protease) )) (PP-TMP (IN during)  (NP (JJ acute)  (NN infection) )) (. .) ) )
(TOP (S (NP-SBJ-50 (NP (NN Transcription) ) (PP (IN of)  (NP (NP (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type-1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (NN genome) ))) (VP-COOD (VP (VBZ is)  (VP (VBN regulated)  (NP (-NONE- *-50) ) (PP (PP (IN in)  (NP (NN part) )) (IN by)  (NP-LGS (JJ cellular)  (NNS factors) )))) (CC and)  (VP (VBZ is)  (VP (VBN stimulated)  (NP (-NONE- *-50) ) (PP (IN by)  (NP-LGS (NP (NN activation) ) (PP (IN of)  (NP (ADJP (RB latently)  (JJ infected) ) (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN T-cell)  (NN activation) ) (ADVP (RB also) ) (VP (VBZ correlates)  (PP (IN with)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NP (DT the)  (NN factor)  (NN NF-kappa)  (NN B) ) (SBAR (WHNP-51 (WDT which) ) (S (NP-SBJ (-NONE- *T*-51) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (CD two)  (JJ adjacent)  (NNS sites) ) (PP (IN in)  (NP (DT the)  (NN HIV-1)  (JJ long)  (JJ terminal)  (NN repeat) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN factor) ) (VP (VBZ consists)  (PP (IN of)  (NP (NP (CD two)  (JJ DNA-binding)  (NNS subunits) ) (PP (IN of)  (NP (JJ relative)  (JJ molecular)  (NN mass)  (NP (NP (CD 50,000) ) (PRN (-LRB- -LRB-)  (NP (CD 50K) ) (-RRB- -RRB-) )))) (VP (VBN associated)  (NP (-NONE- *) ) (PP (IN with)  (NP (CD two)  (CD 65K)  (NNS subunits) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ located)  (PP (IN in)  (NP (NP (DT the)  (NN nucleus) ) (PP (IN in)  (NP (JJ mature)  (NN B)  (NNS cells) )))))) (, ,)  (CC but)  (VP (VBZ is)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (JJ other)  (NN cell)  (NNS types) )) (PP (IN as)  (NP (DT an)  (JJ inactive)  (JJ cytoplasmic)  (NN complex) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ External)  (NNS stimuli) ) (, ,)  (PP (VBG including)  (NP (NP (DT those) ) (SBAR (WHNP-52 (WDT that) ) (S (NP-SBJ (-NONE- *T*-52) ) (VP (VBP activate)  (NP (NN T)  (NNS cells) )))))) (, ,) ) (VP (VBP result)  (PP (IN in)  (NP (NP (JJ nuclear)  (NN translocation) ) (PP (IN of)  (NP (JJ active)  (NN NF-kappa)  (NN B) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN cloning) ) (PP (IN of)  (NP (NP (DT the)  (JJ complementary)  (NN DNA) ) (PP (IN for)  (NP (DT the)  (CD 50K)  (NN subunit) ))))) (VP (VBD helped)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB identify)  (NP (NP (DT an)  (ADJP (RB exclusively)  (JJ cytoplasmic) ) (CD 105K)  (NN precursor) ) (PRN (-LRB- -LRB-)  (NP (NN p105) ) (-RRB- -RRB-) )) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NNP V.B.) ) (, ,)  (NP (NNP P.K.) ) (CC and)  (NP (NNP A.I.) )) (, ,)  (FRAG (NP (NP (NN manuscript) ) (VP (VBN submitted)  (NP (-NONE- *) )))) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (NP-SBJ-54 (NP (DT The)  (NN expression) ) (PP (IN of)  (NP (JJ active)  (NN NF-kappa)  (NN B) ))) (VP (MD might)  (ADVP (RB therefore) ) (ADVP (RB also) ) (VP (VB be)  (VP (VBN regulated)  (NP (-NONE- *-54) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN extent) ) (PP (IN of)  (NP (NP (NN processing) ) (PP (IN of)  (NP (NN p105) ))))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Because)  (S (NP-SBJ (NN HIV-1) ) (VP (VBZ requires)  (NP (JJ active)  (NN NF-kappa)  (NN B) ) (PP (IN for)  (NP (JJ efficient)  (NN transcription) ))))) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD tested)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NN HIV-1)  (NN infection) )) (PP (IN on)  (NP (NP (DT the)  (NN processing) ) (PP (IN of)  (NP (DT the)  (JJ human)  (CD 105K)  (NN precursor) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN HIV-1)  (NN protease) ) (VP-COOD (VP (MD can)  (VP (VB process)  (NP (NN p105) ))) (CC and)  (VP (VBZ increases)  (NP (NP (NNS levels) ) (PP (IN of)  (NP (JJ active)  (JJ nuclear)  (NN NF-kappa)  (NN B)  (NN complex) )))))))) (. .) ) )
(TOP (NP (NP (NN Vitamin)  (NN D)  (NN receptor)  (NN expression) ) (PP (IN in)  (NP (JJ human)  (NNS lymphocytes) )) (. .) ) )
(TOP (NP (NP-COOD (NP (NN Signal)  (NNS requirements) ) (CC and)  (NP (NN characterization) )) (PP (IN by)  (NP-COOD (NP (NN western)  (NNS blots) ) (CC and)  (NP (NN DNA)  (NN sequencing) ))) (. .) ) )
(TOP (S (NP-SBJ-COOD-63 (NP (NP (DT The)  (NNS signals) ) (VP (VBG controlling)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NP (DT the)  (NN receptor)  (NN protein) ) (PP (IN for)  (NP (CD 1)  (NN alpha,25-dihydroxyvitamin)  (NN D3) )))) (PP (IN in)  (NP (JJ normal)  (JJ human)  (NNS lymphocytes) ))))) (CC and)  (NP (NP (DT the)  (NN relationship) ) (PP (IN of)  (NP (DT this)  (NN protein) )) (PP (TO to)  (NP (DT the)  (JJ classical)  (NN vitamin)  (NN D)  (NN receptor) )))) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-63) ))) (. .) ) )
(TOP (S (NP-SBJ-64 (NP (NNS Lymphocytes) ) (VP (VBN activated)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (DT the)  (NN OKT3)  (NN antibody) ) (PP (TO to)  (NP (DT the)  (NN T-cell)  (NN antigen)  (NN receptor) )))))) (VP (VBD expressed)  (NP (JJR fewer)  (VBG binding)  (NNS sites) ) (SBAR (IN as)  (S (NP-SBJ-65 (-NONE- *-64) ) (VP (VBN compared)  (NP (-NONE- *-65) ) (PP (TO to)  (NP (NP (NNS lymphocytes) ) (SBAR (WHNP-66 (WDT that) ) (S (NP-SBJ-67 (-NONE- *T*-66) ) (VP (VBD were)  (VP (VBN activated)  (NP (-NONE- *-67) ) (PP (IN by)  (NP-LGS (NP (DT the)  (JJ polyclonal)  (NN activator)  (NN phytohemagglutinin) ) (PRN (-LRB- -LRB-)  (NP (NN PHA) ) (-RRB- -RRB-) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (NN combination) ) (PP (IN of)  (NP-COOD (NP (NN OKT3) ) (CC and)  (NP (NN phorbol)  (NN myristate)  (NN acetate) )))) (VP (VBD produced)  (NP (NP (DT a)  (NN concentration) ) (PP (IN of)  (NP (VBG binding)  (NNS sites) )) (ADJP (JJ similar)  (PP (TO to)  (NP (DT the)  (JJ PHA-activated)  (NNS cells) ))))) (. .) ) )
(TOP (S (NP-SBJ-68 (NP (DT The)  (NN receptor) ) (PP (IN from)  (NP (ADJP-COOD (ADJP (NP (NN OKT3) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (NN OKT3)  (CC +)  (NN phorbol)  (NN myristate)  (JJ acetate-activated) )) (NNS lymphocytes) ))) (VP (VBD exhibited)  (NP (NP (VBN decreased)  (NN binding) ) (PP (TO to)  (NP (NN DNA-cellulose) ))) (S (NP-SBJ-70 (-NONE- *-68) ) (VP (VBN compared)  (NP (-NONE- *-70) ) (PP (TO to)  (NP (JJ PHA-activated)  (NNS lymphocytes) ))))) (. .) ) )
(TOP (S (PP-COOD (PP (IN In)  (NP (NP (NNS lymphocytes) ) (VP (VBN activated)  (NP (-NONE- *) ) (PP (CC either)  (IN by)  (NP-LGS-COOD (NP (NN PHA) ) (CC or)  (NP (NN OKT3) )))))) (-LRB- -LRB-)  (CC but)  (PP (RB not)  (IN in)  (NP (VBG resting)  (NNS cells) )) (-RRB- -RRB-) ) (, ,)  (NP-SBJ-71 (NP (DT a)  (JJ 50-kDa)  (NNS species) ) (VP (VBG cross-reacting)  (PP (IN with)  (NP (NP (DT a)  (JJ monoclonal)  (NN antibody) ) (PP (IN against)  (NP (DT the)  (JJ intestinal)  (NN vitamin)  (NN D)  (NN receptor) )))))) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-71) ))) (. .) ) )
(TOP (S (ADVP-TMP (RB Finally) ) (, ,)  (NP-SBJ-72 (NP (NN RNA) ) (PP (IN from)  (NP (VBN activated)  (NNS lymphocytes) ))) (VP (VBD was)  (VP (VBN amplified)  (NP (-NONE- *-72) ) (PP (IN by)  (NP (NN polymerase)  (NN chain)  (NN reaction) )) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (NP (NN oligonucleotide)  (NNS primers) ) (VP (VBG flanking)  (NP (NP (DT the)  (CD 196)  (NN base)  (NN pair)  (JJ long)  (NN region) ) (VP (VBG encoding)  (NP (NP (DT the)  (JJ DNA-binding)  (NN domain) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ intestinal)  (NN receptor) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (VBN amplified)  (NN product) ) (VP (VBD showed)  (NP (NP (DT an)  (JJ identical)  (NN nucleotide)  (NN sequence) ) (PP (TO to)  (NP (NP (DT the)  (JJ DNA-binding)  (NN domain) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ intestinal)  (NN receptor) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP suggest)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ-74 (NP (NN expression) ) (PP (IN of)  (NP (DT the)  (NN 1,25--LRB-OH-RRB-2D3)  (NN receptor) )) (PP (IN in)  (NP (NNS lymphocytes) ))) (VP (VBZ is)  (VP (VBN triggered)  (NP (-NONE- *-74) ) (PP (IN by)  (NP-LGS (ADJP-COOD (ADJP (JJ distinct) ) (CC and)  (ADJP (JJ contingent) )) (NNS signals) )))))) (, ,)  (CC and)  (SBAR (IN that)  (S (NP-SBJ (NP-COOD (NP (DT the)  (NN protein) ) (CC and)  (NP (DT the)  (NN mRNA) )) (VP (VBG encoding)  (NP (PRP it) ))) (VP (VBP are)  (ADJP-PRD (JJ identical)  (PP (TO to)  (NP (DT the)  (JJ classical)  (NN vitamin)  (NN D)  (NN receptor) )))))))) (. .) ) )
(TOP (NP (NP (NN Cloning) ) (PP (IN of)  (NP (NP (JJ murine)  (NN TCF-1) ) (, ,)  (NP (NP (DT a)  (ADJP (NN T)  (JJ cell-specific) ) (NN transcription)  (NN factor) ) (VP (VBG interacting)  (PP (IN with)  (NP (NP (JJ functional)  (NNS motifs) ) (PP (IN in)  (NP (DT the)  (NN CD3-epsilon)  (CC and)  (NN T)  (NN cell)  (NN receptor)  (NN alpha)  (NNS enhancers) )))))))) (. .) ) )
(TOP (S (NP-SBJ-44 (NN CD3-epsilon)  (NN gene)  (NN expression) ) (VP (VBZ is)  (VP (VBN confined)  (NP (-NONE- *-44) ) (PP (TO to)  (NP (DT the)  (NN T)  (NN cell)  (NN lineage) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (ADVP-TMP (RB recently) ) (VP-COOD (VP (VBN identified)  (NP (-NONE- *RNR*-45) )) (CC and)  (VP (VBN cloned)  (NP (-NONE- *RNR*-45) ))) (NP-45 (NP (NP (DT a)  (JJ human)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN TCF-1) ) (, ,) ) (SBAR (WHNP-46 (WDT that) ) (S (NP-SBJ (-NONE- *T*-46) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (DT a)  (JJ functional)  (NN element) ) (PP (IN in)  (NP (NP (DT the)  (ADJP (NN T)  (JJ lymphocyte-specific) ) (NN enhancer) ) (PP (IN of)  (NP (NN CD3-epsilon) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (DT a)  (NN panel) ) (PP (IN of)  (NP (JJ human)  (NN cell)  (NNS lines) )))) (, ,)  (NP-SBJ (NN TCF-1)  (NN expression) ) (VP (VBD was)  (ADJP-PRD (JJ restricted)  (PP (TO to)  (NP (NN T)  (NN lineage)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NN TCF-1) ) (VP (VBD belonged)  (PP (TO to)  (NP (NP (DT a)  (JJ novel)  (NN family) ) (PP (IN of)  (NP (NP (NNS genes) ) (SBAR (WHNP-47 (WDT that) ) (S (NP-SBJ (-NONE- *T*-47) ) (VP (VBP contain)  (NP (DT the)  (JJ so-called)  (JJ high)  (NN mobility)  (NN group)  (CD 1)  (-LRB- -LRB-)  (NN HMG)  (-RRB- -RRB-)  (NN box) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP report)  (NP (NP (DT the)  (NN cloning) ) (PP (IN of)  (NP (JJ murine)  (NN TCF-1) )))) (. .) ) )
(TOP (S (NP-SBJ-48 (NP (CD Two)  (NN splice)  (NNS alternatives) ) (SBAR (-NONE- *ICH*-49) )) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-48) ) (SBAR-49 (WHNP-50 (WDT that) ) (S (NP-SBJ-51 (-NONE- *T*-50) ) (VP (VBD were)  (RB not)  (ADVP-TMP (RB previously) ) (VP (VBN observed)  (NP (-NONE- *-51) ) (PP (IN in)  (NP (JJ human)  (NN TCF-1) )))))))) (. .) ) )
(TOP (S (NP-SBJ (ADJP-COOD (ADJP (JJ Murine) ) (CC and)  (ADJP (JJ human) )) (NN TCF-1) ) (VP (VBD displayed)  (NP (DT a)  (QP (CD 95.5)  (NN %) ) (JJ overall)  (NN amino)  (NN acid)  (NN homology) )) (. .) ) )
(TOP (S (NP-SBJ (JJ Recombinant)  (ADJP-COOD (ADJP (JJ murine) ) (CC and)  (ADJP (JJ human) )) (NN TCF-1) ) (VP (VBD recognized)  (NP (DT the)  (JJ same)  (NN sequence)  (NN motif) ) (PP (IN in)  (NP (DT the)  (NN CD3-epsilon)  (NN enhancer) )) (SBAR (IN as)  (S (NP-SBJ-52 (-NONE- *) ) (VP (VBN judged)  (NP (-NONE- *-52) ) (PP (IN by)  (NP (NP-COOD (NP (NN gel)  (NN retardation) ) (CC and)  (NP (NN methylation)  (NN interference) )) (NNS assays) )))))) (. .) ) )
(TOP (S (PP (IN With)  (NP (DT the)  (JJ murine)  (NN cDNA)  (NNS clones) )) (NP-SBJ-53 (NP (JJ several)  (NNS aspects) ) (PP (IN of)  (NP (NN TCF-1) ))) (VP (VBD were)  (VP (VBN analyzed)  (NP (-NONE- *-53) ))) (. .) ) )
(TOP (S (ADVP (RB First) ) (, ,)  (NP-SBJ (NN deletion)  (NN analysis) ) (VP (VBD revealed)  (SBAR (IN that)  (S (NP-SBJ (NP (DT a)  (NN region) ) (PP (IN of)  (NP (NN TCF-1) )) (VP (VBG containing)  (NP (DT the)  (NN HMG)  (NN box) ))) (VP (VBD was)  (ADJP-PRD (JJ sufficient)  (PP (IN for)  (NP (JJ sequence-specific)  (NN binding) ))))))) (. .) ) )
(TOP (S (ADVP (RB Second) ) (, ,)  (PP (IN by)  (NP-COOD (NP (JJ high)  (NN stringency)  (NN Northern)  (NN blotting) ) (CC and)  (NP (ADJP (FW in)  (FW situ) ) (NN hybridization) ))) (, ,)  (NP-SBJ-54 (NN TCF-1)  (NN expression) ) (VP (VBD was)  (VP (VBN shown)  (S (NP-SBJ-55 (-NONE- *-54) ) (VP (TO to)  (VP (VB be)  (VP (VBN confined)  (NP (-NONE- *-55) ) (PP-COOD (PP (TO to)  (NP (DT the)  (NN thymus) )) (CC and)  (PP (TO to)  (NP (NP (DT the)  (NN T)  (NN cell)  (NNS areas) ) (PP (IN of)  (NP (DT the)  (NN spleen) ))))))))))) (. .) ) )
(TOP (S (ADVP (RB Third) ) (, ,)  (NP-SBJ (NN TCF-1) ) (VP (VBD bound)  (ADVP (RB specifically) ) (PP (TO to)  (NP (NP (DT a)  (JJ functional)  (ADJP (NN T)  (JJ cell-specific) ) (NN element) ) (PP (IN in)  (NP (DT the)  (NP (NP (NN T)  (NN cell)  (NN receptor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN TCR-alpha) ) (-RRB- -RRB-) )) (NN enhancer) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (DT The)  (ADJP (NN T)  (JJ lineage-specific) ) (NN expression) ) (CC and)  (NP (NP (DT the)  (NN affinity) ) (PP (IN for)  (NP (NP (JJ functional)  (NNS motifs) ) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN TCR-alpha) ) (CC and)  (NP (NN CD3-epsilon) )) (NNS enhancers) )))))) (VP (VBP imply)  (NP (NP (DT an)  (JJ important)  (NN role) ) (PP (IN for)  (NP (NN TCF-1) )) (PP (IN in)  (NP (NP (DT the)  (NN establishment) ) (PP (IN of)  (NP (DT the)  (JJ mature)  (NN T)  (NN cell)  (NN phenotype) )))))) (. .) ) )
(TOP (NP (NP (NP (NN HIV)  (NN enhancer)  (NN activity) ) (VP (VBN perpetuated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (NN NF-kappa)  (NN B)  (NN induction) ) (PP (IN on)  (NP (NP (NN infection) ) (PP (IN of)  (NP (NNS monocytes) )))))))) (S (-LRB- -LCB-)  (NP-SBJ (-NONE- *) ) (VP (VB see)  (NP (NNS comments) )) (-RRB- -RCB-) )) )
(TOP (S (NP-SBJ (NP (NN Permissiveness) ) (PP (TO to)  (NP (NP (NN replication) ) (PP (IN of)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )))))) (VP (VBZ differs)  (PP (IN in)  (NP-COOD (NP (NN T)  (NNS lymphocytes) ) (CC and)  (NP (NNS macrophages) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN T)  (NNS cells) )) (, ,)  (NP-SBJ-306 (NN HIV)  (NN transcription) ) (VP (VBZ is)  (ADVP (RB poorly) ) (VP (VBN detected)  (NP (-NONE- *-306) ) (ADVP (FW in)  (FW vivo) ))) (. .) ) )
(TOP (S (NP-SBJ (ADJP-COOD (ADJP (VBN Cloned) ) (, ,)  (ADJP (JJ normal) )) (NN T)  (NNS lymphocytes) ) (VP (VBP show)  (NP-COOD (NP (NP (ADJP (RB very)  (JJ little) ) (PRN (, ,)  (SBAR (IN if)  (FRAG (DT any) )) (, ,) ) (JJ basal)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN HIV)  (NN enhancer) ))) (CC and)  (NP (NP (JJ low)  (JJ nuclear)  (NN expression) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B) ) (, ,)  (NP (NP (DT a)  (JJ potent)  (JJ transcriptional)  (NN activator) ) (PP (IN of)  (NP (DT the)  (NN HIV)  (NN enhancer) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-307 (JJ fixed)  (NN tissue)  (NNS macrophages) ) (VP (VBP express)  (NP (JJ detectable)  (NN HIV)  (NNS proteins) ) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (NP (JJ permanent)  (NN virus)  (NN transcription) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (CD One)  (NN explanation) ) (PP (IN for)  (NP (NP (DT the)  (NN perpetuation) ) (PP (IN of)  (NP (NP (NN virus)  (NN infection) ) (PP (IN in)  (NP (NNS macrophages) ))))))) (VP (MD could)  (VP (VB be)  (NP-PRD (JJ sustained)  (JJ nuclear)  (NN NF-kappa)  (NN B)  (NN expression) ))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-309 (NP (DT the)  (NN U937)  (JJ monocytic)  (NN cell)  (NN line) ) (, ,)  (SBAR (WHNP-308 (WDT which) ) (S (NP-SBJ (-NONE- *T*-308) ) (VP (VBZ is)  (ADJP-PRD (RB fully)  (JJ permissive)  (PP (TO to)  (NP (NN HIV)  (NN replication) )))))) (, ,) ) (VP (VBZ is)  (VP (VBN known)  (S (NP-SBJ (-NONE- *-309) ) (VP (TO to)  (VP (VB express)  (NP (NP (ADJP (RB only)  (JJ low) ) (NNS levels) ) (PP (IN of)  (NP (JJ nuclear)  (NN NF-kappa)  (NN B) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ (JJ chronic)  (VBP HIV)  (NN infection) ) (VP (VBZ results)  (PP (IN in)  (NP-COOD (CC both)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NP (DT a)  (JJ nuclear)  (NN factor) ) (PP (IN with)  (NP (NP (JJ antigenic)  (NNS properties) ) (ADJP (JJ indistinguishable)  (PP (IN from)  (NP (DT those)  (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))))))))) (CC and)  (NP (ADJP (RB permanently)  (VBN increased) ) (NN HIV)  (NN enhancer)  (NN activity) ))))))) (. .) ) )
(TOP (S (NP-SBJ-311 (NP (DT This)  (NN phenomenon) ) (, ,)  (SBAR (WHNP-310 (WDT which) ) (S (NP-SBJ (-NONE- *T*-310) ) (VP (VBZ is)  (ADJP-PRD (JJ independent)  (PP (IN of)  (NP (NN tumour)  (NN necrosis)  (NN factor) )))))) (, ,) ) (VP-COOD (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-311) ) (PP (IN with)  (NP (NN HIV)  (NN replication) )))) (, ,)  (CC and)  (VP (VBZ is)  (RB thus)  (ADJP-PRD (JJ likely)  (S (NP-SBJ (-NONE- *-311) ) (VP (TO to)  (VP (VB explain)  (PP (ADVP (IN at)  (JJS least) ) (IN in)  (NP (NN part) )) (NP (NP (DT the)  (NN perpetuation) ) (PP (IN of)  (NP (NP (NN HIV)  (NN infection) ) (PP (IN in)  (NP (NNS monocytes) ))))))))))) (. .) ) )
(TOP (NP (NP (NN Role) ) (PP (IN for)  (NP (DT the)  (JJ Epstein-Barr)  (NN virus)  (JJ nuclear)  (NN antigen)  (CD 2) )) (PP (IN in)  (NP (NP (JJ viral)  (NN promoter)  (VBG switching) ) (PP-TMP (IN during)  (NP (NP (JJ initial)  (NNS stages) ) (PP (IN of)  (NP (NN infection) )))))) (. .) ) )
(TOP (S (PP-TMP (IN During)  (NP (NP (JJ latent)  (NP (NP (JJ Epstein-Barr)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN EBV) ) (-RRB- -RRB-) )) (NN infection) ) (PP (IN of)  (NP (JJ human)  (NN B)  (NNS lymphocytes) )))) (, ,)  (NP-SBJ-52 (NP (CD six)  (JJ viral)  (JJ nuclear)  (NN antigen) ) (PRN (-LRB- -LRB-)  (NP (NNS EBNAs) ) (-RRB- -RRB-) )) (VP (VBP are)  (VP (VBN expressed)  (NP (-NONE- *-52) ) (PP (IN from)  (NP (JJ long)  (JJ primary)  (NNS transcripts) )) (PP (IN by)  (NNS means)  (IN of)  (NP-COOD (NP (JJ alternative)  (NN splicing) ) (CC and)  (NP (JJ alternative)  (NN polyadenylylation)  (NNS sites) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS transcripts) ) (VP (VBP initiate)  (PP (IN from)  (NP (NP (CD one) ) (PP (IN of)  (NP (NP (NP (CD two)  (NNS promoters) ) (, ,)  (NP-COOD (NP (NN Cp) ) (CC or)  (NP (NN Wp) )) (, ,) ) (SBAR (WHNP-53 (WDT that) ) (S (NP-SBJ (-NONE- *T*-53) ) (VP (VBP function)  (PP (IN in)  (NP (DT a)  (ADJP (RB mutually)  (JJ exclusive) ) (NN fashion) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-54 (NN Wp) ) (VP (VBZ is)  (ADVP (RB exclusively) ) (VP (VBN utilized)  (NP (-NONE- *-54) ) (PP-TMP (IN during)  (NP (NP (DT the)  (JJ initial)  (NNS stages) ) (PP (IN of)  (NP (NP (NN infection) ) (PP (IN of)  (NP (JJ primary)  (NN B)  (NNS lymphocytes) )))))) (, ,)  (S (NP-SBJ-200 (-NONE- *) ) (VP (VBN followed)  (NP (-NONE- *-200) ) (PP (IN by)  (NP-LGS (NP (DT a)  (NN switch) ) (PP (TO to)  (NP (NN Cp)  (NN usage) )))))))) (. .) ) )
(TOP (S (NP-SBJ-55 (DT These)  (NNS studies) ) (VP (VBP have)  (VP (VBN been)  (VP (VBN extended)  (S (NP-SBJ (-NONE- *-55) ) (VP (TO to)  (VP (VB show)  (SBAR (IN that)  (S-COOD (S (LST (-LRB- -LRB-)  (LS i)  (-RRB- -RRB-) ) (NP-SBJ-56 (NP (DT a)  (JJ mutant)  (NN EBV)  (NN strain) ) (VP (VBG lacking)  (NP (NP (DT the)  (NN gene) ) (VP (VBG encoding)  (NP (NN EBNA)  (CD 2) ))))) (VP (VBZ fails)  (S (NP-SBJ (-NONE- *-56) ) (VP (TO to)  (VP (VB switch)  (PP (PP (IN from)  (NP (NN Wp)  (NP (-NONE- *RNR*-201) ))) (PP (TO to)  (NP (NN Cp)  (NP (-NONE- *RNR*-201) ))) (NP-201 (NN usage) )) (PP (IN in)  (NP (JJ primary)  (NN B)  (NNS lymphocytes) )) (, ,)  (SBAR (IN although)  (S (NP-SBJ (DT the)  (NN virus) ) (VP (VBZ contains)  (NP (DT a)  (JJ functional)  (NN Cp) ))))))))) (: ;)  (S (LST (-LRB- -LRB-)  (LS ii)  (-RRB- -RRB-) ) (NP-SBJ (NP (DT a)  (NN region) ) (NP (QP (IN from)  (CD -429)  (TO to)  (CD -245) ) (NN base)  (NNS pairs) ) (ADJP (JJ upstream)  (PP (IN of)  (NP (NN Cp) )))) (VP (VBZ is)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (NP (NN Cp)  (NN activity) ) (PP (IN in)  (NP (NN B)  (NNS lymphocytes) )))) (, ,)  (CC but)  (PP (RB only)  (IN in)  (NP (NP (DT the)  (NN context) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ upstream) ) (CC and)  (ADJP (JJ downstream) )) (NNS sequences) ))))))) (: ;)  (S (LST (-LRB- -LRB-)  (LS iii)  (-RRB- -RRB-) ) (NP-SBJ (DT this)  (NN region) ) (VP (VBZ contains)  (NP (DT an)  (NN EBNA)  (JJ 2-dependent)  (NN enhancer) ))) (: ;)  (CC and)  (S (LST (-LRB- -LRB-)  (LS iv)  (-RRB- -RRB-) ) (NP-SBJ (NP (NN DNase)  (CD I)  (NN protection) ) (VP (VBG employing)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP (NP-COOD (NP (NN B) ) (CC and)  (NP (NN T) )) (NNS lymphocytes) ))))) (VP (VBD revealed)  (NP (NP (DT a)  (JJ B-cell-specific)  (NN footprint) ) (PP (IN in)  (NP (NP (DT the)  (NN region) ) (PP (IN of)  (NP (DT the)  (ADJP (NN EBNA)  (JJ 2-dependent) ) (NN enhancer) ))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP support)  (NP (NP (DT a)  (NN model) ) (PP (IN for)  (NP (NP (JJ viral)  (NN promoter)  (NN switching) ) (PP-TMP (IN during)  (NP (NP (DT the)  (JJ initial)  (NNS stages) ) (PP (IN of)  (NP (NN infection) ))) (SBAR (WHPP-57 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (NN Wp)  (NN activity) ) (VP (VBZ leads)  (PP (TO to)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NN EBNA)  (CD 2) )))) (PP (-NONE- *T*-57) ) (, ,)  (S-ADV (NP-SBJ-202 (-NONE- *) ) (VP (VBN followed)  (NP (-NONE- *-202) ) (PP (IN by)  (NP-LGS (NP (NP (NN activation) ) (PP (IN of)  (NP (NN Cp) ))) (PP (IN through)  (NP (DT the)  (ADJP (NN EBNA)  (JJ 2-dependent) ) (NN enhancer) )))))))))))))) (. .) ) )
(TOP (NP (NP (NN Glucocorticoid)  (NN receptor)  (NNS characteristics) ) (PP (IN in)  (NP (NP (NNS monocytes) ) (PP (IN of)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ corticosteroid-resistant)  (JJ bronchial)  (NN asthma) )))))) (. .) ) )
(TOP (S (NP-SBJ-46 (NP (DT The)  (NN mechanism) ) (PP (IN of)  (NP (NN corticosteroid)  (NN resistance) )) (PP (IN in)  (NP (JJ bronchial)  (NN asthma) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN studied)  (NP (-NONE- *-46) ) (PP (IN by)  (S (NP-SBJ (-NONE- *) ) (VP (VBG determining)  (NP (NP (DT the)  (NN rank)  (NN order) ) (PP (IN of)  (NP (NN potency) )) (PP (IN for)  (NP (JJ different)  (NNS corticosteroids) )) (PP (IN in)  (S (NP-SBJ (-NONE- *) ) (VP (VP (VBG inhibiting)  (NP (NP (DT the)  (NN generation) ) (PP (IN of)  (NP (DT a)  (ADJP (CD 3)  (NN kD) ) (NN molecule) )) (PP (IN from)  (NP (NP (JJ peripheral)  (NN blood)  (NNS monocytes) ) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (ADJP-COOD (ADJP (ADJP (JJ corticosteroid-sensitive) ) (PRN (-LRB- -LRB-)  (ADJP (JJ CS) ) (-RRB- -RRB-) )) (CC and)  (ADJP (ADJP (JJ corticosteroid-resistant) ) (PRN (-LRB- -LRB-)  (ADJP (JJ CR) ) (-RRB- -RRB-) ))) (JJ asthmatic)  (NNS subjects) )))))))) (, ,)  (SBAR (WHNP-47 (WDT which) ) (S (NP-SBJ (-NONE- *T*-47) ) (VP (VBZ augments)  (NP (NP (NP (NP (NN leukotriene)  (NN B4) ) (PRN (-LRB- -LRB-)  (NP (NN LTB4) ) (-RRB- -RRB-) )) (NN generation) ) (PP (IN by)  (NP (NP (NP (JJ human)  (NNS neutrophils) ) (PRN (-LRB- -LRB-)  (NP (NN PMN) ) (-RRB- -RRB-) )) (VP (VBN stimulated)  (NP (-NONE- *) ) (PP (IN by)  (NP (NN calcium)  (NN ionophore) ))))))))))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ-49 (NP (VBG binding)  (NNS studies) ) (PP (IN with)  (NP (-LRB- -LRB-)  (NN 3H)  (-RRB- -RRB-)  (NN dexamethasone) ))) (VP (VBP have)  (VP (VBN been)  (VP (VBN performed)  (NP (-NONE- *-49) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB determine)  (NP (NP-COOD (NP (NP (DT the)  (NN dissociation)  (NN constant) ) (PRN (-LRB- -LRB-)  (NP (NN Kd) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN receptor)  (NNS numbers) ) (PRN (-LRB- -LRB-)  (NP (NN Ro) ) (-RRB- -RRB-) ))) (PP (IN in)  (NP (NP (DT the)  (NNS monocytes) ) (PP (IN of)  (NP (NP (DT these)  (CD two)  (NNS groups) ) (PP (IN of)  (NP (NNS subjects) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN concentration) ) (PP (IN of)  (NP (NP (NN corticosteroid) ) (VP (VBG producing)  (NP (NP (CD 50)  (NN %)  (NN inhibition) ) (PRN (-LRB- -LRB-)  (NP (NN IC50) ) (-RRB- -RRB-) )))))) (VP (VBD was)  (NP-PRD-COOD (NP (NP-54 (CD 600)  (NN nM) ) (PP (-NONE- *ICH*-50) )) (, ,)  (NP (NP=54 (CD 70)  (NN nM) ) (NP=51 (-NONE- *ICH*-52) )) (, ,)  (CC and)  (NP (NP=54 (CD 0.5)  (NN nM) ) (NP=51 (-NONE- *ICH*-53) ))) (PP-50 (IN for)  (NP-51 (NN hydrocortisone) )) (, ,)  (NP-52 (NN methylprednisolone) ) (, ,)  (CC and)  (NP-53 (NN dexamethasone) ) (, ,)  (ADVP (RB respectively) ) (, ,)  (PP (IN in)  (NP (NP (NNS monocytes) ) (PP (IN from)  (NP (JJ CS)  (NNS individuals) ))))) (. .) ) )
(TOP (S (NP-SBJ (EX There) ) (VP (VBD was)  (NP-PRD (NP (ADJP (RB only)  (JJ weak) ) (NN inhibition) ) (PP (IN of)  (NP (NP (DT the)  (NN generation) ) (PP (IN of)  (NP (NN enhancing)  (NN activity) )))) (PP (IN by)  (NP (DT the)  (NNS corticosteroids) ))) (PP (IN in)  (NP (DT the)  (ADJP (JJ CR)  (JJ asthmatic) ) (NNS individuals) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN dexamethasone)  (NN Kd) ) (VP (VP-COOD (VP (VBD was)  (NP-PRD-55 (NP (QP (CD 2.45) (CC  +/-)  (CD 0.58) ) (NN nM) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN mean) ) (CC +/-)  (NP (NN SEM) )) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD (CD 6) ))) (-RRB- -RRB-) )) (PP-56 (IN in)  (NP (DT the)  (NP (JJ CS) ) (NN group) ))) (CC and)  (VP (NP-PRD=55 (NP (QP (CD 1.6) (CC  +/-)  (CD 0.35) ) (NN nM) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN mean) ) (CC +/-)  (NP (NN SEM) )) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD (CD 6) ))) (-RRB- -RRB-) )) (PP=56 (IN in)  (NP (DT the)  (NP (JJ CR) ) (NN group) ) (PP (IN of)  (NP (NNS patients) ))))) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (VP (JJ =)  (NP-PRD (CD 0.14) ))) (-RRB- -RRB-) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN Ro) ) (VP (VP-COOD (VP (PP-58 (IN in)  (NP (DT the)  (JJ CS)  (NN group) )) (VBD was)  (NP-PRD-59 (QP (CD 3,605) (CC  +/-)  (CD 984) ) (VBG binding)  (NNS sites) ) (PP-60 (IN per)  (NP (NN nucleus) )) (PRN-61 (-LRB- -LRB-)  (NP-COOD (NP (NN mean) ) (CC +/-)  (NP (NN SEM) )) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD (CD 6) ))) (-RRB- -RRB-) )) (CC and)  (VP (NP-PRD=59 (QP (CD 4,757) (CC  +/-)  (CD 692) ) (VBG binding)  (NNS sites) ) (PP=60 (IN per)  (NP (NN nucleus) )) (PRN=61 (-LRB- -LRB-)  (NP-COOD (NP (NN mean) ) (CC +/-)  (NP (NN SEM) )) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD (CD 6) ))) (-RRB- -RRB-) ) (PP=58 (IN in)  (NP (DT the)  (JJ CR)  (NN group) )))) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (VP (JJ =)  (NP-PRD (CD 0.23) ))) (-RRB- -RRB-) )) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-62 (NP (NN corticosteroid)  (NN resistance) ) (PP (IN in)  (NP (JJ bronchial)  (NN asthma) ))) (VP (MD can)  (RB not)  (VP (VB be)  (VP (VBN explained)  (NP (-NONE- *-62) ) (PP (IN by)  (NP (NP (NNS abnormalities) ) (PP (IN in)  (NP (NP (NN corticosteroid)  (NN receptor) ) (NNS characteristics) )))))))))) (. .) ) )
(TOP (NP (NP (ADJP (JJ Tissue-specific) ) (NN expression) ) (PP (IN of)  (NP (DT the)  (NN platelet)  (NN GPIIb)  (NN gene) )) (. .) ) )
(TOP (S (NP-SBJ (NP (CD One) ) (PP (IN of)  (NP (NP (DT the)  (JJ major)  (NNS objectives) ) (PP (IN in)  (NP (NP (DT the)  (NN study) ) (PP (IN of)  (NP (NN thrombogenesis) ))))))) (VP (VBZ is)  (S-PRD (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB determine)  (NP (NP (DT the)  (NNS mechanisms) ) (SBAR (WHPP-43 (IN by)  (WHNP (WDT which) )) (S (NP-SBJ-44 (DT a)  (JJ hematopoietic)  (NN progenitor) ) (VP (VBZ is)  (VP (VP-COOD (VP (VBN activated)  (NP (-NONE- *-44) )) (CC and)  (VP (VBN committed)  (NP (-NONE- *-44) ) (PP (TO to)  (NP (DT the)  (JJ megakaryocytic)  (NN lineage) )))) (PP (-NONE- *T*-43) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (JJ Recent)  (NN development) ) (PP (IN of)  (NP (NP (JJ primary)  (NNS cultures) ) (PP (IN of)  (NP (JJ human)  (NNS megakaryocytes) ))))) (CC and)  (NP (NP (DT the)  (JJ molecular)  (NN cloning) ) (PP (IN of)  (NP (NP (NNS genes) ) (SBAR (WHNP-46 (WDT that) ) (S (NP-SBJ (-NONE- *T*-46) ) (VP (VBP are)  (ADJP-PRD (JJ specific)  (PP (TO to)  (NP (DT this)  (NN lineage) )))))))))) (VP (VBP offer)  (NP (NP (DT the)  (NN possibility) ) (PP (IN of)  (S (NP-SBJ (-NONE- *) ) (VP (VBG getting)  (NP (NP (DT some)  (NNS insights) ) (PP (IN into)  (NP (NP (DT the)  (JJ genetic)  (NNS mechanisms) ) (SBAR (WHNP-47 (WDT that) ) (S (NP-SBJ (-NONE- *T*-47) ) (VP (VBP control)  (NP (NNS megakaryocytopoiesis) )))))))))))) (. .) ) )
(TOP (S (S (NP-SBJ (NP (CD One)  (NN gene) ) (PP (IN of)  (NP (NN interest) ))) (VP (VBZ is)  (NP-PRD (DT the)  (NP (NP (NN glycoprotein)  (NN IIb) ) (PRN (-LRB- -LRB-)  (NP (NN GPIIb) ) (-RRB- -RRB-) )) (NN gene) )) (: ;) ) (S-COOD (S (NP-SBJ-48 (NP (NN GPIIb) ) (, ,)  (NP (NP (DT the)  (NN alpha)  (NN subunit) ) (PP (IN of)  (NP (DT the)  (NN platelet)  (NN cytoadhesin)  (NN GPIIb-IIIa) ))) (, ,) ) (VP (VBZ is)  (VP (VBN produced)  (NP (-NONE- *-48) ) (PP (IN in)  (NP (NNS megakaryocytes) )) (PP-TMP (IN at)  (NP (NP (DT an)  (JJ early)  (NN stage) ) (PP (IN of)  (NP (DT the)  (NN differentiation) ))))))) (, ,)  (IN whereas)  (S (NP-SBJ-49 (NP (NP (DT the)  (JJ other)  (NN subunit) ) (PP (IN of)  (NP (DT this)  (NN complex) ))) (, ,)  (NP (NN GPIIIa) ) (, ,) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-49) ) (PP (IN in)  (NP (JJ other)  (NNS cells) ))))) (. .) )) )
(TOP (S (PP (IN For)  (NP (DT these)  (NNS reasons) )) (, ,)  (NP-SBJ-50 (NP (DT the)  (JJ 5'-flanking)  (NN region) ) (PP (IN of)  (NP (DT the)  (NN GPIIb)  (NN gene) ))) (VP (VBD was)  (VP (VBN used)  (NP (-NONE- *-50) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB identify)  (NP (NP (DT the)  (NNS regions) ) (SBAR (WHNP-51 (WDT that) ) (S (NP-SBJ (-NONE- *T*-51) ) (VP (VBP interact)  (PP (IN with)  (NP (JJ DNA-binding)  (JJ nuclear)  (NNS factors) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-52 (NP (DT A)  (NN fragment) ) (VP (VBG extending)  (PP-COOD (PP (IN from)  (NP (CD -643) )) (PP (TO to)  (NP (CD +33) ))))) (VP (VBZ is)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-52) ) (VP (VBG controlling)  (NP (NP (DT the)  (JJ tissue-specific)  (NN expression) ) (PP (IN of)  (NP (DT the)  (NN CAT)  (NN gene) ))) (PP (IN in)  (NP (NN transfection)  (NNS experiments) ))))))) (. .) ) )
(TOP (S (PP (IN Within)  (NP (DT this)  (NN region) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP have)  (VP (VBN identified)  (NP (NP (JJ several)  (NNS sequences) ) (SBAR (WHNP-53 (WDT that) ) (S (NP-SBJ-54 (-NONE- *T*-53) ) (VP (VBP are)  (VP (VBN implicated)  (NP (-NONE- *-54) ) (PP (IN in)  (NP (NN DNA)  (NN protein)  (NNS interactions) )) (SBAR (IN as)  (S (NP-SBJ-55 (-NONE- *) ) (VP (VBN shown)  (NP (-NONE- *-55) ) (PP (IN in)  (NP-COOD (NP (NN DNAse)  (NN I)  (NNS footprints) ) (CC and)  (NP (NN gel)  (NN mobility)  (NN shift)  (NNS assays) ))))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (CD One)  (NN region) ) (, ,)  (ADJP (VBN centered)  (PP (IN at)  (NP (CD -54) ))) (, ,) ) (VP (VBZ is)  (ADJP-PRD (JJ similar)  (PP (TO to)  (NP (DT a)  (ADJP (JJ nuclear)  (NN factor)  (JJ E1-binding) ) (NN site) ))))) (, ,)  (CC and)  (S (NP-SBJ (NP (DT a)  (NN region) ) (ADJP (JJ located)  (PP (IN at)  (NP (NN position)  (CD -233) )))) (VP (VBZ contains)  (NP (DT a)  (NN CCAAT)  (NN motif) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (CD Two)  (NNS domains) ) (ADJP (VBN centered)  (PP (IN at)  (NP (NNS positions)  (NP-COOD (NP (CD -345) ) (CC and)  (NP (CD -540) )))) (, ,)  (ADVP (RB respectively) ) (, ,) )) (VP (VBP bind)  (NP (NP (NNS proteins) ) (SBAR (WHNP-56 (WDT that) ) (S (NP-SBJ (-NONE- *T*-56) ) (VP (VBP are)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP-COOD (NP (JJ megakaryocytic)  (NNS cells) ) (CC and)  (NP (JJ nonrelated)  (NNS cells) )))) (PP (RB as)  (ADVP (RB well) ))))))) (. .) ) )
(TOP (S (ADVP (RB Finally) ) (, ,)  (NP-SBJ (NP (CD two)  (JJ other)  (NNS domains) ) (, ,)  (ADJP (JJ located)  (PP (IN at)  (NP (NNS positions)  (NP-COOD (NP (CD -460) ) (CC and)  (NP (CD -510) ))))) (, ,) ) (VP (VBP interact)  (PP (IN with)  (NP (NP (NNS proteins) ) (SBAR (WHNP-57 (WDT that) ) (S (NP-SBJ (-NONE- *T*-57) ) (VP (VBP are)  (ADJP-PRD (RB only)  (JJ present) ) (PP (IN in)  (NP (JJ megakaryocytic)  (NNS cells) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NP (NN deletion) ) (PP (IN of)  (NP (NP (DT the)  (NN region) ) (VP (VBG containing)  (NP (DT these)  (CD two)  (NNS domains) ))))) (VP (VBZ results)  (PP (IN in)  (NP (NP (DT a)  (JJ significant)  (NN decrease) ) (PP (IN of)  (NP (DT the)  (NN promoter)  (NN activity) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP It) ) (SBAR (-NONE- *EXP*-105) )) (VP (VBZ is)  (ADJP-PRD (RB very)  (JJ likely) ) (SBAR-105 (IN that)  (S (NP-SBJ (DT these)  (NNS domains) ) (VP (VBP bind)  (NP (NP (JJ megakaryocyte-specific)  (JJ nuclear)  (NNS proteins) ) (VP (VBG acting)  (PP (IN as)  (NP (JJ positive)  (NN transcription)  (NNS factors) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Inhibition) ) (PP (IN of)  (NP (NN protein)  (NNS phosphatases) )) (PP (IN by)  (NP (JJ okadaic)  (NN acid) ))) (VP (VBZ induces)  (NP (NN AP1) ) (PP (IN in)  (NP (JJ human)  (NN T)  (NNS cells) ))) (. .) ) )
(TOP (S (S (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB examine)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (NN protein)  (NNS phosphatases) )) (PP (IN in)  (NP (NN T)  (NN cell)  (NN activation) )))))) (, ,)  (S-COOD (S (NP-SBJ-38 (NN Jurkat)  (NNS cells) ) (VP (VBD were)  (VP (VBN treated)  (NP (-NONE- *-38) ) (PP (IN with)  (NP (NP (JJ okadaic)  (NN acid) ) (, ,)  (NP (NP (DT an)  (NN inhibitor) ) (PP (IN of)  (NP (NN type)  (CD 1)  (CC and)  (NN 2A)  (NNS phosphatases) ))) (, ,) ))))) (CC and)  (S (NP-SBJ-39 (JJ nuclear)  (NNS extracts) ) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-39) ) (PP (IN for)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NN AP1) )))) (PP (IN as)  (NP (NP (DT a)  (NN measure) ) (PP (IN of)  (NP (JJ early)  (NN T)  (NN cell)  (NN activation) )))))))) (. .) ) )
(TOP (S (NP-SBJ-40 (JJ Okadaic)  (NN acid) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-40) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT a)  (JJ potent)  (NN inducer) ) (PP (IN of)  (NP (NN AP1) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NN contrast)  (TO to)  (NP (NP (NN phorbol)  (NNS esters) ) (PP (JJ such)  (IN as)  (NP (NP (NN phorbol)  (NN myristate)  (NN acetate) ) (PRN (-LRB- -LRB-)  (NP (NN PMA) ) (-RRB- -RRB-) ))))) (, ,)  (NP-SBJ (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NN AP1) )) (PP (IN by)  (NP (JJ okadaic)  (NN acid) ))) (VP (VBZ occurs)  (PP (RB predominantly)  (IN by)  (NP (NP (JJ transcriptional)  (NN activation) ) (PP (IN of)  (NP (NP (DT the)  (NP-COOD (NP (NN jun) ) (CC and)  (NP (NN fos) )) (NN family) ) (PP (IN of)  (NP (NNS proto-oncogenes) ))))))) (. .) ) )
(TOP (S (ADVP (RB Surprisingly) ) (, ,)  (SBAR-ADV (IN while)  (S (NP-SBJ (NP (DT the)  (NN addition) ) (PP (IN of)  (NP (NN phytohemagglutinin) ))) (ADVP (RB further) ) (VP (VBD enhanced)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NN AP1) )))))) (, ,)  (NP-SBJ (NP (DT the)  (NN addition) ) (PP (IN of)  (NP (NN PMA) ))) (VP (VBD inhibited)  (NP (PRP it) )) (. .) ) )
(TOP (S (NP-SBJ-41 (JJ Okadaic)  (NN acid)  (NN treatment) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-41) ) (VP (TO to)  (ADVP (RB dramatically) ) (VP-COOD (VP (VB increase)  (NP (NP (NN mRNA)  (NNS transcripts) ) (PP (IN of)  (NP-42 (NP (DT the)  (NN jun)  (NN family) ) (PP (IN of)  (NP (NNS proto-oncogenes) )) (PP (VBG including)  (NP-COOD (NP (NN c-jun) ) (, ,)  (NP (NN junD) ) (, ,)  (CC and)  (NP (NN junB) ))))))) (CC and)  (VP (PP (TO to)  (NP (DT a)  (JJR lesser)  (NN extent) )) (NP=42 (NP (DT the)  (NN fos)  (NN family) ) (PP (VBG including)  (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN fra-1) )))))))))) (. .) ) )
(TOP (S (PP (IN By)  (NP (NN comparison) )) (, ,)  (NP-SBJ (NN PMA) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (ADJP (RB very)  (JJ inefficient) ) (NN inducer) ) (PP (IN of)  (NP (NP (DT the)  (NN jun)  (NN gene)  (NN family) ) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) )))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-43) ) (ADJP-PRD (JJ Similar)  (PP (TO to)  (NP (NP (PRP$ its)  (NN effect) ) (PP (IN on)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NN AP1) )) (PP (IN by)  (NP (JJ okadaic)  (NN acid) )))))))) (, ,)  (NP-SBJ-43 (NN PMA) ) (VP (VBZ inhibits)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NN c-jun)  (NN mRNA) )) (PP (IN by)  (NP (JJ okadaic)  (NN acid) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Transfection) ) (PP (IN of)  (NP (NN c-jun)  (NN promoter)  (NNS constructs) ))) (VP (VBD confirmed)  (NP (NP (DT the)  (JJ marked)  (NN difference) ) (PP (IN between)  (NP-COOD (NP (NN PMA) ) (CC and)  (NP (JJ okadaic)  (NN acid) ))) (PP (IN in)  (S (NP-SBJ (-NONE- *) ) (VP (VBG inducing)  (NP (NN c-jun)  (NN transcription) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN induction) ) (PP (IN of)  (NP (NN AP1) )) (PP (IN by)  (NP (JJ okadaic)  (NN acid) ))) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ-106 (NP (NN protein)  (NNS phosphatases)  (NP-COOD (NP (CD 1) ) (CC and)  (NP (NN 2A) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN PP1) ) (CC and)  (NP (NN PP2A) )) (-RRB- -RRB-) )) (VP (MD may)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-106) ) (PP (IN in)  (NP (NN T)  (NN cell)  (NN activation) )) (PP (IN as)  (NP (NP (JJ important)  (JJ negative)  (NNS regulators) ) (PP (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NN AP1) )))))))))) (. .) ) )
(TOP (NP (NP (NN Demonstration) ) (PP (IN of)  (NP (NP-COOD (NP (NP-COOD (NP (NN estrogen) ) (CC and)  (NP (NN progesterone) )) (NNS receptors) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (NP-COOD (NP (NN Ki-67) ) (CC and)  (NP (NN p-145) )) (NNS antigens) )) (PP (IN in)  (NP (NP (JJ single)  (NN tumor)  (NNS cells) ) (PP (IN from)  (NP (UCP-COOD (NP (NN blood) ) (CC and)  (ADJP (JJ pleural) )) (NNS effusions) )))))) (VP (VBG using)  (NP (DT a)  (NN slide)  (NN assay) )) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP describe)  (NP (NP (DT a)  (NN slide)  (NN assay) ) (SBAR (WHNP-53 (WDT that) ) (S (NP-SBJ (-NONE- *T*-53) ) (VP (VBZ allows)  (NP (NP (DT the)  (NN demonstration) ) (PP (IN of)  (NP (NP (NNS antigens) ) (ADJP (JJ localized)  (PP (IN in)  (NP (NP (DT the)  (NN nucleus) ) (PP-COOD (PP (IN from)  (NP (VBN isolated)  (JJ white)  (NN blood)  (NNS cells) )) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN from)  (NP (NP (JJ single)  (NN tumor)  (NNS cells) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (JJ malignant)  (NNS effusions) ))))))))))))))))) (. .) ) )
(TOP (S (PP (IN With)  (NP (DT the)  (NNS antibodies)  (NP-COOD (NP (NN Ki-67) ) (CC and)  (NP (NN anti-p-145) )))) (NP-SBJ (NP (DT an)  (VBN increased)  (NN rate) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ nuclear) ) (CC and)  (ADJP (JJ nucleolar) )) (NN staining) ))) (VP (VBD resulted)  (PP (IN in)  (NP (NP (NNS cells) ) (PP (IN from)  (NP (ADJP (RB highly)  (JJ malignant) ) (NNS lymphomas) ))))) (. .) ) )
(TOP (S (NP-SBJ-54 (DT An)  (ADJP (RB almost)  (JJ identical) ) (NN reaction) ) (VP (VBD was)  (VP (VBN obtained)  (NP (-NONE- *-54) ) (SBAR-TMP (WHADVP-104 (WRB when) ) (S (NP-SBJ-55 (NP (NN tumor)  (NNS cells) ) (PP (IN from)  (NP (JJ malignant)  (NNS effusions) ))) (VP (VBD were)  (VP (VBN tested)  (NP (-NONE- *-55) ) (ADVP (-NONE- *T*-104) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Cells) ) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (DT the)  (NN blood) ) (PP (IN of)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NP (JJ leukemic)  (NN spread) ) (PP (IN of)  (NP (NP (NNS lymphomas) ) (PP (IN of)  (NP (JJ low)  (NN malignancy) )))))))))))) (VP (VBD yielded)  (NP (NP (DT a)  (JJ weak)  (NN staining) ) (ADJP (JJ comparable)  (PP (TO to)  (NP (NP (DT that) ) (PP (IN of)  (NP (NP (JJ normal)  (JJ mesothelial)  (NNS cells) ) (PP (IN from)  (NP (JJ non-tumorous)  (NN cavity)  (NNS fluids) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-56 (NP (DT The)  (NN detection) ) (PP (IN of)  (NP (NP (NP (NP-COOD (NP (NN estrogen) ) (CC and)  (NP (NN progesterone) )) (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN ER) ) (CC and)  (NP (NN PR) )) (-RRB- -RRB-) )) (ADJP (JJ localized)  (PP (IN in)  (NP (DT the)  (NN cell)  (NN nucleus) )))))) (VP (MD can)  (VP (VB be)  (VP (VBN achieved)  (NP (-NONE- *-56) ) (PP (IN by)  (NP (DT the)  (JJ same)  (NN assay) ))))) (. .) ) )
(TOP (S (NP-SBJ-57 (DT The)  (NN reaction) ) (VP (VBZ is)  (VP (VBN enhanced)  (NP (-NONE- *-57) ) (PP (IN by)  (NP-LGS (NP (NN incubation) ) (PP (IN of)  (NP (DT the)  (NN tumor)  (NNS cells) )) (PP-TMP (IN for)  (NP (CD 30)  (NN min) )) (PP (IN at)  (NP (CD 37)  (NNS degrees)  (NN C) )) (PP (RB prior)  (TO to)  (NP (NN fixation) )))))) (. .) ) )
(TOP (S (NP-SBJ-58 (NP (JJ Pleural)  (NNS effusions) ) (PP (IN from)  (NP (NP (CD 20)  (NNS patients) ) (PP (IN with)  (NP (NN breast)  (NN cancer) ))))) (VP (VBD were)  (VP (VBN tested)  (NP (-NONE- *-58) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NN ER) ) (VP (VBD was)  (ADJP-PRD (JJ positive) ) (PP (IN in)  (NP (CD 13) )))) (CC and)  (S (NP-SBJ (NN PR) ) (VP (VBD was)  (ADJP-PRD (JJ positive) ) (PP (IN in)  (NP (NP (CD 12) ) (PP (IN of)  (NP (DT the)  (CD 20)  (NNS samples) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (CD 5)  (NNS cases) )) (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (NP (DT a)  (JJ divergent)  (NN reaction) ) (PP (IN with)  (NP (NP-COOD (NP (NN ER) ) (CC and)  (NP (NN PR) )) (NN antibody) )))) (. .) ) )
(TOP (S (NP-SBJ-59 (NP (DT The)  (NN hormone)  (NNS receptors) ) (PP (IN of)  (NP (DT the)  (JJ primary)  (NN tumor) ))) (VP (VBD were)  (VP (VBN known)  (NP (-NONE- *-59) ) (PP (IN in)  (NP (NP-COOD (NP (CD 15)  (PRN (-LRB- -LRB-)  (NP (NN ER) ) (-RRB- -RRB-) ) (NP (-NONE- *RNR*-60) )) (CC and)  (NP (CD 14)  (PRN (-LRB- -LRB-)  (NP (NN PR) ) (-RRB- -RRB-) ) (NP (-NONE- *RNR*-60) ))) (NP-60 (NNS patients) ))) (, ,)  (ADVP (RB respectively) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT each)  (NN cohort) )) (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (NP (QP (RB only)  (CD one) ) (NN case) ) (PP (IN with)  (NP-COOD (NP (NP (DT a)  (JJ negative)  (NN reaction) ) (PP (IN of)  (NP (DT the)  (JJ primary)  (NN tumor) ))) (CC and)  (NP (NP (DT a)  (JJ positive)  (NN reaction) ) (PP (IN with)  (NP (NP (DT the)  (VBN isolated)  (NN tumor)  (NNS cells) ) (PP (IN from)  (NP (DT the)  (JJ pleural)  (NNS effusions) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN demonstration) ) (PP (IN of)  (NP (NP (NN hormone)  (NN receptor)  (NNS proteins) ) (PP (IN in)  (NP (NP (NNS cells) ) (PP (IN from)  (NP (JJ malignant)  (NNS effusions) ))))))) (VP (VBZ is)  (ADJP-PRD (JJ possible) )))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (EX there) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN correlation) ) (PP (IN with)  (NP (NP (DT the)  (NN status) ) (PP (IN of)  (NP (NP (DT the)  (JJ primary)  (NN site) ) (PP (IN of)  (NP (NN cancer) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-36 (VBG Transforming)  (NN growth)  (NN factor-beta) ) (VP (VBZ suppresses)  (NP (JJ human)  (NN B)  (NN lymphocyte)  (NN Ig)  (NN production) ) (PP (IN by)  (S (NP-SBJ (-NONE- *-36) ) (VP (VBG inhibiting)  (NP-COOD (NP (NN synthesis) ) (CC and)  (NP (NP (DT the)  (NN switch) ) (PP (IN from)  (NP (NP (DT the)  (NN membrane)  (NN form) ) (PP (-NONE- *RNR*-37) ))) (PP (TO to)  (NP (NP (DT the)  (JJ secreted)  (NN form) ) (PP (-NONE- *RNR*-37) ))) (PP-37 (IN of)  (NN Ig)  (NN mRNA) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (VBG Transforming)  (NN growth)  (NN factor-beta) ) (PRN (-LRB- -LRB-)  (NP (NN TGF-beta) ) (-RRB- -RRB-) )) (VP-COOD (VP (VBZ inhibits)  (NP (NN B)  (NN cell)  (NN Ig)  (NN secretion) )) (CC and)  (VP (VBZ reduces)  (NP (NN B)  (NN cell)  (NN membrane)  (NN Ig)  (NN expression) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN addition) ) (PP (IN of)  (NP (NN TGF-beta) )) (PP (TO to)  (NP (NP (JJ human)  (NN B)  (NN lymphocyte)  (NNS cultures) ) (VP (VBN stimulated)  (NP (-NONE- *) ) (PP (IN with)  (NP-COOD (NP (FW Staphylococcus)  (FW aureus)  (NN Cowan)  (NN strain)  (NN I) ) (CC and)  (NP (NN IL-2) ))))))) (ADVP (RB completely) ) (VP-COOD (VP (VP (VBD inhibited)  (NP (NN B)  (NN cell)  (NN Ig)  (NN secretion) )) (PRN (-LRB- -LRB-)  (FRAG (ADVP (ADVP (JJR greater) ) (PP (IN than)  (NP (CD 90)  (NN %) )))) (-RRB- -RRB-) )) (CC and)  (VP (VBD decreased)  (NP (NN B)  (NN cell)  (NN surface)  (NP-COOD (NP (NN IgM) ) (, ,)  (NP (NN IgD) ) (, ,)  (NP (NN kappa)  (NN L)  (NN chain) ) (, ,)  (CC and)  (NP (NN lambda)  (NN L)  (NN chain) )) (NN expression) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NN TGF-beta) ) (VP (VBD had)  (NP (ADJP (RB only)  (JJ minimal) ) (NNS effects) ) (PP (IN on)  (NP (NP (CD two)  (JJ other)  (NN B)  (NN cell)  (NN membrane)  (NNS proteins) ) (, ,)  (NP-COOD (NP (NN HLA-DR) ) (CC and)  (NP (NN CD20) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (JJ Internal)  (NN labeling) ) (PP (IN with)  (NP (NN -LCB-35S-RCB-methionine) ))) (CC and)  (NP (NP (NN immunoprecipitation) ) (PP (IN with)  (NP (ADJP-COOD (ADJP (JJ anti-IgM) ) (, ,)  (ADJP (JJ anti-kappa) ) (, ,)  (CC and)  (ADJP (JJ anti-lambda) )) (NNS antibodies) )))) (VP (VBD revealed)  (NP (NP (NP (DT a)  (JJ striking)  (NN reduction) ) (PP (IN in)  (NP (NN kappa)  (NN L)  (NN chain) )) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN TGF-beta) ))))) (. .) ) )
(TOP (S (NP-SBJ-38 (NP (DT A)  (ADJP (RBR less)  (JJ pronounced) ) (NN reduction) ) (PP (IN in)  (NP-COOD (NP (NN lambda)  (NN L)  (NN chain) ) (CC and)  (NP (NN microH)  (NN chain) )))) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN noted)  (NP (-NONE- *-38) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Northern)  (NN blot)  (NN analysis) ) (PP (IN of)  (NP (NP (NN RNA) ) (VP (VBN purified)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (NN B)  (NNS cells) ) (VP (VBN treated)  (NP (-NONE- *) ) (PP (IN with)  (NP (NN TGF-beta) )) (PP-TMP (IN for)  (NP (VBG varying)  (NN time)  (NNS intervals) ))))))))) (VP (VBD revealed)  (NP (NP (DT a)  (JJ significant)  (NN decrease) ) (PP (IN in)  (NP (JJ steady)  (NN state)  (NN kappa)  (CC and)  (NN lambda)  (NN L)  (NN chain)  (NN mRNA)  (NNS levels) )))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-39 (NP (DT a)  (JJ significant)  (NN decrease) ) (PP (IN in)  (NP (NP (DT the)  (NN switch) ) (PP (IN from)  (NP (NP (DT the)  (NN membrane)  (NNS forms) ) (PP (IN of)  (NP-COOD (NP (NN mu) ) (CC and)  (NP (NN gamma) ))))) (PP (TO to)  (NP (PRP$ their)  (JJ respective)  (JJ secreted)  (NNS forms) ))))) (VP (VBD was)  (VP (VBN noted)  (NP (-NONE- *-39) ) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN TGF-beta) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Nuclear)  (JJ run-on)  (NNS experiments) ) (VP (VBD demonstrated)  (NP (NP (VBN decreased)  (NN transcription) ) (PP (IN of)  (NP (NN kappa)  (NN L)  (NN chain) )))) (. .) ) )
(TOP (S (NP-SBJ-40 (NP (DT The)  (NNS effects) ) (PP (IN of)  (NP (NN TGF-beta) )) (PP (IN on)  (NP (NP (NP (CD two)  (JJ transcriptional)  (JJ regulatory)  (NNS factors) ) (, ,)  (NP-COOD (NP (NN Oct-2) ) (CC and)  (NP (NP (NP (JJ nuclear)  (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN NF) ) (-RRB- -RRB-) )) (NN kappa)  (NN B) )) (, ,) ) (VP (VBN known)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ important)  (PP (IN in)  (NP (NN Ig)  (NN gene)  (NN transcription) )))))))))) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-40) ))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP-COOD (NP (NN Oct-2)  (NN mRNA)  (NNS levels) ) (CC and)  (NP (NP-COOD (DT both)  (NP (NN Oct-2) ) (CC and)  (NP (NN NF-kappa)  (NN B) )) (NNS proteins) )) (PP (IN in)  (NP (JJ nuclear)  (NNS extracts) ))) (VP (VBD were)  (RB not)  (VP (VBN altered)  (NP (-NONE- *-41) ) (PP (IN by)  (NP-LGS (NP (NN treatment) ) (PP (IN with)  (NP (NN TGF-beta) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-42 (NP (NNS levels) ) (PP (IN of)  (NP (NP (DT the)  (JJ transcriptional)  (NN factor)  (NN AP-1) ) (, ,)  (SBAR (WHNP-43 (WDT which) ) (S (NP-SBJ-44 (-NONE- *T*-43) ) (VP (VBZ is)  (RB not)  (VP (VBN known)  (S (NP-SBJ (-NONE- *-44) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ important)  (PP (IN in)  (NP (NN B)  (NN cell)  (NN Ig)  (NN production) )))))))))) (, ,) ))) (VP (VBD were)  (VP (VBN reduced)  (NP (-NONE- *-42) ) (PP (IN by)  (NP-LGS (NN TGF-beta) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-45 (NN TGF-beta) ) (VP (VBZ decreases)  (NP (NN B)  (NN lymphocyte)  (NN Ig)  (NN secretion) ) (PP (IN by)  (S-NOM (NP-SBJ (-NONE- *-45) ) (VP-COOD (VP (VBG inhibiting)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NN Ig)  (NN mRNA) )))) (CC and)  (VP (VBG inhibiting)  (NP (NP (DT the)  (NN switch) ) (PP (IN from)  (NP (DT the)  (NN membrane)  (NN form) )) (PP (TO to)  (NP (NP (DT the)  (JJ secreted)  (NNS forms) ) (PP (IN of)  (NP (NP-COOD (NP (NN mu) ) (CC and)  (NP (NN gamma) )) (NN mRNA) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN mechanism) ) (SBAR (WHPP-46 (IN by)  (WHNP (WDT which) )) (S (NP-SBJ (NN TGF-beta) ) (VP (VBZ inhibits)  (NP (NN Ig)  (NN chain)  (NN synthesis) ) (PP (-NONE- *T*-46) ))))) (VP (VBZ is)  (ADJP-PRD (JJ unclear) ) (SBAR (IN although)  (S (NP-SBJ (PRP it) ) (VP (VBZ does)  (RB not)  (VP (VB involve)  (NP (NP (NN inhibition) ) (PP (IN of)  (NP (NP (DT the)  (NN binding) ) (PP (IN of)  (NP-COOD (NP (NN NF-kappa)  (NN B) ) (CC or)  (NP (NN Oct-2) ))) (PP (TO to)  (NP (PRP$ their)  (JJ respective)  (NN target)  (NNS sequences) )))))))))) (. .) ) )
(TOP (NP (NP (JJ Differentiation-associated)  (NN expression) ) (PP (IN of)  (NP (DT the)  (JJ Epstein-Barr)  (NN virus)  (NN BZLF1)  (NN transactivator)  (NN protein) )) (PP (IN in)  (NP (JJ oral)  (JJ hairy)  (NN leukoplakia) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN BZLF1)  (NN protein) ) (PP (IN of)  (NP (NP (JJ Epstein-Barr)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN EBV) ) (-RRB- -RRB-) )))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ key)  (JJ immediate-early)  (NN protein) ) (SBAR (WHNP-34 (WDT which) ) (S (NP-SBJ-35 (-NONE- *T*-34) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-35) ) (VP (TO to)  (VP (VB disrupt)  (NP (NP (NN virus)  (NN latency) ) (PP (IN in)  (NP (JJ EBV-infected)  (NN B)  (NNS cells) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN generated)  (NP (NP (NP (DT a)  (JJ monoclonal)  (NN antibody) ) (, ,)  (NP (NN BZ1) ) (, ,) ) (PP (TO to)  (NP (NN BZLF1) )) (SBAR-COOD (SBAR (WHNP-38 (WDT which) ) (S (NP-SBJ (-NONE- *T*-38) ) (VP (VBZ reacts)  (PP (IN in)  (NP-COOD (NP (NN immunohistology) ) (, ,)  (NP (NN immunoblotting) ) (, ,)  (CC and)  (NP (NN immunoprecipitation) )))))) (CC and)  (SBAR (WHNP-36 (WDT which) ) (S (NP-SBJ (-NONE- *T*-36) ) (VP (VBZ recognizes)  (NP (NP-COOD (CC both)  (NP (NP (DT the)  (ADJP-COOD (ADJP (JJ active) ) (, ,)  (ADJP (JJ dimeric) )) (NN form) )) (CC and)  (NP (NP (DT the)  (ADJP-COOD (ADJP (JJ inactive) ) (, ,)  (ADJP (JJ monomeric) )) (NN form) ))) (PP (IN of)  (NP (DT the)  (NN protein) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-40 (NP (NNS Biopsies) ) (PP (IN of)  (NP (NP (JJ oral)  (JJ hairy)  (NN leukoplakia) ) (, ,)  (NP (NP (DT an)  (JJ AIDS-associated)  (NN lesion) ) (VP (VBN characterized)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (JJ high-level)  (NN EBV)  (NN replication) )))) (, ,) ))) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-40) ) (PP (IN by)  (NP (NP (NN immunohistochemistry) ) (VP (VBG using)  (NP (DT the)  (NN BZ1)  (JJ monoclonal)  (NN antibody) )))))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP (DT A)  (JJ differentiation-associated)  (NN pattern) ) (PP (IN of)  (NP (NN BZLF1)  (NN expression) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-41) ) (, ,)  (S (NP-SBJ (NN BZ1) ) (VP (VBG reacting)  (PP (IN with)  (NP (NP (NNS nuclei) ) (PP (IN of)  (NP (NP (DT the)  (JJ upper)  (JJ spinous)  (NN layer) ) (PP (IN of)  (NP (DT the)  (NN lesion) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN finding) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ-42 (DT the)  (NN BZLF1)  (NN promoter) ) (VP (MD may)  (VP (VB be)  (VP (VBN regulated)  (NP (-NONE- *-42) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN degree) ) (PP (IN of)  (NP (JJ squamous)  (NN differentiation) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (NN comparison) ) (PP (IN of)  (NP-COOD (NP (NP (ADJP (FW in)  (FW situ) ) (NN hybridization) ) (PP (TO to)  (NP (NN EBV)  (NN DNA) ))) (CC and)  (NP (JJ viral)  (NN capsid)  (NN antigen)  (VBG staining) ))) (PP (IN with)  (NP (NN BZ1)  (NN reactivity) ))) (VP (VBD suggested)  (SBAR (IN that)  (S (NP-SBJ (NN BZLF1)  (NN expression) ) (VP (VBZ precedes)  (NP (JJ rampant)  (NN virus)  (NN replication) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN inability)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB detect)  (NP (NP (NN EBV) ) (PP (IN in)  (NP (NP (DT the)  (RBR lower)  (JJ epithelial)  (NNS layers) ) (PP (IN of)  (NP (JJ oral)  (JJ hairy)  (NN leukoplakia) ))))))))) (VP (VBZ raises)  (NP (NP (NNS questions) ) (PP (VBG concerning)  (NP (NP (DT the)  (NN nature) ) (PP (IN of)  (NP (NP (NN EBV)  (NP-COOD (NP (NN latency) ) (CC and)  (NP (NN persistence) ))) (PP (IN in)  (NP (JJ stratified)  (JJ squamous)  (NN epithelium) )))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NP (NN Transactivation) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN promoter) )) (PP (IN by)  (NP (NP (NP (NP (JJ human)  (NN herpesvirus)  (CD 6) ) (PRN (-LRB- -LRB-)  (NP (NN HHV-6) ) (-RRB- -RRB-) )) (VBZ strains) ) (NP-COOD (NP (NN GS) ) (CC and)  (NP (NN Z-29) )))) (PP (IN in)  (NP (JJ primary)  (JJ human)  (NN T)  (NNS lymphocytes) ))) (CC and)  (NP (NP (NN identification) ) (PP (IN of)  (NP (VBG transactivating)  (NN HHV-6)  (-LRB- -LRB-)  (NN GS)  (-RRB- -RRB-)  (NN gene)  (NNS fragments) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Human)  (NN herpesvirus)  (CD 6) ) (PRN (-LRB- -LRB-)  (NP (NN HHV-6) ) (-RRB- -RRB-) )) (VP (MD can)  (VP (VP-COOD (VP (VB activate)  (NP (DT the)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )) (NN promoter) )) (CC and)  (VP (VB accelerate)  (NP (JJ cytopathic)  (NNS effects) ))) (PP (IN in)  (NP (JJ HIV-infected)  (JJ human)  (NN T)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN study) ) (VP (VBZ examines)  (NP (NP (DT the)  (NNS regions) ) (PP (IN of)  (NP (DT the)  (NN HIV)  (NN promoter) )) (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (NP (NN HHV-6)  (NN transactivation) ) (PP (IN in)  (NP (NP (DT a)  (JJ heterogeneous)  (NN population) ) (PP (IN of)  (NP (JJ primary)  (JJ human)  (NN T)  (NNS lymphocytes) )))) (PP (PP-COOD (PP (IN with)  (NP (-NONE- *RNR*-36) )) (CC or)  (PP (IN without)  (NP (-NONE- *RNR*-36) ))) (NP-36 (JJ antigenic)  (NN stimulation) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (CD Two)  (JJ different)  (NNS strains) ) (PP (IN of)  (NP (NN HHV-6) ))) (, ,)  (NP-COOD (NP (NN GS) ) (CC and)  (NP (NN Z29) )) (, ,) ) (VP (VBD transactivated)  (NP (DT the)  (NN HIV)  (NN promoter) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN GS)  (NN strain) ) (VP (VBD transactivated)  (NP (DT the)  (NN promoter) ) (PP (IN in)  (NP (ADJP-COOD (CC both)  (ADJP (VBN stimulated) ) (CC and)  (ADJP (VBG resting) )) (NN T)  (NNS cells) )) (, ,)  (SBAR (IN while)  (S (NP-SBJ (DT the)  (NN Z29)  (NN strain) ) (VP (VBD increased)  (NP (NN HIV)  (NN promoter)  (NN activity) ) (PP (RB only)  (IN in)  (NP (VBN stimulated)  (NN T)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (CD Three)  (NN DNA)  (NNS clones) ) (VP (VBG containing)  (NP (NN HHV-6)  (-LRB- -LRB-)  (NN GS)  (-RRB- -RRB-)  (JJ genomic)  (NNS fragments) ))) (VP (VBD transactivated)  (NP (NP (DT the)  (NN HIV)  (NN promoter) ) (PP (IN in)  (NP (VBN cotransfected)  (NN T)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ 21.4-kb)  (NN DNA)  (NN clone) ) (, ,)  (NP (NN pZVB70) ) (, ,) ) (VP (VBD showed)  (NP (DT the)  (JJS highest)  (NN transactivating)  (NN ability) ) (, ,)  (SBAR (IN while)  (S (NP-SBJ (NP (CD two)  (JJ other)  (NN DNA)  (NNS fragments) ) (, ,)  (NP-COOD (NP (NP (NN pZVB10) ) (PRN (-LRB- -LRB-)  (NP (CD 6.2)  (NN kb) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN pZVH14) ) (PRN (-LRB- -LRB-)  (NP (CD 8.7)  (NN kb) ) (-RRB- -RRB-) ))) (, ,) ) (VP (VBD showed)  (NP (JJR lower)  (NN activity) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (CD One) ) (PP (IN of)  (NP (DT these)  (NNS clones) ))) (, ,)  (NP (NN pZVH14) ) (, ,) ) (VP (VBD activated)  (NP (NP (DT the)  (NN HIV)  (NN promoter)  (NN construct) ) (VP (VBG containing)  (NP (DT a)  (NN mutation) ) (PP (IN in)  (NP (DT the)  (NN NF)  (NN kappa)  (NN B)  (NN site) ))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-38 (DT this)  (VBN mutated)  (NN NF)  (NN kappa)  (NN B)  (NN promoter) ) (VP (VBD was)  (RB not)  (VP (VBN transactivated)  (NP (-NONE- *-38) ) (PP-TMP-COOD (PP (IN during)  (NP (NN HHV-6)  (-LRB- -LRB-)  (NN GS)  (-RRB- -RRB-)  (NN infection) )) (CC or)  (PP (IN after)  (NP (NP (NN cotransfection) ) (PP (IN with)  (NP-COOD (NP (NN pZVB70) ) (CC or)  (NP (NN pZVB10) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN NF)  (NN kappa)  (NN B)  (NNS sites) ) (PP (IN of)  (NP (DT the)  (NN HIV)  (NN promoter) ))) (VP (VBP are)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (NP (PRP$ its)  (NN transactivation) ) (PP-TMP (IN during)  (NP (NN HHV-6)  (-LRB- -LRB-)  (NN GS)  (-RRB- -RRB-)  (NN infection) ))))))))) (. .) ) )
(TOP (S (PP (IN By)  (S (NP-SBJ (-NONE- *-39) ) (VP (VBG increasing)  (NP (NP (NN HIV)  (NN promoter)  (NN activity) ) (PP (IN in)  (NP (JJ primary)  (NN T)  (NNS lymphocytes) )))))) (, ,)  (NP-SBJ-39 (NN HHV-6) ) (VP (MD may)  (ADVP (RB consequently) ) (VP (VB increase)  (NP (NN HIV)  (NN replication) ) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG leading)  (PP (TO to)  (NP (NP (DT an)  (NN increase) ) (PP (IN in)  (NP (NP (DT the)  (JJ cytopathic)  (NN effect) ) (PP (IN on)  (NP (VBN coinfected)  (JJ human)  (NN T)  (NNS cells) )))))))))) (. .) ) )
(TOP (NP (NP (NP (DT The)  (NN rhombotin)  (NN family) ) (PP (IN of)  (NP (JJ cysteine-rich)  (JJ LIM-domain)  (NNS oncogenes) )) (: :) ) (S (NP-SBJ-48 (JJ distinct)  (NNS members) ) (VP (VBP are)  (VP (VBN involved)  (NP (-NONE- *-48) ) (PP (IN in)  (NP (NP (NN T-cell)  (NNS translocations) ) (PP (TO to)  (NP (JJ human)  (NNS chromosomes)  (NP-COOD (NP (NN 11p15) ) (CC and)  (NP (NN 11p13) )))))))) (. .) )) )
(TOP (S (NP-SBJ (NP (DT A)  (NN chromosomal)  (NN translocation) ) (PP (IN in)  (NP (DT a)  (NN T-cell)  (NN leukemia) )) (VP (VBG involving)  (NP (NP (DT the)  (JJ short)  (NN arm) ) (PP (IN of)  (NP (JJ human)  (NN chromosome)  (CD 11) )) (PP (IN at)  (NP (NN band)  (NN 11p15) ))))) (VP (VBZ disrupts)  (NP (DT the)  (NN rhombotin)  (NN gene) )) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN gene) ) (VP (VBZ encodes)  (NP (NP (DT a)  (NN protein) ) (PP (IN with)  (NP (NP (JJ duplicated)  (JJ cysteine-rich)  (NNS regions) ) (VP (VBN called)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN LIM)  (NNS domains) ))) (, ,)  (SBAR (WHNP-49 (WDT which) ) (S (NP-SBJ (-NONE- *T*-49) ) (VP (VBP show)  (NP (NP (NN homology) ) (PP-COOD (PP (TO to)  (NP (JJ zinc-binding)  (NNS proteins) )) (CC and)  (PP (TO to)  (NP (NP (JJ iron-sulfur)  (NNS centers) ) (PP (IN of)  (NP (NNS ferredoxins) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-50 (NP (CD Two)  (NNS homologues) ) (PP (IN of)  (NP (DT the)  (NN rhombotin)  (NN gene) ))) (VP (VBP have)  (ADVP (RB now) ) (VP (VBN been)  (VP (VBN isolated)  (NP (-NONE- *-50) )))) (. .) ) )
(TOP (S (S (NP-SBJ-51 (NP (CD One) ) (PP (IN of)  (NP (DT these) )) (, ,)  (VP (VBN designated)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN Rhom-2) ))) (, ,) ) (VP (VBZ is)  (ADJP-PRD (JJ located)  (PP (IN on)  (NP (NP (JJ human)  (NN chromosome)  (CD 11) ) (PP (IN at)  (NP (NN band)  (NN 11p13) )) (, ,)  (SBAR (WHADVP-52 (WRB where) ) (S (NP-SBJ (NP (DT a)  (NN cluster) ) (PP (IN of)  (NP (NN T-cell)  (JJ leukemia-specific)  (NNS translocations) ))) (VP (VBP occur)  (ADVP (-NONE- *T*-52) )))))))) (: ;) ) (S (NP-SBJ (NP (DT all)  (NN translocation)  (NNS breakpoints) ) (PP (IN at)  (NP (NN 11p13) ))) (VP (VBP are)  (ADJP-PRD (JJ upstream)  (PP (IN of)  (NP (DT the)  (NN Rhom-2)  (NN gene) )))) (. .) )) )
(TOP (S (NP-SBJ-53 (UCP-COOD (ADJP (JJ Human) ) (CC and)  (NP (NN mouse) )) (NN Rhom-2) ) (VP-COOD (VP (VBP are)  (ADVP (RB highly) ) (VP (VBN conserved)  (NP (-NONE- *-53) ))) (CC and)  (, ,)  (VP (PP (IN like)  (NP (NN rhombotin) )) (, ,)  (VP (VBP encode)  (NP (CD two)  (JJ tandem)  (JJ cysteine-rich)  (NN LIM)  (NNS domains) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-54 (NN Rhom-2)  (NN mRNA) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-54) ) (PP (IN in)  (NP (NP (JJ early)  (NN mouse)  (NN development) ) (PP (IN in)  (NP-COOD (NP (JJ central)  (JJ nervous)  (NN system) ) (, ,)  (NP (NN lung) ) (, ,)  (NP (NN kidney) ) (, ,)  (NP (NN liver) ) (, ,)  (CC and)  (NP (NN spleen) )))))))) (CC but)  (S (NP-SBJ (ADJP (RB only)  (RB very)  (JJ low) ) (NNS levels) ) (VP (VBP occur)  (PP (IN in)  (NP (NN thymus) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ other)  (NN gene) ) (, ,)  (VP (VBN designated)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN Rhom-3) ))) (, ,) ) (VP-COOD (VP (VBZ is)  (RB not)  (PP-PRD (IN on)  (NP (NN chromosome)  (CD 11) ))) (CONJP (CC but)  (RB also) ) (VP (VBZ retains)  (NP (NP (NN homology) ) (PP (TO to)  (NP (NP (DT the)  (NN LIM)  (NN domain) ) (PP (IN of)  (NP (NN rhombotin) ))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ (DT the)  (NN Rhom-2)  (NN gene) ) (VP (VBZ is)  (NP-PRD (NP (JJ such)  (DT a)  (JJ common)  (NN site) ) (PP (IN of)  (NP (JJ chromosomal)  (NN damage) )) (PP (IN in)  (NP (NN T-cell)  (NNS tumors) )))))) (, ,)  (NP-SBJ-55 (NP (DT the)  (NN consistency) ) (PP (IN of)  (NP (NP (NNS translocations) ) (PP (IN near)  (NP (DT the)  (NN rhombotin)  (NN gene) ))))) (VP (VBD was)  (ADVP (RB further) ) (VP (VBN examined)  (NP (-NONE- *-55) ))) (. .) ) )
(TOP (S (NP-SBJ-56 (NP (DT A)  (JJ second)  (NN translocation) ) (ADJP (JJ adjacent)  (PP (TO to)  (NP (NN rhombotin) )))) (VP (VBD was)  (UCP-COOD (VP (VBN found)  (NP (-NONE- *-56) )) (CC and)  (PP-PRD (IN at)  (NP (NP (DT the)  (JJ same)  (NN position) ) (PP (IN as)  (FRAG (PP (IN in)  (NP (DT the)  (JJ previous)  (NN example) )))))))) (. .) ) )
(TOP (S (ADVP (RB Therefore) ) (, ,)  (NP-SBJ (NN chromosome)  (NNS bands)  (NP-COOD (NP (NP (NN 11p15) ) (PRN (-LRB- -LRB-)  (NP (NN rhombotin) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN 11p13) ) (PRN (-LRB- -LRB-)  (NP (NN Rhom-2) ) (-RRB- -RRB-) )))) (VP (VBP are)  (NP-PRD (NP (JJ consistent)  (NNS sites) ) (PP (IN of)  (NP (NN chromosome)  (NN translocation) )) (PP (IN in)  (NP (NN T-cell)  (NN leukemia) ))) (, ,)  (SBAR (IN with)  (S (NP-SBJ-102 (DT the)  (NN 11p15)  (NN target) ) (VP (ADVP (RBR more)  (RB rarely) ) (VBN involved)  (NP (-NONE- *-102) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBP define)  (NP (DT the)  (NN rhombotin)  (NN gene)  (NN family) ) (PP (IN as)  (NP (NP (DT a)  (NN class) ) (PP (IN of)  (NP (NN T-cell)  (NNS oncogenes) )) (PP (IN with)  (NP (JJ duplicated)  (JJ cysteine-rich)  (NN LIM)  (NNS domains) ))))) (. .) ) )
(TOP (NP (NP (NP (DT The)  (JJ human)  (JJ myelomonocytic)  (NN cell)  (NN line)  (NN U-937) ) (PP (IN as)  (NP (NP (DT a)  (NN model) ) (PP (IN for)  (S (NP-SBJ (-NONE- *) ) (VP (VBG studying)  (NP (NP (NNS alterations) ) (PP (IN in)  (NP (JJ steroid-induced)  (NN monokine)  (NN gene)  (NN expression) )))))))) (: :) ) (NP (NP (JJ marked)  (NN enhancement) ) (PP (IN of)  (NP (JJ lipopolysaccharide-stimulated)  (NN interleukin-1)  (NN beta)  (NN messenger)  (NN RNA)  (NNS levels) )) (PP (IN by)  (NP (NN 1,25-dihydroxyvitamin)  (NN D3) )) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ active)  (NN metabolite) ) (PP (IN of)  (NP (NP (NN vitamin)  (NN D) ) (, ,)  (NP (NP (NN 1,25-dihydroxyvitamin)  (NN D3) ) (PRN (-LRB- -LCB-)  (NP (NN 1,25--LRB-OH-RRB-2D3) ) (-RRB- -RCB-) ))))) (, ,)  (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potent)  (NN regulator) ) (PP (IN of)  (NP (JJ human) (JJ  monocyte/macrophage)  (NN function) ))) (ADVP (FW in)  (FW vitro) )) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB establish)  (NP (NP (DT a)  (NN model) ) (PP (IN for)  (NP (NP (NN 1,25--LRB-OH-RRB-2D3)  (NN regulation) ) (PP (IN of)  (NP (JJ human)  (NN monocyte)  (NN monokine)  (NN synthesis) )))))))) (, ,)  (NP-SBJ-320 (NP (CD three)  (JJ human)  (NN cell)  (NNS lines) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN U-937) ) (, ,)  (NP (NN THP-1) ) (, ,)  (CC and)  (NP (NN HL-60) )) (-RRB- -RRB-) )) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-320) ) (PP (IN for)  (: :)  (NP-COOD (NP (LST (LS 1)  (-RRB- -RRB-) ) (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (JJ functional)  (NN 1,25--LRB-OH-RRB-2D3)  (NNS receptors) ))) (: ;)  (NP (LST (LS 2)  (-RRB- -RRB-) ) (NP (DT the)  (NN accumulation) ) (PP (IN of)  (NP-COOD (NP (NP (NP (NN interleukin-1)  (NN beta) ) (PRN (-LRB- -LRB-)  (NP (NN IL-1)  (NN beta) ) (-RRB- -RRB-) )) (NN mRNA) ) (CC and)  (NP (NN IL-1)  (NN beta)  (NN protein) ))) (PP (IN in)  (NN response)  (TO to)  (NP (NP (NN lipopolysaccharide) ) (PRN (-LRB- -LRB-)  (NP (NN LPS) ) (-RRB- -RRB-) )))) (: ;)  (CC and)  (NP (LST (LS 3)  (-RRB- -RRB-) ) (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (DT this)  (NN response) )) (PP (IN by)  (NP (NN 1,25--LRB-OH-RRB-2D3) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT All)  (CD three)  (NN cell)  (NNS lines) ) (VP-COOD (VP (VBD expressed)  (NP (NN vitamin)  (NN D)  (NN receptor) )) (CC and)  (VP (VBD had)  (VP (VBN increased)  (NP (NP (NNS levels) ) (PP (IN of)  (NP (NN IL-1)  (NN beta)  (NN mRNA) ))) (PP (IN in)  (NN response)  (TO to)  (NP (NN LPS) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Preincubation) ) (PP (IN of)  (NP (NNS cells) )) (PP (IN with)  (NP (NN 1,25--LRB-OH-RRB-2D3) ))) (VP (VBD augmented)  (NP (NN IL-1)  (NN beta)  (NN mRNA)  (NNS levels) ) (PP (RB only)  (IN in)  (NP (NP-COOD (NP (NN U-937) ) (CC and)  (NP (NN HL-60) )) (NNS cells) ))) (. .) ) )
(TOP (S (UCP-COOD (PP (IN From)  (NP (DT these)  (NNS data) )) (, ,)  (CC and)  (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG taking)  (PP (IN into)  (NP (NN consideration) )) (NP (PRP$ their)  (NP-COOD (NP (NP (NN state) ) (PP (IN of)  (NP (NN differentiation) ))) (CC and)  (NP (NP (JJ relative)  (NN ease) ) (PP (IN of)  (NP (NN culture) )))))))) (, ,)  (NP-SBJ-323 (NN U-937) ) (VP (VBD was)  (VP (VBN chosen)  (NP (-NONE- *-323) ) (PP (IN over)  (NP-COOD (NP (NN HL-60) ) (CC and)  (NP (NN THP-1) ))) (PP (IN as)  (NP (NP (DT the)  (NN cell)  (NN line) ) (SBAR (WHNP-324 (-NONE- 0) ) (S (NP-SBJ (PRP we) ) (ADVP (RB further) ) (VP (VBD characterized)  (NP (-NONE- *T*-324) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN U-937)  (NNS cells) )) (, ,)  (NP-SBJ-325 (NP (JJ optimum)  (NP-COOD (NP (NN time) ) (CC and)  (NP (NN dose) ))) (PP (IN of)  (NP (NP (NN pretreatment) ) (PP (IN with)  (NP (NN 1,25--LRB-OH-RRB-2D3) ))))) (VP (VBD were)  (VP (VBN determined)  (S (NP-SBJ (-NONE- *-325) ) (VP (TO to)  (VP (VB be)  (NP-PRD (QP (CD 12-24) ) (NN h) ) (PP (IN at)  (NP (NP (NP (DT a)  (NN receptor)  (JJ saturating)  (NN concentration) ) (PP (IN of)  (NP (NN 1,25--LRB-OH-RRB-2D3) ))) (PRN (-LRB- -LRB-)  (NP (CD 10)  (NN nM) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Preincubation) ) (PP (IN of)  (NP (NNS cells) )) (PP (IN with)  (NP (NN 1,25--LRB-OH-RRB-2D3) ))) (VP (VBD had)  (NP (DT no)  (NN effect) ) (PP (IN on)  (NP (NP (DT the)  (NN time)  (NN course) ) (PP (IN of)  (NP (NP (NN IL-1)  (NN beta)  (NN mRNA)  (NN appearance) ) (PP (IN in)  (NN response)  (TO to)  (NP (NN LPS) ))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (NN exposure) ) (PP (IN of)  (NP (NN U-937)  (NNS cells) )) (PP (TO to)  (NP (NN 1,25--LRB-OH-RRB-2D3) ))) (VP-COOD (VP (VBD increased)  (PP (IN by)  (NP (CD 200)  (NN %) )) (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NP (NN IL-1)  (NN beta)  (NN mRNA) ) (VP (VBD detected)  (NP (-NONE- *) )))))) (CC and)  (VP (VBD decreased)  (PP (IN by)  (NP (NP (CD three)  (NNS orders) ) (PP (IN of)  (NP (NN magnitude) )))) (NP (NP (DT the)  (NN concentration) ) (PP (IN of)  (NP (NN LPS) )) (VP (VBN required)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB achieve)  (NP (NP (JJ steady)  (NN state)  (NN mRNA)  (NNS levels) ) (ADJP (JJ equivalent)  (PP (TO to)  (NP (NP (DT those) ) (VP (VBN observed)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (NN U-937)  (NNS cells) ) (VP (RB not)  (VBN preincubated)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT the)  (NN hormone.2+o) )))))))))))))))))) )
(TOP (NP (NP (NN Cortivazol)  (VBD mediated)  (NN induction) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NN receptor)  (NN messenger)  (JJ ribonucleic)  (NN acid) ) (PP (IN in)  (NP (ADJP-COOD (ADJP (JJ wild-type) ) (CC and)  (ADJP (JJ dexamethasone-resistant) )) (JJ human)  (NN leukemic)  (-LRB- -LRB-)  (NN CEM)  (-RRB- -RRB-)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NN Cortivazol) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ phenylpyrazolo)  (NN glucocorticoid) ) (PP (IN of)  (NP-COOD (NP (JJ high)  (NN potency) ) (CC and)  (NP (JJ unusual)  (NN structure) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (ADJP-COOD (CC both)  (ADJP (JJ wild-type) ) (CC and)  (ADJP (RB highly)  (NP (NP (NN dexamethasone) ) (PRN (-LRB- -LRB-)  (NP (NN dex) ) (-RRB- -RRB-) )) (JJ -resistant) )) (NNS clones) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ leukemic)  (NN cell)  (NN line)  (NN CEM) )))) (, ,)  (NP-SBJ (NP (NN exposure) ) (PP (TO to)  (NP (NN cortivazol) ))) (VP (VBZ leads)  (PP (TO to)  (NP (NN cell)  (NN death) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN shown)  (ADVP-TMP (RB recently) ) (SBAR (IN that)  (S (PP-COOD (PP (IN in)  (NP (JJ wild-type)  (NN CEM)  (NNS cells) )) (CC but)  (PP (RB not)  (IN in)  (NP (DT a)  (ADJP-COOD (ADJP (JJ dex-resistant) ) (, ,)  (ADJP (NN glucocorticoid)  (NN receptor)  (-LRB- -LRB-)  (NN GR)  (-RRB- -RRB-)  (JJ -defective) )) (NN clone)  (NN ICR-27)  (NN TK-3) ))) (, ,)  (NP-SBJ (NN dex) ) (VP (VBZ induces)  (NP (NN GR)  (NN mRNA) ))))))) (. .) ) )
(TOP (S (S (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB test)  (NP (DT the)  (NN hypothesis)  (SBAR (IN that)  (S (NP-SBJ-301 (NN cortivazol) ) (VP (VBZ acts)  (PP (IN in)  (NP (JJ dex-resistant)  (NNS cells) )) (PP (IN by)  (S (NP-SBJ (-NONE- *-301) ) (VP (VBG making)  (NP (NP (NN use) ) (PP (IN of)  (NP (NP (DT the)  (JJ residual)  (NN GR) ) (VP (VBN found)  (NP (-NONE- *) ) (ADVP (RB there) ))))))))))))))) (, ,)  (S-COOD (S (NP-SBJ-302 (ADJP-COOD (ADJP (JJ wild-type) ) (CC and)  (ADJP (JJ dex-resistant) )) (NNS clones) ) (VP (VBD were)  (VP (VBN treated)  (NP (-NONE- *-302) ) (PP (IN with)  (NP (NP (JJ various)  (NNS concentrations) ) (PP (IN of)  (NP (NN cortivazol) ))))))) (CC and)  (S (NP-SBJ-303 (NP (NN induction) ) (PP (IN of)  (NP (NN GR)  (NN mRNA) ))) (VP (VBD was)  (VP (VBN studied)  (NP (-NONE- *-303) ))))) (. .) ) )
(TOP (S (NP-SBJ (NN Cortivazol) ) (ADVP (RB significantly) ) (VP (VBD induced)  (NP (NP (NN GR)  (NN mRNA) ) (PP-COOD (PP (IN in)  (NP (DT the)  (JJ normal)  (NN CEM-C7) )) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN in)  (NP (NP (CD two)  (NNS classes) ) (PP (IN of)  (NP (JJ dex-resistant)  (NNS clones) )))))) (, ,)  (SBAR (IN although)  (S (NP-SBJ (DT the)  (JJ dex-resistant)  (NNS clones) ) (VP (VBD needed)  (NP (NP (ADJP (QP (IN at)  (JJS least)  (CD 10)  (NNS times) ) (JJR more) ) (NN cortivazol) ) (PP (IN than)  (NP (DT the)  (JJ normal)  (NNS cells) ))) (PP (IN for)  (NP (JJ significant)  (NN GR)  (NN mRNA)  (NN induction) )))))) (. .) ) )
(TOP (S (NP-SBJ-304 (NP (VBN Increased)  (NNS levels) ) (PP (IN of)  (NP (NN GR)  (NN mRNA) ))) (VP (VBD were)  (VP (VBN noticed)  (NP (-NONE- *-304) ) (ADVP-TMP (ADVP (RB as)  (RB early) ) (PP (IN as)  (PP-TMP (NP (CD 3)  (NN h) ) (IN after)  (NP (NN treatment) )))))) (. .) ) )
(TOP (S (NP-SBJ-305 (NP (DT A)  (JJ general)  (NN correlation) ) (PP (IN between)  (NP-COOD (NP (NP (NN induction) ) (PP (IN of)  (NP (NN GR)  (NN mRNA) ))) (CC and)  (NP (NP (NN lysis) ) (PP (IN of)  (NP (DT the)  (ADJP-COOD (ADJP (JJ normal) ) (CC and)  (ADJP (JJ dex-resistant) )) (NNS cells) )))))) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-305) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Positive)  (NN induction) ) (PP (IN of)  (NP (NN GR)  (NN mRNA) ))) (VP-COOD (VP (MD might)  (VP (VB be)  (NP-PRD (NP (CD one) ) (PP (IN of)  (NP (NP (DT the)  (JJS earliest)  (JJ crucial)  (NNS steps) ) (PP (IN in)  (NP (NP (DT the)  (NN lysis) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ normal) ) (CC and)  (ADJP (JJ dex-resistant) )) (NN CEM)  (NNS cells) ))))))))) (, ,)  (CC or)  (VP (MD might)  (VP (VB serve)  (PP (IN as)  (NP (NP (DT a)  (NN marker) ) (PP (IN for)  (NP (DT the)  (NN process) ))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (DT the)  (NN lysis)  (NN pathway) ) (PP (IN in)  (NP (DT the)  (JJ dex-resistant)  (NNS cells) ))) (VP (VBZ is)  (ADJP-PRD (JJ defective) ) (PP (IN in)  (SBAR (IN that)  (S (NP-SBJ (JJ dex-resistant)  (NNS clones) ) (VP (VBD needed)  (NP (NP (ADJP (RB significantly)  (JJR more) ) (NN cortivazol) ) (PP (IN than)  (NP (DT the)  (JJ normal)  (NNS cells) ))) (PP (IN for)  (NP (NP (NN lysis) ) (PP (IN of)  (NP (DT the)  (NNS cells) ))))))))) (. .) ) )
(TOP (NP (NP (NN Expression) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) )) (PP (IN on)  (NP (NP (JJ alveolar)  (NNS lymphocytes) ) (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ pulmonary)  (JJ granulomatous)  (NNS diseases) )))))) (. .) ) )
(TOP (S (NP-SBJ-41 (NN 1,25-LRB-OH-RRB-2D3) ) (VP (VBZ is)  (VP (VBN known)  (S (NP-SBJ-42 (-NONE- *-41) ) (VP (TO to)  (VP (VB be)  (VP (VBN produced)  (NP (-NONE- *-42) ) (PP (IN at)  (NP (NP (NNS sites) ) (PP (IN of)  (NP (JJ granulomatous)  (NNS reactions) )))))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN In)  (NN order)  (TO to)  (S (NP-SBJ-44 (-NONE- *-43) ) (VP (VB characterize)  (NP (NP (DT the)  (NN cell)  (NNS types) ) (SBAR (WHNP-45 (WDT that) ) (S (NP-SBJ (-NONE- *T*-45) ) (VP (VBP are)  (NP-PRD (NP (NNS targets) ) (PP (IN for)  (NP (DT this)  (JJ immunoregulatory)  (NN hormone) )))))))))) (, ,)  (NP-SBJ-43 (PRP we) ) (VP (VBP have)  (VP (VBN evaluated)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) )) (PP (IN on)  (NP-COOD (NP (JJ peripheral)  (NN blood)  (NNS T-lymphocytes) ) (CC and)  (NP (NP (DT those) ) (VP (VBN recovered)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT the)  (NN lung) )) (PP (IN by)  (NP (NP (JJ bronchoalveolar)  (NN lavage) ) (PP-COOD (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NP (JJ pulmonary)  (JJ granulomatous)  (NNS diseases) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN tuberculosis) ) (CC and)  (NP (NN sarcoidosis) )) (-RRB- -RRB-) ))))) (CC and)  (PP (IN from)  (NP (JJ normal)  (NN control)  (NNS subjects) ))))) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (JJ combined)  (ADJP-COOD (ADJP (JJ autoradiographic) ) (CC and)  (ADJP (JJ immunohistochemical) )) (NNS techniques) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (NN Lavage)  (NNS T-lymphocytes) ) (PP (IN from)  (NP (NP (NNS patients) ) (PP-COOD (PP (IN with)  (NP (NN tuberculosis) )) (CC or)  (PP (IN with)  (NP (NN sarcoidosis) )))))) (, ,)  (CONJP (CC but)  (RB not) ) (NP (NP (DT those) ) (PP (IN from)  (NP (JJ normal)  (NN control)  (NNS subjects) ))) (, ,) ) (VP (VBD expressed)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) ) (SBAR (IN as)  (S (NP-SBJ-46 (-NONE- *) ) (VP (VBN demonstrated)  (NP (-NONE- *-46) ) (PP (IN by)  (NP-LGS (NP (NP (NN binding) ) (PP (IN of)  (NP (NN -LCB-3H-RCB-1,25-LRB-OH-RRB-2D3) ))) (, ,)  (SBAR (WHNP-47 (WDT which) ) (S (NP-SBJ-48 (-NONE- *T*-47) ) (VP (VBD was)  (VP (VBN inhibited)  (NP (-NONE- *-48) ) (PP-COOD (PP (IN by)  (NP-LGS (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (JJ excess)  (JJ unlabeled)  (NN 1,25-LRB-OH-RRB-2D3) )))) (, ,)  (CC but)  (PP (RB not)  (IN by)  (NP-LGS (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (JJ unlabeled)  (NN 25-LRB-OH-RRB-D3) ))))))))))) (PRN (-LRB- -LRB-)  (NP (NP (JJ receptor-positive)  (NNS lymphocytes) ) (: :)  (NP-COOD (NP (NP (NN sarcoidosis) ) (, ,)  (FRAG (NP (QP (CD 20) (CC  +/-)  (CD 12) ) (NN %) ))) (: ;)  (NP (NP (NN tuberculosis) ) (, ,)  (FRAG (NP (QP (CD 31) (CC  +/-)  (CD 17) ) (NN %) ))))) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (NN blood)  (NNS lymphocytes) ) (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ granulomatous)  (NNS diseases) ))))) (VP (VBD did)  (RB not)  (VP (VB express)  (NP (JJ detectable)  (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN percentage) ) (PP (IN of)  (NP (NP (NN lavage)  (NNS T-lymphocytes) ) (VP (VBG expressing)  (NP (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) ))))) (VP (VBD was)  (ADJP-PRD (ADJP (RB significantly)  (JJR greater) ) (PP (-NONE- *ICH*-105) )) (PP (IN for)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN tuberculosis) )) (VP (VBG presenting)  (PP (IN with)  (NP (VBN isolated)  (JJ hilar)  (JJ adenopathy) ))))) (PP-105 (IN than)  (FRAG (PP (IN for)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ pulmonary)  (NP-COOD (NP (NNS infiltrates) ) (CC and/or)  (NP (NNS cavities) ))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-49 (NN 1,25-LRB-OH-RRB-2D3)  (NNS receptors) ) (VP (VBD were)  (VP (VBN expressed)  (NP (-NONE- *-49) ) (PP (TO to)  (NP (NP (DT a)  (JJR greater)  (NN extent) ) (PP (-NONE- *ICH*-106) ))) (PP (IN on)  (NP (JJ CD8+)  (NNS T-lymphocytes) )) (PP-106 (IN than)  (FRAG (PP (IN on)  (NP (JJ CD4+)  (NNS T-lymphocytes) )))) (PP (IN in)  (NP (NN sarcoidosis) ))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (NP (NP (DT a)  (JJR greater)  (NN proportion) ) (PP (IN of)  (NP (JJ CD4+)  (NP (-NONE- *RNR*-50) )))) (PP (IN than)  (FRAG (PP (IN of)  (NP (JJ CD8+)  (NP (-NONE- *RNR*-50) ))))) (NP-50 (NNS T-lymphocytes) )) (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN tuberculosis) ))))) (VP (VBD were)  (ADJP-PRD (JJ receptor-positive) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP support)  (NP (DT the)  (NN conclusion)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN interaction) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3) )) (PP (IN with)  (NP (NP (PRP$ its)  (NN receptor) ) (PP (IN on)  (NP (NNS T-lymphocytes) ))))) (VP (MD may)  (VP (VB play)  (NP (DT an)  (JJ important)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (JJ granulomatous)  (NNS reactions) ))))))))))) (, ,)  (CC but)  (S (SBAR-ADV (IN because)  (S (NP-SBJ-51 (DT these)  (NNS receptors) ) (VP (VBP are)  (VP (VBN expressed)  (NP (-NONE- *-51) ) (PP (IN on)  (NP (JJ different)  (NN lymphocyte)  (NNS populations) )))))) (, ,)  (NP-SBJ (NP (DT the)  (JJ net)  (NN effect) ) (PP (IN of)  (NP (DT this)  (JJ potent)  (JJ immunoregulatory)  (NN molecule) ))) (VP (VBZ is)  (ADJP-PRD (RB likely)  (JJ different) ) (PP (IN in)  (NP-COOD (NP (NN sarcoidosis) ) (CC and)  (NP (NN tuberculosis) ))))) (. .) ) )
(TOP (NP (NP (NN Inhibition) ) (PP (IN of)  (NP (NP (NN transcription)  (NNS factors) ) (VP (VBG belonging)  (PP (TO to)  (NP (DT the) (NN  rel/NF-kappa)  (NN B)  (NN family) ))))) (PP (IN by)  (NP (DT a)  (JJ transdominant)  (JJ negative)  (NN mutant) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN KBF1)  (NN factor) ) (, ,)  (SBAR (WHNP-30 (WDT which) ) (S (NP-SBJ (-NONE- *T*-30) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (DT the)  (NN enhancer)  (NN A) ) (VP (JJ located)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (DT the)  (NN promoter) ) (PP (IN of)  (NP (DT the)  (NN mouse)  (NN MHC)  (NN class)  (CD I)  (NN gene)  (NN H-2Kb) )))))))))) (, ,) ) (VP (VBZ is)  (ADJP-PRD (JJ indistinguishable)  (PP (IN from)  (NP (NP (DT the)  (NN p50)  (NN DNA)  (NN binding)  (NN subunit) ) (PP (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) )) (, ,)  (SBAR (WHNP-31 (WDT which) ) (S (NP-SBJ (-NONE- *T*-31) ) (VP (VBZ regulates)  (NP (NP (DT a)  (NN series) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBN involved)  (NP (-NONE- *) ) (PP (IN in)  (NP (ADJP-COOD (ADJP (JJ immune) ) (CC and)  (ADJP (JJ inflammatory) )) (NNS responses) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The) (NN  KBF1/p50)  (NN factor) ) (VP-COOD (VP (VBZ binds)  (PP (IN as)  (NP (DT a)  (NN homodimer) ))) (CC but)  (VP (MD can)  (ADVP (RB also) ) (VP (VB form)  (NP (NNS heterodimers) ) (PP (IN with)  (NP (NP (DT the)  (NNS products) ) (PP (IN of)  (NP (NP (JJ other)  (NNS members) ) (PP (IN of)  (NP (DT the)  (JJ same)  (NN family) )))) (, ,)  (PP (IN like)  (NP (DT the)  (NP-COOD (NP (NN c-rel) ) (CC and)  (NP (NN v-rel) )) (-LRB- -LRB-)  (NN proto)  (-RRB- -RRB-)  (NNS oncogenes) ))))))) (. .) ) )
(TOP (S (NP-SBJ-32 (NP (DT The)  (NN dimerization)  (NN domain) ) (PP (IN of)  (NP (NN KBF1/p50) ))) (VP (VBZ is)  (VP (VBN contained)  (NP (-NONE- *-32) ) (PP (IN between)  (NP (NN amino)  (NNS acids)  (NP-COOD (NP (CD 201) ) (CC and)  (NP (CD 367) )))))) (. .) ) )
(TOP (S (NP-SBJ-35 (NP-33 (NP (DT A)  (NN mutant) ) (PP (IN of)  (NP (NN KBF1/p50)  (-LRB- -LRB-)  (NN delta)  (NN SP)  (-RRB- -RRB-) ))) (, ,)  (ADJP-COOD (ADJP (JJ unable)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB bind)  (PP (TO to)  (NP (NN DNA) )))))) (CC but)  (ADJP (JJ able)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB form)  (NP-COOD (NP (JJ homo-)  (NP (-NONE- *?*) )) (CC or)  (NP (NNS heterodimers) ))))))) (, ,) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN constructed)  (NP (-NONE- *-35) )))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN protein) ) (VP (VP-COOD (VP (VBZ reduces)  (NP (-NONE- *RNR*-36) )) (CC or)  (VP (VBZ abolishes)  (NP (-NONE- *RNR*-36) ))) (ADVP (FW in)  (FW vitro) ) (NP-36 (NP (DT the)  (NN DNA)  (NN binding)  (NN activity) ) (PP (IN of)  (NP (NP (NP (JJ wild-type)  (NNS proteins) ) (PP (IN of)  (NP (DT the)  (JJ same)  (NN family) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN KBF1/p50) ) (, ,)  (NP-COOD (NP (NN c-)  (NP (-NONE- *?*) )) (CC and)  (NP (NN v-rel) ))) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (S (NP-SBJ (DT This)  (JJ mutant) ) (ADVP (RB also) ) (VP (NNS functions)  (ADVP (FW in)  (FW vivo) ) (PP (IN as)  (NP (DT a)  (JJ trans-acting)  (JJ dominant)  (JJ negative)  (NN regulator) ))) (: :) ) (S (NP-SBJ-38 (NP (DT the)  (JJ transcriptional)  (NN inducibility) ) (PP (IN of)  (NP (NP (DT the)  (NN HIV)  (JJ long)  (JJ terminal)  (NN repeat) ) (-LRB- -LRB-)  (SBAR (WHNP-37 (WDT which) ) (S (NP-SBJ (-NONE- *T*-37) ) (VP (VBZ contains)  (NP (CD two)  (JJ potential)  (NN NF-kappa)  (NN B)  (NN binding)  (NNS sites) )))) (-RRB- -RRB-) )) (PP (IN by)  (NP (NP (NN phorbol)  (NN ester) ) (PRN (-LRB- -LRB-)  (NP (NN PMA) ) (-RRB- -RRB-) )))) (VP (VBZ is)  (VP (VBN inhibited)  (NP (-NONE- *-38) ) (SBAR-TMP (WHADVP-39 (WRB when) ) (S (NP-SBJ-40 (PRP it) ) (VP (VBZ is)  (VP (VBN co-transfected)  (NP (-NONE- *-40) ) (PP (IN into)  (NP (JJ CD4+)  (NN T)  (NNS cells) )) (PP (IN with)  (NP (DT the)  (NN delta)  (NN SP)  (NN mutant) )) (ADVP (-NONE- *T*-39) ))))))) (. .) )) )
(TOP (S (ADVP (RB Similarly) ) (NP-SBJ-41 (NP (DT the)  (ADJP-COOD (ADJP (JJ basal) ) (CONJP (RB as)  (RB well)  (IN as) ) (ADJP-COOD (ADJP (NP (NN TNF) ) (ADJP (-NONE- *?*) )) (CC or)  (ADJP (JJ IL1-induced) ))) (NN activity) ) (PP (IN of)  (NP (DT the)  (NN MHC)  (NN class)  (CD I)  (NN H-2Kb)  (NN promoter) ))) (VP (MD can)  (VP (VB be)  (VP (VBN inhibited)  (NP (-NONE- *-41) ) (PP (IN by)  (NP-LGS (DT this)  (NN mutant) )) (PP (IN in)  (NP (CD two)  (JJ different)  (NN cell)  (NNS lines) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP constitute)  (NP (DT the)  (JJ first)  (JJ formal)  (NN demonstration)  (SBAR (IN that)  (S (NP-SBJ-42 (DT these)  (NNS genes) ) (VP (VBP are)  (VP (VBN regulated)  (NP (-NONE- *-42) ) (PP (IN by)  (NP-LGS (NP (NNS members) ) (PP (IN of)  (NP (DT the) (NN  rel/NF-kappa)  (NN B)  (NN family) )))))))))) (. .) ) )
(TOP (NP (NP (NP (JJ Human)  (JJ erythroid)  (NN 5-aminolevulinate)  (NN synthase) ) (: :) ) (NP (NP-COOD (NP (NN promoter)  (NN analysis) ) (CC and)  (NP (NN identification) )) (PP (IN of)  (NP (NP (DT an)  (JJ iron-responsive)  (NN element) ) (PP (IN in)  (NP (DT the)  (NN mRNA) )))) (. .) )) )
(TOP (S (NP-SBJ (NP (NN 5-Aminolevulinate)  (NN synthase) ) (PRN (-LRB- -LRB-)  (NP (NN ALAS) ) (-RRB- -RRB-) )) (VP (VBZ catalyzes)  (NP (NP (DT the)  (JJ first)  (NN step) ) (PP (IN of)  (NP (DT the)  (NN heme)  (JJ biosynthetic)  (NN pathway) )))) (. .) ) )
(TOP (S (NP-SBJ-21 (NP (NN cDNA)  (NNS clones) ) (PP (IN for)  (NP (DT the)  (JJ human)  (JJ erythroid)  (NN ALAS)  (NN isozyme) ))) (VP (VBD were)  (VP (VBN isolated)  (NP (-NONE- *-21) ) (PP (IN from)  (NP (DT a)  (JJ fetal)  (NN liver)  (NN library) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (MD can)  (VP (VB be)  (VP (VBN deduced)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (JJ erythroid)  (NN ALAS)  (NN precursor)  (NN protein) ) (VP-COOD (VP (VBZ has)  (NP (NP (DT a)  (JJ molecular)  (NN weight) ) (PP (IN of)  (NP (CD 64.6)  (NN kd) )))) (, ,)  (CC and)  (VP (VBZ is)  (ADJP-PRD (JJ similar)  (PP (IN in)  (NP (NN size) )) (PP (TO to)  (NP (NP (DT the)  (ADJP (RB previously)  (VBN isolated) ) (JJ human)  (JJ housekeeping)  (NN ALAS)  (NN precursor) ) (PP (IN of)  (NP (JJ molecular)  (NN weight)  (CD 70.6)  (NN kd) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-22 (NP (DT The)  (JJ mature)  (JJ mitochondrial)  (NNS forms) ) (PP (IN of)  (NP (DT the)  (UCP-COOD (ADJP (JJ erythroid) ) (CC and)  (NP (JJ housekeeping) )) (NN ALAS)  (NNS isozymes) ))) (VP (VBP are)  (VP (VBN predicted)  (S (NP-SBJ (-NONE- *-22) ) (VP (TO to)  (VP (VB have)  (NP (NP (JJ molecular)  (NNS weights) ) (PP (IN of)  (NP-COOD (NP (CD 59.5)  (NN kd) ) (CC and)  (NP (CD 64.6)  (NN kd) )))) (, ,)  (ADVP (RB respectively) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (CD two)  (NNS isozymes) ) (VP-COOD (VP (VBP show)  (NP (JJ little)  (NN amino)  (NN acid)  (NN identity) ) (PP (IN in)  (NP (PRP$ their)  (JJ N-terminal)  (NN signal)  (NNS sequences) ))) (CC but)  (VP (VBP have)  (NP (JJ considerable)  (NN sequence)  (NN identity) ) (PP (IN in)  (NP (NP (DT the)  (JJ C-terminal)  (CD two-thirds) ) (PP (IN of)  (NP (PRP$ their)  (NNS proteins) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT An)  (NN analysis) ) (PP (IN of)  (NP (NP (DT the)  (JJ immediate)  (NN promoter) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ erythroid)  (NN ALAS)  (NN gene) ))))) (VP (VBD revealed)  (NP (NP (JJ several)  (JJ putative)  (JJ erythroid-specific)  (JJ cis-acting)  (NNS elements) ) (PP (VBG including)  (NP (NP-COOD (PDT both)  (NP (DT a)  (NN GATA-1)  (NP (-NONE- *RNR*-93) )) (CC and)  (NP (DT an)  (NN NF-E2)  (NP (-NONE- *RNR*-93) ))) (NP-93 (NN binding)  (NN site) ))))) (. .) ) )
(TOP (S (NP-SBJ-23 (DT An)  (NP (NP (JJ iron-responsive)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN IRE) ) (-RRB- -RRB-) )) (NN motif) ) (VP-COOD (VP (VBZ has)  (VP (VBN been)  (VP (VBN identified)  (NP (-NONE- *-23) ) (PP (IN in)  (NP (NP (DT the)  (JJ 5'-untranslated)  (NN region) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ erythroid)  (NN ALAS)  (NN mRNA) ))))))) (, ,)  (CC but)  (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (DT the)  (JJ housekeeping)  (NN ALAS)  (NN mRNA) ))))) (. .) ) )
(TOP (S (NP-SBJ (NN Gel)  (NN retardation)  (NNS experiments) ) (VP (VBD established)  (SBAR (IN that)  (S-COOD (S (NP-SBJ (DT this)  (NN IRE)  (NN motif) ) (VP (VBD formed)  (NP (DT a)  (NP (JJ protein-RNA) ) (NN complex) ) (PP (IN with)  (NP (NP (JJ cytosolic)  (NNS extracts) ) (PP (IN from)  (NP (JJ human)  (NN K562)  (NNS cells) )))))) (CC and)  (S (NP-SBJ-24 (DT this)  (NN binding) ) (VP (VBD was)  (ADVP (RB strongly) ) (VP (VBN competed)  (NP (-NONE- *-24) ) (PP (IN with)  (NP (NP (NN IRE)  (NNS transcripts) ) (PP (IN from)  (NP (NP (NP-COOD (NP (NN ferritin) ) (CC or)  (NP (NN transferrin) )) (NN receptor) ) (NNS mRNAs) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (NN transcript) ) (PP (IN of)  (NP (DT the)  (NN ALAS)  (NN IRE) )) (, ,)  (VP (VBN mutated)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (DT the)  (VBN conserved)  (NN loop) ) (PP (IN of)  (NP (DT the)  (NN IRE) ))))) (, ,) ) (VP (VBD did)  (RB not)  (ADVP (RB readily) ) (VP (VB form)  (NP (DT this)  (NP (JJ protein-RNA) ) (NN complex) ))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP-COOD (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN IRE)  (NN motif) ) (PP (IN in)  (NP (DT the)  (NN ALAS)  (NN mRNA) ))) (VP (VBZ is)  (ADJP-PRD (JJ functional) ))))) (CC and)  (VP (VBP imply)  (SBAR (IN that)  (S (NP-SBJ-25 (NP (NN translation) ) (PP (IN of)  (NP (DT the)  (NN mRNA) ))) (VP (VBZ is)  (VP (VBN controlled)  (NP (-NONE- *-25) ) (PP (IN by)  (NP-LGS (JJ cellular)  (NN iron)  (NN availability) )) (PP-TMP (IN during)  (NP (NN erythropoiesis) )))))))) (. .) ) )
(TOP (NP (NP (JJ Human)  (NN tumor)  (NN necrosis)  (NN factor)  (NN alpha)  (NN gene)  (NN regulation) ) (PP (IN in)  (NP (ADJP (NN phorbol)  (NN ester)  (VBD stimulated) ) (NN T)  (CC and)  (NN B)  (NN cell)  (NNS lines) )) (. .) ) )
(TOP (S (NP-SBJ-28 (NP (DT The)  (JJ minimal)  (NN region) ) (PP (IN of)  (NP (NP (DT the)  (JJ human)  (NN tumor)  (NN necrosis)  (NN factor)  (NN alpha)  (-LRB- -LRB-)  (NN TNF-alpha)  (-RRB- -RRB-)  (NN gene)  (NN promoter) ) (ADJP (JJ necessary)  (PP (IN for)  (NP (NP (PRP$ its)  (JJ transcriptional)  (NN induction) ) (PP (IN by)  (NP (NP (NN phorbol)  (NNS esters) ) (PRN (-LRB- -LRB-)  (NP (NN PMA) ) (-RRB- -RRB-) ))) (PP (IN in)  (NP (JJ human)  (NN T)  (CC and)  (NN B)  (NN lymphocyte)  (NN cell)  (NNS lines) )))))))) (VP (VBZ has)  (VP (VBN been)  (VP (JJ localized)  (NP (-NONE- *-28) ) (PP (IN between)  (NP (NP-COOD (NP (CD -52) ) (CC and)  (NP (CD +89) )) (NP (NP (NNS nucleotides) ) (PRN (-LRB- -LRB-)  (NP (NN nt) ) (-RRB- -RRB-) )))) (ADVP (JJ relative)  (PP (TO to)  (NP (NP (DT the)  (NN gene)  (POS 's) ) (JJ transcriptional)  (NN start)  (NN site) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Comparison) ) (PP (IN of)  (NP (DT these)  (NNS sequences) )) (PP (TO to)  (NP (NP (DT those) ) (VP (VBN required)  (NP-29 (-NONE- *T*) ) (S (NP-SBJ (-NONE- *-29) ) (VP (TO to)  (VP (VB mediate)  (NP (NP (NP-COOD (NP (NN virus) ) (CC or)  (NP (NP (NN lipopolysaccharide) ) (PRN (-LRB- -LRB-)  (NP (NN LPS) ) (-RRB- -RRB-) ))) (NN induction) ) (PP (IN of)  (NP (DT the)  (NN gene) )))))))))) (VP (VB reveal)  (NP (JJ significant)  (NNS differences) ))) (, ,)  (CC and)  (RB thus)  (, ,)  (S (NP-SBJ (NP (DT the)  (NN sequence)  (NNS requirements) ) (PP (IN for)  (NP (NN PMA)  (NN induction) ))) (VP (VBP are)  (ADJP-PRD (JJ distinct)  (PP (IN from)  (NP (NP (DT those) ) (SBAR (WHNP-30 (WDT that) ) (S (NP-SBJ (-NONE- *T*-30) ) (VP (VBP mediate)  (NP (NP (NN induction) ) (PP (IN by)  (NP-COOD (NP (NN virus) ) (CC or)  (NP (NN LPS) )))))))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (NP (NP (CD three)  (NNS sites) ) (PP (IN in)  (NP (DT the)  (NN TNF-alpha)  (NN promoter) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN kappa)  (CD 1) ) (, ,)  (NP (NN kappa)  (CD 2) ) (, ,)  (CC and)  (NP (NN kappa)  (CD 3) )) (-RRB- -RRB-) )) (ADVP (RB specifically) ) (VP (VBP bind)  (NP (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) ) (PP (IN in)  (NP (JJ lymphoid)  (JJ nuclear)  (NNS extracts) )))))) (, ,)  (NP-SBJ (NP (NN TNF-alpha)  (NN mRNA)  (NN induction) ) (PP (IN by)  (NP (NN PMA) ))) (VP (VBZ does)  (RB not)  (VP (VB correlate)  (PP (IN with)  (NP (NP (NN NF-kappa)  (NN B)  (NN binding)  (NNS activities) ) (VP (VBN displayed)  (NP (-NONE- *) ) (PP (IN by)  (NP (JJ different)  (NN T)  (CC and)  (NN B)  (NN cell)  (NNS lines) ))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-COOD-31 (NP (NN kappa)  (CD 1) ) (: -)  (NP (NN kappa)  (CD 3) )) (VP (MD can)  (DT each)  (VP (VB be)  (VP (VBN deleted)  (NP (-NONE- *-31) ) (PP (IN from)  (NP (DT the)  (NN TNF-alpha)  (NN promoter) )) (PP (IN with)  (NP (NP (JJ little)  (NN effect) ) (PP (IN on)  (NP (NP (NP (DT the)  (NN gene)  (POS 's) ) (NN inducibility) ) (PP (IN by)  (NP (NN PMA) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Therefore) ) (, ,)  (NP-SBJ-32 (NP (NN TNF-alpha)  (NN mRNA)  (NN induction) ) (PP (IN by)  (NP (NN PMA) ))) (, ,)  (PP (IN like)  (NP (NP (PRP$ its)  (NN induction) ) (PP (IN by)  (NP-COOD (NP (NN virus) ) (CC and)  (NP (NN LPS) ))))) (, ,)  (VP-COOD (VP (VBZ is)  (RB not)  (ADVP (RB primarily) ) (VP (VBN mediated)  (NP (-NONE- *-32) ) (PP (IN by)  (NP-LGS (NN NF-kappa)  (NN B) )))) (, ,)  (CONJP (CC but)  (RB rather) ) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-32) ) (PP (IN through)  (NP (JJ other)  (NP-COOD (NP (NNS sequences) ) (CC and)  (NP (NN protein)  (NNS factors) ))))))) (. .) ) )
(TOP (S (ADVP (RB Surprisingly) ) (, ,)  (NP-SBJ (NP (NNS multimers) ) (PP (IN of)  (NP-COOD (NP (NN kappa)  (CD 1) ) (: -)  (NP (NN kappa)  (CD 3) )))) (VP (MD can)  (VP (VB confer)  (NP (NN PMA)  (NN inducibility) ) (PP (IN on)  (NP (NP (DT a)  (JJ heterologous)  (NN promoter) ) (PP (IN in)  (NP (NP-COOD (NP (DT a)  (NP (NP (NN B) ) (PRN (-LRB- -LRB-)  (NP (NN Raji) ) (-RRB- -RRB-) )) (NP (-NONE- *RNR*-33) )) (, ,)  (CONJP (CC but)  (RB not) ) (NP (DT a)  (NP (NP (NN T) ) (PRN (-LRB- -LRB-)  (NP (NN HUT78) ) (-RRB- -RRB-) )) (NP (-NONE- *RNR*-33) ))) (NP-33 (NN cell)  (NN line) ))))))) (. .) ) )
(TOP (S (ADVP (WRB However) ) (NP-SBJ (PRP they) ) (VP (VBP are)  (RB not)  (ADJP-PRD (JJ functional) ) (PP (IN on)  (NP (DT a)  (VBN truncated)  (NN TNF-alpha)  (NN promoter) )) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN promoter)  (NN context) ) (CC and)  (NP (NN cell)  (NN type)  (NN specificity) )) (VP (VBP influence)  (NP (NP (DT the)  (NN PMA)  (JJ inducible)  (NN function) ) (PP (IN of)  (NP (DT these)  (NN NF-kappa)  (NN B)  (NN binding)  (NNS sites) ))))))))) (. .) ) )
(TOP (FRAG (PP (IN Towards)  (NP (NP (DT a)  (JJ molecular)  (NN understanding) ) (PP (IN of)  (NP (NN T-cell)  (NN differentiation) ))))) )
(TOP (S (NP-SBJ (JJ Lymphoid)  (NN differentiation) ) (VP (VBZ is)  (NP-PRD (NP (CD one) ) (PP (IN of)  (NP (NP (DT the)  (ADJP (RBS best)  (VBN studied) ) (NNS examples) ) (PP (IN of)  (NP (JJ mammalian)  (NN development) )))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ-COOD (NP (NNP Hans)  (NNP Clevers) ) (CC and)  (NP (NNP Michael)  (NNP Owen) )) (VP (VBP describe)  (SBAR (WHADVP-107 (WRB how) ) (S (NP-SBJ (NP (DT the)  (NN cloning) ) (PP (IN of)  (NP (NP (DT the)  (NNS genes) ) (SBAR (WHNP-68 (WDT that) ) (S (NP-SBJ (-NONE- *T*-68) ) (VP (VBP encode)  (JJ T-cell-specific)  (NN membrane)  (NNS proteins) )))))) (VP (VBZ allows)  (NP (NP (DT the)  (NN identification) ) (PP (IN of)  (NP (NP (NN transcription)  (NNS factors) ) (SBAR (WHNP-69 (WDT that) ) (S (NP-SBJ (-NONE- *T*-69) ) (VP (VBP control)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (DT these)  (NN T-cell)  (NNS genes) ))))))))) (ADVP (-NONE- *T*-107) ))))) (. .) ) )
(TOP (S (NP-SBJ-70 (JJ Such)  (NN transcription)  (NNS factors) ) (VP (VBP play)  (NP (DT a)  (JJ key)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN development) ) (PP (IN of)  (NP (DT the)  (JJ mature)  (NN T-cell)  (NN phenotype) )))) (PP (IN by)  (S (NP-SBJ (-NONE- *-70) ) (VP (VBG functioning)  (PP (IN as)  (`` ')  (NP (NP (JJ master)  (NNS regulators) ) (PP (IN of)  (NP (NN T-cell)  (NN differentiation) ))) ('' ') ))))) (. .) ) )
(TOP (NP (NP (NN Regulation) ) (PP (IN of)  (NP (NP (NN jun)  (CC and)  (NN fos)  (NN gene)  (NN expression) ) (PP (IN in)  (NP (JJ human)  (NNS monocytes) )))) (PP (IN by)  (NP (DT the)  (ADJP (NN macrophage)  (JJ colony-stimulating) ) (NN factor) )) (. .) ) )
(TOP (S (NP-SBJ-26 (DT The)  (NP (ADJP (NN macrophage)  (JJ colony-stimulating) ) (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN M-CSF) ) (-RRB- -RRB-) )) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-26) ) (PP (IN for)  (NP (NP (DT the)  (NP-COOD (NP (NN growth) ) (CC and)  (NP (NN differentiation) ))) (PP (IN of)  (NP (JJ mononuclear)  (NNS phagocytes) )))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (DT the)  (NN signaling)  (NNS events) ) (ADJP (JJ responsible)  (PP (IN for)  (NP (DT these)  (NNS effects) )))) (VP (VBP remain)  (ADJP-PRD (JJ unclear) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ present)  (NNS studies) ) (VP (VBP have)  (VP (VBN examined)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NN M-CSF) )) (PP (IN on)  (NP (NP (JJ potential)  (NN signaling)  (NNS pathways) ) (VP (VBG involving)  (NP (NN expression)  (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN jun) ) (CC and)  (NP (NN fos) )) (JJ early)  (NN response)  (NNS genes) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Low)  (NNS levels) ) (PP (IN of)  (NP (NN c-jun)  (NNS transcripts) ))) (VP (VBD were)  (ADJP-PRD (JJ detectable) ) (PP (IN in)  (NP (VBG resting)  (JJ human)  (JJ peripheral)  (NN blood)  (NNS monocytes) ))) (. .) ) )
(TOP (S (NP-SBJ-27 (NP (NN Treatment) ) (PP (IN of)  (NP (DT these)  (NNS cells) )) (PP (IN with)  (NP (CD 10-LRB-3-RRB-) (NNS  units/ml)  (JJ human)  (JJ recombinant)  (NN M-CSF) ))) (VP (VBD was)  (VP (VBN associated)  (NP (-NONE- *-27) ) (PP (IN with)  (NP (NP (ADJP-COOD (ADJP (JJ rapid) ) (CC and)  (ADJP (JJ transient) )) (NNS increases) ) (PP (IN in)  (NP (NN c-jun)  (NN mRNA)  (NNS levels) )))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (JJ Nuclear)  (JJ run-on)  (NNS assays) ) (CC and)  (NP (NN mRNA)  (NN stability)  (NNS studies) )) (VP (VBD demonstrated)  (SBAR (IN that)  (S (NP-SBJ (NN M-CSF) ) (VP (VBZ regulates)  (NP (NN c-jun)  (NN expression) ) (PP (IN by)  (NP-COOD (CC both)  (NP (NP (DT an)  (NN increase) ) (PP (IN in)  (NP (NN transcription)  (NN rate) ))) (CC and)  (NP (NP (DT a)  (NN prolongation) ) (PP (IN in)  (NP (NP (DT the)  (NN half-life) ) (PP (IN of)  (NP (NN c-jun)  (NNS transcripts) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-28 (NN M-CSF)  (NN treatment) ) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN associated)  (NP (-NONE- *-28) ) (PP (IN with)  (NP (NP (DT a)  (JJ rapid)  (NN induction) ) (PP (IN of)  (NP (DT the)  (NN jun-B)  (NN gene) )))) (, ,)  (SBAR (IN although)  (S (NP-SBJ-29 (NP (NN expression) ) (PP (IN of)  (NP (DT this)  (NN gene) ))) (VP (VBD was)  (VP (JJ prolonged)  (NP (-NONE- *-29) ) (S (NP-SBJ-31 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-31) ) (PP (TO to)  (NP (NP (DT that) ) (PP (IN of)  (NP (NN c-jun) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB further) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NN M-CSF) ) (VP (VBZ increases)  (NP (NP (NN c-fos)  (NN mRNA)  (NNS levels) ) (PP (IN in)  (NP (JJ human)  (NNS monocytes) ))) (PP (IN through)  (NP (NP (NN control) ) (PP (IN at)  (NP (CC both)  (DT the)  (ADJP-COOD (ADJP (JJ transcriptional) ) (CC and)  (ADJP (JJ posttranscriptional) )) (NNS levels) )))))))) (. .) ) )
(TOP (S (NP-SBJ-32 (NP (JJ Maximal)  (NN induction) ) (PP (IN of)  (NP (DT the)  (NN c-fos)  (NN gene) ))) (VP (VBD was)  (VP (VBN followed)  (NP (-NONE- *-32) ) (PP (IN by)  (NP-LGS (NP (DT that) ) (PP (IN for)  (NP (DT the)  (NN fos-B)  (NN gene) )))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-33 (NP (NP (JJ M-CSF-induced)  (NN expression) ) (PP (IN of)  (NP (DT the)  (JJ fos-related)  (NN gene) ))) (, ,)  (NP (NN fra-1) ) (, ,) ) (VP (VBD was)  (VP (VBN delayed)  (NP (-NONE- *-33) ) (S (NP-SBJ-35 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-35) ) (PP (TO to)  (NP (NP (DT that) ) (PP (IN for)  (NP-COOD (DT both)  (NP (NN c-fos) ) (CC and)  (NP (NN fos-B) ))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-37 (-NONE- *-36) ) (VP (VBN Taken)  (NP (-NONE- *-37) ) (ADVP (RB together) ))) (, ,)  (NP-SBJ-36 (DT the)  (NNS results) ) (VP (VBP indicate)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ-38 (NN M-CSF)  (NN treatment) ) (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-38) ) (PP (IN with)  (NP (NP (JJ differential)  (NN activation) ) (PP (IN of)  (NP (NP (JJ multiple)  (NNS members) ) (PP (IN of)  (NP (DT the) (NN  jun/fos)  (NN family) )))))))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (NP (NN expression) ) (PP (IN of)  (NP (DT these)  (NNS genes) ))) (VP (MD could)  (VP (VB contribute)  (PP (TO to)  (NP (NP (JJ nuclear)  (NN signaling)  (NNS mechanisms) ) (SBAR (WHNP-39 (WDT that) ) (S (NP-SBJ (-NONE- *T*-39) ) (VP (VBP regulate)  (NP (NP (DT a)  (JJ specific)  (NN program) ) (PP (IN of)  (NP (NN monocyte)  (NN differentiation) )))))))))))))) (. .) ) )
(TOP (NP (NP (NN Cloning) ) (PP (IN of)  (NP (NP (DT a)  (JJ human)  (NN homeobox)  (NN gene) ) (SBAR (WHNP-57 (WDT that) ) (S (NP-SBJ-58 (-NONE- *T*-57) ) (VP-COOD (VP (VBZ resembles)  (NP (DT a)  (JJ diverged)  (NN Drosophila)  (NN homeobox)  (NN gene) )) (CC and)  (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-58) ) (PP (IN in)  (NP (VBN activated)  (NNS lymphocytes) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-59 (NP (DT A)  (JJ new)  (NN homeobox)  (NN gene) ) (, ,)  (NP (NN HB24) ) (, ,) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN isolated)  (NP (-NONE- *-59) ) (PP (IN from)  (NP (DT a)  (JJ human)  (NN B-lymphocyte)  (NN cDNA)  (NN library) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Northern)  (NN blot)  (NN analysis) ) (PP (IN of)  (NP (NP (JJ polyadenylated)  (NN RNA) ) (VP (VBN purified)  (NP (-NONE- *) ) (PP (IN from)  (NP (VBN activated)  (JJ human)  (NN B)  (NNS cells) )))))) (VP (VBD revealed)  (NP (NP (DT a)  (JJ single)  (NN mRNA)  (NN transcript) ) (PP (IN of)  (NP (QP (RB approximately)  (CD 2.3) ) (NN kb) )))) (. .) ) )
(TOP (S (NP-SBJ-60 (CD Two)  (NN cDNA)  (NNS clones) ) (VP (VBD were)  (VP-COOD (VP (VBN sequenced)  (NP (-NONE- *-60) )) (CC and)  (VP (VBN provided)  (NP (-NONE- *-60) ) (NP (NP (CD 2,250)  (NP (NP (NNS nucleotides) ) (PRN (-LRB- -LRB-)  (NP (NN nt) ) (-RRB- -RRB-) ))) (PP (IN of)  (NP (NN DNA)  (NN sequence)  (NN information) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (EX There) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ single)  (ADJP (NN methionine)  (JJ codon-initiated) ) (JJ open)  (NN reading)  (NN frame) ) (PP (IN of)  (NP (CD 1,458)  (NN nt) ))) (PP (IN in)  (NP (NP (NN frame) ) (PP (IN with)  (NP-COOD (NP (DT a)  (NN homeobox) ) (CC and)  (NP (DT a)  (NN CAX)  (NN repeat) ))))))) (, ,)  (CC and)  (S (NP-SBJ-61 (DT the)  (JJ open)  (NN reading)  (NN frame) ) (VP (VBZ is)  (VP (VBN predicted)  (S (NP-SBJ (-NONE- *-61) ) (VP (TO to)  (VP (VB encode)  (NP (NP (DT a)  (NN protein) ) (PP (IN of)  (NP (CD 51,659)  (NNS daltons) ))))))))) (. .) ) )
(TOP (S-COOD (S (SBAR-TMP (WHADVP-63 (WRB When) ) (S (NP-SBJ-64 (NP (DT the)  (NN homeodomain) ) (PP (IN from)  (NP (NN HB24) ))) (VP (VBD was)  (VP (VBN compared)  (NP (-NONE- *-64) ) (PP (TO to)  (NP (JJ known)  (UCP-COOD (ADJP (JJ mammalian) ) (CC and)  (NP (NN Drosophila) )) (NNS homeodomains) )) (ADVP (-NONE- *T*-63) ))))) (NP-SBJ-62 (PRP it) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-62) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (ADVP (RB only)  (RB moderately) ) (VBN conserved) ))))))) (, ,)  (CC but)  (S (SBAR-TMP (WHADVP-65 (WRB when) ) (S (NP-SBJ-66 (PRP it) ) (VP (VBD was)  (VP (VBN compared)  (NP (-NONE- *-66) ) (PP (TO to)  (NP (NP (DT a)  (ADJP (RB highly)  (JJ diverged) ) (FW Drosophila)  (NN homeodomain) ) (, ,)  (NP (NN H2.0) ) (, ,) )) (ADVP (-NONE- *T*-65) ))))) (NP-SBJ-67 (PRP it) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-67) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (NP (CD 80)  (NN %) ) (JJ identical) ))))))) (. .) ) )
(TOP (S (S (NP-SBJ (DT The)  (NN HB24)  (NN mRNA) ) (VP (VBD was)  (ADJP-PRD-COOD (ADJP (JJ absent) ) (CC or)  (ADJP (JJ present) )) (PP (IN at)  (NP (JJ low)  (NNS levels) )) (PP (IN in)  (NP (JJ normal)  (NP (NP-COOD (NP (NN B) ) (CC and)  (NP (NN T) )) (NNS lymphocytes) )))) (: ;) ) (S (ADVP (RB however) ) (, ,)  (PP (IN with)  (NP (DT the)  (JJ appropriate)  (NN activation)  (NN signal) )) (NP-SBJ-69 (NN HB24)  (NN mRNA) ) (VP (VBD was)  (VP (VBN induced)  (NP (-NONE- *-69) ) (PP-TMP (IN within)  (NP (JJ several)  (NNS hours) )) (PP (RB even)  (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN cycloheximide) )))) (. .) )) )
(TOP (S (NP-SBJ-70 (NP (NN Characterization) ) (PP (IN of)  (NP (NP (NN HB24)  (NN expression) ) (PP (IN in)  (NP-COOD (NP (JJ lymphoid) ) (CC and)  (NP (JJ select)  (VBG developing)  (NNS tissues) )))))) (VP (VBD was)  (VP (VBN performed)  (NP (-NONE- *-70) ) (PP (IN by)  (NP (ADJP (FW in)  (FW situ) ) (NN hybridization) )))) (. .) ) )
(TOP (S (NP-SBJ-71 (JJ Positive)  (NN hybridization) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-71) ) (PP-COOD (PP (IN in)  (NP-COOD (NP (NN thymus) ) (, ,)  (NP (NN tonsil) ) (, ,)  (NP (NN bone)  (NN marrow) ) (, ,)  (NP (VBG developing)  (NNS vessels) ))) (, ,)  (CC and)  (PP (IN in)  (NP (JJ fetal)  (NN brain) ))))) (. .) ) )
(TOP (S (NP-SBJ-72 (NN HB24) ) (VP (VBZ is)  (ADJP-PRD (JJ likely)  (S (NP-SBJ (-NONE- *-72) ) (VP (TO to)  (VP (VB have)  (NP (DT an)  (JJ important)  (NN role) ) (PP-COOD (PP (IN in)  (NP (NNS lymphocytes) )) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN in)  (NP (JJ certain)  (VBG developing)  (NNS tissues) )))))))) (. .) ) )
(TOP (NP (NP (JJ Severe)  (NN 5-fluorouracil)  (NN toxicity) ) (ADJP (JJ secondary)  (PP (TO to)  (NP (NN dihydropyrimidine)  (NN dehydrogenase)  (NN deficiency) ))) (. .) ) )
(TOP (NP (NP (DT A)  (ADJP (RB potentially)  (RBR more)  (JJ common) ) (JJ pharmacogenetic)  (NN syndrome) ) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN study) ) (VP (VBZ describes)  (NP (NP-COOD (NP (NP (DT the)  (NN inheritance) ) (PP (IN of)  (NP (NP (DT a)  (NN defect) ) (PP (IN in)  (NP (NN pyrimidine)  (NN catabolism) ))))) (CC and)  (NP (NP (PRP$ its)  (NN association) ) (PP (IN with)  (NP (JJ drug-induced)  (NN toxicity) )))) (PP (IN in)  (NP (NP (DT a)  (NN patient) ) (VP (VBG receiving)  (NP (NN 5-fluorouracil)  (PRN (-LRB- -LRB-)  (NP (NN FUra) ) (-RRB- -RRB-) )) (PP (IN as)  (NP (NP (JJ adjuvant)  (NN chemotherapy) ) (PP (IN for)  (NP (NN breast)  (NN carcinoma) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN study)  (NN population) ) (VP (VBD included)  (NP-COOD (NP (NP (NP (DT the)  (VBN affected)  (NN patient) ) (PRN (-LRB- -LRB-)  (NP (NN proband) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (CD nine) ) (PP (IN of)  (NP (PRP$ her)  (NN blood)  (NNS relatives) ))) (, ,) ) (CC and)  (NP (CD seven)  (JJ healthy)  (NNS volunteers) ))) (. .) ) )
(TOP (S (NP-SBJ-30 (NP (DT The)  (NN activity) ) (PP (IN of)  (NP (NP (NP (NP (NN dihydropyrimidine)  (NN dehydrogenase) ) (PRN (-LRB- -LRB-)  (NP (NN DPD) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (DT the)  (JJ initial)  (NN enzyme) ) (PP (IN of)  (NP (NP-COOD (NP (NN pyrimidine) ) (-LRB- -LRB-)  (CC and)  (NP (NN FUra) ) (-RRB- -RRB-) ) (NN catabolism) ))) (, ,) ) (PP (IN in)  (NP (JJ peripheral)  (NN blood)  (JJ mononuclear)  (NNS cells) ))))) (VP (VBD was)  (VP (VBN measured)  (NP (-NONE- *-30) ) (PP (IN in)  (NP (DT each)  (NN subject) )) (PP (IN by)  (NP (NP (DT a)  (JJ specific)  (JJ radiometric)  (NN assay) ) (VP (VBG using)  (NP (NN FUra) ) (PP (IN as)  (NP (DT the)  (NN substrate) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN proband) ) (VP (VBD had)  (NP (DT no)  (JJ detectable)  (NN DPD)  (NN activity) )) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-101 (WRB When) ) (S (NP-SBJ-31 (NP (NN enzyme)  (NNS levels) ) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN proband) ) (CC and)  (NP (NNS relatives) ))))) (VP (VBD were)  (VP (VBN compared)  (NP (-NONE- *-31) ) (PP (IN with)  (NP (NP (DT that) ) (PP (IN in)  (NP (NNS controls) )))) (ADVP (-NONE- *T*-101) ))))) (, ,)  (NP-SBJ-32 (NP (DT an)  (JJ autosomal)  (JJ recessive)  (NN pattern) ) (PP (IN of)  (NP (NN inheritance) ))) (VP (VBD was)  (VP (VBN demonstrated)  (NP (-NONE- *-32) ))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ is)  (NP-PRD-COOD (NP (NP (DT the)  (JJ third)  (NN patient) ) (PP (IN with)  (NP (NP (JJ severe)  (NN FUra)  (NN toxicity) ) (ADJP (JJ secondary)  (PP (TO to)  (NP (NP (DT an)  (NN alteration) ) (PP (IN in)  (NP (NN pyrimidine)  (NN catabolism) )))))))) (CC and)  (NP (NP (DT the)  (NN second) ) (PP (IN from)  (NP (PRP$ our)  (NN clinic)  (NN population) )))) (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN frequency) ) (PP (IN of)  (NP (DT this)  (JJ genetic)  (NN defect) ))) (VP (MD may)  (VP (VB be)  (ADJP-PRD (ADJP (JJR greater) ) (SBAR (IN than)  (S (NP-SBJ-33 (-NONE- *) ) (ADVP-TMP (RB previously) ) (VP (VBN thought)  (NP (-NONE- *-33) )))))))))))) (. .) ) )
(TOP (S (S-SBJ (NP-SBJ (-NONE- *) ) (VP (VBG Monitoring)  (NP (NN DPD)  (NN activity) ))) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ important) ) (PP (IN in)  (NP (NP (DT the)  (NN management) ) (PP (IN of)  (NP (NP (NNS patients) ) (VP (VBG experiencing)  (NP (NP (JJ severe)  (NN toxicity) ) (ADJP (JJ secondary)  (PP (TO to)  (NP (NN FUra)  (NN chemotherapy) ))))))))))) (. .) ) )
(TOP (NP (NP (NN Characterization) ) (PP (IN of)  (NP (NP (DT an)  (JJ immediate-early)  (NN gene) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN in)  (NP (JJ adherent)  (NNS monocytes) ))) (SBAR (WHNP-211 (WDT that) ) (S (NP-SBJ (-NONE- *T*-211) ) (VP (VBZ encodes)  (NP (ADJP (NN I)  (NN kappa)  (JJ B-like) ) (NN activity) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN cloned)  (NP (NP (DT a)  (NN group) ) (PP (IN of)  (NP (NP (NNS cDNAs) ) (VP (VBG representing)  (NP (NP (NNS mRNAs) ) (SBAR (WHNP-212 (WDT that) ) (S (NP-SBJ-22 (-NONE- *T*-212) ) (VP (VBP are)  (ADVP-TMP (RB rapidly) ) (VP (VBN induced)  (NP (-NONE- *-22) ) (PP (VBG following)  (NP (NP (NN adherence) ) (PP (IN of)  (NP (JJ human)  (NNS monocytes) ))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (CD One) ) (PP (IN of)  (NP (DT the)  (VBN induced)  (NNS transcripts) ))) (PRN (-LRB- -LRB-)  (NP (NN MAD-3) ) (-RRB- -RRB-) )) (VP (VBZ encodes)  (NP (NP (DT a)  (NN protein) ) (PP (IN of)  (NP (CD 317)  (NN amino)  (NNS acids) )) (PP (IN with)  (NP (NP (CD one)  (NN domain) ) (VP (VBG containing)  (NP (NP (CD five)  (JJ tandem)  (NNS repeats) ) (PP (IN of)  (NP (DT the) (JJ  cdc10/ankyrin)  (NN motif) )))))) (, ,)  (SBAR (WHNP-13 (WDT which) ) (S (NP-SBJ (-NONE- *T*-13) ) (VP (VBZ is)  (ADJP-PRD (ADJP (NP (CD 60)  (NN %) ) (JJ similar)  (PP (-NONE- *ICH*-23) )) (PRN (-LRB- -LRB-)  (ADJP (NP (CD 46)  (NN %) ) (JJ identical)  (PP (-NONE- *?*) )) (-RRB- -RRB-) ) (PP-23 (TO to)  (NP (NP (DT the)  (NN ankyrin)  (NN repeat)  (NN region) ) (PP (IN of)  (NP (NP (DT the)  (NN precursor) ) (PP (IN of)  (NP (NN NF-kappa) (NN  B/KBF1)  (NN p50) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN C-terminus) ) (VP (VBZ has)  (NP (DT a)  (JJ putative)  (NN protein)  (NN kinase)  (NN C)  (NN phosphorylation)  (NN site) )) (. .) ) )
(TOP (S (NP-SBJ-14 (ADJP (ADVP (FW In)  (FW vitro) ) (VBN translated) ) (NN MAD-3)  (NN protein) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-14) ) (VP (TO to)  (ADVP (RB specifically) ) (VP (VB inhibit)  (NP-COOD (NP (NP (DT the)  (JJ DNA-binding)  (NN activity) ) (PP (IN of)  (NP (DT the) (NN  p50/p65)  (NN NF-kappa)  (NN B)  (NN complex) ))) (CONJP (CC but)  (RB not) ) (NP (NP (DT that) ) (PP-COOD (PP (IN of)  (NP (DT the) (NN  p50/p50)  (NN KBF1)  (NN factor) )) (CC or)  (PP (IN of)  (NP (JJ other)  (JJ DNA-binding)  (NNS proteins) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN MAD-3)  (NN cDNA) ) (VP (VBZ encodes)  (NP (NP (DT an)  (ADJP (NN I)  (NN kappa)  (JJ B-like) ) (NN protein) ) (SBAR (WHNP-16 (WDT that) ) (S (NP-SBJ-24 (-NONE- *T*-16) ) (VP (VBZ is)  (ADJP-PRD (JJ likely)  (S (NP-SBJ-25 (-NONE- *-24) ) (VP (TO to)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-25) ) (PP (IN in)  (NP (NP (NN regulation) ) (PP (IN of)  (NP (NP (JJ transcriptional)  (NNS responses) ) (PP (TO to)  (NP (NN NF-kappa)  (NN B) )))) (, ,)  (PP (VBG including)  (NP (NP (JJ adhesion-dependent)  (NNS pathways) ) (PP (IN of)  (NP (NN monocyte)  (NN activation) )))))))))))))))) (. .) ) )
(TOP (NP (NP (JJ Reactive)  (NN oxygen)  (NNS intermediates) ) (PP (IN as)  (ADJP (RB apparently)  (RB widely)  (VBN used) ) (NNS messengers) ) (PP (IN in)  (NP (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN NF-kappa)  (NN B)  (NN transcription)  (NN factor) ) (CC and)  (NP (NN HIV-1) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP-COOD (NP (NN Hydrogen)  (NN peroxide) ) (CC and)  (NP (NN oxygen) )) (NNS radicals) ) (VP (VBP are)  (NP-PRD (NP (NNS agents) ) (VP (ADVP (RB commonly) ) (VP (VBN produced)  (NP (-NONE- *) ) (PP-TMP (IN during)  (NP (JJ inflammatory)  (NNS processes) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ micromolar)  (NNS concentrations) ) (PP (IN of)  (NP (NN H2O2) ))) (VP (MD can)  (VP (VB induce)  (NP (NP (DT the)  (NP-COOD (NP (NN expression) ) (CC and)  (NP (NN replication) ))) (PP (IN of)  (NP (NN HIV-1) )) (PP (IN in)  (NP (DT a)  (JJ human)  (NN T)  (NN cell)  (NN line) )))))))) (. .) ) )
(TOP (S (NP-SBJ-24 (DT The)  (NN effect) ) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-24) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN NF-kappa)  (NN B)  (NN transcription)  (NN factor) ) (SBAR (WHNP-25 (WDT which) ) (S (NP-SBJ-26 (-NONE- *T*-25) ) (VP (VBZ is)  (ADVP-COOD (ADVP (RB potently) ) (CC and)  (ADVP-TMP (RB rapidly) )) (VP (VBN activated)  (NP (-NONE- *-26) ) (IN by)  (NP-LGS (NP (DT an)  (NN H2O2)  (NN treatment) ) (PP (IN of)  (NP (NNS cells) )) (PP (IN from)  (NP (PRP$ its)  (JJ inactive)  (JJ cytoplasmic)  (NN form) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (NN N-acetyl-L-cysteine) ) (PRN (-LRB- -LRB-)  (NP (NN NP) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (DT a)  (ADJP (RB well)  (VBN characterized) ) (NN antioxidant) ) (SBAR (WHNP-27 (WDT which) ) (S (NP-SBJ (-NONE- *T*-27) ) (VP (VBZ counteracts)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NP (JJ reactive)  (NN oxygen)  (NNS intermediates) ) (PRN (-LRB- -LRB-)  (NP (NN ROI) ) (-RRB- -RRB-) ))) (PP (IN in)  (NP (VBG living)  (NNS cells) ))))))) (, ,) ) (VP (VBD prevented)  (NP (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (PP (IN by)  (NP (NN H2O2) )))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN NP) ) (CC and)  (NP (JJ other)  (JJ thiol)  (NNS compounds) )) (ADVP (RB also) ) (VP (VBD blocked)  (NP (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (PP (IN by)  (NP-COOD (NP (NN cycloheximide) ) (, ,)  (NP (ADJP (JJ double-stranded) ) (NN RNA) ) (, ,)  (NP (NN calcium)  (NN ionophore) ) (, ,)  (NP (NN TNF-alpha) ) (, ,)  (NP (JJ active)  (NN phorbol)  (NN ester) ) (, ,)  (NP (NN interleukin-1) ) (, ,)  (NP (NN lipopolysaccharide) ) (CC and)  (NP (NN lectin) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ diverse)  (NNS agents) ) (VP (VBN thought)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB activate)  (NP (NN NF-kappa)  (NN B) ) (PP (IN by)  (NP (JJ distinct)  (JJ intracellular)  (NNS pathways) ))))))) (VP (MD might)  (ADVP (RB all) ) (VP (VB act)  (PP (IN through)  (NP (NP (DT a)  (JJ common)  (NN mechanism) ) (VP (VBG involving)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NN ROI) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-29 (NN ROI) ) (VP (VBP appear)  (S (NP-SBJ (-NONE- *-29) ) (VP (TO to)  (VP (VB serve)  (PP (IN as)  (NP (NP (NNS messengers) ) (VP (VBG mediating)  (ADVP-COOD (ADVP (RB directly) ) (CC or)  (ADVP (RB indirectly) )) (NP (NP (DT the)  (NN release) ) (PP (IN of)  (NP (DT the)  (JJ inhibitory)  (NN subunit)  (NN I)  (NN kappa)  (NN B) )) (PP (IN from)  (NP (NN NF-kappa)  (NN B) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN HTLV-1)  (NN Tax) ) (VP (VBZ induces)  (NP (NP (NN expression) ) (PP (IN of)  (NP (JJ various)  (JJ immediate)  (JJ early)  (NN serum)  (JJ responsive)  (NNS genes) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Human)  (NN T-cell)  (NN leukemia)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HTLV-1) ) (-RRB- -RRB-) )) (VP (VBZ is)  (NP-PRD (NP (DT an)  (JJ etiological)  (NN agent) ) (PP (IN of)  (NP (NP (JJ adult)  (NN T-cell)  (NN leukemia) ) (PRN (-LRB- -LRB-)  (NP (NN ATL) ) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD showed)  (ADVP (RB here) ) (PP (IN by)  (NP (NN mobility-shift)  (NN assay) )) (SBAR (IN that)  (S (NP-SBJ (NP (NN T-cell)  (NNS lines) ) (VP (VBN transformed)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT the)  (NN virus) )))) (VP (VBD contained)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (NN AP-1)  (NNS activities) ))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (ADJP-PRD (JJ Consistent)  (PP (IN with)  (NP (DT this)  (NN result) )))) (, ,)  (NP-SBJ (DT these)  (NN cell)  (NNS lines) ) (VP (VBD expressed)  (NP (NP (VBN increased)  (NNS levels) ) (PP (IN of)  (NP (NP (NNS mRNAs) ) (VP (VBG encoding)  (NP (NP (DT the)  (NN AP-1)  (NNS proteins) ) (, ,)  (NP-COOD (NP (NN c-Fos) ) (, ,)  (NP (NN Fra-1) ) (, ,)  (NP (NN c-Jun) ) (, ,)  (NP (NN JunB) ) (, ,)  (CC and)  (NP (NN JunD) )))))))) (. .) ) )
(TOP (S (ADVP-TMP (RB Previously) ) (, ,)  (NP-SBJ-39 (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (NN c-fos)  (NN gene) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN reported)  (S (NP-SBJ-40 (-NONE- *-39) ) (VP (TO to)  (VP (VB be)  (VP (VBN transactivated)  (NP (-NONE- *-40) ) (PP (IN by)  (NP-LGS (NP (DT the)  (JJ viral)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN Tax1) )))))))))) (. .) ) )
(TOP (S (PP (IN By)  (S (NP-SBJ (-NONE- *-41) ) (VP (VBG using)  (NP (NP (NP (DT the)  (JJ human)  (NN T-cell)  (NN line) ) (PRN (-LRB- -LRB-)  (NP (NN JPX-9) ) (-RRB- -RRB-) )) (, ,)  (SBAR (WHPP-42 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (NP (NN expression) ) (PP (IN of)  (NP (DT the)  (NN Tax1) ))) (VP (VBZ is)  (ADJP-PRD (JJ inducible) ) (ADVP (-NONE- *T*-42) )))))))) (, ,)  (NP-SBJ-41 (PRP we) ) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ-43 (NP (NN expression) ) (PP (IN of)  (NP (NP (NNS mRNAs) ) (PP (IN for)  (NP-COOD (NP (NN Fra-1) ) (, ,)  (NP (NN c-Jun) ) (, ,)  (CC and)  (NP (NN JunD) )))))) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN transactivated)  (NP (-NONE- *-43) ) (PP (IN by)  (NP-LGS (NN Tax1) ))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ (NN Tax1) ) (VP (VBD activated)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NP (NP (NP (CD two)  (JJ other)  (NN transcription)  (NNS factors) ) (VP (VBG having)  (NP (NN zinc)  (NN finger)  (NNS motifs) ))) (, ,)  (NP-COOD (NP (NN Egr-1) ) (CC and)  (NP (NN Egr-2) )) (, ,) ) (PP (IN in)  (NP (DT the)  (JJ same)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ-44 (NP (DT The)  (JJ Tax1-inducible)  (NN transcription)  (NNS factors) ) (VP (VBN identified)  (NP (-NONE- *) ) (ADVP (RB here) ))) (VP (VBP are)  (VP (VBN encoded)  (NP (-NONE- *-44) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NNS members) ) (PP (IN of)  (NP (JJ immediate)  (JJ early)  (NNS genes) )))) (PP (IN under)  (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP (NN growth)  (NNS signals) )))))) (. .) ) )
(TOP (S (RB Thus)  (, ,)  (NP-SBJ-45 (NN Tax1) ) (VP (VBD was)  (VP (VBN suggested)  (S (NP-SBJ (-NONE- *-45) ) (VP (TO to)  (VP (VB replace)  (NP (NN growth)  (NNS signals) ) (, ,)  (PP (ADVP (IN at)  (JJS least) ) (IN in)  (NP (NN part) )) (, ,)  (PP (IN by)  (NP (DT this)  (NN mechanism) ))))))) (. .) ) )
(TOP (NP (NP (NP (NN Contribution) ) (PP (IN of)  (NP (NP-COOD (NP (NN NF-kappa)  (NN B) ) (CC and)  (NP (NN Sp1) )) (NN binding)  (NNS motifs) )) (PP (TO to)  (NP (NP (DT the)  (JJ replicative)  (NN capacity) ) (PP (IN of)  (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) )))) (: :) ) (S (NP-SBJ-26 (NP (JJ distinct)  (NNS patterns) ) (PP (IN of)  (NP (JJ viral)  (NN growth) ))) (VP (VBP are)  (VP (VBN determined)  (NP (-NONE- *-26) ) (PP (IN by)  (NP-LGS (NN T-cell)  (NNS types) )))) (. .) )) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG Starting)  (PP (IN with)  (NP (NP (DT a)  (JJ replication-incompetent)  (JJ molecular)  (NN clone) ) (PP (IN of)  (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) )) (, ,)  (VP (VBG lacking)  (NP (NP (PDT all)  (DT the)  (NP-COOD (NP (NN NF-kappa)  (NN B) ) (CC and)  (NP (NN Sp1) )) (NN binding)  (NNS sites) ) (ADJP (JJ present)  (PP (IN in)  (NP (DT the)  (JJ native)  (NP (NP (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) ))))))))))) (, ,)  (NP-SBJ-27 (NP (NNS proviruses) ) (VP (VBG containing)  (NP (NP (VBN reconstructed)  (NNS LTRs) ) (PP (IN with)  (NP (NP-COOD (NP (JJ individual)  (NP (-NONE- *RNR*-100) )) (CC or)  (NP (NP (NNS combinations) ) (PP (IN of)  (NP (-NONE- *RNR*-100) )))) (NP-100 (NP-COOD (NP (NN NF-kappa)  (NN B) ) (CC and)  (NP (NN Sp1) )) (NNS elements) )))))) (VP (VBD were)  (VP-COOD (VP (VBN generated)  (NP (-NONE- *-27) )) (CC and)  (VP (VBN evaluated)  (NP (-NONE- *-27) ) (PP (IN for)  (NP (PRP$ their)  (NN capacity)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB produce)  (NP (NN virus)  (NN progeny) ) (PP-TMP (VBG following)  (NP (NN transfection-cocultivation) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Virus)  (NNS stocks) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT these)  (NNS experiments) )))) (VP (VBD exhibited)  (NP (NP (DT a)  (NN continuum) ) (PP (IN of)  (NP (JJ replicative)  (NNS capacities) )) (PP (IN in)  (NP (JJ different)  (JJ human)  (NN T-cell)  (NNS types) ))) (PP (VBG depending)  (PP (IN on)  (SBAR (WHNP-30 (WDT which)  (NN element)  (-LRB- -LRB-)  (NNS s)  (-RRB- -RRB-) ) (S (NP-SBJ (-NONE- *T*-30) ) (VP (VBD was)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (DT the)  (NN LTR) ))))))))) (. .) ) )
(TOP (S (PP (IN For)  (NP (NN example) )) (, ,)  (PP (IN in)  (NP (NP (NNS experiments) ) (VP (VBG involving)  (NP (NP (JJ proviral)  (NNS clones) ) (PP (IN with)  (NP (NP (NNS LTRs) ) (VP (VBG containing)  (NP-COOD (NP (QP (CD one)  (CC or)  (CD two) ) (NN NF-kappa)  (NN B)  (NNS elements) ) (-LRB- -LRB-)  (CC and)  (NP (DT no)  (NN Sp1)  (NN binding)  (NNS sites) ) (-RRB- -RRB-) )))))))) (, ,)  (NP-SBJ-31 (NP (DT a)  (NN hierarchy) ) (PP (IN of)  (NP (NP (JJ cellular)  (NN permissivity) ) (PP (TO to)  (NP (NN virus)  (NN replication) )))) (PRN (-LRB- -LRB-)  (S (NP-SBJ (JJ peripheral)  (NN blood)  (NNS lymphocytes) ) (VP (JJ =)  (NP-PRD (NP (NN MT4) ) (ADJP (ADJP (JJR greater) ) (PP (IN than)  (NP (NP (NN H9) ) (ADJP (ADJP (JJR greater) ) (PP (IN than)  (NP (NP (NN CEM) ) (ADJP (ADJP (JJR greater) ) (PP (IN than)  (NP (NN Jurkat) )))))))))))) (-RRB- -RRB-) )) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-31) ))) (. .) ) )
(TOP (SINV (PP-PRD-TPC-32 (IN Of)  (NP (NN note) )) (VP (VBD was)  (PP-PRD (-NONE- *T*-32) )) (NP-SBJ (NP (DT the)  (VBN associated)  (NN emergence) ) (PP (IN of)  (NP (JJ second-site)  (NN LTR)  (NNS revertants) )) (SBAR (WHNP-33 (WDT which) ) (S (NP-SBJ (-NONE- *T*-33) ) (VP (VBD involved)  (NP (NP (DT an)  (NN alteration) ) (PP (IN of)  (NP (DT the)  (NN TATA)  (NN box) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-101 (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN LTR) ) (VP-COOD (VP (VBZ possesses)  (NP (NP (JJ functional)  (NN redundancy) ) (SBAR (WHNP-34 (WDT which) ) (S (NP-SBJ (-NONE- *T*-34) ) (VP (VBZ ensures)  (NP (NP (NN virus)  (NN replication) ) (PP (IN in)  (NP (JJ different)  (NN T-cell)  (NNS types) )))))))) (CC and)  (VP (VBZ is)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-101) ) (VP (VBG changing) ))) (PP (VBG depending)  (PP (IN on)  (NP (NP (DT the)  (JJ particular)  (NN combination) ) (PP (IN of)  (NP (NP (JJ transcriptional)  (NNS factors) ) (ADJP (JJ present) )))))))))))) (. .) ) )
(TOP (NP (NP (NN Enhancement) ) (PP (IN of)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (CD 1)  (NN replication) ) (PP (IN in)  (NP (NNS monocytes) )))) (PP (IN by)  (NP (NN 1,25-dihydroxycholecalciferol) )) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (JJ Human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )) (NP-COOD (NP (NN expression) ) (CC and)  (NP (NN replication) ))) (VP (VBP are)  (PP-PRD (IN under)  (NP (JJ tight)  (JJ regulatory)  (NN control) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (NN 1,25-dihydroxycholecalciferol) ) (PRN (-LRB- -LCB-)  (NP (NN 1,25--LRB-OH-RRB-2D3) ) (-RRB- -RCB-) )) (VP (VBZ enhances)  (NP (NP (DT the)  (NN replication) ) (PP (IN of)  (NP (NP (ADJP-COOD (ADJP (NP (NN monocyte-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ lymphocyte-tropic) )) (NNS strains) ) (PP (IN of)  (NP (NN HIV-1) ))))) (PP (IN up)  (TO to)  (ADVP (RB 10,000-fold) )) (PP (IN in)  (NP-COOD (NP (NN monocyte)  (NN cell)  (NNS lines) ) (, ,)  (NP (JJ peripheral)  (NN blood)  (NNS monocytes) ) (, ,)  (CC and)  (NP (JJ unfractionated)  (JJ peripheral)  (NN blood)  (JJ mononuclear)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN 1,25-LRB-OH-RRB-2D3) ) (VP (VBZ is)  (ADVP (RB therefore) ) (NP-PRD (NP (CD one) ) (PP (IN of)  (NP (NP (DT the)  (ADJP (RBS most)  (JJ potent) ) (NNS regulators) ) (PP (IN of)  (NP (NN HIV-1)  (NN replication) )) (VP (VBN described)  (NP (-NONE- *) ) (PP-TMP (TO to)  (NP (NN date) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Precursors) ) (PP (IN of)  (NP (NN 1,25-LRB-OH-RRB-2D3) ))) (VP (VBP enhance)  (NP (NN HIV-1)  (NN replication) ) (PP (IN in)  (NN proportion)  (TO to)  (NP (NP (PRP$ their)  (NN affinity) ) (PP (IN for)  (NP (DT the)  (NN 1,25-LRB-OH-RRB-2D3)  (JJ intracellular)  (NN receptor) )))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (NN 1,25-LRB-OH-RRB-2D3) ) (VP (VBZ influences)  (NP (NN HIV-1)  (NN replication) ) (PP (IN by)  (NP (NP (NNS mechanisms) ) (VP (VBG involving)  (NP (DT this)  (NN receptor) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS studies) ) (VP (MD may)  (VP (VB have)  (NP (NP (JJ important)  (NNS implications) ) (PP (IN for)  (NP (NP (DT the)  (NN design) ) (PP (IN of)  (NP (NP (JJ effective)  (NN therapy) ) (PP (IN of)  (NP (NN HIV-1)  (NN infection) ))))))))) (. .) ) )
(TOP (NP (NP (NN Inhibition) ) (PP (IN of)  (NP-COOD (NP (NN HIV-1)  (NN replication) ) (CC and)  (NP (NN NF-kappa)  (NN B)  (NN activity) ))) (PP (IN by)  (NP-COOD (NP (NN cysteine) ) (CC and)  (NP (NN cysteine)  (NNS derivatives) ))) (. .) ) )
(TOP (S (NP-SBJ (NN HIV-1)  (JJ proviral)  (NN DNA) ) (VP (VBZ contains)  (NP (NP (CD two)  (VBG binding)  (NNS sites) ) (PP (IN for)  (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ HIV-1-infected)  (NNS individuals) ) (VP (VBP have)  (, ,)  (PP (IN on)  (NP (NN average) )) (, ,)  (NP-COOD (NP (NP (ADJP (RB abnormally)  (JJ high) ) (NNS levels) ) (PP (IN of)  (NP (NP (NN tumour)  (NN necrosis)  (NN factor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN TNF)  (NN alpha) ) (-RRB- -RRB-) )))) (CC and)  (NP (ADJP (RB abnormally)  (JJ low) ) (NN plasma)  (NN cysteine)  (NNS levels) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB therefore) ) (VP (VBD investigated)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP-COOD (NP (NN cysteine) ) (CC and)  (NP (JJ related)  (NNS thiols) ))) (PP (IN on)  (NP-COOD (NP (NN HIV-1)  (NN replication) ) (CC and)  (NP (NN NF-kappa)  (NN B)  (NN expression) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NNS experiments) ) (PP (IN in)  (NP (DT this)  (NN report) ))) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN cysteine) ) (CC or)  (NP (NP (NN N-acetylcysteine) ) (PRN (-LRB- -LRB-)  (NP (NN NP) ) (-RRB- -RRB-) ))) (VP (VP-COOD (VP (VBP raise)  (NP (NP (DT the)  (JJ intracellular)  (NN glutathione)  (-LRB- -LRB-)  (NN GSH)  (-RRB- -RRB-)  (NN level) ) (PP (-NONE- *RNR*-40) ))) (CC and)  (VP (VBP inhibit)  (NP (NP (NN HIV-1)  (NN replication) ) (PP (-NONE- *RNR*-40) )))) (PP-40 (IN in)  (NP (ADJP (RB persistently)  (JJ infected) ) (NP-COOD (NP (NN Molt-4) ) (CC and)  (NP (NN U937) )) (NNS cells) )))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-102 (NP (NN inhibition) ) (PP (IN of)  (NP (NN HIV-1)  (NN replication) ))) (VP (VBZ appears)  (VP (RB not)  (TO to)  (VP (VB be)  (ADVP (RB directly) ) (VP (VBN correlated)  (NP (-NONE- *-102) ) (PP (IN with)  (NP (NN GSH)  (NNS levels) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Cysteine) ) (CC and)  (NP (NN NP) )) (ADVP (RB also) ) (VP (VBP inhibit)  (NP-COOD (NP (NP (NN NF-kappa)  (NN B)  (NN activity) ) (SBAR (IN as)  (S (NP-SBJ-41 (-NONE- *) ) (VP (VBN determined)  (NP (-NONE- *-41) ) (PP (IN by)  (NP (JJ electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) )))))) (CC and)  (NP (NP (NP (NP (NN chloramphenicol)  (NN acetyl-transferase) ) (PRN (-LRB- -LRB-)  (NP (NN CAT) ) (-RRB- -RRB-) )) (NN gene)  (NN expression) ) (PP (IN under)  (NP (NP (NN control) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B)  (NN binding)  (NNS sites) ) (PP (IN in)  (NP (JJ uninfected)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN cysteine)  (NN deficiency) ) (PP (IN in)  (NP (JJ HIV-1-infected)  (NNS individuals) ))) (VP (MD may)  (VP-COOD (VP (VB cause)  (NP (NP (DT an)  (NN over-expression) ) (PP (IN of)  (NP (ADJP (NN NF-kappa)  (JJ B-dependent) ) (NNS genes) )))) (CC and)  (VP (VB enhance)  (NP (NN HIV-1)  (NN replication) ))))))) (. .) ) )
(TOP (S (NP-SBJ-42 (NN NP) ) (VP (MD may)  (VP (VB be)  (VP (VBN considered)  (NP (-NONE- *-42) ) (PP (IN for)  (NP (NP (DT the)  (NN treatment) ) (PP (IN of)  (NP (JJ HIV-1-infected)  (NNS individuals) ))))))) (. .) ) )
(TOP (NP (NP (NN Glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (JJ systemic)  (NN lupus)  (NN erythematosus) )) (. .) ) )
(TOP (S (S-COOD (S (NP-SBJ (NNS Glucocorticosteroids) ) (VP (VBP remain)  (NP-PRD (NP (DT the)  (JJ major)  (NN treatment)  (NN modality) ) (PP (IN for)  (NP (NP (JJ systemic)  (NN lupus)  (NN erythematosus) ) (PRN (-LRB- -LRB-)  (NP (NN SLE) ) (-RRB- -RRB-) )))))) (, ,)  (CC but)  (S (NP-SBJ (NP (PRP$ their)  (NN mechanism) ) (PP (IN of)  (NP (NN action) ))) (VP (VBZ is)  (ADJP-PRD (JJ unclear) )))) (. .) ) )
(TOP (S (PP-TMP (IN Over)  (NP (DT the)  (JJ past)  (NN decade) )) (NP-SBJ (NP (PRP it) ) (SBAR (-NONE- *EXP*-94) )) (VP (VBZ has)  (VP (VBN become)  (ADJP-PRD (JJ clear) ) (SBAR-94 (IN that)  (S (NP-SBJ (NN glucocorticosteroid)  (NNS receptors) ) (VP (VBP play)  (NP (DT a)  (JJ significant)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN mechanism) ) (PP (IN of)  (NP (NN glucocorticosteroid)  (NN action) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD studied)  (NP (NP (NN glucocorticosteroid)  (NN receptor)  (NP-COOD (NP (NN density) ) (CC and)  (NP (NN affinity) ))) (PP (IN on)  (NP (JJ peripheral)  (NN blood)  (JJ mononuclear)  (NNS cells) ))) (PP (IN by)  (NP (DT the)  (NN glucocorticosteroid)  (NN binding)  (NN assay) )) (PP-COOD (PP (IN in)  (NP (NP (CD 33)  (NNS patients) ) (PP (IN with)  (NP (NN SLE) )) (SBAR (WHNP-40 (WP who) ) (S (NP-SBJ (-NONE- *T*-40) ) (VP (VBD had)  (VP (VBN taken)  (NP (DT no)  (NN glucocorticosteroid) ) (PP-TMP (IN for)  (NP (DT the)  (JJ previous)  (CD 6)  (NNS months) )))))))) (CC and)  (PP (IN in)  (NP (CD 32)  (JJ healthy)  (NNS controls) )))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP (NNS Patients)  (POS ') ) (NN disease)  (NN activity) ) (VP (VBD was)  (VP (VBN measured)  (NP (-NONE- *-41) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN SLE)  (NN Disease)  (NN Activity)  (NN Index) ) (PRN (-LRB- -LRB-)  (NP (NN SLEDAI) ) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Glucocorticosteroid)  (NNS receptors) ) (PP (IN on)  (NP (NP (NNS leukocytes) ) (PP (IN of)  (NP (NP (NNS patients) ) (PP (IN with)  (NN SLE) )))))) (VP (VBD were)  (ADJP-PRD (ADJP (ADJP (RB significantly)  (JJR higher) ) (PP (IN than)  (FRAG (PP (IN in)  (NP (JJ healthy)  (NNS controls) ))))) (PRN (-LRB- -LRB-)  (FRAG (NP-COOD (NP (QP (CD 4419) (CC  +/-)  (CD 306) )) (CC vs)  (NP (QP (CD 3369) (CC  +/-)  (CD 196) )))) (, ,)  (S (NP-SBJ (NN p) ) (ADJP-PRD (ADJP (JJR less) ) (PP (IN than)  (NP (CD 0.005) )))) (-RRB- -RRB-) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN binding)  (NN affinity) ) (VP (VBD was)  (RB not)  (ADJP-PRD (JJ different) ) (PP (IN between)  (NP-COOD (NP (NNS patients) ) (CC and)  (NP (NNS controls) )))) (. .) ) )
(TOP (S (NP-SBJ (EX There) ) (VP (VBD was)  (NP-PRD (DT no)  (NN correlation) ) (PP (IN between)  (NP-COOD (NP (NN glucocorticosteroid)  (NN receptor)  (NN number) ) (CC and)  (NP (NN SLE)  (NN disease)  (NN activity) )))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP (NNS Changes) ) (PP (IN in)  (NP (NP (JJ leucocytic)  (NN estrogen)  (NN receptor)  (NNS levels) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN gynecomastia) )))))) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-62 (NP (DT The)  (NN number) ) (PP (IN of)  (NP (NP (NP (NN estrogen)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN ER) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (NP (JJ human)  (JJ peripheral)  (NNS leucocytes) ) (PP (IN in)  (NP (NP (CD 13)  (NNS men) ) (PP (IN with)  (NP (NNS gynecomastia) ))))))))) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-62) ) (PP (IN by)  (NP-LGS (NN radioligand)  (NN binding)  (NN method) )))) (. .) ) )
(TOP (S (NP-SBJ-63 (DT The)  (NNS results) ) (VP (VBD were)  (VP (VBN compared)  (NP (-NONE- *-63) ) (PP (IN with)  (NP (NP (DT those) ) (PP (IN of)  (NP (CD 13)  (ADJP (NN sex-)  (CC and)  (JJ age-matched) ) (JJ healthy)  (NNS subjects) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBD was)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ-64 (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NN ER) ) (PP (IN in)  (NP (NNS leucocytes) ))))) (VP (VBD was)  (ADVP (RB significantly) ) (VP (VBN increased)  (NP (-NONE- *-64) ) (PP (IN in)  (NP (NN gynecomastia) )) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NP (NN Rs) ) (PP (IN of)  (NP (NNS leucocytes) ))) (VP (VBD were)  (NP-PRD (QP (CD 1054) (CC  +/-)  (CD 254) ) (NN sites/cell) ))) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBD suggested)  (SBAR (IN that)  (S (NP-SBJ (NP (NN increase) ) (PP (IN of)  (NP (NN ER)  (NNS levels) ))) (VP (VBP play)  (NP (DT an)  (JJ important)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN pathogenesis) ) (PP (IN of)  (NP (NN gynecomastia) )))))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP-COOD (NP (NP (NNS Changes) ) (PP (IN in)  (NP (NP (NNS levels) ) (PP (IN of)  (NP (NP (JJ leucocytic)  (NN estrogen)  (NN receptor) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ menopausal)  (NN type)  (CD II)  (NNS diabetes) ))))))))) (CC and)  (NP (PRP$ its)  (NN significance) )) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-43 (NP (DT The)  (NN number) ) (PP (IN of)  (NP (NP (NP (NN estrogen)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NN ER) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (NP (JJ human)  (JJ peripheral)  (NNS leucocytes) ) (PP (IN in)  (NP (NP (CD 12)  (NNS women) ) (PP (IN with)  (NP (JJ menopausal)  (NN type)  (CD II)  (NNS diabetes) ))))))))) (VP (VBD was)  (VP (VBN measured)  (NP (-NONE- *-43) ) (PP (IN with)  (NP (JJ radio-ligand)  (NN binding)  (NN method) )))) (. .) ) )
(TOP (S (NP-SBJ-44 (DT The)  (NNS results) ) (VP (VBD were)  (VP (VBN compared)  (NP (-NONE- *-44) ) (PP (IN with)  (NP (NP (DT those) ) (PP (IN of)  (NP-COOD (NP (NP (CD 12)  (JJ menopausal)  (NNS women) ) (PP (IN without)  (NP (NNS diabetes) ))) (CC and)  (NP (NP (CD 12)  (JJ normal)  (NNS women) ) (PP (IN of)  (NP (JJ childbearing)  (NN age) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBD was)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ-45 (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NN ER) ) (PP (IN in)  (NP (DT the)  (NNS patients) ))))) (VP (VBD was)  (ADVP (RB significantly) ) (VP (VBN decreased)  (NP (-NONE- *-45) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS data) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (NN decrease) ) (PP (IN of)  (NP (NP (NN ER)  (NN level) ) (PP (IN in)  (NP (NNS leukocytes) ))))) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ related)  (PP (TO to)  (NP (NP (DT the)  (NN pathogenesis) ) (PP (IN of)  (NP (NN type)  (CD II)  (NNS diabetes) )) (PP (IN in)  (NP (JJ menopausal)  (NN period) )))))))))) (. .) ) )
(TOP (NP (NP (NN Lymphocyte)  (NN glucocorticoid)  (NN receptor)  (NN binding) ) (PP-TMP-COOD (PP (IN during)  (NP (NN depression) )) (CC and)  (PP (IN after)  (NP (JJ clinical)  (NN recovery) ))) (. .) ) )
(TOP (S (NP-SBJ-58 (NN Lymphocyte)  (NN glucocorticoid)  (NN receptor)  (NN binding)  (NNS parameters) ) (VP (VBD were)  (VP-COOD (VP (VBN studied)  (NP (-NONE- *-58) ) (PP-106 (IN in)  (NP (CD 15)  (ADJP (RB severely)  (JJ depressed) ) (NNS patients) )) (PP-TMP-COOD (PP (IN during)  (NP (NN depression) )) (CC and)  (PP (IN after)  (NP (JJ clinical)  (NN recovery) )))) (, ,)  (CC and)  (VP (PP=106 (IN in)  (NP (CD 15)  (JJ healthy)  (NNS controls) ))))) (. .) ) )
(TOP (S (NP-SBJ (EX There) ) (VP (VBD was)  (NP-PRD (NP (DT no)  (NN difference) ) (PP (IN in)  (NP (NN glucocorticoid)  (NN receptor)  (NP-COOD (NP (NN number) ) (CC or)  (NP (NN affinity) )))) (PP (IN between)  (NP-COOD (NP (JJ depressed)  (NNS patients) ) (CC and)  (NP (ADJP-COOD (ADJP (JJ recovered) ) (CC or)  (ADJP (NN control) )) (NNS subjects) ))))) (. .) ) )
(TOP (S (NP-SBJ (NN Afternoon)  (NP-COOD (NP (NN ACTH) ) (CC and)  (NP (NN cortisol) )) (NNS concentrations) ) (VP (VBD did)  (RB not)  (VP (VB differ)  (ADVP (RB significantly) ) (PP (IN between)  (NP (DT the)  (CD three)  (NNS groups) )))) (. .) ) )
(TOP (S (NP-SBJ-59 (DT No)  (NN relationship) ) (VP (MD could)  (VP (VB be)  (VP (VBN established)  (NP (-NONE- *-59) ) (PP (IN between)  (NP-COOD (NP (NN glucocorticoid)  (NN receptor)  (NN binding) ) (CC and)  (NP (JJ antidepressant)  (NN medication) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP support)  (NP-COOD (NP (NP (DT the)  (NN view) ) (PP (IN of)  (NP (NP (DT an)  (ADJP (JJ impaired)  (JJ ligand-induced) ) (NN plasticity) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN receptor)  (NN regulation) ))))) (CONJP (RB rather)  (IN than) ) (NP (NP (DT the)  (NN hypothesis) ) (PP (IN of)  (NP (NP (VBN decreased)  (NN glucocorticoid)  (NN receptor)  (NNS numbers) ) (PP-TMP (IN during)  (NP (NN depression) ))))))) (. .) ) )
(TOP (NP (NP (NP (JJ Nuclear)  (NN association) ) (PP (IN of)  (NP (DT a)  (NN T-cell)  (NN transcription)  (NN factor) )) (VP (VBN blocked)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (NN FK-506) ) (CC and)  (NP (NN cyclosporin)  (NN A) ))))) (PRN (-LRB- -LCB-)  (S (NP-SBJ (-NONE- *) ) (VP (VB see)  (NP (NNS comments) ))) (-RRB- -RCB-) )) )
(TOP (S (NP-SBJ-COOD (NP (NN Cyclosporin)  (NN A) ) (CC and)  (NP (NN FK506) )) (VP (VBP inhibit)  (NP (NP-COOD (NP (ADJP-COOD (ADJP (NN T-)  (NP (-NONE- *?*) )) (CC and)  (ADJP (NN B-cell) )) (NN activation) ) (CC and)  (NP (JJ other)  (NNS processes) )) (ADJP (JJ essential)  (PP (TO to)  (NP (DT an)  (JJ effective)  (JJ immune)  (NN response) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN T)  (NNS lymphocytes) )) (NP-SBJ (DT these)  (NNS drugs) ) (VP (VBP disrupt)  (NP (NP (DT an)  (JJ unknown)  (NN step) ) (PP (IN in)  (NP (NP (DT the)  (NN transmission) ) (PP (IN of)  (NP (NNS signals) )) (PP (IN from)  (NP (DT the)  (NN T-cell)  (NN antigen)  (NN receptor) )) (PP (TO to)  (NP (NP (NN cytokine)  (NNS genes) ) (SBAR (WHNP-24 (WDT that) ) (S (NP-SBJ (-NONE- *T*-24) ) (VP (VBP coordinate)  (NP (DT the)  (JJ immune)  (NN response) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ putative)  (JJ intracellular)  (NNS receptors) ) (PP (IN for)  (NP-COOD (NP (NN FK506) ) (CC and)  (NP (NN cyclosporin) )))) (VP (VBP are)  (NP-PRD (JJ cis-trans)  (JJ prolyl)  (NNS isomerases) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Binding) ) (PP (IN of)  (NP (DT the)  (NN drug) ))) (VP (VBZ inhibits)  (NP (NN isomerase)  (NN activity) ))) (, ,)  (CC but)  (S (NP-SBJ-COOD (NP (NP (NNS studies) ) (PP (IN with)  (NP (JJ other)  (JJ prolyl)  (NN isomerase)  (NNS inhibitors) ))) (CC and)  (NP (NP (NN analysis) ) (PP (IN of)  (NP (NP (JJ cyclosporin-resistant)  (NNS mutants) ) (PP (IN in)  (NP (NN yeast) )))))) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (DT the)  (NN drug) ))) (VP (VBP result)  (PP-COOD (PP (IN from)  (NP (NP (DT the)  (NN formation) ) (PP (IN of)  (NP (DT an)  (JJ inhibitory)  (NN complex) )) (PP (IN between)  (NP-COOD (NP (DT the)  (NN drug) ) (CC and)  (NP (NN isomerase) ))))) (, ,)  (CC and)  (PP (RB not)  (IN from)  (NP (NP (NN inhibition) ) (PP (IN of)  (NP (NN isomerase)  (NN activity) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-104 (NP (NP (DT A)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN NF-AT) ) (, ,) ) (SBAR (WHNP-27 (WDT which) ) (S (NP-SBJ (-NONE- *T*-27) ) (VP (VBZ is)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (JJ early)  (NN T-cell)  (NN gene)  (NN activation) )))))) (, ,) ) (VP (VBZ seems)  (S (NP-SBJ (-NONE- *-104) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT a)  (JJ specific)  (NN target) ) (PP (IN of)  (NP (NP-COOD (NP (NN cyclosporin)  (NN A) ) (CC and)  (NP (NN FK506) )) (NN action) ))) (SBAR (IN because)  (S (NP-SBJ-25 (NP (NN transcription) ) (VP (VBN directed)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT this)  (NN protein) )))) (VP (VBZ is)  (VP (VBN blocked)  (NP (-NONE- *-25) ) (PP (IN in)  (NP (NP (NN T)  (NNS cells) ) (VP (VBN treated)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT these)  (NNS drugs) ))))) (, ,)  (PP (IN with)  (NP (NP (QP (JJ little)  (CC or)  (DT no) ) (NN effect) ) (PP (IN on)  (NP (NP (JJ other)  (NN transcription)  (NNS factors) ) (PP (JJ such)  (IN as)  (NP-COOD (NP (NN AP-1) ) (CC and)  (NP (NN NF-kappa)  (NN B) ))))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-26 (NN NF-AT) ) (VP (VBZ is)  (VP (VBN formed)  (NP (-NONE- *-26) ) (SBAR-TMP (WHADVP-28 (WRB when) ) (S (NP-SBJ-29 (NP (DT a)  (NN signal) ) (PP (IN from)  (NP (DT the)  (NN antigen)  (NN receptor) ))) (VP (VP-COOD (VP (VBZ induces)  (NP (DT a)  (JJ pre-existing)  (JJ cytoplasmic)  (NN subunit) ) (S (NP-SBJ (-NONE- *-29) ) (VP (TO to)  (VP (VB translocate)  (PP (TO to)  (NP (DT the)  (NN nucleus) )))))) (CC and)  (VP (VB combine)  (PP (IN with)  (PP (NP (DT a)  (ADJP (RB newly)  (VBN synthesized) ) (JJ nuclear)  (NN subunit) ) (PP (IN of)  (NP (NN NF-AT) )))))) (ADVP (-NONE- *T*-28) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD-30 (NP (NN FK506) ) (CC and)  (NP (NN cyclosporin)  (NN A) )) (VP (VBP block)  (NP (NP (NN translocation) ) (PP (IN of)  (NP (DT the)  (JJ cytoplasmic)  (NN component) ))) (PP (IN without)  (S (NP-SBJ (-NONE- *-30) ) (VP (VBG affecting)  (NP (NP (NN synthesis) ) (PP (IN of)  (NP (DT the)  (JJ nuclear)  (NN subunit) ))))))) (. .) ) )
(TOP (NP (NP (NP (NN Regulation) ) (PP (IN of)  (NP (NN M-CSF)  (NN expression) )) (PP (IN by)  (NP (NN M-CSF) )) (: :) ) (NP (NP (NN role) ) (PP (IN of)  (NP-COOD (NP (NN protein)  (NN kinase)  (NN C) ) (CC and)  (NP (NN transcription)  (NN factor)  (NN NF)  (NN kappa)  (NN B) ))) (. .) )) )
(TOP (S (NP-SBJ-26 (NP (NP (JJ Macrophage-colony-stimulating)  (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN M-CSF) ) (-RRB- -RRB-) )) (, ,)  (VP (ADVP (RB also) ) (VBN referred)  (PP (TO to)  (NP (-NONE- *) )) (PP (IN as)  (NP (NN CSF-1) ))) (, ,) ) (VP (VBZ regulates)  (NP (NP (DT the)  (NP-COOD (NP (NN survival) ) (, ,)  (NP (NN growth) ) (, ,)  (NP (NN differentiation) ) (CC and)  (NP (JJ functional)  (NN activity) ))) (PP (IN of)  (NP (NNS monocytes) ))) (PP (IN by)  (S (NP-SBJ (-NONE- *-26) ) (VP (VBG binding)  (PP (TO to)  (NP (NP (NP (DT a)  (JJ single)  (NN class) ) (PP (IN of)  (NP (JJ high-affinity)  (NN cell)  (NN surface)  (NNS receptors) ))) (, ,)  (VP (VBN known)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT the)  (NN product) ) (PP (IN of)  (NP (DT the)  (NN c-fms)  (NN protooncogene) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN detection) ) (PP (IN of)  (NP (NP (NP-COOD (CC both)  (NP (NN M-CSF) ) (CC and)  (NP (NN c-fms) )) (NN expression) ) (PP (IN by)  (NP (NP (NNS cells) ) (PP (IN of)  (NP (DT the)  (NN monocyte)  (NN lineage) ))))))) (VP (VBZ has)  (VP (VBN suggested)  (SBAR (IN that)  (S (NP-SBJ (NN M-CSF) ) (VP (MD may)  (VP (VB act)  (PP (IN by)  (NP (DT an)  (JJ autocrine)  (NN mechanism) )))))))) (. .) ) )
(TOP (S (ADVP (RB Interestingly) ) (, ,)  (NP-SBJ (PRP it) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN shown)  (SBAR (IN that)  (S (NP-SBJ (NN M-CSF) ) (VP (MD can)  (VP (VB induce)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (PRP$ its)  (JJ own)  (NN gene) )))))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ-28 (NP (NN sensitivity) ) (PP (TO to)  (NP (NN M-CSF) ))) (VP (MD can)  (VP (VB be)  (VP (VBN modulated)  (NP (-NONE- *-28) ) (PP (IN by)  (NP-LGS (NP (NN regulation) ) (PP (IN of)  (NP (NN receptor)  (NP-COOD (NP (NN expression) ) (CC and)  (NP (NN function) ))))))))))) (, ,)  (NP-SBJ-29 (NN M-CSF)  (NN responsiveness) ) (VP (VBZ is)  (ADVP (RB largely) ) (VP (VBN determined)  (NP (-NONE- *-29) ) (PP (IN at)  (NP (DT a)  (NN postreceptor)  (NN level) )))) (. .) ) )
(TOP (S (PP-TMP (TO To)  (NP (NN date) )) (, ,)  (NP-SBJ-30 (JJ little) ) (VP (VBZ is)  (VP (VBN known)  (NP (-NONE- *-30) ) (PP (IN about)  (NP (NP (DT the)  (JJ intracellular)  (NN pathway) ) (PP (IN of)  (NP (NN M-CSF)  (NN signal)  (NN transduction) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP (RB therefore) ) (VP (VBN investigated)  (NP (NP (DT the)  (NNS changes) ) (PP (IN in)  (NP (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) )) (NN activity) )) (PP (IN upon)  (NP (NP (NN exposure) ) (PP (IN of)  (NP (NNS monocytes) )) (PP (TO to)  (NP (NN M-CSF) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NN M-CSF) ) (VP (VP-COOD (VP (VBZ activates)  (NP (-NONE- *RNR*-31) )) (CC and)  (VP (VBZ translocates)  (NP (-NONE- *RNR*-31) ))) (NP-31 (NN PKC) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Inhibition) ) (PP (IN of)  (NP (NN PKC) )) (PP (IN by)  (NP (DT the)  (NN isoquinoline)  (JJ derivative)  (NN H7) ))) (VP (VBZ abolishes)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NN M-CSF) )) (PP (IN by)  (NP (NN M-CSF) )))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-32 (NP (NN activation) ) (PP (IN of)  (NP (NN PKC) ))) (VP-COOD (VP (VBD was)  (ADJP-PRD (JJ pertussis-toxin-sensitive) )) (CC and)  (VP (VBD was)  (VP (VBN associated)  (NP (-NONE- *-32) ) (PP (IN with)  (NP (NP (DT the)  (NN detection) ) (PP (IN of)  (NP (NP (DT an)  (NN NF)  (NN kappa)  (NN B)  (NN protein) ) (PP-COOD (PP (IN in)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN of)  (NP (JJ M-CSF-induced)  (NN blood)  (NNS monocytes) )))) (CC but)  (PP (RB not)  (IN in)  (NP (NP (NNS monocytes) ) (VP (VBN exposed)  (NP (-NONE- *) ) (PP (TO to)  (NP (NP (NN medium)  (NN treatment) ) (ADVP (RB only) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (NN M-CSF)  (NN induction) ) (PP (IN of)  (NP (NN M-CSF) ))) (VP (VBZ involves)  (NP (NP (NN G)  (NNS proteins) ) (, ,)  (NP-COOD (NP (NN PKC) ) (CC and)  (NP (NN NF)  (NN kappa)  (NN B) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN NF-kappa)  (NN B)  (NN activation) ) (PP (IN by)  (NP (NN tumor)  (NN necrosis)  (NN factor)  (NN alpha) )) (PP (IN in)  (NP (DT the)  (NN Jurkat)  (NN T)  (NN cell)  (NN line) ))) (VP (VBZ is)  (ADJP-PRD (JJ independent)  (PP (IN of)  (NP-COOD (NP (NN protein)  (NN kinase)  (NN A) ) (, ,)  (NP (NN protein)  (NN kinase)  (NN C) ) (, ,)  (CC and)  (NP (JJ Ca-LRB-2+-RRB--regulated)  (NNS kinases) ))))) (. .) ) )
(TOP (S (NP-SBJ (NN NF-kappa)  (NN B) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (ADJP (JJ DNA-binding) ) (JJ regulatory)  (NN factor) ) (ADJP (JJ able)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB control)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NP (DT a)  (NN number) ) (PP (IN of)  (NP (NP (NNS genes) ) (, ,)  (PP (VBG including)  (NP (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )) (NNS genes) ))))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN T)  (NNS cells) )) (, ,)  (NP-SBJ-58 (NN NF-kappa)  (NN B) ) (VP (VBZ is)  (VP (VBN activated)  (NP (-NONE- *-58) ) (PP-TMP (IN upon)  (NP (NP (JJ cellular)  (NN treatment) ) (PP (IN by)  (NP-COOD (NP (NN phorbol)  (NNS esters) ) (CC and)  (NP (DT the)  (NN cytokine)  (NP (NP (NN tumor)  (NN necrosis)  (NN factor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN TNF)  (NN alpha) ) (-RRB- -RRB-) ))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ present)  (NN work) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD investigated)  (NP (NP (DT the)  (JJ molecular)  (NNS events) ) (VP (VBG leading)  (PP (TO to)  (NP (NP (NN NF-kappa)  (NN B)  (NN activation) ) (PP (IN by)  (NP (NN TNF)  (NN alpha) )) (PP (IN in)  (NP-COOD (NP (NP (DT a)  (JJ human)  (NN T)  (NN cell)  (NN line) ) (PRN (-LRB- -LRB-)  (NP (NN Jurkat) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (PRP$ its)  (JJ subclone)  (NN JCT6) ) (, ,)  (SBAR (WHNP-59 (WDT which) ) (S (NP-SBJ (-NONE- *T*-59) ) (VP (VBZ presents)  (NP (NP (DT a)  (NN deficiency) ) (PP (IN in)  (NP (DT the)  (NN PKA)  (NN transduction)  (NN pathway) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD found)  (SBAR (IN that)  (S (PP (IN in)  (NP (DT both)  (NN cell)  (NNS lines) )) (, ,)  (NP-SBJ-COOD-60 (CC both)  (NP (NN phorbol)  (NN ester) ) (CC and)  (NP (NN TNF)  (NN alpha) )) (VP (VBD were)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-60) ) (VP (TO to)  (VP (VB activate)  (NP (NN NF-kappa)  (NN B) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-61 (NN Phorbol)  (NN activation) ) (VP (VBD was)  (ADVP (RB positively) ) (VP (VBN modulated)  (NP (-NONE- *-61) ) (PP (IN by)  (NP-LGS (NN Ca2+)  (NN influx) )) (SBAR (IN while)  (S (NP-SBJ (NN TNF)  (NN alpha)  (NN activation) ) (VP (VBD was)  (RB not)  (VP (-NONE- *?*) )))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (SBAR-ADV (IN while)  (S (NP-SBJ-62 (NN PMA)  (NN activation) ) (VP (VBD was)  (VP (VBN inhibited)  (NP (-NONE- *-62) ) (PP (IN by)  (NP-LGS (DT the)  (NN PKC)  (NN inhibitor)  (NN staurosporin) )))))) (, ,)  (NP-SBJ (DT the)  (NN TNF)  (NN alpha)  (NN effect) ) (VP (VBD was)  (ADJP-PRD (JJ unchanged) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NN TNF)  (NN alpha) ) (VP (VBD did)  (RB not)  (VP (VB activate)  (NP (NN cAMP)  (NN production) )))) (CC and)  (S (NP-SBJ-63 (PRP$ its)  (NN signal) ) (VP (VBD was)  (RB not)  (VP (VBN modulated)  (NP (-NONE- *-63) ) (PP (IN by)  (NP-LGS (NN cAMP)  (NNS activators) ))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ (NN cAMP)  (NNS activators) ) (VP (VBD did)  (RB not)  (VP (VB activate)  (NP (NN NF-kappa)  (NN B) ) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) )))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ-64 (ADJP (NN TNF)  (JJ alpha-induced) ) (NN NF-kappa)  (NN B)  (NN activation) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ-65 (-NONE- *-64) ) (VP (TO to)  (VP (VB be)  (VP (VBN mediated)  (NP (-NONE- *-65) ) (PP (IN by)  (NP-LGS (NP (NN none) ) (PP (IN of)  (NP (NP (DT the)  (JJ major)  (JJ signal-mediating)  (NNS kinases) ) (PP (JJ such)  (IN as)  (NP-COOD (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) )) (, ,)  (NP (NN protein)  (NN kinase)  (NN A) ) (, ,)  (CC or)  (NP (JJ Ca-LRB-2+-RRB--regulated)  (NNS kinases) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD found)  (SBAR (IN that)  (S (NP-SBJ (JJ cytoplasmic)  (NN acidification) ) (VP (VBD facilitated)  (NP (NP (NN NF-kappa)  (NN B)  (NN activation) ) (PP (IN by)  (NP-COOD (CC both)  (NP (NN TNF)  (NN alpha) ) (CC and)  (NP (NN PKC) )))) (, ,)  (PP (IN by)  (NP (NP (DT a)  (NN mechanism) ) (SBAR (WHNP-66 (WDT that) ) (S (NP-SBJ-67 (-NONE- *T*-66) ) (VP (VBZ increases)  (NP (NN NF-kappa) (NN  B/I)  (NN kappa)  (NN B)  (NN dissociation) ) (PP (IN without)  (S (NP-SBJ (-NONE- *-67) ) (VP (VBG affecting)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN translocation)  (NN step) ))))))))))))) (. .) ) )
(TOP (NP (NP (NN NF-kappa)  (NN B)  (NN activity) ) (PP (IN in)  (NP (NP (NN T)  (NNS cells) ) (VP (ADVP (RB stably) ) (VBG expressing)  (NP (NP (DT the)  (NN Tax)  (NN protein) ) (PP (IN of)  (NP (JJ human)  (NN T)  (NN cell)  (JJ lymphotropic)  (NN virus)  (NN type)  (CD I) )))))) (. .) ) )
(TOP (S (NP-SBJ-103 (NP (DT The)  (NN effect) ) (PP (IN of)  (NP (JJ constitutive)  (NN Tax)  (NN expression) )) (PP-COOD (PP (IN on)  (NP (NP (DT the)  (NN interaction) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (PP (IN with)  (NP (PRP$ its)  (NN recognition)  (NN sequence) )))) (CC and)  (PP (IN on)  (NP (ADJP (NN NF-kappa)  (JJ B-dependent) ) (NN gene)  (NN expression) )))) (VP (VBD was)  (VP (VBN examined)  (NP (-NONE- *-103) ) (PP (IN in)  (NP (NP (NP (NN T)  (JJ lymphoid)  (NN Jurkat)  (NN cell)  (NNS lines) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN 19D) ) (CC and)  (NP (NN 9J) )) (-RRB- -RRB-) )) (VP (ADVP (RB stably) ) (VBN transformed)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT a)  (NN Tax)  (NN expression)  (NN vector) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Tax)  (NN expressing)  (NN T)  (NN cell)  (NNS lines) ) (VP (VBD contained)  (NP (NP (DT a)  (JJ constitutive)  (NN level) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B)  (NN binding)  (NN activity) ) (, ,)  (ADJP (JJ detectable)  (PP (IN by)  (NP (NP-COOD (NP (NN mobility)  (NN shift)  (NN assay) ) (CC and)  (NP (NN uv)  (NN cross-linking) )) (VP (VBG using)  (NP (NP (DT a)  (JJ palindromic)  (NN NF-kappa)  (NN B)  (NN probe) ) (ADJP (JJ homologous)  (PP (TO to)  (NP (DT the)  (NN interferon)  (NN beta)  (NN PRDII)  (NN site) )))))))))))) (. .) ) )
(TOP (S-COOD (S (PP (IN In)  (NP-COOD (NP (NN Jurkat) ) (CC and)  (NP (NN NC2.10) ))) (NP-SBJ (NP (NN induction) ) (PP (IN with)  (NP (NN phorbol)  (NNS esters) ))) (VP (VBD resulted)  (PP (IN in)  (NP (NP (DT the)  (NN appearance) ) (PP (IN of)  (NP (NP (JJ new)  (NN DNA)  (NN binding)  (NNS proteins) ) (PP (IN of)  (NP (QP (CD 85)  (, ,)  (CD 75)  (, ,)  (CC and)  (CD 54) ) (NN kDa) )))))))) (, ,)  (IN whereas)  (S (PP (IN in)  (NP (NN Tax)  (NN expressing)  (NNS cells) )) (NP-SBJ-COOD-104 (NP (DT the)  (JJ 85-kDa)  (NN protein) ) (CC and)  (NP (DT a)  (JJ 92-kDa)  (NN DNA)  (NN binding)  (NN protein) )) (VP (VBD were)  (ADVP (RB constitutively) ) (VP (VBN induced)  (NP (-NONE- *-104) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Expression) ) (PP (IN of)  (NP (NP (NN Tax)  (NN protein) ) (PP (IN in)  (NP-COOD (NP (NN 19D) ) (CC and)  (NP (NN 9J) )))))) (VP (VBD resulted)  (PP (IN in)  (NP-COOD (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (JJ endogenous)  (ADJP (NN NF-kappa)  (JJ B-dependent) ) (JJ granulocyte-macrophage)  (NN colony)  (NN stimulating)  (NN factor)  (NN gene) ))) (CC and)  (NP (NP (VBD increased)  (JJ basal)  (NN level)  (NN expression) ) (PP (IN of)  (NP (VBN transfected)  (ADJP (NN NF-kappa)  (JJ B-regulated) ) (NNS promoters) )))))) (. .) ) )
(TOP (S (ADVP (RB Nonetheless) ) (NP-SBJ (NP (NN transcription) ) (PP (IN of)  (NP (NP-COOD (CC both)  (NP (DT the)  (JJ endogenous)  (NP (-NONE- *RNR*-20) )) (CC and)  (NP (DT the)  (VBN transfected)  (NP (-NONE- *RNR*-20) ))) (NP-20 (NN gene) )))) (VP (VBD was)  (ADJP-PRD (JJ inducible)  (PP (IN by)  (NP (NN PMA)  (NN treatment) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Tax)  (NN expression) ) (PP (IN in)  (NP (NN Jurkat)  (NN T)  (NNS cells) ))) (VP (MD may)  (VP-COOD (VP (VB alter)  (NP (NP (DT the)  (NN stoichiometry) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN DNA)  (NN binding)  (NNS proteins) )))) (CC and)  (RB thus)  (VP (VB change)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (ADJP (NN NF-kappa)  (JJ B-regulated) ) (NNS promoters) )))))) (. .) ) )
(TOP (NP (NP (NP (NN Regulation) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (JJ human)  (JJ mononuclear)  (NNS cells) )))) (: :) ) (NP (NP (NP (NNS effects) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN treatment) ))) (, ,)  (NP-COOD (NP (NP (NN Cushing)  (POS 's) ) (NN disease) ) (CC and)  (NP (NN ketoconazole) )) (. .) )) )
(TOP (S (NP-SBJ-31 (NP (NN Glucocorticoid)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NN GcR) ) (-RRB- -RRB-) )) (VP (VBD were)  (VP (VBN determined)  (NP (-NONE- *-31) ) (PP (IN by)  (NP (NP (DT a)  (JJ whole)  (NN cell)  (NN assay) ) (PP (IN in)  (NP (NP (NP (JJ human)  (JJ mononulear)  (NNS leukocytes) ) (PRN (-LRB- -LRB-)  (NP (NN hMNL) ) (-RRB- -RRB-) )) (PP (IN from)  (NP-COOD (NP (NN control)  (NNS subjects) ) (, ,)  (NP (NP (NNS patients) ) (VP (VBG receiving)  (NP (NP (NN glucocorticoid)  (NN therapy) ) (PP (IN for)  (NP (JJ systemic)  (NNS diseases) ))))) (CC and)  (NP (NP (NP (NP (NN Cushing)  (POS 's) ) (NN disease) ) (NNS patients) ) (PP (PP-COOD (PP (IN with)  (NP (-NONE- *RNR*-32) )) (CC or)  (PP (IN without)  (NP (-NONE- *RNR*-32) ))) (NP-32 (NN ketoconazole)  (NN therapy) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Prolonged)  (NN corticosteroid)  (NN treatment) ) (VP (VBD resulted)  (PP (IN in)  (NP (NP (NN down-regulation) ) (PP (IN of)  (NP (NN GcR) )))) (, ,)  (SBAR (IN while)  (S (NP (NP (DT the)  (NN mean)  (NN level) ) (PP (IN of)  (NP (NN GcR) )) (PP (IN in)  (NP (NP (NN Cushing)  (POS 's) ) (NN disease) ))) (VP (VBD was)  (ADJP-PRD (JJ normal) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN group) )) (, ,)  (ADVP (RB however) ) (, ,)  (NP-SBJ-COOD (NP (NN receptor)  (NNS levels) ) (CC and)  (NP (NN morning)  (NN plasma)  (NN cortisol)  (NNS values) )) (VP (VBD showed)  (NP (DT a)  (JJ negative)  (NN correlation) ) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (NP (DT a)  (JJ subtle)  (JJ down-regulatory)  (NN effect) )))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (NN GcR) ) (VP (VBD were)  (ADJP-PRD (JJ unaltered) ) (SBAR-TMP (IN after)  (S (NP-SBJ (DT these)  (NNS patients) ) (VP (VBD received)  (NP (NN ketoconazole) )))) (, ,)  (PP (IN in)  (NN spite)  (IN of)  (NP (NP (DT a)  (JJ marked)  (NN reduction) ) (PP (IN in)  (NP-COOD (NP (NN morning)  (NN plasma)  (NN cortisol) ) (CC and)  (NP (ADJP (JJ urinary)  (JJ free) ) (NN cortisol) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB also) ) (VP (VBD observed)  (SBAR (IN that)  (S (NP-SBJ (NN ketoconazole) ) (VP (VBD was)  (NP-PRD (NP (DT a)  (JJ weak)  (NN competitor) ) (PP (IN of)  (NP (NN GcR) ))) (PP (IN in)  (NP (JJ intact)  (NNS cells) )) (, ,)  (SBAR (IN although)  (S (NP-SBJ (PRP it) ) (ADVP (RB significantly) ) (VP (VBD inhibited)  (NP (NN -LCB-3H-RCB-)  (NN dexamethasone)  (NN binding) ) (PP (IN in)  (NP (NP (JJ cytosolic)  (NNS preparations) ) (PP (IN from)  (NP (NN rat)  (NNS tissues) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBD suggested)  (SBAR (IN that)  (S-COOD (S (NP-SBJ-33 (NP (NN GcR) ) (PP (IN in)  (NP (NN hMNL) ))) (VP (VBP are)  (VP (VBN down-regulated)  (NP (-NONE- *-33) ) (PP (IN by)  (NP (NP (JJ synthetic)  (NNS steroids) ) (VP (VBN given)  (NP (-NONE- *) ) (ADVP (FW in)  (FW vivo) ))))))) (, ,)  (CC but)  (S (NP-SBJ (PRP they) ) (VP (VBD showed)  (NP (ADJP (RB very)  (JJ mild) ) (NN down-regulation) ) (PP (IN in)  (NP (NP (JJ hypercortisolemic)  (NNS patients) ) (VP (VBG suffering)  (PP (IN from)  (NP (NP (NN Cushing)  (POS 's) ) (NN disease) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Finally) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD did)  (RB not)  (VP (VBN observed)  (NP (NP-COOD (CC either)  (NP (NN up-regulation) ) (CC or)  (NP (NN antagonism) )) (PP (IN of)  (NP (NN GcR) )) (PP (IN by)  (NP (NN ketoconazole)  (NN treatment) ))) (, ,)  (PP-TMP (IN at)  (NP (NP (DT the)  (NN time) ) (SBAR (WHADVP-36 (IN that) ) (S (NP-SBJ-37 (NP (NN cortisol)  (NNS levels) ) (PP (IN of)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NP (NN Cushing)  (POS 's) ) (NN disease) ))))) (VP (VBD were)  (VP (VBN reduced)  (NP (-NONE- *-37) ) (ADVP (-NONE- *T*-36) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ indicates)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ beneficial)  (NNS effects) ) (PP (IN of)  (NP (NN ketoconazole) )) (PP (IN in)  (NP (NP (NN Cushing)  (POS 's) ) (NN disease) ))) (VP (VBP are)  (PP-PRD (JJ due)  (PP-COOD (PP (TO to)  (NP (JJ adrenal)  (NN cortisol)  (NN suppression) )) (CC and)  (PP (RB not)  (TO to)  (NP (NP (NN interaction) ) (PP (IN with)  (NP (NP (NN GcR) ) (PP (IN of)  (NP (NN target)  (NNS cells) ))))))))))) (, ,)  (CC and)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN process) ) (PP (IN of)  (NP (NN GcR)  (NN regulation) )) (PP (IN in)  (NP (NN hMNL) ))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ complex)  (NN phenomenon) ) (VP (VBG awaiting)  (NP (RBR further)  (NN elucidation) )))))))) (. .) ) )
(TOP (NP (NP (NN Glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (NP (NNS lymphocytes) ) (PP (IN in)  (NP (NN anorexia)  (NN nervosa) )))) (. .) ) )
(TOP (NP (NP (NP (NN OBJECTIVE)  (: :) ) (S (NP-SBJ (DT The)  (NN aim) ) (VP (VBD was)  (S-PRD (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB explore)  (NP (NP (DT the)  (NN down-regulation) ) (PP (IN of)  (NP (DT the)  (NN glucocorticoid)  (NNS receptors) )) (PP-TMP (IN during)  (NP (NN hypercortisolaemia) )) (PP (IN in)  (NP (NN anorexia)  (NN nervosa) ))))))) (. .) ))) )
(TOP (NP (NP (NN DESIGN)  (: :) ) (S-COOD (S (NP-SBJ-31 (NP-COOD (NP (NN Urine) ) (CC and)  (NP (NN plasma) )) (NNS samples) ) (VP (VBD were)  (VP (VBN obtained)  (NP (-NONE- *-31) ) (PP (IN for)  (NP (NN cortisol)  (NN determination) ))))) (CC and)  (S (NP-SBJ-32 (NN blood)  (NNS lymphocytes) ) (VP (VBD were)  (VP (VBN isolated)  (NP (-NONE- *-32) ) (PP (IN for)  (NP (NN receptor)  (NN binding)  (NNS studies) ))))) (. .) )) )
(TOP (NP (NP (NNS PATIENTS)  (: :) ) (S (NP-SBJ-COOD-33 (NP (NP (CD Sixteen)  (JJ anorexic)  (NNS patients) ) (, ,)  (ADJP (JJ aged)  (NP (QP (CD 16-27) ) (NNS years) )) (, ,)  (PP (IN with)  (NP (NP (DT a)  (NN mean) (CC  +/-)  (NN SEM)  (NN body)  (NN mass)  (NN index) ) (PP (IN of)  (NP (CD 14.2) (CC  +/-)  (CD 2.0) )) (-LRB- -LRB-)  (VP (VBG ranging)  (PP-COOD (PP (IN from)  (NP (CD 11.1) )) (PP (TO to)  (NP (CD 17.4) )))) (-RRB- -RRB-) )) (, ,) ) (CC and)  (NP (CD 15)  (JJ normal)  (NNS women) )) (VP (VBD were)  (VP (VBN studied)  (NP (-NONE- *-33) ))) (. .) )) )
(TOP (S (NP-SBJ-34 (CD Six)  (NNS patients) ) (VP (VBD were)  (VP (VBN reinvestigated)  (NP (-NONE- *-34) ) (PP-TMP (IN after)  (NP (DT a)  (JJ significant)  (NN weight)  (NN gain) )))) (. .) ) )
(TOP (NP (NP (NNS MEASUREMENTS)  (: :) ) (S (NP-SBJ-35 (NP (DT The)  (NP (NN binding)  (NP-COOD (NP (NN capacity) ) (CC and)  (NP (NN affinity) )))) (PP (IN of)  (NP (DT the)  (NN glucocorticoid)  (NNS receptors) ))) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-35) ) (PP (IN with)  (NP (NP (NN dexamethasone) ) (PP (IN as)  (NP (NP (NN ligand) ) (PP (IN on)  (NP (NNS lymphocytes) )))))))) (. .) )) )
(TOP (NP (NP (NNS RESULTS)  (: :) ) (S (PP (IN In)  (NP (NNS patients) )) (, ,)  (NP-SBJ (ADJP-COOD (DT both)  (ADJP (JJ total) ) (CC and)  (ADJP (JJ free) )) (NN plasma)  (NN cortisol)  (NNS concentrations) ) (VP (VBD were)  (ADJP-PRD (ADJP (JJR higher) ) (PP (IN than)  (FRAG (PP (IN in)  (NP (DT the)  (JJ normal)  (NNS women) ))))) (, ,)  (SBAR (IN as)  (SINV (VBD was)  (NP-SBJ (PRP$ their)  (JJ urinary)  (JJ free)  (NN cortisol) ) (ADJP-PRD (-NONE- *?*) )))) (: ;) ) (S (NP-SBJ-COOD (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PP (IN per)  (NP (NN cell) ))) (PRN (-LRB- -LRB-)  (NP (NN Ro) ) (-RRB- -RRB-) )))) (CC and)  (NP (NP (NP (DT the)  (NN binding)  (NN affinity) ) (PRN (-LRB- -LRB-)  (NP (NN Kd) ) (-RRB- -RRB-) )) (PP (IN for)  (NP (NN dexamethasone) )))) (VP (VBD were)  (, ,)  (ADVP (RB however) ) (, ,)  (ADJP-PRD (ADVP (RB not)  (RB significantly) ) (JJ different)  (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (NN Ro) ) (: :)  (NP (QP (CD 7687) (CC  +/-)  (CD 1750)  (CC vs)  (CD 7347) (CC  +/-)  (CD 1285) ) (NN sites/cell) )) (: ;)  (NP (NP (NN Kd) ) (: :)  (NP (NP (QP (CD 7.7) (CC  +/-)  (CD 2.4)  (CC vs)  (CD 7.4) (CC  +/-)  (CD 1.7) ) (NN nM) ) (PP (IN at)  (NP (CD 24)  (NNS degrees)  (NN C) ))))) (-RRB- -RRB-) ))) (. .) )) )
(TOP (S (S (PP-TMP (IN After)  (NP (NP (NN weight)  (NN gain) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 14) (CC  +/-)  (CD 2)  (TO to)  (CD 16) (CC  +/-)  (CD 2) ) (NN kg/m2) ) (-RRB- -RRB-) ))) (, ,)  (NP-SBJ (NN receptor)  (NNS numbers) ) (VP (VBD were)  (NP-PRD (NP (NP-COOD (NP (QP (CD 8421) (CC  +/-)  (CD 2126) ) (NP (-NONE- *RNR*-36) ) (PRN (-LRB- -LRB-)  (FRAG (JJ pre) ) (-RRB- -RRB-) )) (CC and)  (NP (QP (CD 9011) (CC  +/-)  (CD 500) ) (NP (-NONE- *RNR*-36) ) (PRN (-LRB- -LRB-)  (FRAG (JJ post) ) (-RRB- -RRB-) ))) (NP-36 (NN sites/cell) )) (, ,)  (SBAR (WHNP-37 (WDT which) ) (S (NP-SBJ (-NONE- *T*-37) ) (VP (VBP are)  (RB not)  (ADJP-PRD (RB significantly)  (JJ different)  (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (ADJP-PRD (ADJP (JJR greater) ) (PP (IN than)  (NP (CD 0.2) )))) (-RRB- -RRB-) ))))))) (: ;) ) (S (NP-SBJ (DT the)  (NN Kd) ) (VP (VBD was)  (ADJP-PRD (ADJP (JJ unchanged) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 9.3) (CC  +/-)  (CD 2.6)  (CC vs)  (CD 9.2) (CC  +/-)  (CD 2.4) ) (NN nM) ) (-RRB- -RRB-) ))) (. .) )) )
(TOP (NP (NP (NNS CONCLUSIONS) ) (S-COOD (S (NP-SBJ (NN Hypercortisolaemia) ) (VP (VBZ does)  (RB not)  (VP (VB down-regulate)  (NP (NP (DT the)  (NN lymphocyte)  (NN glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (NN anorexia)  (NN nervosa) )))))) (CC and)  (S (NP-SBJ-105 (DT a)  (JJ post-receptor)  (NN defect) ) (VP (MD might)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-105) ) (PP (IN in)  (NP (NP (JJ peripheral)  (NN tissue)  (NN resistance) ) (PP (TO to)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NNS hormones) ) (PP (IN in)  (NP (NN undernutrition) )))))))))))) (. .) )) )
(TOP (NP (NP (NN Tumor)  (NN necrosis)  (NN factor-alpha)  (NN mRNA)  (NN accumulation) ) (PP (IN in)  (NP (JJ human)  (JJ myelomonocytic)  (NN cell)  (NNS lines) )) (. .) ) )
(TOP (NP-COOD (NP (NP (NN Role) ) (PP (IN of)  (NP (NP (JJ transcriptional)  (NN regulation) ) (PP (IN by)  (NP (NN DNA)  (NN sequence)  (NNS motifs) ))))) (CC and)  (NP (NN mRNA)  (NN stabilization) ) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN cytokine)  (NN TNF) ) (VP (VBZ mediates)  (NP (NP (JJ many) ) (PP (IN of)  (NP (NP (DT the)  (JJ pathologic)  (NNS signs) ) (PP (IN of)  (NP-COOD (NP (NN cachexia) ) (, ,)  (NP (NN inflammation) ) (, ,)  (CC and)  (NP (NN sepsis) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ current)  (NN work) ) (VP (VBZ describes)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (NN TNF) )) (PP (IN in)  (NP (JJ human)  (JJ myelomonocytic)  (NN cell)  (NNS lines) )) (PP-TMP (IN after)  (NP (NN PMA)  (NN stimulation) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN cell)  (NNS lines) ) (VP (VBP exhibit)  (NP (NP (DT a)  (JJ low)  (NN level) ) (PP (IN of)  (NP (JJ constitutive)  (NN TNF)  (NN mRNA)  (NN expression) )))) (. .) ) )
(TOP (S (PP-TMP (IN Within)  (NP (NP (QP (CD 2)  (TO to)  (CD 4) ) (NN h) ) (PP (IN of)  (NP (NN PMA)  (NN exposure) )))) (, ,)  (NP-SBJ-27 (NP (JJ steady)  (NN state)  (NNS levels) ) (PP (IN of)  (NP (NN TNF)  (NN mRNA) ))) (VP (VBP are)  (ADVP (RB markedly) ) (VP (JJ elevated)  (NP (-NONE- *-27) ) (PP (IN in)  (NP (NP (DT all)  (JJ myelomonocytic)  (NN cell)  (NNS lines) ) (VP (VBN studied)  (NP (-NONE- *) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN rise) ) (VP (VBZ is)  (PP-PRD (JJ due)  (PP-COOD (PP (TO to)  (NP (NP (VBN increased)  (NN mRNA)  (NN stability) ) (, ,)  (SBAR (WHNP-28 (WDT which) ) (S (NP-SBJ (-NONE- *T*-28) ) (VP (VBD increased)  (PP (IN by)  (NP (RB almost)  (RB twofold) ))))))) (, ,)  (CC and)  (PP (TO to)  (NP (NP (DT an)  (JJ overall)  (NN increase) ) (PP (IN in)  (NP (NN transcription) )) (, ,)  (SBAR (WHNP-29 (WDT which) ) (S (NP-SBJ (-NONE- *T*-29) ) (VP (VBZ rises)  (PP (IN by)  (NP (JJR more)  (IN than)  (RB sixfold) )))))))))) (. .) ) )
(TOP (S (PP (IN At)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (DT the)  (JJ genomic)  (NN TNF)  (NN gene) )))) (, ,)  (NP-SBJ-30 (DT a)  (NN DNase)  (CD I)  (JJ hypersensitive)  (NN site) ) (VP (VBZ is)  (VP (VBN detected)  (NP (-NONE- *-30) ) (PP (IN within)  (NP (NP (DT the)  (NN TNF)  (NN promoter) ) (PP (IN between)  (NP (QP (CD -200)  (TO to)  (CD -100) ) (NN bp) )))) (PP (JJ relative)  (TO to)  (NP (DT the)  (NN transcription)  (NN initiation)  (NN site) )))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (-NONE- *-31) ) (ADJP-PRD (JJ absent)  (PP (IN in)  (NP (VBG nonexpressing)  (NN erythroleukemia)  (NN cell)  (NNS lines) ))))) (, ,)  (NP-SBJ-31 (DT the)  (NN DNase)  (CD I)  (NN site) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (JJ uninduced)  (JJ myelomonocytic)  (NN cell)  (NNS lines) )))) (CC and)  (VP (VBZ is)  (RB not)  (VP (VBN changed)  (NP (-NONE- *-31) ) (PP-TMP (IN after)  (NP (NN PMA)  (NN induction) ))))) (. .) ) )
(TOP (S (S (NP (NP (DT The)  (NN PMA)  (NN induction) ) (PP (IN of)  (NP (NN c-fos)  (NN mRNA) ))) (VP (VBD correlated)  (ADVP (RB well) ) (PP (IN with)  (NP (NN TNF)  (NN gene)  (NN induction) ))) (: ;) ) (S (NP-SBJ-32 (NP (NN expression) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBG encoding)  (NP (NP (JJ other)  (NNS proteins) ) (PP (IN in)  (NP (NP (DT the)  (NN AP-1)  (NN complex) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN junB) ) (CC and)  (NP (NN junD) )) (-RRB- -RRB-) )))))))) (VP (VBD were)  (ADVP (RB also) ) (VP (VBN induced)  (NP (-NONE- *-32) ) (PP (IN by)  (NP-LGS (NN PMA) )))) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP (ADJP-COOD (ADJP (VBG resting) ) (CC and)  (ADJP (VBN induced) )) (NN ML-1)  (NNS cells) ))) (VP (VBP contain)  (NP (NP (NNS proteins) ) (VP (VBG binding)  (ADVP (RB specifically) ) (PP (TO to)  (NP (NP (DT the)  (NP-COOD (NP (NN AP-1) ) (, ,)  (NP (NN AP-2) ) (, ,)  (CC and)  (NP (NN NF)  (NN kappa)  (NN B)  (NN sequence) ))) (ADJP (JJ located)  (PP (IN within)  (NP (DT the)  (NN TNF)  (NN promoter) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NN PMA)  (NN induction) ) (VP (VBZ increases)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NP (DT a)  (NN number) ) (PP (IN of)  (NP (JJ specific)  (VBG binding)  (NNS complexes) ))))) (PP (JJ relative)  (TO to)  (NP (DT the)  (VBG resting)  (NNS cells) ))) (. .) ) )
(TOP (S (NP-SBJ-34 (NP (DT The)  (JJ regulatory)  (NNS mechanisms) ) (PP (IN of)  (NP (DT the)  (ADJP-COOD (ADJP (JJ human) ) (CC and)  (ADJP (JJ murine) )) (NN TNF)  (NNS genes) ))) (VP (VBP are)  (VP (VBN discussed)  (NP (-NONE- *-34) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ USF-related)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN HIV-TF1) ) (, ,) ) (VP (VBZ stimulates)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (JJ human)  (NN immunodeficiency)  (NN virus-1) )))) (. .) ) )
(TOP (S (NP-SBJ-28 (NP (DT The)  (NN transcription)  (NN factor)  (NN HIV-TF1) ) (, ,)  (SBAR (WHNP-27 (WDT which) ) (S (NP-SBJ (-NONE- *T*-27) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (DT a)  (NN region) ) (ADJP (NP (QP (IN about)  (CD 60) ) (NN bp) ) (JJ upstream)  (PP (IN from)  (NP (NP (DT the)  (NN enhancer) ) (PP (IN of)  (NP (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus-1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) ))))))))))) (, ,) ) (VP (VBD was)  (VP (VBN purified)  (NP (-NONE- *-28) ) (PP (IN from)  (NP (JJ human)  (NN B)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NN HIV-TF1) ) (VP (VBD had)  (NP (NP (DT a)  (JJ molecular)  (NN weight) ) (PP (IN of)  (NP (CD 39,000) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Binding) ) (PP (IN of)  (NP (NN HIV-TF1) )) (PP (TO to)  (NP (DT the)  (NN HIV)  (NP (NP (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) ))))) (VP (VBD activated)  (NP (NP (NN transcription) ) (PP (IN from)  (NP (DT the)  (NN HIV)  (NN promoter) ))) (ADVP (FW in)  (FW vitro) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ HIV-TF1-binding)  (NN site) ) (PP (IN in)  (NP (NN HIV)  (NN LTR) ))) (VP (VBD was)  (ADJP-PRD (JJ similar)  (PP (TO to)  (NP (NP (DT the)  (NN site) ) (VP (VBN recognized)  (NP (-NONE- *) ) (PP (IN by)  (NP (NP (NP (JJ upstream)  (JJ stimulatory)  (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN USF) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (DT the)  (NN adenovirus)  (JJ major)  (JJ late)  (NN promoter) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ DNA-binding)  (NNS properties) ) (PP (IN of)  (NP (NN HIV-TF1) ))) (VP (VBD suggested)  (SBAR (IN that)  (S (NP-SBJ (NN HIV-TF1) ) (VP (MD might)  (VP (VB be)  (ADJP-PRD (ADJP-COOD (ADJP (JJ identical)  (PP (-NONE- *RNR*-29) )) (CC or)  (ADJP (JJ related)  (PP (-NONE- *RNR*-29) ))) (PP-29 (TO to)  (NP (NN USF) )))))))) (. .) ) )
(TOP (S (ADVP (RB Interestingly) ) (, ,)  (NP-SBJ (NP (NN treatment) ) (PP (IN of)  (NP (VBN purified)  (NN HIV-TF1) )) (PP (IN by)  (NP (NN phosphatase) ))) (ADVP (RB greatly) ) (VP (VBD reduced)  (NP (PRP$ its)  (JJ DNA-binding)  (NN activity) ) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (NP (NN phosphorylation) ) (PP (IN of)  (NP (NN HIV-TF1) ))) (VP (VBD was)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (NN DNA)  (NN binding) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN disruption) ) (PP (IN of)  (NP (JJ HIV-TF1-binding)  (NN site) ))) (VP (VBD induced)  (NP (NP (DT a)  (NP (CD 60)  (NN %) ) (NP (NN decrease) )) (PP (IN in)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NP (NN transcription) ) (PP (IN from)  (NP (DT the)  (NN HIV)  (NN promoter) ))))))) (ADVP (FW in)  (FW vivo) )) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-100 (NN HIV-TF1) ) (VP (VBZ is)  (VP (VBN involved)  (NP (-NONE- *-100) ) (PP (IN in)  (NP (NP (JJ transcriptional)  (NN regulation) ) (PP (IN of)  (NP (NN HIV-1) ))))))))) (. .) ) )
(TOP (NP (NP (DT The)  (NN effect) ) (PP (IN of)  (NP (NN toremifene)  (NN therapy) )) (PP (IN on)  (NP (NP (NN serum)  (NN immunoglobulin)  (NNS levels) ) (PP (IN in)  (NP (NN breast)  (NN cancer) )))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NNS Estrogens) ) (CC and)  (NP (NNS anti-estrogens) )) (VP (VBP enhance)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (ADJP (NN immunoglobulin)  (-LRB- -LRB-)  (NN Ig)  (-RRB- -RRB-)  (NN -secreting) ) (NNS cells) ))) (PP (IN in)  (NP (ADJP (NN pokeweed)  (NN mitogen)  (-LRB- -LRB-)  (NN PWM)  (-RRB- -RRB-)  (JJ -stimulated) ) (NN lymphocyte)  (NNS cultures) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Lymphocytes) ) (PP (IN from)  (NP (NP (NNS patients) ) (SBAR (WHNP-14 (WP who) ) (S (NP-SBJ (-NONE- *T*-14) ) (VP (VBP have)  (VP (VBN received)  (NP (NN anti-estrogen)  (NN therapy) )))))))) (VP (VBP show)  (NP (NP (NP (JJ similar)  (NN enhancement) ) (PP (IN of)  (NP (JJ Ig-secreting)  (NNS cells) )))) (PP-TMP (IN after)  (NP (NN PWM)  (NN stimulation) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (NP-SBJ-15 (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NN anti-estrogen)  (-LRB- -LRB-)  (NN toremifene)  (-RRB- -RRB-)  (NN therapy) )) (PP (IN on)  (NP (NP (NP (NP (NN serum)  (NN immunoglobulin) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN IgA) ) (, ,)  (NP (NN IgM) ) (, ,)  (NP (NN IgG) )) (-RRB- -RRB-) )) (NNS levels) ) (PP (IN in)  (NP (NN breast)  (NN cancer)  (NNS patients) ))))) (VP (VBD was)  (VP (VBN investigated)  (NP (-NONE- *-15) ))) (. .) ) )
(TOP (S (NP-SBJ-16 (NN Serum)  (NN Ig)  (NNS levels) ) (VP (VBD were)  (VP (VBN followed)  (NP (-NONE- *-16) ) (NP-TMP (QP (RB up)  (TO to)  (CD two) ) (NNS years) ) (PP-TMP (PP-COOD (PP (IN after)  (NP (-NONE- *RNR*-17) )) (CC or)  (PP (IN during)  (NP (-NONE- *RNR*-17) ))) (NP-17 (DT the)  (NN therapy) )))) (. .) ) )
(TOP (S (NP-SBJ (DT An)  (JJ unexpected)  (NN finding) ) (VP (VBD was)  (SBAR-PRD (IN that)  (S (NP-SBJ (DT the)  (NN Ig)  (NNS levels) ) (VP (VBD decreased)  (PP-TMP (IN during)  (NP (DT the)  (JJ follow-up)  (NN period) )))))) (. .) ) )
(TOP (S (NP-SBJ-18 (DT This)  (NN decrease) ) (VP (VBD was)  (VP (VBN seen)  (NP (-NONE- *-18) ) (PP-COOD (PP (IN in)  (NP (NP (NNS patients) ) (SBAR (WHNP-19 (WP who) ) (S (NP-SBJ (-NONE- *T*-19) ) (VP (VBD responded)  (PP (TO to)  (NP (DT the)  (NN therapy) ))))))) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN in)  (NP (NP (DT those) ) (SBAR (WHNP-20 (WP who) ) (S (NP-SBJ (-NONE- *T*-20) ) (VP (VBD did)  (RB not)  (VP (-NONE- *?*) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN HIV1)  (NN infection) ) (PP (IN of)  (NP (JJ human)  (NP-COOD (NP (NNS monocytes) ) (CC and)  (NP (NNS macrophages) ))))) (VP (VBZ promotes)  (NP (NP-COOD (NP (NN induction) ) (CC or)  (NP (NN translocation) )) (PP (IN of)  (NP (JJ NF-KB-related)  (NNS factors) )))) (. .) ) )
(TOP (S (PP-TMP (IN In)  (NP (CD 1991) )) (, ,)  (NP-SBJ-52 (PRP we) ) (VP (VBD demonstrated)  (, ,)  (S (NP-SBJ (-NONE- *-52) ) (VP (VBG using)  (NP (JJ electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) ))) (, ,)  (SBAR (IN that)  (S (NP-SBJ-53 (NP (CD 3)  (JJ different)  (NNS factors) ) (-LRB- -LRB-)  (VP (VBN termed)  (S (NP-SBJ (-NONE- *) ) (NP-PRD-COOD (NP (NN B1) ) (, ,)  (NP (NN B2) ) (CC and)  (NP (NN B3) )))) (-RRB- -RRB-)  (PP (IN with)  (NP (NP (NN affinity) ) (PP (IN for)  (NP (DT the)  (JJ KB-enhancer)  (NN target)  (NN sequence) ))))) (VP (VBD were)  (ADVP (RB specifically) ) (VP (VBN detected)  (NP (-NONE- *-53) ) (PP (IN in)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP (JJ HIV1-infected)  (NP-COOD (NP (NNS monocytes) ) (CC and)  (NP (NNS macrophages) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-54 (DT The)  (NN B2)  (NN factor) ) (VP (VBD was)  (VP (VBN induced)  (NP (-NONE- *-54) ) (PP (IN in)  (NP (NP (DT the)  (NNS nuclei) ) (PP (IN of)  (NP (DT these)  (NNS cells) )))) (PP-TMP (RB only)  (IN upon)  (NP (NN HIV1)  (NN infection) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN B3)  (NN factor) ) (VP-COOD (VP (VBD was)  (ADJP-PRD (ADVP (RB only)  (RB slightly) ) (JJ evident) ) (PP (IN in)  (NP (NP (NNS nuclei) ) (PP (IN of)  (NP (JJ uninfected)  (NNS cells) ))))) (CC but)  (VP (VBD was)  (ADJP-PRD (RB readily)  (JJ detectable) ) (PP (IN in)  (NP (NP (NNS nuclei) ) (PP (IN of)  (NP (JJ infected)  (NNS monocytes) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Its)  (NN expression) ) (VP (VBD remained)  (ADJP-PRD (RB very)  (JJ low)  (PP (IN in)  (NP (NP (NNS nuclei) ) (PP (IN of)  (NP (JJ HIV1-infected)  (NNS macrophages) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN paper) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-56 (DT the)  (NN B2)  (NN factor) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-56) ) (PP (IN in)  (NP (NP (DT the)  (NN cytosol) ) (PP (IN of)  (NP-COOD (NP (NNS monocytes) ) (CC and)  (NP (NNS macrophages) ))))) (PP (IN as)  (NP (DT a)  (JJ DNA-binding)  (NN protein) )) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (SBAR (IN that)  (S (NP-SBJ-57 (PRP it) ) (VP (VBZ is)  (RB not)  (VP (VBN associated)  (NP (-NONE- *-57) ) (PP (IN with)  (NP (NP (DT an)  (NN inhibitor) ) (PRN (-LRB- -LRB-)  (NP (NN IKB) ) (-RRB- -RRB-) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-58 (DT This)  (NN factor) ) (VP-COOD (VP (VBD remained)  (ADJP-PRD (VBN clustered)  (PP (IN in)  (NP (DT the)  (NN cytosol) )))) (CC and)  (VP (VBD was)  (VP (VBN translocated)  (NP (-NONE- *-58) ) (PP (TO to)  (NP (DT the)  (NNS nuclei) )) (PP-TMP (RB only)  (IN after)  (NP (NN HIV1)  (NN infection) ))))) (. .) ) )
(TOP (S (NP-SBJ-59 (DT The)  (NN B3)  (NN factor) ) (VP (VBZ is)  (VP (VBN detected)  (NP (-NONE- *-59) ) (PP (IN in)  (NP (DT the)  (NN cytosol) )) (SBAR-TMP (RB only)  (WHADVP-60 (WRB when) ) (S (NP-SBJ (NNS cells) ) (VP (VBP are)  (ADJP-PRD (JJ HIV1-infected) ) (ADVP (-NONE- *T*-60) )))))) (. .) ) )
(TOP (S (NP-SBJ-61 (NP (DT The)  (NN role) ) (PP (IN of)  (NP (NN HIV1)  (NN infection) )) (PP (IN in)  (NP (NP-COOD (NP (DT the)  (NN expression) ) (CC and)  (NP (DT the)  (NN translocation) )) (PP (IN of)  (NP (DT these)  (NNS factors) ))))) (VP (VBZ is)  (VP (VBN discussed)  (NP (-NONE- *-61) ))) (. .) ) )
(TOP (S (NP-SBJ-49 (NP (NN Induction) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (PP-TMP (IN during)  (NP (NN monocyte)  (NN differentiation) ))) (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-49) ) (PP (IN with)  (NP (NP (NN activation) ) (PP (IN of)  (NP (JJ HIV-gene)  (NN expression) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Cells) ) (PP (IN of)  (NP (DT the)  (JJ monocyte-macrophage)  (NN lineage) ))) (VP (VBP are)  (NP-PRD (NP (JJ important)  (NNS targets) ) (PP (IN of)  (NP (NN HIV)  (NN infection) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP report)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ-50 (NP (DT the)  (JJ phenotypic)  (NN differentiation) ) (PP (IN of)  (NP (NN monocyte)  (NN cell)  (NNS lines) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (NN phorbol)  (NNS esters) ) (CC or)  (NP (NP (NN tumour)  (NN necrosis)  (NN factor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN TNF)  (NN alpha) ) (-RRB- -RRB-) )))))) (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-50) ) (PP (IN with)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NP (JJ nuclear)  (NN factor)  (NN kappa)  (NN B) ) (PRN (-LRB- -LRB-)  (NP (NN NF-kappa)  (NN B) ) (-RRB- -RRB-) )))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NN parallel)  (IN with)  (NP (JJ such)  (NN differentiation) )) (, ,)  (NP-SBJ-51 (NP (NN HIV)  (NN transcription) ) (, ,)  (VP (VBN monitored)  (NP (-NONE- *) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (DT an)  (NN HIV)  (JJ long)  (JJ terminal)  (NN repeat)  (NN reporter)  (NN gene)  (NN construct) )))) (, ,) ) (VP (VBZ is)  (VP (VBN activated)  (NP (-NONE- *-51) ) (PP (IN in)  (NP (JJ such)  (NNS cells) )) (PP (IN under)  (NP (NP (DT the)  (NN influence) ) (PP (IN of)  (NP (VBN enhanced)  (NN NF-kappa)  (NN B)  (NN expression) )))))) (. .) ) )
(TOP (S (ADVP (RB Also) ) (, ,)  (PP (IN in)  (NP (NP (DT a)  (JJ promonocyte)  (NN cell)  (NN line) ) (ADJP (RB chronically)  (VBN infected)  (PP (IN with)  (NP (NN HIV) ))))) (, ,)  (NP-SBJ-COOD-52 (NP (NN NF-kappa)  (NN B)  (NN expression) ) (CC and)  (NP (NN HIV)  (NN transcription) )) (VP (VBD were)  (VP (VBN enhanced)  (NP (-NONE- *-52) ) (PP-TMP (IN on)  (NP (NP (NN stimulation) ) (PP (IN with)  (NP-COOD (NP (NN phorbol)  (NN ester) ) (CC or)  (NP (NN TNF)  (NN alpha) ))))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (NP (NN stimulation) ) (PP (IN of)  (NP (NN monocyte)  (NN cell)  (NNS lines) )) (PP (IN by)  (NP-COOD (NP (NN phorbol)  (NNS esters) ) (CC or)  (NP (NN TNF)  (NN alpha) )))) (VP-COOD (VP (VBZ induces)  (NP (NN cell)  (NN differentiation) )) (CC and)  (VP (VBZ activates)  (NP (NN HIV)  (NN transcription) ))) (. .) ) )
(TOP (S (NP-SBJ (PDT Such)  (DT a)  (NN process) ) (VP-COOD (VP (MD may)  (VP (VB have)  (NP (JJ fundamental)  (NNS implications) ) (PP (IN in)  (NP (NN AIDS)  (NN pathogenesis) )) (ADVP (FW in)  (FW vivo) ))) (CC and)  (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ important)  (PP (IN in)  (NP (NP (NN disease)  (NN progression) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (JJ opportunistic)  (NNS infections) ) (VP (ADVP-COOD (ADVP (RB directly) ) (CC or)  (ADVP (RB indirectly) )) (VBG involving)  (NP (NNS macrophages) ))))))))))) (. .) ) )
(TOP (NP (NP (NP (DT A)  (JJ nuclear)  (NN factor)  (NN NF-GM2) ) (SBAR (WHNP-105 (WDT that) ) (S (NP-SBJ (-NONE- *T*-105) ) (VP (VBZ interacts)  (PP (IN with)  (NP (NP (DT a)  (JJ regulatory)  (NN region) ) (PP (IN of)  (NP (NP (DT the)  (NN GM-CSF)  (NN gene) ) (ADJP (JJ essential)  (PP (IN for)  (NP (PRP$ its)  (NN induction) )) (PP (IN in)  (NNS responses)  (TO to)  (NP (NN T-cell)  (NN activation) )))))))))) (: :) ) (NP (NP (NP (NN purification) ) (PP (IN from)  (NP (JJ human)  (NN T-cell)  (NN leukemia)  (NN line)  (NN Jurkat)  (NNS cells) ))) (CC and)  (NP (NP (NN similarity) ) (PP (TO to)  (NP (NN NF-kappa)  (NN B) ))) (. .) )) )
(TOP (S (NP-SBJ (NP (NN Activation) ) (PP (IN of)  (NP (NN T)  (NNS cells) )) (PP (IN by)  (NP-COOD (NP (NN antigen) ) (, ,)  (NP (NN lectin) ) (, ,)  (CC or)  (NP (NP (DT a)  (NN combination) ) (PP (IN of)  (NP-COOD (NP (NP (NN phorbol-12-myristate)  (NN acetate) ) (PRN (-LRB- -LRB-)  (NP (NN PMA) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN calcium)  (NN ionophore) ) (PRN (-LRB- -LRB-)  (NP (NN A23187) ) (-RRB- -RRB-) )))))))) (VP (VBZ leads)  (PP (TO to)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NP (NNS genes) ) (PP (IN for)  (NP (NP (DT a)  (NN set) ) (PP (IN of)  (NP (NP (NNS lymphokines) ) (, ,)  (PP (VBG including)  (NP (NP (ADJP (JJ granulocyte-macrophage)  (JJ colony-stimulating) ) (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN GM-CSF) ) (-RRB- -RRB-) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD demonstrated)  (PP (IN in)  (NP (JJR earlier)  (NNS studies) )) (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ upstream)  (NN region) ) (PP (IN of)  (NP (DT the)  (NN mouse)  (NN GM-CSF)  (NN promoter) )) (PP (IN at)  (NP (NP (NNS positions) ) (PP (IN between)  (NP-COOD (NP (CD -95) ) (CC and)  (NP (CD -73) )))))) (VP (VBZ is)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (NP (JJ transcriptional)  (NN activation) ) (PP (IN in)  (NN response)  (TO to)  (NP (NN PMA/A23187) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN region) ) (VP (VBZ contains)  (NP (NP (CD two)  (JJ DNA-binding)  (NNS motifs) ) (, ,)  (NP-COOD (NP (NN GM2) ) (CC and)  (NP (NN GC-box) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-107 (NP (DT The)  (NN GM2)  (NN sequence) ) (PRN (-LRB- -LRB-)  (NP (NN GGTAGTTCCC) ) (-RRB- -RRB-) )) (VP (VBZ is)  (VP (VBN recognized)  (NP (-NONE- *-107) ) (PP-108 (IN by)  (NP-LGS (DT an)  (JJ inducible)  (NN factor)  (NN NF-GM2) ))))) (: ;)  (S (NP-SBJ=107 (NP (DT the)  (JJ other) ) (PRN (-LRB- -LRB-)  (NP (NN CCGCCC) ) (-RRB- -RRB-) )) (VP (PP=108 (IN by)  (NP-LGS (JJ constitutive)  (NNS factors)  (NP-COOD (NP (NN A1) ) (, ,)  (NP (NN A2) ) (, ,)  (CC and)  (NP (NN B) )))))) (. .) ) )
(TOP (S (S (NP-SBJ (-NONE- *-109) ) (VP (TO To)  (VP (VB elucidate)  (NP (NP (DT the)  (NN mechanism) ) (PP (IN of)  (NP (NN GM-CSF)  (NN gene)  (NN activation) )))))) (, ,)  (S (NP-SBJ-109 (PRP we) ) (VP (VBP have)  (VP (VBN purified)  (NP (DT the)  (JJ inducible)  (NN factor)  (NN NF-GM2) ) (PP (IN from)  (NP (NP (DT the)  (JJ nuclear)  (NN extract) ) (PP (IN of)  (NP (VBN stimulated)  (NN Jurkat)  (NNS cells) )))) (PP (IN on)  (DT the)  (NN basis)  (IN of)  (NP (JJ specific)  (JJ DNA-binding)  (NN activity) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (VBN purified)  (NN NF-GM2) ) (VP-COOD (VP (VBZ consists)  (PP (IN of)  (NP (NP (NP-COOD (NP (NP (CD 50) ) (PRN (-LRB- -LRB-)  (NP (NN p50) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (CD 65) ) (PRN (-NONE- *ICH*-21) ))) (NN kDa) ) (PRN-21 (-LRB- -LRB-)  (NP (NN p65) ) (-RRB- -RRB-) ) (NNS polypeptides) ))) (CC and)  (VP (VBZ has)  (NP (NP (DT a)  (NN binding)  (NN activity) ) (ADJP (JJ specific)  (PP (IN for)  (NP (CC both)  (DT the)  (NP-COOD (NP (NN GM-CSF) ) (CC and)  (NP (NP (NN immunoglobulin)  (NN kappa) ) (PRN (-LRB- -LRB-)  (NP (NN GGAAAGTCCC) ) (-RRB- -RRB-) ))) (NNS enhancers) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (ADJP (RB Electrophoretically)  (VBN purified) ) (NN p50) ) (ADVP (RB alone) )) (VP (MD can)  (VP (VB form)  (NP (DT a)  (JJ protein-DNA)  (NN complex) )))) (, ,)  (CC but)  (S (PP (IN in)  (NP (DT the)  (NN mixture) )) (, ,)  (NP-SBJ-207 (NN p50) ) (VP (VBZ associates)  (ADVP (RB preferentially) ) (PP (IN with)  (NP (NN p65) )) (S (NP-SBJ (-NONE- *-207) ) (VP (TO to)  (VP (VB form)  (NP (DT the)  (NN NF-GM2)  (NN complex) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NN p65) ) (VP (VBD gave)  (ADVP (FW per)  (FW se) ) (, ,)  (PP (IN with)  (NP (JJ low)  (NN affinity) )) (, ,)  (NP (NP (DT a)  (JJ protein-DNA)  (NN complex) ) (SBAR (WHNP-208 (WDT that) ) (S (NP-SBJ (-NONE- *T*-208) ) (VP (VBD migrated)  (ADVP (ADVP (RBR more)  (RB slowly) ) (PP (IN than)  (NP (JJ native)  (NN NF-GM2)  (NN complex) )))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (NP (DT an)  (NN antiserum) ) (PP (IN against)  (NP (NP (NN KBF1) ) (PRN (-LRB- -LRB-)  (ADJP (JJ identical)  (PP (TO to)  (NP (CD 50)  (NN kDa)  (NN NF-kappa)  (NN B)  (NN protein) ))) (-RRB- -RRB-) )))) (VP (VBD reacted)  (PP (IN with)  (NP (NP (DT the)  (NN p50) ) (PP (IN of)  (NP (NN NF-GM2) )))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (SBAR (IN that)  (S (NP-SBJ-209 (DT the)  (NN NF-GM2)  (NN polypeptide) ) (VP (MD can)  (RB not)  (VP (VB be)  (ADVP (RB immunologically) ) (VP (VBN differentiated)  (NP (-NONE- *-209) ) (PP (IN from)  (NP (NP (DT the)  (CD 50)  (NN kDa)  (NN subunit) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (VBN purified)  (NN NF-GM2) ) (VP (VBD activated)  (NP (NP (ADJP (FW in)  (FW vitro) ) (NN transcription) ) (PP (IN from)  (NP (DT the)  (NN kappa)  (NN B)  (NN enhancer) ))) (, ,)  (SBAR (IN while)  (S (NP-SBJ-210 (PRP it) ) (VP (VBD failed)  (S (NP-SBJ (-NONE- *-210) ) (VP (TO to)  (VP (VB stimulate)  (NP (NP (NN transcription) ) (PP (IN from)  (NP (NP (DT the)  (NN GM-CSF)  (NN promoter) ) (VP (VBG harboring)  (NP (DT the)  (NN GM2)  (NN sequence) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN activation)  (NN mechanism) ) (PP (IN of)  (NP (DT the)  (NN GM-CSF)  (NN gene) )) (PP (IN through)  (NP (DT the) (JJ  GM2/GC-box)  (NN sequence) ))) (VP (VBZ is)  (ADJP-PRD (JJ different)  (PP (IN from)  (NP (NP (DT that) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBG carrying)  (NP (NP (DT the)  (NN kappa)  (NN B)  (NN enhancer) ) (ADVP (RB alone) )))))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (JJ normal)  (NNS leukocytes) )) (: :) ) (NP (NP (NNS effects) ) (PP (IN of)  (NP-COOD (NP (NN age) ) (, ,)  (NP (NN gender) ) (, ,)  (NP (NN season) ) (, ,)  (CC and)  (NP (NN plasma)  (NN cortisol)  (NNS concentrations) ))) (. .) )) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD measured)  (NP (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NN GR) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (NP (NP (JJ mononuclear)  (NNS leukocytes) ) (PRN (-LRB- -LRB-)  (NP (NN MNL) ) (-RRB- -RRB-) )) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (JJ peripheral)  (NN blood) ) (PP (IN of)  (NP (NP (CD 145)  (ADJP (RB apparently)  (JJ healthy) ) (NNS volunteers) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD 86)  (NNS men) ) (CC and)  (NP (CD 59)  (NNS women) )) (-RRB- -RRB-) )))))))))) (. .) ) )
(TOP (S (S (NP-SBJ-7 (NP (DT An)  (JJ age-related)  (NN decrease) ) (PP (IN in)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN GR) ))))) (VP (VBD was)  (VP (VBN suggested)  (NP (-NONE- *-7) ) (PP (IN between)  (NP-COOD (NP (NP (NNS subjects) ) (ADJP (ADJP (JJR younger) ) (PP (IN than)  (NP (CD 20)  (NNS years) )))) (CC and)  (NP (JJ elderly)  (NNS subjects) ))))) (: ;) ) (S (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (NP (DT no)  (JJ apparent)  (JJ seasonal)  (NN variation) ) (PP (IN in)  (NP (NN GR) )))) (. .) )) )
(TOP (S (NP-SBJ (NP (NN Gender)  (NN difference) ) (PP (IN in)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN GR) ))))) (VP (VBD was)  (RB not)  (ADJP-PRD (JJ significant) ) (, ,)  (SBAR (IN although)  (S (NP-SBJ (NNS women) ) (VP (VBD showed)  (NP (ADJP (RB slightly)  (JJR fewer) ) (NN GR) ))))) (. .) ) )
(TOP (S (NP-SBJ-8 (NP (CD Eight)  (NNS patients) ) (PP (IN with)  (NP (NN dermatomyositis/polymyositis) ))) (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-8) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB determine)  (SBAR (IN whether)  (S (NP-SBJ-9 (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NN GR) ) (PP (IN in)  (NP (NN MNL) ))))) (VP (MD could)  (VP (VB be)  (VP (VBN down-regulated)  (NP (-NONE- *-9) ) (PP (IN by)  (NP-LGS (PRP$ their)  (JJ cognate)  (NNS ligands) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-10 (NP (DT The)  (NN number) ) (PP (IN of)  (NP (NP (NN GR) ) (PP (IN in)  (NP (NP (NN MNL) ) (PP (IN from)  (NP (DT these)  (NNS patients) ))))))) (VP (VBD was)  (ADVP (RB significantly) ) (VP (VBN decreased)  (NP (-NONE- *-10) ) (PP-TMP (NP (CD one)  (NN month) ) (IN after)  (NP (NP (DT the)  (NN initiation) ) (PP (IN of)  (NP (NN prednisolone)  (NN therapy) )))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (PP (IN in)  (NP (JJ normal)  (NNS subjects) )) (, ,)  (NP-SBJ (NP (DT the)  (NN GR) ) (PP (IN in)  (NP (NN MNL) ))) (VP (VBD did)  (RB not)  (VP (VB demonstrate)  (NP (JJ circadian)  (NN variation) ) (, ,)  (PP (IN in)  (NN contrast)  (TO to)  (NP (NP (NNS concentrations) ) (PP (IN of)  (NP (NN plasma)  (NN cortisol) )))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Anti-CD2)  (NN receptor)  (NNS antibodies) ) (VP (VBP activate)  (NP (NP (DT the)  (NN HIV)  (JJ long)  (JJ terminal)  (NN repeat) ) (PP (IN in)  (NP (NN T)  (NNS lymphocytes) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN CD2)  (NN T)  (NN lymphocyte)  (NN glycoprotein)  (NN surface)  (NN molecule) ) (VP (VBZ mediates)  (NP (NP-COOD (CC both)  (NP (NN cell)  (TO to)  (NN cell)  (NN adhesion) ) (CC and)  (NP (NN T)  (NN cell)  (NN activation) )) (, ,)  (NP (NP (CD two)  (NNS processes) ) (SBAR (WHNP-20 (WDT that) ) (S (NP-SBJ-21 (-NONE- *T*-20) ) (VP (VBP are)  (VP (VBN involved)  (NP (-NONE- *-21) ) (PP (IN in)  (NP (NP (DT the)  (NN spread) ) (PP (IN of)  (NP (NN HIV)  (NN infection) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-22 (NP (NN Treatment) ) (PP (IN of)  (NP (ADJP (RB chronically)  (JJ HIV-infected) ) (NN PBMC) )) (PP (IN with)  (NP (JJ anti-CD2)  (NN mAb) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-22) ) (VP (TO to)  (VP (VB induce)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NP (JJ infectious)  (NN virus) ) (PP (IN from)  (NP (DT these)  (NNS cultures) ))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (NP-SBJ (PRP we) ) (VP (VBD investigated)  (NP (NP (DT the)  (NNS mechanisms) ) (SBAR (WHADVP-23 (WRB whereby) ) (S (NP-SBJ (JJ anti-CD2)  (NNS antibodies) ) (VP (VBP stimulate)  (NP (JJ viral)  (NN production) ) (PP (-NONE- *T*-23) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (NN treatment) ) (PP (IN of)  (NP (ADJP (RB transiently)  (VBN transfected) ) (NN T)  (NNS lymphocytes) )) (PP (IN with)  (NP (JJ anti-CD2)  (NNS antibodies) ))) (VP (VBZ results)  (PP (IN in)  (NP (NP (NN activation) ) (PP (IN of)  (NP (DT the)  (NN HIV)  (JJ long)  (JJ terminal)  (NN repeat) )))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-COOD (NP (NP (NN CAT)  (NNS assays) ) (VP (VBG using)  (NP (VBN mutated)  (NN HIV)  (ADJP (JJ long)  (JJ terminal)  (NN repeat-CAT) ) (NNS constructs) ))) (CC and)  (NP (NN gel)  (NN shift)  (NNS assays) )) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN activation) ) (VP (VBZ is)  (ADJP-PRD (JJ dependent)  (PP (IN on)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS studies) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (NN interaction) ) (PP (IN of)  (NP (NN CD2) )) (PP (IN with)  (NP (NP (PRP$ its)  (JJ natural)  (NN ligand) ) (, ,)  (NP (NN LFA-3) ) (, ,) ))) (VP (MD may)  (VP (VB play)  (NP (DT a)  (NN role) ) (PP (IN in)  (NP (NP (NN regulation) ) (PP (IN of)  (NP (NN HIV)  (NN expression) ))))))))) (. .) ) )
(TOP (NP (NP (JJ Nuclear)  (NN transcription)  (NNS factors) ) (SBAR (WHNP-6 (WDT that) ) (S (NP-SBJ (-NONE- *T*-6) ) (VP (VBP bind)  (PP (TO to)  (NP (NP (NNS elements) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN promoter) ))))))) (. .) ) )
(TOP (NP (NP (NN Induction)  (NNS requirements) ) (PP (IN in)  (NP (JJ primary)  (JJ human)  (NN T)  (NNS cells) )) (. .) ) )
(TOP (S (NP-SBJ (JJ Prior)  (NNS studies) ) (VP (VBP have)  (VP (VBN identified)  (NP (NP (JJ several)  (NNS elements) ) (SBAR (WHNP-7 (WDT that) ) (S (NP-SBJ (-NONE- *T*-7) ) (VP (VBP contribute)  (PP (TO to)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN promoter) )) (PP (IN in)  (NP (NP (DT the)  (VBN stimulated)  (NN T)  (NN cell)  (NN line) ) (, ,)  (NP (NN Jurkat) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (DT The)  (NNS sites) ) (CC and)  (NP (PRP$ their)  (JJ corresponding)  (JJ nuclear)  (VBG binding)  (NNS factors) )) (VP (VBP include)  (: :)  (NP-COOD (NP (NN NF-kappa)  (NN B) ) (, ,)  (NP (NN AP-1) ) (, ,)  (NP (NN AP-3) ) (, ,)  (NP (NN OCT-1) ) (, ,)  (CC and)  (NP (NN NF-AT) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ latter)  (`` ")  (NP (NP (JJ nuclear)  (NN factor) ) (PP (IN for)  (NP (VBN activated)  (NN T)  (NNS cells) ))) ('' ") ) (ADVP (RB likely) ) (VP (VBZ contributes)  (PP (TO to)  (NP (NP (DT the)  (NN tissue)  (NN specificity) ) (PP (IN of)  (NP (NN IL-2)  (NN gene)  (NN expression) ))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-8) ) (VP (VBG Using)  (NP (JJ electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) ))) (, ,)  (NP-SBJ-8 (PRP we) ) (VP (VBP have)  (VP (VBN studied)  (NP (DT these)  (NP (NP (NN transcription)  (NNS factors) ) (PP (IN in)  (NP (NP (JJ primary)  (NN T)  (NNS cells) ) (PP (IN from)  (NP (JJ human)  (NN blood) )))))) (S (NP-SBJ (-NONE- *-8) ) (VP-COOD (VP (TO to)  (VP (VB verify)  (NP (NP (PRP$ their)  (NN presence) ) (PP (IN in)  (NP (DT a)  (JJ physiologic)  (NN setting) ))))) (CC and)  (VP (TO to)  (VP (VB identify)  (NP (NP (DT the)  (NNS signals) ) (SBAR (WHNP-9 (WDT that) ) (S (NP-SBJ (-NONE- *T*-9) ) (VP (VBP stimulate)  (NP (NN factor)  (NN activity) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-11 (DT All)  (NNS factors) ) (VP (VBP are)  (VP (VBN induced)  (NP (-NONE- *-11) ) (PP (IN in)  (NP (NP (DT the)  (NNS nuclei) ) (PP (IN of)  (NP (NN T)  (NNS cells) )))) (PP (IN upon)  (NP (NP (NN activation) ) (PP-COOD (PP (IN with)  (NP (NNS mitogens) )) (CC but)  (PP (RB not)  (IN with)  (NP (JJ exogenous)  (NN IL-2)  (NN growth)  (NN factor) ))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-COOD (NP (DT the)  (NN signaling)  (NNS requirements) ) (CC and)  (NP (NP (NN sensitivity) ) (PP (TO to)  (NP (NN protein)  (NN synthesis)  (NNS inhibitors) )))) (VP (VBP differ)  (ADVP (RB considerably) )) (. .) ) )
(TOP (S (NP-SBJ (RB Only)  (DT the)  (NNS activities)  (PP (IN for)  (NP (NP-COOD (NP (NN NF-AT) ) (CC and)  (NP (NN AP-1) )) (NNS sites) ))) (VP (VBP require)  (NP (NP (NP (CD two)  (NNS signals) ) (PP (IN for)  (NP (JJ optimal)  (NN induction) ))) (NP (, ,)  (PP (FW i.e.) ) (, ,)  (NP-COOD (NP (NN PMA) ) (CC plus)  (NP-COOD (CC either)  (NP (NN lectin) ) (CC or)  (NP (NP (NN antibody) ) (PP (TO to)  (NP (DT the)  (NP-COOD (NP (NN CD3) ) (CC or)  (NP (NN CD28) )) (NN surface)  (NNS molecules) )))))))) (. .) ) )
(TOP (S (NP-SBJ-12 (JJ Other)  (NNS factors) ) (VP (VBP are)  (VP (VBN induced)  (NP (-NONE- *-12) ) (PP (IN by)  (NP-LGS-COOD (NP (NN lectin) ) (, ,)  (NP (NN antibody) ) (, ,) (CC  and/or)  (NP (NP (NN PMA) ) (ADVP (RB alone) )))))) (. .) ) )
(TOP (S (PP-TMP (IN After)  (NP (JJ appropriate)  (NN stimulation) )) (, ,)  (NP-SBJ-COOD (CC both)  (NP (NN NF-AT) ) (CC and)  (NP (NN AP-1) )) (VP (VBP are)  (ADJP-PRD (RB peculiarly)  (JJ sensitive)  (PP (TO to)  (NP (DT the)  (NN protein)  (NN synthesis)  (NN inhibitor)  (NN anisomycin) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS data) ) (VP (VBP correlate)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP-COOD (NP (NN NF-AT) ) (CC and)  (NP (NN AP-1) ))) (PP (IN in)  (NP (NN gel)  (NN shift)  (NNS assays) ))) (PP (IN with)  (NP (NP (DT the)  (CD two)  (NNS signals)  (NNS requirements) ) (PP (IN for)  (NP (NN IL-2)  (NN gene)  (NN expression) ))))) (. .) ) )
(TOP (NP (NP (NP (DT An)  (ADJP (JJ erythroid)  (JJ specific) ) (NN enhancer) ) (ADJP (JJ upstream)  (PP (TO to)  (NP (NP (DT the)  (NN gene) ) (VP (VBG encoding)  (NP (DT the)  (ADJP (JJ cell-type)  (JJ specific) ) (NN transcription)  (NN factor)  (NN GATA-1) )))))) (. .) ) )
(TOP (S (NP-SBJ-21 (DT The)  (NN transcription)  (NN factor)  (NN GATA-1) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-21) ) (PP (IN in)  (NP (NP (NP (DT a)  (NN subset) ) (PP (IN of)  (NP (JJ hemopoietic)  (NNS cells) ))) (, ,)  (SBAR (WHADVP-22 (WRB where) ) (S (NP-SBJ (PRP it) ) (VP (VBZ mediates)  (NP (NP (DT the)  (ADJP (JJ cell-type)  (JJ specific) ) (NN expression) ) (PP (IN of)  (NP (JJ several)  (NNS genes) )) (ADVP (-NONE- *T*-22) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN cloned)  (NP (DT the)  (NP-COOD (NP (NN mouse) ) (CC and)  (NP (JJ human) )) (NN GATA-1)  (NNS genes) ))) (. .) ) )
(TOP (S (NP-SBJ-23 (NP (DT A)  (NN region) ) (RRC-COOD (ADJP (JJ upstream)  (PP (TO to)  (NP (DT the)  (JJ first)  (NN exon) ))) (, ,)  (CC and)  (VP (ADVP (RB highly) ) (VBN conserved)  (NP (-NONE- *) ) (PP (IN between)  (NP-COOD (NP (NN mouse) ) (CC and)  (NP (NN man) )))) (, ,) )) (VP (VBZ acts)  (PP (IN as)  (NP (DT an)  (ADJP (JJ erythroid)  (JJ specific) ) (NN enhancer) )) (PP (IN in)  (NP (JJ transient)  (NNS assays) )) (, ,)  (SBAR (IN if)  (S (NP-SBJ-24 (-NONE- *-23) ) (VP (VBN linked)  (NP (-NONE- *-24) ) (PP (PP-COOD (PP (TO to)  (NP (DT the)  (NN GATA-1)  (NP (-NONE- *RNR*-203) ))) (CC or)  (PP (TO to)  (NP (DT the)  (NN SV40)  (NP (-NONE- *RNR*-203) )))) (NP-203 (NN promoter) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN enhancer) ))) (VP (VBZ is)  (ADJP-PRD (ADVP (RB almost)  (RB completely) ) (JJ dependent)  (PP (IN on)  (NP (NP (DT the)  (NN integrity) ) (PP (IN of)  (NP (DT a)  (JJ dimeric)  (NN GATA-1)  (NN binding)  (NN site) )))))) (. .) ) )
(TOP (NP (NP (NP (NN Demonstration) ) (PP (IN of)  (NP (NP (DT a)  (ADJP (NN 1,25-dihydroxyvitamin)  (JJ D3-responsive) ) (NN protein) ) (PP (IN in)  (NP (JJ human)  (NNS lymphocytes) )))) (: :) ) (NP (NP-COOD (NP (JJ immunologic)  (NN crossreactivity) ) (CC and)  (NP (JJ inverse)  (NN regulation) )) (PP (IN with)  (NP (DT the)  (NN vitamin)  (NN D)  (NN receptor) ))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-25) ) (VP (VBG Using)  (NP (NP (NN Western)  (NN blot)  (NN analysis) ) (PP (IN with)  (NP (NP (DT a)  (JJ monoclonal)  (NN antibody) ) (VP (VBG recognizing)  (NP (NP (DT a)  (NN 17-amino)  (NN acid)  (NN epitope) ) (PP (IN of)  (NP (DT the)  (NP (NP (NN 1,25-dihydroxyvitamin)  (NN D3) ) (PRN (-LRB- -LCB-)  (NP (NN 1,25-LRB-OH-RRB-2D3) ) (-RRB- -RCB-) )) (NN receptor) ))))))))) (, ,)  (NP-SBJ-25 (PRP we) ) (VP (VBP have)  (VP (VBN detected)  (NP (CD two)  (VBG crossreacting)  (NNS proteins) ) (PP (IN in)  (NP (VBN activated)  (JJ normal)  (JJ human)  (NNS lymphocytes) )))) (. .) ) )
(TOP (S (NP-SBJ-26 (NP (NP (DT The)  (JJR smaller) ) (PP (IN of)  (NP (DT the)  (CD two)  (NNS proteins) ))) (PRN (-LRB- -LRB-)  (NP (CD 50)  (NN kDa) ) (-RRB- -RRB-) )) (VP-COOD (VP (VBD was)  (ADJP-PRD (JJ indistinguishable)  (PP (IN from)  (NP (DT the)  (JJ classical)  (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor) )))) (CC and)  (, ,)  (VP (S-ADV (NP-SBJ (-NONE- *-27) ) (ADJP-PRD (JJ similar)  (PP (TO to)  (NP (DT the)  (JJ classical)  (NN 1,25-LRB-OH-RRB-2D3)  (NN receptor) )) (, ,) )) (VBD was)  (VP (VBN upregulated)  (NP-27 (-NONE- *-26) ) (PP (IN in)  (NP (DT a)  (JJ dose-dependent)  (NN fashion) )) (PP (IN by)  (NP-LGS (NN 1,25-LRB-OH-RRB-2D3) ))))) (. .) ) )
(TOP (S (NP-SBJ-28 (DT The)  (JJR larger)  (VBG crossreacting)  (NN protein) ) (VP-COOD (VP (VBD exhibited)  (NP (NP (DT an)  (JJ electrophoretic)  (NN mobility) ) (PP (IN of)  (NP (CD 80)  (NN kDa) )))) (, ,)  (VP (VBD was)  (VP (JJ localized)  (NP (-NONE- *-28) ) (PP (IN in)  (NP (DT the)  (NN cell)  (NN cytosol) )))) (, ,)  (CC and)  (VP (VBD appeared)  (S (NP-SBJ (-NONE- *-28) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ specific)  (PP (IN for)  (NP (VBN activated)  (NNS lymphocytes) ))) (SBAR (IN since)  (S (NP-SBJ-29 (PRP it) ) (VP (VBD was)  (RB not)  (VP (VBN detected)  (NP (-NONE- *-29) ) (PP (IN in)  (NP (NP (JJ several)  (JJ other)  (JJ human)  (NNS cells) ) (PP (VBG including)  (NP (NNS monocytes) ))))))))))))) (. .) ) )
(TOP (S (S (ADVP (RBR More)  (RB strikingly) ) (, ,)  (NP-SBJ-30 (DT the)  (JJ 80-kDa)  (NN protein) ) (VP (VBD was)  (VP (VBN downregulated)  (NP (-NONE- *-30) ) (PP (IN in)  (NP (DT a)  (JJ dose-dependent)  (NN fashion) )) (PP (IN by)  (NP-LGS (NN 1,25-LRB-OH-RRB-2D3) )))) (: ;) ) (S (NP-SBJ (DT this)  (NN effect) ) (VP (VBD was)  (ADJP-PRD-COOD (ADJP (JJ independent)  (PP (IN of)  (NP (NP (DT the)  (NN mode) ) (PP (IN of)  (NP (NN lymphocyte)  (NN activation) ))))) (CC and)  (ADJP (JJ specific)  (PP (IN for)  (NP (NP (DT the)  (NN 1,25-LRB-OH-RRB-2D3)  (NN metabolite) ) (PP (IN of)  (NP (NN vitamin)  (NN D3) ))))))) (. .) )) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (CD two)  (JJ potent)  (JJ immunosuppressive)  (NNS agents) ) (, ,)  (NP-COOD (NP (NNS glucocorticoids) ) (CC and)  (NP (NN cyclosporin)  (DT A) )) (, ,) ) (ADVP (RB also) ) (VP (VBD inhibited)  (NP (DT the)  (JJ 80-kDa)  (NN protein) )) (. .) ) )
(TOP (S (NP-SBJ-15 (NP (JJ T-helper-cell)  (NNS determinants) ) (PP (IN in)  (NP (NN protein)  (NNS antigens) ))) (VP (VBP are)  (ADVP-PRD (RB preferentially)  (JJ located)  (PP (IN in)  (NP (NP (JJ cysteine-rich)  (NN antigen)  (NNS segments) ) (ADJP (JJ resistant)  (PP (TO to)  (NP (NP (JJ proteolytic)  (NN cleavage) ) (PP (IN by)  (NP (NN cathepsin)  (NP-COOD (NP (NN B) ) (, ,)  (NP (NN L) ) (, ,)  (CC and)  (NP (NN D) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP report)  (PP (IN on)  (NP (NP-16 (DT a)  (NN computer)  (NN algorithm) ) (ADJP (JJ capable)  (PP (IN of)  (S (NP-SBJ-17 (-NONE- *-16) ) (VP (VBG predicting)  (NP (NP (DT the)  (NN location) ) (PP (IN of)  (NP (NN T-helper-cell)  (NNS epitopes) )) (PP (IN in)  (NP (NN protein)  (NP (NP (NN antigen) ) (PRN (-LRB- -LRB-)  (NP (NN Ag) ) (-RRB- -RRB-) ))))) (PP (IN by)  (S (NP-SBJ (-NONE- *-17) ) (VP (VBG analysing)  (NP (DT the)  (NN Ag)  (NN amino)  (NN acid)  (NN sequence) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-18 (DT The)  (NN algorithm) ) (VP (VBD was)  (VP (VBN constructed)  (NP (-NONE- *-18) ) (PP (IN with)  (NP (NP (DT the)  (NN aim) ) (PP (IN of)  (S (NP-SBJ (-NONE- *) ) (VP (VBG identifying)  (NP (NP (NNS segments) ) (PP (IN in)  (NP (NN Ag) )) (SBAR (WHNP-19 (WDT which) ) (S (NP-SBJ (-NONE- *T*-19) ) (VP (VBP are)  (ADJP-PRD (JJ resistant)  (PP (TO to)  (NP (NP (JJ proteolytic)  (NN degradation) ) (PP (IN by)  (NP (DT the)  (NNS enzymes)  (NN cathepsin)  (NP-COOD (NP (NN B) ) (, ,)  (NP (NN L) ) (, ,)  (CC and)  (NP (NN D) )))))))))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (DT These) ) (VP (VBP are)  (NP-PRD (NP (JJ prominent)  (NNS enzymes) ) (PP (IN in)  (NP (NP (DT the)  (JJ endocytic)  (NN pathway) ) (SBAR (WHPP-20 (IN through)  (WHNP (WDT which) )) (S (NP-SBJ (JJ soluble)  (NN protein)  (NN Ag) ) (VP (VBP enter)  (NP (NN APC) ) (PP (-NONE- *T*-20) ))))))))) (, ,)  (CC and)  (S (NP-SBJ-21 (NP (JJ resistant)  (NNS segments) ) (PP (IN in)  (NP (NN Ag) ))) (VP (MD may)  (, ,)  (ADVP (RB therefore) ) (, ,)  (VP (VB be)  (VP (VBN expected)  (S (NP-SBJ (-NONE- *-21) ) (VP (TO to)  (VP (VB contain)  (NP (NP (JJR more)  (NN T-cell)  (NNS determinants) ) (PP (IN than)  (NP (JJ susceptible)  (NNS segments) )))))))))) (. .) ) )
(TOP (S (PP (IN From)  (NP (NP (NN information) ) (ADJP (JJ available)  (PP (IN in)  (NP (NP (DT the)  (NN literature) ) (PP (IN on)  (NP (NP (DT the)  (JJ substrate)  (NN specificity) ) (PP (IN of)  (NP (DT the)  (CD three)  (NNS enzymes) ))))))))) (, ,)  (NP-SBJ (NP (PRP it) ) (SBAR (-NONE- *EXP*-22) )) (VP (VBZ is)  (ADJP-PRD (JJ clear) ) (SBAR-22 (IN that)  (S (NP-SBJ-23 (DT a)  (NN cysteine) ) (VP (VBZ is)  (RB not)  (VP (VBN accepted)  (NP (-NONE- *-23) ) (PP-COOD (PP (IN in)  (NP (NP (DT any) ) (PP (IN of)  (NP (NP (DT the)  (NP-COOD (NP (NN S2) ) (, ,)  (NP (NN S1) ) (, ,)  (NP (NN S1') ) (, ,)  (CC and)  (NP (NN S2') )) (NNS subsites) ) (PP (IN of)  (NP (NN cathepsin)  (NP-COOD (NP (NN B) ) (CC and)  (NP (NN L) )))))))) (, ,)  (CC and)  (PP (RB not)  (IN in)  (NP (NP (DT the)  (NP-COOD (NP (NN S1) ) (CC and)  (NP (NN S1') )) (NNS subsites) ) (PP (IN of)  (NP (NN cathepsin)  (NN D) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP have)  (VP (VBN noticed)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ cysteine-containing)  (NN T-cell)  (NNS determinants) ) (PP (IN in)  (NP (NP (DT a)  (NN number) ) (PP (IN of)  (NP (NN protein)  (NN Ag) ))))) (VP (VBP are)  (ADJP-PRD (RB particularly)  (JJ rich) ) (PP (IN in)  (NP (DT the)  (NN amino)  (NNS acids)  (NP-COOD (NP (NN alanine) ) (, ,)  (NP (NN glycine) ) (, ,)  (NP (NN lysine) ) (, ,)  (NP (NN leucine) ) (, ,)  (NP (NN serine) ) (, ,)  (NP (NN threonine) ) (, ,)  (CC and)  (NP (NN valine) ))))))))) (. .) ) )
(TOP (S (PP (IN By)  (S (NP-SBJ (-NONE- *-24) ) (VP (VBG searching)  (NP (NN protein)  (NN Ag) ) (PP (IN for)  (NP-COOD (NP (NP (NNS clusters) ) (PP (IN of)  (NP (NP (NN amino)  (NNS acids) ) (VP (VBG containing)  (NP (NN cysteine) ))))) (CC and)  (NP (NP (CD two) ) (PP (IN of)  (NP (DT the)  (JJ other)  (NN amino)  (NNS acids) )))))))) (NP-SBJ-24 (PRP we) ) (VP (VBD were)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-24) ) (VP (TO to)  (VP (VB predict)  (NP (NP (QP (CD 17)  (IN out)  (IN of)  (CD 23) ) (ADJP (RB empirically)  (VBN known) ) (NN T-cell)  (NNS determinants) ) (PP (IN in)  (NP (DT the)  (NN Ag) ))) (PP (IN with)  (NP (NP (DT a)  (ADJP (RB relatively)  (JJ low) ) (NN number) ) (PP (IN of)  (NP (ADJP (ADJP (JJ false) ) (PRN (-LRB- -LRB-)  (ADJP (JJ positive) ) (-RRB- -RRB-) )) (NNS predictions) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP present)  (NP (NP (DT a)  (JJ new)  (NN principle) ) (PP (IN for)  (S (NP-SBJ (-NONE- *) ) (VP (VBG searching)  (NP (NN Ag) ) (PP (IN for)  (NP (JJ potential)  (JJ amphipatic)  (JJ alpha-helical)  (NN protein)  (NNS segments) ))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (JJ Such)  (NNS segments) ) (VP (VBP accord)  (ADVP (RB well) ) (PP (IN with)  (NP (ADJP (RB empirically)  (JJ known) ) (NN T-cell)  (NNS determinants) )))) (CC and)  (S (NP-SBJ (PRP$ our)  (NN algorithm) ) (VP (VBZ produces)  (NP (NP (NP (DT a)  (JJR lower)  (NN number) ) (PP (IN of)  (NP (JJ false)  (JJ positive)  (NNS predictions) ))) (PP (IN than)  (NP (NP (DT the)  (NN principle) ) (PP (VBN based)  (PP (IN on)  (NP (NP (JJ discrete)  (NN Fourier)  (NNS transformations) ) (VP (ADVP-TMP (RB previously) ) (VBN described)  (NP (-NONE- *) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ human)  (JJ putative)  (NN lymphocyte) (NN  G0/G1)  (NN switch)  (NN gene) ) (VP (VBG containing)  (NP (DT a)  (JJ CpG-rich)  (NN island) ))) (VP (VBZ encodes)  (NP (NP (DT a)  (JJ small)  (JJ basic)  (NN protein) ) (PP (IN with)  (NP (DT the)  (NN potential)  (S (NP-SBJ-21 (-NONE- *) ) (VP (TO to)  (VP (VB be)  (VP (VBN phosphorylated)  (NP (-NONE- *-21) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-22 (NP (NP (NNS Genes) ) (VP (ADVP (RB actively) ) (VBN involved)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT the) (NN  G0/G1)  (NN switch) )))) (PRN (-LRB- -LRB-)  (NP (NN G0S)  (NNS genes) ) (-RRB- -RRB-) )) (VP (MD may)  (VP (VB be)  (ADVP (RB differentially) ) (VP (VBN expressed)  (NP (-NONE- *-22) ) (PP-TMP (IN during)  (NP (NP (DT the)  (JJ lectin-induced)  (NN switch) ) (PP (IN of)  (NP (NNS lymphocytes) )) (PP (IN from)  (NP (DT the)  (NN G0) )) (PP (TO to)  (NP (NP (DT the)  (NN G1)  (NNS phases) ) (PP (IN of)  (NP (DT the)  (NN cell)  (NN cycle) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN paper) ) (VP (VBZ presents)  (NP (NP (NNS studies) ) (PP (IN of)  (NP (NP (NP (NN G0S2) ) (, ,)  (NP (NP (DT a)  (NN member) ) (PP (IN of)  (NP (NP (DT a)  (NN set) ) (PP (IN of)  (NP (JJ putative)  (NN G0S)  (NNS genes) ))))) (, ,) ) (SBAR (WHPP-23 (IN for)  (WHNP (WDT which) )) (S (NP-SBJ-24 (NNS cDNAs) ) (VP (VBD were)  (VP (VP-COOD (VP (VBN cloned)  (NP (-NONE- *-24) )) (CC and)  (VP (VBN selected)  (NP (-NONE- *-24) ))) (PP (-NONE- *T*-23) ) (PP (IN on)  (DT the)  (NN basis)  (IN of)  (NP (JJ differential)  (NN cDNA)  (NN hybridization) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN G0S2)  (NN mRNA) ) (VP (VBZ increases)  (ADVP (RB transiently) ) (PP-TMP (IN within)  (NP (NP (QP (CD 1-2) ) (NN hr) ) (PP (IN of)  (NP (NP (DT the)  (NN addition) ) (PP (IN of)  (NP-COOD (NP (NN lectin) ) (CC or)  (NP (NN cycloheximide) ))) (PP (TO to)  (NP (VBN cultured)  (NN blood)  (JJ mononuclear)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Comparison) ) (PP (IN of)  (NP (DT a)  (ADJP (RB nearly)  (JJ full-length) ) (NN cDNA)  (NN sequence) )) (PP (IN with)  (NP (DT the)  (JJ corresponding)  (JJ genomic)  (NN sequence) ))) (VP (VBZ reveals)  (NP (NP-COOD (NP (CD one)  (JJ small)  (NN intron) ) (CC and)  (NP (DT an)  (JJ open)  (NN reading)  (NN frame) )) (PP (IN in)  (NP (DT the)  (JJ second)  (NN exon) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (VBN derived)  (JJ 103-amino-acid)  (JJ basic)  (NN protein) ) (VP (VBZ has)  (NP (NP (CD two)  (JJ potential)  (JJ alpha-helical)  (NNS domains) ) (VP (VBN separated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (DT a)  (JJ hydrophobic)  (NN region) ) (PP (IN with)  (NP (DT the)  (NN potential)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP-COOD (VP (VB generate)  (NP (NNS turns) )) (CC and)  (VP (VB assume)  (NP (DT a)  (JJ beta-sheet)  (NN conformation) )))))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-25) ) (ADJP-PRD (JJ Consistent)  (PP (IN with)  (NP (NP (NN involvement) ) (PP (IN in)  (NP (DT the) (NN  G0/G1)  (NN switch) )))))) (, ,)  (NP-SBJ-25 (DT the)  (NN protein) ) (VP (VBZ contains)  (NP (NP (JJ potential)  (NNS sites) ) (PP (IN for)  (NP (NP (NN phosphorylation) ) (PP (IN by)  (NP-COOD (NP (NN protein)  (NN kinase)  (NN C) ) (CC and)  (NP (NN casein)  (NN kinase)  (CD II) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN gene) ) (VP (VBZ contains)  (NP (DT a)  (JJ CpG-rich)  (NN island) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (NP (NP (NN expression) ) (PP (IN in)  (NP (DT the)  (NN germ)  (NN line) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT An)  (JJ upstream)  (NN segment) ) (VP (VBZ contains)  (NP (JJ tandem)  (NN dinucleotide)  (NNS repeats) (NN  -LRB-CT-RRB-19/-LRB-CA-RRB-16) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (EX There) ) (VP (VBZ is)  (NP-PRD (DT a)  (ADJP (RB suitably)  (JJ located) ) (NN TATA)  (NN box) ))) (, ,)  (CC but)  (S (NP-SBJ-26 (NP (JJ potential)  (NNS sites) ) (PP (IN for)  (NP (NN CCAAT-box)  (NN binding)  (NNS factors) ))) (VP (VBP are)  (ADJP-PRD (RB far)  (JJ upstream) ) (, ,)  (S (NP-SBJ (-NONE- *-26) ) (ADJP-PRD (JJ embedded)  (PP (IN in)  (NP (DT a)  (JJ 42-nucleotide)  (NN repeat)  (NN element) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Potential)  (NNS sites) ) (PP (IN for)  (NP (NN transcription)  (NNS factors)  (NP-COOD (NP (NN AP1) ) (, ,)  (NP (NN AP2) ) (, ,)  (CC and)  (NP (NN AP3) ))))) (VP (VBP are)  (ADJP-PRD (JJ consistent)  (PP (IN with)  (NP (NP (JJ rapid)  (JJ transcriptional)  (NN activation) ) (PP (IN in)  (NN response)  (TO to)  (NP (VBG inducing)  (NNS agents) )))))) (. .) ) )
(TOP (NP (NP (NN Synergism) ) (PP (IN between)  (NP (NP (CD two)  (JJ distinct)  (NNS elements) ) (PP (IN of)  (NP (DT the)  (NN HTLV-I)  (NN enhancer) )))) (PP-TMP (IN during)  (NP (NP (NN activation) ) (PP (IN by)  (NP (NP (DT the)  (NN trans-activator) ) (PP (IN of)  (NP (NN HTLV-I) )))))) (. .) ) )
(TOP (S (NP-SBJ-11 (PRP We) ) (VP (VBP have)  (VP (VBN conducted)  (NP (NP (JJ functional)  (NNS studies) ) (PP (IN of)  (NP (NP (DT the)  (NN enhancer)  (NNS elements) ) (PP (IN of)  (NP (NP (JJ human)  (NN T-cell)  (NN leukemia)  (NN virus)  (NN type)  (CD I) ) (PRN (-LRB- -LRB-)  (NP (NN HTLV-I) ) (-RRB- -RRB-) )))))) (S (NP-SBJ (-NONE- *-11) ) (VP (VBG using)  (NP (DT the)  (JJ human)  (NN T-cell)  (NNS lines)  (NP-COOD (NP (NP-COOD (NP (NN Jurkat) ) (CC and)  (NP (NN MOLT)  (CD 4) )) (, ,)  (SBAR (WHNP-12 (WDT which) ) (S (NP-SBJ (-NONE- *T*-12) ) (VP (VBP are)  (ADJP-PRD (JJ negative)  (PP (IN for)  (NP (NN HTLV-I) )))))) (, ,) ) (CC and)  (NP (NP-COOD (NP (NN MT-2) ) (CC and)  (NP (NN TL-Mor) )) (, ,)  (SBAR (WHNP-13 (WDT which) ) (S (NP-SBJ (-NONE- *T*-13) ) (VP (VBP carry)  (NP (NP (DT the)  (JJ proviral)  (NN genome) ) (PP (IN of)  (NP (NN HTLV-I) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-14 (CD Two)  (JJ distinct)  (NNS elements) ) (VP (VBP have)  (VP (VBN been)  (VP (VBN implicated)  (NP (-NONE- *-14) ) (PP (IN in)  (NP (NP (NN function) ) (PP (IN of)  (NP (DT the)  (NN HTLV-I)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (NP-SBJ (CD One) ) (VP (VBZ is)  (NP-PRD (NP (DT the)  (ADJP (JJ 21-base-pair)  (PRN (-LRB- -LRB-)  (NP (NN bp) ) (-RRB- -RRB-) )) (NN core)  (NN element) ) (SBAR-COOD (SBAR (WHNP-15 (WDT that) ) (S (NP-SBJ (-NONE- *T*-15) ) (VP (VBZ is)  (ADJP-PRD (JJ responsible)  (PP (IN for)  (NP (NP (NN trans-activation) ) (PP (IN by)  (NP (DT the)  (NN HTLV-I)  (NN trans-activator)  (NN p40tax) )))))))) (CC and)  (SBAR (WHNP-16 (WDT that) ) (S (NP-SBJ (-NONE- *T*-16) ) (VP (VBZ has)  (NP (DT the)  (NN ability)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB bind)  (PP (TO to)  (NP (ADJP (NN cyclic-AMP)  (JJ responsive)  (NN element)  (NN binding)  (NN factor)  (-LRB- -LRB-)  (NN CREB)  (-RRB- -RRB-)  (JJ -like) ) (NN factor)  (-LRB- -LRB-)  (NNS s)  (-RRB- -RRB-) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ other) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN region) ) (ADJP (VBN interposed)  (PP (IN between)  (NP (DT the)  (JJ 21-bp)  (NNS elements) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-100 (NP (NP (DT a)  (NN subfragment) ) (PRN (-LRB- -LRB-)  (NP (NN C26) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (NP (DT the)  (NN region) ) (PP (IN between)  (NP (DT the)  (JJ 21-bp)  (NNS elements) ))))) (VP (VBZ is)  (VP (VBN involved)  (NP (-NONE- *-100) ) (PP (IN in)  (NP (NP (NN trans-activation) ) (PP (IN by)  (NP (NN p40tax) )))) (, ,)  (PP (RB possibly)  (IN through)  (NP (NP (NN binding) ) (PP (TO to)  (NP (DT an)  (ADJP (NN NF-kappa)  (JJ B-like) ) (JJ nuclear)  (NP-COOD (NP (NN factor) ) (CC or)  (NP (NNS factors) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-18 (NP (NN Formation) ) (PP (IN of)  (NP (DT the)  (JJ protein-DNA)  (NN complex) )) (PP (IN with)  (NP (DT the)  (NN C26)  (NN subfragment) ))) (VP (VBD was)  (ADVP (RB positively) ) (VP (VBN affected)  (NP (-NONE- *-18) ) (PP (IN by)  (NP-LGS (NN p40tax) )))) (. .) ) )
(TOP (S (NP-SBJ-17 (DT The)  (NN C26)  (NN element) ) (VP (VBD conferred)  (NP (NP (JJ partial)  (NN responsiveness) ) (PP (TO to)  (NP (NN p40tax) ))) (SBAR-TMP (WHADVP-101 (WRB when) ) (S (NP-SBJ-19 (-NONE- *-17) ) (VP (VBN linked)  (NP (-NONE- *-19) ) (PP (TO to)  (NP (NP (CD one)  (NN copy) ) (PP (IN of)  (NP (DT the)  (JJ 21-bp)  (NN element) )) (SBAR (WHNP-20 (WDT that) ) (, ,)  (S (NP-SBJ (-NONE- *T*-20) ) (PP (IN by)  (NP (PRP itself) )) (, ,)  (VP (VBD showed)  (NP (JJ little)  (NN activation) ) (PP (IN in)  (NN response)  (TO to)  (NP (NN p40tax) ))))))) (ADVP (-NONE- *T*-101) ))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-22 (NP (DT the)  (NN C26)  (NN element) ) (ADVP (RB alone) )) (, ,)  (SBAR-TMP (WHADVP-102 (RB even)  (WRB when) ) (S (NP-SBJ-23 (-NONE- *-22) ) (VP (VBN repeated)  (NP (-NONE- *-23) ) (ADVP (-NONE- *T*-102) )))) (, ,)  (VP (MD could)  (RB not)  (VP (VB be)  (VP (VBN activated)  (NP (-NONE- *-22) ) (PP (IN by)  (NP-LGS (NN p40tax) )) (, ,)  (PP (IN unlike)  (NP (JJ other)  (ADJP (NN NF-kappa)  (JJ B-binding) ) (NNS elements) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-25 (NP (DT the)  (NN C26)  (NN element) ) (NP (PRP itself) )) (VP (VBD was)  (ADVP (RB profoundly) ) (VP (VBN activated)  (NP (-NONE- *-25) ) (PP-TMP (IN upon)  (NP (NP (NN stimulation) ) (PP (IN with)  (NP (NN 12-O-tetradecanoylphorbol-13-acetate) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (ADVP (RB therefore) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN HTLV-I)  (NN enhancer) ) (VP (VBZ contains)  (NP (NP (ADJP (JJ multiple)  (JJ functional) ) (NNS elements) ) (, ,)  (PP (VBG including)  (NP (NP (VBG binding)  (NNS sites) ) (PP (IN for)  (NP (ADJP (IN at)  (JJS least) ) (ADJP (NN CREB-)  (CC and)  (NN NF-kappa)  (JJ B-like) ) (NNS factors) )))) (, ,)  (SBAR (WHNP-26 (WDT which) ) (S (NP-SBJ (-NONE- *T*-26) ) (ADVP (RB synergistically) ) (VP (VBP cooperate)  (PP (IN in)  (NP (NP (NN activation) ) (PP (IN of)  (NP (DT the)  (NN HTLV-I)  (NN enhancer) )) (PP (IN in)  (NN response)  (TO to)  (NP (NN p40tax) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS results) ) (ADVP (RB also) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-27 (NP (JJ TPA-dependent)  (NN activation) ) (PP (IN of)  (NP (DT the)  (NN HTLV-I)  (NN enhancer) ))) (VP (MD may)  (VP (VB be)  (VP (VBN mediated)  (NP (-NONE- *-27) ) (PP (IN through)  (NP (DT the)  (NN C26)  (NN element) )))))))) (. .) ) )
(TOP (S (NP-SBJ-12 (NN v-erbA)  (NN overexpression) ) (VP (VBZ is)  (VP (VBN required)  (S (NP-SBJ (-NONE- *-12) ) (VP (TO to)  (VP (VB extinguish)  (NP-COOD (NP (NP (NN c-erbA)  (NN function) ) (PP (IN in)  (NP (JJ erythroid)  (NN cell)  (NN differentiation) ))) (CC and)  (NP (NP (NN regulation) ) (PP (IN of)  (NP (DT the)  (NN erbA)  (NN target)  (NN gene)  (NN CAII) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN v-erbA)  (NN oncoprotein) ) (VP (VBZ represents)  (NP (NP (DT a)  (JJ retrovirus-transduced)  (JJ oncogenic)  (NN version) ) (PP (IN of)  (NP (DT the)  (NN thyroid)  (NN hormone)  (-LRB- -LRB-) (NN  T3/T4)  (-RRB- -RRB-)  (NN receptor)  (NN c-erbA)  (-LRB- -LRB-)  (NN type)  (NN alpha)  (-RRB- -RRB-) )))) (. .) ) )
(TOP (S (NP-SBJ-13 (PRP It) ) (VP (VBZ contributes)  (PP (TO to)  (NP (JJ virus-induced)  (NN erythroleukemia) )) (PP-COOD (PP (IN by)  (S (NP-SBJ (-NONE- *-13) ) (ADVP (RB efficiently) ) (VP (VBG arresting)  (NP (NP (NN differentiation) ) (PP (IN of)  (NP (JJ red)  (NN cell)  (NNS progenitors) )))))) (CC and)  (PP (IN by)  (S (NP-SBJ (-NONE- *-13) ) (VP (VBG suppressing)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (JJ erythrocyte-specific)  (NNS genes) )))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN v-erbA) ) (CC and)  (NP (NN c-erbA) )) (VP (VBP bind)  (ADVP (RB directly) ) (PP (TO to)  (NP (NP (NNS sequences) ) (PP (IN within)  (NP (NP (DT the)  (NN promoter) ) (PP (IN of)  (NP (NP (DT the)  (JJ erythrocyte-specific)  (NP (NP (JJ carbonic)  (NN anhydrase)  (CD II) ) (PRN (-LRB- -LRB-)  (NP (NN CAII) ) (-RRB- -RRB-) ))) (, ,)  (NP (NP (DT a)  (NN gene) ) (SBAR (WHNP-15 (WP$ whose)  (NN transcription) ) (S (NP-SBJ-16 (-NONE- *T*-15) ) (VP (VBZ is)  (ADVP (RB efficiently) ) (VP (VBN suppressed)  (NP (-NONE- *-16) ) (PP (IN by)  (NP-LGS (NN v-erbA) ))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (JJ erbA-binding)  (NN site) ) (VP-COOD (VP (VBZ confers)  (NP (NP (NN thyroid)  (NN hormone)  (NN responsiveness) ) (PP (TO to)  (NP (DT a)  (JJ heterologous)  (NN promoter) )) (PP (IN in)  (NP (JJ transient)  (NN expression)  (NNS experiments) )))) (CC and)  (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN target) ) (PP (IN for)  (NP (NP (JJ efficient)  (NN down-regulation) ) (PP (IN of)  (NP (NN CAII)  (NN transcription) )) (PP (IN by)  (NP (DT the)  (NN v-erbA)  (NN oncoprotein) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (ADJP (RB stably)  (VBN transformed) ) (NNS erythroblasts) ) (VP (VBG coexpressing)  (NP-COOD (NP (DT the)  (NN v-erbA)  (NN oncoprotein) ) (CC and)  (NP (DT the) (NN  c-erbA/T3)  (NN receptor) )) (PP (IN at)  (NP (DT an)  (ADJP (RB approximately)  (JJ equimolar) ) (NN ratio) ))))) (, ,)  (NP-SBJ (NN c-erbA)  (NN activity) ) (VP (VBZ is)  (ADJP-PRD (JJ dominant)  (PP (IN over)  (NP (NN v-erbA) )))) (. .) ) )
(TOP (S (NP-SBJ-17 (NN T3) ) (ADVP (RB efficiently) ) (VP (VBD induced)  (NP (JJ erythroid)  (NN differentiation) ) (PP (IN in)  (NP (DT these)  (NNS cells) )) (, ,)  (RB thus)  (S (NP-SBJ (-NONE- *-17) ) (VP (VBG overcoming)  (NP (DT the)  (JJ v-erbA-mediated)  (NN differentiation)  (NN arrest) )))) (. .) ) )
(TOP (S (ADVP (RB Likewise) ) (, ,)  (NP-SBJ (NN T3) ) (VP (VBD activated)  (NP (NP (NN CAII)  (NN transcription) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (NP (JJ transient)  (NN expression) ) (PP (IN of)  (NP (NP (DT a)  (JJ T3-responsive)  (NN reporter)  (NN gene) ) (VP (VBG containing)  (NP (DT the)  (JJ CAII-specific)  (JJ erbA-binding)  (NN site) ))))))) (. .) ) )
(TOP (S (NP-SBJ-18 (NP (DT The)  (JJ c-erbA-dependent)  (NN activation) ) (PP (IN of)  (NP (DT this)  (NN CAII)  (NN reporter)  (NN construct) ))) (VP (MD could)  (ADVP (RB only) ) (VP (VB be)  (VP (VBN suppressed)  (NP (-NONE- *-18) ) (PP (IN by)  (NP-LGS (NP (ADJP (RB very)  (JJ high) ) (NNS amounts) ) (PP (IN of)  (NP (NN v-erbA) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-19 (NP (NN overexpression) ) (PP (IN of)  (NP (NN v-erbA) ))) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-19) ) (PP (IN for)  (NP (NP (PRP$ its)  (NN function) ) (PP (IN as)  (NP (DT an)  (NN oncoprotein) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-13 (NP (NN Inhibition) ) (PP (IN of)  (NP (ADJP (NN phorbol)  (JJ ester-induced) ) (JJ monocytic)  (NN differentiation) )) (PP (IN by)  (NP (NN dexamethasone) ))) (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-13) ) (PP (IN with)  (NP (NP (NN down-regulation) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (PRN (-LRB- -LRB-)  (NP (NN AP-1) ) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Previous)  (NNS studies) ) (VP (VBP have)  (VP (VBN shown)  (SBAR (IN that)  (S (NP-SBJ-14 (NP (NN treatment) ) (PP (IN of)  (NP (JJ human)  (JJ myeloid)  (NN leukemia)  (NNS cells) )) (PP (IN with)  (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate) ) (PRN (-LRB- -LRB-)  (NP (NN TPA) ) (-RRB- -RRB-) )))) (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-14) ) (PP (IN with)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NP (JJ monocytic)  (NP-COOD (NP (NN differentiation) ) (CC and)  (NP (NN expression) ))) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN c-fos) )) (JJ early)  (NN response)  (NNS genes) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ present)  (NN work) ) (VP (VBZ demonstrates)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN glucocorticoid)  (NN dexamethasone) ) (VP (VBZ inhibits)  (NP (NP (JJ TPA-induced)  (NNS increases) ) (PP (IN in)  (NP (NP (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN c-fos) )) (NN mRNA)  (NNS levels) ) (PP (IN in)  (NP (NN U-937)  (NN leukemia)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-15 (DT These)  (NNS findings) ) (VP (VBD were)  (VP (VBN associated)  (NP (-NONE- *-15) ) (PP (IN with)  (NP (NP (DT a)  (NN block) ) (PP (IN in)  (NP (NP (NN appearance) ) (PP (IN of)  (NP (DT the)  (JJ monocytic)  (NN phenotype) )))) (, ,)  (PP (VBG including)  (NP (NP (NN inhibition) ) (PP (IN of)  (NP (NP (JJ TPA-induced)  (NNS increases) ) (PP (IN in)  (NP (NP (NN lamin)  (NN A) ) (, ,)  (NP (NN lamin)  (NN C) ) (, ,)  (CC and)  (NP (NN vimentin)  (NNS transcripts) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Other)  (NNS studies) ) (VP (VBP have)  (VP (VBN demonstrated)  (SBAR (IN that)  (S (NP-SBJ-17 (NP (JJ TPA-induced)  (JJ monocytic)  (NP-COOD (NP (NN differentiation) ) (CC and)  (NP (NN expression) ))) (PP (IN of)  (NP (NP (DT the)  (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN c-fos) )) (NNS genes) ) (PP (IN in)  (NP (JJ myeloid)  (NN leukemia)  (NNS cells) ))))) (VP (VBP are)  (VP (VBN regulated)  (NP (-NONE- *-17) ) (PP (IN by)  (NP-LGS (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN finding)  (SBAR (IN that)  (S (NP-SBJ (NN dexamethasone) ) (VP (VBZ has)  (NP (DT no)  (NN effect) ) (PP (IN on)  (NP (NP (JJ TPA-induced)  (NN activation) ) (PP (IN of)  (NP (NN PKC) )))))))) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN glucocorticoid) ) (VP (VBZ inhibits)  (NP (NP (NNS signals) ) (ADJP (ADJP-COOD (ADJP (JJ downstream)  (PP (-NONE- *RNR*-18) )) (CC or)  (ADJP (JJ parallel)  (PP (-NONE- *RNR*-18) ))) (PP-18 (TO to)  (NP (DT this)  (NN enzyme) )))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Nuclear)  (JJ run-on)  (NNS assays) ) (VP (VBP demonstrate)  (SBAR (IN that)  (: :)  (S-COOD (S (LST (-LRB- -LRB-)  (LS 1)  (-RRB- -RRB-) ) (NP-SBJ-19 (NP (NN induction) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN c-fos) )) (NN expression) )) (PP (IN by)  (NP (NN TPA) ))) (VP (VBZ is)  (VP (VBN regulated)  (NP (-NONE- *-19) ) (PP (IN by)  (NP-LGS (JJ transcriptional)  (NNS mechanisms) ))))) (, ,)  (S (LST (-LRB- -LRB-)  (LS 2)  (-RRB- -RRB-) ) (NP-SBJ (NP (JJ TPA-induced)  (NN expression) ) (PP (IN of)  (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN c-fos) )))) (VP (VBZ does)  (RB not)  (VP (VB require)  (NP (NN protein)  (NN synthesis) )))) (, ,)  (CC and)  (S (LST (-LRB- -LRB-)  (LS 3)  (-RRB- -RRB-) ) (NP-SBJ-20 (NP (JJ TPA-induced)  (NN expression) ) (PP (IN of)  (NP (DT both)  (NNS genes) ))) (VP (VBZ is)  (VP (VBN inhibited)  (NP (-NONE- *-20) ) (PP (IN at)  (NP (DT the)  (JJ transcriptional)  (NN level) )) (PP (IN by)  (NP-LGS (NN dexamethasone) )))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-21) ) (VP (TO To)  (ADVP (RB further) ) (VP (VB define)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NN dexamethasone) )) (PP (IN at)  (NP (DT the)  (JJ molecular)  (NN level) )))))) (, ,)  (NP-SBJ-21 (PRP we) ) (VP (VBD prepared)  (NP (NP (DT a)  (NN series) ) (PP (IN of)  (NP (NP (VBN deleted)  (NN c-jun)  (NN promoter)  (NNS fragments) ) (VP (VBN linked)  (NP (-NONE- *) ) (PP (TO to)  (NP (DT the)  (NP (NP (NN chloramphenicol)  (NN acetyltransferase) ) (PRN (-LRB- -LRB-)  (NP (NN CAT) ) (-RRB- -RRB-) )) (NN gene) ))))))) (. .) ) )
(TOP (S (NP-SBJ-22 (NP (NNS Increases) ) (PP (IN in)  (NP (NP (NN CAT)  (NN activity) ) (PP-TMP (IN during)  (NP (NP (JJ transient)  (NN expression) ) (PP (IN of)  (NP (NP (DT these)  (NNS constructs) ) (PP (IN in)  (NP (JJ TPA-treated)  (NN U-937)  (NNS cells) ))))))))) (VP (MD could)  (VP (VB be)  (VP (VBN assigned)  (NP (-NONE- *-22) ) (PP (TO to)  (NP (NP (NP (DT the)  (NN region) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD -97) ) (TO to)  (NP (CD -20) )) (-RRB- -RRB-) )) (PP (IN of)  (NP (DT the)  (NN promoter) )) (SBAR (WHNP-24 (WDT that) ) (S (NP-SBJ (-NONE- *T*-24) ) (VP (VBZ contains)  (NP (DT the)  (NN AP-1)  (NN binding)  (NN site) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (NN induction) ) (PP (IN of)  (NP (NN CAT)  (NN activity) ))) (VP (VBD was)  (ADJP-PRD (JJ sensitive)  (PP (TO to)  (NP (NN dexamethasone) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-25 (NN dexamethasone) ) (VP (VBZ down-regulates)  (NP (NP (JJ TPA-induced)  (NN transcription) ) (PP (IN of)  (NP (DT the)  (NN c-jun)  (NN gene) ))) (PP-TMP (IN during)  (NP (JJ monocytic)  (NN differentiation) )) (PP (IN by)  (S (NP-SBJ (-NONE- *-25) ) (VP (VBG inhibiting)  (NP (NP (NN activation) ) (PP (IN of)  (NP (DT the)  (NN AP-1)  (NN site) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-1 (ADJP-COOD (ADJP (JJ Charybdotoxin-sensitive) ) (, ,)  (ADJP (JJ Ca-LRB-2+-RRB--dependent) )) (NN membrane)  (JJ potential)  (NNS changes) ) (VP (VBP are)  (RB not)  (VP (VBN involved)  (NP (-NONE- *-1) ) (PP (IN in)  (NP (JJ human)  (NN T)  (CC or)  (NN B)  (NN cell)  (NP-COOD (NP (NN activation) ) (CC and)  (NP (NN proliferation) )))))) (. .) ) )
(TOP (S (NP-SBJ-2 (NP (DT The)  (NN involvement) ) (PP (IN of)  (NP (NN ion)  (NNS channels) )) (PP (IN in)  (NP (NN B)  (CC and)  (NN T)  (NN lymphocyte)  (NN activation) ))) (VP (VBZ is)  (VP (VBN supported)  (NP (-NONE- *-2) ) (PP (IN by)  (NP-LGS (NP (JJ many)  (NNS reports) ) (PP (IN of)  (NP (NP (NNS changes) ) (PP (IN in)  (NP-COOD (NP (NN ion)  (NNS fluxes) ) (CC and)  (NP (NN membrane)  (NN potential) ))) (PP-TMP (IN after)  (NP (NN mitogen)  (NN binding) )))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Human)  (NN T)  (CC and)  (NN B)  (NNS lymphocytes) ) (VP (VBP demonstrate)  (NP (DT an)  (ADJP-COOD (ADJP-TMP (JJ early) ) (CC and)  (ADJP (JJ transient) )) (NN hyperpolarization) ) (PP-TMP (IN after)  (NP (JJ ligand)  (NN binding) ))) (. .) ) )
(TOP (S (SBAR-ADV (RB Inasmuch)  (IN as)  (S (NP-SBJ (NP (DT the)  (NN change) ) (PP (IN in)  (NP (NN membrane)  (NN potential) ))) (VP (VBZ is)  (ADJP-PRD (JJ dependent)  (PP (IN on)  (NP (NP (NN elevation) ) (PP (IN of)  (NP (JJ free)  (JJ cytosolic)  (NN calcium) )))))))) (, ,)  (NP-SBJ (DT the)  (NN hyperpolarization) ) (VP (VBZ is)  (ADVP (RB presumably) ) (PP-PRD (IN through)  (NP (NP (NN opening) ) (PP (IN of)  (NP (JJ Ca-LRB-2+-RRB--stimulated)  (NN K+)  (NNS channels) ))))) (. .) ) )
(TOP (S (NP-SBJ-3 (PRP We) ) (VP (VBP have)  (VP (VBN used)  (NP (NP (NN charybdotoxin) ) (, ,)  (NP (NP (DT a)  (JJ known)  (NN inhibitor) ) (PP (IN of)  (NP (JJ Ca-LRB-2+-RRB--dependent)  (NN K+)  (NNS channels) ))) (, ,) ) (S (NP-SBJ (-NONE- *-3) ) (VP (TO to)  (VP (VB study)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (DT these)  (NNS channels) )) (PP (IN in)  (NP (NN lymphocyte)  (NP-COOD (NP (NN activation) ) (CC and)  (NP (NN mitogenesis) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-4 (NN charybdotoxin) ) (VP (VBZ inhibits)  (NP (NP (DT the)  (JJ ligand-induced)  (JJ transient)  (NN membrane)  (NN hyperpolarization) ) (PP (IN in)  (NP (NP-COOD (NP (NN B) ) (CC and)  (NP (NN T) )) (NNS cells) ))) (PP (IN in)  (NP (DT a)  (JJ dose-dependent)  (NN fashion) )) (, ,)  (PP (IN without)  (S (NP-SBJ (-NONE- *-4) ) (VP (VBG affecting)  (NP (NP (NNS changes) ) (PP (IN in)  (NP (JJ cytosolic)  (NN Ca2+) )))))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-5 (NP (NN blockade) ) (PP (IN of)  (NP (DT the)  (JJ Ca-LRB-2+-RRB--activated)  (NN K+)  (NN channel) ))) (VP (VBZ is)  (RB not)  (VP (VBN associated)  (NP (-NONE- *-5) ) (PP (IN with)  (NP (NP (NNS changes) ) (PP (IN in)  (NP-COOD (NP (JJ cell-cycle)  (NN gene)  (NN activation) ) (, ,)  (NP (NN IL-2)  (NN production) ) (, ,)  (NP (NN IL-2R)  (NN expression) ) (CC or)  (NP (NP-COOD (NP (NN B) ) (CC and)  (NP (NN T) )) (NN cell)  (NN mitogenesis) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP imply)  (SBAR (IN that)  (S (NP-SBJ-6 (NP (NN membrane)  (JJ potential)  (NNS changes) ) (ADJP (JJ secondary)  (PP (TO to)  (NP (NP (DT the)  (JJ ligand-dependent)  (NN opening) ) (PP (IN of)  (NP (JJ Ca-LRB-2+-RRB--activated)  (NN K+)  (NNS channels) )))))) (VP (VBP are)  (RB not)  (VP (VBN involved)  (NP (-NONE- *-6) ) (PP (IN in)  (NP (NP (NP-COOD (NP (NN B) ) (CC and)  (NP (NN T) )) (NN lymphocyte) ) (NP-COOD (NP (NN activation) ) (CC and)  (NP (NN mitogenesis) ))))))))) (. .) ) )
(TOP (NP (NP (NN Evaluation) ) (PP (IN of)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (NP-COOD (NP (NN ligand) ) (CC and)  (NP (JJ thermal)  (NN activation) )) (PP (IN of)  (NP (NP (JJ specific)  (NN DNA)  (NN binding) ) (PP (IN by)  (NP (ADJP (ADVP (FW in)  (FW vitro) ) (VBN synthesized) ) (JJ human)  (NN glucocorticoid)  (NN receptor) )))))))) (. .) ) )
(TOP (S (NP-SBJ-28 (PRP We) ) (VP (VBP have)  (VP (VBN used)  (NP (DT a) (JJ  DNA-binding/immunoprecipitation)  (NN assay) ) (S (NP-SBJ (-NONE- *-28) ) (VP (TO to)  (VP (VB analyze)  (NP (NP (DT the)  (NN capacity)  (S (-NONE- *ICH*-102) )) (PP (IN of)  (NP (NP (NP (JJ human)  (NN glucocorticoid)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN hGR) ) (-RRB- -RRB-) )) (, ,)  (VP (VBN generated)  (NP (-NONE- *) ) (PP (IN in)  (NP (NN rabbit)  (NN reticulocyte)  (NNS lysates) ))))) (, ,) ) (S-102 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB bind)  (NP (NN DNA) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (ADJP (ADVP (FW In)  (FW vitro) ) (VBN translated) ) (NN hGR) ) (VP (VBD was)  (ADJP-PRD (JJ indistinguishable)  (PP (IN from)  (NP (JJ native)  (NN hGR) ))) (, ,)  (SBAR (IN as)  (S (NP-SBJ-30 (-NONE- *) ) (VP (VBN determined)  (NP (-NONE- *-30) ) (PP (IN by)  (NP-LGS-COOD (NP (NP (NN migration) ) (PP (IN on)  (NP (ADJP (NN sodium)  (NN dodecyl)  (JJ sulfate-polyacrylamide) ) (NNS gels) ))) (, ,)  (NP (NP (NN sedimentation) ) (PP (IN on)  (NP (NN sucrose)  (NN density)  (NNS gradients) ))) (, ,)  (CC and)  (NP (NP (NN reactivity) ) (PP (IN with)  (NP (NP (JJ antipeptide)  (NNS antibodies) ) (VP (VBN generated)  (NP (-NONE- *) ) (PP (IN against)  (NP (NN hGR) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (JJ cell-free)  (VBN synthesized)  (NN hGR) ) (VP (VBD was)  (ADJP-PRD (JJ capable)  (PP (IN of)  (NP (NP (JJ specific)  (NN binding) ) (PP (TO to)  (NP (ADJP (NN glucocorticoid)  (NN response)  (NN element)  (-LRB- -LRB-)  (NN GRE)  (-RRB- -RRB-)  (JJ -containing) ) (NN DNA)  (NNS fragments) )))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-31) ) (VP (VBG Using)  (NP (DT this)  (NN assay)  (NN system) ))) (, ,)  (NP-SBJ-31 (PRP we) ) (VP (VBP have)  (VP (VBN evaluated)  (NP (NP (DT the)  (NNS contributions) ) (PP (IN of)  (NP-COOD (NP (NN ligand)  (NN binding) ) (CC and)  (NP (NN heat)  (NN activation) ))) (PP (TO to)  (NP (NP (NN DNA)  (NN binding) ) (PP (IN by)  (NP (DT these)  (NN glucocorticoid)  (NNS receptors) ))))))) (. .) ) )
(TOP (S (NP-SBJ (ADJP (ADVP (FW In)  (FW vitro) ) (VBN translated) ) (NN hGR) ) (VP (VBD was)  (ADJP-PRD (JJ capable)  (PP (IN of)  (NP (JJ selective)  (NN DNA)  (NN binding) )) (PP (RB even)  (IN in)  (DT the)  (NN absence)  (IN of)  (NP (NN glucocorticoid) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN with)  (NP-COOD (NP (NN dexamethasone) ) (CC or)  (NP (DT the)  (JJ antiglucocorticoid)  (NN RU486) )))) (VP (VBD had)  (NP (DT no)  (JJ additional)  (NN effect) ) (PP (IN on)  (NP (DT the)  (JJ DNA-binding)  (NN capacity) )) (SBAR-TMP (WHADVP-32 (WRB when) ) (S (NP-SBJ-33 (NN receptor)  (NNS preparations) ) (VP (VBD were)  (VP (VBN maintained)  (NP (-NONE- *-33) ) (ADVP (-NONE- *T*-32) ) (PP (IN at)  (NP (NP (CD 0)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (DT no)  (NN activation) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (NN addition) ) (PP (IN of)  (NP-COOD (CC either)  (NP (NN ligand) ) (CC or)  (NP (NN antagonist) ))) (PP (IN in)  (NP (NP (NN combination) ) (PP (IN with)  (NP (DT a)  (NN heat)  (NN activation)  (NN step) ))))) (VP (VBD promoted)  (NP (NN DNA)  (NN binding) ) (PP (IN by)  (NP (NP (RB approximately)  (RB 3-fold) ) (PP (IN over)  (NP (NP (DT that) ) (PP (IN of)  (NP (JJ heat-activated)  (JJ unliganded)  (NNS receptors) ))))))) (. .) ) )
(TOP (S (NP-SBJ-34 (NP (NN Agonist) ) (PRN (-LRB- -LRB-)  (NP (NN dexamethasone) ) (-RRB- -RRB-) )) (VP (VBD was)  (ADJP-PRD (ADJP (ADVP (RB slightly)  (JJR more) ) (JJ effective) ) (PP (-NONE- *ICH*-103) )) (PP (IN in)  (S (NP-SBJ (-NONE- *-34) ) (VP (VBG supporting)  (NP (JJ specific)  (NN DNA)  (NN binding) )))) (PP-103 (IN than)  (NP (NP (NN antagonist) ) (PRN (-LRB- -LRB-)  (NP (NN RU486) ) (-RRB- -RRB-) )))) (. .) ) )
(TOP (S (NP-SBJ-35 (NP (NN DNA)  (NN binding) ) (PP (IN by)  (NP (ADJP (ADVP (FW in)  (FW vitro) ) (VBN synthesized) ) (NN GR) ))) (VP (VBD was)  (VP (VBN blocked)  (NP (-NONE- *-35) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN addition) ) (PP (IN of)  (NP (NN sodium)  (NN molybdate) )) (PP (TO to)  (NP (DT the)  (NN receptor)  (NNS preparations) )) (PP-TMP (IN before)  (NP-COOD (NP (NN steroid)  (NN addition) ) (CC and)  (NP (JJ thermal)  (NN activation) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Addition) ) (PP (IN of)  (NP (NN KCl) ))) (VP (VBD resulted)  (PP (IN in)  (NP (RBR less)  (NN DNA)  (NN binding) )) (PP (CC either)  (JJ due)  (TO to)  (NP-COOD (NP (NP (NN blockage) ) (PP (IN of)  (NP (JJ DNA-receptor)  (NN complex)  (NN formation) ))) (CC or)  (NP (NP (NN disruption) ) (PP (IN of)  (NP (DT the)  (NNS complexes) )))))) (. .) ) )
(TOP (S (NP-SBJ-37 (NP (DT The)  (NN specificity) ) (PP (IN of)  (NP (NP (NN DNA)  (NN binding) ) (PP (IN by)  (NP (JJ cell-free)  (VBN synthesized)  (NN hGR) ))))) (VP (VBD was)  (VP (VBN analyzed)  (NP (-NONE- *-37) ) (ADVP (RB further) ) (PP (IN by)  (S (NP-SBJ (-NONE- *) ) (VP (VBG examining)  (NP (NP (NP (DT the)  (NNS abilities)  (S (-NONE- *ICH*-38) )) (PP (IN of)  (NP (JJ various)  (NNS DNAs) ))) (S-38 (NP-SBJ-104 (-NONE- *) ) (VP (TO to)  (VP (VB compete)  (PP (IN for)  (S (NP-SBJ (-NONE- *-104) ) (VP (VBG binding)  (PP (TO to)  (NP (NP (DT a)  (ADJP (RB naturally)  (VBG occurring) ) (NN GRE) ) (VP (VBD found)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT the)  (ADJP (NN mouse)  (JJ mammary)  (NN tumor)  (JJ virus-long)  (JJ terminal) ) (NN repeat) ))))))))))))))))) (. .) ) )
(TOP (S-COOD (S-COOD (S (NP-SBJ (NP (NNS Oligonucleotides) ) (VP (VBG containing)  (NP (DT the)  (NN consensus)  (NN GRE) ))) (VP (VBD were)  (NP-PRD (DT the)  (ADJP (RBS most)  (JJ efficient) ) (NNS competitors) ))) (, ,)  (CC and)  (S (NP-SBJ (NP (NNS fragments) ) (VP (VBG containing)  (NP (NP (JJ regulatory)  (NNS sequences) ) (PP (IN from)  (NP (JJ glucocorticoid-repressible)  (NNS genes) ))))) (VP (VBD were)  (ADJP-PRD (RB somewhat)  (JJ competitive) )))) (, ,)  (IN whereas)  (S (NP-SBJ-39 (ADJP (JJ single)  (JJ stranded) ) (NNS oligonucleotides) ) (VP (VBD were)  (ADJP-PRD (JJ unable)  (S (NP-SBJ (-NONE- *-39) ) (VP (TO to)  (VP (VB compete)  (PP (IN for)  (NP (ADJP (NN mouse)  (JJ mammary)  (NN tumor)  (JJ virus-long)  (JJ terminal)  (NN repeat) ) (NN DNA)  (NN binding) )))))) (, ,)  (PP (IN except)  (SBAR-TMP (WHADVP-40 (WRB when) ) (S (NP-SBJ (NN competitor) ) (VP (VBD was)  (ADJP-PRD (JJ present) ) (PP (IN at)  (NP (ADJP (RB extremely)  (JJ high) ) (NNS concentrations) )) (ADVP (-NONE- *T*-40) ))))))) (. .) ) )
(TOP (S (ADVP (RB Together) ) (NP-SBJ (DT these)  (NNS studies) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (NN hGR) ) (VP (VBN synthesized)  (NP (-NONE- *) ) (PP (IN in)  (NP (NN rabbit)  (NN reticulocyte)  (NNS lysates) )))) (VP (VBZ displays)  (NP (NP (JJ many) ) (PP (IN of)  (NP (NP (DT the)  (JJ same)  (NNS properties) ) (, ,)  (PP (VBG including)  (NP (JJ GRE-specific)  (NN DNA)  (NN binding) )) (, ,)  (VP (VBN observed)  (NP (-NONE- *) ) (PP (IN for)  (NP (NP (NN glucocorticoid)  (NN receptor) ) (ADJP (JJ present)  (PP (IN in)  (NP (NP (JJ cytosolic)  (NNS extracts) ) (PP (IN of)  (NP (JJ mammalian)  (NP-COOD (NP (NNS cells) ) (CC and)  (NP (NNS tissues) ))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Similarities) ) (PP (IN between)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP-COOD (NP (NN dexamethasone) ) (CC and)  (NP (NN RU486) )))))) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ antiglucocorticoid)  (NNS properties) ) (PP (IN of)  (NP (NN RU486) ))) (VP (VBP do)  (RB not)  (VP (VB occur)  (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (JJ specific)  (NN DNA)  (NN binding) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (CD One)  (NN base)  (NN pair)  (NN change) ) (VP (VBZ abolishes)  (NP (NP (DT the)  (ADJP (NN T)  (JJ cell-restricted) ) (NN activity) ) (PP (IN of)  (NP (NP (DT a)  (JJ kB-like)  (NN proto-enhancer)  (NN element) ) (PP (IN from)  (NP (DT the)  (NN interleukin)  (CD 2)  (NN promoter) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (ADJP-COOD (ADJP (JJ inducible) ) (, ,)  (ADJP (NN T)  (JJ cell-specific) )) (NNS enhancers) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ murine) ) (CC and)  (ADJP (JJ human) )) (NP (NP (NN Interleukin)  (CD 2) ) (PRN (-LRB- -LRB-)  (NP (NN Il-2) ) (-RRB- -RRB-) )) (NNS genes) ))) (VP (VBP contain)  (NP (DT the)  (JJ kB-like)  (NN sequence)  (NN GGGATTTCACC) ) (PP (IN as)  (NP (DT an)  (JJ essential)  (JJ cis-acting)  (NN enhancer)  (NN motif) ))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-201 (WRB When) ) (S (NP-SBJ-13 (-NONE- *-12) ) (VP (VBN cloned)  (NP (-NONE- *-13) ) (PP (IN in)  (NP (JJ multiple)  (NNS copies) )) (ADVP (-NONE- *T*-201) )))) (NP-SBJ-12 (DT this)  (JJ so-called)  (NP (NP (NN TCEd) ) (PRN (-LRB- -LRB-)  (NP (JJ distal)  (NN T)  (NN cell)  (NN element) ) (-RRB- -RRB-) ))) (VP (VBZ acts)  (PP (IN as)  (NP (DT an)  (JJ inducible)  (NN proto-enhancer)  (NN element) )) (PP-COOD (PP (IN in)  (NP (NN E14)  (NN T)  (NN lymphoma)  (NNS cells) )) (, ,)  (CC but)  (PP (RB not)  (IN in)  (NP (NN HeLa)  (NNS cells) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (NNS extracts) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (VBN induced) ) (, ,)  (ADJP (NN Il-2)  (NN secreting) )) (NN El4)  (NNS cells) )))) (NP-SBJ (CD three)  (JJ individual)  (NN protein)  (NNS factors) ) (VP (VBP bind)  (PP (TO to)  (NP (NN TCEd)  (NN DNA) ))) (. .) ) )
(TOP (S (NP-SBJ-14 (NP (DT The)  (NN binding) ) (PP (IN of)  (NP (NP (DT the)  (ADJP (RBS most)  (JJ prominent) ) (NN factor) ) (, ,)  (VP (VBN named)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NP (NN TCF-1) ) (PRN (-LRB- -LRB-)  (NP (NN T)  (NN cell)  (NN factor)  (CD 1) ) (-RRB- -RRB-) )))) (, ,) ))) (VP (VBZ is)  (VP (VBN correlated)  (NP (-NONE- *-14) ) (PP (IN with)  (NP (NP (DT the)  (NN proto-enhancer)  (NN activity) ) (PP (IN of)  (NP (NN TCEd) )))))) (. .) ) )
(TOP (S (S (NP-SBJ (NN TCF-1) ) (VP (VBZ consists)  (PP (IN of)  (NP (NP (CD two)  (NNS polypeptides) ) (PP (IN of)  (NP (ADVP-15 (RB about) ) (NP-COOD (NP (QP (ADVP (-NONE- *RNR*-15) ) (CD 50) ) (NN kD) ) (CC and)  (NP (QP (ADVP (-NONE- *RNR*-15) ) (CD 105) ) (NN kD) ))))))) (: ;) ) (S (NP-SBJ-16 (DT the)  (JJ former) ) (VP (VBZ seems)  (S (NP-SBJ (-NONE- *-16) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ related)  (PP (TO to)  (NP (NP (DT the)  (NP (CD 50)  (NN kD) ) (NP (NN polypeptide) )) (PP (IN of)  (NP (NN NF-kB) ))))))))) (. .) )) )
(TOP (S-COOD (S (NP-SBJ-17 (VBN Purified)  (NN NF-kB) ) (VP (VBZ is)  (ADJP-PRD (RB also)  (JJ able)  (S (NP-SBJ (-NONE- *-17) ) (VP (TO to)  (VP (VB bind)  (PP (TO to)  (NP (DT the)  (NN TCEd) ))))))) (, ,) ) (CC but)  (S (NP-SBJ (NN TCF-1) ) (VP (VBZ binds)  (ADVP (ADVP (JJR stronger) ) (PP (IN than)  (NP (NN NF-kB) ))) (PP (TO to)  (NP (NN TCEd)  (NN DNA) ))) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (NN conversion) ) (PP (IN of)  (NP (DT the)  (NN TCEd) )) (PP (TO to)  (NP (DT a)  (`` ')  (JJ perfect)  ('' ')  (NN NF-kB)  (NN binding)  (NN site) ))) (VP-COOD (VP (VBZ leads)  (PP (TO to)  (NP-19 (NP (DT a)  (JJR tighter)  (NN binding) ) (PP (IN of)  (NP (NN NF-kB) )) (PP (TO to)  (NP (NN TCEd)  (NN DNA) ))))) (CC and)  (, ,)  (VP (PP (IN as)  (NP (DT a)  (JJ functional)  (NN consequence) )) (, ,)  (PP (TO to)  (NP=19 (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (DT the)  (`` ')  (VBN converted)  ('' ')  (NN TCEd)  (NNS motifs) )) (PP (IN in)  (NP (NN HeLa)  (NNS cells) )))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (NP (DT the)  (NN substitution) ) (PP (IN of)  (NP (DT the)  (VBN underlined)  (NN A)  (NN residue) )) (PP (TO to)  (NP (DT a)  (NN C) )) (PP (IN within)  (NP (DT the)  (NN GGGATTTCACC)  (NN motif) ))) (VP-COOD (VP (VBZ abolishes)  (NP (PRP$ its)  (ADJP (NN T)  (JJ cell-restricted) ) (NN activity) )) (CC and)  (VP (VBZ leads)  (PP (TO to)  (S-NOM (NP-SBJ (PRP$ its) ) (VP (VBG functioning)  (PP (IN in)  (NP-COOD (CC both)  (NP (NN El4)  (NNS cells) ) (CC and)  (NP (NN HeLa)  (NNS cells) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-20 (NP (JJ lymphocyte-specific)  (NNS factors) ) (VP (VBG binding)  (PP (TO to)  (NP (DT the)  (NN TCEd) )))) (VP (VBP are)  (VP (VBN involved)  (NP (-NONE- *-20) ) (PP (IN in)  (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP (NP (NN T)  (NN cell)  (NN specific-transcription) ) (PP (IN of)  (NP (DT the)  (NN Il-2)  (NN gene) ))))))))))) (. .) ) )
(TOP (NP (NP (NP (JJ Negative)  (NN regulation) ) (PP (IN of)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN expression) ) (PP (IN in)  (NP (NNS monocytes) )))) (: :) ) (NP (NP (NN role) ) (PP (IN of)  (NP (DT the)  (ADJP-COOD (ADJP (JJ 65-kDa) ) (CC plus)  (ADJP (JJ 50-kDa) )) (NN NF-kappa)  (NN B)  (NN dimer) )) (. .) )) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (JJ monocytic)  (NNS cells) ) (VP (MD can)  (VP (VB provide)  (NP (NP (DT a)  (NN reservoir) ) (PP (IN for)  (NP (JJ viral)  (NN production) ))) (ADVP (FW in)  (FW vivo) ))))) (, ,)  (NP-SBJ (NP (PRP$ their)  (NN regulation) ) (PP (IN of)  (NP (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (NN transcription) ))) (VP (MD can)  (VP (VB be)  (ADJP-PRD-COOD (CC either)  (ADJP (JJ latent) ) (, ,)  (ADJP (JJ restricted) ) (, ,)  (CC or)  (ADJP (JJ productive) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT These)  (NNS differences) ) (PP (IN in)  (NP (NN gene)  (NN expression) ))) (VP (VBP have)  (RB not)  (VP (VBN been)  (ADJP-PRD (RB molecularly)  (VBN defined) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (NN THP-1)  (NNS cells) ) (PP (IN with)  (NP (JJ restricted)  (NN HIV)  (NN expression) )))) (, ,)  (NP-SBJ (EX there) ) (VP (VBZ is)  (NP-PRD (NP (DT an)  (NN absence) ) (PP (IN of)  (NP (NP (JJ DNA-protein)  (NN binding)  (NN complex)  (NN formation) ) (PP (IN with)  (NP (NP (DT the)  (NN HIV-1)  (NN promoter-enhancer) ) (VP (VBN associated)  (NP (-NONE- *) ) (PP (IN with)  (NP (ADJP (ADVP (RB markedly)  (JJR less) ) (JJ viral) ) (NN RNA)  (NN production) ))))))))) (. .) ) )
(TOP (S (S (NP-SBJ (NP (DT This)  (NN absence) ) (PP (IN of)  (NP (NN binding) ))) (VP (VBD was)  (ADJP-PRD (JJ localized)  (PP (TO to)  (NP (NP (DT the)  (NN NF-kappa)  (NN B)  (NN region) ) (PP (IN of)  (NP (DT the)  (NN HIV-1)  (NN enhancer) )))))) (: ;) ) (S (NP-SBJ (DT the)  (ADJP-COOD (ADJP (JJ 65-kDa) ) (CC plus)  (ADJP (JJ 50-kDa) )) (NN NF-kappa)  (NN B)  (NN heterodimer) ) (VP (VBD was)  (ADJP-PRD (RB preferentially)  (VBN lost) )) (. .) )) )
(TOP (S (S-SBJ (NP-SBJ (-NONE- *) ) (VP (VBG Adding)  (NP (VBN purified)  (NN NF-kappa)  (NN B)  (NN protein) ) (PP (TO to)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP (NP (NNS cells) ) (PP (IN with)  (NP (JJ restricted)  (NN expression) )))))))) (VP (VBZ overcomes)  (NP (NP (DT this)  (NN lack) ) (PP (IN of)  (NP (NN binding) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NP (NN treatment) ) (PP (IN of)  (NP (DT these)  (JJ nuclear)  (NNS extracts) )) (PP (IN with)  (NP (NN sodium)  (NN deoxycholate) ))) (VP (VBD restored)  (NP (PRP$ their)  (NN ability)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB form)  (NP (DT the)  (NN heterodimer) ))))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NP (DT an)  (NN inhibitor) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN activity) )))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (NP (NN treatment) ) (PP (IN of)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP (DT these)  (NNS cells) )) (SBAR (WHNP-5 (WDT that) ) (S (NP-SBJ (-NONE- *T*-5) ) (VP (VBD had)  (NP (JJ restricted)  (NN expression) )))))) (PP (IN with)  (NP (NN lipopolysaccharide) ))) (VP (VBD increased)  (NP-COOD (NP (JJ viral)  (NN production) ) (CC and)  (NP (NN NF-kappa)  (NN B)  (NN activity) ))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (NN Antiserum) ) (ADJP (JJ specific)  (PP (IN for)  (NP (NN NF-kappa)  (NN B)  (NN binding)  (NNS proteins) )))) (, ,)  (CONJP (CC but)  (RB not) ) (NP (JJ c-rel-specific)  (NN antiserum) ) (, ,) ) (VP (VBD disrupted)  (NP (NN heterodimer)  (NN complex)  (NN formation) )) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ-4 (DT both)  (ADJP (NN NF-kappa)  (JJ B-binding) ) (NNS complexes) ) (VP (VBP are)  (VP (VBN needed)  (NP (-NONE- *-4) ) (PP (IN for)  (NP (JJ optimal)  (JJ viral)  (NN transcription) )))) (. .) ) )
(TOP (S (NP-SBJ-6 (NP (NN Binding) ) (PP (IN of)  (NP (DT the)  (ADJP-COOD (ADJP (JJ 65-kDa) ) (CC plus)  (ADJP (JJ 50-kDa) )) (NN heterodimer) )) (PP (TO to)  (NP (DT the)  (NN HIV-1)  (NN enhancer) ))) (VP (MD can)  (VP (VB be)  (ADVP (RB negatively) ) (VP (VBN regulated)  (NP (-NONE- *-6) ) (PP (IN in)  (NP (NNS monocytes) )) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG providing)  (NP (NP (CD one)  (NN mechanism) ) (VP (VBG restricting)  (NP (NN HIV-1)  (NN gene)  (NN expression) )))))))) (. .) ) )
(TOP (NP (NP (NN Isolation) ) (PP (IN of)  (NP (NP (NP (DT a)  (NN candidate)  (NP (NN repressor/activator) )) (, ,)  (NP (NP (NN NF-E1) ) (PRN (-LRB- -LRB-)  (NP (NN YY-1)  (, ,)  (NN delta) ) (-RRB- -RRB-) )) (, ,) ) (SBAR (WHNP-14 (WDT that) ) (S (NP-SBJ (-NONE- *T*-14) ) (VP (VBZ binds)  (PP (TO to)  (NP-COOD (NP (DT the)  (NN immunoglobulin)  (NN kappa)  (JJ 3')  (NN enhancer) ) (CC and)  (NP (DT the)  (NN immunoglobulin)  (NN heavy-chain)  (NN mu)  (NN E1)  (NN site) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN determined)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ developmental)  (NN control) ) (PP (IN of)  (NP (NN immunoglobulin)  (NN kappa)  (JJ 3')  (NN enhancer)  (-LRB- -LRB-)  (NN kappa)  (NN E3')  (-RRB- -RRB-)  (NN activity) ))) (VP (VBZ is)  (NP-PRD (NP (DT the)  (NN result) ) (PP (IN of)  (NP (NP (DT the)  (JJ combined)  (NN influence) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (ADJP (JJ positive-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ negative-acting) )) (NNS elements) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-15 (NP (DT a)  (JJ central)  (NN core) ) (PP (IN in)  (NP (DT the)  (NN kappa)  (NN E3')  (NN enhancer) ))) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ active) ) (PP-TMP (IN at)  (NP (DT the)  (JJ pre-B-cell)  (NN stage) ))) (CC but)  (VP (VBZ is)  (VP (VBN repressed)  (NP (-NONE- *-15) ) (PP (IN by)  (NP-LGS (VBG flanking)  (JJ negative-acting)  (NNS elements) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ negative-acting)  (NNS sequences) ) (VP (VBP repress)  (NP (NN enhancer)  (NN activity) ) (PP (IN in)  (NP (DT a)  (ADJP-COOD (ADJP (NP (NN position-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ orientation-independent) )) (NN manner) )) (PP-TMP (IN at)  (NP (DT the)  (JJ pre-B-cell)  (NN stage) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN isolated)  (NP (NP (DT a)  (JJ human)  (NN cDNA)  (NN clone) ) (VP (VBG encoding)  (NP (NP (NP (DT a)  (NN zinc)  (NN finger)  (NN protein) ) (PRN (-LRB- -LRB-)  (NP (NN NF-E1) ) (-RRB- -RRB-) )) (SBAR (WHNP-16 (WDT that) ) (S (NP-SBJ (-NONE- *T*-16) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (DT the)  (JJ negative-acting)  (NN segment) ) (PP (IN of)  (NP (DT the)  (NN kappa)  (NN E3')  (NN enhancer) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN protein) ) (ADVP (RB also) ) (VP (VBZ binds)  (PP (TO to)  (NP (DT the)  (NN immunoglobulin)  (NN heavy-chain)  (NN enhancer)  (NN mu)  (NN E1)  (NN site) ))) (. .) ) )
(TOP (S (NP-SBJ-17 (NN NF-E1) ) (VP (VBZ is)  (VP (VBN encoded)  (NP (-NONE- *-17) ) (PP (IN by)  (NP-LGS (NP (NP (DT the)  (JJ same)  (NN gene) ) (PP (IN as)  (NP (DT the)  (NN YY-1)  (NN protein) ))) (, ,)  (SBAR (WHNP-18 (WDT which) ) (S (NP-SBJ (-NONE- *T*-18) ) (VP (VBZ binds)  (PP (TO to)  (NP (DT the)  (JJ adeno-associated)  (NN virus)  (NN P5)  (NN promoter) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN NF-E1) ) (VP (VBZ is)  (ADVP (RB also) ) (NP-PRD (NP (DT the)  (JJ human)  (NN homologue) ) (PP (IN of)  (NP (DT the)  (NN mouse)  (NN delta)  (NN protein) )) (, ,)  (SBAR (WHNP-19 (WDT which) ) (S (NP-SBJ (-NONE- *T*-19) ) (VP (VBZ binds)  (PP (TO to)  (NP (JJ ribosomal)  (NN protein)  (NN gene)  (NNS promoters) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (VBN predicted)  (NN amino)  (NN acid)  (NN sequence) ) (PP (IN of)  (NP (DT this)  (NN protein) ))) (VP (VBZ contains)  (NP (NP (NNS features) ) (ADJP (JJ characteristic)  (PP (IN of)  (NP-COOD (NP (JJ transcriptional)  (NNS activators) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (JJ transcriptional)  (NNS repressors) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Cotransfection)  (NNS studies) ) (PP (IN with)  (NP (DT this)  (NN cDNA) ))) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (PRP it) ) (VP (MD can)  (VP (VB repress)  (NP (JJ basal)  (NN promoter)  (NN activity) )))))) (. .) ) )
(TOP (S (NP-SBJ-20 (NP (DT The)  (JJ apparent)  (JJ dual)  (NN function) ) (PP (IN of)  (NP (DT this)  (NN protein) ))) (VP (VBZ is)  (VP (VBN discussed)  (NP (-NONE- *-20) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Clone)  (NN pAT)  (CD 133) ) (VP (VBZ identifies)  (NP (NP (DT a)  (NN gene) ) (SBAR (WHNP-1 (WDT that) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBZ encodes)  (NP (NP (DT another)  (JJ human)  (NN member) ) (PP (IN of)  (NP (NP (DT a)  (NN class) ) (PP (IN of)  (NP (NP (ADJP (NN growth)  (JJ factor-induced) ) (NNS genes) ) (PP (IN with)  (NP (ADJP (RB almost)  (JJ identical) ) (NN zinc-finger)  (NNS domains) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP-SBJ (PRP We) )) (VP (VBP report)  (NP (NP (DT the)  (NP-COOD (NP (NN structure) ) (CC and)  (NP (NN regulation) ))) (PP (IN of)  (NP (NP (DT a)  (NN gene) ) (VP (VBN represented)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (NN clone)  (NN pAT)  (CD 133) ) (, ,)  (SBAR (WHNP-2 (WDT which) ) (S (NP-SBJ-3 (-NONE- *T*-2) ) (VP (VBZ is)  (VP (VBN induced)  (NP (-NONE- *-3) ) (PP-TMP (IN upon)  (NP (NP (NN transition) ) (PP (IN from)  (NP (NP (DT a)  (JJ resting)  (NN state) ) (PRN (-LRB- -LRB-)  (NP (NN G0) ) (-RRB- -RRB-) ))) (PP (IN through)  (NP (NP (NP (DT the)  (JJ early)  (NN phase) ) (PP (IN of)  (NP (DT the)  (NN cell)  (NN cycle) ))) (PRN (-LRB- -LRB-)  (NP (NN G1) ) (-RRB- -RRB-) )))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-4 (DT The)  (NN pAT)  (CD 133)  (NN gene) ) (VP (VBZ is)  (ADVP-TMP (RB immediately) ) (VP (VBN induced)  (NP (-NONE- *-4) ) (, ,)  (PP (IN with)  (NP (JJ FOS-like)  (NNS kinetics) )) (, ,)  (PP-COOD (PP (IN in)  (NP (JJ human)  (NN T)  (NNS cells) )) (CC and)  (PP (IN in)  (NP (NNS fibroblasts) ))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Primary)  (NN structure)  (NN analysis) ) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (VBN encoded)  (NN protein) ) (VP (VBZ contains)  (NP (NP (CD three)  (JJ tandem)  (NN zinc-finger)  (NNS sequences) ) (PP (IN of)  (NP (DT the)  (NN type)  (NN Cys2-Xaa12-His2) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (NN zinc-finger)  (NN region) ) (, ,)  (SBAR (WHNP-5 (WDT which) ) (S (NP-SBJ-6 (-NONE- *T*-5) ) (VP (VBZ is)  (VP (VBN thought)  (S (NP-SBJ (-NONE- *-6) ) (VP (TO to)  (VP (VB bind)  (NP (NN DNA) ) (PP (IN in)  (NP (DT a)  (JJ sequence-specific)  (NN manner) ))))))))) (, ,) ) (VP (VBZ is)  (ADJP-PRD (ADJP (JJ similar) ) (PRN (-LRB- -LRB-)  (FRAG (NP (QP (JJR greater)  (IN than)  (CD 80) ) (NN %) ) (PP (IN on)  (NP (DT the)  (NN amino)  (NN acid)  (NN level) ))) (-RRB- -RRB-) ) (PP-7 (TO to)  (NP (CD two)  (ADJP (RB previously)  (VBN described) ) (NN transcription)  (NNS factors)  (NP-COOD (NP (NN pAT) (NN  225/EGR1) ) (CC and)  (NP (NN pAT) (NN  591/EGR2) )))))) (. .) ) )
(TOP (S (PP (IN Except)  (IN for)  (NP (DT the)  (VBN conserved)  (NN zinc-finger)  (NNS domains) )) (, ,)  (NP-SBJ (NP (DT the)  (NN amino)  (NN acid)  (NNS sequences) ) (PP (IN of)  (NP (DT the)  (CD three)  (NNS proteins) ))) (VP (VBP are)  (ADJP-PRD (JJ distinct) )) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (JJ structural)  (NN similarity) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN pAT)  (CD 133)  (NN gene) ) (VP (VBZ encodes)  (NP (NP (DT a)  (NN transcription)  (NN factor) ) (PP (IN with)  (NP (DT a)  (JJ specific)  (JJ biological)  (NN function) ))))))) (. .) ) )
(TOP (S (S-SBJ (NP-SBJ (-NONE- *) ) (VP (VBG Comparing)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (DT these)  (JJ related)  (JJ zinc-finger-encoding)  (NNS genes) ))))) (VP (VBD showed)  (NP (NP (JJ coordinate)  (NN induction) ) (PP-TMP (IN upon)  (NP (NP (JJ mitogenic)  (NN stimulation) ) (PP-COOD (PP (IN of)  (NP (VBG resting)  (NN T)  (NNS lymphocytes) )) (CC and)  (PP (IN of)  (NP (VBG resting)  (NNS fibroblasts) ))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (PP-TMP (IN upon)  (NP (NP (NN transition) ) (PP (IN from)  (NP (NP (NP (DT a)  (JJ proliferating)  (NP (-NONE- *RNR*-100) )) (PRN (-LRB- -LRB-)  (NP (NN G1) ) (-RRB- -RRB-) )) (PP (-NONE- *RNR*-101) ))) (PP (TO to)  (NP (NP (DT a)  (JJ resting)  (NP (-NONE- *RNR*-100) )) (PP (-NONE- *RNR*-101) ))) (NP-100 (NN state) ) (PP-101 (IN of)  (NP (DT the)  (NN cell)  (NN cycle) )))) (NP-SBJ-8 (DT the)  (CD three)  (NNS genes) ) (VP (VBD were)  (ADVP (RB differently) ) (VP (VBN regulated)  (NP (-NONE- *-8) ))) (. .) ) )
(TOP (S-COOD (S (PP (IN In)  (NP (JJ human)  (JJ histiocytic)  (NN U937)  (NNS cells) )) (NP-SBJ-9 (NP (NN mRNA) ) (PP (IN of)  (NP (NN clone)  (NN pAT)  (CD 133) ))) (VP (VBD was)  (ADVP (RB constitutively) ) (VP (VBN expressed)  (NP (-NONE- *-9) )))) (, ,)  (IN whereas)  (S (NP-SBJ-10 (NP (NN mRNA) ) (PP (IN of)  (NP (NN pAT) (NN  225/EGR1) ))) (VP (VBD was)  (VP (VBN induced)  (NP (-NONE- *-10) ) (PP-TMP (IN upon)  (NP (NP (NN induction) ) (PP (IN of)  (NP (JJ terminal)  (NN differentiation) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (NP-SBJ-11 (NP (NN mRNA) ) (VP (VBG representing)  (NP (NN pAT) (NN  591/EGR2) ))) (VP (VBD was)  (RB not)  (VP (VBN expressed)  (NP (-NONE- *-11) ) (PP (IN in)  (NP (DT these)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (NN difference) ) (PP (IN in)  (NP (NN gene)  (NN regulation) ))) (VP (VBZ suggests)  (NP (NP (JJ distinct)  (JJ biological)  (NNS roles) ) (PP (IN in)  (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP (NN cell)  (NN proliferation) )))) (PP (IN for)  (NP (DT the)  (JJ respective)  (NNS proteins) )))) (. .) ) )
(TOP (NP (NP (NP (JJ cAMP-dependent)  (NN regulation) ) (PP (IN of)  (NP (NN proenkephalin) )) (PP (IN by)  (NP-COOD (NP (NN JunD) ) (CC and)  (NP (NN JunB) ))) (: :) ) (NP (NP (ADJP-COOD (ADJP (JJ positive) ) (CC and)  (ADJP (JJ negative) )) (NNS effects) ) (PP (IN of)  (NP (NN AP-1)  (NNS proteins) )) (. .) )) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (NN JunD) ) (, ,)  (NP (NP (DT a)  (NN component) ) (PP (IN of)  (NP (DT the)  (NN AP-1)  (NN transcription)  (NN factor)  (NN complex) ))) (, ,) ) (VP (VBZ activates)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN proenkephalin)  (NN gene) ))) (PP (IN in)  (NP (NP (DT a)  (NN fashion) ) (SBAR (WHNP-1 (WDT that) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBZ is)  (ADJP-PRD (RB completely)  (JJ dependent)  (PP (IN upon)  (NP (NP (DT the)  (JJ cAMP-dependent)  (NN protein)  (NN kinase) ) (, ,)  (NP (NN protein)  (NN kinase)  (NN A) ))))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Activation) ) (PP (IN of)  (NP (NN proenkephalin)  (NN transcription) )) (PP (IN by)  (NP (NN JunD) ))) (VP (VBZ is)  (ADJP-PRD (JJ dependent)  (PP (IN upon)  (NP (DT a)  (ADJP (RB previously)  (VBN characterized) ) (ADJP-COOD (ADJP (NP (NN cAMP-) ) (ADJP (-NONE- *?*) )) (, ,)  (ADJP (NP (NN phorbol)  (NN ester-) ) (ADJP (-NONE- *?*) )) (, ,)  (CC and)  (ADJP (JJ Ca-LRB-2+-RRB--inducible) )) (NN enhancer) ))))) (, ,)  (CC and)  (S (NP-SBJ-3 (NN JunD) ) (VP (VBZ is)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-3) ) (VP (TO to)  (VP (VB bind)  (NP (DT the)  (NN enhancer) ) (PP (IN as)  (NP (DT a)  (NN homodimer) )))))))) (. .) ) )
(TOP (S (NP-SBJ-4 (NP (NP (DT Another)  (NN component) ) (PP (IN of)  (NP (DT the)  (NN AP-1)  (NN transcription)  (NN complex) ))) (, ,)  (NP (NN JunB) ) (, ,) ) (VP (VBZ is)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-4) ) (VP (TO to)  (VP (VB inhibit)  (NP (NP (NN activation) ) (VP (VBN mediated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN JunD) ))))))))) (. .) ) )
(TOP (S-COOD (S (PP (IN As)  (NP (DT a)  (NN homodimer) )) (NP-SBJ-5 (NN JunB) ) (VP (VBZ is)  (ADJP-PRD (JJ unable)  (S (NP-SBJ (-NONE- *-5) ) (VP (TO to)  (VP (VB bind)  (NP (DT the)  (NN enhancer) ))))))) (: ;)  (RB however)  (S (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN c-Fos) )) (, ,)  (NP-SBJ-6 (JJ high-affinity)  (NN binding) ) (VP (VBZ is)  (VP (VBN observed)  (NP (-NONE- *-6) )))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-7 (NN JunD) ) (VP (VBZ is)  (VP (VBN shown)  (S (NP-SBJ-8 (-NONE- *-7) ) (VP (TO to)  (VP (VB activate)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBN linked)  (NP (-NONE- *) ) (PP (TO to)  (NP (NP-COOD (CC both)  (NP (NN cAMP) ) (CC and)  (NP (NN phorbol)  (NN ester) )) (NN response)  (NNS elements) )))))) (PP (IN in)  (NP (DT a)  (ADJP (NN protein)  (NN kinase)  (JJ A-dependent) ) (NN fashion) )) (, ,)  (S (NP-SBJ (-NONE- *-8) ) (ADVP (RB further) ) (VP (VBG blurring)  (NP (NP (DT the)  (NN distinction) ) (PP (IN between)  (NP (DT these)  (NN response)  (NNS elements) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP-COOD (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-9 (NP (DT the)  (JJ transcriptional)  (NN activity) ) (PP (IN of)  (NP (DT an)  (JJ AP-1-related)  (NN protein) ))) (VP (VBZ is)  (VP (VBN regulated)  (NP (-NONE- *-9) ) (PP (IN by)  (NP-LGS (DT the)  (JJ cAMP-dependent)  (NN second-messenger)  (NN pathway) ))))))) (CC and)  (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN JunD) ) (CC and)  (NP (JJ other)  (JJ AP-1-related)  (NNS proteins) )) (VP (MD may)  (VP (VB play)  (NP (DT an)  (JJ important)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (NN gene)  (NN expression) )) (PP (IN by)  (NP (JJ cAMP-dependent)  (JJ intracellular)  (NN signaling)  (NNS pathways) )))))))))) (. .) ) )
(TOP (NP (NP (NN Glucocorticoid)  (NN resistance) ) (PP (IN in)  (NP (JJ chronic)  (NN asthma) )) (. .) ) )
(TOP (NP-COOD (NP (NN Glucocorticoid)  (NNS pharmacokinetics) ) (, ,)  (NP (NN glucocorticoid)  (NN receptor)  (NNS characteristics) ) (, ,)  (CC and)  (NP (NP (NN inhibition) ) (PP (IN of)  (NP (JJ peripheral)  (NN blood)  (NN T)  (NN cell)  (NN proliferation) )) (PP (IN by)  (NP (NNS glucocorticoids) )) (ADJP (FW in)  (FW vitro) )) (. .) ) )
(TOP (S (NP-SBJ-7 (NP (DT A)  (NN total) ) (PP (IN of)  (NP (NP (CD 37)  (ADJP-COOD (ADJP (JJ chronic) ) (, ,)  (ADJP (JJ severe) ) (, ,)  (ADJP (JJ nonsmoking) )) (JJ asthmatic)  (NNS patients) ) (PP (IN with)  (NP (JJ documented)  (JJ reversible)  (NNS airways)  (NN obstruction) ))))) (VP (VBD were)  (VP (VBN classified)  (NP (-NONE- *-7) ) (PP (IN as)  (ADJP-COOD (ADJP (JJ glucocorticoid-sensitive) ) (CC or)  (ADJP (NP (-NONE- *?*) ) (JJ -resistant) ))) (PP (IN on)  (DT the)  (NN basis)  (IN of)  (NP (NP (NNS changes) ) (PP (IN in)  (NP-COOD (NP (NN FEV1) ) (, ,)  (NP (NN FVC) ) (, ,)  (CC and)  (NP (NP (JJ peak)  (NN expiratory)  (NN flow) ) (PRN (-LRB- -LRB-)  (NP (NN PEF) ) (-RRB- -RRB-) )))) (PP-TMP (IN after)  (NP (JJ oral)  (NN prednisolone) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ resistant)  (NNS patients) ) (VP (VBD showed)  (NP (NP (DT no)  (JJ significant)  (NNS improvements) ) (PP (IN in)  (NP (NN airflow)  (NN limitation) )))) (. .) ) )
(TOP (S (NP-SBJ-9 (NP (ADJP (NN Phytohemagglutinin)  (-LRB- -LRB-)  (NN PHA)  (-RRB- -RRB-)  (JJ -induced) ) (NN proliferation) ) (PP (IN of)  (NP (NP (JJ peripheral)  (NN blood)  (NN T)  (NNS lymphocytes) ) (PP (IN from)  (NP (NP-COOD (NP (DT the)  (JJ sensitive)  (NP (-NONE- *RNR*-8) )) (CONJP (CC but)  (RB not) ) (NP (DT the)  (JJ resistant)  (NP (-NONE- *RNR*-8) ))) (NP-8 (JJ asthmatic)  (NNS patients) )))))) (VP (VBD was)  (ADVP (RB significantly)  (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (ADJP-PRD (ADJP (JJR less) ) (PP (IN than)  (NP (CD 0.01) )))) (-RRB- -RRB-) )) (VP (VBN inhibited)  (NP (-NONE- *-9) ) (PP (IN by)  (NP-LGS (NP (NN dexamethasone) ) (PRN (-LRB- -LRB-)  (NP (CD 10-LRB--7-RRB-) (NN  mol/L) ) (-RRB- -RRB-) ))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG reflecting)  (NP (NP (DT a)  (NN shift) ) (PP (IN of)  (NP (DT the)  (JJ dose-response)  (NN curve) ))))))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-200 (WRB When) ) (S (NP-SBJ-33 (PDT all)  (DT the)  (JJ asthmatic)  (NNS patients) ) (VP (VBD were)  (VP (VBN analyzed)  (NP (-NONE- *-33) ) (ADVP (RB together) ) (ADVP (-NONE- *T*-200) ))))) (, ,)  (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (NP (DT a)  (JJ significant)  (NN correlation) ) (PP (IN between)  (NP-COOD (NP (NP (DT the)  (NN degree) ) (PP (IN of)  (NP (NP (NN sensitivity) ) (PP (IN of)  (NP (NN T)  (NNS cells) )) (PP (TO to)  (NP (NN dexamethasone) ))))) (CC and)  (NP (NP (DT the)  (JJ clinical)  (NN responsiveness) ) (PP (TO to)  (NP (JJ prednisolone) )))))) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (ADJP-PRD (ADJP (RBR less) ) (PP (IN than)  (NP (CD 0.01) )))) (-RRB- -RRB-) )) (. .) ) )
(TOP (S (NP-SBJ-10 (DT No)  (NNS differences) ) (VP (VBD were)  (VP (VBN observed)  (NP (-NONE- *-10) ) (PP (IN between)  (NP (NP (CD six) ) (PP (IN of)  (NP (DT the)  (ADJP-COOD (ADJP (JJ sensitive) ) (CC and)  (ADJP (JJ resistant) )) (NNS patients) )))) (PP (IN in)  (NP (NP (DT the)  (NN clearance) ) (PP (IN of)  (NP (NP (NN plasma)  (JJ prednisolone) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (ADJP (RB orally)  (VBN administered) ) (NN prednisone) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-11 (JJ Peripheral)  (NN blood)  (JJ mononuclear)  (NN cell)  (NN glucocorticoid)  (NNS receptors) ) (VP (VBD were)  (ADVP (RB also) ) (VP (VBN characterized)  (NP (-NONE- *-11) ) (PP (IN in)  (NP (NP-COOD (NP (CD five)  (JJ sensitive)  (NP (-NONE- *RNR*-12) )) (CC and)  (NP (CD seven)  (JJ resistant)  (NP (-NONE- *RNR*-12) ))) (NP-12 (NNS patients) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NP-COOD (NP (NNS numbers) ) (CC and)  (NP (NN binding)  (NNS affinities) ))) (PP (IN of)  (NP (DT these)  (NNS receptors) ))) (VP (MD could)  (RB not)  (VP (VB account)  (PP (IN for)  (NP (NP (DT the)  (VBN observed)  (NN difference) ) (PP (IN in)  (NP (NP (DT the)  (NN susceptibility) ) (PP (IN of)  (NP (DT these)  (NNS cells) )) (PP (TO to)  (NP (NP (JJ functional)  (NN inhibition) ) (PP (IN by)  (NP (NN dexamethasone) )) (ADJP (FW in)  (FW vitro) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ clinical)  (NN glucocorticoid)  (NN resistance) ) (PP (IN in)  (NP (JJ chronic)  (NN asthma) ))) (VP-COOD (VP (VBZ does)  (RB not)  (VP (VB reflect)  (NP (JJ abnormal)  (NN glucocorticoid)  (NN clearance) ))) (CC but)  (VP (MD may)  (VP (VB be)  (PP-PRD (JJ due)  (ADVP (ADVP (IN at)  (JJS least) ) (RB partly) ) (TO to)  (NP (NP (DT a)  (JJ relative)  (NN insensitivity) ) (PP (IN of)  (NP (NN T)  (NNS lymphocytes) )) (PP (TO to)  (NP (NNS glucocorticoids) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (NN lack) ) (PP (IN of)  (NP (NN sensitivity) ))) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ unexplained) )) (CC but)  (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ attributable)  (PP (TO to)  (NP (NP (NNS abnormalities) ) (PP (IN of)  (NP (JJ cellular)  (NN glucocorticoid)  (NNS receptors) ))))))) (. .) ) )
(TOP (NP (NP (NP (NN Regulation) ) (PP (IN of)  (NP (NN interleukin-1)  (NN beta)  (NN production) )) (PP (IN by)  (NP (NNS glucocorticoids) )) (PP (IN in)  (NP (JJ human)  (NNS monocytes) )) (: :) ) (S (NP-SBJ (NP (DT the)  (NN mechanism) ) (PP (IN of)  (NP (NN action) ))) (VP (VBZ depends)  (PP (IN on)  (NP (DT the)  (NN activation)  (NN signal) ))) (. .) )) )
(TOP (S (NP-SBJ-1 (NNS Glucocorticoids) ) (VP (VBP are)  (VP (VBN known)  (S (NP-SBJ (-NONE- *-1) ) (VP (TO to)  (VP (VB downregulate)  (NP (NP (NN interleukin-1)  (NN beta)  (NN production) ) (PP (IN in)  (NP (JJ monocytic)  (NNS cells) ))) (PP (IN by)  (NP (NP (CD two)  (JJ different)  (NNS mechanims) ) (: :)  (NP-COOD (NP (NP (JJ direct)  (NN inhibition) ) (PP (IN of)  (NP (DT the)  (NN gene)  (NN transcription) ))) (CC and)  (NP (NP (NN destabilization) ) (PP (IN of)  (NP (DT the)  (JJ preformed)  (NN interleukin-1)  (NN beta)  (NN mRNA) ))))))))))) (. .) ) )
(TOP (S (ADVP-TMP (RB Now) ) (NP-SBJ (PRP we) ) (VP (VBP have)  (VP (VBN examined)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NP (DT the)  (NN nature) ) (PP (IN of)  (NP (DT the)  (NN monocyte)  (NN activating)  (NN signal) )))) (PP (IN on)  (NP (DT these)  (CD two)  (JJ inhibitory)  (NNS mechanims) ))))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-100 (WRB When) ) (S (NP-SBJ-10 (JJ human)  (NNS monocytes) ) (VP (VBD were)  (VP-COOD (VP (VBN preincubated)  (NP (-NONE- *-10) ) (PP (IN with)  (NP (NN dexamethasone) )) (PP-TMP (IN for)  (NP (CD 1)  (NN hour) )) (ADVP (-NONE- *T*-100) )) (CC and)  (RB then)  (VP (VBN stimulated)  (NP (-NONE- *-10) ) (PP (CC either)  (IN with)  (NP-COOD (NP (JJ bacterial)  (NN lipopolysaccharide) ) (CC or)  (NP (NN phorbol)  (NN myristate) ))) (ADVP (-NONE- *T*-100) )))))) (, ,)  (NP-SBJ (PRP it) ) (VP (VBD was)  (VP (VBN found)  (SBAR (IN that)  (S-COOD (S (NP-SBJ (NN dexamethasone) ) (VP (VBD inhibited)  (NP (DT the)  (JJ lipopolysaccharide-induced)  (NN interleukin-1)  (NN beta)  (NN protein)  (NN production) ))) (, ,)  (CC but)  (S (NP-SBJ-3 (DT the)  (ADJP (NN phorbol)  (JJ myristate-induced) ) (NN production) ) (VP (VBD was)  (VP (VBN increased)  (NP (-NONE- *-3) ) (NP (QP (CD 3-10) ) (RB fold) )))))))) (. .) ) )
(TOP (S (NP-SBJ-2 (DT This)  (NN difference) ) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN seen)  (NP (-NONE- *-2) ) (PP (IN at)  (NP (DT the)  (NN mRNA)  (NN level) )))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-101 (WRB When) ) (S (NP-SBJ-4 (NN dexamethasone) ) (VP (VBD was)  (VP (VBN added)  (NP (-NONE- *-4) ) (PP (TO to)  (NP (DT the)  (NNS cultures) )) (PP-TMP (NP (CD 3)  (NNS hours) ) (IN after)  (NP (DT the)  (NNS stimulators) )) (ADVP (-NONE- *T*-101) ))))) (, ,)  (NP-SBJ (PRP it) ) (ADVP (RB clearly) ) (VP (VBD decreased)  (NP (DT the)  (NN interleukin-1)  (NN beta)  (NN mRNA)  (NNS levels) ) (ADVP (RB regardless)  (PP (IN of)  (NP (NP (DT the)  (NN stimulator) ) (VP (VBN used)  (NP (-NONE- *) ))))) (-LRB- -LRB-)  (SBAR (IN although)  (S (NP-SBJ (DT the)  (NN effect) ) (VP (VBD was)  (ADJP-PRD (RB clearly)  (JJR weaker) ) (PP (IN on)  (NP (DT the)  (JJ PMA-induced)  (NN mRNA) ))))) (-RRB- -RRB-) ) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (NP-SBJ (DT these)  (NNS data) ) (VP (VBP suggest)  (SBAR (IN that)  (S-COOD (S (NP-SBJ-5 (NP (DT the)  (ADJP (NN phorbol)  (JJ myristate-induced) ) (NN signal) ) (PRN (-LRB- -LRB-)  (FRAG (NP (JJ prolonged)  (NN protein)  (NN kinase)  (NN C)  (NN activation) ) (. ?) ) (-RRB- -RRB-) )) (VP (MD can)  (RB not)  (VP (VB be)  (VP (VBN inhibited)  (NP (-NONE- *-5) ) (PP (IN by)  (NP-LGS (NP (JJ prior)  (NN incubation) ) (PP (IN with)  (NP (NN dexamethasone) )))))))) (CC and)  (S (NP-SBJ (PRP it) ) (ADVP (RB also) ) (VP (VBZ protects)  (NP (DT the)  (VBN induced)  (NN mRNA) ) (PP (IN for)  (NP (NP (DT the)  (JJ degradative)  (NN action) ) (PP (IN of)  (NP (NN dexamethasone) ))))))))) (. .) ) )
(TOP (NP (NP (NN Identification) ) (PP (IN of)  (NP (NP (JJ transcriptional)  (NN suppressor)  (NNS proteins) ) (SBAR (WHNP-1 (WDT that) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBP bind)  (PP (TO to)  (NP (NP (DT the)  (JJ negative)  (JJ regulatory)  (NN element) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-2 (NP (CD Two)  (JJ different)  (NNS proteins) ) (SBAR (WHNP-3 (WDT which) ) (S (NP-SBJ (-NONE- *T*-3) ) (ADVP (RB independently) ) (VP (VBD bound)  (PP (TO to)  (NP (NP (VBG neighboring)  (NNS sequences) ) (PP (IN within)  (NP (NP (NP (DT the)  (JJ negative)  (JJ regulatory)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN NRE) ) (-RRB- -RRB-) )) (PP (IN of)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) ))))))))))) (VP (VBD were)  (VP (VBN detected)  (NP (-NONE- *-2) ) (PP (IN in)  (NP (NP (DT the)  (JJ nuclear)  (NN extract) ) (PP (IN of)  (NP (DT a)  (JJ virus-infected)  (JJ human)  (NN T)  (NN cell)  (NN line) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (CD One) ) (PP (IN of)  (NP (DT the)  (NNS factors) ))) (VP (VBD bound)  (PP (TO to)  (NP (DT a)  (JJ novel)  (NN dyad)  (JJ symmetrical)  (NN sequence) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-4 (DT This)  (NN sequence) ) (VP (VBZ is)  (ADVP (RB well) ) (VP (VBN conserved)  (NP (-NONE- *-4) ) (PP (IN in)  (NP (JJ various)  (NN HIV-1)  (NNS isolates) ))))) (CC and)  (S (NP-SBJ-5 (JJ partial)  (NN homology) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-5) ) (PP (IN with)  (NP (NP (DT the)  (JJ promoter)  (NN region) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN retinoblastoma)  (NN gene) ))))))) (. .) ) )
(TOP (S (NP-SBJ-6 (JJ Similar)  (NN DNA)  (NN binding)  (NN activity) ) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-6) ) (PP (IN in)  (NP (NP (DT a)  (NN variety) ) (PP (IN of)  (NP (JJ virus-uninfected)  (JJ human)  (NP-COOD (NP (NN T)  (NN cell)  (NNS lines) ) (CC and)  (NP (NN HeLa)  (NNS cells) )))))) (PP (IN by)  (NNS means)  (IN of)  (NP (DT a)  (NN gel)  (NN mobility)  (NN shift)  (NN assay) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ other)  (NN factor) ) (VP (VBN bound)  (PP (TO to)  (NP (NP (DT a)  (JJ putative)  (NN AP-1)  (NN recognition)  (NN sequence) ) (VP (VBD predicted)  (NP (-NONE- *) ) (PP (IN for)  (NP (DT the)  (NN HIV-1)  (NN NRE) )))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (DT this)  (NN factor) ) (VP (VBD did)  (RB not)  (VP (VB bind)  (PP (TO to)  (NP (DT a)  (JJ typical)  (NN AP-1)  (NN site) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN insertion) ) (PP (IN of)  (NP (NP (JJ multiple)  (NNS copies) ) (PP (IN of)  (NP (NP (DT the)  (VBG binding)  (NN site) ) (PP (IN for)  (NP (DT the)  (ADJP-COOD (ADJP (JJ former) ) (CC or)  (ADJP (JJ latter) )) (NN factor) )))))) (PP (IN into)  (NP (DT a)  (JJ heterologous)  (NN promoter) ))) (VP (VBD reduced)  (NP (DT the)  (NN promoter)  (NN activity) ) (PP (TO to)  (NP-COOD (NP (CD one-tenth) ) (CC or)  (NP (CD one-third) ))) (, ,)  (ADVP (RB respectively) )) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (DT each)  (NN factor) ) (VP (MD may)  (VP (VB function)  (PP (IN as)  (NP (NP (DT a)  (JJ novel)  (JJ negative)  (NN regulator) ) (PP (IN of)  (NP (NN transcription) )))))) (. .) ) )
(TOP (NP (NP (JJ Constitutive)  (NN activation) ) (PP (IN of)  (NP (NN NF-kB) )) (PP (IN in)  (NP (JJ human)  (NNS thymocytes) )) (. .) ) )
(TOP (S (NP-SBJ (NN NF-kB) ) (VP (VBZ is)  (NP-PRD (DT a)  (JJ eukaryotic)  (NN transcription)  (JJ regulatory)  (NN factor) )) (. .) ) )
(TOP (S (PP (IN In)  (NP-COOD (NP (NN T)  (NNS cells) ) (CC and)  (NP (NN T)  (NN cell)  (NNS lines) ))) (, ,)  (NP-SBJ-1 (NN NF-kB) ) (VP (VBZ is)  (VP (VBN bound)  (NP (-NONE- *-1) ) (PP (TO to)  (NP (NP (DT a)  (JJ cytoplasmic)  (JJ proteic)  (NN inhibitor) ) (, ,)  (NP (DT the)  (NN IkB) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN of)  (NP (NN T)  (NNS cells) )) (PP (IN with)  (NP-COOD (NP (NP (NNS mitogens) ) (PRN (-LRB- -LRB-)  (NP (NN phorbol)  (NNS esters) ) (-RRB- -RRB-) )) (CC or)  (NP (NP (NNS cytokines) ) (PRN (-LRB- -LRB-)  (NP (NN TNF)  (NN alpha) ) (-RRB- -RRB-) ))))) (VP (VBZ induces)  (NP-COOD (NP (NN NF-kB)  (JJ nuclear)  (NN translocation) ) (CC and)  (NP (NP (DT the)  (JJ subsequent)  (NN expression) ) (PP (IN of)  (NP (ADJP (NN NF-kB)  (JJ dependent) ) (NN T)  (NN cell)  (NNS genes) ))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBD examined)  (NP (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN NF-kB) )) (PP (IN in)  (NP (JJ human)  (NN T)  (NN cell)  (JJ thymic)  (NNS progenitors) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP report)  (NP (NP (NNS differences) ) (PP (IN in)  (NP (NP (NN -LRB-Ca2+-RRB-i)  (NN requirement) ) (IN for)  (NP (NP (NN NF-kB)  (NN activation) ) (PP (IN in)  (NP (NNS thymocytes) ))))) (SBAR (IN as)  (S (NP-SBJ-2 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-2) ) (PP (TO to)  (NP (JJ mature)  (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-3 (PRP$ our)  (NNS results) ) (VP (VBD indicated)  (SBAR (IN that)  (S (NP-SBJ (NNS thymocytes) ) (VP (VBP have)  (NP (NP (DT a)  (ADJP (RB constitutively)  (JJ active) ) (NN form) ) (PP (IN of)  (NP (NN NF-kB) )))))) (, ,)  (S (NP-SBJ (-NONE- *-3) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ-4 (PRP they) ) (VP (VBP are)  (VP (VBN activated)  (NP (-NONE- *-4) ) (ADVP (FW in)  (FW vivo) )))))))) (. .) ) )
(TOP (NP (NP (DT The)  (NN role) ) (PP (IN of)  (NP (NN jun)  (CC and)  (NN fos)  (NN gene)  (NN family)  (NNS members) )) (PP (IN in)  (NP (ADJP (NN 12-O-tetradecanoylphorbol-13-acetate)  (VBD induced) ) (JJ hemopoietic)  (NN differentiation) )) (. .) ) )
(TOP (S (NP-SBJ-19 (NP (JJ Terminal)  (NN differentiation) ) (PP (IN of)  (NP (DT the)  (JJ leukemic)  (NN cell)  (NNS lines)  (NP-COOD (NP (NN U-937) ) (CC and)  (NP (NN HL-60) )))) (PP (IN by)  (NP (NN 12-O-tetradecanoylphorbol-13-acetate) ))) (VP (VBZ is)  (VP (VBN accompanied)  (NP (-NONE- *-19) ) (PP (IN by)  (NP-LGS (NP (JJ marked)  (NNS changes) ) (PP (IN in)  (NP (NN gene)  (NN expression) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-20 (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NN jun)  (CC and)  (NN fos)  (NN gene)  (NN family)  (NNS members) ))) (VP (VBZ is)  (VP (VBN induced)  (NP (-NONE- *-20) ) (PP (IN with)  (NP (JJ variable)  (NNS kinetics) )) (PP-TMP (IN during)  (NP (ADJP (NN 12-O-tetradecanoylphorbol-13-acetate)  (VBD induced) ) (NN differentiation) )) (, ,)  (PP (IN with)  (S (NP-SBJ (NN c-jun)  (NN expression) ) (ADVP (RB best) ) (VP (JJ paralleling)  (NP (NN differentiation) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN generation) ) (PP (IN of)  (NP (NN AP-1)  (NNS complexes) )) (, ,)  (SBAR (IN as)  (S (NP-SBJ-21 (-NONE- *) ) (VP (VBN measured)  (NP (-NONE- *-21) ) (PP (IN by)  (NP (NN DNA)  (NN binding)  (NN activity) ))))) (, ,) ) (ADVP (RB closely) ) (VP (VBZ parallels)  (NP (JJ morphological)  (NN differentiation) )) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-22 (NP (DT the)  (NN ability)  (S (-NONE- *ICH*-101) )) (PP (IN of)  (NP (DT these)  (NNS complexes) )) (S-101 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB regulate)  (NP (NN gene)  (NN expression) ))))) (VP (VBZ is)  (VP (VBN demonstrated)  (NP (-NONE- *-22) ) (PP (IN by)  (NP-LGS-COOD (NP (NP (VBN increased)  (NN transcription) ) (PP (IN from)  (NP (DT an)  (ADJP (NN AP-1)  (VBN driven) ) (NN reporter)  (NN construct) ))) (CC and)  (NP (NP (JJ marked)  (NNS increases) ) (PP (IN in)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (JJ endogenous)  (NN AP-1)  (JJ regulated)  (NNS genes) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Differentiation)  (NNS assays) ) (VP (VBG using)  (NP (ADJP (NN water)  (JJ soluble) ) (NN phorbol)  (NNS esters) ))) (VP (VBP reveal)  (SBAR (IN that)  (S (NP-SBJ (NN differentiation) ) (VP (VBZ becomes)  (ADJP-PRD (JJ irreversible) ) (ADVP-TMP (RB soon)  (SBAR-TMP (IN after)  (S (NP-SBJ (NN AP-1) ) (VP (VBZ appears) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (JJ tight)  (NN correlation) ) (PP (IN between)  (NP-COOD (NP (NN c-jun)  (NN expression) ) (, ,)  (NP (NP (DT the)  (NN generation) ) (PP (IN of)  (NP (NN AP-1)  (NN activity) ))) (, ,)  (CC and)  (NP (NN differentiation) )))) (VP (VBZ suggests)  (NP (NP (DT a)  (JJ critical)  (NN role) ) (PP (IN for)  (NP (DT this)  (UCP-COOD (NP (NN gene) ) (CC and)  (ADJP (JJ transcriptional) )) (NN complex) )) (PP-TMP (IN during)  (NP (DT this)  (NN process) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN TCF-1) ) (, ,)  (NP (NP (DT a)  (ADJP (NN T)  (JJ cell-specific) ) (NN transcription)  (NN factor) ) (PP (IN of)  (NP (DT the)  (NN HMG)  (NN box)  (NN family) ))) (, ,) ) (VP (VBZ interacts)  (PP (IN with)  (NP (NP (NN sequence)  (NNS motifs) ) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN TCR)  (NN beta) ) (CC and)  (NP (NN TCR)  (NN delta) )) (NNS enhancers) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-TMP (RB recently) ) (VP (VP-COOD (VP (VBN identified)  (NP (-NONE- *RNR*-5) )) (CC and)  (VP (VBN cloned)  (NP (-NONE- *RNR*-5) ))) (NP-5 (NP (NN TCF-1) ) (, ,)  (NP (NP (DT a)  (ADJP (NN T)  (JJ cell-specific) ) (NN transcription)  (NN factor) ) (PP (IN with)  (NP (NP (NN specificity) ) (PP-COOD (PP (IN for)  (NP (NP (DT the)  (NN AACAAAG)  (NN motif) ) (PP (IN in)  (NP (DT the)  (NN CD3)  (NN epsilon)  (NN enhancer) )))) (CC and)  (PP (IN for)  (NP (NP (DT the)  (NN TTCAAAG)  (NN motif) ) (PP (IN in)  (NP (DT the)  (NN TCR)  (NN alpha)  (NN enhancer) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN TCF-1) ) (VP (VBZ belongs)  (PP (TO to)  (NP (NP (DT the)  (NN family) ) (PP (IN of)  (NP (NP (JJ transcription-regulating)  (NNS proteins) ) (SBAR (WHNP-6 (WDT which) ) (S (NP-SBJ (-NONE- *T*-6) ) (VP (VBP share)  (NP (NP (DT a)  (NN region) ) (PP (IN of)  (NP (NN homology) )) (VP (VBN termed)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (DT the)  (NN HMG-box) )))))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP show)  (PP (IN by)  (NP (NN gel)  (NN retardation)  (NN analysis) )) (SBAR (IN that)  (NP-SBJ (NN TCF-1) ) (ADVP (RB specifically) ) (VP (VBZ recognizes)  (NP-COOD (NP (NP (DT the)  (NN T)  (NN beta)  (CD 5)  (NN element) ) (PP (IN of)  (NP (DT the)  (NN TCR)  (NN beta)  (NN enhancer) ))) (CC and)  (NP (NP (DT the)  (NN T)  (NN delta)  (CD 7)  (NN element) ) (PP (IN of)  (NP (DT the)  (NN TCR)  (NN delta)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Comparison) ) (PP (IN of)  (NP (NP (DT the)  (NNS sequences) ) (PP (IN of)  (NP (NP (DT all)  (NNS elements) ) (VP (VBN recognized)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN TCF-1) )))))))) (VP (VBZ defines)  (NP (DT a)  (NN consensus)  (NN motif) (NN  A/T) (NN  A/T)  (NN C)  (NN A) (NN  A/G)  (NN A)  (NN G) )) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS observations) ) (VP (VBP imply)  (SBAR (IN that)  (S (NP-SBJ-7 (NN TCF-1) ) (VP-COOD (VP (VBZ is)  (VP (VBN involved)  (NP (-NONE- *-7) ) (PP (IN in)  (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP (JJ several)  (ADJP (NN T)  (JJ cell-specific) ) (NNS genes) )))))) (CC and)  (VP (MD might)  (ADVP (RB thus) ) (VP (VB play)  (NP (NP (DT an)  (JJ important)  (NN role) ) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN establishment) ) (CC and)  (NP (NN maintenance) )) (PP (IN of)  (NP (DT the)  (JJ mature)  (NN T)  (NN cell)  (NN phenotype) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ cellular)  (NN oncogene)  (NN c-myb) ) (VP (MD can)  (VP (VB interact)  (ADVP (RB synergistically) ) (PP (IN with)  (NP (DT the)  (JJ Epstein-Barr)  (NN virus)  (NN BZLF1)  (NN transactivator) )) (PP (IN in)  (NP (JJ lymphoid)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ-60 (NP (NN Regulation) ) (PP (IN of)  (NP (NP (JJ replicative)  (NNS functions) ) (PP (IN in)  (NP (DT the)  (NP (NP (JJ Epstein-Barr)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN EBV) ) (-RRB- -RRB-) )) (NN genome) ))))) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-60) ) (PP (IN through)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NP (DT a)  (ADJP (RB virally)  (VBN encoded) ) (NN transcription)  (NN factor) ) (, ,)  (NP (NP (NN Z) ) (PRN (-LRB- -LRB-)  (NP (NN BZLF1) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN shown)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN Z)  (NN gene)  (NN product) ) (, ,)  (SBAR (WHNP-61 (WDT which) ) (S (NP-SBJ (-NONE- *T*-61) ) (VP-COOD (VP (VBZ binds)  (PP (TO to)  (NP (NN AP-1)  (NNS sites) )) (PP (IN as)  (NP (DT a)  (NN homodimer) ))) (CC and)  (VP (VBZ has)  (NP (NP (NN sequence)  (NN similarity) ) (PP (TO to)  (NP (NN c-Fos) ))))))) (, ,) ) (VP (MD can)  (ADVP (RB efficiently) ) (VP (VB activate)  (NP (NP (DT the)  (NN EBV)  (JJ early)  (NN promoter) ) (, ,)  (NP (NN BMRF1) ) (, ,) ) (PP (IN in)  (NP-COOD (NP (NP (JJ certain)  (NN cell)  (NNS types) ) (PRN (-LRB- -LRB-)  (NP (FW i.e.)  (, ,)  (NP (NN HeLa)  (NNS cells) )) (-RRB- -RRB-) )) (CONJP (CC but)  (RB not) ) (NP (NP (NNS others) ) (PRN (-LRB- -LRB-)  (NP (FW i.e.)  (, ,)  (NP (NN Jurkat)  (NNS cells) )) (-RRB- -RRB-) )))))))))) (. .) ) )
(TOP (S-COOD (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-62 (NP (DT the)  (NN c-myb)  (NN proto-oncogene)  (NN product) ) (, ,)  (SBAR (WHNP-63 (WDT which) ) (S (NP-SBJ (-NONE- *T*-63) ) (VP (VBZ is)  (NP (PRP itself) ) (NP-PRD-COOD (NP (DT a)  (JJ DNA-binding)  (NN protein) ) (CC and)  (NP (JJ transcriptional)  (NN transactivator) ))))) (, ,) ) (VP (MD can)  (VP (VB interact)  (ADVP (RB synergistically) ) (PP (IN with)  (NP (NN Z) )) (PP (IN in)  (S (NP-SBJ (-NONE- *-62) ) (VP (VBG activating)  (NP (DT the)  (NN BMRF1)  (NN promoter) ) (PP (IN in)  (NP-COOD (NP (NP (NN Jurkat)  (NNS cells) ) (PRN (-LRB- -LRB-)  (NP (DT a)  (NN T-cell)  (NN line) ) (-RRB- -RRB-) )) (CC or)  (NP (NP (NN Raji)  (NNS cells) ) (PRN (-LRB- -LRB-)  (NP (DT an)  (JJ EBV-positive)  (NN B-cell) ) (-RRB- -RRB-) ))))))))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (DT the)  (NN c-myb)  (NN gene)  (NN product) ) (PP (IN by)  (NP (PRP itself) ))) (VP (VBZ has)  (NP (JJ little)  (NN effect) ))) (. .) ) )
(TOP (S (NP-SBJ-64 (DT The)  (JJ simian)  (NN virus)  (CD 40)  (JJ early)  (NN promoter) ) (VP (VBZ is)  (ADVP (RB also) ) (ADVP (RB synergistically) ) (VP (VBN activated)  (NP (-NONE- *-64) ) (PP (IN by)  (NP-LGS (DT the) (NN  Z/c-myb)  (NN combination) )))) (. .) ) )
(TOP (S (NP-SBJ-65 (NP (JJ Synergistic)  (NN transactivation) ) (PP (IN of)  (NP (DT the)  (NN BMRF1)  (NN promoter) )) (PP (IN by)  (NP (DT the) (NN  Z/c-myb)  (NN combination) ))) (VP (VBZ appears)  (S (NP-SBJ (-NONE- *-65) ) (VP (TO to)  (VP (VB involve)  (NP (NP (JJ direct)  (NN binding) ) (PP (IN by)  (NP-COOD (NP (DT the)  (NN Z)  (NN protein) ) (CONJP (CC but)  (RB not) ) (NP (DT the)  (NN c-myb)  (NN protein) )))))))) (. .) ) )
(TOP (S (NP-SBJ-66 (NP (DT A)  (JJ 30-bp)  (NN sequence) ) (PP (IN in)  (NP (NP (DT the)  (NN BMRF1)  (NN promoter) ) (SBAR (WHNP-67 (WDT which) ) (S (NP-SBJ (-NONE- *T*-67) ) (VP (VBZ contains)  (NP (NP (DT a)  (NN Z)  (NN binding)  (NN site) ) (PRN (-LRB- -LRB-)  (NP (DT a)  (NN consensus)  (NN AP-1)  (NN site) ) (-RRB- -RRB-) )))))))) (VP (VBZ is)  (ADJP-PRD (JJ sufficient)  (S (NP-SBJ (-NONE- *-66) ) (VP (TO to)  (VP (VB transfer)  (NP (NP (JJ high-level)  (JJ lymphoid-specific)  (NN responsiveness) ) (PP (TO to)  (NP (DT the) (NN  Z/c-myb)  (NN combination) ))) (PP (TO to)  (NP (DT a)  (JJ heterologous)  (NN promoter) ))))))) (. .) ) )
(TOP (S (SBAR-SBJ (IN That)  (S (NP-SBJ (DT the)  (NN c-myb)  (NN oncogene)  (NN product) ) (VP (MD can)  (VP (VB interact)  (ADVP (RB synergistically) ) (PP (IN with)  (NP (NP (DT an)  (JJ EBV-encoded)  (NN member) ) (PP (IN of)  (NP (DT the)  (NN leucine)  (NN zipper)  (NN protein)  (NN family) )))))))) (VP (VBZ suggests)  (SBAR (WHNP (-NONE- 0) ) (S (NP-SBJ-68 (NN c-myb) ) (VP (VBZ is)  (ADJP-PRD (JJ likely)  (S (NP-SBJ (-NONE- *-68) ) (VP (TO to)  (VP (VB engage)  (PP (IN in)  (NP (NP (JJ similar)  (NNS interactions) ) (PP (IN with)  (NP (ADJP (RB cellularly)  (VBN encoded) ) (NN transcription)  (NNS factors) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ 29-kDa)  (NNS proteins) ) (VP (VBN phosphorylated)  (NP (-NONE- *) ) (PP (IN in)  (NP (JJ thrombin-activated)  (JJ human)  (NNS platelets) )))) (VP (VBP are)  (NP-PRD (NP (NNS forms) ) (PP (IN of)  (NP (DT the)  (ADJP (NN estrogen)  (JJ receptor-related) ) (JJ 27-kDa)  (NN heat)  (NN shock)  (NN protein) )))) (. .) ) )
(TOP (S (NP-SBJ (NN Thrombin) ) (VP (VBZ plays)  (NP (DT a)  (JJ critical)  (NN role) ) (PP (IN in)  (NP-COOD (NP (NN platelet)  (NN activation) ) (, ,)  (NP (NN hemostasis) ) (, ,)  (CC and)  (NP (NN thrombosis) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Cellular)  (NN activation) ) (PP (IN by)  (NP (NN thrombin) ))) (VP (VBZ leads)  (PP (TO to)  (NP (NP (DT the)  (NN phosphorylation) ) (PP (IN of)  (NP (NP (JJ multiple)  (NNS proteins) ) (, ,)  (SBAR (WHNP-1 (NP (JJS most) ) (WHPP (IN of)  (WHNP (WDT which) ))) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBP are)  (ADJP-PRD (JJ unidentified) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN characterized)  (NP (NP (JJ several)  (JJ 29-kDa)  (NNS proteins) ) (SBAR (WHNP-2 (WDT that) ) (S (NP-SBJ-3 (-NONE- *T*-2) ) (VP (VBP are)  (ADVP-TMP (RB rapidly) ) (VP (VBN phosphorylated)  (NP (-NONE- *-3) ) (PP-TMP (VBG following)  (NP (NP (NN exposure) ) (PP (IN of)  (NP (JJ intact)  (JJ human)  (NNS platelets) )) (PP (TO to)  (NP (NN thrombin) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ murine)  (JJ monoclonal)  (NN antibody) ) (VP (VBN raised)  (PP (TO to)  (NP (DT an)  (JJ unidentified)  (ADJP (NN estrogen)  (JJ receptor-related) ) (JJ 29-kDa)  (NN protein) )))) (ADVP (RB selectively) ) (VP (VBD recognized)  (NP-COOD (NP (DT these)  (NNS proteins) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (DT a)  (ADJP-COOD (ADJP (RBR more)  (JJ basic) ) (, ,)  (ADJP (JJ unphosphorylated) )) (JJ 27-kDa)  (NN protein) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Cellular)  (NN activation) ) (PP (IN by)  (NP (NN thrombin) ))) (VP (VBN led)  (PP (TO to)  (NP (NP (DT a)  (JJ marked)  (NN shift) ) (PP (IN in)  (NP (NP (DT the)  (NN proportion) ) (PP (IN of)  (NP (NN protein) )))) (PP (IN from)  (NP (DT the)  (JJ 27-kDa)  (JJ unphosphorylated)  (NN form) )) (PP (TO to)  (NP (DT the)  (JJ 29-kDa)  (NN phosphoprotein)  (NNS species) ))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-4) ) (VP (VBG Using)  (NP (DT this)  (NN antibody) ))) (, ,)  (NP-SBJ-4 (PRP we) ) (VP (VP-COOD (VP (VBD isolated)  (NP (-NONE- *RNR*-5) )) (CC and)  (VP (VBD sequenced)  (NP (-NONE- *RNR*-5) ))) (NP-5 (NP (DT a)  (JJ human)  (NN cDNA)  (NN clone) ) (VP (VBG encoding)  (NP (NP (DT a)  (NN protein) ) (SBAR (WHNP-6 (WDT that) ) (S (NP-SBJ (-NONE- *T*-6) ) (VP (VBD was)  (ADJP-PRD (JJ identical)  (PP (TO to)  (NP (NP (NP (DT the)  (JJ mammalian)  (JJ 27-kDa)  (NN heat)  (NN shock)  (NN protein) ) (PRN (-LRB- -LRB-)  (NP (NN HSP27) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (DT a)  (NN protein) ) (PP (IN of)  (NP (JJ uncertain)  (NN function) )) (SBAR (WHNP-7 (WDT that) ) (S (NP-SBJ-8 (-NONE- *T*-7) ) (VP (VBZ is)  (VP (VBN known)  (S (NP-SBJ-9 (-NONE- *-8) ) (VP-COOD (VP (TO to)  (VP (VB be)  (VP (VBN phosphorylated)  (NP (-NONE- *-9) ) (PP (TO to)  (NP (JJ several)  (NNS forms) )) (PP (-NONE- *RNR*-12) )))) (CC and)  (VP (TO to)  (VP (VB be)  (ADVP (RB transcriptionally) ) (VP (VBN induced)  (NP (-NONE- *-10) ) (PP (-NONE- *RNR*-12) ))))) (PP-12 (IN by)  (NP-LGS (NN estrogen) )))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-13 (DT The)  (JJ 29-kDa)  (NNS proteins) ) (VP (VBD were)  (VP (VBN confirmed)  (S (NP-SBJ (-NONE- *-13) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (VBN phosphorylated)  (NNS forms) ) (PP (IN of)  (NP (NN HSP27) )))))) (PP (IN by)  (NP-LGS (NN immunoprecipitation)  (NNS studies) )))) (. .) ) )
(TOP (S-COOD (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (DT the)  (`` ")  (ADJP (NN estrogen)  (JJ receptor-related) ) (NN protein)  ('' ") ) (VP (VBZ is)  (NP-PRD (NN HSP27) ))) (, ,)  (CC and)  (S (NP-SBJ (NP (DT the)  (CD three)  (JJ major)  (JJ 29-kDa)  (NNS proteins) ) (VP (VBN phosphorylated)  (NP (-NONE- *) ) (PP (IN in)  (NP (JJ thrombin-activated)  (NNS platelets) )))) (VP (VBP are)  (NP-PRD (NP (NNS forms) ) (PP (IN of)  (NP (NN HSP27) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP suggest)  (NP (NP (DT a)  (NN role) ) (PP (IN for)  (NP (NN HSP27) )) (PP (IN in)  (NP (NP (DT the)  (NN signal)  (NN transduction)  (NNS events) ) (PP (IN of)  (NP (NN platelet)  (NN activation) )))))) (. .) ) )
(TOP (NP (NP (NN Characterization) ) (PP (IN of)  (NP (NP (DT a)  (NN cofactor) ) (SBAR (WHNP-1 (WDT that) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBZ regulates)  (NP (NP (NN dimerization) ) (PP (IN of)  (NP (DT a)  (JJ mammalian)  (NN homeodomain)  (NN protein) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Dimerization) ) (PP (IN among)  (NP (NN transcription)  (NNS factors) ))) (VP (VBZ has)  (VP (VBN become)  (NP-PRD (NP (DT a)  (JJ recurrent)  (NN theme) ) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (JJ eukaryotic)  (NN gene)  (NN expression) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Hepatocyte)  (JJ nuclear)  (NN factor-1)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN HNF-1)  (NN alpha) ) (-RRB- -RRB-) )) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ homeodomain-containing)  (NN protein) ) (SBAR (WHNP-2 (WDT that) ) (S (NP-SBJ (-NONE- *T*-2) ) (VP (VBZ functions)  (PP (IN as)  (NP (DT a)  (NN dimer) ))))))) (. .) ) )
(TOP (S (NP-SBJ-4 (NP (NP (DT A)  (NN dimerization)  (NN cofactor) ) (PP (IN of)  (NP (NP (NN HNF-1)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN DCoH) ) (-RRB- -RRB-) )))) (SBAR (-NONE- *ICH*-3) )) (VP (VBD was)  (VP (VBN identified)  (NP (-NONE- *-4) ) (SBAR-3 (WHNP-5 (WDT that) ) (S (NP-SBJ (-NONE- *T*-5) ) (VP-COOD (VP (VBD displayed)  (NP (DT a)  (JJ restricted)  (NN tissue)  (NN distribution) )) (CC and)  (VP (VBD did)  (RB not)  (VP (VB bind)  (PP (TO to)  (NP (NN DNA) )))) (, ,)  (CONJP (CC but)  (, ,)  (RB rather) ) (, ,)  (VP (ADVP (RB selectively) ) (VBD stabilized)  (NP (NN HNF-1)  (NN alpha)  (NNS dimers) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (DT The)  (NN formation) ) (PP (IN of)  (NP (DT a)  (JJ stable)  (JJ tetrameric)  (NN DCoH-HNF-1)  (NN alpha)  (NN complex) ))) (, ,)  (SBAR (WHNP-6 (WDT which) ) (S (NP-SBJ (-NONE- *T*-6) ) (VP (VBD required)  (NP (NP (DT the)  (NN dimerization)  (NN domain) ) (PP (IN of)  (NP (NN HNF-1)  (NN alpha) )))))) (, ,) ) (VP-COOD (VP (VBD did)  (RB not)  (VP (VB change)  (NP (NP (DT the)  (NN DNA)  (NN binding)  (NNS characteristics) ) (PP (IN of)  (NP (NN HNF-1)  (NN alpha) ))))) (, ,)  (CC but)  (VP (VBD enhanced)  (NP (PRP$ its)  (JJ transcriptional)  (NN activity) ))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NN DCoH) ) (VP (VBD did)  (RB not)  (VP (VB confer)  (NP (JJ transcriptional)  (NN activation) ) (PP (TO to)  (NP (DT the)  (NN GAL4)  (NN DNA)  (NN binding)  (NN domain) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NN DCoH) ) (VP-COOD (VP (VBZ regulates)  (NP (NP (NN formation) ) (PP (IN of)  (NP (ADJP (RB transcriptionally)  (JJ active) ) (JJ tetrameric)  (NNS complexes) )))) (CC and)  (VP (MD may)  (VP (VB contribute)  (PP (TO to)  (NP (NP (DT the)  (JJ developmental)  (NN specificity) ) (PP (IN of)  (NP (DT the)  (NN complex) )))))))))) (. .) ) )
(TOP (S (NP (NP (JJ High)  (NN affinity)  (NN aldosterone) ) (VP (VBG binding)  (PP (TO to)  (NP (NP (NN plasma)  (NN membrane)  (JJ rich)  (NNS fractions) ) (PP (IN from)  (NP (JJ mononuclear)  (NNS leukocytes) )))))) (: :)  (SQ (VBZ is)  (NP-SBJ (EX there) ) (NP-PRD (NP (DT a)  (NN membrane)  (NN receptor) ) (PP (IN for)  (NP (NNS mineralocorticoids) ))) (. ?) )) )
(TOP (S (NP-SBJ-COOD-56 (NP (NP (ADJP (FW In)  (FW vitro) ) (NNS effects) ) (PP (IN of)  (NP (NN aldosterone) )) (PP (IN on)  (NP (NP (DT the)  (JJ intracellular)  (NNS concentrations) ) (PP (IN of)  (NP-COOD (NP (NN sodium) ) (, ,)  (NP (NN potassium) ) (CC and)  (NP (NN calcium) )))))) (, ,)  (NP (NN cell)  (NN volume) ) (CC and)  (NP (DT the)  (NN sodium-proton-antiport) )) (VP (VBP have)  (VP (VBN been)  (VP (VBN described)  (NP (-NONE- *-56) ) (PP (IN in)  (NP (JJ intact)  (NP (NP (JJ human)  (JJ mononuclear)  (NNS leukocytes) ) (PRN (-LRB- -LRB-)  (NP (NN HML) ) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ present)  (NN paper) )) (, ,)  (NP-SBJ-57 (NP (DT the)  (NN binding) ) (PP (IN of)  (NP (DT a)  (JJ -LCB-125I-RCB--labeled)  (NN aldosterone)  (JJ derivative) )) (PP (TO to)  (NP (NP (ADJP (NP (NN plasma)  (NN membrane) ) (JJ rich) ) (NNS fractions) ) (PP (IN of)  (NP (NN HML) ))))) (VP (VBD was)  (VP (VBN studied)  (NP (-NONE- *-57) ))) (. .) ) )
(TOP (S (NP-SBJ-58 (NP (JJ High)  (NN affinity)  (NN binding) ) (PP (IN of)  (NP (DT the)  (NN radioligand) )) (PP (IN with)  (NP (NP (DT an)  (JJ apparent)  (NN Kd) ) (PP (IN of)  (NP (QP (RB approximately)  (CD 0.1) ) (NN nM) ))))) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-58) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Aldosterone) ) (VP (VBD displaced)  (NP (DT the)  (NN tracer) ) (PP (IN at)  (NP (DT a)  (JJ similar)  (NN Kd) ))) (. .) ) )
(TOP (S (NP-SBJ-COOD (CC Both)  (NP (NN canrenone) ) (CC and)  (NP (NN cortisol) )) (VP (VBD were)  (ADJP-PRD (JJ inactive) ) (PP (IN as)  (NP (NNS ligands) )) (PP (RB up)  (TO to)  (NP (NP (NNS concentrations) ) (PP (IN of)  (NP (CD 0.1)  (NN microM) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS findings) ) (VP (VBP are)  (NP-PRD (NP (DT the)  (JJ first) ) (SBAR (WHNP-305 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-305) ) (VP (TO to)  (VP (VB demonstrate)  (NP (NP (NN membrane)  (NN binding)  (NNS sites) ) (PP (IN with)  (NP (DT a)  (JJ high)  (NN affinity) )) (PP-COOD (PP (IN for)  (NP (NN aldosterone) )) (, ,)  (CC but)  (PP (RB not)  (IN for)  (NP (NN cortisol) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP-COOD (VP (VBP are)  (ADJP-PRD (RB perfectly)  (JJ compatible)  (PP (IN with)  (NP (NP (JJ major)  (NNS properties) ) (PP (IN of)  (NP (NP (JJ steroidal)  (NNS effects) ) (PP (IN on)  (NP (NP (DT the)  (NN sodium-proton-antiport) ) (PP (IN in)  (NP (NN HML) )))))))))) (CC and)  (RB thus)  (VP (ADVP (RB very)  (RB likely) ) (VBP represent)  (NP (NP (NN membrane)  (NNS receptors) ) (PP (IN for)  (NP (NN aldosterone) ))))) (. .) ) )
(TOP (NP (NP (NN Transcription)  (NN factor)  (NNS requirements) ) (PP (IN for)  (NP (ADJP (NN U2)  (JJ snRNA-encoding) ) (NN gene)  (NN activation) )) (PP (IN in)  (NP (NN B)  (JJ lymphoid)  (NNS cells) )) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Transcription) ) (PP (IN of)  (NP (NP (DT a)  (JJ human)  (ADJP (NN U2)  (JJ small)  (JJ nuclear)  (NN RNA)  (-LRB- -LRB-)  (NN snRNA)  (-RRB- -RRB-)  (JJ -encoding) ) (NN gene) ) (PP (IN in)  (NP (NN HeLa)  (NNS cells) ))))) (VP (VBZ requires)  (NP (NP (DT a)  (JJ distal)  (NN enhancer)  (NN element) ) (, ,)  (SBAR (WHNP-1 (WDT which) ) (S (NP-SBJ-2 (-NONE- *T*-1) ) (VP (VBZ is)  (VP (VBN composed)  (NP (-NONE- *-2) ) (PP (IN of)  (NP-COOD (NP (CD one)  (NP (NN octamer)  (NN motif) ) (PRN (-LRB- -LRB-)  (NP (NN Oct) ) (-RRB- -RRB-) )) (CC and)  (NP (CD three)  (ADJP (NN Sp)  (JJ 1-binding) ) (NNS sites) ))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB study)  (NP (NP (DT the)  (NN transcription)  (NN factor)  (NN requirement) ) (PP (IN in)  (NP (NNS B-cells) )))))) (, ,)  (NP-SBJ-3 (JJ different)  (NN U2)  (NN enhancer)  (NNS constructions) ) (VP (VBD were)  (VP (VBN transfected)  (NP (-NONE- *-3) ) (PP (IN into)  (NP (NP (DT the)  (JJ lymphoid)  (NN cell)  (NN line) ) (, ,)  (NP (NN BJA-B) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN U2)  (NN snRNA)  (NN transcription) )) (PP (IN in)  (NP (NNS B-cells) ))) (ADVP (RB also) ) (VP (VBZ requires)  (NP (NP (DT an)  (NN enhancer) ) (VP (VBG comprising)  (NP-COOD (CC both)  (NP (DT the)  (NN Oct) ) (CC and)  (NP (QP (IN at)  (JJS least)  (CD one) ) (ADJP (NN Sp)  (JJ 1-binding) ) (NN site) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Deletion) ) (PP (IN of)  (NP (PDT all)  (DT the)  (ADJP (NN Sp)  (JJ 1-binding) ) (NNS sites) )) (PP (IN from)  (NP (DT the)  (NN enhancer) ))) (VP (VBZ reduces)  (NP (NN transcription) ) (PP (IN by)  (NP (QP (CD 80-90) ) (NN %) )) (PP (PP-COOD (PP (IN in)  (NP (NN HeLa)  (NP (-NONE- *RNR*-4) ))) (, ,)  (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN in)  (NP (NN BJA-B)  (NP (-NONE- *RNR*-4) )))) (NP-4 (NNS cells) )))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (DT the)  (NN removal) ) (PP (IN of)  (NP (DT the)  (JJ octamer-binding)  (NN site) ))) (VP (VBZ reduces)  (NP (NN transcription) ) (PP (TO to)  (NP (NP (NNS levels) ) (PP (IN below)  (NP (NN detection) )))) (PP (IN in)  (NP (DT both)  (NN cell)  (NNS types) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Enhancers) ) (VP (VBG containing)  (NP (DT a)  (JJ single)  (NN Oct) ))) (VP (VBP have)  (, ,)  (ADVP (RB nevertheless) ) (, ,)  (NP (DT the)  (NN capacity)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (ADVP (RB partially) ) (VP (VB activate)  (NP (NN U2)  (NN snRNA)  (NN transcription) ))))) (PP-COOD (PP (IN in)  (NP (NP (DT both)  (NN HeLa)  (NNS cells) ) (, ,)  (SBAR (WHPP-5 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ-6 (RB only)  (NN OTF-1) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-6) ) (PP (-NONE- *T*-5) ))))))) (, ,)  (CC and)  (PP (IN in)  (NP (NP (NN BJA-B)  (NNS cells) ) (SBAR (WHPP-7 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (NN OTF-2) ) (VP (VBZ is)  (NP-PRD (DT the)  (ADJP (RB predominantly)  (VBN expressed) ) (JJ octamer-binding)  (NN factor) ) (PP (-NONE- *T*-7) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (ADJP (RBS most)  (JJ likely) ) (NN interpretation) ) (PP (IN of)  (NP (PRP$ our)  (NNS results) ))) (VP (VBZ is)  (SBAR-PRD (IN that)  (S (NP-SBJ-COOD (CC both)  (NP (NP (DT the)  (JJ ubiquitous)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN OTF-1) ) (, ,) ) (CC and)  (NP (NP (DT the)  (JJ B-cell-specific)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN OTF-2) ) (, ,) )) (VP (MD can)  (VP (VB activate)  (NP (NN U2)  (NN snRNA)  (NN transcription) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (ADVP (RB also) ) (VP (VBD revealed)  (NP (NP (DT a)  (JJ similar)  (JJ functional)  (NN cooperation) ) (PP (IN between)  (NP (NP (DT the)  (NN transcription)  (NNS factors) ) (SBAR (WHNP-8 (WDT which) ) (S (NP-SBJ (-NONE- *T*-8) ) (VP (VBP bind)  (PP (TO to)  (NP (NP-COOD (NP (DT the)  (NN Oct)  (ADJP (-NONE- *?*) ) (NP (-NONE- *RNR*-200) )) (CC and)  (NP (DT the)  (JJ adjacent)  (ADJP (NN Sp)  (JJ 1-binding) ) (NP (-NONE- *RNR*-200) ))) (NP-200 (NN site) ))) (PP (IN in)  (NP (NN BJA-B)  (NNS cells) )) (, ,)  (SBAR (IN as)  (S (NP-SBJ-9 (-NONE- *) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN observed)  (NP (-NONE- *-9) ) (PP (IN in)  (NP (NN HeLa)  (NNS cells) ))))))))))))) (, ,)  (SBAR (IN since)  (S (NP-SBJ (NP (DT a)  (NN template) ) (SBAR (WHNP-10 (WDT which) ) (S (NP-SBJ (-NONE- *T*-10) ) (VP (VBZ contains)  (NP (NP (DT a)  (JJ weak)  (VBG binding)  (NN site) ) (PP (IN for)  (NP (NNS OTFs) ))))))) (VP (VBZ expresses)  (NP (NP (JJ wild-type)  (NNS levels) ) (PP (IN of)  (NP (NN U2)  (NN snRNA) ))) (PP (IN in)  (NP (DT both)  (NN cell)  (NNS types) )) (SBAR-TMP (WHADVP-100 (WRB when) ) (S (NP-SBJ-11 (DT the)  (JJ weak)  (JJ octamer-binding)  (NN site) ) (VP (VBZ is)  (VP (VBN combined)  (NP (-NONE- *-11) ) (PP (IN with)  (NP (DT a)  (ADJP (NN Sp)  (JJ 1-binding) ) (NN site) )) (ADVP (-NONE- *T*-100) ))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Cortisol)  (NN receptor)  (NN resistance) ) (: :) ) (NP (NP (DT the)  (NN variability) ) (PP (IN of)  (NP (PRP$ its)  (NP-COOD (NP (JJ clinical)  (NN presentation) ) (CC and)  (NP (NP (NN response) ) (PP (TO to)  (NP (NN treatment) )))))) (. .) )) )
(TOP (S (NP-SBJ-33 (JJ Primary)  (-LRB- -LRB-)  (JJ partial)  (-RRB- -RRB-)  (NN cortisol)  (NN receptor)  (NN resistance) ) (VP (VBD was)  (ADVP-TMP (RB previously) ) (VP (VBN reported)  (NP (-NONE- *-33) ) (PP (IN in)  (NP (NP (DT a)  (NN total) ) (PP (IN of)  (NP-COOD (NP (CD 7)  (NNS patients) ) (CC and)  (NP (CD 14)  (JJ asymptomatic)  (NN family)  (NNS members) ))))))) (. .) ) )
(TOP (S (NP-SBJ-34 (PRP$ Its)  (NN occurrence) ) (VP (VBZ is)  (VP (VBN considered)  (S (NP-SBJ (-NONE- *-34) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (RB extremely)  (JJ rare) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ present)  (NN study) )) (NP-SBJ (PRP we) ) (VP (VBP report)  (PP (IN on)  (NP (NP (NP (CD 6)  (NNS patients) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD 2)  (NNS males) ) (CC and)  (NP (CD 4)  (NNS females) )) (-RRB- -RRB-) )) (PP (IN with)  (NP (DT the)  (NN syndrome) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ first)  (JJ male)  (NN patient) ) (VP (VBD presented)  (PP (IN with)  (NP (JJ mild)  (NN hypertension) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Hydrochlorothiazide)  (NN therapy) ) (VP (VBD resulted)  (PP (IN in)  (NP (JJ life-threatening)  (NN hypokalemia) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ second)  (JJ male)  (NN patient) ) (VP (VBD had)  (NP (NP (JJ slight)  (NN hypertension) ) (PP (IN without)  (NP (NN hypokalemia) )))) (. .) ) )
(TOP (S (NP-SBJ (DT All)  (CD four)  (JJ female)  (NNS patients) ) (VP (VBD presented)  (PP (IN between)  (NP (NP (DT the)  (NN age) ) (PP (IN of)  (NP (QP (CD 20-30) ) (NN yr) )))) (PP (IN with)  (NP-COOD (NP (NN acne) ) (, ,)  (NP (NN hirsutism) ) (, ,)  (CC and)  (NP (JJ irregular)  (NNS menstruations) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Low)  (NN dose)  (NN dexamethasone)  (NN therapy) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 1-1.5) ) (NN mg/day) ) (-RRB- -RRB-) )) (VP (VBD was)  (PP-PRD (IN of)  (NP (JJ clinical)  (NN benefit) )) (PP (IN in)  (NP (DT these)  (NNS patients) ))) (. .) ) )
(TOP (S (NP-SBJ (DT All)  (NNS patients) ) (VP (VBD showed)  (NP (NP (JJ insufficient)  (NN suppression) ) (PP (IN of)  (NP (NN serum)  (NN cortisol)  (NNS concentrations) ))) (PP (IN in)  (NP (DT the)  (JJ overnight)  (JJ 1-mg)  (NN dexamethasone)  (NN test) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ diurnal)  (NN rhythm) ) (PP (IN of)  (NP-COOD (NP (NN ACTH) ) (CC and)  (NP (NN cortisol) )))) (VP (VBD was)  (ADJP-PRD (JJ intact) ) (, ,)  (PP (IN albeit)  (FRAG (PP (IN at)  (NP (DT an)  (JJ elevated)  (NN level) ))))) (. .) ) )
(TOP (S (NP-SBJ (EX There) ) (VP (VBD was)  (NP (NP-PRD (DT a)  (JJ normal)  (NN increase) ) (PP (IN in)  (NP-COOD (NP (NN ACTH) ) (, ,)  (NP (NN cortisol) ) (, ,)  (CC and)  (NP (NN GH) )))) (-LRB- -LRB-)  (PP (IN except)  (FRAG (PP (IN in)  (NP (CD one)  (JJ obese)  (NN patient) )))) (-RRB- -RRB-)  (PP (IN in)  (NN response)  (TO to)  (NP (JJ insulin-induced)  (NN hypoglycemia) )) (, ,)  (SBAR (IN while)  (S (NP-SBJ-35 (NN cortisol)  (NN production) ) (VP (VBD was)  (VP (JJ elevated)  (NP (-NONE- *-35) ) (PP (IN in)  (NP (CD three)  (NNS patients) ))))))) (. .) ) )
(TOP (S (NP-SBJ-36 (VBG Circulating)  (JJ adrenal)  (NN androgen)  (NNS levels) ) (VP (VBD were)  (VP (VBN increased)  (NP (-NONE- *-36) ) (PP (IN in)  (NP (DT all)  (NNS patients) )))) (. .) ) )
(TOP (S (NP-SBJ-37 (NN Glucocorticoid)  (NNS receptors) ) (VP (VBD were)  (VP (VBN investigated)  (NP (-NONE- *-37) ) (PP (IN in)  (NP (DT a)  (JJ whole)  (NN cell)  (NN dexamethasone)  (NN binding)  (NN assay) )) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ first)  (JJ male)  (NN patient) )) (, ,)  (NP-SBJ (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NNS receptors) ))) (VP (VBD was)  (ADJP-PRD (RB very)  (JJ low) ) (, ,)  (SBAR (IN while)  (S (NP-SBJ (DT the)  (NN affinity) ) (VP (VBD was)  (ADJP-PRD (ADJP (JJR lower) ) (PP (IN than)  (NP (NP (DT that) ) (PP (IN in)  (NP (NNS controls) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-38 (NP (DT A)  (JJ lowered)  (NN affinity) ) (PP (TO to)  (NP (NN dexamethasone) ))) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-38) ) (PP (IN in)  (NP (CD one)  (JJ female)  (NN patient) )) (, ,)  (SBAR (IN while)  (S (NP-SBJ-39 (NP (DT a)  (JJ lowered)  (NN number) ) (PP (IN of)  (NP (NNS receptors) ))) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-39) ) (PP (IN in)  (NP (CD three)  (NNS patients) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ second)  (JJ male)  (NN patient) )) (, ,)  (NP-SBJ-40 (DT no)  (NNS abnormalities) ) (VP (VBD were)  (VP (VBN found)  (NP (-NONE- *-40) ))) (. .) ) )
(TOP (S (PP (IN As)  (NP (NP (DT a)  (NN bioassay) ) (PP (IN for)  (NP (NN glucocorticoid)  (NN action) )))) (NP-SBJ (PRP we) ) (ADVP (RB also) ) (VP (VBD measured)  (NP (NP (NN dexamethasone)  (NN suppressibility) ) (PP (IN of)  (NP (NP (JJ mitogen-stimulated)  (NN incorporation) ) (PP (IN of)  (NP (NN -LCB-3H-RCB-thymidine) )) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (DT the)  (JJ male)  (NN patient) ) (PP (IN with)  (NP (JJ normal)  (NN receptor)  (NN status) )))) (, ,)  (NP-SBJ (NP (NN dexamethasone)  (NN suppressibility) ) (PP (IN of)  (NP (NN -LCB-3H-RCB-thymidine)  (NN incorporation) ))) (VP (VBD was)  (ADJP-PRD (ADJP (RB significantly)  (JJR lower) ) (PP (IN than)  (NP (NP (DT that) ) (PP (IN in)  (NP (JJ healthy)  (NNS controls) ))))) (PP (IN with)  (NN respect)  (TO to)  (NP-COOD (CC both)  (NP (JJ maximal)  (NN suppression) ) (CC and)  (NP (NN IC50) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Partial)  (NN cortisol)  (NN receptor)  (NN resistance) ) (VP (MD might)  (VP (VB be)  (ADJP-PRD (ADJP (RBR less)  (JJ rare) ) (SBAR (IN than)  (FRAG (VP (ADVP-TMP (RB previously) ) (VBN thought) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (DT the)  (CD six)  (NNS patients) ) (VP (VBN presented)  (NP (-NONE- *) )))) (, ,)  (NP-SBJ-41 (QP (IN at)  (JJS least)  (CD three) ) (JJ different)  (NNS forms) ) (VP (MD can)  (VP (VB be)  (VP (VBN recognized)  (NP (-NONE- *-41) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Therapy) ) (PP (IN with)  (NP (NN dexamethasone) ))) (VP (VBD was)  (ADJP-PRD (JJ successful) ) (PP (IN in)  (NP (NP (JJ female)  (NNS patients) ) (PP (IN with)  (NP-COOD (NP (NN acne) ) (CC and)  (NP (NN hirsutism) ))))) (, ,)  (SBAR (IN as)  (S (NP-SBJ-42 (NP (DT the)  (JJ secondary)  (NN increase) ) (PP (IN in)  (NP (NP (DT the)  (NN production) ) (PP (IN of)  (NP (JJ adrenal)  (NNS androgens) ))))) (VP (VBD was)  (ADVP (RB effectively) ) (VP (VBN controlled)  (NP (-NONE- *-42) )))))) (. .) ) )
(TOP (S (NP-SBJ-11 (ADJP (NN Kappa)  (JJ B-specific) ) (NN DNA)  (NN binding)  (NNS proteins) ) (VP (VBP are)  (ADVP (RB differentially) ) (VP (VBN inhibited)  (NP (-NONE- *-11) ) (PP (IN by)  (NP-LGS-COOD (NP (NN enhancer)  (NNS mutations) ) (CC and)  (NP (JJ biological)  (NN oxidation) ))))) (. .) ) )
(TOP (S (NP-SBJ-12 (NP (NP (NP (NN Kappa)  (NN B) ) (PRN (-LRB- -LRB-)  (NP (NN kappa)  (NN B) ) (-RRB- -RRB-) )) (NN enhancer)  (NN binding)  (NNS proteins) ) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (DT the)  (NNS nuclei) ) (PP (IN of)  (NP (VBN activated)  (JJ human)  (NN T)  (NNS cells) )))))) (VP (VBP produce)  (NP (CD two)  (JJ distinct)  (NN nucleoprotein)  (NNS complexes) ) (SBAR-TMP (WHADVP-14 (WRB when) ) (S (NP-SBJ-13 (-NONE- *-12) ) (VP (VBN incubated)  (NP (-NONE- *-13) ) (PP (IN with)  (NP (NP (DT the)  (NN kappa)  (NN B)  (NN element) ) (PP (IN from)  (NP (DT the)  (NP (NP (NN interleukin-2)  (NN receptor-alpha) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2R)  (NN alpha) ) (-RRB- -RRB-) )) (NN gene) )))) (ADVP (-NONE- *T*-14) ))))) (. .) ) )
(TOP (S (NP-SBJ-15 (DT These)  (CD two)  (JJ DNA-protein)  (NNS complexes) ) (VP (VBP are)  (VP (VBN composed)  (NP (-NONE- *-15) ) (PP (IN of)  (NP (NP (NP (QP (IN at)  (JJS least)  (CD four) ) (NN host)  (NNS proteins) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN p50) ) (, ,)  (NP (NN p55) ) (, ,)  (NP (NN p75) ) (, ,)  (NP (NN p85) )) (-RRB- -RRB-) )) (, ,)  (SBAR (WHNP-16 (NP (DT each) ) (WHPP (IN of)  (WHNP (WDT which) ))) (S (NP-SBJ (-NONE- *T*-16) ) (VP (VBZ shares)  (NP (JJ structural)  (NN similarity) ) (PP (IN with)  (NP (DT the)  (NN v-rel)  (NN oncogene)  (NN product) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-17 (NP (JJ Nuclear)  (NN expression) ) (PP (IN of)  (NP (DT these)  (NNS proteins) ))) (VP (VBZ is)  (VP (VBN induced)  (NP (-NONE- *-17) ) (PP (IN with)  (NP (ADJP (RB distinctly)  (JJ biphasic) ) (NNS kinetics) )) (PP-TMP (VBG following)  (NP (NN phorbol)  (NN ester)  (NN activation) ) (PP (IN of)  (NP (NP-100 (NN T)  (NNS cells) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN p55/p75)  (JJ early)  (NP (-NONE- *RNR*-100) )) (CC and)  (NP (NN p50/p85)  (JJ late)  (NP (-NONE- *RNR*-100) ))) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (NP-SBJ (JJ DNA-protein)  (NN crosslinking)  (NNS studies) ) (VP (VBP have)  (VP (VBN revealed)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (ADJP (ADVP-TMP (RBR more)  (RB rapidly) ) (VBG migrating) ) (NN B2)  (NN complex) ) (VP (VBZ contains)  (NP-COOD (CC both)  (NP (NN p50) ) (CC and)  (NP (NN p55) )) (SBAR (IN while)  (S (NP-SBJ-18 (DT the)  (ADJP (ADVP-TMP (RBR more)  (RB slowly) ) (VBG migrating) ) (NN B1)  (NN complex) ) (VP (VBZ is)  (VP (VBN composed)  (NP (-NONE- *-18) ) (PP (IN of)  (NP-COOD (NP (NN p50) ) (, ,)  (NP (NN p55) ) (, ,)  (NP (NN p75) ) (, ,)  (CC and)  (NP (NN p85) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Site-directed)  (NN mutagenesis) ) (PP (IN of)  (NP (NP (DT the)  (JJ wild-type)  (NN IL-2R)  (NN alpha)  (NN kappa)  (NN B)  (NN enhancer) ) (PRN (-LRB- -LRB-)  (NP (NN GGGGAATCTCCC) ) (-RRB- -RRB-) )))) (VP (VBZ has)  (VP (VBN revealed)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN binding) ) (PP (IN of)  (NP (NP-COOD (NP (NN p50) ) (CC and)  (NP (NN p55) )) (PRN (-LRB- -LRB-)  (NP (NN B2)  (NN complex) ) (-RRB- -RRB-) )))) (VP (VBZ is)  (ADJP-PRD (RB particularly)  (JJ sensitive)  (PP (TO to)  (NP (NP (NN alteration) ) (PP (IN of)  (NP (NP (DT the)  (JJ 5')  (NN triplet) ) (PP (IN of)  (NP (NN deoxyguanosine)  (NNS residues) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (NP (NN formation) ) (PP (IN of)  (NP (DT the)  (NN B1)  (NN complex) ))) (, ,)  (VP (VBG reflecting)  (NP (NP (DT the)  (NN binding) ) (PP (IN of)  (NP-COOD (NP (NN p75) ) (CC and)  (NP (NN p85) ))))) (, ,) ) (ADVP (RB critically) ) (VP (VBZ depends)  (PP (IN upon)  (NP (NP (DT the)  (RBR more)  (JJ 3')  (NNS sequences) ) (PP (IN of)  (NP (DT this)  (NN enhancer)  (NN element) ))))) (. .) ) )
(TOP (S (NP-SBJ-19 (NP (NN DNA)  (NN binding) ) (PP (IN by)  (NP (NP (DT all)  (CD four) ) (PP (IN of)  (NP (DT these)  (JJ Rel-related)  (NNS factors) ))))) (VP (VBZ is)  (VP (VBN blocked)  (NP (-NONE- *-19) ) (PP (IN by)  (NP-LGS (NP (JJ selective)  (JJ chemical)  (NN modification) ) (PP (IN of)  (NP (NP-COOD (NP (NN lysine) ) (CC and)  (NP (NN arginine) )) (NNS residues) )))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ-21 (NP (DT both) ) (PP (IN of)  (NP (DT these)  (JJ basic)  (NN amino)  (NNS acids) ))) (VP (VBP are)  (VP (VBN required)  (NP (-NONE- *-21) ) (PP (IN for)  (S (NP-SBJ (-NONE- *) ) (VP (VBG binding)  (PP (TO to)  (NP (DT the)  (NN kappa)  (NN B)  (NN element) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Similarly) ) (, ,)  (NP-SBJ (NP (JJ covalent)  (NN modification) ) (PP (IN of)  (NP (JJ free)  (NN sulfhydryl)  (NNS groups) )) (PP (IN with)  (NP-COOD (NP (NP (NN diamide) ) (PRN (-LRB- -LRB-)  (FRAG (ADJP (JJ reversible) )) (-RRB- -RRB-) )) (CC or)  (NP (NP (NN N-ethylmaleimide) ) (PRN (-LRB- -LRB-)  (FRAG (ADJP (JJ irreversible) )) (-RRB- -RRB-) ))))) (VP (VBZ results)  (PP (IN in)  (NP (NP (DT a)  (JJ complete)  (NN loss) ) (PP (IN of)  (NP (NN DNA)  (NN binding)  (NN activity) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-23 (NP (JJ mild)  (NN oxidation) ) (PP (IN with)  (NP (NN glucose)  (NN oxidase) ))) (ADVP (RB selectively) ) (VP (VBZ inhibits)  (NP (NP-COOD (NP (NN p75) ) (CC and)  (NP (NN p85) )) (NN binding) ) (SBAR (IN while)  (S (NP-SBJ (-NONE- *-23) ) (VP (RB not)  (VBG blocking)  (NP (NP-COOD (NP (NN p50) ) (CC and)  (NP (NN p55) )) (NNS interactions) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (VBN reduced)  (NN cysteine)  (NNS thiols) ) (VP (VBP play)  (NP (DT an)  (JJ important)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN DNA)  (NN binding)  (NN activity) ) (PP (IN of)  (NP (NP (DT this)  (NN family) ) (PP (IN of)  (NP (JJ Rel-related)  (NN transcription)  (NNS factors) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ novel)  (JJ mitogen-inducible)  (NN gene)  (NN product) ) (ADJP (JJ related)  (PP (TO to)  (NP (NN p50/p105-NF-kappa)  (NN B) )))) (VP (VBZ participates)  (PP (IN in)  (NP (NN transactivation) )) (PP (IN through)  (NP (DT a)  (NN kappa)  (NN B)  (NN site) ))) (. .) ) )
(TOP (S (NP-SBJ-63 (DT A)  (ADJP-COOD (ADJP (JJ Rel-related) ) (, ,)  (ADJP (JJ mitogen-inducible) ) (, ,)  (ADJP (NN kappa)  (JJ B-binding) )) (NN protein) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN cloned)  (NP (-NONE- *-63) ) (PP (IN as)  (NP (NP (DT an)  (JJ immediate-early)  (NN activation)  (NN gene) ) (PP (IN of)  (NP (JJ human)  (JJ peripheral)  (NN blood)  (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN cDNA) ) (VP (VBZ has)  (NP (NP (DT an)  (JJ open)  (NN reading)  (NN frame) ) (PP (IN of)  (NP (CD 900)  (NN amino)  (NNS acids) )) (ADJP (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *) ) (VP (VBG encoding)  (NP (DT a)  (JJ 97-kDa)  (NN protein) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN protein) ) (VP (VBZ is)  (ADJP-PRD (RBS most)  (JJ similar)  (PP (TO to)  (NP (NP (DT the)  (JJ 105-kDa)  (NN precursor)  (NN polypeptide) ) (PP (IN of)  (NP (NN p50-NF-kappa)  (NN B) )))))) (. .) ) )
(TOP (S (PP (IN Like)  (NP (DT the)  (JJ 105-kDa)  (NN precursor) )) (, ,)  (NP-SBJ (PRP it) ) (VP (VBZ contains)  (NP-COOD (NP (NP (DT an)  (JJ amino-terminal)  (JJ Rel-related)  (NN domain) ) (PP (IN of)  (NP (QP (IN about)  (CD 300) ) (NN amino)  (NNS acids) ))) (CC and)  (NP (NP (DT a)  (JJ carboxy-terminal)  (NN domain) ) (VP (VBG containing)  (NP (CD six)  (NP-COOD (NP (JJ full)  (NN cell)  (NN cycle) ) (CC or)  (NP (NN ankyrin) )) (NNS repeats) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (FW In)  (JJ vitro-translated) ) (NNS proteins) ) (, ,)  (VP-COOD (VP (VBN truncated)  (NP (-NONE- *) ) (ADVP (RB downstream)  (PP (IN of)  (NP (DT the)  (NN Rel)  (NN domain) )))) (CC and)  (VP (VBG excluding)  (NP (DT the)  (NNS repeats) ))) (, ,) ) (VP (VBP bind)  (NP (NN kappa)  (NN B)  (NNS sites) )) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP refer)  (PP-COOD (PP (TO to)  (NP (NP (DT the)  (ADJP (NN kappa)  (JJ B-binding) )) (, ,)  (NP (NP (VBN truncated)  (NN protein) ) (PP (IN as)  (NP (NN p50B) )) (PP (IN by)  (NP (NP (NN analogy) ) (PP (IN with)  (NP (NN p50-NF-kappa)  (NN B) ))))))) (CC and)  (PP (TO to)  (NP (NP (DT the)  (JJ full-length)  (NN protein) ) (PP (IN as)  (NP (NN p97) )))))) (. .) ) )
(TOP (S (NP-SBJ-64 (NN p50B) ) (VP (VBZ is)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-64) ) (VP (TO to)  (VP (VB form)  (NP (JJ heteromeric)  (ADJP (NN kappa)  (JJ B-binding) ) (NNS complexes) ) (PP-COOD (PP (IN with)  (NP (NN RelB) )) (, ,)  (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN with)  (NP (NP-COOD (NP (NN p65) ) (CC and)  (NP (NN p50) )) (, ,)  (NP (NP (DT the)  (CD two)  (NNS subunits) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Transient-transfection)  (NNS experiments) ) (PP (IN in)  (NP (JJ embryonal)  (NN carcinoma)  (NNS cells) ))) (VP (VBP demonstrate)  (NP (NP (DT a)  (JJ functional)  (NN cooperation) ) (PP (IN between)  (NP-COOD (NP (NN p50B) ) (CC and)  (NP-COOD (NP (NN RelB) ) (CC or)  (NP (NN p65) )))) (PP (IN in)  (NP (NP (NP (NN transactivation) ) (PP (IN of)  (NP (DT a)  (NN reporter)  (NN plasmid) ))) (ADJP (JJ dependent)  (PP (IN on)  (NP (DT a)  (NN kappa)  (NN B)  (NN site) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS data) ) (VP (VBP imply)  (NP (NP (DT the)  (NN existence) ) (PP (IN of)  (NP (NP (DT a)  (JJ complex)  (NN family) ) (PP (IN of)  (NP (ADJP (NN NF-kappa)  (JJ B-like) ) (NN transcription)  (NNS factors) )))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP-COOD (NP (NP (NNS Changes) ) (PP (IN in)  (NP (NP (JJ leucocytic)  (NN estrogen)  (NN receptor)  (NNS levels) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ climacteric)  (NN syndrome) ))))))) (CC and)  (NP (NP (JJ therapeutic)  (NN effect) ) (PP (IN of)  (NP (FW liuwei)  (FW dihuang)  (NNS pills) )))) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-24 (NP (DT The)  (NNS numbers) ) (PP (IN of)  (NP (NP (NP (NN estrogen)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN ER) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (NP (JJ human)  (JJ peripheral)  (NNS leucocytes) ) (PP (IN in)  (NP (NP (CD 22)  (NNS women) ) (PP (IN with)  (NP (JJ climacteric)  (NN syndrome) ))))))))) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-24) ) (PP (IN by)  (NP (NN radioligand)  (NN method) )))) (. .) ) )
(TOP (S (NP-SBJ-25 (DT The)  (NNS results) ) (VP (VBD were)  (VP (VBN compared)  (NP (-NONE- *-25) ) (PP (IN with)  (NP (NP (DT those) ) (PP (IN of)  (NP (CD 12)  (JJ normal)  (JJ child-bearing-age)  (NNS women) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBD wat)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NNS contents) ) (PP (IN of)  (NP (NP (JJ leucocytic)  (NN ER) ) (PP (IN in)  (NP (JJ climacteric)  (NN syndrome)  (NNS patients) ))))) (VP (VBD were)  (ADJP-PRD (ADJP (RB significantly)  (JJR lower) ) (PP (IN than)  (NP (JJ normal)  (JJ child-bearing-age)  (NNS women) )))))))) (. .) ) )
(TOP (S (NP-SBJ-26 (DT The)  (NNS authors) ) (VP (VBD used)  (NP (NP (DT a)  (JJ Chinese)  (NN prescription) ) (: --)  (NP (NP (FW Liuwei)  (FW Dihuang)  (NNS Pills) ) (PRN (-LRB- -LRB-)  (NP (NN LDP) ) (-RRB- -RRB-) ))) (S (NP-SBJ (-NONE- *-26) ) (VP (TO to)  (VP (VB treat)  (NP (DT the)  (NNS patients) ) (PP-TMP (IN for)  (NP (CD 2)  (NNS months) )))))) (. .) ) )
(TOP (S (NP-SBJ-27 (NP (DT The)  (NNS numbers) ) (PP (IN of)  (NP (JJ leucocytic)  (NN ER) ))) (VP (VBD were)  (ADVP (RB significantly) ) (VP (VBN increased)  (NP (-NONE- *-27) ) (PP-TMP (IN after)  (NP (NN treatment) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS data) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (NN decrease) ) (PP (IN of)  (NP (NP (NN ER)  (NNS levels) ) (PP (IN in)  (NP (NN cell) ))))) (VP (MD may)  (VP (VB involve)  (PP (IN in)  (NP (NP (DT the)  (NN pathogenesis) ) (PP (IN of)  (NP (JJ climacteric)  (NN syndrome) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN LDP) ) (VP-COOD (CONJP (RB not)  (RB only) ) (VP (VBZ increases)  (NP (NN plasma)  (NN estradiol)  (NNS levels) )) (, ,)  (CONJP (CC but)  (RB also) ) (VP (VBZ increases)  (NP (DT the)  (JJ leucocytic)  (NN ER)  (NNS levels) ))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (MD may)  (VP (VB be)  (NP-PRD (NP (DT the)  (NN basis) ) (PP (IN of)  (NP (NP (DT the)  (JJ therapeutic)  (NN effect) ) (PP (IN on)  (NP (DT the)  (NN disease) ))))))) (. .) ) )
(TOP (NP (NP (DT A)  (JJ novel)  (NN primer)  (NN extension)  (NN method) ) (SBAR (WHNP-64 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-64) ) (VP (TO to)  (VP (VB detect)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NN CAG)  (NNS repeats) ) (PP (IN in)  (NP (NP (DT the)  (NN androgen)  (NN receptor)  (NN gene) ) (PP (IN in)  (NP (NP (NNS families) ) (PP (IN with)  (NP (JJ X-linked)  (ADJP-COOD (ADJP (JJ spinal) ) (CC and)  (ADJP (JJ bulbar) )) (JJ muscular)  (NN atrophy) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-65 (NP (NP (JJ X-linked)  (ADJP-COOD (ADJP (JJ spinal) ) (CC and)  (ADJP (JJ bulbar) )) (JJ muscular)  (NN atrophy) ) (PRN (-LRB- -LRB-)  (NP (NN SBMA) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (DT an)  (JJ adult-onset)  (NN form) ) (PP (IN of)  (NP (NN motor)  (NN neuron)  (NN disease) ))) (, ,) ) (VP (VBD was)  (ADVP-TMP (RB recently) ) (VP (VBN reported)  (S (NP-SBJ-66 (-NONE- *-65) ) (VP (TO to)  (VP (VB be)  (VP (VBN caused)  (NP (-NONE- *-66) ) (PP (IN by)  (NP-LGS (NP (NN amplification) ) (PP (IN of)  (NP (NP (DT the)  (NN CAG)  (NNS repeats) ) (PP (IN in)  (NP (DT the)  (NN androgen)  (NN receptor)  (NN gene) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-67 (PRP We) ) (VP (VBP report)  (ADVP (RB here) ) (NP (NP (DT a)  (ADJP-COOD (ADJP (JJ simple) ) (CC and)  (ADJP (JJ rapid) )) (NN strategy) ) (SBAR (WHADVP-107 (-NONE- 0) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB detect)  (NP (NP (DT the)  (JJ precise)  (NN number) ) (PP (IN of)  (NP (DT the)  (NNS CAGs) ))) (ADVP (-NONE- *T*-107) ))))))) (. .) ) )
(TOP (S (S (SBAR-TMP (IN After)  (S (NP-SBJ-68 (NP (DT the)  (NN DNA)  (NN fragment) ) (VP (VBG containing)  (NP (DT the)  (NN CAG)  (NNS repeats) ))) (VP (VBZ is)  (VP (VBN amplified)  (NP (-NONE- *-68) ) (PP (IN by)  (NP-LGS (DT the)  (NN polymerase)  (NN chain)  (NN reaction) )))))) (, ,)  (NP-SBJ-69 (DT a)  (NN primer)  (NN extension) ) (VP (VBZ is)  (VP (VBN carried)  (PRT (RP out) ) (NP (-NONE- *-69) ))) (: ;) ) (S (NP-SBJ (NP (DT the)  (NN extension) ) (PP (IN of)  (NP (NP (DT the)  (JJ end-labelled)  (JJ reverse)  (NN primer) ) (ADJP (JJ adjacent)  (PP (TO to)  (NP (NP (JJ 3')  (NN end) ) (PP (IN of)  (NP (NN CAG)  (NNS repeats) )))))))) (VP (VBZ stops)  (PP (IN at)  (NP (NP (DT the)  (JJ first)  (NN T) ) (PP-TMP (IN after)  (NP (NN CAG)  (NNS repeats) )))) (PP (IN with)  (NP (NP (DT the)  (NN incorporation) ) (PP (IN of)  (NP (JJ dideoxy)  (NN ATP) )) (PP (IN in)  (NP (DT the)  (NN reaction)  (NN mixture) ))))) (. .) )) )
(TOP (S (NP-SBJ-70 (DT The)  (JJ resultant)  (NN primer)  (NNS products) ) (VP (VBP are)  (VP (VBN analysed)  (NP (-NONE- *-70) ) (PP (IN by)  (S (NP-SBJ (-NONE- *) ) (VP (VBG denaturing)  (NP-COOD (NP (NN polyacrylamide)  (NN gel)  (NN electrophoresis) ) (CC and)  (NP (NN autoradiography) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN method) ) (VP (MD could)  (VP (VB be)  (ADJP-PRD (RB quite)  (JJ useful)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB detect)  (NP-COOD (CONJP (RB not)  (RB only) ) (NP (NP (NN CAG)  (NNS repeats) ) (PP (IN in)  (NP (NN SBMA) ))) (CONJP (CC but)  (RB also) ) (NP (JJ other)  (JJ polymorphic)  (NP-COOD (NP (JJ dinucleotide) ) (CC and)  (NP (JJ trinucleotide) )) (NNS repeats) )))))))) (. .) ) )
(TOP (S (NP-SBJ-7 (NP (NN Activity) ) (PP (IN of)  (NP (NP (DT the)  (NN kappa)  (NN B)  (NN enhancer) ) (PP (IN of)  (NP (DT the)  (NN interleukin-2)  (NN receptor)  (NN alpha)  (NN chain) )))) (PP (IN in)  (NP (JJ somatic)  (NN cell)  (NNS hybrids) ))) (VP (VBZ is)  (VP (VBN accompanied)  (NP (-NONE- *-7) ) (PP (IN by)  (NP-LGS (NP (DT the)  (JJ nuclear)  (NN localization) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))))) (. .) ) )
(TOP (S (NP-SBJ-COOD-8 (NP (NP (DT The)  (CD two)  (JJ nuclear)  (NNS proteins)  (NN NF-kappa)  (NN B) ) (-LRB- -LRB-)  (VP (VBG consisting)  (PP (IN of)  (NP (NNS subunits)  (NP-COOD (NP (NN p50) ) (CC and)  (NP (NN p65) ))))) (-RRB- -RRB-) ) (CC and)  (NP (NP (NP (DT the)  (JJ DNA-binding)  (NN subunit) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B) ) (PRN (-LRB- -LRB-)  (NP (NN p50) ) (-RRB- -RRB-) ))) (PP (IN by)  (NP (PRP itself) ))) (, ,)  (VP (ADVP (RB also) ) (VBN called)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN KBF1) )))) (, ,) ) (VP (VBP are)  (ADVP (RB constitutively) ) (VP (VP-COOD (VP (VBN expressed)  (NP-9 (-NONE- *-8) )) (CC and)  (VP (JJ localized)  (NP (-NONE- *-9) ))) (PP (IN in)  (NP (DT the)  (NN nucleus) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN T-cell)  (NN line)  (NN IARC)  (CD 301.5) ))))) (. .) ) )
(TOP (S (SBAR-ADV (IN In)  (NN order)  (TO to)  (S (NP-SBJ (-NONE- *-10) ) (VP (VB define)  (NP (NP (DT the)  (NNS roles) ) (PP (IN of)  (NP (NP (DT these)  (CD two)  (NNS factors) ) (, ,)  (SBAR (WHNP-11 (WDT which) ) (S (NP-SBJ (-NONE- *T*-11) ) (VP (VBP bind)  (PP (TO to)  (NP (DT the)  (JJ same)  (NN kappa)  (NN B)  (NNS enhancers) ))))))))))) (, ,)  (PP (IN in)  (NP (NN transcription)  (NN activation) )) (NP-SBJ-10 (PRP we) ) (VP (VBP have)  (VP (VBN prepared)  (NP (NP (JJ somatic)  (NN cell)  (NNS hybrids) ) (PP (IN between)  (NP-COOD (NP (NN IARC)  (CD 301.5) ) (CC and)  (NP (DT a)  (JJ murine)  (NN myeloma) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (JJS Most)  (NNS hybrids) ) (VP (VBP express)  (NP-COOD (CC both)  (NP (NN KBF1) ) (CC and)  (NP (NN NF-kappa)  (NN B) )) (PP (IN in)  (NP (PRP$ their)  (NNS nuclei) )))) (, ,)  (CC but)  (S (NP-SBJ (CD one)  (NN hybrid) ) (VP (VBZ expresses)  (NP (RB only)  (NN KBF1) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN kappa)  (NN B)  (NN enhancer) ) (PP (IN of)  (NP (NP (DT the)  (NN gene) ) (VP (VBG encoding)  (NP (NP (DT the)  (NP (NP (NN interleukin-2) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2) ) (-RRB- -RRB-) )) (NN receptor)  (NN alpha)  (NN chain) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2R)  (NN alpha) ) (-RRB- -RRB-) )))))) (VP (VBZ is)  (ADJP-PRD (JJ functional) ) (PP (RB only)  (IN in)  (NP (NP (DT the)  (NNS hybrids) ) (VP (VBG expressing)  (NP (JJ nuclear)  (NN NF-kappa)  (NN B) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-12 (JJ nuclear)  (NN NF-kappa)  (NN B) ) (VP (VBZ is)  (ADJP-PRD (JJ necessary)  (S (NP-SBJ (-NONE- *-12) ) (VP (TO to)  (VP (VB activate)  (NP (DT the)  (NN kappa)  (NN B)  (NN enhancer) ))))) (, ,)  (SBAR (IN while)  (S (NP-SBJ (NP (NN KBF1) ) (PP (IN by)  (NP (PRP itself) ))) (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ sufficient) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP-COOD (VP (VBP propose)  (SBAR (IN that)  (S (NP-SBJ (NN KBF1) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ competitive)  (NN inhibitor) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))))) (CC and)  (VP (VB discuss)  (SBAR (WHADVP-13 (WRB how) ) (S (NP-SBJ-14 (DT these)  (NNS factors) ) (VP (MD may)  (VP (VB be)  (VP (VBN involved)  (NP (-NONE- *-14) ) (PP (IN in)  (NP (NP (DT the)  (JJ transient)  (NN expression) ) (PP (IN of)  (NP (NP-COOD (NP (NN IL-2) ) (CC and)  (NP (NN IL-2)  (NN alpha) )) (NNS genes) )) (PP-TMP (IN during)  (NP (DT the)  (JJ immune)  (NN response) )))) (ADVP (-NONE- *T*-13) )))))))) (. .) ) )
(TOP (NP (NP (NN Influence) ) (PP (IN of)  (NP-COOD (NP (NN estradiol) ) (CC and)  (NP (NN tamoxifen) ))) (PP (IN on)  (NP (NP (NN susceptibility) ) (PP (IN of)  (NP (JJ human)  (NN breast)  (NN cancer)  (NN cell)  (NNS lines) )) (PP (TO to)  (NP (NP (NN lysis) ) (PP (IN by)  (NP (JJ lymphokine-activated)  (NN killer)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ-58 (NP (DT The)  (NN design) ) (PP (IN of)  (NP (NP (NN combination)  (ADJP-COOD (ADJP (JJ hormonal) ) (CC and)  (ADJP (JJ immunotherapeutic) )) (NNS protocols) ) (PP (IN for)  (NP (NN breast)  (NN cancer)  (NNS patients) ))))) (VP (MD may)  (VP (VB be)  (VP (VBN facilitated)  (NP (-NONE- *-58) ) (PP (IN by)  (NP-LGS (NP (NN analysis) ) (PP (IN of)  (NP (JJ preclinical)  (ADJP (FW in)  (FW vitro) ) (JJ model)  (NNS systems) ))))))) (. .) ) )
(TOP (S (NP-SBJ-200 (NN Estrogen)  (NN receptor)  (ADJP-COOD (ADJP (ADJP (JJ positive) ) (PRN (-LRB- -LRB-)  (FRAG (ADJP (JJ ER+) ) (: :)  (NP (NN MCF-7) )) (-RRB- -RRB-) )) (CC and)  (ADJP (ADJP (JJ negative) ) (PRN (-LRB- -LRB-)  (FRAG (ADJP (JJ ER-) ) (: :)  (NP (NN MDA-MB-231) )) (-RRB- -RRB-) ))) (JJ human)  (NN breast)  (NN cancer)  (NN cell)  (NNS lines) ) (VP (VBD were)  (VP (VBN utilized)  (NP (-NONE- *-200) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB evaluate)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP-COOD (NP (NP (NN tamoxifen) ) (PRN (-LRB- -LRB-)  (NP (NN TAM) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN estradiol) ) (PRN (-LRB- -LRB-)  (NP (NN E2) ) (-RRB- -RRB-) )))) (PP (IN on)  (NP (NP (NN modulation) ) (PP (IN of)  (NP (NP (NN breast)  (NN cancer)  (NN target)  (NN susceptibility) ) (PP (TO to)  (NP (NP (NN lysis) ) (PP (IN by)  (NP (NP (NP (JJ lymphokine-activated)  (NN killer) ) (PRN (-LRB- -LRB-)  (NP (NN LAK) ) (-RRB- -RRB-) )) (NNS cells) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ E2-stimulated)  (JJ ER+)  (NNS cells) ) (VP (VBD were)  (ADJP-PRD (ADJP (RBR more)  (JJ susceptible)  (PP (TO to)  (NP (NP (NN lysis) ) (PP (IN by)  (NP (NN LAK)  (NNS cells) ))))) (PP (IN than)  (NP (VBG corresponding)  (UCP-COOD (ADJP (JJ TAM-treated) ) (CC or)  (NP (NN control) )) (NNS cells) ))) (, ,)  (SBAR (IN while)  (S (NP-SBJ (NP (NN treatment) ) (PP (IN of)  (NP (JJ ER-)  (NNS cells) )) (PP (IN with)  (NP (NP-COOD (CC either)  (NP (NN E2) ) (CC or)  (NP (NN TAM) )) (ADVP (RB alone) )))) (VP (VBD did)  (RB not)  (VP (VB alter)  (PP (IN from)  (NP (NN control) )) (NP (NP (PRP$ their)  (NN susceptibility) ) (PP (TO to)  (NP (DT this)  (JJ immune-mediated)  (NN lysis) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT All)  (ADJP-COOD (ADJP (JJ ER+) ) (CC and)  (ADJP (JJ ER-) )) (NNS cells) ) (VP (VBN tested)  (NP (-NONE- *) ))) (VP (VBD remained)  (ADJP-PRD (JJ sensitive)  (PP (-NONE- *ICH*-201) )) (PP-TMP (IN after)  (NP (NP (NN treatment) ) (PP (IN with)  (NP (NN TAM) )))) (PP-201 (TO to)  (NP (NP (NN lysis) ) (PP (IN by)  (NP (NN LAK)  (NNS cells) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ-59 (NP (DT an)  (ADJP (NP (NN adenocarcinoma) ) (JJ reactive) ) (ADJP (JJ human-mouse)  (JJ chimeric) ) (JJ monoclonal)  (NN antibody) ) (PRN (-LRB- -LRB-)  (NP (NN ING-1) ) (-RRB- -RRB-) )) (VP (VBD was)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-59) ) (VP (TO to)  (ADVP (RB significantly) ) (VP (VB boost)  (NP (NP (ADJP (ADVP (FW in)  (FW vivo) ) (VBN generated) ) (ADJP (NN LAK)  (JJ cell-mediated) ) (NN lysis) ) (PP (IN of)  (NP (UCP-COOD (NP (NN control) ) (, ,)  (ADJP (JJ E2-treated) ) (, ,)  (CC and)  (ADJP (JJ TAM-treated) )) (ADJP-COOD (ADJP (JJ ER+) ) (CC and)  (ADJP (JJ ER-) )) (NNS cells) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (ADJP (FW in)  (FW vitro) ) (NNS results) ) (VP (VBP provide)  (NP (NP (DT a)  (JJ preclinical)  (NN rationale) ) (PP (IN for)  (NP (NP (ADJP (FW in)  (FW vivo) ) (NN testing) ) (PP (IN of)  (NP (NP-COOD (NP (NN TAM) ) (, ,)  (NP (NP (NN interleukin-2) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2) ) (-RRB- -RRB-) )) (, ,)  (CC and)  (NP (NN breast)  (NN cancer)  (JJ reactive)  (JJ antibody-dependent)  (JJ cellular)  (NN cytotoxicity) )) (VP (VBG facilitating)  (NP (NN antibody) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (UCP-COOD (ADJP (JJ refractory) ) (CC or)  (NP (JJ high)  (NN risk) )) (NN breast)  (NN cancer) ))))))))))) (. .) ) )
(TOP (NP (NP (NP-COOD (NP (NN Glucocorticoid)  (NN receptor) ) (CC and)  (NP (NP (NN inhibition) ) (PP (IN of)  (NP (NN 3-O-methyl-D-glucose)  (NN uptake) )) (PP (IN by)  (NP (NNS glucocorticoids) )))) (PP (IN in)  (NP (NP (JJ peripheral)  (NN blood)  (NNS leukocytes) ) (PP (IN from)  (NP (JJ normal)  (NNS humans) )))) (: :) ) (NP (NP (NN correlation) ) (PP (IN between)  (NP (NP-COOD (NP (NN receptor)  (NN level) ) (CC and)  (NP (NN hormone)  (NN effect) )) (ADVP (FW in)  (FW vitro) ))) (. .) )) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN measured)  (NP (NP (DT the)  (NN glucocorticoid)  (NN receptor)  (NN concentration) ) (PP (IN in)  (NP (NP (ADJP-COOD (ADJP (JJ mononuclear) ) (CC and)  (ADJP (JJ polymorphonuclear) )) (NNS leukocytes) ) (, ,)  (SBAR (WHNP-51 (NP (DT both) ) (WHPP (IN of)  (WHNP (WDT which) ))) (S (NP-SBJ-52 (-NONE- *T*-51) ) (VP (VBD were)  (VP (VBN isolated)  (NP (-NONE- *-52) ) (PP (IN from)  (NP (NP (JJ peripheral)  (NN blood) ) (PP (IN from)  (NP (CD ten)  (JJ healthy)  (JJ male)  (NNS volunteers) ))))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN parallel) )) (, ,)  (NP-SBJ-53 (NP (DT the)  (JJ inhibitory)  (NN effect) ) (PP (IN of)  (NP (NN dexamethasone) )) (PP (IN on)  (NP (NN 3-O-methyl-D-glucose)  (NN uptake) ))) (VP (VBD was)  (VP (VBN assayed)  (NP (-NONE- *-53) ) (PP (IN in)  (NP (DT the)  (JJ corresponding)  (JJ mononuclear)  (NNS leukocytes) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (DT The)  (NN glucocorticoid)  (NN receptor)  (NNS levels) ) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) ))) (VP (VBD correlated)  (PP (IN with)  (NP (NP (DT those) ) (PP (IN in)  (NP (JJ polymorphonuclear)  (NNS leukocytes) )))))) (, ,)  (CC and)  (S (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (DT a)  (JJ linear)  (NN relationship) ) (PP (IN between)  (NP (NP (NP-COOD (NP (DT the)  (JJ cellular)  (NN glucocorticoid)  (NN receptor)  (NNS levels) ) (CC and)  (NP (NP (JJ glucocorticoid-mediated)  (NN inhibition) ) (PP (IN of)  (NP (NP (DT the)  (NN uptake) ) (PP (IN of)  (NP (NN 3-O-methyl-D-glucose) ))))))) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) )))))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-54 (WRB When) ) (S (NP-SBJ-55 (JJ mononuclear)  (NNS leukocytes) ) (VP (VBD were)  (VP (VBN incubated)  (NP (-NONE- *-55) ) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN 8-bromo-cAMP) )) (ADVP (-NONE- *T*-54) ))))) (, ,)  (S-COOD (S (NP-SBJ (JJ cellular)  (NN glucocorticoid)  (NN receptor)  (NNS levels) ) (VP (VBD increased) )) (CC and)  (S (NP-SBJ-56 (NP (DT a)  (ADJP (RBR more)  (JJ pronounced) ) (JJ inhibitory)  (NN effect) ) (PP (IN of)  (NP (NN dexamethasone) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-56) ) (PP (IN on)  (NP (NP (DT the)  (NN transport) ) (PP (IN of)  (NP (NN 3-O-methyl-D-glucose) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP conclude)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ cellular)  (NN glucocorticoid)  (NN receptor)  (NNS levels) ) (PP (IN in)  (NP (JJ peripheral)  (NN blood)  (NNS leukocytes) ))) (VP (VBP reflect)  (NP (NP (ADJP (FW in)  (FW vitro) ) (NN responsiveness) ) (PP (TO to)  (NP (NP (NNS glucocorticoids) ) (PP (IN in)  (NP (NP (JJ mononuclear)  (NNS leukocytes) ) (PP (IN from)  (NP (JJ healthy)  (NNS males) )))))))))) (, ,)  (CC and)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (JJ individual)  (NN responsiveness) ) (VP (MD may)  (VP (VB alter)  (PP-TMP (IN upon)  (NP (NP (NNS changes) ) (PP (IN in)  (NP (NP (DT the)  (JJ cellular)  (NNS levels) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN receptor) )))))))))))) (. .) ) )
(TOP (NP (NP (NN Stimulation) ) (PP (IN of)  (NP (NP (NN interferon)  (NN beta)  (NN gene)  (NN transcription) ) (ADVP (FW in)  (FW vitro) ))) (PP (IN by)  (NP-COOD (NP (VBN purified)  (NN NF-kappa)  (NN B) ) (CC and)  (NP (DT a)  (JJ novel)  (NN TH)  (NN protein) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ human)  (NP (NP (NN interferon)  (NN beta) ) (PRN (-LRB- -LRB-)  (NP (NN IFN-beta) ) (-RRB- -RRB-) )) (JJ regulatory)  (NN element) ) (VP (VBZ consists)  (PP (IN of)  (NP (NP (JJ multiple)  (NN enhanson)  (NNS domains) ) (SBAR (WHNP-35 (WDT which) ) (S (NP-SBJ (-NONE- *T*-35) ) (VP (VBP are)  (NP-PRD (NP (NNS targets) ) (PP (IN for)  (NP (NP (NN transcription)  (NNS factors) ) (VP (VBN involved)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (JJ inducible)  (NN expression) ) (PP (IN of)  (NP (DT the)  (NN promoter) )))))))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (TO To)  (ADVP (RB further) ) (VP (VB characterize)  (NP (NP (DT the)  (JJ protein-DNA)  (NNS interactions) ) (VP (VBG mediating)  (NP (NN IFN-beta)  (NN induction) )))))) (, ,)  (NP-SBJ-36 (NP (NP (JJ positive)  (JJ regulatory)  (NN domain) ) (PRN (-LRB- -LRB-)  (NP (NN PRD) ) (-RRB- -RRB-) )) (CD II)  (NN binding)  (NNS proteins) ) (VP (VBD were)  (VP (VBN purified)  (NP (-NONE- *-36) ) (PP-COOD (PP (IN from)  (NP (ADJP (NP (NN phorbol)  (NN ester) ) (JJ induced) ) (NN Jurkat)  (NNS T-cells) )) (CC and)  (PP (IN from)  (ADJP-COOD (ADJP (NP (NN IFN) ) (VBN primed) ) (, ,)  (ADJP (NP (JJ cycloheximide/polyinosinic-polycytidylic)  (NN acid) ) (VBN treated) )) (NN HeLa)  (NN S3)  (NNS cells) )))) (. .) ) )
(TOP (S-COOD (S (PP (IN From)  (NP (NN HeLa)  (NNS cells) )) (, ,)  (NP-SBJ (NP (CD two)  (JJ major)  (NNS proteins) ) (PP (IN of)  (NP (QP (NP (CD 52) ) (CC and)  (NP (CD 45) )) (NP (NP (NNS kilodaltons) ) (PRN (-LRB- -LRB-)  (NP (NN kD) ) (-RRB- -RRB-) ))))) (VP (VBD copurified)  (PP (IN with)  (NP (NN DNA)  (NN binding)  (NN activity) )))) (, ,)  (IN whereas)  (S (PP (IN from)  (NP (NNS T-cells) )) (, ,)  (NP-SBJ-37 (NP (CD four)  (NNS proteins) ) (: --)  (NP-COOD (NP (NP (DT a)  (JJ major)  (NN protein) ) (PP (IN of)  (NP (CD 52)  (NN kD) ))) (CC and)  (NP (NP (CD three)  (JJ minor)  (NNS proteins) ) (PP (IN of)  (NP (QP (CD 82)  (, ,)  (CD 67)  (, ,)  (CC and)  (CD 43-47) ) (NN kD) )))) (: --) ) (VP (VBD were)  (VP (VBN purified)  (NP (-NONE- *-37) )))) (. .) ) )
(TOP (S (ADVP (RB Also) ) (, ,)  (NP-SBJ-38 (DT an)  (ADJP (NP (NN induction) ) (JJ specific) ) (NN DNA)  (NN binding)  (NN protein) ) (VP (VBD was)  (VP (VBN purified)  (NP (-NONE- *-38) ) (PP (IN from)  (NP (NP (NN HeLa)  (NNS cells) ) (SBAR (WHNP-39 (WDT that) ) (S (NP-SBJ (-NONE- *T*-39) ) (VP (VBD interacted)  (PP (IN with)  (NP-COOD (NP (DT the)  (-LRB- -LRB-)  (NN AAGTGA)  (-RRB- -RRB-)  (CD 4)  (NN tetrahexamer)  (NN sequence) ) (CC and)  (NP (DT the)  (NN PRDI)  (NN domain) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN protein) ) (VP (VBZ is)  (ADJP-PRD (RB immunologically)  (JJ distinct)  (PP (IN from)  (NP (NN IRF-1/ISGF2) )))) (. .) ) )
(TOP (S (NP-SBJ-40 (ADJP-COOD (ADJP (JJ Uninduced) ) (CC or)  (ADJP (NP (NN Sendai)  (NN virus) ) (JJ induced) )) (NN HeLa)  (NNS extracts) ) (VP (VBD were)  (VP (VBN used)  (NP (-NONE- *-40) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB examine)  (NP (NN transcription) ) (ADVP (FW in)  (FW vitro) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (NP (DT a)  (NN series) ) (PP (IN of)  (NP (NN IFN)  (NN beta)  (NN promoter)  (NNS deletions) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP (NNS Deletions) ) (ADJP (JJ upstream)  (PP (IN of)  (NP (DT the)  (NN PRDII)  (NN element) )))) (VP (VBD increased)  (NP (NN transcription) ) (PP (IN in)  (NP (DT the)  (JJ uninduced)  (NN extract) )) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (NP (NP (ADJP (RB predominantly)  (JJ negative) ) (NN regulation) ) (PP (IN of)  (NP (DT the)  (NN promoter) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-42 (NP (DT A)  (JJ 2-4-fold)  (NN increase) ) (PP (IN in)  (NP (NN IFN-beta)  (NN promoter)  (NN transcription) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-42) ) (PP (IN in)  (NP (ADJP (NP (NN Sendai)  (NN virus) ) (JJ induced) ) (NNS extracts) ))))) (, ,)  (CC and)  (S (NP-SBJ (NP (NN deletion) ) (PP (IN of)  (NP (NP-COOD (NP (NN PRDI) ) (CC and)  (NP (NN PRDII) )) (NNS elements) ))) (VP (VBD decreased)  (NP (NP (DT this)  (VBN induced)  (NN level) ) (PP (IN of)  (NP (NN transcription) ))))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-43 (WRB When) ) (S (NP-SBJ-COOD-44 (NP (VBN purified)  (NN PRDII) ) (CC and)  (NP (NN tetrahexamer)  (NN binding)  (NNS proteins) )) (VP (VBD were)  (VP (VBN added)  (NP (-NONE- *-44) ) (PP (TO to)  (NP (DT the)  (VBN induced)  (NN extract) )) (ADVP (-NONE- *T*-43) ))))) (, ,)  (NP-SBJ-45 (NP (DT a)  (JJ 4-fold)  (NN increase) ) (PP (IN in)  (NP (NN transcription) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-45) ))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS experiments) ) (VP-COOD (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (PRP it) ) (S (-NONE- *EXP*-46) )) (VP (VBZ is)  (ADJP-PRD (JJ possible) ) (S-46 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB modulate)  (NP (NN IFN-beta)  (NN transcription) ) (ADVP (FW in)  (FW vitro) )))))))) (CC but)  (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-47 (JJ additional)  (NNS proteins) ) (VP (MD may)  (VP (VB be)  (VP (VBN required)  (S (NP-SBJ (-NONE- *-47) ) (VP (TO to)  (ADVP (RB fully) ) (VP (VB activate)  (NP (NN IFN-beta)  (NN transcription) ))))))))))) (. .) ) )
(TOP (NP (NP (NN Structure)  (NN function)  (NN analysis) ) (PP (IN of)  (NP (NP (NN vitamin)  (NN D)  (NNS analogs) ) (PP (IN with)  (NP (NN C-ring)  (NNS modifications) )))) (. .) ) )
(TOP (S (NP-SBJ-52 (NP (NNS Analogs) ) (PP (IN of)  (NP (NP (CD 1)  (NN alpha,25-dihydroxyvitamin)  (NN D3) ) (PRN (-LRB- -LRB-)  (NP (CD 1)  (NN alpha,25--LRB-OH-RRB-)  (NN 2D3) ) (-RRB- -RRB-) ))) (PP (IN with)  (NP (NP (NNS substitutions) ) (PP (IN on)  (NP (NN C-11) ))))) (VP (VBD were)  (VP (VBN synthesized)  (NP (-NONE- *-52) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (JJ Small)  (JJ apolar)  (NNS substitutions) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD 11)  (NN alpha-methyl) ) (, ,)  (NP (CD 11)  (NN alpha-fluoromethyl) )) (-RRB- -RRB-) )) (VP (VBD did)  (RB not)  (ADVP (RB markedly) ) (VP (VB decrease)  (NP (NP (DT the)  (NN affinity) ) (PP (IN for)  (NP (DT the)  (NN vitamin)  (NN D)  (NN receptor) )))))) (, ,)  (CC but)  (S (NP-SBJ (NP (ADJP-COOD (ADJP (JJR larger)  (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD 11)  (NN alpha-chloromethyl) ) (CC or)  (NP (NP (CD 11)  (NN alpha-) ) (CC or)  (CD 11)  (NN beta-phenyl) )) (-RRB- -RRB-) )) (CC or)  (ADJP (RBR more)  (JJ polar) )) (NNS substitutions) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD 11)  (NN alpha-hydroxymethyl) ) (, ,)  (NP (CD 11)  (NN alpha--LRB-2-hydroxyethyl) )) (-RRB- -RCB-) )) (VP (VBD decreased)  (NP (DT the)  (NN affinity) ) (PP (TO to)  (NP (NP (QP (JJR less)  (IN than)  (CD 5) ) (NN %) ) (PP (IN of)  (NP (NP (DT that) ) (PP (IN of)  (NP (CD 1)  (NN alpha,25-OH-RRB-2D3) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP$ Their)  (NN affinity) ) (PP (IN for)  (NP (DT the)  (ADJP (NN vitamin)  (JJ D-binding) ) (NN protein) ))) (, ,)  (ADVP (RB however) ) (, ,)  (VP (VBD increased)  (ADVP (RB up)  (TO to)  (RB 4-fold) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (DT The)  (JJ biological)  (NN activity) ) (PP (IN of)  (NP (CD 11)  (NN alpha-methyl-1)  (NN alpha,25--LRB-OH-RRB-2D3) ))) (ADVP (RB closely) ) (VP (VBD resembled)  (NP (NP (DT that) ) (PP (IN of)  (NP (DT the)  (JJ natural)  (NN hormone) )) (PP (IN on)  (NP (ADJP-COOD (ADJP (JJ normal) ) (CC and)  (ADJP (JJ leukemic) )) (NP-COOD (NP (NN cell)  (NN proliferation) ) (CC and)  (NP (NN bone)  (NN resorption) ))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (PRP$ its)  (ADJP (FW in)  (FW vivo) ) (NN effect) ) (PP (IN on)  (NP (NP (NN calcium)  (NN metabolism) ) (PP (IN of)  (NP (DT the)  (JJ rachitic)  (NN chick) ))))) (VP (VBD was)  (NP-PRD (NP (QP (IN about)  (CD 50) ) (NN %) ) (PP (IN of)  (NP (NP (DT that) ) (PP (IN of)  (NP (CD 1)  (NN alpha,25--LRB-OH-RRB-2D3) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (CD 11)  (NN beta-methyl)  (NN analog) ) (VP (VBD had)  (NP (DT a)  (ADJP (ADVP (JJR greater)  (IN than)  (RB 10-fold) ) (JJR lower) ) (NN activity) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (DT The)  (JJ differentiating)  (NNS effects) ) (PP (IN of)  (NP (DT the)  (JJ other)  (NN C-11)  (NNS analogs) )) (PP (IN on)  (NP (NP (JJ human)  (JJ promyeloid)  (NN leukemia)  (NNS cells) ) (PRN (-LRB- -LRB-)  (NP (NN HL-60) ) (-RRB- -RRB-) )))) (VP (VBD agreed)  (ADVP (RB well) ) (PP (IN with)  (NP (PRP$ their)  (NP-COOD (NP (JJ bone-resorbing)  (NN activity) ) (CC and)  (NP (NN receptor)  (NN affinity) )))))) (, ,)  (CC but)  (S (NP-SBJ (PRP they) ) (VP (VBD demonstrated)  (NP (JJR lower)  (JJ calcemic)  (NNS effects) ) (ADVP (FW in)  (FW vivo) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP-COOD (ADJP (JJ Large) ) (CC or)  (ADJP (JJ polar) )) (NNS substitutions) ) (PP (IN on)  (NP (NP (NN C-11) ) (PP (IN of)  (NP (CD 1)  (NN alpha,25--LRB-OH-RRB-2D3) ))))) (ADVP (RB thus) ) (VP-COOD (VP (VBP impair)  (NP (NP (DT the)  (NN binding) ) (PP (IN of)  (NP (DT the)  (NN vitamin)  (NN D)  (NN receptor) )))) (CC but)  (VP (VBP increase)  (NP (NP (DT the)  (NN affinity) ) (PP (TO to)  (NP (ADJP (NN vitamin)  (JJ D-binding) ) (NN protein) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NNS effects) ) (PP (IN of)  (NP (JJ many)  (JJ C-11-substituted)  (CD 1)  (NN alpha,25--LRB-OH-RRB-2D3)  (NNS analogs) )) (PP (IN on)  (NP (NN HL-60)  (NN cell)  (NN differentiation) ))) (VP (VBD exceeded)  (NP (NP (PRP$ their)  (NN activity) ) (PP (IN on)  (NP (NN calcium)  (NN metabolism) )))) (. .) ) )
(TOP (NP (NP (NP (JJ Transcriptional)  (NN regulation) ) (PP-TMP (IN during)  (NP (NN T-cell)  (NN development) )) (: :) ) (NP (NP (DT the)  (NN alpha)  (NN TCR)  (NN gene) ) (PP (IN as)  (NP (DT a)  (JJ molecular)  (NN model) )) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (NN regulation) ) (PP (IN of)  (NP (NN gene)  (NN expression) )) (PP-TMP (IN during)  (NP (NN lymphocyte)  (NN differentiation) ))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ complex)  (NN process) ) (VP (VBG involving)  (NP (NP (NNS interactions) ) (PP (IN between)  (NP (JJ multiple)  (ADJP-COOD (ADJP (JJ positive) ) (CC and)  (ADJP (JJ negative) )) (JJ transcriptional)  (JJ regulatory)  (NNS elements) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN article) )) (, ,)  (NP-SBJ-62 (NP (JJ transcriptional)  (NN regulation) ) (PP (IN of)  (NP (NP (DT the)  (JJ archetypal)  (JJ T-cell-specific)  (NN gene) ) (, ,)  (NP (NN alpha)  (NN TCR) ) (, ,) ))) (VP (VBZ is)  (VP (VBN discussed)  (NP (-NONE- *-62) ))) (. .) ) )
(TOP (S (NP-SBJ-63 (NP (JJ Major)  (JJ recent)  (NNS developments) ) (, ,)  (PP (VBG including)  (NP (NP (DT the)  (NN identification) ) (PP (IN of)  (NP (NP (JJ novel)  (NNS families) ) (PP (IN of)  (NP (NP (NN transcription)  (NNS factors) ) (SBAR (WHNP-64 (WDT that) ) (S (NP-SBJ (-NONE- *T*-64) ) (VP (VBP regulate)  (NP (JJ multiple)  (NN T-cell)  (NNS genes) ) (PP-TMP (IN during)  (NP-COOD (NP (NN thymocyte)  (NN ontogeny) ) (CC and)  (NP (NN T-cell)  (NN activation) )))))))))))) (, ,) ) (VP (VBP are)  (VP (VBN described)  (NP (-NONE- *-63) ))) (. .) ) )
(TOP (NP (NP (NN Cortisol)  (NN resistance) ) (PP (IN in)  (NP (VBN acquired)  (NN immunodeficiency)  (NN syndrome) )) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN study) ) (VP (VBZ concerns)  (NP (CD 9)  (NN iv)  (NN drug)  (NNS abusers) ) (PP (IN with)  (NP (NP (VBN acquired)  (NN immunodeficiency)  (NN syndrome) ) (PRN (-LRB- -LRB-)  (NP (NN AIDS) ) (-RRB- -RRB-) ))) (SBAR (WHNP-50 (WP who) ) (S (NP-SBJ (-NONE- *T*-50) ) (VP (VBD developed)  (NP (NN hypercortisolism) ) (PP (IN without)  (NP (NP (DT the)  (NP-COOD (NP (JJ clinical)  (NNS signs) ) (CC or)  (NP (JJ metabolic)  (NNS consequences) ))) (PP (IN of)  (NP (NN hypercortisolism) )))))))) (. .) ) )
(TOP (S (NP-SBJ-51 (DT All)  (NNS patients) ) (VP (VBD were)  (VP (VBN characterized)  (NP (-NONE- *-51) ) (PP (IN by)  (NP (NP (DT an)  (JJ Addisonian)  (NN picture) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN weakness) ) (, ,)  (NP (NN weight)  (NN loss) ) (, ,)  (NP (NN hypotension) ) (, ,)  (NP (NN hyponatremia) ) (, ,)  (CC and)  (NP (JJ intense)  (JJ mucocutaneous)  (NN melanosis) )) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (NP-SBJ-52 (NP (DT An)  (JJ acquired)  (NN form) ) (PP (IN of)  (NP (NP (JJ peripheral)  (NN resistance) ) (PP (TO to)  (NP (NNS glucocorticoids) ))))) (VP (VBD was)  (VP (VBN suspected)  (NP (-NONE- *-52) ))) (. .) ) )
(TOP (S (NP-SBJ-53 (PRP We) ) (, ,)  (ADVP (RB therefore) ) (, ,)  (VP (VBD examined)  (NP (NP (NN glucocorticoid)  (NN receptor)  (NNS characteristics) ) (PP (IN on)  (NP (JJ mononuclear)  (NNS leukocytes) ))) (PP (IN by)  (S (NP-SBJ (-NONE- *-53) ) (VP (VBG measuring)  (NP-COOD (NP (NN -LCB-3H-RCB-dexamethasone)  (NN binding) ) (CC and)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NN dexamethasone) )) (PP (IN on)  (NP (NP (NN -LCB-3H-RCB-thymidine)  (NN incorporation) ) (, ,)  (SBAR (WHNP-54 (WDT which) ) (S (NP-SBJ (-NONE- *T*-54) ) (VP (VBZ is)  (NP-PRD (NP (CD one) ) (PP (IN of)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN receptor)  (NN activation) )))))))))))))))) (. .) ) )
(TOP (S (S (NP-SBJ-55 (NN Glucocorticoid)  (NN receptor)  (NN density) ) (VP (VBD was)  (VP (VBN increased)  (NP-105 (-NONE- *-55) ) (PP (IN in)  (NP (NP (NP (NN AIDS)  (NNS patients) ) (PP (IN with)  (NP (DT an)  (JJ Addisonian)  (NN picture) ))) (PRN (-LRB- -LRB-)  (FRAG (NP (NP (NN group)  (CD 1) ) (: ;)  (NP (QP (CD 16.2) (CC  +/-)  (CD 9.4) ) (NN fmol/million)  (NNS cells) ))) (-RRB- -RRB-) ))) (S (NP-SBJ-106 (-NONE- *-105) ) (VP (VBN compared)  (NP (-NONE- *-106) ) (PP (TO to)  (NP (NP (NNS values) ) (PP (IN in)  (NP-COOD (NP (NP (NP (CD 12)  (NN AIDS)  (NNS patients) ) (PP (IN without)  (NP (DT an)  (JJ Addisonian)  (NN picture) ))) (PRN (-LRB- -LRB-)  (FRAG (NP (NP (NN group)  (CD 2) ) (: ;)  (NP (QP (CD 6.05) (CC  +/-)  (CD 2.6) ) (NN fmol/million)  (NNS cells) ))) (: ;)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.01) ))) (-RRB- -RRB-) )) (CC and)  (NP (NP (ADJP-COOD (ADJP (NP (NN sex-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ age-matched) )) (NNS controls) ) (PRN (-LRB- -LRB-)  (FRAG (NP (QP (CD 3.15) (CC  +/-)  (CD 2.3) ) (NN fmol/million)  (NNS cells) )) (: ;)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.01) ))) (-RRB- -RRB-) )))))))))) (. .) )) )
(TOP (S (NP-SBJ-56 (NP (NP (DT The)  (NN affinity) ) (PP (IN of)  (NP (NN glucocorticoid)  (NNS receptors) ))) (PRN (-LRB- -LRB-)  (NP (NN Kd) ) (-RRB- -RRB-) )) (VP (VBD was)  (ADVP (RB strikingly) ) (VP (VP (VBN decreased)  (NP (-NONE- *-56) )) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (QP (CD 9.36) (CC  +/-)  (CD 3.44) ) (NN nM) ) (PP (IN in)  (NP (NN group)  (CD 1) ))) (: ;)  (NP (NP (QP (CD 3.2) (CC  +/-)  (CD 1.5) ) (NN nM) ) (PP (IN in)  (NP (NN group)  (CD 2) ))) (: ;)  (NP (NP (QP (CD 2.0) (CC  +/-)  (CD 0.8) ) (NN nM) ) (PP (IN in)  (NP (NNS controls) )))) (: ;)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.01) ))) (-RRB- -RRB-) ))) (. .) ) )
(TOP (S (S (NP-SBJ-57 (NN -LCB-3H-RCB-Thymidine)  (NN incorporation) ) (VP (VBD was)  (VP (VBN decreased)  (NP (-NONE- *-57) ) (ADVP (RB dose-dependently) ) (PP (IN by)  (NP-LGS (NN dexamethasone) )) (PP (IN in)  (NP-COOD (NP (NNS controls) ) (CC and)  (NP (NNS patients) ))))) (: ;) ) (S (NP-SBJ-58 (DT the)  (NN effect) ) (VP (VBD was)  (ADVP (RB significantly) ) (VP (VP (VBN blunted)  (NP (-NONE- *-58) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.05) ))) (-RRB- -RRB-) ) (PP (IN in)  (NP (NN group)  (CD 1)  (NNS patients) ))) (, ,)  (SBAR (WHNP-60 (WDT which) ) (S (NP-SBJ (-NONE- *T*-60) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (NP (NN activation) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN receptor) ))) (VP (VBZ is)  (ADJP-PRD (JJ impaired) ) (PP (IN as)  (NP (NP (DT a)  (NN result) ) (PP (IN of)  (NP (DT the)  (NN glucocorticoid)  (NN receptor)  (NN abnormality) )))))))))))) (. .) )) )
(TOP (S (PP (IN In)  (NP (NN conclusion) )) (, ,)  (NP-SBJ-62 (NP (NN AIDS)  (NNS patients) ) (PP (IN with)  (NP-COOD (NP (NN hypercortisolism) ) (CC and)  (NP (NP (JJ clinical)  (NNS features) ) (PP (IN of)  (NP (NP (JJ peripheral)  (NN resistance) ) (PP (TO to)  (NP (NNS glucocorticoids) )))))))) (VP (VBP are)  (VP (VBN characterized)  (NP (-NONE- *-62) ) (PP (IN by)  (NP-LGS (NP (JJ abnormal)  (NN glucocorticoid)  (NNS receptors) ) (PP (IN on)  (NP (NNS lymphocytes) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Resistance) ) (PP (TO to)  (NP (NNS glucocorticoids) ))) (VP (VBZ implies)  (NP (NP (DT a)  (JJ complex)  (NN change) ) (PP (IN in)  (NP (NP (JJ immune-endocrine)  (NN function) ) (, ,)  (SBAR (WHNP-63 (WDT which) ) (S (NP-SBJ (-NONE- *T*-63) ) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ important) ) (PP (IN in)  (NP (NP (DT the)  (NN course) ) (PP (IN of)  (NP (NN immunodeficiency)  (NN syndrome) )))))))))))) (. .) ) )
(TOP (NP (NP (NN Induction) ) (PP (IN of)  (NP-COOD (NP (JJ monocytic)  (NN differentiation) ) (CC and)  (NP (ADJP (NN NF-kappa)  (JJ B-like) ) (NNS activities) ))) (PP (IN by)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (CD 1)  (NN infection) ) (PP (IN of)  (NP (JJ myelomonoblastic)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ-25 (NP (DT The)  (NNS effects) ) (PP (IN of)  (NP (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (NN infection) )) (PP (IN on)  (NP-COOD (NP (JJ cellular)  (NN differentiation) ) (CC and)  (NP (NN NF-kappa)  (NN B)  (NN DNA)  (NN binding)  (NN activity) )))) (VP (VBP have)  (VP (VBN been)  (VP (VBN investigated)  (NP (-NONE- *-25) ) (PP (IN in)  (NP (NP (DT a)  (JJ new)  (NN model) ) (PP (IN of)  (NP (JJ myeloid)  (NN differentiation) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN PLB-985)  (NNS cells) ) (VP (VBP represent)  (NP (NP (DT a)  (JJ bipotential)  (JJ myelomonoblastic)  (NN cell)  (NN population) ) (ADJP (JJ capable)  (PP (IN of)  (NP (NP (ADJP-COOD (CC either)  (ADJP (JJ granulocytic) ) (CC or)  (ADJP (JJ monocytic) )) (NN differentiation) ) (PP-TMP (IN after)  (NP (NP (NN induction) ) (PP (IN with)  (NP (JJ appropriate)  (NNS inducers) ))))))))) (. .) ) )
(TOP (S (PP (IN By)  (NN virtue)  (IN of)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NN CD4) )) (PP (IN on)  (NP (DT the)  (NN cell)  (NN surface) )))) (, ,)  (NP-SBJ-26 (NN PLB-985)  (NNS cells) ) (VP (VBD were)  (ADVP (RB chronically) ) (VP (VBN infected)  (NP (-NONE- *-26) ) (PP (IN with)  (NP (NN HIV-1)  (NN strain)  (NN IIIB) )))) (. .) ) )
(TOP (S (NP-SBJ (NN PLB-IIIB)  (NNS cells) ) (ADVP (RB clearly) ) (VP (VBD possessed)  (NP (NP (DT a)  (ADJP (RBR more)  (JJ monocytic) ) (NN phenotype) ) (PP (IN than)  (NP (DT the)  (JJ parental)  (NNS myeloblasts) ))) (, ,)  (SBAR (IN as)  (S (NP-SBJ-27 (-NONE- *) ) (VP (VBN determined)  (NP (-NONE- *-27) ) (PP (IN by)  (NP-LGS-COOD (NP (JJ differential)  (NN staining) ) (, ,)  (NP (NP (VBN increased)  (NN expression) ) (PP (IN of)  (NP (DT the)  (JJ myeloid-specific)  (NN surface)  (NNS markers) ))) (, ,)  (CC and)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (NN c-fms)  (NN proto-oncogene) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN NF-kappa)  (NN B)  (NN binding)  (NN activity) ) (VP (VBD was)  (ADJP-PRD (JJ inducible) ) (PP (IN by)  (NP-COOD (NP (NN tumor)  (NN necrosis)  (NN factor) ) (CC and)  (NP (NN phorbol)  (NN myristate)  (NN acetate) ))) (PP (IN in)  (NP (NN PLB-985) ))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (PP (IN in)  (NP (NN PLB-IIIB)  (NNS cells) )) (, ,)  (NP-SBJ-28 (NP (JJ constitutive)  (NN expression) ) (PP (IN of)  (NP (DT a)  (JJ novel)  (NN NF-kappa)  (NN B)  (NN complex) ))) (VP (VBD was)  (VP (VBN detected)  (NP-29 (-NONE- *-28) ) (, ,)  (S (NP-SBJ-30 (-NONE- *-29) ) (VP (VBN composed)  (NP (-NONE- *-30) ) (PP (IN of)  (NP (NP (NNS proteins) ) (VP (VBG ranging)  (PP (IN between)  (NP (QP (CD 70)  (CC and)  (CD 110) ) (NN kD) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS proteins) ) (VP (VBD interacted)  (PP (RB specifically)  (IN with)  (NP (NP (DT the)  (JJ symmetric)  (NN NF-kappa)  (NN B)  (NN site) ) (PP (IN from)  (NP (DT the)  (NP (NP (NN interferon)  (NN beta) ) (PRN (-LRB- -LRB-)  (NP (NN IFN-beta) ) (-RRB- -RRB-) )) (NN promoter) ))))) (. .) ) )
(TOP (S (NP-SBJ-31 (NP (NNS Mutations) ) (VP (VBG affecting)  (NP (NP (DT the)  (JJ 5')  (JJ guanine)  (NNS residues) ) (PP (IN of)  (NP (DT the)  (NN kappa)  (NN B)  (NN site) ))))) (VP (VBD were)  (ADJP-PRD (JJ unable)  (S (NP-SBJ (-NONE- *-31) ) (VP (TO to)  (VP (VB compete)  (PP (IN for)  (NP (DT these)  (ADJP (NN NF-kappa)  (JJ B-related) ) (NNS proteins) ))))))) (. .) ) )
(TOP (S (NP-SBJ-32 (NP (NN Inducibility) ) (PP (IN of)  (NP (JJ endogenous)  (NP-COOD (NP (NN IFN-beta) ) (CC and)  (NP (NN IFN-alpha) )) (NN RNA) ))) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN increased)  (NP (-NONE- *-32) ) (PP (IN in)  (NP (NN PLB-IIIB)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS studies) ) (VP (VBP indicate)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NP (NN HIV-1)  (NN infection) ) (PP (IN of)  (NP (JJ myelomonoblastic)  (NNS cells) ))) (VP (MD may)  (VP (VB select)  (PP (IN for)  (NP (DT a)  (ADJP (RBR more)  (JJ mature) ) (JJ monocytic)  (NN phenotype) )))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ unique)  (NN subunit)  (NNS associations) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN DNA)  (NN binding)  (NNS proteins) ))) (VP (MD may)  (VP (VB contribute)  (PP (TO to)  (NP (JJ differential)  (ADJP (NN NF-kappa)  (JJ B-mediated) ) (NN gene)  (NN expression) )))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD-49 (NP (NP (DT The)  (NN AP-1)  (NN site) ) (PP (IN at)  (NP (CD -150)  (NN bp) ))) (, ,)  (CONJP (CC but)  (RB not) ) (NP (DT the)  (NN NF-kappa)  (NN B)  (NN site) ) (, ,) ) (VP (VBZ is)  (ADJP-PRD (JJ likely)  (S (NP-SBJ (-NONE- *-49) ) (VP (TO to)  (VP (VB represent)  (NP (NP (DT the)  (JJ major)  (NN target) ) (PP (IN of)  (NP (NN protein)  (NN kinase)  (NN C) ))) (PP (IN in)  (NP (DT the)  (NN interleukin)  (CD 2)  (NN promoter) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Stimulation) ) (PP (IN of)  (NP (NN T)  (NNS cells) )) (PP (IN with)  (NP (NN antigen) ))) (VP (VBZ results)  (PP (IN in)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NP (JJ several)  (NNS kinases) ) (, ,)  (PP (VBG including)  (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) ))) (, ,)  (SBAR (WHNP-50 (WDT that) ) (S (NP-SBJ (-NONE- *T*-50) ) (VP (MD may)  (VP (VB mediate)  (NP (NP (DT the)  (JJ later)  (NN induction) ) (PP (IN of)  (NP (JJ activation-related)  (NNS genes) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN examined)  (NP (NP (DT the)  (JJ potential)  (NN role) ) (PP (IN of)  (NP (NN PKC) )) (PP (IN in)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NP (DT the)  (NP (NP (NN interleukin)  (CD 2) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2) ) (-RRB- -RRB-) )) (NN gene) ) (PP (IN in)  (NP (NP (NN T)  (NNS cells) ) (VP (VBN stimulated)  (NP (-NONE- *) ) (PP (IN through)  (NP (DT the)  (NN T)  (NN cell) (NN  receptor/CD3)  (NN complex) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-TMP (RB previously) ) (VP (VBN shown)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ prolonged)  (NN treatment) ) (PP (IN of)  (NP (DT the)  (JJ untransformed)  (NN T)  (NN cell)  (NN clone)  (NN Ar-5) )) (PP (IN with)  (NP (NN phorbol)  (NNS esters) ))) (VP-COOD (VP (VBZ results)  (PP (IN in)  (NP (NP (NN downmodulation) ) (PP (IN of)  (NP (NP (DT the)  (NP-COOD (NP (NN alpha) ) (CC and)  (NP (NN beta) )) (NNS isozymes) ) (PP (IN of)  (NP (NN PKC) ))))))) (, ,)  (CC and)  (VP (VBZ abrogates)  (NP (NP (NN induction) ) (PP (IN of)  (NP-COOD (NP (NN IL-2)  (NN mRNA) ) (CC and)  (NP (NN protein) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NN phorbol)  (NN ester)  (NN treatment) ) (ADVP (RB also) ) (VP (VBZ abolishes)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NP (JJ chloramphenicol)  (NN acetyltransferase)  (NN activity) ) (PP (IN in)  (NP (NP (NN Ar-5)  (NNS cells) ) (VP (VBN transfected)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (DT a)  (NN plasmid) ) (VP (VBG containing)  (NP (NP (DT the)  (NN IL-2)  (NN promoter) ) (VP (VBN linked)  (NP (-NONE- *) ) (PP (TO to)  (NP (DT this)  (NN reporter)  (NN gene) ))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN IL-2)  (NN promoter) ) (VP (VBZ contains)  (NP (NP (VBG binding)  (NNS sites) ) (PP (IN for)  (NP (NP (JJ nuclear)  (NNS factors) ) (PP (VBG including)  (NP (NP-COOD (NP (NN NFAT-1) ) (, ,)  (NP (NN Oct) ) (, ,)  (NP (NN NF-kappa)  (NN B) ) (, ,)  (CC and)  (NP (NN AP-1) )) (, ,)  (SBAR (WHNP-51 (WDT which) ) (S (NP-SBJ (-NONE- *T*-51) ) (VP (VBP are)  (ADJP-PRD (DT all)  (RB potentially)  (JJ sensitive)  (PP (TO to)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NN PKC) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NP (NN induction) ) (PP (IN of)  (NP (NP (DT a)  (NN trimer) ) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN NFAT) ) (CC and)  (NP (NN Oct) )) (NNS sites) ))))) (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ sensitive)  (PP (TO to)  (NP (NN phorbol)  (NN ester)  (NN treatment) )))))) (, ,)  (CC and)  (SBAR (IN that)  (S (NP-SBJ (NP (NNS mutations) ) (PP (IN in)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN site) ))) (VP (VBP have)  (NP (DT no)  (NN effect) ) (PP (IN on)  (NP (NP (NN inducibility) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN promoter) ))))))))) (. .) ) )
(TOP (S-COOD (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (NNS mutations) ) (PP (IN in)  (NP (NP (DT the)  (NN AP-1)  (NN site) ) (ADJP (JJ located)  (PP (IN at)  (NP (CD -150)  (NN bp) )))))) (ADVP (RB almost)  (RB completely) ) (VP (VBP abrogate)  (NP (NP (NN induction) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN promoter) ))))) (, ,)  (CC and)  (S (NP-SBJ (NP (NN appearance) ) (PP (IN of)  (NP (NP (DT an)  (JJ inducible)  (JJ nuclear)  (NN factor) ) (VP (VBG binding)  (PP (TO to)  (NP (DT this)  (NN site) )))))) (VP (VBZ is)  (ADJP-PRD (JJ sensitive)  (PP (TO to)  (NP (NN PKC)  (NN depletion) ))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ (NP (NNS cotransfections) ) (PP (IN with)  (NP (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN expression)  (NNS plasmids) ))) (ADVP (RB markedly) ) (VP (VBP enhance)  (NP (NP (NN induction) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN promoter) )) (PP (IN in)  (NP (ADJP (RB minimally)  (VBN stimulated) ) (NN T)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN AP-1)  (NN site) ) (PP (IN at)  (NP (CD -150)  (NN bp) ))) (VP (VBZ represents)  (NP (NP (NP (DT a)  (JJ major)  (NP (-NONE- *RNR*-107) )) (PRN (, ,)  (SBAR (IN if)  (FRAG (RB not)  (NP (DT the)  (JJ only)  (NP (-NONE- *RNR*-107) )))) (, ,) ) (NP-107 (NN site) )) (PP (IN of)  (NP (NN PKC)  (NN responsiveness) )) (PP (IN in)  (NP (DT the)  (NN IL-2)  (NN promoter) ))))))) (. .) ) )
(TOP (S (NP-SBJ-59 (NP (ADJP (NN Interleukin)  (JJ 6-induced) ) (NN differentiation) ) (PP (IN of)  (NP (DT a)  (JJ human)  (NN B)  (NN cell)  (NN line) )) (PP (IN into)  (NP (JJ IgM-secreting)  (NN plasma)  (NNS cells) ))) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-59) ) (PP (IN by)  (NP-LGS (NN c-fos) )))) (. .) ) )
(TOP (S (NP-SBJ-60 (NP (DT The)  (NN role) ) (PP (IN of)  (NP (DT the)  (NN protooncogene)  (NN c-fos) )) (PP (IN in)  (NP (ADJP (NN interleukin)  (-LRB- -LRB-)  (NN IL)  (-RRB- -RRB-)  (JJ 6-induced) ) (NN B)  (NN cell)  (NN differentiation) ))) (VP (VBD was)  (VP (VBN assessed)  (NP (-NONE- *-60) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN of)  (NP (NN SKW)  (CD 6.4)  (NNS cells) )) (PP (IN with)  (NP (NN IL)  (CD 6) ))) (VP (VBD induced)  (NP (NP (DT a)  (ADJP-COOD (ADJP (JJ transient) ) (CC and)  (ADJP (JJ early) )) (NN stimulation) ) (PP (IN of)  (NP (NN c-fos)  (NN sense)  (NN mRNA)  (NN expression) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN effect) ) (VP-COOD (VP (VBD appeared)  (PP-TMP (IN within)  (NP (CD 30)  (NN min) ))) (CC and)  (VP (VBD returned)  (PP (TO to)  (NP (JJ basal)  (NNS levels) )) (PP-TMP (IN after)  (NP (CD 2)  (NN h) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (DT The)  (NN addition) ) (PP (IN of)  (NP (JJ antisense)  (NNS oligonucleotides) )) (PP (TO to)  (NP (NN c-fos) ))) (ADVP (RB significantly) ) (VP (VBD inhibited)  (NP (ADJP (NN IL)  (JJ 6-induced) ) (NN IgM)  (NN production) ) (PP (IN by)  (NP (NN SKW)  (CD 6.4)  (NNS cells) )) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.001) ))) (-RRB- -RRB-) ))) (, ,)  (IN whereas)  (S (NP-SBJ (NN control)  (NNS oligonucleotides) ) (VP (VBD had)  (NP (DT no)  (JJ inhibitory)  (NN effect) ))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-61 (NP (NN activation) ) (PP (IN of)  (NP (NN c-fos) ))) (VP (VBZ is)  (VP (VBN involved)  (NP (-NONE- *-61) ) (PP (IN in)  (NP (NP (ADJP (NN IL)  (JJ 6-induced) ) (NN differentiation) ) (PP (IN of)  (NP (NN SKW)  (CD 6.4)  (NNS cells) )) (PP (IN into)  (NP (JJ IgM-secreting)  (NNS cells) ))))))))) (. .) ) )
(TOP (NP (NP (NN Binding) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ erythroid) ) (CC and)  (ADJP (JJ non-erythroid) )) (JJ nuclear)  (NNS proteins) )) (PP (TO to)  (NP (NP (DT the)  (NN silencer) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ epsilon-globin-encoding)  (NN gene) )))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-76) ) (VP (TO To)  (VP (VB clarify)  (NP (NP (DT the)  (JJ molecular)  (NNS mechanisms) ) (VP (VBN involved)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (DT the)  (JJ developmental)  (NN control) ) (PP (IN of)  (NP (JJ hemoglobin-encoding)  (NNS genes) ))))))))) (NP-SBJ-76 (PRP we) ) (VP (VBP have)  (VP (VBN been)  (VP (VBG studying)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (DT these)  (NNS genes) )) (PP (IN in)  (NP (NP (JJ human)  (NNS cells) ) (PP (IN in)  (NP (JJ continuous)  (NN culture) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-TMP (RB previously) ) (VP (VBN reported)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NP (DT a)  (JJ transcriptional)  (NN control)  (NN element) ) (PP (IN with)  (NP (NP (DT the)  (NNS properties) ) (PP (IN of)  (NP (NP (DT a)  (NN silencer) ) (VP (VBG extending)  (PP (PP-COOD (PP (IN from)  (NP (CD -392)  (NP (-NONE- *RNR*-77) ))) (PP (TO to)  (NP (CD -177)  (NP (-NONE- *RNR*-77) )))) (NP-77 (NN bp) )) (PP (JJ relative)  (TO to)  (NP (NP (DT the)  (NN cap)  (NN site) ) (PP (IN of)  (NP (DT the)  (JJ human)  (JJ epsilon-globin-encoding)  (NN gene) )))))))))))) (PRN (-LRB- -LCB-)  (FRAG (NP-COOD (NP (NNP Cao) ) (FW et)  (NP (FW al.) )) (, ,)  (NP (NNP Proc.Natl.Acad.Sci.USA)  (CD 86)  (-LRB- -LRB-)  (CD 1989)  (-RRB- -RRB-)  (CD 5306-5309) )) (-RRB- -RCB-) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB also) ) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN silencer) ) (VP (VBZ has)  (NP (JJR stronger)  (JJ inhibitory)  (NN activity) ) (PP (IN in)  (NP (NN HeLa)  (NNS cells) )) (, ,)  (SBAR (IN as)  (S (NP-SBJ-78 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-78) ) (PP (TO to)  (NP (NN K562)  (JJ human)  (NN erythroleukemia)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG Using)  (NP-COOD (NP (NN deletion)  (NNS mutants) ) (CC and)  (NP (JJ cis-cloned)  (JJ synthetic)  (NNS oligodeoxyribonucleotides) )) (PP (IN in)  (NP (JJ transient)  (NN expression)  (NNS assays) )))) (, ,)  (NP-SBJ-79 (NP (NN nucleotide)  (NNS sequences) ) (ADJP (JJ responsible)  (PP (IN for)  (NP (DT this)  (NN effect) )))) (VP (VBP have)  (ADVP-TMP (RB now) ) (VP (VBN been)  (ADVP (RBR further) ) (VP (VBN delimited)  (NP (-NONE- *-79) ) (PP (TO to)  (NP (NP (CD 44)  (NN bp) ) (ADJP (JJ located)  (PP (PP-COOD (PP (IN from)  (NP (CD -294)  (NP (-NONE- *RNR*-80) ))) (PP (TO to)  (NP (CD -251)  (NP (-NONE- *RNR*-80) )))) (NP-80 (NN bp) )))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN Gel)  (NN electrophoresis)  (NN mobility)  (NN shift)  (NNS assays) ) (CC and)  (NP (NN DNaseI)  (NN footprinting)  (NNS assays) )) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-81 (DT these)  (JJ negative)  (JJ regulatory)  (NNS sequences) ) (VP (VBP are)  (VP (VBN recognized)  (NP (-NONE- *-81) ) (ADVP (RB differently) ) (PP (IN by)  (NP-LGS (NP (NNS proteins) ) (ADJP (JJ present)  (PP (IN in)  (NP (NP (JJ nuclear)  (NNS extracts) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP-COOD (NP (NN HeLa) ) (CC and)  (NP (NN K562) )) (NNS cells) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-82 (CD Two)  (VBG binding)  (NNS proteins) ) (VP (VBP are)  (VP (VBN detected)  (NP (-NONE- *-82) ) (PP (IN in)  (NP (NN K562)  (JJ nuclear)  (NNS extracts) )) (, ,)  (SBAR (IN while)  (S (NP-SBJ-83 (QP (RB only)  (CD one) )) (VP (VBZ is)  (VP (VBN found)  (NP (-NONE- *-83) ) (PP (IN in)  (NP (NP (NNS extracts) ) (PP (IN from)  (NP (NN HeLa)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-84 (NP (JJ Possible)  (NNS mechanisms) ) (SBAR (WHPP-85 (IN by)  (WHNP (WDT which) )) (S (NP-SBJ (DT these)  (NNS proteins) ) (VP (MD may)  (VP (VB regulate)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (JJ epsilon-globin-encoding)  (NN gene) )) (PP (IN in)  (NP (ADJP-COOD (ADJP (JJ erythroid) ) (CC and)  (ADJP (JJ non-erythroid) )) (NNS cells) ))) (PP (-NONE- *T*-85) )))))) (VP (VBP are)  (VP (VBN discussed)  (NP (-NONE- *-84) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Gangliosides) ) (VP (VBP suppress)  (NP (NP (NN tumor)  (NN necrosis)  (NN factor)  (NN production) ) (PP (IN in)  (NP (JJ human)  (NNS monocytes) )))) (. .) ) )
(TOP (S (NP-SBJ (ADJP-COOD (CC Both)  (ADJP (JJ normal) ) (CC and)  (ADJP (JJ malignant) )) (NNS cells) ) (VP (VBP contain)  (NP (NNS gangliosides) ) (PP (IN as)  (NP (NP (JJ important)  (NN cell)  (NN membrane)  (NNS constituents) ) (SBAR (WHNP-48 (WDT that) ) (, ,)  (S (PP-TMP (IN after)  (S (NP-SBJ-50 (-NONE- *-49) ) (VP (VBG being)  (VP (VBN shed)  (NP (-NONE- *-50) ))))) (, ,)  (NP-SBJ-49 (-NONE- *T*-48) ) (VP (MD may)  (VP (VB influence)  (NP (NP (NNS cells) ) (PP (IN of)  (NP (DT the)  (JJ immune)  (NN system) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN studied)  (NP (NP (DT the)  (NN impact) ) (PP (IN of)  (NP (NNS gangliosides) )) (PP (IN on)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NN TNF) )) (PP-COOD (PP (IN in)  (NP (NN blood)  (NNS monocytes) )) (CC and)  (PP (IN in)  (NP (DT the)  (JJ monocytic)  (NN cell)  (NN line)  (NN Mono)  (NN Mac)  (CD 6) )))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (PP (IN under)  (NP (JJ standard)  (NN culture)  (NNS conditions) )) (, ,)  (NP-SBJ (NP (JJ bovine)  (NN brain)  (NNS gangliosides) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 100) (NNS  micrograms/ml) )) (-RRB- -RRB-) )) (VP-COOD (VP (VBD suppressed)  (NP (JJ LPS-stimulated)  (NN TNF)  (NN production) ) (ADVP-107 (RB 5-fold) ) (PP-108 (IN in)  (NP (NN PBMC) ))) (CC and)  (VP (ADVP=107 (RB 10-fold) ) (PP=108 (IN in)  (NP (NN Mono)  (NN Mac)  (CD 6)  (NNS cells) )))))) (, ,)  (NP-SBJ (NN suppression) ) (VP (VBD was)  (ADJP-PRD (RBR more)  (JJ efficient) ) (PP (IN under)  (NP (JJ serum-free)  (NNS conditions) ))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG Looking)  (PP (IN at)  (NP (ADJP (RB highly)  (VBN purified) ) (NNS gangliosides) )))) (, ,)  (NP-SBJ-COOD-51 (NP (NN GD3) ) (, ,)  (NP (NN GD1a) ) (, ,)  (NP (NN GM3) ) (, ,)  (NP (NN GM2) ) (, ,)  (CC and)  (NP (NN GM1) )) (VP (VBD were)  (ADJP-PRD (DT all)  (JJ effective) ) (PP (IN in)  (S (NP-SBJ (-NONE- *-51) ) (VP (VBG reducing)  (NP (NP (NN TNF)  (NN production) ) (PP-COOD (PP (IN in)  (NP (NN PBMC) )) (, ,)  (CC and)  (PP (IN in)  (NP (NN Mono)  (NN Mac)  (CD 6) ))) (PP (IN by)  (NP (NN factor)  (NP-COOD (NP (CD 10) ) (TO to)  (NP (CD 50) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-52 (DT The)  (JJ suppressive)  (NN activity) ) (VP (VBD was)  (VP (VBN lost)  (NP-53 (-NONE- *-52) ) (PP (IN in)  (NP (NNS molecules) )) (, ,)  (S (NP-SBJ (-NONE- *-53) ) (VP (VBG lacking)  (NP-COOD (NP (DT the)  (NN sugar)  (NN moiety) ) (CC or)  (NP (DT the)  (NN lipid)  (NN moiety) )))))) (. .) ) )
(TOP (S (NP-SBJ-54 (NNS Gangliosides) ) (VP (VBP appear)  (S (NP-SBJ (-NONE- *-54) ) (VP (TO to)  (VP (VB act)  (PP (IN at)  (NP (NP (DT an)  (JJ early)  (NN step) ) (PP (IN of)  (NP (NN activation) )) (SBAR (WHPP-109 (IN in)  (WHNP (IN that) )) (S-COOD (S (NP-SBJ-55 (NN TNF)  (NNS transcripts) ) (VP (VBD were)  (VP (VBN reduced)  (NP (-NONE- *-55) ) (PP (-NONE- *T*-109) )))) (CC and)  (S (NP-SBJ-56 (NP (DT the)  (NN mobilization) ) (PP (IN of)  (NP (DT the)  (JJ nuclear)  (NN factor)  (NN kappa)  (NN B) ))) (VP (VBD was)  (VP (VBN blocked)  (NP (-NONE- *-56) ) (PP (-NONE- *T*-109) )))))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (PP (IN in)  (NP (NN time)  (NNS kinetics) )) (, ,)  (NP-SBJ (NNS gangliosides) ) (VP (VBD were)  (ADJP-PRD (JJ effective) ) (UCP-TMP-COOD (PP (IN for)  (NP (NP (QP (RB up)  (TO to)  (CD 30) ) (NN min) ) (PP-TMP (IN after)  (NP (NP (NN addition) ) (PP (IN of)  (NP (NN LPS) )))))) (, ,)  (CC but)  (ADVP (RB not)  (RB thereafter) ))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-57 (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NP (DT the)  (NN CD14)  (NN Ag) ) (, ,)  (NP (NP (DT a)  (NN receptor)  (NN molecule) ) (PP (IN for)  (NP (NN LPS-LPS)  (NN binding)  (NN protein)  (NNS complexes) ))) (, ,) ))) (VP (VBD was)  (VP (JJ unaffected)  (NP (-NONE- *-57) ) (PP (IN by)  (NP-LGS (NNS gangliosides) )))) (. .) ) )
(TOP (S (ADVP (RB Finally) ) (, ,)  (SBAR-TMP (WHADVP-58 (WRB when) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP-COOD (NP (FW Staphylococcus)  (FW aureus) ) (CC or)  (NP (NN platelet)  (NN activating)  (NN factor) )) (PP (IN as)  (NP (DT a)  (NN stimulus) )) (ADVP (-NONE- *T*-58) )))) (, ,)  (NP-SBJ-59 (NNS gangliosides) ) (VP (VBD were)  (ADJP-PRD (JJ able)  (S (NP-SBJ (-NONE- *-59) ) (VP (TO to)  (VP (VB suppress)  (NP (NP (NN TNF)  (NN production) ) (PP (IN in)  (NP (NN Mono)  (NN Mac)  (CD 6)  (NNS cells) ))) (PP (IN by)  (NP (NN factor)  (NP-COOD (NP (CD 5) ) (TO to)  (NP (CD 10) )))) (, ,)  (PP (RB as)  (ADVP (RB well) ))))))) (. .) ) )
(TOP (S (PP (IN On)  (NP (DT the)  (JJ other)  (NN hand) )) (, ,)  (NP-SBJ (NP (ADJP (NN phorbol)  (JJ ester-induced) ) (NN production) ) (PP (IN of)  (NP (NN O2-) ))) (VP (VBD was)  (ADJP-PRD (JJ similar) ) (PP (IN in)  (NP (NP (NNS cells) ) (VP (VBN treated)  (NP (-NONE- *) ) (PP (PP-COOD (PP (IN with)  (NP (-NONE- *RNR*-60) )) (CC and)  (PP (IN without)  (NP (-NONE- *RNR*-60) ))) (NP-60 (NNS gangliosides) )))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-61 (-NONE- *) ) (VP (VBN Taken)  (NP (-NONE- *-61) ) (ADVP (RB together) ))) (, ,)  (NP-SBJ (PRP$ our)  (NNS data) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-62 (NP (NN TNF)  (NN gene)  (NN expression) ) (PP (IN in)  (NP (NNS monocytes) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP (NP (JJ different)  (NNS types) ) (PP (IN of)  (NP (NNS stimuli) )))))) (VP (MD can)  (VP (VB be)  (VP (VBN blocked)  (NP (-NONE- *-62) ) (PP (IN by)  (NP-LGS (NNS gangliosides) )) (PP-TMP (IN at)  (NP (NP (DT an)  (JJ early)  (NN step) ) (PP (IN of)  (NP (JJ signal)  (NN transduction) )))))))))) (. .) ) )
(TOP (NP (NP (ADJP (NN T)  (JJ cell-specific) ) (JJ negative)  (NN regulation) ) (PP (IN of)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN cytokine)  (NN IL-4) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN IL-4) ) (VP (VBN secreted)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (VBN activated)  (NN T)  (NNS cells) )))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ pleiotropic)  (NN cytokine) ) (VP (VBG affecting)  (NP (NP-COOD (NP (NN growth) ) (CC and)  (NP (NN differentiation) )) (PP (IN of)  (NP (NP (JJ diverse)  (NN cell)  (NNS types) ) (PP (JJ such)  (IN as)  (NP-COOD (NP (NN T)  (NNS cells) ) (, ,)  (NP (NN B)  (NNS cells) ) (, ,)  (CC and)  (NP (NN mast)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD investigated)  (NP (NP (DT the)  (JJ upstream)  (JJ regulatory)  (NNS elements) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN IL-4)  (NN promoter) )))) (. .) ) )
(TOP (S (NP-SBJ-53 (NP (NP (NP (DT A)  (JJ novel)  (ADJP (NN T)  (JJ cell-specific) ) (JJ negative)  (JJ regulatory)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN NRE) ) (-RRB- -RRB-) )) (NP (-NONE- *ICH*-52) )) (VP (VBN composed)  (NP (-NONE- *) ) (PP (IN of)  (NP (CD two)  (JJ protein-binding)  (NNS sites) )))) (VP (VBD were)  (VP (VBN mapped)  (NP (-NONE- *-53) ) (PP (IN in)  (NP (NP (DT the)  (JJ 5')  (JJ flanking)  (NN region) ) (PP (IN of)  (NP (DT the)  (NN IL-4)  (NN gene) )))) (: :)  (NP-COOD-52 (NP (NP (NN -311CTCCCTTCT-303) ) (PRN (-LRB- -LRB-)  (NP (NN NRE-I) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN -288CTTTTTGCTT-TGC-300) ) (PRN (-LRB- -LRB-)  (NP (NN NRE-II) ) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (NP-SBJ-54 (NP-COOD (NP (DT A)  (ADJP (NN T)  (JJ cell-specific) ) (NN protein)  (NN Neg-1) ) (CC and)  (NP (DT a)  (JJ ubiquitous)  (NN protein)  (NN Neg-2) )) (VP (VBG binding)  (PP (TO to)  (NP-COOD (NP (NN NRE-I) ) (CC and)  (NP (NN NRE-II) ))) (, ,)  (ADVP (RB respectively) ) (, ,) )) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-54) ))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ-55 (DT a)  (JJ positive)  (JJ regulatory)  (NN element) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-55) ) (ADVP (NP (CD 45)  (NN bp) ) (RB downstream)  (PP (IN of)  (NP (DT the)  (NN NRE) ))))) (. .) ) )
(TOP (S (NP-SBJ-56 (NP (DT The)  (NN enhancer)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN PRE) ))) (VP (VBD was)  (ADVP (RB completely) ) (VP (VBN suppressed)  (NP (-NONE- *-56) ) (SBAR-TMP (WHADVP-57 (WRB when) ) (S (NP-SBJ (DT the)  (NN NRE) ) (VP (VBD was)  (ADJP-PRD (JJ present) ) (ADVP (-NONE- *T*-57) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-58 (NN IL-4)  (NN promoter)  (NN activity) ) (VP (VBZ is)  (ADVP (RB normally) ) (VP (VBN down-regulated)  (NP (-NONE- *-58) ) (PP (IN by)  (NP-LGS (DT an)  (NN NRE) )) (PP (IN via)  (NP (NP (NN repression) ) (PP (IN of)  (NP (DT the)  (NN enhancer)  (JJ positive)  (JJ regulatory)  (NN element) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (MD may)  (VP (VB have)  (NP (NP (NNS implications) ) (PP (IN for)  (NP (NP (DT the)  (JJ stringent)  (NN control) ) (PP (IN of)  (NP (NP (NN IL-4)  (NN expression) ) (PP (IN in)  (NP (NN T)  (NNS cells) ))))))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP (JJ Regulatory)  (NN effect) ) (PP (IN of)  (NP (NN insulin) )) (PP (IN on)  (NP (NP (NN glucocorticoid)  (NN receptor) ) (PP (IN in)  (NP (JJ human)  (JJ peripheral)  (NNS leukocytes) )))) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-8 (NP (DT The)  (JJ regulatory)  (NN effect) ) (PP (IN of)  (NP (NN insulin) )) (PP (IN on)  (NP (NP (DT the)  (JJ specific)  (VBG binding)  (NN power) ) (PP (IN of)  (NP (NP (NP (NN glucocorticoid)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN GR) ) (-RRB- -RRB-) )) (PP (IN of)  (NP (JJ human)  (NNS leukocytes) ))))))) (VP (VBD was)  (VP (VBN assessed)  (NP (-NONE- *-8) ) (PP (IN by)  (NP (NP (DT the)  (JJ unoccupied)  (NN receptor)  (NNS sites) ) (ADJP (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *) ) (VP (VBG combining)  (PP (IN with)  (NP (NP (NN -LCB-3H-RCB-)  (JJ labelled)  (NN dexamethasone) ) (VP (VBN measured)  (NP (-NONE- *) ) (PP-TMP (IN at)  (NP (NP (QP (CD 3)  (CC and)  (CD 24) ) (NN h) ) (PP-TMP (IN after)  (NP (NN incubation)  (PP (IN with)  (NP (NP (JJ various)  (NNS concentrations) ) (PP (IN of)  (NP (NN insulin) )) (VP (VBN added)  (NP (-NONE- *) ) (PP (TO to)  (NP (DT the)  (NN medium) )))))))))))))))))))) (. .) ) )
(TOP (S (PP-TMP (IN After)  (NP (ADJP (CD 3)  (NN h) ) (NN incubation) )) (NP-SBJ-10 (NP (DT the)  (JJ specific)  (VBG binding)  (NN power) ) (PP (IN with)  (NP (NN -LCB-3H-RCB-)  (NN Dex) ))) (VP (VBD was)  (VP (VBN decreased)  (NP (-NONE- *-10) ) (PP (IN by)  (NP (NP (NP-COOD (NP (QP (CD 23.3) (CC  +/-)  (CD 10.0) ) (NP (-NONE- *RNR*-90) )) (, ,)  (NP (QP (CD 32.2) (CC  +/-)  (CD 13.2) ) (NP (-NONE- *RNR*-90) )) (CC and)  (NP (QP (CD 54.3) (CC  +/-)  (CD 9.2) ) (NP (-NONE- *RNR*-90) ))) (NP-90 (NN %) )) (PRN (-LRB- -LRB-)  (NP (NP-COOD (NP (NP (NN P) ) (ADJP (ADJP (JJR greater) ) (PP (IN than)  (NP (CD 0.05) )))) (, ,)  (NP (NP (NN P) ) (ADJP (ADJP (JJR greater) ) (PP (IN than)  (NP (CD 0.05) )))) (CC and)  (NP (NP (NN P) ) (ADJP (ADJP (JJR less) ) (PP (IN than)  (NP (CD 0.01) ))))) (SBAR (IN as)  (S (NP-SBJ-11 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-11) ) (PP (IN with)  (NP (NP (NP (DT the)  (NN control)  (NN value) ) (PP (IN of)  (NP (CD 100) ))) (PP (IN in)  (DT the)  (NN absence)  (IN of)  (NP (NN insulin) )))))))) (-RRB- -RRB-) ))) (ADVP (RB respectively) ) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NP (NP-COOD (NP (NP (CD 20) (NN  mU/L) ) (PRN (-LRB- -LRB-)  (NP (JJ physiological)  (NN testing)  (NN concentration) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (CD 200) (NN  mU/L) ) (PRN (-LRB- -LRB-)  (NP (JJ physiological)  (JJ upper)  (NN limit) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (CD 2,000) (NN  mU/L) ) (PRN (-LRB- -LRB-)  (NP (JJ pharmacological)  (NN concentration) ) (-RRB- -RRB-) ))) (NN insulin) ) (PP (IN in)  (NP (DT the)  (NN incubation)  (NN medium) )))))) (. .) ) )
(TOP (S (PP-TMP (IN After)  (NP (ADJP (CD 24)  (NN h) ) (NN incubation) )) (NP-SBJ (NP (DT the)  (NN decrease) ) (PP (IN of)  (NP (DT these)  (NNS values) ))) (VP (VBD increased)  (ADVP (RB respectively) ) (PP (TO to)  (NP (NP-COOD (NP (QP (CD 43.5) (CC  +/-)  (CD 19.0) )) (, ,)  (NP (QP (CD 56.1) (CC  +/-)  (CD 20.7) )) (CC and)  (NP (QP (CD 80.2) (CC  +/-)  (CD 15.5) ))) (PRN (-LRB- -LRB-)  (NP (NP-COOD (NP (NP (NN P) ) (ADJP (ADJP (JJR less) ) (PP (IN than)  (NP (CD 0.05) )))) (, ,)  (NP (NP (NN P) ) (ADJP (ADJP (JJR less) ) (PP (IN than)  (NP (CD 0.01) )))) (CC and)  (NP (NP (NN P) ) (ADJP (ADJP (JJR less) ) (PP (IN than)  (NP (CD 0.01) ))))) (S (NP-SBJ-92 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-92) ) (PP (IN with)  (NP (NN control) ))))) (-RRB- -RRB-) )))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (NP-SBJ (NP (DT the)  (JJ inhibitory)  (NN effect) ) (PP (IN of)  (NP (NN insulin) )) (PP (IN on)  (NP (DT the)  (NN GR)  (NN binding)  (NN power) ))) (VP (VP (VBZ is)  (ADJP-PRD (CC both)  (ADJP-COOD (ADJP (NP (NN dose-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ time-dependent) )))) (, ,)  (SBAR (WHNP-12 (WDT which) ) (S (NP-SBJ (-NONE- *T*-12) ) (ADVP (RB strongly) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ-13 (NN GR) ) (VP (VBZ is)  (ADVP (RB tonically) ) (VP (VBN controlled)  (NP (-NONE- *-13) ) (PP (IN by)  (NP-LGS (NP (NN insulin)  (NN concentration)  (NN change) ) (PP (IN under)  (NP (JJ physiological)  (NNS conditions) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Human)  (NN T)  (NN cell)  (NN activation) ) (PP (IN through)  (NP (DT the)  (JJ activation-inducer) (NN  molecule/CD69) ))) (VP (VBZ enhances)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (NN transcription)  (NN factor)  (NN AP-1) )))) (. .) ) )
(TOP (S (NP-SBJ-38 (NP (DT The)  (NN induction) ) (PP (IN of)  (NP (DT the)  (NN AP-1)  (NN transcription)  (NN factor) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN ascribed)  (NP (-NONE- *-38) ) (PP (TO to)  (NP (NP (DT the)  (JJ early)  (NNS events) ) (VP (VBG leading)  (PP (TO to)  (NP (NN T)  (NN cell)  (NP-COOD (NP (NN differentiation) ) (CC and)  (NP (NN activation) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN studied)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (NN AP-1)  (NN activity) )) (PP (IN in)  (NP (NP (JJ human)  (JJ peripheral)  (NN blood)  (NN T)  (NNS lymphocytes) ) (VP (VBN stimulated)  (NP (-NONE- *) ) (PP (IN through)  (NP (DT the)  (NN activation)  (NN inducer)  (NN molecule)  (-LRB- -LRB-)  (NN AIM)  (-RRB- -RRB-) (NN  /CD69)  (NN activation)  (NN pathway) )))))))) (. .) ) )
(TOP (S (NP-SBJ-39 (NN Phorbol)  (NNS esters) ) (VP (VBP are)  (VP (VBN required)  (UCP-COOD (S (NP-SBJ-40 (-NONE- *-39) ) (VP (TO to)  (VP (VB induce)  (NP (NN AIM/CD69)  (JJ cell-surface)  (NN expression) )))) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN for)  (S (NP-SBJ (-NONE- *-40) ) (VP (VBG triggering)  (NP (NP (DT the)  (NN proliferation) ) (PP (IN of)  (NP (NN T)  (NNS cells) ))) (PP (IN in)  (NN conjunction)  (IN with)  (NP (JJ anti-AIM)  (NN mAb) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Mobility)  (NN shift)  (NNS assays) ) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ (NP (NN addition) ) (PP (IN of)  (NP (JJ anti-AIM)  (NN mAb) )) (PP (TO to)  (NP (JJ PMA-treated)  (NN T)  (NNS lymphocytes) ))) (ADVP (RB markedly) ) (VP (VBD enhanced)  (NP (NP (DT the)  (NN binding)  (NN activity) ) (PP (IN of)  (NP (NN AP-1) )) (PP (TO to)  (NP (NP (PRP$ its)  (JJ cognate)  (NN sequence) ) (, ,)  (NP (DT the)  (NN phorbol)  (NN ester)  (NN response)  (NN element) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NN anti-AIM)  (NN mAb) ) (VP (VBD did)  (RB not)  (VP (VB induce)  (NP (NP (DT any)  (NN change) ) (PP (IN in)  (NP (NP (DT the)  (NN binding)  (NN activity) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B) ) (, ,)  (NP (NP (DT a)  (NN transcription)  (NN factor) ) (SBAR (WHNP-41 (WP$ whose)  (NN activity) ) (S (NP-SBJ-42 (-NONE- *T*-41) ) (VP (VBZ is)  (ADVP (RB also) ) (VP (VBN regulated)  (NP (-NONE- *-42) ) (PP (IN by)  (NP-LGS (NN protein)  (NN kinase)  (NN C) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-43 (NP (DT The)  (NN increase) ) (PP (IN in)  (NP (JJ AP-1-binding)  (NN activity) ))) (VP (VBD was)  (VP (VBN accompanied)  (NP (-NONE- *-43) ) (PP (IN by)  (NP-LGS (NP (DT the)  (JJ marked)  (NN stimulation) ) (PP (IN of)  (NP-COOD (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (NN c-fos) ))) (CONJP (CC but)  (RB not) ) (NP (DT that)  (PP (IN of)  (NP (NN c-jun) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Blockade) ) (PP (IN of)  (NP (DT the)  (JJ DNA-binding)  (NNS complexes) )) (PP (IN with)  (NP (DT an)  (JJ anti-Fos)  (NN mAb) ))) (VP (VBD demonstrated)  (NP (NP (DT a)  (JJ direct)  (NN participation) ) (PP (IN of)  (NP (NN c-Fos) )) (PP (IN in)  (NP (NP (DT the)  (NN AP-1)  (NNS complexes) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN anti-AIM)  (NN mAb) ))))))) (. .) ) )
(TOP (S (NP-SBJ-44 (NP (JJS Most) ) (PP (IN of)  (NP (DT the)  (NN AP-1)  (NN activity) ))) (VP (MD could)  (VP (VB be)  (VP (VBN eliminated)  (NP-45 (-NONE- *-44) ) (SBAR-TMP (WHADVP-46 (WRB when) ) (S (NP-SBJ-47 (DT the)  (NN anti-AIM)  (NN mAb) ) (VP (VBD was)  (VP (VBN added)  (NP (-NONE- *-47) ) (PP (TO to)  (NP (DT the)  (NN culture)  (NN medium) )) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NN cycloheximide) )) (ADVP (-NONE- *T*-46) ))))) (, ,)  (S (NP-SBJ (-NONE- *-45) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (ADJP (FW de)  (FW novo) ) (NN protein)  (NN synthesis) ) (VP (VBZ is)  (ADJP-PRD (JJ crucial)  (PP (IN for)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (JJ AP-1-binding)  (NN activity) ))))))))))))) (. .) ) )
(TOP (S (NP (DT These)  (NNS data) ) (VP (VBP provide)  (NP (DT the)  (NN evidence)  (SBAR (IN that)  (NP-SBJ (NP (NN activation) ) (PP (IN of)  (NP (JJ human)  (JJ peripheral)  (NN blood)  (NN T)  (NNS cells) )) (PP (IN through)  (NP (DT the)  (NN AIM)  (NN activation)  (NN pathway) ))) (VP (VBP regulate)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (NN AP-1) ))))))) (. .) ) )
(TOP (S (ADVP (RB Therefore) ) (, ,)  (NP-SBJ (DT this)  (NN pathway) ) (VP (VBZ appears)  (PP (IN as)  (NP (NP (DT a)  (JJ crucial)  (NN step) ) (PP (IN in)  (NP (NP (DT the)  (NN initiation) ) (PP (IN of)  (NP (JJ early)  (NN T)  (NN cell)  (NN activation)  (NNS events) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ cis-acting)  (NNS sequences) ) (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (JJ inducible)  (NN interleukin-2)  (NN enhancer)  (NN function) )))) (VP (VBP bind)  (NP (NP (DT a)  (JJ novel)  (JJ Ets-related)  (NN protein) ) (, ,)  (NP (NN Elf-1) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ recent)  (NN definition) ) (PP (IN of)  (NP (NP (DT a)  (NN consensus)  (NN DNA)  (NN binding)  (NN sequence) ) (PP (IN for)  (NP (NP (DT the)  (NN Ets)  (NN family) ) (PP (IN of)  (NP (NN transcription)  (NNS factors) ))))))) (VP (VBZ has)  (VP (VBN allowed)  (NP (NP (DT the)  (NN identification) ) (PP (IN of)  (NP (NP (JJ potential)  (NN Ets)  (NN binding)  (NNS sites) ) (PP (IN in)  (NP (NP (DT the)  (NP-COOD (NP (NNS promoters) ) (CC and)  (NP (NNS enhancers) ))) (PP (IN of)  (NP (JJ many)  (JJ inducible)  (NN T-cell)  (NNS genes) ))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (DT the)  (NNS studies) ) (VP (VBN described)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT this)  (NN report) ))))) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP have)  (VP (VBN identified)  (NP (NP (NP (CD two)  (JJ potential)  (NNS Ets)  (NN binding)  (NNS sites) ) (, ,)  (NP-COOD (NP (NN EBS1) ) (CC and)  (NP (NN EBS2) )) (, ,) ) (SBAR (WHNP-68 (WDT which) ) (S (NP-SBJ-69 (-NONE- *T*-68) ) (VP (VBP are)  (VP (VBN conserved)  (NP (-NONE- *-69) ) (PP (IN in)  (NP (CC both)  (DT the)  (ADJP-COOD (ADJP (JJ human) ) (CC and)  (ADJP (JJ murine) )) (NN interleukin-2)  (NNS enhancers) ))))))))) (. .) ) )
(TOP (S (PP (IN Within)  (NP (DT the)  (JJ human)  (NN enhancer) )) (, ,)  (NP-SBJ-70 (DT these)  (CD two)  (NNS sites) ) (VP (VBP are)  (ADJP-PRD (JJ located)  (PP (IN within)  (NP (NP (DT the)  (ADJP (RB previously)  (VBN defined) ) (NN DNase)  (CD I)  (NNS footprints) ) (, ,)  (NP-COOD (NP (NN NFAT-1) ) (CC and)  (NP (NN NFIL-2B) )) (, ,) )) (ADVP (RB respectively) ))) (. .) ) )
(TOP (S (NP-SBJ (NP-COOD (NP (JJ Electrophoretic)  (NN mobility)  (NN shift) ) (CC and)  (NP (NN methylation)  (NN interference) )) (NNS analyses) ) (VP (VBD demonstrated)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN EBS1) ) (CC and)  (NP (NN EBS2) )) (VP (VBP are)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (NP (DT the)  (NN formation) ) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN NFAT-1) ) (CC and)  (NP (NN NFIL-2B) )) (JJ nuclear)  (NN protein)  (NNS complexes) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (ADJP (FW in)  (FW vitro) ) (NN mutagenesis)  (NNS experiments) ) (VP (VBD demonstrated)  (SBAR (IN that)  (S (NP-SBJ (JJ inducible)  (NN interleukin-2)  (NN enhancer)  (NN function) ) (VP (VBZ requires)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP-COOD (CC either)  (NP (NN EBS1) ) (CC or)  (NP (NN EBS2) )))))))) (. .) ) )
(TOP (S (NP-SBJ-71 (NP (CD Two)  (JJ well-characterized)  (NN Ets)  (NN family)  (NNS members) ) (, ,)  (NP-COOD (NP (NN Ets-1) ) (CC and)  (NP (NN Ets-2) )) (, ,) ) (VP (VBP are)  (ADVP (RB reciprocally) ) (VP (VBN expressed)  (NP (-NONE- *-71) ) (PP-TMP (IN during)  (NP (NN T-cell)  (NN activation) )))) (. .) ) )
(TOP (S (ADVP (RB Surprisingly) ) (, ,)  (ADVP (RB however) ) (, ,)  (NP-SBJ (NP (DT neither) ) (PP (IN of)  (NP (DT these)  (NNS proteins) ))) (VP (VBD bound)  (ADVP (FW in)  (FW vitro) ) (PP (TO to)  (NP-COOD (NP (NN EBS1) ) (CC or)  (NP (NN EBS2) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB therefore) ) (VP-COOD (VP (VBD screened)  (NP (DT a)  (NN T-cell)  (NN cDNA)  (NN library) ) (PP (IN under)  (NP (NN low-stringency)  (NNS conditions) )) (PP (IN with)  (NP (NP (DT a)  (NN probe) ) (PP (IN from)  (NP (NP (DT the)  (NN DNA)  (NN binding)  (NN domain) ) (PP (IN of)  (NP (NN Ets-1) ))))))) (CC and)  (VP (VBD isolated)  (NP (NP (DT a)  (JJ novel)  (NN Ets)  (NN family)  (NN member) ) (, ,)  (NP (NN Elf-1) )))) (. .) ) )
(TOP (S (NP-SBJ (NN Elf-1) ) (VP (VBZ contains)  (NP (NP (DT a)  (NN DNA)  (NN binding)  (NN domain) ) (SBAR (WHNP-72 (WDT that) ) (S (NP-SBJ (-NONE- *T*-72) ) (VP (VBZ is)  (ADJP-PRD (RB nearly)  (JJ identical)  (PP (TO to)  (NP (NP (DT that) ) (PP (IN of)  (NP (NP (NN E74) ) (, ,)  (NP (NP (DT the)  (JJ ecdysone-inducible)  (NN Drosophila)  (NN transcription)  (NN factor) ) (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (NN metamorphosis) ))))))))))))) (PRN (-LRB- -LRB-)  (FRAG (ADVP (RB hence) ) (NP (DT the)  (NN name)  (NN Elf-1) ) (, ,)  (PP (IN for)  (NP (JJ E74-like)  (NN factor)  (CD 1) ))) (-RRB- -RRB-) )) (. .) ) )
(TOP (S (NP-SBJ (NN Elf-1) ) (VP (VBD bound)  (PP (RB specifically)  (TO to)  (NP-COOD (CC both)  (NP (NN EBS1) ) (CC and)  (NP (NN EBS2) ))) (PP (IN in)  (NP (JJ electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (ADVP (RB also) ) (VP (VBD bound)  (PP (TO to)  (NP (NP (DT the)  (JJ purine-rich)  (NN CD3R)  (NN element) ) (PP (IN from)  (NP (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 2)  (JJ long)  (JJ terminal)  (NN repeat) ) (, ,)  (SBAR (WHNP-73 (WDT which) ) (S (NP-SBJ-74 (-NONE- *T*-73) ) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-74) ) (PP (IN for)  (NP (NP (JJ inducible)  (NN virus)  (NN expression) ) (PP (IN in)  (NN response)  (TO to)  (NP (NP (NN signalling) ) (PP (IN through)  (NP (DT the)  (NN T-cell)  (NN receptor) ))))))))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-75 (-NONE- *) ) (VP (VBN Taken)  (NP (-NONE- *-75) ) (ADVP (RB together) ))) (, ,)  (NP-SBJ (DT these)  (NNS results) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ multiple)  (NN Ets)  (NN family)  (NNS members) ) (PP (IN with)  (NP (ADJP (RB apparently)  (JJ distinct) ) (NN DNA)  (NN binding)  (NNS specificities) ))) (VP (VBP regulate)  (NP (NP (JJ differential)  (NN gene)  (NN expression) ) (PP (IN in)  (NP (ADJP-COOD (ADJP (VBG resting) ) (CC and)  (ADJP (VBN activated) )) (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NNPS Mineralocorticoids) ) (CC and)  (NP (NN mineralocorticoid)  (NNS receptors) )) (PP (IN in)  (NP (NP (JJ mononuclear)  (NNS leukocytes) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ pregnancy-induced)  (NN hypertension) )))))) (. .) ) )
(TOP (S (S-PRP (NP-SBJ (-NONE- *-48) ) (VP (TO To)  (VP (VB examine)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (NNS mineralocorticoids) )) (PP (IN in)  (NP (NP (DT the)  (NN pathophysiology) ) (PP (IN of)  (NP (NP (JJ pregnancy-induced)  (NN hypertension) ) (PRN (-LRB- -LRB-)  (NP (NN PIH) ) (-RRB- -RRB-) ))))))))) (, ,)  (NP-SBJ-48 (PRP we) ) (VP (VBD studied)  (NP (NP (NP-COOD (NP (NN plasma)  (NN aldosterone) ) (CC and)  (NP (NN 18-hydroxycorticosterone) )) (NNS levels) ) (PP (IN in)  (NP-COOD (NP (NP (CD 25)  (NNS women) ) (PP (IN with)  (NP (NN PIH) ))) (CC and)  (NP (NP (CD 25)  (JJ normal)  (JJ pregnant)  (NNS women) ) (, ,)  (PP (IN as)  (NP (NNS controls) ))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD evaluated)  (NP (NP (NP (DT the)  (NP (NP (NN mineralocorticoid)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN MR) ) (-RRB- -RRB-) )) (NN status) ) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) ))) (PP (IN in)  (NP (DT the)  (CD 2)  (NNS groups) )))) (. .) ) )
(TOP (S (NP-SBJ-49 (NN MR)  (NN count) ) (VP (VBD was)  (ADVP (RB significantly) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.0005) ))) (-RRB- -RRB-) ) (VP (VBN decreased)  (NP (-NONE- *-49) ) (PP (IN in)  (NP (NP (DT the)  (NN PIH)  (NN group) ) (PRN (-LRB- -LRB-)  (FRAG (NP (QP (CD 148) (CC  +/-)  (CD 9) ) (VBG binding) (NNS  sites/cell) )) (-RRB- -RRB-) ))) (PP (VBN compared)  (PP (IN with)  (NP (NP (DT the)  (NN control)  (NN group) ) (PRN (-LRB- -LRB-)  (FRAG (NP (NP (QP (CD 300) (CC  +/-)  (CD 17) ) (VBG binding) (NNS  sites/cell) ) (: ;)  (NP (NN mean) (CC  +/-)  (NN SEM) ))) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (S (NP-SBJ (NP (NN Plasma)  (NN aldosterone) ) (PP (IN in)  (NP (NP (NNS women) ) (PP (IN with)  (NP (NN PIH) ))))) (VP (VBD was)  (NP-PRD (QP (CD 281) (CC  +/-)  (CD 61) ) (NN pmol/L) )) (: ;) ) (S (PP (IN in)  (NP (JJ normal)  (JJ pregnant)  (NNS women) )) (NP-SBJ (PRP it) ) (VP (VBD was)  (NP-PRD (QP (CD 697) (CC  +/-)  (CD 172) ) (NN pmol/L) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.025) ))) (-RRB- -RRB-) )) (. .) )) )
(TOP (S (NP-SBJ (NN Plasma)  (NN 18-hydroxycorticosterone) ) (VP (VBD was)  (ADVP (RB also) ) (ADJP-PRD (ADJP (RB significantly)  (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.025) ))) (-RRB- -RRB-) ) (JJR lower) ) (PRN (-LRB- -LRB-)  (FRAG-COOD (FRAG (NP (NN PIH) ) (, ,)  (NP (QP (CD 1071) (CC  +/-)  (CD 149) ) (NN pmol/L) )) (: ;)  (FRAG (NP (NNS controls) ) (, ,)  (NP (QP (CD 1907) (CC  +/-)  (CD 318) ) (NN pmol/L) ))) (-RRB- -RRB-) ))) (. .) ) )
(TOP (S (NP-SBJ-50 (DT These)  (NNS values) ) (VP (VBD were)  (VP (VBN determined)  (NP (-NONE- *-50) ) (PP-TMP (IN at)  (NP (NP (DT the)  (NN onset) ) (PP (IN of)  (NP (NP (JJ clinical)  (NNS symptoms) ) (PP (IN of)  (NP (NN PIH) )))))))) (. .) ) )
(TOP (S (S (NP-SBJ-51 (DT These)  (NNS results) ) (VP (MD can)  (RB not)  (VP (VB be)  (VP (VBN explained)  (NP (-NONE- *-51) ) (PP (IN by)  (NP-LGS (NP (NN receptor)  (NN down-regulation) ) (PP (JJ due)  (TO to)  (NP (NP (JJR higher)  (NNS levels) ) (PP (IN of)  (NP (NP (NNS mineralocorticoids) ) (PP (IN in)  (NP (NN PIH) ))))))))))) (: ;) ) (S (NP-SBJ (DT a)  (ADJP (RB hitherto)  (JJ unknown) ) (NN mineralocorticoid) ) (VP (MD may)  (, ,)  (ADVP (RB thus) ) (, ,)  (VP (VB be)  (ADJP-PRD (JJ responsible)  (PP (IN for)  (NP (DT the)  (NP-COOD (NP (NN hypertension) ) (CC and)  (NP (JJ altered)  (NN MR) )) (NN status) ))))) (. .) )) )
(TOP (NP (NP (NN Mineralocorticoid)  (NN effector)  (NN mechanism) ) (PP (IN in)  (NP (NN preeclampsia) )) (. .) ) )
(TOP (S (NP-SBJ-36 (NN Mineralocorticoid)  (NN effector)  (NNS mechanisms) ) (VP (VBD were)  (VP (VBN evaluated)  (NP (-NONE- *-36) ) (PP-COOD (PP (IN in)  (NP (NP (CD 29)  (NNS patients) ) (PP (IN with)  (NP (NN preeclampsia) )))) (CC and)  (PP (IN in)  (NP (CD 25)  (JJ uncomplicated)  (NNS pregnancies) ))) (PP (IN by)  (NP (NP (NN measurement) ) (PP (IN of)  (NP-COOD (NP (NN plasma)  (NN aldosterone) ) (, ,)  (NP (NP (NNS levels) ) (PP (IN of)  (NP (NP (NP (NN mineralocorticoid)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN MR) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (JJ mononuclear)  (NNS leucocytes) ))))) (, ,)  (CC and)  (NP (NP (NN subtraction)  (NN potential)  (NN difference) ) (PRN (-LRB- -LRB-)  (NP (NN SPD) ) (: ;)  (NP (ADJP-COOD (ADJP (JJ rectal) ) (CC minus)  (ADJP (JJ oral) )) (NNS values) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Mean)  (NNS values) ) (PP (IN for)  (NP (NN plasma)  (NN aldosterone) ))) (VP (VBD were)  (RB not)  (ADJP-PRD (JJ different) ) (PP (IN between)  (NP (DT the)  (CD two)  (NNS groups) )))) (, ,)  (CC but)  (S (NP-SBJ-37 (JJ significant)  (NNS differences) ) (VP (VBD were)  (VP (VBN observed)  (NP (-NONE- *-37) ) (PP (IN for)  (NP-COOD (NP (NP (NN MR) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (NN preeclampsia) ) (, ,)  (NP (QP (CD 81) (CC  +/-)  (CD 44) ) (NNS receptors/cell) )) (: ;)  (NP (NP (NNS controls) ) (, ,)  (NP (QP (CD 306) (CC  +/-)  (CD 168) )))) (-RRB- -RRB-) )) (CC and)  (NP (NN SPD)  (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (NN preeclampsia) ) (, ,)  (NP (QP (CD 65) (CC  +/-)  (CD 7) ) (NN mV) )) (: ;)  (NP (NP (NNS controls) ) (, ,)  (NP (QP (CD 12) (CC  +/-)  (CD 5) ) (NN mV) ))) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (CD six)  (NNS cases) )) (NP-SBJ (PRP we) ) (VP (VBD determined)  (NP (NP-COOD (NP (NN MR) ) (, ,)  (NP (NN plasma)  (NN aldosterone) ) (, ,)  (CC and)  (NP (NN SPD) )) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN preeclampsia) )) (PP-TMP (PP-COOD (PP (IN before)  (NP (-NONE- *RNR*-38) )) (CC and)  (PP (NP (CD 3)  (NNS months) ) (IN after)  (NP (-NONE- *RNR*-38) ))) (NP-38 (NN delivery) )))))) (. .) ) )
(TOP (S (S-COOD (S (NP-SBJ-39 (NNS MR) ) (VP (VBD were)  (VP (VP (VBN reduced)  (NP (-NONE- *-39) ) (PP-TMP (IN before)  (NP (NN delivery) ))) (PRN (-LRB- -LRB-)  (NP (QP (CD 96) (CC  +/-)  (CD 27) ) (NNS receptors/cell) ) (-RRB- -RRB-) )))) (, ,)  (CC and)  (S (NP-SBJ (NN SPD) ) (VP (VP (VBD increased) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 64) (CC  +/-)  (CD 8) ) (NN mV) ) (-RRB- -RRB-) )))) (, ,)  (PP (IN with)  (S (NP-SBJ (DT both)  (NNS parameters) ) (VP (VP (VBG normalizing)  (PP-TMP (IN after)  (NP (NN delivery) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (NN MR) ) (, ,)  (NP (QP (CD 242) (CC  +/-)  (CD 79) ))) (: ;)  (NP (NP (NN SPD) ) (, ,)  (NP (QP (CD 14.0) (CC  +/-)  (CD 4) ) (NN mV) ))) (-RRB- -RRB-) )))) (. .) ) )
(TOP (S (NP-SBJ (NN Aldosterone)  (NNS levels) ) (VP (VBD returned)  (PP (TO to)  (NP (JJ normal)  (JJ nonpregnant)  (NNS values) )) (PP-TMP (IN after)  (NP (NN delivery) ))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP-COOD (VP (VBP suggest)  (NP (NP (DT an)  (JJ important)  (NN role) ) (PP (IN for)  (NP (NP (NNS abnormalities) ) (PP (IN in)  (NP (NN mineralocorticoid)  (NN effector)  (NNS mechanisms) )))) (PP (IN in)  (NP (NP (DT the)  (NN etiology) ) (PP (IN of)  (NP (NN preeclampsia) )))))) (CC and)  (VP (MD could)  (VP (VB be)  (NP-PRD (NP (DT an)  (JJ useful)  (NN marker) ) (PP (IN for)  (NP (NN diagnosis) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (ADJP (JJ lymphoid)  (JJ cell-specific) ) (JJ nuclear)  (NN factor) ) (VP (VBG containing)  (NP (JJ c-Rel-like)  (NNS proteins) ))) (ADVP (RB preferentially) ) (VP (VBZ interacts)  (PP (IN with)  (NP (NP (ADJP (NN interleukin-6)  (NN kappa)  (JJ B-related) ) (NNS motifs) ) (SBAR (WHNP-43 (WP$ whose)  (NNS activities) ) (S (NP-SBJ-44 (-NONE- *T*-43) ) (VP (VBP are)  (VP (VBN repressed)  (NP (-NONE- *-44) ) (PP (IN in)  (NP (JJ lymphoid)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN proto-oncoprotein)  (NN c-Rel) ) (VP (VBZ is)  (NP-PRD (NP (NP (DT a)  (NN member) ) (PP (IN of)  (NP (NP (DT the)  (JJ nuclear)  (NN factor)  (NN kappa)  (NN B)  (NN transcription)  (NN factor)  (NN family) ) (, ,)  (SBAR (WHNP-45 (WDT which) ) (S (NP-SBJ (-NONE- *T*-45) ) (VP (VBZ includes)  (NP (NP (DT the)  (NP-COOD (NP (NN p50) ) (CC and)  (NP (NN p65) )) (NNS subunits) ) (PP (IN of)  (NP (JJ nuclear)  (NN factor)  (NN kappa)  (NN B) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ (NN c-Rel) ) (VP (VBZ binds)  (PP (TO to)  (NP (NN kappa)  (NN B)  (NNS sites) )) (PP (IN as)  (NP-COOD (NP (NNS homodimers) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (NP (NNS heterodimers) ) (PP (IN with)  (NP (NN p50) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NP-COOD (NP (NNS homodimers) ) (CC and)  (NP (NNS heterodimers) ))) (VP (VBP show)  (NP-COOD (NP (JJ distinct)  (JJ DNA-binding)  (NNS specificities) ) (CC and)  (NP (NP (NNS affinities) ) (PP (IN for)  (NP (JJ various)  (NN kappa)  (NN B)  (NNS motifs) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (JJ particular) )) (, ,)  (NP-SBJ (DT the)  (NN c-Rel)  (NN homodimer) ) (VP (VBZ has)  (NP (NP (DT a)  (JJ high)  (NN affinity) ) (PP (IN for)  (NP (NP-COOD (NP (NP (NN interleukin-6) ) (PRN (-LRB- -LRB-)  (NP (NN IL-6) ) (-RRB- -RRB-) )) (CC and)  (NP (NN beta)  (NN interferon)  (NN kappa)  (NN B) )) (NNS sites) )))) (. .) ) )
(TOP (S (S (PP (IN In)  (NN spite)  (IN of)  (NP (NP (PRP$ its)  (NN association) ) (PP (IN with)  (NP (NN p50) )) (ADVP (FW in)  (FW vitro) ))) (, ,)  (ADVP (RB however) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD found)  (NP (NP (DT a)  (ADJP (JJ lymphoid)  (JJ cell-specific) ) (JJ nuclear)  (NN factor) ) (SBAR (-NONE- *ICH*-102) )) (ADVP (FW in)  (FW vivo) ) (SBAR-102 (WHNP-46 (WDT that) ) (S (NP-SBJ (-NONE- *T*-46) ) (VP (VBZ contains)  (NP (NP-COOD (NP (NN c-Rel) ) (CONJP (CC but)  (RB not) ) (NP (NN p50) )) (NNS epitopes) ))))) (: ;) ) (S (NP-SBJ-47 (NP (DT this)  (NN factor) ) (, ,)  (VP (VBN termed)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN IL-6)  (NN kappa)  (NN B)  (NN binding)  (NN factor)  (CD II) ))) (, ,) ) (VP-COOD (VP (VBZ appears)  (S (NP-SBJ (-NONE- *-47) ) (VP (TO to)  (VP (VB contain)  (NP (DT the)  (NN c-Rel)  (NN homodimer) ))))) (CC and)  (VP (ADVP (RB preferentially) ) (VBZ recognizes)  (NP (JJ several)  (ADJP (NN IL-6)  (NN kappa)  (JJ B-related) ) (NN kappa)  (NN B)  (NNS motifs) ))) (. .) )) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (PRP it) ) (VP (VBZ has)  (VP (VBN been)  (ADVP-TMP (RB previously) ) (VP (VBN shown)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN IL-6)  (NN kappa)  (NN B)  (NN motif) ) (VP (VBZ functions)  (PP (IN as)  (NP (DT a)  (JJ potent)  (ADJP (NN IL-1/tumor)  (NN necrosis)  (JJ factor-responsive) ) (NN element) )) (PP (IN in)  (NP (JJ nonlymphoid)  (NNS cells) )))))))))) (, ,)  (NP-SBJ-48 (PRP$ its)  (NN activity) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ-49 (-NONE- *-48) ) (VP (TO to)  (VP (VB be)  (VP (VBN repressed)  (NP (-NONE- *-49) ) (PP (IN in)  (NP (NP (JJ lymphoid)  (NNS cells) ) (PP (JJ such)  (IN as)  (NP (DT a)  (NN Jurkat)  (NN T-cell)  (NN line) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB also) ) (VP (VBP present)  (NP (NN evidence)  (SBAR (IN that)  (S (NP-SBJ (NN IL-6)  (NN kappa)  (NN B)  (NN binding)  (NN factor)  (CD II) ) (VP (VBZ functions)  (PP (IN as)  (NP (NP (DT a)  (NN repressor) ) (ADJP (JJ specific)  (PP (IN for)  (NP (ADJP (NN IL-6)  (NN kappa)  (JJ B-related) ) (NN kappa)  (NN B)  (NNS motifs) ))))) (PP (IN in)  (NP (JJ lymphoid)  (NNS cells) ))))))) (. .) ) )
(TOP (NP (NP (NP (NN Modulation) ) (PP (IN of)  (NP (JJ normal)  (JJ erythroid)  (NN differentiation) )) (PP (IN by)  (NP (DT the)  (NP-COOD (NP (JJ endogenous)  (NN thyroid)  (NN hormone) ) (CC and)  (NP (JJ retinoic)  (NN acid) )) (NNS receptors) )) (: :) ) (NP (NP (DT a)  (JJ possible)  (NN target) ) (PP (IN for)  (NP (NN v-erbA)  (NN oncogene)  (NN action) )) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (NN v-erbA)  (NN oncogene) ) (, ,)  (NP (NP (DT a)  (VBN mutated)  (NN version) ) (PP (IN of)  (NP (NP (DT the)  (NN thyroid)  (NN hormone)  (NN receptor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN c-erbA/TR-alpha) ) (-RRB- -RRB-) )))) (, ,) ) (VP (VP-COOD (VP (VBZ inhibits)  (NP (JJ erythroid)  (NN differentiation) )) (CC and)  (VP (ADVP (RB constitutively) ) (VBZ represses)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (JJ certain)  (NN erythrocyte)  (NNS genes) ))))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (NP (NP (DT a)  (JJ normal)  (NN function) ) (PP (IN of)  (NP (DT the)  (NN proto-oncogene)  (NN c-erbA) )) (PP (IN in)  (NP (NN erythropoiesis) )))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NP (DT the)  (JJ endogenous)  (NN thyroid)  (NN hormone)  (NN receptor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN c-erbA/TR-alpha) ) (-RRB- -RRB-) )) (CC and)  (NP (DT the)  (ADJP (RB closely)  (JJ related) ) (NP (NP (JJ retinoic)  (NN acid)  (NN receptor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN RAR-alpha) ) (-RRB- -RRB-) )))) (VP (VBP play)  (NP (DT a)  (NN role) ) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (JJ normal)  (JJ erythroid)  (NN differentiation) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Retinoic)  (NN acid) ) (PRN (-LRB- -LRB-)  (NP (NN RA) ) (-RRB- -RRB-) )) (ADVP (RB distinctly) ) (VP (VBD modulated)  (NP (NP (DT the)  (JJ erythroid)  (NN differentiation)  (NN program) ) (PP (IN of)  (NP (NP-COOD (NP (JJ normal)  (JJ erythroid)  (NNS progenitors) ) (CC and)  (NP (NNS erythroblasts) )) (VP (ADVP (RB reversibly) ) (VBN transformed)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT a)  (JJ conditional)  (NN tyrosine)  (NN kinase)  (NN oncogene) ))))))) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-70 (WRB When) ) (S (NP-SBJ-71 (-NONE- *-105) ) (VP (VBN added)  (NP (-NONE- *-71) ) (ADVP (RB pulsewise) ) (PP (TO to)  (NP (JJ immature)  (NNS cells) )) (ADVP (-NONE- *T*-70) )))) (, ,)  (NP-SBJ-72 (NN differentiation) ) (VP (VBD was)  (VP (VBN accelerated)  (NP-105 (-NONE- *-72) ) (SBAR (IN while)  (S (NP-SBJ (ADJP (RBR more)  (JJ mature) ) (NNS cells) ) (VP (VBD underwent)  (NP (JJ premature)  (NN cell)  (NN death) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (NN Thyroid)  (NN hormone) ) (PRN (-LRB- -LRB-)  (NP (NN T3) ) (-RRB- -RRB-) )) (ADVP (RB alone) )) (VP (VBD caused)  (NP (ADJP-COOD (ADJP (JJ similar) ) (CC but)  (ADJP (JJR weaker) )) (NNS effects) )) (. .) ) )
(TOP (S (ADVP (RB Interestingly) ) (, ,)  (NP-SBJ (NN T3) ) (ADVP (RB strongly) ) (VP (VBD enhanced)  (NP (NP (DT the)  (NN action) ) (PP (IN of)  (NP (NN RA) ))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (NP (NP (JJ cooperative)  (NN action) ) (PP (IN of)  (NP (DT the)  (CD two)  (NNS receptors) )) (PP (IN in)  (S (NP-SBJ (-NONE- *) ) (VP (VBG modulating)  (NP (JJ erythroid)  (NN differentiation) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Expression) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN RAR-alpha) )) (PP (IN in)  (NP (JJ receptor-negative)  (NNS erythroblasts) ))) (VP (VBD conferred)  (NP (JJ RA-induced)  (NN regulation) ) (PP (IN of)  (NP (NN differentiation) )) (PP (TO to)  (NP (DT the)  (ADJP (RB otherwise)  (JJ unresponsive) ) (NNS cells) )) (, ,)  (RB thus)  (S (NP-SBJ (-NONE- *) ) (VP (VBG showing)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN RAR-alpha) ) (VP (VBZ is)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (DT the)  (NN RA)  (NN effect) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Likewise) ) (, ,)  (NP-SBJ (NP (VBN enhanced)  (NN expression) ) (PP (IN of)  (NP (JJ exogenous) (NN  c-erbA/TR-alpha) )) (PP (IN in)  (NP (NNS erythroblasts) ))) (VP (VBD rendered)  (S (NP-SBJ (PRP them) ) (ADJP-PRD (JJ susceptible)  (PP (TO to)  (NP (NP (NN modulation) ) (PP (IN of)  (NP (NN differentiation) )) (PP (IN by)  (NP (NN T3) )))))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (NP (NP (DT a)  (JJ similar)  (NN function) ) (PP (IN of)  (NP (DT both)  (NNS receptors) )))))) (. .) ) )
(TOP (S (NP-SBJ (NN Leukotriene)  (NN B4) ) (VP (VBZ stimulates)  (NP (NP-COOD (NP (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN gene)  (NN transcription) ) (CC and)  (NP (NN AP-1)  (NN binding)  (NN activity) )) (PP (IN in)  (NP (JJ human)  (NNS monocytes) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN examined)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NP (NP (NN leukotriene)  (NN B4) ) (PRN (-LRB- -LRB-)  (NP (NN LTB4) ) (-RRB- -RRB-) )) (, ,)  (NP (DT a)  (JJ potent)  (NN lipid)  (JJ proinflammatory)  (NN mediator) ) (, ,) )) (PP (IN on)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (DT the)  (NNS proto-oncogenes)  (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN c-fos) ))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD looked)  (PP (IN at)  (NP (NP (DT the)  (NN modulation) ) (PP (IN of)  (NP (NP (JJ nuclear)  (NNS factors) ) (VP (VBG binding)  (PP (RB specifically)  (TO to)  (NP (DT the)  (NN AP-1)  (NN element) )) (PP-TMP (IN after)  (NP (NN LTB4)  (NN stimulation) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NN LTB4) ) (VP (VBD increased)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (DT the)  (NN c-fos)  (NN gene) ))) (PP (IN in)  (NP (DT a)  (ADJP-COOD (ADJP (NP (NN time-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ concentration-dependent) )) (NN manner) ))) (. .) ) )
(TOP (S (NP-SBJ-59 (NP (DT The)  (NN c-jun)  (NN mRNA) ) (, ,)  (SBAR (WHNP-60 (WDT which) ) (S (NP-SBJ-61 (-NONE- *T*-60) ) (VP (VBZ is)  (ADVP (RB constitutively) ) (VP (VBN expressed)  (NP (-NONE- *-61) ) (PP (IN in)  (NP (JJ human)  (NN peripheral-blood)  (NNS monocytes) )) (PP (IN at)  (NP (ADJP (RB relatively)  (JJ high) ) (NNS levels) )))))) (, ,) ) (VP (VBD was)  (ADVP (RB also) ) (ADVP (RB slightly) ) (VP (JJ augmented)  (NP (-NONE- *-59) ) (PP (IN by)  (NP-LGS (NN LTB4) )) (, ,)  (SBAR-ADV (IN although)  (FRAG (PP (TO to)  (NP (NP (DT a)  (ADJP (RB much)  (JJR lower) ) (NN extent) ) (PP (IN than)  (NP (NN c-fos) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NNS kinetics) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP (DT the)  (CD two)  (NNS genes) ))))) (VP (VBD were)  (ADJP-PRD (RB also)  (RB slightly)  (JJ different) ) (, ,)  (PP (IN with)  (S-COOD (S (NP-SBJ-62 (NN c-fos)  (NN mRNA) ) (VP (VBG reaching)  (NP (DT a)  (NN peak) ) (PP-TMP-63 (IN at)  (NP (NP (CD 15)  (NN min) ) (PP-TMP (IN after)  (NP (NN stimulation) )))))) (CC and)  (S (NP-SBJ=62 (NN c-jun) ) (PP-TMP=63 (IN at)  (NP (CD 30)  (NN min) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT Both)  (NNS messages) ) (ADVP-TMP (RB rapidly) ) (VP (VBD declined)  (ADVP (RB thereafter) )) (. .) ) )
(TOP (S (NP-SBJ-64 (NP (NN Stability) ) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN mRNA) ))) (VP (VBD was)  (RB not)  (VP (VBN affected)  (NP-103 (-NONE- *-64) ) (PP (IN by)  (NP-LGS (NN LTB4) )) (, ,)  (SBAR (IN as)  (S (NP-SBJ-65 (-NONE- *-103) ) (VP (VBN assessed)  (NP (-NONE- *-65) ) (PP-TMP (IN after)  (NP (NN actinomycin)  (NN D)  (NN treatment) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Nuclear)  (NN transcription)  (NNS studies) ) (ADVP (FW in)  (FW vitro) )) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ (NN LTB4) ) (VP-COOD (VP (VBD increased)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP-66 (DT the)  (NN c-fos)  (NN gene) ))) (ADVP-67 (RB 7-fold) )) (CC and)  (VP (NP=66 (DT the)  (NN c-jun)  (NN gene) ) (ADVP=67 (RB 1.4-fold) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (VBG Resting)  (NNS monocytes) ) (VP (VBD contained)  (NP (NP (JJ nuclear)  (NNS factors) ) (VP (VBG binding)  (PP (TO to)  (NP (DT the)  (NN AP-1)  (NN element) )))))) (, ,)  (CC but)  (S (NP-SBJ (NP (NN stimulation) ) (PP (IN of)  (NP (NNS monocytes) )) (PP (IN with)  (NP (NN LTB4) ))) (VP (VBD induced)  (NP (NP (JJR greater)  (JJ AP-1-binding)  (NN activity) ) (PP (IN of)  (NP (JJ nuclear)  (NNS proteins) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-68 (NN LTB4) ) (VP (MD may)  (VP (VB regulate)  (NP (NP (DT the)  (NN production) ) (PP (IN of)  (NP (JJ different)  (NNS cytokines) ))) (PP (IN by)  (S (NP-SBJ (-NONE- *-68) ) (VP (VBG modulating)  (NP (NP-COOD (NP (DT the)  (NN yield) ) (CC and/or)  (NP (DT the)  (NN function) )) (PP (IN of)  (NP (NP (NN transcription)  (NNS factors) ) (PP (JJ such)  (IN as)  (NP (JJ AP-1-binding)  (NN proto-oncogene)  (NNS products) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT An)  (JJ 11-base-pair)  (NN DNA)  (NN sequence)  (NN motif) ) (ADJP (RB apparently)  (JJ unique)  (PP (TO to)  (NP (DT the)  (JJ human)  (NN interleukin)  (CD 4)  (NN gene) )))) (VP (VBZ confers)  (NP (NP (NN responsiveness) ) (PP (TO to)  (NP (NN T-cell)  (NN activation)  (NNS signals) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN identified)  (NP (NP (DT a)  (NN DNA)  (NN segment) ) (SBAR (WHNP-46 (WDT that) ) (S (NP-SBJ (-NONE- *T*-46) ) (VP (VBZ confers)  (NP (NP (NN responsiveness) ) (PP (TO to)  (NP (NN antigen)  (NN stimulation)  (NNS signals) ))) (PP (IN on)  (NP (NP (DT the)  (JJ human)  (NP (NP (NN interleukin) ) (PRN (-LRB- -LRB-)  (NP (NN IL) ) (-RRB- -RRB-) )) (CD 4)  (NN gene) ) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-47 (NP (DT The)  (JJ human)  (NN IL-4)  (NN gene) ) (, ,)  (PP (IN of)  (NP (CD 10)  (NNS kilobases) )) (, ,) ) (VP (VBZ is)  (VP (VBN composed)  (NP (-NONE- *-47) ) (PP (IN of)  (NP-COOD (NP (CD four)  (NNS exons) ) (CC and)  (NP (CD three)  (NNS introns) ))))) (. .) ) )
(TOP (S (S (NP-SBJ (NP (DT A)  (JJ cis-acting)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN P)  (NN sequence) ) (-RRB- -RRB-) )) (VP (VBZ resides)  (PP (IN in)  (NP (DT the)  (ADJP (NP (JJ 5') ) (JJ upstream) ) (NN region) ))) (: ;) ) (S (NP-SBJ-48 (NP (DT no)  (JJ additional)  (NN DNA)  (NNS segments) ) (PP (IN with)  (NP (NN enhancer)  (NN activity) ))) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-48) ) (PP (IN in)  (NP (DT the)  (JJ human)  (NN IL-4)  (NN gene) )))) (. .) )) )
(TOP (S (PP (IN For)  (NP (JJ further)  (NN mapping)  (NNS purposes) )) (, ,)  (NP-SBJ-49 (DT a)  (NN fusion)  (NN promoter) ) (VP (VBD was)  (VP (VBN constructed)  (NP (-NONE- *-49) ) (PP (IN with)  (NP (NP (DT the)  (ADJP (JJ granulocyte/macrophage)  (JJ colony-stimulating) ) (NN factor)  (JJ basic)  (NN promoter) ) (VP (VBG containing)  (NP-COOD (NP (NP (CD 60)  (NN base)  (NNS pairs) ) (PP (IN of)  (NP (NN sequence) )) (ADJP (JJ upstream)  (PP (IN from)  (NP (NP (DT the)  (NN cap)  (NN site) ) (PP (IN of)  (NP (DT the)  (NN mouse)  (ADJP (JJ granulocyte/macrophage)  (JJ colony-stimulating) ) (NN factor)  (NN gene) )))))) (CC and)  (NP (NP (JJ various)  (NNS lengths) ) (PP (IN of)  (NP (NP (DT the)  (ADJP (NP (JJ 5') ) (JJ upstream) ) (NN sequence) ) (PP (IN of)  (NP (DT the)  (NN IL-4)  (NN gene) ))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-50 (DT The)  (NN P)  (NN sequence) ) (VP (VBD was)  (ADJP-PRD (JJ located)  (PP (IN between)  (NP (NNS positions)  (NP-COOD (NP (CD -79) ) (CC and)  (NP (CD -69) )))) (PP (JJ relative)  (TO to)  (NP (NP (DT the)  (NN transcription)  (NN start)  (NN site) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN IL-4)  (NN gene) ))))))) (, ,)  (CC and)  (S (NP-SBJ-51 (DT this)  (NN location) ) (VP (VBD was)  (VP (VBN confirmed)  (NP (-NONE- *-51) ) (PP (IN by)  (NP-LGS (NN base-substitution)  (NNS mutations) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NNS plasmids) ) (VP (VBG carrying)  (NP (NP (JJ multiple)  (NNS copies) ) (PP (IN of)  (NP (DT the)  (NN P)  (NN sequence) ))))) (VP (VBD showed)  (NP (NP (JJR higher)  (NN responsiveness) ) (PP (TO to)  (NP (DT the)  (NN stimulation) )))) (. .) ) )
(TOP (S (NP-SBJ-52 (NP (DT The)  (VBG binding)  (NN protein)  (-LRB- -LRB-)  (NNS s)  (-RRB- -RRB-) ) (SBAR (WHNP-53 (WDT that) ) (S (NP-SBJ (-NONE- *T*-53) ) (VP (VBP recognize)  (NP (NP (DT the)  (NN P)  (NN sequence) ) (PP (IN of)  (NP (DT the)  (NN IL-4)  (NN gene) ))))))) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-52) ) (PP (IN by)  (NP-LGS (JJ DNA-mobility-shift)  (NNS assays) )))) (. .) ) )
(TOP (S (NP-SBJ-54 (NP (DT The)  (NN binding) ) (PP (IN of)  (NP (NP (NN NF-LRB-P-RRB-) ) (PRN (-LRB- -LRB-)  (NP (NP (DT a)  (NN DNA)  (NN binding)  (NN protein) ) (SBAR (WHNP-56 (WDT that) ) (S (NP-SBJ (-NONE- *T*-56) ) (ADVP (RB specifically) ) (VP (VBZ recognizes)  (NP (DT the)  (NN P)  (NN sequence) ))))) (-RRB- -RRB-) ))) (PP (TO to)  (NP (DT the)  (NN P)  (NN sequence) ))) (VP (VBD was)  (VP (VBN abolished)  (NP (-NONE- *-54) ) (SBAR-TMP (WHADVP-57 (WRB when) ) (S (NP-SBJ-58 (NP (NNS oligonucleotides) ) (VP (VBG carrying)  (NP (NN base)  (NNS substitutions) ))) (VP (VBD were)  (VP (VBN used)  (NP (-NONE- *-58) ) (ADVP (-NONE- *T*-57) ))))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG indicating)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN NF-LRB-P-RRB-)  (NN interaction) ) (VP (VBZ is)  (ADJP-PRD (JJ sequence-specific) )))) (CC and)  (SBAR (IN that)  (NP-SBJ (NP (NN binding)  (NN specificity) ) (PP (IN of)  (NP (DT the)  (NN protein) ))) (VP (VBD paralleled)  (NP (NP (DT the)  (NN sequence)  (NNS requirements) ) (PP (IN for)  (NP (NN IL-4)  (NN expression) )) (ADVP (FW in)  (FW vivo) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN P)  (NN sequence) ) (VP (VBZ does)  (RB not)  (VP (VB share)  (NP (NN homology) ) (PP (IN with)  (NP (NP (DT the)  (ADJP (NP (JJ 5') ) (JJ upstream) ) (NN sequence) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN gene) )))) (, ,)  (SBAR (RB even)  (IN though)  (S (NP-SBJ (NP (VBG surrounding)  (NNS sequences) ) (PP (IN of)  (NP (DT the)  (NN IL-4)  (NN gene) ))) (VP (NN share)  (NP (JJ high)  (NN homology) ) (PP (IN with)  (NP (DT the)  (NN IL-2)  (NN gene) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP conclude)  (SBAR (IN that)  (S (NP-SBJ (NP (DT a)  (JJ different)  (NN set) ) (PP (IN of)  (NP (NNS proteins) ))) (VP (VBP recognize)  (NP (NP-COOD (NP (NN IL-2) ) (CC and)  (NP (NN IL-4) )) (NNS genes) ))))) (. .) ) )
(TOP (NP (NP (NP (NN Glucocorticoid)  (NN receptor)  (NN binding) ) (PP (IN in)  (NP (NP (CD three)  (JJ different)  (NN cell)  (NNS types) ) (PP (IN in)  (NP (JJ major)  (JJ depressive)  (NN disorder) )))) (: :) ) (NP (NP (NN lack) ) (PP (IN of)  (NP (NP (NN evidence) ) (PP (IN of)  (NP (NN receptor)  (NN binding)  (NN defect) )))) (. .) )) )
(TOP (S (S (LST (LS 1)  (. .) ) (SBAR-PRP (IN In)  (NN order)  (TO to)  (S (NP-SBJ (-NONE- *) ) (ADVP (RB further) ) (VP (VB understand)  (NP (NP (DT the)  (JJ apparent)  (NN glucocorticoid)  (NN resistance) ) (PP (IN in)  (NP (JJ major)  (JJ depressive)  (NN disorder) )))))) (, ,)  (NP-SBJ-COOD-54 (NP (NP (JJ circadian)  (NN variation) ) (PP (IN in)  (NP (NN cortisol)  (NN concentration) ))) (, ,)  (NP (NN dexamethasone)  (NN suppression) ) (CC and)  (NP (NP (NN glucocorticoid)  (NN receptor)  (NN binding) ) (PP (IN in)  (NP-COOD (NP (JJ mononuclear)  (NNS leukocytes) ) (, ,)  (NP (JJ polymorphonuclear)  (NNS leukocytes) ) (CC and)  (NP (VBN cultured)  (NN skin)  (NNS fibroblasts) ))))) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-54) ) (PP (IN in)  (NP-COOD (NP (ADJP (RB rigidly)  (VBN defined) ) (JJ major)  (JJ depressive)  (NN disorder)  (NNS patients) ) (CC and)  (NP (JJ non-depressed)  (JJ psychiatric)  (NNS controls) )))))) (. .) ) )
(TOP (S (LST (LS 2)  (. .) ) (S-COOD (S (NP-SBJ (NP (JJ Mononuclear)  (NNS leukocytes) ) (VP (VBG binding)  (PP (TO to)  (NP (NN glucocorticoid) )))) (VP (VBD correlated)  (ADVP (RB significantly) ) (PP (IN with)  (NP (NP (JJ polymorphonuclear)  (NNS leukocytes) ) (VP (VBG binding)  (PP (TO to)  (NP (NN glucocorticoid) ))))))) (, ,)  (CC but)  (S (NP-SBJ-55 (DT both)  (NNS determinations) ) (VP (VBD failed)  (S (NP-SBJ (-NONE- *-55) ) (VP (TO to)  (VP (VB differentiate)  (NP-COOD (NP (JJ major)  (JJ depressive)  (NN disorder) ) (CC and)  (NP (NN control)  (NNS subjects) )))))))) (. .) ) )
(TOP (S (LST (LS 3)  (. .) ) (NP-SBJ (NP (ADJP-COOD (ADJP (JJ Initial) ) (CC and)  (ADJP (JJ post-dexamethasone) )) (ADJP (FW in)  (FW vitro) ) (NN fibroblast) ) (VP (VBG binding)  (PP (TO to)  (NP (NN glucocorticoid) )))) (VP (VBD was)  (RB not)  (ADJP-PRD (JJ different) ) (PP (IN between)  (NP-COOD (NP (JJ major)  (JJ depressive)  (NN disorder) ) (CC and)  (NP (JJ non-depressed)  (NN control)  (NNS subjects) )))) (. .) ) )
(TOP (S (LST (LS 4)  (. .) ) (NP-SBJ (NP (DT The)  (NN phenomenon) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN resistance) )) (PP (IN in)  (NP (JJ major)  (JJ depressive)  (NN disorder) ))) (VP (VBZ remains)  (ADJP-PRD (JJ unexplained) )) (. .) ) )
(TOP (NP (NP (NP-COOD (NP (NP (NNS Kinetics) ) (PP (IN of)  (NP (JJ nuclear)  (NN translocation) ))) (CC and)  (NP (NP (NN turnover) ) (PP (IN of)  (NP (DT the)  (NN vitamin)  (NN D)  (NN receptor) )))) (PP (IN in)  (NP-COOD (NP (JJ human)  (NN HL60)  (NN leukemia)  (NNS cells) ) (CC and)  (NP (JJ peripheral)  (NN blood)  (NNS lymphocytes) ))) (: --) ) (NP (NP (JJ coincident)  (NN rise) ) (PP (IN of)  (NP (JJ DNA-relaxing)  (NN activity) )) (PP (IN in)  (NP (JJ nuclear)  (NNS extracts) )) (. .) )) )
(TOP (S (NP-SBJ-40 (NP (NP (JJ High)  (NN affinity)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NN VDR) ) (-RRB- -RRB-) )) (PP (IN for)  (NP (NP (NN 1,25-dihydroxycholecalciferol) ) (PRN (-LRB- -LRB-)  (NP (NN calcitriol) ) (-RRB- -RRB-) )))) (VP (VBP are)  (VP (VBN expressed)  (NP (-NONE- *-40) ) (PP-COOD (PP (IN in)  (NP (NN HL60)  (JJ human)  (NN leukemia)  (NNS cells) )) (CC and)  (PP (IN in)  (NP (NP (JJ low)  (NNS numbers) ) (PP (IN in)  (NP (NP (JJ peripheral)  (NN blood)  (NNS lymphocytes) ) (PRN (-LRB- -LRB-)  (NP (NN PBL) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP (NN HL60)  (NNS cells) ) (, ,)  (VP (VBG expressing)  (NP (NP (DT some)  (NNS characteristics) ) (PP (IN of)  (NP (NNS promyelocytes) )))) (, ,) ) (VP (MD can)  (VP (VB be)  (VP (VBN induced)  (NP (-NONE- *-41) ) (PP (TO to)  (NP (NN monocytoid)  (NN differentiation) )) (PP (IN by)  (NP-LGS (NN calcitriol) ))))) (. .) ) )
(TOP (S (NP-SBJ-42 (NP (JJ Specific)  (JJ nuclear)  (NN translocation) ) (PP (IN of)  (NP (NN -LCB-3H-RCB-calcitriol/VDR) ))) (VP (VBD was)  (VP (VBN examined)  (NP (-NONE- *-42) ) (PP-TMP (IN after)  (NP-COOD (NP (NP (NN exposure) ) (PP (IN of)  (NP (JJ whole)  (NNS cells) )) (PP (TO to)  (NP (ADJP (CD 10-LRB--9-RRB-) (NN  M/l) ) (NN calcitriol) )) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN presence) ) (CC and)  (NP (NN absence) )) (PP (IN of)  (NP (NP (DT a)  (JJ 500-fold)  (NN excess) ) (PP (IN of)  (NP (JJ unlabeled)  (NN ligand) ))))))) (CC and)  (NP (NP (JJ subsequent)  (NN isolation) ) (PP (IN of)  (NP (NNS nuclei) ))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-43 (NP (JJ Specific)  (JJ nuclear)  (NN translocation) ) (PP (IN of)  (NP (NN -LCB-3H-RCB-calcitriol/VDR) ))) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ-44 (-NONE- *-43) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (NN time)  (JJ dependent) ) (S (NP-SBJ (-NONE- *-44) ) (VP (VBG reaching)  (NP-45 (NP (DT a)  (NN maximum) ) (PP (IN of)  (NP (QP (RB approximately)  (CD 2100) ) (VBG binding) (NNS  sites/nucleus) ))) (PP-TMP (IN after)  (NP (NP (CD 3)  (NN h) ) (PP (IN of)  (NP (NN incubation) )) (PP (IN in)  (NP (NN HL60)  (NNS cells) )))))))))))) (, ,)  (IN whereas)  (S (NP-SBJ=45-46 (NP (DT a)  (NN maximum) ) (PP (IN of)  (NP (QP (RB approximately)  (CD 310) ) (VBG binding) (NNS  sites/nucleus) ))) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-46) ) (PP-TMP (IN after)  (NP (NP (CD 3)  (NN h) ) (PP (IN in)  (NP (NN PBL) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Pulse)  (NN exposure) ) (PP (IN of)  (NP (NN HL60) )) (PP (TO to)  (NP (VBN radiolabeled)  (NN hormone) )) (PP-TMP (IN for)  (NP (CD 3)  (NN h) )) (VP (VBN followed)  (NP (-NONE- *) ) (PP (IN by)  (NP (NP (NN culture) ) (PP (IN in)  (NP (NN medium) )) (PP (IN without)  (NP-COOD (NP (NN serum) ) (CC and)  (NP (NN calcitriol) ))))))) (VP (VBD lead)  (PP (TO to)  (NP-COOD (NP (NP (JJ nuclear)  (NN retention) ) (PP (IN of)  (NP-102 (QP (RB approximately)  (CD 1600) ) (VBN radiolabeled)  (NN VDR) )) (PP-TMP-103 (IN by)  (NP (CD 8)  (NN h) ))) (CC and)  (NP (NP=102 (QP (RB approximately)  (CD 1000) ) (NN VDR) ) (PP-TMP=103 (IN by)  (NP (CD 24)  (NN h) )))))) (. .) ) )
(TOP (S (NP-SBJ (VBN Radiolabeled)  (NN VDR) ) (VP (VBD disappeared)  (PP (IN from)  (NP (DT the)  (JJ nuclear)  (NN compartment) )) (PP (IN with)  (NP (NP (DT a)  (NN halflife) ) (PP-TMP (IN of)  (NP (QP (RB approximately)  (CD 30) ) (NN min) )))) (SBAR (IN if)  (S (NP-SBJ-47 (NNS cells) ) (VP (VBD were)  (VP (VP (VBN cultured)  (NP (-NONE- *-47) ) (PP (IN with)  (NP (NP (JJ identical)  (NNS concentrations) ) (PP (IN of)  (NP (JJ unlabeled)  (NN hormone) )))) (PP (IN after)  (NP (DT the)  (NN pulse) ))) (PRN (-LRB- -LRB-)  (NP (NNS pulse/chase-experiments) ) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (NP-SBJ-48 (NP (DT No)  (NN difference) ) (PP (IN of)  (NP (NN VDR)  (NN retention) )) (PP (IN in)  (NP-COOD (NP (NN pulse) ) (CC and)  (NP (NNS pulse/chase-experiments) )))) (VP (VBD was)  (VP (VBN seen)  (NP (-NONE- *-48) ) (PP (IN in)  (NP (NP (NN PBL) ) (, ,)  (SBAR (WHADVP-49 (WRB where) ) (S (NP-SBJ (NN VDR)  (NN halflife) ) (VP (VBD was)  (NP-PRD-TMP (QP (RB approximately)  (CD 30) ) (NN min) ) (ADVP (-NONE- *T*-49) )))))))) (. .) ) )
(TOP (S (NP-SBJ-50 (NP (DT No)  (JJ specific)  (NN translocation) ) (PP (IN into)  (NP (DT the)  (JJ nuclear)  (NN compartment) ))) (VP (VBD was)  (VP (VBN seen)  (NP (-NONE- *-50) ) (SBAR-TMP (WHADVP-51 (WRB when) ) (S (NP-SBJ-52 (VBN isolated)  (NNS nuclei) ) (VP (VBD were)  (VP (VBN incubated)  (NP (-NONE- *-52) ) (PP (IN in)  (NP (NN -LCB-3H-RCB-calcitriol) )) (ADVP (-NONE- *T*-51) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (VBN Radiolabeled) (NN  hormone/receptor)  (NNS complexes) ) (PP (IN of)  (NP (NNS nuclei) )) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (NNS cells) ) (VP (VBN exposed)  (NP (-NONE- *) ) (PP-TMP (IN for)  (NP (CD 3)  (NN h) )) (PP (TO to)  (NP (VBN radiolabeled)  (NN hormone) )) (: --)  (PP (IN in)  (NN contrast)  (TO to)  (NP (NP (JJ identical)  (NNS experiments) ) (PP (IN with)  (NP (JJ intact)  (NNS cells) )))) (: --) ))))) (VP (VBD did)  (RB not)  (VP (VB disappear)  (PP (IN from)  (NP (DT the)  (JJ nuclear)  (NN compartment) )) (PP-TMP (IN upon)  (NP (NP (NN incubation) ) (PP (IN of)  (NP (NNS nuclei) )) (PP (IN with)  (NP (NP (JJ identical)  (NNS concentrations) ) (PP (IN of)  (NP (DT the)  (JJ unlabeled)  (NN compound) )))))))) (. .) ) )
(TOP (S (NP-SBJ-53 (NP (DT The)  (NN activity) ) (PP (IN of)  (NP (NP (NP (NN DNA)  (NN relaxing)  (NNS enzymes) ) (-LRB- -LRB-)  (ADVP (FW e.g.)  (NP (NNS topoisomerases)  (NP-COOD (NP (CD I) ) (CC and)  (NP (CD II) )))) (-RRB- -RRB-) ) (PP (IN in)  (NP (JJ nuclear)  (NNS extracts) ))))) (VP (VBD was)  (VP (VBN measured)  (NP (-NONE- *-53) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (DT a)  (NN PBR)  (NN 322-relaxation-assay) ))))) (. .) ) )
(TOP (S (NP-SBJ-54 (VBN Enhanced)  (JJ overall)  (NN enzyme)  (NN activity) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-54) ) (PP (IN in)  (NP (JJ nuclear)  (NNS extracts) )) (PP-TMP (IN by)  (NP (NP (CD 1)  (NN h) ) (PP (IN after)  (NP (NP (NN incubation) ) (PP (IN with)  (NP (NP (NN calcitriol) ) (PRN (-LRB- -LRB-)  (FRAG (NP (JJ final)  (NN ethanol)  (NN concentration)  (NP (ADJP (CD 0.0001)  (NN %) ) (NN v/v) ))) (-RRB- -RRB-) ))) (PP (IN in)  (NP-COOD (NP (NN HL60) ) (CC and)  (NP (NN PBL) ))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (DT The)  (VBN enhanced)  (NN activity) ) (VP (VBD disappeared)  (PP-TMP (IN after)  (NP (NP (CD 2)  (NN h) ) (PP (IN in)  (NP (NN PBL) )))))) (, ,)  (IN whereas)  (S (NP-SBJ-55 (PRP it) ) (VP (VBD was)  (ADVP (RB still) ) (VP (VBN enhanced)  (NP (-NONE- *-55) ) (PP-TMP (IN by)  (NP (CD 4)  (NN h) )) (PP (IN in)  (NP (NN HL60) ))))) (. .) ) )
(TOP (S (NP-SBJ-56 (DT No)  (NN effect) ) (VP (VBD was)  (VP (VBN seen)  (NP (-NONE- *-56) ) (PP (IN in)  (NP (ADJP (NN ethanol)  (JJ treated) ) (NNS controls) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP conclude)  (SBAR (IN that)  (S (NP-SBJ (DT a)  (JJ specific)  (JJ nuclear)  (NN translocation)  (NN mechanism) ) (VP (VBZ exists)  (PP (IN for)  (NP (NN calcitriol) )) (PP (IN in)  (NP (NP (DT both)  (NN cell)  (NNS types) ) (VP (VBN examined)  (NP (-NONE- *) )))) (, ,)  (PP (ADVP (RBS most)  (RB likely) ) (IN due)  (TO to)  (NP (NP (NN translocation) ) (PP (IN of)  (NP (NN receptor)  (NNS proteins) )) (PP-TMP (IN after)  (NP (NN hormone)  (NN binding) )))))))) (. .) ) )
(TOP (S (NP-SBJ (VBN Translocated) (NN  hormone/receptor)  (NNS complexes) ) (VP (VBP compete)  (PP (IN for)  (NP (NP (DT a)  (JJ limited)  (NN number) ) (PP (IN of)  (NP (JJ specific)  (JJ nuclear)  (VBG binding)  (NNS sites) ))))) (. .) ) )
(TOP (S (NP-SBJ-57 (NP (VBN Enhanced)  (NN activity) ) (PP (IN of)  (NP (NNS topoisomerases) )) (PP (IN in)  (NP (JJ nuclear)  (NNS extracts) )) (PP-TMP (IN upon)  (NP (NP (NN translocation) ) (PP (IN of)  (NP (NN VDR) ))))) (VP (MD might)  (VP (VB reflect)  (NP (NP (NN interaction) ) (PP (IN of)  (NP (DT both) )) (PP (IN within)  (NP (DT the)  (JJ nuclear)  (NN compartment) ))) (, ,)  (S (ADVP (RB thus) ) (NP-SBJ (-NONE- *-57) ) (VP (VBG initiating)  (NP (NP (NN DNA-unwinding) ) (, ,)  (NP (NP (DT a)  (NN prerequisite) ) (PP (IN of)  (NP (NN transcription)  (NN initiation) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (ADJP (NN B)  (JJ cell-specific) ) (JJ nuclear)  (NN factor)  (NN OTF-2) ) (ADVP (RB positively) ) (VP (VBZ regulates)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NP (DT the)  (JJ human)  (NN class)  (CD II)  (NN transplantation)  (NN gene) ) (, ,)  (NP (NN DRA) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN promoter) ) (PP (IN of)  (NP (DT the)  (JJ major)  (NN histocompatibility)  (NN class)  (CD II)  (NN gene)  (NN DRA) ))) (VP (VBZ contains)  (NP (NP (NP (DT an)  (NN octamer)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN ATTTGCAT) ) (-RRB- -RRB-) )) (SBAR (WHNP-36 (WDT that) ) (S (NP-SBJ-37 (-NONE- *T*-36) ) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-37) ) (PP (IN for)  (NP (NP (JJ efficient)  (NN DRA)  (NN expression) ) (PP (IN in)  (NP (NN B)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-38 (JJ Several)  (JJ DNA-binding)  (NNS proteins) ) (VP (VBP are)  (VP (VBN known)  (S (NP-SBJ (-NONE- *-38) ) (VP (TO to)  (VP (VB bind)  (NP (DT this)  (NN sequence) )))))) (. .) ) )
(TOP (SINV (ADJP-PRD-TPC-39 (DT The)  (RBS best)  (VBN characterized) ) (VP (VBP are)  (ADJP-PRD (-NONE- *T*-39) )) (NP-SBJ-COOD (NP (DT the)  (ADJP (NN B)  (JJ cell-specific) ) (NN OTF-2) ) (CC and)  (NP (DT the)  (JJ ubiquitous)  (NN OTF-1) )) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN report) ) (ADVP (RB directly) ) (VP (VBZ demonstrates)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN OTF-2) ) (CONJP (CC but)  (RB not) ) (NP (NN OTF-1) )) (VP (VBZ regulates)  (NP (DT the)  (NN DRA)  (NN gene) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (FW In)  (FW vitro) ) (NN transcription)  (NN analysis) ) (VP (VBG using)  (NP (NP (NN protein)  (NNS fractions) ) (ADJP (VBN enriched)  (PP (IN for)  (NP (DT the)  (JJ octamer-binding)  (NN protein)  (NN OTF-2) )))))) (VP (VBP demonstrate)  (NP (NP (DT a)  (JJ positive)  (JJ functional)  (NN role) ) (PP (IN for)  (NP (NN OTF-2) )) (PP (IN in)  (NP (NN DRA)  (NN gene)  (NN transcription) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (JJ OTF-1-enriched)  (NN protein)  (NNS fractions) ) (VP (VBD did)  (RB not)  (VP (VB affect)  (NP (NN DRA)  (NN gene)  (NN transcription) ) (SBAR (IN although)  (S (NP-SBJ (PRP it) ) (ADVP (RB functionally) ) (VP (VBD enhanced)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (DT another)  (NN gene) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Recombinant)  (NN OTF-2)  (NN protein) ) (VP (VBN produced)  (NP (-NONE- *) ) (PP (IN by)  (NP (ADJP (FW in)  (FW vitro) ) (NN transcription/translation) )))) (VP (MD could)  (ADVP (RB also) ) (VP (VB enhance)  (NP (NN DRA)  (NN gene)  (NN transcription) ) (ADVP (FW in)  (FW vitro) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (FW In)  (FW vivo) ) (JJ transient)  (NN transfection)  (NNS studies) ) (VP (VBG utilizing)  (NP (DT an)  (NN OTF-2)  (NN expression)  (NN vector) ))) (VP (VBD resulted)  (PP (IN in)  (NP (JJ similar)  (NNS findings)  (: :)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NN OTF-2)  (NN protein) ) (VP (VBD enhanced)  (NP (NN DRA)  (NN gene)  (NN transcription) )))) (, ,)  (CC and)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN effect) ) (VP (VBZ requires)  (NP (DT an)  (JJ intact)  (NN octamer)  (NN element) )))))))) (. .) ) )
(TOP (S (ADVP (RB Together) ) (NP-SBJ (DT these)  (NNS results) ) (VP (VBP constitute)  (NP (NP (DT the)  (JJ first)  (JJ direct)  (NN evidence) ) (PP (IN of)  (NP (NP (DT a)  (JJ positive)  (NN role) ) (PP (IN for)  (NP (DT the)  (JJ lymphoid-specific)  (JJ octamer-binding)  (NN factor) )) (PP (IN in)  (NP (NN DRA)  (NN gene)  (NN transcription) )))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP (NN Regulation) ) (PP (IN of)  (NP (NP (JJ intracellular)  (NN cholesterol)  (NN synthesis) ) (PP (IN in)  (NP (NN hypercholesterolemia) )))) (PP (IN by)  (NP (NNS glucocorticoids) )) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-1 (NP (DT The)  (NN rate) ) (PP (IN of)  (NP (NP (JJ endogenous)  (NN cholesterol)  (NN synthesis) ) (PP (IN in)  (NP (NP-COOD (NP (NN blood)  (NNS lymphocytes) ) (CC and)  (NP (NN skin)  (NNS fibroblasts) )) (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN type)  (NN IIa)  (NN hyperlipidemia) ))))))))) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ-2 (-NONE- *-1) ) (VP (TO to)  (VP (VB be)  (VP (VBN increased)  (NP (-NONE- *-2) ) (PP (IN in)  (NN comparison)  (IN with)  (NP (JJ healthy)  (NNS donors) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NNS cells) ) (PP (IN of)  (NP (JJ hyperlipidemic)  (NNS patients) ))) (VP (VBD had)  (NP (NP (JJ lowered)  (NNS levels) ) (PP (IN of)  (NP (NN glucocorticoid)  (NNS receptors) ))) (PP (RB concomitantly)  (IN with)  (NP (NP (DT a)  (JJ partial)  (NN loss) ) (PP (IN of)  (NP (NP (PRP$ their)  (NN sensitivity) ) (PP (TO to)  (NP (NNS glucocorticoids) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (NNS fibroblasts) ) (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NP (JJ hereditary)  (NN hypercholesteremia) ) (PP (IN of)  (NP (JJ homozygous)  (NN type) )))))))) (NP-SBJ (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN glucocorticoid)  (NNS receptors) ))) (VP (VBD did)  (RB not)  (VP (VB exceed)  (NP (NP (CD 10)  (NN %) ) (PP (IN of)  (NP (NP (PRP$ their)  (NN content) ) (PP (IN in)  (NP (JJ normal)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ-3 (NP (DT The)  (NN decrease) ) (PP (IN of)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN type)  (NN IIa)  (NN hyperlipidemia) ))))))))) (VP (VBZ seems)  (S (NP-SBJ (-NONE- *-3) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT a)  (JJ compensatory)  (NN response) ) (PP (IN of)  (NP (NP (NNS cells) ) (VP (VBG culminating)  (PP (IN in)  (NP (NP (NN activation) ) (PP (IN of)  (NP (JJ endogenous)  (NN cholesterol)  (NN synthesis) )))))))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NN Transcription)  (NN factor)  (NN activation) ) (CC and)  (NP (JJ functional)  (NN stimulation) )) (PP (IN of)  (NP (JJ human)  (NNS monocytes) )) (. .) ) )
(TOP (NP (NP (NP (NN Activation) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBG encoding)  (NP (NN transcription)  (NNS factors) )))))) (: :) ) (S (NP-SBJ-57 (NP-COOD (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (CC and)  (NP (NP (NN formation) ) (PP (IN of)  (NP (NN AP1)  (JJ transcriptional)  (NN complex) )))) (PP (IN in)  (NP (JJ human)  (NNS monocytes) ))) (VP (VBD was)  (VP (VBN investigated)  (NP (-NONE- *-57) ))) (. .) )) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBD was)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ (NN lipopolysaccharide) ) (VP (VBD induced)  (ADVP (RB strongly) ) (NP-COOD (NP (NP-COOD (CC both)  (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN expression) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (NN AP1)  (NN formation) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Interferon)  (NN gamma) ) (VP-COOD (VP (VBD activated)  (ADVP-110 (RB strongly) ) (NP-111 (NN c-fos) )) (CC and)  (VP (ADVP=110 (RB weakly) ) (NP-COOD=111 (NP (NN c-jun) ) (CC and)  (NP (NN AP1) )))) (. .) ) )
(TOP (S (NP-SBJ (NN Tumor)  (NN necrosis)  (NN factor) ) (VP-COOD (VP (VBD induced)  (ADVP (RB slightly) ) (NP (NN c-fos) )) (CC and)  (VP (VBD had)  (NP (QP (RB almost)  (DT no) ) (NN effect) ) (PP (IN on)  (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN AP1) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS data) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (NNS differences) ) (PP (IN in)  (NP (NP (JJ functional)  (NNS responses) ) (VP (VBN elicited)  (NP (-NONE- *) ) (PP (IN in)  (NP (NNS monocytes) )) (PP (IN by)  (NP-LGS (QP (DT all)  (CD three) ) (NNS factors) )))))) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ dependent)  (PP (IN on)  (NP (NP (JJ different)  (NNS routes) ) (PP (IN on)  (NP (NP (JJ nuclear)  (NN signalling) ) (VP (VBN employed)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT the)  (NNS factors) ))))))))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NN Corticosteroid)  (NNS receptors) ) (CC and)  (NP (NN lymphocyte)  (NNS subsets) )) (PP (IN in)  (NP (NP (JJ mononuclear)  (NNS leukocytes) ) (PP (IN in)  (NP (NN aging) )))) (. .) ) )
(TOP (S (NP-SBJ-42 (NP-COOD (NP (NN Plasma)  (NN cortisol) ) (CC and)  (NP (NP (NN aldosterone)  (NP-COOD (NP (NNS levels) ) (CC and)  (NP (NN number) ))) (PP (IN of)  (NP (JJ related)  (NNS receptors) )))) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) ))) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-42) ) (PP-COOD (PP (IN in)  (NP (NP (CD 49)  (JJ healthy)  (JJ aged)  (NNS subjects) ) (PRN (-LRB- -LRB-)  (FRAG (NP (QP (CD 62-97) ) (NN yr) )) (-RRB- -RRB-) ))) (CC and)  (PP (IN in)  (NP (NP (CD 21)  (JJ adult)  (NNS controls) ) (PRN (-LRB- -LRB-)  (FRAG (NP (QP (CD 21-50) ) (NN yr) )) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT all)  (NNS subjects) )) (, ,)  (PP (IN in)  (NP (NN addition) )) (, ,)  (NP-SBJ-43 (NN lymphocyte)  (NNS subsets) ) (VP (VBD were)  (VP (VBN determined)  (NP (-NONE- *-43) ) (PP (IN as)  (NP (NP (DT an)  (NN index) ) (PP (IN of)  (NP (NN corticosteroid)  (NN action) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN mean)  (NN number) ) (PP (IN of)  (NP (NP-COOD (NP (NN type)  (CD I) ) (CC and)  (NP (NN type)  (CD II) )) (NNS receptors) ))) (VP (VP (VBD was)  (ADJP-PRD (ADJP (RB significantly)  (JJR lower) ) (PP (-NONE- *ICH*-44) )) (PP (IN in)  (NP (JJ aged)  (NNS subjects) )) (PP-44 (IN than)  (FRAG (PP (IN in)  (NP (NNS controls) ))))) (PRN (-LRB- -LRB-)  (FRAG (ADVP (RB respectively) ) (, ,)  (NP (NP-COOD (NP (NP (QP (CD 198) (CC  +/-)  (CD 96)  (CC and)  (CD 272) (CC  +/-)  (CD 97) ) (NNS receptors/cell) ) (PP (IN for)  (NP (NN type)  (CD I)  (NP (-NONE- *RNR*-45) )))) (, ,)  (CC and)  (NP (NP (QP (CD 1,794) (CC  +/-)  (CD 803)  (CC and)  (CD 3,339) (CC  +/-)  (CD 918) )) (PP (IN for)  (NP (NN type)  (CD II)  (NP (-NONE- *RNR*-45) ))))) (NP-45 (NNS receptors) ))) (-RRB- -RRB-) )) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN Plasma)  (NP-COOD (NP (NN aldosterone) ) (CC and)  (NP (NN cortisol) ))) (CC and)  (NP (NN lymphocyte)  (NNS subsets) )) (VP (VBD were)  (RB not)  (ADJP-PRD (JJ different) ) (PP (IN in)  (NP (DT the)  (CD two)  (NNS groups) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-46 (NP (DT All) ) (PP (IN of)  (NP (DT the)  (NNS parameters) ))) (VP (VBD were)  (ADVP (RB also) ) (VP (VBN tested)  (NP (-NONE- *-46) ) (PP (IN for)  (NP (NN correlation) ))))) (, ,)  (CC and)  (S (NP-SBJ-47 (DT a)  (JJ significant)  (JJ inverse)  (NN correlation) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-47) ) (PP (IN between)  (NP-COOD (NP (NN age) ) (CC and)  (NP (NP-COOD (NP (NN type)  (CD I) ) (CC and)  (NP (NN type)  (CD II) )) (NNS receptors) ))) (SBAR-TMP (WHADVP-48 (WRB when) ) (S (NP-SBJ-49 (DT all)  (NNS subjects) ) (VP (VBD were)  (VP (VBN plotted)  (NP (-NONE- *-49) ) (CC and)  (PP (IN between)  (NP (JJ aged)  (CC and)  (NN CD4)  (CC and)  (NN age)  (CC and) (NN  CD4/CD8) )) (PP (IN in)  (NP (DT the)  (JJ aged)  (NN group) )) (ADVP (-NONE- *T*-48) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP show)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (JJ aged)  (NNS subjects) ) (VP (VBP have)  (NP (NP (NNS reductions) ) (PP (IN of)  (NP (NN corticosteroid)  (NNS receptors) )) (SBAR (WHNP-50 (WDT that) ) (S (NP-SBJ-51 (-NONE- *T*-50) ) (VP (VBP are)  (RB not)  (VP (VBN associated)  (NP (-NONE- *-51) ) (PP (IN with)  (NP (NP (NN increase) ) (PP (IN of)  (NP (JJ related)  (NNS steroids) )))))))))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN situation) ) (ADVP (RB probably) ) (VP (VBZ represents)  (NP (NP (DT a)  (NN concomitant) ) (PP (IN of)  (NP (DT the)  (JJ normal)  (NN aging)  (NN process) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Stable)  (NN expression) ) (PP (IN of)  (NP (NP (NN HB24) ) (, ,)  (NP (DT a)  (JJ diverged)  (JJ human)  (NN homeobox)  (NN gene) ) (, ,) )) (PP (IN in)  (NP (NN T)  (NNS lymphocytes) ))) (VP (VBZ induces)  (NP (NP (NNS genes) ) (VP (VBN involved)  (NP (-NONE- *) ) (PP (IN in)  (NP (NN T)  (NN cell)  (NP-COOD (NP (NN activation) ) (CC and)  (NP (NN growth) ))))))) (. .) ) )
(TOP (S (NP-SBJ-53 (NP (NP (DT A)  (JJ diverged)  (NN homeobox)  (NN gene) ) (, ,)  (NP (NN HB24) )) (, ,)  (SBAR (WHNP-54 (WDT which) ) (S (NP-SBJ-55 (-NONE- *T*-54) ) (VP (VBZ is)  (VP (VBN known)  (S (NP-SBJ-56 (-NONE- *-55) ) (VP (TO to)  (VP (VB be)  (VP (VBN induced)  (NP (-NONE- *-56) ) (PP-TMP (VBG following)  (NP (NN lymphocyte)  (NN activation) )))))))))) (, ,) ) (VP (VBD was)  (VP (VBN introduced)  (NP (-NONE- *-53) ) (PP (IN into)  (NP (NN Jurkat)  (NN T)  (NNS cells) )) (PP (IN under)  (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP (DT a)  (JJ constitutive)  (NN promoter) )))))) (. .) ) )
(TOP (S (NP-SBJ-57 (NP (JJ Stable)  (NNS transfectants) ) (PP (IN of)  (NP (NN HB24) )) (SBAR (-NONE- *ICH*-58) )) (VP (VBD were)  (VP (VBN established)  (NP (-NONE- *-57) ) (SBAR-58 (WHNP-59 (WDT that) ) (S (NP-SBJ (-NONE- *T*-59) ) (VP-COOD (VP (VBD expressed)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (NN HB24)  (NN mRNA) )))) (CC and)  (VP (VBD possessed)  (NP (NP (DT an)  (JJ altered)  (NN phenotype) ) (ADJP (JJ suggestive)  (PP (IN of)  (NP (VBN activated)  (NN T)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-60 (NP (DT A)  (NN number) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP-COOD (VP (VBN known)  (S (NP-SBJ-62 (-NONE- *) ) (VP (TO to)  (VP (VB be)  (VP (VBN induced)  (NP (-NONE- *-62) ) (PP-TMP (VBG following)  (NP (NN T)  (NN cell)  (NN activation) ))))))) (CC and)  (VP (VBN associated)  (NP (-NONE- *) ) (PP (IN with)  (NP (NN cell)  (NN growth) ))))))) (VP (VBD were)  (VP (VBN increased)  (NP (-NONE- *-60) ) (PP (IN in)  (NP (NP (DT the)  (NNS transfectants) ) (, ,)  (PP (VBG including)  (NP-COOD (NP (NN c-fos) ) (, ,)  (NP (NN c-myc) ) (, ,)  (NP (NN c-myb) ) (, ,)  (NP (NN HLA-DR) ) (, ,)  (NP (NN lck) ) (, ,)  (NP (NN NF-kappa)  (NN B) ) (, ,)  (NP (NN interleukin-2) ) (CC and)  (NP (NP (NN interleukin-2)  (NN receptor)  (NN alpha) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2R)  (NN alpha) ) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Analysis) ) (PP (IN of)  (NP (NP (NN IL-2R)  (NN alpha)  (NN expression) ) (PP (IN by)  (NP (NP (JJ transient)  (NN transfection) ) (PP (IN of)  (NP (NN IL-2R)  (NN alpha)  (NN promoter)  (NNS constructs) )) (PP (IN into)  (NP (DT the)  (NN HB24)  (NNS transfectants) ))))))) (VP (VBD revealed)  (NP (NP (NP (JJ constitutive)  (NN expression) ) (PRN (-LRB- -LRB-)  (FRAG (NP (NP (QP (RB about)  (CD 60) ) (NN %) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (NP (NN phytohemagglutinin-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (NN phorbol)  (JJ ester-activated) )) (NN Jurkat)  (NNS cells) )))) (-RRB- -RRB-) )) (SBAR (WHNP-63 (WDT that) ) (S (NP-SBJ (-NONE- *T*-63) ) (VP (VBD was)  (ADJP-PRD (JJ dependent)  (PP (IN on)  (NP (NP (DT the)  (NN kappa)  (NN B)  (NN site) ) (PP (IN in)  (NP (DT the)  (NN IL-2R)  (NN alpha)  (NN promoter) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (PP (IN as)  (NP (NP (DT a)  (NN consequence) ) (PP (IN of)  (NP (DT the)  (VBN increased)  (NN HB24)  (NN mRNA)  (NNS levels) )))) (, ,)  (NP-SBJ (DT the)  (NN Jurkat)  (NN HB24)  (NNS transfectants) ) (VP (VBD proliferated)  (ADVP-TMP (ADVP (RBR more)  (RB rapidly) ) (PP (IN than)  (NP (NN control)  (NN cell)  (NNS lines) )))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ-64 (NP (JJ stable)  (NN expression) ) (PP (IN of)  (NP (NN HB24) ))) (VP (VBZ confers)  (NP (DT an)  (NN activation)  (NN phenotype) ) (PP (IN on)  (NP (DT a)  (JJ human)  (NN T)  (NN cell)  (NN line) )) (, ,)  (S (NP-SBJ (-NONE- *-64) ) (VP (VBG implicating)  (NP (DT this)  (NN gene) ) (PP (IN as)  (NP (NP (DT an)  (JJ important)  (JJ transcriptional)  (NN factor) ) (PP-TMP (IN during)  (NP (NN T)  (NN cell)  (NP-COOD (NP (NN activation) ) (CC and)  (NP (NN growth) ))))))))) (. .) ) )
(TOP (NP (NP (NNS Studies) ) (PP (IN on)  (NP (NP (DT the)  (JJ biological)  (NN activity) ) (PP (IN of)  (NP (NN triiodothyronine)  (NN sulfate) )))) (. .) ) )
(TOP (S (NP-SBJ (NP-COOD (NP (JJ Hepatic)  (NNS microsomes) ) (CC and)  (NP (VBN isolated)  (NNS hepatocytes) )) (PP (IN in)  (NP (JJ short)  (NN term)  (NN culture) ))) (VP (VBP desulfate)  (NP (NP (NN T3)  (NN sulfate) ) (PRN (-LRB- -LRB-)  (NP (NN T3SO4) ) (-RRB- -RRB-) ))) (. .) ) )
(TOP (S (NP-SBJ-33 (PRP We) ) (, ,)  (ADVP (RB therefore) ) (, ,)  (VP (VBD wished)  (S (NP-SBJ (-NONE- *-33) ) (VP (TO to)  (VP (VB determine)  (SBAR (IN whether)  (S (NP-SBJ (NN T3SO4) ) (VP (MD could)  (VP (VB mimic)  (NP (NP (DT the)  (NN action) ) (PP (IN of)  (NP (NN thyroid)  (NN hormone) ))) (ADVP (FW in)  (FW vitro) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN T3SO4) ) (VP (VBD had)  (NP (DT no)  (JJ thyromimetic)  (NN effect) ) (PP (IN on)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (NN Ca-LRB-2+-RRB--ATPase) )) (PP (IN in)  (NP (JJ human)  (NN erythrocyte)  (NNS membranes) )))) (PP (IN at)  (NP (NP (NNS doses) ) (NP (NP (NP (QP (RB up)  (TO to)  (CD 10,000)  (NNS times) ) (DT the)  (ADJP (RB maximally)  (JJ effective) ) (NN dose) ) (PP (IN of)  (NP (NN T3) ))) (PRN (-LRB- -LRB-)  (NP (CD 10/-LRB--10-RRB-) (NN  mol/L) ) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN GH4C1)  (JJ pituitary)  (NNS cells) )) (, ,)  (NP-SBJ-34 (NN T3SO4) ) (VP (VBD failed)  (S (NP-SBJ (-NONE- *-34) ) (VP (TO to)  (VP (VB displace)  (NP (NN -LCB-125I-RCB-T3) ) (PP (IN from)  (NP (NP (JJ nuclear)  (NNS receptors) ) (PP (IN in)  (NP-COOD (NP (JJ intact)  (NNS cells) ) (CC or)  (NP (JJ soluble)  (NNS preparations) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (NN T3SO4) ) (VP (VBD was)  (RB not)  (ADVP (RB directly) ) (ADJP-PRD (JJ thyromimetic) ) (PP (IN in)  (NP (NP-COOD (CC either)  (NP (DT an)  (VBN isolated)  (JJ human)  (NN membrane)  (NN system) ) (CC or)  (NP (DT a)  (JJ pituitary)  (NN cell)  (NN system) )) (SBAR (WHPP-35 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (JJ nuclear)  (NN receptor)  (NN occupancy) ) (VP (VBZ correlates)  (PP (IN with)  (NP (NN GH)  (NN synthesis) )) (PP (-NONE- *T*-35) ))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NN Thyroid)  (NNS hormones) ) (VP (VBP inhibit)  (NP (NN -LCB-3H-RCB-glycosaminoglycan)  (NN synthesis) ) (PP (IN by)  (NP (VBN cultured)  (JJ human)  (JJ dermal)  (NNS fibroblasts) )))) (, ,)  (CC and)  (S (NP-SBJ (NN T3SO4) ) (VP (VBN displayed)  (NP (NP (NP (QP (IN about)  (CD 0.5) ) (NN %) ) (NP (DT the)  (NN activity) )) (PP (IN of)  (NP (NN T3) ))) (PP-TMP (IN at)  (NP (CD 72)  (NN h) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Human)  (NNS fibroblasts) ) (VP (VBD contained)  (NP (NP (NP (ADVP (RB roughly) ) (DT the)  (JJ same)  (NN level) ) (PP (IN of)  (NP (JJ microsomal)  (NN p-nitrophenyl)  (NN sulfatase)  (NN activity) ))) (PP (IN as)  (NP (NP (DT that) ) (VP (ADVP-TMP (RB previously) ) (VBN observed)  (NP (-NONE- *) ) (PP (IN in)  (NP (JJ hepatic)  (NNS microsomes) ))))))) (. .) ) )
(TOP (S (NP-SBJ-36 (NP (NN Propylthiouracil) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 50) (NN  mumol/L) )) (-RRB- -RRB-) )) (VP (VBD did)  (RB not)  (VP (VB affect)  (NP (NP (DT the)  (NN action) ) (PP (IN of)  (NP (NN T3SO4) ))) (, ,)  (S (NP-SBJ (-NONE- *-36) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (NN deiodination) ) (VP (VBD was)  (RB not)  (ADJP-PRD (JJ important)  (PP (IN for)  (NP (NP (DT this)  (NN activity) ) (PP (IN of)  (NP (NN T3SO4) )))))))))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (PRP it) ) (VP (VBZ appears)  (SBAR (WHNP (-NONE- 0) ) (S (NP-SBJ-37 (NN T3SO4) ) (VP-COOD (VP (VBZ has)  (NP (DT no)  (JJ intrinsic)  (JJ biological)  (NN activity) )) (, ,)  (CC but)  (, ,)  (VP (PP (IN under)  (NP (JJ certain)  (NNS circumstances) )) (, ,)  (VP (MD may)  (VP (VB be)  (VP (VBN reactivated)  (NP (-NONE- *-37) ) (PP (IN by)  (NP-LGS (NN desulfation) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Nuclear)  (NN factor) ) (PP (IN of)  (NP (VBN activated)  (NN T)  (NNS cells) ))) (VP (VBZ contains)  (NP-COOD (NP (NN Fos) ) (CC and)  (NP (NN Jun) ))) (. .) ) )
(TOP (S (NP-SBJ-38 (NP (DT The)  (JJ nuclear)  (NN factor)  (NN NF-AT) ) (PRN (-LRB- -LRB-)  (NP (NN ref.)  (CD 1) ) (-RRB- -RRB-) )) (VP-COOD (VP (VBZ is)  (VP (VBN induced)  (NP-39 (-NONE- *-38) ) (PP (IN in)  (NP (NP (NN T)  (NNS cells) ) (VP (VBN stimulated)  (NP (-NONE- *) ) (PP (IN through)  (NP (DT the)  (ADJP (NN T-cell) (NN  receptor/CD3) ) (NN complex) ))))))) (, ,)  (CC and)  (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-39) ) (PP (IN for)  (NP (NP (NP (NN interleukin-2) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2) ) (-RRB- -RRB-) )) (NN gene)  (NN induction) ))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ-40 (NN NF-AT) ) (VP (VBZ has)  (RB not)  (VP (VBN been)  (VP-COOD (VP (VBN cloned)  (NP (-NONE- *-40) )) (CC or)  (VP (VBN purified)  (NP (-NONE- *-40) ))))))) (, ,)  (NP-SBJ (EX there) ) (VP (VBZ is)  (NP-PRD (NN evidence)  (SBAR (IN that)  (S (NP-SBJ (PRP it) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ major)  (NN target) ) (PP (IN for)  (NP (NP (NN immunosuppression) ) (PP (IN by)  (NP-COOD (NP (NP (NN cyclosporin)  (NN A) ) (PRN (-LRB- -LRB-)  (NP (NN CsA) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN FK506) ) (PRN (-LRB- -LRB-)  (NP (NNS refs)  (NP (CD 2-7) )) (-RRB- -RRB-) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN NF-AT)  (NN induction) ) (VP (MD may)  (VP (VB require)  (NP (NP (CD two)  (JJ activation-dependent)  (NNS events) ) (: :)  (NP (NP (NP (DT the)  (JJ CsA-sensitive)  (NN translocation) ) (PP (IN of)  (NP (DT a)  (JJ pre-existing)  (NN component) ))) (CC and)  (NP (NP (DT the)  (JJ CsA-resistant)  (NN synthesis) ) (PP (IN of)  (NP (DT a)  (JJ nuclear)  (NN component) ))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP report)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (ADJP (RB newly)  (VBN synthesized) ) (JJ nuclear)  (NN component) ) (PP (IN of)  (NP (NN NF-AT) ))) (VP (VBZ is)  (NP-PRD (DT the)  (NN transcription)  (NN factor)  (NN AP-1) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ inducible)  (JJ nuclear)  (NN form) ) (PP (IN of)  (NP (NN NF-AT) ))) (VP (VBZ contains)  (NP (NP-COOD (NP (NN Fos) ) (CC and)  (NP (NN Jun) )) (NNS proteins) ))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP identify)  (NP (NP (DT a)  (JJ pre-existing)  (JJ NF-AT-binding)  (NN factor) ) (SBAR (WHNP-42 (WDT that) ) (S (NP-SBJ (-NONE- *T*-42) ) (VP (VBZ is)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (NP (JJ hypotonic)  (NNS extracts) ) (PP (IN of)  (NP (JJ unstimulated)  (NN T)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (PP (IN On)  (DT the)  (NN basis)  (IN of)  (NP (NP-COOD (NP (NN binding) ) (, ,)  (NP (NN reconstitution) ) (CC and)  (NP (NN cotransfection) )) (NNS experiments) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP propose)  (SBAR (IN that)  (S (NP-SBJ (NP (NN activation) ) (PP (IN of)  (NP (NN NF-AT) ))) (VP (VBZ occurs)  (PP (IN in)  (NP (NP (QP (IN at)  (JJS least)  (CD two) ) (NNS stages) ) (: :)  (NP (NP (NP (DT a)  (JJ CsA-sensitive)  (NN stage) ) (VP (VBG involving)  (NP (NP-COOD (NP (NN modification) ) (CC and/or)  (NP (NN translocation) )) (PP (IN of)  (NP (DT the)  (JJ pre-existing)  (NN NF-AT)  (NN complex) ))))) (, ,)  (CC and)  (NP (NP (DT a)  (JJ CsA-insensitive)  (NN stage) ) (VP (VBG involving)  (NP (NP (DT the)  (NN addition) ) (PP (IN of)  (NP (ADJP (RB newly)  (VBN synthesized) ) (NP-COOD (NP (NN Fos) ) (CC or)  (NP (NN Fos/Jun) )) (NNS proteins) )) (PP (TO to)  (NP (DT the)  (JJ pre-existing)  (NN complex) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Interferon-gamma) ) (VP (VBZ potentiates)  (NP (NP-COOD (NP (DT the)  (JJ antiviral)  (NN activity) ) (CC and)  (NP (DT the)  (NN expression) )) (PP (IN of)  (NP (JJ interferon-stimulated)  (NNS genes) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN interferon-alpha) )) (PP (IN in)  (NP (NN U937)  (NNS cells) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Binding) ) (PP (IN of)  (NP (NP (NN type)  (CD I)  (NN interferon) ) (PRN (-LRB- -LRB-)  (NP (NN IFN-alpha/beta) ) (-RRB- -RRB-) ))) (PP (TO to)  (NP (JJ specific)  (NNS receptors) ))) (VP (VBZ results)  (PP (IN in)  (NP (NP (DT the)  (JJ rapid)  (JJ transcriptional)  (NN activation) ) (, ,)  (ADJP (JJ independent)  (PP (IN of)  (NP (NN protein)  (NN synthesis) ))) (, ,)  (PP (IN of)  (NP (NP (NP (JJ IFN-alpha-stimulated)  (NNS genes) ) (PRN (-LRB- -LRB-)  (NP (NNS ISGs) ) (-RRB- -RRB-) )) (PP (IN in)  (NP-COOD (NP (JJ human)  (NNS fibroblasts) ) (CC and)  (NP (NP-COOD (NP (NN HeLa) ) (CC and)  (NP (NN Daudi) )) (NN cell)  (NNS lines) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN binding) ) (PP (IN of)  (NP (NP (NN ISGF3) ) (PRN (-LRB- -LRB-)  (NP (JJ IFN-stimulated)  (NN gene)  (NN factor)  (CD 3) ) (-RRB- -RRB-) ))) (PP (TO to)  (NP (DT the)  (VBN conserved)  (NP (JJ IFN-stimulated)  (NN response)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN ISRE) ) (-RRB- -RRB-) )))) (VP (VBZ results)  (PP (IN in)  (NP (JJ transcriptional)  (NN activation) ))) (. .) ) )
(TOP (S (NP-SBJ-40 (DT This)  (NN factor) ) (VP (VBZ is)  (VP (VBN composed)  (NP (-NONE- *-40) ) (PP (IN of)  (NP-COOD (NP (NP (NP (DT a)  (JJ DNA-binding)  (NN protein) ) (PRN (-LRB- -LRB-)  (NP (NN ISGF3)  (NN gamma) ) (-RRB- -RRB-) )) (, ,)  (SBAR (WHNP-41 (WDT which) ) (S (NP-SBJ (-NONE- *T*-41) ) (ADVP (RB normally) ) (VP (VBZ is)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (DT the)  (NN cytoplasm) )))))) (, ,) ) (CC and)  (NP (NP (JJ other)  (JJ IFN-alpha-activated)  (NNS proteins) ) (SBAR (WHNP-42 (WDT which) ) (S (NP-SBJ (-NONE- *T*-42) ) (VP (VBP preexist)  (PP (IN as)  (NP (NP (JJ latent)  (JJ cytoplasmic)  (NNS precursors) ) (PRN (-LRB- -LRB-)  (NP (NN ISGF3)  (NN alpha) ) (-RRB- -RRB-) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ (NP (NN ISG)  (NN expression) ) (PP (IN in)  (NP (DT the)  (JJ monocytic)  (NN U937)  (NN cell)  (NN line) ))) (VP (VBZ differs)  (PP (IN from)  (NP (NP (JJS most)  (NN cell)  (NNS lines) ) (VP (ADVP-TMP (RB previously) ) (VBN examined)  (NP (-NONE- *) ))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NN U937)  (NNS cells) ) (VP (VBP express)  (NP (NP-COOD (CC both)  (NP (NN type)  (CD I) ) (CC and)  (NP (NN type)  (CD II) )) (NN IFN)  (NNS receptors) ))) (, ,)  (CC but)  (S (NP-SBJ-43 (RB only)  (NN IFN-alpha) ) (VP (VBZ is)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-43) ) (VP (VBG inducing)  (NP (JJ antiviral)  (NN protection) ) (PP (IN in)  (NP (DT these)  (NNS cells) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Pretreatment) ) (PP (IN with)  (NP (NN IFN-gamma) ))) (VP (VBZ potentiates)  (NP (DT the)  (JJ IFN-alpha-induced)  (NN protection) ))) (, ,)  (CC but)  (S (NP-SBJ (NP (NN IFN-gamma) ) (ADVP (RB alone) )) (VP (VBZ does)  (RB not)  (VP (VB have)  (NP (DT any)  (JJ antiviral)  (NN activity) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN ISG15)  (NN mRNA)  (NN accumulation) ) (PP (IN in)  (NP (NN U937)  (NNS cells) ))) (VP-COOD (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ detectable) ) (PP-TMP (IN before)  (NP (NP (CD 6)  (NN h) ) (PP (IN of)  (NP (NN IFN-alpha)  (NN treatment) ))))) (, ,)  (VP (VBZ peaks)  (PP-TMP (IN at)  (NP (CD 24)  (NN h) ))) (, ,)  (CC and)  (VP (VBZ requires)  (NP (NN protein)  (NN synthesis) ))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (NP (NN IFN-gamma) ) (ADVP (RB alone) )) (VP (VBZ does)  (RB not)  (VP (VB induce)  (NP (NN ISG)  (NN expression) ))))) (, ,)  (NP-SBJ (NN IFN-gamma)  (NN pretreatment) ) (ADVP (RB markedly) ) (VP (VP-COOD (VP (VBZ increases)  (NP (-NONE- *RNR*-108) )) (CC and)  (VP (VBZ hastens)  (NP (-NONE- *RNR*-108) ))) (NP-COOD-108 (NP (NN ISG)  (NN expression) ) (CC and)  (NP (JJ transcriptional)  (NN induction) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Nuclear)  (NNS extracts) ) (VP (VBN assayed)  (NP (-NONE- *) ) (PP (IN for)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NN ISRE)  (NN binding)  (NNS factors) )))) (PP (IN by)  (NP (JJ electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) )))) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ-44 (NN ISGF3) ) (VP (VBZ is)  (VP (VBN induced)  (NP (-NONE- *-44) ) (PP (IN by)  (NP-LGS (NN IFN-alpha) )) (PP-TMP (IN within)  (NP (CD 6)  (NN h) )) (PP (IN from)  (NP (JJ undetectable)  (JJ basal)  (NNS levels) )) (PP (IN in)  (NP (JJ untreated)  (NN U937)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Activation) ) (PP (IN of)  (NP (NP (NN ISGF3)  (NN alpha) ) (, ,)  (NP (NP (DT the)  (JJ latent)  (NN component) ) (PP (IN of)  (NP (NN ISGF3) ))) (, ,) ))) (VP (VBZ occurs)  (ADVP-TMP (RB rapidly) )) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (DT the)  (NN increase) ) (PP (IN in)  (NP (NN ISGF3)  (NN activity) ))) (ADVP (RB ultimately) ) (VP (VBZ correlates)  (PP (IN with)  (NP (NP (DT the)  (NN accumulation) ) (PP (IN of)  (NP (NN ISGF3)  (NN gamma) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (NN IFN-alpha) ) (CC or)  (NP (NN IFN-gamma) ))))))) (. .) ) )
(TOP (S (-LRB- -LRB-)  (NP-SBJ-109 (NN ABSTRACT) ) (VP (VBN TRUNCATED)  (NP (-NONE- *-109) ) (PP (IN AT)  (NP (CD 250)  (NNS WORDS) ))) (-RRB- -RRB-) ) )
(TOP (NP (NP (DT The)  (NN mechanism) ) (PP (IN of)  (NP (NP (NN action) ) (PP (IN of)  (NP-COOD (NP (NN cyclosporin)  (NN A) ) (CC and)  (NP (NN FK506) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN CsA) ) (CC and)  (NP (NN FK506) )) (VP (VBP are)  (NP-PRD (NP (JJ powerful)  (NNS suppressors) ) (PP-COOD (PP (IN of)  (NP (DT the)  (JJ immune)  (NN system) )) (, ,)  (PP (ADVP (RBS most)  (RB notably) ) (IN of)  (NP (NN T)  (NNS cells) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP They) ) (VP (VBP act)  (PP (IN at)  (NP (NP (DT a)  (NN point) ) (PP (IN in)  (NP (NN activation) )) (SBAR (WHNP-22 (WDT that) ) (S (NP-SBJ (-NONE- *T*-22) ) (VP (VBZ lies)  (PP (IN between)  (NP-COOD (NP (NN receptor)  (NN ligation) ) (CC and)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (JJ early)  (NNS genes) ))))))))))) (. .) ) )
(TOP (S (S (ADVP (RB Here) ) (, ,)  (NP-SBJ-COOD (NP (NNP Stuart)  (NNP Schreiber) ) (CC and)  (NP (NNP Gerald)  (NNP Crabtree) )) (VP (VBP review)  (NP (NP (JJ recent)  (NNS findings) ) (SBAR (WHNP-23 (WDT that) ) (S (NP-SBJ (-NONE- *T*-23) ) (S (VBP indicate)  (SBAR (WHNP (-NONE- 0) ) (S (NP-SBJ-COOD (NP (NN CsA) ) (CC and)  (NP (NN FK506) )) (VP (VBP operate)  (PP (IN as)  (NP (NNS prodrugs) )))))))))) (: :) ) (S-COOD (S (NP-SBJ (PRP they) ) (VP (VBP bind)  (NP (NP (JJ endogenous)  (JJ intracellular)  (NNS receptors) ) (, ,)  (NP (DT the)  (NNS immunophilins) )))) (, ,)  (CC and)  (S (NP-SBJ-24 (DT the)  (VBG resulting)  (NN complex) ) (VP (VBZ targets)  (NP (NP (DT the)  (NN protein)  (NN phosphatase) ) (, ,)  (NP (NN calcineurin) ) (, ,) ) (S (NP-SBJ (-NONE- *-24) ) (VP (TO to)  (VP (VB exert)  (NP (DT the)  (JJ immunosuppressive)  (NN effect) )))))) (. .) )) )
(TOP (NP (-LRB- -LCB-)  (NP-COOD (NP (NN Plasma)  (NN cortisol)  (NN concentration) ) (CC and)  (NP (NP (NN blood)  (NN leukocyte)  (NN content) ) (PP (IN of)  (NP (NN glucocorticoid)  (NNS receptors) )))) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (ADJP-COOD (ADJP (JJ deficiency-cold) ) (CC vs)  (ADJP (JJ deficiency-heat) )) (NNS syndromes) )))) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-COOD-10 (NP (NN Plasma)  (NN cortisol)  (NN concentration) ) (CC and)  (NP (NP (NN blood)  (NN leukocyte)  (NN content) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NN GCR) ) (-RRB- -RRB-) ))))) (VP (VBD were)  (VP (VP-COOD (VP (VBN assayed)  (NP (-NONE- *-10) ) (PP-11 (IN in)  (NP (NP (NP (CD 20)  (NNS patients) ) (PP (IN with)  (NP (NN deficiency)  (NNS syndromes) ))) (, ,)  (NP-COOD (NP (NP (QP (CD 10) )) (ADJP (ADJP (JJ cold)  (PP (IN in)  (NP (NN property) ))) (PRN (-LRB- -LRB-)  (ADJP (JJ deficiency-cold) ) (-RRB- -RRB-) ))) (, ,)  (NP (NP (DT the)  (JJ other)  (NP (QP (CD 10) ))) (ADJP (ADJP (JJ hot)  (PP (IN in)  (NP (NN property) ))) (PRN (-LRB- -LRB-)  (ADJP (JJ deficiency-heat) ) (-RRB- -RRB-) ))))))) (, ,)  (CC and)  (RB also)  (VP (PP=11 (IN in)  (NP (CD 10)  (JJ healthy)  (NNS individuals) )) (PP (IN as)  (NP (JJ normal)  (NN control) )))) (PP (IN for)  (NP (NP (DT the)  (NN purpose) ) (PP (IN of)  (S (NP-SBJ (-NONE- *) ) (VP (VBG investigating)  (NP (NP (DT the)  (NN nature) ) (PP (IN of)  (NP (UCP-COOD (ADJP (NN cold) ) (CC and)  (NP (NN heat) )) (NNS syndromes) )))))))))) (. .) ) )
(TOP (S (S (PP (IN As)  (NP (DT a)  (NN result) )) (, ,)  (NP-SBJ-14 (NP (DT the)  (NNS cases) ) (PP (IN of)  (NP (NP (JJ deficiency-cold)  (NN syndrome) ) (PRN (-LRB- -LRB-)  (NP (NN DCS) ) (-RRB- -RRB-) )))) (VP (VBD had)  (NP-COOD (NP (NP (DT a)  (JJ normal)  (NN concentration) ) (PP (IN of)  (NP (NN plasma)  (NN cortisol) ))) (CC but)  (NP (NP (DT a)  (JJ lowered)  (NN content) ) (PP (IN of)  (NP (NP (NN GCR) ) (PP (IN in)  (NP (NNS leukocytes) )))))) (SBAR-TMP (WHADVP-13 (WRB when) ) (S (NP-SBJ-15 (-NONE- *-14) ) (VP (VBN compared)  (NP (-NONE- *-15) ) (PP (IN with)  (NP (NP (DT the)  (JJ normal)  (NN control) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.05) ))) (-RRB- -RRB-) ))) (ADVP (-NONE- *T*-13) ))))) (: ;) ) (S (NP-SBJ (NP (DT the)  (NNS cases) ) (PP (IN of)  (NP (NP (JJ deficiency-heat)  (NN syndrome) ) (PRN (-LRB- -LRB-)  (NP (NN DHS) ) (-RRB- -RRB-) )))) (VP (VBD had)  (NP (NP-COOD (NP (NP (DT a)  (JJR higher)  (NN concentration) ) (PP (IN of)  (NP (NN plasma)  (NN cortisol) ))) (NP (-NONE- *ICH*-100) )) (PP (IN than)  (NP (NP (DT the)  (JJ normal)  (NN control) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN P) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.05) ))) (-RRB- -RRB-) ))) (CC and)  (NP-100 (NP (DT a)  (ADJP (RB slightly)  (JJR higher) ) (NN content) ) (PP (IN of)  (NP (NN GCR) )) (PP (IN in)  (NP (NNS leukocytes) ))))) (. .) )) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBD was)  (VP (VBN concluded)  (SBAR (IN that)  (S-COOD (S (NP-SBJ-17 (DT the)  (NN DCS) ) (VP (VBZ is)  (VP (VBN characterized)  (NP (-NONE- *-17) ) (PP-18 (IN by)  (NP-LGS (NP (VBN diminished)  (JJ biological)  (NNS effects) ) (PP (IN of)  (NP (JJ adrenocortical)  (NN activity) ))))))) (, ,)  (IN while)  (S (NP-SBJ=17 (DT the)  (NN DHS) ) (, ,)  (PP=18 (IN by)  (NP-LGS (NP (JJ augmented)  (JJ biological)  (NNS effects) ) (PP (IN of)  (NP (JJ adrenocortical)  (NN activity) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-44 (JJ Specific)  (NN NF-kappa)  (NN B)  (NNS subunits) ) (VP (VBP act)  (PP (IN in)  (NN concert)  (IN with)  (NP (NN Tat) )) (S (NP-SBJ (-NONE- *-44) ) (VP (TO to)  (VP (VB stimulate)  (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN transcription) ))))) (. .) ) )
(TOP (S (NP-SBJ (NN NF-kappa)  (NN B) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN protein)  (NN complex) ) (SBAR (WHNP-46 (WDT which) ) (S (NP-SBJ-45 (-NONE- *T*-46) ) (VP (VBZ functions)  (PP (IN in)  (NN concert)  (IN with)  (NP (DT the)  (NN tat-I)  (NN gene)  (NN product) )) (S (NP-SBJ (-NONE- *-45) ) (VP (TO to)  (VP (VB stimulate)  (NP (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )) (NN transcription) ))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-47) ) (VP (TO To)  (VP (VB determine)  (SBAR (IN whether)  (S (NP-SBJ (NP (JJ specific)  (NNS members) ) (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN family) ))) (VP (VBP contribute)  (PP (TO to)  (NP (DT this)  (NN effect) )))))))) (, ,)  (NP-SBJ-47 (PRP we) ) (VP (VBP have)  (VP (VBN examined)  (NP (NP (DT the)  (NNS abilities)  (S (-NONE- *ICH*-48) )) (PP (IN of)  (NP (JJ different)  (NN NF-kappa)  (NN B)  (NNS subunits) )) (S-48 (NP-SBJ-102 (-NONE- *) ) (VP (TO to)  (VP (VB act)  (PP (IN with)  (NP (NN Tat-I) )) (S (NP-SBJ (-NONE- *-102) ) (VP (TO to)  (VP (VB stimulate)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NN HIV) )) (PP (IN in)  (NP (NN Jurkat)  (NN T-leukemia)  (NNS cells) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ-49 (DT the)  (NN p49)  (-LRB- -LRB-)  (CD 100)  (-RRB- -RRB-)  (NN DNA)  (NN binding)  (NN subunit) ) (, ,)  (PP (RB together)  (IN with)  (NP (NN p65) )) (, ,)  (VP (MD can)  (VP (VB act)  (PP (IN in)  (NN concert)  (IN with)  (NP (NN Tat-I) )) (S (NP-SBJ (-NONE- *-49) ) (VP (TO to)  (VP (VB stimulate)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NN HIV-CAT)  (NN plasmid) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-50 (JJ Little)  (NN effect) ) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-50) ) (PP (IN with)  (NP (NP (ADJP (JJ 50-kDa) ) (NNS forms) ) (PP (IN of)  (NP-COOD (NP (NN p105)  (NN NF-kappa)  (NN B) ) (CC or)  (NP (NN rel) ))))) (, ,)  (PP (IN in)  (NP (NP (NN combination) ) (PP (IN with)  (NP (NP-COOD (NP (NP (NN p65) ) (SBAR (-NONE- *RNR*-103) )) (CC or)  (NP (NP (JJ full-length)  (NN c-rel) ) (SBAR (-NONE- *RNR*-103) ))) (, ,)  (SBAR-103 (WHNP-51 (WDT which) ) (S (NP-SBJ (-NONE- *T*-51) ) (VP (VBP do)  (RB not)  (VP (VB stimulate)  (NP (NP (DT the)  (NN HIV)  (NN enhancer) ) (PP (IN in)  (NP (DT these)  (NNS cells) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-52 (NP (DT the)  (NN combination) ) (PP (IN of)  (NP-COOD (NP (NN p49)  (-LRB- -LRB-)  (CD 100)  (-RRB- -RRB-) ) (CC and)  (NP (NN p65)  (NN NF-kappa)  (NN B) )))) (VP (MD can)  (VP (VB act)  (PP (IN in)  (NN concert)  (IN with)  (NP (DT the)  (NN tat-I)  (NN gene)  (NN product) )) (S (NP-SBJ (-NONE- *-52) ) (VP (TO to)  (VP (VB stimulate)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NN HIV)  (NN RNA) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Activation) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN enhancer) ))) (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ dependent)  (PP (IN on)  (NP (NN NFAT-1) )))) (. .) ) )
(TOP (S (NP-SBJ-33 (NP (DT The)  (NN function) ) (PP (IN of)  (NP (DT a)  (JJ putative)  (NN NFAT-1)  (NN site) )) (PP (IN in)  (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN enhancer) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN analyzed)  (NP (-NONE- *-33) )))) (. .) ) )
(TOP (S (NP-SBJ-34 (NP (NN Activation) ) (PP (IN by)  (NP (DT the)  (NN T-cell)  (NN antigen)  (NN receptor) ))) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ minimal) ) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) ))) (CC and)  (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-34) ) (PP (IN by)  (NP-LGS (DT the)  (NN kappa)  (NN B)  (NNS sites) ))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-35 (DT The)  (JJ putative)  (NN NFAT-1)  (NN region) ) (VP (VBZ is)  (RB not)  (VP (VBN required)  (NP (-NONE- *-35) ) (PP (IN for)  (NP (NP (DT the)  (NN response) ) (PP-COOD (PP (TO to)  (NP (NN anti-CD3) )) (CC or)  (PP (TO to)  (NP (NNS mitogens) ))) (PP (IN in)  (NP (NP-COOD (NP (NN T-cell) ) (, ,)  (NP (NN B-cell) ) (, ,)  (CC or)  (NP (NN monocyte/macrophage)  (NN leukemia) )) (NNS lines) ))))))) (, ,)  (CC nor)  (SINV (VP (VBZ is) ) (NP-SBJ (PRP it) ) (NP-PRD (DT a)  (JJ cis-acting)  (JJ negative)  (JJ regulatory)  (NN element) )) (. .) ) )
(TOP (NP (NP-COOD (NP (NN Protein)  (NN kinase)  (NN C)  (NN activation) ) (CC and)  (NP (NN protooncogene)  (NN expression) )) (PP (IN in)  (NP (NP (NN differentiation/retrodifferentiation) ) (PP (IN of)  (NP (JJ human)  (NN U-937)  (NN leukemia)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Human)  (NN U-937)  (NN leukemia)  (NNS cells) ) (VP (VBP differentiate)  (PP (IN along)  (NP (DT the)  (JJ monocytic)  (NN lineage) )) (PP-TMP (VBG following)  (NP (NP (JJ 3-day)  (NNS exposures) ) (PP (TO to)  (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate) ) (PRN (-LRB- -LRB-)  (NP (NN TPA) ) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (NP-SBJ-7 (NP (DT This)  (NN induction) ) (PP (IN of)  (NP (NN differentiation) ))) (VP (VBZ is)  (VP (VBN accompanied)  (NP (-NONE- *-7) ) (PP (IN by)  (NP-LGS-COOD (NP (NP-COOD (NP (NN adherence) ) (CC and)  (NP (NN loss) )) (PP (IN of)  (NP (NN proliferation) ))) (, ,)  (CONJP (RB as)  (RB well)  (IN as) ) (NP (NP (NN expression/repression) ) (PP (IN of)  (NP (JJ differentiation-associated)  (NNS genes) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (JJ Long)  (NN term) ) (NN culture) ) (PP (IN of)  (NP (JJ TPA-differentiated)  (NN U-937)  (NNS cells) )) (PP (IN in)  (DT the)  (NN absence)  (IN of)  (NP (NN phorbol)  (NN ester) )) (PP-TMP (IN for)  (NP (QP (CD 32-36) ) (NNS days) ))) (VP (VBD resulted)  (PP (IN in)  (NP (NP (DT a)  (NN process) ) (PP (IN of)  (NP (NN retrodifferentiation) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (VBN retrodifferentiated)  (NNS cells) ) (VP-COOD (VP (VBD detached)  (PP (IN from)  (NP (DT the)  (NN substrate) ))) (CC and)  (VP (VBD reinitiated)  (NP (NN proliferation) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Other)  (JJ cellular)  (NNS parameters) ) (, ,)  (PP (JJ such)  (IN as)  (NP-COOD (NP (NN glycosidase)  (NNS activities) ) (, ,)  (NP (NN cytokine)  (NN release) ) (, ,)  (CC and)  (NP (NN filament)  (NN expression) ))) (, ,) ) (VP (VBD returned)  (PP (TO to)  (NP (NP (NNS levels) ) (ADJP (JJ similar)  (PP (TO to)  (NP (NP (DT that) ) (VP (VBN observed)  (NP (-NONE- *) ) (PP (IN in)  (NP (JJ uninduced)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN of)  (NP (NN U-937)  (NNS cells) )) (PP (IN with)  (NP (NN TPA) ))) (VP (VBD resulted)  (PP (IN in)  (NP (NP (DT a)  (JJ rapid)  (NN translocation) ) (PP (IN of)  (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) ))) (PP (IN from)  (NP (DT the)  (NN cytosol) )) (PP (TO to)  (NP (NN cell)  (NN membrane)  (NNS fractions) )) (PP-TMP (IN within)  (NP (QP (CD 2-8) ) (NN min) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (VBN Increased)  (NNS levels) ) (PP (IN of)  (NP (JJ membrane-associated)  (NN PKC)  (NN activity) ))) (VP (VBD persisted)  (PP-TMP (IN until)  (NP (QP (CD 17-29) ) (NNS days) ))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-8 (NP (JJR longer)  (NNS periods) ) (PP (IN of)  (NP (NN incubation) ))) (VP (VBD were)  (VP (VBN associated)  (NP (-NONE- *-8) ) (PP (IN with)  (NP (NP (DT a)  (NN return) ) (PP (TO to)  (NP (NP (DT the)  (NN distribution) ) (PP (IN of)  (NP (NN PKC) )) (PP (IN in)  (NP (NN control)  (NNS cells) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-9 (NP (NN Activation) ) (PP (IN of)  (NP (NN PKC) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN implicated)  (NP (-NONE- *-9) ) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (JJ certain)  (JJ immediate)  (JJ early)  (NN response)  (NNS genes) )))))))) (, ,)  (CC and)  (S (PP (IN in)  (NP (DT the)  (JJ present)  (NNS studies) )) (, ,)  (NP-SBJ (NN TPA) ) (ADVP-TMP (RB rapidly) ) (VP (VBD induced)  (NP (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN gene)  (NN expression) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Levels) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NNS transcripts) ))) (VP (VP-COOD (VP (VBD remained)  (ADJP-PRD (JJ elevated) ) (PP-TMP (IN during)  (NP (NP (NNS periods) ) (PP (IN of)  (NP (NN PKC)  (NN activation) ))))) (CC and)  (RB also)  (VP (VBD returned)  (PP (TO to)  (NP (NP (NNS levels) ) (VP (VBN observed)  (NP (-NONE- *) ) (PP (IN in)  (NP (NN control)  (NNS cells) )) (PP-TMP (IN by)  (NP (QP (CD 30-36) ) (NNS days) ))))))) (, ,)  (SBAR-TMP (WHADVP-10 (WRB when) ) (S (NP-SBJ (DT the)  (NNS cells) ) (VP (VBD entered)  (NP (NN retrodifferentiation) ) (ADVP (-NONE- *T*-10) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Staurosporine) ) (, ,)  (NP (NP (DT a)  (JJ nonspecific)  (NN inhibitor) ) (PP (IN of)  (NP (NN PKC) ))) (, ,) ) (VP-COOD (VP (ADVP (RB partially) ) (VBD blocked)  (NP-COOD (NP (JJ TPA-induced)  (NN adherence) ) (CC and)  (NP (NN growth)  (NN inhibition) ))) (CC and)  (VP (ADVP (RB concomitantly) ) (VBD prevented)  (NP (JJ TPA-induced)  (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN gene)  (NN expression) ))) (. .) ) )
(TOP (S (-LRB- -LRB-)  (NP-SBJ-300 (NN ABSTRACT) ) (VP (VBN TRUNCATED)  (NP (-NONE- *-300) ) (PP (IN AT)  (NP (CD 250)  (NNS WORDS) ))) (-RRB- -RRB-) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN promoter) ) (PP (IN of)  (NP (DT the)  (NN CD19)  (NN gene) ))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN target) ) (PP (IN for)  (NP (DT the)  (JJ B-cell-specific)  (NN transcription)  (NN factor)  (NN BSAP) )))) (. .) ) )
(TOP (S (NP-SBJ-26 (DT The)  (NN CD19)  (NN protein) ) (VP-COOD (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-26) ) (PP (IN on)  (NP (NP (DT the)  (NN surface) ) (PP (IN of)  (NP (DT all)  (JJ B-lymphoid)  (NNS cells) )))) (PP (IN with)  (NP (NP (DT the)  (NN exception) ) (PP (IN of)  (NP (ADJP (RB terminally)  (VBN differentiated) ) (NN plasma)  (NNS cells) )))))) (CC and)  (VP (VBZ has)  (VP (VBN been)  (VP (VBN implicated)  (NP (-NONE- *-26) ) (PP (IN as)  (NP (DT a)  (JJ signal-transducing)  (NN receptor) )) (PP (IN in)  (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP-COOD (NP (NN proliferation) ) (CC and)  (NP (NN differentiation) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (NP (NP (JJ complete)  (NN correlation) ) (PP (IN between)  (NP-COOD (NP (NP (DT the)  (NN expression)  (NN pattern) ) (PP (IN of)  (NP (DT the)  (NN CD19)  (NN gene) ))) (CC and)  (NP (NP (DT the)  (JJ B-cell-specific)  (NN transcription)  (NN factor)  (NN BSAP) ) (PP (IN in)  (NP (NP (DT a)  (JJ large)  (NN panel) ) (PP (IN of)  (NP (JJ B-lymphoid)  (NN cell)  (NNS lines) ))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-28 (DT The)  (JJ human)  (NN CD19)  (NN gene) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN cloned)  (NP (-NONE- *-28) ))))) (, ,)  (CC and)  (S (NP-SBJ-29 (JJ several)  (JJ BSAP-binding)  (NNS sites) ) (VP (VBP have)  (VP (VBN been)  (VP (VBN mapped)  (NP (-NONE- *-29) ) (PP (IN by)  (NP (ADJP (FW in)  (FW vitro) ) (JJ protein-DNA)  (NN binding)  (NNS studies) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (JJ particular) )) (, ,)  (NP-SBJ-COOD (NP (DT a)  (JJ high-affinity)  (JJ BSAP-binding)  (NN site) ) (CONJP (RB instead)  (IN of) ) (NP (DT a)  (NN TATA)  (NN sequence) )) (VP (VBZ is)  (ADJP-PRD (JJ located)  (PP (IN in)  (NP (NP (DT the)  (CD -30)  (NN promoter)  (NN region) ) (ADJP (JJ upstream)  (PP (IN of)  (NP (NP (DT a)  (NN cluster) ) (PP (IN of)  (NP (JJ heterogeneous)  (NN transcription)  (NN start)  (NNS sites) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-31 (DT this)  (NN site) ) (VP (VBZ is)  (VP (VBN occupied)  (NP (-NONE- *-31) ) (PP (IN by)  (NP-LGS (NP (NN BSAP) ) (ADVP (FW in)  (FW vivo) ))) (PP-COOD (PP (IN in)  (NP (DT a)  (JJ CD19-expressing)  (NN B-cell)  (NN line) )) (CC but)  (PP (RB not)  (IN in)  (NP (NP-COOD (NP (NN plasma) ) (CC or)  (NP (NN HeLa) )) (NNS cells) ))))) (. .) ) )
(TOP (S (NP-SBJ-32 (DT This)  (JJ high-affinity)  (NN site) ) (VP-COOD (VP (VBZ has)  (VP (VBN been)  (VP (VBN conserved)  (NP (-NONE- *-32) ) (PP (IN in)  (NP (NP (DT the)  (NNS promoters) ) (PP (IN of)  (NP (UCP-COOD (CC both)  (ADJP (JJ human) ) (CC and)  (NP (NN mouse) )) (NN CD19)  (NNS genes) ))))))) (CC and)  (VP (VBD was)  (ADVP (RB furthermore) ) (VP (VBN shown)  (S (NP-SBJ (-NONE- *-32) ) (VP (TO to)  (VP (VB confer)  (NP (NN B-cell)  (NN specificity) ) (PP (TO to)  (NP (DT a)  (NN beta-globin)  (NN reporter)  (NN gene) )) (PP (IN in)  (NP (JJ transient)  (NN transfection)  (NNS experiments) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ-34 (NN BSAP) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-34) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT the)  (RB only)  (JJ abundant)  (JJ DNA-binding)  (NN activity) ) (PP (IN of)  (NP (NN B-cell)  (JJ nuclear)  (NNS extracts) )) (SBAR (WHNP-35 (WDT that) ) (S (NP-SBJ (-NONE- *T*-35) ) (VP (VBZ interacts)  (PP (IN with)  (NP (DT the)  (NN CD19)  (NN promoter) ))))))))))) (. .) ) )
(TOP (S (ADVP (RB Together) ) (, ,)  (NP-SBJ (DT this)  (NN evidence) ) (ADVP (RB strongly) ) (VP (VBZ implicates)  (NP (NN BSAP) ) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (DT the)  (NN CD19)  (NN gene) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (VBN Reduced)  (NN susceptibility) ) (PP (TO to)  (NP (NP (NN HIV-1)  (NN infection) ) (PP (IN of)  (NP (JJ ethyl-methanesulfonate-treated)  (NN CEM)  (NNS subclones) ))))) (VP (VBZ correlates)  (PP (IN with)  (NP (NP (DT a)  (NN blockade) ) (PP (IN in)  (NP (PRP$ their)  (NN protein)  (NN kinase)  (NN C)  (NN signaling)  (NN pathway) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN described)  (NP (NP (DT the)  (NN isolation) ) (PP (IN of)  (NP (NP (ADJP (RB chemically)  (VBN induced) ) (NN CEM)  (NNS subclones) ) (SBAR (WHNP-33 (WDT that) ) (S (NP-SBJ (-NONE- *T*-33) ) (VP-COOD (VP (VBP express)  (NP (NN CD4)  (NNS receptors) )) (CC and)  (VP (VBP bind)  (NP (JJ soluble)  (NN gp120) )) (, ,)  (RB yet)  (VP (VBP show)  (NP (NP (DT a)  (ADJP (RB markedly)  (VBN reduced) ) (NN susceptibility) ) (PP (TO to)  (NP (NP (NN infection) ) (PP (IN with)  (NP (NN HIV-1) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-34 (CD Two)  (NNS subclones) ) (VP (VBD were)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-34) ) (VP (TO to)  (VP (VB have)  (NP (NP (DT an)  (JJ abnormal)  (NN response) ) (PP (TO to)  (NP (DT the)  (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) )) (NN activator)  (NN PMA) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NN PMA)  (NN treatment) ) (VP (VBD induced)  (NP (NP-COOD (NP (NN CD3) ) (CC and)  (NP (NP (NN CD25) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2R) ) (-RRB- -RRB-) ))) (NNS receptors) ) (PP-COOD (PP (IN on)  (NP (DT the)  (JJ parental)  (NN line) )) (CC and)  (PP (IN on)  (NP (JJ other)  (JJ ethyl-methanesulfonate-derived)  (NNS subclones) )) (, ,)  (CC but)  (PP (RB not)  (IN on)  (NP (DT these)  (CD two)  (NNS mutants) )))) (. .) ) )
(TOP (S (NP-SBJ-35 (NP (JJ Direct)  (NNS assays) ) (PP (IN of)  (NP (NN PKC)  (NN activity) ))) (VP (VBD were)  (VP (VBN conducted)  (NP (-NONE- *-35) ))) (. .) ) )
(TOP (S (NP-SBJ-36 (JJ Total)  (JJ cellular)  (NN PKC)  (JJ enzymatic)  (NN activity) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-36) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ normal) ) (PP (IN in)  (NP (DT these)  (NNS subclones) ))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ PMA-induced)  (NN CD4)  (NN down-modulation) ) (VP (VBD occurred)  (ADVP (RB normally) )) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NP (NN activation) ) (PP (IN of)  (NP (NN c-raf)  (NN kinase) ))) (VP (VBD was)  (ADJP-PRD (JJ normal) )) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ (NN HIV-1)  (JJ long)  (JJ terminal)  (NN repeat) ) (VP (VBZ contains)  (NP (CD two)  (JJ functional)  (NP (NP (JJ nuclear)  (NN factor)  (NN kB) ) (PRN (-LRB- -LRB-)  (NP (NN NF-kB) ) (-RRB- -RRB-) )) (JJ regulatory)  (NNS elements) )))) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD studied)  (NP (NP (DT the)  (NN ability)  (S (-NONE- *ICH*-37) )) (PP (IN of)  (NP (NN PMA) )) (S-37 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB induce)  (NP (NN NF-kB)  (NN binding)  (NN activity) ) (PP (IN by)  (NP (JJ different)  (NNS assays) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (NP (NN Chloramphenicol)  (NN acetyl)  (NN transferase) ) (PRN (-LRB- -LRB-)  (NP (NN CAT) ) (-RRB- -RRB-) )) (NNS assays) ) (VP (VBG using)  (NP (DT the)  (NN HIV-1)  (ADJP (-LRB- -LRB-)  (CD -139)  (-RRB- -RRB-)  (JJ long)  (JJ terminal)  (JJ repeat-CAT) ) (NN construct) ))) (VP (VBD showed)  (NP (NP (DT no)  (NN PMA)  (NN induction) ) (PP (IN of)  (NP (NN CAT)  (NN activity) ))) (PP (IN in)  (NP (DT these)  (NNS subclones) )) (-LRB- -LRB-)  (PP (IN unlike)  (NP-COOD (NP (DT the)  (JJ parental)  (NN line) ) (CC and)  (NP (JJ other)  (NNS subclones) ))) (-RRB- -RRB-) ) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Okadaic)  (NN acid) ) (, ,)  (NP (NP (DT an)  (NN inhibitor) ) (PP (IN of)  (NP (NNS phosphatases)  (NP-COOD (NP (CD 1) ) (CC and)  (NP (NN 2A) ))))) (, ,) ) (VP (VBD did)  (RB not)  (VP (VB overcome)  (NP (NP (DT the)  (NN defect) ) (PP (IN in)  (NP (DT these)  (NNS subclones) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Gel)  (NN retardation)  (NNS assays) ) (, ,)  (VP (VBG using)  (NP (NP (DT a)  (NN 32P-probe) ) (VP (VBG containing)  (NP-COOD (NP (DT the)  (NN HIV-1)  (NN NF-kB)  (NN probe) ) (CC and)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN from)  (NP (JJ PMA-treated)  (NNS cells) ))))))) (, ,) ) (VP (VBD showed)  (NP (NP (ADJP (RB significantly)  (VBN reduced) ) (NN induction) ) (PP (IN of)  (NP (JJ nuclear)  (NN NF-kB)  (NN binding)  (NNS proteins) ))) (PP (IN in)  (NP (DT these)  (CD two)  (NNS subclones) )) (PP (VBN compared)  (PP (IN with)  (NP-COOD (NP (JJ wild)  (NN type)  (NN CEM) ) (CC and)  (NP (DT a)  (NN control)  (NN subclone) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Deoxycholate)  (NN treatment) ) (PP (IN of)  (NP (NP (JJ cytoplasmic)  (NNS extracts) ) (PP (IN from)  (NP (DT these)  (NNS subclones) ))))) (VP (VBD released)  (NP (ADJP (JJ much)  (VBN reduced) ) (NN NF-kB)  (NN binding)  (NNS proteins) ) (PP (IN from)  (NP (PRP$ their)  (JJ cytoplasmic)  (NNS pools) ))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (NP (JJ reduced)  (NNS levels) ) (PP (IN of)  (NP (JJ PKC-induced)  (JJ nuclear)  (NN NF-kB)  (NN activity) )) (PP (IN in)  (NP (CD two)  (NN T)  (NN cell)  (NNS subclones) ))) (VP-COOD (VP (VBD did)  (RB not)  (VP (VB affect)  (NP (PRP$ their)  (JJ normal)  (NN cell)  (NN growth) ))) (, ,)  (CC but)  (VP (VBD correlated)  (PP (IN with)  (NP (NP (DT a)  (JJ pronounced)  (NN reduction) ) (PP (IN in)  (NP (NP (PRP$ their)  (NN susceptibility) ) (PP (TO to)  (NP (NN HIV-1)  (NN infection) )))))))) (. .) ) )
(TOP (NP (NP (NNS Eicosanoids) ) (PP (IN in)  (NP (NN breast)  (NN cancer)  (NNS patients) )) (PP-TMP (PP-COOD (PP (IN before)  (NP (-NONE- *RNR*-36) )) (CC and)  (PP (IN after)  (NP (-NONE- *RNR*-36) ))) (NP-36 (NN mastectomy) )) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (CD 19)  (NNS patients) ) (PP (IN with)  (NP (DT a)  (JJ malignant)  (NN breast)  (NN tumor) )))) (, ,)  (NP-SBJ-COOD-301 (NP (NN tumor)  (NN tissue) ) (CC and)  (NP (NN blood) )) (VP (VBD were)  (VP (VBN taken)  (NP (-NONE- *-301) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB determine)  (NP (DT the)  (NP-COOD (NP (NN eicosanoid)  (NN profile) ) (CC and)  (NP (NN platelet)  (NN aggregation) )))))))) (. .) ) )
(TOP (S (NP-SBJ-37 (NNS Values) ) (VP (VBD were)  (VP (VBN compared)  (NP (-NONE- *-37) ) (PP (IN with)  (NP (NP (DT those) ) (PP (IN of)  (NP (NP (NNS patients) ) (UCP-COOD (PP (IN with)  (NP (NP (JJ benign)  (NNS tumors) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP (CD 4) ))) (-RRB- -RRB-) ))) (, ,)  (CC or)  (VP (VBG undergoing)  (NP (NP (DT a)  (JJ mammary)  (NN reduction) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP (CD 7) ))) (-RRB- -RRB-) )))))))))) (. .) ) )
(TOP (S (ADVP-TMP (RB Postoperatively) ) (, ,)  (NP-SBJ-38 (NN blood) ) (VP (VBD was)  (VP (VBN taken)  (NP (-NONE- *-38) ) (PP (RB as)  (ADVP (RB well) )) (SBAR (IN in)  (NN order)  (TO to)  (S (NP-SBJ (-NONE- *) ) (VP (VB compare)  (NP (ADJP-COOD (ADJP (JJ pre-)  (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ postoperative) )) (NNS values) )))))) (. .) ) )
(TOP (S (S (NP-SBJ-39 (NNS Eicosanoids) ) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-39) ) (PP (IN in)  (NP-COOD (NP (JJ peripheral)  (NN blood)  (NNS monocytes) ) (CC and)  (NP (JJ mammary)  (NN tissue) ))) (PP (IN by)  (NNS means)  (IN of)  (NP (NN HPLC) )))) (: ;) ) (S (ADVP (RBR furthermore) ) (, ,)  (NP-SBJ-COOD-40 (NP (NN TXA2) ) (, ,)  (NP (NN 6-keto-PGF1)  (NN alpha) ) (, ,)  (CC and)  (NP (NN PGE2) )) (VP (VBD were)  (VP (VBN determined)  (NP (-NONE- *-40) ) (PP (IN by)  (NP-LGS (NN RIA) )))) (. .) )) )
(TOP (S (S (NP-SBJ-41 (NP (NNS Differences) ) (PP (IN in)  (NP (NP (ADJP-COOD (ADJP (JJ pre-)  (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ postoperative) )) (NNS values) ) (PP (IN of)  (NP (NN cancer)  (NNS patients) ))))) (VP (VBD were)  (VP (VBN seen)  (NP (-NONE- *-41) ) (PP (IN in)  (NP (NN plasma)  (NN RIA)  (NNS values) )))) (: :) ) (S-COOD (S (NP-SBJ-COOD-302 (NP (NN PGE2) ) (CC and)  (NP (NN 6-k-PGF1)  (NN alpha) )) (VP (VBD were)  (ADJP-PRD (RB significantly)  (JJR higher) ) (ADVP-TMP (RB preoperatively) ) (SBAR-TMP (WHADVP-42 (WRB when) ) (S (NP-SBJ-303 (-NONE- *-302) ) (VP (VBN compared)  (NP (-NONE- *-303) ) (PP (IN with)  (FRAG (ADVP (RB postoperatively) ))) (ADVP (-NONE- *T*-42) )))))) (, ,)  (RB however)  (, ,)  (S (NP-SBJ-43 (JJ such)  (NNS differences) ) (VP (VBD were)  (VP (VBN seen)  (NP (-NONE- *-43) ) (PP (IN in)  (NP (DT the)  (NN control)  (NNS groups) )) (PP (RB as)  (ADVP (RB well) )))))) (. .) ) )
(TOP (S (PP (VBN Compared)  (PP (TO to)  (NP (NP-COOD (NP (JJ benign)  (NN tumor) ) (CC or)  (NP (JJ mammary)  (NN reduction) )) (NN test)  (NN material) ))) (NP-SBJ-44 (NP (DT the)  (NN eicosanoid)  (NN profile) ) (PP (IN of)  (NP (NP (NN tissue) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN from)  (NP (JJ malignant)  (JJ mammary)  (NNS tumors) )))))) (VP (VBD showed)  (NP (JJ important)  (NNS differences) )) (. .) ) )
(TOP (S-COOD (S (PP (IN Except)  (IN for)  (NP-COOD (NP (NN PGF2)  (NN alpha) ) (, ,)  (NP (NN HHT) ) (CC and)  (NP (NN 15-HETE) ))) (NP-SBJ-46 (NP (DT no)  (JJ detectable)  (NNS quantities) ) (PP (IN of)  (NP (NNS eicosanoids) ))) (VP (VBD were)  (VP (VBN found)  (NP (-NONE- *-46) ) (PP (IN in)  (NP (DT the)  (JJ non-tumor)  (NN material) ))))) (, ,)  (IN whereas)  (S (PP (IN in)  (NP (DT the)  (JJ malignant)  (NN tumor)  (NN material) )) (NP-SBJ (NP (JJ substantial)  (NNS quantities) ) (PP (IN of)  (NP (NP (DT a)  (NN number) ) (PP (IN of)  (NP (NN eicosanoid)  (NNS metabolites) ))))) (VP (VBD were)  (ADJP-PRD (JJ present) ))) (. .) ) )
(TOP (S (NP-SBJ-47 (ADJP (RB Statistically)  (JJ significant) ) (NNS correlations) ) (VP (MD could)  (VP (VB be)  (VP (VBN established)  (NP (-NONE- *-47) ) (PP (PP (IN between)  (NP-COOD (NP (NN patient/histopathology)  (NNS data) ) (CC and)  (NP (NP (DT the)  (NNS results) ) (PP (IN of)  (NP (DT the)  (NN platelet)  (NN aggregation)  (NNS assays) ))))) (, ,)  (FW e.g.)  (PP (IN between)  (NP-COOD (NP-COOD (NP (JJ menopausal)  (NN status) ) (CC and)  (NP (NN ADP)  (NN aggregation) )) (: ;)  (NP-COOD (NP (NN oestrogen)  (NN receptor)  (PRN (-LRB- -LRB-)  (NP (JJ +/-) ) (-RRB- -RRB-) )) (CC and)  (NP (NN collagen) ) (CC and)  (NP (JJ arachidonic)  (NN acid)  (NN aggregation) )) (, ,)  (NP-COOD (NP (JJ inflammatory)  (NN cell)  (NN infiltration)  (NN score) ) (CC and)  (NP (JJ arachidonic)  (NN acid)  (NN aggregation) )) (CC and)  (NP-COOD (NP (NN fibrosis)  (NN score) ) (CC and)  (NP (NN ADP)  (NN aggregation) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBP show)  (SBAR (IN that)  (S (NP-SBJ (NP (NN eicosanoid)  (NN synthesis) ) (PP (IN in)  (NP (NP (NN material) ) (PP (IN from)  (NP (JJ mammary)  (NN cancer)  (NNS patients) ))))) (VP (VBZ is)  (ADJP-PRD (JJ different)  (PP (IN from)  (NP (NP (DT that) ) (PP (IN in)  (NP (JJ benign)  (JJ mammary)  (NN tissue) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NNS implications) ) (PP (, ,)  (PP (IN in)  (NP (JJ particular) )) (, ,)  (IN in)  (NN relation)  (TO to)  (NP (NP (JJ future)  (NN prognosis) ) (PP (IN of)  (NP (DT the)  (NN patient) ))) (, ,) )) (VP (VBP remain)  (ADJP-PRD (JJ obscure) )) (. .) ) )
(TOP (NP (NP (NN c-myc)  (NN mRNA)  (NN expression) ) (PP (IN in)  (NP (NP (JJ minor)  (JJ salivary)  (NNS glands) ) (PP (IN of)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NP (NN Sjogren)  (POS 's) ) (NN syndrome) )))))) (. .) ) )
(TOP (S (S-COOD (S (NP-SBJ-29 (NN c-myc)  (NN protooncogene) ) (VP (VBZ is)  (VP (VBN implicated)  (NP (-NONE- *-29) ) (PP (IN in)  (NP (NP (DT the)  (NN pathogenesis) ) (PP (IN of)  (NP (NN B)  (NN cell)  (JJ lymphoid)  (NNS malignancies) ))))))) (CC and)  (S (NP-SBJ-31 (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (NN c-myc)  (NN mRNA)  (NN expression) ))) (VP (VBP are)  (VP (VBN observed)  (NP (-NONE- *-31) ) (PP (IN in)  (NP (VBN activated)  (NN blood)  (JJ mononuclear)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ-32 (NP (NP (NN Sjogren)  (POS 's) ) (NN syndrome) ) (PRN (-LRB- -LRB-)  (NP (NN SS) ) (-RRB- -RRB-) )) (VP (VBZ is)  (VP (VBN characterized)  (NP (-NONE- *-32) ) (PP (IN by)  (NP-LGS (NP (NP (JJ lymphocytic)  (NNS infiltrates) ) (PP (IN of)  (NP (JJ exocrine)  (NNS glands) ))) (, ,)  (NP (JJ remarkable)  (NN B)  (NN cell)  (NN hyperreactivity) ) (CC and)  (NP (NP (DT a)  (JJ strong)  (NN predisposition) ) (PP (TO to)  (NP (NN B)  (NN cell)  (NN neoplasia) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (, ,)  (NP-SBJ-33 (NP (NN c-myc)  (NN protooncogene)  (NN mRNA)  (NN expression) ) (PP (IN in)  (NP (NP (CD 29)  (JJ labial)  (JJ minor)  (JJ salivary)  (NN gland)  (NNS biopsies) ) (PP (IN from)  (NP-COOD (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ primary)  (NNS SS) ))) (CC and)  (NP (CD 15)  (NNS controls) )))))) (VP (VBD was)  (VP (VBN examined)  (NP (-NONE- *-33) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (ADJP (FW in)  (FW situ) ) (NN hybridization)  (NN histochemistry) ))))) (. .) ) )
(TOP (S (NP-SBJ-35 (NP (CD Two)  (JJ 40mer)  (NNS oligonucleotides) ) (PP (IN from)  (NP (NP (NP-COOD (NP (DT the)  (JJ 1st)  (NP (-NONE- *RNR*-34) )) (CC and)  (NP (DT the)  (JJ 2nd)  (NP (-NONE- *RNR*-34) ))) (NP-34 (NN exon) )) (PP (IN of)  (NP (DT the)  (NN c-myc)  (NN gene) )))) (, ,)  (VP (VBN labeled)  (NP (-NONE- *) ) (PP (IN with)  (NP (NN 35S) ))) (, ,) ) (VP (VBD were)  (VP (VBN used)  (NP (-NONE- *-35) ) (PP (IN as)  (NP (NNS probes) )))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB detect)  (NP (NP (DT the)  (NN origin) ) (PP (IN of)  (NP (NP (DT the)  (NN cell) ) (VP (VBN hybridized)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT a)  (NN c-myc)  (NN probe) ))))))))) (, ,)  (NP-SBJ-37 (DT a)  (JJ combined)  (NN immunochemistry)  (ADJP (FW in)  (FW situ) ) (NN hybridization)  (NN histochemistry)  (NN technique) ) (VP (VBD was)  (VP (VBN used)  (NP (-NONE- *-37) ))) (. .) ) )
(TOP (S (NP-SBJ-36 (JJ High)  (NN c-myc)  (NN mRNA)  (NN expression) ) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-36) ) (PP (IN on)  (NP (JJ acinar)  (JJ epithelial)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NN c-myc) ) (VP (VBD did)  (RB not)  (VP (VB correlate)  (PP (IN with)  (NP (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )) (NN protein)  (NN expression) )))) (. .) ) )
(TOP (S (NP-SBJ-38 (JJR Stronger)  (NN c-myc)  (NN mRNA)  (NN expression) ) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-38) ) (PP (IN in)  (NP (NP (JJ labial)  (JJ salivary)  (NNS glands) ) (PP (IN of)  (NP (NP (NNS patients) ) (PP (IN with)  (NP-COOD (NP (NP (JJR longer)  (NN disease)  (NN duration) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (NP-PRD (QP (JJR less)  (IN than)  (CC or)  (JJ equal)  (TO to)  (CD 0.002) ))) (-RRB- -RRB-) )) (CC and)  (NP (NP (ADJP (RBR more)  (JJ intense) ) (NN T)  (NN lymphocyte)  (NNS infiltrates) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN p) ) (NP-PRD (QP (JJR less)  (IN than)  (CD 0.05) ))) (-RRB- -RRB-) )))))))) (SBAR (IN although)  (S (NP-SBJ (DT these)  (NNS patients) ) (VP (VBD revealed)  (NP-PRD (DT no)  (NN hypergammaglobulinemia) )))))) (. .) ) )
(TOP (S (NP-SBJ-40 (DT No)  (NN correlation) ) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-40) ) (PP (IN between)  (NP-COOD (NP (NN c-myc)  (NN mRNA) ) (CC and)  (NP (NN B)  (NN lymphocyte)  (NP-COOD (NP (NN monoclonicity) ) (CC or)  (NP (NN lymphoma) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN conclusion) )) (, ,)  (NP-SBJ-41 (JJ strong)  (NN c-myc)  (NN mRNA)  (NN expression) ) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-41) ) (PP (IN on)  (NP (NP (JJ epithelial)  (NNS cells) ) (PP (IN of)  (NP (NP (JJ labial)  (JJ salivary)  (NNS glands) ) (PP (IN from)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (JJ primary)  (NN SS) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS findings) ) (VP (MD may)  (VP (VB indicate)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NP (DT a)  (VBN reactivated)  (NN virus) ) (VP (VBN hosted)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT these)  (NNS cells) )))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (JJ Cytoplasmic)  (NN domain)  (NN heterogeneity) ) (CC and)  (NP (NNS functions) )) (PP (IN of)  (NP (NN IgG)  (NN Fc)  (NNS receptors) )) (PP (IN in)  (NP (NN B)  (NNS lymphocytes) )) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN B)  (NNS lymphocytes) ) (CC and)  (NP (NNS macrophages) )) (VP (VBP express)  (NP (NP (ADJP (RB closely)  (JJ related) ) (NP (NP (NN immunoglobulin)  (NN G) ) (PRN (-LRB- -LRB-)  (NP (NN IgG) ) (-RRB- -RRB-) )) (NP (NP (NN Fc)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (PRN (NN Fc)  (NN gamma)  (NN RII) ) (-RRB- -RRB-) ))) (SBAR (WHNP-16 (WDT that) ) (S (NP-SBJ (-NONE- *T*-16) ) (VP (VBP differ)  (ADVP (RB only)  (IN in)  (NP (NP (DT the)  (NNS structures) ) (PP (IN of)  (NP (PRP$ their)  (JJ cytoplasmic)  (NNS domains) ))))))))) (. .) ) )
(TOP (S (PP (IN Because)  (IN of)  (NP (ADJP (NN cell)  (JJ type-specific) ) (JJ alternative)  (NN messenger)  (NN RNA)  (NN splicing) )) (, ,)  (NP-SBJ (NN B-cell)  (NN Fc)  (NN gamma)  (NN RII) ) (VP (VBZ contains)  (NP (NP (DT an)  (NN insertion) ) (PP (IN of)  (NP (CD 47)  (NN amino)  (NNS acids) )) (SBAR (WHNP-17 (WDT that) ) (S (NP-SBJ (-NONE- *T*-17) ) (VP (VBZ participates)  (PP (IN in)  (S (NP-SBJ (-NONE- *) ) (VP (VBG determining)  (NP (NP (NN receptor)  (NN function) ) (PP (IN in)  (NP (DT these)  (NNS cells) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Transfection) ) (PP (IN of)  (NP (DT an)  (ADJP (NN Fc)  (NN gamma)  (JJ RII-negative) ) (NN B-cell)  (NN line) )) (PP (IN with)  (S (NP-SBJ (JJ complementary)  (NN DNA)  (POS 's) ) (VP (VBG encoding)  (NP-COOD (NP (DT the)  (CD two)  (NN splice)  (NNS products) ) (CC and)  (NP (JJ various)  (NN receptor)  (NNS mutants) )))))) (VP (VBD indicated)  (SBAR (IN that)  (S (NP-SBJ-18 (DT the)  (NN insertion) ) (VP (VBD was)  (ADJP-PRD (JJ responsible)  (PP (IN for)  (S (NP-SBJ (-NONE- *-18) ) (VP (VBG preventing)  (NP-COOD (CC both)  (NP (ADJP (NN Fc)  (NN gamma)  (JJ RII-mediated) ) (NN endocytosis) ) (CC and)  (NP (ADJP (NN Fc)  (NN gamma)  (JJ RII-mediated) ) (NN antigen)  (NN presentation) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-19 (DT The)  (NN insertion) ) (VP (VBD was)  (RB not)  (VP (VBN required)  (NP (-NONE- *-19) ) (PP (IN for)  (S (NP-SBJ (NN Fc)  (NN gamma)  (NN RII) ) (VP (TO to)  (VP (VB modulate)  (NP (NN surface)  (JJ immunoglobulin-triggered)  (NN B-cell)  (NN activation) ))))))) (. .) ) )
(TOP (S (ADVP (RB Instead) ) (, ,)  (NP-SBJ (NP (NN regulation) ) (PP (IN of)  (NP (NN activation) ))) (VP (VBD involved)  (NP (NP (DT a)  (NN region) ) (PP (IN of)  (NP (DT the)  (JJ cytoplasmic)  (NN domain) )) (ADJP (JJ common)  (PP (TO to)  (NP (CC both)  (DT the)  (NP-COOD (NP (NN lymphocyte) ) (CC and)  (NP (NN macrophage) )) (NN receptor)  (NNS isoforms) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (DT the)  (NN insertion) ) (VP (VBD did)  (VP (VB contribute)  (PP (TO to)  (NP (NP (DT the)  (NN formation) ) (PP (IN of)  (NP (NNS caps) )))) (PP (IN in)  (NN response)  (TO to)  (NP (NN receptor)  (NN cross-linking) )) (, ,)  (S (NP-SBJ (-NONE- *) ) (ADJP-PRD (JJ consistent)  (PP (IN with)  (NP (NNS suggestions)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NP-COOD (NP (NN lymphocyte) ) (CONJP (CC but)  (RB not) ) (NP (NN macrophage) )) (NN form) ) (PP (IN of)  (NP (DT the)  (NN receptor) ))) (VP (MD can)  (VP (VB associate)  (PP (IN with)  (NP (DT the)  (JJ detergent-insoluble)  (NN cytoskeleton) )))))))))))) (. .) ) )
(TOP (S (S (NP-SBJ (DT Every)  (NN enhancer) ) (VP (VBZ works)  (PP (IN with)  (NP (DT every)  (NN promoter) )) (PP (IN for)  (NP (NP (PDT all)  (DT the)  (NNS combinations) ) (VP (VBN tested)  (NP (-NONE- *) ))))) (: :) ) (SQ (MD could)  (NP-SBJ (JJ new)  (JJ regulatory)  (NNS pathways) ) (VP (VBP evolve)  (PP (IN by)  (NP (NN enhancer)  (NN shuffling) ))) (. ?) )) )
(TOP (S (S-COOD (S (NP-SBJ-60 (NP (DT The)  (NP-COOD (NP (NNS promoters) ) (CC and)  (NP (NNS enhancers) ))) (PP (IN of)  (NP (ADJP (NN cell)  (JJ type-specific) ) (NNS genes) ))) (VP (VBP are)  (ADVP (RB often) ) (VP (VBN conserved)  (NP (-NONE- *-60) ))) (PP (IN in)  (NP (NN evolution) ))) (, ,)  (CC and)  (RB hence)  (S (NP-SBJ (NN one) ) (VP (MD might)  (VP (VB expect)  (SBAR (IN that)  (S (NP-SBJ-61 (DT a)  (JJ given)  (NN enhancer) ) (VP (VBZ has)  (VP (VBN evolved)  (S (NP-SBJ (-NONE- *-61) ) (VP (TO to)  (VP (VB work)  (ADVP (RBS best) ) (PP (IN with)  (NP (PRP$ its)  (JJ own)  (NN promoter) )))))))))))) (. .) )) )
(TOP (S (SBAR (IN While)  (S (NP-SBJ-62 (DT this)  (NN expectation) ) (VP (MD may)  (VP (VB be)  (VP (VBN realized)  (NP (-NONE- *-62) ) (PP (IN in)  (NP (DT some)  (NNS cases) ))))))) (, ,)  (S (NP-SBJ (PRP we) ) (VP (VBP have)  (RB not)  (VP (VBN found)  (NP (NP (NN evidence) ) (PP (IN for)  (NP (PRP it) )))))) (. .) ) )
(TOP (S (NP-SBJ-63 (NP (DT A)  (NN total) ) (PP (IN of)  (NP (NP (CD 27)  (NNS combinations) ) (PP (IN of)  (NP (JJ different)  (NP-COOD (NP (NNS promoters) ) (CC and)  (NP (NNS enhancers) ))))))) (VP (VBD were)  (VP (VBN tested)  (NP (-NONE- *-63) ) (PP (IN by)  (NP-LGS (NP (NN transfection) ) (PP (IN into)  (NP (VBN cultured)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD found)  (SBAR (IN that)  (S-COOD (S (NP-SBJ (NP (DT the)  (JJ relative)  (NN efficiency) ) (PP (IN of)  (NP (DT the)  (NNS enhancers) ))) (VP (VBZ is)  (NP-PRD (ADVP (RB approximately) ) (DT the)  (JJ same) ) (, ,)  (ADJP (JJ irrespective)  (PP (IN of)  (NP (NP (DT the)  (NN type) ) (PP (IN of)  (NP (NP (NN promoter) ) (VP (VBN used)  (NP (-NONE- *) ))))))) (, ,) )) (FW i.e.)  (, ,)  (S (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (NP (DT no)  (JJ strong)  (NN preference) ) (PP (IN for)  (NP (DT any)  (JJ given)  (ADJP (JJ enhancer/promoter) ) (NN combination) )))))))) (. .) ) )
(TOP (S (ADVP (RB Notably) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP do)  (RB not)  (VP (VB see)  (NP (ADJP (RB particularly)  (JJ strong) ) (NN transcription) ) (SBAR-TMP (WHADVP-64 (WRB when) ) (S (NP-SBJ-COOD-65 (NP (DT the)  (NN immunoglobulin)  (NN kappa)  (NN enhancer) ) (-LRB- -LRB-)  (CC or)  (NP (DT the)  (NN immunoglobulin)  (JJ heavy)  (NN chain)  (NN enhancer) ) (-RRB- -RRB-) ) (VP (VBZ is)  (VP (VBN used)  (NP-66 (-NONE- *-65) ) (S (NP-SBJ (-NONE- *-66) ) (VP (TO to)  (VP (VB activate)  (NP (DT a)  (NN kappa)  (NN gene)  (NN promoter) ) (ADVP (-NONE- *T*-64) )))))))))) (. .) ) )
(TOP (S (S (NP-SBJ (PRP We) ) (VP (VBP propose)  (SBAR (IN that)  (S-COOD (S (NP-SBJ (DT a)  (ADJP (RB generally)  (JJ permissive) ) (ADJP (JJ enhancer/promoter) ) (NN interaction) ) (VP (VBZ is)  (PP-PRD (IN of)  (NP (NP (JJ evolutionary)  (NN benefit) ) (PP (IN for)  (NP (JJR higher)  (NNS eukaryotes) )))))) (: :)  (S (PP (IN by)  (NP (NN enhancer)  (NN shuffling) )) (, ,)  (NP-SBJ-67 (NNS genes) ) (VP (MD could)  (VP (VB be)  (ADVP (RB easily) ) (VP (VBN brought)  (NP (-NONE- *-67) ) (PP (IN under)  (NP (NP (DT a)  (JJ new)  (NN type) ) (PP (IN of)  (NP (NN inducibility/cell)  (NN type)  (NN specificity) ))))))))))) (. .) )) )
(TOP (NP (NP-COOD (NP (NN Heterodimerization) ) (CC and)  (NP (JJ transcriptional)  (NN activation) )) (ADVP (FW in)  (FW vitro) ) (PP (IN by)  (NP (NN NF-kappa)  (NN B)  (NNS proteins) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN NF-kappa)  (NN B)  (NN family) ) (PP (IN of)  (NP (NN transcription)  (NNS proteins) ))) (VP (VBZ represents)  (NP (NP (JJ multiple)  (NN DNA)  (NN binding) ) (, ,)  (NP (NP (ADJP (NP (NN rel) ) (JJ related) ) (NNS polypeptides) ) (SBAR (WHNP-27 (WDT that) ) (S (NP-SBJ (-NONE- *T*-27) ) (VP (VBP contribute)  (PP (TO to)  (NP-COOD (NP (NP (NN regulation) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBN involved)  (NP (-NONE- *) ) (PP (IN in)  (NP-COOD (NP (JJ immune)  (NN responsiveness) ) (CC and)  (NP (NN inflammation) ))))))) (, ,)  (CONJP (RB as)  (RB well)  (IN as) ) (NP (NP (NN activation) ) (PP (IN of)  (NP (DT the)  (NN HIV)  (JJ long)  (JJ terminal)  (NN repeat) ))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN study) )) (NP-SBJ-28 (NP (JJ multiple)  (ADJP (NP (NN NF-kappa)  (NN B) ) (JJ related) ) (NNS polypeptides) ) (VP (VBG ranging)  (PP (QP (IN from)  (CD 85)  (TO to)  (CD 45) ) (NN kDa) ))) (VP-COOD (VP (VBD were)  (VP (VBN examined)  (NP (-NONE- *-28) ) (PP (IN for)  (NP (PRP$ their)  (NN capacity)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB interact)  (PP (IN with)  (NP (NP (DT the)  (NN PRDII)  (JJ regulatory)  (NN element) ) (PP (IN of)  (NP (NN interferon)  (NN beta) ))))))))))) (CC and)  (VP (VBD were)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-28) ) (VP (TO to)  (VP-COOD (VP (VB possess)  (NP (NP (JJ distinct)  (JJ intrinsic)  (NN DNA)  (NN binding)  (NNS affinities) ) (PP (IN for)  (NP (DT this)  (NN NF-kappa)  (NN B)  (NN site) )))) (CC and)  (VP (VB form)  (NP (JJ multiple)  (NN DNA)  (NN binding)  (JJ homo-)  (CC and)  (NN heterodimer)  (NNS complexes) ) (PP (IN in)  (NP (NN co-renaturation)  (NNS experiments) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (NP (NN DNA)  (NNS templates) ) (VP (VBG containing)  (NP (NP (CD two)  (NNS copies) ) (PP (IN of)  (NP (NP (DT the)  (NN PRDII)  (NN domain) ) (VP (VBN linked)  (NP (-NONE- *) ) (PP (TO to)  (NP (DT the)  (NN rabbit)  (NN beta)  (NN globin)  (NN gene) )))))))))) (, ,)  (NP-SBJ (DT the)  (VBN purified)  (NNS polypeptides) ) (ADVP (RB specifically) ) (VP (VBD stimulated)  (NP (NP (ADJP (NP (NN NF-kappa)  (NN B) ) (JJ dependent) ) (NN transcription) ) (PP (IN in)  (NP (DT an)  (ADJP (FW in)  (FW vitro) ) (NN reconstitution)  (NN assay) ))) (PP-COOD (PP (IN as)  (NP (NNS heterodimers) )) (CC but)  (PP (RB not)  (IN as)  (NP (NN p50)  (NNS homodimers) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS experiments) ) (VP (VBP emphasize)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN dimerization) )) (PP (IN as)  (NP (NP (DT a)  (JJ distinct)  (NN level) ) (PP (IN of)  (NP (NP (JJ transcriptional)  (NN control) ) (SBAR (WHNP-30 (WDT that) ) (S (NP-SBJ (-NONE- *T*-30) ) (VP (MD may)  (VP (VB permit)  (NP (NP (JJ functional)  (NN diversification) ) (PP (IN of)  (NP (NP (DT a)  (JJ limited)  (NN number) ) (PP (IN of)  (NP (JJ regulatory)  (NNS proteins) ))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Oct2)  (NN transactivation) ) (PP (IN from)  (NP (DT a)  (JJ remote)  (NN enhancer)  (NN position) ))) (VP (VBZ requires)  (NP (DT a)  (JJ B-cell-restricted)  (NN activity) )) (. .) ) )
(TOP (S (NP-SBJ (JJ Previous)  (NN cotransfection)  (NNS experiments) ) (VP (VBD had)  (VP (VBN demonstrated)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ ectopic)  (NN expression) ) (PP (IN of)  (NP (DT the)  (JJ lymphocyte-specific)  (NN transcription)  (NN factor)  (NN Oct2) ))) (VP (MD could)  (ADVP (RB efficiently) ) (VP (VB activate)  (NP (NP (DT a)  (NN promoter) ) (VP (VBG containing)  (NP (DT an)  (NN octamer)  (NN motif) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-18 (NN Oct2)  (NN expression) ) (VP (VBD was)  (ADJP-PRD (JJ unable)  (S (NP-SBJ (-NONE- *-18) ) (VP (TO to)  (VP (VB stimulate)  (NP (NP (DT a)  (JJ multimerized)  (NN octamer)  (NN enhancer)  (NN element) ) (PP (IN in)  (NP (NN HeLa)  (NNS cells) ))))))) (, ,)  (ADVP (RB however) )) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN tested)  (NP (NP (DT a)  (NN variety) ) (PP (IN of)  (NP (NP (NN Oct2)  (VBZ isoforms) ) (VP (VBN generated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (JJ alternative)  (NN splicing) )))))) (PP (IN for)  (NP (DT the)  (NN capability)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB activate)  (NP (DT an)  (NN octamer)  (NN enhancer) ) (PP (IN in)  (NP-COOD (NP (JJ nonlymphoid)  (NNS cells) ) (CC and)  (NP (DT a)  (NN B-cell)  (NN line) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP$ Our)  (NNS analyses) ) (VP (VBP show)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (JJ several)  (NN Oct2)  (NNS isoforms) ) (VP (MD can)  (VP (VB stimulate)  (PP (IN from)  (NP (DT a)  (JJ remote)  (NN position) )))))) (CC but)  (SBAR (IN that)  (S (NP-SBJ-20 (DT this)  (NN stimulation) ) (VP (VBZ is)  (VP (JJ restricted)  (NP (-NONE- *-20) ) (PP (TO to)  (NP (NN B)  (NNS cells) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN result) ) (VP (VBZ indicates)  (NP (NP (DT the)  (NN involvement) ) (PP (IN of)  (NP-COOD (CC either)  (NP (DT a)  (JJ B-cell-specific)  (NN cofactor) ) (CC or)  (NP (NP (DT a)  (JJ specific)  (NN modification) ) (PP (IN of)  (NP-COOD (NP (DT a)  (NN cofactor) ) (CC or)  (NP (DT the)  (NN Oct2)  (NN protein) )))))) (PP (IN in)  (NP (JJ Oct2-mediated)  (NN enhancer)  (NN activation) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Mutational)  (NNS analyses) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ carboxy-terminal)  (NN domain) ) (PP (IN of)  (NP (NN Oct2) ))) (VP (VBZ is)  (ADJP-PRD (JJ critical)  (PP (IN for)  (NP (NN enhancer)  (NN activation) ))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-21 (DT this)  (NN domain) ) (VP (VBD conferred)  (NP (NN enhancing)  (NN activity) ) (SBAR-TMP (ADVP-23 (WRB when) ) (S (NP-SBJ-22 (-NONE- *-21) ) (VP (VBN fused)  (NP (-NONE- *-22) ) (PP (TO to)  (NP (NP (DT the)  (NN Oct1)  (NN protein) ) (, ,)  (SBAR (WHNP-24 (WDT which) ) (S (NP-SBJ-25 (-NONE- *T*-24) ) (PP (IN by)  (NP (PRP itself) )) (VP (VBD was)  (ADJP-PRD (JJ unable)  (S (NP-SBJ (-NONE- *-25) ) (VP (TO to)  (VP (VB stimulate)  (PP (IN from)  (NP (DT a)  (JJ remote)  (NN position) ))))))))))) (ADVP (-NONE- *T*-23) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (DT The)  (JJ glutamine-rich)  (NN activation)  (NN domain) ) (ADJP (JJ present)  (PP (IN in)  (NP (NP (DT the)  (JJ amino-terminal)  (NN portion) ) (PP (IN of)  (NP (NN Oct2) )))))) (CC and)  (NP (DT the)  (NN POU)  (NN domain) )) (VP (VBP contribute)  (ADVP (RB only)  (RB marginally) ) (PP (TO to)  (NP (DT the)  (NN transactivation)  (NN function) )) (PP (IN from)  (NP (DT a)  (JJ distal)  (NN position) ))) (. .) ) )
(TOP (NP (NP (NN Induction) ) (PP (IN of)  (NP (DT the)  (NN POU)  (NN domain)  (NN transcription)  (NN factor)  (NN Oct-2) )) (PP-TMP (IN during)  (NP (NN T-cell)  (NN activation) )) (PP (IN by)  (NP (JJ cognate)  (NN antigen) )) (. .) ) )
(TOP (S (NP-SBJ (NN Oct-2) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN transcription)  (NN factor) ) (SBAR (WHNP-22 (WDT that) ) (S (NP-SBJ (-NONE- *T*-22) ) (VP (VBZ binds)  (PP (RB specifically)  (TO to)  (NP (NP (NN octamer)  (NN DNA)  (NNS motifs) ) (PP (IN in)  (NP (NP (DT the)  (NNS promoters) ) (PP (IN of)  (NP (NP-COOD (NP (NN immunoglobulin) ) (CC and)  (NP (NN interleukin-2) )) (NNS genes) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (DT All)  (NN tumor)  (NN cell)  (NNS lines) ) (PP (IN from)  (NP (DT the)  (NN B-cell)  (NN lineage) ))) (CC and)  (NP (NP (DT a)  (JJ few) ) (PP (IN from)  (NP (DT the)  (NN T-cell)  (NN lineage) )))) (VP (VBP express)  (NP (NN Oct-2) )) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-23) ) (VP (TO To)  (VP (VB address)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (NN Oct-2) )) (PP (IN in)  (NP (DT the)  (NN T-cell)  (NN lineage) )))))) (, ,)  (NP-SBJ-23 (PRP we) ) (VP (VBD studied)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP-COOD (NP (NN Oct-2)  (NN mRNA) ) (CC and)  (NP (NN protein) ))) (PP (IN in)  (NP (JJ nontransformed)  (UCP-COOD (ADJP (JJ human) ) (CC and)  (NP (NN mouse) )) (NN T)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ-24 (NN Oct-2) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-24) ) (PP-COOD (PP (IN in)  (NP (NP (ADJP-COOD (ADJP (JJ CD4+) ) (CC and)  (ADJP (JJ CD8+) )) (NN T)  (NNS cells) ) (VP (VBN prepared)  (NP (-NONE- *) ) (PP (IN from)  (NP (JJ human)  (JJ peripheral)  (NN blood) ))))) (CC and)  (PP (IN in)  (NP (NN mouse)  (NN lymph)  (NN node)  (NN T)  (NNS cells) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (DT a)  (NN T-cell)  (NN clone) ) (ADJP (JJ specific)  (PP (IN for)  (NP (NN pigeon)  (NN cytochrome)  (NN c) )) (PP (IN in)  (DT the)  (NN context)  (IN of)  (NP (NN I-Ek) ))))) (, ,)  (NP-SBJ-25 (NN Oct-2) ) (VP (VBD was)  (VP (VBN induced)  (NP (-NONE- *-25) ) (PP (IN by)  (NP-LGS (NN antigen)  (NN stimulation) )) (, ,)  (SBAR (IN with)  (S (NP-300 (NP (DT the)  (NN increase) ) (PP (IN in)  (NP (NN Oct-2)  (NN protein) ))) (VP-COOD (VP (VBN seen)  (NP (-NONE- *-300) ) (ADVP (RB first) ) (PP-TMP (IN at)  (NP (NP (CD 3)  (NN h) ) (PP-TMP (IN after)  (NP (NN activation) ))))) (CC and)  (VP (VBG continuing)  (PP-TMP (IN for)  (NP (QP (IN at)  (JJS least)  (CD 24) ) (NN h) )))))))) (. .) ) )
(TOP (S (NP-SBJ-26 (NP (NN Oct-2)  (NN mRNA)  (NN induction) ) (PP-TMP (IN during)  (NP (JJ antigen-driven)  (NN T-cell)  (NN activation) ))) (VP (VBD was)  (VP (VBN blocked)  (NP (-NONE- *-26) ) (PP-COOD (PP (IN by)  (NP-LGS (NN cyclosporin)  (NN A) )) (, ,)  (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN by)  (NP-LGS (NN protein)  (NN synthesis)  (NNS inhibitors) ))))) (. .) ) )
(TOP (S (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NN Oct-2) ) (VP (VBZ participates)  (PP (IN in)  (NP (NP (JJ transcriptional)  (NN regulation) ) (PP-TMP (IN during)  (NP (NN T-cell)  (NN activation) )))))))) (. .) ) (S (NP-SBJ (NP (DT The)  (ADJP-TMP (RB relatively)  (VBN delayed) ) (NNS kinetics) ) (PP (IN of)  (NP (NN Oct-2)  (NN induction) ))) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (NN Oct-2) ) (VP (VBZ mediates)  (NP (NP (DT the)  (NNS changes) ) (PP (IN in)  (NP (NN gene)  (NN expression) )) (SBAR (WHNP-27 (WDT which) ) (S (NP-SBJ (-NONE- *T*-27) ) (VP (VBP occur)  (PP-TMP (NP (JJ many)  (NP-COOD (NP (NNS hours) ) (CC or)  (NP (NNS days) ))) (VBG following)  (NP (NP (NN antigen)  (NN stimulation) ) (PP (IN of)  (NP (NN T)  (NNS lymphocytes) )))))))))))) (. .) )) )
(TOP (NP (-LRB- -LCB-)  (NP-COOD (NP (NP (NNS Changes) ) (PP (IN in)  (NP (NN plasma)  (NN interleukin-1) ))) (CC and)  (NP (NP (PRP$ their)  (JJ possible)  (NN relationship) ) (PP (IN with)  (NP (NP (DT the)  (NNS changes) ) (PP (IN in)  (NP (NN glucocorticoid)  (NN receptor) )))))) (PP (IN in)  (NP (JJ aged)  (JJ long-distance)  (NN runner) )) (-RRB- -RCB-) ) )
(TOP (S (PP (IN For)  (NP (NP (DT the)  (NN study) ) (PP (IN of)  (NP-COOD (NP (NP (DT the)  (NNS changes) ) (PP (IN in)  (NP (NN plasma)  (NP (NP (NN interleukin-1) ) (PRN (-LRB- -LRB-)  (NP (NN IL-1) ) (-RRB- -RRB-) ))))) (CC and)  (NP (NP (PRP$ their)  (JJ possible)  (NN relationship) ) (PP (IN with)  (NP (NP (DT the)  (NNS changes) ) (PP (IN in)  (NP (NP (NN glucocorticoid)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN GR) ) (-RRB- -RRB-) )))))))))) (, ,)  (NP-SBJ-31 (NP-COOD (NP (NN plasma)  (NN IL-1) ) (CC and)  (NP (NN GR) )) (PP (IN in)  (NP (NP (JJ peripheral)  (NN blood)  (NNS leukocytes) ) (PP (IN in)  (NP (JJ aged)  (JJ long-distance)  (NN runner) ))))) (VP (VBD were)  (VP (VBN measured)  (NP (-NONE- *-31) ) (ADVP (RB simultaneously) ))) (. .) ) )
(TOP (S (NP-SBJ-32 (NP (DT The)  (NN activity) ) (PP (IN of)  (NP (NN IL-1) ))) (VP (VBD was)  (VP (VBN expressed)  (NP (-NONE- *-32) ) (PP (IN as)  (NP (PRP$ its)  (NN ability)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB stimulate)  (NP (NN 3H-TdR)  (NN incorporation) ) (PP (IN in)  (NP (NP (DT the)  (NNS thymocytes) ) (PP (IN of)  (NP (NN C57)  (NNS mice) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-33 (NN GR) ) (VP (VBD was)  (VP (VBN determined)  (NP (-NONE- *-33) ) (PP (IN by)  (NP (NP (JJ whole)  (NN cell)  (NN assay) ) (PP (IN with)  (NP (NN 3H-Dex) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBD showed)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (NP (NN plasma)  (NN IL-1) ) (PP (IN in)  (NP (JJ aged)  (JJ long-distance)  (NN runner) ))))) (VP (VBD was)  (NP-PRD (NP-COOD (NP (CD 209)  (NN %) ) (, ,)  (NP (CD 223)  (NN %) ) (CC and)  (NP (CD 145)  (NN %) )) (PP (IN of)  (NP (DT the)  (NN control) ))) (PP (IN at)  (NP (ADJP (QP-COOD (QP (CD 14.7-18.7) ) (, ,)  (QP (CD 3.8-7.0) ) (CC and)  (QP (CD 1.5-2.6) )) (NN KD) ) (NP (NNS fractions) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN GR) ) (PP (IN in)  (NP (NP (JJ peripheral)  (NN blood)  (NNS leukocytes) ) (PP (IN in)  (NP (JJ aged)  (NN runner) ))))) (VP (VBD was)  (NP-PRD (NP (CD 65)  (NN %) ) (PP (IN of)  (NP (DT the)  (NN control) )))) (. .) ) )
(TOP (S (NP-SBJ-COOD-35 (NP (NP (JJ Possible)  (NN relationship) ) (PP (IN between)  (NP (NP (DT the)  (NNS changes) ) (PP (IN in)  (NP (NP-COOD (NP (NN IL-1) ) (CC and)  (NP (NN GR) )) (PP (IN in)  (NP (JJ aged)  (JJ long-distance)  (NN runner) ))))))) (CC and)  (NP (PRP$ its)  (JJ physiological)  (NN significance) )) (VP (VBP are)  (VP (VBN discussed)  (NP (-NONE- *-35) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Transcription)  (NN factor)  (NN AP-2) ) (VP (VBZ activates)  (NP (NP (NN gene)  (NN expression) ) (PP (IN of)  (NP (NN HTLV-I) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN HTLV-I)  (NN LTR) ) (VP (VBZ contains)  (NP (NP (CD three)  (VBN conserved)  (JJ regulatory)  (NNS elements) ) (VP (VBN known)  (NP (-NONE- *) ) (PP (IN as)  (NP (NP (ADJP (CD 21)  (NN base)  (NN pair) ) (NNS repeats) ) (SBAR (WHNP-27 (WDT which) ) (S (NP-SBJ-28 (-NONE- *T*-27) ) (VP (VBP are)  (VP (VBN required)  (NP (-NONE- *-28) ) (PP (IN for)  (NP (NP (NN stimulation) ) (PP (IN of)  (NP (NN gene)  (NN expression) )) (PP (IN by)  (NP (DT the)  (NN transactivator)  (NN protein)  (NN tax) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Mutagenesis) ) (VP (VBZ indicates)  (SBAR (IN that)  (S (NP-SBJ-29 (DT the)  (ADJP (CD 21)  (NN bp) ) (NNS repeats) ) (VP (MD can)  (VP (VB be)  (VP (VBN subdivided)  (NP (-NONE- *-29) ) (PP (IN into)  (NP (NP (NP (CD three)  (NNS motifs) ) (, ,)  (NP-COOD (NP (NN A) ) (, ,)  (NP (NN B) ) (CC and)  (NP (NN C) ))) (, ,)  (SBAR (WHNP-30 (NP (DT each) ) (WHPP (IN of)  (WHNP (WDT which) ))) (S (NP-SBJ (-NONE- *T*-30) ) (VP (VBZ influences)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NN tax)  (NN activation) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN A)  (NN site) ) (PP (IN in)  (NP (DT the)  (ADJP (CD 21)  (NN bp) ) (NN repeat) ))) (VP (VBZ has)  (NP (NP (JJ strong)  (NN homology) ) (PP (IN with)  (NP (NP (ADJP (RB previously)  (VBN described) ) (VBG binding)  (NNS sites) ) (PP (IN for)  (NP (DT the)  (NN transcription)  (NN factor)  (NN AP-2) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD demonstrated)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NN AP-2)  (NN mRNA) ) (VP (VBD was)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (NNS T-lymphocytes) )))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ cellular)  (NNS factors) ) (PP (IN from)  (NP (ADJP-COOD (CC both)  (ADJP (JJ non-transformed) ) (CC and)  (ADJP (VBN transformed) )) (NNS T-lymphocytes) ))) (ADVP (RB specifically) ) (VP (VBD bound)  (PP (TO to)  (NP (NP (DT the)  (NN consensus)  (NN motif) ) (PP (IN for)  (NP (NN AP-2) )) (PP (IN in)  (NP (DT each)  (CD 21)  (NN bp) ))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-31) ) (VP (TO To)  (VP (VB determine)  (NP (NP (DT the)  (NN role) ) (PP (IN of)  (NP (NN AP-2) )) (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (DT the)  (NN HTLV-I)  (NN LTR)  (NN gene)  (NN expression) )))))))) (, ,)  (NP-SBJ-31 (PRP we) ) (VP (VBD used)  (NP (DT an)  (NN AP-2)  (NN cDNA) ) (PP (IN in)  (NP (NP-COOD (NP (NN DNA)  (NN binding) ) (CC and)  (NP (JJ transient)  (NN expression) )) (NNS assays) ))) (. .) ) )
(TOP (S (NP-SBJ (NP-COOD (NP (NN Gel)  (NN retardation) ) (CC and)  (NP (NN methylation)  (NN interference) )) (NNS studies) ) (VP (VBD revealed)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (ADJP (RB bacterially)  (VBN produced) ) (NN AP-2) ) (VP (VBD bound)  (UCP-COOD (ADVP (RB specifically) ) (CC and)  (PP (IN with)  (NP (JJ high)  (NN affinity) ))) (PP (TO to)  (NP (QP (DT all)  (CD three) ) (ADJP (CD 21)  (NN bp) ) (NNS repeats) ))))) (, ,)  (CC and)  (SBAR (IN that)  (S (NP-SBJ (PRP it) ) (VP (VBD required)  (NP (DT the)  (NN core)  (NN sequence)  (NN AGGC) ) (PP (IN for)  (NP (JJ specific)  (NN binding) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Binding) ) (PP (IN of)  (NP (NN AP-2) ))) (VP (VBD prevented)  (NP (NP (DT the)  (JJ subsequent)  (NN binding) ) (PP (IN of)  (NP (NP (NNS members) ) (PP (IN of)  (NP (DT the) (NN  CREB/ATF)  (NN family) )))) (PP (TO to)  (NP (NP (DT an)  (JJ adjacent)  (JJ regulatory)  (NN motif) ) (PP (IN in)  (NP (DT the)  (ADJP (CD 21)  (NN bp) ) (NN repeat) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Transfection) ) (PP (IN of)  (NP (DT an)  (NN AP-2)  (NN expression)  (NN construct) )) (PP (IN into)  (NP (NNS T-lymphocytes) ))) (VP (VBD activated)  (NP (NP (NN gene)  (NN expression) ) (PP (IN from)  (NP (DT the)  (NN HTLV-I)  (NN LTR) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-32 (QP (IN At)  (JJS least)  (CD two) ) (ADJP (CD 21)  (NN bp) ) (NNS repeats) ) (VP (VBD were)  (VP (VBN required)  (NP (-NONE- *-32) ) (PP (IN for)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (NN AP-2)  (NN activation) ))))))) (CC and)  (S (NP-SBJ (NP (NN mutagenesis) ) (PP (IN of)  (NP (NP (DT the)  (NN AP-2)  (NN consensus)  (NN binding)  (NNS sequences) ) (PP (IN in)  (NP (DT the)  (ADJP (CD 21)  (NN bp) ) (NNS repeats) ))))) (VP (VBP eliminate)  (NP (DT this)  (NN activation) ))) (. .) ) )
(TOP (S (-LRB- -LRB-)  (NP-SBJ-103 (NN ABSTRACT) ) (VP (VBN TRUNCATED)  (NP (-NONE- *-103) ) (PP (IN AT)  (NP (CD 250)  (NNS WORDS) ))) (-RRB- -RRB-) ) )
(TOP (NP (NP-COOD (NP (ADJP (NN Cell)  (JJ cycle-dependent) ) (NN initiation) ) (CC and)  (NP (JJ lineage-dependent)  (NN abrogation) )) (PP (IN of)  (NP (NN GATA-1)  (NN expression) )) (PP (IN in)  (NP (JJ pure)  (VBG differentiating)  (JJ hematopoietic)  (NNS progenitors) )) (. .) ) )
(TOP (S (NP-SBJ-37 (NP (DT The)  (VBN programmed) (NN  activation/repression) ) (PP (IN of)  (NP (NN transcription)  (NNS factors) )) (PP (IN in)  (NP (JJ early)  (JJ hematopoietic)  (NN differentiation) ))) (VP (VBZ has)  (RB not)  (ADVP (RB yet) ) (VP (VBN been)  (VP (VBN explored)  (NP (-NONE- *-37) )))) (. .) ) )
(TOP (S (NP-SBJ-38 (DT The)  (JJ DNA-binding)  (NN protein)  (NN GATA-1) ) (VP-COOD (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-38) ) (PP (IN for)  (NP (JJ normal)  (JJ erythroid)  (NN development) )))) (CC and)  (VP (VBZ regulates)  (NP (JJ erythroid-expressed)  (NNS genes) ) (PP (IN in)  (NP (VBG maturing)  (NNS erythroblasts) )))) (. .) ) )
(TOP (S (NP-SBJ-39 (PRP We) ) (VP (VBD analyzed)  (NP (NP (NN GATA-1)  (NN expression) ) (PP (IN in)  (NP (JJ early)  (JJ human)  (JJ adult)  (NN hematopoiesis) ))) (PP (IN by)  (S (NP-SBJ (-NONE- *-39) ) (VP (VBG using)  (NP (NP (DT an)  (ADJP (FW in)  (FW vitro) ) (NN system) ) (SBAR (WHPP-40 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ-41 (`` ")  (JJ pure)  ('' ")  (JJ early)  (JJ hematopoietic)  (NNS progenitors) ) (VP (VBP are)  (VP (VBN induced)  (NP (-NONE- *-41) ) (PP (TO to)  (NP (ADJP-COOD (ADJP (JJ gradual) ) (CC and)  (ADJP (VBD synchronized) )) (NN differentiation) )) (ADVP (RB selectively) ) (PP (IN along)  (NP (DT the)  (ADJP-COOD (ADJP (JJ erythroid) ) (CC or)  (ADJP (JJ granulocyte-macrophage) )) (NN pathway) )) (PP (IN by)  (NP (NP (JJ differential)  (NN treatment) ) (PP (IN with)  (NP (JJ hematopoietic)  (NN growth)  (NNS factors) )))) (PP (-NONE- *T*-40) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-42 (NP (DT The)  (NN GATA-1)  (NN gene) ) (, ,)  (SBAR (IN though)  (FRAG (ADJP-PRD (RB virtually)  (JJ silent)  (PP (IN in)  (NP (JJ quiescent)  (NNS progenitors) ))))) (, ,) ) (VP (VBZ is)  (VP (VBN activated)  (NP (-NONE- *-42) ) (PP-TMP (IN after)  (NP (NP (NN entrance) ) (PP (IN into)  (NP (DT the)  (NN cell)  (NN cycle) )))) (PP-TMP (IN upon)  (NP (NP (NN stimulation) ) (PP (IN with)  (NP (JJ hematopoietic)  (NN growth)  (NNS factors) )))))) (. .) ) )
(TOP (S (ADVP (RB Subsequently) ) (, ,)  (NP-SBJ (NP (VBG increasing)  (NN expression) ) (PP (IN along)  (NP (DT the)  (JJ erythroid)  (NN pathway) ))) (VP (VBZ contrasts)  (PP (IN with)  (NP (NP (DT an)  (JJ abrupt)  (NN downregulation) ) (PP (IN in)  (NP (DT the)  (JJ granulocyte-macrophage)  (NN lineage) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (NP (NP (DT a)  (ADJP-COOD (ADJP (JJ microenvironment-directed) ) (, ,)  (ADJP (JJ two-step) )) (NN model) ) (PP (IN for)  (NP (NN GATA-1)  (NN expression) )) (PP (IN in)  (NP (VBG differentiating)  (JJ hematopoietic)  (NNS progenitors) )) (SBAR (WHNP-43 (WDT that) ) (S (NP-SBJ (-NONE- *T*-43) ) (VP (VBZ involves)  (NP-COOD (NP (LST (-LRB- -LRB-)  (LS i)  (-RRB- -RRB-) ) (JJ cycle-dependent)  (NN initiation) ) (CC and)  (NP (LST (-LRB- -LRB-)  (LS ii)  (-RRB- -RRB-) ) (JJ lineage-dependent)  (NP-COOD (NP (NN maintenance) ) (CC or)  (NP (NN suppression) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Hypothetically) ) (, ,)  (NP-SBJ (NP (ADJP (JJ on/off) ) (NNS switches) ) (PP (IN of)  (NP (JJ lineage-restricted)  (NNS transactivators) ))) (VP (MD may)  (VP (VB underlie)  (NP (NP (DT the)  (JJ binary)  (NN fate)  (NNS decisions) ) (PP (IN of)  (NP (JJ hematopoietic)  (NNS progenitors) ))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP (JJ Age-related)  (NNS changes) ) (PP (IN in)  (NP (NP (NP-COOD (NP (NN glucocorticoid) ) (CC and)  (NP (NN mineralocorticoid) )) (NNS receptors) ) (PP (IN in)  (NP (NP (NNS lymphocytes) ) (PP (IN of)  (NP-COOD (NP (JJ healthy)  (NNS persons) ) (CC and)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN hypertension) ))))))))) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN found)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN glucocorticoid)  (NNS receptors) )) (PP (IN in)  (NP (NP (NNS lymphocytes) ) (PP (IN of)  (NP (NP (DT the)  (JJ peripheral)  (NN blood) ) (PP (IN of)  (NP (JJ healthy)  (JJ elderly)  (NNS subjects) ))))))) (VP (VBZ increases)  (, ,)  (SBAR (IN while)  (S (NP-SBJ (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN mineralocorticoid)  (NNS receptors) ))) (VP (VBZ decreases) ))))))))) (. .) ) )
(TOP (S (S (NP-SBJ-20 (NP (DT The)  (NNS mechanisms) ) (PP (IN of)  (NP (NN hormone-receptor)  (NNS interactions) )) (PP (IN in)  (NP (NN hypertension) ))) (VP (VBP are)  (VP (VBN activated)  (NP (-NONE- *-20) ))) (: :) ) (S (NP-SBJ (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NP-COOD (NP (NN glucocorticoid) ) (CC and)  (NP (NN mineralocorticoid) )) (NN binding)  (NNS sites) ))) (VP (VBZ grows)  (PP (IN in)  (NP (JJ hypertensive)  (NNS patients) ))) (. .) )) )
(TOP (S (ADVP (RB Still) ) (NP-SBJ-21 (NP (DT a)  (ADJP (RBR more)  (JJ essential) ) (NN rise) ) (PP (IN in)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NNS receptors) )))) (PP (-NONE- *ICH*-105) )) (VP (VBZ is)  (VP (VBN observed)  (NP (-NONE- *-21) ) (PP (IN in)  (NP (JJ mid-age)  (NN hypertensive)  (NNS patients) )) (PP-105 (IN than)  (FRAG (PP (IN in)  (NP (JJ elderly)  (NNS ones) )))))) (. .) ) )
(TOP (NP (NP (NP (ADJP (FW In)  (FW vivo) ) (NN footprint)  (NN analysis) ) (PP (IN of)  (NP (DT the)  (NN HLA-DRA)  (NN gene)  (NN promoter) )) (: :) ) (NP-COOD (NP (NP (JJ cell-specific)  (NN interaction) ) (PP (IN at)  (NP (DT the)  (NN octamer)  (NN site) ))) (CC and)  (NP (NP (NN up-regulation) ) (PP (IN of)  (NP (NN X)  (NN box)  (NN binding) )) (PP (IN by)  (NP (NN interferon)  (NN gamma) ))) (. .) )) )
(TOP (S (NP-SBJ (NP (NN Analysis) ) (PP (IN of)  (NP (DT the)  (JJ major)  (NN histocompatibility)  (NN complex)  (NN class)  (CD II)  (NN gene)  (NN promoter)  (NN DRA) ))) (VP (VBZ has)  (ADVP-TMP (RB previously) ) (VP (VBN identified)  (NP (NP (QP (IN at)  (JJS least)  (CD five) ) (JJ cis-acting)  (NNS regions) ) (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (JJ maximal)  (NN expression) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN examined)  (NP (NP (DT the)  (NN DRA)  (NN promoter) ) (PP (IN for)  (NP (NP (JJ protein-DNA)  (NNS interactions) ) (PP (IN in)  (NP (DT the)  (JJ intact)  (NN cell) )))) (, ,)  (SBAR (WHNP-24 (WDT which) ) (S (NP-SBJ (-NONE- *T*-24) ) (VP (MD may)  (VP (VB mediate)  (NP (JJ transcriptional)  (NN activation) )))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-25) ) (VP (VBG Using)  (NP (ADJP (FW in)  (FW vivo) ) (JJ genomic)  (NN footprinting) ))) (NP-SBJ-25 (PRP we) ) (VP (VBD identified)  (NP (NP (NNS interactions) ) (PP (IN in)  (NP (NN B-cell)  (NNS lines) ))) (PP (IN at)  (NP-COOD (NP (DT the)  (NN octamer)  (NN site) ) (CC and)  (NP (DT the)  (NP-COOD (NP (NN Y) ) (, ,)  (NP (NN X1) ) (, ,)  (CC and)  (NP (NN X2) )) (NNS boxes) )))) (. .) ) )
(TOP (S (NP-SBJ (NN Class)  (CD II)  (NN antigen)  (VBG expressing)  (NN T-cell)  (NNS lines) ) (VP (VBD maintained)  (NP (NP (NNS contacts) ) (ADJP (JJ identical)  (PP (TO to)  (NP (NN B-cell)  (NNS lines) )))) (, ,)  (SBAR (IN while)  (S (NP-SBJ (ADJP (NN class)  (JJ II-negative) ) (NN T-cell)  (NNS lines) ) (VP (VBD exhibited)  (NP (DT no)  (NNS interactions) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (JJ lymphoid)  (NN cell)  (NNS lines) )) (, ,)  (NP-SBJ-26 (DT the)  (NN octamer)  (NN site) ) (VP (VBZ is)  (VP-COOD (VP (VBN occupied)  (NP (-NONE- *-26) )) (CC and)  (VP (VBN required)  (NP (-NONE- *-26) ) (PP (IN for)  (NP (JJ maximal)  (NN expression) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ is)  (PP-PRD (ADVP (RBS most)  (RB likely) ) (JJ due)  (TO to)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (DT the)  (JJ lymphoid-specific)  (NN OTF-2)  (NN factor) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (DT the)  (ADJP (NN class)  (JJ II-positive) ) (JJ nonlymphoid)  (NN glioblastoma)  (NN cell)  (NN line) ) (VP (VBZ does)  (RB not)  (VP-COOD (VP (VB exhibit)  (NP (NNS interactions) ) (PP (IN at)  (NP-102 (DT the)  (NN octamer)  (NN site) )) (PP (IN despite)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (DT the)  (JJ ubiquitous)  (NN OTF-1)  (NN factor) ))))) (CC and)  (VP (NP=102 (DT an)  (JJ open)  (VBG binding)  (NN site) )))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (DT the)  (NN DRA)  (NN promoter) ) (VP (VBZ discriminates)  (PP (IN against)  (NP (NP (NN OTF-1)  (NN activation) ) (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NN DNA)  (NN binding) )))))) (PP (IN in)  (NP (DT the)  (NN glioblastoma)  (NN line) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Interferon)  (NN gamma) ) (VP-COOD (VP (VBZ induces)  (NP (NN class)  (CD II)  (NN expression) ) (PP (IN in)  (NP (DT this)  (NN glioblastoma)  (NN cell)  (NN line) ))) (CC and)  (, ,)  (VP (PP (IN in)  (NP (NN parallel) )) (, ,)  (VBZ up-regulates)  (NP (NP-COOD (NP (NN X1) ) (CC and)  (NP (NN X2) )) (NN box)  (JJ protein-DNA)  (NNS interactions) ) (, ,)  (SBAR (IN while)  (S (NP-SBJ (DT all)  (JJ other)  (NNS interactions) ) (VP (VBP remain)  (ADJP-PRD (JJ unchanged) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-28 (NN interferon)  (NN gamma) ) (VP (VBZ functions)  (PP (IN on)  (NP (DT a)  (VBN poised)  (NN promoter) )) (PP (IN by)  (S (NP-SBJ (-NONE- *-28) ) (VP (VBG altering)  (NP (NP (JJ weak)  (, ,)  (JJ nonproductive)  (NNS interactions) ) (PP (IN at)  (NP (DT the)  (NN X)  (NNS boxes) ))) (PP (TO to)  (NP (JJ strong)  (NNS interactions) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP provide)  (NP (JJ direct)  (ADJP (FW in)  (FW vivo) ) (NN evidence)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (ADVP (RB strongly) ) (VP (VB suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN modulation) ) (PP (IN of)  (NP (NP-COOD (NP (NN X1) ) (CC and)  (NP (NN X2) )) (NNS interactions) ))) (VP (VBZ is)  (NP-PRD (NP (DT an)  (JJ important)  (NN constituent) ) (PP (IN of)  (NP (DT the)  (NN interferon)  (NN gamma)  (NN induction)  (NN pathway) ))))))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NP (JJ Simple)  (NN derivation) ) (PP (IN of)  (NP (JJ TFIID-dependent)  (NN RNA)  (NN polymerase)  (CD II)  (NN transcription)  (NNS systems) )) (PP (IN from)  (NP-COOD (NP (FW Schizosaccharomyces)  (FW pombe) ) (CC and)  (NP (JJ other)  (NNS organisms) )))) (, ,)  (CC and)  (NP (NP (NNS factors) ) (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (JJ transcriptional)  (NN activation) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Resolution) ) (PP (IN of)  (NP (JJ whole)  (NN cell)  (NN extract) )) (PP (IN through)  (NP (CD two)  (JJ chromatographic)  (NNS steps) ))) (VP (VBZ yields)  (NP (NP (DT a)  (JJ single)  (NN protein)  (NN fraction) ) (VP (VBG requiring)  (NP (NP (RB only)  (DT the)  (NN addition) ) (PP (IN of)  (NP (NN TFIID) ))) (PP (IN for)  (NP (NP (DT the)  (NN initiation) ) (PP (IN of)  (NP (NN transcription) )) (PP (IN at)  (NP (NN RNA)  (NN polymerase)  (CD II)  (NNS promoters) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN approach) ) (VP (VBZ allows)  (NP (NP (DT the)  (JJ convenient)  (NN generation) ) (PP (IN of)  (NP (NN RNA)  (NN polymerase)  (CD II)  (NN transcription)  (NNS systems) )) (PP (IN from)  (NP-COOD (NP (FW Saccharomyces)  (FW cerevisiae) ) (, ,)  (NP (JJ human)  (NNS lymphocytes) ) (, ,)  (CC and)  (NP (FW Schizosaccharomyces)  (FW pombe) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS TFIIDs) ) (PP (IN from)  (NP (DT all)  (CD three)  (NNS organisms) ))) (VP (VBP are)  (ADJP-PRD (JJ interchangeable)  (PP (IN among)  (NP (DT all)  (CD three)  (NNS systems) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NP-COOD (NP (FW S.)  (FW cerevisiae) ) (CC and)  (NP (FW Sch.)  (FW pombe) )) (NNS systems) ) (VP (VBP support)  (NP (NP (NNS effects) ) (PP (IN of)  (NP (JJ acidic)  (NN activator)  (NNS proteins) ))) (, ,)  (PP (VBN provided)  (SBAR (WHNP (-NONE- 0) ) (S (NP-SBJ-25 (NP (DT a)  (JJ further)  (NN protein)  (NN fraction) ) (PP (IN from)  (NP (FW S.)  (FW cerevisiae) ))) (VP (VBZ is)  (VP (VBN supplied)  (NP (-NONE- *-25) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (JJ further)  (NN fraction) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ distinct)  (PP (IN from)  (NP (NP (DT the)  (NN mediator) ) (PP (IN of)  (NP (JJ transcriptional)  (NN activation) )) (VP (VBN described)  (NP (-NONE- *) ) (ADVP-TMP (RB previously) )))))) (CC and)  (VP (VBZ represents)  (NP (DT a)  (JJ second)  (NN component) ) (PP (IN in)  (NN addition)  (TO to)  (NP (NP (JJ general)  (NN initiation)  (NNS factors) ) (SBAR (WHNP-26 (WDT that) ) (S (NP-SBJ (-NONE- *T*-26) ) (VP (MD may)  (VP (VB facilitate)  (NP (NP (DT a)  (NN response) ) (PP (TO to)  (NP (JJ acidic)  (NNS activators) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (NN NF-kappa)  (JJ B-dependent) ) (NN induction) ) (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN p50)  (NN subunit)  (NN gene)  (NN promoter) ))) (VP (VBZ underlies)  (NP (NP (NN self-perpetuation) ) (PP (IN of)  (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN transcription) )) (PP (IN in)  (NP (JJ monocytic)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ-23 (NP (DT The)  (JJ molecular)  (NNS mechanisms) ) (VP (VBG underlying)  (NP (NP (DT the)  (JJ sustained)  (JJ nuclear)  (NN translocation) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (VP (VBN observed)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (NN U937)  (JJ monocytic)  (NNS cells) ) (VP (ADVP (RB chronically) ) (VP (VBN infected)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) ))))))))))) (VP (VBD were)  (VP (VBN studied)  (NP (-NONE- *-23) ))) (. .) ) )
(TOP (S (NP-SBJ-24 (NP (DT The)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN promoter) )) (VP (VBG regulating)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NP (DT the)  (NN p105)  (NN precursor) ) (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN p50)  (NN subunit) ))))))) (VP (VBD was)  (VP (VBN enhanced)  (NP (-NONE- *-24) ) (PP (IN in)  (NP (DT these)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Deletions) ) (PP (IN in)  (NP (DT this)  (NN promoter) ))) (VP (VBD indicated)  (SBAR (IN that)  (S (NP-SBJ-25 (DT this)  (NN upregulation) ) (VP (VBD was)  (VP (VBN mediated)  (NP (-NONE- *-25) ) (PP (IN through)  (NP (NP-COOD (NP (DT the)  (ADJP (NP (NN NF-kappa)  (NN B-) ) (ADJP (-NONE- *?*) )) (NP (-NONE- *RNR*-101) )) (CONJP (CC but)  (RB not) ) (NP (DT the)  (JJ AP-1-binding)  (NP (-NONE- *RNR*-101) ))) (NP-101 (NN motif) ))) (, ,)  (PP (IN by)  (NP (ADJP (FW bona)  (FW fide) ) (NN p50/p65)  (NNS heterodimers) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Analysis) ) (PP (IN of)  (NP (JJ cytosolic)  (NNS extracts) ))) (VP (VBD indicated)  (SBAR (IN that)  (S (NP-SBJ-26 (NN NF-kappa)  (NN B)  (NNS levels) ) (VP (VBD were)  (VP (VBN increased)  (NP (-NONE- *-26) ) (PP (IN in)  (NP (JJ HIV-infected)  (NNS cells) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NN contrast)  (TO to)  (NP (NP (DT the)  (JJ transient)  (NN NF-kappa)  (NN B)  (NN activation) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN phorbol)  (NN ester) ))))) (, ,)  (NP-SBJ-102 (NP (DT the)  (JJ permanent)  (NN NF-kappa)  (NN B)  (NN translocation) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN HIV)  (NN infection) )))) (VP (VBD was)  (RB not)  (ADJP-PRD (JJ dependent)  (PP (IN on)  (NP (NN PKC)  (NNS isoenzymes)  (NP-COOD (NP (NN alpha) ) (CC and)  (NP (NN beta) ))))) (SBAR (IN as)  (S (NP-SBJ-27 (-NONE- *-102) ) (VP (VBN shown)  (NP (-NONE- *-27) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN use) ) (PP (IN of)  (NP (NP (DT a)  (JJ specific)  (NN inhibitor) ) (PRN (-LRB- -LRB-)  (NP (NN GF)  (NN 109203X) ) (-RRB- -RRB-) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS observations) ) (VP (VBP indicate)  (SBAR (IN that)  (S (PP-TMP (IN during)  (NP (NP (JJ chronic)  (NN HIV)  (NN infection) ) (PP (IN of)  (NP (NN U937)  (NNS cells) )))) (, ,)  (NP-SBJ (JJ continuous)  (NN NF-kappa)  (NN B)  (PRN (-LRB- -LRB-)  (NP (NN p50/p65) ) (-RRB- -RRB-) ) (NN translocation) ) (VP (VBZ results)  (PP (IN in)  (NP (NP (NN p105)  (NN promoter)  (NN upregulation) ) (PP (IN with)  (NP (NP (JJ subsequent)  (JJ cytosolic)  (NN NF-kappa)  (NN B)  (NN accumulation) ) (, ,)  (ADJP (JJ ready)  (PP (IN for)  (NP (JJ further)  (NN translocation) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (JJ HIV-mediated)  (NN mechanism) ) (VP (VBZ results)  (PP (IN in)  (NP (NP (DT a)  (JJ self-perpetuating)  (NN loop) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN production) ))))) (. .) ) )
(TOP (NP (NP (DT The)  (NN development) ) (PP (IN of)  (NP (ADJP (RB functionally)  (JJ responsive) ) (NN T)  (NNS cells) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN work) ) (VP (VBN reviewed)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT this)  (NN article) )))) (VP (VBZ separates)  (NP (NN T)  (NN cell)  (NN development) ) (PP (IN into)  (NP (CD four)  (NNS phases) ))) (. .) ) )
(TOP (SINV (ADJP-PRD-TPC-106 (JJ First) ) (VP (VBZ is)  (ADJP-PRD (-NONE- *T*-106) )) (NP-SBJ (NP (DT an)  (NN expansion)  (NN phase) ) (PP (RB prior)  (TO to)  (NP (NN TCR)  (NN rearrangement) )) (, ,)  (SBAR (WHNP-43 (WDT which) ) (S (NP-SBJ-44 (-NONE- *T*-43) ) (VP (VBZ appears)  (S (NP-SBJ-45 (-NONE- *-44) ) (VP (TO to)  (VP (VB be)  (VP (VBN correlated)  (NP (-NONE- *-45) ) (PP (IN with)  (NP (NP (NN programming) ) (PP (IN of)  (NP (QP (IN at)  (JJS least)  (DT some) ) (NN response)  (NNS genes) )) (PP (IN for)  (NP (NN inducibility) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN phase) ) (VP (MD can)  (VP (VB occur)  (PP (TO to)  (NP (DT some)  (NN extent) )) (ADVP (IN outside)  (PP (IN of)  (NP (DT the)  (NN thymus) ))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (DT the)  (JJ profound)  (NN T)  (NN cell)  (NN deficit) ) (PP (IN of)  (NP (JJ nude)  (NNS mice) ))) (VP (VBZ indicates)  (SBAR (IN that)  (S (NP-SBJ-46 (DT the)  (NN thymus) ) (VP (VBZ is)  (PP (IN by)  (ADVP (RB far) )) (NP (NP (DT the)  (ADJP (RBS most)  (JJ potent) ) (NN site) ) (PP (IN for)  (S (NP-SBJ (-NONE- *-46) ) (VP (VBG inducing)  (NP (DT the)  (NN expansion) ) (ADVP (FW per)  (FW se) ))))) (, ,)  (SBAR (RB even)  (IN if)  (S (NP-SBJ (JJ other)  (NNS sites) ) (VP (MD can)  (VP (VB induce)  (NP (DT some)  (NN response)  (NN acquisition) ))))))))) (. .) ) )
(TOP (SINV (ADJP-PRD-TPC-107 (JJ Second) ) (VP (VBZ is)  (ADJP-PRD (-NONE- *T*-107) )) (NP-SBJ (NP (DT a)  (JJ controlled)  (NN phase) ) (PP (IN of)  (NP (NN TCR)  (NN gene)  (NN rearrangement) ))) (. .) ) )
(TOP (S (NP-SBJ-47 (NP (DT The)  (NNS details) ) (PP (IN of)  (NP (NP (DT the)  (JJ regulatory)  (NN mechanism) ) (SBAR (WHNP-48 (WDT that) ) (S (NP-SBJ (-NONE- *T*-48) ) (VP (VBZ selects)  (NP (NP (JJ particular)  (NNS loci) ) (PP (IN for)  (NP (NN rearrangement) ))))))))) (VP (VBP are)  (ADVP (RB still) ) (RB not)  (VP (VBN known)  (NP (-NONE- *-47) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (PRP It) ) (VP (VBZ seems)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN rearrangement) ) (PP (IN of)  (NP (DT the)  (NN TCR)  (NN gamma)  (NNS loci) )) (PP (IN in)  (NP (DT the)  (NN gamma)  (NN delta)  (NN lineage) ))) (VP (MD may)  (RB not)  (ADVP-TMP (RB always) ) (VP (VB take)  (NP (NN place) ) (PP (IN at)  (NP (NP (DT a)  (JJ developmental)  (NN stage) ) (ADJP (RB strictly)  (JJ equivalent)  (PP (TO to)  (NP (NP (DT the)  (NN rearrangement) ) (PP (IN of)  (NP (NN TCR)  (NN beta) )) (PP (IN in)  (NP (DT the)  (NN alpha)  (NN beta)  (NN lineage) ))))))))))))) (, ,)  (CC and)  (S (NP-SBJ (NP (PRP it) ) (SBAR (-NONE- *EXP*-49) )) (VP (VBZ is)  (RB not)  (ADJP-PRD (JJ clear) ) (SBAR-49 (WHADVP-50 (RB just)  (WRB how)  (RB early) ) (S (NP-SBJ (DT the)  (CD two)  (NNS lineages) ) (VP (VBP diverge)  (ADVP (-NONE- *T*-50) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (NN TCR)  (NN alpha)  (NN beta)  (NN lineage) )) (, ,)  (ADVP (RB however) ) (, ,)  (NP-SBJ-51 (DT the)  (JJ final)  (NN gene)  (NN rearrangement)  (NNS events) ) (VP (VBP are)  (VP (VBN accompanied)  (NP (-NONE- *-51) ) (PP (IN by)  (NP-LGS-COOD (NP (JJ rapid)  (NN proliferation) ) (CC and)  (NP (NP (DT an)  (NN interruption) ) (PP (IN in)  (NP (JJ cellular)  (NN response)  (NN gene)  (NN inducibility) ))))))) (. .) ) )
(TOP (S (NP-SBJ-52 (NP (DT The)  (NN loss) ) (PP (IN of)  (NP (JJ conventional)  (NN responsiveness) ))) (VP-COOD (VP (VBZ is)  (ADVP (RB probably) ) (VP (VBN caused)  (NP (-NONE- *-52) ) (PP (IN by)  (NP-LGS (NNS alterations) )) (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NN signaling) )))))) (, ,)  (CC and)  (VP (MD may)  (VP (VB be)  (NP-PRD (NP (DT a)  (NN manifestation) ) (PP (IN of)  (NP (NP (DT the)  (JJ physiological)  (NN state) ) (SBAR (WHNP-53 (WDT that) ) (S (NP-SBJ (-NONE- *T*-53) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN precondition) ) (PP (IN for)  (NP (NN selection) )))))))))))) (. .) ) )
(TOP (SINV (ADJP-PRD-TPC-108 (JJ Third) ) (VP (VBZ is)  (ADJP-PRD (-NONE- *T*-108) )) (NP-SBJ (NP (DT the)  (JJ complex)  (NN process) ) (PP (IN of)  (NP (NN selection) ))) (. .) ) )
(TOP (S (SBAR (IN Whereas)  (S (NP-SBJ (JJ peripheral)  (NN T)  (NNS cells) ) (VP (MD can)  (VP (VB undergo)  (NP (NP (NNS forms) ) (PP (IN of)  (NP-COOD (NP (NP (JJ positive)  (NN selection) ) (-LRB- -LRB-)  (PP (IN by)  (NP (JJ antigen-driven)  (JJ clonal)  (NN expansion) )) (-RRB- -RRB-) ) (CC and)  (NP (NP (JJ negative)  (NN selection) ) (-LRB- -LRB-)  (PP (IN by)  (NP (NP (JJ abortive)  (NN stimulation) ) (VP (VBG leading)  (PP (TO to)  (NP-COOD (NP (NN anergy) ) (CC or)  (NP (NN death) )))))) (-RRB- -RRB-) )))))))) (, ,)  (S (NP-SBJ (DT neither) ) (VP (VBZ is)  (NP-PRD (NP (ADJP (RB exactly)  (DT the)  (JJ same) ) (NN phenomenon) ) (SBAR (WHNP-54 (WDT that) ) (S (NP-SBJ (-NONE- *T*-54) ) (VP (VBZ occurs)  (PP (IN in)  (NP (DT the)  (JJ thymic)  (NN cortex) )))))))) (. .) ) )
(TOP (S (S (NP-SBJ-55 (NP (JJ Negative)  (NN selection) ) (PP (IN in)  (NP (DT the)  (NN cortex) ))) (VP (VBZ appears)  (S (NP-SBJ (-NONE- *-55) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT a)  (JJ suicidal)  (NN inversion) ) (PP (IN of)  (NP (NN antigen)  (NN responsiveness) ))))))) (: :) ) (S (PP (RB instead)  (IN of)  (S (NP-SBJ (-NONE- *-56) ) (VP (VBG turning)  (PRT (IN on) ) (NP (NN IL-2)  (NN expression) )))) (, ,)  (NP-SBJ-56 (DT the)  (VBN activated)  (NN cell) ) (VP (VBZ destroys)  (NP (PRP$ its)  (JJ own)  (NN chromatin) )) (. .) )) )
(TOP (S-COOD (S (NP-SBJ-57 (NP (DT The)  (NNS genes) ) (SBAR (WHNP-58 (WDT that) ) (S (NP-SBJ-59 (-NONE- *T*-58) ) (VP (VBP need)  (S (NP-SBJ-60 (-NONE- *-59) ) (VP (TO to)  (VP (VB be)  (VP (VBN induced)  (NP (-NONE- *-60) ) (PP (IN for)  (NP (DT this)  (NN response) )))))))))) (VP (VBP are)  (RB not)  (ADVP (RB yet) ) (VP (VBN identified)  (NP (-NONE- *-57) )))) (, ,)  (CC but)  (S (NP-SBJ (PRP it) ) (VP (VBZ is)  (ADVP (RB unquestionably) ) (NP-PRD (NP (DT a)  (NN form) ) (PP (IN of)  (NP (NN activation) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP It) ) (SBAR (-NONE- *EXP*-61) )) (VP (VBZ is)  (ADJP-PRD (JJ interesting) ) (SBAR-61 (IN that)  (S (PP (IN in)  (NP-COOD (NP (NNS humans) ) (CC and)  (NP (NNS rats) ))) (, ,)  (NP-SBJ-62 (NP (JJ cortical)  (NNS thymocytes) ) (VP (VBG undergoing)  (NP (JJ negative)  (NN selection) ))) (VP (MD can)  (VP (VP-COOD (VP (ADVP (RB still) ) (VP (VB induce)  (NP (NN IL-2R)  (NN alpha)  (NN expression) ))) (CC and)  (VP (ADVP (RB even) ) (VP (VB be)  (VP (VBN rescued)  (NP (-NONE- *-62) ) (ADVP (FW in)  (FW vitro) ))))) (, ,)  (SBAR-ADV (IN if)  (S (NP-SBJ-63 (JJ exogenous)  (NN IL-2) ) (VP (VBZ is)  (VP (VBN provided)  (NP (-NONE- *-63) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Perhaps) ) (NP-SBJ-64 (JJ murine)  (NNS thymocytes) ) (VP (VBP are)  (VP (VBN denied)  (NP (-NONE- *-64) ) (NP (NP (DT this)  (NN form) ) (PP (IN of)  (NP (NN rescue) ))) (SBAR-COOD (SBAR (IN because)  (S (NP-SBJ (PRP they) ) (VP (VBD shut)  (PRT (RP off) ) (NP (NN IL-2R)  (NN beta)  (NN chain)  (NN expression) ) (PP-TMP (IN at)  (NP (DT an)  (JJR earlier)  (NN stage) ))))) (CC or)  (SBAR (IN because)  (S (NP-SBJ (PRP they) ) (VP (MD may)  (VP (VB be)  (ADJP-PRD (RB uncommonly)  (NP (NN Bcl-2) ) (JJ deficient) )))))) (PRN (-LRB- -LRB-)  (S (NP-SBJ (-NONE- *) ) (VP (VBP cf.)  (NP-COOD (NP (NNP Sentman)  (FW et)  (FW al.)  (, ,)  (CD 1991) ) (: ;)  (NP (NNP Strasser)  (FW et)  (FW al.)  (, ,)  (CD 1991) )))) (-RRB- -RRB-) ))) (. .) ) )
(TOP (S (ADVP (RB Even)  (RB so) ) (, ,)  (NP-SBJ (JJ medullary)  (NNS thymocytes) ) (VP (VBP remain)  (ADJP-PRD (ADVP (ADVP (IN at)  (JJS least) ) (RB partially) ) (JJ susceptible)  (PP (TO to)  (NP (JJ negative)  (NN selection) ))) (SBAR (RB even)  (IN as)  (S (NP-SBJ-65 (PRP they) ) (VP (VBP continue)  (S (NP-SBJ (-NONE- *-65) ) (VP (TO to)  (VP (VB mature) ))))))) (. .) ) )
(TOP (NP (NP (NP-COOD (NP (JJ SRC-related)  (NNS proto-oncogenes) ) (CC and)  (NP (NN transcription)  (NNS factors) )) (PP (IN in)  (NP (JJ primary)  (JJ human)  (NN T)  (NNS cells) )) (: :) ) (NP (NP (NN modulation) ) (PP (IN by)  (NP-COOD (NP (NN cyclosporin)  (NN A) ) (CC and)  (NP (NN FK506) ))) (. .) )) )
(TOP (S (NP-SBJ (NP (NN Activation) ) (PP (IN of)  (NP (NN T)  (NNS lymphocytes) ))) (VP (VBZ induces)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NP (NNS genes) ) (VP (VBG encoding)  (PP (IN for)  (NP (NNS lymphokines) ))))))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP (NP (NN Interleukin-2) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2) ) (-RRB- -RRB-) )) (NN gene)  (NN expression) ) (VP (VBZ is)  (VP (VBN controlled)  (NP (-NONE- *-41) ) (ADVP (RB transcriptionally) ) (PP (IN by)  (NP-LGS (NP (DT the)  (JJ cooperative)  (NN activity) ) (PP (IN of)  (NP (NP (JJ specific)  (JJ trans-activating)  (NNS factors) ) (SBAR (WHNP-42 (WDT that) ) (S (NP-SBJ (-NONE- *T*-42) ) (VP (VBP bind)  (PP (TO to)  (NP (DT the)  (NN IL-2)  (NN enhancer) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (NN Cyclosporin)  (NN A) ) (PRN (-LRB- -LRB-)  (NP (NN CsA) ) (-RRB- -RRB-) )) (CC and)  (NP (NN FK506) )) (VP (VBP inhibit)  (NP (NP (DT the)  (NN production) ) (PP (IN of)  (NP (NN IL-2) )) (PP (IN in)  (NP (NN T)  (NNS lymphocytes) )) (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NN gene)  (NN transcription) )))))) (. .) ) )
(TOP (S (NP-SBJ-43 (NP (NP (DT A)  (NN member) ) (PP (IN of)  (NP (DT the)  (NN src)  (NN gene)  (NN family) ))) (, ,)  (NP (NP (DT the)  (JJ lymphocyte-specific)  (NN protein)  (NN tyrosine)  (NN kinase) ) (, ,)  (NP (NN p56lck) ) (, ,) )) (VP (VBZ has)  (VP (VBN been)  (VP (VBN implicated)  (NP (-NONE- *-43) ) (PP (IN in)  (NP (NN IL-2)  (NN production) ))))) (. .) ) )
(TOP (S (NP-SBJ-44 (NN CsA) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-44) ) (VP (RB not)  (TO to)  (VP (VB inhibit)  (NP-COOD (NP (NN lck)  (NN gene)  (NN expression) ) (, ,)  (CC nor)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN lck)  (NN gene)  (NN product) ))))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-COOD (NP (NN CsA) ) (CC and)  (NP (NN FK506) )) (VP (VBP inhibit)  (NP (NP (DT the)  (NN appearance) ) (PP (IN of)  (NP (NP (NN DNA)  (NN binding)  (NN activity) ) (PP (IN of)  (NP (NP (NNS factors) ) (SBAR (WHNP-45 (WDT that) ) (S (NP-SBJ (-NONE- *T*-45) ) (VP (VBP bind)  (PP (TO to)  (NP (DT the)  (NP-COOD (NP (NN NF-AT) ) (CC and)  (NP (NN AP-1) )) (NNS sites) )) (PP (IN in)  (NP (DT the)  (NN IL-2)  (NN enhancer) ))))))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ-46 (NP (DT the)  (NN induction) ) (PP (IN of)  (NP-COOD (NP (NN NF-AT) ) (CC and)  (NP (NN AP-1) )))) (VP (VBZ is)  (VP (VBN induced)  (NP (-NONE- *-46) ) (PP (IN by)  (NP-LGS (NP (DT the)  (JJ same)  (NNS stimuli) ) (SBAR (WHNP-47 (WDT that) ) (S (NP-SBJ (-NONE- *T*-47) ) (VP (VBP stimulate)  (NP (NN IL-2)  (NN production) )))))))))) (, ,)  (NP-SBJ (DT these)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-48 (NP (DT the)  (JJ immunosuppressant)  (NN action) ) (PP (IN of)  (NP-COOD (NP (NN CsA) ) (CC and)  (NP (NN FK506) )))) (VP (VBZ is)  (VP (VBN exerted)  (NP (-NONE- *-48) ) (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (DT these)  (JJ trans-activating)  (NNS factors) ))))))))) (. .) ) )
(TOP (NP (NP (NP (JJ TAR-independent)  (NN transactivation) ) (PP (IN by)  (NP (NN Tat) )) (PP (IN in)  (NP (NP (NNS cells) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT the)  (NN CNS) ))))) (: :) ) (NP (NP (DT a)  (JJ novel)  (NN mechanism) ) (PP (IN of)  (NP (NN HIV-1)  (NN gene)  (NN regulation) )) (. .) )) )
(TOP (S (NP-SBJ (NP (DT The)  (NN Tat)  (NN protein) ) (PP (IN of)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )))) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ essential)  (PP (IN for)  (NP (JJ productive)  (NN infection) )))) (CC and)  (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potential)  (NN target) ) (PP (IN for)  (NP (JJ antiviral)  (NN therapy) ))))) (. .) ) )
(TOP (S (NP-SBJ-16 (NP (NN Tat) ) (, ,)  (NP (NP (DT a)  (JJ potent)  (NN activator) ) (PP (IN of)  (NP (NN HIV-1)  (NN gene)  (NN expression) ))) (, ,) ) (VP (VBZ serves)  (S (NP-SBJ (-NONE- *-16) ) (VP (TO to)  (ADVP (RB greatly) ) (VP (VB increase)  (NP (NP (DT the)  (NN rate) ) (PP (IN of)  (NP (NP (NN transcription) ) (VP (VBN directed)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT the)  (JJ viral)  (NN promoter) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (NN induction) ) (, ,)  (SBAR (WHNP-17 (WDT which) ) (S (NP-SBJ-18 (-NONE- *T*-17) ) (VP (VBZ seems)  (S (NP-SBJ (-NONE- *-18) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT an)  (JJ important)  (NN component) ) (PP (IN in)  (NP (NP (DT the)  (NN progression) ) (PP (IN of)  (NP (NP (VBN acquired)  (JJ immune)  (NN deficiency)  (NN syndrome) ) (PRN (-LRB- -LRB-)  (NP (NN AIDS) ) (-RRB- -RRB-) )))))))))))) (, ,) ) (VP (MD may)  (VP (VB be)  (PP-PRD (JJ due)  (TO to)  (NP-COOD (NP (VBN increased)  (JJ transcriptional)  (NN initiation) ) (, ,)  (NP (VBN increased)  (JJ transcriptional)  (NN elongation) ) (, ,)  (CC or)  (NP (NP (DT a)  (NN combination) ) (PP (IN of)  (NP (DT these)  (NNS processes) ))))))) (. .) ) )
(TOP (S (NP-SBJ-19 (JJ Much)  (NN attention) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN focused)  (NP (-NONE- *-19) ) (PP (IN on)  (NP (NP (DT the)  (NN interaction) ) (PP (IN of)  (NP (NN Tat) )) (PP (IN with)  (NP (NP (DT a)  (JJ specific)  (NN RNA)  (NN target) ) (VP (VBN termed)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NP (NN TAR) ) (PRN (-LRB- -LRB-)  (NP (NN transactivation)  (NN responsive) ) (-RRB- -RRB-) )))) (SBAR (WHNP-20 (WDT which) ) (S (NP-SBJ (-NONE- *T*-20) ) (VP (VBZ is)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (NP (DT the)  (NN leader)  (NN sequence) ) (PP (IN of)  (NP (DT all)  (NN HIV-1)  (NNS mRNAs) ))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-21 (DT This)  (NN interaction) ) (VP (VBZ is)  (VP (VBN believed)  (S (NP-SBJ (-NONE- *-21) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT an)  (JJ important)  (NN component) ) (PP (IN of)  (NP (NP (DT the)  (NN mechanism) ) (PP (IN of)  (NP (NN transactivation) )))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN report) )) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (PP (IN in)  (NP (JJ certain)  (JJ CNS-derived)  (NNS cells) )) (NP-SBJ-22 (NN Tat) ) (VP (VBZ is)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-22) ) (VP (VBG activating)  (NP (NN HIV-1) ) (PP (IN through)  (NP (DT a)  (JJ TAR-independent)  (NN pathway) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-23 (DT A)  (JJ Tat-responsive)  (NN element) ) (VP (VBZ is)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-23) ) (ADVP-PRD (RB upstream)  (PP (IN within)  (NP (NP (DT the)  (JJ viral)  (NN promoter) ) (SBAR (WHNP-24 (WDT that) ) (S (PP (IN in)  (NP (JJ glial-derived)  (NN cell)  (NNS lines) )) (NP-SBJ (-NONE- *T*-24) ) (VP (VBZ allows)  (NP (NN transactivation) ) (PP (IN in)  (DT the)  (NN absence)  (IN of)  (NP (NN TAR) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN Deletion)  (NN mapping) ) (CC and)  (NP (NN hybrid)  (NN promoter)  (NNS constructs) )) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (ADJP (RB newly)  (VBN identified) ) (JJ Tat-responsive)  (NN element) ) (VP (VBZ corresponds)  (PP (TO to)  (NP (NP (DT a)  (NN sequence) ) (PP (IN within)  (NP (DT the)  (JJ viral)  (NP (NP (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) )))) (VP (ADVP-TMP (RB previously) ) (VBN identified)  (NP (-NONE- *) ) (PP (IN as)  (NP (NP (DT the)  (NN HIV-1)  (NN enhancer) ) (, ,)  (CC or)  (NP (NN NF-kappa)  (NN B)  (NN domain) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN DNA)  (JJ band-shift)  (NN analysis) ) (VP (VBZ reveals)  (NP (NP (NN NF-kappa)  (NN B)  (NN binding)  (NN activity) ) (PP (IN in)  (NP (JJ glial)  (NNS cells) )) (SBAR (WHNP-25 (WDT that) ) (S (NP-SBJ (-NONE- *T*-25) ) (VP (VBZ differs)  (PP (IN from)  (NP (NP (DT that) ) (ADJP (JJ present)  (PP (IN in)  (NP (NN T)  (JJ lymphoid)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Further) ) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP observe)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ TAR-deleted)  (NNS mutants) ) (PP (IN of)  (NP (NN HIV-1) ))) (VP (VBP demonstrate)  (NP (NP (JJ normal)  (JJ late)  (NN gene)  (NN expression) ) (PP (IN in)  (NP (JJ glial)  (NNS cells) ))) (SBAR (IN as)  (S (NP-SBJ-26 (-NONE- *) ) (VP (VBN evidenced)  (NP (-NONE- *-26) ) (PP (IN by)  (NP-LGS (NP (NN syncytia)  (NP-COOD (NP (NN formation) ) (CC and)  (NP (NN production) ))) (PP (IN of)  (NP (JJ viral)  (NN p24)  (NN antigen) ))))))))))) (. .) ) )
(TOP (S (-LRB- -LRB-)  (NP-SBJ-100 (NN ABSTRACT) ) (VP (VBN TRUNCATED)  (NP (-NONE- *-100) ) (PP (IN AT)  (NP (CD 250)  (NNS WORDS) ))) (-RRB- -RRB-) ) )
(TOP (NP (NP (NP (NN Bcl-2) ) (: :)  (NP (NP (DT a)  (NN repressor) ) (PP (IN of)  (NP (NN lymphocyte)  (NN death) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NP-COOD (NP (NNS genes) ) (CC and)  (NP (NNS mechanisms) ))) (SBAR (WHNP-14 (WDT that) ) (S (NP-SBJ (-NONE- *T*-14) ) (VP (VBP control)  (NP (VBN programmed)  (NN cell)  (NN death) ))))) (VP (VBP are)  (ADVP-TMP (RB currently) ) (NP-PRD (NP (DT the)  (NN subject) ) (PP (IN of)  (NP (JJ intense)  (NN study) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN bcl-2)  (NN gene) ) (, ,)  (NP (NP (DT a)  (NN repressor) ) (PP (IN of)  (NP (NN lymphocyte)  (NN death) ))) (, ,) ) (VP (VBZ is)  (ADVP (RB perhaps) ) (NP-PRD (NP (DT the)  (JJS best)  (VBN understood) ) (PP (IN of)  (NP (DT the)  (ADJP (NP (VBN programmed)  (NN cell)  (NN death) ) (JJ associated) ) (NNS genes) )))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (, ,)  (NP-SBJ-15 (NNP Stanley)  (NNP Korsmeyer) ) (VP (VBZ provides)  (NP (NP (DT a)  (JJ brief)  (NN overview) ) (PP (IN of)  (NP (NN bcl-2) ))) (, ,)  (S (NP-SBJ (-NONE- *-15) ) (VP (VBG concentrating)  (PP (IN on)  (NP (NP (PRP$ its)  (NNS roles) ) (PP-COOD (PP (IN in)  (NP (NP (NP (NN B-)  (NP (-NONE- *?*) )) (CC and)  (NP (NN T-cell) )) (NN development) )) (CC and)  (PP (IN in)  (NP (NN oncogenesis) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Mitogen)  (NN stimulation) ) (PP (IN of)  (NP (NNS T-cells) ))) (VP (VBZ increases)  (NP-COOD (NP (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )) (NN protein)  (NNS levels) ) (, ,)  (NP (NN AP-1)  (NN binding) ) (CC and)  (NP (NN AP-1)  (JJ transcriptional)  (NN activity) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN analysed)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (JJ mitogenic)  (NNS lectins) )) (PP-COOD (PP (IN on)  (NP (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )) (NN protein)  (NNS levels) )) (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN on)  (NP-COOD (NP (NP (NP (NN activator)  (NN protein-1) ) (PRN (-LRB- -LRB-)  (NP (NN AP-1) ) (-RRB- -RRB-) )) (NN binding) ) (CC and)  (NP (NN enhancer)  (NN activity) )))) (PP (IN in)  (NP (NN Jurkat)  (NNS T-cells) ))))) (. .) ) )
(TOP (S (NP-SBJ-38 (NP-COOD (CC Both)  (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )) (NN protein)  (NNS levels) ) (VP (VBD were)  (VP (VBN increased)  (NP (-NONE- *-38) ) (PP-TMP (IN after)  (NP (NP-COOD (NP (NN Con)  (NN A) ) (CC and)  (NP (NN PHA) )) (NN stimulation) )))) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ (NN T-cell)  (NN stimulation) ) (VP-COOD (VP (VBZ increases)  (NP (CC both)  (JJ intracellular)  (NP-COOD (NP (NN Ca2+) ) (CC and)  (NP (NN cAMP) )) (NNS levels) )) (CC and)  (VP (VBZ activates)  (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) )))))) (, ,)  (NP-SBJ-39 (NP (DT the)  (JJ possible)  (NN involvement) ) (PP (IN of)  (NP (DT these)  (JJ intracellular)  (NNS messengers) )) (PP (IN in)  (NP (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )) (NN induction) ))) (VP (VBD was)  (VP (VBN tested)  (NP (-NONE- *-39) ))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN PMA) ) (, ,)  (SBAR (WHNP-40 (WDT which) ) (S (NP-SBJ (-NONE- *T*-40) ) (ADVP (RB directly) ) (VP (VBZ activates)  (NP (NN PKC) )))) (, ,) ) (VP (VBD mimicked)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (DT the)  (NNS lectins) )) (PP (IN on)  (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )))))) (, ,)  (CC but)  (S (NP-SBJ (NP (NN elevation) ) (PP (IN of)  (NP (CC either)  (JJ intracellular)  (NP-COOD (NP (NN Ca2+) ) (CC or)  (NP (NN cAMP) )) (NNS levels) ))) (VP (VBD had)  (NP (ADJP-COOD (ADJP (JJ little) ) (CC or)  (ADJP (DT no) )) (NN effect) ))) (. .) ) )
(TOP (S (NP-SBJ-41 (NP (DT The)  (JJ mitogen-induced)  (NN increase) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )) (NN immunoreactivity) ))) (VP (VBD was)  (VP-COOD (VP (VBN inhibited)  (NP (-NONE- *-41) ) (PP-102 (IN by)  (NP-LGS (NP (NN H-7) ) (, ,)  (NP (NP (DT a)  (NN kinase)  (NN inhibitor) ) (PP (IN with)  (NP (NP (ADJP (RB relatively)  (JJ high) ) (NN specificity) ) (PP (IN for)  (NP (NN PKC) ))))) (, ,) ))) (CC and)  (VP (ADVP (RBR less)  (RB efficiently) ) (PP=102 (IN by)  (NP (NN H-8) ) (, ,)  (NP (NP (DT a)  (ADJP (RB structurally)  (JJ related) ) (NN kinase)  (NN inhibitor) ) (ADJP-COOD (ADJP (RBR less)  (JJ active)  (PP (IN on)  (NP (NN PKC) ))) (, ,)  (CC but)  (ADJP (RBR more)  (JJ active)  (PP (IN on)  (NP (ADJP (JJ cyclic)  (JJ nucleotide-dependent) ) (NNS kinases) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-42 (NN Con)  (NN A)  (NN stimulation) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-42) ) (VP (TO to)  (VP (VB increase)  (NP (NP-COOD (CC both)  (NP (NP (NN binding) ) (PP (IN of)  (NP (NN AP-1) )) (PP (TO to)  (NP (NP (DT the)  (NN AP-1)  (NN consensus)  (NN sequence) ) (, ,)  (NP (NN TRE) ) (, ,) ))) (CC and)  (NP (NN AP-1)  (NN enhancer)  (NN activity) )) (, ,)  (PP (IN in)  (NP (NN Jurkat)  (NNS cells) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-43 (NN PMA) ) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN found)  (S (NP-SBJ (-NONE- *-43) ) (VP (TO to)  (VP (VB increase)  (NP (DT the)  (NN AP-1)  (NN enhancer)  (NN activity) ))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (NN elevation) ) (PP (IN of)  (NP-COOD (NP (NN Ca2+) ) (CC or)  (NP (NN cAMP) )))) (VP (VBD had)  (NP (ADJP (RB only)  (JJ minor) ) (NNS effects) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP conclude)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ-44 (NP (NN stimulation) ) (PP (IN with)  (NP (JJ mitogenic)  (NNS lectins) ))) (VP (VBZ is)  (ADJP-PRD (JJ sufficient)  (S (NP-SBJ (-NONE- *-44) ) (VP (TO to)  (VP (VB increase)  (NP (NP-COOD (NP (NP-COOD (CC both)  (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) )) (NN protein)  (NNS levels) ) (, ,)  (NP (NN AP-1)  (NN binding) ) (CC and)  (NP (NN AP-1)  (NN enhancer)  (NN activity) )) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) )))))))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (PRP they) ) (VP (VBP act)  (PP (IN via)  (NP (NP (NNS mechanisms) ) (SBAR (WHNP-45 (WDT that) ) (S (NP-SBJ (-NONE- *T*-45) ) (VP (MD could)  (VP (VB involve)  (NP (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN PKC) )))))))))))))) (. .) ) )
(TOP (NP (NP (JJ Functional)  (NN interaction) ) (PP (IN between)  (NP (NP (DT the)  (CD two)  (NN zinc)  (NN finger)  (NNS domains) ) (PP (IN of)  (NP (DT the)  (NN v-erb)  (NN A)  (NN oncoprotein) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN v-erb)  (NN A)  (NN oncogene) ) (PP (IN of)  (NP (JJ avian)  (NN erythroblastosis)  (NN virus) ))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (ADJP-COOD (ADJP (VBN mutated) ) (CC and)  (ADJP (RB virally)  (VBN transduced) )) (NN copy) ) (PP (IN of)  (NP (NP (DT a)  (NN host)  (NN cell)  (NN gene) ) (VP (VBG encoding)  (NP (DT a)  (NN thyroid)  (NN hormone)  (NN receptor) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN protein) ) (VP (VBN expressed)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT the)  (NN v-erb)  (NN A)  (NN oncogene) )))) (VP-COOD (VP (VBZ binds)  (PP (TO to)  (NP (NN DNA) ))) (CC and)  (VP (VBZ acts)  (PP (IN as)  (NP (NP (DT a)  (JJ dominant)  (JJ negative)  (NN inhibitor) ) (PP (IN of)  (NP-COOD (CC both)  (NP (DT the)  (NN thyroid)  (NN hormone)  (NN receptor) ) (CC and)  (NP (DT the)  (ADJP (RB closely)  (JJ related) ) (JJ retinoic)  (NN acid)  (NN receptor) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN v-erb)  (NN A)  (NN protein) ) (VP (VBZ has)  (VP (VBN sustained)  (NP (CD two)  (NN amino)  (NN acid)  (NNS alterations) ) (PP (IN within)  (NP (PRP$ its)  (JJ DNA-binding)  (NN domain) )) (PP (JJ relative)  (TO to)  (NP (NP (DT that) ) (PP (IN of)  (NP (NP (NN c-erb)  (NN A) ) (, ,)  (SBAR (WHNP-65 (WHNP (NP (CD one) ) (WHPP (IN of)  (WHNP (WDT which) ))) (, ,)  (PP (IN at)  (NP (NN serine)  (CD 61) ))) (, ,)  (S (NP-SBJ-66 (-NONE- *T*-65) ) (VP (VBZ is)  (VP (VBN known)  (S (NP-SBJ (-NONE- *-66) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ important)  (PP (IN for)  (NP (NP (NN v-erb)  (NN A)  (NN function) ) (PP (IN in)  (NP (DT the)  (JJ neoplastic)  (NN cell) )))))))))))))))))) (. .) ) )
(TOP (S (S (NP-SBJ (PRP We) ) (VP (VBP report)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ second)  (NN alteration) ) (, ,)  (PP (IN at)  (NP (NN threonine)  (CD 78) )) (, ,) ) (ADVP (RB also) ) (VP (VBZ plays)  (NP (DT an)  (ADJP-COOD (ADJP (JJ important) ) (, ,)  (IN although)  (ADJP (RBR more)  (JJ indirect) ) (, ,) ) (NN role) ))))) (: :) ) (S (NP-SBJ (NP (NN alteration) ) (PP (IN of)  (NP (DT the)  (NN sequence) )) (PP (IN at)  (NP (NN threonine)  (CD 78) )) (SBAR (JJ such)  (IN that)  (S (NP-SBJ (PRP it) ) (VP (VBZ resembles)  (NP (NP (DT that) ) (PP (IN of)  (NP (NN c-erb)  (NN A) ))))))) (VP-COOD (VP (MD can)  (VP (VB act)  (PP (IN as)  (NP (DT an)  (JJ intragenic)  (NN suppressor) )))) (CC and)  (VP (MD can)  (ADVP (RB partially) ) (VP (VB restore)  (NP (NN function) ) (PP (TO to)  (NP (NP (DT a)  (NN v-erb)  (NN A)  (NN protein) ) (VP (VBN rendered)  (S (NP-SBJ (-NONE- *) ) (ADJP-PRD (JJ defective) )) (PP (JJ due)  (TO to)  (NP (NP (DT a)  (NN mutation) ) (PP (IN at)  (NP (NN position)  (CD 61) )))))))))) (. .) )) )
(TOP (S (NP-SBJ (NN Threonine)  (CD 78) ) (VP-COOD (VP (VBZ lies)  (PP (IN within)  (NP (NP (DT the)  (NN D-box) ) (PP (IN of)  (NP (DT the)  (NN v-erb)  (NN A)  (NN protein) ))) (, ,)  (NP (NP-67 (DT a)  (NN region) ) (VP (VBN thought)  (S (NP-SBJ (-NONE- *-67) ) (VP (TO to)  (VP (VB mediate)  (NP (JJ receptor-receptor)  (NNS dimerizations) )))))))) (, ,)  (CC and)  (VP (VBZ is)  (RB not)  (PP-PRD (IN in)  (NP (NP (JJ physical)  (NN proximity) ) (PP (TO to)  (NP (NP (DT the)  (NN serine) ) (PP (IN at)  (NP (NN position)  (CD 61) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (ADVP (RB therefore) ) (VP (VBZ appears)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (DT an)  (JJ indirect)  (NN interaction) ) (VP (VBZ occurs)  (PP (IN between)  (NP (DT these)  (CD two)  (NNS sites) ))))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN interaction) ) (VP (VBZ is)  (ADJP-PRD (JJ crucial)  (PP (IN for)  (NP (NN v-erb)  (NN A)  (NN function) )))))))) (. .) ) )
(TOP (S (NP-SBJ-25 (NN Pax-5) ) (VP-COOD (VP (VBZ encodes)  (NP (DT the)  (NN transcription)  (NN factor)  (NN BSAP) )) (CC and)  (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-25) ) (PP (IN in)  (NP-COOD (NP (NN B)  (NNS lymphocytes) ) (, ,)  (NP (DT the)  (VBG developing)  (NNS CNS) ) (, ,)  (CC and)  (NP (JJ adult)  (NN testis) )))))) (. .) ) )
(TOP (S (NP-SBJ-26 (NN BSAP) ) (VP (VBZ has)  (VP (VBN been)  (VP (VBN identified)  (NP (-NONE- *-26) ) (ADVP-TMP (RB previously) ) (PP (IN as)  (NP (NP (DT a)  (NN transcription)  (NN factor) ) (SBAR (WHNP-27 (WDT that) ) (S (NP-SBJ-28 (-NONE- *T*-27) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-28) ) (PP-TMP (IN at)  (NP (NP (ADJP-COOD (ADJP (JJ early) ) (, ,)  (CC but)  (ADJP (RB not)  (JJ late) ) (, ,) ) (NNS stages) ) (PP (IN of)  (NP (NN B-cell)  (NN differentiation) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (JJ Biochemical)  (NN purification) ) (CC and)  (NP (NN cDNA)  (NN cloning) )) (VP (VBZ has)  (ADVP-TMP (RB now) ) (VP (VBN revealed)  (SBAR (IN that)  (S (NP-SBJ (NN BSAP) ) (VP (VBZ belongs)  (PP (TO to)  (NP (NP (DT the)  (NN family) ) (PP (IN of)  (NP (JJ paired)  (NN domain)  (NNS proteins) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-29 (NN BSAP) ) (VP-COOD (VP (VBZ is)  (VP (VBN encoded)  (NP (-NONE- *-29) ) (PP (IN by)  (NP-LGS (DT the)  (NN Pax-5)  (NN gene) )))) (CC and)  (VP (VBZ has)  (VP (VBN been)  (ADVP (RB highly) ) (VP (VBN conserved)  (NP (-NONE- *-29) ) (PP (IN between)  (NP-COOD (NP (JJ human) ) (CC and)  (NP (NN mouse) ))))))) (. .) ) )
(TOP (S (NP-SBJ-31 (DT An)  (JJ intact)  (JJ paired)  (NN domain) ) (VP (VBD was)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-31) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (ADJP-COOD (CC both)  (ADJP (JJ necessary) ) (CC and)  (ADJP (JJ sufficient) )) (PP (IN for)  (NP (NP (NN DNA)  (NN binding) ) (PP (IN of)  (NP (NN BSAP) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (VBG Binding)  (NNS studies) ) (PP (IN with)  (NP (JJ several)  (NN BSAP)  (NN recognition)  (NNS sequences) ))) (VP (VBD demonstrated)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NN sequence)  (NN specificity) ) (PP (IN of)  (NP (NN BSAP) ))) (VP (VBZ differs)  (PP (IN from)  (NP (NP (DT that) ) (PP (IN of)  (NP (DT the)  (ADJP (RB distantly)  (JJ related) ) (JJ paired)  (NN domain)  (NN protein)  (NN Pax-1) )))))))) (. .) ) )
(TOP (S (PP-TMP (IN During)  (NP (NN embryogenesis) )) (, ,)  (NP-SBJ-32 (DT the)  (NN BSAP)  (NN gene) ) (VP (VBZ is)  (ADVP-TMP (RB transiently) ) (VP (VBN expressed)  (NP (-NONE- *-32) ) (PP (IN in)  (NP (DT the)  (NP-COOD (NP (NN mesencephalon) ) (CC and)  (NP (JJ spinal)  (NN cord) )))) (PP (IN with)  (NP (NP (DT a)  (ADJP-COOD (ADJP (JJ spatial) ) (CC and)  (ADJP (JJ temporal) )) (NN expression)  (NN pattern) ) (SBAR (WHNP-33 (WDT that) ) (S (NP-SBJ (-NONE- *T*-33) ) (VP (VBZ is)  (ADJP-PRD (JJ distinct)  (PP (IN from)  (NP (NP (DT that) ) (PP (IN of)  (NP (NP (JJ other)  (NN Pax)  (NNS genes) ) (PP (IN in)  (NP (DT the)  (VBG developing)  (NP (NP (JJ central)  (JJ nervous)  (NN system) ) (PRN (-LRB- -LRB-)  (NP (NN CNS) ) (-RRB- -RRB-) )))))))))))))))) (. .) ) )
(TOP (S (ADVP-TMP (RB Later) ) (, ,)  (NP-SBJ (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (DT the)  (NN BSAP)  (NN gene) ))) (VP (VBZ shifts)  (PP (TO to)  (NP (NP (DT the)  (JJ fetal)  (NN liver) ) (SBAR (WHADVP-34 (WRB where) ) (S (NP-SBJ (PRP it) ) (VP (VBZ correlates)  (PP (IN with)  (NP (NP (DT the)  (NN onset) ) (PP (IN of)  (NP (NN B)  (NN lymphopoiesis) )))) (ADVP (-NONE- *T*-34) ))))))) (. .) ) )
(TOP (S (NP-SBJ-35 (NN BSAP)  (NN expression) ) (VP-COOD (VP (VBZ persists)  (PP (IN in)  (NP (NN B)  (NNS lymphocytes) ))) (CC and)  (VP (VBZ is)  (ADVP (RB also) ) (VP (VBN seen)  (NP (-NONE- *-35) ) (PP (IN in)  (NP (NP (DT the)  (NN testis) ) (PP (IN of)  (NP (DT the)  (JJ adult)  (NN mouse) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT All) ) (PP (IN of)  (NP (DT this)  (NN evidence) ))) (VP (VBZ indicates)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN transcription)  (NN factor)  (NN BSAP) ) (VP (MD may)  (VP-COOD (CONJP (RB not)  (RB only) ) (VP (VB play)  (NP (DT an)  (JJ important)  (NN role) ) (PP-36 (IN in)  (NP (NN B-cell)  (NN differentiation) ))) (CONJP (CC but)  (RB also) ) (VP (PP=36 (IN in)  (NP-COOD (NP (JJ neural)  (NN development) ) (CC and)  (NP (NN spermatogenesis) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Okadaic)  (NN acid) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potent)  (NN inducer) ) (PP (IN of)  (NP (NP-COOD (NP (NN AP-1) ) (, ,)  (NP (NN NF-kappa)  (NN B) ) (, ,)  (CC and)  (NP (NN tumor)  (NN necrosis)  (NN factor-alpha) )) (PP (IN in)  (NP (JJ human)  (NN B)  (NNS lymphocytes) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN of)  (NP (JJ human)  (NN B)  (NNS lymphocytes) )) (PP (IN with)  (NP (NP (DT an)  (JJ optimal)  (NN concentration) ) (PP (IN of)  (NP (NP (JJ okadaic)  (NN acid) ) (, ,)  (NP (NP (DT an)  (NN inhibitor) ) (PP (IN of)  (NP (NNS phosphatases)  (NP-COOD (NP (CD 1) ) (CC and)  (NP (NN 2A) ))))) (, ,) ))))) (VP (VBD resulted)  (PP (IN in)  (NP-COOD (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NP (DT the)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN AP-1) )))) (CC and)  (NP (NP (DT a)  (JJ marked)  (NN increase) ) (PP (IN in)  (NP (NN NF-kappa)  (NN B)  (NNS levels) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-24 (NP (DT no)  (NN effect) ) (PP (IN on)  (NP (NP (DT the)  (NNS levels) ) (PP (IN of)  (NP (NP (DT the)  (NN octamer)  (NN binding)  (NNS proteins) ) (, ,)  (NP-COOD (NP (NN Oct-1) ) (CC or)  (NP (NN Oct-2) )) (, ,) ))))) (VP (VBD were)  (VP (VBN found)  (NP (-NONE- *-24) ))) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ-COOD-25 (CC both)  (NP (NN AP-1) ) (CC and)  (NP (NN NF-kappa)  (NN B) )) (VP (VBP have)  (VP (VBN been)  (VP (VBN reported)  (S (NP-SBJ (-NONE- *-25) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ important)  (PP (IN in)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (DT the)  (NP (NP (NN tumor)  (NN necrosis)  (NN factor-alpha) ) (PRN (-LRB- -LRB-)  (NP (NN TNF-alpha) ) (-RRB- -RRB-) )) (NN gene) ))))))))))))) (NP-SBJ (PRP we) ) (VP (VBD examined)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (JJ okadaic)  (NN acid) )) (PP (IN on)  (NP (NN TNF-alpha)  (NN mRNA)  (NNS levels) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Treatment) ) (PP (IN with)  (NP (JJ okadaic)  (NN acid) ))) (VP (VBD resulted)  (PP (IN in)  (NP (NP (DT a)  (JJ striking)  (NN increase) ) (PP (IN in)  (NP (NN TNF-alpha)  (NN mRNA)  (NNS transcripts) )))) (PP-TMP (IN within)  (NP (NP (CD 1)  (NN h) ) (PP (IN of)  (NP (NN stimulation) )))))) (CC and)  (S (NP-SBJ-26 (NP (JJ large)  (NNS amounts) ) (PP (IN of)  (NP (NN TNF-alpha) ))) (VP (VBD were)  (VP (VBN released)  (NP (-NONE- *-26) ) (PP (IN into)  (NP (DT the)  (NN culture)  (NNS media) ))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (JJ okadaic)  (NN acid) ) (VP (VBZ provides)  (NP (NP (DT a)  (JJ potent)  (JJ inductive)  (NN signal) ) (PP (IN for)  (NP-COOD (NP (NN AP-1) ) (CC and)  (NP (NN NF-kappa)  (NN B) ))))))) (NP-SBJ (PRP it) ) (VP (VBD did)  (RB not)  (VP (VB induce)  (NP-COOD (CC either)  (NP (NN B)  (NN cell)  (NN proliferation) ) (CC or)  (NP (NN immunoglobulin)  (NN secretion) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ novel)  (JJ Ets-related)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN Elf-1) ) (, ,) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 2)  (JJ regulatory)  (NNS elements) ) (SBAR (WHNP-11 (WDT that) ) (S (NP-SBJ-12 (-NONE- *T*-11) ) (VP (VBP are)  (VP (VBN required)  (NP (-NONE- *-12) ) (PP (IN for)  (NP (NP (JJ inducible)  (JJ trans)  (NN activation) ) (PP (IN in)  (NP (NN T)  (NNS cells) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NP (JJ Human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (CC and)  (NP (NN HIV-2) )) (VP (VBP are)  (NP-PRD (NP (ADJP (RB structurally)  (JJ related) ) (NNS retroviruses) ) (SBAR (WHNP-13 (WDT which) ) (S (NP-SBJ (NP (-NONE- *T*-13) )) (VP (DT both)  (VP (VBP cause)  (NP (NN AIDS) ) (PP (IN in)  (NP (NNS humans) )))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ (DT both)  (NNS viruses) ) (VP (VBP establish)  (NP (NN latency) ) (PP (IN in)  (NP (JJ quiescent)  (JJ human-peripheral-blood)  (NN T)  (NNS cells) ))))) (, ,)  (NP-SBJ (NP (DT the)  (JJ asymptomatic)  (NN phase) ) (PP (IN of)  (NP (NN HIV-2)  (NN infection) ))) (VP (MD may)  (VP (VB be)  (ADJP-PRD (ADJP (JJR more)  (JJ prolonged) ) (PP (IN than)  (NP (NP (DT that) ) (PP (IN of)  (NP (NN HIV-1) ))))))) (. .) ) )
(TOP (S (NP-SBJ-14 (NP (DT The)  (JJ latent)  (NNS phases) ) (PP (IN of)  (NP (NP-COOD (CC both)  (NP (NN HIV-1) ) (CC and)  (NP (NN HIV-2) )) (NN infection) ))) (VP (VBP have)  (VP (VBN been)  (VP (VBN shown)  (S (NP-SBJ-15 (-NONE- *-14) ) (VP (TO to)  (VP (VB be)  (VP (VP (VBN disrupted)  (NP (-NONE- *-15) ) (PP (IN by)  (NP-LGS (NN T-cell)  (NN activation) ))) (, ,)  (NP (NP (DT a)  (NN process) ) (SBAR (WHNP-16 (WDT that) ) (S (NP-SBJ (-NONE- *T*-16) ) (VP (VBZ requires)  (NP (NN host)  (NN cell)  (NN transcription)  (NNS factors) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (DT the)  (NN case) ) (PP (IN of)  (NP (NN HIV-1) )))) (, ,)  (NP-SBJ (DT the)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) ) (VP (VBZ is)  (ADJP-PRD (JJ sufficient)  (PP (IN for)  (NP (JJ inducible)  (JJ transcriptional)  (NN activation) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-17 (NP (NNS factors) ) (PP (IN in)  (NN addition)  (TO to)  (NP (NN NF-kappa)  (NN B) ))) (VP (VBP are)  (VP (VBN required)  (S (NP-SBJ (-NONE- *-17) ) (VP (TO to)  (VP (VB activate)  (NP (NN HIV-2)  (NN transcription) ) (PP (IN in)  (NP (JJ infected)  (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT this)  (NN report) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (DT a)  (JJ novel)  (JJ Ets-related)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN Elf-1) ) (, ,) ) (VP (VBZ binds)  (ADVP (RB specifically) ) (PP (TO to)  (NP (NP (CD two)  (JJ purine-rich)  (NNS motifs) ) (PP (IN in)  (NP (DT the)  (NN HIV-2)  (NN enhancer) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Mutagenesis)  (NNS experiments) ) (VP (VBD demonstrated)  (SBAR (IN that)  (S (NP-SBJ-19 (DT these)  (NN Elf-1)  (NN binding)  (NNS sites) ) (VP (VBP are)  (VP (VBN required)  (NP (-NONE- *-19) ) (PP (IN for)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NN HIV-2)  (NN transcription) )) (PP-TMP (VBG following)  (NP (JJ T-cell-receptor-mediated)  (NN T-cell)  (NN activation) ))))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ (NN Elf-1) ) (VP (VBZ is)  (NP-PRD (NP (DT the)  (JJ only)  (NN factor) ) (ADJP (JJ present)  (PP (IN in)  (NP (NP (VBN activated)  (NN T-cell)  (JJ nuclear)  (NNS extracts) ) (SBAR (WHNP-20 (WDT that) ) (S (NP-SBJ (-NONE- *T*-20) ) (VP (VBZ binds)  (PP (TO to)  (NP (DT these)  (NNS sites) )) (PP (IN in)  (NP (JJ electrophoretic)  (NN mobility)  (NN shift)  (NNS assays) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Thus) ) (, ,)  (NP-SBJ (NN Elf-1) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ novel)  (NN transcription)  (NN factor) ) (SBAR (WHNP-21 (WDT that) ) (S (NP-SBJ-22 (-NONE- *T*-21) ) (VP (VBZ appears)  (S (NP-SBJ-23 (-NONE- *-22) ) (VP (TO to)  (VP (VB be)  (VP (VBN required)  (NP (-NONE- *-23) ) (PP (IN for)  (NP (NP (DT the)  (JJ T-cell-receptor-mediated)  (JJ trans)  (NN activation) ) (PP (IN of)  (NP (NN HIV-2)  (NN gene)  (NN expression) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP-COOD (VP (MD may)  (VP (VB explain)  (NP (NP (NNS differences) ) (PP (IN in)  (NP (NP (DT the)  (JJ clinical)  (NNS spectra) ) (PP (IN of)  (NP (NP (NNS diseases) ) (VP (VBN caused)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (NN HIV-1) ) (CC and)  (NP (NN HIV-2) ))))))))))) (CC and)  (VP (MD may)  (ADVP (RB also) ) (VP (VB have)  (NP (NP (NNS implications) ) (PP (IN for)  (NP (NP (DT the)  (NN design) ) (PP (IN of)  (NP (NP (JJ therapeutic)  (NNS approaches) ) (PP (TO to)  (NP (NN HIV-2)  (NN infection) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN Nef)  (NN protein) ) (VP (VBZ inhibits)  (NP (NP (NN NF-kappa)  (NN B)  (NN induction) ) (PP (IN in)  (NP (JJ human)  (NN T)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (VP (MD can)  (VP (VB establish)  (NP (NP (DT a)  (ADJP-COOD (ADJP (JJ persistent) ) (CC and)  (ADJP (JJ latent) )) (NN infection) ) (PP (IN in)  (NP (JJ CD4+)  (NN T)  (NNS lymphocytes) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (NNP W.C.Greene) ) (, ,)  (NP (NNP N.Engl.J.)  (NNP Med.324)  (: :)  (CD 308-317) ) (, ,)  (NP-TMP (CD 1991) )) (: ;)  (NP (NP-COOD (NP (NNP S.M.Schnittman) ) (, ,)  (NP (NNP M.C.Psallidopoulos) ) (, ,)  (NP (NNP H.C.)  (NNP Lane) ) (, ,)  (NP (NNP L.Thompson) ) (, ,)  (NP (NNP M.Baseler) ) (, ,)  (NP (NNP F.Massari) ) (, ,)  (NP (NNP C.H.Fox) ) (, ,)  (NP (NNP N.P.Salzman) ) (, ,)  (CC and)  (NP (NNP A.S.Fauci) )) (, ,)  (NP (NNP Science)  (CD 245)  (: :)  (CD 305-308) ) (, ,)  (NP-TMP (CD 1989) ))) (-RRB- -RRB-) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Production) ) (PP (IN of)  (NP (NN HIV-1) )) (PP (IN from)  (NP (ADJP (RB latently)  (JJ infected) ) (NNS cells) ))) (VP (VBZ requires)  (NP (NP (NN host)  (NN cell)  (NN activation) ) (PP (IN by)  (NP (NN T-cell)  (NNS mitogens) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP-COOD (NP (NNP T.Folks) ) (, ,)  (NP (NNP D.M.Powell) ) (, ,)  (NP (NNP M.M.Lightfoote) ) (, ,)  (NP (NNP S.Benn) ) (, ,)  (NP (NNP M.A.)  (NNP Martin) ) (, ,)  (CC and)  (NP (NNP A.S.Fauci) )) (, ,)  (NP (NNP Science)  (CD 231)  (: :)  (CD 600-602) ) (, ,)  (NP-TMP (CD 1986) )) (: ;)  (NP (NP-COOD (NP (NNP D.Zagury) ) (, ,)  (NP (NNP J.)  (NNP Bernard) ) (, ,)  (NP (NNP R.Leonard) ) (, ,)  (NP (NNP R.Cheynier) ) (, ,)  (NP (NNP M.Feldman) ) (, ,)  (NP (NNP P.S.Sarin) ) (, ,)  (CC and)  (NP (NNP R.C.)  (NNP Gallo) )) (, ,)  (NP (NNP Science)  (CD 231)  (: :)  (CD 850-853) ) (, ,)  (NP-TMP (CD 1986) ))) (-RRB- -RRB-) )) (. .) ) )
(TOP (S (NP-SBJ-6 (DT This)  (NN activation) ) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-6) ) (PP (IN by)  (NP-LGS (DT the)  (NN host)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) )) (PRN (-LRB- -LCB-)  (NP (NP-COOD (NP (NNP G.Nabel) ) (CC and)  (NP (NNP D.Baltimore) )) (, ,)  (NP (NNP Nature)  (-LRB- -LRB-)  (NNP London)  (-RRB- -RRB-)  (CD 326)  (: :)  (CD 711-717) ) (, ,)  (NP-TMP (CD 1987) )) (-RRB- -RCB-) ))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP report)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ (DT the)  (JJ HIV-1-encoded)  (NN Nef)  (NN protein) ) (VP (VBZ inhibits)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (JJ DNA-binding)  (NN activity) )) (PP (IN by)  (NP (NN T-cell)  (NNS mitogens) ))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NN Nef) ) (VP (VBZ does)  (RB not)  (VP (VB affect)  (NP (NP (DT the)  (JJ DNA-binding)  (NN activity) ) (PP (IN of)  (NP (NP (JJ other)  (NN transcription)  (NNS factors) ) (VP (VBN implicated)  (NP (-NONE- *) ) (PP (IN in)  (NP (NN HIV-1)  (NN regulation) ))) (, ,)  (PP (VBG including)  (NP-COOD (NP (NN SP-1) ) (, ,)  (NP (NN USF) ) (, ,)  (NP (NN URS) ) (, ,)  (CC and)  (NP (NN NF-AT) )))))))) (. .) ) )
(TOP (S (ADVP (RB Additionally) ) (, ,)  (S-COOD (S (NP-SBJ (NN Nef) ) (VP (VBZ inhibits)  (NP (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (NP (NN HIV-1-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (NN interleukin)  (JJ 2-directed) )) (NN gene)  (NN expression) ))))) (, ,)  (CC and)  (S (NP-SBJ (NP (DT the)  (NN effect) ) (PP (IN on)  (NP (NN HIV-1)  (NN transcription) ))) (VP (VBZ depends)  (PP (IN on)  (NP (DT an)  (JJ intact)  (NN NF-kappa)  (JJ B-binding)  (NN site) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ defective)  (NN recruitment) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))) (VP (MD may)  (VP (VB underlie)  (NP (NP (NP (NN Nef)  (POS 's) ) (JJ negative)  (JJ transcriptional)  (NNS effects) ) (PP (IN on)  (NP (DT the)  (NP (NP (NN HIV-1) ) (CC and)  (NP (NN interleukin)  (CD 2) )) (NNS promoters) )))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Further)  (NN evidence) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ-7 (NN Nef) ) (VP (VBZ inhibits)  (NP (NN NF-kappa)  (NN B)  (NN induction) ) (PP (IN by)  (S (NP-SBJ (-NONE- *-7) ) (VP (VBG interfering)  (PP (IN with)  (NP (NP (DT a)  (NN signal) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT the)  (NN T-cell)  (NN receptor)  (NN complex) )))))))))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP (NN Effect) ) (PP (IN of)  (NP (NP (JJ antihypertensive)  (NN therapy) ) (PP (IN with)  (NP (NN captopril) )))) (PP (IN on)  (NP (NP (NP-COOD (NP (NP (JJ gluco-) ) (NP (-NONE- *?*) )) (CC and)  (NP (NN mineralocorticoid) )) (NNS receptors) ) (PP (IN of)  (NP (NP (JJ peripheral)  (NN blood)  (NNS lymphocytes) ) (PP (IN in)  (NP (NP (JJ hypertensive)  (NNS patients) ) (PP (IN of)  (NP (JJ various)  (NN age) )))))))) (-RRB- -RCB-) ) )
(TOP (S (NP-SBJ-52 (NP (NN Binding) ) (PP (IN of)  (NP-COOD (NP (NN 3H-dexamethasone) ) (CC and)  (NP (NN 3H-aldosterone) ))) (PP (IN by)  (NP (JJ peripheral)  (NN lymphocyte)  (NNS receptors) ))) (VP (VBD was)  (VP (VBN investigated)  (NP (-NONE- *-52) ) (PP (IN in)  (NP-COOD (NP (JJ healthy)  (NNS persons) ) (CC and)  (NP (JJ hypertensive)  (NNS patients) ))) (PP-TMP (PP-COOD (PP (IN before)  (NP (-NONE- *RNR*-53) )) (CC and)  (PP (IN after)  (NP (-NONE- *RNR*-53) ))) (NP-53 (ADJP (JJ 2-week) ) (NN captopril)  (NN treatment) )))) (. .) ) )
(TOP (S (NP-SBJ-54 (NP (DT The)  (NN number) ) (PP (IN of)  (NP (NP-COOD (NP (NN glucocorticoid) ) (CC and)  (NP (NN mineralocorticoid) )) (NN binding)  (NNS sites) ))) (VP (VBD was)  (VP (VBN increased)  (NP (-NONE- *-54) ) (PP (IN in)  (NP-COOD (NP (NNS hypertensives) ) (CC vs)  (NP (NNS normotensives) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN treatment) ) (PP (IN with)  (NP (DT the)  (NN ACE)  (NN inhibitor)  (NN captopril) ))) (VP (VBD led)  (PP (TO to)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NN hormone-receptor)  (NNS interactions) ))))) (. .) ) )
(TOP (S (NP-SBJ (EX There) ) (VP (VBD was)  (NP-PRD (NP (DT a)  (ADJP (RBR more)  (JJ marked) ) (NN rise) ) (PP (IN of)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NNS receptors) )))) (PP (IN in)  (NP-COOD (NP (ADJP (ADJP (JJ middle-aged) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 44-55) ) (NNS years) ) (-RRB- -RRB-) )) (NNS hypertensives) ) (CC vs)  (NP (ADJP (ADJP (JJ elderly) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 61-80) ) (NNS years) ) (-RRB- -RRB-) )) (NNS subjects) )))) (PP-TMP (IN after)  (NP (NN captopril)  (NN treatment) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Leukotriene)  (NN B4) ) (ADVP (RB transcriptionally) ) (VP (VBZ activates)  (NP (NP (NN interleukin-6)  (NN expression) ) (VP (VBG involving)  (NP-COOD (NP (NN NK-chi)  (NN B) ) (CC and)  (NP (NN NF-IL6) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Leukotriene)  (NN B4) ) (PRN (-LRB- -LRB-)  (NP (NN LTB4) ) (-RRB- -RRB-) )) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ notable)  (NN participant) ) (PP (IN in)  (NP-COOD (NP (NN inflammation) ) (CC and)  (NP (NN chemotaxis) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP It) ) (SBAR (-NONE- *EXP*-4) )) (VP (VBZ is)  (, ,)  (ADVP (RB however) ) (, ,)  (ADJP-PRD (RB still)  (JJ unclear) ) (SBAR-4 (IN whether)  (S (NP-SBJ (NN LTB4) ) (VP (VBZ acts)  (PP (IN in)  (NP (DT this)  (NN regard) )) (ADVP-COOD (ADVP (RB directly) ) (CC or)  (ADVP (RB indirectly) )) (PP (IN by)  (S (NP-SBJ (-NONE- *) ) (VP (VBG stimulating)  (NP (NP (DT the)  (NN release) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ chemotactic) ) (CC and)  (ADJP (JJ inflammatory) )) (NNS cytokines) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP report)  (SBAR (IN that)  (S (NP-SBJ (NN LTB4) ) (VP (VBZ induces)  (NP (NP (NN synthesis) ) (PP (IN of)  (NP (NP (NP (NN interleukin) ) (PRN (-LRB- -LRB-)  (NP (NN IL) ) (-RRB- -RRB-) )) (CD -6) )) (PP (IN by)  (NP (JJ human)  (NN blood)  (NNS monocytes) ))) (PP (IN through)  (NP (NP (JJ transcriptional)  (NN activation) ) (PP (IN of)  (NP (DT the)  (NN IL-6)  (NN gene) )))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB furthermore) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (DT this)  (NN process) ) (VP (VP-COOD (VP (VBZ involves)  (NP (NP (NN activation) ) (PP-102 (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-chi)  (NN B) )))) (CC and)  (VP (, ,)  (PP (TO to)  (NP (DT a)  (JJR lesser)  (NN extent) )) (, ,)  (NP (NP (-NONE- *) ) (PP=102 (IN of)  (NP (NN NF-IL6) ))))) (, ,)  (SBAR (IN while)  (NP-SBJ-6 (NP-8 (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NN AP-1) ))) (, ,)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (ADVP (RB otherwise) ) (VP (VB confer)  (NP (NN IL-6)  (NN inducibility) ))))) (, ,) ) (VP (VBD appeared)  (S (NP-SBJ-7 (-NONE- *-6) ) (VP (TO to)  (VP (VB be)  (VP (JJ unaffected)  (NP (-NONE- *-7) ) (PP (IN by)  (NP-LGS (NN LTB4) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-10 (NP (NN Involvement) ) (PP (IN of)  (NP-COOD (NP (NN NF-chi)  (NN B) ) (CC and)  (NP (NN NF-IL6) ))) (PP (IN in)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NN IL-6)  (NN transcription) )) (PP (IN by)  (NP (NNS monocytes) ))))) (VP (VBD was)  (VP (VBN demonstrated)  (NP (-NONE- *-10) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (NP (JJ deleted)  (NNS forms) ) (PP (IN of)  (NP (DT the)  (NN IL-6)  (NN promoter) ))))))) (. .) ) )
(TOP (S (NP-SBJ-11 (NP (NN Activation) ) (PP (IN of)  (NP (DT the)  (NN IL-6)  (NN promoter) )) (PP (IN by)  (NP (NN LTB4) ))) (VP-COOD (VP (VBD was)  (CONJP (RB not)  (RB only) ) (VP (VBN associated)  (NP (-NONE- *-11) ) (PP (IN with)  (NP (NP (NN accumulation) ) (PP (IN of)  (NP (DT the)  (JJ respective)  (NNS transcripts) )))))) (CC but)  (VP (VBD resulted)  (PP (IN in)  (NP (NP (NN synthesis) ) (PP (IN of)  (NP (JJ functional)  (NN IL-6)  (NN protein) )))) (PP (RB as)  (ADVP (RB well) )))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NN LTB4) ) (VP (VBD mediated)  (NP (NP (NN transactivation) ) (PP (IN of)  (NP (NP (DT a)  (JJ heterologous)  (NN promoter)  (NN construct) ) (VP (VBG containing)  (NP-COOD (NP (NP-COOD (NP (DT the)  (NN NF-chi)  (NN B)  (NP (-NONE- *RNR*-103) )) (CC or)  (NP (DT the)  (NN NF-IL6)  (NP (-NONE- *RNR*-103) ))) (NP-103 (NN enhancer) )) (, ,)  (CONJP (CC but)  (RB not) ) (NP (DT the)  (NN AP-1)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (NP-SBJ-12 (NP (DT The)  (NN signaling)  (NNS events) ) (VP (VBG mediating)  (NP (DT this)  (NN effect) ))) (VP (VBD appeared)  (S (NP-SBJ (-NONE- *-12) ) (VP (TO to)  (VP (VB involve)  (NP (NP (DT the)  (NN release) ) (PP (IN of)  (NP (NN H2O2) ))) (, ,)  (SBAR (IN since)  (S (NP-SBJ-13 (NN LTB4) ) (VP (VBD failed)  (S (NP-SBJ (-NONE- *-13) ) (VP (TO to)  (VP (VB induce)  (NP-COOD (NP (NN NF-chi)  (NN B) ) (CC or)  (NP (NN NF-IL6) )) (PP (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NP (NP (DT the)  (NN scavenger) ) (PP (IN of)  (NP (NN H2O2) ))) (, ,)  (NP (NN N-acetyl-L-cysteine) ))))))))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NP (NN Estrogen)  (NN binding)  (NNS sites) ) (PP (IN in)  (NP (JJ peripheral)  (NN blood)  (NNS monocytes) ))) (CC and)  (NP (NP (NNS effects) ) (PP (IN of)  (NP (NN danazol) )) (PP (IN on)  (NP (NP (PRP$ their)  (NNS sites) ) (ADVP (FW in)  (FW vitro) ))))) (. .) ) )
(TOP (S (LST (LS 1)  (. .) ) (NP-SBJ-29 (DT This)  (NN study) ) (VP (VBD was)  (VP (VBN designed)  (NP-30 (-NONE- *-29) ) (S (NP-SBJ (-NONE- *-30) ) (VP (TO to)  (VP (VB investigate)  (NP-COOD (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (NN estrogen)  (NP-COOD (NP (NP (NN type)  (CD I) ) (PRN (-LRB- -LRB-)  (FRAG (NP-COOD (NP (JJ high)  (NN affinity) ) (, ,)  (NP (JJ low)  (NN capacity) ))) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN type)  (CD II) ) (PRN (-LRB- -LRB-)  (FRAG (NP-COOD (NP (JJ low)  (NN affinity) ) (, ,)  (NP (JJ high)  (NN capacity) ))) (-RRB- -RRB-) ))) (NN binding)  (NNS sites) )) (PP (IN in)  (NP (JJ human)  (JJ peripheral)  (NN blood)  (NNS monocytes) ))) (CC and)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NN danazol) )) (PP (IN on)  (NP (DT these)  (NNS sites) ))))))))) (. .) ) )
(TOP (S (LST (LS 2)  (. .) ) (NP-SBJ (NP (DT These)  (CD two)  (NNS types) ) (PP (IN of)  (NP (NN estrogen)  (NN binding)  (NNS sites) ))) (VP (VBD existed)  (PP (IN in)  (NP (JJ human)  (JJ peripheral)  (NN blood)  (NNS monocytes) ))) (. .) ) )
(TOP (S (LST (LS 3)  (. .) ) (NP-SBJ (NN Danazol) ) (VP-COOD (VP (VBD bound)  (PP (TO to)  (NP (DT these)  (NNS sites) )) (PP (IN in)  (NP (NP (JJ high)  (NN concentration) ) (PRN (-LRB- -LRB-)  (NP (NP (UCP-COOD (NP (CD 10-LRB--6-RRB-)  (NN M) ) (, ,)  (ADJP (JJ clinical) )) (NN serum)  (NN concentration) ) (PP-TMP (IN during)  (NP (NN danazol)  (NN therapy) ))) (-RRB- -RRB-) )))) (CC and)  (VP (VBD decreased)  (NP (NP (DT the)  (NN number) ) (PP (IN of)  (NP (DT both)  (NNS sites) ))))) (. .) ) )
(TOP (S (LST (LS 4)  (. .) ) (NP-SBJ (PRP It) ) (VP (VBZ is)  (VP (VBN suggested)  (SBAR (IN that)  (S (NP-SBJ (NN danazol) ) (VP (VBZ has)  (NP (NP (DT an)  (JJ anti-estrogenic)  (NN action) ) (PP (TO to)  (NP (DT the)  (NNS monocytes) ))) (PP (IN through)  (NP (NP (DT the)  (NP-COOD (NP (NN competition) ) (CC and)  (NP (NN suppression) ))) (PP (IN of)  (NP (NN estrogen)  (NN binding)  (NNS sites) )))) (SBAR (IN as)  (S (NP-SBJ-31 (-NONE- *) ) (VP (VBN seen)  (NP (-NONE- *-31) ) (PP (IN in)  (NP (DT the)  (NN estrogen)  (NN target)  (NN organ) )))))))))) (. .) ) )
(TOP (NP (-LRB- -LCB-)  (NP (NN Mechanism) ) (PP (IN of)  (NP (NP (NN action) ) (PP (IN of)  (NP (NN steroid)  (NNS hormones)  (. .)  (LS I)  (. .)  (NNS Estrogens) )))) (-RRB- -RCB-) ) )
(TOP (S (S (NP-SBJ (DT The)  (NN steroid)  (NN hormone) ) (VP (VBP are)  (NP-PRD (ADJP (RB very)  (JJ versatile) ) (NNS molecules) )) (: :) ) (S (SBAR-ADV (IN although)  (S (NP-SBJ (PRP they) ) (VP (VBP are)  (ADJP-PRD (JJ related) ) (PP (IN among)  (NP (PRP them) )) (PP (IN by)  (NP-PRD (PRP$ their)  (JJ chemical)  (NN structure) ))))) (, ,)  (NP-SBJ (PRP they) ) (VP (VBP have)  (NP (NP (ADJP (RB very)  (JJ diverse) ) (NNS functions) ) (CC and)  (PP (VBG including)  (NP (JJ antagonic) )))) (. .) )) )
(TOP (S (NP-SBJ-27 (PRP$ Their)  (NN action)  (NN mechanism) ) (VP (VBZ is)  (RB not)  (ADVP (RB completely) ) (VP (VBN cleared)  (NP (-NONE- *-27) ))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS estrogens) ) (VP (VBP participate)  (PP (IN in)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (NP (QP (RB practically)  (PDT all) ) (DT the)  (ADJP-COOD (ADJP (JJ reproductive) ) (CC and)  (ADJP (JJ sexual) )) (NNS events) ) (PP (IN of)  (NP (DT the)  (NN female) )))))) (, ,)  (SBAR-ADV (IN although)  (S-COOD (S (NP-SBJ-28 (NP (DT the)  (JJ intracellular)  (NNS actions) ) (SBAR (WHPP-29 (IN by)  (WHNP (WDT which) )) (S (NP-SBJ (PRP they) ) (VP (VBP take)  (NP (NN place) ) (PP (-NONE- *T*-29) ))))) (VP (VBP are)  (RB not)  (ADVP (RB well) ) (VP (VBN known)  (NP (-NONE- *-28) )))) (CC and)  (S (NP-SBJ (DT the)  (JJ proposed)  (NNS models) ) (VP (VBP do)  (RB not)  (ADVP (RB adequately) ) (VP (VB satisfy)  (NP (DT the)  (NNS questions) ))))))) (. .) ) )
(TOP (S (ADVP-TMP (RB Currently) ) (NP-SBJ (PRP it) ) (VP (VBZ is)  (VP (VBN accepted)  (NP (NP (DT the)  (NN existence) ) (PP (IN of)  (NP (DT a)  (ADJP-COOD (ADJP (JJ cytoplasmic) ) (CC and/or)  (ADJP (JJ nuclear) )) (NN receptor) ))) (, ,)  (PP (IN without)  (S (NP-SBJ (-NONE- *) ) (VP (VBG explaining)  (ADVP (RB satisfactorily) ) (SBAR (WHADVP-100 (WRB how) ) (S (NP-SBJ (DT the)  (NNS hormones) ) (VP (VBN come)  (PP (TO to)  (NP (DT the)  (NN nucleus) )) (ADVP (-NONE- *T*-100) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ endocrine)  (NNS events) ) (SBAR (WHNP-30 (WDT that) ) (S (NP-SBJ-31 (-NONE- *T*-30) ) (VP (VBP are)  (ADVP-TMP (ADVP (RB rapidly) ) (PRN (-NONE- *ICH*-101) )) (VP (VBN expressed)  (NP (-NONE- *-31) ) (PRN-101 (-LRB- -LRB-)  (NP-TMP (NNS seconds) ) (-RRB- -RRB-) )))))) (VP (VBP are)  (PP-PRD (JJ due)  (TO to)  (NP (NP (DT a)  (JJ possible)  (NN interaction) ) (PP (IN with)  (NP (JJ cellular)  (NN membrane) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN purpose) ) (PP (IN of)  (NP (DT this)  (NN review) ))) (VP (VBZ is)  (S-PRD (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VP-COOD (VP (VB analyze)  (NP (-NONE- *RNR*-32) )) (CC and)  (VP (VB concilliate)  (NP (-NONE- *RNR*-32) ))) (NP-32 (NP (DT the)  (VBN reported)  (NNS data) ) (PP (IN on)  (NP (NP (DT the)  (NN mechanism) ) (PP (IN of)  (NP (NP (NN action) ) (PP (IN of)  (NP (NNS estrogens) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Stable)  (NN expression) ) (PP (IN of)  (NP (JJ transdominant)  (NN Rev)  (NN protein) )) (PP (IN in)  (NP (JJ human)  (NN T)  (NNS cells) ))) (VP (VBZ inhibits)  (NP (JJ human)  (NN immunodeficiency)  (NN virus)  (NN replication) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )) (NN Rev)  (NN protein) ) (VP (VBZ is)  (ADJP-PRD (JJ essential)  (PP-COOD (PP (IN for)  (NP (NP (JJ viral)  (JJ structural)  (NN protein)  (NN expression) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN Gag) ) (, ,)  (NP (NN Pol) ) (, ,)  (CC and)  (NP (NN Env) )) (-RRB- -RRB-) ))) (CC and)  (, ,)  (RB hence)  (, ,)  (PP (IN for)  (NP (JJ viral)  (NN replication) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (JJ transient)  (NN transfection)  (NNS assays) )) (, ,)  (NP-SBJ-17 (NP (JJ mutant)  (NNS forms) ) (PP (IN of)  (NP (NN Rev) )) (SBAR (-NONE- *ICH*-100) )) (VP (VBP have)  (VP (VBN been)  (VP (VBN identified)  (NP (-NONE- *-17) ) (SBAR-100 (WHNP-18 (WDT that) ) (S (NP-SBJ (-NONE- *T*-18) ) (VP-COOD (VP (VBP inhibit)  (NP (JJ wild-type)  (NN Rev)  (NN activity) )) (CC and)  (RB therefore)  (VP (VBP suppress)  (NP (JJ viral)  (NN replication) )))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB determine)  (SBAR (IN whether)  (S (NP-SBJ-19 (JJ such)  (JJ transdominant)  (NN Rev)  (NNS proteins) ) (VP (MD could)  (VP (VB provide)  (NP (NP (JJ long-term)  (NN protection) ) (PP (IN against)  (NP (NN HIV)  (NN infection) ))) (PP (IN without)  (S (NP-SBJ (-NONE- *-19) ) (VP (VBG affecting)  (NP (NN T)  (NN cell)  (NN function) ))))))))))) (, ,)  (NP-SBJ-20 (NN T)  (NN leukemia)  (NN cell)  (NNS lines) ) (VP (VBD were)  (ADVP (RB stably) ) (VP (VBN transduced)  (NP (-NONE- *-20) ) (PP (IN with)  (NP (NP (DT a)  (JJ retroviral)  (NN vector) ) (VP (VBG encoding)  (NP (NP (NP (DT a)  (JJ transdominant)  (NN mutant) ) (PP (IN of)  (NP (DT the)  (NN Rev)  (NN protein) ))) (, ,)  (NP (NN M10) ))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN While)  (S (NP-SBJ (PDT all)  (DT the)  (JJ M10-expressing)  (NN cell)  (NNS lines) ) (VP (VBD remained)  (ADJP-PRD (JJ infectable)  (PP (IN by)  (NP (NN HIV-1) )))))) (, ,)  (NP-SBJ-21 (DT these)  (JJ same)  (NNS cells) ) (VP (VBD failed)  (S (NP-SBJ-22 (-NONE- *-21) ) (VP (TO to)  (VP (VB support)  (NP (DT a)  (JJ productive)  (NN replication)  (NN cycle) ) (SBAR-TMP (WHADVP-24 (WRB when) ) (S (NP-SBJ-23 (-NONE- *-22) ) (VP (VBN infected)  (NP (-NONE- *-23) ) (PP (IN with)  (NP (NP (DT a)  (VBN cloned)  (NN isolate) ) (PP (IN of)  (NP (NN HIV-1) )))) (ADVP (-NONE- *T*-24) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (QP (CD two)  (IN out)  (IN of)  (CD three) ) (JJ M10-expressing)  (NN CEM)  (NNS clones) ) (VP (VBD were)  (ADJP-PRD (RB also)  (JJ resistant)  (PP (TO to)  (NP (NP (ADJP (RB highly)  (JJ productive) ) (NN infection) ) (PP (IN by)  (NP (DT a)  (JJ heterogeneous)  (NN HIV-1)  (NN pool) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Expression) ) (PP (IN of)  (NP (NN M10) ))) (VP (VBD did)  (RB not)  (VP (VB affect)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NN HIV)  (NN transcription) )) (VP (VBN mediated)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (DT the)  (NN kappa)  (NN B)  (JJ regulatory)  (NN element) ) (CC or)  (NP (NN Tat) ))))))) (. .) ) )
(TOP (S (ADVP (RB Importantly) ) (, ,)  (NP-SBJ (NP (JJ constitutive)  (NN expression) ) (PP (IN of)  (NP (NN Rev)  (NN M10) ))) (VP (VBD did)  (RB not)  (VP (VB alter)  (NP (NP (DT the)  (NN secretion) ) (PP (IN of)  (NP (NN interleukin)  (CD 2) ))) (PP (IN in)  (NN response)  (TO to)  (NP (NP (NN mitogen)  (NN stimulation) ) (PP (IN of)  (NP (NP-COOD (NP (NN EL-4) ) (CC and)  (NP (NN Jurkat) )) (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN inhibition) ) (PP (IN of)  (NP (NN HIV)  (NN infection) )) (PP (IN in)  (NP (NP (NNS cells) ) (VP (ADVP (RB stably) ) (VBG expressing)  (NP (DT a)  (JJ transdominant)  (NN Rev)  (NN protein) )))) (, ,)  (PP (IN in)  (DT the)  (NN absence)  (IN of)  (NP (NP (DT any)  (JJ deleterious)  (NN effect) ) (PP (IN on)  (NP (NN T)  (NN cell)  (NN function) )))) (, ,) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (PDT such)  (DT a)  (NN strategy) ) (VP (MD could)  (VP (VB provide)  (NP (DT a)  (JJ therapeutic)  (NN effect) ) (PP (IN in)  (NP (NP (DT the)  (NN T)  (NNS lymphocytes) ) (PP (IN of)  (NP (VBN acquired)  (NN immunodeficiency)  (NN syndrome)  (NNS patients) ))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Glucocorticoid)  (NN receptor) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN lupus)  (NN nephritis) )))) (: :) ) (NP (NP (NN relationship) ) (PP (IN between)  (NP-COOD (NP (NP (NN receptor)  (NNS levels) ) (PP (IN in)  (NP (JJ mononuclear)  (NNS leukocytes) ))) (CC and)  (NP (NP (NN effect) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN therapy) ))))) (. .) )) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBD investigated)  (NP (NP (DT the)  (JJ clinical)  (NN significance) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NN receptor)  (NN determination) ) (PP (IN in)  (NP (NP (CD 20)  (NNS patients) ) (PP (IN with)  (NP (NP (JJ systemic)  (NN lupus)  (NN erythematosus) ) (PRN (-LRB- -LRB-)  (NP (NN SLE) ) (-RRB- -RRB-) ))) (SBAR (WHNP-28 (WP who) ) (S (NP-SBJ (-NONE- *T*-28) ) (ADVP-TMP (RB afterwards) ) (VP (VBD developed)  (NP (JJ nephrotic)  (NN syndrome) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Glucocorticoid)  (NN receptor)  (NNS concentrations) ) (PP (IN in)  (NP (NP (JJ mononuclear)  (NNS leukocytes) ) (PRN (-LRB- -LRB-)  (NP (NNS MNL) ) (-RRB- -RRB-) ))) (PP (IN in)  (NP (DT these)  (NNS patients) ))) (VP (VBD were)  (ADJP-PRD (JJ comparable)  (PP (IN with)  (NP (NP (DT those) ) (PP (IN in)  (NP-COOD (CC both)  (NP (NP (JJ other)  (NNS patients) ) (PP (IN with)  (NP (NN SLE) ))) (CC and)  (NP (JJ healthy)  (NNS persons) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Improvement) ) (PP-COOD (PP (IN in)  (NP (JJ urinary)  (NN protein)  (NN excretion) )) (CC and)  (PP (IN in)  (NP (NN disease)  (NN activity) ))) (, ,)  (SBAR (WHNP-29 (WDT which) ) (S (NP-SBJ-30 (-NONE- *T*-29) ) (VP (VBD was)  (VP (VBN scored)  (NP (-NONE- *-30) ) (PP (VBG according)  (PP (TO to)  (NP (NP (DT the)  (NNP SLE)  (NNP Disease)  (NNP Activity)  (NNP Index)  (NN system) ) (PP (IN of)  (NP (NP (DT the)  (NNP University) ) (PP (IN of)  (NP (NNP Toronto) ))))))))))) (, ,) ) (ADVP (RB closely) ) (VP (JJ related)  (PP (TO to)  (NP (NP (DT the)  (NN glucocorticoid)  (NN receptor)  (NNS concentrations) ) (PP (IN in)  (NP (NP (NN MNL) ) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT the)  (JJ corresponding)  (NNS patients) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN summary) )) (, ,)  (NP-SBJ (NP (NN glucocorticoid)  (NN receptor)  (NN determination) ) (PP (IN in)  (NP (NP (NNS patients) ) (PP (IN with)  (NP (NN lupus)  (NN nephritis) ))))) (VP (MD may)  (VP (VB be)  (NP-PRD (NP (DT a)  (JJ predictive)  (NN clue) ) (PP (IN for)  (S (NP-SBJ (-NONE- *) ) (VP (VBG assessing)  (NP (NP (NN responsiveness) ) (PP (TO to)  (NP (NN glucocorticoid)  (NN therapy) ))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Selection) ) (PP (IN of)  (NP (JJ optimal)  (ADJP (NN kappa) (NN  B/Rel) ) (JJ DNA-binding)  (NNS motifs) )) (: :) ) (S (NP-SBJ-11 (NP (NN interaction) ) (PP (IN of)  (NP (NP (DT both)  (NNS subunits) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))) (PP (IN with)  (NP (NN DNA) ))) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-11) ) (PP (IN for)  (NP (JJ transcriptional)  (NN activation) )))) (. .) )) )
(TOP (S (NP-SBJ (NP (NN Analysis) ) (PP (IN of)  (NP (NP (DT the)  (NP-COOD (NP (NN p50) ) (CC and)  (NP (NN p65) )) (NNS subunits) ) (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN transcription)  (NN factor)  (NN complex) ))))) (VP (VBZ has)  (VP (VBN revealed)  (SBAR (IN that)  (S (NP-SBJ (DT both)  (NNS proteins) ) (VP (MD can)  (VP (VB interact)  (PP (IN with)  (NP (JJ related)  (NN DNA)  (NNS sequences) )) (PP (IN through)  (NP (NP-COOD (CC either)  (NP (ADJP (JJ homo-) ) (NP (-NONE- *?*) )) (CC or)  (NP (NN heterodimer) )) (NN formation) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NP (DT the)  (NN product) ) (PP (IN of)  (NP (DT the)  (NN proto-oncogene)  (NN c-rel) ))) (VP (MD can)  (VP (VB bind)  (PP (TO to)  (NP (JJ similar)  (NN DNA)  (NNS motifs) )) (PP-COOD (PP (IN by)  (NP (PRP itself) )) (CC or)  (PP (IN as)  (NP (NP (DT a)  (NN heterodimer) ) (PP (IN with)  (NP-COOD (NP (NN p50) ) (CC or)  (NP (NN p65) )))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (S-COOD (S (NP-SBJ (DT these)  (NNS studies) ) (VP (VBP have)  (VP (VBN used)  (NP (NP (DT a)  (JJ limited)  (NN number) ) (PP (IN of)  (NP (JJ known)  (NN kappa)  (NN B)  (NN DNA)  (NNS motifs) )))))) (, ,)  (CC and)  (S (NP-SBJ-12 (NP (DT the)  (NN question) ) (PP (IN of)  (NP (NP (DT the)  (JJ optimal)  (NN DNA)  (NNS sequences) ) (VP (VBN preferred)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT each)  (NN homodimer) )))))) (VP (VBZ has)  (RB not)  (VP (VBN been)  (VP (VBN addressed)  (NP (-NONE- *-12) )))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG Using)  (NP (VBN purified)  (JJ recombinant)  (NP-COOD (NP (NN p50) ) (, ,)  (NP (NN p65) ) (, ,)  (CC and)  (NP (NN c-Rel) )) (NNS proteins) ))) (, ,)  (NP-SBJ-13 (JJ optimal)  (JJ DNA-binding)  (NNS motifs) ) (VP (VBD were)  (VP (VBN selected)  (NP (-NONE- *-13) ) (PP (IN from)  (NP (NP (DT a)  (NN pool) ) (PP (IN of)  (NP (JJ random)  (NNS oligonucleotides) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (NN Alignment) ) (PP (IN of)  (NP (DT the)  (VBN selected)  (NNS sequences) ))) (VP (VBD allowed)  (S (NP-SBJ (PRP us) ) (VP (TO to)  (VP (VB predict)  (NP (NP (DT a)  (NN consensus)  (NN sequence) ) (PP (IN for)  (NP (NP (NN binding) ) (PP (IN of)  (NP (DT the)  (JJ individual)  (JJ homodimeric)  (JJ Rel-related)  (NNS proteins) )))))))))) (, ,)  (CC and)  (S (NP-SBJ (NP (NN DNA-protein)  (NN binding)  (NN analysis) ) (PP (IN of)  (NP (DT the)  (VBN selected)  (NN DNA)  (VBZ sequences) ))) (VP (VBD revealed)  (NP (NP (NN sequence)  (NN specificity) ) (PP (IN of)  (NP (DT the)  (NNS proteins) ))))) (. .) ) )
(TOP (S (PP (JJ Contrary)  (TO to)  (NP (JJ previous)  (NNS assumptions) )) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD observed)  (SBAR (IN that)  (S (NP-SBJ (NN p65)  (NNS homodimers) ) (VP (MD can)  (VP (VB interact)  (PP (IN with)  (NP (NP (DT a)  (NN subset) ) (PP (IN of)  (NP (NP (NN DNA)  (VBZ sequences) ) (VP (RB not)  (VBN recognized)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN p50)  (NNS homodimers) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ-14 (JJ Differential)  (NN binding)  (NNS affinities) ) (VP (VBD were)  (ADVP (RB also) ) (VP (VBN obtained)  (NP (-NONE- *-14) ) (PP (IN with)  (NP (ADJP-COOD (ADJP (NP (NN p50-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ c-Rel-selected) )) (NNS sequences) )))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (VBG Using)  (NP (NP (CC either)  (DT a)  (ADJP-COOD (ADJP (NP (NN p50-) ) (ADJP (-NONE- *?*) )) (CC or)  (ADJP (JJ p65-selected) )) (NN kappa)  (NN B)  (NN motif) ) (, ,)  (SBAR (WHNP-15 (WDT which) ) (S (NP-SBJ (-NONE- *T*-15) ) (VP (VBD displayed)  (NP (JJ differential)  (NN binding) ) (PP (IN with)  (NN respect)  (TO to)  (NP (DT the)  (JJ other)  (NN protein) ))))) (, ,) ))) (NP-SBJ-16 (QP (JJ little)  (TO to)  (DT no) ) (NN binding) ) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-16) ) (PP (IN with)  (NP (DT the)  (JJ heterodimeric)  (NN NF-kappa)  (NN B)  (NN complex) )))) (. .) ) )
(TOP (S-COOD (S (ADVP (RB Similarly) ) (, ,)  (PP (IN in)  (NP (NP (NN transfection)  (NNS experiments) ) (SBAR (WHPP-17 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ-18 (DT the)  (JJ selective)  (NN kappa)  (NN B)  (NN binding)  (NNS sites) ) (VP (VBD were)  (VP (VBN used)  (NP-19 (-NONE- *-18) ) (S (NP-SBJ (-NONE- *-19) ) (VP (TO to)  (VP (VB drive)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (DT a)  (NN chloramphenicol)  (NN acetyltransferase)  (NN reporter)  (NN construct) )))))) (PP (-NONE- *T*-17) ))))))) (, ,)  (NP-SBJ-20 (DT the)  (ADJP-COOD (ADJP (NP (NN p65-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ p50-selected) )) (NNS motifs) ) (VP (VBD were)  (VP (VBN activated)  (NP (-NONE- *-20) ) (PP (RB only)  (IN in)  (DT the)  (NN presence)  (IN of)  (NP (NP-COOD (NP (NN p65) ) (CC and)  (NP (NP (NN p50/65) ) (PRN (-LRB- -LRB-)  (NP (NP (DT a)  (JJ chimeric)  (NN protein) ) (PP (IN with)  (NP (DT the)  (NP-COOD (NP (NN p50)  (NN DNA)  (NN binding)  (NN domain) ) (CC and)  (NP (NN p65)  (NN activation)  (NN domain) ))))) (-RRB- -RRB-) ))) (NN expression)  (NNS vectors) )) (, ,)  (ADVP (RB respectively) )))) (, ,)  (CC and)  (S (NP-SBJ (DT neither) ) (VP (VBD demonstrated)  (NP (NP (DT a)  (JJ significant)  (NN response) ) (PP (TO to)  (NP (NP (NNS stimuli) ) (SBAR (WHNP-21 (WDT that) ) (S (NP-SBJ (-NONE- *T*-21) ) (VP (VBP induce)  (NP (NN NF-kappa)  (NN B)  (NN activity) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP-COOD (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-22 (NP (NN interaction) ) (PP (IN of)  (NP (NP (DT both)  (NNS subunits) ) (PP (IN of)  (NP (DT the)  (JJ heterodimeric)  (NN NF-kappa)  (NN B)  (NN complex) )))) (PP (IN with)  (NP (NN DNA) ))) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-22) ) (PP (IN for)  (NP-COOD (NP (NN DNA)  (NN binding) ) (CC and)  (NP (JJ transcriptional)  (NN activation) )))))))) (CC and)  (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ transcriptional)  (NN activation) ) (VP (VBN mediated)  (NP (-NONE- *) ) (PP (IN by)  (NP (DT the)  (JJ individual)  (JJ rel-related)  (NNS proteins) )))) (VP (MD will)  (VP (VB differ)  (ADVP (RB dramatically) ) (, ,)  (PP (VBG depending)  (PP (IN on)  (NP (NP (DT the)  (JJ specific)  (NN kappa)  (NN B)  (NNS motifs) ) (ADJP (JJ present) )))))))))) (. .) ) )
(TOP (NP (NP (NN Characterization) ) (PP (IN of)  (NP (NP (DT a)  (JJ new)  (JJ tissue-specific)  (NN transcription)  (NN factor) ) (VP (VBG binding)  (PP (TO to)  (NP (DT the)  (JJ simian)  (NN virus)  (CD 40)  (NN enhancer)  (NN TC-II)  (-LRB- -LRB-)  (NN NF-kappa)  (NN B)  (-RRB- -RRB-)  (NN element) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-COOD (ADVP (RB biochemically) ) (CC and)  (ADVP (RB functionally) )) (VP (VBN characterized)  (NP (NP (NP (DT a)  (JJ new)  (NN transcription)  (NN factor) ) (, ,)  (NP (NN NP-TCII) ) (, ,) ) (SBAR (WHNP-15 (WDT which) ) (S (NP-SBJ-16 (-NONE- *T*-15) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ present)  (PP (IN in)  (NP (NP (NNS nuclei) ) (PP (IN from)  (NP (JJ unstimulated)  (NP-COOD (NP (NN T) ) (CC and)  (NP (NN B) )) (NNS lymphocytes) )))))) (CC but)  (VP (VBZ is)  (RB not)  (VP (VBN found)  (NP (-NONE- *-16) ) (PP (IN in)  (NP (JJ nonhematopoietic)  (NNS cells) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN factor) ) (VP-COOD (VP (VBZ has)  (NP (NP (DT a)  (JJ DNA-binding)  (NN specificity) ) (ADJP (JJ similar)  (PP (TO to)  (NP (NP (DT that) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))))) (CC but)  (VP (VBZ is)  (ADJP-PRD (JJ unrelated)  (PP (TO to)  (NP-COOD (ADJP-COOD (ADJP (DT this) ) (CC or)  (ADJP (JJ other) )) (NN Rel)  (NNS proteins) )) (PP (IN by)  (NP (ADJP-COOD (ADJP (JJ functional) ) (CC and)  (ADJP (JJ biochemical) )) (NNS criteria) ))))) (. .) ) )
(TOP (S (NP-SBJ-17 (PRP It) ) (VP (MD can)  (ADVP (RB also) ) (VP (VB be)  (VP (VBN distinguished)  (NP (-NONE- *-17) ) (PP (IN from)  (NP (JJ other)  (ADJP (RB previously)  (VBN described) ) (JJ lymphocyte-specific)  (JJ DNA-binding)  (NNS proteins) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN candidate)  (NN oncoprotein)  (NN Bcl-3) ) (VP (VBZ is)  (NP-PRD (NP (DT an)  (NN antagonist) ) (PP (IN of)  (NP (ADJP (NN p50/NF-kappa)  (JJ B-mediated) ) (NN inhibition) )))) (. .) ) )
(TOP (S (NP-SBJ-18 (DT The)  (NN candidate)  (NN oncogene)  (NN bcl-3) ) (VP (VBD was)  (VP (VBN discovered)  (NP (-NONE- *-18) ) (PP (IN as)  (NP (NP (DT a)  (NN translocation) ) (PP (IN into)  (NP (DT the)  (NN immunoglobulin)  (NN alpha-locus) )))) (PP (IN in)  (NP (NP (DT some)  (NNS cases) ) (PP (IN of)  (NP (NN B-cell)  (JJ chronic)  (JJ lymphocytic)  (NNS leukaemias) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN protein)  (NN Bcl-3) ) (VP (VBZ contains)  (NP (CD seven)  (JJ so-called)  (NN ankyrin)  (NNS repeats) )) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-19 (JJ Similar)  (NN repeat)  (NNS motifs) ) (VP (VBP are)  (VP (VBN found)  (NP (-NONE- *-19) ) (PP (IN in)  (NP (NP (DT a)  (NN number) ) (PP (IN of)  (NP (JJ diverse)  (JJ regulatory)  (NNS proteins) ))))))) (CC but)  (S (NP-SBJ (NP (DT the)  (NNS motifs) ) (PP (IN of)  (NP (NN Bcl-3) ))) (VP (VBP are)  (ADJP-PRD (ADVP (RBS most)  (RB closely) ) (JJ related)  (PP (TO to)  (NP (NP (DT those) ) (VP (VBN found)  (NP (-NONE- *) ) (PP (IN in)  (NP (NP (NN I)  (NN kappa)  (NN B)  (NNS proteins) ) (SBAR (WHPP-21 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ-22 (DT the)  (NN ankyrin)  (NN repeat)  (NN domain) ) (VP (VBZ is)  (VP (VBN thought)  (S (NP-SBJ-23 (-NONE- *-22) ) (VP (TO to)  (VP (VB be)  (ADVP (RB directly) ) (VP (VBN involved)  (NP (-NONE- *-23) ) (PP (IN in)  (NP (NP (NN inhibition) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN activity) )))) (PP (-NONE- *T*-21) ))))))))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-24 (DT No)  (JJ biological)  (NN function) ) (VP (VBZ has)  (ADVP (RB yet) ) (VP (VBN been)  (VP (VBN described)  (NP (-NONE- *-24) ) (PP (IN for)  (NP (NN Bcl-3) )))))) (, ,)  (CC but)  (S (NP-SBJ (PRP it) ) (VP (VBD was)  (VP (VBN noted)  (ADVP-TMP (RB recently) ) (SBAR (IN that)  (S (NP-SBJ (NN Bcl-3) ) (VP (VBZ interferes)  (PP (IN with)  (NP (NP (NN DNA-binding) ) (PP (IN of)  (NP (NP (DT the)  (NN p50)  (NN subunit) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))))) (ADVP (FW in)  (FW vitro) ))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-25 (NN Bcl-3) ) (VP (MD can)  (VP (VB aid)  (NP (ADJP (NN kappa)  (NN B)  (JJ site-dependent) ) (NN transcription) ) (ADVP (FW in)  (FW vivo) ) (PP (IN by)  (S (NP-SBJ (-NONE- *-25) ) (VP (VBG counteracting)  (NP (NP (DT the)  (JJ inhibitory)  (NNS effects) ) (PP (IN of)  (NP (NN p50/NF-kappa)  (NN B)  (NNS homodimers) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Bcl-3) ) (VP (MD may)  (ADVP (RB therefore) ) (VP (VB aid)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NP (JJ select)  (ADJP (NN NF-kappa)  (JJ B-regulated) ) (NNS genes) ) (, ,)  (PP (VBG including)  (NP (NP (DT those) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus) ))))))))) (. .) ) )
(TOP (NP (NP (NP (DT A)  (NN microtitre)  (NN assay)  (NN system) ) (PP (IN for)  (NP (NN glucocorticoid)  (NNS receptors) )) (: :) ) (NP (NP (VBN decreased)  (NN receptor)  (NN concentration) ) (PP (IN in)  (NP (JJ myocardial)  (NN infarction) )) (. .) )) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ major)  (NN difficulty) ) (PP (IN in)  (NP (NP (NN determination) ) (PP (IN of)  (NP (NN glucocorticoid)  (NN receptor)  (NNS sites) ))))) (VP (VBZ is)  (NP-PRD (DT the)  (ADJP (RB very)  (JJ complicated) ) (NN assay)  (NN procedure) )) (. .) ) )
(TOP (S (ADVP (RB Therefore) ) (, ,)  (NP-SBJ-32 (PRP we) ) (VP (VBP describe)  (NP (NP (DT a)  (NN microtitre)  (NN assay)  (NN system) ) (PP (IN for)  (NP (NN glucocorticoid)  (NNS receptors) )) (SBAR (WHNP-33 (WDT which) ) (S (NP-SBJ (-NONE- *T*-33) ) (VP (VBZ is)  (NP-PRD (DT a)  (JJ whole-cell)  (JJ competitive)  (NN binding)  (NN radioassay) ))))) (S (NP-SBJ (-NONE- *-32) ) (VP (VBG using)  (NP (NN -LCB-3H-RCB--dexamethasone) ) (PP (IN as)  (NP (NN radioligand) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (NN modification) ) (PP (IN of)  (NP (DT a)  (ADJP (RB previously)  (VBN described) ) (NN protocol) ))) (VP-COOD (VP (VP-COOD (VP (VBZ simplifies)  (NP (-NONE- *RNR*-34) )) (CC and)  (VP (VBZ reduces)  (NP (-NONE- *RNR*-34) ))) (NP-34 (NN laboratory)  (NN work) )) (CC and)  (VP (VBZ allows)  (S (NP-SBJ-35 (NN assay)  (NN reproducibility) ) (VP (TO to)  (VP (VB be)  (VP (VBN controlled)  (NP (-NONE- *-35) ) (ADVP (RBR more)  (RB reliably) ))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-37 (-NONE- *-36) ) (VP (ADVP (RB Thus) ) (VBN enabled)  (S (NP-SBJ-38 (-NONE- *-37) ) (VP (TO to)  (VP (VB perform)  (NP (DT the)  (NN test) ) (PP (IN on)  (NP (JJ multiple)  (NN blood)  (NNS samples) )) (PP (IN in)  (NP (NN parallel) ))))))) (, ,)  (NP-SBJ-36 (PRP we) ) (VP (VBD investigated)  (NP (JJ cardiac)  (NN infarction)  (NNS patients) ) (PP-TMP (IN over)  (NP (DT a)  (JJ 12-day)  (NN period) )) (S (NP-SBJ (-NONE- *-38) ) (VP (TO to)  (VP (VB test)  (SBAR (IN if)  (S (NP-SBJ-39 (NN glucocorticoid)  (NN receptor)  (NN binding) ) (VP (VBZ is)  (VP (VBN altered)  (NP (-NONE- *-39) ) (PP (IN in)  (NP (DT this)  (`` ')  (JJ stressful)  ('' ')  (NN disease) )))))))))) (. .) ) )
(TOP (S-COOD (S (PP-TMP (IN On)  (NP (NP (DT the)  (JJ first)  (NN day) ) (PP (IN of)  (NP (DT the)  (NN disease) )))) (, ,)  (NP-SBJ-40 (NN glucocorticoid)  (NN receptor)  (NN capacity) ) (VP (VBD was)  (ADVP (RB significantly) ) (VP (VBN decreased)  (NP (-NONE- *-40) ) (PP (IN without)  (NP (NP (NN alteration) ) (PP (IN of)  (NP (DT the)  (JJ receptor-ligand)  (NN affinity) ))))))) (, ,)  (IN whereas)  (S (PP-TMP (IN on)  (NP (NNS days)  (NP-COOD (NP (CD 4) ) (CC and)  (NP (CD 12) )))) (NP-SBJ (NP (DT the)  (NN number) ) (PP (IN of)  (NP (NN receptor)  (NNS sites) ))) (VP (VBD was)  (ADJP-PRD (JJ normal) ) (ADVP (RB again) ))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN result) ) (VP (VBZ fits)  (ADVP (RB well) ) (PP (IN into)  (NP (NP (DT the)  (JJ general)  (NN observation) ) (PP (IN of)  (NP (NP (JJ stress-induced)  (NN down-regulation) ) (PP (IN of)  (NP (JJ immune)  (NNS responses) ))))))) (. .) ) )
(TOP (NP (NP (NN Regulation) ) (PP (IN of)  (NP (NN c-jun)  (NN expression) )) (PP-TMP (IN during)  (NP (NP (NN induction) ) (PP (IN of)  (NP (JJ monocytic)  (NN differentiation) )))) (PP (IN by)  (NP (JJ okadaic)  (NN acid) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ present)  (NN work) ) (VP (VBZ has)  (VP (VBN examined)  (NP (NP (DT the)  (NNS effects) ) (PP (IN of)  (NP (NP (JJ okadaic)  (NN acid) ) (, ,)  (NP (NP (DT an)  (NN inhibitor) ) (PP (IN of)  (NP (NN type)  (NP-COOD (NP (CD 1) ) (CC and)  (NP (NN 2A) )) (NN protein)  (NNS phosphatases) ))) (, ,) )) (PP (IN on)  (NP (NP (DT the)  (NN regulation) ) (PP (IN of)  (NP (NN c-jun)  (NN expression) )) (PP-TMP (IN during)  (NP (NP (JJ monocytic)  (NN differentiation) ) (PP (IN of)  (NP (NN U-937)  (NN leukemia)  (NNS cells) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ-27 (JJ okadaic)  (NN acid)  (NN treatment) ) (VP (VBZ is)  (VP (VBN associated)  (NP (-NONE- *-27) ) (PP (IN with)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NP (DT a)  (VBN differentiated)  (NN monocyte)  (NN phenotype) ) (VP (VBN characterized)  (NP (-NONE- *) ) (PP (IN by)  (: :)  (NP-LGS-COOD (NP (LST (-LRB- -LRB-)  (LS a)  (-RRB- -RRB-) ) (NN growth)  (NN arrest) ) (: ;)  (NP (LST (-LRB- -LRB-)  (LS b)  (-RRB- -RRB-) ) (NP (NNS increases) ) (PP (IN in)  (NP (NN Mac-1)  (NN cell)  (NN surface)  (NN antigen)  (NN expression) ))) (: ;)  (NP (LST (-LRB- -LRB-)  (LS c)  (-RRB- -RRB-) ) (NP (NN down-regulation) ) (PP (IN of)  (NP (NN c-myc)  (NNS transcripts) ))) (: ;)  (CC and)  (NP (LST (-LRB- -LRB-)  (LS d)  (-RRB- -RRB-) ) (NP (NN induction) ) (PP (IN of)  (NP (NN tumor)  (NN necrosis)  (NN factor)  (NN gene)  (NN expression) ))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-28 (NP (DT This)  (NN induction) ) (PP (IN of)  (NP (JJ monocytic)  (NN differentiation) ))) (VP (VBD was)  (VP (VBN associated)  (NP (-NONE- *-28) ) (PP (IN with)  (NP (NP (JJ transient)  (NNS increases) ) (PP (IN in)  (NP (NP (NN c-jun)  (NN mRNA)  (NNS levels) ) (, ,)  (SBAR (WHNP-29 (WDT which) ) (S (NP-SBJ (-NONE- *T*-29) ) (VP (VBD were)  (ADJP-PRD (JJ maximal) ) (PP-TMP (IN at)  (NP (CD 6)  (NN h) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-30 (JJ Similar)  (NNS effects) ) (VP (VBD were)  (VP (VBN obtained)  (NP (-NONE- *-30) ) (PP (IN for)  (NP (DT the)  (NN c-fos)  (NN gene) )))) (. .) ) )
(TOP (S (NP-SBJ (JJ Run-on)  (NN analysis) ) (VP (VBD demonstrated)  (UCP-COOD (NP (NP (JJ detectable)  (NNS levels) ) (PP (IN of)  (NP (NN c-jun)  (NN transcription) )) (PP (IN in)  (NP (NN U-937)  (NNS cells) ))) (CC and)  (SBAR (IN that)  (S (NP-SBJ-31 (DT this)  (NN rate) ) (VP (VBZ is)  (VP (VBN increased)  (NP (-NONE- *-31) ) (ADVP (RB approximately)  (RB 40-fold) ) (PP-TMP (VBG following)  (NP (JJ okadaic)  (NN acid)  (NN exposure) )))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-32 (NN c-jun)  (NN mRNA)  (NNS levels) ) (VP (VBD were)  (VP (VBN superinduced)  (NP (-NONE- *-32) ) (PP (IN in)  (NP (NP (NNS cells) ) (VP (VBN treated)  (NP (-NONE- *) ) (PP (IN with)  (NP-COOD (CC both)  (NP (JJ okadaic)  (NN acid) ) (CC and)  (NP (NN cycloheximide) ))))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (NN inhibition) ) (PP (IN of)  (NP (NN protein)  (NN synthesis) ))) (VP (VBD had)  (NP (NP (JJ little)  (PRN (, ,)  (SBAR (IN if)  (FRAG (ADJP (DT any) ))) (, ,) ) (NN effect) ) (PP (IN on)  (NP (ADJP (JJ okadaic)  (JJ acid-induced) ) (NN c-jun)  (NN transcription) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN half-life) ) (PP (IN of)  (NP (NN c-jun)  (NN mRNA) ))) (VP (VBD was)  (ADJP-PRD (ADJP (JJ similar) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 45-50) ) (NN min) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (ADJP-COOD (CC both)  (ADJP (JJ untreated) ) (CC and)  (ADJP (JJ okadaic)  (JJ acid-induced) )) (NNS cells) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-33 (NP (NN treatment) ) (PP (IN with)  (NP-COOD (DT both)  (NP (JJ okadaic)  (NN acid) ) (CC and)  (NP (NN cycloheximide) )))) (VP (VBD was)  (VP (VBN associated)  (NP (-NONE- *-33) ) (PP (IN with)  (NP (NP (NP (NN stabilization) ) (PRN (-LRB- -LRB-)  (S (NP-SBJ (NN t) (CD  1/2) ) (VP (JJ =)  (NP (CD 90)  (NN min) ))) (-RRB- -RRB-) )) (PP (IN of)  (NP (NN c-jun)  (NNS transcripts) )))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-34 (-NONE- *) ) (VP (VBN Taken)  (NP (-NONE- *-34) ) (ADVP (RB together) ))) (, ,)  (NP-SBJ (DT these)  (NNS findings) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ-35 (NP (DT the)  (NN induction) ) (PP (IN of)  (NP (NN c-jun)  (NN transcription) )) (PP (IN by)  (NP (JJ okadaic)  (NN acid) ))) (VP (VBZ is)  (VP (VBN controlled)  (NP (-NONE- *-35) ) (ADVP (RB primarily) ) (PP (IN by)  (NP-LGS (DT a)  (JJ transcriptional)  (NN mechanism) ))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Since)  (S (NP-SBJ (JJ previous)  (NNS studies) ) (VP (VBP have)  (VP (VBN demonstrated)  (SBAR (IN that)  (S (NP-SBJ-36 (DT the)  (NN c-jun)  (NN gene) ) (VP (VBZ is)  (VP (VBN autoinduced)  (NP (-NONE- *-36) ) (PP (IN by)  (NP-LGS (NN Jun/AP-1) )))))))))) (, ,)  (NP-SBJ (PRP we) ) (ADVP (RB also) ) (VP (VBD studied)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NN c-jun)  (NN promoter)  (PRN (-LRB- -LRB-)  (NP (NNS positions)  (NP-COOD (NP (CD -132/+170) ))) (-RRB- -RRB-) ) (JJ -reporter)  (NN gene)  (NNS constructs) )) (PP (PP-COOD (PP (IN with)  (NP (-NONE- *RNR*-37) )) (CC and)  (PP (IN without)  (NP (-NONE- *RNR*-37) ))) (NP-37 (DT a)  (VBN mutated)  (NN AP-1)  (NN element) )))) (. .) ) )
(TOP (S (-LRB- -LRB-)  (NP-SBJ-101 (NN ABSTRACT) ) (VP (VBN TRUNCATED)  (NP (-NONE- *-101) ) (PP (IN AT)  (NP (CD 250)  (NNS WORDS) ))) (-RRB- -RRB-) ) )
(TOP (NP (NP (NN Activation) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (PP (IN by)  (NP (NN interleukin)  (CD 2) )) (PP (IN in)  (NP (JJ human)  (NN blood)  (NNS monocytes) )) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP report)  (ADVP (RB here) ) (SBAR (IN that)  (S (NP-SBJ-28 (NP (NN interleukin)  (CD 2) ) (PRN (-LRB- -LRB-)  (NP (NN IL-2) ) (-RRB- -RRB-) )) (VP (VBZ acts)  (PP (IN on)  (NP (JJ human)  (NN blood)  (NNS monocytes) )) (PP (IN by)  (S (NP-SBJ (-NONE- *-28) ) (VP (VBG enhancing)  (NP (NP (NN binding)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) )) (PP (TO to)  (NP (NP (PRP$ its)  (NN consensus)  (NN sequence) ) (PP (IN in)  (NP (NP (NP (DT the)  (JJ 5')  (JJ regulatory)  (NN enhancer)  (NN region) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN receptor)  (NN alpha)  (NN chain) ))) (PRN (-LRB- -LRB-)  (NP (NN p55) ) (-RRB- -RRB-) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Similarly) ) (, ,)  (NP-SBJ (NN IL-2) ) (VP (VBZ activates)  (NP (NN NF-kappa)  (NN B) ) (PP-COOD (PP (IN in)  (NP (DT the)  (JJ human)  (JJ monocytic)  (NN cell)  (NN line)  (NN U)  (CD 937) )) (, ,)  (CC but)  (PP (RB not)  (IN in)  (NP (VBG resting)  (JJ human)  (NNS T-cells) )))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN effect) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (JJ detectable) ) (PP-TMP (IN within)  (NP (CD 15)  (NN min) ))) (CC and)  (VP (VBZ peaks)  (PP-TMP (NP (CD 1)  (NN h) ) (IN after)  (NP (NP (NN exposure) ) (PP (TO to)  (NP (NN IL-2) )))))) (. .) ) )
(TOP (S (NP-SBJ-29 (VBN Enhanced)  (NN NF-kappa)  (NN B)  (NN binding)  (NN activity) ) (VP (VBZ is)  (VP (VBN followed)  (NP (-NONE- *-29) ) (PP (IN by)  (NP-LGS (NP (JJ functional)  (NN activation) ) (WHPP-105 (IN in)  (SBAR-COOD (SBAR (WHNP (IN that) ) (S (NP-SBJ-30 (NP (NN inducibility) ) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN receptor)  (NN alpha)  (NN chain) ))) (VP (VBZ is)  (VP (VBN mediated)  (NP (-NONE- *-30) ) (PP (IN by)  (NP-LGS (VBN enhanced)  (NN NF-kappa)  (NN B)  (NN binding) )) (PP (-NONE- *T*-105) ))))) (CC and)  (SBAR (WHNP (IN that) ) (S (NP-SBJ-31 (NP (DT a)  (JJ heterologous)  (NN promoter) ) (VP (VBG containing)  (NP (NP (NP (DT the)  (NN NF-kappa)  (NN B)  (NN consensus)  (NN sequence) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD -291) ) (TO to)  (NP (CD -245) )) (-RRB- -RRB-) )) (PP (IN of)  (NP (DT the)  (NN IL-2)  (NN receptor)  (NN alpha)  (NN chain)  (NN gene) ))))) (VP (VBZ is)  (VP (VBN activated)  (NP (-NONE- *-31) ) (PP (-NONE- *T*-105) ))))))))))) (. .) ) )
(TOP (S-COOD (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ-32 (NN IL-2) ) (VP (VBZ is)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-32) ) (VP (VBG increasing)  (NP (NP (NN transcript)  (NNS levels) ) (PP (IN of)  (NP (NP (DT the)  (NN p50)  (NN gene) ) (VP (VBG coding)  (PP (IN for)  (NP (NP (DT the)  (NN p50)  (NN subunit) ) (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN transcription)  (NN factor) )))))))))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (NN mRNA)  (NNS levels) ) (PP (IN of)  (NP (DT the)  (NN p65)  (NN NF-kappa)  (NN B)  (NN gene) ))) (VP (VBD remained)  (ADJP-PRD (JJ unchanged) ))) (. .) ) )
(TOP (NP (NP (JJ Single)  (NN point)  (NN estimation) ) (PP (IN of)  (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PP (IN in)  (NP (NP (NNS lymphocytes) ) (PP-COOD (PP (IN of)  (NP (JJ normal)  (NNS subjects) )) (CC and)  (PP (IN of)  (NP (NP (NNS children) ) (PP (IN under)  (NP (JJ long)  (NN term)  (NN glucocorticoid)  (NN treatment) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-45 (NP (DT A)  (JJ single)  (NN point)  (NN assay) ) (PP (IN of)  (NP (NP (NP (NN glucocorticoid)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NN GR) ) (-RRB- -RRB-) )) (PP (IN in)  (NP (JJ human)  (NNS lymphocytes) )))) (PP (VBN based)  (PP (IN on)  (NP (NP (DT the)  (NN measurement) ) (PP (IN of)  (NP (JJ specific)  (NN dexamethasone)  (NN binding) )))))) (VP (VBZ has)  (VP (VBN been)  (VP-COOD (VP (VBN developed)  (NP (-NONE- *-45) )) (CC and)  (VP (VBN compared)  (NP (-NONE- *-45) ) (PP (IN with)  (NP (DT a)  (JJ common)  (JJ multi-point)  (NN Scatchard)  (NN analysis) )))))) (. .) ) )
(TOP (S (NP-SBJ-47 (NP (DT The)  (NN assay)  (NN conditions) ) (: -)  (NP-COOD (NP (NP (NN concentration)  (PP (IN of)  (NP (DT the)  (NN ligand) ))) (NP (CD 20) (NN  nmol/l) )) (, ,)  (NP (NN incubation)  (NN time)  (CD 2)  (NN h) ) (CC and)  (NP (NP (DT the)  (NN cell)  (NN count)  (QP (CD 2-6) ) (CD mil.) (NNS  cells/tube) ) (PP (IN in)  (NP (DT the)  (NN assay)  (NN volume)  (CD 0.25)  (NN ml) ))))) (VP (VBD were)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-47) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (JJ optimal) )))))) (. .) ) )
(TOP (S (NP-SBJ-46 (DT An)  (NN attempt)  (S (-NONE- *ICH*-48) )) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN undertaken)  (NP (-NONE- *-46) ) (S-48 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB use)  (NP (DT a)  (NN cell)  (NN harvester) ) (PP (IN for)  (NP (NP (DT the)  (NN separation) ) (PP (IN of)  (NP (NNS cells) )) (PP (IN from)  (NP (JJ unbound)  (NN ligand) ))))))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Though)  (S (NP-SBJ-COOD (NP (NP (ADJP (RB specifically)  (VBN bound) ) (NN dexamethasone) ) (VP (VBN measured)  (NP (-NONE- *) ) (PP (IN by)  (NP (JJ whole-cell)  (NN assay) )))) (CC and)  (NP (NP (DT that) ) (VP (VBG using)  (NP (NN cell)  (NN harvester) )))) (VP (VBD correlated)  (ADVP (RB well) )))) (, ,)  (NP-SBJ (NP (ADJP (PP (RB almost)  (IN by)  (NP (CD one)  (NN order) )) (JJR lower) ) (NNS values) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT the)  (JJ latter)  (NN method) )))) (VP (VBP render)  (S (NP-SBJ (PRP it) ) (ADJP-PRD (JJ non-applicable)  (PP (IN for)  (NP (NN receptor)  (NN quantitation) ))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (DT The)  (NNS results) ) (PP (IN from)  (NP (CD 9)  (JJ healthy)  (NNS volunteers) ))) (PRN (-LRB- -LRB-)  (FRAG (NP (JJ average)  (NN GR)  (NN concentration)  (NP (QP (CD 7131) (CC  +/-)  (CD 1256) ) (NNS sites/cell) ))) (-RRB- -RRB-) )) (VP (VBD correlated)  (ADVP (RB excellently) ) (PP (IN with)  (NP (NP (DT those) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN by)  (NP (DT the)  (NN Scatchard)  (NN analysis) )))))) (. .) ) )
(TOP (S (NP-SBJ-49 (DT The)  (JJ single)  (NN point)  (NN assay) ) (VP (VBZ has)  (VP (VBN been)  (ADVP (RB also) ) (VP (VBN applied)  (NP (-NONE- *-49) ) (PP (IN for)  (NP (NP (NN determination) ) (PP (IN of)  (NP (NP (NN GH) ) (PP (IN in)  (NP (NP (CD 10)  (NNS children) ) (VP (VBN treated)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (JJ large)  (NNS doses) ) (PP (IN of)  (NP (NN prednisone) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ average)  (NNS values) ) (PP (IN from)  (NP (JJ healthy)  (NNS volunteers) ))) (VP (VBD did)  (RB not)  (VP (VB differ)  (ADVP (RB significantly) ) (PP (IN from)  (NP (NP (DT those) ) (VP (VBN found)  (NP (-NONE- *) ) (PP (IN in)  (NP (DT these)  (NNS children) ))))) (, ,)  (SBAR (RB though)  (S (NP-SBJ-50 (ADJP (RB much)  (JJR broader) ) (NN range) ) (VP (VBD was)  (VP (VBN found)  (NP (-NONE- *-50) ) (PP (IN in)  (NP (NNS patients) )))))))) (. .) ) )
(TOP (S (NP-SBJ (DT A)  (JJ novel)  (ADJP (NN B)  (JJ cell-derived) ) (NN coactivator) ) (VP (VBZ potentiates)  (NP (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN immunoglobulin)  (NNS promoters) )) (PP (IN by)  (NP (JJ octamer-binding)  (NN transcription)  (NNS factors) )))) (. .) ) )
(TOP (S (NP-SBJ-11 (NP (DT A)  (JJ novel)  (ADJP (NN B)  (JJ cell-restricted) ) (NN activity) ) (, ,)  (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (JJ octamer/Oct-dependent)  (NN transcription) )) (PP (IN from)  (NP (DT an)  (NP (NP (NN immunoglobulin)  (JJ heavy)  (NN chain) ) (PRN (-LRB- -LRB-)  (NP (NN IgH) ) (-RRB- -RRB-) )) (NN promoter) ))))) (, ,) ) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-11) ) (PP (IN in)  (NP (NP (DT an)  (ADJP (FW in)  (FW vitro) ) (NN system) ) (VP (VBG consisting)  (PP (IN of)  (NP (NP (ADJP (NN HeLa)  (JJ cell-derived) ) (NNS extracts) ) (VP (VBN complemented)  (NP (-NONE- *) ) (PP (IN with)  (NP (VBN fractionated)  (NN B)  (NN cell)  (JJ nuclear)  (NNS proteins) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-12 (NP (DT The)  (NN factor) ) (ADJP (JJ responsible)  (PP (IN for)  (NP (DT this)  (NN activity) )))) (VP (VBD was)  (VP (VBN designated)  (S (NP-SBJ (-NONE- *-12) ) (NP-PRD (NP (NP (NN Oct)  (NN coactivator) ) (PP (IN from)  (NP (NN B)  (NNS cells) ))) (PRN (-LRB- -LRB-)  (NP (NN OCA-B) ) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (NP-SBJ (NN OCA-B) ) (VP-COOD (VP (VBZ stimulates)  (NP (NP (DT the)  (NN transcription) ) (PP (IN from)  (NP (DT an)  (NN IgH)  (NN promoter) ))) (PP (IN in)  (NN conjunction)  (IN with)  (NP-COOD (CC either)  (NP (NN Oct-1) ) (CC or)  (NP (NN Oct-2) )))) (CC but)  (VP (VBZ shows)  (NP (NP (DT no)  (JJ significant)  (NN effect) ) (PP (IN on)  (NP-COOD (NP (NP (DT the) (JJ  octamer/Oct-dependent)  (NN transcription) ) (PP (IN of)  (NP (DT the)  (ADJP (RB ubiquitously)  (VBN expressed) ) (NN histone)  (NN H2B)  (NN promoter) ))) (CC and)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (NP (NN USF-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ Sp1-regulated) )) (NNS promoters) )))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ-13 (-NONE- *-100) ) (VP (VBN Taken)  (NP (-NONE- *-13) ) (ADVP (RB together) ))) (, ,)  (NP-SBJ-100 (PRP$ our)  (NNS results) ) (VP (VBP suggest)  (SBAR-COOD (SBAR (IN that)  (S (NP-SBJ (NN OCA-B) ) (VP (VBZ is)  (NP-PRD (DT a)  (ADJP-COOD (ADJP (NP (NN tissue-) ) (ADJP (-NONE- *?*) )) (, ,)  (ADJP (NP (NN promoter-) ) (ADJP (-NONE- *?*) )) (, ,)  (CC and)  (ADJP (JJ factor-specific) )) (NN coactivator) )))) (CC and)  (SBAR (IN that)  (S (NP-SBJ (NN OCA-B) ) (VP (MD may)  (VP (VB be)  (NP-PRD (NP (DT a)  (JJ major)  (NN determinant) ) (PP (IN for)  (NP (NP (ADJP (NN B)  (JJ cell-specific) ) (NN activation) ) (PP (IN of)  (NP (NN immunoglobulin)  (NNS promoters) ))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NN light)  (IN of)  (NP (NP (DT the)  (NN evidence) ) (VP (VBG showing)  (NP (NP (ADJP-COOD (ADJP (JJ physical) ) (CC and)  (ADJP (JJ functional) )) (NNS interactions) ) (PP (IN between)  (NP-COOD (NP (NN Oct)  (NNS factors) ) (CC and)  (NP (NN OCA-B) ))))))) (, ,)  (NP-SBJ (PRP we) ) (VP-COOD (VP (VBP propose)  (NP (NP (DT a)  (NN mechanism) ) (PP (IN of)  (NP (NN action) )) (PP (IN for)  (NP (NN OCA-B) )))) (CC and)  (VP (VBP discuss)  (NP (NP (DT the)  (NNS implications) ) (PP (IN of)  (NP (NN OCA-B) )) (PP (IN for)  (NP (NP (DT the)  (JJ transcriptional)  (NN regulation) ) (PP (IN of)  (NP (JJ other)  (JJ tissue-specific)  (NNS promoters) ))))))) (. .) ) )
(TOP (NP (NP (DT The)  (NN regulation) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN tumor)  (NN necrosis)  (NN factor)  (NN alpha)  (NN promoter)  (NN region) )) (PP (IN in)  (NP (NP-COOD (NP (NN macrophage) ) (, ,)  (NP (NN T)  (NN cell) ) (, ,)  (CC and)  (NP (NN B)  (NN cell) )) (NNS lines) )) (. .) ) )
(TOP (S (NP-SBJ-10 (DT The)  (ADJP (JJ 1311-base)  (NN pair) ) (JJ human)  (NN tumor)  (NN necrosis)  (NN factor)  (-LRB- -LRB-)  (NN TNF)  (-RRB- -RRB-)  (NN alpha)  (NN promoter)  (NN region) ) (VP (VBD was)  (VP-COOD (VP (VBN fused)  (NP (-NONE- *-10) ) (PP (TO to)  (NP (DT the)  (NP (NP (NN luciferase) ) (PRN (-LRB- -LRB-)  (NP (NN Luc) ) (-RRB- -RRB-) )) (NN reporter)  (NN gene) ))) (CC and)  (VP (VBN studied)  (NP (-NONE- *-10) ) (PP (IN in)  (NP (DT a)  (JJ transient)  (NN transfection)  (NN system) )) (PP (IN in)  (NP (NP (CD three)  (NN TNF)  (NN producing)  (NN cell)  (NNS lines) ) (, ,)  (NP-COOD (NP (DT the)  (NN U937)  (NN macrophage)  (NN cell)  (NN line) ) (, ,)  (NP (DT the)  (NN MLA)  (CD 144)  (NN T)  (NN cell)  (NN line) ) (, ,)  (CC and)  (NP (DT the)  (CD 729-6)  (NN B)  (NN cell)  (NN line) ))))))) (. .) ) )
(TOP (S (NP-SBJ-12 (DT This)  (JJ full)  (NN length)  (NN promoter)  (NN construct) ) (VP (MD can)  (VP (VB be)  (VP (VBN induced)  (NP (-NONE- *-12) ) (PP (IN by)  (NP-LGS (NP (NN phorbol)  (NN 13-myristate)  (NN acetate) ) (PRN (-LRB- -LRB-)  (NP (NN PMA) ) (-RRB- -RRB-) ))) (PP (IN in)  (NP (NP (DT each) ) (PP (IN of)  (NP (DT these)  (NN cell)  (NNS types) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Analysis) ) (PP (IN of)  (NP (NP (DT a)  (NN series) ) (PP (IN of)  (NP (NNS 5'-truncations) ))))) (VP (VBD showed)  (NP (NP (JJ several)  (NNS peaks) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ basal) ) (CC and)  (ADJP (NN PMA)  (JJ induced) )) (NN activity) )) (VP (VBG suggesting)  (NP (NP (DT the)  (NN presence) ) (PP (IN of)  (NP (JJ several)  (ADJP-COOD (ADJP (JJ positive) ) (CC and)  (ADJP (JJ negative) )) (JJ regulatory)  (NNS elements) )))))) (. .) ) )
(TOP (S (NP-SBJ-13 (DT A)  (NN PMA)  (JJ responsive)  (NN element) ) (VP (VBD was)  (VP (JJ localized)  (NP (-NONE- *-13) ) (PP (TO to)  (NP (NP (DT a)  (NN region) ) (PP (IN between)  (NP (NP-COOD (NP (CD -95) ) (CC and)  (NP (CD -36) )) (NN bp) )) (ADJP (JJ relative)  (PP (TO to)  (NP (DT the)  (NN transcription)  (NN start)  (NN site) ))))))) (. .) ) )
(TOP (S (PP (IN Within)  (NP (DT this)  (NN region) )) (, ,)  (NP-SBJ-14 (JJ single)  (ADJP (ADJP-COOD (ADJP (NN AP-2-) ) (CC and)  (ADJP (JJ AP-1-like) ))) (NN consensus)  (NNS sequences) ) (VP (VBD were)  (VP (VBN noted)  (NP (-NONE- *-14) ))) (. .) ) )
(TOP (S (NP-SBJ-15 (DT These)  (NP-COOD (NP (NN AP-2) ) (CC and)  (NP (NN AP-1) )) (NNS sites) ) (VP (VBD were)  (DT each)  (VP (VBN modified)  (NP (-NONE- *-15) ) (PP (IN with)  (NP (DT a)  (JJ double)  (NN point)  (NN mutation) )))) (. .) ) )
(TOP (S (NP-SBJ-16 (NP (DT A)  (ADJP (ADJP (JJ modest) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 20-50) ) (NN %) ) (-RRB- -RRB-) )) (NN reduction) ) (PP (IN in)  (NP (NN TNF)  (NN promoter)  (NN activity) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-16) ) (PP (IN with)  (NP (DT the)  (NN AP-2)  (NN site)  (NN mutation) )))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NP (NN mutation) ) (PP (IN of)  (NP (DT the)  (NN AP-1)  (NN site) ))) (ADVP (RB markedly) ) (VP (VBD diminished)  (NP (CC both)  (DT the)  (ADJP-COOD (ADJP (JJ basal) ) (CC and)  (ADJP (JJ PMA-activated) )) (NN promoter)  (NN activity) )) (. .) ) )
(TOP (S (ADVP (RB Also) ) (NP-SBJ (NP (NNS co-transfections) ) (PP (IN of)  (NP (DT the)  (JJ wild-type)  (NN promoter)  (NN construct) )) (PP (IN with)  (NP (DT an) (NN  AP-1/c-jun)  (NN expression)  (NN vector) ))) (VP (VBD resulted)  (PP (IN in)  (NP (JJ augmented)  (ADJP-COOD (ADJP (JJ basal) ) (CC and)  (ADJP (JJ PMA-induced) )) (NN promoter)  (NN activity) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Redox)  (NN status) ) (PP (IN of)  (NP (NNS cells) ))) (VP (VBZ influences)  (NP (NP-COOD (NP (ADJP-COOD (ADJP (JJ constitutive) ) (CC or)  (ADJP (VBN induced) )) (NN NF-kappa)  (NN B)  (NN translocation) ) (CC and)  (NP (NN HIV)  (JJ long)  (JJ terminal)  (NN repeat)  (NN activity) )) (PP (IN in)  (NP (JJ human)  (UCP-COOD (NP (NN T) ) (CC and)  (ADJP (JJ monocytic) )) (NN cell)  (NNS lines) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN tested)  (NP (DT the)  (NN hypothesis)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ cellular)  (NN activation)  (NNS events) ) (VP-COOD (VP (VBG occurring)  (PP (IN in)  (NP-COOD (NP (NN T)  (NNS lymphocytes) ) (CC and)  (NP (NNS monocytes) )))) (CC and)  (VP (VBN mediated)  (NP (-NONE- *) ) (PP (IN through)  (NP (NP (NN translocation) ) (PP (IN of)  (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-kappa)  (NN B) ))))))) (VP (VBP are)  (ADJP-PRD (JJ dependent)  (PP (IN upon)  (NP (NP (DT the)  (JJ constitutive)  (NN redox)  (NN status) ) (PP (IN of)  (NP (DT these)  (NNS cells) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ-7 (PRP We) ) (VP (VBD used)  (NP (NP (ADJP-COOD (ADJP (JJ phenolic) ) (, ,)  (ADJP (JJ lipid-soluble) ) (, ,)  (ADJP (JJ chain-breaking) )) (NNS antioxidants) ) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NP (VBN butylated)  (NN hydroxyanisole) ) (PRN (-LRB- -LRB-)  (NP (NN BHA) ) (-RRB- -RRB-) )) (, ,)  (NP (JJ nordihydroquairetic)  (NN acid) ) (, ,)  (CC or)  (NP (NP (NN alpha-tocopherol) ) (PRN (-LRB- -LRB-)  (NP (NN vitamin)  (NN E) ) (-RRB- -RRB-) ))))) (S (NP-SBJ (-NONE- *-7) ) (VP (TO to)  (VP (VB show)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ peroxyl)  (JJ radical)  (NN scavenging) ) (PP (IN in)  (NP (ADJP-COOD (ADJP (JJ unstimulated) ) (CC and)  (ADJP-COOD (ADJP (NP (NN PMA-) ) (ADJP (-NONE- *?*) )) (CC or)  (ADJP (JJ TNF-stimulated) ))) (NNS cells) ))) (VP (VBZ blocks)  (NP (DT the)  (NNS functions) ) (PP (VBG depending)  (PP (IN on)  (NP (NN NF-kappa)  (NN B)  (NN activation) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-8 (NN BHA) ) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-8) ) (VP (TO to)  (VP (VB suppress)  (NP (NP (ADJP (CONJP (RB not)  (RB only) ) (ADJP-COOD (ADJP (NP (NN PMA-) ) (ADJP (-NONE- *?*) )) (CC or)  (ADJP (JJ TNF-induced) )) (, ,)  (CONJP (CC but)  (RB also) ) (ADJP (JJ constitutive) ) (, ,) ) (JJ HIV-enhancer)  (NN activity) ) (ADJP (JJ concomitant)  (PP (TO to)  (NP (NP (DT an)  (NN inhibition) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B)  (NN binding)  (NN activity) ) (PP (IN in)  (NP (ADJP-COOD (CC both)  (ADJP (JJ lymphoblastoid)  (NN T)  (PRN (-LRB- -LRB-)  (NP (NN J.Jhan) ) (-RRB- -RRB-) )) (CC and)  (ADJP (JJ monocytic)  (PRN (-LRB- -LRB-)  (NP (NN U937) ) (-RRB- -RRB-) ))) (NN cell)  (NNS lines) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBD was)  (ADVP (RB also) ) (ADJP-PRD (JJ true) ) (PP (IN for)  (NP (NP (NP (NP (NN KBF) ) (PRN (-LRB- -LRB-)  (NP (NN p50)  (NN homodimer) ) (-RRB- -RRB-) )) (NN binding)  (NN activity) ) (PP (IN in)  (NP (NN U937)  (NNS cells) ))))) (. .) ) )
(TOP (S (NP-SBJ-9 (NP (NN Secretion) ) (PP (IN of)  (NP (NP (NN TNF) ) (, ,)  (NP (NP (DT the)  (NN product) ) (PP (IN of)  (NP (DT another)  (ADJP (NN NF-kappa)  (JJ B-dependent) ) (NN gene) ))) (, ,) ))) (VP (VBD was)  (VP (VBN abolished)  (NP (-NONE- *-9) ) (PP (IN by)  (NP (NN BHA) )) (PP (IN in)  (NP (JJ PMA-stimulated)  (NN U937)  (NNS cells) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-10 (NP (DT The)  (JJ anti-oxidative)  (NN effect) ) (PP (IN of)  (NP (NN BHA) ))) (VP (VBD was)  (VP (VBN accompanied)  (NP (-NONE- *-10) ) (PP (IN by)  (NP-LGS (NP (DT an)  (NN increase) ) (PP (IN in)  (NP (NP (NP-COOD (NP (NN thiol) ) (, ,)  (CONJP (CC but)  (RB not) ) (NP (NN glutathione) ) (, ,) ) (NN content) ) (PP (IN in)  (NP (ADJP-COOD (ADJP (VBN stimulated) ) (CC and)  (ADJP (JJ unstimulated) )) (NN T)  (NN cell) ))))))))) (, ,)  (IN whereas)  (S (NP-SBJ (NP (NN TNF)  (NN stimulation) ) (NP (PRP itself) )) (ADVP (RB barely) ) (VP (VBD modified)  (NP (DT the)  (JJ cellular)  (NN thiol)  (NN level) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Oxidative)  (NN stress) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN by)  (NP (NP (DT the)  (NN addition) ) (PP (IN of)  (NP (NN H2O2) )) (PP (TO to)  (NP (NP (DT the)  (NN culture)  (NN medium) ) (PP (IN of)  (NP (NP-COOD (NP (NN J.Jhan) ) (CC or)  (NP (NN U937) )) (NNS cells) )))))))) (VP (MD could)  (RB not)  (PP (IN by)  (NP (PRP itself) )) (VP (VB induce)  (NP (NN NF-kappa)  (NN B)  (NN activation) ))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS observations) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ-COOD (NP (NN TNF) ) (CC and)  (NP (NN PMA) )) (VP (VBP do)  (RB not)  (VP (VB lead)  (PP (TO to)  (NP (NP (NN NF-kappa)  (NN B)  (NN activation) ) (PP (IN through)  (NP (NP (NN induction) ) (PP (IN of)  (NP (NP (NNS changes) ) (PP (IN in)  (NP (DT the)  (NN cell)  (NN redox)  (NN status) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Rather) ) (, ,)  (NP-SBJ-COOD (NP (NN TNF) ) (CC and)  (NP (NN PMA) )) (VP (MD can)  (VP (VB exert)  (NP (PRP$ their)  (NN effect) ) (SBAR (RB only)  (IN if)  (S (NP-SBJ (NNS cells) ) (VP (VBP are)  (PP-PRD (IN in)  (NP (DT an)  (JJ appropriate)  (NN redox)  (NN status) )) (, ,)  (SBAR (IN because)  (S (NP-SBJ (NP (JJ prior)  (NN modification) ) (PP (IN toward)  (NP (NN reduction) )) (PP (IN with)  (NP (NN BHA)  (NN treatment) ))) (VP (VBZ prevents)  (VP (DT this)  (NN activation) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP It) ) (VP (VBZ appears)  (SBAR (IN that)  (S (NP-SBJ (NP (DT a)  (JJ basal)  (NN redox)  (NN equilibrium) ) (VP (VBG tending)  (PP (IN toward)  (NP (NN oxidation) )))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (NN prerequisite) ) (PP (IN for)  (NP (NP (NP (JJ full)  (NN activation) ) (PP (IN of)  (NP (NN transduction)  (NNS pathways) ))) (VP (VBG regulating)  (NP (NP (DT the)  (NN activity) ) (PP (IN of)  (NP (ADJP (NN NF-kappa)  (JJ B-dependent) ) (NNS genes) ))))))))))) (. .) ) )
(TOP (NP (NP (NN Expression) ) (PP (IN of)  (NP-COOD (NP (NN c-fos) ) (, ,)  (NP (NN c-jun) ) (CC and)  (NP (NN jun)  (NN B) ))) (PP (IN in)  (NP (NP (JJ peripheral)  (NN blood)  (NNS lymphocytes) ) (PP (IN from)  (NP (ADJP-COOD (ADJP (JJ young) ) (CC and)  (ADJP (JJ elderly) )) (NNS adults) )))) (. .) ) )
(TOP (S (NP-SBJ-8 (NP (DT The)  (NN expression) ) (PP (IN of)  (NP (NP-COOD (NP (NN c-fos) ) (, ,)  (NP (NN c-jun) ) (CC and)  (NP (NN jun)  (NN B) )) (NNS proto-oncogenes) ))) (VP (VBD was)  (VP (VBN studied)  (NP (-NONE- *-8) ) (PP (IN in)  (NP (NP (ADJP (NP (NP (NN phytohemagglutinin) ) (PRN (-LRB- -LRB-)  (NP (NN PHA) ) (-RRB- -RRB-) )) (VBN activated) ) (NP (NP (JJ peripheral)  (NN blood)  (NNS lymphocytes) ) (PRN (-LRB- -LRB-)  (NP (NN PBL) ) (-RRB- -RRB-) ))) (PP (IN from)  (NP (ADJP-COOD (ADJP (JJ young) ) (CC and)  (ADJP (JJ aged) )) (NNS humans) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Specific)  (NNS mRNAs) ) (PP (IN for)  (NP-COOD (NP (NN c-fos) ) (CC and)  (NP (NN c-jun) )))) (VP-COOD (VP (VBD were)  (ADJP-PRD (JJ detectable) ) (PP-TMP (IN within)  (NP (NP (CD 30)  (NN min) ) (PP-TMP (IN after)  (NP (NN cell)  (NN activation) ))))) (CC and)  (VP (VBD reached)  (NP (JJ maximal)  (NNS levels) ) (PP-TMP (IN within)  (NP (CD 2)  (NN h) )))) (. .) ) )
(TOP (S (NP-SBJ (NP-COOD (CC Both)  (NP (NN c-fos) ) (CC and)  (NP (NN jun)  (NN B) )) (NNS mRNAs) ) (VP (VBD decreased)  (PP (TO to)  (NP (NN pre-activation)  (NNS levels) )) (PP-TMP (IN within)  (NP (CD 6)  (NN h) )) (, ,)  (SBAR (IN while)  (S (NP-SBJ (NN c-jun)  (NN mRNA) ) (VP (VBD remained)  (ADJP-PRD (JJ elevated) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (JJ PHA-activated)  (NN PBL) )) (, ,)  (NP-SBJ-9 (DT no)  (JJ age-related)  (NNS differences) ) (VP (VBD were)  (VP (VBN observed)  (NP (-NONE- *-9) ) (PP (IN in)  (NP (NP-COOD (NP (NN c-fos) ) (CC or)  (NP (NN jun)  (NN B) )) (NN mRNA)  (NN expression) )))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ (NN c-jun)  (NN mRNA)  (NNS levels) ) (VP (VBD decreased)  (ADVP (ADVP (RB significantly) ) (PRN (-LRB- -LRB-)  (FRAG (NP (NP-COOD (NP (QP (CD 1.73) (CC  +/-)  (CD 0.08) ) (NP (-NONE- *RNR*-10) )) (CC vs.)  (NP (QP (CD 1.16) (CC  +/-)  (CD 0.09) ) (NP (-NONE- *RNR*-10) ))) (NP-10 (JJ arbitrary)  (NNS units) ))) (, ,)  (S (NP-SBJ (NN P) ) (VP (VBG &lt;)  (NP (CD 0.01) ))) (, ,)  (FRAG (ADJP-COOD (ADJP (JJ young) ) (CC vs.)  (ADJP (JJ old) ))) (-RRB- -RRB-) )) (PP (IN in)  (NP (NN PBL) ) (PP (IN from)  (NP (JJ elderly)  (NNS individuals) )) (VP (VBN activated)  (NP (-NONE- *) ) (PP (IN with)  (NP (NN PHA) ))))) (. .) ) )
(TOP (S (SBAR-PRP (IN Because)  (S (NP-SBJ (JJ previous)  (NN work) ) (VP (VBZ has)  (VP (VBN demonstrated)  (SBAR (IN that)  (S (NP-SBJ-11 (NP (NN T)  (NNS cells) ) (PP (IN from)  (NP (JJ elderly)  (NNS individuals) ))) (VP (MD may)  (VP (VB display)  (NP (JJ normal)  (JJ proliferative)  (NNS responses) ) (SBAR-TMP (WHADVP-12 (WRB when) ) (S (NP-SBJ-13 (-NONE- *-11) ) (VP (VBN activated)  (NP (-NONE- *-13) ) (PP (IN via)  (NP (DT the)  (JJ anti-CD2)  (NN pathway) )) (ADVP (-NONE- *T*-12) )))))))))))) (, ,)  (NP-SBJ-14 (NP-COOD (NP (NN c-jun) ) (CC and)  (NP (NN jun)  (NN B) )) (NN mRNA)  (NN expression) ) (VP (VBD was)  (ADVP (RB also) ) (VP (VBN studied)  (NP (-NONE- *-14) ) (PP (IN in)  (NP (JJ anti-CD2-activated)  (VBN purified)  (NN T)  (NNS cells) )))) (. .) ) )
(TOP (S (NP-SBJ-15 (DT No)  (JJ age-related)  (NNS differences) ) (VP (VBD were)  (VP (VBN found)  (NP (-NONE- *-15) ) (PP (IN in)  (NP (NP (DT the)  (NN expression) ) (PP (IN of)  (NP (NP (DT either) ) (PP (IN of)  (NP (DT these)  (CD two)  (NNS proto-oncogenes) )))) (PP (IN by)  (NP (NN anti-CD2)  (JJ activated)  (NN T)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP-COOD (NP (DT the)  (VBN decreased)  (NN IL-2)  (NN production) ) (CC and)  (NP (JJ proliferative)  (NN response) )) (VP (VBN displayed)  (NP (-NONE- *) ) (PP (IN by)  (NP (NP (JJ PHA-activated)  (NN PBL) ) (PP (IN from)  (NP (JJ elderly)  (NNS adults) )))))) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ related)  (PP (TO to)  (NP (NP (JJ age-related)  (NNS changes) ) (PP-COOD (PP (IN in)  (NP (NN c-jun)  (NN mRNA)  (NN expression) )) (CC and)  (PP (IN in)  (NP (NP (DT the)  (NN ratio) ) (PP (IN of)  (NP (NN c-fos)  (NP (-NONE- *RNR*-17) ))) (PP (TO to)  (NP (NN c-jun)  (NP (-NONE- *RNR*-17) )) (NP-17 (NN mRNA) ))))))))))))) (. .) ) )
(TOP (NP (NP (NN Characterization) ) (PP (IN of)  (NP (NP (DT a)  (JJ novel)  (NN T)  (NN lymphocyte)  (NN protein) ) (SBAR (WHNP-10 (WDT which) ) (S (NP-SBJ (-NONE- *T*-10) ) (VP (VBZ binds)  (PP (TO to)  (NP (NP (DT a)  (NN site) ) (ADJP (JJ related)  (PP (TO to)  (NP (NP (NP (JJ steroid/thyroid) ) (NN hormone)  (NN receptor)  (NN response)  (NNS elements) ) (PP (IN in)  (NP (NP (DT the)  (JJ negative)  (JJ regulatory)  (NN sequence) ) (PP (IN of)  (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (JJ long)  (JJ terminal)  (NN repeat) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-TMP (RB previously) ) (VP (VBN identified)  (NP (NP (DT a)  (NN T)  (NN lymphocyte)  (NN protein) ) (SBAR (WHNP-11 (WDT which) ) (S (NP-SBJ (-NONE- *T*-11) ) (VP-COOD (VP (VBZ binds)  (PP (TO to)  (NP (NP (DT a)  (NN site) ) (PP (IN within)  (NP (NP (DT the)  (NN LTR) ) (PP (IN of)  (NP (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )))))))) (CC and)  (VP (VBZ exerts)  (NP (DT an)  (JJ inhibitory)  (NN effect) ) (PP (IN on)  (NP (NN virus)  (NN gene)  (NN expression) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NP (DT The)  (JJ palindromic)  (NN site) ) (PRN (-LRB- -LRB-)  (NP (NN site)  (NN B) ) (-RRB- -RRB-) )) (VP (VBN recognized)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT this)  (NN protein) )))) (VP (VBZ is)  (ADJP-PRD (JJ related)  (PP (TO to)  (NP (NP (DT the)  (JJ palindromic)  (VBG binding)  (NNS sites) ) (PP (IN of)  (NP (NP (NNS members) ) (PP (IN of)  (NP (DT the)  (NP (JJ steroid/thyroid) ) (NN hormone)  (NN receptor)  (NN family) )))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP characterize)  (NP (NP (DT the)  (NN T)  (NN cell)  (NN protein) ) (VP (VBG binding)  (PP (TO to)  (NP (DT this)  (NN site) )))) (PP (IN as)  (NP (NP (DT a)  (ADJP (CD 100)  (NN kD) ) (NN protein) ) (SBAR-COOD (SBAR (WHNP-13 (WDT which) ) (S (NP-SBJ (-NONE- *T*-13) ) (VP (VBZ is)  (ADJP-PRD (RBS most)  (JJ abundant)  (PP (IN in)  (NP (NN T)  (NNS cells) )))))) (CC and)  (SBAR (WHNP-14 (WDT which) ) (S (NP-SBJ (-NONE- *T*-14) ) (VP (VBZ binds)  (PP (TO to)  (NP (NN site)  (NN B) )) (PP (IN as)  (NP (DT a)  (ADJP (CD 200)  (NN kD) ) (NN complex) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN protein) ) (VP (VBZ is)  (ADJP-PRD (JJ distinct)  (PP (IN from)  (NP (NP (JJ other)  (NNS members) ) (PP (IN of)  (NP (DT the)  (NP (JJ steroid/thyroid) ) (NN hormone)  (NN receptor)  (NN family) )) (PP (VBG including)  (NP (NP (DT the)  (NN COUP)  (NN protein) ) (SBAR (WHNP-15 (WDT which) ) (S (NP-SBJ (-NONE- *T*-15) ) (VP (VBZ has)  (NP (DT a)  (ADJP (RB closely)  (JJ related) ) (NN DNA)  (NN binding)  (NN specificity) )))))))))) (. .) ) )
(TOP (NP (NP (NP (DT A)  (NN mechanism) ) (PP (IN for)  (NP (NP (DT the)  (JJ antiinflammatory)  (NNS effects) ) (PP (IN of)  (NP (NNS corticosteroids) )))) (: :) ) (S (NP-SBJ (DT the)  (NN glucocorticoid)  (NN receptor) ) (VP (VBZ regulates)  (NP-COOD (NP (NP (NN leukocyte)  (NN adhesion) ) (PP (TO to)  (NP (JJ endothelial)  (NNS cells) ))) (CC and)  (NP (NP (NN expression) ) (PP (IN of)  (NP-COOD (NP (JJ endothelial-leukocyte)  (NN adhesion)  (NN molecule)  (CD 1) ) (CC and)  (NP (JJ intercellular)  (NN adhesion)  (NN molecule)  (CD 1) )))))) (. .) )) )
(TOP (S (NP-SBJ (NNS Corticosteroids) ) (VP (VBP are)  (NP-PRD (DT the)  (JJ preeminent)  (JJ antiinflammatory)  (NNS agents) ) (SBAR (IN although)  (S (NP-SBJ-9 (NP (DT the)  (JJ molecular)  (NNS mechanisms) ) (SBAR (WHNP-10 (WDT that) ) (S (NP-SBJ (-NONE- *T*-10) ) (VP (VBP impart)  (NP (PRP$ their)  (NN efficacy) ))))) (VP (VBP have)  (RB not)  (VP (VBN been)  (VP (VBN defined)  (NP (-NONE- *-9) ))))))) (. .) ) )
(TOP (S (NP-SBJ-11 (DT The)  (NN endothelium) ) (VP (VBZ plays)  (NP (DT a)  (JJ critical)  (NN role) ) (PP (IN in)  (NP (NN inflammation) )) (PP (IN by)  (S (NP-SBJ-12 (-NONE- *-11) ) (VP (VBG directing)  (NP (VBG circulating)  (NNS leukocytes) ) (PP (IN into)  (NP (JJ extravascular)  (NNS tissues) )) (PP (IN by)  (S (NP-SBJ (-NONE- *-12) ) (VP (VBG expressing)  (NP (NP (NP (JJ adhesive)  (NNS molecules) ) (PP (IN for)  (NP (NNS leukocytes) ))) (PRN (-LRB- -LCB-)  (PP (FW e.g.)  (, ,)  (NP-COOD (NP (NP (JJ endothelial-leukocyte)  (NN adhesion)  (NN molecule)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN ELAM-1) ) (-RRB- -RRB-) )) (CC and)  (NP (NP (JJ intercellular)  (NN adhesion)  (NN molecule)  (CD 1) ) (PRN (-LRB- -LRB-)  (NP (NN ICAM-1) ) (-RRB- -RRB-) )))) (-RRB- -RCB-) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (ADVP (RB therefore) ) (VP (VBD determined)  (SBAR (IN whether)  (S (NP-SBJ-13 (NNS corticosteroids) ) (VP (VBP suppress)  (NP (NN inflammation) ) (PP (IN by)  (S (NP-SBJ (-NONE- *-13) ) (VP (VBG inhibiting)  (NP (NP (JJ endothelial)  (NN expression) ) (PP (IN of)  (NP (NP (NP (NN adhesion)  (NNS molecules) ) (PP (IN for)  (NP (NNS neutrophils) ))) (PRN (-LRB- -LRB-)  (NP (JJ polymorphonuclear)  (NNS leukocytes) ) (-RRB- -RRB-) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Preincubation) ) (PP (IN of)  (NP (JJ endothelial)  (NNS cells) )) (PP (IN with)  (NP (NP (NN endotoxin) ) (PRN (-LRB- -LCB-)  (FRAG (NP (NP (NN lipopolysaccharide) ) (PRN (-LRB- -LRB-)  (NP (NN LPS) ) (-RRB- -RRB-) )) (, ,)  (NP (CD 1) (NN  microgram/ml) )) (-RRB- -RCB-) )))) (VP (VBD led)  (PP (TO to)  (NP (NP (NP (DT a)  (ADJP (JJ 4-fold) ) (NN increase) ) (PP (IN in)  (NP (NP (JJ subsequent)  (NN adherence) ) (PP (IN of)  (NP (NP (JJ polymorphonuclear)  (NNS leukocytes) ) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (NN P) ) (VP (VBG &lt;)  (NP (CD 0.0001) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD (CD 10) )))) (-RRB- -RRB-) ))) (PP (TO to)  (NP (JJ endothelial)  (NNS cells) ))))) (, ,)  (NP (NP (DT an)  (NN increase) ) (SBAR (WHNP-14 (WDT that) ) (S (NP-SBJ-15 (-NONE- *T*-14) ) (VP (VBD was)  (ADVP (RB markedly) ) (VP (VBN attenuated)  (NP (-NONE- *-15) ) (SBAR-TMP (WHADVP-16 (WRB when) ) (S (NP-SBJ-17 (JJ endothelial)  (NNS cells) ) (VP (VBD were)  (VP (VBN treated)  (NP (-NONE- *-17) ) (PP (IN with)  (NP (NP (NN dexamethasone) ) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (NN IC50) ) (VP (VBG &lt;)  (NP (CD 1)  (NN nM) ))) (, ,)  (S (NP-SBJ (NN P) ) (VP (VBG &lt;)  (NP (CD 0.0001) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (VBG =)  (NP-PRD-COOD (NP (CD 6) ) (CC or)  (NP (CD 7) ))))) (-RRB- -RRB-) ))) (PP-TMP (IN during)  (NP (NP (NN preincubation) ) (PP (IN with)  (NP (NN LPS) )))) (ADVP (-NONE- *T*-16) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Moreover) ) (, ,)  (NP-SBJ-COOD (NP (NP (DT the)  (NN steroid)  (NN receptor)  (NN agonist)  (NN cortisol) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 10)  (NN microM) )) (-RRB- -RRB-) )) (, ,)  (CONJP (CC but)  (RB not) ) (NP (NP (PRP$ its)  (JJ inactive)  (NN metabolite)  (NN tetrahydrocortisol) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 10)  (NN microM) )) (-RRB- -RRB-) )) (, ,) ) (VP (VBD diminished)  (NP (JJ LPS-induced)  (JJ endothelial)  (NN cell)  (NN adhesiveness) )) (. .) ) )
(TOP (S (NP-SBJ-18 (JJ Further)  (NN evidence)  (SBAR (IN that)  (S (NP-SBJ-19 (NP (DT the)  (NN action) ) (PP (IN of)  (NP (NN dexamethasone) ))) (VP (VBD was)  (VP (VBN mediated)  (NP (-NONE- *-19) ) (PP (IN through)  (NP (NP (NN ligation) ) (PP (IN of)  (NP (NP (NN corticosteroid)  (NNS receptors) ) (PRN (-LRB- -LCB-)  (NP (NP (JJ human)  (NN glucocorticoid)  (NNS receptors) ) (PRN (-LRB- -LRB-)  (NP (NNS hGRs) ) (-RRB- -RRB-) )) (-RRB- -RCB-) )))))))))) (VP (VBD was)  (VP (VBN provided)  (NP (-NONE- *-18) ) (PP (IN by)  (NP-LGS (NP (NNS experiments) ) (VP (VBG utilizing)  (NP (DT the)  (NN steroid)  (NN antagonist)  (NN RU-486) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN RU-486) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 10)  (NN microM) )) (-RRB- -RRB-) ) (, ,)  (SBAR (WHNP-20 (WDT which) ) (S (NP-SBJ-21 (-NONE- *T*-20) ) (VP (VBZ prevents)  (NP (NP (NN translocation) ) (PP (IN of)  (NP (VBN ligated)  (NN hGR) )) (PP (TO to)  (NP (DT the)  (NN nucleus) ))) (PP (IN by)  (S (NP-SBJ (-NONE- *-21) ) (VP (VBG inhibiting)  (NP (NP (NN dissociation) ) (PP (IN of)  (NP (NN hGR) )) (PP (IN from)  (NP (NN heat)  (NN shock)  (NN protein)  (CD 90) ))))))))) (, ,) ) (ADVP (RB completely) ) (VP (VBD aborted)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NN dexamethasone) )) (PP (IN on)  (NP (NP (NN adhesiveness) ) (PP (IN of)  (NP (NP (JJ endothelial)  (NNS cells) ) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (NN P) ) (VP (VBG &lt;)  (NP (CD 0.0005) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD (CD 3) )))) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN of)  (NP (JJ endothelial)  (NNS cells) )) (PP (IN with)  (NP (NP (NN LPS) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 1) (NN  microgram/ml) )) (-RRB- -RRB-) )))) (VP-COOD (VP (VBD stimulated)  (NP-100 (NP (NN transcription) ) (PP (IN of)  (NP (NN ELAM-1) ))) (, ,)  (SBAR-101 (IN as)  (S (NP-SBJ-22 (-NONE- *) ) (VP (VBN shown)  (NP (-NONE- *-22) ) (PP (IN by)  (NP (NN Northern)  (NN blot)  (NN analysis) )))))) (, ,)  (CC and)  (VP (NP=100 (NP (NN expression) ) (PP (IN of)  (NP (JJ membrane-associated)  (NP-COOD (NP (NN ELAM-1) ) (CC and)  (NP (NN ICAM-1) ))))) (, ,)  (SBAR=101 (IN as)  (S (NP-SBJ-23 (-NONE- *) ) (VP (VBN shown)  (NP (-NONE- *-23) ) (PP (IN by)  (NP (NP (JJ quantitative)  (NN immunofluorescence) ) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (DT both)  (NN P) ) (VP (VBG &lt;)  (NP (CD 0.001) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (VBG =)  (NP-PRD (CD 9) )))) (-RRB- -RRB-) )))))))) (. .) ) )
(TOP (S (S (NP-SBJ (NN Dexamethasone) ) (ADVP (RB markedly) ) (VP (VBD inhibited)  (NP-COOD (NP (NP (JJ LPS-stimulated)  (NN accumulation) ) (PP (IN of)  (NP (NP (NN mRNA) ) (PP (IN for)  (NP (NN ELAM-1) ))))) (CC and)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NP-COOD (NP (NN ELAM-1) ) (CC and)  (NP (NN ICAM-1) )) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (NN IC50) ) (VP (VBG &lt;)  (NP (CD 10)  (NN nM) ))) (, ,)  (S (NP-SBJ (DT both)  (NN P) ) (VP (VBG &lt;)  (NP (CD 0.001) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (VBG =)  (NP-PRD (CD 4-9) )))) (-RRB- -RRB-) )))))) (: ;) ) (S (NP-SBJ-24 (NP (NN inhibition) ) (PP (IN of)  (NP (NN expression) )) (PP (IN by)  (NP (NN dexamethasone) ))) (VP (VBD was)  (VP (VBN reversed)  (NP (-NONE- *-24) ) (PP (IN by)  (NP-LGS (NP (NN RU-486) ) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (DT both)  (NN P) ) (VP (VBG &lt;)  (NP (CD 0.005) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (VBG =)  (NP-PRD (CD 4-6) )))) (-RRB- -RRB-) ))))) (. .) )) )
(TOP (S (SBAR-ADV (IN As)  (FRAG (PP (IN in)  (NP (DT the)  (NN adhesion)  (NNS studies) )))) (, ,)  (NP-SBJ-COOD (NP (NN cortisol) ) (CONJP (CC but)  (RB not) ) (NP (NN tetrahydrocortisol) )) (VP (VBD inhibited)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NP-COOD (NP (NN ELAM-1) ) (CC and)  (NP (NN ICAM-1) )) (PRN (-LRB- -LRB-)  (S-COOD (S (NP-SBJ (DT both)  (NN P) ) (VP (VBG &lt;)  (NP (CD 0.005) ))) (, ,)  (S (NP-SBJ (NN n) ) (VP (JJ =)  (NP-PRD-COOD (NP (CD 3) ) (CC or)  (NP (CD 4) ))))) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (NN sodium)  (NN salicylate) ) (PRN (-LRB- -LRB-)  (FRAG (NP (CD 1)  (NN mM) )) (-RRB- -RRB-) )) (VP (VBD inhibited)  (NP (NP-COOD (CC neither)  (NP (NN adhesion) ) (CC nor)  (NP (NN expression) )) (PP (IN of)  (NP (DT these)  (NN adhesion)  (NNS molecules) )))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS studies) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (NN antagonism) ) (PP (IN by)  (NP (NN dexamethasone) )) (PP (IN of)  (NP (JJ endotoxin-induced)  (NN inflammation) ))) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ specific)  (NN instance) ) (PP (IN of)  (NP (DT the)  (JJ general)  (JJ biological)  (NN principle)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (NN glucocorticoid)  (NN receptor) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ hormone-dependent)  (NN regulator) ) (PP (IN of)  (NP (NN transcription) ))))))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Membrane)  (NNS receptors) ) (PP (IN for)  (NP (NN aldosterone) )) (: :) ) (NP (NP (DT a)  (JJ novel)  (NN pathway) ) (PP (IN for)  (NP (NN mineralocorticoid)  (NN action) )) (. .) )) )
(TOP (S (NP-SBJ-2 (NP (JJ Rapid)  (JJ nongenomic)  (ADJP (FW in)  (FW vitro) ) (NNS effects) ) (PP (IN of)  (NP (NN aldosterone) )) (PP (IN on)  (NP-COOD (NP (JJ intracellular)  (NNS electrolytes) ) (, ,)  (NP (NN cell)  (NN volume) ) (, ,)  (CC and)  (NP (JJ Na-LRB-+-RRB--H+)  (NN antiport) )))) (VP (VBP have)  (VP (VBN been)  (VP (VBN found)  (NP (-NONE- *-2) ) (PP (IN in)  (NP (NP (JJ human)  (JJ mononuclear)  (NNS leukocytes) ) (PRN (-LRB- -LRB-)  (NP (NN HML) ) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Binding) ) (PP (IN of)  (NP (JJ 125I-labeled)  (NN aldosterone) )) (PP (TO to)  (NP (NP (NN plasma)  (NNS membranes) ) (PP (IN of)  (NP (NN HML) ))))) (VP (VBZ shares)  (NP (JJ important)  (NNS features) ) (PP (IN with)  (NP (DT these)  (JJ functional)  (NNS data) ))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ includes)  (NP-COOD (NP (NP (NP (DT a)  (ADJP (RB very)  (JJ low) ) (JJ apparent)  (NP (NP (NN dissociation)  (NN constant) ) (PRN (-LRB- -LRB-)  (NP (NN Kd) ) (-RRB- -RRB-) ))) (PP (IN of)  (NP (CD 0.1)  (NN nM) ))) (PP (IN for)  (NP-COOD (CC both)  (NP (NN aldosterone) ) (CC and)  (NP (NP (DT the)  (NN effect) ) (PP (IN on)  (NP (DT the)  (NN Na-LRB-+-RRB--H-LRB-+-RRB--antiport) )))))) (, ,)  (NP (DT a)  (JJ high)  (NN turnover)  (NN rate) ) (, ,)  (CC and)  (NP (NP (DT the)  (ADJP (RB almost)  (JJ exclusive) ) (NN binding)  (NN selectivity) ) (PP (IN for)  (NP (NN aldosterone) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN Dexamethasone) ) (, ,)  (NP (NN RU)  (CD 26988) ) (, ,)  (NP (NN corticosterone) ) (, ,)  (NP (NN ouabain) ) (, ,)  (NP (NN amiloride) ) (, ,)  (CC and)  (NP (NN 18-hydroxyprogesterone) )) (VP (VBD were)  (ADJP-PRD (JJ inactive) ) (PP (IN as)  (NP (NNS ligands) ))) (. .) ) )
(TOP (S (NP-SBJ (NN Deoxycorticosterone)  (NN acetate) ) (VP (VBD had)  (NP (DT an)  (JJ intermediate)  (NN activity) ) (PP (IN with)  (NP (NP (DT an)  (JJ apparent)  (NN Kd) ) (PP (IN of)  (NP (CD 100)  (NN nM) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS findings) ) (VP (VBP are)  (NP-PRD (NP (DT the)  (JJ first) ) (SBAR (WHNP-101 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-101) ) (VP (TO to)  (VP (VB demonstrate)  (S (NP-SBJ (NP (NN membrane)  (NN binding) ) (PP (IN of)  (NP (NN aldosterone) ))) (VP (VBG being)  (ADJP-PRD (JJ compatible)  (PP (IN with)  (NP (NP (JJ major)  (NNS aspects) ) (PP (IN of)  (NP (PRP$ its)  (JJ nongenomic)  (NNS effects) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Reticuloendotheliosis)  (NN virus)  (JJ long)  (JJ terminal)  (NN repeat)  (NNS elements) ) (VP (VBP are)  (NP-PRD (NP (JJ efficient)  (NNS promoters) ) (PP (IN in)  (NP (NP (NNS cells) ) (PP (IN of)  (NP (NP (JJ various)  (NP-COOD (NP (NNS species) ) (CC and)  (NP (NN tissue) ))) (NN origin) )) (, ,)  (PP (VBG including)  (NP (JJ human)  (JJ lymphoid)  (NNS cells) )))))) (. .) ) )
(TOP (S (S (S (NP-SBJ-9 (NP (JJ Promiscuous)  (JJ transcriptional)  (NN activity) ) (PP (IN of)  (NP (NP (NP (DT the)  (NN reticuloendotheliosis)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN REV) ) (-RRB- -RRB-) )) (NP (NP (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) ))))) (VP (VBD was)  (VP (VBN detected)  (NP (-NONE- *-9) ) (PP (IN in)  (NP (JJ transient)  (NN expression)  (NNS assays) )) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP-COOD (NP (NN LTR-chloramphenicol)  (JJ acetyltransferase-encoding)  (NN gene)  (NNS chimeras) ) (, ,)  (CC and)  (NP (NP (NNS cells) ) (PP (IN of)  (NP (NP (JJ diverse)  (NP-COOD (NP (NNS species) ) (CC and)  (NP (NN tissue) ))) (NN type) )))))))) (: ;) ) (S (NP-SBJ (NP (NNS levels) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN from)  (NP (CD two)  (JJ different)  (NN REV)  (NNS LTRs) ))))) (VP (VBP correlate)  (PP (IN with)  (NP (NP (NNS reports) ) (PP (IN of)  (NP (NP (NN pathogenicity) ) (PP (IN of)  (NP (DT the)  (JJ respective)  (NNS viruses) )) (ADVP (FW in)  (FW vivo) )))))) (. .) ))) )
(TOP (S-COOD (S (NP-SBJ (NNS REVs) ) (VP (VBP do)  (RB not)  (VP (VB encode)  (NP (NP (DT a)  (NN transactivator) ) (VP (VBN targeted)  (NP (-NONE- *) ) (PP (TO to)  (NP (DT the)  (JJ viral)  (NN LTR) ))))))) (, ,)  (CC and)  (S (NP-SBJ (NP (NNS cells) ) (VP (VBN infected)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (NP (NN Marek)  (POS 's) ) (NN disease)  (NN virus) ) (, ,)  (NP (NP (DT a)  (NN herpesvirus) ) (PP (IN with)  (NP (DT an)  (VBG overlapping)  (NN host)  (NN range) ))) (, ,) )))) (VP (VBP do)  (RB not)  (VP (VB express)  (NP (NP (NNS factors) ) (SBAR (WHNP-10 (WDT that) ) (S (NP-SBJ (-NONE- *T*-10) ) (ADVP (RB preferentially) ) (VP (VBP enhance)  (NP (NP (NN expression) ) (PP (IN from)  (NP-COOD (NP (NN REV) ) (CC or)  (NP (JJ avian) (NN  sarcoma/leukemia)  (NN virus)  (NNS LTRs) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN REV)  (NNS LTRs) ) (VP-COOD (VP (VBP work)  (ADVP (RB efficiently) ) (PP (IN in)  (NP (JJ human)  (JJ lymphoid)  (NNS cells) ))) (, ,)  (CC and)  (VP (VBP are)  (NP-PRD (NP (JJ viable)  (NNS alternatives) ) (PP (TO to)  (NP (NP (NNS promoters) ) (VP (ADVP (RB commonly) ) (VBN used)  (NP (-NONE- *) ) (PP (IN for)  (NP (NP (NN expression) ) (PP (IN of)  (NP (VBN cloned)  (NNS genes) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP They) ) (VP (MD may)  (ADVP (RB also) ) (VP (VB prove)  (ADJP-PRD (JJ useful) ) (PP (IN in)  (NP (NP (DT the)  (NN identification) ) (PP (IN of)  (NP (ADJP-COOD (ADJP (JJ new) ) (, ,)  (ADJP (JJ ubiquitous) )) (JJ cellular)  (NN transcription)  (NNS factors) )))))) (. .) ) )
(TOP (NP (NP (NP (JJ Natural)  (NNS variants) ) (PP (IN of)  (NP (DT the)  (NN HIV-1)  (JJ long)  (JJ terminal)  (NN repeat) )) (: :) ) (NP (NP (NN analysis) ) (PP (IN of)  (NP (NP (NNS promoters) ) (PP (IN with)  (NP (JJ duplicated)  (NN DNA)  (JJ regulatory)  (NNS motifs) )))) (. .) )) )
(TOP (S (NP-SBJ-1 (NP (NN Sequence)  (NN variation) ) (PP (IN in)  (NP (NP (DT the)  (NP (NP (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) )) (NN region) ) (PP (IN of)  (NP (NN HIV-1) ))))) (VP (VBD was)  (VP (VBN analyzed)  (NP (-NONE- *-1) ) (PP (IN in)  (NP (NP (JJ viral)  (NNS isolates) ) (PP (IN of)  (NP (CD 17)  (JJ infected)  (NNS individuals) )))))) (. .) ) )
(TOP (S (NP-SBJ-2 (NP (CD Two)  (NNS classes) ) (PP (IN of)  (NP (NN LTR)  (NN size)  (NNS variants) ))) (VP (VBD were)  (VP (VBN found)  (NP (-NONE- *-2) ))) (. .) ) )
(TOP (S (NP-SBJ-3 (CD One)  (NN HIV-1)  (NN variant) ) (VP (VBD was)  (VP (VBN detected)  (S-ADV (NP-SBJ (-NONE- *-3) ) (VP-4 (VBG containing)  (NP (NP (DT an)  (JJ additional)  (VBG binding)  (NN site) ) (PP (IN for)  (NP (DT the)  (NN transcription)  (NN factor)  (NN Sp1) ))))))) (. .) ) )
(TOP (S (NP-SBJ-5 (DT Another)  (NN LTR)  (NN size)  (NN variation) ) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-5) ) (PP (IN in)  (NP (CD four)  (NNS patients) )) (PP (IN in)  (NP (NP (DT a)  (NN region) ) (ADJP (RB just)  (JJ upstream)  (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN enhancer) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN variation) ) (VP (VBD was)  (NP-PRD (NP (DT the)  (NN result) ) (PP (IN of)  (NP (NP (DT a)  (NN duplication) ) (PP (IN of)  (NP (NP (DT a)  (JJ short)  (NN DNA)  (NN sequence) ) (PRN (-LRB- -LRB-)  (NP (NN CTG-motif) ) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Cell)  (NN culture)  (NNS experiments) ) (VP (VBD demonstrated)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (JJ natural)  (NN variant) ) (PP (IN with)  (NP (CD four)  (NN Sp1)  (NNS sites) ))) (VP (VBD had)  (NP (NP (DT a)  (ADJP (RB slightly)  (JJR higher) ) (NP-COOD (NP (NN promoter)  (NN activity) ) (CC and)  (NP (JJ viral)  (NN replication)  (NN rate) ))) (PP (IN than)  (NP (NP (DT the)  (JJ isogenic)  (NN control)  (NN LTR) ) (PP (IN with)  (NP (CD three)  (NN Sp1)  (NNS sites) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-6 (NP (DT No)  (JJ positive)  (NN effect) ) (PP (IN of)  (NP (DT the)  (JJ duplicated)  (NN CTG-motif) ))) (VP (MD could)  (VP (VB be)  (VP (VBN detected)  (NP (-NONE- *-6) )))) (. .) ) )
(TOP (S (SBAR-ADV (IN In)  (NN order)  (TO to)  (S (NP-SBJ (-NONE- *) ) (VP (VB measure)  (NP (NP (JJ small)  (NNS differences) ) (PP (IN in)  (NP (NN virus)  (NN production) ))) (ADVP (RBR more)  (RB accurately) )))) (, ,)  (NP-SBJ-7 (NP (JJ equal)  (NNS amounts) ) (PP (IN of)  (NP-COOD (NP (DT a)  (NN size)  (NN variant) ) (CC and)  (NP (DT the)  (JJ wild-type)  (NN plasmid) )))) (VP (VBD were)  (VP (VBN cotransfected)  (NP (-NONE- *-7) ) (PP (IN into)  (NP (NNS T-cells) )))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (DT The)  (NN virus) ) (PP (IN with)  (NP (CD four)  (NN Sp1)  (NNS sites) ))) (VP (VBD did)  (VP (VB outgrow)  (NP (DT the)  (CD three)  (NN Sp1)  (NN virus) ) (PP-TMP (IN in)  (NP (NP (CD 35)  (NNS days) ) (PP (IN of)  (NP (NN culture) ))))))) (CC and)  (S (NP-SBJ (NN CTG-monomer)  (NN virus) ) (VP (VBD outcompeted)  (NP (DT the)  (NN CTG-dimer)  (NN virus) ) (PP-TMP (IN in)  (NP (CD 42)  (NNS days) )))) (. .) ) )
(TOP (S (PP (VBN Based)  (PP (IN on)  (NP (DT these)  (NNS results) ))) (NP-SBJ (PRP we) ) (VP (VBP estimate)  (NP (NP (DT a)  (ADJP (QP (CD 5-10) ) (NN %) ) (NN difference) ) (PP (IN in)  (NP-8 (NP (NN virus)  (NN production) ) (PP (IN of)  (NP (DT the)  (NN LTR)  (NNS variants) ))))) (SBAR-TMP (WHADVP-10 (WRB when) ) (S (NP-SBJ-9 (-NONE- *) ) (VP (VBN compared)  (NP (-NONE- *-9) ) (PP (TO to)  (NP (NP (DT that) ) (PP (IN of)  (NP (NN wild-type) )))) (ADVP (-NONE- *T*-10) ))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NN SCL) ) (CC and)  (NP (JJ related)  (JJ hemopoietic)  (JJ helix-loop-helix)  (NN transcription)  (NNS factors) )) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (ADJP (ADJP (JJ helix-loop-helix) ) (PRN (-LRB- -LRB-)  (ADJP (JJ HLH) ) (-RRB- -RRB-) )) (NNS proteins) ) (VP (VBP are)  (NP-PRD (NP (DT a)  (NN family) ) (PP (IN of)  (NP (NP (NN transcription)  (NNS factors) ) (SBAR (WHNP-14 (WDT that) ) (S (NP-SBJ (-NONE- *T*-14) ) (VP (VBP include)  (NP (NP (NNS proteins) ) (ADJP (JJ critical)  (PP (TO to)  (NP (NP-COOD (NP (NN differentiation) ) (CC and)  (NP (NN development) )) (PP (IN in)  (NP (NP (NNS species) ) (VP (VBG ranging)  (PP-COOD (PP (IN from)  (NP (NNS plants) )) (PP (TO to)  (NP (NNS mammals) ))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-15 (NP (NP (CD Five)  (NNS members) ) (PP (IN of)  (NP (DT this)  (NN family) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN MYC) ) (, ,)  (NP (NN SCL) ) (, ,)  (NP (NN TAL-2) ) (, ,)  (NP (NN LYL-1) ) (CC and)  (NP (NN E2A) )) (-RRB- -RRB-) )) (VP (VBP are)  (VP (VBN implicated)  (NP (-NONE- *-15) ) (PP (IN in)  (NP (NP (JJ oncogenic)  (NNS events) ) (PP (IN in)  (NP (JJ human)  (JJ lymphoid)  (NNS tumors) )))) (PP (IN because)  (IN of)  (NP (NP (PRP$ their)  (JJ consistent)  (NN involvement) ) (PP (IN in)  (NP (JJ chromosomal)  (NNS translocations) )))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ-17 (-NONE- *) ) (VP (VBN activated)  (NP (-NONE- *-17) ) (PP (IN in)  (NP (NN T)  (NN cell)  (NNS leukemias) ))))) (, ,)  (NP-SBJ (NP (NN expression) ) (PP (IN of)  (NP-COOD (NP (NN SCL) ) (CC and)  (NP (NN LYL-1) )))) (VP (VBZ is)  (ADJP-PRD (ADJP-COOD (ADJP (JJ low) ) (CC or)  (ADJP (JJ undetectable) )) (PP (IN in)  (NP (JJ normal)  (NN T)  (NN cell)  (NNS populations) )))) (. .) ) )
(TOP (S (NP-SBJ-18 (NN SCL) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-18) ) (PP (IN in)  (NP (NP (UCP-COOD (ADJP (JJ erythroid) ) (, ,)  (NP (NN megakaryocyte) ) (CC and)  (NP (NN mast)  (NN cell) )) (NNS populations) ) (PRN (-LRB- -LRB-)  (NP (NP (DT the)  (JJ same)  (NN cell)  (NNS lineages) ) (PP (IN as)  (NP (NP (NN GATA-1) ) (, ,)  (NP (DT a)  (NN zinc-finger)  (NN transcription)  (NN factor) )))) (-RRB- -RRB-) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ-COOD-19 (CC both)  (NP (NN SCL) ) (CC and)  (NP (NN GATA-1) )) (VP (VP-COOD (VP (VBP undergo)  (NP (JJ coordinate)  (NN modulation) ) (PP-TMP (IN during)  (NP (NP (ADJP (RB chemically)  (VBN induced) ) (JJ erythroid)  (NN differentiation) ) (PP (IN of)  (NP (NN mouse)  (NN erythroleukemia)  (NNS cells) ))))) (CC and)  (VP (VBP are)  (VP (VBN down-modulated)  (NP-20 (-NONE- *-19) ) (PP-TMP (IN during)  (NP (NP (JJ myeloid)  (NN differentiation) ) (PP (IN of)  (NP (JJ human)  (NN K562)  (NNS cells) ))))))) (, ,)  (S (ADVP (RB thus) ) (NP-SBJ (-NONE- *-20) ) (VP (VBG implying)  (NP (NP (DT a)  (NN role) ) (PP (IN for)  (NP (NN SCL) )) (PP (IN in)  (NP (JJ erythroid)  (NN differentiation)  (NNS events) )))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (PP (IN in)  (NN contrast)  (TO to)  (NP (NN GATA-1) )) (, ,)  (NP-SBJ-21 (NN SCL) ) (VP (VBZ is)  (VP (VBN expressed)  (NP (-NONE- *-21) ) (PP (IN in)  (NP (DT the)  (VBG developing)  (NN brain) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Studies) ) (PP (IN of)  (NP (NP (DT the)  (NN function) ) (PP (IN of)  (NP (NN SCL) ))))) (VP (VBP suggest)  (SBAR (-NONE- 0)  (S (NP-SBJ (PRP it) ) (VP (VBZ is)  (ADJP-PRD (RB also)  (JJ important) ) (PP (IN in)  (NP (NP (UCP-COOD (NP (NN proliferation) ) (CC and)  (ADJP (JJ self-renewal) )) (NNS events) ) (PP (IN in)  (NP (JJ erythroid)  (NNS cells) )))))))) (. .) ) )
(TOP (NP (NP (NN Transcription) ) (PP (IN of)  (NP (DT the)  (JJ hypersensitive)  (NN site)  (NN HS2)  (NN enhancer) )) (PP (IN in)  (NP (JJ erythroid)  (NNS cells) )) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ human)  (NN genome) )) (, ,)  (NP-SBJ (DT the)  (JJ erythroid-specific)  (JJ hypersensitive)  (NN site)  (NN HS2)  (NN enhancer) ) (VP (VBZ regulates)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (NP (DT the)  (JJ downstream)  (JJ beta-like)  (NN globin)  (NNS genes) ) (ADVP (NP (QP (CD 10-50) ) (NNS kilobases) ) (RB away) ))))) (. .) ) )
(TOP (S (NP-SBJ-1 (NP (DT The)  (NN mechanism) ) (PP (IN of)  (NP (NN HS2)  (NN enhancer)  (NN function) ))) (VP (VBZ is)  (RB not)  (VP (VBN known)  (NP (-NONE- *-1) ))) (. .) ) )
(TOP (S (NP-SBJ-2 (DT The)  (JJ present)  (NN study) ) (VP (VBZ employs)  (NP (NN RNA)  (NN protection)  (NNS assays) ) (S (NP-SBJ (-NONE- *-2) ) (VP (TO to)  (VP (VB analyze)  (NP (NP (DT the)  (JJ transcriptional)  (NN status) ) (PP (IN of)  (NP (DT the)  (NN HS2)  (NN enhancer) )) (PP (IN in)  (NP (VBN transfected)  (JJ recombinant)  (NP (NP (NN chloramphenicol)  (NN acetyltransferase) ) (PRN (-LRB- -LRB-)  (NP (NN CAT) ) (-RRB- -RRB-) )) (NNS plasmids) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (JJ erythroid)  (NN K562)  (NNS cells) ) (SBAR (WHPP-3 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (DT the)  (NN HS2)  (NN enhancer) ) (VP (VBZ is)  (ADJP-PRD (JJ active) ) (PP (-NONE- *T*-3) )))))) (, ,)  (NP-SBJ (DT the)  (NN HS2)  (NN sequence) ) (VP (VBZ directs)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NP (JJ long)  (NN enhancer)  (NNS transcripts) ) (SBAR (WHNP-4 (WDT that) ) (S (NP-SBJ-5 (-NONE- *T*-4) ) (VP (VBP are)  (VP-COOD (VP (VBN initiated)  (NP (-NONE- *-5) ) (ADVP (RB apparently) ) (PP (IN from)  (PP (IN within)  (NP (DT the)  (NN enhancer) )))) (CC and)  (VP (VBN elongated)  (NP (-NONE- *-5) ) (PP (IN through)  (NP (DT the)  (VBG intervening)  (NN DNA) )) (PP (IN into)  (NP (DT the)  (JJ cis-linked)  (NN CAT)  (NN gene) ))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (JJ nonerythroid)  (NN HL-60)  (NNS cells) ) (SBAR (WHPP-7 (IN in)  (WHNP (WDT which) )) (S (NP-SBJ (DT the)  (NN HS2)  (NN enhancer) ) (VP (VBZ is)  (ADJP-PRD (JJ inactive) ) (PP (-NONE- *T*-7) )))))) (, ,)  (NP-SBJ (JJ long)  (NN enhancer)  (NNS transcripts) ) (VP (VBP are)  (RB not)  (ADJP-PRD (JJ detectable) )) (. .) ) )
(TOP (S (S-SBJ (NP-SBJ (-NONE- *) ) (VP (VBG Splitting)  (NP (DT the)  (NN HS2)  (NN enhancer) ) (PP (IN between)  (NP (CD two)  (JJ tandem)  (NN Ap1)  (NNS sites) )))) (VP-COOD (VP (VBZ abolishes)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NP (DT a)  (NN group) ) (PP (IN of)  (NP (JJ long)  (NN enhancer)  (NNS transcripts) )))))) (CC and)  (VP (VBZ results)  (PP (IN in)  (NP-COOD (NP (NP (NN loss) ) (PP (IN of)  (NP (NN enhancer)  (NN function) ))) (CC and)  (NP (NP (JJ transcriptional)  (NN silencing) ) (PP (IN of)  (NP (DT the)  (JJ cis-linked)  (NN CAT)  (NN gene) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (S (NP-SBJ (-NONE- *-8) ) (VP (VBG directing)  (NP (NP (DT the)  (NN synthesis) ) (PP (IN of)  (NP (NN RNA) ))) (PP (IN through)  (NP-COOD (NP (DT the)  (VBG intervening)  (NN DNA) ) (CC and)  (NP (DT the)  (NN gene) ))) (PP (IN by)  (NP (DT a)  (NP-COOD (NP (NN tracking) ) (CC and)  (NP (NN transcription) )) (NN mechanism) ))))) (, ,)  (NP-SBJ-8 (DT the)  (NN HS2)  (NN enhancer) ) (VP (MD may)  (VP-COOD (VP (LST (-LRB- -LRB-)  (LS i)  (-RRB- -RRB-) ) (VB open)  (PRT (RP up) ) (NP (NP (DT the)  (NN chromatin)  (NN structure) ) (PP (IN of)  (NP (DT a)  (NN gene)  (NN domain) )))) (CC and)  (VP (LST (-LRB- -LRB-)  (LS ii)  (-RRB- -RRB-) ) (VB deliver)  (NP (NN enhancer)  (NN binding)  (NNS proteins) ) (PP (TO to)  (NP (NP (DT the)  (NN promoter)  (NN sequence) ) (SBAR (WHADVP-9 (WRB where) ) (S (NP-SBJ (PRP they) ) (VP (MD may)  (VP (VB stimulate)  (NP (NP (DT the)  (NN transcription) ) (PP (IN of)  (NP (DT the)  (NN gene) ))) (PP (IN at)  (NP (DT the)  (NN cap)  (NN site) )) (ADVP (-NONE- *T*-9) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN Phorbol)  (NN ester) ) (VP (VP-COOD (VP (VBZ reduces)  (NP (JJ constitutive)  (JJ nuclear)  (NN NF)  (NN kappa)  (NN B) )) (CC and)  (VP (VBZ inhibits)  (NP (NN HIV-1)  (NN production) ))) (PP (IN in)  (NP (JJ mature)  (JJ human)  (JJ monocytic)  (NNS cells) ))) (. .) ) )
(TOP (S (NP-SBJ-1 (NN NF)  (NN kappa)  (NN B) ) (VP-COOD (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potent)  (NN mediator) ) (PP (IN of)  (NP (NP (JJ specific)  (NN gene)  (NN expression) ) (PP (IN in)  (NP (JJ human)  (NNS monocytes) )))))) (CC and)  (VP (VBZ has)  (VP (VBN been)  (VP (VBN shown)  (S (NP-SBJ (-NONE- *-1) ) (VP (TO to)  (VP (VB play)  (NP (DT a)  (NN role) ) (PP (IN in)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (NP (DT the)  (NN HIV-1)  (NN genome) ) (PP (IN in)  (NP (JJ promonocytic)  (NNS leukemias) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (EX There) ) (VP (VBZ is)  (NP-PRD (NP (JJ little)  (NN information) ) (ADJP (JJ available) ) (PP (IN on)  (NP (NP (DT the)  (NN response) ) (PP (IN of)  (NP (NN NF)  (NN kappa)  (NN B) )) (PP (TO to)  (NP (NNS cytokines) )) (PP (IN in)  (NP (JJ normal)  (JJ human)  (NNS monocytes) )))))) (. .) ) )
(TOP (S (NP-SBJ-2 (PRP We) ) (VP (VBP have)  (VP (VBN used)  (NP (NP (DT a)  (JJ 32P-labeled)  (NN oligonucleotide) ) (VP (VBN derived)  (NP (-NONE- *) ) (PP (IN from)  (NP (NP (NP (NP (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV-1) ) (-RRB- -RRB-) )) (JJ long)  (JJ terminal)  (NN repeat) ) (, ,)  (SBAR (WHNP-3 (WDT which) ) (S (NP-SBJ (-NONE- *T*-3) ) (VP (VBZ contains)  (NP (NP (DT a)  (JJ tandem)  (NN repeat) ) (PP (IN of)  (NP (DT the)  (NN NF)  (NN kappa)  (NN B)  (NN binding)  (NN sequence) )))))) (, ,) )))) (PP (IN as)  (NP (DT a)  (NN probe) )) (PP (IN in)  (NP (DT a)  (NN gel)  (NN retardation)  (NN assay) ))) (S (NP-SBJ (-NONE- *-2) ) (VP (TO to)  (VP (VB study)  (NP (DT this)  (NN transcription)  (NN factor) ))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-4) ) (VP (VBG Using)  (NP (DT this)  (NN assay) ))) (, ,)  (NP-SBJ-4 (PRP we) ) (VP (VBP have)  (VP (VBN detected)  (NP (NN NF)  (NN kappa)  (NN B) ) (PP (IN in)  (NP (NP (NNS extracts) ) (PP (IN of)  (NP (NP (NNS nuclei) ) (PP (IN from)  (NP (JJ normal)  (JJ human)  (NNS monocytes) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Treatment) ) (PP (IN of)  (NP (JJ normal)  (NNS monocytes) )) (PP (IN with)  (NP (NP (JJ 12-0-tetradecanoyl)  (NN phorbol-13-acetate) ) (PRN (-LRB- -LRB-)  (NP (NN TPA) ) (-RRB- -RRB-) ))) (PP-TMP (IN for)  (NP (QP (CD 4-24) ) (NN h) ))) (VP (VBD caused)  (NP (NP (DT the)  (JJ complete)  (NN disappearance) ) (PP (IN of)  (NP (NN NF)  (NN kappa)  (NN B) )) (PP (IN from)  (NP (NP (JJ nuclear)  (NNS extracts) ) (PP (IN of)  (NP (NNS monocytes) )))))) (. .) ) )
(TOP (S (NP-SBJ-5 (DT A)  (JJ similar)  (NN result) ) (VP (VBD was)  (VP (VBN obtained)  (NP (-NONE- *-5) ) (PP (IN with)  (NP (DT the)  (JJ mature)  (JJ monocytic)  (NN leukemia)  (NN cell)  (NN line)  (NN THP-1) )))) (. .) ) )
(TOP (S (NP-SBJ-6 (DT The)  (JJ constitutive)  (NN transcription)  (NN factor)  (NN SP1) ) (VP (VBD was)  (VP (JJ unaffected)  (NP (-NONE- *-6) ) (PP (IN by)  (NP-LGS (NP (NN addition) ) (PP (IN of)  (NP (NN TPA) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN disappearance) ) (PP (IN of)  (NP (NN NF)  (NN kappa)  (NN B) )) (PP (IN from)  (NP (DT the)  (NN nucleus) ))) (VP (VBD was)  (ADJP-PRD (NP (NN concentration) ) (JJ dependent) ) (PP (IN between)  (NP (NP (QP (CD 10)  (CC and)  (CD 50) ) (NN ng/ml) ) (PP (IN of)  (NP (NN phorbol)  (NN ester) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN THP-1)  (NNS cells) )) (, ,)  (NP-SBJ (NN TPA) ) (ADVP (RB also) ) (VP (VBD induced)  (NP (NP (DT a)  (ADJP-COOD (ADJP (JJ new) ) (, ,)  (ADJP (JJ faster-migrating) )) (NN NF)  (NN kappa)  (NN B)  (NNS species) ) (VP (RB not)  (VBN induced)  (NP (-NONE- *) ) (PP (IN in)  (NP (NNS monocytes) ))))) (. .) ) )
(TOP (S (NP-SBJ-COOD (NP (NN Protein)  (NN kinase)  (NN C)  (NN inhibitor)  (NN staurosporine) ) (, ,)  (CONJP (CC but)  (RB not) ) (NP (ADJP (JJ cyclic)  (JJ nucleotide-dependent) ) (NN protein)  (NN kinase)  (NN inhibitor)  (NN HA-1004) ) (, ,) ) (ADVP (RB also) ) (ADVP (RB dramatically) ) (VP (VBD reduced)  (NP (NP (JJ constitutive)  (NNS levels) ) (PP (IN of)  (NP (JJ nuclear)  (NN NF)  (NN kappa)  (NN B) )))) (. .) ) )
(TOP (S (ADVP (RB Finally) ) (, ,)  (NP-SBJ (NP (NN TPA)  (NN addition) ) (PP (TO to)  (NP (NP (NNS monocytes) ) (VP (VBN infected)  (NP (-NONE- *) ) (PP (IN with)  (NP (NN HIV-1) )))))) (VP (VBD inhibited)  (NP (NN HIV-1)  (NN replication) ) (, ,)  (SBAR (IN as)  (S (NP-SBJ-8 (-NONE- *) ) (VP (VBN determined)  (NP (-NONE- *-8) ) (PP (IN by)  (NP (JJ reverse)  (NN transcriptase)  (NNS assays) ))))) (, ,)  (PP (IN in)  (NP (DT a)  (JJ concentration-dependent)  (NN manner) ))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP-COOD (VP (VBP are)  (PP (IN in)  (NP (NP (JJ striking)  (NN contrast) ) (PP (TO to)  (NP (NP (DT the)  (NN increase) ) (PP (IN in)  (NP (NP-COOD (NP (JJ nuclear)  (NN NF)  (NN kappa)  (NN B) ) (CC and)  (NP (NN HIV-1)  (NN replication) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN phorbol)  (NNS esters) )) (PP (IN in)  (NP (JJ promonocytic)  (NN leukemia)  (NNS cells)  (NP-COOD (NP (NN U937) ) (CC and)  (NP (NN HL-60) )))))))))))) (, ,)  (CC and)  (VP (VBP emphasize)  (NP (NP (DT the)  (NN importance) ) (PP (IN of)  (S (NP-SBJ (-NONE- *) ) (VP (VBG studying)  (NP (NP (NN cytokine)  (NN regulation) ) (PP (IN of)  (NP (NN HIV-1) )) (PP (IN in)  (NP (JJ normal)  (NNS monocytes) ))))))))) (. .) ) )
(TOP (NP (NP (NP (NN Ablation) ) (PP (IN of)  (NP (NP (VBN transplanted)  (ADJP (NN HTLV-I)  (JJ Tax-transformed) ) (NNS tumors) ) (PP (IN in)  (NP (NNS mice) )))) (PP (IN by)  (NP (NP (JJ antisense)  (NN inhibition) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) ))))) (S (-LRB- -LCB-)  (NP-SBJ (VBN published)  (NN erratum) ) (VP (VBZ appears)  (PP (IN in)  (NP (NNP Science)  (CD 1993)  (NNP Mar)  (CD 12)  (: ;)  (CD 259)  (-LRB- -LRB-)  (CD 5101)  (-RRB- -RRB-)  (: :)  (CD 1523) ))) (-RRB- -RCB-) )) )
(TOP (S (NP-SBJ (NP (NNS Mice) ) (ADJP (JJ transgenic)  (PP (IN for)  (NP (DT the)  (NP (NP (JJ human)  (NN T)  (NN cell)  (NN leukemia)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HTLV-I) ) (-RRB- -RRB-) )) (NN Tax)  (NN gene) )))) (VP (VBP develop)  (NP (NP (JJ fibroblastic)  (NNS tumors) ) (SBAR (WHNP-1 (WDT that) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBP express)  (NP (ADJP (NN NF-kappa)  (JJ B-inducible) ) (JJ early)  (NNS genes) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (ADJP (FW In)  (FW vitro) ) (NN inhibition) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN expression) )) (PP (IN by)  (NP (JJ antisense)  (NP (NP (NNS oligodeoxynucleotides) ) (PRN (-LRB- -LRB-)  (NP (NNS ODNs) ) (-RRB- -RRB-) ))))) (VP (VBD inhibited)  (NP (NP (NN growth) ) (PP (IN of)  (NP-COOD (NP (DT these)  (JJ culture-adapted)  (JJ Tax-transformed)  (NNS fibroblasts) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (DT an)  (JJ HTLV-I-transformed)  (JJ human)  (NN lymphocyte)  (NN line) ))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ (NP (JJ antisense)  (NN inhibition) ) (PP (IN of)  (NP (NP (NN Tax) ) (NP (PRP itself) )))) (VP (VBD had)  (NP (DT no)  (JJ apparent)  (NN effect) ) (PP (IN on)  (NP (NN cell)  (NN growth) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Mice) ) (VP (VBN treated)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (NN antisense) ) (PP (TO to)  (NP (NN NF-kappa)  (NN B)  (NNS ODNs) )))))) (VP (VBD showed)  (NP (NP (JJ rapid)  (NN regression) ) (PP (IN of)  (NP (VBN transplanted)  (NNS fibrosarcomas) )))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP-COOD (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ (NN NF-kappa)  (NN B)  (NN expression) ) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ necessary)  (PP (IN for)  (NP (NP (DT the)  (NN maintenance) ) (PP (IN of)  (NP (DT the)  (JJ malignant)  (NN phenotype) )))))))))) (CC and)  (VP (VBZ provides)  (NP (NP (DT a)  (JJ therapeutic)  (NN approach) ) (PP (IN for)  (NP (JJ HTLV-I-associated)  (NN disease) ))))) (. .) ) )
(TOP (NP (NP (NN Inhibition) ) (PP (IN of)  (NP (ADJP (JJ anti-CD3)  (JJ monoclonal)  (JJ antibody-induced) ) (NN T-cell)  (NN proliferation) )) (PP (IN by)  (NP (NP-COOD (NP (NN dexamethasone) ) (, ,)  (NP (NN isoproterenol) ) (, ,)  (CC or)  (NP (NN prostaglandin)  (NN E2) )) (UCP-COOD (CC either)  (ADVP (RB alone) ) (CC or)  (PP (IN in)  (NP (NN combination) ))))) (. .) ) )
(TOP (S (LST (LS 1)  (. .) ) (NP-SBJ (NP (DT The)  (NN purpose) ) (PP (IN of)  (NP (DT these)  (NNS studies) ))) (VP (VBD was)  (S-PRD (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB investigate)  (NP (NP (DT the)  (NN modulation) ) (PP (IN of)  (NP (NP (DT the)  (NN proliferation) ) (PP (IN of)  (NP (NP (JJ human)  (NN T)  (NNS cells) ) (VP (VBN obtained)  (NP (-NONE- *) ) (PP (IN from)  (NP (JJ peripheral)  (NN blood) ))))))) (PP (IN by)  (NP-COOD (NP (NP (NN dexamethasone) ) (PRN (-LRB- -LRB-)  (NP (NN DEX) ) (-RRB- -RRB-) )) (, ,)  (NP (NP (NN isoproterenol) ) (PRN (-LRB- -LRB-)  (NP (NN ISO) ) (-RRB- -RRB-) )) (, ,)  (CC and)  (NP (NP (NN prostaglandin)  (NN E2) ) (PRN (-LRB- -LRB-)  (NP (NN PGE2) ) (-RRB- -RRB-) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (JJ former)  (CD two)  (NNS substances) ) (VP (VBP interact)  (PP (IN with)  (NP (NN T)  (NNS cells) )) (PP (IN via)  (NP (DT the)  (UCP-COOD (NP (NN glucocorticoid) ) (CC and)  (ADJP (JJ beta-adrenergic) )) (NNS receptors) )) (ADVP (RB respectively) )) (. .) ) )
(TOP (S (SBAR-TMP (WHADVP-11 (WRB When) ) (S (NP-SBJ-13 (-NONE- *-12) ) (VP (VBN occupied)  (NP-14 (-NONE- *-13) ) (PP (IN by)  (NP-LGS (NP (PRP$ their)  (JJ natural)  (NNS ligands) ) (, ,)  (NP-COOD (NP (NNS glucocorticosteroids) ) (CC and)  (NP (NNS catecholamines) ))) (ADVP (-NONE- *T*-11) ))))) (, ,)  (NP-SBJ-12 (DT these)  (NNS receptors) ) (VP (VBP have)  (NP (DT a)  (NN role) ) (PP (IN in)  (S (NP-SBJ (-NONE- *-14) ) (VP (VBG modulating)  (NP (NN T-cell)  (NN function) ) (PP-TMP (IN during)  (NP (NN stress) )))))) (. .) ) )
(TOP (S (PP-TMP (IN During)  (NP (DT the)  (JJ inflammatory)  (NN response) )) (NP-SBJ (NP (VBN increased)  (NNS levels) ) (PP (IN of)  (NP (NN PGE2) ))) (VP-COOD (VP (VBP bind)  (PP (TO to)  (NP (NP (PRP$ their)  (NNS receptors) ) (PP (IN on)  (NP (NN T)  (NNS cells) ))))) (CC and)  (RB thus)  (VP (VBP alter)  (NP (NN responsiveness) ))) (. .) ) )
(TOP (S (NP-SBJ-15 (NP (NN Proliferation) ) (PP (IN of)  (NP (NN T)  (NNS cells) ))) (VP (VBD was)  (VP (VBN induced)  (NP (-NONE- *-15) ) (PP (IN by)  (NP-LGS (VBN immobilized)  (JJ anti-CD3)  (NP (NP (JJ monoclonal)  (NN antibody) ) (PRN (-LRB- -LRB-)  (NP (NN mAb) ) (-RRB- -RRB-) )))) (PP (IN in)  (NP (NP (DT the)  (NP-COOD (NP (NN presence) ) (CC or)  (NP (NN absence) ))) (PP (IN of)  (NP (NP (DT an)  (JJ additional)  (JJ costimulatory)  (NN signal) ) (VP (VBN delivered)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (JJ anti-CD28)  (NN mAb) ))))))))) (. .) ) )
(TOP (S (LST (LS 2)  (. .) ) (S-COOD (S (NP-SBJ-16 (NP (JJ Various)  (JJ physiologic)  (NNS concentrations) ) (PP (IN of)  (NP-COOD (NP (NN DEX) ) (, ,)  (NP (NN ISO) ) (, ,)  (CC or)  (NP (NN PGE2) )))) (VP (VBD were)  (VP (VBN added)  (NP (-NONE- *-16) ) (PP-TMP (IN at)  (NP (NP (DT the)  (NN time) ) (PP (IN of)  (NP (NP (NN initiation) ) (PP (IN of)  (NP (DT the)  (NNS cultures) ))))))))) (CC and)  (S (NP-SBJ-17 (NP (JJ subsequent)  (NN proliferation) ) (PP (IN of)  (NP (DT the)  (JJ unstimulated)  (NN T)  (NNS cells) ))) (VP (VBD was)  (VP (VBN determined)  (NP (-NONE- *-17) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NP (JJ physiologic)  (NNS concentrations) ) (PP (IN of)  (NP (NP (DT all)  (CD three) ) (PP (IN of)  (NP (DT these)  (NNS agents) ))))) (VP (VBP inhibit)  (NP (NP (DT the)  (ADJP (JJ anti-CD3)  (JJ mAb-induced) ) (NN proliferation) ) (PP (IN of)  (NP (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (S (LST (LS 3)  (. .) ) (SBAR-ADV (IN Although)  (S (NP-SBJ-COOD-18 (NP (NN DEX) ) (CC and)  (NP (NN PGE2) )) (VP (VBD were)  (ADJP-PRD (JJ equipotent) ) (PP (IN in)  (S (NP-SBJ (-NONE- *-18) ) (VP (JJ suppressing)  (NP (NN T-cell)  (NN proliferation) ))))))) (, ,)  (NP-SBJ (NN ISO) ) (VP (VBD was)  (ADJP-PRD (ADVP (RB much)  (RBR less) ) (JJ effective) )) (. .) ) )
(TOP (S (LST (LS 4)  (. .) ) (SBAR-ADV (IN Because)  (S (NP-SBJ (NP (JJ concomitant)  (NNS elevations) ) (PP (IN in)  (NP (NP (DT the)  (JJ peripheral)  (NNS levels) ) (PP (IN of)  (NP (DT these)  (NNS substances) ))))) (VP (MD may)  (VP (VB occur) )))) (, ,)  (NP-SBJ-19 (NNS experiments) ) (VP (VBD were)  (VP (VBN performed)  (NP (-NONE- *-19) ) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB determine)  (NP (NP (DT the)  (NN T-cell)  (JJ inhibitory)  (NNS effects) ) (PP (IN of)  (NP (NN DEX) )) (PP (RB together)  (IN with)  (NP-COOD (CC either)  (NP (NN PGE2) ) (CC or)  (NP (NN ISO) ))))))))) (. .) ) )
(TOP (S (NP-SBJ-20 (NP (JJ Synergistic)  (NN suppression) ) (PP (IN of)  (NP (NN T-cell)  (NN proliferation) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-20) ) (SBAR-TMP (WHADVP-21 (WRB when) ) (S (NP-SBJ-22 (NP (JJ various)  (NNS concentrations) ) (PP (IN of)  (NP-COOD (NP-COOD (NP (NN DEX) ) (CC and)  (NP (NN PGE2) )) (, ,)  (CONJP (CC but)  (RB not) ) (NP-COOD (NP (NN DEX) ) (CC and)  (NP (NN ISO) )) (, ,) ))) (VP (VBD were)  (VP (VBN added)  (NP (-NONE- *-22) ) (PP (TO to)  (NP (NNS cultures) )) (ADVP (-NONE- *T*-21) ))))))) (. .) ) )
(TOP (S (NP-SBJ-23 (DT This)  (JJ synergistic)  (NN suppression) ) (VP (MD could)  (RB not)  (VP (VB be)  (VP (VBN explained)  (NP (-NONE- *-23) ) (PP (IN by)  (NP-LGS (NP (DT an)  (NN increase) ) (PP (IN in)  (NP (NP (NN cAMP)  (NN accumulation) ) (PP (IN in)  (NP (NP (NN T)  (NNS cells) ) (VP (VBN stimulated)  (NP (-NONE- *) ) (PP (IN with)  (NP-COOD (NP (NN DEX) ) (CC and)  (NP (NN PGE2) ))))))))))))) (. .) ) )
(TOP (S (LST (LS 5)  (. .) ) (ADVP (RB Finally) ) (, ,)  (NP-SBJ (NP (DT the)  (NN addition) ) (PP (IN of)  (NP (JJ anti-CD28)  (NN mAb) )) (PP (TO to)  (NP (ADJP (JJ anti-CD3)  (JJ mAb-stimulated) ) (NN T)  (NNS cells) ))) (VP (VBD overcame)  (NP (NP (JJ much) ) (PP (IN of)  (NP (NP (DT the)  (NN suppression) ) (PP (IN of)  (NP (NN proliferation) )) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (NN PGE2) ) (CC or)  (NP (NN ISO) ))))))) (CC but)  (ADVP (ADVP (RBR less)  (RB so) ) (PP (IN than)  (NP (NP (DT that) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN DEX) ))))))) (. .) ) )
(TOP (NP (NP (VBN Targeted)  (NN degradation) ) (PP (IN of)  (NP-COOD (NP (NN c-Fos) ) (, ,)  (CONJP (CC but)  (RB not) ) (NP (NN v-Fos) ) (, ,) )) (PP (IN by)  (NP (NP (DT a)  (JJ phosphorylation-dependent)  (NN signal) ) (PP (IN on)  (NP (NN c-Jun) )))) (. .) ) )
(TOP (S (NP-SBJ-1 (DT The)  (NN proto-oncogene)  (NNS products)  (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN c-Jun) ))) (VP (VBP heterodimerize)  (PP (IN through)  (NP (PRP$ their)  (NN leucine)  (NNS zippers) )) (S (NP-SBJ (-NONE- *-1) ) (VP (TO to)  (VP (VB form)  (NP (DT the)  (NN AP-1)  (NN transcription)  (NN factor) ))))) (. .) ) )
(TOP (S (NP-SBJ-2 (NP (DT The)  (JJ transcriptional)  (NN activity) ) (PP (IN of)  (NP (DT the)  (NN heterodimer) ))) (VP (VBZ is)  (VP (VBN regulated)  (NP (-NONE- *-2) ) (PP (IN by)  (NP-LGS (JJ signal-dependent)  (NP-COOD (NP (NN phosphorylation) ) (CC and)  (NP (NN dephosphorylation) )) (NNS events) )))) (. .) ) )
(TOP (S (NP-SBJ-3 (NP (DT The)  (NN stability) ) (PP (IN of)  (NP (NN c-Fos) ))) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ-4 (-NONE- *-3) ) (VP (TO to)  (ADVP (RB also) ) (VP (VB be)  (VP (VBN controlled)  (NP (-NONE- *-4) ) (PP (IN by)  (NP-LGS (JJ intracellular)  (NN signal)  (NN transduction) )))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP-COOD (NP (JJ transient)  (NN expression) ) (CC and)  (NP (ADJP (FW in)  (FW vitro) ) (NN degradation) )) (NNS experiments) )) (, ,)  (NP-SBJ-5 (NP (DT the)  (NN stability) ) (PP (IN of)  (NP (NN c-Fos) ))) (VP (VBD was)  (VP (VBN decreased)  (NP (-NONE- *-5) ) (SBAR-TMP (WHADVP-6 (WRB when) ) (S (NP-SBJ-7 (DT the)  (NN protein) ) (VP (VBD was)  (VP (JJ dimerized)  (NP (-NONE- *-7) ) (PP (IN with)  (NP (VBN phosphorylated)  (NN c-Jun) )) (ADVP (-NONE- *T*-6) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN c-Jun)  (NN protein) ) (VP (VBN isolated)  (NP (-NONE- *) ) (PP (IN from)  (NP (ADJP (NN phorbol)  (JJ ester-induced) ) (NNS cells) )))) (VP (VP (VBD did)  (RB not)  (VP (VB target)  (NP (NN c-Fos) ) (PP (IN for)  (NP (NN degradation) )))) (, ,)  (SBAR (WHNP-8 (WDT which) ) (S (NP-SBJ (-NONE- *T*-8) ) (VP (VBZ suggests)  (SBAR (IN that)  (S (NP-SBJ-9 (NN c-Fos) ) (VP (VBZ is)  (ADVP-TMP (RB transiently) ) (VP (VBN stabilized)  (NP (-NONE- *-9) ) (PP-TMP (IN after)  (NP (NP (NN stimulation) ) (PP (IN of)  (NP (NN cell)  (NN growth) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN v-Fos)  (NN protein) ) (, ,)  (NP (NP (DT the)  (JJ retroviral)  (NN counterpart) ) (PP (IN of)  (NP (NN c-Fos) ))) (, ,) ) (VP (VBD was)  (RB not)  (ADJP-PRD (JJ susceptible)  (PP (TO to)  (NP (NP (NN degradation) ) (VP (VBN targeted)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN c-Jun) ))))))) (. .) ) )
(TOP (NP (NP (NNS Mutations) ) (PP (IN in)  (NP (NP (DT the)  (NN Pit-1)  (NN gene) ) (PP (IN in)  (NP (NP (NNS children) ) (PP (IN with)  (NP (JJ combined)  (JJ pituitary)  (NN hormone)  (NN deficiency) )))))) (. .) ) )
(TOP (S (NP-SBJ (NN Pit-1) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ pituitary-specific)  (NN transcription)  (NN factor) ) (SBAR (WHNP-1 (WDT that) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VP-COOD (VP (VBZ binds)  (PP (TO to)  (NP (-NONE- *RNR*-2) ))) (CC and)  (VP (VBZ transactivates)  (NP (-NONE- *RNR*-2) ))) (NP-COOD-2 (NP (NNS promoters)  (PP (IN of)  (NP (NN growth)  (NN hormone) ))) (CC and)  (NP (NN prolactin)  (NNS genes) ))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NP (CD three)  (JJ unrelated)  (JJ Japanese)  (NNS children) ) (PP (IN with)  (NP (JJ combined)  (JJ pituitary)  (NN hormone)  (NN deficiency) )))) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD identified)  (NP (NP (NP (NP (CD three)  (NN point)  (NNS mutations) ) (PP (IN in)  (NP (DT the)  (NN Pit-1)  (NN gene) ))) (, ,)  (NP-COOD (NP (NN Pro24Leu) ) (, ,)  (NP (NN Arg143Gln) ) (, ,)  (CC and)  (NP (NN Arg271Trp) )) (, ,) ) (ADJP (JJ located)  (PP (IN on)  (NP (NP (DT the)  (JJ major)  (NN transactivation)  (NN region) ) (, ,)  (NP-COOD (NP (JJ POU-specific)  (NN domain) ) (, ,)  (CC and)  (NP (NN POU-homeodomain) )) (, ,) )) (ADVP (RB respectively) )))) (. .) ) )
(TOP (NP (NP (NN Calcitriol)  (: :) ) (FRAG (NP (DT a)  (NN hematolymphopoietrope) ) (. ?) ) (FRAG (-LRB- -LCB-)  (NP (NN editorial) ) (-RRB- -RCB-) )) )
(TOP (S (NP-SBJ-86 (NP (DT A)  (NN MEDLINE)  (NN search) ) (PP (IN of)  (NP (DT the)  (JJ English-language)  (NN literature) ))) (VP (VBD was)  (VP (VBN conducted)  (NP (-NONE- *-86) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (NP (DT the)  (NN indexing)  (NNS terms) ) (PRN (`` ')  (NP-COOD (NP (NN immunology) ) (, ,)  (NP (NN calcitriol) ) (CC and)  (NP (NN vitamin)  (NN D) )) ('' ') )))) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB identify)  (NP (NP (NNS studies) ) (VP (VBG indicating)  (NP (NP (DT a)  (NN role) ) (PP (IN for)  (NP (NN calcitriol) )) (PP (IN as)  (NP (DT a)  (JJ primary)  (NN immunomodulator) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-87 (NP (CD Sixty-six)  (NNS papers) ) (VP (VBN published)  (PP-TMP (IN between)  (NP-COOD (NP (NNP January)  (CD 1956) ) (CC and)  (NP (NNP June)  (CD 1991) ))))) (VP (VBD were)  (VP (VBN identified)  (NP (-NONE- *-87) ))) (. .) ) )
(TOP (S (NP-SBJ-88 (NP (CD Forty-five) ) (PP (IN of)  (NP (DT these)  (NNS reports) ))) (VP (VBP are)  (VP (VBN cited)  (NP (-NONE- *-88) ) (PP (IN in)  (NP (DT this)  (NN review) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS data) ) (ADVP (RB strongly) ) (VP (VBP suggest)  (NP (NP (NP (DT an)  (ADJP-COOD (ADJP (NN endocrine) ) (, ,)  (ADJP (NN autocrine) ) (CC and/or)  (ADJP (NN paracrine) )) (NN role) ) (PP (IN for)  (NP (NN calcitriol) ))) (PP (IN in)  (NP (JJ immune)  (NN regulation) )))) (. .) ) )
(TOP (S (NP-SBJ (NP-89 (DT No)  (JJ unifying)  (NN hypothesis) ) (S (-NONE- *ICH*-90) )) (VP (VBZ has)  (ADVP (RB yet) ) (VP (VBN emerged)  (S-90 (NP-SBJ (-NONE- *-89) ) (VP (VBG explaining)  (NP (NP (DT this)  (NN collection) ) (PP (IN of)  (NP (NNS data) ))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN paper) ) (VP (VBZ provides)  (NP (NP (DT a)  (JJ brief)  (NN review) ) (PP (IN of)  (NP (NP (JJ immune)  (NNS properties) ) (VP (ADVP-TMP (RB currently) ) (VBN attributed)  (NP (-NONE- *) ) (PP (TO to)  (NP (NN calcitriol) ))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD-3 (NP (NP (NN Activation) ) (PP (IN of)  (NP (NN protein)  (NN kinase)  (NN C) ))) (CC and)  (NP (NP (NN elevation) ) (PP (IN of)  (NP (NN cAMP) )))) (VP (VBP interact)  (ADVP (RB synergistically) ) (S (NP-SBJ (-NONE- *-3) ) (VP (TO to)  (VP (VB raise)  (NP (NP (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN AP-1) )) (NN activity) ) (PP (IN in)  (NP (NN Jurkat)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-TMP (RBR earlier) ) (VP (VBN found)  (SBAR (IN that)  (S (PP (IN in)  (NP (NN Jurkat)  (NNS cells) )) (NP-SBJ (NP (NN activation) ) (PP (IN of)  (NP (NP (NN protein)  (NN kinase)  (NN C) ) (PRN (-LRB- -LRB-)  (NP (NN PKC) ) (-RRB- -RRB-) )))) (VP (VBZ enhances)  (NP (NP (DT the)  (NP (NP (JJ cyclic)  (NN adenosine)  (NN monophosphate) ) (PRN (-LRB- -LRB-)  (NP (NN cAMP) ) (-RRB- -RRB-) )) (NN accumulation) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS-COOD (NP (NN adenosine)  (NN receptor)  (NN stimulation) ) (CC or)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NN Gs) )))))))))))) (. .) ) )
(TOP (S (ADVP (RB Here) ) (NP-SBJ (PRP we) ) (VP (VBP have)  (ADVP (RB therefore) ) (VP (VBN examined)  (NP (NP (DT the)  (NN effect) ) (PP (IN of)  (NP (NP (DT the)  (NN phorbol)  (NN ester)  (NP (NP (NN PMA) ) (PRN (-LRB- -LRB-)  (NP (NN phorbol)  (NN 12-myristate)  (NN 13-acetate) ) (-RRB- -RRB-) ))) (SBAR (WHNP-4 (WDT which) ) (S (NP-SBJ (-NONE- *T*-4) ) (VP (VBZ stimulates)  (S (NP-SBJ-COOD (NP (NN PKC) ) (CC and)  (NP (NP (DT a)  (NN combination) ) (PP (IN of)  (NP-COOD (NP (DT the)  (NN adenosine)  (NN receptor)  (NN agonist)  (NP (NP (NN NECA) ) (PRN (-LRB- -LRB-)  (NP (JJ 5'--LRB-N-ethyl-RRB--carboxamido)  (NN adenosine) ) (-RRB- -RRB-) ))) (CC and)  (NP (NN forskolin) ))))) (VP (TO to)  (VP (VB raise)  (NP (NN cAMP) ))))))))) (, ,)  (PP-COOD (PP (IN on)  (NP (NP (DT the)  (NNS levels) ) (PP (IN of)  (NP-COOD (NP (NN c-Fos) ) (CC and)  (NP (NN Jun) ))))) (CC and)  (PP (IN on)  (NP (NP (DT the)  (NP-COOD (NP (VBG binding) ) (CC and)  (NP (JJ transcriptional)  (NN activity) ))) (PP (IN of)  (NP (NP (DT the)  (NN transcription)  (NN factor) ) (, ,)  (NP (NP (NN activator)  (NN protein-1) ) (PRN (-LRB- -LRB-)  (NP (NN AP-1) ) (-RRB- -RRB-) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NN PMA)  (NN treatment) ) (VP (VBD caused)  (NP (NP (DT a)  (ADJP-COOD (ADJP (NP (NN concentration-) ) (ADJP (-NONE- *?*) )) (CC and)  (ADJP (JJ time-dependent) )) (NN increase) ) (PP (IN in)  (NP (NP-COOD (CC both)  (NP (NN c-Fos) ) (CC and)  (NP (NN Jun) )) (NN immunoreactivity) ))) (PP (IN in)  (NN contrast)  (TO to)  (NP (NP (NN cAMP)  (NN elevation) ) (SBAR (WHNP-5 (WDT that) ) (S (NP-SBJ (-NONE- *T*-5) ) (VP (VBD had)  (NP (RB only)  (DT a)  (JJ slight)  (NN effect) ))))))) (. .) ) )
(TOP (S (NP-SBJ-COOD-6 (CC Both)  (NP (NN PMA) ) (CC and)  (NP (NP (DT the)  (NN combination) ) (PP (IN of)  (NP-COOD (NP (NN NECA) ) (CC and)  (NP (NN forskolin) ))))) (VP (VBD acted)  (ADVP (RB together) ) (S (NP-SBJ-7 (-NONE- *-6) ) (VP (CC either)  (VP (TO to)  (VP (VP-COOD (VP (VB increase)  (NP (-LRB- -LRB-)  (NP (NN c-Fos) ) (-RRB- -RRB-)  (NP (-NONE- *RNR*-8) ))) (CC or)  (VP (VB decrease)  (NP (-LRB- -LRB-)  (NP (NN Jun) ) (-RRB- -RRB-)  (NP (-NONE- *RNR*-8) )))) (NP-8 (NN protein)  (NNS levels) ) (PP (RB as)  (RB well)  (IN as)  (S (NP-SBJ (-NONE- *-7) ) (VP (VP (VBG increasing)  (NP-101 (NN AP-1)  (NN binding) ) (, ,)  (SBAR (IN as)  (S (NP-SBJ-9 (-NONE- *) ) (VP (VBN judged)  (NP (-NONE- *-9) ) (PP (IN by)  (NP-LGS (NN gel-shift)  (NN assay) ))))) (, ,) ) (CC and)  (VP (NP=101 (NN AP-1)  (JJ transcriptional)  (NN activity) )))))))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (NP-SBJ (EX there) ) (VP (VBD was)  (NP-PRD (DT a)  (JJ clear-cut)  (NN synergy) ) (PP (IN between)  (NP-COOD (NP (DT the)  (NN PKC)  (NN stimulator) ) (CC and)  (NP (DT the)  (NN cAMP)  (NN elevating)  (NNS agents) )))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NNS results) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (DT the)  (JJ simultaneous)  (NP-COOD (NP (NP (NN activation) ) (PP (IN of)  (NP (NN PKC) ))) (CC and)  (NP (NP (NN elevation) ) (PP (IN of)  (NP (NN cAMP) ))))) (VP (VBZ leads)  (PP (TO to)  (NP (NP (DT an)  (VBN enhanced)  (NN AP-1)  (JJ transcriptional)  (NN activity) ) (PP (IN in)  (NP (DT a)  (NN T-leukemia)  (NN cell)  (NN line) )))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG suggesting)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (ADJP (RB previously)  (VBN observed) ) (NN interaction) ) (PP (IN between)  (NP (DT the)  (JJ parallel)  (NN signal)  (NN transduction)  (NNS pathways) ))) (VP (MD may)  (VP (VB have)  (NP (JJ functional)  (NNS consequences) ) (PP (IN at)  (NP (NP (DT the)  (NN level) ) (PP (IN of)  (NP (NN gene)  (NN transcription) )))))))))))))) (. .) ) )
(TOP (NP (NP (DT The)  (NN use) ) (PP (IN of)  (NP (JJ interferon-gamma-treated)  (NN U937)  (NNS cells) )) (PP (IN in)  (NP (NN chemiluminescence)  (NNS assays) )) (SBAR (WHNP-55 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-55) ) (VP (TO to)  (VP (VB detect)  (NP (NP-COOD (NP (JJ red)  (NN cell) ) (, ,)  (NP (NN platelet) ) (CC and)  (NP (NN granulocyte)  (NNS antibodies) )) (PP (IN of)  (NP (JJ potential)  (JJ clinical)  (NN significance) ))))))) (. .) ) )
(TOP (S (NP-SBJ-56 (NP (DT The)  (ADJP (ADJP (JJ chemiluminescent) ) (PRN (-LRB- -LRB-)  (ADJP (JJ CL) ) (-RRB- -RRB-) )) (NN response) ) (PP (IN of)  (NP (NP (NP (JJ interferon-gamma-treated)  (NN U937) ) (PRN (-LRB- -LRB-)  (NP (NN IFN-U937) ) (-RRB- -RRB-) )) (NNS cells) )) (PP (TO to)  (NP (VBN sensitized)  (NN target)  (NNS cells) ))) (VP (VBZ has)  (VP (VBN been)  (VP (VBN used)  (NP-57 (-NONE- *-56) ) (S (NP-SBJ (-NONE- *-57) ) (VP (TO to)  (VP (VB detect)  (NP-COOD (NP (JJ red)  (NN cell) ) (, ,)  (NP (NN platelet) ) (CC and)  (NP (NN granulocyte)  (NNS antibodies) )))))))) (. .) ) )
(TOP (S (NP-SBJ-58 (NP (DT A)  (NN clone) ) (PP (IN of)  (NP (NN U937)  (NNS cells) )) (SBAR (-NONE- *ICH*-59) )) (VP (VBD was)  (VP (VBN selected)  (NP (-NONE- *-58) ) (SBAR-COOD-59 (SBAR (WHNP-60 (WDT which) ) (S (NP-SBJ (-NONE- *T*-60) ) (VP (VBD expressed)  (NP (NP (NN Fc)  (NN receptor)  (NN I) ) (PRN (-LRB- -LRB-)  (NP (NN Fc)  (NN gamma)  (NN RI) ) (-RRB- -RRB-) ))))) (CC and)  (SBAR (WHNP-61 (WDT which) ) (, ,)  (S (PP-TMP (IN after)  (NP (NP (NN incubation) ) (PP (IN with)  (NP (NN IFN-gamma) )) (PP-TMP (IN for)  (NP (CD 72)  (NN h) )))) (, ,)  (NP-SBJ-62 (-NONE- *T*-61) ) (VP (VBD was)  (ADJP-PRD (JJ capable)  (PP (IN of)  (S (NP-SBJ (-NONE- *-62) ) (VP (VBG generating)  (NP (NP (JJ high)  (NNS levels) ) (PP (IN of)  (NP (JJ lucigenin-enhanced)  (NN CL) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-63 (NP (DT The)  (NN CL)  (NNS responses) ) (PP (IN of)  (NP-COOD (NP (NN IFN-U937)  (NNS cells) ) (CC and)  (NP (JJ peripheral)  (NN blood)  (JJ human)  (NNS monocytes) ))) (PP (TO to)  (NP (VBN sensitized)  (NP-COOD (NP (JJ red)  (NNS cells) ) (, ,)  (NP (NNS platelets) ) (CC or)  (NP (NNS granulocytes) ))))) (VP (VBD were)  (ADVP (RB then) ) (VP (VBN compared)  (NP (-NONE- *-63) ))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Assays) ) (VP (VBG using)  (NP-COOD (NP (NNS monocytes) ) (CC or)  (NP (NN IFN-U937)  (NNS cells) )))) (VP (VBD were)  (PP-PRD (IN of)  (NP (NP (JJ comparable)  (NN sensitivity) ) (PP (IN for)  (NP (NP (NN detection) ) (PP (IN of)  (NP (NP (NNS antibodies) ) (PP (IN against)  (NP (NP (DT all)  (CD three)  (NNS types) ) (PP (IN of)  (NP (NN target)  (NN cell) ))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NP (DT the)  (NN use) ) (PP (IN of)  (NP (NN IFN-U937)  (NNS cells) ))) (VP-COOD (VP (VBD reduced)  (NP (JJ interassay)  (NN variation) )) (CC and)  (VP (VBD simplified)  (NP (NN assay)  (NN performance) ))) (. .) ) )
(TOP (S (NP-SBJ-64 (NP (DT The)  (JJ potential)  (JJ clinical)  (NN usefulness) ) (PP (IN of)  (NP (DT these)  (NN CL)  (NNS assays) ))) (VP (VBD was)  (VP (VBN suggested)  (NP (-NONE- *-64) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN ability)  (S (-NONE- *ICH*-65) )) (PP (IN of)  (NP-COOD (CC both)  (NP (NNS monocytes) ) (CC and)  (NP (NN IFN-U937)  (NNS cells) ))) (S-65 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB respond)  (PP (TO to)  (NP (NP-COOD (NP (JJ red)  (NNS cells) ) (, ,)  (NP (NNS platelets) ) (CC or)  (NP (NNS granulocytes) )) (VP (VBN sensitized)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (NN sera) ) (PP (IN from)  (NP (NP (JJ pregnant)  (NNS women) ) (SBAR (WHNP-66 (WP$ whose)  (NNS babies) ) (S (NP-SBJ (-NONE- *T*-66) ) (VP (VBD had)  (NP-COOD (CC either)  (NP (NP (JJ haemolytic)  (NN disease)  (IN of)  (DT the)  (JJ newborn) ) (PRN (-LRB- -LRB-)  (NP (NN HDN) ) (-RRB- -RRB-) )) (, ,)  (NP (JJ alloimmune)  (NN thrombocytopenia) ) (CC or)  (NP (JJ alloimmune)  (NN neutropenia) )) (ADVP (RB respectively) )))))))))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (NP-COOD (NP (NNS monocytes) ) (CC and)  (NP (NN IFN-U937)  (NNS cells) )) (NP (DT both) )) (VP (VBD responded)  (PP (TO to)  (NP (NP (JJ red)  (NNS cells) ) (VP (VBN sensitized)  (NP (-NONE- *) ) (PP (IN with)  (NP (NP (NNS antibodies) ) (PP (IN against)  (NP (NP (DT a)  (NN variety) ) (PP (IN of)  (NP (NP (NNS specificities) ) (PP (IN of)  (NP (NP (ADJP-COOD (ADJP (VBN assumed) ) (-LRB- -LRB-)  (IN although)  (ADJP (RB not)  (VBN documented) ) (-RRB- -RRB-) ) (JJ clinical)  (NN significance) ) (PP (IN for)  (NP (NN blood)  (NN transfusion)  (NNS recipients) )))))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-COOD (NP (NNS monocytes) ) (CC and)  (NP (NN IFN-U937)  (NNS cells) )) (VP (VBD responded)  (ADVP (RB only)  (RB weakly) ) (PP (TO to)  (NP (NP (JJ red)  (NNS cells) ) (VP (VBN sensitized)  (NP (-NONE- *) ) (PP-COOD (PP (IN with)  (CC either)  (NP (NP (JJ anti-D) ) (PP (IN in)  (NP (NP (NN sera) ) (PP (IN from)  (NP (NP (NNS mothers) ) (PP (IN of)  (NP (NP (NNS babies) ) (VP (JJ unaffected)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NN HDN) ))))))))))) (, ,)  (CC or)  (PP (IN with)  (NP (NP (NNS antisera) ) (VP (VBG containing)  (NP (NP (JJ high)  (NN titre)  (NNS antibodies) ) (PP (IN with)  (NP (NP (NNS specificities) ) (VP (RB not)  (ADVP (RB normally) ) (VBN associated)  (NP (-NONE- *) ) (PP (IN with)  (NP (ADJP (RB significantly)  (VBN reduced) ) (JJ red)  (NN cell)  (NN survival) )))))))))))))) (. .) ) )
(TOP (NP (NP (NN Photoaffinity)  (NN labeling) ) (PP (IN of)  (NP (NP (NN plasma)  (NN membrane)  (NNS receptors) ) (PP (IN for)  (NP (NN aldosterone) )) (PP (IN from)  (NP (JJ human)  (JJ mononuclear)  (NNS leukocytes) )))) (. .) ) )
(TOP (S (NP-SBJ-1 (NP (JJ Non-genomic)  (NNS effects) ) (PP (IN of)  (NP (NN aldosterone) )) (PP (IN on)  (NP (DT the)  (NN sodium-proton-antiport) ))) (VP (VBP have)  (VP (VBN been)  (VP (VBN shown)  (NP (-NONE- *-1) ) (PP (IN in)  (NP (NP (JJ human)  (JJ mononuclear)  (NNS leukocytes) ) (SBAR (WHNP-2 (WDT which) ) (S (NP-SBJ (-NONE- *T*-2) ) (VP (MD could)  (VP (VB be)  (ADJP-PRD (JJ related)  (PP (TO to)  (NP (DT a)  (JJ new)  (NN aldosterone)  (NN membrane)  (NN receptor) )))))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (DT the)  (JJ present)  (NN paper) )) (NP-SBJ-4 (NP (NN plasma)  (NNS membranes) ) (PP (IN from)  (NP (JJ human)  (JJ mononuclear)  (NNS leukocytes) ))) (VP (VBD were)  (ADVP (RB covalently) ) (VP (VBN photolabeled)  (NP (-NONE- *-4) ) (PP (IN with)  (NP (DT a)  (NN -LCB-125I-RCB--aldosterone)  (NN derivative) )))) (. .) ) )
(TOP (S (NP-SBJ (ADJP (NN Sodium)  (NN dodecyl)  (JJ sulfate-polyacrylamide) ) (NN gel)  (NN electrophoresis) ) (VP (VBD showed)  (NP (NP (JJ significant)  (NN aldosterone)  (NN binding) ) (PP (IN at)  (NP (NP (DT a)  (JJ molecular)  (NN weight) ) (PP (IN of)  (NP (QP (RB approximately)  (CD 50000) ) (NN Dalton) ))))) (SBAR (WHNP-5 (WDT which) ) (S (NP-SBJ (-NONE- *T*-5) ) (VP (VBD was)  (ADJP-PRD (JJ absent) ) (PP (IN with)  (NP (NP-COOD (NP (NP (CD 1)  (NN microM) ) (NP (JJ cold)  (NN aldosterone) )) (, ,)  (CONJP (CC but)  (RB not) ) (NP (NN cortisol) )) (PP (IN in)  (NP (DT the)  (VBG binding)  (NNS media) )))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN presence) ) (PP (IN of)  (NP (DT the)  (NN sulfhydryl)  (NN agent)  (NN dithiothreitol) ))) (VP (VBD did)  (RB not)  (VP (VB affect)  (NP (NP (NNS results) ) (VP (VBG suggesting)  (NP (NP (DT the)  (NN absence) ) (PP (IN of)  (NP (NN disulfide)  (NNS bridges) )) (PP (IN in)  (NP (NP (DT the)  (NN steroid)  (NN binding)  (NN domain) ) (PP (IN of)  (NP (DT the)  (NN receptor) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS data) ) (VP (VBP are)  (NP-PRD (NP (DT the)  (JJ first) ) (SBAR (WHNP-100 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-100) ) (VP (TO to)  (VP (VB define)  (NP (NP (DT the)  (JJ molecular)  (NN weight) ) (PP (IN of)  (NP (NP (DT the)  (NN membrane)  (NN receptor) ) (PP (IN for)  (NP (NN aldosterone) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Alpha-lipoic)  (NN acid) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (JJ potent)  (NN inhibitor) ) (PP (IN of)  (NP (NP (NN NF-kappa)  (NN B)  (NN activation) ) (PP (IN in)  (NP (JJ human)  (NN T)  (NNS cells) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (VBN Acquired)  (NN immunodeficiency)  (NN syndrome) ) (PRN (-LRB- -LRB-)  (NP (NN AIDS) ) (-RRB- -RRB-) )) (VP (VBZ results)  (PP (IN from)  (NP (NP (NN infection) ) (PP (IN with)  (NP (NP (DT a)  (JJ human)  (NN immunodeficiency)  (NN virus) ) (PRN (-LRB- -LRB-)  (NP (NN HIV) ) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ (NP (DT The)  (NP (NP (JJ long)  (JJ terminal)  (NN repeat) ) (PRN (-LRB- -LRB-)  (NP (NN LTR) ) (-RRB- -RRB-) )) (NN region) ) (PP (IN of)  (NP (NN HIV)  (JJ proviral)  (NN DNA) ))) (VP (VBZ contains)  (NP (NP (VBG binding)  (NNS sites) ) (PP (IN for)  (NP (NP (JJ nuclear)  (NN factor)  (NN kappa)  (NN B) ) (PRN (-LRB- -LRB-)  (NP (NN NF-kappa)  (NN B) ) (-RRB- -RRB-) )))))) (, ,)  (CC and)  (S (NP-SBJ-1 (DT this)  (JJ transcriptional)  (NN activator) ) (VP (VBZ appears)  (S (NP-SBJ (-NONE- *-1) ) (VP (TO to)  (VP (VB regulate)  (NP (NN HIV)  (NN activation) )))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Recent)  (NNS findings) ) (VP (VBP suggest)  (NP (NP (DT an)  (NN involvement) ) (PP (IN of)  (NP (NP (JJ reactive)  (NN oxygen)  (NNS species) ) (PRN (-LRB- -LRB-)  (NP (NN ROS) ) (-RRB- -RRB-) ))) (PP (IN in)  (NP (NP (NN signal)  (NN transduction)  (NNS pathways) ) (VP (VBG leading)  (PP (TO to)  (NP (NN NF-kappa)  (NN B)  (NN activation) ))))))) (. .) ) )
(TOP (S (NP-200 (DT The)  (JJ present)  (NN study) ) (VP (VBD was)  (VP (VBN based)  (NP (-NONE- *-200) ) (PP (IN on)  (NP (NNS reports)  (SBAR (IN that)  (S-COOD (S (NP-SBJ (NP (NNS antioxidants) ) (SBAR (WHNP-2 (WDT which) ) (S (NP-SBJ (-NONE- *T*-2) ) (VP (VBP eliminate)  (NP (NN ROS) ))))) (VP (MD should)  (VP-COOD (VP (VB block)  (NP-3 (NP (DT the)  (NN activation) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )))) (CC and)  (VP (ADVP (RB subsequently) ) (NP=3 (NN HIV)  (NN transcription) ))))) (, ,)  (CC and)  (RB thus)  (S (NP-SBJ-4 (NNS antioxidants) ) (VP (MD can)  (VP (VB be)  (VP (VBN used)  (NP (-NONE- *-4) ) (PP (IN as)  (NP (NP (JJ therapeutic)  (NNS agents) ) (PP (IN for)  (NP (NN AIDS) )))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-5 (NP (NN Incubation) ) (PP (IN of)  (NP (NP (NN Jurkat)  (NN T)  (NNS cells) ) (PRN (-LRB- -LRB-)  (NP (QP (CD 1)  (CC x)  (CD 10-LRB-6-RRB-) ) (NNS cells/ml) ) (-RRB- -RRB-) ))) (PP (IN with)  (NP (DT a)  (JJ natural)  (NN thiol)  (ADJP-COOD (ADJP (NN antioxidant) ) (, ,)  (ADJP (JJ alpha-lipoic) )) (NN acid) )) (, ,)  (PP (JJ prior)  (TO to)  (NP (NP (DT the)  (NN stimulation) ) (PP (IN of)  (NP (NNS cells) ))))) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-5) ) (VP (TO to)  (VP (VB inhibit)  (NP (NP (NN NF-kappa)  (NN B)  (NN activation) ) (VP (VBN induced)  (NP (-NONE- *) ) (PP-COOD (PP (IN by)  (NP (NP (NN tumor)  (NN necrosis)  (NN factor-alpha) ) (PRN (-LRB- -LRB-)  (NP (CD 25) (NN  ng/ml) ) (-RRB- -RRB-) ))) (CC or)  (PP (IN by)  (NP (NP (NN phorbol)  (NN 12-myristate)  (NN 13-acetate) ) (PRN (-LRB- -LRB-)  (NP (CD 50) (NN  ng/ml) ) (-RRB- -RRB-) ))))))))))) (. .) ) )
(TOP (S-COOD (S (NP-SBJ-6 (NP (DT The)  (JJ inhibitory)  (NN action) ) (PP (IN of)  (NP (JJ alpha-lipoic)  (NN acid) ))) (VP (VBD was)  (VP (VBN found)  (S (NP-SBJ (-NONE- *-6) ) (VP (TO to)  (VP (VB be)  (ADJP-PRD (RB very)  (JJ potent) ) (SBAR (IN as)  (S (NP-SBJ-7 (QP (RB only)  (CD 4) ) (NN mM) ) (VP (VBD was)  (VP (VBN needed)  (NP (-NONE- *-7) ) (PP (IN for)  (NP (DT a)  (JJ complete)  (NN inhibition) )))))))))))) (, ,)  (IN whereas)  (S (NP-SBJ-8 (CD 20)  (NN mM) ) (VP (VBD was)  (VP (VBN required)  (NP (-NONE- *-8) ) (PP (IN for)  (NP (NN N-acetylcysteine) ))))) (. .) ) )
(TOP (S (NP-SBJ (DT These)  (NNS results) ) (VP (VBP indicate)  (SBAR (IN that)  (S (NP-SBJ (JJ alpha-lipoic)  (NN acid) ) (VP (MD may)  (VP (VB be)  (ADJP-PRD (JJ effective) ) (PP (IN in)  (NP (NN AIDS)  (NNS therapeutics) ))))))) (. .) ) )
(TOP (NP (NP (NP (NN Activation) ) (PP (IN of)  (NP (NN lymphokine)  (NNS genes) )) (PP (IN in)  (NP (NN T)  (NNS cells) )) (: :) ) (NP (NP (NN role) ) (PP (IN of)  (NP (NP (JJ cis-acting)  (NN DNA)  (NNS elements) ) (SBAR (WHNP-77 (WDT that) ) (S (NP-SBJ (-NONE- *T*-77) ) (VP (VBP respond)  (PP (TO to)  (NP (NN T)  (NN cell)  (NN activation)  (NNS signals) ))))))) (. .) )) )
(TOP (S (NP-SBJ-78 (NP (NN Activation) ) (PP (IN of)  (NP (NN T)  (NNS cells) ))) (VP (VBZ is)  (VP (VBN initiated)  (NP (-NONE- *-78) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN recognition) ) (PP (IN of)  (NP (NN antigen) )) (PP (IN on)  (NP (NN antigen)  (NN presenting)  (NNS cells) )) (SBAR (WHNP-107 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-107) ) (VP (TO to)  (VP (VB exert)  (NP (DT the)  (NN effector)  (NNS functions) ) (PP (IN in)  (NP (ADJP-COOD (ADJP (JJ immune) ) (CC and)  (ADJP (JJ inflammatory) )) (NNS responses) )))))))))) (. .) ) )
(TOP (S (NP-SBJ-80 (NP (NP (CD Two)  (NNS types) ) (PP (IN of)  (NP (NP (NP (NN helper)  (NN T)  (NN cell) ) (PRN (-LRB- -LRB-)  (NP (NN Th) ) (-RRB- -RRB-) )) (NNS clones) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (NN Th1) ) (CC and)  (NP (NN Th2) )) (-RRB- -RRB-) )) (VP (VBP are)  (VP (VBN defined)  (NP (-NONE- *-80) ) (PP (IN on)  (DT the)  (NN basis)  (IN of)  (NP (NP (JJ different)  (NNS patterns) ) (PP (IN of)  (NP (NP (NP (NN cytokine) ) (PRN (-LRB- -LRB-)  (NP (NN lymphokine) ) (-RRB- -RRB-) )) (NN secretion) )))))) (. .) ) )
(TOP (S (NP-SBJ (PRP They) ) (VP (VBP determine)  (NP (NP (DT the)  (NN outcome) ) (PP (IN of)  (NP (NP (DT an)  (JJ antigenic)  (NN response) ) (PP (IN toward)  (NP (ADJP-COOD (ADJP (JJ humoral) ) (CC or)  (ADJP (JJ cell-mediated) )) (NN immunity) )))))) (. .) ) )
(TOP (S (SBAR-ADV (IN Although)  (S (NP-SBJ-81 (NN lymphokine)  (NNS genes) ) (VP (VBP are)  (ADVP (RB coordinately) ) (VP (VBN regulated)  (NP (-NONE- *-81) ) (PP (IN upon)  (NP (NN antigen)  (NN stimulation) )))))) (, ,)  (NP-SBJ-82 (PRP they) ) (VP (VBP are)  (VP (VBN regulated)  (NP (-NONE- *-82) ) (PP (IN by)  (NP-LGS-COOD (NP (NP (DT the)  (NNS mechanisms) ) (ADJP (JJ common)  (PP (TO to)  (NP (DT all) )))) (CONJP (RB as)  (RB well)  (IN as) ) (NP (NP (DT those) ) (SBAR (WHNP-83 (WDT which) ) (S (NP-SBJ (-NONE- *T*-83) ) (VP (VBP are)  (ADJP-PRD (JJ unique)  (PP (TO to)  (NP (DT each)  (NN gene) ))))))))))) (. .) ) )
(TOP (S (PP (IN For)  (NP (JJS most)  (NN lymphokine)  (NNS genes) )) (, ,)  (NP-SBJ-84 (NP (DT a)  (NN combination) ) (PP (IN of)  (NP-COOD (NP (NP (NN phorbol)  (NNS esters) ) (PRN (-LRB- -LRB-)  (NP (NP (NN phorbol)  (NN 12-myristate)  (CD 13)  (NN acetate) ) (, ,)  (NP (NN PMA) )) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN calcium)  (NNS ionophores) ) (PRN (-LRB- -LRB-)  (NP (NN A23187) ) (-RRB- -RRB-) ))))) (VP (VBZ is)  (VP (VBN required)  (NP (-NONE- *-84) ) (PP (IN for)  (NP (PRP$ their)  (JJ maximal)  (NN induction) )))) (. .) ) )
(TOP (S (RB Yet)  (NP-SBJ-COOD (NP (NP (NN phorbol)  (NN ester) ) (ADVP (RB alone) )) (CC or)  (NP (NP (NN calcium)  (NN ionophore) ) (ADVP (RB alone) ))) (VP (VBP produce)  (NP (JJ several)  (NNS lymphokines) )) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN production) ) (PP (IN of)  (NP (NP (DT the)  (JJ granulocyte-macrophage)  (NN colony)  (NN stimulating)  (NN factor) ) (PRN (-LRB- -LRB-)  (NP (NN GM-CSF) ) (-RRB- -RRB-) )))) (VP (VBZ is)  (ADJP-PRD (RB completely)  (JJ dependent)  (PP (IN on)  (NP (DT the)  (CD two)  (NNS signals) )))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (ADVP-TMP (RB previously) ) (VP (VBN found)  (NP (NP (DT a)  (JJ cis-acting)  (NN region) ) (VP (VBG spanning)  (NP (NP (NP (DT the)  (NN GM-CSF)  (NN promoter)  (NN region) ) (PRN (-LRB- -LRB-)  (NP (NNS positions)  (NP-COOD (NP (CD -95) ) (TO to)  (NP (CD +27) ))) (-RRB- -RRB-) )) (SBAR (WHNP-85 (WDT that) ) (S (NP-SBJ (-NONE- *T*-85) ) (VP (VBZ confers)  (NP (NN inducibility) ) (PP (TO to)  (NP (NN reporter)  (NNS genes) )) (PP (IN in)  (NP (JJ transient)  (NN transfection)  (NNS assays) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (JJ Further)  (NN analysis) ) (VP (VBD identified)  (NP (NP (CD three)  (NNS elements) ) (VP (VBN required)  (NP (-NONE- *) ) (PP (IN for)  (NP (JJ efficient)  (NN induction) ))) (, ,)  (VP (VBN referred)  (PP (TO to)  (NP (-NONE- *) )) (PP (IN as)  (NP-COOD (NP (NN GM2) ) (, ,)  (NP (NN GC-box) ) (CC and)  (NP (NP (VBN conserved)  (NN lymphokine)  (NN element) ) (PRN (-LRB- -LRB-)  (NP (NN CLE0) ) (-RRB- -RRB-) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN GM2) ) (VP (VBZ defines)  (NP (NP (DT a)  (VBG binding)  (NN site) ) (PP (IN for)  (NP (NP (NN protein)  (-LRB- -LRB-)  (NNS s)  (-RRB- -RRB-) ) (SBAR (WHNP-88 (WP$ whose)  (NN binding) ) (S (NP-SBJ (-NONE- *T*-88) ) (VP (VBZ is)  (ADJP-PRD (JJ inducible)  (PP (IN by)  (NP (NN PMA) )))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (CD One)  (NN protein) ) (, ,)  (NP (NN NF-GM2) )) (VP (VBZ is)  (ADJP-PRD (JJ similar)  (PP (TO to)  (NP (DT the)  (NN transcription)  (NN factor)  (NN NF-kB) )))) (. .) ) )
(TOP (S (NP-SBJ (NN GC-box) ) (VP (VBZ is)  (NP-PRD (NP (DT a)  (VBG binding)  (NN site) ) (PP (IN for)  (NP (ADJP (RB constitutively)  (VBN bound) ) (NNS proteins) )))) (. .) ) )
(TOP (S (NP-SBJ (NN CLEO) ) (VP (VBZ defines)  (NP (NP (DT a)  (VBG binding)  (NN site) ) (PP (IN for)  (NP (NP (NN protein)  (-LRB- -LRB-)  (NNS s)  (-RRB- -RRB-) ) (SBAR (WHNP-89 (WP$ whose)  (NN optimum)  (NN binding) ) (S (NP-SBJ-90 (-NONE- *T*-89) ) (VP (VBZ is)  (VP (VBN stimulated)  (NP (-NONE- *-90) ) (PP (IN by)  (NP-LGS-COOD (NP (NN PMA) ) (CC and)  (NP (NN A23187) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Viral)  (NNS trans-activators) ) (PP (JJ such)  (IN as)  (NP (NP-COOD (NP (NP (NN Tax) ) (PRN (-LRB- -LRB-)  (NP (NP (JJ human)  (NN T)  (NN cell)  (NN leukemia)  (NN virus-1) ) (, ,)  (NP (NN HTLV-1) )) (-RRB- -RRB-) )) (CC and)  (NP (NP (NN E2) ) (PRN (-LRB- -LRB-)  (NP (NP (JJ bovine)  (NN papilloma)  (NN virus) ) (, ,)  (NP (NN BPV) )) (-RRB- -RRB-) ))) (NNS proteins) ))) (VP (VBP are)  (NP-PRD (NP (JJ other)  (NNS agents) ) (SBAR (WHNP-91 (WDT which) ) (S (NP-SBJ-92 (-NONE- *T*-91) ) (VP (VBP activate)  (NP (NN lymphokine)  (NN gene)  (NN expression) ) (PP (IN by)  (S (NP-SBJ (-NONE- *-92) ) (VP (VBG bypassing)  (NP (ADJP (NP (NP (NN T)  (NN cell)  (NN receptor) ) (PRN (-LRB- -LRB-)  (NP (NN TCR) ) (-RRB- -RRB-) )) (JJ mediated) ) (NN signaling) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN trans-activation)  (NN domain) ) (PP (IN of)  (NP-COOD (NP (NN E2) ) (CC and)  (NP (NN Tax) )))) (VP (VBZ is)  (ADJP-PRD (JJ interchangeable) ) (SBAR (IN although)  (S (NP-SBJ (PRP they) ) (VP (VBP have)  (NP (NP (DT no)  (JJ obvious)  (NN sequence)  (NN homology) ) (PP (IN between)  (NP (PRP them) ))))))) (. .) ) )
(TOP (S (NP-SBJ-93 (DT The)  (JJ viral)  (NNS trans-activators) ) (VP (VBP appear)  (S (NP-SBJ (-NONE- *-93) ) (VP (TO to)  (VP-COOD (VP (VB target)  (NP (NP (JJ specific)  (NN DNA)  (NN binding)  (NN protein) ) (PP (JJ such)  (IN as)  (NP-COOD (NP (NN NF-kB) ) (CC and)  (NP (NN Sp1) )))) (PP (TO to)  (NP (JJ cis-acting)  (NN DNA)  (NN site) ))) (CC and)  (VP (VB promote)  (NP (NN lymphokine)  (NN gene)  (NN expression) ) (PP (IN without)  (NP (JJ TCR-mediated)  (NN stimulation) ))))))) (. .) ) )
(TOP (S (NP-SBJ (NN I)  (NN kappa) (NN  B/MAD-3) ) (VP-COOD (VP (VBZ masks)  (NP (NP (DT the)  (JJ nuclear)  (NN localization)  (NN signal) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN p65) )))) (CC and)  (VP (VBZ requires)  (S (NP-SBJ (DT the)  (NN transactivation)  (NN domain) ) (VP (TO to)  (VP (VB inhibit)  (NP (NN NF-kappa)  (NN B)  (NN p65)  (NN DNA)  (NN binding) )))))) (. .) ) )
(TOP (S (NP-SBJ-1 (NP (DT The)  (JJ active)  (JJ nuclear)  (NN form) ) (PP (IN of)  (NP (DT the)  (NN NF-kappa)  (NN B)  (NN transcription)  (NN factor)  (NN complex) ))) (VP (VBZ is)  (VP (VBN composed)  (NP (-NONE- *-1) ) (PP (IN of)  (NP (NP (NP (CD two)  (NN DNA)  (NN binding)  (NNS subunits) ) (, ,)  (NP-COOD (NP (NN NF-kappa)  (NN B)  (NN p65) ) (CC and)  (NP (NN NF-kappa)  (NN B)  (NN p50) )) (, ,) ) (SBAR (WHNP-2 (NP (DT both) ) (WHPP (IN of)  (WHNP (WDT which) ))) (S (NP-SBJ (-NONE- *T*-2) ) (VP (VBP share)  (NP (JJ extensive)  (JJ N-terminal)  (NN sequence)  (NN homology) ) (PP (IN with)  (NP (DT the)  (NN v-rel)  (NN oncogene)  (NN product) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT The)  (NN NF-kappa)  (NN B)  (NN p65)  (NN subunit) ) (VP-COOD (VP (VBZ provides)  (NP (DT the)  (NN transactivation)  (NN activity) ) (PP (IN in)  (NP (DT this)  (JJ complex) ))) (CC and)  (VP (VBZ serves)  (PP (IN as)  (NP (NP (DT an)  (JJ intracellular)  (NN receptor) ) (PP (IN for)  (NP (NP (DT a)  (JJ cytoplasmic)  (NN inhibitor) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B) )) (, ,)  (VP (VBN termed)  (S (NP-SBJ (-NONE- *) ) (NP-PRD (NN I)  (NN kappa)  (NN B) ))))))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-3 (NP (NN NF-kappa)  (NN B)  (NN p50) ) (ADVP (RB alone) )) (VP-COOD (VP (VBZ fails)  (S (NP-SBJ (-NONE- *-3) ) (VP (TO to)  (VP (VB stimulate)  (NP (ADJP (NN kappa)  (JJ B-directed) ) (NN transcription) ))))) (, ,)  (CC and)  (VP (PP (VBN based)  (PP (IN on)  (NP (JJ prior)  (ADJP (FW in)  (FW vitro) ) (NNS studies) ))) (, ,)  (VP (VBZ is)  (RB not)  (ADVP (RB directly) ) (VP (VBN regulated)  (NP (-NONE- *-3) ) (PP (IN by)  (NP-LGS (NN I)  (NN kappa)  (NN B) )))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *) ) (VP (TO To)  (VP (VB investigate)  (NP (NP (DT the)  (JJ molecular)  (NN basis) ) (PP (IN for)  (NP (NP (DT the)  (JJ critical)  (JJ regulatory)  (NN interaction) ) (PP (IN between)  (NP-COOD (NP (NN NF-kappa)  (NN B) ) (CC and)  (NP (NN I)  (NN kappa) (NN  B/MAD-3) ))))))))) (, ,)  (NP-SBJ-5 (NP (NP (DT a)  (NN series) ) (PP (IN of)  (NP (NP (JJ human)  (NN NF-kappa)  (NN B)  (NN p65)  (NNS mutants) ) (SBAR (-NONE- *ICH*-6) ))))) (VP (VBD was)  (VP (VBN identified)  (NP (-NONE- *-5) ) (SBAR-6 (WHNP-7 (WDT that) ) (S (NP-SBJ (-NONE- *T*-7) ) (ADVP (RB functionally) ) (VP (VBD segregated)  (NP (NP-COOD (NP (NN DNA)  (NN binding) ) (, ,)  (NP (ADJP (NN I)  (NN kappa)  (JJ B-mediated) ) (NN inhibition) ) (, ,)  (CC and)  (NP (ADJP (NN I)  (NN kappa)  (JJ B-induced) ) (JJ nuclear)  (NN exclusion) )) (PP (IN of)  (NP (DT this)  (NN transcription)  (NN factor) )))))))) (. .) ) )
(TOP (S (S (NP-SBJ (NP (NNS Results) ) (PP (IN from)  (NP (NP (ADJP (FW in)  (FW vivo) ) (NN expression)  (NNS studies) ) (VP (VBN performed)  (NP (-NONE- *) ) (PP (IN with)  (NP (DT these)  (NN NF-kappa)  (NN B)  (NN p65)  (NNS mutants) )))))) (VP (VBD revealed)  (NP (DT the)  (NN following) )) (: :) ) (S-COOD (S (LST (LS 1)  (-RRB- -RRB-) ) (NP-SBJ (NN I)  (NN kappa) (NN  B/MAD-3) ) (ADVP (RB completely) ) (VP (VBZ inhibits)  (NP (NP (ADJP (NN NF-kappa)  (NN B)  (JJ p65-dependent) ) (JJ transcriptional)  (NN activation) ) (VP (VBN mediated)  (NP (-NONE- *) ) (PP (IN through)  (NP (NP (DT the)  (JJ human)  (NN immunodeficiency)  (NN virus)  (NN type)  (CD 1)  (NN kappa)  (NN B)  (NN enhancer) ) (PP (IN in)  (NP (JJ human)  (NN T)  (NNS lymphocytes) )))))))) (, ,)  (S (LST (LS 2)  (-RRB- -RRB-) ) (NP-SBJ (NP (DT the)  (NN binding) ) (PP (IN of)  (NP (NN I)  (NN kappa) (NN  B/MAD-3) )) (PP (TO to)  (NP (NN NF-kappa)  (NN B)  (NN p65) ))) (VP (VBZ is)  (ADJP-PRD (JJ sufficient)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB retarget)  (NP (NN NF-kappa)  (NN B)  (NN p65) ) (PP (IN from)  (NP (DT the)  (NN nucleus) )) (PP (TO to)  (NP (DT the)  (NN cytoplasm) )))))))) (, ,)  (S (LST (LS 3)  (-RRB- -RRB-) ) (NP-SBJ (NP (JJ selective)  (NN deletion) ) (PP (IN of)  (NP (NP (DT the)  (JJ functional)  (JJ nuclear)  (NN localization)  (NN signal) ) (ADJP (JJ present)  (PP (IN in)  (NP (NP (DT the)  (NN Rel)  (NN homology)  (NN domain) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN p65) )))))))) (VP (VBZ disrupts)  (NP (PRP$ its)  (NN ability)  (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB engage)  (NP (NN I)  (NN kappa) (NN  B/MAD-3) ))))))) (, ,)  (CC and)  (S (LST (LS 4)  (-RRB- -RRB-) ) (NP-SBJ (NP (DT the)  (JJ unique)  (NN C-terminus) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN p65) ))) (VP-COOD (VP (VBZ attenuates)  (NP (PRP$ its)  (JJ own)  (JJ nuclear)  (NN localization) )) (CC and)  (VP (VBZ contains)  (NP (NP (NNS sequences) ) (SBAR (WHNP-9 (WDT that) ) (S (NP-SBJ-10 (-NONE- *T*-9) ) (VP (VBP are)  (VP (VBN required)  (NP (-NONE- *-10) ) (PP (IN for)  (NP (NP (ADJP (NN I)  (NN kappa)  (JJ B-mediated) ) (NN inhibition) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN p65)  (NN DNA)  (NN binding)  (NN activity) )))))))))))) (. .) )) )
(TOP (S (ADVP (RB Together) ) (, ,)  (NP-SBJ (DT these)  (NNS findings) ) (VP (VBP suggest)  (SBAR (IN that)  (S (NP-SBJ (NP (DT the)  (NP-COOD (NP (JJ nuclear)  (NN localization)  (NN signal) ) (CC and)  (NP (NN transactivation)  (NN domain) ))) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN p65) ))) (VP (VBP constitute)  (NP (NP (DT a)  (JJ bipartite)  (NN system) ) (SBAR (WHNP-11 (WDT that) ) (S (NP-SBJ-12 (-NONE- *T*-11) ) (VP (VBZ is)  (ADVP (RB critically) ) (VP (VBN involved)  (NP (-NONE- *-12) ) (PP (IN in)  (NP (NP (DT the)  (JJ inhibitory)  (NN function) ) (PP (IN of)  (NP (NN I)  (NN kappa) (NN  B/MAD-3) ))))))))))))) (. .) ) )
(TOP (S (ADVP (RB Unexpectedly) ) (, ,)  (NP-SBJ (PRP$ our)  (ADJP (FW in)  (FW vivo) ) (NNS studies) ) (ADVP (RB also) ) (VP (VBP demonstrate)  (SBAR (IN that)  (S (NP-SBJ (NN I)  (NN kappa) (NN  B/MAD-3) ) (VP (VBZ binds)  (ADVP (RB directly) ) (PP (TO to)  (NP (NN NF-kappa)  (NN B)  (NN p50) )))))) (. .) ) )
(TOP (S (NP-SBJ (DT This)  (NN interaction) ) (VP (VBZ is)  (ADJP-PRD (JJ functional) ) (SBAR (IN as)  (S (NP-SBJ (PRP it) ) (VP (VBZ leads)  (PP (TO to)  (NP (NP (NN retargeting) ) (PP (IN of)  (NP (NN NF-kappa)  (NN B)  (NN p50) )) (PP (IN from)  (NP (DT the)  (NN nucleus) )) (PP (TO to)  (NP (DT the)  (NN cytoplasm) )))))))) (. .) ) )
(TOP (S (ADVP (RB However) ) (, ,)  (NP-SBJ-13 (NP (DT no)  (NN loss) ) (PP (IN of)  (NP (NN DNA)  (NN binding)  (NN activity) ))) (VP (VBZ is)  (VP (VBN observed)  (NP (-NONE- *-13) ) (, ,)  (S (NP-SBJ (-NONE- *) ) (ADVP (RB presumably) ) (VP (VBG reflecting)  (NP (NP (DT the)  (JJ unique)  (JJ C-terminal)  (NN domain) ) (SBAR (WHNP-14 (WDT that) ) (S (NP-SBJ (-NONE- *T*-14) ) (VP (VBZ is)  (ADJP-PRD (JJ distinct)  (PP (IN from)  (NP (NP (DT that) ) (ADJP (JJ present)  (PP (IN in)  (NP (NN NF-kappa)  (NN B)  (NN p65) )))))))))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (NN Surrogate)  (NN thyroglobulin)  (NNS receptors) ) (CC and)  (NP (NN T)  (NN cell)  (NN proliferation) )) (PP (IN in)  (NP (NP (NN Hashimoto)  (POS 's) ) (NN thyroiditis) )) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Immunoglobulin)  (NNS molecules) ) (PP (IN on)  (NP (NP (DT the)  (NN surface) ) (PP (IN of)  (NP (DT a)  (NN B)  (NN lymphocyte) ))))) (VP (VBP are)  (NP-PRD (NP (DT the)  (JJ endogenous)  (`` ")  (NNS receptors)  ('' ") ) (SBAR (WHPP-65 (TO to)  (WHNP (WDT which) )) (S (NP-SBJ (JJ specific)  (NNS antigens) ) (VP (VBP bind)  (PP (-NONE- *T*-65) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Studies) ) (PP (IN in)  (NP (NNS mice) ))) (VP (VBP have)  (VP (VBN shown)  (SBAR (IN that)  (S (NP-SBJ-66 (NP (DT a)  (JJ monoclonal)  (NN antibody) ) (, ,)  (VP (VBN conjugated)  (NP-68 (-NONE- *) ) (PP (IN with)  (NP (NN palmitate) )) (S (NP-SBJ (-NONE- *-68) ) (VP (TO to)  (VP (VB provide)  (NP (DT a)  (NN lipid)  (NN tail) ))))) (, ,) ) (VP (MD can)  (VP (VB be)  (VP (VBN inserted)  (NP-67 (-NONE- *-66) ) (PP (IN into)  (NP (DT the)  (NN cell)  (NN membrane) )) (S (NP-SBJ (-NONE- *-67) ) (VP (TO to)  (VP (VB provide)  (NP (DT a)  (`` ")  (JJ surrogate)  ('' ")  (NN antigen)  (NN receptor) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP have)  (VP (VBN investigated)  (SBAR (IN whether)  (S (NP-SBJ (NP (DT a)  (JJ palmitate)  (NN conjugate) ) (PP (IN of)  (NP (DT a)  (JJ human)  (JJ monoclonal)  (NN antibody) )) (ADJP (JJ specific)  (PP (IN for)  (NP (NP (NN thyroglobulin) ) (PRN (-LRB- -LRB-)  (NP (NN TG) ) (-RRB- -RRB-) ))))) (VP (MD could)  (VP (VB function)  (PP (IN as)  (NP (DT a)  (JJ surrogate)  (NN TG)  (NN receptor) )) (PP (IN on)  (NP (NP (NN blood)  (JJ mononuclear)  (NNS cells) ) (VP (VBN separated)  (NP (-NONE- *) ) (PP (IN into)  (NP (NP (NNS fractions) ) (VP-COOD (VP (VBN enriched)  (NP (-NONE- *) ) (PP (IN for)  (NP (NN T)  (NNS cells) ))) (CC or)  (VP (VBN depleted)  (NP (-NONE- *) ) (PP (IN of)  (NP (NP (NN T)  (NNS cells) ) (PRN (-LRB- -LRB-)  (NP (JJ non-T)  (NNS cells) ) (-RRB- -RRB-) )))))))))))))))) (. .) ) )
(TOP (S (S-ADV (NP-SBJ (-NONE- *-69) ) (VP (VBG Using)  (NP (NN flow)  (NN cytometry) ))) (, ,)  (NP-SBJ-69 (PRP we) ) (VP (VBD detected)  (NP (JJ surrogate)  (NN TG)  (NNS receptors) ) (PP (PP-COOD (PP (IN on)  (NP (JJ non-T)  (NP (-NONE- *RNR*-70) ))) (-LRB- -LRB-)  (CC but)  (PP (RB not)  (IN on)  (NP (NN T)  (NP (-NONE- *RNR*-70) ))) (-RRB- -RRB-) ) (NP-70 (NP (NNS cells) ) (PP (IN from)  (NP (NP (NP (QP (CD 11)  (IN of)  (CD 11) ) (NNS individuals) ) (VP (VBN studied)  (NP (-NONE- *) ))) (PRN (-LRB- -LRB-)  (NP-COOD (NP (CD 5)  (NN Hashimoto)  (NNS patients) ) (CC and)  (NP (CD 6)  (NN control)  (NNS donors) )) (-RRB- -RRB-) )))))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN contrast) )) (, ,)  (NP-SBJ-71 (JJ endogenous)  (NN TG)  (NNS receptors) ) (VP (MD could)  (ADVP (RB only) ) (VP (VB be)  (VP (VBN detected)  (NP (-NONE- *-71) ) (PP (IN on)  (NP (NP (JJ non-T)  (NNS cells) ) (PP-COOD (PP (IN from)  (NP (QP (CD 1)  (IN of)  (CD 3) ) (NN Hashimoto)  (NNS patients) )) (CC and)  (PP (IN from)  (NP (QP (CD 0)  (IN of)  (CD 4) ) (NN control)  (NNS donors) )))))))) (. .) ) )
(TOP (S (PP (IN Because)  (IN of)  (NP (NP (DT the)  (JJ efficient)  (NN binding) ) (PP (IN of)  (NP (NN TG) )) (PP (IN by)  (NP (JJ surrogate)  (NNS receptors) )) (PP (IN on)  (NP (JJ non-T)  (NNS cells) )))) (, ,)  (NP-SBJ (PRP we) ) (VP (VBD assessed)  (NP (NP (NP (DT the)  (NN ability)  (S (-NONE- *ICH*-72) )) (PP (IN of)  (NP (JJ such)  (NNS cells) ))) (S-72 (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB present)  (NP (NN TG) ) (PP (TO to)  (NP (NN T)  (NNS cells) ))))))) (. .) ) )
(TOP (S (NP-SBJ-73 (NP (NN Proliferation) ) (PP (IN in)  (NN response)  (TO to)  (NP (NN TG) ))) (VP (VBD was)  (VP (VBN observed)  (NP (-NONE- *-73) ) (PP (IN in)  (NP (NP (NN T)  (NNS cells) ) (PP (IN from)  (NP (QP (RB only)  (CD 1)  (IN of)  (CD 5) ) (NN Hashimoto)  (NNS patients) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT This)  (JJ low)  (NN frequency) ) (PP (IN of)  (NP (NN response) ))) (VP (VBD was)  (ADJP-PRD (RB no)  (JJ different)  (PP (IN from)  (NP (NP (DT that) ) (VP (ADVP (RB previously) ) (VBN detected)  (NP (-NONE- *) ) (S (NP-SBJ (-NONE- *) ) (VP (VBG using)  (NP (NP (NNS cultures) ) (PP (IN of)  (NP-COOD (NP (NN T)  (NNS cells) ) (CC and)  (NP (JJ autologous)  (JJ dendritic)  (NNS cells) ))))))))))) (. .) ) )
(TOP (S (ADVP (RB Therefore) ) (, ,)  (NP-SBJ-74 (NP (DT the)  (JJ successful)  (NN generation) ) (PP (IN of)  (NP (JJ surrogate)  (NNS receptors) )) (PP (IN on)  (NP (JJ non-T)  (NNS cells) ))) (VP (VBZ is)  (RB not)  (VP (VBN associated)  (NP (-NONE- *-74) ) (PP (IN with)  (NP (NP (ADJP (RBR more)  (JJ efficient) ) (NN TG)  (NN presentation) ) (PP (IN of)  (NP (NN T)  (NNS cells) )))))) (. .) ) )
(TOP (S (ADVP (RB Furthermore) ) (, ,)  (NP-SBJ (NP (DT the)  (NN significance) ) (PP (IN of)  (NP (DT the)  (JJ present)  (NN study) ))) (VP (VBZ is)  (SBAR-PRD (IN that)  (S (NP-SBJ-COOD-75 (NP (DT the)  (NN T)  (NNS cells) ) (, ,)  (RB not)  (NP (DT the)  (JJ antigen-presenting)  (NNS cells) ) (, ,) ) (VP (VBP are)  (ADJP-PRD (JJ likely)  (S (NP-SBJ (-NONE- *-75) ) (VP (TO to)  (VP (VB be)  (NP-PRD (NP (DT the)  (VBG limiting)  (NN element) ) (PP (IN in)  (NP (NP (DT the)  (NN T)  (NN cell)  (JJ proliferative)  (NN response) ) (PP (TO to)  (NP-COOD (NP (NN TG) ) (CC and)  (NP (JJ other)  (NN thyroid)  (NNS autoantigens) )))))))))))))) (. .) ) )
(TOP (NP (NP-COOD (NP (JJ Aldosterone-specific)  (NN membrane)  (NNS receptors) ) (CC and)  (NP (NP (JJ rapid)  (JJ non-genomic)  (NNS actions) ) (PP (IN of)  (NP (NNS mineralocorticoids) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (JJ Functional)  (NNS studies) ) (PP (IN in)  (NP (NP (ADJP-COOD (ADJP (JJ extrarenal) ) (, ,)  (ADJP (JJ non-epithelial) )) (NNS cells) ) (PP (JJ such)  (IN as)  (NP-COOD (NP (JJ smooth)  (NN muscle)  (NNS cells) ) (CC and)  (NP (ADVP-TMP (RBR more)  (RB recently) ) (VBG circulating)  (JJ human)  (NNS lymphocytes) )))))) (VP (VBP have)  (VP (VBN provided)  (NP (VBG increasing)  (NN evidence)  (SBAR (IN that)  (S (NP-SBJ (NN aldosterone) ) (VP (VBZ produces)  (NP (NP-COOD (CONJP (RB not)  (RB only) ) (NP (JJ classical)  (JJ genomic)  (NNS effects) ) (, ,)  (CONJP (CC but)  (RB also) ) (NP (ADJP-COOD (ADJP (JJ rapid) ) (, ,)  (ADJP (JJ non-genomic) )) (NNS effects) )) (PP (IN on)  (NP (NN transmembrane)  (NN electrolyte)  (NNS movements) ))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT These) ) (VP (VBP involve)  (NP (NP (NN activation) ) (PP (IN of)  (NP (NP (DT the) (NN  sodium/proton)  (NN exchanger) ) (PP (IN of)  (NP (DT the)  (NN cell)  (NN membrane) )))) (PP (IN at)  (NP (NP (ADJP-COOD (ADJP (RB very)  (JJ low) ) (, ,)  (ADJP (JJ physiological) )) (NNS concentrations) ) (PP (IN of)  (NP (NN aldosterone) )))) (PP (IN with)  (NP (NP (DT an)  (JJ acute)  (NN onset) ) (PP-TMP (IN within)  (NP (QP (CD 1-2) ) (NN min) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT A)  (JJ second)  (NN messenger)  (NN cascade) ) (VP (VBN involved)  (NP (-NONE- *) ))) (VP (VBZ is)  (NP-PRD (NP (DT the)  (NN inositol) (NN  1,4,5-trisphosphate/calcium)  (NN pathway) ) (SBAR (WHNP-1 (WDT which) ) (S (NP-SBJ (-NONE- *T*-1) ) (VP (VBZ responds)  (PP-TMP (IN over)  (NP (DT the)  (JJ same)  (JJ rapid)  (NN time)  (NN course) ))))))) (. .) ) )
(TOP (S (NP-SBJ-2 (JJ Such)  (NNS changes) ) (ADVP (RB clearly) ) (VP (MD can)  (RB not)  (VP (VB be)  (VP (VBN explained)  (NP (-NONE- *-2) ) (PP (IN by)  (NP-LGS (NP (JJ genomic)  (NNS mechanisms) ) (, ,)  (SBAR (WHNP-3 (WDT which) ) (S (NP-SBJ (-NONE- *T*-3) ) (VP (VBP are)  (ADJP-PRD (JJ responsible)  (PP (IN for)  (NP (NP (JJ later)  (NNS effects) ) (PP (IN than)  (NP (DT the)  (ADJP (NP (NN membrane) ) (JJ related) ) (JJ rapid)  (NNS responses) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-4 (NP (DT The)  (NNS mechanisms) ) (VP (VBG underlying)  (NP (NP (DT these)  (JJ rapid)  (NNS effects) ) (PP (IN of)  (NP (NN aldosterone) )) (PP (IN on)  (NP (NNS electrolytes) ))))) (VP (VBP have)  (VP (VBN been)  (ADVP (RB extensively) ) (VP (VBN studied)  (NP (-NONE- *-4) ) (PP (IN in)  (NP (NP (JJ human)  (NNS lymphocytes) ) (, ,)  (SBAR (WHNP-5 (WDT which) ) (S (ADVP (RB thus) ) (NP-SBJ (-NONE- *T*-5) ) (VP (MD may)  (VP (VB represent)  (NP (NP (JJ valuable)  (NNS tools) ) (PP (IN in)  (NP (NP (DT the)  (NN delineation) ) (PP (IN of)  (NP (NP (DT the)  (JJ receptor-effector)  (NNS mechanisms) ) (VP (VBN involved)  (NP (-NONE- *) )))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (JJ unique)  (NNS characteristics) ) (PP (IN of)  (NP (NP (DT this)  (JJ new)  (NN pathway) ) (PP (IN for)  (NP (NN steroid)  (NN action) ))))) (VP (VBP include)  (NP-COOD (NP (PRP$ its)  (JJ rapid)  (NN time)  (NN course) ) (, ,)  (NP (NP (JJ 10,000-fold)  (NN selectivity) ) (PP (IN for)  (NP (NN aldosterone) )) (PP (IN over)  (NP (NN cortisol) ))) (CC and)  (NP (NP (DT the)  (NN ineffectiveness) ) (PP (IN of)  (NP (NP (NNS spironolactones) ) (, ,)  (NP (JJ classical)  (NN mineralocorticoid)  (NNS antagonists) ) (, ,) )) (PP (IN as)  (NP (NP (NNS antagonists) ) (PP (IN of)  (NP (DT the)  (NN response) ))))))) (. .) ) )
(TOP (NP (NP (UCP-COOD (ADJP (JJ Cellular)  (JJ immune) ) (CC and)  (NP (NN cytokine) )) (NNS pathways) ) (VP (VBG resulting)  (PP (IN in)  (NP-COOD (NP (NN tissue)  (NN factor)  (NN expression) ) (CC and)  (NP (NP (NN relevance) ) (PP (TO to)  (NP (JJ septic)  (NN shock) )))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NNS Cells) ) (PP (IN of)  (NP (NN monocyte)  (NN lineage) ))) (VP (VBP serve)  (PP (IN as)  (NP (NN effector)  (NNS cells) )) (PP (IN in)  (NP (DT the)  (JJ cellular)  (JJ immune)  (NN response) ))) (. .) ) )
(TOP (S (PP (IN In)  (NP (NN addition) )) (, ,)  (NP-SBJ (PRP they) ) (VP (VBP respond)  (PP (TO to)  (NP-COOD (NP (NN LPS) ) (CC and)  (NP (NNS cytokines) ))) (PP (IN with)  (NP (NP-COOD (NP (NN activation) ) (CC and)  (NP (NN expression) )) (PP (IN of)  (NP (NP (JJ inflammatory)  (NN effector)  (NN gene)  (NNS products) ) (ADJP (JJ similar)  (PP (TO to)  (NP (NP (DT those) ) (VP (VBN elicited)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (DT the)  (ADJP (NP (NN antigen) ) (JJ driven) ) (NN response) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (DT The)  (NN response) ) (PP (TO to)  (NP (NN antigen) ))) (VP (VBZ proceeds)  (PP (IN at)  (NP (DT the)  (NN T)  (NN helper)  (NN cell)  (NN level) )) (PP (IN through)  (NP (NP (NP (CD two)  (JJ independent)  (NNS forms) ) (PP (IN of)  (NP (JJ cellular)  (NN collaboration) ))) (, ,)  (NP-COOD (NP (NN contact) ) (CC and)  (NP (NN lymphokine) ))))) (. .) ) )
(TOP (S (NP-SBJ (PRP We) ) (VP (VBP review)  (NP-COOD (NP (NP (DT the)  (NN control) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP (DT the)  (NP (NP (NN Tissue)  (NN Factor) ) (PRN (-LRB- -LRB-)  (NP (NN TF) ) (-RRB- -RRB-) )) (NN gene) ))))) (CC and)  (NP (NP (DT the)  (NN function) ) (PP (IN of)  (NP (DT the)  (NN TF)  (NN protein) ))))) (. .) ) )
(TOP (S (NP-SBJ-72 (NP (DT The)  (VBN enhanced)  (NN initiation) ) (PP (IN of)  (NP (NP (NN transcription) ) (PP (IN of)  (NP (DT the)  (NN TF)  (NN gene) ))))) (VP (VBZ appears)  (S (NP-SBJ (-NONE- *-72) ) (VP (TO to)  (VP (VB require)  (NP (NP (NN engagement) ) (PP (IN of)  (NP (NP (DT a)  (ADJP (CD 56)  (NN bp) ) (NN LPS)  (NN Response)  (NN Element) ) (, ,)  (NP (NP (DT an)  (NN enhancer) ) (SBAR (WHNP-73 (WDT that) ) (S (NP-SBJ-74 (-NONE- *T*-73) ) (VP (VBZ is)  (VP (VBN engaged)  (NP (-NONE- *-74) ) (PP (IN by)  (NP-LGS-COOD (DT both)  (NP (NN AP-1)  (NN type)  (JJ heterodimeric)  (NNS complexes) ) (CONJP (RB as)  (RB well)  (IN as) ) (NP (ADJP (NP (NN NF)  (NN kappa)  (NN B) ) (IN like) ) (JJ heterodimeric)  (NNS complexes) ))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (NN Dissociation) ) (PP (IN of)  (NP (NN NF)  (NN kappa)  (NN B) )) (PP (IN from)  (NP (NN Ig)  (NN kappa)  (NN B) )) (PP (IN by)  (NP-COOD (NP (NP-COOD (NP (NN cytokine) ) (CC and)  (NP (NN LPS) )) (NN stimulation) ) (, ,)  (CC and)  (NP (ADVP (RB possibly) ) (VBN activated)  (NN T)  (NNS cells) ) (, ,) ))) (VP (MD may)  (VP (VB represent)  (NP (NP (DT a)  (JJ common)  (NN pathway) ) (PP (TO to)  (NP (NP (NN induction) ) (PP (IN of)  (NP (DT the)  (NP-COOD (NP (NN TF)  (NP (-NONE- *RNR*-108) )) (CC and)  (NP (JJ other)  (JJ inflammatory)  (NP (-NONE- *RNR*-108) ))) (NP-108 (NNS genes) )))))))) (. .) ) )
(TOP (S (NP-SBJ-75 (NP (NN Enhancement) ) (PP (IN of)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NN TF) ))))) (VP (VBZ is)  (VP (VBN observed)  (NP (-NONE- *-75) ) (PP-TMP-COOD (PP (IN upon)  (NP (NP (NN adhesion) ) (PP (IN of)  (NP (NN Mo) )) (PP (TO to)  (NP-COOD (NP (JJ endothelial)  (NNS cells) ) (CC and)  (NP (JJ extracellular)  (JJ matrix)  (NNS proteins) ))))) (, ,)  (CONJP (RB as)  (RB well)  (IN as) ) (PP (IN upon)  (NP (NP (NN engagement) ) (PP (IN of)  (NP (NN leukocyte)  (NNS integrins) ))))))) (. .) ) )
(TOP (S (NP-SBJ-76 (NP (DT The)  (JJ biological)  (NNS effects) ) (SBAR (WHNP-77 (WDT that) ) (S (NP-SBJ (-NONE- *T*-77) ) (VP (VBP follow)  (PP (IN from)  (NP (NP (NN expression) ) (PP (IN of)  (NP (NN TF) )) (PP (IN by)  (NP (JJ vascular)  (NNS cells) )))))))) (VP (VBP have)  (VP (VBN been)  (VP (VBN resolved)  (NP (-NONE- *-76) ) (PP (IN by)  (NP-LGS (NP (NN analysis) ) (PP (IN of)  (NP (NN function) )) (VP (VBN aided)  (NP (-NONE- *) ) (PP (IN by)  (NP-LGS (NP (DT the)  (NN use) ) (PP (IN of)  (NP-COOD (NP (JJ recombinant)  (JJ full)  (NN length)  (NN TF) ) (CC and)  (NP (NP (VBN truncated)  (NN surface)  (NN domain) ) (PP (IN of)  (NP (NN TF) ))))))))))))) (. .) ) )
(TOP (S (NP-SBJ-78 (NP (DT The)  (NNS rules) ) (PP (IN of)  (NP (NP (NN assembly) ) (PP (IN of)  (NP (NP (NP (DT the)  (JJ cognate)  (NNS ligands) ) (PP (IN of)  (NP (NN TF) ))) (, ,)  (RB namely)  (NP-COOD (NP (DT the)  (NN zymogen)  (NN plasma)  (NNS factors)  (NN VII) ) (CC and)  (NP (DT the)  (NN serine)  (NN protease)  (NN factor)  (NN VIIa) )) (, ,) )) (PP (IN with)  (NP (NP (DT the)  (JJ soluble)  (NN surface)  (NN domain) ) (PP (IN of)  (NP (NN TF) )) (PP (IN in)  (NP (JJ free)  (NN solution) )))))) (, ,)  (PP (IN in)  (NP (NP (DT the)  (NN presence) ) (PP-COOD (PP (IN of)  (NP-COOD (NP (JJ phospholipid)  (NNS surfaces) ) (CC and)  (NP (NN cell)  (NN surface) ))) (CC and)  (PP (IN of)  (NP (DT the)  (VBN anchored)  (NN TF)  (NN molecule) )))))) (VP (VBP have)  (VP (VBN been)  (VP (VBN described)  (NP (-NONE- *-78) )))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP It) ) (SBAR (-NONE- *EXP*-79) )) (VP (VBZ is)  (ADJP-PRD (JJ evident) ) (SBAR-79 (IN that)  (S (NP-SBJ (NP (NN assembly) ) (PP (IN of)  (NP (NP (DT the)  (NN surface)  (NN domain) ) (PP (IN of)  (NP (NN TF) )))) (PP (IN with)  (NP (NN VIIa) )) (SBAR (WHNP-80 (-NONE- 0) ) (S (NP-SBJ (-NONE- *T*-80) ) (VP (TO to)  (VP (VB form)  (NP (DT the)  (JJ binary)  (NN TF.VIIa)  (NN complex) )))))) (VP (VBZ induces)  (NP (NP (DT a)  (JJ significant)  (NN increase) ) (PP (IN in)  (NP (NP (DT the)  (NN Kcat) ) (PP (IN of)  (NP (NP (DT the)  (JJ catalytic)  (NN domain) ) (PP (IN of)  (NP (NN VIIa) )) (PP-COOD (PP (IN for)  (NP (JJ small)  (JJ peptidyl)  (NNS substrates) )) (CC and)  (PP (ADVP (JJR more)  (RB profoundly) ) (IN for)  (NP (NN protein)  (NN substrate) )))))))))))) (. .) ) )
(TOP (S (NP-SBJ (DT This) ) (VP (VBZ provides)  (NP (NP (JJ substantial)  (NN evidence) ) (PP (IN for)  (NP (NP (DT an)  (JJ allosteric)  (NN effect) ) (PP (IN on)  (NP (NP (DT the)  (JJ catalytic)  (NN cleft) ) (PP (IN of)  (NP (NP (NN VIIa) ) (SBAR (WHNP-81 (WDT that) ) (S (NP-SBJ-82 (-NONE- *T*-81) ) (VP (VBZ is)  (VP (VBN imparted)  (NP-83 (-NONE- *-82) ) (PP (IN by)  (S (NP-SBJ (-NONE- *-83) ) (VP (VBG binding)  (PP (TO to)  (NP (NP (NN TF) ) (, ,)  (NP (PRP$ its)  (JJ cognate)  (JJ catalytic)  (NN cofactor) )))))))))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP It) ) (SBAR (-NONE- *EXP*-300) )) (VP (VBZ is)  (ADJP-PRD (RB also)  (JJ evident) ) (SBAR-300 (IN that)  (S (NP-SBJ (DT the)  (NN TF.VIIa)  (NN complex) ) (VP-COOD (VP (VBZ is)  (ADJP-PRD (RB proteolytically)  (JJ active) )) (CC and)  (VP (MD can)  (VP (VB activate)  (NP (DT the)  (NN zymogen)  (NN plasma)  (NN factor)  (NN X) ) (PP (TO to)  (NP (NP (DT the)  (NN serine)  (NN protease)  (NN Xa) ) (PP (IN in)  (NP (JJ free)  (NN solution) ))))))))) (, ,)  (S (NP-SBJ (-NONE- *) ) (VP (VBG inferring)  (SBAR (IN that)  (S (NP-SBJ-301 (NP (VBN extended)  (NN substrate)  (NN recognition) ) (PP (IN by)  (NP (NP (VBN induced)  (JJ structural)  (NNS loci) ) (PP (IN of)  (NP (DT the)  (NN TF.VIIa)  (NN complex) ))))) (VP (VBP are)  (VP (VBN created)  (NP (-NONE- *-301) ) (PP (IN from)  (NP (NP-COOD (NP (DT either)  (NP (-NONE- *RNR*-302) )) (CC or)  (NP (DT both)  (NP (-NONE- *RNR*-302) ))) (NP-302 (NNS proteins) ))) (S (NP-SBJ (-NONE- *) ) (VP (TO to)  (VP (VB constitute)  (NP (DT a)  (JJ new)  (NN recognition)  (NN structure) ))))))))))) (. .) ) )
(TOP (S (NP-SBJ (NP (PRP It) ) (SBAR (-NONE- *EXP*-84) )) (VP (VBZ is)  (ADJP-PRD (RB also)  (JJ evident) ) (SBAR-84 (IN that)  (S (NP-SBJ-85 (NP (NN association) ) (PP (IN of)  (NP (NN X) )) (PP (IN with)  (NP (JJ charged)  (JJ phospholipid)  (NNS surfaces) ))) (VP (VBZ enhances)  (NP (NP (DT the)  (JJ proteolytic)  (NN activation) ) (PP (IN of)  (NP (DT this)  (NN zymogen) ))) (PP (IN by)  (S (NP-SBJ (-NONE- *-85) ) (VP (VBG increasing)  (NP (NP-COOD (NP (NN recognition) ) (CC and)  (NP (NN susceptibility) )) (PP (IN of)  (NP (NP (DT the)  (NN sessile)  (NN peptide)  (NN bond) ) (VP (VBN deduced)  (NP (-NONE- *) ) (PP (IN from)  (NP (DT the)  (NP (ADVP-109 (RB markedly) ) (NP-COOD (NP (ADJP (ADVP (-NONE- *RNR*-109) ) (VBN decreased) ) (NN Km) ) (CC and)  (NP (ADJP (ADVP (-NONE- *RNR*-109) ) (VBN increased) ) (NN Kcat) )))))))))))))))) (. .) ) )
(TOP (NP (NP (NN Involvement)) (PP (IN of) (NP (NN Alu) (NNS sequences))) (PP (IN in) (NP (NP (DT the) (JJ cell-specific) (NN regulation)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (NN gamma) (NN chain)) (PP (IN of) (NP (NP-COOD (NP (NN Fc)) (CC and) (NP (NN T) (NN cell))) (NNS receptors))))))))) (. .)))
(TOP (S (NP-SBJ-42 (DT The) (NN Fc) (NN epsilon) (NN RI-gamma) (NNS chains)) (VP (VBP are) (VP (VBN expressed) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (JJ hematopoietic) (NNS cells)) (SBAR (WHADVP-43 (WRB where)) (S (NP-SBJ (PRP they)) (VP (VBP play) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NN signal) (NN transduction)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP They)) (VP (VBP are) (NP-PRD-COOD (NP (NP (NN part)) (PP (IN of) (NP (DT the) (JJ high) (NN affinity) (NN IgE) (NN receptor))) (PP (IN in) (NP-COOD (NP (NN mast) (NNS cells)) (, ,) (NP (NNS basophils)) (, ,) (NP (NN Langerhans) (NNS cells)) (, ,) (CC and) (NP (RB possibly) (JJ other) (NNS cells))))) (: ;) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (NP (DT the) (JJ low) (NN affinity) (NN receptor)) (PP (IN for) (NP (NN IgG) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Fc) (NN gamma) (NN RIIIA)) (CC or) (NP (NN CD16))) (-RRB- -RRB-)))))) (PP (IN in) (NP-COOD (NP (JJ natural) (NN killer) (NNS cells)) (CC and) (NP (NNS macrophages))))) (: ;) (CC and) (NP (NP (NN part)) (PP (IN of) (NP (DT the) (NN T) (NN cell) (NN antigen) (NN receptor))) (PP (IN in) (NP (NP (NNS subsets)) (PP (IN of) (NP (NN T) (NNS cells)))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ-44 (PRP we)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NN gamma) (NN chain) (NN gene)))) (PP (IN by) (S (VP (VBG analyzing) (NP (NP (DT the) (JJ 2.5-kilobase) (NN sequence)) (ADVP (JJ upstream) (PP (IN of) (NP (DT the) (NN transcription) (NN start) (NN site)))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN sequence)) (VP (VBZ contains) (NP (NP (DT a) (NN promoter)) (ADJP (JJ specific) (PP (TO to) (NP (NP (NNS cells)) (PP (IN of) (NP (JJ hematopoietic) (NN lineage)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (NN tissue) (NN specificity)) (PP (IN of) (NP (DT this) (NN promoter)))) (VP (VBZ is) (ADJP-PRD (RB only) (JJ partial)) (SBAR (IN because) (S (NP-SBJ (PRP it)) (VP (VBZ is) (ADJP-PRD (JJ active)) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (NP (DT the) (JJ hematopoietic) (NNS cells)) (VP (VBN tested) (ADVP (RB here))))))) (, ,) (ADVP (RB regardless) (PP (IN of) (SBAR (IN whether) (S (NP-SBJ (PRP they)) (ADVP (RB constitutively)) (VP (VBP express) (NP (NN Fc) (NN epsilon) (SYM RI-) (NN gamma) (NN chain) (NNS transcripts))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN identified) (NP (NP (CD two) (JJ adjacent) (JJ cis-acting) (JJ regulatory) (NNS elements)) (, ,) (SBAR (WHNP-45 (NP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (NP-PRD (NP (NN part)) (PP (IN of) (NP (DT an) (NN Alu) (NN repeat)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ first)) (PRN (-LRB- -LRB-) (NP (CD -445/-366)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ positive) (NN element)) (ADJP (JJ active) (PP (IN in) (NP-COOD (CC both) (NP (NNS basophils)) (CC and) (NP (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ second)) (PRN (-LRB- -LRB-) (NP (CD -365/-264)) (-RRB- -RRB-))) (VP-COOD (VP (VBZ binds) (PP (TO to) (NP (NP (JJ nuclear) (NNS factors)) (, ,) (SBAR (WHNP-46 (WDT which)) (S (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ different)) (PP (IN in) (NP-COOD (NP (NNS basophils)) (CC and) (NP (NN T) (NNS cells))))))))))))) (, ,) (CC and) (VP-COOD (VP (VBZ acts) (PP-48 (IN as) (NP (DT a) (JJ negative) (NN element))) (PP-49 (IN in) (NP (NNS basophils)))) (CC and) (VP (PP=48 (IN as) (NP (DT a) (JJ positive) (NN one))) (PP=49 (IN in) (NP (NN T) (NNS cells)))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-50 (NP (DT this) (NN Alu) (NN repeat)) (-LRB- -LRB-) (ADJP (NP (CD 90)) (NN %) (PP (JJ identical) (NP (TO to) (NN Alu) (NN consensus)))) (NNS sequences)) (VP (-RRB- -RRB-) (VP (VBZ has) (S (VP (VBN evolved) (VP (TO to) (NP-PRD (VB become) (CC both) (ADJP-COOD (ADJP (DT a)) (JJ positive) (ADJP (CC and))) (JJ negative))))))) (NN regulator)))
(TOP (S (NP-SBJ (NP (JJ Human) (NN immunodeficiency) (NNS viruses)) (VP (VBG containing) (NP (JJ heterologous) (NNS enhancer/promoters)))) (VP-COOD (VP (VBP are) (ADJP-PRD (NN replication) (JJ competent))) (CC and) (VP (VBP exhibit) (NP (JJ different) (NN lymphocyte) (NNS tropisms)))) (. .)))
(TOP (S (NP-SBJ (DT The) (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))) (NN type) (CD 1) (NP (NP (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-)))) (VP (VBZ contains) (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (NP-COOD (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (CC and) (NP (DT the) (ADJP (RB constitutively) (VBN expressed)) (NN transcription) (NN factor) (NN Sp1))) (, ,) (SBAR (WHNP-59 (NP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (VP (ADVP (RB highly)) (VBN conserved) (PP (IN in) (NP (NP-COOD (NP (NN HIV)) (CC and) (NP (JJ simian) (NN immunodeficiency) (NN virus))) (NNS isolates))))))))))) (. .)))
(TOP (S (S (VP-COOD (VP (TO To) (VP (VB delineate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT these) (NNS motifs))) (PP (IN on) (NP (NP (DT the) (JJ replicative) (NN capacity)) (PP (IN of) (NP (NN HIV)))))))) (CC and) (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN possibility)) (PP (IN of) (S (VP (VBG extending) (NP (DT the) (NN virus) (NN host) (NN range)))))))))) (, ,) (NP-SBJ-61 (VBN known) (JJ heterologous) (NNS enhancer/promoters)) (VP (VBD were) (VP (VBN inserted) (PP (IN into) (NP (DT the) (NN HIV-1) (NN LTR))) (PP (IN in) (NN place) (IN of) (NP (DT the) (NP-COOD (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN Sp1))) (NN binding) (NNS sites))))) (. .)))
(TOP (S (NP-SBJ-62 (NP (DT The) (NNS effects)) (PP (IN of) (NP (DT these) (NNS substitutions))) (PP-COOD (PP (IN on) (NP (NP (JJ viral) (NN replication)) (PP (IN in) (NP (VBN transfected) (NN HeLa) (NNS cells))))) (CC and) (PP (IN on) (NP (NP (NN HIV) (NN infection)) (PP (IN of) (NP-COOD (NP (JJ human) (JJ peripheral) (NN blood) (NNS lymphocytes)) (CC or) (NP (JJ continuous) (NN T-leukemia) (NN cell) (NNS lines)))))))) (VP (VBD were) (VP (VBN evaluated))) (. .)))
(TOP (S (NP-SBJ-63 (NP (NN HIVs)) (SBAR (WHPP-64 (IN in) (WHNP (WDT which))) (S (NP-SBJ-COOD-65 (NP (DT the) (NN NF-) (NN kappa) (NN B/Sp1) (NN enhancer)) (CC plus) (NP (DT the) (JJ downstream) (NN TATA) (NN element))) (VP (VBD were) (VP (VBN replaced) (PP (IN with) (NP (JJ heterologous) (NNS enhancer/promoters)))))))) (VP (VBD were) (VP (ADVP (RB also)) (VBN constructed))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Viruses)) (VP (VBG containing) (NP (DT the) (JJ human) (NN cytomegalovirus) (JJ immediate-early) (NN enhancer)))) (VP-COOD (VP (VBD exhibited) (NP (NP (JJ infectious) (NNS kinetics)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (JJ wild-type) (NN HIV))))))) (PP (IN in) (NP-COOD (NP (VBN activated) (JJ human) (JJ peripheral) (NN blood) (NNS lymphocytes)) (CC and) (NP (NN AA2) (NNS cells))))) (CC but) (VP (VBD replicated) (ADVP (RBR less) (RB efficiently)) (PP (IN in) (NP (NP-COOD (NP (NN H9)) (CC and) (NP (NN CEM))) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-103 (JJ heterologous) (NN enhancer) (NNS elements)) (VP (VBP are) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG restoring) (NP (NP (NN Tat) (NN responsiveness)) (PP (TO to) (NP (DT the) (NN HIV) (NN LTR)))) (PP-COOD (PP (IN in) (DT the) (NN context) (IN of) (S (VP (VBG directing) (NP (NN reporter) (NN gene) (NN expression))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (JJ infectious) (NN progeny) (NNS virions)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Tyrosine) (NN phosphorylation)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ mandatory) (JJ proximal) (NN step)) (PP (IN in) (NP (NP (JJ radiation-induced) (NN activation)) (PP (IN of) (NP (DT the) (NN protein) (NN kinase) (NN C) (NN signaling) (NN pathway))) (PP (IN in) (NP (JJ human) (NN B-) (NN lymphocyte) (NNS precursors)))))) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP Proc) (NNP Natl) (NNP Acad) (NNP Sci) (NNP U) (NNP S) (NNP A)) (NP-TMP (CD 1993) (NNP Apr) (CD 15)) (: ;) (NP (CD 90) (-LRB- -LRB-) (CD 8) (-RRB- -RRB-) (: :) (CD 3775)))))) (-RRB- -RCB-)))))
(TOP (S (NP-SBJ (VBG Ionizing) (NN radiation)) (VP (VBZ triggers) (NP (NP (DT a) (NN signal)) (PP (IN in) (NP (JJ human) (NN B-lymphocyte) (NNS precursors))) (SBAR (WHNP-66 (WDT that)) (S (VP (VBZ is) (VP (ADVP (RB intimately)) (VBN linked) (PP (TO to) (NP (DT an) (JJ active) (NN protein-tyrosine) (NN kinase) (JJ regulatory) (NN pathway))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (PP (IN in) (NP (NN B-lymphocyte) (NNS precursors))) (, ,) (NP-SBJ (NP (NN irradiation)) (PP (IN with) (NP (NNS gamma-rays)))) (VP (VBZ leads) (PP (TO to) (NP-COOD (NP (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (NN stimulation)) (PP (IN of) (NP (NN phosphatidylinositol) (NN turnover)))) (: ;) (NP (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (NP (JJ downstream) (NN activation)) (PP (IN by) (NP (NP (JJ covalent) (NN modification)) (PP (IN of) (NP (NP (JJ multiple) (JJ serine-specific) (NN protein) (NNS kinases)) (, ,) (PP (VBG including) (NP (NN protein) (NN kinase) (NN C)))))))) (: ;) (CC and) (NP (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP (NN activation)) (PP (IN of) (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)))))))))) (. .)))
(TOP (S (NP-SBJ-68 (NP (DT All)) (PP (IN of) (NP (DT the) (JJ radiation-induced) (NNS signals)))) (VP (VBD were) (VP (ADVP (RB effectively)) (VBN prevented) (PP (IN by) (NP-LGS (DT the) (NN protein-tyrosine) (NN kinase) (NNS inhibitors) (NP-COOD (NP (NN genistein)) (CC and) (NP (NN herbimycin) (NN A))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NN tyrosine) (NN phosphorylation)) (VP (VBZ is) (NP-PRD (NP (DT an) (ADJP-COOD (ADJP (JJ important)) (CC and) (ADJP (ADVP (RB perhaps)) (JJ mandatory))) (JJ proximal) (NN step)) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NN protein) (NN kinase) (NN C) (NN signaling) (NN cascade))) (PP (IN in) (NP (JJ human) (NN B-lymphocyte) (NNS precursors))))))) (. .)))
(TOP (S (NP-SBJ-69 (PRP$ Our) (VBP report)) (VP (NNS expands) (NP (NP (JJ current) (NN knowledge)) (PP (IN of) (NP (DT the) (JJ radiation-induced) (NN signaling) (NN cascade)))) (PP (IN by) (S (VP (VBG clarifying) (NP (NP (DT the) (JJ chronological) (NN sequence)) (PP (IN of) (NP (NP (JJ biochemical) (NNS events)) (SBAR (WHNP-70 (WDT that)) (S (VP (VBP follow) (NP (NN irradiation)))))))))))) (. .)))
(TOP (NP (NP (DT A) (JJ human) (JJ putative) (NN lymphocyte) (NN G0/G1) (VBP switch) (NN gene)) (ADJP (JJ homologous) (PP (TO to) (NP (NP (DT a) (JJ rodent) (NN gene)) (VP (VBG encoding) (NP (DT a) (JJ zinc-binding) (JJ potential) (NN transcription) (NN factor)))))) (. .)))
(TOP (S (NP-SBJ (NN G0S24)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN member)) (PP (IN of) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (NP (NNS genes)) (PRN (-LRB- -LRB-) (NP (JJ putative) (NN G0/G1) (NN switch) (JJ regulatory) (NNS genes)) (-RRB- -RRB-))) (SBAR (WHNP-87 (WDT that)) (S (VP (VBP are) (VP (VBN expressed) (ADVP-TMP (RB transiently)) (PP-TMP (IN within) (NP (NP (QP (CD 1-2)) (NN hr)) (PP (IN of) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP-COOD (NP (NN lectin)) (CC or) (NP (NN cycloheximide)))) (PP (TO to) (NP (JJ human) (NN blood) (JJ mononuclear) (NNS cells))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Comparison)) (PP (IN of) (NP (DT a) (JJ full-length) (NN cDNA) (NN sequence))) (PP (IN with) (NP (DT the) (JJ corresponding) (JJ genomic) (NN sequence)))) (VP (VBZ reveals) (NP (NP (DT an) (JJ open) (NN reading) (NN frame)) (PP (IN of) (NP (CD 326) (NN amino) (NNS acids))) (, ,) (VP (VBN distributed) (PP (IN across) (NP (CD two) (NNS exons)))))) (. .)))
(TOP (S (NP-SBJ (JJ Potential) (NN phosphorylation) (NNS sites)) (VP (VBP include) (NP (NP (DT the) (NN sequence) (NN PSPTSPT)) (, ,) (SBAR (WHNP-89 (WDT which)) (S (VP (VBZ resembles) (NP (NP (DT an) (NN RNA) (NN polymerase) (CD II) (NN repeat)) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (NP-PRD (NP (DT a) (NN target)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle) (NN control) (NN kinase) (NN cdc2)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Comparison)) (PP (IN of) (NP (DT the) (VBN derived) (NN protein) (NN sequence))) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (JJ rodent) (NNS homologs)))))) (VP (VBZ allows) (NP (NP (NN classification)) (PP (IN into) (NP (CD three) (NNS groups))))) (. .)))
(TOP (S (NP-SBJ (NN Group) (CD 1)) (VP (VBZ contains) (NP-COOD (NP (NN G0S24)) (CC and) (NP (NP (DT the) (NP-COOD (NP (NN rat)) (CC and) (NP (NN mouse))) (NN TIS11) (NNS genes)) (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP-COOD (NP (NN TTP)) (, ,) (NP (NN Nup475)) (, ,) (CC and) (NP (NN Zfp36))))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Members)) (PP (IN of) (NP (DT this) (NN group)))) (VP (VBP have) (NP (CD three) (JJ tetraproline) (NNS repeats))) (. .)))
(TOP (S (NP-SBJ (NNS Groups) (NP-COOD (NP (CD 1)) (CC and) (NP (CD 2)))) (VP (VBP have) (NP-COOD (NP (DT a) (JJ serine-rich) (NN region)) (CC and) (NP (NP (DT an) (`` ") (NN arginine) (NN element) ('' ")) (PRN (-LRB- -LRB-) (NP (NN RRLPIF)) (-RRB- -RRB-)))) (PP (IN at) (NP (DT the) (NN carboxyl) (NN terminus)))) (. .)))
(TOP (S (NP-SBJ (DT All) (NNS groups)) (VP (VBP contain) (NP-COOD (NP (ADJP-COOD (ADJP (NP (NN cysteine-))) (CC and) (ADJP (JJ histidine-rich))) (JJ putative) (NN zinc) (NN finger) (NNS domains)) (CC and) (NP (NP (DT a) (JJ serine-phenylalanine) (`` ") (NNS SFS) ('' ") (NN domain)) (ADJP (JJ similar) (PP (TO to) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT the) (JJ large) (NN subunit)) (PP (IN of) (NP (JJ eukaryotic) (NN RNA) (NN polymerase) (CD II))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Comparison)) (PP (IN of) (NP (NN group) (CD 1) (UCP-COOD (ADJP (JJ human)) (CC and) (NP (NN mouse))) (JJ genomic) (NNS sequences)))) (VP (VBZ shows) (NP (NP (JJ high) (NN conservation)) (PP (IN in) (NP-COOD (NP (DT the) (JJ 5') (NN flank)) (CC and) (NP (NNS exons)))))) (. .)))
(TOP (S (NP-SBJ (DT A) (NN CpG) (NN island)) (VP (VBZ suggests) (NP (NP (NN expression)) (PP (IN in) (NP (DT the) (NN germ) (NN line))))) (. .)))
(TOP (S (S (NP-SBJ (NN G0S24)) (VP (VBZ has) (NP (NP (JJ potential) (NNS sites)) (PP (IN for) (NP (NN transcription) (NNS factors)))) (PP (IN in) (NP-COOD (NP (DT the) (JJ 5') (NN flank)) (CC and) (NP (NN intron))))) (: ;)) (S (NP-SBJ (DT these)) (VP (VBP include) (NP (DT a) (NN serum) (NN response) (NN element))) (. .))))
(TOP (S (NP-SBJ (UCP-COOD (NP (NN Protein)) (CC and) (ADJP (JJ genomic))) (NNS sequences)) (VP (VBP show) (NP (NP (NNS similarities)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS proteins)) (VP (VBN involved) (PP (IN in) (NP (NN transcription))))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (DT the) (NN G0S24) (NN product)) (VP (VBZ has) (NP (DT a) (JJ similar) (NN role)))))))) (. .)))
(TOP (S (NP-SBJ (NN Interleukin-4)) (VP (VBZ inhibits) (NP (NP (DT the) (NP-COOD (NP (NP (JJ lipopolysaccharide-induced) (NN expression)) (PP (IN of) (NP (NP-COOD (NP (NN c-jun)) (CC and) (NP (NN c-fos))) (NN messenger) (NN RNA)))) (CC and) (NP (NN activator) (NN protein-1) (NN binding) (NN activity)))) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN interleukin-4)) (PRN (-LRB- -LRB-) (NP (NN IL-4)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))) (NN induction)) (PP (IN of) (NP (CD two) (JJ immediate) (JJ early) (NNS genes) (NP-COOD (NP (NN c-fos)) (CC and) (NP (NN c-jun))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS genes)) (VP (VBP encode) (NP (NP (NNS proteins)) (SBAR (WHNP-80 (WDT that)) (S (VP (VBP form) (NP (NP (NP (DT the) (JJ dimeric) (NN complex) (NN activator) (NN protein-1)) (PRN (-LRB- -LRB-) (NP (NN AP-1)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP-81 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ active)) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN factor)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Maximal) (NN accumulation)) (PP (IN of) (NP (NP-COOD (CC either) (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (NP (NP (NN messenger) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN mRNA)) (-RRB- -RRB-)))))) (VP (VBD occurred) (PP-TMP (NP (CD 30) (NNS minutes)) (IN after) (NP (NN LPS) (NN addition)))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-82 (WRB When)) (S (NP-SBJ-83 (NNS cells)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NN IL-4))) (PP-TMP (IN for) (NP (CD 5) (NNS hours))) (PP-TMP (IN before) (NP (NN LPS) (NN activation))))))) (, ,) (NP-SBJ-84 (NP-COOD (CC both) (NP (DT the) (NN c-fos)) (CC and) (NP (DT the) (NN c-jun))) (NP-85 (NN mRNA) (NN expression))) (VP (VBD was) (VP (VBN decreased))) (. .)))
(TOP (S (NP-SBJ-86 (NP (DT The) (NN inhibition)) (PP (IN of) (NP (NP-COOD (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (NN expression))) (PP (IN by) (NP (NN IL-4))) (PP (IN in) (NP (JJ LPS-treated) (NNS cells)))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (NP (DT a) (JJR lower) (NN transcription) (NN rate)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (NNS genes)))))))))) (. .)))
(TOP (S (NP-SBJ (NN IL-4)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN stability)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (NNS transcripts)))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (S (VP (VBG using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))) (, ,) (NP-SBJ-101 (NN evidence)) (VP (VBD was) (VP (VBN obtained) (SBAR-100 (IN that) (S (NP-SBJ (NN IL-4)) (VP (VBZ inhibits) (NP (NP (JJ LPS-induced) (NN expression)) (PP (IN of) (NP (NN AP-1) (NN protein))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN IL-4)) (VP (VBZ suppresses) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN transcription) (NNS factors))) (PP (IN in) (NP (JJ human) (VBN activated) (NNS monocytes)))))))) (. .)))
(TOP (S (NP-SBJ-65 (NP (NN Ras) (NN oncogene) (NN transformation)) (PP (IN of) (NP (JJ human) (NN B) (NNS lymphoblasts)))) (VP (VBZ is) (VP (VBN associated) (PP-COOD (PP (IN with) (NP (NN lymphocyte) (NN activation))) (CC and) (PP (IN with) (NP (NP (DT a) (NN block)) (PP (IN of) (NP (NN differentiation)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN p21ras) (JJ small) (NN GTP) (NN binding) (NNS proteins)) (VP-COOD (VP (VBP participate) (PP (IN in) (NP (NP (JJ signal) (NN transduction)) (PP (IN from) (NP (NN cell) (NN surface) (NNS receptors)))))) (CC and) (VP (VB affect) (NP (NP (JJ neoplastic) (NP-COOD (NP (NN transformation)) (CC and) (NP (NN development)))) (PP (IN in) (NP (JJ many) (JJ different) (NN cell) (NNS types)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN ras) (NP-COOD (NP (NN transformation)) (CC and) (NP (NN differentiation)))) (PP (IN of) (NP (JJ human) (NN B) (NNS lymphocytes))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-66 (NP (DT the) (JJ constitutive) (NN expression)) (PP (IN of) (NP (DT the) (NN T24) (NN Ha-ras) (NN oncogene))) (PP (IN in) (NP (JJ EBV-immortalized) (NN B) (NNS lymphoblasts)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (DT the) (NN interleukin) (CD 2) (NN receptor) (NN alpha) (NN subunit))))) (, ,) (PP (IN with) (NP-COOD (NP (DT an) (JJ impaired) (NN immunoglobulin) (NN gene) (NN expression)) (, ,) (NP (JJ altered) (NN adhesion) (NNS properties)) (CC and) (NP (NP (VBN increased) (NN survival)) (PP (IN in) (NP (JJ serum-free) (NN medium))))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (NP (NN induction)) (PP (IN of) (NP (DT the) (NN IL-2) (NN receptor) (NN alpha) (NN subunit)))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN hallmark)) (PP (IN of) (NP (NN lymphocyte) (NN activation))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN p21ras)) (ADVP (RB naturally)) (VP (VBZ triggers) (NP (NN B) (NN cell) (NN activation)))))) (. .)))
(TOP (S (S (NP-SBJ (DT The) (JJ ras-transformed) (NNS lymphocytes)) (VP (VBD displayed) (NP (DT a) (ADJP (RB fully) (JJ functional)) (NN IL-2r)) (, ,) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (NN c-fos) (NN induction)) (PP-TMP (VBG following) (NP (NP (NN treatment)) (PP (IN with) (NP (NN IL-2)))))))))))) (: ;) (S (ADVP (RB nevertheless)) (, ,) (NP-SBJ (PRP they)) (VP (VBD were) (RB not) (NP-PRD (NP (NN growth)) (VP (VBN stimulated) (PP (IN by) (NP (DT this) (NN lymphokine))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (VBN decreased) (NN expression)) (PP (IN of) (NP (NN immunoglobulin) (NNS genes)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ-68 (DT the) (NN ras) (NN oncogene)) (VP (VBZ blocks) (NP (NP (JJ terminal) (NN differentiation)) (PP (TO to) (NP (NN plasma) (NNS cells)))) (, ,) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ lymphocyte-specific) (NN transcription) (NNS factors))))))))))) (. .)))
(TOP (S (ADVP (RB Somewhat) (RB unexpectedly)) (, ,) (NP-SBJ (DT the) (JJ constitutive) (NN p21ras) (NN activity)) (VP (VBD did) (RB not) (VP (VB cause) (NP (NP (DT an) (VBN increased) (NN DNA) (NN binding)) (PP (IN of) (NP (NN transcription) (NNS factors) (NP-COOD (NP (NP (NN PEA1)) (PRN (-LRB- -LRB-) (NP (NN AP1)) (-RRB- -RRB-))) (, ,) (NP (NN PEA3)) (, ,) (NP (NN Oct-2)) (CC or) (NP (NN NF-kB)))))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Transcription) (NN factor) (NN GATA-1)) (CC and) (NP (JJ erythroid) (NN development))) (. .)))
(TOP (S (PP (IN In) (NP (NN summary))) (, ,) (NP-SBJ (PRP we)) (VP (VBD derived) (NP (NP (DT an) (JJ experimental) (NN system)) (SBAR (WHNP-62 (WDT that)) (S (VP (VBZ allows) (S (NP-SBJ (PRP us)) (VP (TO to) (VP (VB dissect) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NN GATA-1))) (PP (IN in) (NP (JJ red) (NN cell) (NN development))) (PP (IN at) (NP (DT a) (JJ genetic) (NN level)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN established) (NP (NP (DT the) (JJ essential) (NN nature)) (PP (IN of) (NP (NN GATA-1))) (PP-TMP (IN during) (NP (ADJP-COOD (CC both) (ADJP (JJ primitive)) (CC and) (ADJP (JJ definitive))) (NN erythropoiesis)))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG ablating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (JJ endogenous) (NN GATA-1) (NN gene))))))) (, ,) (NP-SBJ-63 (PRP we)) (VP (VBP are) (PP-PRD (IN in) (NP (NP (DT a) (NN position)) (SBAR (S (VP (TO to) (VP (VB introduce) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS constructs)) (SBAR (WHNP-65 (WDT that)) (S (VP (VBP harbor) (NP (NP (JJ subtle) (NNS modifications)) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ flanking)) (CC or) (ADJP (JJ protein-coding))) (NNS sequences))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (MD can) (ADVP-TMP (RB now)) (VP (VP (VB study) (NP (NP-COOD (NP (JJ regulatory) (NNS regions)) (CC and) (NP (JJ functional) (NNS domains))) (PP (IN of) (NP (DT the) (NN protein))) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (DT a) (JJ true) (JJ erythroid) (NN environment))))))) (, ,) (NP (NP (NNS experiments)) (SBAR (WHNP-66 (WDT that)) (S (VP (VBP have) (RB not) (VP (VBN been) (ADJP-PRD (JJ possible)) (ADVP-TMP (RB heretofore))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (DT the) (NN assay)) (VP (VBZ involves) (NP (NP (DT the) (JJ dramatic) (NN loss)) (PP (IN of) (NP (JJ red) (NN cell) (NN production))))))) (, ,) (NP-SBJ (NP (PRP it))) (VP (MD should) (VP (VB be) (ADJP-PRD (JJ possible)) (S-67 (VP (TO to) (VP (VB define) (NP (NP (JJ important) (JJ regulatory) (NNS domains)) (SBAR (WHNP-68 (WDT that)) (S (VP (MD can) (ADVP (RB then)) (VP (VB be) (VP (VBN assayed) (S (VP (VBG using) (NP (NP (ADJP (RBR less) (JJ stringent)) (NNS systems)) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ cell-free) (NNS extracts)) (PP (IN for) (NP (ADJP (FW in) (FW vitro)) (NN transcription))))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ ideal) (NN situation)) (VP (MD would) (VP (VB be) (NP-PRD (NP (NNS analyses)) (VP (VBN conducted) (PP (IN in) (NP (JJ GATA-1-) (NN erythroid) (NNS cells))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (DT these) (NNS cells)) (VP (VBP have) (VP (VBN been) (ADJP-PRD (JJ impossible) (SBAR (S (VP (TO to) (VP (VB generate)))))) (PP (VBN given) (NP (NP (DT the) (NN requirement)) (PP (IN of) (NP (NN GATA-1))) (PP (IN for) (NP-COOD (NP (NN Epo) (NN receptor) (NN expression)) (CC and) (NP (JJ red) (NN cell) (NN viability)))))) (PRN (-LRB- -LRB-) (FRAG (NP-COOD (NP (NNP C.) (NNP Simon)) (CC and) (NP (NNP S.) (NNP Orkin))) (, ,) (NP (JJ unpublished) (NNS observations))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ (NP (PRP It))) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ possible)) (S-71 (VP (TO to) (VP (VB produce) (NP (JJ such) (NNS cells)) (PP (IN by) (S (VP-COOD (VP (ADVP-TMP (RB first)) (VBG expressing) (NP (DT the) (NN Epo) (NN receptor)) (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (DT a) (JJ constitutive) (NN promoter)))))) (CC and) (VP (ADVP-TMP (RB then)) (VBG targeting) (NP (DT the) (NN GATA-1) (NN gene))))))))))) (. .)))
(TOP (S (SBAR (IN If) (S (NP-SBJ (JJ GATA-1-) (JJ -red) (NNS cells)) (VP (VBD were) (ADJP-PRD (JJ available))))) (, ,) (NP-SBJ (DT the) (NNS analyses)) (VP (MD would) (VP (VB involve) (NP (DT the) (NP-COOD (NP (NP (JJ actual) (NN transcription)) (PP (IN of))) (CC or) (NP (NP (NN chromatin) (NN structure)) (VP (VBG surrounding)))) (NP-73 (DT the) (NN globin) (NNS genes))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-74 (NP (JJ Structure-function) (NNS studies)) (PP (IN of) (NP (DT the) (NN GATA-1) (NN protein)))) (VP (MD could) (VP (VB be) (VP-75 (ADVP (RB greatly)) (VBN simplified))))) (CC and) (S (NP-SBJ=74-76 (NP (DT a) (JJR larger) (NN number)) (PP (IN of) (NP (NNS mutants)))) (VP=75 (VBN studied))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-77 (DT the) (NN ES) (NN cell) (NN system)) (VP (MD can) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (DT an) (NN alternative))) (SBAR-TMP (IN until) (S (NP-SBJ (VBN targeted) (NN erythroleukemia) (NNS cells)) (VP (VBP become) (ADJP-PRD (JJ available)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Other) (NNS applications)) (VP (VBP involve) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (JJ other) (JJ GATA-binding) (NN protein) (NN family) (NNS members))) (SBAR (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (PRP they)) (VP (VBP rescue) (NP (DT the) (NN mutation))))))))))) (. .)))
(TOP (S (SBAR (IN If) (S (NP-SBJ (PRP they)) (VP (MD can) (RB not)))) (, ,) (NP-SBJ-79 (JJ chimeric) (NNS proteins)) (VP (MD can) (VP (VB be) (VP (VBN tested) (S (VP (TO to) (VP (VB identify) (SBAR (WHNP-80 (WDT which) (NN amino) (NNS acids)) (S (VP (VBP distinguish) (NP (DT the) (JJ different) (NN family) (NNS members))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP feel) (SBAR (IN that) (S (NP-SBJ (DT these) (NNS experiments)) (VP (VBP are) (ADJP-PRD (JJ vital) (PP (TO to) (S (VP (VBG understanding) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NN GATA-1))) (PP-TMP (IN during) (NP (JJ erythroid) (NN ontogeny)))))))))))) (. .)))
(TOP (SBARQ (WHADVP-81 (WRB How)) (SQ (VBZ does) (NP-SBJ (NN GATA-1)) (VP (VB regulate) (NP (NP (JJ red) (NN cell) (NNS genes)) (PP (IN like) (NP-COOD (NP (NN globin)) (CC or) (NP (DT the) (NN Epo) (NN receptor))))))) (. ?)))
(TOP (S (SBAR-TMP (IN Once) (S (NP-SBJ (PRP we)) (VP (VB identify) (NP (NP (DT the) (JJ functional) (NNS domains)) (PP (IN of) (NP (DT the) (JJ GATA-binding) (NNS proteins))))))) (, ,) (NP-SBJ-82 (PRP we)) (VP (VBP hope) (S (VP (TO to) (VP (VB learn) (SBAR (WHNP-83 (WP what) (NNS proteins)) (S (NP-SBJ (NN GATA-1)) (VP (VBZ binds) (PP (TO to)) (PP-COOD (PP (IN in) (NP (DT the) (JJ basic) (NN transcription) (NN machinery))) (CC or) (PP (IN in) (NP (NN chromatin))))))))))) (. .)))
(TOP (SQ (VBZ Is) (NP-SBJ (NN GATA-1)) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NN globin) (NN gene) (NN switching)))) (. ?)))
(TOP (S (NP-SBJ-84 (NN GATA-1)) (VP (MD may) (VP (VB be) (VP (VBN modified) (ADVP (RB differently)) (PP-TMP (IN during) (NP (NN development))) (SBAR (IN so) (IN that) (S (NP-SBJ (DT the) (NN locus) (NN control) (NN region)) (VP (MD can) (VP (VB interact) (PP (IN with) (NP (JJ different) (NN globin) (NNS promoters)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (MD may) (VP (VB find) (SBAR (IN that) (S-COOD (S (NP-SBJ-85 (NP (CD one) (NN region)) (PP (IN of) (NP (DT the) (NN protein)))) (VP (VBZ is) (VP (VBN required) (PP-86 (IN for) (NP (JJ embryonic) (NN expression)))))) (CC and) (S (NP-SBJ=85 (DT another)) (PP=86 (IN for) (NP (JJ adult) (NN globin) (NN gene) (NN expression)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN zinc) (NN finger) (NN transcription) (NN factor) (NN Egr-1)) (VP (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for)))) (CC and) (VP (VBZ restricts))) (NP-55 (NP (NN differentiation)) (PP (IN along) (NP (DT the) (NN macrophage) (NN lineage))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN isolated) (NP (NP (NN cDNA) (NNS clones)) (PP (IN of) (NP (NP (NP (JJ myeloid) (NN differentiation) (JJ primary) (NN response)) (PRN (-LRB- -LRB-) (NP (NN MyD)) (-RRB- -RRB-))) (NNS genes))) (, ,) (VP (VBN activated) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NP (ADJP (FW de) (FW novo)) (NN protein) (NN synthesis)) (PP-TMP (VBG following) (NP (NP (NN induction)) (PP (IN for) (NP (NP (NN differentiation)) (PP (IN along) (NP (NP (CC either) (DT the) (NP-COOD (NP (NN macrophage)) (CC or) (NP (NN granulocyte))) (NN lineage)) (PP (IN in) (NP (JJ human) (JJ myeloblastic) (NN leukemia) (NN HL-60) (NNS cells))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD One) (NN cDNA) (NN clone)) (PP (IN of) (NP (DT a) (JJ primary) (NN response) (NN gene))) (, ,) (VP (VBN expressed) (PP-TMP (IN upon) (NP (NN macrophage) (NN differentiation)))) (, ,)) (VP (VBD encoded) (PP (IN for) (NP (NP (NN Egr-1)) (, ,) (NP (DT a) (NN zinc) (NN finger) (NN transcription) (NN factor))))) (. .)))
(TOP (S (NP-SBJ-56 (DT The) (NN Egr-1) (NN gene)) (VP (VBD was) (VP (VBN observed) (S (VP (TO to) (VP (VP-COOD (VP (VB be) (ADVP (RB transcriptionally)) (ADJP-PRD-102 (JJ silent)) (PP-103 (IN in) (NP (NN HL-60) (NNS cells)))) (, ,) (CC but) (VP (ADJP-PRD=102 (JJ active)) (PP=103 (IN in) (NP (NP-COOD (NP (NN U-937)) (CC and) (NP (NN M1))) (NNS cells))))) (, ,) (S (NP-SBJ (DT the) (JJ latter) (CD two)) (VP (VBG being) (ADJP-PRD (VBN predetermined)) (PP (IN for) (NP (NN macrophage) (NN differentiation)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Egr-1) (JJ antisense) (NNS oligomers)) (PP (IN in) (NP (DT the) (NN culture) (NNS media)))) (VP (VBD blocked) (NP (NN macrophage) (NN differentiation)) (PP (IN in) (NP-COOD (DT both) (NP (JJ myeloid) (NN leukemia) (NN cell) (NNS lines)) (CC and) (NP (JJ normal) (NNS myeloblasts))))) (. .)))
(TOP (S (NP-SBJ-58 (NP (NN HL-60) (NNS cells)) (VP (ADVP (RB constitutively)) (VBG expressing) (NP (NP (DT an) (NN Egr-1) (NN transgene)) (PRN (-LRB- -LRB-) (NP (NN HL-60Egr-1)) (-RRB- -RRB-))))) (VP (MD could) (VP (VB be) (VP (VBN induced) (PP (IN for) (NP (NP-COOD (NP (NN macrophage)) (, ,) (CONJP (CC but) (RB not)) (NP (NN granulocyte)) (, ,)) (NN differentiation)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (NN Egr-1)))) (VP (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for)))) (CC and) (VP (VBZ restricts))) (NP-59 (NP (NN differentiation)) (PP (IN of) (NP (NNS myeloblasts))) (PP (IN along) (NP (DT the) (NN macrophage) (NN lineage)))))))) (. .)))
(TOP (NP (NP (NN Expression)) (PP (IN of) (NP (ADJP-COOD (ADJP (NP (NN tal-1))) (CC and) (ADJP (JJ GATA-binding))) (NNS proteins))) (PP-TMP (IN during) (NP (JJ human) (NN hematopoiesis))) (. .)))
(TOP (S (NP-SBJ-61 (NN Tal-1) (NNS rearrangements)) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (QP (RB nearly) (CD 30)) (NN %)) (PP (IN of) (NP (JJ human) (NN T) (JJ acute) (JJ lymphoblastic) (NN leukemia))))))) (. .)))
(TOP (S (NP-SBJ-62 (NN Tal-1) (NN gene)) (VP-COOD (VP (VBZ encodes) (NP (NP (DT a) (JJ putative) (NN transcription) (NN factor)) (PP (IN with) (NP (DT a) (JJ basic) (JJ helix-loop-helix) (NN domain))))) (CC and) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB be) (ADVP (RB predominantly)) (VP (VBN expressed) (PP (IN in) (NP (JJ hematopoietic) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NP (NN tal-1) (NN expression)) (PP (IN in) (NP (VBN purified) (JJ human) (JJ hematopoietic) (NNS cells)))))) (PP (IN by) (NP-COOD (NP (ADJP (FW in) (FW situ)) (NN hybridization)) (CC and) (NP (JJ reverse) (NN transcriptase) (NN polymerase) (NN chain) (NN reaction) (NN analysis))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (NNS methods)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-64 (DT the) (NN tal-1) (NN gene)) (VP (VBZ is) (VP (VBN expressed) (PP-COOD (PP (IN in) (NP-COOD (NP (NNS megakaryocytes)) (CC and) (NP (NNS erythroblasts)))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (JJ basophilic) (NNS granulocytes))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (PRP$ our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN tal-1) (NN 1A) (NN promoter)) (, ,) (SBAR (WHNP-65 (WDT which)) (S (VP (VBZ contains) (NP (CD two) (NN consensus) (JJ GATA-binding) (NNS sites))))) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ active)) (PP (RB mainly) (IN in) (NP (DT these) (NNS lineages))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP-SBJ-66 (DT the) (NN GATA-1) (NN gene)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB transactivate) (NP (NP (JJ several) (NNS genes)) (ADJP (JJ specific) (PP (IN for) (NP (DT the) (ADJP-COOD (ADJP (JJ erythroid)) (, ,) (ADJP (JJ megakaryocytic)) (, ,) (CC and) (ADJP (JJ mastocytic/basophilic))) (NNS lineages)))))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD studied) (NP (NP (NN GATA-1) (NN expression)) (PP (IN in) (NP (DT these) (VBN purified) (JJ hematopoietic) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-67 (NP-COOD (NP (NN GATA-1)) (CC and) (NP (NN tal-1))) (NNS genes)) (VP (VBP are) (VP (VBN coexpressed) (PP (IN in) (NP (DT these) (CD three) (NNS lineages)))))))) (. .)))
(TOP (S (ADVP (RB Remarkably)) (, ,) (NP-SBJ-68 (NP (DT the) (NN expression)) (PP (IN of) (NP (DT both) (NNS genes)))) (VP (VBZ is) (VP (VBN downmodulated) (PP-TMP (IN during) (NP (ADJP-COOD (ADJP (JJ erythroid)) (CC and) (ADJP (JJ megakaryocytic))) (JJ terminal) (NN maturation))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ immature) (JJ hematopoietic) (NNS cells))) (, ,) (NP-SBJ-69 (NP-COOD (NP (NN tal-1)) (CC and) (NP (NN GATA-1))) (NNS genes)) (VP (VBP are) (VP (VBN coexpressed) (PP (IN in) (NP (NP (VBN committed) (NNS progenitors) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ CD34+/CD38-LRB-2+-RRB-)) (-RRB- -RRB-)))) (, ,) (SBAR (IN whereas) (S (NP-SBJ (PRP they)) (VP (VBP are) (RB not) (ADJP-PRD (JJ detectable)) (PP (IN in) (NP (NP (DT the) (ADJP (RBS most) (JJ primitive)) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ CD34-LRB-2+-RRB-/CD38-)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (S-COOD (S (NP-SBJ-70 (NN GATA-2)) (VP (VBZ is) (ADVP (RB strongly)) (VP (VBN expressed) (PP (IN in) (NP (NP-COOD (CC both) (NP (ADJP (RBS most) (JJ primitive))) (CC and) (NP (VBN committed) (NNS progenitors))) (NP-101 (NNS cells))))))) (, ,) (IN whereas) (S (NP-SBJ-72 (NN GATA-3)) (VP (VBZ is) (ADVP (RB mostly)) (VP (VBN detected) (PP (IN in) (NP (ADJP (RBS most) (JJ primitive)) (NNS ones))))))) (. .)))
(TOP (S (ADVP (RB Altogether)) (NP-SBJ (PRP$ our) (NNS results)) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN GATA-1)) (VP (VBZ modulates) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN tal-1)))) (PP-TMP (IN during) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (DT the) (ADJP-COOD (ADJP (JJ erythroid)) (, ,) (ADJP (JJ megakaryocytic)) (, ,) (CC and) (ADJP (JJ basosophilic))) (NNS lineages))))))))) (. .)))
(TOP (NP (NP (JJ Cell-type-specific) (NN transactivation)) (PP (IN of) (NP (DT the) (ADJP (JJ parathyroid) (JJ hormone-related)) (NN protein) (NN gene) (NN promoter))) (PP (IN by) (NP (DT the) (NP-COOD (NP (NP (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD I)) (PRN (-LRB- -LRB-) (NP (NN HTLV-I)) (-RRB- -RRB-)) (NN tax)) (CC and) (NP (NN HTLV-II) (NN tax))) (NNS proteins))) (. .)))
(TOP (S (NP-SBJ (DT The) (NP-COOD (NP (NP (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD I)) (PRN (-LRB- -LRB-) (NP (NN HTLV-I)) (-RRB- -RRB-))) (CC and) (NP (NN HTLV-II))) (NN Tax) (NNS proteins)) (VP (VBP are) (NP-PRD (NP (JJ potent) (NNS transactivators)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ viral)) (CC and) (ADJP (JJ cellular))) (NN gene) (NN expression))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NN deletion) (NNS mutants)))) (, ,) (NP-SBJ-40 (DT the) (JJ downstream) (NP (NP (ADJP (JJ parathyroid) (JJ hormone-related)) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN PTHrP)) (-RRB- -RRB-))) (NN promoter)) (VP (VBZ is) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ responsive) (PP (TO to) (NP-COOD (NP (NP-COOD (CC both) (NP (NN HTLV-I)) (CC and) (NP (NN HTLV-II))) (NN Tax)) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (NN AP1/c-jun) (NN proto-oncogene)))))))))) (. .)))
(TOP (S (NP-SBJ-41 (NP (NN Transactivation)) (PP (IN of) (NP (NN PTHrP))) (PP (IN by) (NP (NN Tax)))) (VP (VBD was) (VP (VBN seen) (PP-COOD (PP (IN in) (NP (NN T) (NNS cells))) (CC but) (PP (RB not) (IN in) (NP-COOD (NP (NN B-cell) (NNS lines)) (CC or) (NP (NNS fibroblasts))))))) (. .)))
(TOP (S (NP-SBJ (DT A) (NN carboxy) (JJ terminal) (NN Tax) (NN deletion) (NN mutant)) (VP (VBD was) (ADJP-PRD (JJ deficient)) (PP (IN in) (NP (NP (NN transactivation)) (PP (IN of) (NP-COOD (NP (CC both) (DT the) (NP-COOD (NP (NN PTHrP)) (CC and) (NP (NN IL2R) (NN alpha))) (NNS promoters)) (CONJP (CC but) (RB not)) (NP (DT the) (NN HTLV-I) (NP (NP (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Exogenous) (NN provision)) (PP (IN of) (NP (NN NFkB)))) (VP (VBD rescued) (NP-COOD (NP (NN IL2R) (NN alpha) (NN expression)) (CONJP (CC but) (RB not)) (NP (DT the) (NN PTHrP) (NN promoter)))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-COOD (NP (NN HTLV-I) (NN Tax)) (, ,) (NP (NN HTLV-II) (NN Tax)) (, ,) (CC and) (NP (NN c-jun))) (VP-COOD (VP (VBP transactivate) (NP (NN PTHrP))) (CC and) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN hypercalcemia))) (PP (IN in) (NP (JJ adult) (NN T-cell) (NN leukemia)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Interleukin-3) (NN expression)) (PP (IN by) (NP (VBN activated) (NN T) (NNS cells)))) (VP (VBZ involves) (NP-COOD (NP (DT an) (ADJP-COOD (ADJP (JJ inducible)) (, ,) (ADJP (JJ T-cell-specific))) (NN factor)) (CC and) (NP (DT an) (NN octamer) (NN binding) (NN protein)))) (. .)))
(TOP (S (NP-SBJ-68 (NP (NN Interleukin-3)) (PRN (-LRB- -LRB-) (NP (NN IL-3)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VP (ADVP (RB exclusively)) (VBN expressed) (PP (IN by) (NP-LGS (NP-COOD (NP (VBN activated) (NN T)) (CC and) (NP (JJ natural) (NN killer))) (NP-69 (NNS cells))))) (, ,) (NP (NP (DT a) (NN function)) (SBAR (WHNP-70 (WDT that)) (S (VP (VBZ is) (ADVP (RB tightly)) (VP (VBN controlled) (PP (PP-COOD (CC both) (PP (IN in) (NP (DT a) (JJ lineage-specific))) (CC and) (PP (IN in) (NP (DT a) (JJ stimulation-dependent)))) (NP-72 (NN manner)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NP-COOD (NP (NN protein) (NN binding) (NNS characteristics)) (CC and) (NP (JJ functional) (NN importance)))) (PP (IN of) (NP (NP (DT the) (JJ ACT-1-activating) (NN region)) (PP (IN of) (NP (DT the) (NN IL-3) (NN promoter)))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN region)) (VP (VBZ binds) (NP (DT an) (ADJP-COOD (ADJP (JJ inducible)) (, ,) (ADJP (JJ T-cell-specific))) (NN factor)) (PP (IN over) (NP (NP (PRP$ its) (JJ 5') (NN end)) (, ,) (NP (NP (DT a) (NN site)) (SBAR (WHNP-73 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN IL-3)))))) (PP (IN in) (DT the) (NN absence) (IN of) (NP (JJ other) (JJ upstream) (NNS elements)))))))))) (. .)))
(TOP (S (PP (IN Over) (NP (PRP$ its) (JJ 3') (NN end))) (, ,) (NP-SBJ (PRP it)) (VP (VBZ binds) (NP (NP (DT a) (NN factor)) (SBAR (WHNP-74 (WDT that)) (S (VP (VBZ is) (ADVP-COOD (ADVP (RB ubiquitously)) (CC and) (ADVP (RB constitutively))) (VP (VBN expressed))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT This) (NN factor)) (VP (VBZ is) (NP-PRD-COOD (NP (NN Oct-1)) (CC or) (NP-LGS (DT an) (ADJP (RB immunologically) (JJ related)) (JJ octamer-binding) (NN protein))))) (, ,) (CC and) (S (NP-SBJ-77 (PRP it)) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG coordinating) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ several) (JJ regulatory) (NNS elements))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS characteristics)) (VP (VBP make) (S (NP-SBJ (DT the) (NN ACT-1) (NN site)) (ADJP-PRD (JJ analogous) (PP (TO to) (NP (NP (DT the) (VBG activating) (NN ARRE-1) (NN site)) (PP (IN in) (NP (DT the) (NN IL-2) (NN promoter)))))))) (. .)))
(TOP (S (UCP-COOD (ADVP (RB Furthermore)) (, ,) (CC and) (PP (IN despite) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NN sequence) (NN homology)))))) (, ,) (NP-SBJ (NP (DT the) (NNS promoters)) (PP (IN of) (NP-COOD (NP (NN IL-3)) (CC and) (NP (NN IL-2))))) (VP (VBP share) (NP (NP (DT an) (JJ organizational) (NN pattern)) (PP (IN of) (NP (JJ regulatory) (NNS elements))) (SBAR (WHNP-78 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (JJ likely) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ important)) (PP (IN for) (NP (NP (DT the) (JJ T-cell-specific) (NN expression)) (PP (IN of) (NP (DT these) (NNS genes)))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ Epstein-Barr) (NN virus) (JJ nuclear) (NN antigen) (CD 2)) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT an) (ADJP (NN EBNA2) (JJ responsive)) (NN cis-element)) (PP (IN of) (NP (DT the) (JJ terminal) (NN protein) (CD 1) (NN gene) (NN promoter)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ Epstein-Barr) (NN virus) (NN protein) (NN EBNA2)) (VP-COOD (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (JJ transcriptional) (NN activator)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ cellular)) (CC and) (ADJP (JJ viral))) (NNS genes)))))) (CC and) (VP (VBZ plays) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (NP (NP (DT the) (NN immortalization)) (PP (IN of) (NP (JJ human) (JJ primary) (NNS B-cells))) (PP (IN by) (NP (NN EBV))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN shown) (ADVP-TMP (RB previously)) (SBAR (IN that) (S (NP-SBJ (NN EBNA2)) (VP (VBZ transactivates) (NP (NP (DT the) (NNS promoters)) (PP (IN of) (NP (DT the) (JJ latent) (NN membrane) (NNS antigens) (NP-COOD (NP (NN LMP)) (, ,) (NP (NN TP1)) (CC and) (NP (NN TP2))))))))))) (. .)))
(TOP (S (NP-SBJ-60 (NP (DT The) (NN promoter)) (PP (IN of) (NP (DT the) (NN TP1) (NN gene)))) (VP (VBD was) (VP (VBN chosen) (PP (IN as) (NP (NP (DT a) (JJ model) (NN system)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ molecular) (NN mechanism)) (PP (IN of) (NP (ADJP (NN EBNA2) (JJ mediated)) (NN transactivation)))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB identify) (NP (DT an) (ADJP (NN EBNA2) (JJ dependent)) (JJ cis-acting) (NN element))))) (, ,) (NP-SBJ-61 (JJ various) (NN TP1) (NN promoter-reporter) (NN gene) (NNS constructs)) (VP (VBD were) (VP (VBN transfected) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN absence)) (CC and) (NP (NN presence)))) (PP (IN of) (NP (DT an) (NN EBNA2) (NN expression) (NN vector))))) (PP (IN into) (NP (DT the) (JJ established) (NN B-cell) (NN line) (NN BL41-P3HR1))))) (. .)))
(TOP (S (NP-SBJ-62 (PRP We)) (VP (VBD were) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB delineate) (NP (NP (DT an) (CD 81) (NN bp) (ADJP (NN EBNA2) (JJ responsive)) (NN region)) (PP (IN between) (NP (NP-COOD (NP (CD -258)) (CC and) (NP (CD -177))) (PP (JJ relative) (TO to) (NP (DT the) (NN TP1) (NN RNA) (NN start) (NN site))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN element)) (VP-COOD (VP (VBD worked) (PP (IN in) (NP (DT either) (NN orientation)))) (CC and) (VP (MD could) (VP (VB mediate) (NP (NP (ADJP (NN EBNA2) (JJ dependent)) (NN transactivation)) (PP (IN on) (NP (DT a) (JJ heterologous) (NN promoter))))))) (. .)))
(TOP (S (NP-SBJ (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD revealed) (NP (NP (CD three) (JJ specific) (NN protein-DNA) (NNS complexes)) (VP (VBN formed) (PP (IN with) (NP (NP (NNS sequences)) (PP (IN of) (NP (DT the) (ADJP (NN EBNA2) (JJ responsive)) (NN element)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (CD Two)) (PP (IN of) (NP (DT these)))) (VP (VBD were) (RB not) (ADJP-PRD (NP (NN cell) (NN type)) (JJ specific)))) (, ,) (CC but) (S (NP-SBJ-65 (DT the) (JJ third)) (VP (VBD was) (VP (VBN detected) (PP (RB only) (IN in) (NP (ADJP (NN EBNA2) (JJ positive)) (NN cell) (NNS extracts)))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Gel-shift) (NN analysis)) (PP (IN in) (DT the) (NN presence) (IN of) (NP (ADJP (NN EBNA2) (JJ specific)) (JJ monoclonal) (NNS antibodies)))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (NN EBNA2)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN component)) (PP (IN of) (NP (DT the) (JJ third) (NN complex)))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (DT these) (NNS experiments)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NN EBNA2)) (VP (VBZ interacts) (PP (IN with) (NP (NP (DT an) (ADJP (NN EBNA2) (JJ responsive)) (NN cis-element)) (PP (IN of) (NP (DT the) (NN TP1) (NN promoter))))))))) (. .)))
(TOP (S (NP-SBJ (NN ras) (NN protein) (NN activity)) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NN T-cell) (NN antigen) (NN receptor) (NN signal) (NN transduction))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT a) (NN Jurkat) (NN cell) (NN model)) (PP (IN of) (NP (NN T-cell) (NN activation))))) (NP-SBJ-48 (DT an) (NN interleukin-2) (NN promoter/reporter) (NN gene) (NN construct)) (VP (VBD was) (VP (VBN activated) (PP (IN by) (NP-LGS (NP (NN antigen) (NN receptor) (NN agonism)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (DT the) (NN lymphokine) (NN interleukin-1))))))))) (. .)))
(TOP (S (NP-SBJ-49 (NN Antigen) (NN receptor) (NNS signals)) (VP (MD could) (VP (VB be) (VP (VBN mimicked) (PP (IN by) (NP-LGS (NP (JJ suboptimal) (NN activation)) (PP (IN of) (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-)))) (PP (IN with) (NP (NN phorbol) (NNS esters))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN calcium) (NN mobilization)) (PP (IN by) (NP (DT an) (NN ionophore)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN cotransfection) (NNS experiments))) (, ,) (NP-SBJ (JJ oncogenic) (NNS rats)) (VP-COOD (VP (VBD obviated) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NN PKC) (NN stimulation))))) (CC but) (VP (VBD did) (RB not) (VP (VB replace) (NP-COOD (CC either) (NP (DT the) (NN calcium) (NN signal)) (CC or) (NP (NN interleukin-1)))))) (. .)))
(TOP (S (NP-SBJ (VBN Activated) (NN ras) (NN expression)) (ADVP (RB also)) (VP (VBD replaced) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (NN PKC) (NN stimulation))) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN T-cell) (NN transcription) (NN factor) (NN NF-AT))))))) (. .)))
(TOP (S (NP-SBJ (DT A) (JJ dominant) (JJ inhibitory) (NN ras) (NN mutant)) (ADVP (RB specifically)) (VP (VBD blocked) (NP (NN antigen) (NN receptor) (NN agonism)) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-50 (NN ras) (NN activity)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NN antigen) (NN receptor) (NN signaling)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN PKC)))) (VP (VBD blocked) (NP-COOD (CC both) (NP (VBD activated) (NN ras)) (CC and) (NP (NN phorbol) (NN ester) (NN stimulation))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (NN ras)) (ADVP (JJ upstream) (PP (IN of) (NP (NN PKC)))))))))) (. .)))
(TOP (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ nuclear)) (CC and) (ADJP (JJ cytoplasmic))) (NNS components)) (PP (IN of) (NP (DT the) (JJ lymphoid-specific) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))) (NN complex))))) (. .)))
(TOP (S (NP-SBJ-58 (NP (DT The) (JJ lymphoid-specific) (NN transcription) (NN complex)) (, ,) (NP (NN NF-AT)) (, ,)) (VP-COOD (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (JJ early) (NN gene) (NN activation)) (PP (IN in) (NP (NN T) (NNS cells))))))) (CC and) (VP (VBZ is) (VP (VBN assembled) (PP (IN from) (NP-COOD (NP (DT a) (ADJP-COOD (ADJP (JJ pre-existing)) (, ,) (ADJP (NP (NN T) (NN cell)) (JJ restricted))) (JJ cytoplasmic) (NN factor)) (CC and) (NP (DT an) (JJ inducible) (JJ ubiquitous) (JJ nuclear) (NN component)))) (PP-TMP (NP (QP (IN within) (CD 30)) (NN min)) (IN after) (NP (NP (NN activation)) (PP (IN through) (NP (DT the) (NN antigen) (NN receptor)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Recent) (NNS studies)) (VP (VBP have) (VP (VBN implicated) (NP (NP (DT the) (NN family)) (PP (IN of) (NP (NN AP1) (NNS factors)))) (PP (IN as) (NP (NP (NNS components)) (PP (IN of) (NP (DT the) (JJ murine) (NN NF-AT) (NN complex))))))) (. .)))
(TOP (S (NP-SBJ-60 (NN Evidence)) (VP (VBZ is) (VP (VBN provided) (ADVP (RB here)) (SBAR-61 (IN that) (S (NP-SBJ (NP (DT the) (JJ nuclear) (NN component)) (PP (IN of) (NP (JJ human) (NN NF-AT)))) (VP (VBZ contains) (NP (NP (DT the) (ADJP (NN phorbol) (JJ ester-inducible)) (NN transcription) (NN factor) (NN AP1)) (PRN (-LRB- -LRB-) (NP (NN Jun/Fos)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB further)) (VP (VBP characterize) (SBAR (WHNP-62 (WDT which) (NN AP1) (NN family) (NNS members)) (S (VP (MD can) (VP (VB assume) (NP (DT this) (NN role))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Antisera)) (PP (TO to) (NP (NN Fos)))) (VP (VBZ inhibits) (NP (NN NF-AT) (NN DNA) (NN binding)) (SBAR (IN as) (SINV (VBZ does) (NP-SBJ (NP (DT an) (NN oligonucleotide)) (VP (VBG containing) (NP (NP (DT a) (VBG binding) (NN site)) (PP (IN for) (NP (NN AP1))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-63 (NP (NP (JJ Constitutive) (NN expression)) (ADVP (FW in) (FW vivo)) (PP (IN of) (NP-103 (NN Fos)))) (, ,) (CC and) (NP (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (NP=103 (NN Fra-1))) (, ,)) (VP (VBZ eliminates) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (NN stimulation)))) (, ,) (S (VP (VBG leaving) (S (NP-SBJ (JJ NF-AT-directed) (NN transcription)) (ADJP-PRD (JJ responsive) (PP (TO to) (NP (NP (NN calcium) (NN ionophore)) (ADVP (RB alone))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP-COOD (NP-COOD (NP (NN cJun)) (CC or) (NP (NN JunD))) (, ,) (CONJP (CC but) (RB not)) (NP (NN JunB)) (, ,)))) (ADVP (RB also)) (VP (VBZ eliminates) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (NN PMA)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (ADJP-COOD (ADJP (JJ many)) (CC but) (ADJP (RB not) (DT all))) (ADJP-COOD (ADJP (NP (NN Jun-))) (CC and) (ADJP (JJ Fos-related))) (NNS proteins)) (ADVP (RB functionally)) (VP (VBP activate) (NP (JJ NF-AT-dependent) (NN transcription)) (PP (IN in) (DT the) (NN presence) (IN of) (NP (DT the) (JJ cytoplasmic) (NN component))))))))) (. .)))
(TOP (S (NP-SBJ-65 (NN NF-AT) (NN DNA) (NN binding)) (VP (MD can) (VP (VB be) (VP (VBN reconstituted) (ADVP (FW in) (FW vitro)) (S (VP (VBG using) (NP (NP (JJ semi-purified) (NN AP1) (NNS proteins)) (VP (VBN mixed) (PP (IN with) (NP (NP (NN cytosol)) (PP (IN from) (NP (NN T) (NNS lymphocytes)))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-67 (NN Fos) (NNS proteins)) (VP (VBP are) (RB not) (VP (VBN needed) (PP (IN for) (NP (DT this) (NN reconstitution)))))) (, ,) (CC and) (S (SBAR (IN although) (S (NP-SBJ (NN JunB)) (VP (VBZ is) (RB not) (ADJP-PRD (JJ functional))))) (, ,) (NP-SBJ (PRP it)) (VP (MD can) (VP (VB participate) (PP (IN in) (NP (DT the) (NN NF-AT) (NN DNA) (NN binding) (NN complex)))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (PRP we)) (VP-COOD (VP (VBP have) (ADVP (RB partially)) (VP (VBN purified) (NP (NP (DT the) (JJ cytoplasmic) (NN component)) (PP (IN of) (NP (NN NF-AT)))))) (CC and) (VP (VBP show) (PP (IN by) (NP (NP-COOD (NP (NN elution)) (CC and) (NP (NN renaturation))) (PP (IN from) (NP (NN SDS-polyacrylamide) (NN gel) (NN electrophoresis) (NNS gels))))) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP-COOD (VP (VBZ has) (NP (NP (DT a) (JJ molecular) (NN mass)) (NP (QP (IN between) (CD 94) (CC and) (CD 116)) (NN kDa)))) (CC and) (VP (MD may) (VP (VB have) (NP (JJ multiple) (ADJP (RB differentially) (JJ modified)) (NNS forms))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN c-rel) (NN protooncogene) (NN product)) (VP (VBZ represses) (NP (NP (ADJP (NN NF-kappa) (NN B) (JJ p65-mediated)) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ long) (JJ terminal) (NN repeat)) (PP (IN of) (NP (NN type) (CD 1) (JJ human) (NN immunodeficiency) (NN virus))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (NP (DT The) (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (NN type) (CD 1) (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT the) (JJ 5') (JJ regulatory) (NN region)) (PP (IN of) (NP (NP (DT the) (NN gene)) (VP (VBG encoding) (NP (NP (DT the) (NN interleukin) (CD 2) (NN receptor) (NN alpha) (NN subunit)) (PRN (-LRB- -LRB-) (NP (NN IL-2R) (NN alpha)) (-RRB- -RRB-)))))))) (VP (NN share) (NP (NP (JJ functional) (NN kappa) (NN B) (NN enhancer) (NNS elements)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT these) (JJ inducible) (NN transcription) (NNS units))) (PP-TMP (IN during) (NP (NN T-cell) (NN activation)))))))) (. .)))
(TOP (S (NP-SBJ-56 (DT These) (NN kappa) (NN B) (NN enhancer) (NNS elements)) (VP (VBP are) (VP (VBN recognized) (PP (IN by) (NP (NP (DT a) (ADJP (RB structurally) (JJ related)) (NN family)) (PP (IN of) (NP (JJ interactive) (NNS proteins))) (SBAR (WHNP-57 (WDT that)) (S (VP (VBZ includes) (NP-COOD (NP (NN p50)) (, ,) (NP (NN p65)) (, ,) (CC and) (NP (NP (NP (DT the) (NN product)) (PP (IN of) (NP (DT the) (NN c-rel) (NN protooncogene)))) (PRN (-LRB- -LRB-) (NP (NN c-Rel)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Recent) (JJ biochemical) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN p65)) (CC and) (NP (NN p50))) (VP (VBP form) (NP (NP (DT the) (JJ prototypical) (NN NF-kappa) (NN B) (NN complex)) (, ,) (SBAR (WHNP-58 (WDT which)) (S (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN translocated) (PP (IN from) (NP (DT the) (NN cytoplasm))) (PP (TO to) (NP (DT the) (NN nucleus))) (PP-TMP (IN during) (NP (NN T-cell) (NN activation))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ intracellular) (NN signaling) (NN complex)) (ADVP (RB potently)) (VP (VBZ stimulates) (NP (NP (ADJP (NN kappa) (JJ B-directed)) (NN transcription)) (PP (IN from) (NP-COOD (CC either) (NP (DT the) (NN HIV-1) (NN LTR)) (CC or) (NP (DT the) (NN IL-2R) (NN alpha) (NN promoter))))) (PP (IN via) (NP (NP (DT the) (JJ strong) (NN transactivation) (NN domain)) (ADJP (JJ present) (PP (IN in) (NP (NN p65))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (JJ nuclear) (NN expression)) (PP (IN of) (NP (JJ human) (NN c-Rel))) (, ,) (SBAR (WHNP-60 (WDT which)) (S (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP-COOD (DT either) (NP (NN phorbol) (NN ester)) (CC or) (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)))) (PP (IN with) (NP (NP (VBN delayed) (NNS kinetics)) (ADJP (JJ relative) (PP (TO to) (NP (NN p65)))))))))) (, ,)) (ADVP (RB markedly)) (VP (VBZ represses) (NP (NP (JJ p65-mediated) (NN activation)) (PP (IN of) (NP (DT these) (NN transcription) (NNS units)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT These) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NN c-Rel)))) (VP (VBP correlate) (PP-COOD (PP (IN with) (NP (PRP$ its) (JJ DNA-binding) (NN activity))) (CC but) (PP (RB not) (IN with) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB heterodimerize) (PP (IN with) (NP (NN p50))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN c-Rel) (NN inhibition)) (VP (VBZ involves) (NP (NP (NN competition)) (PP (IN with) (NP (NN p50/p65))) (PP (IN for) (NP (NP (NN occupancy)) (PP (IN of) (NP (DT the) (NN kappa) (NN B) (NN enhancer) (NN element)))))))))))) (. .)))
(TOP (S (ADVP (RB Together)) (, ,) (NP-SBJ (DT these) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (CD one) (NN function)) (PP (IN of) (NP (NN c-Rel)))) (VP (VBZ is) (S-PRD (PP (IN as) (NP (NP (DT a) (JJ physiologic) (NN repressor)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN HIV-1) (NN LTR)) (CC and) (NP (NN IL-2R) (NN alpha))) (NNS promoters))))) (, ,) (VP (VBG serving) (S (VP (TO to) (VP (ADVP (RB efficiently)) (VB counter) (NP (NP (DT the) (JJ strong) (JJ transcriptional) (JJ activating) (NNS effects)) (PP (IN of) (NP (NN p65))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Protease) (NN treatment)) (PP (IN of) (NP (JJ nuclear) (NNS extracts)))) (VP (VBZ distinguishes) (PP (IN between) (NP (NP (NN class) (CD II) (NN MHC) (NN X1) (NN box) (JJ DNA-binding) (NNS proteins)) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ wild-type)) (CC and) (ADJP (NN class) (JJ II-deficient))) (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN X) (NN box) (NN region)) (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (IN for) (S (VP (VBG directing) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN class) (CD II) (JJ major) (NN histocompatibility) (NN complex) (NNS genes))) (PP (IN in) (NP (NN B) (NNS lymphocytes))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-49 (JJ several) (NN class) (CD II) (JJ promoter-specific) (NN DNA) (NN binding) (NNS factors)) (VP (VBP have) (VP (VBN been) (VP (VBN described)))))) (, ,) (NP-SBJ-50 (NP (RB only) (DT the) (NN X) (NN box) (NN region) (NN factor)) (, ,) (NP (NN RFX)) (, ,)) (VP (VBZ shows) (NP (NP (DT a) (JJ genetic) (NN correlation)) (PP (IN with) (NP (NN class) (CD II) (NN expression)))) (, ,) (S (VP (VBG being) (ADJP-PRD (JJ deficient)) (PP (IN in) (NP (NP (DT some) (NN B) (NN cell) (NNS lines)) (VP (VBN derived) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (NN class) (JJ II-deficient)) (JJ congenital) (NN immunodeficiency))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (ADVP (RB further)) (VB evaluate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN X) (NN box) (JJ DNA-binding) (NNS proteins))) (PP (IN in) (NP (NN class) (CD II) (NN gene) (NN expression))))))) (, ,) (NP-SBJ-51 (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (NN X) (NN box) (NN region)))) (VP (VBD was) (VP (VBN examined) (PP (IN in) (NP (ADJP-COOD (DT both) (ADJP (NN class) (JJ II-positive)) (CC and) (ADJP (JJ -negative))) (JJ lymphoid) (NNS cells))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (DT the) (JJ wild-type) (NN B) (NN cell) (NN line) (NN Raji))) (, ,) (NP-SBJ-COOD-52 (NP (NP (CD two) (ADJP (NN class) (CD II) (JJ transcriptional)) (JJ mutant) (NN cell) (NNS lines)) (, ,) (NP-COOD (NP (NN SJO)) (CC and) (NP (NN RJ2.2.5))) (, ,)) (CC and) (NP (NP (NN Jurkat)) (, ,) (NP (DT a) (ADJP (NN class) (CD II) (JJ negative)) (NN T) (NN cell) (NN line)) (, ,))) (VP (VBD were) (VP (VBN examined))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (JJ wild-type) (NN B) (NNS cells))) (, ,) (NP-SBJ (NP (DT neither)) (PP (IN of) (NP (DT the) (NN class) (CD II) (JJ mutant) (NN cell) (NNS lines)))) (VP (MD could) (VP (VB use) (NP-53 (DT the) (NN X) (NN box) (NN region)) (S (VP (TO to) (VP (VB direct) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT a) (ADJP (RB transiently) (VBN transfected)) (NN reporter) (NN gene))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (DT the) (ADJP (NN X) (JJ box-dependent)) (JJ transcriptional) (NN pathway)) (VP (VBZ is) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (DT these) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ-55 (NP (DT The) (NN binding) (NN activity)) (PP (IN of) (NP (DT the) (NN X1) (NN box) (JJ DNA-binding) (NN protein) (NN RFX)))) (VP-COOD (VP (VBD was) (VP-COOD (VP (VBN examined)) (CC and) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ present) (PP (IN in) (NP-COOD (NP (JJ wild-type) (NN B) (NNS cells)) (CC and) (NP (DT the) (JJ mutant) (NN RJ2.2.5))))))))))) (CC but) (VP (VBD was) (ADJP-PRD (JJ absent) (PP (IN in) (NP-COOD (NP (NN SJO)) (CC and) (NP (NN Jurkat))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-57 (JJ other) (ADJP (NN X1) (JJ box-specific)) (NNS activities)) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (DT all) (DT these) (NN cell) (NNS lines))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (DT these) (JJ different) (NN X1) (NN box) (NNS activities)) (VP (VBD represented) (NP-COOD (NP (JJ distinct) (NN DNA) (NN binding) (NNS proteins)) (CC or) (NP (NP (JJ multimeric) (NNS forms)) (PP (IN of) (NP (DT the) (JJ same) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))))))))))) (, ,) (NP-SBJ-58 (NP (NN protease) (NN treatment)) (PP (IN of) (NP (DT the) (JJ crude) (JJ nuclear) (NNS extracts))) (VP (VBN followed) (PP (IN by) (NP (JJ DNA-binding) (NNS assays))))) (VP-COOD (VP (VBD were) (VP (VBN carried) (PRT (RP out)))) (CC and) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NN B) (NN cell) (NNS extracts)) (VP (VBP contain) (NP (QP (IN at) (JJS least) (CD two)) (JJ X1-specific) (NNS factors))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (CD One)) (PP (IN of) (NP (DT these) (VBN cleaved) (NNS products)))) (PRN (-LRB- -LRB-) (NP (NN band) (CD 1) (NN pk)) (-RRB- -RRB-))) (VP (VBZ correlates) (PP (IN with) (NP (NN RFX) (NN activity)))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ similar) (NN comparison)) (PP (IN with) (NP (NP (JJ protease-treated) (NNS extracts)) (VP (VBN prepared) (PP (IN from) (NP (NN Jurkat) (NNS cells))))))) (VP (VBD demonstrated) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (NN band) (NN 1pk) (NN activity)))) (PP (IN despite) (NP (NP (DT an) (NN absence)) (PP (IN of) (NP (DT the) (JJ native) (NN RFX) (NN activity)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN protease) (NP-COOD (NP (NN treatment)) (CC and) (NP (NN analysis)))) (PP (IN of) (NP (NN SJO) (NNS extracts)))) (VP (VBD showed) (NP (NP (DT no) (JJ detectable) (NNS levels)) (PP (IN of) (NP (DT the) (NN band) (NN 1pk) (NN activity))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (JJ multiple) (ADJP (NN X1) (JJ box-specific)) (JJ DNA-binding) (NNS activities)) (VP (VBP exist) (PP (IN in) (NP (DT all) (JJ lymphoid) (NNS cells)))))))) (, ,) (CC but) (S (NP-SBJ (NP (DT the) (NN presence)) (PP (IN of) (NP (DT an) (ADJP (RB actively) (NN binding)) (NN RFX) (NNS species)))) (VP (VBZ correlates) (PP (IN with) (NP (NN class) (CD II) (NN transcription))))) (. .)))
(TOP (NP (NP (NN Replication)) (PP (IN of) (NP (NP (NN type) (CD 1) (JJ human) (NN immunodeficiency) (NNS viruses)) (VP (VBG containing) (NP (NN linker) (NN substitution) (NNS mutations)) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (CD -201)) (TO to) (NP (CD -130))) (NP (NN region))) (PP (IN of) (NP (DT the) (JJ long) (JJ terminal) (NN repeat)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ previous) (NN transfection) (NNS analyses)) (VP (VBG using) (NP (DT the) (JJ chloramphenicol) (NN acetyltransferase) (NN reporter) (NN gene) (NN system))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD determined) (SBAR (IN that) (S (NP-SBJ (NP (NP (NP (NN linker) (NN substitution)) (PRN (-LRB- -LRB-) (NP (NN LS)) (-RRB- -RRB-))) (NNS mutations)) (PP (IN between) (NP (NP-COOD (NP (CD -201)) (CC and) (NP (CD -130))) (-LRB- -LRB-) (ADJP (JJ relative) (PP (TO to) (NP (DT the) (NN transcription) (NN start) (NN site)))) (-RRB- -RRB-) (PP (IN of) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (NP (NP (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-)))))))) (VP (VBD caused) (NP (NP (JJ moderate) (NNS decreases)) (PP (IN in) (NP (NP (NN LTR) (JJ transcriptional) (NN activity)) (PP (IN in) (NP (DT a) (NN T-cell) (NN line))))))))) (PRN (-LRB- -LRB-) (FRAG (NP-COOD (NP (NNP S.L.Zeichner)) (, ,) (NP (NNP J.Y.H.) (NNP Kim)) (, ,) (CC and) (NP (NNP J.C.Alwine)) (, ,) (NP (NNP J.Virol.65))) (: :) (NP (CD 2436-2444)) (, ,) (NP (CD 1991))) (-RRB- -RRB-))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (TO to) (S (VP (VB confirm) (NP (NP (DT the) (NN significance)) (PP (IN of) (NP (DT this) (NN region))) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (JJ viral) (NN replication))))))))) (, ,) (NP-SBJ-56 (PRP we)) (VP-COOD (VP (VBD constructed) (NP (NP (NP (NP (JJ several)) (PP (IN of) (NP (DT these) (NN LS) (NNS mutations)))) (PRN (-LRB- -LRB-) (NP-COOD (NP-COOD (NP (CD -201)) (TO to) (NP (SYM -) (CD 184))) (, ,) (NP-COOD (NP (CD -183)) (TO to) (NP (CD -166))) (, ,) (NP-COOD (NP (CD -165)) (TO to) (NP (CD -148))) (, ,) (CC and) (NP-COOD (NP (CD -148)) (TO to) (NP (CD -130)))) (-RRB- -RRB-))) (PP (IN in) (NP (NNS proviruses))))) (CC and) (VP (VBD prepared) (NP (JJ viral) (NNS stocks)) (PP (IN by) (NP (NP (NN cocultivation)) (PP (IN of) (NP (VBN transfected) (NN RD) (NNS cells))) (PP (IN with) (NP (NN CEMx174) (NNS cells))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-57 (NP (CD two) (NNS mutations)) (PP-COOD (PP (IN between) (NP-COOD (NP (CD -93)) (CC and) (NP (CD -76)))) (CC and) (PP (IN between) (NP-COOD (NP (CD -75)) (CC and) (NP (CD -58)))))) (VP (VBD were) (VP (VBN utilized) (, ,) (SBAR (IN since) (S (NP-SBJ-58 (PRP they)) (VP-COOD (VP (VBP affect) (NP (DT the) (ADJP-COOD (ADJP (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-)) (: -))) (CC and) (ADJP (JJ Sp1-binding))) (NNS sites))) (CC and) (VP (VBD were) (VP (VBN expected) (S (VP (TO to) (VP (VB diminish) (NP (JJ viral) (NN replication)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (SBAR (IN while) (S (NP-SBJ (NN transfection) (NNS analyses)) (VP (VBP offer) (NP (NP (DT an) (JJ adequate) (NN approximation)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (NN LS) (NNS mutations))))))))) (, ,) (NP-SBJ (NP (DT the) (NN analysis)) (PP (IN of) (NP (NP (JJ viral) (NN replication)) (VP (VBG using) (NP (DT a) (JJ mutant) (JJ viral) (NN stock)))))) (VP (VBZ presents) (NP (NP (DT a) (ADJP (RBR more) (JJ accurate)) (NN picture)) (, ,) (SBAR (WHNP-59 (WDT which)) (S (VP (VBZ is) (ADVP-TMP (RB sometimes)) (PP-PRD (IN at) (NN variance) (IN with) (NP (DT the) (NN transfection) (NNS results))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (CD Three) (NNS mutants)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD -201/-184) (NN NXS)) (, ,) (NP (CD -165/-148) (NN NXS)) (, ,) (CC and) (NP (CD -147/-130) (NN NXS))) (-RRB- -RRB-))) (VP (VBD had) (NP (NP (NNS effects))) (PP (IN on) (NP (JJ viral) (NN replication))) (SBAR-102 (WHNP-60 (WDT that)) (S (VP (VBD were) (ADJP-PRD (ADJP (ADVP (RB much) (RBR more)) (JJ severe)) (PP (IN than) (NP (NP (DT the) (NNS effects)) (VP (VBN predicted) (PP (IN from) (NP (NP (PRP$ their) (NN performance)) (PP (IN in) (NP (NN transfection) (NNS analyses)))))))))))))) (, ,) (CC and) (S (NP-SBJ-61 (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (CD two) (NN LS) (NNS mutations)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD -201/-184) (NN NXS)) (CC and) (NP (CD -183/-166) (NN NXS))) (-RRB- -RRB-))))) (VP (VBD were) (RB not) (VP (VBN predicted) (PP (IN by) (NP (NP (PRP$ their) (NNS effects)) (PP (IN in) (NP (NN transfection)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (PRP we)) (VP (VBD observed) (NP (NP (ADJP (NN cell) (JJ type-specific)) (NN permissiveness)) (PP (TO to) (NP (NP (NN replication)) (PP (IN of) (NP (DT some) (JJ mutant) (NNS viruses))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT the) (NN cell) (NNS types)) (VP (VBN tested)))) (, ,) (NP-SBJ (DT the) (NN LS) (NNS mutations)) (VP (VBD indicated) (NP (NP (DT an) (JJ apparent) (NN requirement)) (PP-COOD (CONJP (RB not) (RB only)) (PP (IN for) (NP (DT the) (JJ intact) (ADJP-COOD (ADJP (NP (NN NF-kappa) (NN B))) (CC and) (ADJP (JJ SP1-binding))) (NNS sites))) (CONJP (CC but) (RB also)) (PP (IN for) (NP (NP (JJ several) (NNS regions)) (PP (IN between) (NP-COOD (NP (CD -201)) (CC and) (NP (CD -130)))) (VP (RB not) (ADVP-TMP (RB previously)) (VBN associated) (PP (IN with) (NP (JJ viral) (NN infectivity))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ human) (NN prointerleukin) (CD 1) (NN beta) (NN gene)) (VP (VBZ requires) (NP (NP (NN DNA) (NNS sequences)) (ADJP (ADJP-COOD (CC both) (ADJP (JJ proximal)) (CC and) (ADJP (JJ distal))) (PP (TO to) (NP (DT the) (NN transcription) (NN start) (NN site))))) (PP (IN for) (NP (JJ tissue-specific) (NN induction)))) (. .)))
(TOP (S (PP (IN In) (NP (DT these) (NNS studies))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN identified) (NP (NP-COOD (NP (NN DNA) (NNS sequences)) (CC and) (NP (JJ specific) (NN protein) (NNS interactions))) (ADJP (JJ necessary) (PP (IN for) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (JJ human) (NP (NP (NN prointerleukin) (CD 1) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN proIL-1) (NN beta)) (-RRB- -RRB-))) (NN gene))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ cell-type-independent) (ADJP (NN lipopolysaccharide) (-LRB- -LRB-) (NN LPS) (-RRB- -RRB-) (JJ -responsive)) (NN enhancer) (NN element)) (ADJP (JJ located) (PP (IN between) (NP (NP-COOD (NP (CD -3757)) (CC and) (NP (CD -2729))) (NN bp))) (ADVP (RB upstream) (PP (IN from) (NP (NP (DT the) (NN transcription) (NN start) (NN site)) (PRN (-LRB- -LRB-) (NP (NN cap) (NN site)) (-RRB- -RRB-))))))) (VP (VBD consisted) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD six)) (JJ discrete) (NNS subregions)) (SBAR (WHNP-50 (WDT which)) (S (VP (VBD were) (ADJP-PRD (JJ essential) (PP (TO to) (NP (NP (DT the) (JJ maximal) (NN induction)) (PP (IN by) (NP (NN LPS))) (PP (IN in) (NP (VBN transfected) (NNS monocytes)))))))))))) (. .)))
(TOP (S (NP-SBJ-51 (DT The) (NN enhancer)) (ADVP (RB also)) (VP (VBD appeared) (S (VP (TO to) (VP (VB mediate) (NP-COOD (NP (NP (NN phorbol) (NN myristate) (NN acetate) (NN induction)) (PP (IN in) (NP (NNS monocytes)))) (CC and) (NP (NP (NN IL-1) (NN responsiveness)) (PP (IN in) (NP (NNS fibroblasts))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP-COOD (NP (NN Deletion)) (CC and) (NP (NN base) (NN substitution) (NNS mutations))) (CONJP (IN along) (IN with)) (NP (NN DNA) (NN binding) (NNS studies))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (DT the) (NN enhancer)) (VP (VBD contained) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (NP (CD three) (JJ functional) (NN protein) (NN binding) (NNS sequences)) (, ,) (SBAR (WHNP-52 (NP (CD two)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ important) (PP (IN for) (NP (NN gene) (NN induction))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD One)) (PP (IN of) (NP (NP (DT the) (JJ essential) (NNS proteins)) (SBAR (WHNP-54 (WDT which)) (S (VP (VBD bound) (PP (TO to) (NP (DT the) (NN enhancer))))))))) (VP (VBD was) (ADJP-PRD (ADJP-COOD (ADJP (JJ similar)) (CC or) (ADJP (JJ identical))) (PP-101 (TO to) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (NN C/EBP) (NN family)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (VBN required) (PP (IN for) (NP (NP (ADJP-COOD (CC both) (ADJP (NP (NN IL-1-))) (CC and) (ADJP (JJ LPS-specific))) (NN induction)) (PP (IN of) (NP (NP (DT the) (NN IL-6) (NN gene)) (PRN (-LRB- -LRB-) (NP (ADVP (FW i.e.)) (, ,) (DT the) (NN NF-IL6) (NNS proteins)) (-RRB- -RRB-))))))))))))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-56 (WRB When)) (S (VP (VBN ligated) (PP (TO to) (NP (NP (DT the) (NN proIL-1) (NN beta) (ADJP (NN cap) (JJ site-proximal)) (NN region)) (-LRB- -LRB-) (ADJP (JJ located) (PP (IN between) (NP-COOD (NP (CD -131)) (TO to) (NP (CD +12))))) (-RRB- -RRB-)))))) (, ,) (NP-SBJ-COOD-55 (CC both) (NP (DT the) (NN proIL-1) (NN beta)) (CC and) (NP (DT the) (JJ simian) (NN virus) (CD 40) (NN enhancer) (NNS elements))) (VP (VBD functioned) (ADVP (ADVP (RBR more) (RB efficiently))) (PP (IN in) (NP (NNS monocytes))) (PP-58 (IN than) (FRAG (PP (IN in) (NP (NP (NN HeLa) (NNS cells)) (, ,) (SBAR (WHNP-59 (WDT which)) (S (VP (VBP are) (RB not) (ADVP (RB normally)) (ADJP-PRD (JJ competent) (PP (IN for) (NP (NN IL-1) (NN beta) (NN expression)))))))))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-61 (WRB When)) (S (VP (VBN ligated) (PP (TO to) (NP (DT the) (JJ murine) (NN c-fos) (NN promoter)))))) (, ,) (ADVP (RB however)) (, ,) (NP-SBJ-60 (DT the) (NN proIL-1) (NN beta) (NN enhancer)) (VP (VBD was) (ADJP-PRD (JJ inducible)) (PP (IN in) (NP (ADJP (NN phorbol) (NN myristate) (JJ acetate-stimulated)) (NN HeLa) (NNS cells))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (ADJP (NN proIL-1) (NN beta) (JJ promoter-proximal)) (NN requirement)) (PP (IN for) (NP (NN tissue) (NN specificity))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (NP (NN PILOT)) (, ,) (NP (DT a) (JJ putative) (NN transcription) (NN factor)) (, ,)))) (VP (VP-COOD (VP (VBZ requires) (NP (CD two) (NNS signals))) (CC and) (VP (VBZ is) (ADJP-PRD (NP (NN cyclosporin) (NN A)) (JJ sensitive)))) (PP (IN in) (NP (NN T) (NNS cells)))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-67 (NP (JJ Few) (JJ known) (NNS genes)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN IL-2)) (, ,) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NN IL-8) (NN family)))) (, ,) (NP (NN interferon-gamma))) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN induced) (PP (IN in) (NP (NN T) (NNS cells))) (PP (RB only) (IN through) (NP (NP (DT the) (JJ combined) (NN effect)) (PP (IN of) (NP-COOD (NP (NP (NN phorbol) (JJ myristic) (NN acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (CC and) (NP (DT a) (NN Ca-LRB-2+-RRB--ionophore))))))))) (, ,) (CC and) (S (NP-SBJ-69 (NP (NN expression)) (PP (IN of) (NP (RB only) (DT these) (NNS genes)))) (VP (MD can) (VP (VB be) (VP (ADVP (RB fully)) (VBN suppressed) (PP (IN by) (NP-LGS (NP (NN Cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CyA)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN identified) (NP (NP (DT a) (JJ putative) (NN transcription) (NN factor)) (, ,) (VP (VBN designated) (S (NP-PRD (NN PILOT)))) (, ,) (PP (IN with) (NP (NP (DT an) (JJ identical) (JJ dual) (NN signal) (NN requirement)) (PP (IN for) (NP (NN expression)))))))) (. .)))
(TOP (S (NP-SBJ-70 (NP (NN Induction)) (PP (IN of) (NP (DT the) (NN PILOT) (NN gene)))) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ detectable)) (PP (IN in) (NP (JJ human) (NN T) (NNS cells))) (PP-TMP (NP (CD 20) (NN min)) (VBG following) (NP (NN activation))) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NN cycloheximide)))) (CC and) (VP (VBZ is) (VP (ADVP (RB fully)) (VBN suppressed) (PP (IN by) (NP-LGS (NN CyA)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN PILOT) (NN protein)) (VP-COOD (VP (VBZ has) (NP (NP (DT a) (VBN calculated) (NN M-LRB-r-RRB-)) (PP (IN of) (NP (CD 42.6) (NN kDa))))) (CC and) (VP (VBZ contains) (NP (NP (CD three) (NN zinc) (NNS fingers)) (PP (IN of) (NP (DT the) (NN C2H2-type)))) (PP (IN at) (NP (DT the) (NN carboxyl-terminus))) (SBAR-102 (WHNP-71 (WDT which)) (S (VP (VBP are) (ADJP-PRD (RB highly) (JJ homologous) (PP (TO to) (NP (NP (DT the) (NN zinc) (NN finger) (NNS regions)) (PP (IN of) (NP (DT the) (NN transcription) (NNS factors) (NP-COOD (NP (NNS EGR1)) (, ,) (NP (NNS EGR2)) (, ,) (CC and) (NP (NN pAT) (CD 133))))))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NN T) (NNS cells))) (, ,) (PP (IN in) (NP (NNS fibroblasts))) (NP-SBJ-72 (NN PILOT) (NN gene) (NN expression)) (VP-COOD (VP (VBZ requires) (NP (NP (QP (RB only) (CD one)) (NN signal)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-)))) (CC and) (VP (VBZ is) (RB not) (VP (VBN affected) (PP (IN by) (NP-LGS (NN CyA)))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN observation)) (ADVP (RB directly)) (VP (VBZ demonstrates) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (ADJP (NN Ca2+) (JJ signal-dependent)) (JJ regulatory) (NN element)) (ADJP (JJ obligatory) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT some) (NNS genes))) (PP-COOD (PP (IN in) (NP (NN T) (NNS cells))) (CC but) (PP (RB not) (IN in) (NP (NNS fibroblasts))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ differential) (NN expression) (NN model)) (VP (MD will) (VP (VB be) (ADJP-PRD (JJ valuable)) (PP (IN in) (NP-COOD (NP (NP (DT the) (NN dissection)) (PP (IN of) (NP (DT the) (JJ dual) (NN signal) (NN pathway))) (PP (IN in) (NP (NN T) (NNS cells)))) (CC and) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN CyA))) (PP (IN upon) (NP (PRP it)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Human) (NN CD4) (NNS lymphocytes)) (ADVP (RB specifically)) (VP (VBP recognize) (NP (NP (DT a) (NN peptide)) (VP (VBG representing) (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (NP (DT the) (NN hybrid) (NN protein) (NN pml/RAR) (NN alpha)) (ADJP (JJ present) (PP (IN in) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Fusion) (NNS proteins)) (ADJP (JJ present) (PP (IN in) (NP (JJ leukemic) (NNS cells))))) (ADVP-TMP (RB frequently)) (VP (VBP contain) (NP (DT a) (JJ new) (NN amino) (NN acid)) (PP (IN at) (NP (DT the) (NN fusion) (NN point)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD tested) (SBAR (IN whether) (S (NP-SBJ-51 (NP (NP (DT a) (NN peptide)) (PRN (-LRB- -LRB-) (NP (NN BCR1/25)) (-RRB- -RRB-))) (VP (VBG encompassing) (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN hybrid) (NN molecule) (NN pml/RAR) (NN alpha))))) (, ,) (SBAR (WHNP-52 (WDT which)) (S (VP (VBZ is) (VP (ADVP (RB selectively)) (VBN expressed) (PP (IN by) (NP-LGS (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (NNS cells))))))) (, ,)) (VP (MD can) (VP (VB be) (VP (VBN recognized) (PP (IN by) (NP-LGS (JJ human) (NN T) (NNS lymphocytes))) (ADVP (FW in) (FW vitro)))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ CD4+) (NNS lymphocytes)) (, ,) (PP (IN at) (NP (ADJP-COOD (CC both) (ADJP (JJ polyclonal)) (CC and) (ADJP (JJ clonal))) (NN level))) (, ,)) (VP (VBD recognized) (NP (NN peptide) (NN BCR1/25)) (PP (IN in) (NP (DT an) (JJ HLA-DR--restricted) (NN fashion))) (PP (IN on) (NP (NP (NN presentation)) (PP-COOD (PP (IN by) (NP (JJ autologous) (NP (NP (JJ antigen-presenting) (NN cell)) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))))) (CC or) (PP (IN by) (NP (NP (NN APC)) (VP (VBG expressing) (NP (DT the) (NN HLA-DR11) (NN restricting) (NN molecule))))))))) (. .)))
(TOP (S (NP-SBJ-54 (NP (NN Control) (NNS peptides)) (VP (VBG corresponding) (PP (TO to) (NP (DT the) (NP-COOD (NP (JJ normal) (NN pml)) (CC and) (NP (NN RAR) (NN alpha))) (NNS proteins))))) (VP (VBD were) (RB not) (VP (VBN recognized))) (. .)))
(TOP (S (NP-SBJ (NP (CD One) (NN clone)) (PRN (-LRB- -LRB-) (NP (NN DEG5)) (-RRB- -RRB-))) (ADVP (RB also)) (VP (VBD exerted) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ high)) (CC and) (ADJP (JJ specific))) (NN cytotoxicity)) (PP (IN against) (NP (NP (JJ autologous) (NNS cells)) (VP (VBN pulsed) (PP (IN with) (NP (NN BCR1/25)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ autologous) (NN DE) (NN LCL)) (VP-COOD (VP (VBG containing) (NP (DT a) (VBN transduced) (NN pml/RAR) (NN alpha) (NN fusion) (NN gene))) (CC and) (VP (VBG expressing) (NP (NP (DT a) (NN bcr1) (NN type)) (PP (IN of) (NP (DT the) (NN pml/RAR) (NN alpha) (NN hybrid) (NN protein))))))) (VP (VBD induced) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (NN DE) (CD anti-BCR1/25) (NN T) (NN cell) (NNS clones))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN concluded) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN bcr1) (NN type-pml/RAR) (NN alpha) (NN fusion) (NN protein)) (PP (IN of) (NP (NN APL)))) (VP (VBZ contains) (NP (NP (DT an) (JJ antigenic) (NN site)) (, ,) (UCP-COOD (ADJP (JJ absent) (PP (IN from) (NP (DT the) (JJ normal) (NN parent) (NNS molecules)))) (CC and) (VP (VBN recognized) (PP (IN by) (NP-LGS (JJ human) (JJ CD4+) (NNS lymphocytes))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (DT A) (NN serum) (NN response) (NN element)) (CC and) (NP (NP (DT a) (VBG binding) (NN site)) (PP (IN for) (NP (NN NF-Y))))) (VP (VB mediate) (NP (NP (DT the) (NN serum) (NN response)) (PP (IN of) (NP (DT the) (JJ human) (NN thrombospondin) (CD 1) (NN gene))))) (. .)))
(TOP (S (NP-SBJ-34 (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NP (NN thrombospondin) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN TSP) (CD 1)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN member)) (PP (IN of) (NP (DT the) (NN TSP) (NN gene) (NN family)))) (, ,)))) (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN induced) (PP (IN by) (NP-LGS (NN growth) (NNS factors))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD tested) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ human) (NN TSP) (JJ 1-chloramphenicol) (NN acetyltransferase) (NNS constructs))) (S-35 (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NN serum))) (PP (IN in) (NP (ADJP (RB stably) (VBN transfected)) (NN NIH-3T3) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-COOD-36 (NP (NP (CD Two) (JJ transcriptional) (NNS elements)) (PP (IN in) (NP (DT the) (NN TSP) (CD 1) (NN promoter)))) (, ,) (NP-COOD (NP (NP (DT a) (JJ distal) (NN element)) (PP (IN at) (NP (CD -1280)))) (CC and) (NP (NP (DT a) (JJ proximal) (NN element)) (PP (IN at) (NP (CD -65))))) (, ,)) (VP (VBD were) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (DT the) (JJ human) (NN TSP) (CD 1) (NN gene))) (PP (TO to) (NP (NN serum))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ distal) (NN element)) (VP (VBZ contains) (NP (NP (DT the) (SYM 5'-CC-LRB-A) (SYM +) (NN T-RRB-6GG-3') (NN consensus) (NN sequence)) (ADJP (JJ characteristic) (PP (IN of) (NP (NP (DT a) (JJ serum-response) (NN element)) (PRN (-LRB- -LRB-) (NP (NN SRE)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NNS Deletions)) (CC or) (NP (NNS mutations))) (PP (IN in) (NP (DT this) (NN element)))) (VP (VBD reduced) (NP (NP (DT the) (NN serum) (NN response)) (PP (IN of) (NP (DT the) (NN TSP) (CD 1) (NN gene)))) (PP (IN by) (NP (QP (CD 80-90)) (NN %)))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (JJ gel-shift) (NNS assays))) (, ,) (NP-SBJ-COOD (NP (DT the) (CD -1280) (NN element)) (CC and) (NP (DT the) (NN c-fos) (NN SRE))) (VP (VBD cross-competed))) (, ,) (IN whereas) (S (NP-SBJ (PRP$ their) (ADJP-COOD (ADJP (JJ functional)) (CC and) (ADJP (VBG binding))) (NNS mutants)) (VP (VBD did) (RB not))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ proximal) (NN element)) (VP (VBZ contains) (NP (NP (DT the) (NN sequence) (NN 5'-GGCCAATGGG-3')) (, ,) (SBAR (WHNP-37 (WDT which)) (S (VP (ADVP (RB closely)) (VBZ resembles) (NP (NP (DT the) (NN consensus) (NN binding) (NN motif)) (PP (IN for) (NP (NP (DT the) (JJ CCAAT-binding) (NN factor) (NN NF-Y)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN CBF)) (, ,) (NP (NN CP1)) (, ,) (NP (NN alpha) (NN CP1))) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NNS Deletions)) (CC or) (NP (NNS mutations))) (PP (IN in) (NP (DT this) (NN element)))) (ADVP (RB also)) (VP (VBD reduced) (NP (DT the) (NN serum) (NN response)) (PP (IN by) (NP (QP (CD 80-90)) (NN %)))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Methylation) (NN interference) (NN analysis)) (PP (IN of) (NP (DT the) (CD -65) (NN region)))) (VP (VBD identified) (NP (NP (NP (DT a) (NN pattern)) (PP (IN of) (NP (NP (NNS contacts)) (PP (IN with) (NP (JJ nuclear) (NNS factors))))) (VP (VBG resembling) (NP (NP (DT that)) (PP (IN for) (NP (NN NF-Y)))))) (, ,) (CC and) (NP (NP-COOD (NP (DT an) (JJ NF-Y-binding) (NN site)) (CC and) (NP (DT the) (JJ proximal) (NN TSP) (CD 1) (NN element))) (VP (VBD cross-competed) (PP (IN in) (NP (JJ gel-shift) (NNS assays)))))))) (, ,) (IN whereas) (S (NP-SBJ (PRP$ their) (VBG binding) (NNS mutants)) (VP (VBD did) (RB not))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (NP (DT an) (VBN abbreviated) (NN TSP) (CD 1) (NN promoter/5'-flank)) (, ,) (VP (VBG containing) (NP (DT the) (ADJP-COOD (ADJP (NP (NN SRE-))) (CC and) (ADJP (JJ NF-Y-binding))) (NNS sites))) (, ,)) (VP (VBD mediated) (NP (NP (DT a) (NN serum) (NN response)) (SBAR (WHNP-38 (WDT that)) (S (VP (VBD was) (ADJP-PRD (JJ close)) (PP (IN in) (NP (NN magnitude))) (PP-39 (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NN parent) (NN promoter)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN serum) (NN response)) (PP (IN of) (NP (DT the) (JJ human) (NN TSP) (CD 1) (NN gene)))) (VP (VBZ requires) (NP (NP (DT the) (VBN coordinated) (NN function)) (PP (IN of) (NP (DT an) (ADJP-COOD (ADJP (NP (NN SRE-))) (CC and) (ADJP (JJ NF-Y-binding))) (NN site)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Suppression)) (PP (IN of) (NP (DT a) (JJ cellular) (NN differentiation) (NN program))) (PP (IN by) (NP (NN phorbol) (NNS esters)))) (VP (VBZ coincides) (PP (IN with) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN binding)) (PP (IN of) (NP (NP (DT a) (JJ cell-specific) (NN transcription) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN NF-E2)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (DT an) (NN enhancer) (NN element)) (VP (VBN required) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT an) (JJ erythroid-specific) (NN gene))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Induction)) (PP (IN by) (NP (NN hemin)))) (VP (VBZ increases) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (NN induction)) (PP (IN with) (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))))) (VP (VBZ represses)))) (, ,) (NP-61 (NP (JJ erythroid-specific) (NN gene) (NN expression)) (PP (IN in) (NP (DT the) (JJ human) (NN cell) (NN line) (NN K562))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD analyzed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP-COOD (NP (NN hemin)) (CC or) (NP (NN TPA))) (NN induction))) (PP (IN on) (NP (NP (DT the) (NP-COOD (NP (NN binding)) (CC and) (NP (NN activity)))) (PP (IN of) (NP (NN transcription) (NNS factors))) (PP (IN at) (NP (NP (DT a) (JJ regulatory) (NN element)) (VP (VBN found) (PP (IN within) (NP (NP (DT the) (ADJP (JJ transcriptional) (JJ regulatory)) (NNS sequences)) (PP (IN of) (NP (JJ many) (JJ erythroid-specific) (NNS genes)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN TPA) (NN induction)) (VP (VBZ increases) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ ubiquitous) (NN AP-1) (NNS factors))) (PP (TO to) (NP (DT this) (NN element))))) (. .)))
(TOP (S (NP-SBJ (NN TPA) (NN induction)) (VP (VBZ inhibits) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (DT the) (ADJP (NN lineage) (JJ limited)) (NN transcription) (NN factor) (NN NF-E2))) (PP (TO to) (NP (DT this) (JJ transcriptional) (NN control) (NN element))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Hemin) (NN induction)) (PP (IN of) (NP (NN K562) (NNS cells)))) (VP (VBZ does) (RB not) (VP (VB facilitate) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN NF-E2))) (PP (TO to) (NP (PRP$ its) (NN recognition) (NN site)))))) (. .)))
(TOP (S (NP-SBJ-65 (NN Hemin) (NN induction)) (VP (VBZ appears) (S (VP (TO to) (ADVP (RB nonspecifically)) (VP (VB increase) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (ADJP (RB transiently) (VBN transfected)) (NNS genes))) (PP (IN in) (NP (NN K562) (NNS cells)))))))) (. .)))
(TOP (S (PP (IN Beyond) (NP (NP (DT this) (JJ nonspecific) (NN increase)) (PP (IN in) (NP (NN gene) (NN expression))))) (, ,) (NP-SBJ-66 (NN hemin) (NN induction)) (VP (VBZ acts) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (ADJP (NN lineage) (JJ limited)) (NN transcription) (NN factor) (NN NF-E2)))))))) (. .)))
(TOP (S (NP-SBJ-67 (NP (DT The) (JJ divergent) (NNS effects)) (PP (IN of) (NP-COOD (NP (NN hemin)) (CC and) (NP (NN TPA)))) (PP (IN on) (NP (NP (NN gene) (NN expression)) (PP (IN in) (NP (NN K562) (NNS cells)))))) (VP (VBP are) (VP (VBN mediated) (PP (, ,) (PP (IN in) (NP (NN part))) (, ,) (IN by) (NP-LGS (NP (PRP$ their) (JJ contrasting) (NNS effects)) (PP (IN on) (NP (DT the) (NN transcription) (NN factor) (NN NF-E2))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN interleukin) (CD 2) (JJ CD28-responsive) (NN complex)) (VP (VBZ contains) (NP (NP (NP (QP (IN at) (JJS least) (CD three)) (NNS members)) (PP (IN of) (NP (DT the) (NN NF) (NN kappa) (NN B) (NN family)))) (: :) (NP-COOD (NP (NN c-Rel)) (, ,) (NP (NN p50)) (, ,) (CC and) (NP (NN p65))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Optimal) (NN activation)) (PP (IN of) (NP (NN T) (NNS cells)))) (VP (VBZ requires) (NP (QP (IN at) (JJS least) (CD two)) (NNS signals))) (. .)))
(TOP (S-COOD (S (NP-SBJ-55 (CD One) (NN signal)) (VP (MD can) (VP (VB be) (VP (VBN delivered) (PP (IN by) (NP-LGS (DT the) (JJ antigen-specific) (NN T-cell) (NN receptor))))))) (, ,) (CC and) (S (NP-SBJ-56 (DT the) (JJ second) (NN signal)) (VP (VBZ is) (VP (VBN provided) (PP (IN by) (NP-LGS (NP (DT the) (JJ costimulatory) (NN molecule) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (VP (VBN delivered) (PP (IN by) (NP-LGS (DT the) (JJ antigen-presenting) (NN cell))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN CD28)) (VP (VBZ is) (NP-PRD (DT a) (NN T-cell) (NN surface) (NN molecule)))) (CC and) (S (NP-SBJ-57 (NP (NN stimulation)) (PP (IN through) (NP (DT this) (NN protein)))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG delivering) (NP (DT the) (JJ second) (NN activation) (NN signal))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS cells))) (, ,) (NP-SBJ (JJ CD28-mediated) (NN signal) (NN transduction)) (VP (VBZ involves) (NP (NP (DT the) (NN rel) (NN family) (NNS proteins)) (: --) (NP-COOD (NP (NN c-Rel)) (, ,) (NP (NN p50)) (, ,) (CC and) (NP (NN p65)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN T) (NNS cells))) (PP (IN with) (NP-COOD (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ anti-CD28) (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN mAb)) (-RRB- -RRB-)))))) (VP (VBZ results) (PP (IN in) (NP (NP (NN augmentation)) (PP (IN of) (NP (JJ nuclear) (NP-COOD (NP (NN c-Rel)) (, ,) (NP (NN p50)) (, ,) (CC and) (NP (NN p65))))))))) (, ,) (CC and) (S (NP-SBJ (DT this) (NN augmentation)) (VP (MD can) (VP (VB occur) (PP (IN in) (DT the) (NN presence) (IN of) (NP (DT the) (JJ immunosuppressant) (NN cyclosporin) (NN A)))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN shown) (PP (IN in) (NP (DT this) (NN report))) (SBAR (IN that) (, ,) (S (PP (IN in) (NN response) (TO to) (NP-COOD (NP (JJ PMA/anti-CD28) (NN mAb)) (CC or) (NP (JJ anti-CD3/anti-CD28) (NN mAb)))) (, ,) (NP-SBJ-COOD-58 (NP (NN c-Rel)) (, ,) (NP (NN p50)) (, ,) (CC and) (NP (NN p65))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ CD28-responsive) (NN element)) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (DT the) (JJ human) (NN interleukin) (CD 2) (NN gene)))))))))))))) (. .)))
(TOP (S (NP-SBJ-59 (NP (DT The) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (NN c-Rel) (NN involvement)) (PP (IN in) (NP (DT the) (JJ CD28-responsive) (NN complex)))))) (VP (VBZ is) (VP (VBN demonstrated) (PP (IN by) (NP-LGS (NP (JJ transient) (NN transfection) (NN analysis)) (, ,) (SBAR (WHADVP-60 (WRB where)) (S (NP-SBJ (NP (NN cotransfection)) (PP (IN of) (NP (NN c-Rel)))) (VP (VBZ augments) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT a) (JJ chloramphenicol) (NN acetyltransferase) (NN reporter) (NN gene)) (VP (VBN linked) (PP (TO to) (NP (DT the) (JJ CD28-responsive) (NN element)))))))))))))))) (. .)))
(TOP (NP (NP (NN Expression)) (PP (IN of) (NP (NP (DT the) (NN Tat) (NN protein)) (PP (IN of) (NP (NN HIV1))))) (PP (IN in) (NP (JJ human) (JJ promonocytic) (NN U937) (NNS cells))) (. .)))
(TOP (S (NP-SBJ (JJ Numerous) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (, ,) (S (PP-TMP (IN upon) (NP (NN HIV1) (NN infection))) (, ,) (NP-SBJ-51 (JJ human) (JJ promonocytic) (NN U937) (NNS cells)) (VP (VBD were) (VP (VBN induced) (S (VP (TO to) (VP (VB differentiate) (, ,) (SBAR (IN as) (S (VP (VBN indicated) (, ,) (PP (IN for) (NP (NN example))) (, ,) (PP (IN by) (NP-LGS (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NN adhesion) (NNS molecules))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD One)) (PP (IN of) (NP (NP (DT the) (JJ viral) (NNS proteins)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN process))))))) (VP (MD might) (VP (VB be) (NP-PRD (DT the) (NN Tat) (NN protein)))) (. .)))
(TOP (S (ADVP (RB Indeed)) (, ,) (NP-SBJ-54 (NP (DT this) (JJ viral) (NN protein)) (, ,) (SBAR (WHNP-53 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (JJ productive) (NN infection))))))) (, ,)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB display) (NP-COOD (NP (JJ growth-stimulating) (NNS properties)) (CC and) (NP (JJ immunomodulatory) (NNS activities))))))))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (TO to) (S (VP (VB apprehend) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (NN HIV1) (NN tat) (NN gene))) (PP (IN in) (S (VP (VBG inducing) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (JJ HIV1-infected) (NN U937) (NNS cells))))))))))) (, ,) (NP-SBJ-55 (PRP we)) (VP (VBP have) (ADVP (RB successfully)) (VP (VBN introduced) (NP (DT this) (NN gene)) (PP (IN into) (NP (NN U937) (NNS cells))) (PP (IN by) (S (VP (VBG infecting) (NP (PRP them)) (PP (IN with) (NP (JJ retroviral) (NNS particles) (VBG transducing) (NN tat)))))))) (. .)))
(TOP (S (NP-SBJ-57 (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (DT the) (NN Tat) (NN protein)) (VP (ADVP (RB constitutively)) (VBN expressed) (PP (IN by) (NP-LGS (DT these) (NNS cells))) (PP-TMP (IN upon) (NP (PRP$ their) (NN differentiation))))))) (VP (VBD was) (ADVP-TMP (RB then)) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG looking) (PP (IN for) (NP (NP (DT the) (NN expression)) (PP (PP-COOD (PP (IN of) (NP (NP (DT the) (NN c-fos)))) (CC and) (PP (IN of) (NP (NP (DT the) (NN c-fms))))) (NP-101 (NNS proto-oncogenes)) (SBAR-58 (WHNP-59 (WDT which)) (S (VP (VBP are) (VP (VBN linked) (PP (TO to) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (JJ myelomonoblastic) (NNS cells))))))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN Northern) (NN blot) (NN analysis)) (VP (VBD revealed) (PP (IN in) (NP (DT these) (NNS cells))) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (DT these) (CD two) (NNS proto-oncogenes)))))))) (, ,) (CC and) (S (NP-SBJ-61 (DT this) (NN increase)) (VP (VBD was) (VP (VBN amplified) (PP-TMP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NN phorbol) (NN myristate) (NN acetate)))))))) (. .)))
(TOP (S (NP-SBJ-62 (DT No) (JJ such) (NN increase)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NN control) (NN U937) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP-COOD (VP (VBP indicate) (SBAR (IN that) (, ,) (S (PP (IN among) (NP (NN HIV1) (NN gene) (NNS products))) (, ,) (NP-SBJ-63 (DT the) (NN Tat) (NN protein)) (VP (VBZ appears) (S (VP (TO to) (VP (VB trigger) (NP (JJ monocytic) (NN differentiation))))))))) (, ,) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (DT this) (JJ viral) (NN protein)) (VP (VBZ directs) (NP (NP (NNS progenitors)) (PP (IN of) (NP (DT the) (NN monocyte/macrophage) (NN lineage)))) (PP (IN towards) (NP (NP (DT a) (NN differentiation) (NN stage)) (SBAR (WHPP-64 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NP (NN production)) (PP (IN of) (NP-COOD (NP (JJ viral) (NNS antigens)) (CC and) (NP (NNS virions))))) (VP (MD might) (VP (VB be) (ADJP-PRD (RBR more) (JJ efficient))))))))))))) (. .)))
(TOP (NP (NP (JJ Transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NN pyruvate) (NN kinase) (JJ erythroid-specific) (NN promoter))) (. .)))
(TOP (S (NP-SBJ-47 (JJ Mammal) (NN pyruvate) (NNS kinases)) (VP (VBP are) (VP (VBN encoded) (PP (IN by) (NP-LGS (CD two) (NNS genes))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN L) (NN gene)) (VP (VBZ produces) (NP (NP-COOD (NP (NP (DT the) (JJ erythroid)) (PRN (-LRB- -LRB-) (NP (NN R-PK)) (-RRB- -RRB-))) (CC or) (NP (NP (DT the) (JJ hepatic)) (PRN (-LRB- -LRB-) (NP (JJ L-PK)) (-RRB- -RRB-)))) (NP-102 (NNS isozymes))) (PP (IN by) (NP (NP (DT the) (JJ alternative) (NN use)) (PP (IN of) (NP (CD two) (NNS promoters)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN characterization)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (NP (JJ cis-))) (CC and) (ADJP (JJ trans-acting))) (NNS elements)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ tissue-specific) (NN activity)) (PP (IN of) (NP (DT the) (NN L) (NN gene) (JJ erythroid) (NN promoter)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (NN R-PK) (NN DNA) (NN fragment)) (VP (VBG extending) (PP-COOD (PP (IN from) (NP (CD -870))) (PP (TO to) (NP (CD +54)))) (PP (JJ relative) (TO to) (NP (DT the) (NN cap) (NN site))))) (VP (VBZ confers) (NP (JJ erythroid) (NN specificity)) (PP (TO to) (NP (DT a) (NN reporter) (NN gene)))) (. .)))
(TOP (S (PP (IN Within) (NP (DT this) (NN region))) (, ,) (NP-SBJ (PRP we)) (VP (VBP define) (NP (NP (NP (DT a) (JJ minimal) (NN promoter)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD -62)) (TO to) (NP (CD +54))) (-RRB- -RRB-))) (SBAR (WHNP-48 (WDT that)) (S (VP-COOD (VP (VBZ displays) (NP (JJ erythroid-specific) (NN activity))) (CC and) (VP (VBZ contains) (NP (CD two) (NN DNA) (NN binding) (NNS sites)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (CD One)) (, ,) (ADJP (JJ located) (PP (IN at) (NP (CD -50)))) (, ,)) (VP (VBZ binds) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NN CCACC/Sp1) (NN family)))))) (CC and) (S (NP-SBJ (NP (DT the) (JJ other)) (, ,) (ADJP (JJ located) (PP (IN at) (NP (CD -20)))) (, ,)) (VP (VBZ binds) (NP (DT the) (JJ erythroid) (NN factor) (NN GATA-1)))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (DT the) (CD -20) (NN GATA) (NN binding) (NN site)) (PRN (-LRB- -LRB-) (NP (NN AGATAA)) (-RRB- -RRB-))) (VP (VBZ is) (ADVP (RB also)) (NP-PRD (DT a) (JJ potential) (NN TFIID) (NN binding) (NN site))))) (, ,) (NP-SBJ (PRP it)) (VP (VBZ does) (RB not) (VP (VB bind) (NP (NN TFIID)))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (DT the) (NN substitution)) (PP (IN of) (NP (DT this) (NN GATA) (NN binding) (NN site))) (PP (IN by) (NP (DT a) (JJ canonical) (NN TFIID) (NN binding) (NN site)))) (VP (VBZ suppresses) (NP (DT the) (NN promoter) (NN activity))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NNS Mutations)) (CC and) (NP (NNS deletions))) (PP (IN of) (NP (DT both) (NNS sites)))) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (RB only) (DT the) (NN association)) (PP (IN of) (NP (NP-COOD (NP (NN CCACC/Sp1)) (CC and) (NP (NN GATA))) (NN binding) (NNS sites)))) (VP (MD can) (VP (VB drive) (NP (NP (ADJP-COOD (ADJP (JJ efficient)) (CC and) (ADJP (JJ tissue-specific))) (NN expression)) (PP (IN of) (NP (DT this) (NN R-PK) (JJ minimal) (NN promoter))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (PP (IN by) (NP (NN co-transfection) (NNS experiments))) (, ,) (NP-SBJ (PRP we)) (VP (VBD study) (NP (NP (DT the) (NNS elements)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN hGATA-1) (NN transactivation)) (PP (IN of) (NP (DT the) (NN R-PK) (NN promoter))) (PP (IN in) (NP (NN HeLa) (NNS cells)))))))) (. .)))
(TOP (NP (NP (NN Stimulation)) (PP (IN of) (NP (NP (NP-COOD (NP (NN interleukin-1) (NN alpha)) (CC and) (NP (NN interleukin-1) (NN beta))) (NN production)) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (PP (IN by) (NP (NN protein) (NN phosphatase) (NP-COOD (NP (CD 1)) (CC and) (NP (NN 2A))) (NNS inhibitors))) (. .)))
(TOP (S (NP-SBJ-48 (NN Protein) (NNS phosphatases) (NP-COOD (NP (CD 1)) (CC and) (NP (NN 2A)))) (VP (VBP are) (ADJP-PRD (JJ important)) (PP (IN in) (S (VP (VBG regulating) (NP (JJ cellular) (NNS functions)) (PP (IN by) (S (VP (VBG controlling) (NP (NP (DT the) (NN phosphorylation) (NN state)) (PP (IN of) (NP (PRP$ their) (NNS substrates))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ human) (NNS monocytes))) (, ,) (NP-SBJ-50 (NP (NP (DT the) (NNS inhibitors)) (PP (IN of) (NP (DT these) (NNS phosphatases)))) (, ,) (NP-COOD (NP (JJ okadaic) (NN acid)) (CC and) (NP (NN calyculin) (NN A))) (, ,)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NP-COOD (NP (NN mRNA) (NN accumulation)) (CC and) (NP (NN cytokine) (NN production)))) (PP (IN of) (NP-COOD (NP (NN interleukin-1) (NN beta)) (CC and) (NP (NN interleukin-1) (NN alpha)))))))))) (. .)))
(TOP (S (NP-SBJ-51 (DT The) (VBN increased) (NN mRNA) (NN accumulation)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (PP-PRD (RB primarily) (IN because) (IN of) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN transcription) (NN rate)) (PP (IN of) (NP (DT the) (NN interleukin-1) (NNS genes)))))))))))) (. .)))
(TOP (S (NP-SBJ-52 (NP (NN Stimulation)) (PP (IN of) (NP (NN interleukin-1) (NN gene) (NN transcription)))) (VP (MD may) (VP (VB be) (VP (VBN caused) (PP (IN by) (NP-LGS (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NP (NN transcription) (NN factor) (NNS activities)) (, ,) (PP (VBG including) (NP (NP (DT those)) (PP (IN of) (NP (NN AP-1))))) (, ,))) (PP (IN by) (NP (DT these) (NN protein) (NN phosphatase) (NNS inhibitors)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Okadaic) (NN acid)) (VP (VBD increased) (NP-COOD (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (DT the) (NN interleukin-1) (NN beta) (UCP-COOD (NP (NN precursor)) (CC and) (ADJP (JJ mature))) (NNS forms)))) (CC and) (NP (PRP$ their) (NN secretion)))) (. .)))
(TOP (S (NP-SBJ (DT This) (VBD increased) (NP-COOD (NP (NN processing)) (CC and) (NP (NN secretion)))) (VP (VBN correlated) (PP (IN with) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN IL-1) (NN beta) (NN convertase) (NN mRNA) (NN accumulation)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN stimulation)) (PP (IN of) (NP (NN interleukin-1) (NN alpha) (NN production))) (PP (IN by) (NP (JJ okadaic) (NN acid)))) (VP (VBD was) (ADJP-PRD (ADJP (RBR more) (JJ modest)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NN interleukin-1) (NN beta))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-53 (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (DT the) (NN precursor) (NN interleukin-1) (NN alpha) (NN cytokine)))) (VP (VBD was) (VP (VBN increased))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP-COOD (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN protein) (NN phosphatase) (NP-COOD (NP (CD 1)) (CC and) (NP (NN 2A))) (NNS inhibitors)) (VP (VBP exert) (NP (JJ multiple) (NNS effects)) (PP (IN on) (NP (NP (NN cytokine) (NN production)) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-54 (DT these) (CD two) (NNS phosphatases)) (VP (VBP play) (NP (JJ important) (NNS roles)) (PP (IN in) (S (VP (VBG regulating) (NP (NN interleukin-1) (NN production)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP-COOD (ADJP (NP (NN Cell) (NN type-))) (CC and) (ADJP (JJ stage-specific))) (NN expression)) (PP (IN of) (NP (DT the) (NN CD20/B1) (NN antigen)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (DT a) (JJ diverged) (NN octamer) (NN DNA) (NN motif)) (ADJP (JJ present) (PP (IN in) (NP (PRP$ its) (NN promoter))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN CD20) (-LRB- -LRB-) (NN B1) (-RRB- -RRB-) (NN gene)) (VP (VBZ encodes) (NP (NP (DT a) (ADJP (NN B) (JJ cell-specific)) (NN protein)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ human) (NN B) (NN cell) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN differentiation)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Studies)) (PP (IN with) (NP (JJ 5') (NN deletion) (NN CD20) (NN promoter-CAT) (NNS constructs)))) (VP (VBP have) (VP (ADVP-TMP (RB previously)) (VBN revealed) (NP (NP (CD two) (NNS regions)) (PP (IN of) (NP (DT the) (NN promoter))) (PP-COOD (PP (IN between) (NP (NNS bases) (NP-COOD (NP (CD -186)) (CC and) (NP (CD -280))))) (CC and) (PP (IN between) (NP (NNS bases) (NP-COOD (NP (CD -280)) (CC and) (NP (CD -454)))))) (SBAR (WHNP-43 (WDT which)) (S (VP (VBD contained) (NP (JJ positive) (JJ regulatory) (NNS elements)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ (PRP we)) (VP (VBD identified) (NP (NP (DT a) (NN sequence) (NN element)) (ADJP (JJ present) (PP (IN in) (NP (NP (NP (DT the) (ADJP (RBS most) (JJ proximal)) (NN region)) (ADJP (JJ located) (PP (IN between) (NP (NNS bases) (NP-COOD (NP (CD -214)) (CC and) (NP (CD -201))))))) (, ,) (NP (NN TTCTTCTAATTAA))))) (, ,) (SBAR (WHNP-44 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ important)) (PP (IN in) (NP-COOD (NP (NP (DT the) (JJ high) (JJ constitutive) (NN expression)) (PP (IN of) (NP (NN CD20))) (PP (IN in) (NP (JJ mature) (NN B) (NNS cells)))) (CC and) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN CD20))) (PP (IN in) (NP (JJ pre-B) (NNS cells))))))))))) (. .)))
(TOP (S (S (NP-SBJ-45 (DT This) (NN sequence) (NN element)) (VP (VBD was) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (DT the) (NN BAT) (NN box)))))) (CC and) (S (NP-SBJ (PRP$ its) (NN deletion)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT a) (NN CD20) (JJ promoter-CAT) (NN construct))) (PP (IN in) (NP (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Mobility) (NN shift) (NNS assays)) (PP (IN with) (NP-COOD (NP (JJ various) (JJ mutant) (NNS probes)) (CC and) (NP (NN B) (NN cell) (JJ nuclear) (NNS extracts))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (DT the) (NN core) (NN sequence) (NN TAAT)) (VP (VBD was) (ADJP-PRD (JJ essential) (PP (IN for) (S (VP (VBG binding) (PP (TO to) (NP (DT this) (NN site))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Cross) (NN competition) (NNS experiments)) (PP (IN with) (NP-COOD (NP (NP (DT an) (NN octamer) (NN sequence)) (PP (IN from) (NP (DT the) (NN Ig) (JJ heavy) (NN chain) (NN promoter)))) (, ,) (NP (DT the) (NN BAT) (NN box)) (, ,) (CC and) (NP (NP (DT a) (JJ TA-rich) (NN sequence)) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN CD21) (NN promoter)))))))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (DT all) (CD three) (NNS sequences)) (VP (VBD bound) (NP (DT the) (JJ same) (JJ nuclear) (NNS proteins)) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (DT the) (NN BAT) (NN box) (NN binding) (NNS proteins)) (VP (VBD were) (NP-PRD-COOD (NP (NN Oct-1)) (CC and) (NP (NN Oct-2)))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN Southwestern) (NN blotting)) (CC and) (NP (NN UV) (NN cross-linking) (NNS studies))) (VP (VBD confirmed) (SBAR (IN that) (S (NP-SBJ (DT the) (NN BAT) (NN box) (NN binding) (NNS proteins)) (VP (VBD were) (NP-PRD-COOD (NP (NN Oct-1)) (CC and) (NP (NN Oct-2))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (NN affinity)) (PP (IN of) (NP (NP (DT the) (NN BAT) (NN box) (NN binding) (NNS proteins)) (PP (IN for) (NP (DT the) (NN BAT) (NN box)))))) (VP (VBD was) (ADJP-PRD (ADJP (ADVP (RB approximately) (RB 25-fold)) (JJR less)) (PP (IN than) (FRAG (PP (IN for) (NP (DT the) (NN octamer) (NN sequence)))))))) (CC and) (S (NP-SBJ (DT the) (NN BAT) (NN box) (NN binding) (NNS proteins)) (VP (VBD dissociated) (PP (IN from) (NP (DT the) (NN BAT) (NN box))) (ADVP (ADVP-TMP (ADVP (RB 10-fold) (RBR more)) (RB rapidly)) (PP (IN than) (FRAG (PP (IN from) (NP (DT the) (NN octamer) (NN sequence)))))))) (. .)))
(TOP (S (PP (IN Despite) (NP (DT this) (JJR lower) (NN affinity))) (, ,) (NP-SBJ-47 (NP (DT a) (NN trimer)) (PP (IN of) (NP (DT the) (NN BAT) (NN box) (NN sequence)))) (VP (VBD was) (ADVP (ADVP (IN as) (RB efficiently))) (VP (VBN transactivated) (PP (IN by) (NP-LGS (DT an) (NN Oct-2) (NN expression) (NN vector))) (SBAR-100 (IN as) (SINV (VBD was) (NP-SBJ (NP (DT a) (NN trimer)) (PP (IN of) (NP (DT the) (NN octamer) (NN sequence))) (PP (IN in) (NP (NN HeLa) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-48 (DT The) (NP-COOD (NP (NN BAT) (NN box)) (CC and) (NP (NN Oct-2)))) (VP (VBD were) (ADVP (RB also)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN CD20))) (PP (IN in) (NP (NP (DT the) (JJ pre-B) (NN cell) (NN line)) (, ,) (NP (NN PB-697)))))) (, ,) (PP (IN via) (NP (NN phorbol) (NNS esters))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-49 (NP (DT The) (NN induction)) (PP (IN of) (NP (NN CD20) (NN mRNA)))) (VP (VBD was) (VP (ADVP-TMP (RB temporally)) (VBN associated) (PP (IN with) (NP (NP (NN induction)) (PP (IN of) (NP (NN Oct-2) (NN mRNA)))))))) (CC and) (S (NP-SBJ-50 (DT a) (ADJP (NN BAT) (JJ box-deleted)) (NN CD20-CAT) (NN construct)) (, ,) (PP (IN in) (NN contrast) (TO to) (NP (DT the) (JJ wild) (NN type))) (, ,) (VP (VBD was) (VP (ADVP (RB poorly)) (VBN induced) (PP (IN by) (NP-LGS (NN phorbol) (NNS esters)))))) (. .)))
(TOP (S (ADVP (RB Together)) (NP-SBJ (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (DT the) (NN BAT) (NN box) (NN binding) (NNS proteins)) (VP-COOD (VP (VBP are) (ADJP-PRD (JJ important)) (PP (IN in) (NP (NP (DT the) (ADJP (NP (NN B) (NN cell)) (JJ specific)) (NN expression)) (PP (IN of) (NP-101 (NN CD20)))))) (CC and) (VP (ADVP (RB perhaps)) (NP=101 (NN CD21))))))) (. .)))
(TOP (S (NP-SBJ (NN Transcription) (NN factor) (NN jun-B)) (VP (VBZ is) (NP-PRD (NP (NN target)) (PP (IN of) (NP (NP (JJ autoreactive) (NNS T-cells)) (PP (IN in) (NP (NN IDDM))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Target) (NNS antigens)) (VP (VBN defined) (PP (IN by) (NP (NP (NNS autoantibodies)) (PP (IN in) (NP (NN IDDM))))))) (VP (VBP include) (NP-COOD (NP (NN insulin)) (, ,) (NP (NP (DT a) (JJ putative) (NN glycolipid)) (SBAR (WHNP-41 (WDT that)) (S (VP (VBZ reacts) (PP (IN with) (NP (NN islet) (NN cell) (NNS antibodies))))))) (, ,) (CC and) (NP (NP (DT a) (JJ 64,000-M-LRB-r-RRB-) (NN protein)) (VP (ADVP-TMP (RB recently)) (VBN identified) (PP (IN as) (NP (JJ glutamic) (NN acid) (NN decarboxylase))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (DT some) (NN IDDM) (NN sera)) (SBAR (WHNP-42 (WDT that)) (S (VP (VBP contain) (NP (NP (NNS antibodies)) (PP (TO to) (NP (JJ glutamic) (NN acid) (NN decarboxylase)))))))) (ADVP (RB also)) (VP (VBP coprecipitate) (NP (NP (DT a) (JJ 38,000-M-LRB-r-RRB-) (NN protein)) (PP (IN from) (NP (NNS islets))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN study)) (VP-COOD (VP (VBD used) (NP-43 (DT a) (JJ high) (NN titer) (JJ anti-38,000-M-LRB-r-RRB-) (NN serum)) (S (VP (TO to) (VP (VB screen) (NP (NN bacteriophage) (NN lambda) (NN cDNA) (NN expression) (NNS libraries)))))) (CC and) (VP (VBD identified) (NP (NP-COOD (NP (JJ human) (NN islet)) (CC and) (NP (JJ placental) (NNS clones))) (VP (VBG encoding) (NP (NP (NP (NN jun-B)) (, ,) (NP (DT the) (JJ nuclear) (NN transcription) (NN protein)) (, ,)) (PP (IN of) (NP (VBN predicted) (CD 38,000) (NN M-LRB-r-RRB-)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Peripheral) (NN blood) (NNS T-cells)) (VP (VBD exhibited) (NP (JJ significant) (NN proliferation)) (PP (IN in) (NN response) (TO to) (NP (NP (DT a) (JJ recombinant) (NN fragment)) (PP (IN of) (NP (NP (NP (NN jun-B)) (PRN (-LRB- -LRB-) (NP (NN amino) (NNS acids) (CD 1-180)) (-RRB- -RRB-))) (PP (IN in) (NP-COOD (NP (QP (QP (CD 12) (IN of) (CD 17)) (PRN (-LRB- -LRB-) (NP (CD 71) (NN %)) (-RRB- -RRB-))) (JJ recent-onset) (NN IDDM) (NNS subjects)) (, ,) (NP (NP (QP (QP (CD 8) (IN of) (CD 16)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN %)) (-RRB- -RRB-))) (JJ ICA-positive) (JJ first-degree) (NNS relatives)) (PP (IN of) (NP (NP (NN IDDM) (NNS subjects)) (SBAR (WHNP-44 (WP who)) (S (VP (VBD were) (PP-PRD (IN at) (NP (NN risk))))))))) (, ,) (NP (QP (QP (CD 3) (IN of) (CD 12)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (JJ other) (JJ autoimmune) (NN disease) (NNS subjects)) (, ,) (CC and) (NP (QP (CD 0) (IN of) (CD 10)) (JJ healthy) (NN control) (NNS subjects))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Proliferation)) (PP (TO to) (NP (NN tetanus) (NN toxoid)))) (VP (VBD did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (NNS groups))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Responses)) (PP (TO to) (NP (NN jun-B)))) (VP (VBD were) (RB not) (ADJP-PRD (JJ related) (PP (TO to) (NP-COOD (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (CC or) (NP (JJ human) (NN leukocyte) (NN antigen) (NN status)))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-45 (JJ autoreactive) (NNS T-cells)) (VP-COOD (VP (VBP identify) (NP (NP (NP (DT a) (JJ novel) (NN antigen)) (, ,) (NP (NN p38) (NN jun-B)) (, ,)) (PP (IN in) (NP (NN IDDM))))) (CC and) (VP (VBP appear) (S (VP (TO to) (VP (VB indicate) (NP (NP (NNS subjects)) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ clinical) (NN disease))))))))))))) (. .)))
(TOP (NP (NP (JJ Transcriptional) (NN regulation)) (PP (IN of) (NP (NP (NP (NN interleukin) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN IL3)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ primary) (JJ human) (NN T) (NNS lymphocytes))))) (. .)))
(TOP (NP (NP (NN Role)) (PP (IN of) (NP (ADJP-COOD (ADJP (NP (NN AP-1-))) (CC and) (ADJP (JJ octamer-binding))) (NNS proteins))) (PP (IN in) (NP (NP (NN control)) (PP (IN of) (NP (NN IL3) (NN gene) (NN expression))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ molecular)) (CC and) (ADJP (JJ biochemical))) (NN basis)) (PP (IN for) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NP (NP (NN interleukin) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN IL3)) (-RRB- -RRB-))) (NN gene) (NN expression)) (PP (IN in) (NP (JJ primary) (JJ human) (NN T) (NNS lymphocytes))))) (PP-TMP (VBG following) (NP (NP (NP-COOD (NP (NN CD3)) (CC and) (NP (NN CD2))) (NN receptor) (NP-COOD (NP (NN stimulation)) (CC or) (NP (NN activation)))) (PP (IN by) (NP-COOD (NP (NN phytohemagglutinin)) (CC plus) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate))))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NP (NP-COOD (NP (NN transfection)) (CC and) (NP (NN reporter) (NN gene))) (NNS assays)) (VP (ADVP (RB specifically)) (VBN designed) (PP (IN for) (NP (JJ primary) (NN T) (NNS lymphocytes))) (PP (IN in) (NN conjunction) (IN with) (NP-COOD (NP (NN gel) (NN retardation) (NNS assays)) (, ,) (NP (NN Western) (NN blot) (NNS analyses)) (CC and) (NP (NN UV) (JJ cross-linking) (NNS studies)))))))) (, ,) (NP-SBJ-46 (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (UCP-COOD (NP (NN c-Jun)) (, ,) (NP (NN c-Fos)) (, ,) (CC and) (ADJP (NN octamer-binding))) (NNS proteins)) (VP (VBP play) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NN IL3) (NN gene))))) (PP (IN via) (NP (NP (PRP$ their) (NN interaction)) (PP (IN with) (NP (NP (CD two) (JJ specific) (NNS regions)) (VP (VBN contained) (PP (IN within) (NP (DT the) (NN IL3) (JJ 5'-flanking) (NN sequence)))))))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP-SBJ (NP (DT the) (NN region)) (PP (IN between) (NP (NP (NNS bases) (NP-COOD (NP (CD -107)) (CC and) (NP (CD -59)))) (PP (IN of) (NP (NP (DT the) (NN IL3) (NN promoter)) (VP (VBG containing) (NP (JJ putative) (NP-COOD (NP (NN AP-2)) (CC and) (NP (NN Sp1))) (NN binding) (NNS motifs)))))))) (VP (VBZ appears) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NP (JJ basal) (NN level) (NN expression)) (PP (IN of) (NP (DT the) (NN IL3) (NN gene))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS data)) (ADVP (RB also)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN CD2) (NN receptor) (NN activation)) (CC and) (NP (NP-COOD (NP (NN phytohemagglutinin)) (CC plus) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate))) (NN stimulation))) (VP (VBP augment) (NP (NN T) (NN cell) (NN IL3) (NN gene) (NN expression)) (PP (IN through) (NP (DT the) (JJ same) (ADJP-COOD (ADJP (NP (JJ cis-))) (CC and) (ADJP (JJ trans-activating))) (NNS signals))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (MD should) (VP (VB contribute) (PP (TO to) (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN IL3) (NN gene) (NN expression)) (PP (IN in) (NP (JJ human) (NN T) (NNS lymphocytes))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Transcriptional) (NN activation)) (PP (IN of) (NP (JJ human) (NN zeta) (CD 2) (NN globin) (NN promoter))) (PP (IN by) (NP (NP (DT the) (NN alpha) (NN globin) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN HS-40)) (-RRB- -RRB-)))) (: :)) (NP (NP (JJ functional) (NN role)) (PP (IN of) (NP (ADJP (JJ specific) (JJ nuclear) (JJ factor-DNA)) (NNS complexes))) (. .))))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD studied) (NP (NP (DT the) (JJ functional) (NN interaction)) (PP (IN between) (NP-COOD (NP (JJ human) (JJ embryonic) (NN zeta) (CD 2) (NN globin) (NN promoter)) (CC and) (NP (NP (NP (DT the) (NN alpha) (NN globin) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN HS-40)) (-RRB- -RRB-))) (ADJP (JJ located) (ADVP (NP (CD 40) (NN kb)) (RB upstream) (PP (IN of) (NP (DT the) (NN zeta) (CD 2) (NN globin) (NN gene)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBD was) (VP (VBN shown) (PP (IN by) (NP-LGS (JJ transient) (NN expression) (NN assay))) (SBAR (IN that) (S (NP-SBJ (NN HS-40)) (VP (VBD behaved) (PP (IN as) (NP (NP (NP (DT an) (JJ authentic) (NN enhancer)) (PP (IN for) (NP (NP (JJ high-level) (NN zeta) (CD 2) (NN globin) (NN promoter) (NN activity)) (PP (IN in) (NP (NN K562) (NNS cells)))))) (, ,) (NP (NP (DT an) (JJ erythroid) (NN cell) (NN line)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ embryonic)) (CC and/or) (ADJP (JJ fetal))) (NN origin))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (NNS sequences)) (ADJP (JJ located) (PP (IN between) (NP (NP-COOD (NP (CD -559)) (CC and) (NP (CD -88))) (PP (IN of) (NP (DT the) (NN zeta) (CD 2) (NN globin) (NN gene))))))) (VP (VBD were) (ADJP-PRD (JJ dispensable) (PP (IN for) (NP (NP (PRP$ its) (NN expression)) (PP (IN on) (NP (NN enhancerless) (NNS plasmids))))))))) (, ,) (NP-SBJ-38 (PRP they)) (VP (VBD were) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (ADJP (NN HS-40) (JJ enhancer-mediated)) (NN activity)) (PP (IN of) (NP (DT the) (NN zeta) (CD 2) (NN globin) (NN promoter))))))) (. .)))
(TOP (S (NP-SBJ (JJ Site-directed) (NN mutagenesis)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-39 (DT this) (ADJP (NN HS-40) (NN enhancer-zeta) (CD 2) (NN globin) (NN promoter)) (NN interaction)) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT the) (CD two) (NN GATA-1) (NN factor) (NN binding) (NNS motifs)) (ADJP (JJ located) (PP (IN at) (NP (NP-COOD (NP (CD -230)) (CC and) (NP (CD -104))) (, ,) (ADVP (RB respectively)))))))))))) (. .)))
(TOP (S (NP-SBJ-40 (NP (DT The) (JJ functional) (NNS domains)) (PP (IN of) (NP (NN HS-40)))) (VP (VBD were) (VP (ADVP (RB also)) (VBN mapped))) (. .)))
(TOP (S (NP-SBJ (NN Bal) (CD 31) (NN deletion) (VBG mapping) (NNS data)) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NP-COOD (NP (CD one) (NN GATA-1) (NN motif)) (, ,) (NP (CD one) (NN GT) (NN motif)) (, ,) (CC and) (NP (CD two) (NN NF-E2/AP1) (NNS motifs))) (ADVP (RB together))) (VP (VBD formed) (NP (NP (DT the) (JJ functional) (NN core)) (PP (IN of) (NP (NN HS-40)))) (PP (IN in) (NP (NP (DT the) (JJ erythroid-specific) (NN activation)) (PP (IN of) (NP (DT the) (NN zeta) (CD 2) (NN globin) (NN promoter))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Site-directed) (NN mutagenesis)) (ADVP (RBR further)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-41 (NP (DT the) (NN enhancer) (NN function)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (CD two) (NN NF-E2/AP1) (NNS motifs)) (PP (IN of) (NP (NN HS-40)))))))) (VP (VBZ is) (VP (VBN mediated) (PP (IN through) (NP (NP (PRP$ its) (NN binding)) (PP (TO to) (NP-COOD (NP (NN NF-E2)) (CONJP (CC but) (RB not)) (NP (NN AP1) (NN transcription) (NN factor))))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (PRP we)) (VP (VBD did) (NP (NP (JJ genomic) (NN footprinting)) (PP (IN of) (NP (NP (DT the) (NN HS-40) (NN enhancer) (NN region)) (PP (IN in) (NP-COOD (NP (NN K562) (NNS cells)) (, ,) (NP (JJ adult) (JJ nucleated) (NNS erythroblasts)) (, ,) (CC and) (NP (JJ different) (JJ nonerythroid) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-42 (NP (DT All) (NN sequence) (NNS motifs)) (PP (IN within) (NP (NP (DT the) (JJ functional) (NN core)) (PP (IN of) (NP (NN HS-40))))) (, ,) (SBAR (IN as) (S (VP (VBN mapped) (PP (IN by) (NP (JJ transient) (NN expression) (NN analysis)))))) (, ,)) (VP (VBD appeared) (S (VP (TO to) (VP (VB bind) (NP (NP (DT a) (JJ nuclear) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (PP-COOD (PP (IN in) (NP (VBG living) (NN K562) (NNS cells))) (CC but) (PP (RB not) (IN in) (NP (JJ nonerythroid) (NNS cells))))))))) (. .)))
(TOP (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP-SBJ-44 (NP (QP (RB only) (CD one))) (PP (IN of) (NP (DT the) (ADJP (RB apparently) (JJ nonfunctional)) (NN sequence) (NNS motifs)))) (VP (VBD was) (VP (VBN bound) (PP (IN with) (NP (NNS factors))) (ADVP (FW in) (FW vivo)))) (. .)))
(TOP (S (PP (IN In) (NN comparison) (TO to) (NP (NN K562))) (, ,) (NP-SBJ (NP (JJ nucleated) (NNS erythroblasts)) (PP (IN from) (NP (JJ adult) (JJ human) (NN bone) (NN marrow)))) (VP (VBD exhibited) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ similar)) (CC but) (ADJP (JJ nonidentical))) (NN pattern)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN binding)) (ADVP (FW in) (FW vivo))))) (PP (IN at) (NP (DT the) (NN HS-40) (NN region)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-45 (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP-COOD (NP (JJ human) (JJ embryonic) (NN zeta) (CD 2) (NN globin) (NN gene)) (CC and) (NP (DT the) (JJ fetal/adult) (NN alpha) (NN globin) (NNS genes))))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (ADJP (ADJP-COOD (ADJP (JJ erythroid) (JJ cell-specific)) (CC and) (ADJP (JJ developmental) (JJ stage-specific))) (JJ nuclear) (NN factor-DNA)) (NNS complexes)) (SBAR (WHNP-46 (WDT which)) (S (VP (VBP form) (PP (IN at) (NP-COOD (NP (NP (DT the) (NN enhancer)) (PRN (-LRB- -LRB-) (NP (NN HS-40)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NN globin) (NNS promoters)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Interaction)) (PP (IN between) (NP (ADJP-COOD (ADJP (NP (NN NF-kappa) (NN B-))) (CC and) (ADJP (NN serum) (NN response) (JJ factor-binding))) (NNS elements)))) (VP (VBZ activates) (NP (DT an) (NN interleukin-2) (NN receptor) (JJ alpha-chain) (NN enhancer)) (ADVP (RB specifically)) (PP (IN in) (NP (NN T) (NNS lymphocytes)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP-SBJ-45 (NP (DT a) (JJ short) (NN enhancer) (NN element)) (VP (VBG containing) (NP (NP (DT the) (NN NF-kappa) (NN B) (NN binding) (NN site)) (PP (IN from) (NP (NP (DT the) (NN interleukin-2) (NN receptor) (JJ alpha-chain) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN IL-2R) (NN alpha)) (-RRB- -RRB-))))))) (VP (VBZ is) (VP (ADVP (RB preferentially)) (VBN activated) (PP (IN in) (NP (NN T) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-46 (DT The) (NN IL-2R) (NN alpha) (NN enhancer)) (VP-COOD (VP (VBZ binds) (NP (NN NF-kappa) (NN B)) (ADVP (RB poorly))) (CC and) (VP (VBZ is) (VP (ADVP (RB only) (RB weakly)) (VBN activated) (PP (IN by) (NP-LGS (NP (DT the) (NN NF-kappa) (NN B) (NN site)) (ADVP (RB alone))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Serum) (NN response) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN SRF)) (-RRB- -RRB-))) (VP (VBZ binds) (PP (TO to) (NP (NP (DT a) (NN site)) (ADJP (JJ adjacent) (PP (TO to) (NP (NP (DT the) (NN NF-kappa) (NN B) (NN site)) (PP (IN in) (NP (DT the) (NN IL-2R) (NN enhancer)))))))))) (, ,) (CC and) (S (NP-SBJ (NP (DT both) (NNS sites)) (ADVP (RB together))) (VP (VBP have) (NP (JJ strong) (JJ transcriptional) (NN activity)) (ADVP (RB specifically)) (PP (IN in) (NP (NN T) (NNS cells))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (NP-SBJ (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN SRF)) (VP (ADVP (RB constitutively)) (VBN expressed) (PP (IN in) (NP (NN T) (NNS cells))))))) (VP (VBP are) (ADVP-TMP (RB consistently)) (ADJP-PRD (ADJP (JJR higher)) (PP (IN than) (FRAG (PP (IN in) (NP (JJ other) (NN cell) (NNS types))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP (NN SRF))) (PP (IN in) (NP (NN B) (NNS cells)))) (VP (VBZ causes) (S (NP-SBJ (DT the) (NN IL-2R) (NN enhancer)) (VP (TO to) (VP (VB function)))) (SBAR (RB as) (RB well) (IN as) (S (NP-SBJ (PRP it)) (VP (VBZ does) (VP (PP (IN in) (NP (NN T) (NNS cells))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ high) (NN level)) (PP (IN of) (NP (NP (NN SRF) (NN binding)) (PP (IN in) (NP (NN T) (NNS cells)))))) (VP (VBZ is) (ADVP (RB functionally)) (ADJP-PRD (JJ important)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (ADJP (RB transcriptionally) (JJ active)) (NNS factors)) (VP (VBG mediating) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NN HTLV-I) (NN Tax) (NN transactivator))) (PP (IN on) (NP (DT the) (NN IL-2R) (NN alpha) (NN kappa) (NN B) (NN enhancer)))))) (VP (VBP include) (NP (NP (DT the) (NN product)) (PP (IN of) (NP (DT the) (NN c-rel) (NN proto-oncogene))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN transactivator) (NN HTLV-I) (NN Tax)) (VP (VBZ activates) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (NP (DT the) (NN gene)) (VP (VBG coding) (PP (IN for) (NP (NP (DT the) (NN interleukin) (CD 2) (JJ alpha-chain) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IL-2R) (NN alpha)) (-RRB- -RRB-)))) (PP (IN via) (NP (NP (DT a) (NN kappa) (NN B) (NN site)) (SBAR (WHNP-38 (WDT that)) (S (VP (MD can) (VP (VB bind) (NP (NP (JJ several) (NN protein) (NNS species)) (PP (IN of) (NP (DT the) (NN rel) (NN family))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Tax1)) (ADVP (RB strongly)) (VP (VBZ activates) (NP (NP (DT the) (NN enhancer) (NN activity)) (PP (IN of) (NP (DT this) (NN motif)))) (, ,) (PP (IN in) (NP (NP-COOD (CC both) (NP (JJ epithelial) (NN HeLa)) (CC and) (NP (JJ lymphoid) (NN Jurkat))) (NNS cells)))) (. .)))
(TOP (S (NP-SBJ-39 (DT This) (NN activation)) (VP (VBD was) (RB not) (VP (VBN observed) (PP (IN in) (NP (JJ undifferentiated) (NN embryocarcinoma) (NN F9) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP (NP (DT the) (NP-COOD (NP (NN p50)) (, ,) (NP (NN p65)) (CC and) (NP (NN Rel))) (NNS proteins)) (PP (IN in) (NP (DT these) (NNS cells)))))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-40 (NP (JJ significant) (NN activation)) (PP (IN of) (NP (DT the) (NN IL-2R) (NN alpha) (NN kappa) (NN B) (NN site)))) (VP (VBD was) (VP (VBN observed) (PP (RB only) (IN with) (NP-COOD (NP (NN Rel)) (CC and) (NP-COOD (NP (NN Rel)) (CC plus) (NP (NN p65)))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (SBAR (IN whereas) (S (NP-SBJ-COOD-41 (CC both) (NP (NN Tax)) (CC and) (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-)))) (VP (VBP are) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (ADVP (RB efficiently)) (VB induce) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (TO to) (NP (DT the) (NN IL-2R) (NN alpha) (NN kappa) (NN B) (NN site))))))))))) (, ,) (NP-SBJ (NN PMA)) (VP (VBZ is) (ADVP (RB functionally)) (ADJP-PRD (JJ inactive))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (DT the) (NN DNA) (NN affinity) (NN precipitation) (NN assay)))) (, ,) (NP-SBJ-42 (PRP we)) (VP (VBD observed) (SBAR (IN that) (S-COOD (S (NP-SBJ-43 (NN Tax1)) (VP (VBZ is) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (ADVP (RB efficiently)) (VB induce) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN Rel)))))))))) (, ,) (IN whereas) (S (NP-SBJ (NN PMA)) (VP (VBZ is) (RB not)))))) (. .)))
(TOP (S (NP-SBJ-44 (DT This)) (VP (VBD established) (NP (NP (DT a) (JJ clear) (NN difference)) (PP (IN between) (NP (DT both) (NNS stimuli)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NN Rel)) (VP (VBZ is) (NP-PRD (DT the) (ADJP (RB functionally) (JJ active)) (NN factor)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP conclude) (PP (IN from) (NP (DT these) (NNS results))) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-45 (NP (DT the) (JJ functional) (NN activity)) (PP (IN of) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NN rel) (NN family)))))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS (NP (PRP$ their) (NN interaction)) (PP (IN with) (NP (NN DNA))))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NN Rel)) (VP (MD can) (VP (VB be) (NP-PRD (DT a) (JJ potent) (JJ transcriptional) (NN activator)) (PP (IN on) (NP (JJ specific) (NN kappa) (NN B) (NNS sites))))))))) (. .)))
(TOP (S (S (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (VBZ controls) (NP (NP (NN expression)) (PP (IN of) (NP (NN inhibitor) (NN I) (NN kappa) (NN B) (NN alpha)))))) (: :) (NP (NP (NN evidence)) (PP (IN for) (NP (DT an) (JJ inducible) (JJ autoregulatory) (NN pathway))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ eukaryotic) (NN transcription) (NN factor) (NP (NP (JJ nuclear) (NN factor-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-)))) (VP (VBZ participates) (PP (IN in) (NP (NP (JJ many) (NNS parts)) (PP (IN of) (NP (NP (DT the) (JJ genetic) (NN program)) (VP (VBG mediating) (NP (NN T) (NN lymphocyte) (NP-COOD (NP (NN activation)) (CC and) (NP (NN growth)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Nuclear) (NN expression)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ occurs) (PP-TMP (IN after) (NP (NP (PRP$ its) (VBN induced) (NN dissociation)) (PP (IN from) (NP (PRP$ its) (JJ cytoplasmic) (NN inhibitor) (NN I) (NN kappa) (NN B) (NN alpha)))))) (. .)))
(TOP (S (NP-SBJ-48 (NP (NP-COOD (NP (NN Phorbol) (NN ester)) (CC and) (NP (NN tumor) (NN necrosis) (NN factor-alpha))) (NN induction)) (PP (IN of) (NP (JJ nuclear) (NN NF-kappa) (NN B)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP-COOD (CC both) (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (VBN performed) (NN I) (NN kappa) (NN B) (NN alpha)))) (CC and) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN I) (NN kappa) (NN B) (NN alpha) (NN gene) (NN expression)))))))) (. .)))
(TOP (S (NP-SBJ (NN Transfection) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-49 (DT the) (NN I) (NN kappa) (NN B) (NN alpha) (NN gene)) (VP (VBZ is) (ADVP (RB specifically)) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (DT the) (JJ 65-kilodalton) (VBG transactivating) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Association)) (PP (IN of) (NP (DT the) (ADJP (RB newly) (VBN synthesized)) (NN I) (NN kappa) (NN B) (NN alpha))) (PP (IN with) (NP (NN p65)))) (VP-COOD (VP (VBZ restores) (NP (NP (JJ intracellular) (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN DNA) (NN binding) (NN activity))))) (CC and) (VP (VBZ prolongs) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (DT this) (JJ labile) (NN inhibitor)))))) (. .)))
(TOP (S (ADVP (RB Together)) (, ,) (NP-SBJ (DT these) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (VBZ controls) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN I) (NN kappa) (NN B) (NN alpha)))) (PP (IN by) (NNS means) (IN of) (NP (DT an) (JJ inducible) (JJ autoregulatory) (NN pathway))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NN p105)) (CC and) (NP (NN p98))) (NN precursor) (NNS proteins)) (VP (VBP play) (NP (DT an) (JJ active) (NN role)) (PP (IN in) (NP (ADJP (NN NF-kappa) (JJ B-mediated)) (NN signal) (NN transduction)))) (. .)))
(TOP (S (NP-SBJ-40 (NP (DT The) (NN Rel/NF-kappa) (NN B) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBZ is) (VP (VBN composed) (PP (IN of) (NP (NP (CD two) (JJ distinct) (NNS subgroups)) (, ,) (NP-COOD (NP (NP (NP (NNS proteins)) (SBAR (WHNP-41 (WDT that)) (S (VP-COOD (VP (VBP undergo) (NP (JJ proteolytic) (NN processing))) (CC and) (VP (VBP contain) (NP (NN SWI6/ankyrin) (NNS repeats)) (PP (IN in) (NP (PRP$ their) (NN carboxyl) (NNS termini)))))))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN p105)) (, ,) (NP (NN p98))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (DT those)) (PP (IN without) (NP (JJ such) (NNS repeats))) (SBAR (WHNP-42 (WDT that)) (S (VP (VBP do) (RB not) (VP (VB require) (NP (NN processing))))))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN p65)) (, ,) (NP (NN c-Rel)) (, ,) (NP (NN RelB)) (, ,) (CC and) (NP (NN Dorsal))) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (DT the) (NP-COOD (NP (NN p105)) (CC and) (NP (NN p98))) (NNS precursors)) (VP (VBP share) (NP (JJ functional) (NNS properties)) (PP (IN with) (NP (NP (DT the) (NN I) (NN kappa) (NN B) (NNS proteins)) (, ,) (SBAR (WHNP-43 (WDT which)) (S (ADVP (RB also)) (VP (VBP contain) (NP (NN SWI6/ankyrin) (NNS repeats))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-44 (CC Both) (NP (NN p105)) (CC and) (NP (NN p98))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB form) (NP (JJ stable) (NNS complexes)) (PP (IN with) (NP (NP (JJ other) (NN Rel/NF-kappa) (NN B) (NN family) (NNS members)) (, ,) (PP (VBG including) (NP-COOD (NP (NN p65)) (CC and) (NP (NN c-Rel))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Association)) (PP (IN with) (NP (DT the) (NNS precursors)))) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (PP (IN for) (NP (NP (JJ cytoplasmic) (NN retention)) (PP (IN of) (NP (NP-COOD (CC either) (NP (NN p65)) (CC or) (NP (NN c-Rel))) (, ,) (SBAR (WHNP-45 (NP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (ADVP (RB otherwise)) (ADJP-PRD (JJ nuclear))))))))))) (. .)))
(TOP (S (NP-SBJ-46 (DT These) (NNS complexes)) (VP (VBP undergo) (NP (JJ stimulus-responsive) (NN processing)) (S (VP (TO to) (VP (VB produce) (NP (JJ active) (ADJP-COOD (ADJP (NN p50/c-Rel)) (CC and) (ADJP (NN p55/c-Rel))) (NNS complexes)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS observations)) (VP (VBP suggest) (NP (NP (DT a) (JJ second) (NN pathway)) (VP (VBG leading) (PP (TO to) (NP (NN NF-kappa) (NN B) (NN induction)))) (, ,) (SBAR (WHPP-47 (IN in) (WHNP (WDT which))) (S (NP-SBJ-COOD (NP (NP (NN processing)) (PP (IN of) (NP (DT the) (NNS precursors)))) (CONJP (RB rather) (IN than)) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN I) (NN kappa) (NN B))))) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role))))))) (. .)))
(TOP (NP (NP (JJ Mutual) (NN regulation)) (PP (IN of) (NP-COOD (NP (DT the) (JJ transcriptional) (NN activator) (NN NF-kappa) (NN B)) (CC and) (NP (NP (PRP$ its) (NN inhibitor)) (, ,) (NP (NN I) (NN kappa) (NN B-alpha))))) (. .)))
(TOP (S (NP-SBJ-48 (DT The) (NN NK-kappa) (NN B) (NN transcription) (NN factor) (NN complex)) (VP (VBZ is) (VP (VBN sequestered) (PP (IN in) (NP (DT the) (NN cytoplasm))) (PP (IN by) (NP-LGS (DT the) (JJ inhibitory) (NN protein) (NP (NP (NN I) (NN kappa) (NN B-alpha)) (PRN (-LRB- -LRB-) (NP (NN MAD-3)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ (JJ Various) (JJ cellular) (NNS stimuli)) (VP (VBP relieve) (NP (DT this) (NN inhibition)) (PP (IN by) (NP (NP (NNS mechanisms)) (ADJP (RB largely) (JJ unknown)))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP-COOD (NP (NN NF-kappa) (NN B) (JJ nuclear) (NN localization)) (CC and) (NP (NP (NN transactivation)) (PP (IN of) (NP (PRP$ its) (NN target) (NNS genes))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN demonstrated) (ADVP (RB here)) (PP (IN with) (NP (JJ human) (NP-COOD (NP (NN T) (NNS lymphocytes)) (CC and) (NP (NNS monocytes))))) (SBAR (IN that) (S (NP-SBJ (NP (JJ different) (NNS stimuli)) (, ,) (PP (VBG including) (NP-COOD (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (CC and) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)))) (, ,)) (VP (VB cause) (NP (NP (JJ rapid) (NN degradation)) (PP (IN of) (NP (NN I) (NN kappa) (NN B-alpha)))) (, ,) (PP (IN with) (NP (NP (JJ concomitant) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP-LGS (NP (DT a) (JJ dramatic) (NN increase)) (PP (IN in) (NP (NN I) (NN kappa) (NN B-alpha) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))) (NN synthesis)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Transfection) (NNS studies)) (VP (VBP reveal) (SBAR (IN that) (S (NP-SBJ-COOD-49 (NP (DT the) (NN I) (NN kappa) (NN B-alpha) (NN mRNA)) (CC and) (NP (DT the) (VBN encoded) (NN protein))) (VP (VBP are) (ADVP (RB potently)) (VP (VBN induced) (PP-COOD (PP (IN by) (NP-LGS (NN NF-kappa) (NN B))) (CC and) (PP (IN by) (NP-LGS (NP (NNS homodimers)) (PP-COOD (PP (IN of) (NP (NN p65))) (CC and) (PP (IN of) (NP (NN c-Rel)))))))))))) (. .)))
(TOP (S (S (NP-SBJ (PRP We)) (VP (VBP propose) (NP (NP (DT a) (NN model)) (SBAR (WHPP-50 (IN in) (WHNP (WDT which))) (S (NP-SBJ-COOD (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN I) (NN kappa) (NN B-alpha))) (ADVP (RB mutually)) (VP (VBP regulate) (NP (DT each) (JJ other)) (PP (IN in) (NP (DT a) (NN cycle)))))))) (: :)) (S (NP-SBJ-52 (NP (JJ saturating) (NNS amounts)) (PP (IN of) (NP (DT the) (JJ inhibitory) (NN I) (NN kappa) (NN B-alpha) (NN protein)))) (VP (VBP are) (VP (VBN destroyed) (PP (IN upon) (NP (NN stimulation))) (, ,) (S (VP (VBG allowing) (NP (VP (JJ rapid) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))))))) (. .))))
(TOP (S (ADVP (RB Subsequently)) (, ,) (NP-SBJ-51 (NN I) (NN kappa) (NN B-alpha) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))) (NNS levels)) (VP (VBP are) (VP (ADVP-TMP (RB quickly)) (VBN induced) (PP (IN by) (NP-LGS (DT the) (VBN activated) (NN NF-kappa) (NN B))))) (. .)))
(TOP (S (NP-SBJ-53 (NP (DT This) (NN resurgence)) (PP (IN of) (NP (NN I) (NN kappa) (NN B-alpha) (NN protein)))) (VP (VBZ acts) (S (VP (TO to) (VP (VB restore) (NP (NP (DT an) (NN equilibrium)) (SBAR (WHPP-54 (IN in) (WHNP (WDT which))) (S (NP-SBJ-55 (NN NF-kappa) (NN B)) (VP (VBZ is) (ADVP-TMP (RB again)) (VP (VBN inhibited)))))))))) (. .)))
(TOP (NP (NP (NP (VBN Induced) (JJ myeloid) (NN differentiation)) (PP (IN of) (NP (NN K562) (NNS cells))) (PP (IN with) (NP (NP (NN downregulation)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ erythroid)) (CC and) (ADJP (JJ megakaryocytic))) (NN transcription) (NNS factors))))) (: :)) (NP (NP (DT a) (JJ novel) (JJ experimental) (NN model)) (PP (IN for) (NP (JJ hemopoietic) (NN lineage) (NN restriction))) (. .))))
(TOP (S (NP-SBJ-28 (DT The) (JJ human) (NN erythroleukemia) (NN cell) (NN line) (NN K562)) (VP (MD can) (VP (VB be) (VP (VBN induced) (S (VP (TO to) (VP (VB differentiate) (PP (IN along) (NP (DT the) (ADJP-COOD (ADJP (JJ erythroid)) (CC and) (ADJP (JJ megakaryocytic))) (NNS lineages))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN hexamethylene) (NN bisacetamide)) (PRN (-LRB- -LRB-) (NP (NN HMBA)) (-RRB- -RRB-))) (VP (VBD induced) (S (NP-SBJ (NN K562) (NNS cells)) (VP (TO to) (VP (VB differentiate) (PP (IN along) (NP (DT a) (JJ third) (NN pathway)))))))))) (. .)))
(TOP (S (NP-SBJ-29 (DT This)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NP (NN downregulation)) (PP (IN of) (NP (NP (CD two) (NN transcription) (NNS factors)) (VP (ADVP (RB normally)) (VBN expressed) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ erythroid)) (, ,) (ADJP (NN mast)) (CC and) (ADJP (NN megakaryocyte))) (NNS lineages)))))))))) (. .)))
(TOP (S (NP-SBJ (NN Northern) (NN analysis)) (VP (VBD demonstrated) (NP (NP (JJ coordinate) (NN downregulation)) (PP (IN of) (NP-COOD (NP (NN alpha) (NN globin)) (CC and) (NP (NN gamma) (NN globin)) (CONJP (IN in) (NN addition) (TO to)) (NP (NP (DT the) (CD two) (JJ lineage-restricted) (NN transcription) (NNS factors)) (, ,) (NP-COOD (NP (NN SCL)) (CC and) (NP (NN GATA-1)))))))) (. .)))
(TOP (S (NP-SBJ-30 (NP (NN Proliferation)) (PP (IN of) (NP (DT the) (NN K562) (NNS cells)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN suppressed))) (. .)))
(TOP (S (NP-SBJ (JJ Clonal) (NN assay)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (DT the) (NN suppression)) (VP-COOD (VP (VBD was) (ADJP-PRD (JJ irreversible))) (CC and) (VP (VBD appeared) (ADJP-PRD (JJ analogous) (PP (TO to) (NP (NP (DT the) (NN commitment)) (PP (IN of) (NP (NP (NP (JJ murine) (NN erythroleukemia)) (PRN (-LRB- -LRB-) (NP (NN MEL)) (-RRB- -RRB-))) (NNS cells))) (PP (TO to) (NP (JJ terminal) (NN differentiation))))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NN MEL) (NNS cells))) (, ,) (ADVP (RB however)) (, ,) (NP-SBJ (NN K562) (NNS cells)) (VP-COOD (VP (VBD acquired) (NP (DT a) (JJ macrophage-like) (NN morphology))) (CC and) (VP (VBD exhibited) (NP (DT a) (JJ complete) (NN failure) (S (VP (TO to) (VP (VB generate) (NP (JJ benzidine-positive) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NN Electron) (NN microscopy)) (VP (VBD revealed) (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NP (NNS granules)) (VP (VBG resembling) (NP (NP (DT those)) (ADJP (JJ specific) (PP (IN for) (NP (NNS eosinophils)))))))))) (. .)))
(TOP (S (NP-SBJ (NN Surface) (NN marker) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (JJ HMBA-induced) (NNS cells)) (VP (VBD expressed) (NP (NP (VBN reduced) (NNS levels)) (PP (IN of) (NP-COOD (NP (NN glycophorin) (NN A)) (, ,) (NP (NN CD5)) (, ,) (NP (NN CD7)) (CC and) (NP (NN CD11b))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT No) (NN upregulation)) (PP (IN of) (NP (ADJP-COOD (ADJP (NN megakaryocyte)) (CC or) (ADJP (JJ lymphoid))) (NNS markers)))) (VP (VBD occurred)) (. .)))
(TOP (S (ADVP (RB Thus)) (NP-SBJ (NP (DT the) (NN response)) (PP (IN of) (NP (NN K562) (NNS cells))) (PP (TO to) (NP (NN HMBA)))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ useful) (JJ experimental) (NN system)) (PP (IN for) (S (VP (VBG studying) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (NN downmodulation)) (PP (IN of) (NP (JJ lineage-restricted) (NN transcription) (NNS factors))) (PP-TMP (IN during) (NP (JJ hemopoietic) (NN lineage) (NN commitment))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN Sp1) (NN transcription) (NN factor)) (VP-COOD (VP (VBZ binds) (NP (DT the) (NN CD11b) (NN promoter)) (PP (RB specifically) (IN in) (NP (JJ myeloid) (NNS cells))) (ADVP (FW in) (FW vivo))) (CC and) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (JJ myeloid-specific) (NN promoter) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ-35 (DT The) (JJ myeloid) (NN integrin) (NN CD11b)) (VP (VBZ is) (VP (VBN expressed) (ADVP (RB selectively)) (PP (IN on) (NP (NP (DT the) (NN surface)) (PP (IN of) (NP-COOD (NP (JJ mature) (NNS macrophages)) (, ,) (NP (NNS monocytes)) (, ,) (NP (NNS neutrophils)) (, ,) (CC and) (NP (JJ natural) (NN killer) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-36 (JJ Lineage-specific) (NN expression)) (VP (VBZ is) (VP (VBN controlled) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN mRNA) (NN transcription))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Recent) (NN isolation)) (PP (IN of) (NP (DT the) (NN CD11b) (NN promoter)))) (VP (VBZ shows) (SBAR (IN that) (S (NP-SBJ (NP (CD 92) (NP (NP (NN base) (NNS pairs)) (PRN (-LRB- -LRB-) (NP (NN bp)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ 5'-flanking) (NN DNA)))) (VP (VBP are) (ADJP-PRD (JJ sufficient) (S (VP (TO to) (VP (VB direct) (NP (NP (JJ myeloid-specific) (NN expression)) (PP (IN of) (NP (DT a) (NN reporter) (NN gene)))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB characterize) (NP (NP (JJ regulatory) (NNS sequences)) (ADJP (JJ important) (PP (IN for) (NP (NN promoter) (NN activity)))))))) (, ,) (NP-SBJ-37 (PRP we)) (VP-COOD (VP (VBD performed) (NP (NP (NN linker) (NN scanning) (NN analysis)) (PP (IN of) (NP (DT the) (JJ 92-bp) (NN CD11b) (NN promoter))))) (CC and) (VP (VB demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (NN sequence)) (PP (IN at) (NP (NN bp) (CD -60)))) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NN CD11b) (NN promoter) (NN activity))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (DT this) (NN sequence)) (VP (VBZ binds) (NP (DT the) (NN transcription) (NN factor) (NN Sp1)) (ADVP-COOD (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo))))))) (. .)))
(TOP (S (ADVP (FW In) (FW vivo)) (NP-SBJ-38 (DT the) (NN Sp1) (NN site)) (VP (VBZ is) (VP (VBN bound) (PP-COOD (PP (RB only) (IN in) (NP (ADJP (ADJP (JJ myeloid)) (PRN (-LRB- -LRB-) (NP (NN U937)) (-RRB- -RRB-))) (NNS cells))) (, ,) (PP (RB not) (IN in) (NP (NP (NP (JJ cervical) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HeLa)) (-RRB- -RRB-))) (NNS cells)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (DT the) (NN macrophage) (NN transcription) (NN factor) (NN PU.1)) (VP (VBZ binds) (NP (DT the) (NN CD11b) (NN promoter)) (ADVP-COOD (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo))) (ADVP (RB close) (PP (TO to) (NP (DT the) (NN Sp1) (NN site))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP propose) (NP (NP (DT a) (NN model)) (SBAR (WHPP-39 (IN in) (WHNP (WDT which))) (S (NP-SBJ-40 (NP (NN binding)) (PP (IN of) (NP (NP (DT a) (JJ myeloid-specific) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN PU.1)) (-RRB- -RRB-))))) (VP (VBZ allows) (S (NP-SBJ (NP (DT a) (JJ general) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Sp1)) (-RRB- -RRB-))) (VP (TO to) (VP (VB bind) (PP (IN in) (NP (DT a) (JJ tissue-specific) (NN fashion)))))) (S (ADVP (RB thereby)) (VP (VBG contributing) (PP (TO to) (NP (NP (DT the) (JJ myeloid-specific) (NN expression)) (PP (IN of) (NP (NN CD11b)))))))))))) (. .)))
(TOP (NP (NP (NN Costimulation)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN T) (NN cell) (NN activation))) (PP (IN by) (NP (JJ human) (JJ endothelial) (NNS cells))) (. .)))
(TOP (S (NP-SBJ (VBD Enhanced) (NN IL-2) (NN transcription)) (VP (VBZ correlates) (PP (IN with) (NP-COOD (NP (VBN increased) (NN c-fos) (NN synthesis)) (CC and) (NP (NP (VBN increased) (NN Fos) (NN content)) (PP (IN of) (NP (NN AP-1))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN EC)) (-RRB- -RRB-))) (VP-COOD (VP (VBP act) (PP (IN as) (NP (NP (NN APC)) (PP (IN for) (NP (VBG resting) (NN PBL))))) (ADVP (FW in) (FW vitro))) (, ,) (CC and) (VP (MD may) (VP (VB have) (NP (JJ important) (NNS roles)) (ADVP (FW in) (FW vivo)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP-COOD (NP (NN allograft) (NN rejection)) (CC and) (NP (VBN delayed) (NN hypersensitivity))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB previously)) (VP (VBD reported) (SBAR (IN that) (S (NP-SBJ (JJ human) (JJ umbilical) (NN vein) (NN EC)) (VP (VBP provide) (NP (JJ costimulatory) (NNS signals)) (PP-DTV (TO to) (NP (JJ PHA-stimulated) (NN PBL))) (PP (IN via) (NP-COOD (NP (ADJP (NN CD2:lymphocyte) (JJ function-associated)) (NN Ag-3)) (CC and) (NP (DT an) (JJ unidentified) (NN ligand) (NN pair)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (QP (CD three-) (TO to) (JJ eight-fold)) (NN enhancement)) (PP (IN of) (NP (NN IL-2) (NN production))))))))))) (. .)))
(TOP (S (NP-SBJ-31 (NP (DT The) (JJ physiologic) (NN relevance)) (PP (IN of) (NP (DT this) (NN increase)))) (VP (VBD was) (VP (VBN demonstrated) (PP (IN by) (NP-LGS (NP (DT the) (JJ proliferative) (NN advantage)) (VP (VBN provided) (PP (IN by) (NP-LGS (NN EC))) (PP-DTV (TO to) (NP (NP (NN PBL)) (VP (ADVP (RB suboptimally)) (VBN stimulated) (PP (IN with) (NP (NN mAb) (NN OKT3))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NN EC) (NN costimulation)) (VP (VBZ causes) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NN IL-2) (NN mRNA)))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (VBN increased) (NN IL-2) (NN transcription)) (PP (IN in) (NP (NN PBL))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB therefore)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN EC))) (PP (IN on) (NP (NP (NN T) (NN cell) (JJ nuclear) (NNS factors)) (VP (VBN known) (S (VP (TO to) (VP (VB regulate) (NP (NN IL-2) (NN transcription)))))) (, ,) (PP (VBG including) (NP (NP (NP-COOD (NP (NN c-jun)) (CC and) (NP (NN c-fos-two))) (NNS components)) (PP (IN of) (NP-COOD (NP (DT the) (NN transcription) (NN factor) (NN AP-1)) (, ,) (NP (NN NFAT)) (, ,) (CC and) (NP (NNS others)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN PBL)) (ADVP (RB constitutively)) (VP (VBP express) (NP (NN c-jun) (NNS transcripts)))) (, ,) (CC and) (S (NP-SBJ-33 (NP (DT the) (NN level)) (PP (IN of) (NP (NN c-jun) (NN mRNA)))) (VP (VBZ is) (RB not) (VP (VBN altered) (PP (IN by) (NP-LGS (NN PHA) (NN activation))) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN absence)) (CC or) (NP (NN presence)))) (PP (IN of) (NP (NN EC)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-34 (NN c-fos) (NN mRNA)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ absent) (PP (IN from) (NP (VBG resting) (NN T) (NNS cells))))) (CC and) (VP (VBZ is) (VP (VBN induced) (PP-TMP (IN on) (NP (NN PHA) (NN activation)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN EC)) (ADVP (RB alone))) (VP-COOD (VP (VBP do) (RB not) (VP (VB induce) (NP (NN c-fos) (NN mRNA)))) (CC but) (VP (VBP augment) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN c-fos) (NN mRNA))) (PP (IN in) (NP (JJ PHA-activated) (NN T) (NNS cells)))) (PP (IN by) (NP (CD 3-) (TO to) (RB 10-fold))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN effect)) (VP (VBZ is) (ADJP-PRD (RB largely) (JJ independent) (PP (IN of) (NP (DT the) (ADJP (NN CD2:lymphocyte) (JJ function-associated)) (NN Ag-3) (NN pathway))))) (. .)))
(TOP (S (NP-SBJ (NN Gel-shift) (NN analysis)) (VP (VBZ reveals) (NP (NP (DT the) (JJ constitutive) (NN presence)) (PP (IN of) (NP (NP (JJ nuclear) (NNS factors)))) (PP (IN in) (NP (VBG resting) (NN PBL))) (SBAR-COOD-101 (SBAR (WHNP-35 (WDT that)) (S (VP (VBP bind) (PP (TO to) (NP (NP (DT the) (JJ proximal) (NN AP-1) (NN site)) (PP (IN of) (NP (DT the) (NN IL-2) (NN promoter)))))))) (CC and) (SBAR (WHNP-36 (IN that)) (S (VP (VBP contain) (NP (JJ immunoreactive) (NP-COOD (NP (NN c-Jun)) (CONJP (CC but) (RB not)) (NP (NN c-Fos))) (NN protein)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN AP-1)) (PP (IN from) (NP (JJ PHA-activated) (NNS cells)))) (VP (VBZ contains) (NP-COOD (NP (NN c-Jun)) (CC and) (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (NN c-Fos)))))) (. .)))
(TOP (S (ADVP (RB Strikingly)) (, ,) (NP-SBJ (NP (NN costimulation)) (PP (IN with) (NP (NN EC)))) (VP (VBZ results) (PP (IN in) (NP (NP (NP (DT a) (JJ dramatic) (NN increase)) (PRN (-LRB- -LRB-) (NP (QP (NN up) (TO to) (JJ 15-fold))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NN c-Fos) (NN content)) (PP (IN of) (NP (NN AP-1)))))))) (. .)))
(TOP (S (NP-SBJ-37 (NP (NNS Levels)) (PP (IN of) (NP (NP (JJ other) (JJ nuclear) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NN IL-2) (NN regulation))))))) (VP (VBD were) (RB not) (VP (VBN altered) (PP (IN by) (NP-LGS (NN EC))) (, ,) (SBAR (IN although) (S (NP-SBJ (NN NFAT-DNA) (NNS complexes)) (VP (VBD migrated) (PP (IN at) (NP (DT a) (ADJP (RB slightly) (JJ different)) (NN mobility)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN summary))) (, ,) (NP-SBJ (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN composition)) (PP (IN of) (NP (NN transcription) (NN factor) (NN AP-1)))))) (VP-COOD (VP (VBZ is) (NP-PRD (NP (DT a) (JJ key) (JJ molecular) (NN mechanism)) (PP (IN for) (NP (VBG increasing) (NN IL-2) (NN transcription))))) (CC and) (VP (MD may) (VP (VB underlie) (NP (NP (DT the) (NN phenomenon)) (PP (IN of) (NP (NP (NN costimulation)) (PP (IN by) (NP (NN EC)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (NN protein)) (PP (IN of) (NP (DT the) (NN AP-1) (NN family)))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN component)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (JJ Nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ transcriptional) (NN activator)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN IL-2) (NN gene) (NN expression)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN response) (NN element)) (PP (IN for) (NP (NN NF-AT)))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN sequence)) (VP (JJ localized) (PP (IN between) (NP (NP (CD -285/-254)) (PP (IN in) (NP (DT the) (NN IL-2) (JJ regulatory) (NN region)))))))) (. .)))
(TOP (S (NP-SBJ-40 (NP (DT The) (NN composition)) (PP (IN of) (NP (NN NF-AT) (NN protein)))) (VP (VBZ is) (ADVP (RB still)) (ADVP (RB not) (RB fully)) (VP (VBN elucidated))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (, ,) (S (PP (IN in) (NP (JJ normal) (JJ human) (NN T) (NNS cells))) (, ,) (NP-SBJ (DT an) (NN AP-1) (NN protein)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN component)) (PP (IN of) (NP (DT the) (NN NF-AT) (NN protein) (NN complex)))))))) (. .)))
(TOP (S (NP-SBJ-41 (DT This)) (VP (VBD was) (VP (VBN evidenced) (PP-COOD (PP (IN by) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN AP-1) (NN site))) (S-42 (VP (TO to) (VP (VB compete) (PP (IN with) (NP (DT the) (NN NF-AT) (NN site))) (PP (IN for) (S (VP (NN binding) (PP (TO to) (NP (NN NF-AT))))))))))) (CC and) (PP (IN by) (NP (NP (DT the) (NN capacity)) (PP (IN of) (NP (VBN immobilized) (ADJP-COOD (ADJP (JJ anti-Jun)) (CC and) (ADJP (JJ anti-Fos))) (NNS antibodies))) (S-43 (VP (TO to) (VP (VB deplete) (NP (NN NF-AT-binding) (NN activity)) (PP (IN from) (NP (NP (JJ nuclear) (NNS extracts)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (EX There)) (VP (VBD was) (NP-PRD (NP (DT no) (JJ detectable) (NN binding)) (PP (IN of) (NP (ADJP (ADVP (FW in) (FW vitro)) (VBN translated)) (NP (NP (NN Jun/Fos) (NN heterodimer)) (PRN (-LRB- -LRB-) (NP (NN AP-1)) (-RRB- -RRB-))))) (PP (TO to) (NP (DT the) (NN NF-AT) (NN sequence)))))) (, ,) (CC and) (S (NP-SBJ-44 (DT the) (NN NF-AT) (NN sequence)) (VP (VBD was) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN Jun/Fos))) (PP (TO to) (NP (DT the) (NN AP-1) (NN sequence)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN presence)) (PP (IN of) (NP (DT an) (NN AP-1) (NN protein))) (PP (IN in) (NP (DT the) (NN NF-AT) (NN protein) (NN complex)))) (VP (MD may) (VP (VB regulate) (NP (JJ NF-AT-binding) (NN activity)) (PP (IN through) (NP (JJ protein-protein) (NN interaction))))) (. .)))
(TOP (NP (NP (JJ Functional) (NN antagonism)) (PP (IN between) (NP-COOD (NP (NN vitamin) (NN D3)) (CC and) (NP (JJ retinoic) (NN acid)))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP-COOD (NP (NN CD14)) (CC and) (NP (NN CD23))) (NN expression))) (PP-TMP (IN during) (NP (NP (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (NN U-937) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (CD 1,25) (NN alpha-Dihydroxicholecalciferol)) (PRN (-LRB- -LRB-) (NP (NN VitD3)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-)))) (VP (VBP are) (NP-PRD (NP (JJ important) (NNS regulators)) (PP (IN of) (NP (NP (DT the) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN differentiation)))) (PP (IN of) (NP (JJ several) (NN cell) (NNS types))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN paper)) (VP (VBZ describes) (SBAR (WHADVP-24 (WRB how)) (S (NP-SBJ-COOD-25 (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ monocyte-macrophage) (NN Ag)) (, ,) (NP (NN CD14)) (, ,)))) (CC and) (NP (NP (NP (DT the) (JJ low) (NN affinity) (NN Fc) (NN receptor)) (PP (IN for) (NP (NN IgE)))) (, ,) (NP (NN CD23)) (, ,))) (VP (VBD were) (VP (ADVP (RB inversely)) (VBN regulated) (PP-TMP (IN during) (NP (NP (ADJP-COOD (ADJP (NP (NN VitD3-))) (CC and) (ADJP (JJ RA-induced))) (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (JJ human) (NN U-937) (NNS monoblasts)))))))))) (. .)))
(TOP (S (NP-SBJ (NN PMA)) (VP (VBD induced) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP-COOD (CC both) (NP (NN CD14)) (CC and) (NP (NN CD23))) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Exposure)) (PP (TO to) (NP (NN VitD3)))) (ADVP-TMP (RB rapidly)) (VP (VBD induced) (NP (NP (DT the) (ADJP (FW de) (FW novo)) (NN expression)) (PP (IN of) (NP (NN CD14) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN addition)) (PP (IN of) (NP (NN cycloheximide)))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NN VitD3) (NN induction)) (PP (IN of) (NP (NN CD14) (NN mRNA) (NN expression)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (DT the) (NN induction)) (VP (VBD was) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (JJ ongoing) (NN protein) (NN synthesis)))))))))) (. .)))
(TOP (S (SBAR (IN While) (S (VP (VBG inducing) (NP (NN CD14) (NN expression))))) (, ,) (NP-SBJ-27 (NN VitD3)) (ADVP-TMP (RB concomitantly)) (VP (VBD suppressed) (NP (DT the) (ADJP-COOD (ADJP (JJ basal)) (, ,) (ADJP (NP (NN PMA-))) (, ,) (CC and) (ADJP (JJ RA-inducible))) (NN CD23) (NN expression)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
(TOP (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN U-937) (NNS cells)) (VP (VBN induced) (PP (IN by) (NP-LGS (NN RA))))) (ADVP (RB strongly)) (VP (VBD increased) (NP (NP (PRP$ their) (NN expression)) (PP (IN of) (NP (NN CD23) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein)))))))) (, ,) (IN whereas) (S (NP-SBJ (PRP they)) (ADVP (RB completely)) (VP (VBD lacked) (NP (JJ detectable) (NN CD14) (NP-COOD (NP (NN cell) (NN surface)) (CC or) (NP (NN mRNA))) (NN expression)))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-28 (NP-COOD (NP (DT the) (ADJP (NP (NN VitD3-)))) (CC and) (NP (DT the) (JJ PMA-induced))) (NP-29 (NN CD14) (NN expression))) (VP (VBD was) (VP (VBN inhibited) (PP (IN as) (NP (NP (DT a) (JJ temporal) (NN consequence)) (PP (IN of) (NP (DT the) (JJ RA-induced) (NN differentiation))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (EX there)) (VP (VBZ exists) (NP-PRD (NP (DT a) (JJ functional) (NN antagonism)) (PP (IN between) (NP-COOD (NP (NN VitD3)) (CC and) (NP (NN RA)))) (SBAR (WHNP-30 (WDT that)) (S (VP (MD may) (VP (VB have) (NP (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ certain) (ADJP-COOD (ADJP (JJ immune)) (CC and) (ADJP (JJ inflammatory))) (NNS responses)))))) (PP (IN through) (NP (NP (PRP$ their) (JJ inverse) (NNS effects)) (PP (IN on) (NP (NP-COOD (NP (NN CD14)) (CC and) (NP (NN CD23))) (NN gene) (NN expression)))))))))))))) (. .)))
(TOP (S (NP-SBJ-74 (NP (DT The) (JJ lytic) (NN transition)) (PP (IN of) (NP (JJ Epstein-Barr) (NN virus)))) (VP (VBZ is) (VP (VBN imitated) (PP (IN by) (NP-LGS (JJ recombinant) (NNS B-cells))))) (. .)))
(TOP (S (NP-SBJ-75 (NP (JJ Lytic) (NN transition)) (PP (IN of) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN initiated) (PP (IN by) (NP-LGS (NP (JJ distinct) (JJ immediate) (JJ early) (NNS regulators)) (PP (IN of) (NP (DT the) (JJ viral) (NN cycle))))) (, ,) (PP-TMP (IN in) (NP (NP (NN synchronization)) (PP (TO to) (NP (NP (ADJP-COOD (ADJP-TMP (JJ temporary)) (, ,) (ADJP (JJ permissive))) (NNS conditions)) (PP-TMP (IN during) (NP (NN host) (NN cell) (NN differentiation))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD developed) (NP (NP (JJ eukaryotic) (NNS vectors)) (ADJP (JJ suitable) (S (VP (TO to) (VP (VB imitate) (NP (NP (DT the) (NNS processes)) (VP (VBN involved) (PP (IN in) (NP (NP (JJ lytic) (NN transition)) (PP (IN in) (NP (NN cell) (NN culture) (NNS systems))))))))))))) (. .)))
(TOP (S (S (NP-SBJ-77 (CD Two) (JJ stable) (NN B) (NN cell) (NNS lines)) (VP (VBD were) (VP (VBN established))) (: :)) (S (NP-SBJ-76 (NN R59Z) (NN activator) (NNS cells)) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB induce) (NP (JJ lytic) (NN EBV) (NN expression)) (PP (IN in) (NP (DT a) (JJ constitutive) (NN manner))) (PP (IN by) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (DT the) (NN BZLF) (CD 1) (NN trans-activator)) (PRN (-LRB- -LRB-) (NP (NN Zta)) (-RRB- -RRB-))))))))))) (. .))))
(TOP (S (NP-SBJ (NN R7-57) (NN reporter) (NNS cells)) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (VBD signaled) (NP (NP (VBN induced) (NN activity)) (PP (IN of) (NP (NP (NP (DT the) (JJ lytic) (NN origin)) (PP (IN of) (NP (NN EBV) (NN replication)))) (PRN (-LRB- -LRB-) (NP (NN ori) (NN Lyt)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Different) (NNS modes)) (, ,) (PP (IN like) (NP-COOD (NP (JJ chemical) (NN induction)) (, ,) (NP (NP (JJ lytic) (NN superinfection)) (PP (IN with) (NP (NN EBV)))) (CC and) (NP (JJ single) (NN gene) (NN trans-activation))))) (VP (VBD converted) (NP (NP (DT the) (JJ recombinant) (NN ori) (NN Lyt) (NN element)) (PP (IN in) (NP (NN R7-57) (NN reporter) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (NN BZLF) (CD 1)) (, ,) (VP (ADVP-TMP (RB transiently)) (VBN expressed) (PP (IN in) (NP (NN R7-57) (NN reporter) (NNS cells)))) (, ,)) (VP (VBD was) (NP-PRD (NP (DT the) (JJ only) (NN EBV) (NN trans-activator)) (VP (VBN found)) (, ,) (ADJP (JJ sufficient) (PP (NN in) (S (VP (VBG inducing) (NP (DT the) (JJ viral) (JJ lytic) (NN cycle)))))))) (. .)))
(TOP (S (PP (VBG Basing) (PP (IN on) (NP (DT these) (NNS experiments)))) (, ,) (NP-SBJ-79 (NP (JJ trans-cellular) (NN activation)) (PP (IN of) (NP (NN EBV)))) (VP (VBD was) (VP (VBN tested) (PP (IN by) (NP (NP (NN cocultivation)) (PP (IN of) (NP (ADJP (NN BZLF) (JJ 1-expressing)) (NN R59Z) (NN activator) (NNS cells))) (PP (IN with) (NP (DT the) (NN R7-57) (NN reporter) (NN line))))))) (. .)))
(TOP (S (NP-SBJ-80 (NP (DT No) (JJ lytic) (NN effect)) (PP (IN on) (NP (DT the) (NN reporter) (NNS cells)))) (VP (MD could) (VP (VB be) (VP (VBN measured) (, ,) (PP-COOD (CC neither) (PP (IN by) (NP (NP (NN cocultivation)) (PP (IN of) (NP (NN activator) (NNS cells))))) (CC nor) (PP (IN by) (NP (NP (NN coincubation)) (PP (IN of) (NP (ADJP (NN BZLF) (JJ 1-containing)) (NN cell) (NNS lysates))))))))) (. .)))
(TOP (S (NP-SBJ-81 (NN Latency) (NN breaking) (NN activity)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD was) (VP (VBN transferred) (PP (IN from) (NP (NN activator))) (PP (TO to) (NP (NN reporter) (NNS cells))) (SBAR-TMP (WHADVP-82 (WRB when)) (S (NP-SBJ-83 (ADJP-COOD (ADJP (JJ active)) (, ,) (ADJP (JJ exogenous))) (NN virus)) (VP (VBD was) (VP (VBN added))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN cell) (NN system)) (VP (VBN described) (PP (IN in) (NP (DT these) (NNS experiments))))) (VP-COOD (VP (VBZ provides) (NP (NP (DT a) (NN tool)) (PP (IN for) (NP (NP (DT the) (NN detection)) (PP (IN of) (NP (NN EBV) (NN reactivation))))))) (CC and) (VP (VBZ demonstrates) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (DT the) (JJ lytic) (JJ regulatory) (NN gene) (NN BZLF) (CD 1)))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Immobilization)) (CC and) (NP (NN recovery))) (PP (IN of) (NP-COOD (NP (NN fusion) (NNS proteins)) (CC and) (NP (NN B-lymphocyte) (NNS cells)))) (VP (VBG using) (NP (JJ magnetic) (NN separation))) (. .)))
(TOP (S (NP-SBJ-42 (NP (DT A) (JJ new) (NN approach)) (SBAR (S (VP (TO to) (VP (VB facilitate) (NP (NP-COOD (NP (NN immobilization)) (CC and) (NP (NN affinity) (NN purification))) (PP (IN of) (NP-COOD (NP (JJ recombinant) (NNS proteins)) (CC and) (NP (VBN selected) (JJ human) (NN B) (NNS lymphocytes)))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN developed)))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NP (JJ magnetic) (NNS beads)) (PP (IN with) (NP (NP (VBN attached) (NN DNA)) (VP (VBG containing) (NP (DT the) (FW Escherichia) (FW coli) (NN lac) (NN operator)))))))) (, ,) (NP-SBJ-44 (NP (NN fusion) (NNS proteins)) (VP (VBG comprising) (NP (DT the) (JJ DNA-binding) (NN lac) (NN repressor)))) (VP (MD could) (VP (VB be) (VP (VP-COOD (VP (JJ affinity-purified)) (CC and) (VP (VBN recovered))) (PP-COOD (PP (IN by) (NP (NP (JJ gentle) (NN elution) (NNS conditions)) (, ,) (PP (JJ such) (IN as) (FRAG (PP (IN with) (NP (DT a) (NN lactose) (NN analogue))))))) (CC or) (PP (IN by) (NP (NP (JJ enzymatic) (NNS means)) (VP (VBG using) (NP-COOD (CC either) (NP (NP (NN deoxyribonuclease)) (PRN (-LRB- -LRB-) (NP (NN DNase)) (-RRB- -RRB-))) (CC or) (NP (NN restriction) (NNS endonucleases)))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS results)) (VP (VBP show) (PP-TMP (IN for) (NP (DT the) (JJ first) (NN time))) (SBAR (IN that) (S (NP-SBJ-45 (DT a) (JJ DNA-binding) (NN protein)) (VP (MD can) (VP (VB be) (VP (VBN used) (PP (IN for) (NP (NP (NN affinity) (NN purification)) (PP (IN of) (NP (NN fusion) (NNS proteins))))) (SBAR (IN as) (S (VP (VBN exemplified) (PP (IN by) (NP-LGS (NP (DT the) (ADJP-COOD (ADJP (JJ specific)) (CC and) (ADJP (JJ gentle))) (NN recovery)) (PP (IN of) (NP-COOD (NP (NN beta-galactosidase)) (CC and) (NP (NN alkaline) (NN phosphatase)))) (PP (IN from) (NP (JJ bacterial) (NNS lysates))))) (S (VP (VBG using) (NP (JJ immunomagnetic) (NN separation))))))))))))) (. .)))
(TOP (S (NP-SBJ-47 (DT The) (NN approach)) (VP (VBD was) (ADVP (RB further)) (VP (VBN extended) (PP (TO to) (NP (NP (NN cell) (NN separation)) (PP (IN by) (NP (NP (DT the) (JJ efficient) (NP-COOD (NP (NN recovery)) (CC and) (NP (NN elution)))) (PP (IN of) (NP (NP (JJ human) (NN CD37) (NN B) (NNS lymphocytes)) (PP (IN from) (NP (JJ peripheral) (NN blood))))))))))) (. .)))
(TOP (NP (NP (JJ Negative) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (JJ human) (NP (NP (NN interleukin) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN gene))) (PP (IN by) (NP (NNS glucocorticoids))) (PP (IN through) (NP (NP (NN interference)) (PP (IN with) (NP (JJ nuclear) (NN transcription) (NNS factors) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-AT))))))) (. .)))
(TOP (S (NP-SBJ-42 (NN IL-2) (NN gene) (NN transcription)) (VP (VBZ is) (VP (VBN affected) (PP (IN by) (NP-LGS (JJ several) (JJ nuclear) (NNS proteins))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD asked) (SBAR (IN whether) (S (NP-SBJ-COOD-43 (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NN Dex)) (-RRB- -RRB-))) (CC and) (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-)))) (VP (VBP inhibit) (NP (NN IL-2) (NN gene) (NN transcription)) (PP (IN by) (S (VP (VBG interfering) (PP (IN with) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (JJ nuclear) (NNS proteins)) (SBAR (WHNP-44 (WDT that)) (S (VP (VBP bind) (PP (TO to) (NP (DT the) (NN IL-2) (NN promoter))))))))))))))))) (. .)))
(TOP (S (NP-SBJ-45 (NP (JJ Nuclear) (NNS extracts)) (PP (IN from) (PP (JJ primary) (JJ human) (NN T) (NNS lymphocytes)))) (VP (VBD were) (VP (VBN analyzed) (PP (IN by) (NP (JJ electrophoretic) (NN DNA) (NN mobility) (NN shift) (NNS assays))))) (. .)))
(TOP (S (NP-SBJ-COOD (CC Both) (NP (NN Dex)) (CC and) (NP (NN CsA))) (VP (VBD inhibited) (NP (NP (DT the) (NN binding)) (PP-COOD (PP (IN of) (NP (NN transcription) (NNS factors) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-AT))))) (, ,) (CC but) (PP (RB not) (IN of) (NP-COOD (NP (NN NF-kB)) (CC and) (NP (NN OCT-1/OAF))))) (, ,) (PP (TO to) (NP (NP (PRP$ their) (JJ corresponding) (NNS sites)) (PP (IN on) (NP (DT the) (NN IL-2) (NN gene) (NN promoter))))))) (. .)))
(TOP (S (S (VP (TO To) (VP-COOD (VP (VB correlate) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ nuclear) (NN factor) (NN binding))) (ADVP (FW in) (FW vitro))) (PP (IN with) (NP (NP (JJ transcriptional) (NN activity)) (ADVP (FW in) (FW vivo))))) (CC and) (VP (VB define) (NP (NP (DT the) (JJ structural) (NNS requirements)) (PP (IN for) (NP (NN IL-2) (NN promoter) (NN repression)))))))) (, ,) (NP-SBJ-46 (PRP we)) (VP (VBD used) (NP (JJ transient) (NN DNA) (NNS transfections))) (. .)))
(TOP (S (NP-SBJ-47 (NN Jurkat) (NNS cells)) (VP (VBD were) (VP (VBN transfected) (PP (IN with) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP-COOD (CC either) (NP (DT the) (JJ intact) (NN IL-2) (NN promoter)) (CC or) (NP (PRP$ its) (NP-COOD (NP (NN AP-1)) (, ,) (NP (NN NF-AT)) (, ,) (CC and) (NP (NN NF-kB))) (NNS motifs)))))))) (. .)))
(TOP (S (NP-SBJ (NN Dex)) (VP (VBD inhibited) (NP (NP-COOD (NP-COOD (NP (DT the) (NN IL-2) (NN promoter)) (CC and) (NP (DT the) (NN AP-1))) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (NP-COOD (NP (NN NF-AT)) (CC and) (NP (NN NF-kB))))) (NP-111 (NNS plasmids)))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NN CsA)) (VP (VBD inhibited) (NP (NP-COOD (NP-COOD (NP (DT the) (NN IL-2) (NN promoter)) (CC and) (NP (DT the) (NN NF-AT))) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-kB))))) (NP-112 (NNS plasmids)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NP (JJ human) (NN T) (NNS lymphocytes))) (NP-SBJ-COOD (CC both) (NP (NN Dex)) (CC and) (NP (NN CsA))) (VP (VBD inhibited) (NP (NN IL-2) (NN gene) (NN transcription)) (PP (IN through) (NP (NP (NN interference)) (PP (IN with) (NP (NN transcription) (NNS factors) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-AT))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP propose) (SBAR (IN that) (S (SBAR (, ,) (S (NP-SBJ (IN while) (NN maximum)) (VP (NN inhibition) (VP (MD may) (NP (NP (VB involve)) (PP (NN interaction) (NP (IN with) (DT both) (NN transcription)))))))) (NNS factors) (NP-SBJ (, ,)) (VP (NN AP-1) (NP-PRD (NP (VBZ is) (DT the) (JJ primary)) (PP (NN target) (NP (IN of)))))))) (NN Dex)))
(TOP (S (NP-SBJ (NP (NNS Lymphocytes)) (PP (IN from) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (NN disease)))))) (VP (VBP suggest) (SBAR (S (NP-SBJ (NN adenovirus)) (VP (VBZ is) (NP-PRD (NP (CD one) (NN cause)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ persistent)) (CC or) (ADJP (JJ recurrent))) (JJ inflammatory) (NN arthritis)))))))) (. .)))
(TOP (S (NP-SBJ-64 (NP (DT The) (NN assessment)) (PP (IN of) (NP (NP (JJ synovial) (NN lymphocyte) (NN reactivity)) (PP (TO to) (NP (NN adenovirus) (NN antigen) (NN stimulation)))))) (VP (VBD was) (VP (VBN undertaken) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP-COOD (ADJP (JJ persistent)) (CC or) (ADJP (JJ recurrent))) (JJ inflammatory) (NN arthritis))))))) (. .)))
(TOP (S (NP-SBJ-65 (DT The) (JJ 3H-thymidine) (NN uptake) (NN procedure)) (VP (VBD was) (VP (VBN employed) (, ,) (S (VP (VBG incorporating) (NP (JJ multiple) (JJ microbiological) (NNS antigens)))))) (. .)))
(TOP (S (S (NP-SBJ-66 (CD Five) (NNS patients)) (VP (VBD were) (VP (VBN found) (S (PP-PRD (IN with) (NP (NP (VBN repeated) (JJ maximal) (NNS responses)) (PP (TO to) (NP (NN adenovirus) (NN antigen))))))))) (: ;) (S (PP (IN in) (NP (NP (CD one)) (PP (IN of) (NP (DT these))))) (NP-SBJ (NN adenovirus) (NN nucleotide) (NNS sequences)) (VP (VBD were) (ADJP-PRD (JJ present) (PP (IN in) (NP (DT a) (JJ synovial) (NN biopsy) (NN specimen)))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN concluded) (SBAR (IN that) (S (NP-SBJ (NN adenovirus)) (VP (MD may) (VP (VB be) (NP-PRD (NP (CD one) (NN cause)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ persistent)) (CC or) (ADJP (JJ recurrent))) (JJ inflammatory) (NN arthritis)))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Human) (JJ CD3-CD16+) (JJ natural) (NN killer) (NNS cells)) (VP (VBP express) (NP-COOD (NP (DT the) (NN hGATA-3) (NN T) (NN cell) (NN transcription) (NN factor)) (CC and) (NP (DT an) (JJ unrearranged) (JJ 2.3-kb) (NN TcR) (NN delta) (NN transcript)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (S-COOD (S (NP-SBJ (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NP (NP (NN T) (NN cell) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TcR)) (-RRB- -RRB-))) (NN delta) (NNS transcripts)) (VP (VBN expressed) (PP (IN by) (NP-LGS (JJ CD3-CD16+) (NNS cells))))))) (CC and) (S (NP-SBJ (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP-SBJ (DT these) (NNS cells)) (VP (VBD expressed) (NP-COOD (NP (DT the) (NN hGATA-3) (NN T) (NN cell) (NN transcription) (NN factor)) (CC and) (NP (DT the) (JJ recombination-activating) (NN gene) (-LRB- -LRB-) (NN RAG) (-RRB- -RRB-) (CD -1))))))))) (. .)))
(TOP (S (NP-SBJ-27 (NP (JJ Multiple) (NN TcR) (NN delta) (NNS transcripts)) (VP (VBG deriving) (PP (IN from) (NP (DT an) (JJ unrearranged) (NN TcR) (NN delta) (NN gene))))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (ADJP-COOD (CC both) (ADJP (JJ polyclonal)) (CC and) (ADJP (JJ clonal))) (JJ CD3-CD16+) (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (NN cell) (NNS lines))))) (. .)))
(TOP (S (NP-SBJ (CD Two) (JJ unrearranged) (NN TcR) (NN delta) (NNS transcripts)) (VP (VBD had) (NP (NP (DT a) (NN size)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (NP (DT the) (JJ functional) (NN TcR) (NN delta) (NN mRNA)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.3) (CC and) (CD 1.3)) (NN kb)) (-RRB- -RRB-))) (VP (VBN found) (PP (IN in) (NP (ADJP (NN TcR) (JJ gamma/delta+)) (NN T) (NNS lymphocytes))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Sequence) (NN analysis)) (PP (IN of) (NP (NP (CD nine) (JJ different) (JJ 2.3-kb) (NN cDNA) (NNS clones)) (VP (VBN obtained) (PP (IN from) (NP (JJ NK-derived) (JJ polyA+) (NN RNA))))))) (VP (VBD confirmed) (SBAR (IN that) (S (NP-SBJ (PRP they)) (VP (VBD corresponded) (PP (TO to) (NP (DT an) (JJ unrearranged) (NN TcR) (NN delta) (NN gene))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT These) (NN cDNA)) (VP (VBD were) (ADJP-PRD (NP (CD 2343) (NN bp)) (JJ long)))) (CC and) (S (NP-SBJ (PRP$ their) (NN transcription) (NN initiation) (NN site)) (VP (VBD was) (ADJP-PRD (JJ located) (ADVP (NP (CD 814) (NN bp)) (RB upstream) (PP (IN from) (NP (DT the) (NN J) (NN delta) (CD 1) (NN segment))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN sequence)) (ADJP (JJ located) (ADVP (RB upstream) (PP (IN of) (NP (DT the) (NN J) (NN delta) (CD 1) (NN segment)))))) (VP (VBD corresponded) (PP (TO to) (NP (DT the) (ADJP (RB previously) (VBN reported)) (JJ germ-line) (NN sequence)))) (. .)))
(TOP (S (S (NP-SBJ-30 (DT The) (NN J) (NN delta) (CD 1) (NN segment)) (VP (VBD was) (VP (ADVP (RB correctly)) (VBN spliced) (PP (TO to) (NP (NN C) (NN delta)))))) (: ;) (S (PP (IN in) (NP (NN addition))) (NP-SBJ-31 (DT the) (CD four) (NN C) (NN delta) (NNS exons)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (ADVP-TMP (RB already)) (VBN assembled)))))))) (. .)))
(TOP (S (NP-SBJ (CD Two) (NN polyadenylation) (NNS sites)) (VP (VBD were) (ADJP-PRD (JJ present) (PP (IN in) (NP (DT the) (JJ fourth) (NN C) (NN delta) (NN exon))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-33 (NP (JJ only) (WDT that)) (ADJP (JJ located) (PP (IN at) (NP (DT the) (JJ 3') (NN end))))) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (VP (VBN utilized) (PP (IN in) (NP (DT the) (JJ 2.3-kb) (NN cDNA)))))))) (. .)))
(TOP (S (NP-SBJ-35 (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN hGATA-3)) (, ,) (NP (NP (DT a) (ADJP (NN T) (JJ cell-specific)) (NN factor)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN TcR) (NN delta) (NN locus))))))))))))) (, ,)))) (VP (VBD was) (VP (VBN analyzed) (PP (IN by) (NP (NN Northern) (NN blot))) (, ,) (PP-COOD (PP (IN in) (NP (VBN cultured) (NN NK) (NP-COOD (NP (NN cell) (NN population)) (CC and) (NP (NNS clones))))) (-LRB- -LRB-) (CC but) (PP (RB not) (IN in) (NP (ADJP (RB freshly) (VBN derived)) (NN cell) (NNS populations))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ-38 (NP (DT All) (NN NK) (NP-COOD (NP (NNS clones)) (CC and) (NP (NN cell) (NNS lines)))) (VP (VBN studied))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB express) (NP (JJ hGATA-3-specific) (NN mRNA)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ-40 (NN hGATA-3)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (JJ unrearranged) (NN TcR) (NN delta) (NN gene) (NN expression)) (PP (IN in) (NP (NN NK) (NNS cells))))))))))))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ-41 (NP (DT no) (NN transcription)) (PP (IN of) (NP (DT the) (NN RAG-1) (NN gene)))) (VP (MD could) (VP (VB be) (VP (VBN detected) (PP (IN in) (NP (NP (DT all) (NN NK) (NP-COOD (NP (NN cell) (NNS lines)) (CC or) (NP (NNS clones)))) (VP (VBN analyzed))))))) (. .)))
(TOP (NP (NP (JJ Cell-specific) (NN expression)) (PP (IN of) (NP (NP (JJ helix-loop-helix) (NN transcription) (NNS factors)) (VP (VBN encoded) (PP (IN by) (NP-LGS (DT the) (NN E2A) (NN gene)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN E2A) (NN gene)) (VP (VBZ encodes) (NP (NP (NN transcription) (NNS factors)) (PP (IN of) (NP (DT the) (JJ helix-loop-helix) (NN family))) (SBAR (WHNP-36 (WDT that)) (S (VP (VBP are) (VP (VBN implicated) (PP (IN in) (NP (JJ cell-specific) (NN gene) (NN expression))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (JJ dimeric) (NNS complexes)) (SBAR (WHNP-38 (WDT that)) (S (VP (VBP interact) (PP (IN with) (NP (NN E) (NN box) (NN enhancer) (NNS elements)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ has) (ADVP-TMP (RB previously)) (VP (VBN been) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-39 (NP (NNS transcripts)) (PP (IN of) (NP (DT the) (NN E2A) (NN gene)))) (VP (MD can) (VP (VB be) (VP (VBN detected) (PP (IN in) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NN cell) (NNS types))))))))))))) (. .)))
(TOP (S (NP-SBJ-41 (PRP We)) (VP (VBP have) (ADVP-TMP (RB now)) (VP (VBN examined) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN mouse) (NN E2A) (NN gene))) (PP (IN at) (NP (DT the) (NN protein) (NN level)))) (S (VP (VBG using) (NP (NP (JJ polyclonal) (NNS antisera)) (VP (VBN directed) (PP (IN against) (NP (NP (JJ distinct) (NNS portions)) (PP (IN of) (NP (DT the) (NN E2A) (NN protein))))))) (S (VP (TO to) (VP (NN probe) (NP (NP (NNS blots)) (PP (IN of) (NP (JJ cellular) (NNS extracts))))))))))) (. .)))
(TOP (S (S (NP-SBJ-44 (DT A) (CD 73) (NN kDa) (NN protein)) (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP-LGS (DT this) (NN analysis))))) (: :)) (S (NP-SBJ-45 (DT this) (NN protein)) (VP (VBZ is) (ADJP-PRD (RB highly) (VBN enriched)) (PP (IN in) (NP (NP (NN cell) (NNS lines)) (PP (IN of) (NP (NN B) (JJ lymphoid) (NN origin))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP-COOD (NP (JJ pancreatic) (NNS beta-cells)) (CC and) (NP (NN fibroblast) (NNS cells)))))))) (. .))))
(TOP (S (S (NP-SBJ (NP (DT The) (NN detection)) (PP (IN of) (NP (DT this) (NN protein))) (PP (RB selectively) (IN in) (NP (NP (NNS extracts)) (PP (IN of) (NP (JJ lymphoid) (NNS cells)))))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT the) (ADJP (NN E) (JJ box-binding)) (NN activity) (NN LEF1/BCF1))) (PP (IN in) (NP (DT these) (NNS cells)))))) (: ;)) (S (NP-SBJ-47 (DT this) (NN binding) (NN activity)) (VP (VBD was) (ADVP-TMP (RB previously)) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADVP (RB efficiently)) (VP (VBN recognized) (PP (IN by) (NP-LGS (NP (NN antiserum)) (VP (VBN directed) (PP (IN against) (NP (NN E2A) (NN gene) (NNS products)))))))))))) (. .))))
(TOP (S (NP-SBJ (NP (NN Transfection)) (PP (IN of) (NP (NNS cells))) (PP (IN with) (NP (JJ full) (NN length) (NN E2A) (NN cDNA)))) (VP (VBZ leads) (PP (TO to) (NP (NP (NN appearance)) (PP (IN of) (NP (NP (NN protein)) (VP-COOD (VP (VBG co-migrating) (PP (IN with) (NP (DT the) (CD 73) (NN kDa) (NN protein))) (PP (IN on) (NP (NN SDS) (NN gel) (NN electrophoresis)))) (CC and) (VP (VBG co-migrating) (PP (IN with) (NP (NN LEF1/BCF1))) (PP (IN on) (NP (NN mobility) (NN shift) (NN analysis)))))))))) (. .)))
(TOP (S (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP are) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (DT the) (NN view) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ DNA-binding) (NN activity) (NN LEF1/BCF1)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN homodimer)) (PP (IN of) (NP (NN E2A) (NNS proteins))))))))))) (: ;)) (S (NP-SBJ-49 (NP (DT the) (JJ selective) (NN appearance)) (PP (IN of) (NP (DT this) (JJ putative) (JJ cell-specific) (NN transcription) (NN factor))) (PP (IN in) (NP (NN B) (JJ lymphoid) (NNS cells)))) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ attributable) (PP (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (TO to) (NP (NP (DT the) (JJ elevated) (NN E2A) (NN protein) (NNS concentrations)) (PP (IN in) (NP (DT these) (NNS cells)))))))))) (. .))))
(TOP (S (NP-SBJ (NN HIV-1) (NN Nef) (NN protein)) (VP (VBZ inhibits) (NP (NP (DT the) (NN recruitment)) (PP (IN of) (NP (NP (NN AP-1) (JJ DNA-binding) (NN activity)) (PP (IN in) (NP (JJ human) (NNS T-cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (JJ long) (JJ terminal) (NN repeat)) (, ,) (NP (NN HIV-1-LTR)) (, ,)) (VP (VBZ contains) (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (JJ several) (JJ cellular) (NN transcription) (NNS factors)) (SBAR (WHNP-13 (WDT which)) (S (VP (VBP contribute) (PP (TO to) (NP (NN HIV-1) (NN gene) (NN expression)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (PRP$ Our) (JJ previous) (NNS studies)) (PP (IN on) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT the) (JJ HIV-1-encoded) (NN Nef) (NN protein)))))) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NN Nef)) (VP (MD may) (VP (VB be) (NP-PRD (DT an) (NN inhibitor) (NN HIV-1) (NN transcription))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (NN Nef)) (VP (VBZ affects) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ cellular) (NNS factors))) (VP (VBN implicated) (PP (IN in) (NP (NN HIV-1) (NN regulation))))))))))) (, ,) (NP-SBJ-14 (NP (JJ 32P-labeled) (NNS oligonucleotides)) (VP (VBG corresponding) (PP (TO to) (NP (DT the) (VBG binding) (NNS sites))))) (VP (VBD were) (VP (VBN incubated) (PP (IN with) (NP (NP (JJ nuclear) (NNS extracts)) (VP (VBN prepared) (PP (IN from) (NP (NP (JJ Nef-expressing) (NN T-cell) (NNS lines)) (SBAR (WHNP-15 (WDT that)) (S (VP (VP-COOD (VP (VBD were) (RB not) (VP (VBN stimulated))) (CC or) (VP (VBD were) (VP (VBN stimulated)))) (PP (IN with) (NP (NN T-cell) (NNS mitogens))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NN Nef)) (VP (VBD inhibited) (NP (NP (DT the) (NN recruitment)) (PP (IN of) (NP (NP (NN AP-1) (JJ DNA-binding) (NN activity)) (PP (IN in) (NP (JJ mitogen-stimulated) (JJ human) (NNS T-cells)))))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP-SBJ-18 (NN Nef) (NN expressing) (NNS cells)) (VP (VBD were) (VP (ADVP-TMP (RB transiently)) (VBN transfected) (PP (IN with) (NP (NP (DT a) (NN plasmid)) (SBAR (WHPP-19 (IN in) (WHNP (WDT which))) (S (NP-SBJ-20 (NN HIV-1) (NN AP-1) (NN DNA) (NN recognition) (NNS sequences)) (VP (VBD were) (VP (VBN cloned) (ADVP (RB downstream) (PP (IN of) (NP (DT the) (NP (NP (NN chloramphenicol) (NN acetyltransferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (NN gene)))))))))))) (. .)))
(TOP (S (NP-SBJ-21 (NP (JJ Mitogen-mediated) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NN CAT) (NN gene))) (PP (IN in) (NP (DT this) (NN construct)))) (VP (VBD was) (VP (VBN inhibited) (PP-COOD (PP (IN in) (NP (JJ Nef-expressing) (NNS cells))) (CC but) (PP (RB not) (IN in) (NP (NN control) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (PP (, ,) (S (VP (IN by) (NP (VBG inhibiting) (NN AP-1))))) (NN activation) (NP-SBJ-22 (, ,)) (VP (NN Nef) (VP (MD may) (NP (VB play) (DT a)) (PP (NN role) (S (VP (IN in) (NP (NP (VBG regulating) (NN HIV-1) (NN gene)) (PP (NN expression) (NP (IN in) (JJ infected)))))))))))) (NNS T-cells)))
(TOP (NP (NP (NN Hypertension)) (PP (IN in) (NP (NN pregnancy))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Pregnancy-induced) (NN hypertension)) (PRN (-LRB- -LRB-) (NP (NN PIH)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ frequent) (NN cause)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ maternal)) (CC and) (ADJP (JJ neonatal))) (NP-COOD (NP (NN morbidity)) (CC and) (NP (NN mortality))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP-SBJ (PRP we)) (VP (VBD focused) (PP (PP (IN on) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NN PIH))))) (, ,) (PP (RB mainly) (IN on) (NP-COOD (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNS mineralocorticoids)))) (, ,) (NP (VBN reversed) (NN blood) (NN pressure) (NNS patterns)) (, ,) (CC and) (NP (NP (DT the) (VBG resulting) (NN necessity)) (PP (IN of) (NP (NP (JJ continuous) (NN monitoring)) (PP (IN of) (NP (DT the) (JJ preeclamptic) (NN mother)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-52 (NP (NNS Problems)) (PP (IN of) (NP (JJ antihypertensive) (NN therapy)))) (VP (VBP are) (VP (VBN discussed)))) (CC and) (S (NP-SBJ-53 (NP (DT the) (JJ first) (NNS results)) (PP (IN of) (NP (NP (DT a) (NN pilot) (NN study)) (PP (IN with) (NP (NN Urapidil)))))) (VP (VBP are) (VP (VBN presented)))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNS mineralocorticoids))) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NN PIH))))))))) (, ,) (NP-SBJ-54 (PRP we)) (VP (VBD studied) (NP (NP (NP-COOD (NP (NN plasma) (NN aldosterone)) (CC and) (NP (NP (NN 18-hydroxy-corticosterone)) (PRN (-LRB- -LRB-) (NP (NN 18-OH-B)) (-RRB- -RRB-)))) (NNS levels)) (PP-COOD (PP (IN in) (NP (NP (CD 25) (NNS women)) (PP (IN with) (NP (NN PIH))))) (CC and) (PP (IN in) (NP (CD 25) (JJ healthy) (JJ pregnant) (NNS women)))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD evaluated) (NP (NP (NP (NP (DT the) (NN mineralocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN MR)) (-RRB- -RRB-))) (NN count)) (PP (IN in) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PP (IN in) (NP (DT the) (CD 2) (NNS groups))))))) (. .)))
(TOP (S (NP-SBJ-55 (DT The) (NN MR-count)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN in) (NP (DT the) (NN PIH-group))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS values)) (PP (IN of) (NP-COOD (NP (NN plasma) (NN aldosterone)) (CC and) (NP (NN 18-OH-B))))) (VP (VBD were) (ADVP (RB also)) (ADJP-PRD (JJ low))) (. .)))
(TOP (S (NP-SBJ-56 (DT These) (NNS results)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP-LGS (NP (NN receptor) (NN down-regulation)) (PP (JJ due) (TO to) (NP (NP (JJR higher) (NN level)) (PP (IN of) (NP (NP (NNS mineralocorticoids)) (PP (IN of) (NP (DT the) (NN zona) (NN glomerulosa)))))))))))) (. .)))
(TOP (S (ADVP (RB Perhaps)) (NP-SBJ-COOD (NP (NN deoxycorticosterone)) (CC or) (NP (DT a) (RB hitherto) (JJ unknown) (NN mineralocorticoid))) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (DT the) (NP-COOD (NP (NN hypertension)) (CC and) (NP (JJ altered) (NN MR-status))))))) (. .)))
(TOP (S (NP-SBJ-57 (NP (DT The) (JJ first) (NNS results)) (PP (IN of) (NP (NP (JJ continuous) (NN blood) (NN pressure) (NNS measurements)) (PP (IN with) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ noninvasive)) (, ,) (ADJP (JJ real-time))) (NN blood) (NN pressure) (NN monitor)) (PRN (-LRB- -LRB-) (NP (NN Finapres)) (-RRB- -RRB-))))))) (VP (VBP are) (VP (VBN presented))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN comparison)) (PP (IN of) (NP (DT the) (VBN obtained) (NNS values))) (PP (IN with) (NP (JJ intraarterial) (NNS measurements)))) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ good) (NN correlation)) (PP (IN between) (NP (DT the) (CD two) (NNS methods))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBP report) (PP (IN on) (NP (NP (DT the) (JJ first) (NNS experiences)) (PP (IN with) (NP (NN Urapidil))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN hypertension)) (PP (IN in) (NP (JJ severe) (NN preeclampsia)))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-59 (NP (NN hypertension)) (PP (IN in) (NP (JJ preeclamptic) (NNS women)))) (VP (MD can) (VP (VB be) (VP (VBN treated) (PP (IN by) (NP-LGS (NN Urapidil))) (PP (IN without) (NP-COOD (NP (JJ side) (NNS effects)) (CC or) (NP (NN reflex-tachycardia)))))))))) (. .)))
(TOP (S (NP-SBJ-60 (JJ Further) (NNS studies)) (VP (MD will) (VP (VB have) (S (VP (TO to) (VP (VB prove) (SBAR (IN if) (S (NP-SBJ (NN Urapidil)) (VP (VBZ is) (ADJP-PRD (VBN suited) (PP (IN for) (NP (NP (JJ prepartal) (NN treatment)) (PP (IN of) (NP (NN PIH))))) (ADVP (RB as) (RB well))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Adenovirus) (NN E1A)) (VP (VBZ inhibits) (NP (NP (JJ IFN-induced) (NN resistance)) (PP (TO to) (NP (NP (NN cytolysis)) (PP (IN by) (NP (JJ natural) (NN killer) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Infection)) (PP (IN of) (NP (NN target) (NNS cells))) (PP (IN with) (NP (JJ cytopathic) (NNS viruses)))) (VP (VBZ inhibits) (NP (NP (NP (NN IFN) (NN induction)) (PP (IN of) (NP (NP (JJ cytolytic) (NN resistance)) (PP (TO to) (NP (ADJP (NN NK) (JJ cell-mediated)) (NN cytolysis)))))) (PRN (-LRB- -LCB-) (NP (NP (JJ IFN-mediated) (NN cytoprotection)) (PRN (-LRB- -LRB-) (NP (NN IFN-MCP)) (-RRB- -RRB-))) (-RRB- -RCB-)))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN thought) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (ADJP (RB virally) (VBN induced)) (NN inhibition)) (PP (IN of) (NP (NN IFN-MCP)))) (VP (VBZ is) (ADJP-PRD (JJ secondary) (PP (TO to) (NP (NP (DT the) (NN shutdown)) (PP (IN of) (NP (NP (JJ cellular) (JJ macromolecular) (NN synthesis)) (SBAR (WHNP-33 (WDT that)) (S (VP (VBZ accompanies) (NP (JJ cytopathic) (NN virus) (NNS infections)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Group) (NN C) (, ,) (NP (NP (NN adenovirus) (NN serotype) (CD 5)) (PRN (-LRB- -LRB-) (NP (NN Ad5)) (-RRB- -RRB-))) (NN infection)) (VP (VBZ inhibits) (NP-COOD (CC both) (NP (NN IFN-MCP)) (CC and) (NP (JJ cellular) (NN protein) (NN synthesis)))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN study)) (VP (VBD determined) (SBAR (IN if) (S (NP-SBJ (NP (DT the) (JJ Ad5-induced) (NN inhibition)) (PP (IN of) (NP (NN IFN-MCP)))) (VP (VBD was) (ADJP-PRD-COOD (ADJP (JJ independent) (PP (IN of) (NP (NP (NP (NN adenovirus)) (PRN (-LRB- -LRB-) (NP (NN Ad)) (-RRB- -RRB-))) (NN infection)))) (CC and) (ADJP (JJ secondary) (PP (RB only) (TO to) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN Ad) (NP (NP (JJ early) (NN region) (NN 1A) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN E1A)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB test) (NP (DT this) (NN hypothesis))))) (, ,) (NP-SBJ-34 (JJ 4-h) (NN NK) (NN cytolysis) (NNS assays)) (VP (VBD were) (VP (VBN performed) (PP (IN on) (NP (NP (JJ IFN-gamma-treated) (JJ human) (NNS cells)) (ADJP-COOD (ADJP (VBN infected) (PP (IN with) (NP (NP (DT an) (NN Ad5) (NN E1A) (NN deletion) (NN mutant)) (, ,) (NP (NN dl343))))) (, ,) (CC or) (ADJP (VBN transfected) (PP (IN with) (NP (DT the) (NN Ad5) (NN E1A) (NN gene))))))))) (. .)))
(TOP (S (NP-SBJ-35 (NN IFN-MCP)) (VP (VBD was) (RB not) (VP (VBN inhibited) (PP (IN by) (NP-LGS (NP (NN infection)) (PP (IN with) (NP (NN dl343))))) (, ,) (PP (IN despite) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ large) (NNS amounts)) (PP (IN of) (NP (NP-COOD (CC both) (NP (NP (JJ early)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN E1B)) (, ,) (NP (NN p55))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ late)) (PRN (-LRB- -LRB-) (NP (NN hexon)) (-RRB- -RRB-)))) (NP-36 (NN Ad) (NNS proteins)))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (ADJP-COOD (ADJP (JJ E1A-negative)) (, ,) (ADJP (JJ parental))) (NN cell) (NNS lines))) (, ,) (NP-SBJ-37 (NN IFN-MCP)) (VP (VBD was) (VP (VBN blocked) (PP (IN in) (NP (ADJP (NN Ad5) (JJ E1A-transfected)) (ADJP-COOD (ADJP (JJ epithelial)) (CC and) (ADJP (JJ fibroblastic))) (NN cell) (NNS lines))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Genetic) (NN mapping) (NNS studies)) (PP (IN within) (NP (DT the) (NN E1A) (NN gene)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (NP (RB only) (DT the) (JJ first) (NN exon)) (PP (IN of) (NP (NN E1A)))))) (VP (VBD was) (ADJP-PRD (JJ sufficient) (S (VP (TO to) (VP (VB inhibit) (NP (NN IFN-MCP)))))))))) (. .)))
(TOP (S (NP-SBJ-38 (NP (NN DNA) (NN sequence) (NN homology)) (PP (IN of) (NP (NN E1A) (NNS genes))) (PP (IN between) (NP (NP (JJ different) (NN Ad) (NNS groups)) (PRN (-LRB- -LRB-) (FRAG (FRAG (NP (NN group) (NN A)) (, ,) (NP (NN Ad12))) (: ;) (FRAG (NP (NN group) (NN C)) (, ,) (NP (NN Ad5)))) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN limited) (PP (ADVP (RB almost) (RB entirely)) (TO to) (NP (NP (CD three) (VBN conserved) (NNS regions)) (ADJP (JJ located) (PP (IN within) (NP (NP (DT the) (JJ first) (NN exon)) (PP (IN of) (NP (NN E1A)))))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP-SBJ-39 (NN IFN-MCP)) (VP (VBD was) (ADVP (RB also)) (VP (VBN blocked) (PP (IN in) (NP (NN Ad12) (JJ E1A-transfected) (NN cell) (NNS lines))))))) (, ,) (NP-SBJ-100 (NP (NN expression)) (PP (IN of) (NP (NP (QP (CD one) (CC or) (JJR more))) (PP (IN of) (NP (DT the) (JJ E1A-conserved) (NNS regions)))))) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ necessary) (S (VP (TO to) (VP (VB inhibit) (NP (NN IFN-MCP)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN summary))) (, ,) (NP-SBJ (NP (DT the) (NN expression)) (PP (IN of) (NP (NN E1A) (NN gene) (NNS products)))) (VP (VBD inhibited) (NP (NN IFN-MCP)) (ADVP (RB independently)) (PP (IN of) (NP (NN virus) (NN infection)))) (. .)))
(TOP (S (NP-SBJ (NP (NP (NN E1A)) (POS 's)) (PP (NN inhibition) (NP (IN of)))) (VP (NN IFN-MCP) (NP (NP (VBZ has) (DT the) (JJ net)) (PP (NN effect) (S (VP (IN of) (NP (NP (VBG promoting) (DT the) (ADJP (JJ selective) (NN NK)) (JJ cell-mediated)) (PP (NN clearance) (NP (ADJP-COOD (ADJP (IN of)) (JJ Ad-infected) (ADJP (CC or))) (JJ Ad-transformed) (JJ human))))))))) (NNS cells)))
(TOP (S (NP-SBJ (DT A) (JJ chimeric) (NN type) (CD II) (: /) (NN type) (CD I) (NN interleukin-1) (NN receptor)) (VP (MD can) (VP (VB mediate) (NP (NP (NN interleukin-1) (NN induction)) (PP (IN of) (NP (NN gene) (NN expression))) (PP (IN in) (NP (NN T) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ-100 (DT The) (NN type) (CD I) (NP (NP (NN interleukin-1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IL-1R)) (-RRB- -RRB-)))) (VP (VBZ is) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG transducing) (NP (NP (DT a) (NN signal)) (VP (VBG resulting) (PP (IN in) (NP (NP (NN promoter) (NN activation)) (PP (IN in) (NP (NN T) (NNS cells)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN signal) (NN transduction)) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NP (DT the) (JJ cytoplasmic) (NN domain)) (, ,) (SBAR (WHNP-22 (WDT which)) (S (VP (VBZ consists) (PP (IN of) (NP (CD 213) (NN amino) (NNS acids)))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (DT the) (NN type) (CD I) (NN receptor))) (, ,) (S-COOD (S (NP-SBJ (DT the) (NN type) (CD II) (NN IL-1R)) (VP (VBZ has) (NP (DT a) (JJ small) (JJ cytoplasmic) (NN tail)))) (, ,) (CC and) (S (NP-SBJ (NP (PRP it))) (VP (VBZ is) (RB not) (ADJP-PRD (JJ clear)) (SBAR-23 (IN whether) (S (NP-SBJ (DT this) (NN receptor)) (VP (VBZ is) (NP-PRD (NP-COOD (NP (DT a) (JJ signal-transducing)) (CC or) (NP (DT a) (JJ regulatory))) (NP-101 (NN molecule))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (DT the) (NN type) (CD II) (NN IL-1R)) (VP (VBZ does) (RB not) (VP (VB mediate) (NP (NP (NN gene) (NN activation)) (PP (IN in) (NP (NN Jurkat) (NNS cells))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-102 (NP (DT a) (NN hybrid) (NN receptor)) (VP (VBN composed) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ extracellular)) (CC and) (ADJP (NN transmembrane))) (NNS regions)) (PP (IN of) (NP (NP (DT the) (JJ human) (NN type) (CD II) (NN interleukin-1)) (VP (VBN fused) (PP (TO to) (NP (NP (DT the) (JJ cytoplasmic) (NN domain)) (PP (IN of) (NP (DT the) (JJ human) (NN type) (CD I) (NN IL-1R)))))))))))) (VP (VBD was) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG transducing) (NP (NP (DT a) (NN signal))) (PP (IN across) (NP (DT the) (NN membrane))) (VP-105 (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN pattern)) (PP (IN of) (NP (NP (NN gene) (NN activation)) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT that)) (VP (VBN mediated) (PP (IN by) (NP-LGS (DT the) (NN type) (CD I) (NN IL-1R))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ-103 (NP (DT the) (JJ extracellular) (NN domain)) (PP (IN of) (NP (DT the) (NN type) (CD II) (NN IL-1R)))) (VP (VBD was) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP-COOD (VP (ADVP (RB functionally)) (VBG interacting) (PP (IN with) (NP (NN interleukin-1)))) (CC and) (VP (VBG transmitting) (NP (DT the) (VBG resulting) (NN signal)) (PP (TO to) (NP (DT a) (JJ heterologous) (JJ cytoplasmic) (NN domain)))))))))))) (. .)))
(TOP (NP (NP (DT A) (NN mutation)) (PP (IN of) (NP (DT the) (NN glucocorticoid) (NN receptor))) (PP (IN in) (NP (JJ primary) (NN cortisol) (NN resistance))) (. .)))
(TOP (S (NP-SBJ-24 (NP (DT The) (JJ precise) (JJ molecular) (NNS abnormalities)) (SBAR (WHNP-104 (WDT that)) (S (VP (VBP cause) (NP (JJ primary) (NN cortisol) (NN resistance)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (ADVP (RB completely)) (VBN described)))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT a) (NN subject)) (PP (IN with) (NP (JJ primary) (NN cortisol) (NN resistance))))) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN observed) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN hGR)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (DT a) (VBN decreased) (NN affinity)) (PP (IN for) (NP (NN dexamethasone)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (NN mutation)) (PP (IN of) (NP (DT the) (NN hGR) (JJ glucocorticoid-binding) (NN domain)))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN cause)) (PP (IN of) (NP (NN cortisol) (NN resistance)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-25 (NP (JJ Total) (NN RNA)) (VP (VBN isolated) (PP (IN from) (NP (NP (DT the) (NN index) (NN subject) (POS 's)) (JJ mononuclear) (NNS leukocytes))))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB produce) (NP (JJ first) (NN strand) (NN hGR) (NNS cDNAs)))))))) (, ,) (CC and) (S (NP-SBJ-27 (DT the) (JJ entire) (NN hGR) (NN cDNA)) (VP (VBD was) (VP-COOD (VP (VBN amplified) (PP (IN in) (NP (NNS segments)))) (CC and) (VP (VBN sequenced))))) (. .)))
(TOP (S (PP (IN At) (NP (NN nucleotide) (CD 2,317))) (NP-SBJ (PRP we)) (VP (VBD identified) (NP (NP (DT a) (JJ homozygous) (NN A)) (PP (IN for) (NP (NP (NN G) (NN point) (NN mutation)) (SBAR (WHNP-29 (WDT that)) (S (VP (VBZ predicts) (NP (NP (NP (DT an) (NN isoleucine)) (PRN (-LRB- -LRB-) (NP (NN ATT)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (NN valine) (-LRB- -LRB-) (NN GTT) (-RRB- -RRB-) (NN substitution)) (PP (IN at) (NP (NN amino) (NN acid) (CD 729))))))))))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-30 (WRB When)) (S (NP-SBJ-COOD-31 (NP (DT the) (JJ wild-type) (NN hGR)) (CC and) (NP (NN hGR-Ile) (CD 729))) (VP (VBD were) (VP (VP-COOD (VP (VBN expressed) (PP (IN in) (NP (NN COS-1) (NNS cells)))) (CC and) (VP (VBN assayed) (PP (IN for) (NP (NN -LCB-3H-RCB--Dexamethasone) (NN binding))))))))) (, ,) (NP-SBJ (DT the) (NN dissociation) (NNS constants)) (VP (VBD were) (NP-PRD (NP (QP-COOD (QP (CD 0.799) (CC +/-) (CD 0.068)) (CC and) (QP (CD 1.54) (CC +/-) (CD 0.06))) (NN nM)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN mean)) (CC +/-) (NP (NN SEM))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-)) (, ,) (ADVP (RB respectively)))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-34 (WRB When)) (S (NP-SBJ-COOD-35 (NP (DT the) (JJ wild-type) (NN hGR)) (CC and) (NP (NN hGR-Ile) (CD 729))) (VP (VBD were) (VP (VBN expressed) (PP (IN in) (NP (NP (NN CV-1) (NNS cells)) (SBAR (WHNP-36 (WDT that)) (S (VP (VBD were) (VP (VBN cotransfected) (PP (IN with) (NP (NP (DT the) (NN mouse) (JJ mammary) (NN tumor) (NN virus) (JJ long) (JJ terminal) (NN repeat)) (VP (VBN fused) (PP (TO to) (NP (DT the) (NP (NP (NN chloramphenicol) (NN acetyl) (NN transferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (NN gene)))))))))))))))) (, ,) (NP-SBJ (DT the) (NN hGR-Ile) (CD 729)) (VP (VBD conferred) (NP (NP (DT a) (JJ fourfold) (NN decrease)) (PP (IN in) (NP (JJ apparent) (NN potency)))) (PP (IN on) (NP (NP (NN dexamethasone) (NN stimulation)) (PP (IN of) (NP (NN CAT) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN isoleucine)) (PP (IN for) (NP (NP (NN valine) (NN substitution)) (PP (IN at) (NP (NN amino) (NN acid) (CD 729)))))) (VP-COOD (VP (VBZ impairs) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT the) (NN hGR))))) (CC and) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ likely) (NN cause)) (PP (IN of) (NP (NP (JJ primary) (NN cortisol) (NN resistance)) (PP (IN in) (NP (DT this) (NN subject)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Mice)) (ADJP (NN deficient) (PP (IN for) (NP (DT the) (ADJP (CD 55) (JJ kd)) (NN tumor) (NN necrosis) (NN factor) (NN receptor))))) (VP-COOD (VP (VBP are) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (JJ endotoxic) (NN shock))))) (, ,) (RB yet) (VP (VBP succumb) (PP (TO to) (NP (FW L.) (NNS monocytogenes) (NN infection))))) (. .)))
(TOP (S (NP-SBJ-25 (NP (DT The) (JJ multiple) (JJ biological) (NNS activities)) (PP (IN of) (NP (NP (NN tumor) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))))) (VP (VBP are) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (CD two) (JJ distinct) (NN cell) (NN surface) (NNS receptors)) (PP (IN of) (NP-COOD (NP (NP (CD 55) (NNS kd)) (PRN (-LRB- -LRB-) (NP (NN TNFRp55)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 75) (NN kd)) (PRN (-LRB- -LRB-) (NP (NN TNFRp75)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NN gene) (NN targeting)))) (, ,) (NP-SBJ-26 (PRP we)) (VP (VBD generated) (NP (DT a) (JJ TNFRp55-deficient) (NN mouse) (NN strain))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Cells)) (PP (IN from) (NP (JJ TNFRp55-/-mutant) (NNS mice)))) (VP-COOD (VP (VBP lack) (NP (NP (NN expression)) (PP (IN of) (NP (NN TNFRp55))))) (CC but) (VP (VBP display) (NP (NP (JJ normal) (NNS numbers)) (PP (IN of) (NP (JJ high) (NN affinity) (NN TNFRp75) (NNS molecules)))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-COOD (NP (NN Thymocyte) (NN development)) (CC and) (NP (NN lymphocyte) (NNS populations))) (VP (VBP are) (ADJP-PRD (JJ unaltered)))) (, ,) (CC and) (S (NP-SBJ (NP (JJ clonal) (NN deletion)) (PP (IN of) (NP (ADJP (RB potentially) (JJ self-reactive)) (NN T) (NNS cells)))) (VP (VBZ is) (RB not) (ADJP-PRD (JJ impaired)))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-27 (NN TNF) (NN signaling)) (VP (VBZ is) (VP (ADVP (RB largely)) (VBN abolished) (, ,) (SBAR (IN as) (S (VP (VBN judged) (PP (IN by) (NP (NP (DT the) (NN failure)) (PP (IN of) (NP (NN TNF))) (S-100 (VP (TO to) (VP (VB induce) (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (NP (NN T) (NNS lymphocytes)) (PP (IN from) (NP (JJ TNFRp55-deficient) (NNS mice))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN loss)) (PP (IN of) (NP (NN TNFRp55) (NN function)))) (VP (VBZ renders) (S (NP-SBJ (NNS mice)) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (NP (JJ lethal) (NNS dosages)) (PP (IN of) (NP-COOD (CC either) (NP (NNS lipopolysaccharides)) (CC or) (NP (FW S.) (FW aureus) (NN enterotoxin) (NN B))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-29 (JJ TNFRp55-deficient) (NNS mice)) (VP-COOD (VP (VBP are) (ADJP-PRD (RB severely) (JJ impaired) (S (VP (TO to) (VP (VB clear) (NP (FW L.) (FW monocytogenes))))))) (CC and) (VP (ADVP (RB readily)) (VBP succumb) (PP (TO to) (NP (NN infection))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (DT the) (CD 55) (NN kd) (NN TNFR)) (VP (VBZ plays) (NP (DT a) (JJ decisive) (NN role)) (PP (IN in) (NP (NP (NP (DT the) (NN host)) (POS 's)) (PP (NN defense) (NP-COOD (NP (IN against)) (NNS microorganisms) (NP (CC and) (PRP$ their) (JJ pathogenic))))))) (NNS factors)))
(TOP (NP (NP-COOD (NP (NN Cloning)) (CC and) (NP (JJ functional) (NN characterization))) (PP (IN of) (NP (NP (JJ early) (NN B-cell) (NN factor)) (, ,) (NP (NP (DT a) (NN regulator)) (PP (IN of) (NP (JJ lymphocyte-specific) (NN gene) (NN expression)))))) (. .)))
(TOP (S (NP-SBJ-27 (NP (JJ Early) (NN B-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN EBF)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN identified) (ADVP-TMP (RB previously)) (PP (IN as) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ tissue-specific)) (CC and) (ADJP (NN differentiation) (JJ stage-specific))) (JJ DNA-binding) (NN protein)) (SBAR (WHNP-29 (WDT that)) (S (VP (VBZ participates) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (ADJP (NP-COOD (NP (JJ pre-B)) (CC and) (NP (NN B))) (JJ lymphocyte-specific)) (NN mb-1) (NN gene)))))))))))) (. .)))
(TOP (S (NP-SBJ-30 (NP (JJ Partial) (NN amino) (NN acid) (NNS sequences)) (VP (VBN obtained) (PP (IN from) (NP (VBN purified) (NN EBF))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB isolate) (NP (NP (NN cDNA) (NNS clones)) (, ,) (SBAR (WHNP-32 (WDT which)) (S (PP (IN by) (NP (JJ multiple) (NNS criteria))) (VP (VB encode) (NP (NN EBF))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ recombinant) (NN polypeptide)) (VP (VBD formed) (NP (NP (JJ sequence-specific) (NNS complexes)) (PP (IN with) (NP (NP (DT the) (NN EBF-binding) (NN site)) (PP (IN in) (NP (DT the) (NN mb-1) (NN promoter))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT The) (NN cDNA)) (VP (VBD hybridized) (PP (TO to) (NP (JJ multiple) (NNS transcripts))) (PP (IN in) (NP (NP-COOD (NP (JJ pre-B)) (CC and) (NP (NN B-cell))) (NNS lines))))) (, ,) (CC but) (S (NP-SBJ-33 (NNS transcripts)) (VP (VBD were) (RB not) (VP (VBN detected) (PP (IN at) (NP (JJ significant) (NNS levels))) (PP (IN in) (NP (UCP-COOD (NP (NN plasmacytoma)) (, ,) (NP (NN T-cell)) (, ,) (CC and) (ADJP (JJ nonlymphoid))) (NN cell) (NNS lines)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (JJ recombinant) (NN EBF))) (PP (IN in) (NP (VBN transfected) (JJ nonlymphoid) (NNS cells)))) (ADVP (RB strongly)) (VP (VBD activated) (NP (NP (NN transcription)) (PP (IN from) (NP (NP (NN reporter) (NNS plasmids)) (VP (VBG containing) (NP (JJ functional) (JJ EBF-binding) (NNS sites))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (NN DNA) (NN binding)) (PP (IN by) (NP (NP (NN deletion) (NNS mutants)) (PP (IN of) (NP (NN EBF)))))))) (VP (VBD identified) (NP (NP (DT an) (JJ amino-terminal) (JJ cysteine-rich) (JJ DNA-binding) (NN domain)) (VP (VBG lacking) (NP (NP (JJ obvious) (NN sequence) (NN similarity)) (PP (TO to) (NP (JJ known) (NN transcription) (NNS factors))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ DNA-binding) (NNS assays)) (PP (IN with) (NP (NP (NP-COOD (NP (VBN cotranslated) (JJ wild-type)) (CC and) (NP (JJ truncated))) (NP-35 (NNS forms))) (PP (IN of) (NP (NN EBF)))))) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ (DT the) (NN protein)) (VP (VBZ interacts) (PP (IN with) (NP (PRP$ its) (NN site))) (PP (IN as) (NP (DT a) (NN homodimer))))))) (. .)))
(TOP (S (NP-SBJ (NNS Deletions)) (VP (VBD delineated) (NP (NP (DT a) (JJ carboxy-terminal) (NN dimerization) (NN region)) (VP (VBG containing) (NP (NP (CD two) (NNS repeats)) (PP (IN of) (NP (CD 15) (NN amino) (NNS acids))) (SBAR (WHNP-40 (WDT that)) (S (VP (VBP show) (NP (NP (NN similarity)) (PP (IN with) (NP (NP (DT the) (NN dimerization) (NNS domains)) (PP (IN of) (NP (JJ basic-helix-loop-helix) (NNS proteins))))))))))))) (. .)))
(TOP (S (ADVP (RB Together)) (, ,) (NP-SBJ (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN EBF)) (VP (VBZ represents) (NP (NP (DT a) (JJ novel) (NN regulator)) (PP (IN of) (NP (ADJP (NN B) (JJ lymphocyte-specific)) (NN gene) (NN expression)))))))) (. .)))
(TOP (NP (-LRB- -LCB-) (NP (DT The) (NN trend)) (PP (IN of) (NP (NP (JJ molecular) (NN biology) (NN study)) (PP (IN on) (NP (NNS eosinophils))))) (-RRB- -RCB-)))
(TOP (S (ADVP-TMP (RB Recently)) (, ,) (NP-SBJ (JJ many) (NNS investigators)) (VP (VBP have) (VP (VBN been) (ADJP-PRD (JJ interested) (PP (IN in) (NP (NP (DT the) (NN study)) (PP (IN on) (NP (NN eosinophil) (NN biology)))))) (SBAR (IN since) (S (NP-SBJ-53 (NP (NNS genes) (NN association)) (PP (IN with) (NP (NP (NNS eosinophils)) (PP (JJ such) (IN as) (NP-COOD (NP (NN interleukin-5)) (CC or) (NP (NP (NN eosinophil) (NN granule) (NNS proteins)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN EPO)) (, ,) (NP (NN ECP)) (, ,) (NP (NN EDN)) (, ,) (NP (NN MBP)) (, ,) (CC and) (NP (NN CLC))) (-RRB- -RRB-)))))))) (, ,) (VP (VBD were) (VP (VBN isolated))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-54 (NP (DT the) (JJ molecular) (NN basis)) (PP (IN for) (NP (NP (DT the) (NN commitment)) (PP (IN of) (NP (NNS progenitors))) (PP (TO to) (NP (DT the) (NN eosinophil) (NN lineage)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN determined)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN mechanism)) (SBAR (WHPP-55 (IN by) (WHNP (WDT which))) (S (NP-SBJ-56 (NP (JJ eosinophil-specific) (NNS genes)) (VP (VBG encoding) (NP (NP (ADJP-COOD (ADJP (JJ primary)) (CC and) (ADJP (JJ secondary))) (NN granule) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (NP-COOD (NP (NN ECP)) (, ,) (NP (NN EDN)) (, ,) (NP (NN EPO)) (, ,) (NP (NN MBP)) (, ,) (CC and) (NP (NN CLC)))) (-RRB- -RRB-))))) (VP (VBP are) (VP (VP-COOD (VP (VBN expressed)) (CC and) (VP (VBN regulated))) (PP-TMP (IN during) (NP (NN eosinophilopoiesis)))))))) (VP (VBZ is) (ADVP (RB also)) (ADJP-PRD (JJ unknown))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP-SBJ (PRP I)) (VP (VBD described) (NP-COOD (NP (NP (DT the) (NN characterization)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBG encoding) (NP (NN eosinophil) (NN granule) (NNS proteins)))))) (CC and) (NP (NP (DT the) (NN mRNA) (NN expression)) (PP (IN of) (NP (NN GATA-1) (NN binding) (NN transcription) (NN factor))) (PP-TMP (IN during) (NP (NN eosinophil) (NN differentiation)))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (DT the) (JJ Ets-related) (NN transcription) (NN factor) (NN Elf-1))) (PP (IN by) (S (VP (VBG binding) (PP (TO to) (NP (DT the) (NN retinoblastoma) (NN protein)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN retinoblastoma) (NN gene) (NN product)) (PRN (-LRB- -LRB-) (NP (NN Rb)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ nuclear) (NN phosphoprotein)) (SBAR (WHNP-20 (WDT that)) (S (VP (VBZ regulates) (NP (NN cell) (NN cycle) (NN progression))))))) (. .)))
(TOP (S (NP-SBJ (NN Elf-1)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ lymphoid-specific) (NN Ets) (NN transcription) (NN factor)) (SBAR (WHNP-21 (WDT that)) (S (VP (VBZ regulates) (NP (JJ inducible) (NN gene) (NN expression)) (PP-TMP (IN during) (NP (NN T) (NN cell) (NN activation)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP it)) (VP (VBZ is) (VP (VBN demonstrated) (SBAR (IN that) (S (NP-SBJ (NN Elf-1)) (VP (VBZ contains) (NP (NP (DT a) (NN sequence) (NN motif)) (SBAR (WHNP-22 (WDT that)) (S (VP-COOD (VP (VBZ is) (ADJP-PRD (RB highly) (JJ related) (PP (TO to) (NP (NP (DT the) (NN Rb) (NN binding) (NNS sites)) (PP (IN of) (NP (JJ several) (JJ viral) (NNS oncoproteins))))))) (CC and) (VP (VBZ binds) (PP (TO to) (NP (NP (DT the) (NN pocket) (NN region)) (PP (IN of) (NP (NN Rb))))) (ADVP-COOD (CC both) (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo))))))))))))) (. .)))
(TOP (S (NP-SBJ-24 (NN Elf-1)) (VP-COOD (VP (VBZ binds) (ADVP (RB exclusively)) (PP (TO to) (NP (NP (DT the) (JJ underphosphorylated) (NN form)) (PP (IN of) (NP (NN Rb)))))) (CC and) (VP (VBZ fails) (S (VP (TO to) (VP (VB bind) (PP (TO to) (NP (NP (NN Rb) (NNS mutants)) (VP (VBN derived) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (NN retinoblastoma))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Co-immunoprecipitation) (NNS experiments)) (VP (VBD demonstrated) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP-COOD (NP (NN Elf-1)) (CC and) (NP (NN Rb))) (PP (IN in) (NP (VBG resting) (JJ normal) (JJ human) (NN T) (NNS cells))))))) (. .)))
(TOP (S (PP-TMP (IN After) (NP (NN T) (NN cell) (NN activation))) (, ,) (NP-SBJ (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN Rb)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NN Elf-1))) (, ,) (SBAR (WHNP-25 (WDT which)) (S (VP (VBZ is) (VP (VBN correlated) (ADVP-TMP (RB temporally)) (PP (IN with) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ Elf-1-mediated) (NN transcription)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP (NP (DT a) (JJ phosphorylation-defective) (NN form)) (PP (IN of) (NP (NN Rb)))))) (VP (VBD inhibited) (NP (JJ Elf-1-dependent) (NN transcription)) (PP-TMP (IN during) (NP (NN T) (NN cell) (NN activation)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NN Rb)) (VP (VBZ interacts) (ADVP (RB specifically)) (PP (IN with) (NP (DT a) (JJ lineage-restricted) (NN Ets) (NN transcription) (NN factor))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ regulated) (NN interaction)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ important)) (PP (IN for) (NP (NP (DT the) (NN coordination)) (PP (IN of) (NP (NP (JJ lineage-specific) (NN effector) (NNS functions)) (PP (JJ such) (IN as) (NP (NN lymphokine) (NN production))))) (PP (IN with) (NP (NP (NN cell) (NN cycle) (NN progression)) (PP (IN in) (NP (VBN activated) (NN T) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (JJ primary) (JJ human) (NNS T-lymphocytes))) (PP (IN through) (NP (NP-COOD (NP (NN CD2)) (CC plus) (NP (NN CD28))) (NN adhesion) (NNS molecules)))) (VP (VBZ induces) (NP (NP (JJ long-term) (JJ nuclear) (NN expression)) (PP (IN of) (NP (NN NF-kappa) (NN B))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (ADJP (RB highly) (VBN purified)) (JJ human) (NNS T-cells))) (PP (IN via) (NP (NP-COOD (NP (NN CD2)) (CC and) (NP (NN CD28))) (NN adhesion) (NNS molecules)))) (VP (VP-COOD (VP (VBZ induces)) (CC and) (VP (VBZ maintains))) (NP-32 (NN proliferation)) (PP-TMP-33 (IN for) (NP (QP (JJR more) (IN than) (CD 3)) (NNS weeks)))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ potent) (ADJP (NN interleukin) (CD 2) (-LRB- -LRB-) (NN IL-2) (-RRB- -RRB-) (JJ -dependent)) (NN activation)) (VP (VBZ does) (RB not) (VP (VB require) (NP-COOD (NP (NNS monocytes)) (CC or) (NP (JJ accessory) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ-100 (JJ Long-lasting) (NN IL-2) (NN receptivity)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ high-level) (NN expression)) (PP (IN of) (NP (DT the) (JJ inducible) (NP (NP (NN IL-2) (NN receptor) (NN alpha) (NN chain)) (PRN (-LRB- -LRB-) (NP (NN IL-2R) (NN alpha)) (-RRB- -RRB-))) (NN gene))) (SBAR (WHNP-34 (WDT that)) (S (VP (VBZ is) (VP (VBN regulated) (PP (IN at) (NP (ADJP-COOD (CC both) (ADJP (JJ transcriptional)) (CC and) (ADJP (JJ posttranscriptional))) (NNS levels))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Increase)) (PP (IN of) (NP (NN IL-2R) (NN alpha) (NN gene) (NN transcription)))) (VP (VBZ involves) (NP (NP (DT the) (VBN enhanced) (NN binding)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN NF-kappa) (NN B))) (PP (TO to) (NP (NP (PRP$ its) (NN consensus) (NN sequence)) (PP (IN in) (NP (NP (DT the) (JJ 5'-regulatory) (NN region)) (PP (IN of) (NP (DT the) (NN IL-2R) (NN alpha) (NN gene))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB dissect) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN for) (NP (NP (DT the) (ADJP (RB unusually) (JJ persistent)) (NN transcription)) (PP (IN of) (NP (DT the) (NN IL-2R) (NN alpha) (NN gene))))))))) (, ,) (NP-SBJ-37 (PRP we)) (VP (VBD analyzed) (NP (NP (JJ nuclear) (NN NF-kappa) (NN B) (VBG binding)) (PP (TO to) (NP (DT a) (VBN radiolabeled) (NN IL-2R) (NN alpha) (ADJP (NN kappa) (JJ B-specific)) (NN oligonucleotide) (NN probe))) (PP-TMP (IN during) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NP-COOD (NP (NN CD2)) (CC +) (NP (NN CD28))) (NN activation))))))) (. .)))
(TOP (S (NP-SBJ (VBG Resting) (NN T-cell) (JJ nuclear) (NNS extracts)) (VP (VBD contained) (NP (NN KBF1/p50) (NN homodimer))) (. .)))
(TOP (S (PP-TMP (IN After) (NP (NN stimulation))) (, ,) (NP-SBJ-38 (CD two) (JJ new) (ADJP (NN kappa) (JJ B-specific)) (NNS complexes)) (VP (VBD were) (VP (VBN identified) (PP (IN as) (NP-COOD (NP (NN NF-kappa) (NN B) (NN p50-p65) (NN heterodimer)) (CC and) (NP (JJ putative) (NP-COOD (NP (NN c-Rel) (NN homodimer)) (CC or) (NP (NN c-Rel-p65) (NN heterodimer)))))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (JJ inducible) (NNS complexes)) (VP (VBD persisted) (PP-TMP (IN for) (NP (QP (IN at) (JJS least) (CD 3)) (NNS weeks)))) (. .)))
(TOP (S (NP-SBJ (PRP$ Their) (JJ relative) (NNS levels)) (VP (VBD were) (ADJP-PRD (RB very) (JJ similar)) (PP-TMP (IN for) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN proliferation)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN parallel))) (, ,) (NP-SBJ (NP-COOD (NP (NN CD2)) (CC +) (NP (NN CD28))) (NN activation)) (VP (VBD triggered) (NP (DT a) (JJ significant) (JJ intracellular) (NN thiol) (NN decrease)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ-40 (NN oxygen) (NNS radicals)) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN signaling) (NN pathway)) (PP (IN of) (NP (NN adhesion) (NNS molecules)))))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (NP (JJ micromolar) (NNS amounts)) (PP (IN of) (NP (NP (NN pyrrolidine) (NN dithiocarbamate)) (, ,) (NP (NP (DT an) (ADJP (NN oxygen) (NN radical)) (NN scavenger)) (SBAR (WHNP-41 (WDT that)) (S (ADVP (RB efficiently)) (VP (VBD blocked) (NP (NP (DT the) (JJ nuclear) (NN appearance)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (NNS T-lymphocytes)))))))) (, ,)))) (ADVP (RB also)) (VP (VBD inhibited) (NP-COOD (NP (NN IL-2) (NN secretion)) (, ,) (NP (NN IL-2R) (NN alpha) (NN cell) (NN surface) (NN expression)) (, ,) (CC and) (NP (NN T-cell) (NN proliferation)))) (. .)))
(TOP (S (ADVP (RB Together)) (, ,) (NP-SBJ (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (JJ long-term) (NN activation)) (PP (IN of) (NP (JJ human) (JJ primary) (NNS T-lymphocytes))) (PP (IN via) (NP-COOD (NP (NN CD2)) (CC +) (NP (NN CD28)))))))))) (. .)))
(TOP (NP (NP (JJ Oxidoreductive) (NN regulation)) (PP (IN of) (NP (JJ nuclear) (NN factor) (NN kappa) (NN B))) (. .)))
(TOP (NP (NP (NN Involvement)) (PP (IN of) (NP (DT a) (JJ cellular) (NN reducing) (NN catalyst) (NN thioredoxin))) (. .)))
(TOP (S (NP-SBJ-14 (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT an) (JJ oxidoreductive) (JJ regulatory) (NN pathway)) (PP (IN for) (NP (NP (DT the) (NN DNA) (NN binding) (NN activity)) (PP (IN of) (NP (NP (DT a) (JJ pleiotropic) (JJ cellular) (NN transcription) (NN factor)) (, ,) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF) (NN kappa) (NN B)) (-RRB- -RRB-))) (, ,)))))) (VBZ has) (VBN been) (VBN investigated) (PP (IN by) (S (VP (VBG using) (NP (NP (NN NF) (NN kappa) (NN B)) (VP (VBN prepared) (PP (IN from) (NP (NP-COOD (NP (DT the) (NN nucleus)) (CC and) (NP (DT the) (NN cytosol))) (PP (IN of) (NP (DT the) (JJ primary) (JJ human) (NN T) (NNS lymphocytes)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (DT a) (JJ cellular) (NN reducing) (NN catalyst) (NP (NP (NN thioredoxin)) (PRN (-LRB- -LRB-) (NP (NN Trx)) (-RRB- -RRB-)))) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP-COOD (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (NN DNA) (NN binding)) (PP (IN of) (NP (NN NF) (NN kappa) (NN B))) (ADVP (FW in) (FW vitro))))) (CC and) (NP (NP (NN stimulation)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN from) (NP (DT the) (ADJP (NN NF) (NN kappa) (JJ B-dependent)) (NN gene) (NN expression)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (NP (NP (NN evidence)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ-15 (NP (NN redox) (NN regulation)) (PP (IN of) (NP (NN NF) (NN kappa) (NN B))) (PP (IN by) (NP (NN Trx)))) (VP (MD might) (VP (VB be) (VP (VBN exerted) (PP-TMP (IN at) (NP (NP (DT a) (NN step)) (PP-TMP (IN after) (NP (NP (NN dissociation)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory) (NN molecule) (NN I) (NN kappa) (NN B)) (, ,) (NP (NP (DT a) (JJ cytosolic-anchoring) (NN protein)) (PP (IN for) (NP (NN NF) (NN kappa) (NN B)))))))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN Trx))) (PP (IN in) (NP (JJ intact) (NNS cells))))))) (, ,) (NP-SBJ-16 (PRP we)) (VP (VBD performed) (NP (JJ transient) (NN assay)) (PP (IN with) (NP-COOD (NP (NP (DT a) (ADJP (NN chloramphenicol) (JJ acetyltransferase-expressing)) (NN plasmid)) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))) (JJ long) (JJ terminal) (NN repeat)))))) (CC and) (NP (NP (DT an) (NN effector) (NN plasmid)) (VP (VBG expressing) (NP (JJ human) (NN Trx))))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (DT The) (NN promoter) (NN activity)) (PP (IN from) (NP (NN HIV) (JJ long) (JJ terminal) (NN repeat)))) (VP (VBD was) (VP (ADVP (RB greatly)) (VBN augmented) (PP (IN by) (S-LGS (VP (VBG co-transfecting) (NP (NP (DT the) (NN Trx-expressing) (NN plasmid)) (, ,) (SBAR (WHNP-18 (WP$ whose) (NN effect)) (S (VP (VBD was) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (DT the) (ADJP (NN NF) (NN kappa) (NN B-binding)) (NNS sites))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP have) (VP (VBN suggested) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-20 (NP (NN cysteine) (NN residue) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (PP (IN of) (NP (NN NF) (NN kappa) (NN B)))) (VP (MD might) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN DNA-recognition)) (PP (IN by) (NP (NN NF) (NN kappa) (NN B)))))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN redox) (NN control) (NN mechanism)) (VP (VBN mediated) (PP (IN by) (NP-LGS (NN Trx))))) (VP (MD might) (VP (VB have) (NP (DT a) (JJ regulatory) (NN role)) (PP (IN in) (NP (DT the) (ADJP (NN NF) (NN kappa) (JJ B-mediated)) (NN gene) (NN expression)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (MD may) (ADVP (RB also)) (VP (VB provide) (NP (NP (DT a) (NN clue)) (PP (TO to) (NP (NP (NN understanding)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NN process)) (PP (IN of) (NP-COOD (NP (NN AIDS) (NN pathogenesis)) (CC and) (NP (PRP$ its) (JJ possible) (JJ biochemical) (NN intervention))))))))))) (. .)))
(TOP (NP (NP (NP (NN Expression) (NNS levels)) (PP (IN of) (NP (DT the) (NN thyrotropin) (NN receptor) (NN gene))) (PP (IN in) (NP (JJ autoimmune) (NN thyroid) (NN disease))) (: :)) (NP-COOD (NP (NP (NN coregulation)) (PP (IN with) (NP (NP (NNS parameters)) (PP (IN of) (NP (NN thyroid) (NN function)))))) (CC and) (NP (NP (JJ inverse) (NN relation)) (PP (TO to) (NP (JJ major) (NN histocompatibility) (NN complex) (NNS classes) (NP-COOD (NP (CD I)) (CC and) (NP (CD II)))))) (. .))))
(TOP (S (S (S (VP (VBG Using) (NP (DT a) (JJ human) (NP (NP (NN TSH) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TSH-R)) (-RRB- -RRB-))) (NN cDNA) (NN probe)))) (, ,) (NP-SBJ-20 (PRP we)) (VP (VBD investigated) (NP (NP (NN TSH-R) (NN transcript) (NNS levels)) (PP (IN in) (NP (CD 13) (JJ human) (NN thyroid) (NNS fragments)))) (PP (IN by) (NP (NN Northern) (NN blot) (NN analysis)))) (: ;)) (S (NP-SBJ-COOD-21 (NP (CD 7) (NP (NN Graves) (POS ')) (NN disease)) (, ,) (NP (CD 2) (NP (NN Hashimoto) (POS 's)) (NN disease)) (, ,) (NP (CD 3) (JJ endemic) (NN goiter)) (, ,) (CC and) (NP (CD 1) (JJ healthy) (NN thyroid) (NN gland))) (VP (VBD were) (VP (VBN studied))) (. .))))
(TOP (S (NP-SBJ (NN TSH-R) (NN expression) (NNS levels)) (VP-COOD (VP (VBD were) (ADJP-PRD (JJ variable))) (, ,) (CC but) (VP (VBD displayed) (NP (NP (DT a) (JJ close) (NN correlation)) (PP (TO to) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP-COOD (NP (NP (NN thyroid) (NN peroxidase)) (PRN (-LRB- -LRB-) (S-COOD (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.703)))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.05))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN thyroglobulin)) (PRN (-LRB- -LRB-) (S-COOD (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.817)))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (DT the) (JJ nuclear) (NN oncogene) (NN c-fos)) (PRN (-LRB- -LRB-) (S-COOD (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.935)))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.001))))) (-RRB- -RRB-))) (, ,) (CONJP (CC but) (RB not)) (NP (NN c-myc))))))))) (. .)))
(TOP (S (ADVP (RB Overall)) (, ,) (NP-SBJ (NN TSH-R) (NN transcript) (NNS levels)) (VP (VBD were) (ADJP-PRD-COOD (ADJP (JJ low)) (CC or) (ADJP (JJ absent))) (PP (IN in) (NP (NP (DT those) (NNS thyroids)) (SBAR (WHPP-23 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ major) (NN histocompatibility) (NN complex) (NN class) (NP-COOD (NP (CD I)) (CC or) (NP (CD II)))) (PRN (-LRB- -LRB-) (NP (NN MHC) (NP-COOD (NP (CD I)) (CC or) (NP (CD II)))) (-RRB- -RRB-))))) (VP (VBD was) (ADJP-PRD (JJ high))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG establishing) (NP (DT an) (JJ inverse) (NN relation)))) (PRN (-LRB- -LRB-) (NP-COOD (S (LST (NN MHC) (NN I)) (, ,) (S-COOD (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD -0.791)))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))))) (: ;) (S (LST (NN MHC) (CD II)) (, ,) (S-COOD (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (NN -0.784)))) (: ;) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01))))))) (-RRB- -RRB-))) (. .)))
(TOP (S (NP-SBJ (ADJP (FW In) (FW situ)) (NN hybridization)) (VP (VBD showed) (SBAR (IN that) (S (PP (RB apart) (IN from) (NP (NNS lymphocytes))) (, ,) (NP-SBJ (NP (NN thyroid) (NNS cells)) (NP (PRP themselves))) (VP (VBD were) (NP-PRD (NP (DT the) (NN source)) (PP (IN of) (NP (NN MHC) (CD II) (NNS transcripts)))))))) (. .)))
(TOP (S (NP-SBJ (NN gamma-Interferon) (NN expression)) (VP (VBD was) (ADJP-PRD (RB only) (JJ detectable)) (PP (IN in) (NP (CD 1) (NP (NN Hashimoto) (POS 's)) (NN goiter)))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (ADVP (JJ next) (PP (TO to) (NP (NN lymphocyte) (NN infiltration)))) (, ,) (NP-SBJ (NP (JJ active) (JJ regulatory) (NNS events)) (PP (IN in) (NP (DT the) (NN thyrocyte)))) (VP (VBP are) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ inverse) (NN relation)) (PP (IN between) (NP-COOD (NP (NP (JJ functional) (NNS parameters)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN TSH-R)) (, ,) (NP (NN thyroid) (NN peroxidase)) (, ,) (NP (NN thyroglobulin)) (, ,) (CC and) (NP (NN c-fos))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ immunological) (NNS markers)) (PRN (-LRB- -LRB-) (NP (NN MHC) (NP-COOD (NP (CD I)) (CC and) (NP (CD II)))) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (NP (NP (NN Synergism)) (PP (IN between) (NP (DT the) (ADJP-COOD (ADJP (NP (NN CD3) (NN antigen-))) (CC and) (ADJP (NN CD2) (JJ antigen-derived))) (NNS signals))) (. .)))
(TOP (NP-COOD (NP (NP (NN Exploration)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NN induction)) (PP (IN of) (NP (JJ DNA-binding) (NNS proteins)))))))) (CC and) (NP (NP (NN characterization)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory) (NN activity)) (PP (IN of) (NP (NN cyclosporine)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN demonstrated) (ADVP-TMP (RBR earlier)) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN crosslinkage)) (PP (IN of) (NP (DT the) (NN CD3/TCR) (NN complex))) (PP (IN with) (NP (DT the) (NN CD2) (NN antigen)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (JJ normal) (JJ human) (NN T) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN effect)) (PP (IN of) (NP (DT this) (NN synergism)))) (VP (VBD was) (ADJP-PRD (JJ perceptible)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN IL-2) (NN gene)))) (, ,) (NP (NP (DT a) (NN process)) (ADJP (JJ critical) (PP (IN for) (NP (NN T) (NN cell) (NN growth)))))))))) (. .)))
(TOP (S (S (VP (TO To) (ADVP (RB further)) (VP (VB understand) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ molecular)) (CC and) (ADJP (JJ nuclear))) (NN basis)) (PP (IN for) (NP (DT this) (NN synergism))))))) (, ,) (NP-SBJ-21 (PRP we)) (VP (VBP have) (VP (VBN explored) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ DNA-binding) (NNS proteins))) (PP (IN in) (NP (NP (ADJP (RB highly) (VBN purified)) (JJ normal) (JJ human) (NN T) (NNS cells)) (VP (VBN signaled) (PP (IN via) (NP (DT the) (NP-COOD (NP (NN CD3)) (CC and/or) (NP (NN CD2))) (NNS proteins))))))))) (. .)))
(TOP (S (NP-SBJ-23 (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NN transmembrane) (NN signaling)) (PP (IN of) (NP (NN T) (NNS cells))) (PP (IN with) (NP-COOD (NP (NN ionomycin)) (, ,) (CC and/or) (NP (NN sn-1,2) (NN dioctanoyl) (NN glycerol)) (, ,)))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN determined))) (. .)))
(TOP (S (NP-SBJ-24 (NP (DT The) (NN emergence)) (PP (IN of) (NP (JJ nuclear) (NN binding) (NNS proteins)))) (VP (VBD was) (VP (VBN investigated) (S (VP (VBG using) (NP (ADJP (NN interleukin-2) (NN sequence) (JJ specific)) (NN oligonucleotide) (NNS probes)) (PP (IN in) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS studies)) (VP (VBP demonstrate) (PP-TMP (IN for) (NP (DT the) (JJ first) (NN time))) (SBAR (IN that) (S (NP-SBJ-COOD-25 (NP (ADJP (NN CD3) (JJ antigen-derived)) (NNS signals)) (CC and) (NP (ADJP (NN CD2) (JJ antigen-derived)) (NNS signals))) (VP (VBP are) (ADJP-PRD (JJ synergistic)) (PP (IN in) (S (VP (VBG inducing) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (SBAR (WHNP-26 (WDT that)) (S (VP (VBP bind) (PP (TO to) (NP (NP (DT the) (NP-COOD (NP (NN NF-AT1)) (, ,) (NP (NN AP-1)) (, ,) (CC and) (NP (NN NF-kB))) (NNS sites)) (ADJP (JJ located) (PP (IN in) (NP (NP (DT the) (NN promoter/enhancer) (NN region)) (PP (IN of) (NP (DT the) (NN IL-2) (NN gene))))))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-27 (NP (NN cyclosporine)) (, ,) (PP (IN at) (NP (NP (NNS concentrations)) (VP (ADVP (RB readily)) (VBN accomplished) (PP (IN in) (NP (JJ clinical) (NN practice)))))) (, ,)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (DT these) (JJ DNA-binding) (NNS proteins))) (PP-COOD (PP (IN in) (NP (NP (JJ normal) (JJ human) (NN T) (NNS cells)) (VP (VBN signaled) (PP (IN via) (NP (NP (NN cell) (NN surface) (NNS proteins)) (VP (VBN implicated) (PP (IN in) (NP (JJ antigen-dependent) (NN T) (NN cell) (NN activation))))))))) (CC and) (PP (IN in) (NP (NP (NN T) (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP-LGS-COOD (NP (NP (NN mobilization)) (PP (IN of) (NP (JJ cellular) (NN calcium)))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NN protein) (NN kinase) (NN C)))))))))))))))) (. .)))
(TOP (NP (NP (ADJP (NN Calcium) (JJ dependent)) (NN activation)) (PP (IN of) (NP (DT the) (NN NF-AT) (NN transcription) (NN factor))) (PP (IN by) (NP (NN p59fyn))) (. .)))
(TOP (S (NP-SBJ-14 (NP (DT A) (NN reporter) (NN gene)) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT a) (NN T-cell) (NN antigen) (NN receptor) (NN element)))))) (VP (VBD was) (VP (VBN activated) (PP (IN in) (NP (NN Jurkat) (NNS cells))) (PP-COOD (PP (IN by) (NP-LGS (NN antigen) (NN receptor) (NN triggering))) (CC or) (PP (IN by) (NP-LGS (NP (DT a) (NN combination)) (PP (IN of) (NP-COOD (NP (NP (NN phorbol) (NN myristate) (NN acetate)) (, ,) (SBAR (WHNP-15 (WDT which)) (S (VP (VBZ activates) (NP (NN protein) (NN kinase) (NN C))))) (, ,)) (CC and) (NP (DT a) (NN calcium) (NN ionophore))))))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (DT these) (NNS signals)) (VP (VBD were) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN reporter) (NN gene))))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-19 (WRB When)) (S (VP (VBN co-transfected) (PP (IN with) (NP (NP (DT a) (NN construct)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG overexpressing) (NP (DT the) (NN tyrosine) (NN kinase) (NN p59fyn))))))))))) (, ,) (NP-SBJ-17 (DT the) (NN reporter) (NN gene)) (VP (VBD was) (VP (VBN activated) (PP (IN by) (NP-LGS (NP (NN PMA)) (ADVP (RB alone)))))) (. .)))
(TOP (S (ADVP (RB Thus)) (NP-SBJ (NN p59fyn)) (VP (MD could) (VP (VB replace) (NP-COOD (NP (DT the) (NN calcium) (NN ionophore)) (CONJP (CC but) (RB not)) (NP (NP (NN activation)) (PP (IN of) (NP (NN protein) (NN kinase) (NN C))))))) (. .)))
(TOP (S (NP-SBJ-20 (NP (DT The) (NN activation)) (PP (IN by) (NP-COOD (NP (NN p59fyn)) (CC plus) (NP (NN PMA))))) (VP (VBD was) (VP (VBN blocked) (PP-COOD (PP (IN by) (NP-LGS (NN EGTA))) (CC and) (PP (IN by) (NP-LGS (DT the) (JJ immunosuppressant) (NN drug) (NN cyclosporin) (NN A)))))) (. .)))
(TOP (NP (NP (JJ Cell-specific) (JJ bifunctional) (NN role)) (PP (IN of) (NP (NN Jun) (NN oncogene) (NN family) (NNS members))) (PP (IN on) (NP (ADJP (NN glucocorticoid) (JJ receptor-dependent)) (NN transcription))) (. .)))
(TOP (S (NP-SBJ-31 (NP (NN Interaction)) (PP (IN between) (NP (ADJP-COOD (ADJP (NP (NN protein) (NN kinase) (NN C) (-LRB- -LRB-) (NN PKC) (-RRB- -RRB-) (: -))) (CC and) (ADJP (NN glucocorticoid) (NN receptor) (-LRB- -LRB-) (NN GR) (-RRB- -RRB-) (JJ -mediated))) (NN signaling)))) (VP (VBZ is) (VP (VBN suggested) (PP (IN by) (NP-LGS (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN PKC) (NN activating) (NN phorbol) (NN ester) (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))))) (S-32 (VP (TO to) (VP (VB inhibit) (NP (NP (JJ GR-dependent) (NN transcription)) (PP (IN of) (NP (DT the) (NP (NP (NN mouse) (JJ mammary) (NN tumor) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN MMTV)) (-RRB- -RRB-))) (NP (NP (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (DT this) (NN interference)) (VP (VBZ is) (ADJP-PRD (NN cell) (JJ specific)) (, ,) (SBAR (IN as) (S (NP-SBJ (NN TPA)) (VP-COOD (VP (VBD augmented) (NP (NP (JJ dexamethasone-induced) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NN MMTV) (NN LTR)))) (PP (IN in) (NP (JJ several) (NN T) (NN cell) (NNS lines)))) (CC but) (VP (VBD was) (ADJP-PRD (JJ inhibitory)) (PP (IN in) (NP (NN NIH-3T3) (NNS fibroblasts))))))))))) (. .)))
(TOP (S (NP-SBJ-33 (NN TPA-GR) (NN synergism)) (VP (VBD was) (VP (VBN determined) (S (VP (TO to) (VP (VB have) (VP (VBN occurred) (PP (IN at) (NP (DT the) (NP (NP (JJ GR-responsive) (NN element)) (PRN (-LRB- -LRB-) (NP (NN GRE)) (-RRB- -RRB-))) (NN level))))))) (PP (IN by) (NP-LGS (NP (JJ functional) (NN analysis)) (PP (IN of) (NP (NP-COOD (NP (NN deletion) (NNS mutants)) (CC or) (NP (JJ synthetic) (NN GRE) (NNS oligonucleotides))) (VP (VBG driving) (NP (NN chloramphenicol) (NN acetyl-transferase) (NN expression))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN Synergism)) (VP (VBD required) (NP (DT an) (JJ intact) (NN GR) (JJ DNA-binding) (NN domain)))) (, ,) (IN whereas) (S (NP-SBJ (ADJP-COOD (ADJP (NN amino-)) (CC or) (ADJP (JJ carboxyl-terminal))) (NNS domains)) (VP (VBD were) (ADJP-PRD (JJ dispensable)))) (. .)))
(TOP (S (NP-SBJ-34 (DT The) (NN effect)) (VP (VBD was) (VP (VBN abrogated) (PP (IN by) (NP-LGS (DT the) (NN PKC) (NN inhibitor) (NN staurosporine))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN PKC)))))))) (. .)))
(TOP (S (NP-SBJ-COOD-36 (NP (NP (VBN Increased) (NP-COOD (NP (NN c-jun)) (, ,) (NP (NN jun-B)) (, ,) (CC and) (NP (NN jun-D))) (NN expression)) (PP (IN above) (NP (JJ basal) (NNS levels)))) (CC and) (NP (NP (VBN increased) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (NN AP-1/TPA) (JJ responsive) (NNS elements)) (VP (VBN fused) (PP (TO to) (NP (NN chloramphenicol) (NN acetyl-transferase) (NNS vectors)))))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (NN T) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (NN TPA)) (UCP-COOD (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN dexamethasone))))))))))))) (. .)))
(TOP (S (NP-SBJ-37 (NP (DT The) (NN ability)) (PP (IN of) (NP (NN Jun) (NNS proteins))) (S-38 (VP (TO to) (VP (VB cooperate) (PP (IN with) (NP (NN GR))) (PP (IN in) (NP (NN T) (NNS cells))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN investigated) (PP-TMP (IN after) (NP (NP (NN transfection)) (PP (IN of) (NP (NP-COOD (NP (NN c-jun)) (, ,) (NP (NN jun-B)) (, ,) (CC or) (NP (NN jun-D))) (NN expression) (NNS vectors))) (, ,) (SBAR (WHNP-39 (WDT which)) (S (VP (VBD augmented) (NP (NP (JJ GR-dependent) (NN transcription)) (PP (IN from) (NP-COOD (CC either) (NP (NN MMTV) (NN LTR)) (CC or) (NP (NN GRE))))))))))))) (. .)))
(TOP (S (ADVP (RB Conversely)) (, ,) (NP-SBJ (NP-COOD (NP (NN c-jun)) (CC and) (NP (NN jun-B))) (NN transfection)) (VP (VBD blunted) (NP (NP (JJ GR-dependent) (NN transcription)) (PP (IN in) (NP (NN HeLa) (NNS cells))))) (. .)))
(TOP (S (S (NP-SBJ (NP (DT The) (NN presence)) (PP (IN of) (NP (NN c-fos)))) (VP-COOD (VP (VBD had) (NP (DT a) (JJ negative) (NN influence)) (PP (IN on) (NP (NN GR) (NN function)))) (CC and) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (JJ cell-specific) (ADJP-COOD (ADJP (JJ synergistic)) (CC or) (ADJP (JJ antagonistic))) (NN activity)) (PP (IN of) (NP (NN Jun))))) (PP (IN with) (NN respect) (TO to) (NP (NN GR))))) (: ;)) (S (NP-SBJ-COOD-40 (NP (NP (JJ high) (JJ basal) (NN expression)) (PP (IN of) (NP (NN c-fos)))) (CONJP (RB as) (RB well) (IN as)) (NP-COOD (NP (NN AP-1) (NN DNA) (NN binding)) (CC and) (NP (JJ transcriptional) (NN activity)))) (VP (VBD were) (VP (VBN observed) (PP-COOD (PP (IN in) (NP (NN HeLa) (NNS cells))) (, ,) (CC but) (PP (RB not) (IN in) (NP (NN T) (NNS cells)))))) (. .))))
(TOP (S (ADVP (RB Furthermore)) (NP-SBJ (NP (NN overexpression)) (PP (IN of) (NP (JJ exogenous) (NN c-fos)))) (VP (VBZ has) (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (JJ GR-dependent) (NN transcription)) (PP (IN from) (NP (NN GRE))) (PP (IN in) (NP (NN T) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ-41 (NN Jun)) (VP (VBZ plays) (NP (DT a) (JJ bifunctional) (NN role)) (PP (IN on) (NP (NP (JJ GR-dependent) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NN GRE))))) (, ,) (S (VP (VBG selecting) (NP (ADJP-COOD (CC either) (ADJP (JJ synergistic)) (CC or) (ADJP (JJ antagonistic))) (NN activity)) (PP (VBG depending) (PP (IN on) (NP (DT the) (JJ cell-specific) (NN microenvironment)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN regard))) (, ,) (NP-SBJ-42 (NP (JJ intracellular) (NNS levels)) (PP (IN of) (NP (NN c-fos)))) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ influential)))))) (. .)))
(TOP (NP (NP (DT A) (JJ concatenated) (NN form)) (PP (IN of) (NP (JJ Epstein-Barr) (JJ viral) (NN DNA))) (PP (IN in) (NP (NP (JJ lymphoblastoid) (NN cell) (NNS lines)) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (NN transfection)) (PP (IN with) (NP (NN BZLF1)))))))) (. .)))
(TOP (S (NP-SBJ-15 (NP (DT The) (JJ replicative) (NN form)) (PP (IN of) (NP (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (NN DNA)))) (VP (VBD was) (VP (VBN studied) (S (VP (VBG using) (NP (NP (NP (CD two) (JJ lymphoblastoid) (NN cell) (NNS lines)) (, ,) (NP-COOD (NP (NN X50-7)) (CC and) (NP (NN 6F11))) (, ,)) (SBAR (WHNP-16 (WDT which)) (S (VP (VBP are) (VP (ADVP (RB latently)) (VBN infected) (PP (IN by) (NP-LGS (JJ Epstein-Barr) (NN virus)))))))))))) (. .)))
(TOP (S (NP-SBJ-18 (NP (DT The) (JJ lytic) (NN cycle)) (PP (IN of) (NP (NN EBV) (NN infection)))) (VP (VBD was) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (NN transfection)) (PP (IN of) (NP (DT the) (NNS cells))) (PP (IN with) (NP (NP (DT the) (NN BRLF1/BZLF1) (NN coding) (NN region)) (PP (IN of) (NP (DT the) (NN P3HR-1) (JJ defective) (NN genome))))))))) (. .)))
(TOP (S (NP-SBJ-19 (PRP We)) (VP (VBD combined) (NP (CD two) (NNS techniques)) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (JJ productive) (JJ replicative) (NN form)) (PP (IN of) (NP (JJ Epstein-Barr) (JJ viral) (NN DNA))) (PP (IN in) (NP (DT the) (ADJP (JJ lytic) (JJ cycle-induced)) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Restriction) (NN enzyme) (NN analysis)) (VP (VBN followed) (PP (IN by) (NP-LGS (NN Southern) (NN blot) (NN hybridization))))) (VP (VBD identified) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (VBN fused) (NN fragment)) (VP (VBG encompassing) (NP (NP (DT both) (NNS ends)) (PP (IN of) (NP (NN EBV) (NN DNA))))))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBZ indicates) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP-COOD (CC either) (NP (JJ episomal) (NN DNA)) (CC or) (NP (JJ concatameric) (JJ linear) (NN DNA)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Southern) (NN blot) (NN analysis)) (PP (IN of) (NP (ADJP (FW in) (FW situ)) (VBG lysing) (NNS gels)))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ-64 (NP (DT the) (JJ cellular) (NN content)) (PP (IN of) (NP (JJ linear) (NN EBV) (NN DNA)))) (VP (VBD was) (VP (ADVP (RB also)) (VBN increased) (ADVP (RB significantly)) (PP-TMP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (DT the) (JJ viral) (JJ lytic) (NN cycle))))) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (DT the) (NN amount)) (PP (IN of) (NP (JJ circular) (NN DNA)))) (VP (VBD remained) (ADJP-PRD (RB approximately) (JJ constant)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP propose) (PP (IN from) (NP (DT these) (NNS results))) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN source)) (PP (IN of) (NP (NP (DT the) (VBN fused) (NN fragment)) (VP (VBG encompassing) (NP (NP (DT both) (NNS ends)) (PP (IN of) (NP (NN EBV) (NN DNA)))))))) (VP (VBZ is) (NP-PRD (DT a) (VBN concatenated) (JJ linear) (NN EBV) (NN DNA) (NN molecule))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (PDT such) (DT a) (VBN concatenated) (NN molecule)) (ADVP (RBS most) (RB likely)) (VP (VBZ represents) (NP (NP (DT a) (JJ replicative) (NN form)) (PP (IN of) (NP (NP (NN EBV) (NN DNA)) (PP (IN in) (NP (ADJP (RB productively) (JJ infected)) (NNS cells))))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (DT the) (NN beta-globin) (NN locus))) (. .)))
(TOP (S (NP-SBJ (NP (NN Transcription)) (PP (IN of) (NP (DT the) (JJ human) (NN beta-globin) (NN gene) (NN cluster)))) (VP (VBZ depends) (PP (IN upon) (NP (NP (JJ upstream) (JJ regulatory) (NNS sequences)) (, ,) (SBAR (WHNP-24 (WDT which)) (S (VP (VBP are) (VP (ADVP (RB collectively)) (VBN termed) (S (NP-PRD (DT the) (NN locus) (NN control) (NN region)))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Recent) (NNS studies)) (VP (VBP have) (VP (VBN provided) (NP (NP (JJ new) (NNS insights)) (PP (IN into) (SBAR (WHADVP-25 (WRB how)) (S (NP-SBJ-26 (NP (DT the) (JJ individual) (NNS genes)) (PP (IN of) (NP (DT the) (NN cluster)))) (VP (VBP are) (VP (VBN regulated) (PP (IN through) (NP (NN development))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN crux)) (PP (IN of) (NP (JJ transcriptional) (NN activation)))) (VP (VBZ is) (SBAR-PRD (WHADVP-27 (WRB how)) (S (NP-SBJ (DT the) (NN locus) (NN control) (NN region)) (VP (VBZ communicates) (PP (IN with) (NP (DT the) (JJ gene-proximal) (JJ regulatory) (NNS elements))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Ectopic) (NN expression)) (PP (IN of) (NP (DT a) (JJ conditional) (NN GATA-2/estrogen) (NN receptor) (NN chimera)))) (VP (VBZ arrests) (NP (JJ erythroid) (NN differentiation)) (PP (IN in) (NP (DT a) (JJ hormone-dependent) (NN manner)))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN GATA) (NNS factors)) (VP (VBP are) (NP-PRD (NP (DT a) (NN family)) (PP (IN of) (NP (NP (JJ transcriptional) (JJ regulatory) (NNS proteins)) (PP (IN in) (NP (NP (NNS eukaryotes)) (SBAR (WHNP-13 (WDT that)) (S (VP (VBP share) (NP (NP (JJ extensive) (NN homology)) (PP (IN in) (NP (PRP$ their) (JJ DNA-binding) (NNS domains))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD One) (JJ enigmatic) (NN aspect)) (PP (IN of) (NP (NN GATA) (NN factor) (NN expression)))) (VP (VBZ is) (SBAR-PRD (IN that) (S (NP-SBJ-14 (NP (JJ several) (NN GATA) (NNS proteins)) (, ,) (SBAR (WHNP-15 (WDT which)) (S (ADVP (RB ostensibly)) (VP (VBP share) (NP (DT the) (JJ same) (JJ DNA-binding) (NN site) (NN specificity))))) (, ,)) (VP (VBP are) (VP (VBN coexpressed) (PP (IN in) (NP (JJ erythroid) (NNS cells)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (JJ individual) (NN GATA) (NNS factors))) (PP (IN in) (NP (NN erythropoiesis))))))) (, ,) (NP-SBJ-16 (NP (JJ conditional) (NNS alleles)) (PP (IN of) (NP-COOD (NP (NN GATA-1)) (, ,) (NP (NN GATA-2)) (, ,) (CC and) (NP (NN GATA-3))))) (VP (VBD were) (VP (VBN prepared) (PP (IN by) (S (VP (VBG fusing) (NP (NP (DT each)) (PP (IN of) (NP (DT the) (NNS factors)))) (PP (TO to) (NP (NP (DT the) (JJ hormone-binding) (NN domain)) (PP (IN of) (NP (DT the) (JJ human) (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (S (NP-SBJ-18 (DT These) (NN GATA/ER) (JJ chimeric) (NNS factors)) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP-PRD (JJ hormone-inducible) (JJ trans-activating) (NNS proteins))))) (PP (IN in) (NP (JJ transient) (NN transfection) (NNS assays))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-19 (WRB When)) (S (ADVP (RB stably)) (VP (VBN introduced) (PP (IN into) (NP-COOD (NP (JJ primary) (NNS erythroblasts)) (CC or) (NP (ADJP (RB conditionally) (VBN transformed)) (JJ erythroid) (NNS progenitors) (NNS cells))))))) (, ,) (NP-SBJ-20 (JJ exogenous) (NN GATA-2/ER)) (VP (VP-COOD (VP (VBD promoted) (NP (NN proliferation))) (CC and) (VP (VBD inhibited) (NP (JJ terminal) (NN differentiation)))) (PP (IN in) (NP (DT an) (JJ estrogen-dependent) (NN manner)))) (. .)))
(TOP (S (NP-SBJ (DT These) (JJ phenotypic) (NNS effects)) (VP (VBP are) (ADVP (RB specifically)) (ADJP-PRD (JJ attributable) (PP (TO to) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (ADJP (RB ectopically) (VBN expressed)) (NN GATA-2/ER)))))) (SBAR-COOD (SBAR (IN because) (S (NP-SBJ-22 (NP (NNS erythroblasts)) (VP (VBG expressing) (NP (JJ exogenous) (NN GATA-2)))) (VP (VBP are) (VP (ADVP (RB constitutively)) (VBN arrested) (PP (IN in) (NP (NN differentiation))))))) (CC and) (SBAR (IN because) (S (NP-SBJ (NP (JJ erythroid) (NNS progenitors)) (VP (VBG expressing) (NP-COOD (CC either) (NP (NN Gal/ER)) (CC or) (NP (NN GATA-3/ER))))) (VP (VBP do) (RB not) (VP (VB display) (NP (DT a) (JJ hormone-responsive) (NN block)) (PP (IN in) (NP (NN differentiation))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-23 (DT the) (NN GATA-2) (NN transcription) (NN factor)) (VP (VBZ appears) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (JJ self-renewal) (NN capacity)) (PP (IN of) (NP (JJ early) (JJ erythroid) (NN progenitor) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Lipopolysaccharide)) (VP (VBZ induces) (NP (NP-COOD (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN MAD3)))) (CC and) (NP (NP (NN activation)) (PP (IN of) (NP (NP-COOD (NP (NN c-Rel)) (CC and) (NP (JJ related) (NN NF-kappa) (NN B))) (NNS proteins))))) (PP (IN in) (NP (JJ human) (JJ monocytic) (NN THP-1) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ-19 (NP (JJ Many) (NNS effects)) (PP (IN of) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-)))) (PP (IN on) (NP (NN gene) (NN expression))) (, ,) (PP (VBG including) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-)))))) (, ,) (PP (IN in) (NP (JJ monocytic) (NNS cells)))) (VP (VBP are) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (NN activation)) (PP (IN of) (NP (NN kappa) (NN B) (JJ DNA-binding) (NNS proteins))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-COOD (NP (NP (DT the) (JJ specific) (NNS members)) (PP (IN of) (NP (NP (DT the) (NN NF-kappa) (NN B/Rel) (NN transcription) (NN factor) (NN family)) (VP (VBN involved) (PP (IN in) (NP (DT the) (NN LPS) (NN response))))))) (, ,) (CC and) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP-20 (IN through) (WHNP (WDT which))) (S (NP-SBJ-21 (JJ LPS-generated) (NNS signals)) (VP (VBP are) (VP (VBN transduced))))))) (VP (VBP remain) (ADJP-PRD (JJ unclear))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN LPS)) (VP (VBZ induces) (NP (NP (JJ nuclear) (NN expression)) (PP (IN of) (NP-COOD (NP (NN c-Rel/p50) (NNS heterodimers)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (NN p50/p65)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (NN kappa) (NN B) (JJ DNA-binding) (NNS complexes))))) (PP (IN in) (NP (JJ human) (JJ monocytic) (NN THP-1) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Nuclear) (NN localization)) (PP (IN of) (NP (DT these) (NNS proteins)))) (VP-COOD (VP (VBD occurred) (PP (RB concomitantly) (IN with) (NP (NP (DT a) (JJ rapid) (NN decrease)) (PP (IN in) (NP (PRP$ their) (JJ cytosolic) (NNS levels)))))) (CC and) (VP (VBD was) (ADJP-PRD (JJ independent) (PP (IN of) (NP (ADJP (NN phorbol) (JJ ester-sensitive)) (NN protein) (NN kinase) (NN C)))))) (. .)))
(TOP (S (PP-TMP (IN Within) (NP (NP (CD 24) (NN h)) (PP-TMP (VBG following) (NP (NN LPS) (NN stimulation))))) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (DT a) (JJ striking) (NN increase)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP-COOD (NP (NN c-Rel)) (, ,) (NP (NN p105)) (, ,) (CC and) (NP (NN p50))) (PP (IN in) (NP (DT the) (NN cytosol)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (VBN increased) (NNS levels)) (PP (IN of) (NP (DT these) (NNS proteins)))) (VP (VBD correlated) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (DT the) (NNS amounts)) (PP (IN of) (NP (PRP$ their) (NNS mRNAs))))) (PP-TMP (IN during) (NP (NP (NN LPS) (NN activation)) (PP (IN of) (NP (NN THP-1) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN LPS) (NN activation)) (PP (IN of) (NP (NN THP-1) (NNS cells)))) (VP (VBD resulted) (PP (IN in) (NP-COOD (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (NN MAD3)) (PRN (-LRB- -LRB-) (NP (DT an) (ADJP (NN I) (NN kappa) (JJ B-like)) (NN protein)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT a) (JJ rapid) (NN increase)) (PP (IN in) (NP (NN MAD3) (NN mRNA)))) (, ,) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN MAD3) (NN protein))) (PP-TMP (IN by) (NP (CD 2) (NN h))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (NN LPS) (NN activation)) (PP (IN of) (NP (JJ human) (JJ monocytic) (NNS cells)))) (VP-COOD (VP (VBZ results) (PP (IN in) (NP (NP (JJ nuclear) (NN expression)) (PP (IN of) (NP-COOD (NP (NN c-Rel/p50)) (CC and) (NP (NP (NN p50/p65)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-)))))))) (CC and) (VP (VBZ induces) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN MAD3)))))) (. .)))
(TOP (NP (NP (NN Induction)) (PP (IN of) (NP (NN CD8) (NP-COOD (NP (NN antigen)) (CC and) (NP (NN suppressor))) (NN activity))) (PP (IN by) (NP (NNS glucocorticoids))) (PP (IN in) (NP (DT a) (NN CEM) (JJ human) (JJ leukemic) (NN cell) (NN clone))) (. .)))
(TOP (S (NP-SBJ-25 (NP (DT The) (NN relationship)) (PP (IN between) (NP-COOD (NP (NN glucocorticoid) (NN effect)) (CC and) (NP (NP (NN regulation)) (PP (IN of) (NP (NN cell) (NN surface) (NNS antigens))))))) (VP (VBD was) (VP (VBN investigated) (PP (IN in) (NP (NP (NP (CD two) (NNS models)) (PP (IN of) (NP (JJ leukemic) (NN cell) (NNS lines)))) (, ,) (NP-COOD (NP (NP (NN CEM) (NN C7)) (VP (VBN denoted)) (-LRB- -LRB-) (ADJP-COOD (ADJP (JJ r+)) (, ,) (ADJP (JJ ly+))) (-RRB- -RRB-)) (CC and) (NP (NP (NN CEM) (NN C1)) (-LRB- -LRB-) (ADJP-COOD (ADJP (JJ r+)) (, ,) (ADJP (JJ ly-))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ-27 (NP (DT The) (NN reactivity)) (PP (IN of) (NP (NP (JJ murine) (JJ monoclonal) (NNS antibodies)) (, ,) (NP-COOD (NP (NN anti-CD4-FITC)) (, ,) (NP (NN anti-CD8-FITC)) (, ,) (NP (NN anti-CD2-FITC)) (CC and) (NP (NN anti-calla-FITC))) (, ,)))) (VP (VBD were) (VP (VBN analyzed) (S (VP (VBG using) (NP (NN flow) (NN cytometry)))))) (. .)))
(TOP (S (NP-SBJ-28 (DT The) (NN suppressor) (NN function)) (VP (VBD was) (VP (VBN determined) (S (VP (VBG using) (NP (NP (NN -LCB-3H-RCB-thymidine) (NN incorporation)) (PP (IN into) (NP (JJ phytohemagglutinin-activated) (JJ peripheral) (NN blood) (NNS lymphocytes)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Dexamethasone) (NN treatment)) (PP (IN of) (NP (DT a) (JJ human) (JJ leukemic) (NN cell) (NN clone) (NN CEM) (NN C7)))) (VP (VBD caused) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NP (NNS cells)) (VP (VBG expressing) (NP (NP (DT the) (NN surface) (NN antigen) (NN CD8)) (, ,) (SBAR (WHNP-29 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ present) (PP (IN on) (NP (UCP-COOD (NP (NN suppressor)) (CC and) (ADJP (JJ cytotoxic))) (NNS T-lymphocytes))))))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN comparison))) (, ,) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT no) (NN modification)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN CD4) (NN antigen)) (, ,) (SBAR (WHNP-30 (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (PP (IN at) (NP (JJ high) (NNS levels))) (PP (IN in) (NP (DT these) (NNS cells))))))))))))) (. .)))
(TOP (S (PP-TMP (IN After) (NP (NP (CD two) (NNS days)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (ADJP (QP (CD 5) (NN x) (SYM 10-LRB--8-RRB-)) (NN M)) (NN dexamethasone))))))) (, ,) (NP-SBJ (NN CEM) (NN C7) (NNS cells)) (VP (VBD showed) (NP (NP (DT a) (JJ two-fold) (NN increase)) (PP (IN in) (NP (NN suppressor) (NN activity))) (PP (VBN compared) (PP (TO to) (NP (JJ untreated) (NNS cells)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT no) (NN regulation)) (PP (IN by) (NP (NP (NNS glucocorticoids)) (PP (IN of) (NP (NP (CC either) (DT the) (NP-COOD (NP (NN CD8)) (CC or) (NP (NN CD4))) (NNS antigens)) (PP (IN in) (NP (DT the) (JJ leukemic) (NN clone) (NN CEM) (NN C1))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-32 (NP (DT no) (NN modification)) (PP (IN of) (NP (NP (DT the) (NN suppressor) (NN function)) (PP (IN in) (NP (NN CEM) (NN C1) (NNS cells))))) (PP (IN by) (NP (NN dexamethasone)))) (VP (VBD was) (VP (VBN observed))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT the) (JJ human) (JJ leukemic) (NNS cells)) (VP (VBN studied) (ADVP (RB here))))) (, ,) (NP-SBJ (DT the) (NN ability) (S (VP (TO to) (VP (VB induce) (NP (NN CD8) (NN antigen) (NN expression)) (PP (IN in) (NP (DT a) (JJ CD4+) (NNS cells))))))) (VP (VBZ correlates) (PP (IN with) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB induce) (NP (NN cell) (NN lysis)) (PP (IN in) (NP (DT a) (NN glucocorticoid) (NN receptor) (JJ positive) (NN cell) (NN population))))))))) (. .)))
(TOP (NP (NP (JJ Molecular) (NN basis)) (PP (IN of) (NP (NP (DT a) (JJ multiple) (NN lymphokine) (NN deficiency)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ severe) (JJ combined) (NN immunodeficiency))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN reported) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN T) (NNS lymphocytes)) (PP (IN of) (NP (NP (DT a) (NN child)) (PP (IN with) (NP (JJ severe) (JJ combined) (NN immunodeficiency)))))) (VP (VBP are) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NP (JJ several) (NN lymphokine) (NNS genes)) (SBAR (WHNP-27 (WDT that)) (S (VP (VBP include) (NP (NP-COOD (NP (NN IL2)) (, ,) (NP (NN IL3)) (, ,) (NP (NN IL4)) (, ,) (CC and) (NP (NN IL5))) (, ,) (SBAR (WHNP-28 (WDT which)) (S (VP (VBP encode) (NP (NP (NNS interleukins) (NP-COOD (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (NP (CD 4)) (, ,) (CC and) (NP (CD 5)))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN IL-2)) (, ,) (NP (CD -3)) (, ,) (NP (CD -4)) (, ,) (CC and) (NP (CD -5))) (-RRB- -RRB-))))))))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (NP (DT the) (NN defect)) (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN T) (NNS lymphocytes)))) (VP (VBD involved) (NP (NP (DT a) (JJ trans-acting) (NN factor)) (ADJP (JJ common) (PP (TO to) (NP (DT the) (VBN affected) (NN lymphokine) (NNS genes))))))))))) (, ,) (NP-SBJ-29 (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (JJ nuclear) (NNS factors)) (PP (IN from) (NP (NP (DT the) (NN patient) (POS 's)) (NN T) (NNS lymphocytes))))) (S-30 (VP (TO to) (VP (VB bind) (NP (NP (NN response) (NNS elements)) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (JJ regulatory) (NN region)) (PP (IN of) (NP (NN IL2)))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ Nuclear) (NN factor) (NN NF-kB)) (, ,) (NP (NP (NN activation) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN AP-1)) (-RRB- -RRB-))) (, ,) (NP (NN OCT-1)) (, ,) (CC and) (NP (NN NF-IL-2B) (NN binding) (NN activity))) (VP (VBD were) (ADJP-PRD (JJ normal))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NP (DT the) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-)))) (PP-COOD (PP (TO to) (NP (NP (PRP$ its) (NN response) (NN element)) (PP (IN in) (NP (DT the) (NN IL2) (NN enhancer))))) (CC and) (PP (TO to) (NP (NP (DT an) (JJ NF-AT-like) (NN response) (NN element)) (ADJP (JJ present) (PP (IN in) (NP (DT the) (NN IL4) (NN enhancer)))))))) (VP (VBD was) (ADJP-PRD (JJ abnormal))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB ascertain) (SBAR (IN whether) (S (NP-SBJ (DT the) (JJ abnormal) (NN NF-AT) (NN binding) (NN activity)) (VP (VBD was) (ADJP-PRD (JJ related) (PP (TO to) (NP (DT an) (JJ impaired) (NN function)))))))))) (, ,) (NP-SBJ-31 (PRP we)) (VP (VBD transfected) (NP (NP-COOD (NP (NN patient)) (CC and) (NP (NN control))) (NN T) (NNS lymphocytes)) (PP (IN with) (NP (NP (NNS constructs)) (VP (VBG containing) (NP (NP (DT the) (NN reporter) (NN gene)) (VP (JJ encoding) (NP (NP (NP (NN chloramphenicol) (NN acetyl) (NN transferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (PP (IN under) (NP (NP (DT the) (NN control)) (PP-COOD (PP (IN of) (NP (DT the) (JJ entire) (NN IL2) (JJ regulatory) (NN region))) (CC or) (PP (IN of) (NP (NP (NNS multimers)) (PP (IN of) (NP (JJ individual) (NN enhancer) (NNS sequences))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN CAT) (NN expression)) (VP (VBN directed) (PP-COOD (PP (IN by) (NP-LGS (DT the) (NN IL2) (JJ regulatory) (NN region))) (CC or) (PP (IN by) (NP-LGS (NP (DT a) (NN multimer)) (PP (IN of) (NP (DT the) (JJ NF-AT-binding) (NN site)))))))) (VP (VBD was) (ADJP-PRD (RB markedly) (JJR lower)) (PP (IN in) (NP (DT the) (NN patient))) (PP (JJ relative) (TO to) (NP (NNS controls)))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN CAT) (NN gene) (NN expression)) (VP (VBN directed) (PP (IN by) (NP-LGS (NP (DT a) (NN multimer)) (PP (IN of) (NP (DT the) (ADJP (NN OCT-1) (NN proximal) (-LRB- -LRB-) (NN OCT-1p) (-RRB- -RRB-) (JJ -binding)) (NN site))))))) (VP (VBD was) (ADJP-PRD (JJ equivalent)) (PP (IN in) (NP-COOD (NP (NN patient)) (CC and) (NP (NNS controls))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (DT an) (NN abnormality)) (UCP (UCP-COOD (PP (IN of)) (CC /) (VP (CC or))) (NP-32 (JJ influencing)))) (VP (NN NF-AT) (VP (MD may) (NP (NP (VB underlie) (DT the) (JJ multiple) (NN lymphokine)) (PP (NN deficiency) (NP (IN in) (DT this))))))))) (NN patient)))
(TOP (NP (NP (NP (NN Expression)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN for) (NP (DT the) (JJ GATA-binding) (NNS proteins))))) (PP (IN in) (NP (JJ human) (NP-COOD (NP (NNS eosinophils)) (CC and) (NP (NNS basophils))))) (: :)) (NP (NP (JJ potential) (NN role)) (PP (IN in) (NP (NN gene) (NN transcription))) (. .))))
(TOP (S (NP-SBJ-12 (NP (DT The) (NN expression)) (PP (IN of) (NP (DT the) (JJ hematopoietic) (NN transcription) (NNS factors) (NP-COOD (NP (NN GATA-1)) (, ,) (NP (NN GATA-2)) (, ,) (CC and) (NP (NN GATA-3)))))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP-COOD (NP (NNS eosinophils)) (CC and) (NP (NNS basophils)))))) (. .)))
(TOP (S (NP-SBJ (NNS Eosinophils)) (VP (VBP express) (NP (NP (NN mRNA)) (PP (IN for) (NP-COOD (NP (NN GATA-1)) (, ,) (NP (NN GATA-2)) (, ,) (CC and) (NP (NN GATA-3)))))) (. .)))
(TOP (S (NP-SBJ (NNS Basophils)) (VP (VBP express) (NP-COOD (NP (NN GATA-2)) (CC and) (NP (NN GATA-3)))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (NN HL-60) (JJ eosinophilic) (NNS sublines))) (PP (IN with) (NP-COOD (CC either) (NP (NN interleukin-5)) (CC or) (NP (JJ butyric) (NN acid))))) (VP (VBD increased) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN GATA-1) (NN mRNA)))) (ADJP (JJ concomitant) (PP (IN with) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ eosinophil-specific) (NNS genes)))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NNS levels)) (PP (IN of) (NP (NN GATA-2) (NN mRNA)))) (VP (VBD remained) (ADJP-PRD (RB relatively) (JJ constant)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN presence)) (PP (IN of) (NP (NP (NN mRNA)) (PP (IN for) (NP (DT these) (NNS proteins))))) (PP (IN in) (NP-COOD (NP (NNS eosinophils)) (CC and) (NP (NNS basophils))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ-13 (NP (NN gene) (NN transcription)) (PP (IN in) (NP (DT these) (NNS lineages)))) (VP (MD may) (VP (VB be) (VP (VBN regulated) (PP (IN by) (NP-LGS (JJ GATA-binding) (NNS proteins))))))))) (. .)))
(TOP (NP (NP (NN Proliferation) (NN index)) (PP (IN as) (NP (NP (DT a) (JJ prognostic) (NN marker)) (PP (IN in) (NP (NN breast) (NN cancer))))) (. .)))
(TOP (NP (NN BACKGROUND) (. .)))
(TOP (S (NP-SBJ-6 (NP (DT The) (JJ proliferative) (NN activity)) (PP (IN of) (NP (NNS tumors)))) (VP (VBZ has) (VP (VBN been) (VP (ADVP (RB extensively)) (VBN investigated) (PP (IN with) (NP (NP (JJ different) (NNS approaches)) (, ,) (SBAR (WHPP-7 (IN among) (WHNP (WDT which))) (S (NP-SBJ (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (JJ monoclonal) (NN antibody) (NN Ki-67)))) (VP (VBZ represents) (NP (NP (DT an) (ADJP-COOD (ADJP (JJ easy)) (CC and) (ADJP (JJ reliable))) (NN means)) (PP (IN of) (S (VP (VBG assessing) (NP (NN cell) (NN proliferation)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (S-COOD (S (NP-SBJ-8 (NP (DT the) (JJ proliferative) (NN activity)) (PP (IN of) (NP (CD 129) (JJ primary) (NN breast) (NNS cancers)))) (VP (VBD was) (VP (VBN investigated)))) (, ,) (CC and) (S (NP-SBJ-105 (DT the) (NNS results)) (VP (VBD were) (VP (JJ related) (PP (TO to) (NP (NN prognosis))))))) (. .)))
(TOP (NP (NNS METHODS) (. .)))
(TOP (S (NP-SBJ-10 (NP (NN Tumor) (NNS samples)) (, ,) (VP (VBN obtained) (PP (IN from) (NP (NP (CD 129) (NNS patients)) (SBAR (WHNP-11 (WP who)) (S (VP (VBD underwent) (NP (NN surgery)) (PP-TMP (IN between) (NP-COOD (NP (NNP January) (CD 1987)) (CC and) (NP (NNP December) (CD 1988)))))))))) (, ,)) (VP (VBD were) (VP (VBN processed) (PP (IN for) (NP (VBG staining))) (PP (IN by) (NP (NP (DT an) (JJ immunohistochemical) (NN procedure)) (PRN (-LRB- -LRB-) (NP (NN avidin-biotin) (NN complex)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ median) (NN time)) (PP (IN of) (NP (NN observation)))) (VP (VBD was) (NP-PRD (CD 42) (NNS months)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN range)) (, ,) (NP-PRD (QP (CD 31-55)) (NNS months))) (-RRB- -RRB-))) (. .)))
(TOP (S (NP-SBJ-12 (NP (JJ Life-table) (NN analysis)) (PRN (-LRB- -LRB-) (NP (NN Mantel-Cox)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN probability)) (PP (IN of) (NP-COOD (NP (NP (JJ disease-free) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN DFS)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ overall) (NN survival)) (PRN (-LRB- -LRB-) (NP (NN OS)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (NP (NNS RESULTS) (. .)))
(TOP (S (NP-SBJ-14 (NP (NNS Tumors)) (PP (IN with) (NP (NP (JJ high) (NN Ki-67) (NN proliferation) (NNS indices)) (PRN (-LRB- -LRB-) (NP (QP (JJR &gt;) (CD 20)) (NN %)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (JJ 4-year) (NN probability)) (PP (IN of) (NP-COOD (NP (NP (NP (NN relapse)) (PP (IN of) (NP (NN disease)))) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD 55.3) (NN %)) (CC versus) (NP (CD 79.1) (NN %))) (: ;) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.003)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN death)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD 71) (NN %)) (CC versus) (NP (CD 95.6) (NN %))) (: ;) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.00005)))) (-RRB- -RRB-))))))) (SBAR-TMP (WHADVP-15 (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNS tumors)) (PP (IN with) (NP (JJ low) (NN Ki-67) (NNS values)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (DT this) (JJ proliferative) (NN parameter)) (VP (VBD maintained) (NP (PRP$ its) (JJ prognostic) (NN significance)) (SBAR-TMP (WHADVP-16 (WRB when)) (S (NP-SBJ-17 (DT the) (NNS patients)) (VP (VBD were) (VP (VBN stratified) (PP (VBG according) (PP (TO to) (NP-COOD (NP (NN lymph) (NN node) (NN involvement)) (, ,) (NP (JJ menopausal) (NN status)) (, ,) (CC and) (NP (JJ nuclear) (NN estrogen) (NN receptor) (NN content)))))))))) (. .)))
(TOP (NP (NNS CONCLUSIONS) (. .)))
(TOP (S (NP-SBJ-18 (NP (NN Tumor) (JJ proliferative) (NN activity)) (SBAR (IN as) (S (VP (VBN evaluated) (PP (IN by) (NP (DT the) (JJ monoclonal) (NN antibody) (NN Ki-67))))))) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (NP-PRD (NP (DT an) (JJ effective) (NN indicator)) (PP (IN of) (NP (NP (NN prognosis)) (PP (IN in) (NP (NN breast) (NN cancer))))) (PP (IN for) (NP-COOD (NP (NN DFS)) (CC and) (NP (NN OS))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Defective) (NN translocation)) (PP (IN of) (NP (NN protein) (NN kinase) (NN C))) (PP (IN in) (NP (JJ multidrug-resistant) (NN HL-60) (NNS cells)))) (VP (VBZ confers) (NP (NP (DT a) (JJ reversible) (NN loss)) (PP (IN of) (NP (ADJP (NN phorbol) (JJ ester-induced)) (JJ monocytic) (NN differentiation))))) (. .)))
(TOP (S (NP-SBJ (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP-SBJ (JJ human) (NN HL-60) (JJ myeloid) (NN leukemia) (NNS cells)) (VP (VBP differentiate) (PP (IN in) (NN response) (TO to) (NP (NN phorbol) (NNS esters)))))))) (. .)))
(TOP (S (NP-SBJ-17 (DT This) (NN event)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP-COOD (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN c-jun) (JJ early) (NN response) (NN gene)))) (CC and) (NP (NP (NN appearance)) (PP (IN of) (NP (DT a) (JJ monocytic) (NN phenotype)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ present) (NNS studies)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ vincristine-selected)) (, ,) (ADJP (JJ multidrug))) (NN resistance))) (PP (IN on) (NP (ADJP (NN 12-O-tetradecanoylphorbol-13-acetate) (-LRB- -LRB-) (NN TPA) (-RRB- -RRB-) (JJ -induced)) (NN HL-60) (NN cell) (NN differentiation)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-18 (NP (JJ multidrug-resistant) (NN HL-60) (NNS cells)) (, ,) (VP (VBN designated) (S (NP-PRD (NN HL-60/vinc)))) (, ,)) (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NN TPA))) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP-COOD (NP (NN c-jun) (NNS transcripts)) (CC or) (NP (NP (JJ other) (JJ phenotypic) (NNS characteristics)) (PP (IN of) (NP (JJ monocytic) (NN differentiation))))))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN treatment)) (PP (IN of) (NP (NN HL-60/vinc) (NNS cells))) (PP (IN with) (NP (NP (JJ okadaic) (NN acid)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN serine/threonine) (NN protein) (NNS phosphatases)))) (, ,)))) (VP (VBZ induces) (NP-COOD (NP (NN c-jun) (NN transcription)) (, ,) (NP (NN growth) (NN arrest)) (, ,) (CC and) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN c-fms) (NN gene)))))) (. .)))
(TOP (S (NP-SBJ-20 (NNS Studies)) (VP (VBD were) (VP (ADVP (RB also)) (VBN performed) (PP (IN with) (NP (NP (DT an) (ADJP (ADJP (NN HL-60/vinc) (NN revertant)) (PRN (-LRB- -LRB-) (ADJP-PRD (NN HL-60/vinc/R)) (-RRB- -RRB-))) (NN line)) (SBAR (WHNP-21 (WDT that)) (S (VP (VBZ has) (VP (VBN regained) (NP (NP (JJ partial) (NN sensitivity)) (PP (TO to) (NP (NN vincristine)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN finding) (SBAR (IN that) (S (NP-SBJ (NN HL-60/vinc/R) (NNS cells)) (VP (VBP respond) (PP (TO to) (NP (NN TPA))) (PP (IN with) (NP-COOD (NP (NP (NN induction)) (PP (IN of) (NP (DT a) (JJ monocytic) (NN phenotype)))) (, ,) (CONJP (CC but) (RB not)) (NP (NN c-jun) (NN expression)) (, ,))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NN c-jun) (NN induction)) (VP (VBZ is) (RB not) (ADJP-PRD (JJ obligatory) (PP (IN for) (NP (JJ monocytic) (NN differentiation)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (JJ Other) (NNS studies)) (ADVP (RB further)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-22 (DT the) (NP-COOD (NP (NN jun-B)) (CC and) (NP (NN fra-1))) (NNS genes)) (VP (VBP are) (VP (VBN induced) (PP (IN by) (NP-LGS (NN TPA))) (PP (IN in) (NP (ADJP-COOD (CC both) (ADJP (NN HL-60/vinc)) (CC and) (ADJP (NN HL-60/vinc/R))) (NNS cells))))))))) (, ,) (IN whereas) (S (NP-SBJ-23 (NN c-fos) (NN expression)) (VP (VBZ is) (VP (VBN attenuated) (PP (IN in) (NP (DT the) (NN HL-60/vinc) (NN line)))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (NN TPA)) (VP (VBZ activates) (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (NN translocation)) (PP (IN of) (NP (NN PKC))) (PP (IN from) (NP (DT the) (NN cytosol))) (PP (TO to) (NP (DT the) (NN membrane) (NN fraction))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (UCP-COOD (NP (NN HL-60)) (CC and) (ADJP (NN HL-60/vinc/R))) (NNS cells)) (VP (VBD demonstrated) (NP (NP (NN translocation)) (PP (IN of) (NP (NN PKC) (NN activity))))))) (, ,) (NP-SBJ (DT this) (JJ subcellular) (NN redistribution)) (VP (VBD was) (ADJP-PRD (JJ undetectable)) (PP (IN in) (NP (NN HL-60/vinc) (NNS cells)))) (. .)))
(TOP (S (NP-SBJ-24 (NP (NN Activity)) (PP (IN of) (NP (DT the) (JJ mitogen-activated) (NN protein) (NN kinase) (NN family))) (PP (IN with) (NP (NP (JJ associated) (NN phosphorylation)) (PP (IN of) (NP (NN c-Jun) (NN Y-peptide)))))) (VP (VBD was) (VP (ADVP (RB markedly)) (VBN diminished) (PP (IN in) (NP (JJ TPA-treated) (NN HL-60/vinc) (NNS cells))) (, ,) (CC but) (PP (RB not) (IN in) (NN response) (TO to) (NP (JJ okadaic) (NN acid))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-25 (DT these) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN vincristine) (NN resistance)) (VP-COOD (VP (VBZ confers) (NP (NP (NN insensitivity)) (PP (TO to) (NP (JJ TPA-induced) (NN differentiation))))) (CC and) (VP (MD can) (VP (VB include) (NP (NP (NNS defects)) (PP (IN in) (NP-COOD (NP (JJ PKC-mediated) (NN signaling) (NNS events)) (CC and) (NP (NP (NN induction)) (PP (IN of) (NP (NN jun/fos) (JJ early) (NN response) (NN gene) (NN expression))))))))))))) (. .)))
(TOP (NP (NP (JJ Differential) (NN contribution)) (PP (IN of) (NP (NN herpes) (NN simplex) (NN virus) (NN type) (CD 1) (NP-COOD (NP (NN gene) (NNS products)) (CC and) (NP (JJ cellular) (NNS factors))))) (PP (TO to) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (NN provirus))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN reported) (SBAR (IN that) (S (NP-SBJ (NP (NN infection)) (PP (IN with) (NP (NP (NN herpes) (NN simplex) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HSV-1)) (-RRB- -RRB-))))) (VP (VBZ activates) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))) (NN provirus))) (PP (IN in) (NP (NN T) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (DT the) (NN HIV-1) (NN provirus)))) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP-COOD (NP (NP (NN binding)) (PP (IN of) (NP (ADJP-COOD (ADJP (NP (CD 55-))) (CC and) (ADJP (JJ 85-kDa))) (NNS proteins))) (PP (TO to) (NP (DT the) (NN kappa) (NN B) (NN enhancer)))) (CC and) (NP (NP (NN binding)) (PP (IN of) (NP (DT the) (JJ 50-kDa) (NN HLP-1) (NN protein))) (PP (TO to) (NP (NP (DT the) (NN LBP-1) (NNS sequences)) (PP (IN of) (NP (DT the) (NN HIV-1) (JJ long) (JJ terminal) (NN repeat))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (RB Further) (NN examination)) (PP (IN of) (NP (DT this) (NN system)))) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NN HSV-1) (NN replication))) (PP (IN by) (NP (DT the) (JJ antiviral) (NN drug) (NN acyclovir)))) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (JJ HSV-1-mediated) (NN induction)) (PP (IN of) (NP (NN HIV-1) (NN provirus)))))))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (NP-SBJ-1 (DT the) (NP-COOD (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN HLP-1))) (NN binding) (NNS activities)) (VP (VBD were) (VP (ADVP (RB substantially)) (VBN inhibited) (PP (IN in) (NP (JJ acyclovir-treated) (NNS cells))))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (DT the) (JJ transient-transfection) (NN assay))) (, ,) (NP-SBJ-COOD (NP (NN ICP0)) (, ,) (CONJP (CC but) (RB not)) (NP (NN ICP4)) (, ,)) (VP (VBD activated) (NP (DT the) (NN HIV-1) (JJ long) (JJ terminal) (NN repeat) (NN promoter) (NN region)))) (CC and) (S (NP-SBJ-2 (NP (DT the) (NN effect)) (PP (IN of) (NP (NN ICP0)))) (VP (VBD was) (VP (ADVP (RB greatly)) (VBN enhanced) (PP (IN in) (DT the) (NN presence) (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN binding) (NNS proteins))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (NN induction)) (PP (IN of) (NP (DT the) (NN HIV-1) (NN provirus)))) (VP (VBZ involves) (NP (NP (NN cooperation)) (PP (IN between) (NP-COOD (NP (NP (DT the) (JJ HSV-1-activated) (JJ cellular) (NN factor)) (, ,) (NP (NN NF-kappa) (NN B))) (, ,) (CC and) (NP (NP (DT the) (JJ virus-encoded) (NN transactivator)) (, ,) (NP (NN ICP0)))))))))))))) (. .)))
(TOP (NP (NP (NN Glucocorticoid) (NNS receptors)) (PP (IN in) (NP (NP (JJ mononuclear) (NNS cells)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN sepsis))))))) (. .)))
(TOP (S (NP-SBJ-69 (NP (NP (NN Glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (NN hormone-binding) (NN activity)) (VP (VBD was) (VP (VBN studied) (PP (IN by) (NP (DT a) (JJ whole-cell) (NN method))) (PP (IN in) (NP (NP (NP (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN MNC)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (JJ peripheral) (NN blood)) (PP (IN of) (NP (CD 7) (NNS patients))))))) (PP-TMP (IN during) (NP (NP (DT the) (JJ hemodynamic) (JJ compensatory) (NN phase)) (PP (IN of) (NP (NN sepsis))))))) (. .)))
(TOP (S (NP-SBJ (CD 4) (NNS patients)) (VP (VBD were) (VP (VBG receiving) (NP (NP (NN dopamine)) (, ,) (SBAR (WHNP-70 (WDT which)) (S (VP (VBD did) (RB not) (VP (VB affect) (NP (DT the) (NN GR) (NN count))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS patients) (POS ')) (NN plasma) (NN cortisol) (NNS concentrations)) (VP (VBD were) (ADJP-PRD-COOD (ADJP (JJ normal)) (CC or) (ADJP (RB slightly) (JJ elevated)))) (. .)))
(TOP (S (PP (IN Despite) (NP (DT a) (JJ wide) (NN range))) (, ,) (NP-SBJ (NP (DT the) (NN mean) (NN GR) (NP-COOD (NP (NN count)) (CC and) (NP (NN affinity)))) (PP (IN in) (NP (NP (NN MNC)) (PP (IN from) (NP (JJ septic) (NNS patients)))))) (VP (VBD did) (RB not) (VP (VB differ) (PP (IN from) (NP (NP (DT those)) (PP (IN in) (NP (JJ normal) (NNS controls))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NNS glucocorticoids)) (VP (MD could) (VP (ADVP (RB still)) (VP (VB be) (ADJP-PRD (JJ effective)) (PP (IN in) (NP (NP (DT the) (JJ hemodynamic) (JJ compensatory) (NN phase)) (PP (IN of) (NP (NN sepsis)))))))))))))) (. .)))
(TOP (S (NP-SBJ-4 (NP (JJ Transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NN macrophage) (JJ colony-stimulating) (NN factor) (NN gene))) (PP (IN by) (NP (NN IL-2)))) (VP-COOD (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN secretion)) (PP (IN of) (NP (JJ bioactive) (NN macrophage) (JJ colony-stimulating) (NN factor) (NN protein))) (PP (IN by) (NP (NNS monocytes))))))) (CC and) (VP (VBZ involves) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN NF-kappa) (NN B)))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (JJ Human) (JJ peripheral) (NN blood) (NP (NP (NNS monocytes)) (PRN (-LRB- -LRB-) (NP (NN Mo)) (-RRB- -RRB-)))) (ADVP (RB constitutively)) (VP (VBP display) (NP (NP (DT the) (NN beta-chain)) (PP (IN of) (NP (NP (DT the) (NN receptor)) (PP (IN for) (NP (NN IL-2)))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (DT the) (NN IL-2R) (NN alpha-chain)))) (VP (VBZ is) (ADJP-PRD (ADJP-COOD (RB not) (ADJP (JJ constitutive)) (CC but) (ADJP (JJ inducible))) (PP-5 (IN with) (NP (NN IL-2))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NP (NN binding)) (PP (IN of) (NP (JJ human) (NN IL-2))) (PP (TO to) (NP (PRP$ its) (VBG binding) (NN site)))) (VP (VBZ leads) (PP (TO to) (NP-COOD (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NP (NP (NN macrophage) (NN CSF)) (PRN (-LRB- -LRB-) (NP (NN M-CSF)) (-RRB- -RRB-))) (NN gene))) (PP (IN in) (NP (NN Mo))) (VP (VBG resulting) (PP (IN in) (NP (NP-COOD (NP (NP (NN accumulation)) (PP (IN of) (NP (NN M-CSF) (NN mRNA)))) (CC and) (NP (NP (JJ subsequent) (NN release)) (PP (IN of) (NP (JJ bioactive) (NN M-CSF) (NN protein))))) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP-LGS (NN ELISA)))))))))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (ADJP (NN IL-2) (JJ induced)) (NN release)) (PP (IN of) (NP (NP (DT an) (JJ activity-stimulating) (NN growth)) (PP (IN of) (NP (JJ monocyte-type) (NNS colonies))))))) (PP (IN by) (NP (DT a) (VBG neutralizing) (JJ anti-M-CSF) (NN antibody)))))))))) (. .)))
(TOP (S (NP-SBJ-7 (NP (JJ Transcriptional) (NN activation)) (PP (IN of) (NP (DT the) (NN M-CSF) (NN gene))) (PP (IN by) (NP (NN IL-2)))) (VP (VBZ is) (VP (VBN preceded) (PP (IN by) (NP-LGS (NP (VBN enhanced) (NN binding) (NN activity)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN NF-kappa) (NN B))) (PP (TO to) (NP (NP (PRP$ its) (NN recognition) (NN sequence)) (PP (IN in) (NP (NP (DT the) (JJ 5') (JJ regulatory) (NN enhancer) (NN region)) (PP (IN of) (NP (DT the) (NN M-CSF) (NN gene))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (S (VP (VBG using) (NP (NP (NP (NP (DT a) (JJ heterologous) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NN herpes) (NN thymidine) (NN kinase)) (-RRB- -RRB-))) (NN construct)) (VP (VBG containing) (NP (DT the) (NN NF-kappa) (NN B) (NN consensus) (NN sequence)))))) (, ,) (NP-SBJ (PRP it)) (VP (VBZ is) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NP (NN NF-kappa) (NN B) (NN binding)) (PP (IN by) (NP (DT an) (JJ IL-2-induced) (JJ monocyte-derived) (JJ nuclear) (NN protein)))) (VP (VBZ confers) (NP (NP (NP (NN reporter) (NN gene)) (PRN (-LRB- -LRB-) (NP (JJ human) (NN growth) (NN hormone)) (-RRB- -RRB-))) (NN activity))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-100 (PRP$ our) (NNS findings)) (VP-COOD (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN IL-2)) (VP (VBZ induces) (NP (NP (NN gene) (NN expression)) (PP (IN of) (NP (NN M-CSF))) (PP (IN in) (NP (JJ human) (JJ blood-derived) (NN Mo)))))))) (CC and) (VP (VBP provide) (NP (NP (NN evidence)) (PP (IN for) (NP (NP (NN involvement)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT this) (NN gene)))))))))) (. .)))
(TOP (NP (NP (JJ Comparative) (NN analysis)) (PP (IN of) (NP (NP (NP (NP (NN NFAT)) (PRN (-LRB- -LRB-) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (-RRB- -RRB-))) (JJ complex)) (PP (IN in) (NP (JJ human) (NP-COOD (NP (NN T)) (CC and) (NP (NN B))) (NNS lymphocytes))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (NP (JJ Nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NFAT)) (-RRB- -RRB-))) (VP-COOD (VP (VBZ is) (NP-PRD (NP (DT a) (JJ transcriptional) (NN activator)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBZ binds) (PP (TO to) (NP (NP (NNS sequences)) (PP (IN in) (NP (DT the) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN promoter)))))))))) (CC and) (VP (VBZ is) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (ADJP-PRD (RB largely) (JJ responsible) (PP (IN for) (NP (NP (DT the) (ADJP (NN T) (JJ cell-specific)) (NN inducibility)) (PP (IN of) (NP (NN IL-2) (NN expression)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (PRN (-LRB- -LRB-) (NP (NN EMSA)) (-RRB- -RRB-))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-3 (JJ specific) (NN NFAT) (NN binding) (NN activity)) (VP (MD could) (ADVP (RB also)) (VP (VB be) (VP (VBN induced) (PP (IN in) (NP (JJ human) (NN B) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN B) (NN cell) (NN NFAT) (NN complex)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD was) (RB not) (ADJP-PRD (JJ functional)) (, ,) (SBAR (IN since) (S (NP-SBJ-4 (PRP it)) (VP (VBD failed) (S (VP (TO to) (VP (VB activate) (NP (NP (NN transcription)) (PP (IN from) (NP (DT an) (JJ NFAT-driven) (NP (NP (NN chloramphenicol) (NN acetyltransferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (NN construct))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Competition)) (PP-COOD (PP (IN with) (NP (DT an) (NN AP-1) (NN motif))) (CC or) (PP (IN with) (NP (ADJP-COOD (ADJP (JJ anti-Jun)) (CC and) (ADJP (JJ anti-Fos))) (NNS antibodies))))) (VP (VBD abolished) (NP (NP (NN binding)) (PP (TO to) (NP (DT the) (NN NFAT) (NN motif))) (PP (IN in) (NP (NP-COOD (CC both) (NP (NN T)) (CC and) (NP (NN B))) (NNS cells)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN Jun)) (CC and) (NP (NN Fos))) (VP (VBP are) (ADJP-PRD (JJ critical) (PP (IN for) (NP (NP (NN NFAT) (NN complex) (NN formation)) (PP (IN in) (NP (DT both) (NN cell) (NNS types)))))))))))) (. .)))
(TOP (S (NP-SBJ-5 (VBN Purified) (JJ recombinant) (NP-COOD (NP (NN Jun)) (CC and) (NP (NN Fos))) (NNS proteins)) (VP (VBD failed) (S (VP (TO to) (VP (VB bind) (ADVP (RB directly)) (PP (TO to) (NP (DT the) (NN NFAT) (NN motif))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (SBAR-TMP (WHADVP-9 (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (JJ unstimulated) (NP-COOD (NP (NN B)) (CC or) (NP (NN T))) (NN cell) (NNS extracts)))))) (, ,) (NP-SBJ-6 (ADJP-COOD (ADJP (JJ full-length)) (, ,) (CC but) (ADJP (RB not) (VBN truncated)) (, ,)) (NN Jun/Fos) (NNS heterodimers)) (VP (VBD were) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB form) (NP (DT an) (NN NFAT) (NN complex)) (, ,) (S (VP (VBG indicating) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (ADJP (RB constitutively) (VBN expressed)) (JJ nuclear) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))) (PP (IN in) (NP (NP-COOD (NP (NN B)) (CC and) (NP (NN T))) (NNS cells))) (ADJP (JJ necessary) (PP (IN for) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (DT the) (NN NFAT) (NN complex))))) (PP (IN in) (NP (DT both) (NN cell) (NNS types)))))))))))) (. .)))
(TOP (S (NP-SBJ-10 (NP (DT An) (NN NFAT) (NN oligonucleotide)) (VP (VBG carrying) (NP (NNS mutations)) (PP (IN in) (NP (NP (DT the) (JJ 5') (JJ purine-rich) (NN part)) (PP (IN of) (NP (DT the) (NN NFAT) (NN sequence))))))) (VP (VBD failed) (S (VP (VP-COOD (VP (TO to) (VP (VB form) (NP (DT a) (NN complex)))) (CC and) (VP (TO to) (VP (VB compete) (PP (IN with) (NP (DT the) (JJ wild) (NN type) (NN motif))) (PP (IN for) (NP (NN NFAT) (NN complex) (NN formation)))))) (PP (IN in) (NP (NP-COOD (CC both) (NP (NN T)) (CC and) (NP (NN B))) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB therefore)) (VP (VBP propose) (NP (NP (DT a) (NN model)) (SBAR (WHADVP-11 (WRB whereby)) (S (S-COOD (S (NP-SBJ-12 (NP (DT a) (NN core) (NN NFAT) (NN complex)) (VP (VBG consisting) (PP (IN of) (NP-COOD (NP (NN Jun)) (, ,) (NP (NN Fos)) (, ,) (CC and) (NP (DT a) (JJ constitutive) (JJ nuclear) (NN factor)))))) (VP (VBZ is) (VP (VBN formed) (PP (IN in) (NP (NP-COOD (DT both) (NP (NN T)) (CC and) (NP (NN B))) (NNS cells)))))) (, ,) (CC but) (S (NP-SBJ-13 (NP-COOD (NP (DT an) (JJ additional) (NN factor)) (CC and/or) (NP (NP (JJ post-translational) (NN modification)) (PP (IN of) (NP (DT a) (NN factor))))) (, ,) (ADJP (VBG missing) (PP (IN in) (NP (NN B) (NNS cells)))) (, ,)) (VP (MD might) (VP (VB be) (VP (VBN required) (PP (IN for) (NP (NP (NN transactivation)) (PP (IN by) (NP (NN NFAT)))))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN 1,25-Dihydroxy) (NN vitamin) (NN D3)) (CC and) (NP (NN 12-O-tetradecanoyl) (NN phorbol-13-acetate))) (ADVP (RB synergistically)) (VP (VBP induce) (NP (NP (JJ monocytic) (NN cell) (NN differentiation)) (: :) (NP (NP-COOD (NP (NN FOS)) (CC and) (NP (NN RB))) (NN expression)))) (. .)))
(TOP (S (NP-SBJ-COOD-8 (NP (NN 1,25-dihydroxy) (NN vitamin) (NN D3)) (CC and) (NP (NP (NN 12-O-tetradecanoyl) (NN phorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-)))) (VP (VBP interact) (ADVP (RB synergistically)) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ monocytic) (NN differentiation)) (PP (IN of) (NP (NN U937) (JJ histiocytic) (NN lymphoma) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Addition)) (PP (IN of) (NP (NN TPA)))) (VP (VBZ causes) (S (NP-SBJ (NP (DT an) (ADJP (JJ otherwise) (JJ ineffective)) (NN dose)) (PP (IN of) (NP (NN 1,25-dihydroxy) (NN vitamin) (NN D3)))) (VP (TO to) (VP (VB induce) (NP (NN differentiation)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (VBD induced) (NN differentiation)) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (ADJP-TMP-COOD (ADJP (JJ simultaneous)) (-LRB- -LRB-) (CC vs.) (ADJP (JJ sequential)) (-RRB- -RRB-)) (NN presence)) (PP (IN of) (NP (DT both) (NNS agents)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS kinetics)) (PP (IN of) (NP (JJ induced) (NN differentiation)))) (VP (VBP are) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (DT a) (ADJP (NN G1) (JJ specific)) (JJ cellular) (NN response)) (SBAR (S (VP (TO to) (VP (VB initiate) (NP (NP (DT the) (JJ metabolic) (NN cascade)) (VP (VBG culminating) (PP (IN in) (NP (NN cell) (NN differentiation))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (VBD induced) (NN differentiation)) (VP (VBZ occurs) (PP (IN with) (NP-COOD (NP (NP (NN down-regulation)) (PP (IN of) (NP (NN c-fos) (NN protein)))) (CC and) (NP (NP (DT an) (VBG accompanying) (NN up-regulation)) (PP (IN of) (NP (NN RB) (NN protein) (NN expression)))))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (DT a) (JJ possible) (NN need) (SBAR (IN for) (S (NP-SBJ (JJ up-regulated) (NN RB) (NN expression)) (VP (TO to) (VP-COOD (VP (VB maintain) (NP (DT a) (JJ given) (VBN differentiated) (NN phenotype))) (CC and) (VP (VB suppress) (NP (NP (JJ transcriptional) (NNS activators)) (SBAR (WHNP-11 (WDT that)) (S (VP (MD might) (VP (ADVP (RB typically)) (VB be) (VP (VBN associated) (PP (IN with) (NP (NN proliferation)))))))))))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (JJ lymphoid-specific) (NN immunoglobulin) (NN mu) (NN heavy) (NN chain) (NN gene) (NN enhancer))) (PP (IN by) (NP (JJ ETS-domain) (NNS proteins))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN enhancer)) (PP (IN for) (NP (NP (DT the) (NN immunoglobulin) (NN mu) (NN heavy) (NN chain) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN IgH)) (-RRB- -RRB-))))) (VP (VBZ activates) (NP (DT a) (JJ heterologous) (NN gene)) (PP-TMP (IN at) (NP (NP (DT the) (ADJP (JJ pre-B) (NN cell)) (NN stage)) (PP (IN of) (NP (NN B) (NN lymphocyte) (NN differentiation)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ lymphoid-specific) (NN element)) (, ,) (NP (NN microB)) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NP (NN enhancer) (NN function)) (PP (IN in) (NP (JJ pre-B) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-1 (DT A) (NN microB) (NN binding) (NN protein)) (VP (VBZ is) (VP (VBN encoded) (PP (IN by) (NP-LGS (DT the) (NN PU.1/Spi-1) (NN proto-oncogene))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (DT Another) (NN sequence) (NN element)) (, ,) (NP (NN microA)) (, ,)) (VP (VBD was) (VP (VBN identified) (PP (IN in) (NP (NP (DT the) (NN mu) (NN enhancer)) (SBAR (WHNP-3 (WDT that)) (S (VP (VBZ binds) (NP (NP (DT the) (NN product)) (PP (IN of) (NP (DT the) (NN ets-1) (NN proto-oncogene))))))))))) (. .)))
(TOP (S (NP-SBJ-4 (DT The) (NN microA) (NN motif)) (VP (VBD was) (VP (VP (VBN required) (PP (IN for) (NP (JJ microB-dependent) (NN enhancer) (NN activity)))) (, ,) (SBAR (WHNP-5 (WDT which)) (S (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ-6 (DT a) (JJ minimal) (ADJP (NN B) (JJ cell-specific)) (NN enhancer)) (VP (VBZ is) (VP (VBN composed) (PP (IN of) (NP (CC both) (DT the) (NP-COOD (NP (NN PU.1)) (CC and) (NP (NN Ets-1))) (NN binding) (NNS sites)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Co-expression)) (PP (IN of) (NP-COOD (CC both) (NP (NN PU.1)) (CC and) (NP (NN Ets-1)))) (PP (IN in) (NP (JJ nonlymphoid) (NNS cells)))) (VP (JJ trans-activated) (NP (NP (NN reporter) (NNS plasmids)) (SBAR (WHNP-7 (WDT that)) (S (VP (VBD contained) (NP (DT the) (JJ minimal) (NN mu) (NN enhancer))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP implicate) (NP (NP (CD two) (NNS members)) (PP (IN of) (NP (DT the) (NN Ets) (NN family)))) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN IgH) (NN gene) (NN expression)))))) (. .)))
(TOP (NP (NP (JJ Differential) (NN autoregulation)) (PP (IN of) (NP (NN glucocorticoid) (NN receptor) (NN expression))) (PP (IN in) (NP (JJ human) (NP-COOD (NP (NN T-)) (CC and) (NP (NN B-cell))) (NNS lines))) (. .)))
(TOP (S (NP-SBJ-14 (NP (NN Regulation)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (NN expression))) (PP (IN by) (NP (PRP$ its) (JJ cognate) (NN ligand)))) (VP (VBD was) (VP (VBN examined) (PP-COOD (PP (IN in) (NP (DT the) (JJ glucocorticoid-sensitive) (JJ human) (JJ leukemic) (NN T-cell) (NN line) (NN 6TG1.1))) (CC and) (PP (IN in) (NP (DT the) (JJ human) (NN B-cell) (NN line) (NN IM-9)))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NN GR) (NN mRNA))) (VP (VBN seen) (PP (IN in) (NP (NN IM-9) (NNS cells))) (PP-TMP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (ADJP (CD 1) (NN microM)) (NN dexamethasone))) (PP-TMP (IN for) (NP (QP (CD 16-18)) (NN h)))))))) (, ,) (NP-SBJ (NP (NN treatment)) (PP (IN of) (NP (NN 6TG1.1) (NNS cells)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (JJ 8-fold) (NN increase)) (PP (IN in) (NP (NN GR) (NN mRNA))))) (, ,) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP-COOD (NP (NN Northern) (NN blot)) (CC and) (NP (NN RNase) (NN protection))) (NN analysis)))))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ corresponding) (ADJP-COOD (ADJP (NP (CD 3-))) (TO to) (ADJP (JJ 4-fold))) (NN increase)) (PP (IN in) (NP (NN GR) (NN protein)))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-16 (NP (JJ Half-maximal) (NN induction)) (PP (IN of) (NP (NN GR) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))))) (PP (IN in) (NP (NN 6TG1.1) (NNS cells)))) (VP (VBD was) (VP (VBN observed) (PP (IN between) (NP (ADJP (QP (CD 10-100)) (NN nM)) (NN dexamethasone)))))) (, ,) (CC and) (S (NP-SBJ (NP (NN inclusion)) (PP (IN of) (NP (ADJP (CD 1) (NN microM)) (NN RU) (CD 38486)))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (ADJP (CD 100) (NN nM)) (NN dexamethasone)))) (, ,) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP-SBJ (NP (JJ positive) (NN autoregulation)) (PP (IN of) (NP (NN GR) (NN expression))) (PP (IN in) (NP (NN 6TG1.1) (NNS cells)))) (VP (VBZ is) (NP-PRD (DT a) (JJ receptor-mediated) (NN response))))))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (JJ Positive) (NN autoregulation)) (PP (IN of) (NP (NN GR) (NN expression)))) (VP (VBD was) (VP (ADVP (RB also)) (VBN observed) (PP (IN in) (NP (NP (JJ glucocorticoid-resistant) (NN CEM-C1) (NNS cells)) (, ,) (SBAR-COOD (SBAR (WHNP-18 (WDT which)) (S (VP (VBP contain) (NP (JJ functional) (NN GR))))) (, ,) (CC but) (SBAR (WHNP-20 (WP$ whose) (NN growth)) (S (VP (VBZ is) (VP (VBN unaffected) (PP (IN by) (NP-LGS (NNS glucocorticoids)))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (JJ positive) (NN autoregulation)) (VP (VBZ is) (NP-PRD (NP-COOD (CC neither) (NP (DT a) (NN consequence)) (CC nor) (NP (DT the) (JJ sole) (NN cause))) (PP (IN of) (NP (NN growth) (NN arrest))))) (. .)))
(TOP (S (NP-SBJ-21 (NP (DT The) (NN degree)) (PP (IN of) (NP-COOD (NP (NP (JJ negative) (NN autoregulation)) (PP (IN in) (NP (NN IM-9) (NNS cells)))) (CC and) (NP (NP (JJ positive) (NN autoregulation)) (PP (IN in) (NP (NN 6TG1.1) (NNS cells))))))) (VP (VBD was) (VP (VBN unaffected) (PP (IN by) (NP-LGS (NP (NN inhibition)) (PP (IN of) (NP (NP (NN protein) (NN synthesis)) (PP (IN with) (NP (NN cycloheximide))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Measurement)) (PP (IN of) (NP (NP (NN GR) (NN mRNA) (NN turnover)) (PP (IN in) (NP (NP (NN 6TG1.1) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN actinomycin-D))))))))) (VP (VBD revealed) (NP (NP (DT a) (NN half-life)) (PP (IN of) (NP (CD 2.5) (NN h))) (, ,) (SBAR (WHNP-22 (WDT which)) (S (VP (VBD was) (VP (JJ unaffected) (PP (IN by) (NP-LGS (NN dexamethasone) (NN treatment))))))))) (. .)))
(TOP (S (NP-SBJ-24 (DT A) (JJ similar) (NN half-life)) (VP-COOD (VP (VBD was) (VP (VBN determined) (PP (IN in) (NP (NN IM-9) (NNS cells))))) (CC and) (VP (VBD was) (ADVP (RB also)) (VP (JJ unaffected) (PP (IN by) (NP-LGS (NN steroid) (NN treatment)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP are) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (DT the) (NN interpretation) (SBAR (IN that) (S (NP-SBJ (NP (JJ glucocorticoid-mediated) (NN autoregulation)) (PP (IN of) (NP (NN GR) (NN expression)))) (VP (VBZ is) (NP-PRD (DT a) (JJ tissue-specific) (JJ primary) (JJ transcriptional) (NN response))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN p65) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ regulates) (NP (NN I) (NN kappa) (NN B)) (PP (IN by) (NP (CD two) (JJ distinct) (NNS mechanisms)))) (. .)))
(TOP (S (NP-SBJ-11 (NP (NN Transcription) (NN factor) (NN NF-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN p50/p65)) (-RRB- -RRB-))) (VP (VBZ is) (VP (ADVP (RB generally)) (JJ localized) (PP (TO to) (NP (DT the) (NN cytoplasm))) (PP (IN by) (NP-LGS (PRP$ its) (NN inhibitor) (NN I) (NN kappa) (NN B))))) (. .)))
(TOP (S (NP-SBJ-12 (NP (JJ Overproduced) (NN I) (NN kappa) (NN B)) (, ,) (ADJP (JJ free) (PP (IN from) (NP (NN NF-kappa) (NN B)))) (, ,)) (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN degraded))) (. .)))
(TOP (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP (NN p65)))) (VP (VBZ increases) (NP (NP (JJ endogenous) (NN I) (NN kappa) (NN B) (NN protein)) (PP (IN in) (NP-COOD (CC both) (NP (NN carcinoma)) (CC and) (NP (JJ lymphoid) (NNS cells))))) (PP (IN by) (NP (NP (CD two) (NNS mechanisms)) (: :) (NP-COOD (NP (NN protein) (NN stabilization)) (CC and) (NP (NP (VBN increased) (NN transcription)) (PP (IN of) (NP (NN I) (NN kappa) (NN B) (NN mRNA)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-13 (NP (NN p65) (NN delta)) (, ,) (NP (DT a) (ADJP (RB naturally) (VBG occurring)) (NN splice) (NN variant)) (, ,)) (VP (VBZ fails) (S (VP (TO to) (VP (ADVP (RB markedly)) (VB augment) (NP (NN I) (NN kappa) (NN B) (NN protein) (NNS levels)))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-COOD (CC Both) (NP (JJ overexpressed) (NN p65)) (CC and) (NP (JJ coexpressed) (NN p50))) (VP (VBP are) (ADJP-PRD (JJ cytoplasmic)))) (, ,) (IN whereas) (S (NP-SBJ (NN p65) (NN delta)) (VP (VBZ is) (ADJP-PRD (RB partly) (JJ nuclear))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN I) (NN kappa) (NN B)) (VP (VBN induced) (PP (IN by) (NP-LGS (NN p65))))) (VP (MD can) (VP (VB maintain) (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (DT the) (NN cytoplasm))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-COOD-15 (NP (NN p65)) (CC and) (NP (NN I) (NN kappa) (NN B))) (VP (VBP are) (VP (VBN linked) (PP (IN in) (NP (DT an) (JJ autoregulatory) (NN loop))) (, ,) (S (VP (VBG ensuring) (SBAR (IN that) (S (NP-SBJ-17 (NN NF-kappa) (NN B)) (VP (VBZ is) (VP (VBN held) (PP (IN in) (NP (DT the) (NN cytoplasm))) (SBAR-TMP (IN until) (S (NP-SBJ-18 (NNS cells)) (VP (VBP are) (VP (ADVP (RB specifically)) (VBN induced) (S (VP (TO to) (VP (VB translocate) (NP (PRP it)) (PP (TO to) (NP (DT the) (NN nucleus)))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Cell) (NN cycle) (NN analysis)) (PP (IN of) (NP (NP (NN E2F)) (PP (IN in) (NP (JJ primary) (JJ human) (NN T) (NNS cells)))))) (VP (VBZ reveals) (NP-COOD (NP (JJ novel) (NN E2F) (NNS complexes)) (CC and) (NP (NP (ADJP (RB biochemically) (JJ distinct)) (NNS forms)) (PP (IN of) (NP (JJ free) (NN E2F)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN transcription) (NN factor) (NN E2F)) (VP (VBZ activates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ multiple) (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (NN cell) (NN proliferation)))) (, ,) (PP (JJ such) (IN as) (NP-COOD (NP (NN c-myc)) (CC and) (NP (DT the) (JJ dihydrofolate) (NN reductase) (NN gene)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Regulation)) (PP (IN of) (NP (NN E2F)))) (VP (VBZ involves) (NP (NP (PRP$ its) (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (JJ cellular) (NNS proteins)) (, ,) (PP (VBG including) (NP-COOD (NP (NP (DT the) (NN retinoblastoma) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN Rb)) (-RRB- -RRB-))) (, ,) (NP (DT the) (JJ Rb-related) (NN protein) (NN p107)) (, ,) (NP (NN cyclin) (NN A)) (, ,) (CC and) (NP (NN cdk2)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD undertook) (NP (NP (DT a) (JJ detailed) (NN analysis)) (PP (IN of) (NP (NP-COOD (NP (NN E2F) (JJ DNA-binding) (NNS activities)) (CC and) (NP (PRP$ their) (NN cell) (NN cycle) (NN behavior))) (PP (IN in) (NP (JJ primary) (JJ human) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-9 (CD Three) (NN E2F) (JJ DNA-binding) (NNS activities)) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (VBG resting) (-LRB- -LRB-) (NN G0) (-RRB- -RRB-) (NN T) (NNS cells))) (S (PP-PRD (IN with) (NP (NP (NNS mobilities)) (ADJP (PP (IN in) (NP (NN gel) (NN shift) (NNS assays))) (JJ distinct) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (ADJP (RB previously) (VBN defined)) (NN E2F) (NNS complexes))))))))))) (. .)))
(TOP (S (NP-SBJ-11 (NP (CD One)) (PP (IN of) (NP (DT these) (NNS activities)))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (NP-PRD (DT a) (ADJP-COOD (ADJP (JJ novel)) (, ,) (ADJP (RBR less) (JJ abundant)) (, ,) (ADJP (NN Rb-E2F))) (NN complex))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (ADJP (RBS most) (JJ prominent)) (NN E2F) (NN activity)) (PP (IN in) (NP (VBG resting) (NN T) (NNS cells))) (-LRB- -LRB-) (VP (VBN termed) (S (NP-PRD (JJ complex) (NN X)))) (-RRB- -RRB-)) (VP (VP-COOD (VP (VBD was) (ADJP-PRD (JJ abundant)) (PP (IN in) (NP-COOD (CC both) (NP (NN G0)) (CC and) (NP (NN G1))))) (CC but) (VP (VBD disappeared) (SBAR-TMP (IN as) (S (NP-SBJ (NNS cells)) (VP (VBD entered) (NP (NN S) (NN phase))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ possible) (NN role)) (PP (IN in) (NP (ADJP (RB negatively) (VBG regulating)) (NN E2F) (NN function))))))) (. .)))
(TOP (S (NP-SBJ-12 (NN Complex) (NN X)) (VP (MD could) (VP (VB be) (VP (VBN dissociated) (PP (IN by) (NP-LGS (NN adenovirus) (NN E1A))) (PP (IN with) (NP (NP (DT a) (NN requirement)) (PP (IN for) (NP (DT an) (JJ intact) (NN E1A) (VBN conserved) (NN region) (CD 2)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-13 (NN X)) (VP (VBD failed) (S (VP (TO to) (VP (VB react) (PP (IN with) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS antibodies)) (PP (IN against) (NP-COOD (NP (NN Rb)) (CC or) (NP (NN p107))))))))))) (, ,) (S (VP (VBG implicating) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (DT an) (JJ E1A-binding) (NN protein)) (PP (JJ other) (IN than) (NP-COOD (NP (NN Rb)) (CC or) (NP (NN p107)))))))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (DT these) (JJ novel) (NN E2F) (NNS complexes))) (, ,) (NP-SBJ-14 (NP (CD three) (JJ distinct) (NNS forms)) (PP (IN of) (NP (ADJP (ADJP (JJ unbound)) (PRN (-LRB- -LRB-) (ADJP (JJ free)) (-RRB- -RRB-))) (NN E2F)))) (VP (VBD were) (VP (VBN resolved) (PP (IN in) (NP (NN gel) (NN shift) (NNS experiments))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS species)) (VP (VBD showed) (NP (JJ different) (NN cell) (NN cycle) (NNS kinetics))) (. .)))
(TOP (S (NP-SBJ (NN UV) (JJ cross-linking) (NNS experiments)) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ-15 (DT a) (JJ distinct) (NN E2F) (JJ DNA-binding) (NN protein)) (VP-COOD (VP (VBZ is) (VP (ADVP (RB uniquely)) (VBN associated) (PP (IN with) (NP (DT the) (NN S-phase) (NN p107) (NN complex))))) (CC and) (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NN Rb))))))))) (. .)))
(TOP (S (ADVP (RB Together)) (, ,) (NP-SBJ (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN E2F)) (VP (VBZ consists) (PP (IN of) (NP (NP (ADJP-COOD (ADJP (JJ multiple)) (, ,) (ADJP (RB biochemically) (JJ distinct))) (JJ DNA-binding) (NNS proteins)) (SBAR (WHNP-16 (WDT which)) (S (VP (VBP function) (PP-TMP (IN at) (NP (NP (JJ different) (NNS points)) (PP (IN in) (NP (DT the) (NN cell) (NN cycle)))))))))))))) (. .)))
(TOP (NP (NP (NN Occurrence)) (PP (IN of) (NP (NP (DT a) (NN silencer)) (PP (IN of) (NP (DT the) (NN interleukin-2) (NN gene))))) (PP (PP-COOD (PP (IN in) (NP (JJ naive))) (CC but) (PP (RB not) (IN in) (NP (NN memory) (VBG resting)))) (NP-6 (NN T) (NN helper) (NNS lymphocytes))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ immune) (NN system))) (NP-SBJ (NP (DT the) (JJ first) (NN activation)) (PP (IN of) (NP (DT a) (JJ naive) (NN T) (NN cell))) (PP (IN by) (NP (NN antigen)))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ key) (NN step)) (PP (IN in) (NP (DT the) (NP-COOD (NP (NP (NN shaping)) (PP (IN of) (NP (DT the) (JJ peripheral) (NN T) (NN cell) (NN specificity) (NN repertoire)))) (CC and) (NP (NP (NN maintenance)) (PP (IN of) (NP (NN self-tolerance))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP-SBJ (NP (NN analysis)) (PP (IN of) (NP (DT the) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN gene) (NN activation)))) (VP (VBZ shows) (SBAR (IN that) (S (NP-SBJ (NP (JJ naive) (JJ human) (NN helper) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN cord) (NN blood) (JJ CD4+) (NN T) (NNS cells)) (, ,) (NP (JJ adult) (JJ CD4+CD45RO-) (NN T) (NNS cells))) (-RRB- -RRB-))) (VP (VBP regulate) (NP (NN IL-2) (NN transcription)) (PP (IN by) (NP (NP (DT a) (NN mechanism)) (VP (VBG involving) (NP (NP-COOD (CC both) (NP (DT a) (NN silencer)) (CC and) (NP (DT an) (NN activator))) (VP (VBG acting) (PP (IN on) (NP (NP (DT the) (JJ purine-rich) (NN IL-2) (NN promoter) (NNS elements)) (PRN (-LRB- -LRB-) (NP (NN NF-AT) (NN binding) (NNS sites)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN memory) (NNS cells)) (, ,) (NP-COOD (CC either) (NP (NP (ADJP (ADVP (FW in) (FW vitro)) (VBN activated)) (NN helper) (NN T) (NNS cells)) (VP (VBG reverting) (PP (TO to) (NP (DT a) (JJ resting) (NN state))))) (, ,) (CC or) (NP (JJ CD4+) (NN T) (-LRB- -LRB-) (NN memory) (-RRB- -RRB-) (NNS clones)) (, ,) (CC or) (NP (NP (JJ CD4+CD45RO+) (NN T) (NNS cells)) (VP (VBN isolated) (ADVP (FW ex) (FW vivo))))) (, ,)) (ADVP-TMP (RB no) (RB longer)) (VP (VBP have) (NP (DT a) (NN silencer))) (. .)))
(TOP (S (S (NP-SBJ-7 (PRP$ Their) (NN IL-2) (NN transcription)) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (VP (VBN controlled) (PP (RB solely) (IN by) (NP-LGS (NP (DT the) (NN transition)) (PP (PP (IN from) (NP (JJ inactive))) (PP (TO to) (NP (JJ active))) (NP-9 (NP (JJ functional) (NN state)) (PP (IN of) (NP (NP (DT a) (JJ positive) (NN transcription) (NN factor)) (VP (VBG binding) (PP (TO to) (NP-COOD (NP (DT these) (NN promoter) (NNS elements)) (CONJP (RB as) (RB well) (IN as)) (NP (PRP$ its) (ADJP-COOD (ADJP (JJ cytoplasmic)) (CC or) (ADJP (JJ nuclear))) (NN location)))))))))))))))) (: :)) (S-COOD (S (PP (IN in) (NP (VBG resting) (NN memory) (NN T) (NNS cells))) (NP-SBJ (DT the) (NN activator)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ located) (PP (IN in) (NP (DT the) (NN cytoplasm))))) (CC and) (VP (VBZ is) (ADJP-PRD (JJ inactive))))) (, ,) (IN whereas) (S (PP (IN in) (NP (VBN stimulated) (NNS cells))) (NP-SBJ-10 (PRP it)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ functional)) (PP (IN in) (S (VP (VBG promoting) (NP (NN transcription)))))) (CC and) (VP (ADVP-TMP (RB now)) (VBZ resides) (PP (IN in) (NP (DT the) (NN nucleus)))))) (. .))))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (NN gene) (VBG coding)) (PP (IN for) (NP (DT the) (JJ main) (NN T) (NN cell) (NN growth) (NN factor)))))) (VP (VBZ changes) (ADVP (RB irreversibly)) (PP-TMP (IN after) (NP (NP (DT the) (JJ first) (NN encounter)) (PP (IN of) (NP (NN T) (NNS cells))) (PP (IN with) (NP (NN antigen)))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (ADJP-PRD (RBS most) (JJ likely) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (NN silencer)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (ADJP (RBR more) (JJ stringent)) (NN activation) (NNS requirements)) (PP (IN of) (NP (JJ naive) (JJ CD4+) (NN T) (NNS cells)))))))))) (. .)))
(TOP (NP (NP (NP (JJ Single) (NN strand) (NN conformation) (NN polymorphism) (NN analysis)) (PP (IN of) (NP (NP (NN androgen) (NN receptor) (NN gene) (NNS mutations)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN androgen) (NN insensitivity) (NNS syndromes))))))) (: :)) (NP (NP (NN application)) (PP (IN for) (NP-COOD (NP (NN diagnosis)) (, ,) (NP (JJ genetic) (NN counseling)) (, ,) (CC and) (NP (NN therapy)))) (. .))))
(TOP (S (NP-SBJ (JJ Recent) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-1 (NP (NNS mutations)) (PP (IN in) (NP (DT the) (NN androgen) (NN receptor) (NN gene)))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (NN androgen) (NN insensitivity) (NNS syndromes)) (, ,) (NP (NP (DT a) (JJ heterogeneous) (NN group)) (PP (IN of) (NP (NP (JJ related) (NNS disorders)) (VP (VBG involving) (NP (NP (JJ defective) (JJ sexual) (NN differentiation)) (PP (IN in) (NP (JJ karyotypic) (NNS males))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP address) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ rapid) (JJ mutational) (NN analysis)) (PP (IN of) (NP (DT the) (NN androgen) (NN receptor) (NN gene))) (PP (IN for) (NP (NP-COOD (NP (JJ initial) (NN diagnosis)) (, ,) (NP (JJ genetic) (NN counseling)) (, ,) (CC and) (NP (JJ molecular) (NN subclassification))) (PP (IN of) (NP-COOD (NP (VBN affected) (NNS patients)) (CC and) (NP (PRP$ their) (NNS families)))))))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (NN DNA)) (PP (IN from) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN of) (NP (NP (CD six) (NNS patients)) (PP (IN from) (NP (CD five) (NNS families))) (PP (IN with) (NP (NP (JJ various) (NNS degrees)) (PP (IN of) (NP (NN androgen) (NN insensitivity)))))))))) (VP (VBD was) (VP (VBN studied))) (. .)))
(TOP (S (NP-SBJ-3 (NP (NNS Exons) (NP-COOD (NP (CD 2)) (TO to) (NP (CD 8)))) (PP (IN of) (NP (DT the) (NN androgen) (NN receptor) (NN gene)))) (VP (VBD were) (VP (VBN analyzed) (S (VP (VBG using) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP-COOD (NP (JJ single) (NN strand) (NN conformation) (NN polymorphism) (NN analysis)) (CC and) (NP (JJ direct) (NN DNA) (NN sequencing))))))))) (. .)))
(TOP (S (NP-SBJ-4 (JJ Female) (NN family) (NNS members)) (VP (VBD were) (VP (ADVP (RB also)) (VBN studied) (S (VP (TO to) (VP (VB identify) (NP (NN heterozygote) (NNS carriers))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-5 (NP (NN Point) (NNS mutations)) (PP (IN in) (NP (DT the) (NN AR) (NN gene)))) (VP (VBD were) (VP (VBN identified) (PP (IN in) (NP (QP (DT all) (CD six)) (NNS patients)))))) (, ,) (CC and) (S (NP-SBJ (DT all) (NNS mutations)) (VP (VBD caused) (NP (NN amino) (NN acid) (NNS substitutions)))) (. .)))
(TOP (S (NP-SBJ (NP (CD One) (NN patient)) (PP (IN with) (NP (JJ incomplete) (NN androgen) (NN insensitivity)))) (VP (VBD was) (NP-PRD (NP (DT a) (NN mosaic)) (PP (IN for) (NP (DT the) (NN mutation))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (CD Four)) (PP (IN of) (NP (DT the) (CD five) (NNS mothers)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ young) (NN sister)) (PP (IN of) (NP (CD one) (NN patient)))) (, ,)) (VP (VBD were) (NP-PRD (NP (NNS carriers)) (PP (IN of) (NP (NP (DT the) (NN mutation)) (ADJP (JJ present) (PP (IN in) (NP (DT the) (VBN affected) (NN child)))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-100 (JJ new) (NNS mutations)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (DT the) (NN androgen) (NN receptor) (NN gene))) (S (VP (VBG leading) (PP (TO to) (NP (JJ sporadic) (NN androgen) (NN insensitivity) (NN syndrome)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Molecular) (JJ genetic) (NN characterization)) (PP (IN of) (NP (DT the) (JJ variant) (NN allele)))) (VP-COOD (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ primary) (NN tool)) (PP (IN for) (NP-COOD (NP (NN diagnosis)) (CC and) (NP (JJ subsequent) (NN therapy)))))))) (, ,) (CC and) (VP (MD can) (VP (VB provide) (NP (NP (DT a) (NN basis)) (PP (IN for) (S (VP (VBG distinguishing) (NP (NP (JJ heterozygous) (NNS carriers)) (PP (IN in) (NP (JJ familial) (NN androgen) (NN resistance))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN identification)) (PP (IN of) (NP (NNS carriers)))) (VP (VBZ is) (PP-PRD (IN of) (NP (JJ substantial) (JJ clinical) (NN importance))) (PP (IN for) (NP (JJ genetic) (NN counseling)))) (. .)))
(TOP (S (NP-SBJ-1 (NP (ADJP (RB Minimally) (VBN modified) (JJ low) (NN density) (JJ lipoprotein-induced)) (JJ inflammatory) (NNS responses)) (PP (IN in) (NP (JJ endothelial) (NNS cells)))) (VP (VBP are) (VP (VBN mediated) (PP (IN by) (NP-LGS (JJ cyclic) (NN adenosine) (NN monophosphate))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-3 (NP (ADJP (RB minimally) (VBN oxidized)) (NN LDL)) (PRN (-LRB- -LRB-) (NP (NN MM-LDL)) (-RRB- -RRB-))) (VP (VBD activated) (NP-2 (JJ endothelial) (NNS cells)) (S (VP (TO to) (VP (VB increase) (NP (NP (PRP$ their) (NN interaction)) (PP (IN with) (NP-COOD (NP (NNS monocytes)) (CONJP (CC but) (RB not)) (NP (NNS neutrophils)))))))) (, ,) (S (VP (VBG inducing) (NP (NP (NP-COOD (NP (NN monocyte)) (CONJP (CC but) (RB not)) (NP (NN neutrophil))) (NP-COOD (NP (NN binding)) (CC and) (NP (NN synthesis)))) (PP (IN of) (NP-COOD (NP (NN monocyte) (JJ chemotactic) (NN protein-1)) (CC and) (NP (NP (NN monocyte) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN M-CSF)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NNS studies))) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NN signaling) (NNS pathways)) (SBAR (WHPP-4 (IN by) (WHNP (WDT which))) (S (NP-SBJ-5 (DT this) (JJ monocyte-specific) (NN response)) (VP (VBZ is) (VP (VBN induced)))))))) (. .)))
(TOP (S (NP-SBJ-6 (NP (CC Both) (NP (NP (NN induction)) (PP (IN of) (NP (NN monocyte) (NN binding)))) (CC and) (NP (NP (NN mRNA) (NNS levels)) (PP (IN for) (NP (NN M-CSF))))) (PP (IN by) (NP (NN MM-LDL)))) (VP (VBD were) (RB not) (VP (VBN inhibited) (PP (IN in) (NP (ADJP (NN protein) (NN kinase) (JJ C-depleted)) (JJ endothelial) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (NN number)) (PP (IN of) (NP (PRP$ our) (NNS studies)))) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN cAMP)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ second) (NN messenger)) (PP (IN for) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN MM-LDL))) (VP (VBN cited) (ADVP (RB above)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Incubation)) (PP (IN of) (NP (JJ endothelial) (NNS cells))) (PP (IN with) (NP (NN MM-LDL) (VBD caused)))) (VP (DT a) (NP (NP (CD 173) (ADJP (NN %)) (NN increase)) (PP (IN in) (NP (JJ intracellular) (NN cAMP) (NNS levels))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Agents)) (SBAR (WHNP-8 (WDT which)) (S (VP (VBD increased) (NP (NN cAMP) (NNS levels))))) (, ,) (PP (VBG including) (NP-COOD (NP (NN cholera) (NN toxin)) (, ,) (NP (NN pertussis) (NN toxin)) (, ,) (NP (NN dibutyryl) (NN cAMP)) (, ,) (CC and) (NP (NN isoproterenol))))) (VP (VBD mimicked) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (NN MM-LDL))))) (. .)))
(TOP (S (NP-SBJ-9 (NP (NNS Agents)) (SBAR (WHNP-10 (WDT which)) (S (VP (VBD elevated) (NP (NN cAMP)))))) (VP (VBD were) (ADVP (RB also)) (VP (VBN shown) (S (VP (TO to) (VP (VB activate) (NP (NN NF) (NN kappa) (NN B)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT this) (NN transcription) (NN factor))) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (JJ monocyte-endothelial) (NNS interactions))))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-12 (NP (NP (JJ endothelial) (NN leukocyte) (NN adhesion) (NN molecule)) (PRN (-LRB- -LRB-) (NP (NN ELAM)) (-RRB- -RRB-))) (NN mRNA) (NN synthesis)) (VP (MD can) (VP (VB be) (VP (VBN regulated) (PP (IN by) (NP-LGS (NN NF) (NN kappa) (NN B)))))))) (, ,) (S-COOD (S (NP-SBJ-14 (NN ELAM)) (VP (VBD was) (RB not) (VP (VBN expressed)))) (CC and) (S (NP-SBJ-13 (NN ELAM) (NN mRNA)) (VP (VBD was) (ADVP (RB only) (RB slightly)) (VP (JJ elevated) (PP (IN in) (NN response) (TO to) (NP (NN MM-LDL))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP present) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ-15 (NP (NN induction)) (PP (IN of) (NP (NN neutrophil) (NN binding))) (PP (IN by) (NP (NN LPS)))) (VP (VBZ is) (ADVP (RB actually)) (VP (VBN suppressed) (PP (IN by) (NP-LGS (NP (NNS agents)) (SBAR (WHNP-16 (WDT that)) (S (VP (VBD elevated) (NP (NN cAMP) (NNS levels))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Antisense) (NNS oligonucleotides)) (PP (TO to) (NP (NP (DT the) (NN p65) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B)))))) (VP-COOD (VP (VBP block) (NP (NN CD11b) (NN expression))) (CC and) (VP (VBP alter) (NP (NP (NN adhesion) (NNS properties)) (PP (IN of) (NP (VBN differentiated) (NN HL-60) (NNS granulocytes)))))) (. .)))
(TOP (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ pleiotropic) (NN regulator)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (JJ cellular) (NN response)) (PP (TO to) (NP (NN injury)))))))))))) (. .)))
(TOP (S (NP-SBJ-1 (DT This) (NN function)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (VBN coordinated) (NN binding)) (PP (IN of) (NP (NP (NNS subunits)) (PP (IN of) (NP (NN NF-kappa) (NN B))))) (PP (TO to) (NP (NP (JJ distinct) (NNS regions)) (PP (IN of) (NP (NP (DT the) (JJ promoter) (NNS elements)) (PP (IN of) (NP (JJ numerous) (NNS genes))) (, ,) (PP (VBG including) (NP-COOD (NP (NNS cytokines)) (, ,) (NP (NN growth) (NN factor) (NNS receptors)) (, ,) (CC and) (NP (NN adhesion) (NNS molecules))))))))))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (JJ Antisense) (JJ phosphorothioate) (NNS oligonucleotides)) (PP (TO to) (NP (NP (DT the) (NP-COOD (NP (NN p50)) (CC and) (NP (NN p65))) (NNS subunits)) (PP (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN complex)))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB define) (NP (NP (DT the) (JJ physiologic) (NN role)) (PP (IN of) (NP (DT this) (NN transcription) (NN factor))) (PP (IN in) (NP (ADJP-COOD (ADJP (VBG resting)) (CC and) (ADJP (VBN stimulated))) (NNS granulocytes))))))))) (. .)))
(TOP (S (NP-SBJ-4 (NP (DT A) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN p65)))))) (VP (VBD was) (VP (VBN produced) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (DT the) (JJ phosphorothioate) (JJ antisense) (NN oligodeoxynucleotide))))))) (. .)))
(TOP (S (NP-SBJ-5 (DT This) (NN reduction)) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NP (JJ rapid) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ cellular) (NN adhesion)) (PP (IN of) (NP (NP (ADJP (JJ dimethyl) (JJ sulfoxide-differentiated)) (NN HL-60) (NN leukemia) (NNS cells)) (VP (VBN stimulated) (PP (IN by) (NP-LGS (NP (NN 12-O-tetradecanoylphorbol) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (NP-SBJ-6 (DT These) (NNS effects)) (VP (VBD were) (VP (VBN characterized) (PP (IN by) (NP-LGS (NP (DT a) (JJ marked) (NN reduction)) (PP (IN in) (NP (NP (NN CD11b) (JJ integrin) (NN expression)) (PP (IN on) (NP (NP (DT the) (NN surface)) (PP (IN of) (NP (VBN treated) (NNS cells))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (DT the) (NN p65) (JJ antisense) (NN oligomer)) (ADVP (RB effectively)) (VP (VBD abolished) (NP (NP (DT an) (NN upregulation)) (PP (IN of) (NP (NP (NN CD11b)) (SBAR (WHNP-7 (WDT that)) (S (VP (VBD was) (VP (VBN produced) (PP (IN by) (NP-LGS-COOD (NP (NN formyl-met-leu-phe)) (CC and) (NP (NN TPA)))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (DT the) (NN p65) (JJ antisense) (JJ phosphorothioate) (NN oligodeoxynucleotide)) (VP (VBD had) (NP (DT no) (JJ significant) (NN effect)) (PP-COOD (PP (IN on) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (JJ reactive) (NN oxygen) (NNS intermediates))))) (CC or) (PP (IN on) (NP (NP (NNS phagocytosis)) (PP (IN by) (NP (DT these) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-9 (NP (JJ antisense) (NNS oligomers)) (PP (TO to) (NP (NN p65)))) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB define) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (NP (DT the) (NN activation) (NNS pathways)) (PP (IN of) (NP (NNS neutrophils))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Costimulation)) (PP (IN of) (NP (NP-COOD (NP (NN cAMP)) (CC and) (NP (NN protein) (NN kinase) (NN C))) (NNS pathways)))) (VP-COOD (VP (VBZ inhibits) (NP (DT the) (JJ CD3-dependent) (NN T) (NN cell) (NN activation))) (CC and) (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJ persistent) (NN expression)) (PP (IN of) (NP (DT the) (NN AP-1) (NN transcription) (NN factor))))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-1 (NP (DT The) (NNS effects)) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT a) (JJ combined) (NN stimulation)) (PP (IN of) (NP (ADJP-COOD (ADJP (NP (NN cAMP-))) (CC and) (ADJP (NN protein) (NN kinase) (NN C) (-LRB- -LRB-) (NN PKC) (-RRB- -RRB-) (JJ -dependent))) (NNS pathways))))))) (VP (VBP have) (VP (VBN been) (VP (VBN investigated) (PP (IN in) (NP (JJ different) (JJ cellular) (NNS systems))))))) (, ,) (CC and) (S (NP-SBJ (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-2 (PRP they)) (VP (MD may) (VP (VB complement) (NP (DT each) (JJ other)) (PP (IN in) (S (VP (VBG activating) (NP (NN cell) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN differentiation)))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (PP-TMP (IN upon) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (DT both) (NNS pathways))))) (NP-SBJ (NN T) (NNS lymphocytes)) (VP (VBD became) (ADJP-PRD (JJ refractory) (PP (TO to) (NP (NP (NN activation)) (PP (IN via) (NP (DT the) (NN CD3/T) (NN cell) (NN receptor) (-LRB- -LRB-) (NN TcR) (-RRB- -RRB-) (NN complex)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN T) (NNS cells)) (VP (VBN preincubated) (PP (IN with) (NP-COOD (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (CC and) (NP (NP (NN dibutyryl) (NN cAMP)) (PRN (-LRB- -LRB-) (NP (NN Bt2cAMP)) (-RRB- -RRB-))))))) (VP (VBD displayed) (NP (DT a) (JJ deficient) (JJ proliferative) (NN ability)) (PP (IN in) (NN response) (TO to) (NP (JJ anti-CD3) (NN mAb) (NN stimulation))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NNS lymphocytes)) (VP (VBN treated) (ADVP (RB individually)) (PP (IN with) (NP-COOD (CC either) (NP (NN Bt2cAMP)) (CC or) (NP (NN PMA)))))) (VP (VBD responded) (ADVP (RB comparably)) (PP (TO to) (NP (JJ untreated) (NNS samples))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD detected) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (DT the) (NP-COOD (NP (VBN reduced) (JJ mitogenic) (NN response)) (CC and) (NP (JJ low) (NN expression)))) (PP (IN of) (NP-COOD (CC both) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT the) (NN alpha) (NN chain)) (PRN (-LRB- -LRB-) (NP (NN CD25)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (NN IL-2) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IL-2R)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (JJ intracellular) (NN Ca2+) (NN mobilization)))) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ-3 (DT the) (JJ CD3/TcR-dependent) (NN signal) (NN transduction)) (VP (VBD was) (VP (JJ impaired) (PP (IN in) (NP (JJ PMA/Bt2cAMP-treated) (NNS cells)))))))) (. .)))
(TOP (S-COOD (S (ADVP (RB Remarkably)) (, ,) (NP-SBJ (PRP we)) (VP (VBD observed) (SBAR (IN that) (S (NP-SBJ (DT these) (NNS samples)) (VP (VBD displayed) (NP (NP (DT a) (JJ persistent) (NN expression)) (PP (IN of) (NP (DT the) (NN c-fos) (NN protooncogene))) (, ,) (VP (VBN associated) (PP (TO to) (NP (DT an) (VBN increased) (NN AP-1) (JJ DNA-binding) (NN activity)))))))))) (, ,) (IN whereas) (S (NP-SBJ-4 (NP (DT no) (NNS variations)) (PP (IN of) (NP-COOD (NP (NN CREB)) (CC or) (NP (NN NF-kB))))) (VP (VBD were) (VP (VBN detected)))) (. .)))
(TOP (S (NP-SBJ-COOD (CC Neither) (NP (NN Bt2cAMP)) (CC nor) (NP (NN PMA))) (ADVP (RB individually)) (VP (VBD mediated) (NP (NP (DT these) (JJ sustained) (NNS effects)) (, ,) (SBAR (WHNP-5 (WDT which)) (S (ADVP (RB therefore)) (VP (VBP appear) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (DT the) (NN interplay)) (PP (IN between) (NP (DT both) (JJ metabolic) (NNS stimuli)))))))))))) (. .)))
(TOP (S (ADVP (RB Altogether)) (, ,) (NP-SBJ (DT the) (NNS data)) (VP (VBP provide) (NP (DT the) (NN evidence) (SBAR (IN that) (S (NP-SBJ-6 (DT both) (NNS pathways)) (VP-COOD (VP (VBP complement) (NP (DT each) (JJ other)) (PP (IN in) (S (VP (VBG regulating) (NP (NN gene) (NN expression)))))) (CC and) (VP (ADVP (, ,)) (RB conversely) (, ,) (NP (VBP downregulate) (DT the) (NN TcR) (NN transduction)))))))) (NNS mechanisms)))
(TOP (NP (NP (JJ Nuclear) (NN factor) (NN kappa) (NN B)) (, ,) (NP (NP (DT a) (NN mediator)) (PP (IN of) (NP (NN lipopolysaccharide) (NNS effects)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Exposure)) (PP (IN of) (NP (JJ certain) (NN cell) (NNS types))) (PP (TO to) (NP (JJ bacterial) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-)))))) (VP (VBZ leads) (PP (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ inducible) (NN transcription) (NN factor))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD One)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B) (POS 's)) (JJ unique) (NNS properties)))) (VP (VBZ is) (NP-PRD (NP (PRP$ its) (JJ posttranslational) (NN activation)) (PP (IN via) (NP (NP (NN release)) (PP (IN of) (NP (NP (DT an) (JJ inhibitory) (NN subunit)) (, ,) (VP (VBN called) (S (NP-PRD (NP (NP (NN inhibitor)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (PRN (-LRB- -LRB-) (NP (NN I) (NN kappa) (NN B)) (-RRB- -RRB-))))) (, ,))) (PP (IN from) (NP (DT a) (JJ sequestered) (JJ cytoplasmic) (NN form))))))) (. .)))
(TOP (S (NP-SBJ-48 (DT This) (NN event)) (VP (VBZ is) (VP (ADVP (RB also)) (VBN triggered) (PP (IN under) (NP (NP (JJ various) (JJ other) (NNS conditions)) (PP (IN of) (NP (JJ biomedical) (NN importance))))))) (. .)))
(TOP (S (NP-SBJ-COOD-49 (NP (JJ Other) (JJ bacterial) (NNS toxins)) (, ,) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (, ,) (NP (NP (NN interleukin-1)) (PRN (-LRB- -LRB-) (NP (NN IL-1)) (-RRB- -RRB-))) (, ,) (NP (NN T) (NN cell) (NNS mitogens)) (, ,) (NP (NN UV) (NN light)) (, ,) (NP (NN gamma) (NNS rays)) (CC and) (NP (JJ oxidative) (NN stress))) (VP (VBD were) (VP (VBN reported) (S (VP (TO to) (VP (VB induce) (NP (NN NF-kappa) (NN B))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ activated) (NN form)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (, ,) (SBAR (WHNP-50 (WDT which)) (S (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN taken) (PRT (RP up)) (PP (IN into) (NP (NNS nuclei))))))) (, ,)) (VP (VBZ initiates) (NP (NP (NN transcription)) (PP (IN from) (NP (JJ immediate) (JJ early) (NNS genes))) (PP (IN in) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NN cell) (NNS types))))))) (. .)))
(TOP (S (NP-SBJ-52 (NP (JJS Most)) (PP (IN of) (NP (NP (DT the) (NN target) (NNS genes)) (PP (IN for) (NP (NN NF-kappa) (NN B)))))) (VP-COOD (VP (VBP are) (PP-PRD (IN of) (NP (NN relevance))) (PP (IN for) (NP (DT the) (JJ immune) (NN response)))) (CC and) (VP (MD can) (VP (VB be) (VP (VBN grouped) (PP (IN into) (NP (NP (DT those)) (VP (JJ encoding) (NP-COOD (NP (NNS cytokines)) (, ,) (NP (NN cell) (NN surface) (NNS receptors)) (, ,) (NP (JJ acute) (NN phase) (NNS proteins)) (CC and) (NP (JJ viral) (NNS genomes)))) (, ,) (PP (JJ such) (IN as) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (MD will) (VP (VB discuss) (NP (NP (JJ recent) (JJ experimental) (NNS evidences)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN LPS)) (VP (MD might) (VP (VB share) (NP (NP (DT a) (NN pathway)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activation)))) (PP (IN with) (NP (NP (JJ other) (NNS inducers)) (PP (IN of) (NP (DT the) (NN factor))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ common) (NN pathway)) (VP (MD may) (VP (VB involve) (NP (NP (JJ reactive) (NN oxygen) (NNS intermediates)) (PRN (-LRB- -LRB-) (NP (NN ROI)) (-RRB- -RRB-))) (PP (IN as) (NP (NN messenger) (NNS molecules))))) (. .)))
(TOP (S (NP-SBJ (JJ Human) (NN T) (NN cell) (NN transcription) (NN factor) (NN GATA-3)) (VP (VBZ stimulates) (NP (NN HIV-1) (NN expression))) (. .)))
(TOP (S (NP-SBJ-17 (NP (NP (DT A) (NN family)) (PP (IN of) (NP (JJ transcriptional) (VBG activating) (NNS proteins)))) (, ,) (NP (DT the) (NN GATA) (NNS factors)) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB bind) (PP (TO to) (NP (DT a) (NN consensus) (NN motif))) (PP (IN through) (NP (DT a) (ADJP (RB highly) (VBN conserved)) (NN C4) (NN zinc) (NN finger) (NN DNA) (NN binding) (NN domain))))))))) (. .)))
(TOP (S (NP-SBJ-18 (NP (NP (CD One) (NN member)) (PP (IN of) (NP (DT this) (JJ multigene) (NN family)))) (, ,) (NP (NN GATA-3)) (, ,)) (VP (VBZ is) (ADVP-PRD (RBS most) (RB abundantly)) (VP (VBN expressed) (PP (IN in) (NP (NP (NN T) (NNS lymphocytes)) (, ,) (NP (NP (DT a) (JJ cellular) (NN target)) (PP (IN for) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))) (NP-COOD (NP (NN infection)) (CC and) (NP (NN replication)))))))))) (. .)))
(TOP (S (NP-SBJ (ADJP (FW In) (FW vitro)) (NN DNase) (CD I) (NN footprinting) (NN analysis)) (VP (VBD revealed) (NP (NP (CD six) (NN hGATA-3) (NN binding) (NNS sites)) (PP (IN in) (NP (NP (NP (DT the) (NN U3) (NN region)) (PRN (-LRB- -LRB-) (NP (DT the) (ADJP (JJ transcriptional) (JJ regulatory)) (NN domain)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN HIV-1) (NN LTR))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Cotransfection)) (PP (IN of) (NP (DT an) (NN hGATA-3) (NN expression) (NN plasmid))) (PP (IN with) (NP (NP (DT a) (NN reporter) (NN plasmid)) (SBAR (WHNP-19 (WP$ whose) (NN transcription)) (S (VP (VBZ is) (VP (VBN directed) (PP (IN by) (NP-LGS (DT the) (NN HIV-1) (NN LTR)))))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (QP (CD 6-) (TO to) (JJ 10-fold)) (NN stimulation)) (PP (IN of) (NP (JJ LTR-mediated) (NN transcription))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (ADJP (NN site) (JJ specific)) (NN mutation)) (PP (IN of) (NP (DT these) (NN GATA) (NNS sites)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ virtual) (NN abrogation)) (PP (IN of) (NP (NP (DT the) (NN activation)) (PP (IN by) (NP (NN hGATA-3))))))))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (NP-SBJ (NP (NN deletion)) (PP (IN of) (NP (DT the) (NN hGATA-3) (JJ transcriptional) (NN activation) (NN domain)))) (VP (VBD abolished) (NP (JJ GATA-dependent) (NN HIV-1) (NN trans-activation)) (, ,) (S (VP (VBG showing) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NP (JJ viral) (NN transcription)) (VP (VBN observed))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (VBN cotransfected) (NN hGATA-3)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Introduction)) (PP (IN of) (NP (NP (DT the) (NN HIV-1) (NNS plasmids)) (SBAR (WHPP-22 (IN in) (WHNP (WDT which))) (S (NP-SBJ-21 (DT the) (NN GATA) (NNS sites)) (VP (VBP have) (VP (VBN been) (VP (VBN mutated) (PP (IN into) (NP (JJ human) (NN T) (NNS lymphocytes))))))))))) (ADVP (RB also)) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (JJ LTR-mediated) (NN transcription)))) (PP-COOD (PP (IN at) (NP (CC both) (DT the) (JJ basal) (NN level))) (CC and) (PP (IN in) (NP (ADJP (-LRB- -LRB-) (NP-COOD (NP (NN PHA-)) (CC plus) (NP (NN PMA-))) (-RRB- -RRB-) (JJ stimulated)) (NN T) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NN addition) (TO to) (NP (NP (PRP$ its) (JJ normal) (NN role)) (PP (IN in) (NP (NN T) (NN lymphocyte) (NN gene) (NN regulation))))) (, ,) (NP-SBJ (NN hGATA-3)) (VP (MD may) (ADVP (RB also)) (VP (VB play) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (NP (NN HIV-1) (JJ transcriptional) (NN activation)))))))) (. .)))
(TOP (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ preexisting)) (CC and) (ADJP (JJ nuclear))) (NNS forms)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (NP (DT The) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))) (CD 3)) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ inducible) (JJ DNA-binding) (NN protein)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (JJ transcriptional) (NN induction)) (PP (IN of) (NP (DT the) (NN IL-2) (NN gene))) (PP-TMP (IN during) (NP (NN T) (NN cell) (NN activation))))))))))) (. .)))
(TOP (S (NP-SBJ-2 (NN NF-AT)) (VP (VBZ is) (VP (VBN thought) (S (VP (TO to) (VP (VB consist) (PP (IN of) (NP (NP (CD two) (NNS components)) (: :) (NP-COOD (NP (NP (DT a) (ADJP-COOD (ADJP (JJ ubiquitous)) (, ,) (ADJP (JJ inducible))) (JJ nuclear) (NN component)) (SBAR (WHNP-3 (WDT that)) (S (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN identified) (PP (IN as) (NP (NP-COOD (NP (NN Fos)) (CC and) (NP (NN Jun))) (NNS proteins)))))))) (, ,) (CC and) (NP (NP (NP (DT a) (ADJP-COOD (ADJP (VBG preexisting)) (, ,) (ADJP (NN T) (JJ cell-specific))) (NN component)) (PRN (-LRB- -LRB-) (NP (NN NF-ATp)) (-RRB- -RRB-))) (SBAR (WHNP-4 (WDT which)) (S (VP (VBZ is) (NP-PRD (NP (DT the) (NN target)) (PP (IN for) (NP (DT the) (JJ immunosuppressive) (NNS agents) (NP-COOD (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))) (CC and) (NP (NN FK506)))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NP (JJ nuclear) (NNS extracts)) (PP (IN from) (NP (VBN activated) (NN T) (NNS cells)))) (VP (VBP form) (NP (NP (CD two) (JJ inducible) (NN NF-AT) (NNS complexes)) (PP (IN with) (NP (NP (DT an) (NN oligonucleotide)) (VP (VBG corresponding) (PP (TO to) (NP (NP (DT the) (JJ distal) (NN NF-AT) (NN site)) (PP (IN of) (NP (DT the) (JJ murine) (NN IL-2) (NN promoter))))))))) (, ,) (SBAR (IN although) (S (NP-SBJ (NP (JJ hypotonic) (NNS extracts)) (PP (IN of) (NP (JJ unstimulated) (NN T) (NNS cells)))) (VP (VBP form) (NP (NP (DT a) (JJ single) (NN complex)) (VP (VBG containing) (NP (NN NF-ATp)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB detect) (NP (NN NF-ATp)) (PP (IN in) (NP (DT a) (NN gel) (NN shift) (NN assay))))))) (, ,) (SBAR (WHNP-6 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP-COOD (NP (NN purification)) (CC and) (NP (JJ biochemical) (NNS studies))) (PP (IN of) (NP (DT this) (NN protein))))))))) (, ,)) (VP (VBZ is) (ADJP-PRD (RB strikingly) (JJ dependent) (PP (IN on) (NP (NP (DT the) (JJ precise) (NN sequence)) (PP (IN of) (NP (NP (DT the) (NN NF-AT) (NN oligonucleotide)) (VP (VBN used) (PP (IN as) (NP (DT the) (JJ labeled) (NN probe))))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (NP-SBJ (PRP we)) (VP (VBP present) (NP (NN evidence) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-5 (NP (DT the) (NN component)) (SBAR (WHNP-7 (WDT that)) (S (VP (VBZ forms) (NP (DT the) (ADJP (ADJP (JJ faster-migrating)) (PRN (-LRB- -LRB-) (`` ") (ADJP (JJR lower)) ('' ") (-RRB- -RRB-))) (JJ nuclear) (NN NF-AT) (NN complex)))))) (VP (VBZ is) (VP (VBN derived) (PP (IN by) (NP-LGS (NP (DT a) (ADJP-COOD (ADJP (JJ calcium-dependent)) (, ,) (ADJP (JJ cyclosporin-sensitive)) (, ,) (ADJP-TMP (JJ posttranslational))) (NN modification)) (PP (IN of) (NP (NN NF-ATp))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (NP-COOD (NP (NN Fos)) (CC and) (NP (NN Jun))) (NNS proteins)) (VP (VBP stabilize) (NP (NP (PRP$ its) (NN interaction)) (PP (IN with) (NP (NN DNA)))))))))) (. .)))
(TOP (S (NP-SBJ-8 (DT The) (NNS results)) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (DT a) (NN model)) (VP (VBG relating) (NP (DT the) (CD two) (JJ nuclear) (NN NF-AT) (NNS complexes)) (PP (TO to) (NP (NN NF-ATp)))))))))) (. .)))
(TOP (NP (NP (NN Enhancing) (NN effect)) (PP (IN of) (NP (CD 17) (NN beta-estradiol))) (PP (IN on) (NP (JJ human) (NN NK) (NN cell) (NN activity))) (. .)))
(TOP (S (NP-SBJ-28 (NP (DT The) (ADJP (FW in) (FW vitro)) (NN effect)) (PP (IN of) (NP (CD 17) (NN beta-estradiol))) (PP (IN on) (NP (NN NK) (NN activity)))) (VP (VBD was) (VP (VBN studied))) (. .)))
(TOP (S-COOD (S (NP-SBJ-29 (NP (DT The) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN NK) (NN activity)))) (PP (IN of) (NP (NP (NN YT-N17)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ human) (JJ NK-like) (NN cell) (NN line)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN enhanced) (PP (IN by) (NP-LGS (NP (CD 17) (NN beta-estradiol)) (PRN (-LRB- -LRB-) (NP (NN E2)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP-SBJ-30 (DT the) (NN enhancement)) (VP (VBD was) (VP (VBN blocked) (PP (IN by) (NP-LGS (NP (NP (NN tamoxifen)) (PRN (-LRB- -LRB-) (NP (NN Tx)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN antagonist)) (PP (IN of) (NP (NN E2))))))))) (. .)))
(TOP (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP-SBJ (NP (JJ other) (NN steroid) (NNS hormones)) (PP (JJ such) (IN as) (NP-COOD (NP (NN Tx)) (, ,) (NP (NN progesterone)) (, ,) (CC and) (NP (NN testosterone))))) (VP (VBD had) (NP (DT no) (NN effect))) (. .)))
(TOP (S (NP-SBJ (NN YT-N17)) (VP (VBD contained) (NP (NP (NP (NP (ADJP (CD 11.8) (NN fmol/mg)) (NN protein)) (PP (IN of) (NP (NN estrogen) (NN receptor)))) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (PP (IN of) (NP (CD two) (JJ independent) (NNS assays)))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN value)) (SBAR (WHNP-31 (WDT which)) (S (VP (VBD was) (ADJP-PRD (ADJP (RB 5-10-fold) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (JJ other) (JJ hematopoietic) (NN cell) (NNS lines)))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-32 (NP (DT An) (NN enhancement)) (PP (IN of) (NP (NN NK) (NN activity))) (PP (IN by) (NP (NN E2)))) (VP (VBD was) (VP (ADVP (RB also)) (VBN seen) (PP (IN in) (NP (NP (JJ large) (JJ granular) (NNS lymphocytes)) (VP (VBN obtained) (PP (IN from) (NP (JJ normal) (NNS subjects))))))))) (, ,) (CC and) (S (NP-SBJ-33 (PRP it)) (VP (VBD was) (VP (ADVP-TMP (RB again)) (VBN suppressed) (PP (IN by) (NP-LGS (NN Tx)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN E2)) (VP (VBZ is) (NP-PRD (NP (CD one)) (PP (IN of) (NP (NP (DT the) (VBG activating) (NNS factors)) (PP (IN for) (NP (NN NK/LGL) (NNS cells)))))))))) (. .)))
(TOP (NP (NP (NN Cytokine) (NN modulation)) (PP (IN of) (NP (NN HIV) (NN expression))) (. .)))
(TOP (S (NP-SBJ-23 (NP (NNS Cytokines)) (, ,) (NP (NP (DT the) (NN peptide) (NNS hormones)) (SBAR (WHNP-24 (WDT which)) (S (VP-COOD (VP (VBP control) (NP (NP (DT the) (NN homeostasis)) (PP (IN of) (NP (DT the) (JJ immune) (NN system))))) (CC and) (RB also) (VP (VBP play) (NP (DT a) (JJ fundamental) (NN role)) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ inflammatory)) (CC and) (ADJP (JJ immune) (JJ mediated))) (NNS reactions)))))))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN involved) (PP (IN at) (NP (NP (JJ multiple) (NNS levels)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (DT the) (VBN acquired) (JJ immune) (NN deficiency) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN AIDS)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ-25 (NP (NN Infection)) (PP (IN with) (NP (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (NP (NN production)) (PP (IN of) (NP (JJ several) (NNS cytokines)))) (ADVP-COOD (CC both) (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo))))))))) (. .)))
(TOP (S (ADVP (RB Conversely)) (, ,) (NP-SBJ (JJ several) (NNS cytokines)) (VP (VBP modulate) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN HIV) (NN expression))) (PP (IN in) (NP (NP (JJ infected) (NNS cells)) (PP (IN of) (NP (ADJP-COOD (CC both) (ADJP (NN T) (JJ lymphocytic)) (CC and) (ADJP (JJ mononuclear) (JJ phagocytic))) (NN lineage))))))) (. .)))
(TOP (S (NP-SBJ (NP (VBN Activated) (JJ mononuclear) (NNS cells)) (, ,) (NP (NP (RB particularly) (NN B) (NNS cells)) (SBAR (WHNP-26 (WDT which)) (S (VP (VBP are) (PP-PRD (IN in) (NP (NP (DT a) (NN state)) (PP (IN of) (NP (JJ chronic) (NN activation))))) (PP (IN in) (NP (ADJP (NN HIV) (JJ infected)) (NNS individuals))))))) (, ,)) (VP-COOD (VP (VBP release) (NP (JJ HIV-inductive) (NNS cytokines))) (CC and) (RB thus) (VP (VBP play) (NP (DT a) (ADJP (RB potentially) (JJ important)) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN HIV) (NN infection))))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Tumor) (NN necrosis) (NN factor) (NN receptor) (NN expression)) (CC and) (NP (NN signal) (NN transduction))) (PP (IN in) (NP (JJ HIV-1-infected) (NNS cells))) (. .)))
(TOP (S (NP (NN OBJECTIVE) (: :)) (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN inter-relationship)) (PP (IN between) (NP-COOD (NP (NN HIV-1) (NN infection)) (CC and) (NP (NP (DT the) (NN cell) (NN surface) (NNS receptors)) (PP (IN for) (NP (NP (NN tumor) (NN necrosis) (NN factor) (-LRB- -LRB-) (NN TNF) (-RRB- -RRB-) (NN -alpha)) (, ,) (NP (NP (DT an) (JJ immunoregulatory) (NN cytokine)) (SBAR (WHNP-1 (WDT that)) (S (VP (MD can) (VP (VB enhance) (NP (NN HIV-1) (NN replication))))))))))))))) (. .))))
(TOP (S (NP (NN DESIGN) (: :)) (S (NP-SBJ-2 (JJ Infected) (ADJP-COOD (ADJP (JJ promyelocytic)) (CC and) (ADJP (JJ promonocytic))) (NNS cells)) (VP (VBD were) (VP (VBN examined) (SBAR (IN because) (S (NP-SBJ (PRP they)) (ADVP (RB normally)) (VP (VBP express) (NP (NP (DT both) (NNS types)) (PP (IN of) (NP (NN TNF) (NNS receptors))))))))) (. .))))
(TOP (S (NP (NNS METHODS) (: :)) (S-COOD (S (NP-SBJ-3 (NN TNF) (NN receptor) (NN surface) (NN expression)) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP-LGS-COOD (NP (JJ specific) (JJ monoclonal) (NN antibody) (NN recognition)) (CC and) (NP (NN flow) (NN cytometry))))))) (, ,) (CC and) (S (NP-SBJ-4 (NN signal) (NN transduction)) (VP (VBD was) (VP (VBN detected) (PP (IN by) (NP-LGS (NN gel) (NN shift) (NN analysis)))))) (. .))))
(TOP (S (NP-SBJ-5 (NN HIV-1) (NP-COOD (NP (NN activation)) (CC and) (NP (NN expression)))) (VP (VBD was) (VP (VBN quantitated) (PP (IN by) (NP-LGS (JJ reverse) (NN transcriptase) (NN assay))))) (. .)))
(TOP (S (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NP (DT the) (NN OM-10.1) (JJ promyelocytic) (NN model)) (PP (IN of) (NP (JJ chronic) (NN infection))))) (, ,) (NP-SBJ (JJ TNF-alpha-induced) (NN HIV-1) (NN expression)) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ substantial) (NN increase)) (PP (IN in) (NP (NP (NP (CD 75) (NN kd) (NN TNF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TR75)) (-RRB- -RRB-))) (NN expression))))) (SBAR (IN although) (S (NP-SBJ-6 (NP (NP (CD 55) (NN kD) (NN TNF) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TR55)) (-RRB- -RRB-))) (NNS levels)) (VP (VBD were) (RB not) (ADVP (RB dramatically)) (VP (VBN altered)))))) (. .))))
(TOP (S (NP-SBJ (NP (DT A) (NN series)) (PP (IN of) (NP (JJ uninfected) (JJ parental) (NN HL-60) (NNS subclones))) (ADVP (DT all))) (VP (VBD reduced) (NP (NN TR75) (NN surface) (NN expression)) (PP (IN in) (NN response) (TO to) (NP (NN TNF-alpha) (NN treatment)))) (. .)))
(TOP (S (NP-SBJ (NP (VBN Enhanced) (NN TR75) (NN expression)) (PP (IN on) (NP (NN OM-10.1) (NNS cells)))) (VP (VBD followed) (NP (NP (DT the) (JJ same) (NN TNF-alpha-dose) (NN dependency)) (PP (IN as) (NP (NP (WDT that)) (VP (VBN observed) (PP (IN for) (NP (NN HIV-1) (NN production)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (NN increase)) (PP (IN in) (NP (NN TR75) (NN expression)))) (VP (VBD was) (ADVP (RB also)) (ADJP-PRD (JJ evident)) (PP-TMP (IN during) (NP (NP (DT the) (NN peak)) (PP (IN of) (NP (NP (DT an) (JJ acute) (NN HIV-1) (NN infection)) (PP (IN of) (NP (NN HL-60) (NNS promyelocytes)))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NN TR55) (NN expression)) (VP (VBD was) (ADJP-PRD (JJ unaltered)) (PP-TMP (IN during) (NP (JJ TNF-alpha-induced) (NN HIV) (NN activation)))))) (, ,) (NP-SBJ-8 (DT this) (NN receptor)) (VP (VBD was) (ADVP (RB still)) (VP (VBN involved) (PP (IN in) (NP (DT the) (JJ viral) (NN activation) (NN process))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Antibody) (NN cross-linking)) (PP (IN of) (NP (NN TR55)))) (, ,) (PP (IN in) (DT the) (NN absence) (IN of) (NP (JJ exogenous) (NN TNF-alpha))) (, ,) (VP (VBN induced) (NP (NP-COOD (NP (JJ maximal) (NN HIV-1) (NN expression)) (, ,) (NP (NP (DT an) (NN up-modulation)) (PP (IN of) (NP (NN surface) (NN TR75)))) (, ,) (CC and) (NP (JJ nuclear) (NN NF-kappa) (NN B) (NN activity))) (PP (IN in) (NP (NN OM-10.1) (NNS cultures))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (NP-SBJ (DT this)) (VP (VBD was) (NP-PRD (DT the) (NN case)) (SBAR-TMP (WHADVP-9 (RB even) (WRB when)) (S (NP-SBJ-10 (DT an) (JJ antagonistic) (JJ anti-TR55) (NN antibody)) (VP (VBD was) (VP (VBN used)))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Anti-TR55) (NN antibody) (NN cross-linking)) (PP (IN in) (NP (ADJP (RB chronically) (JJ infected)) (NN U1) (JJ promonocytic) (NNS cultures)))) (VP (MD could) (ADVP (RB only) (RB partially)) (VP (VB substitute) (PP (IN for) (NP (JJ TNF-alpha-induced) (NN HIV-1) (NN expression))))) (. .)))
(TOP (S (NP (NNS CONCLUSIONS) (: :)) (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-11 (NN HIV-1) (NN infection)) (VP (MD can) (ADVP (RB selectively)) (VP (VB influence) (NP (NP (DT the) (NN surface) (NN expression)) (PP (IN of) (NP (NN TNF) (NNS receptors)))) (, ,) (S (ADVP (RB potentially)) (VP-COOD (VP (VBG influencing) (NP (PRP$ its) (JJ own) (NN expression))) (CC and) (VP (VBG altering) (NP (JJ normal) (JJ immunoregulatory) (NN signal) (NN transduction)))))))))) (. .))))
(TOP (NP (NP (NP-COOD (NP (NN FK506)) (CC and) (NP (NN ciclosporin))) (: :) (NP (NP (JJ molecular) (NNS probes)) (PP (IN for) (S (VP (VBG studying) (NP (JJ intracellular) (NN signal) (NN transduction))))))) (. .)))
(TOP (S (NP-SBJ-33 (DT The) (NNS immunosuppressants) (NP-COOD (NP (NN ciclosporin)) (CC and) (NP (NN FK506)))) (VP (VBP block) (NP (NP (DT the) (JJ Ca-LRB-2+-RRB--dependent) (NN signal-transduction) (NN pathway)) (VP (VBG emanating) (PP (IN from) (NP (DT the) (NN T-cell) (NN receptor))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG inhibiting) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN helper) (NN T) (NNS cells))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (DT these) (NNS drugs)) (PP (IN as) (NP (NNS probes))))) (, ,) (NP-SBJ-COOD-34 (NP (NNS chemists)) (CC and) (NP (NNS biologists))) (VP (VBP have) (VP (VBN uncovered) (NP (NP (JJ several) (JJ intracellular) (NN signalling) (NNS molecules)) (VP (VBG bridging) (NP-COOD (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN second-messenger) (NN Ca2+) (NNS ions)))) (CC and) (NP (NP (DT the) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NN IL-2)))))) (, ,) (SBAR (WHPP-35 (IN among) (WHNP (WDT which))) (SINV (VP (VBP are)) (NP-SBJ-COOD (NP (NN calmodulin)) (, ,) (NP (NN calcineurin)) (CC and) (NP (NP (NP (DT the) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (S (ADVP (RB Hence)) (, ,) (NP-SBJ (NN Ca2+)) (VP (VBZ binds) (PP (TO to) (NP (NN calmodulin))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN calmodulin))) (PP (TO to) (NP (NN calcineurin))))))))) (: ;) (S (NP-SBJ (DT the) (VBN activated) (NN calcineurin)) (, ,) (PP (IN in) (NP (NN turn))) (, ,) (VP (MD may) (VP (VB dephosphorylate) (NP (NP (DT the) (JJ cytoplasmic) (NN subunit)) (PP (IN of) (NP (NN NF-AT)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (PRP$ its) (NN translocation)) (PP (IN from) (NP (DT the) (NN cytoplasm))) (PP (IN into) (NP (DT the) (NN nucleus))) (SBAR (S (VP (TO to) (VP (VB form) (NP (DT a) (JJ competent) (JJ transcriptional) (NN activator))))))))))))) (. .)))
(TOP (S (SBAR (IN As) (S (VP (VBN described) (PP (IN by) (NP-LGS (NNP Jun) (NNP Liu)))))) (, ,) (NP-SBJ (DT these) (NNS drugs)) (VP (VBP manifest) (NP (PRP$ their) (NNS effects)) (PP (IN in) (NP (DT an) (JJ unprecedented) (NN fashion)))) (. .)))
(TOP (S (NP-SBJ (PRP They)) (VP (VBP do) (RB not) (ADVP (RB directly)) (VP (VB intercept) (NP (JJ intracellular) (NN signalling) (NNS molecules)))) (. .)))
(TOP (S (ADVP (RB Instead)) (, ,) (NP-SBJ-38 (PRP they)) (VP-COOD (VP (VBP form) (NP (JJ tight) (NNS complexes)) (PP (IN with) (NP (NP (CD two) (JJ different) (NNS classes)) (PP (IN of) (NP (NP (JJ abundant) (JJ cytosolic) (NNS receptors)) (VP (VBN called) (S (NP-PRD (NNS immunophilins)))))))) (PP-TMP (IN upon) (S (VP (VBG entering) (NP (DT the) (NN cell)))))) (, ,) (CC and) (VP (ADVP (RB consequently)) (VBP inhibit) (NP (PRP$ their) (JJ peptidyl) (JJ prolyl) (JJ cis-trans) (NN isomerase) (NNS activities)))) (. .)))
(TOP (S (NP-SBJ (DT The) (CD two) (ADJP (RB structurally) (JJ distinct)) (JJ immunophilin-drug) (NNS complexes)) (VP (VP-COOD (VP (VBP bind) (PP (TO to))) (, ,) (CC and) (VP (VBP inhibit)) (, ,)) (NP-39 (NP (DT the) (JJ phosphatase) (NN activity)) (PP (IN of) (NP (NN calcineurin))))) (. .)))
(TOP (NP (NP (DT The) (JJ impaired) (NN transcription) (NN factor) (NN AP-1) (NN DNA) (NN binding) (NN activity)) (PP (IN in) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (PP (IN from) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (DT some) (NNS symptoms)) (PP (IN of) (NP (JJ premature) (NN aging)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN study)) (PP (IN of) (NP (NP (JJ human) (NNS disorders)) (VP (VBN known) (PP (IN as) (NP (JJ premature) (NN aging) (NNS syndromes))))))) (VP (MD may) (VP (VB provide) (NP (NP (NN insight)) (PP (IN into) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (JJ cellular) (NN senescence)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ main) (NN feature)) (PP (IN of) (NP (NP (JJ cellular) (NN senescence)) (ADVP (FW in) (FW vitro))))) (VP (VBZ is) (NP-PRD (NP (NN cessation)) (PP (IN of) (NP (NN cell) (NN proliferation))))) (. .)))
(TOP (S (NP-SBJ-COOD-72 (NP (NP (NN Down) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN DS)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ neuronal) (NN ceroid-lypofuscinosis)) (PRN (-LRB- -LRB-) (NP (NN NCL)) (-RRB- -RRB-)))) (VP (VBP are) (VP (ADVP (RB clinically)) (VBN characterized) (PP (IN by) (NP-LGS (NP (DT the) (JJ premature) (NN onset)) (PP (IN of) (NP (NP (JJ numerous) (NNS features)) (VP (ADVP (RB normally)) (VBN associated) (PP (IN with) (NP (JJ human) (NN aging)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (NP (NN Phytohemagglutinin)) (JJ stimulated)) (NNS lymphocytes)) (VP (VBN derived) (PP (IN from) (NP (NN DS) (NNS subjects))))) (VP (VBD showed) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (VBN diminished) (NN proliferation) (NN capacity)) (PP (IN in) (NN comparison) (IN with) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (PP (IN from) (NP (UCP-COOD (NP (NN NCL)) (CC and) (ADJP (JJ healthy))) (NNS individuals))))))) (. .)))
(TOP (S (NP-SBJ-73 (PRP We)) (VP (VBD demonstrated) (, ,) (PP (IN by) (S (VP (VBG applying) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))))) (, ,) (NP-COOD (NP (NP (ADJP-114 (RB slightly) (JJ impaired)) (NN AP-1) (NN DNA) (NN binding) (NN activity)) (PP-113 (IN in) (NP (NN NCL) (NNS lymphocytes)))) (CC and) (NP (ADJP=114 (JJ strong)) (PP=113 (IN in) (NP (NN DS) (NNS ones)))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ same) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NN proliferation) (NN cessation)))) (VP (MD could) (VP (VB exist) (PP-COOD (PP (IN in) (NP (NP (NNS fibroblasts)) (VP (VBN characterized) (PP (IN by) (NP-LGS (JJ replicative) (NN senescence)))))) (CC and) (PP (IN in) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (PP (IN from) (NP (NP (NNS individuals)) (PP (IN with) (NP (NP (JJ premature) (NN aging) (NNS syndromes)) (PRN (-LRB- -LRB-) (NP (NN Down)) (-RRB- -RRB-))))))))))))))) (. .)))
(TOP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN HIV-1) (NN latency) (NN reactivation))) (PP (IN by) (NP-COOD (NP (NP (NN dehydroepiandrosterone)) (PRN (-LRB- -LRB-) (NP (NN DHEA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT an) (NN analog)) (PP (IN of) (NP (NN DHEA)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ initial) (NN infection)) (PP (IN with) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJS most) (NNS individuals)))) (ADVP-TMP (RB usually)) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN establishment)) (PP (IN of) (NP (DT a) (ADJP-COOD (ADJP (JJ latent)) (CC or) (ADJP (JJ chronic))) (NN infection))) (PP-TMP (IN before) (NP (NP (JJ eventual) (NN progression)) (PP (IN toward) (NP (VBN acquired) (NN immunodeficiency) (NN syndrome)))))))) (. .)))
(TOP (S (NP-SBJ (NN HIV-1)) (VP (MD can) (ADVP (RB also)) (VP (VB establish) (NP (DT a) (ADJP-COOD (ADJP (JJ latent)) (CC or) (ADJP (JJ persistent))) (NN infection)) (PP (IN in) (NP (NP (DT some) (NN T) (NN cell) (NNS lines)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBP show) (NP (JJ minimal) (JJ constitutive) (NN virus) (NN expression))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-2 (NP (NN activation)) (PP (IN of) (NP (DT the) (NN T) (NN cell) (NNS lines))) (VP (VBG leading) (PP (TO to) (NP (VBN enhanced) (NN HIV-1) (NN replication))))) (VP (MD can) (VP (VB be) (VP (VBN induced) (PP (IN by) (NP-LGS (NP-COOD (NP (NNS antigens)) (, ,) (NP (NNS mitogens)) (, ,) (CC and) (NP (NNS cytokines))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LCB-) (NP (NN TNF-alpha)) (-RRB- -RCB-))) (, ,) (NP (NN interleukin) (CD 1)) (, ,) (CC and) (NP (NN interleukin-2))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Various) (NN gene) (NNS products)) (PP (IN from) (NP (NP (JJ other) (NNS viruses)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN HTLV-1)) (, ,) (NP (NN HSV)) (, ,) (NP (NN EBV)) (, ,) (NP (NN CMV)) (, ,) (NP (NN HBV)) (, ,) (CC and) (NP (NN HHV-6))) (-RRB- -RRB-))))) (VP (MD can) (ADVP (RB also)) (VP (VB enhance) (NP (NN HIV-1) (ADJP (JJ long) (JJ terminal) (NN repeat) (-LRB- -LRB-) (NN LTR) (-RRB- -RRB-) (JJ -driven)) (NN reporter) (NN gene) (NN activity)))) (. .)))
(TOP (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (DT these) (NNS observations))) (, ,) (NP-SBJ (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN proposed) (SBAR (IN that) (S (NP-SBJ (NP (NN reactivation)) (PP (IN of) (NP (NP (JJ latent) (NN HIV-1)) (VP (VBN harbored) (PP (IN in) (NP (ADJP (RB chronically) (JJ infected)) (NP-COOD (NP (NN T) (NNS lymphocytes)) (, ,) (NP (NNS monocytes)) (, ,) (CC or) (NP (NNS macrophages))))))))) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN AIDS))))))))))) (. .)))
(TOP (S (ADVP-TMP (RB So) (RB far)) (, ,) (NP-SBJ (EX there)) (VP (VBP are) (NP-PRD (NP (DT no) (NP-COOD (NP (NNS drugs)) (CC or) (NP (NN therapy)))) (ADJP (JJ available)) (SBAR (WHNP-3 (WDT that)) (S (VP (MD can) (VP (VB provide) (NP (NP (NN protection)) (PP (IN against) (NP (NN HIV-1) (NN latency) (NN reactivation)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN ACH-2)) (, ,) (VP (VBN derived) (PP (IN from) (NP (NP (DT a) (JJ human) (NN T) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN CEM)) (-RRB- -RRB-))))) (, ,)) (VP (VBZ is) (ADJP-PRD (RB chronically) (VBN infected) (PP (IN with) (NN HIV-1))) (, ,) (PP (IN with) (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (JJ constitutive) (NN virus) (NN expression)))))) (. .)))
(TOP (S (NP-SBJ-4 (NN ACH-2)) (VP (MD can) (VP (VB be) (VP (VBN converted) (PP (TO to) (NP-COOD (NP (NP (JJ productive) (NN infection)) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN of) (NP (DT the) (NNS cells))) (PP (IN with) (NP-COOD (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))) (, ,) (NP (NN mitogen)) (CC or) (NP (NP (NNS cytokines)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-)))))))) (, ,) (CC or) (NP (NP (NN infection)) (PP (IN with) (NP (NN HSV))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (NP-SBJ (DT the) (NN ACH-2) (NN cell) (NN line)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ good) (NN candidate)) (PP (IN for) (S (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS drugs))) (PP (IN on) (NP (NN HIV-1) (NN activation))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Previously)) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN reported) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN DHEA)) (CC and) (NP (NP (JJ synthetic) (NNS analogs)) (PP (IN of) (NP (NN DHEA))))) (VP (MD can) (VP (VB be) (NP-PRD (NP (JJ modest) (NNS inhibitors)) (PP (IN of) (NP (NN HIV-1) (NN IIIB) (NN replication)))) (PP (IN in) (NP (JJ phytohemagglutinin-stimulated) (JJ peripheral) (NN blood) (NN lymphocyte) (NNS cultures))))))))) (. .)))
(TOP (S (-LRB- -LRB-) (NP-SBJ-5 (NN ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-)))
(TOP (NP (NP (NN Visualization)) (PP (IN of) (NP (NP (DT the) (JJ endogenous) (NN NF-kappa) (NN B) (NN p50) (NN subunit)) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (JJ follicular) (JJ dendritic) (NNS cells))))))) (PP (IN in) (NP (JJ germinal) (NNS centers))) (. .)))
(TOP (S (NP-SBJ (NP (NN NF-kappa) (NN B)) (, ,) (NP (DT a) (ADJP (ADJP (CD 50) (CD kDa/65) (NN kDa)) (PRN (-LRB- -LRB-) (ADJP (NN p50/p65)) (-RRB- -RRB-))) (NN heterodimer)) (, ,)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ ubiquitous) (NN transcription) (NN factor)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ positive) (NN regulation)) (PP (IN of) (NP (JJ various) (JJ immune) (NNS genes)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S-PRD (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (VBZ is) (ADJP-PRD (JJ related) (PP (TO to) (NP (NP (DT a) (NP-COOD (NP (JJ particular) (NN cell) (NN type)) (CC and/or) (NP (NN differentiation) (NN step)))) (PP-TMP (IN during) (NP (NN immunopoiesis))))))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (ADJP (FW in) (FW situ)) (NN hybridization)) (PP (IN on) (NP (NP (NNS sections)) (PP (IN from) (NP (ADJP (JJ non) (NN HIV)) (JJ hyperplastic) (NN lymph) (NNS nodes))))))) (, ,) (NP-SBJ-20 (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-21 (NP (DT the) (NN gene)) (PP (IN of) (NP (NP (DT the) (ADJP (CD 105) (NN kDa)) (NN precursor)) (PP (IN of) (NP (NN p50)))))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NP (DT the) (JJ light) (NN zone)) (PP (IN of) (NP (JJ germinal) (NNS centers))))) (, ,) (PP (IN with) (NP (NP (DT a) (NN network) (NN aspect)) (, ,) (SBAR (WHNP-22 (WDT which)) (S (VP (VBD suggested) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (JJ follicular) (JJ dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN FDC)) (-RRB- -RRB-))))))))))))))) (. .)))
(TOP (S (PP-TPC-101 (IN By) (NP-LGS (NN immunohistochemistry))) (, ,) (NP-SBJ-23 (NN p50) (NN protein)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN cytoplasm)) (CC and) (NP (NN nucleus)))) (PP (IN of) (NP (NN FDC))))) (, ,) (S (VP (VBG confirming) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NN FDC)))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-25 (NN p50) (NN protein)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (DT all) (NNS lymphocytes))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (PRP we)) (VP (VBD focused) (NP (PRP$ our) (NN study)) (PP (IN on) (NP (NP (VBN isolated) (NN FDC) (NNS clusters)) (PP (IN from) (NP (JJ normal) (NNS tonsils)))))) (. .)))
(TOP (S (SBAR (IN As) (S (VP (VBN showed) (PP (IN on) (NP (NN tissue) (NNS sections)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD detected) (NP (DT the) (NN p50)) (PP (IN in) (NP (NP-COOD (CC both) (NP (NN cytoplasm)) (CC and) (NP (NN nucleus))) (PP (IN of) (NP (NN FDC)))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Nuclei)) (PP (IN of) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (NN FDC) (NNS clusters)))))) (VP (VBD were) (ADJP-PRD (JJ negative))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB next)) (VP (VBD studied) (NP (NP (NP-COOD (NP (NN p65)) (CC and) (NP (NN c-Rel) (NN protein))) (NN expression)) (PP (IN in) (NP (NN FDC) (NNS clusters))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-27 (NN p65)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (NN FDC)))))))) (, ,) (IN whereas) (S (NP-SBJ (NNS nuclei)) (VP (VBD were) (ADJP-PRD (JJ negative)))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-28 (NN p65)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (DT some) (NNS lymphocytes))))))) (. .)))
(TOP (S (NP-SBJ-29 (NN c-Rel) (NN protein)) (VP (VBD was) (VP (VBN detected) (PP-COOD (PP (RB only) (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (NNS lymphocytes))))) (CC and) (PP (RB not) (IN in) (NP (NP (DT the) (NP-COOD (NP (NN nucleus)) (CC and) (NP (NN cytoplasm)))) (PP (IN of) (NP (NN FDC)))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (, ,) (S-COOD (S (PP (IN in) (DT the) (NN context) (IN of) (NP (NP (ADJP (NN T) (JJ cell-dependent)) (NN B) (NN cell) (NN immunopoiesis)) (VP (VBG occurring) (PP (IN in) (NP (NN FDC) (NNS clusters)))))) (, ,) (NP-SBJ (NN p50)) (VP (VBZ is) (ADVP (RB mainly)) (ADJP-PRD (JJ related) (PP (TO to) (NP (NP (NN FDC)) (PP (IN with) (NP (NP (DT a) (JJ massive) (NN overexpression)) (PP (IN in) (NP (DT the) (NNS nuclei)))))))))) (, ,) (IN whereas) (S-COOD (S (NP-SBJ-31 (NN p65)) (VP (VBZ is) (VP (VBN expressed) (PP-32 (IN in) (NP (DT a) (VBN scattered) (NN manner))) (PP-33 (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (NNS lymphocytes)))))))) (CC and) (S (NP-SBJ=31 (NN c-Rel) (NN protein)) (ADVP=32 (RB exclusively)) (PP=33 (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (NN FDC) (NNS clusters)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NP (DT the) (CD two) (NNS subunits)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (CC and) (NP (DT the) (NN c-Rel) (NN protein))) (VP (VBP have) (NP (JJ different) (NNS roles)) (PP (IN in) (NP (JJ different) (NN cell) (NNS types))) (PP-TMP (IN during) (NP (NN B) (NN cell) (NN immunopoiesis))))))) (. .)))
(TOP (NP (NP (NN Involvement)) (PP (IN of) (NP (NN transcription) (NN factor) (NN YB-1))) (PP (IN in) (NP (JJ human) (NN T-cell) (JJ lymphotropic) (NN virus) (NN type) (CD I) (JJ basal) (NN gene) (NN expression))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Sequences)) (SBAR (WHNP-27 (WDT which)) (S (VP (VBP control) (NP (JJ basal) (NP (NP (JJ human) (NN T-cell) (NN lymphotropic) (NN virus) (NN type) (CD I)) (PRN (-LRB- -LRB-) (NP (NN HTLV-I)) (-RRB- -RRB-))) (NN transcription)))))) (ADVP (RB likely)) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP-COOD (NP (NN initiation)) (CC and) (NP (NN maintenance))) (PP (IN of) (NP (NN virus) (NN replication)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB previously)) (VP (VP-COOD (VP (VBD identified)) (CC and) (VP (VBD analyzed))) (NP-28 (NP (NP (NP (DT a) (JJ 45-nucleotide) (NN sequence)) (PRN (-LRB- -LRB-) (NP (NP (JJ downstream) (JJ regulatory) (NN element) (CD 1)) (PRN (-LRB- -LCB-) (NP (NN DRE) (CD 1)) (-RRB- -RCB-))) (-RRB- -RRB-))) (, ,) (NP-COOD (NP (CD +195)) (TO to) (NP (CD +240)))) (, ,) (PP (IN at) (NP (NP (DT the) (NN boundary)) (PP (IN of) (NP (NP (DT the) (NN R/U5) (NN region)) (PP (IN of) (NP (DT the) (JJ long) (JJ terminal) (NN repeat))) (SBAR (WHNP-29 (WDT which)) (S (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NN HTLV-I) (JJ basal) (NN transcription))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD identified) (NP (NP (NP (DT a) (NN protein)) (, ,) (NP (NN p37)) (, ,)) (SBAR (WHNP-31 (WDT which)) (S (ADVP (RB specifically)) (VP (VBD bound) (PP (TO to) (NP (NN DRE) (CD 1)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (NN affinity) (NN column) (NN fraction)) (, ,) (VP (VBG containing) (NP (NN p37))) (, ,)) (VP (VBD stimulated) (NP (NN HTLV-I) (NN transcription)) (ADVP (RB approximately) (RB 12-fold)) (ADVP (FW in) (FW vitro))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP report) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (NP (DT a) (NN cDNA) (NN clone)) (PRN (-LRB- -LRB-) (NP (NN 15B-7)) (-RRB- -RRB-))) (, ,) (PP (IN from) (NP (DT a) (NN Jurkat) (NN expression) (NN library))) (, ,) (SBAR (WHNP-32 (WDT that)) (S (VP (VBZ binds) (ADVP (RB specifically)) (PP (TO to) (NP (DT the) (NN DRE) (CD 1) (JJ regulatory) (NN sequence)))))))))) (. .)))
(TOP (S (NP-SBJ-33 (NP (NN Binding)) (PP (IN of) (NP (DT the) (NN cDNA) (NN fusion) (NN protein))) (, ,) (PP (ADVP (RB similarly)) (TO to) (NP (NP (DT the) (NNS results)) (VP (VBN obtained) (PP (IN with) (NP (VBN purified) (NN Jurkat) (NN protein)))))) (, ,)) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP-LGS (NP (NN introduction)) (PP (IN of) (NP (JJ site-specific) (NNS mutations))) (PP (IN in) (NP (DT the) (NN DRE) (CD 1) (JJ regulatory) (NN sequence))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (FW In) (FW vitro)) (NP-COOD (NP (NN transcription)) (CC and) (NP (NN translation)))) (PP (IN of) (NP (NN 15B-7) (NN cDNA)))) (VP (VBD produced) (NP (NP (DT a) (NN fusion) (NN protein)) (SBAR (WHNP-34 (WDT which)) (S (VP (VBD bound) (ADVP (RB specifically)) (PP (TO to) (NP (DT the) (NN HTLV-I) (NP-COOD (NP (CD +195)) (TO to) (NP (CD +240))) (NN oligonucleotide)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ partial) (NN cDNA)) (VP (VBZ encodes) (NP (NP (DT a) (NN protein)) (SBAR (WHNP-35 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ homologous) (PP (TO to) (NP (NP (DT the) (JJ C-terminal) (CD 196) (NN amino) (NNS acids)) (PP (IN of) (NP (NP (DT the) (JJ 36-kDa) (NN transcription) (NN factor)) (, ,) (NP (NN YB-1)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Cotransfection)) (PP (IN of) (NP (DT a) (NN YB-1) (NN expression) (NN plasmid)))) (VP (VBZ increases) (NP (NN HTLV-I) (JJ basal) (NN transcription)) (ADVP (RB approximately) (RB 14-fold)) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS lymphocytes)))) (. .)))
(TOP (S (PP (IN On) (DT the) (NN basis) (IN of) (NP-COOD (NP (DT the) (JJ molecular) (NN weight)) (, ,) (NP (JJ DNA-binding) (NNS characteristics)) (, ,) (CC and) (NP (ADJP (FW in) (FW vivo)) (NN transactivation) (NN activity)))) (, ,) (NP-SBJ (PRP we)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (ADJP (RB previously) (VBN identified)) (ADJP (NN DRE) (JJ 1-binding)) (NN protein)) (, ,) (NP (NN p37)) (, ,)) (VP (VBZ is) (NP-PRD (NN YB-1)))))) (. .)))
(TOP (NP (NP-COOD (NP (VBN Chlorinated) (NP-COOD (NP (NNS dibenzo-p-dioxins)) (CC and) (NP (NNS dibenzofurans)))) (CC and) (NP (DT the) (JJ human) (JJ immune) (NN system))) (. .)))
(TOP (NP (LST (LS 1) (. .)) (NP (NN Blood) (NN cell) (NNS receptors)) (PP (IN in) (NP (NP (NNS volunteers)) (PP (IN with) (NP (ADJP (RB moderately) (VBN increased)) (NN body) (NNS burdens))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP-COOD (NP (NP (JJ monoclonal) (NNS antibodies)) (PRN (-LRB- -LRB-) (NP (NNS mAbs)) (-RRB- -RRB-))) (CC and) (NP (NN flow) (NN cytometry))))) (, ,) (NP-SBJ-51 (PRP we)) (VP (VBD studied) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN surface) (NNS receptors)))) (PP (IN on) (NP (NP (NN lymphocyte) (NNS subpopulations)) (PP (IN of) (NP (NP (NNS workers)) (PP (IN with) (NP (NP (ADJP (RB moderately) (VBN increased)) (NN body) (NNS burdens)) (PP-COOD (PP (IN of) (NP (NP (NN 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (PRN (-LRB- -LRB-) (NP (NN TCDD)) (-RRB- -RRB-)))) (CC and) (PP (IN of) (NP (JJ other) (NP (NP (VBN polychlorinated) (NP-COOD (NP (NNS dibenzo-p-dioxins)) (CC and) (NP (NNS dibenzofurans)))) (PRN (-LRB- -LRB-) (NP (NN PCDD/PCDF)) (-RRB- -RRB-)))))) (, ,) (VP (VBN expressed) (ADVP (RB here)) (PP (IN as) (NP (NP (NN International-Toxicity) (NN Equivalencies)) (PRN (-LRB- -LRB-) (NP (NN I-TE)) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN hypothesis)) (SBAR (S (VP (TO to) (VP (VB be) (VP (VBN tested))))))) (VP (VBD was) (SBAR-PRD (IN whether) (CC or) (RB not) (S (NP-SBJ (NNS humans)) (VP (VBP exhibit) (NP (NP (DT a) (JJ similar) (NN susceptibility)) (PP (TO to) (NP (NNS PCDDs/PCDFs)))) (PP (IN with) (NN respect) (TO to) (NP (NP (DT the) (NN surface) (NNS receptors)) (VP (VBN found) (ADVP-TMP (RB previously)) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (JJ small) (NNS doses)) (PP (IN of) (NP (NP (NN 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (PRN (-LRB- -LRB-) (NP (NN TCDD)) (-RRB- -RRB-)))) (PP (IN in) (NP (FW Callithrix) (FW jacchus))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These)) (VP (VBP are) (: :) (NP-PRD-COOD (NP (NP (NP (NP (JJ helper-inducer)) (PRN (-LRB- -LRB-) (NP (NN memory)) (-RRB- -RRB-))) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ CD4+CD45R0+CD45RA-CD29highCD11a+)) (-RRB- -RRB-))) (, ,) (NP (JJ CD20+) (NN B) (NNS cells)) (, ,) (CC and) (NP (NP (JJ cytotoxic) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (JJ CD8+CD56+/CD57+)) (-RRB- -RRB-))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-55 (NP (CD 68) (NNS triple-labellings)) (PP (IN with) (NP (NNS mAbs)))) (VP (VBD were) (VP (VBN performed) (PP (IN on) (NP (NP (DT the) (NNS cells)) (PP (IN of) (NP (DT each) (NN volunteer))))) (S (VP (TO to) (VP (ADVP (RB possibly)) (VB generate) (NP (JJ further) (NNS hypotheses))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBD was) (VP (VBN evaluated) (SBAR (IN whether) (S (NP-SBJ-56 (NP (DT any)) (PP (IN of) (NP (DT the) (NNS variables)))) (VP (MD might) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN biomarker)) (PP (IN of) (NP (NNS effects))) (PP (IN for) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NNS compounds)))))))))))))) (. .)))
(TOP (S (NP-SBJ (EX There)) (VP (VBD were) (NP-PRD (NP (CD two) (JJ main) (NNS goals)) (: :) (S-COOD (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (VP (TO to) (VP (VB evaluate) (SBAR (IN whether) (S (NP-SBJ (NP (NNS workers)) (PP (IN with) (NP (NP (DT a) (ADJP (RB moderately) (VBN increased)) (NN PCDD/PCDF-body) (NN burden)) (PRN (-LRB- -LCB-) (NP (NP-COOD (NP (ADJP (QP (CD 25-140)) (NN ppt)) (NN TCDD)) (CC or) (NP (ADJP (QP (CD 104-522)) (NN ppt)) (NN I-TE))) (PP (IN in) (NP (NN blood) (NN fat)))) (-RRB- -RCB-))))) (VP (VBP exhibit) (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN surface) (NNS receptors)) (PP (IN of) (NP (JJ white) (NN blood) (NNS cells))))) (, ,) (SBAR (IN as) (S (VP (VBN observed) (PP (IN in) (NP (NP (JJ previous) (NNS studies)) (PP (IN in) (NP (JJ non-human) (NNS primates)))))))))))))) (, ,) (CC and) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (VP (TO to) (VP (VB clarify) (SBAR (IN whether) (S (NP-SBJ-102 (NP (NNS persons)) (PP (IN at) (NP (NP (NP (DT the) (JJ upper) (NN range)) (PRN (-LRB- -LCB-) (NP (NP-COOD (NP (ADJP (QP (CD 10-23)) (NN ppt)) (NN TCDD)) (CC or) (NP (ADJP (QP (CD 30-90)) (NN ppt)) (NN I-TE))) (PP (IN in) (NP (NN blood) (NN fat)))) (-RRB- -RCB-))) (PP (IN of) (NP (DT the) (NN body) (NN burden) (NN reference) (NNS values))) (PP (IN of) (NP (DT a) (ADJP (ADVP (RB not) (RB particularly)) (VBN exposed)) (NN population)))))) (VP (VBP show) (NP (JJ detectable) (NNS deviations)) (PP (IN in) (NP (DT these) (JJ immunological) (NNS variables))) (, ,) (SBAR-TMP (WHADVP-58 (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNS persons)) (PP (IN at) (NP (NP (NP (DT the) (ADJP-COOD (ADJP (JJR lower)) (CC and) (ADJP (NN medium))) (NN range)) (PRN (-LRB- -LCB-) (NP-COOD (NP (ADJP (QP (CD 1-3)) (NN ppt)) (NN TCDD)) (CC or) (NP (ADJP (QP (CD 9-29)) (NN ppt)) (NN I-TE))) (-RRB- -RCB-))) (PP (IN of) (NP (DT these) (NN body) (NN burden) (NN reference) (NNS values))))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Regression) (NN analysis)) (PP (IN of) (NP (PRP$ our) (NNS data)))) (VP (VBD revealed) (NP (NP (JJ slight) (NNS trends)) (PP (IN for) (NP (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNS biomarkers)))) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (JJ CD45R0+)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (PP (IN With) (NP (CD one) (NN exception))) (, ,) (NP-SBJ (DT these)) (VP (VBD were) (ADVP (DT all)) (NP-PRD (NNS increases))) (. .)))
(TOP (S (NP-SBJ (NP (NN None)) (PP (IN of) (NP (NP (DT the) (NNS alterations)) (VP (VBN observed))))) (VP (VBP are) (PP-PRD (IN of) (NP (JJ medical) (NN relevance)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ slight) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (JJ CD4+CD45R0+) (NNS cells)))))) (VP (VBD remained) (ADJP-PRD (JJ significant)) (PP-TMP (RB even) (IN after) (NP (NP (JJ covariant) (NN analysis)) (VP (VBG taking) (NP (JJ age-related) (NNS changes)) (PP (IN into) (NP (NN account))))))) (. .)))
(TOP (S (ADVP (RB Altogether)) (, ,) (NP-SBJ (DT the) (NNS data)) (VP (VBP do) (RB not) (VP (VB provide) (NP (NP (DT any) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (NP (DT an) (NN assumption) (SBAR (IN that) (S (NP-SBJ (NP (ADJP (RB moderately) (VBN increased)) (NN body) (NNS burdens)) (PP (IN of) (NP (NNS PCDDs/PCDFs))) (PP (IN in) (NP (NNS adults)))) (VP (VBP induce) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (DT the) (JJ cellular) (NNS components)) (PP (IN of) (NP (DT the) (JJ human) (JJ immune) (NN system))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Adult) (NNS humans)) (ADVP (RB certainly)) (VP (VBP are) (ADJP-PRD (ADJP (RBR less) (JJ susceptible) (PP (TO to) (NP (NP (DT this) (NN action)) (PP (IN of) (NP (NNS PCDDs/PCDFs)))))) (PP (IN than) (NP (JJ adolescent) (FW Callithrix) (FW jacchus))))) (. .)))
(TOP (S (NP-SBJ-7 (DT The) (NN lymphotoxin) (NN promoter)) (VP (VBZ is) (VP (VBN stimulated) (PP (IN by) (NP-LGS (NP (NN HTLV-I) (NN tax) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (JJ human) (NN T-cell) (NNS lines))))))) (. .)))
(TOP (S (NP-SBJ-8 (DT The) (NN HTLV-I) (JJ transcriptional) (NN activator) (NN tax)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB gain) (NP (NP (NN insight)) (PP (IN into) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NP (NN lymphotoxin)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN LT)) (: ;) (NP (NN TNF-beta))) (-RRB- -RRB-))) (NN gene) (NN induction))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Tax-expressing) (NN cell) (NNS lines)) (VP (VBP produce) (NP (NN LT) (JJ biologic) (NN activity))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (NP (NP (NN LT) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NN LT-293)) (-RRB- -RRB-))) (NN CAT) (NN construct)) (SBAR (WHNP-10 (WDT that)) (S (VP (VBD contained) (NP (DT an) (NN NF-kappa) (NN B) (NN site)))))) (VP (VBD was) (ADJP-PRD (JJ active)) (PP (IN in) (NP (NP (DT the) (JJ LT-producing) (NN C81-66-45) (NN cell) (NN line)) (, ,) (SBAR (WHNP-11 (WDT which)) (S (VP-COOD (VP (VBZ contains) (NP (JJ defective) (NN HTLV-I))) (CC but) (VP (VBZ expresses) (NP (NN tax))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN observation) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (VBN mutated) (NN LT-kappa) (NN B) (NN construct)) (PRN (-LRB- -LRB-) (NP (NN M1-CAT)) (-RRB- -RRB-))) (VP (VBD was) (ADJP-PRD (JJ inactive)) (PP (IN in) (NP (NN C81-66-45))))))) (, ,) (VP (VBD confirmed) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (NN LT) (NN gene) (NN expression))))) (. .)))
(TOP (S (NP-SBJ-12 (NN Tax)) (VP (VBD was) (VP (VBN transfected) (PP (IN into) (NP (JJ HTLV-I-negative) (JJ human) (NN T-cell) (NNS lines))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Jurkat) (NN T) (NNS cells)) (VP (ADVP (RB stably)) (VBG expressing) (NP (NN tax)))) (VP (VBD contained) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (SBAR (WHNP-13 (WDT that)) (S (VP (ADVP (RB directly)) (VBD bound) (PP (TO to) (NP (DT the) (NN LT-kappa) (NN B) (NN site)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Tax)) (VP (VBN co-transfected) (PP (IN with) (NP (NN reporter) (NNS constructs))) (PP (IN into) (NP (NN Jurkat) (NNS cells))))) (VP-COOD (VP (ADVP (RB maximally)) (VBD activated) (NP-COOD (NP (NN HTLV-I-LTR-CAT)) (CC and) (NP (NN kappa) (NN B-fos-CAT)))) (CC and) (RB also) (VP (VBD activated) (NP (NN LT-293)) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))))) (. .)))
(TOP (S (PP (IN In) (NP (NN JM) (NN T) (NNS cells))) (, ,) (NP-SBJ (NN tax)) (VP (JJ induced) (NP (NN LT-293) (NN activity)) (PP (IN by) (NP-COOD (NP (CD two-)) (TO to) (NP (JJ four-fold)))) (, ,) (SBAR (IN though) (S (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT no) (NN induction)) (PP (IN of) (NP (NN M1-CAT)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN increase)) (PP (IN in) (NP (NN LT-293) (NN CAT) (NN activity)))) (VP (VBD mirrored) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN LT) (JJ biologic) (NN activity))) (VP (VBN seen) (PP (IN under) (NP (DT these) (NNS conditions)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT These) (NNS studies)) (, ,) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB demonstrate) (NP (NP (NN induction)) (PP (IN of) (NP (NN LT) (NN promoter) (NN activity))) (PP (IN over) (NP (JJ basal) (NNS levels))))))))) (, ,)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN HTLV-I) (NN tax)) (VP (VBZ causes) (NP (NP (JJ low-level) (NN activation)) (PP (IN of) (NP-COOD (CC both) (NP (JJ endogenous) (NN LT)) (CC and) (NP (DT the) (NN LT) (NN promoter))))) (, ,) (PP (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (IN through) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))))) (. .)))
(TOP (NP (NP (JJ Transient) (NN pseudohypoaldosteronism)) (PP (IN in) (NP (JJ obstructive) (JJ renal) (NN disease))) (PP (IN with) (NP (NP (JJ transient) (NN reduction)) (PP (IN of) (NP (JJ lymphocytic) (NN aldosterone) (NNS receptors))))) (. .)))
(TOP (NP (NP (NNS Results)) (PP (IN in) (NP (CD two) (JJ affected) (NNS infants))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP report) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (NP (JJ transient) (NN pseudohypoaldosteronism)) (PP (JJ due) (TO to) (NP (JJ obstructive) (JJ renal) (NN disease))))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (NNS patients)) (VP (VBD presented) (PP (IN with) (NP (DT a) (JJ salt-losing) (NN episode) (VBG simulating) (JJ adrenal) (NN insufficiency)))) (. .)))
(TOP (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP-SBJ-90 (NP (JJ transient) (NN reduction)) (PP (IN of) (NP (NN aldosterone) (NNS receptors)))) (VP (MD could) (VP (VB be) (VP (VBN documented) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (DT the) (JJ second) (NN patient))) (NP-SBJ (DT the) (ADJP-COOD (ADJP (JJ clinical)) (CC and) (ADJP (JJ biochemical))) (NNS parameters)) (VP (VBD were) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (JJ transient) (NN pseudohypoaldosteronism)))))))))) (. .)))
(TOP (S (NP-SBJ-91 (NN Aldosterone) (NNS receptors)) (VP (VBD were) (ADJP-PRD (JJ normal)) (PP (IN in) (NP (DT both) (NNS patients))) (SBAR-TMP (WHADVP-92 (IN when)) (S (VP (VBN studied) (PP-TMP (IN after) (NP (NP (DT the) (JJ surgical) (SYM correctionNN)) (PP (IN of) (NP (DT the) (NN obstruction))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN macrophage) (NN transcription) (NN factor) (NN PU.1)) (VP (VBZ directs) (NP (NP (JJ tissue-specific) (NN expression)) (PP (IN of) (NP (DT the) (NN macrophage) (JJ colony-stimulating) (NN factor) (NN receptor))))) (. .)))
(TOP (S (NP-SBJ-13 (DT The) (NP (NP (NN macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN M-CSF)) (-RRB- -RRB-))) (NN receptor)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (DT a) (JJ tissue-specific) (NN fashion))) (PP (IN from) (NP (NP (CD two) (JJ distinct) (NNS promoters)) (PP (IN in) (NP-COOD (NP (NNS monocytes/macrophages)) (CC and) (NP (DT the) (NN placenta)))))))) (. .)))
(TOP (S (SBAR (IN In) (NN order) (TO to) (S (ADVP (RB further)) (VP (VB understand) (NP (NP (DT the) (NN transcription) (NNS factors)) (SBAR (WHNP-15 (WDT which)) (S (VP (VBP play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN commitment)) (PP (IN of) (NP (JJ multipotential) (NNS progenitors))) (PP (TO to) (NP (DT the) (NN monocyte/macrophage) (NN lineage)))))))))))) (, ,) (NP-SBJ-14 (PRP we)) (VP (VBP have) (VP (VBN initiated) (NP (NP (DT an) (NN investigation)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (SBAR (WHNP-16 (WDT which)) (S (VP (VBP activate) (NP (DT the) (NN M-CSF) (NN receptor)) (ADVP-TMP (RB very) (RB early)) (PP-TMP (IN during) (NP (DT the) (NN monocyte) (NN differentiation) (NN process))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ human) (JJ monocytic) (NN M-CSF) (NN receptor) (NN promoter)) (VP (VBZ directs) (NP (NN reporter) (NN gene) (NN activity)) (PP (IN in) (NP (DT a) (JJ tissue-specific) (NN fashion))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ few) (NN transcription) (NNS factors)) (SBAR (WHNP-18 (WDT which)) (S (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN monocyte) (NNS genes))))))))))))) (VP (VBZ is) (NP-PRD (DT the) (ADJP-COOD (ADJP (NP (NN macrophage-))) (CC and) (ADJP (JJ B-cell-specific))) (NN PU.1) (NN transcription) (NN factor))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP-SBJ (NN PU.1)) (VP (VP-COOD (VP (VBZ binds)) (CC and) (VP (VBZ activates))) (NP-19 (DT the) (NN M-CSF) (NN receptor) (NN promoter)))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-COOD (CC both) (NP (ADJP (FW in) (VBN vitro-translated)) (NN PU.1)) (CC and) (NP (NP (NN PU.1)) (PP (IN from) (NP (JJ nuclear) (NNS extracts))))) (VP (VBP bind) (PP (TO to) (NP (NP (DT a) (JJ specific) (NN site)) (PP (IN in) (NP (DT the) (NN M-CSF) (NN receptor) (NN promoter))) (ADVP (RB just) (JJ upstream) (PP (IN from) (NP (DT the) (JJ major) (NN transcription) (NN initiation) (NN site)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Mutations)) (PP (IN in) (NP (DT this) (NN site))) (SBAR (WHNP-20 (WDT which)) (S (VP (VB eliminate) (NP (NN PU.1) (NN binding)))))) (VP (VBP decrease) (NP (NN M-CSF) (NN receptor) (NN promoter) (NN activity)) (ADVP (RB significantly)) (PP (IN in) (NP (NP (JJ macrophage) (NN cell) (NNS lines)) (ADVP (RB only))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NN PU.1)) (VP (VBZ transactivates) (NP (NP (DT the) (NN M-CSF) (NN receptor) (NN promoter)) (PP (IN in) (NP (JJ nonmacrophage) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-21 (NN PU.1)) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NN macrophage) (NN gene) (NP-COOD (NP (NN regulation)) (CC and) (NP (NN development))))) (PP (IN by) (S (VP (VBG directing) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN receptor)) (PP (IN for) (NP (DT a) (JJ key) (NN macrophage) (NN growth) (NN factor))))))))))))) (. .)))
(TOP (S (NP-SBJ (VBN Increased) (JJ natural) (NN killer) (NN cell) (NN activity)) (VP (VBZ correlates) (PP (IN with) (NP (NP (ADJP-COOD (ADJP (JJ low)) (CC or) (ADJP (JJ negative))) (NN expression)) (PP (IN of) (NP (DT the) (NN HER-2/neu) (NN oncogene))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))))) (. .)))
(TOP (NP (NN BACKGROUND) (. .)))
(TOP (S (NP-SBJ-22 (NP (VBN Increased) (NN expression)) (PP (IN of) (NP (DT the) (NN HER-2/neu) (NN oncogene))) (PP (IN in) (NP (NN breast) (NN cancer)))) (VP-COOD (VP (VBZ correlates) (PP (IN with) (NP (VBN decreased) (NN estrogen) (NN receptor) (NN concentration)))) (CC and) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (NP-PRD (DT an) (JJ important) (JJ prognostic) (NN factor))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS authors)) (VP (VBD investigated) (SBAR (IN whether) (S (NP-SBJ (EX there)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN correlation)) (PP (IN between) (NP (NP-COOD (NP (NN HER-2/neu) (NN expression)) (CC and) (NP (NP (JJ immunologic) (NNS parameters)) (VP (VBG representing) (NP (NN tumor) (NN defense))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))))))))) (. .)))
(TOP (NP (NN METHOD) (. .)))
(TOP (S-COOD (S (NP-SBJ-23 (DT A) (JJ Western) (NN blot) (NN analysis)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB investigate) (NP (NN HER-2/neu) (NN expression)))))))) (, ,) (IN whereas) (S (NP-SBJ-24 (NP (DT a) (NN chromium-release) (NN assay)) (VP (VBG using) (NP (DT the) (NN K562) (NN cell) (NN line)) (PP (IN as) (NP (NN target))))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (NN cell) (NN activity)))))))) (. .)))
(TOP (NP (NNS RESULTS) (. .)))
(TOP (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer))))) (, ,) (NP-SBJ (NN NK) (NN cell) (NN activity)) (VP (VBD was) (ADJP-PRD (RB significantly) (JJR higher)) (PP (VBN compared) (PP (IN with) (NP-COOD (NP (NP (NP (NNS patients)) (PP (IN with) (NP (JJ benign) (NNS tumors)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.006)))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ healthy) (NN control) (NNS subjects)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.002)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ (NP (CD 23.3) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN breast) (NN cancer)))))) (VP (VBD showed) (NP (NP (DT an) (NN overexpression)) (PP (IN of) (NP (NN HER-2/neu) (NN protein))))) (. .)))
(TOP (S (PP (IN Within) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))))) (, ,) (NP-SBJ (NN NK) (NN cell) (NN activity)) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR lower)) (PRN (-LRB- -LRB-) (NP (QP (CD 45.6) (CC +/-) (CD 16.1)) (NN %)) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (DT the) (NN group)) (PP (IN with) (NP (DT no) (NN HER-2/neu) (NN overexpression)))) (PRN (-LRB- -LRB-) (NP (QP (CD 57.3) (CC +/-) (CD 11.0)) (NN %)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ (NN NK) (NN cell) (NN activity)) (VP (VBD did) (RB not) (VP (VB increase) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN HER-2/neu) (NN overexpression))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN correlation)) (PP (IN of) (NP (JJ cytolytic) (NN effector) (NN cell) (NN function))) (PP (IN with) (NP-COOD (NP (NP (NP (NN HER-2/neu) (NN expression)) (PP (IN of) (NP (DT the) (NN tumor)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.003)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (NN HER-2/neu) (NN overexpression)) (VP (VBD correlated) (PP (IN with) (NP (DT a) (JJ negative) (NN estrogen) (NN receptor) (NN status))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.005)))) (-RRB- -RRB-))))))) (. .)))
(TOP (NP (NN CONCLUSION) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP add) (NP (JJ further) (NN evidence)) (PP (TO to) (NP (NP (JJ previous) (NNS observations)) (PP (IN from) (NP (NP (DT the) (NNS authors)) (POS '))) (SBAR-25 (NN laboratory) (S (NP-SBJ-26 (IN that) (JJ certain) (NN tumor)) (VP (NNS characteristics) (VP (MD may) (VP (VB be) (PP (VBN associated) (NP (NP (IN with)) (PP (NNS reactions) (NP (NP (IN of) (DT the)) (PP (NN host) (NP (IN with) (NN breast))))))))))))))) (NN cancer)))
(TOP (NP (NP (NN Induction)) (PP (IN of) (NP-COOD (NP (NN tyrosine) (NN phosphorylation)) (CC and) (NP (NN T-cell) (NN activation)))) (PP (IN by) (NP (NP (NN vanadate) (NN peroxide)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN protein) (NN tyrosine) (NNS phosphatases)))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Rapid) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (JJ key) (JJ cellular) (NNS proteins)))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ crucial) (NN event)) (PP (IN in) (NP (NP (DT the) (NN transduction)) (PP (IN of) (NP (NN activation) (NNS signals))) (PP (TO to) (NP (NNS T-lymphocytes))))))) (. .)))
(TOP (S (NP-SBJ-35 (NP (DT The) (JJ regulatory) (NN role)) (PP (IN of) (NP (NP (NN protein) (NN tyrosine) (NNS phosphatases)) (PRN (-LRB- -LRB-) (NP (NNS PTPases)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT this) (NN process)))) (VP (VBD was) (VP (VBN explored) (PP (IN by) (S (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ powerful) (NN PTPase) (NN inhibitor)) (, ,) (NP (NP (NN vanadate) (NN peroxide)) (PRN (-LRB- -LRB-) (NP (NN pervanadate)) (-RRB- -RRB-))) (, ,))) (PP (IN on) (NP (NP (DT the) (NN activation) (NN cascade)) (PP (IN of) (NP (NN Jurkat) (JJ human) (JJ leukaemic) (NNS T-cells))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Pervanadate)) (VP (VBD induced) (NP-COOD (NP (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN tyrosine) (NNS kinases) (NP-COOD (NP (NN lck)) (CC and) (NP (NN fyn)))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 4-) (CC and) (JJ 3-fold))) (ADVP (RB respectively))) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ dramatic) (NN increase)) (PP (IN in) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (JJ cellular) (NNS proteins)) (, ,) (NP (RB notably) (NN phospholipase) (NN C) (NN gamma) (CD 1))))))))) (. .)))
(TOP (S (PP-TMP (IN After) (NP (DT this) (NN event))) (, ,) (NP-SBJ (PRP we)) (VP (VBD observed) (NP (NP (DT a) (NN rise)) (PP (IN in) (NP (JJ intracellular) (NN Ca2+) (NN concentration))) (, ,) (VP (VBG corresponding) (PP (TO to) (NP (DT an) (NN influx)))))) (. .)))
(TOP (S (NP-SBJ-36 (DT This) (NN effect)) (VP-COOD (VP (VBD required) (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP (DT the) (NN CD45) (NN PTPase))))) (CC and) (VP (VBD was) (RB not) (VP (VBN observed) (PP (IN in) (NP (NP (JJ CD45-deficient) (NNS variants)) (PP (IN of) (NP (NN Jurkat) (NNS cells)))))))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (DT the) (JJ CD45-negative) (NN variant))) (, ,) (NP-SBJ-37 (NP (DT the) (NN effect)) (PP (IN of) (NP (NN pervanadate))) (PP (IN on) (NP (NN tyrosine) (NN phosphorylation)))) (VP (VBD was) (ADVP (RB globally)) (VP (VBN decreased)))) (CC and) (S (NP-SBJ (DT some) (VBN phosphorylated) (NNS substrates)) (VP (VBD were) (ADVP (RB specifically)) (ADJP-PRD (JJ missing)))) (. .)))
(TOP (S (NP-SBJ (NN Pervanadate)) (ADVP (RB also)) (VP (VBD stimulated) (NP-COOD (NP (NP (NN transcription)) (PP (IN of) (NP (DT the) (NN c-fos) (NN gene)))) (CC and) (NP (NP (NN accumulation)) (PP (IN of) (NP (PRP$ its) (NN mRNA)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ several) (JJ other) (NNS hallmarks)) (PP (IN of) (NP (NN T-lymphocyte) (NN activation))) (PP (JJ such) (IN as) (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP-COOD (NP (DT the) (NN CD69) (NN antigen)) (CC and) (NP (NP (DT the) (NN interleukin) (CD 2) (NN receptor) (NN alpha-chain)) (PRN (-LRB- -LRB-) (NP (NN CD25)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ-38 (NN Pervanadate)) (VP (VBD synergized) (PP (IN with) (NP (NP (NNS signals)) (VP (VBN delivered) (PP-COOD (PP (IN by) (NP-LGS (NN T-cell) (NN antigen) (NN receptor) (NN engagement))) (CC or) (PP (IN by) (NP-LGS (DT a) (NN phorbol) (NN ester))))))) (S (VP (TO to) (VP (VB induce) (NP (NN interleukin) (CD 2) (NN production)))))) (. .)))
(TOP (S (NP-SBJ (NN Pervanadate)) (VP (VBD activated) (NP (NN NF-kappa) (NN B)) (, ,) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ DNA-binding) (NN activity)) (PP (IN of) (NP (DT this) (NN transcription) (NN factor))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB thus)) (VP (VBP conclude) (SBAR (IN that) (S (NP-SBJ (NNS PTPases)) (VP (VBP play) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ negative) (NN regulation)) (PP (IN of) (NP (NP (NN signal) (NN transduction)) (VP (VBG culminating) (PP (IN in) (NP (NN T-lymphocyte) (NN activation)))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ (NP (NN induction)) (PP (IN of) (NP (NN tyrosine) (NN phosphorylation)))) (VP (VBZ appears) (ADJP-PRD (JJ sufficient) (ADVP (FW per) (FW se)) (S (VP (TO to) (VP (VB initiate) (NP (DT a) (JJ complete) (NN activation) (NN programme))))))) (. .)))
(TOP (NP (JJ Steroid-resistant) (NN asthma) (. .)))
(TOP (NP (NP (JJ Cellular) (NNS mechanisms)) (VP (VBG contributing) (PP (TO to) (NP (NP (JJ inadequate) (NN response)) (PP (TO to) (NP (NN glucocorticoid) (NN therapy)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ current) (NN study)) (VP (VBD examined) (SBAR (IN whether) (S (NP-SBJ (NP (NNS alterations)) (PP (IN in) (NP (NP (NP (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (NN binding)))) (VP (VBP contribute) (PP (TO to) (NP (NP (JJ poor) (NN response)) (PP (TO to) (NP (NP (NN glucocorticoid) (NN therapy)) (PP (IN in) (NP (NN asthma))))))))))) (. .)))
(TOP (S (NP-SBJ-19 (NP (CD 29) (NN asthma) (NNS patients)) (PP (IN with) (NP (NP (NP (NP (NP (VBN forced) (JJ expiratory) (NN volume)) (PP (IN in) (NP (CD 1) (NN s)))) (PRN (-LRB- -LRB-) (NP (NN FEV1)) (-RRB- -RRB-))) (NP (QP (JJR &lt;) (CD 70)) (NN %))) (VP (VBN predicted))))) (VP (VBD were) (VP (VBN studied))) (. .)))
(TOP (S (NP-SBJ-20 (NNS Patients)) (VP (VBD were) (VP-COOD (VP (VBN classified) (PP (IN as) (ADJP-102 (ADJP (NN steroid) (JJ sensitive)) (PRN (-LRB- -LRB-) (ADJP (JJ SS)) (-RRB- -RRB-)))) (SBAR-103 (IN if) (S (NP-SBJ (PRP$ their) (NN morning) (NN FEV1)) (VP (VBD increased) (NP (QP (RBR &gt;) (CD 30)) (NN %)) (PP-TMP (IN after) (NP (NP (DT a) (JJ 1-wk) (NN course)) (PP (IN of) (NP (NP (JJ oral) (NN prednisone)) (NP (CD 20) (NN mg)) (ADVP (RB twice) (RB daily)))))))))) (CC and) (VP (ADJP=102 (ADJP (NN steroid) (JJ resistant)) (PRN (-LRB- -LRB-) (ADJP (JJ SR)) (-RRB- -RRB-))) (SBAR=103 (IN if) (S (NP-SBJ-21 (PRP they)) (VP (VBD failed) (S (VP (TO to) (VP (VB increase) (NP (QP (RBR &gt;) (CD 15)) (NN %))))))))))) (. .)))
(TOP (S (NP-SBJ-22 (NP (NN PBMC)) (VP (VBN obtained) (PP (IN from) (NP-COOD (NP (NP (DT these) (CD two) (NNS groups)) (, ,) (NP-COOD (NP (CD 17) (JJ SR)) (CC and) (NP (CD 12) (JJ SS))) (, ,)) (CONJP (RB as) (RB well) (IN as)) (NP (CD 12) (JJ normal) (NNS controls)))))) (VP (VBD were) (VP (VBN analyzed))) (. .)))
(TOP (S (S (NP-SBJ (JJ SR) (NNS patients)) (VP (VBD had) (NP (CD two) (JJ distinguishable) (NN GR) (NN binding) (NNS abnormalities))) (: :)) (S (NP-SBJ-104 (NP (CD 15)) (PP (IN of) (NP (DT the) (CD 17) (JJ SR) (NNS patients)))) (VP (VBD demonstrated) (NP (DT a) (ADJP (RB significantly) (VBN reduced)) (NN GR) (NN binding) (NN affinity)) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP-COOD (NP (NP (JJ SS) (NNS patients)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.0001)))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ normal) (NNS controls)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (VP (JJ =) (NP-PRD (CD 0.0001)))) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ-23 (DT This) (NN defect)) (VP-COOD (VP (VBD was) (VP (JJ localized) (PP (TO to) (NP (NN T) (NNS cells))))) (CC and) (VP (VBD reverted) (PP (TO to) (NP (JJ normal))) (PP-TMP (IN after) (NP (NP (CD 48) (NN h)) (PP (IN in) (NP (NN culture) (NNS media))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (NN incubation)) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))))))) (VP (VBD sustained) (NP (DT this) (NN abnormality))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ other) (CD two) (JJ SR) (NNS patients)) (VP (VBD had) (NP (NP (DT an) (ADJP (RB abnormally) (JJ low)) (NN GR) (NN number)) (PP (IN with) (NP (NP (JJ normal) (NN binding) (NN affinity)) (SBAR (WHNP-24 (WDT that)) (S (VP (VBD was) (RB not) (ADJP-PRD (VBN limited) (PP (TO to) (NP (NN T) (NNS cells))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-26 (NN GR) (NN number)) (VP (VBD failed) (S (VP (TO to) (VP (VB normalize) (PP-TMP (IN after) (NP (NP (NN incubation)) (PP (IN in) (NP-COOD (NP (NP (NNS media)) (ADVP (RB alone))) (CC or) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (JJ SR) (NN asthma)) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (NP (QP (JJR more) (IN than) (CD one)) (NN abnormality)) (, ,) (NP-COOD (NP (NP (DT the) (NN majority)) (ADJP (JJ related) (PP (TO to) (NP (NP (DT a) (JJ reversible) (JJ cytokine-induced) (NN reduction)) (PP (IN in) (NP (NN GR) (NN binding) (NN affinity))))))) (CC and) (NP (NP (DT the) (JJ second)) (ADJP (JJ related) (PP (TO to) (NP (NP (DT an) (JJ irreversible) (NN reduction)) (PP (IN in) (NP (NN GR) (NN number)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (MD may) (VP (VB have) (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN design)) (PP (IN of) (NP (NP (JJ alternative) (NN treatment) (NNS approaches)) (PP (IN for) (NP (JJ recalcitrant) (NN asthma))))))))) (. .)))
(TOP (S (NP-SBJ (NNS Rhabdomyosarcomas)) (VP (VBP do) (RB not) (VP (VB contain) (NP (NNS mutations)) (PP (IN in) (NP (NP (DT the) (NN DNA) (NN binding) (NNS domains)) (PP (IN of) (NP (JJ myogenic) (NN transcription) (NNS factors))))))) (. .)))
(TOP (S (NP-SBJ-22 (JJ Skeletal) (NN myogenesis)) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NP (NN transcription) (NNS factors)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN MyoD)) (, ,) (NP (NN myogenin)) (, ,) (NP (NN myf5)) (, ,) (CC and) (NP (NN myf6))) (-RRB- -RRB-))) (SBAR (WHNP-23 (WDT that)) (S (VP (VBP are) (NP-PRD (NP (`` ") (JJ basic) (JJ helix-loop-helix) ('' ") (NNS proteins)) (SBAR (WHNP-24 (WDT that)) (S (VP-COOD (VP (VBP bind) (PP (TO to) (NP (NP (DT the) (NNS promoters)) (PP (IN of) (NP (JJ muscle-specific) (NNS genes)))))) (CC and) (VP (VBP promote) (NP (PRP$ their) (NN expression)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (PP-TMP (IN after) (NP (NP (DT a) (NN mutation)) (PP (IN of) (NP (NN Leu122))) (PP (TO to) (NP (NN Arg))))) (NP-SBJ (NP (DT the) (NN DNA) (NN binding) (JJ basic) (NN domain)) (PP (IN of) (NP (NN MyoD)))) (VP (VBZ confers) (NP (JJ c-myc-like) (JJ functional) (NNS characteristics)) (PP (TO to) (NP (DT the) (NN protein)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ (PRP we)) (VP (VBD used) (NP-25 (JJ single-strand) (NN conformation) (NN polymorphism) (NN analysis)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (JJ such) (NNS mutations)) (VP (VBP occur) (ADVP (RB naturally)) (PP (IN in) (NP (NNS rhabdomyosarcomas)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ basic) (NNS domains)) (PP (IN of) (NP (PDT all) (DT the) (JJ myogenic) (NNS factors)))) (VP (VBP remain) (ADJP-PRD (JJ unaltered)) (PP (IN in) (NP (NNS rhabdomyosarcomas)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Selection)) (PP (IN against) (NP (JJ such) (NNS mutations)))) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ functional) (NN redundancy)) (PP (IN of) (NP (DT these) (JJ myogenic) (NN transcription) (NNS factors)))))))) (. .)))
(TOP (NP (NP (VBN Increased) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN gene) (NN expression)))) (PP-TMP (IN after) (NP (NP (NN stimulation)) (PP (IN of) (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))) (PP (IN through) (NP (NP (DT a) (NN surface) (NN ganglioside)) (PRN (-LRB- -LRB-) (NP (NN GD3)) (-RRB- -RRB-)))))) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP J) (NNP Immunol)) (NP-TMP (CD 1994) (NNP Jul) (CD 15)) (: ;) (NP (CD 153) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (: :) (NP (CD 910)))))) (-RRB- -RCB-))))
(TOP (S (NP-SBJ (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (NNS gangliosides)) (VP (VBP have) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NN cell) (NP-COOD (NP (NN signaling)) (CC and) (NP (NN recognition)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-13 (NP (PRP$ their) (JJ specific) (NN function)) (PP (IN in) (NP (DT these) (NNS processes)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB clearly)) (VP (VBN defined)))) (. .)))
(TOP (S (NP-SBJ-14 (NP (NP (DT A) (NN mAb)) (, ,) (NP (NN R24)) (, ,)) (SBAR (WHNP-15 (WDT that)) (S (VP (VBZ reacts) (ADVP (RB specifically)) (PP (IN with) (NP (NP (DT a) (NN cell) (NN surface) (NN ganglioside)) (PRN (-LRB- -LRB-) (NP (NN GD3)) (-RRB- -RRB-)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB stimulate) (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (NN T) (NNS cells)) (VP (VBN derived) (PP (IN from) (NP (JJ human) (JJ peripheral) (NN blood))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP-16 (IN by) (WHNP (WDT which))) (S (NP-SBJ (DT the) (NN R24) (NN mAb)) (VP (VBZ affects) (NP (NN T) (NN cell) (NNS functions)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN observed) (SBAR (IN that) (S (NP-SBJ (DT the) (NN R24) (NN mAb)) (VP (VBZ stimulates) (NP (NP (JJ GD3+) (NN T) (NN cell) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN surface) (NN marker) (NN expression)))) (PP (IN of) (NP-COOD (NP (NN IL-2R) (NN alpha-chain)) (, ,) (NP (NN IL-2R) (NN beta-chain)) (, ,) (NP (NN HLA-DR)) (, ,) (NP (NN CD11a)) (, ,) (CC and) (NP (NN CD11c)))))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP-SBJ-COOD (NP (NN IFN-gamma) (NN activity)) (CONJP (CC but) (RB not)) (NP (NP-COOD (NP (NN IL-1)) (, ,) (NP (NN IL-2)) (, ,) (CC or) (NP (NN IL-4))) (NN activity))) (VP (VBD was) (ADJP-PRD (JJ present) (PP (IN in) (NP (NN culture) (NNS supernatants)))) (PP-TMP (NP (CD 72) (NN h)) (IN after) (NP (NN R24) (NN stimulation)))) (. .)))
(TOP (S (PP (IN In) (NP (DT some) (NNS donors))) (, ,) (NP-SBJ-17 (VBN increased) (NP-COOD (NP (NN IL-6)) (CC and) (NP (NN TNF-alpha))) (NN activity)) (ADVP (RB also)) (VP (VBD was) (VP (VBN detected) (PP-TMP (IN after) (NP (NN R24) (NN treatment))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NN R24) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP-COOD (NP (NP (NN translocation)) (PP (IN of) (NP-COOD (NP (NN c-rel)) (, ,) (CC but) (NP (ADJP-COOD (ADJP (JJ little)) (CC or) (ADJP (DT no))) (NN NF) (NN kappa) (NN B) (NP-COOD (NP (NN p50)) (CC or) (NP (NN p65)))) (, ,))) (PP (IN from) (NP (DT the) (NN cytoplasm))) (PP (TO to) (NP (DT the) (NN nucleus)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (ADJP (NN NF) (NN kappa) (NN B) (NN binding)) (NNS complexes)) (VP (VBG containing) (NP-COOD (NP (NN c-rel)) (CC and) (NP (NN p50)))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN treatment)) (ADVP (RB also)) (VP (VBD caused) (NP (NP (VBN increased) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (JJ specific) (NN protein) (NNS substrates))))) (. .)))
(TOP (S (NP-SBJ-18 (NP (JJ R24-stimulated) (NNS increases)) (PP (IN in) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN cell) (NN surface) (NN protein) (NN expression))))) (VP (MD could) (VP (VB be) (VP (VBN blocked) (PP (IN by) (NP-LGS-COOD (NP (NN cyclosporin)) (CC and) (NP (NN staurosporin)))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-COOD-20 (NP (NN cyclophilin/calcineurin)) (CC and) (NP (NN protein) (NN kinase) (NN C))) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (DT the) (NN R24) (NN signaling) (NN pathway))))))))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP-SBJ (NP (NN herbimycin) (NN A)) (, ,) (NP (DT a) (NN tyrosine) (NN kinase) (NN inhibitor)) (, ,)) (VP (VBD blocked) (NP (NP (DT the) (JJ R24-stimulated) (NN increase)) (PP (IN in) (NP-COOD (NP (NN proliferation)) (CONJP (CC but) (RB not)) (NP (NN cytotoxicity))))) (PP (IN at) (NP (NP (NNS concentrations)) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NN specificity)) (PP (IN for) (NP (NN tyrosine) (NNS kinases))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-21 (JJ multiple) (JJ biochemical) (NNS pathways)) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ human) (NN T) (NNS cells))) (PP (IN by) (NP (NN R24)))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN SCL) (NN protein)) (VP (VBZ displays) (NP (NP (JJ cell-specific) (NN heterogeneity)) (PP (IN in) (NP (NN size))))) (. .)))
(TOP (S (NP-SBJ-19 (NN SCL) (NN protein) (NN production)) (VP (VBD was) (VP (VBN examined) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ hemopoietic) (NN cell) (NNS lines))))) (PP (IN by) (NP (NP (VBG immunoblotting)) (VP (VBG using) (NP (JJ specific) (JJ polyclonal) (NNS antisera))))))) (. .)))
(TOP (S (NP-SBJ-20 (NN SCL) (NN protein)) (VP (VBD was) (VP (VBN detected) (PP-COOD (PP (IN in) (NP (UCP-COOD (ADJP (JJ erythroid)) (, ,) (NP (NN megakaryocyte)) (, ,) (NP (NN mast)) (CC and) (ADJP (JJ early) (JJ myeloid))) (NN cell) (NNS lines))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (JJ several) (JJ lymphoid) (NN leukemia) (NN cell) (NNS lines)) (SBAR (WHNP-21 (WDT which)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB harbor) (NP (NN SCL) (NN gene) (NNS rearrangements)))))))))))))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (JJS most) (NN cell) (NNS lines))) (, ,) (NP-SBJ-23 (NP (NNS proteins)) (PP (IN of) (NP (NP (JJ molecular) (NN weight)) (NP (QP (CD 49) (CC and) (CD 44)) (NN kDa))))) (VP (VBD were) (VP (VBN found)))) (, ,) (S (ADVP (RB however)) (NP-SBJ (CD two) (JJ myeloid) (NN cell) (NNS lines)) (VP (VBD expressed) (NP (NP (RB only) (JJR lower) (JJ molecular) (NN weight) (NNS species)) (PP (IN of) (NP (QP (CD 24) (CC and) (CD 22)) (NN kDa)))))) (. .)))
(TOP (S (NP-SBJ-24 (DT This) (NN size) (NN discrepancy)) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (JJ cell-specific) (JJ translational) (NN regulation)))))) (, ,) (SBAR (IN since) (S (NP-SBJ (NP (NN overexpression)) (PP (IN of) (NP (DT a) (ADJP (RB retrovirally) (VBN transfected)) (NN SCL) (NN gene)))) (VP-COOD (VP (VBD yielded) (NP-25 (DT the) (JJR higher) (JJ molecular) (NN weight) (NNS forms)) (PP-26 (IN in) (NP (NP (JJS most) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN GP+E-86)) (, ,) (NP (NN AT2.5)) (, ,) (NP (NN M1))) (-RRB- -RRB-))))) (CC but) (VP (NP=25 (RB only) (DT the) (ADJP (CD 22) (NN kDa)) (NN form)) (PP=26 (IN in) (NP (NP (DT the) (JJ myeloid) (NN cell) (NN line)) (, ,) (NP (NN WEHI-3B/D+))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP (JJ full-length) (NN SCL) (NN protein))) (PP (IN in) (NP (NP (DT the) (JJ lymphoid) (NN cell) (NNS lines)) (, ,) (NP-COOD (NP (NN SupT1)) (CC and) (NP (NN Raji))) (, ,)))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NN cell) (NN phenotype))))) (CC and) (S (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT no) (NN evidence)) (PP (IN for) (NP (NP (NN autoregulation)) (PP (IN of) (NP (NN SCL) (NN transcription)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ restricted) (NN pattern)) (PP (IN of) (NP (NN SCL) (NN protein) (NN synthesis)))) (VP (VBZ is) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (DT the) (JJ restricted) (NN expression)) (PP (IN of) (NP (NN SCL) (NN mRNA))) (VP (VBN documented) (ADVP-TMP (RB previously))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (DT the) (JJ present) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-27 (NN SCL) (NN protein) (NN size)) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP-LGS (NP (NN regulation)) (PP (IN of) (NP (NN translation))))) (PP (IN in) (NP (DT a) (JJ cell-specific) (NN manner)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (DT the) (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor) (NN promoter))) (PP (IN in) (NP (NN T) (NNS cells)))) (VP (VBZ requires) (NP (NP (JJ cooperative) (NN binding)) (PP (IN of) (NP (NP-COOD (NP (NN Elf-1)) (CC and) (NP (NN AP-1))) (NN transcription) (NNS factors))))) (. .)))
(TOP (S (NP-SBJ-9 (DT The) (NP (NP (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (NN gene)) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (ADVP (RB extensively)) (PP (IN as) (NP (NP (DT a) (NN model) (NN system)) (PP (IN of) (NP (NP (JJ transcriptional) (NN induction)) (PP-TMP (IN during) (NP (NN T-lymphocyte) (NN activation)))))))))) (. .)))
(TOP (S (NP-SBJ-10 (DT The) (NN GM-CSF) (NN gene)) (VP-COOD (VP (VBZ is) (RB not) (VP (VBN expressed) (PP (IN in) (NP (VBG resting) (JJ peripheral) (NN blood) (NN T) (NNS cells))))) (CC but) (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN induced) (PP (IN at) (NP (DT the) (JJ transcriptional) (NN level))) (PP-TMP (VBG following) (NP (NN activation))) (PP (IN through) (NP (DT the) (NN cell) (NN surface) (NN T-cell) (NN receptor)))))) (. .)))
(TOP (S (NP-SBJ-12 (NP (DT A) (ADJP (RB highly) (VBN conserved)) (JJ 19-bp) (NN element)) (ADJP (JJ located) (ADVP (RB immediately) (NP (NP (NP (JJ 5')) (PP (IN of) (NP (DT the) (JJ human) (NN GM-CSF) (NN TATA) (NN box)))) (PRN (-LRB- -LRB-) (NP (NP (NN bp)) (PP (NP (CD -34)) (TO to) (NP (CD -52)))) (-RRB- -RRB-))))) (, ,) (VP (ADVP (RB herein)) (VBN called) (S (NP-PRD (NP (NN purine) (NN box) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN PB1)) (-RRB- -RRB-))))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP-COOD (VP (TO to) (VP (VB bind) (NP (DT a) (NN T-cell) (JJ nuclear) (NN protein) (NN complex)))) (CC and) (VP (TO to) (VP (VB be) (VP (VBN required) (PP (IN for) (NP (NP (JJ transcriptional) (NN induction)) (PP (IN of) (NP (DT the) (NN GM-CSF) (NN gene))) (PP-TMP (VBG following) (NP (NN T-cell) (NN activation))))))))))))) (. .)))
(TOP (S (NP-SBJ-14 (DT The) (NN PB1) (NN sequence) (NN motif)) (VP (VBZ is) (ADJP-PRD (RB highly) (VBN conserved)) (PP (IN in) (NP (ADJP-COOD (CC both) (ADJP (JJ human)) (CC and) (ADJP (JJ murine))) (NN GM-CSF) (NNS genes)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN PB1) (NN element)) (ADVP (RB alone))) (VP (VBZ confers) (NP (NN inducibility)) (PP (IN on) (NP (DT a) (JJ heterologous) (NN promoter))) (PP-TMP (VBG following) (NP (NP (NN transfection)) (PP (IN into) (NP (JJ human) (NN Jurkat) (NN T) (NNS cells))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (PRP we)) (VP (VBP identify) (NP (NP (DT a) (JJ major) (NN PB1) (JJ nuclear) (JJ protein-binding) (NN complex)) (SBAR (WHNP-15 (WDT that)) (S (VP-COOD (VP (VBZ is) (RB not) (ADJP-PRD (JJ present) (PP (IN in) (NP (VBG resting) (JJ peripheral) (NN blood) (NN T) (NNS cells))))) (CC but) (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN induced) (PP-TMP (VBG following) (NP (NN T-cell) (NN activation)))))))))) (. .)))
(TOP (S (NP-SBJ (NN Sequence) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ-17 (NN PB1)) (VP (VBZ is) (VP (VBN composed) (PP (IN of) (NP (NP (JJ adjacent) (VBG binding) (NNS sites)) (PP (IN for) (NP-COOD (NP (NN Ets)) (CC and) (NP (NN AP-1) (NN transcription) (NNS factors))))))))))) (. .)))
(TOP (S (NP-SBJ (ADJP (FW In) (FW vitro)) (NN mutagenesis) (NNS experiments)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-18 (CC both) (DT the) (NP-COOD (NP (NNS Ets)) (CC and) (NP (NN AP-1) (NNS sites)))) (VP (VBP are) (VP (VBN required) (PP (PP-COOD (PP (IN for) (NP (NP (NN binding)) (PP (IN of) (NP (DT the) (JJ inducible) (NN PB1) (JJ nuclear) (NN protein) (NN complex))))) (CC and) (PP (IN for) (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP-COOD (NP (DT this) (NN element)) (CC and) (NP (DT the) (NN GM-CSF) (NN promoter))))))) (PP-100 (IN in) (NP (VBN activated) (NN T) (NNS cells))))))))) (. .)))
(TOP (S (-LRB- -LRB-) (NP-SBJ-101 (NN ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-)))
(TOP (S (S (NP-SBJ-11 (JJ Human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD I) (NN Tax)) (VP (VP-COOD (VP (VBZ associates) (PP (IN with))) (CC and) (VP (VBZ is) (VP (ADVP (RB negatively)) (VBN regulated) (PP (IN by))))) (NP-12 (DT the) (NN NF-kappa) (NN B2) (NN p100) (NN gene) (NN product))) (: :)) (NP (NP (NNS implications)) (PP (IN for) (NP (JJ viral) (NN latency))) (. .))))
(TOP (S (NP-SBJ (NP (JJ Human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD I)) (PRN (-LRB- -LRB-) (NP (NN HTLV-I)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ etiologic) (NN agent)) (PP (IN of) (NP (NP (DT the) (JJ adult) (NN T-cell) (NN leukemia)) (, ,) (NP (NP (DT an) (ADJP-COOD (ADJP (JJ aggressive)) (CC and) (ADJP (ADVP-TMP (RB often)) (JJ fatal))) (NN malignancy)) (PP (IN of) (NP (VBN activated) (JJ human) (NN CD4) (NN T) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NN HTLV-I)) (VP (VBZ encodes) (NP (NP (DT an) (JJ essential) (JJ 40-kDa) (NN protein)) (VP (VBN termed) (S (NP-PRD (NN Tax)))) (SBAR (WHNP-16 (WDT that)) (S (VP-COOD (CONJP (RB not) (RB only)) (VP (VBZ transactivates) (NP (NP (DT the) (JJ long) (JJ terminal) (NN repeat)) (PP (IN of) (NP (DT this) (NN retrovirus))))) (CONJP (CC but) (RB also)) (VP (VBZ induces) (NP (NP (DT an) (NN array)) (PP (IN of) (NP (JJ cellular) (NNS genes)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Tax-mediated) (NN transformation)) (PP (IN of) (NP (NN T) (NNS cells)))) (ADVP (RB likely)) (VP (VBZ involves) (NP (NP (DT the) (VBN deregulated) (NN expression)) (PP (IN of) (NP (NP (JJ various) (JJ cellular) (NNS genes)) (SBAR (WHNP-15 (WDT that)) (S (ADVP (RB normally)) (VP (VBP regulate) (NP (NP (NN lymphocyte) (NN growth)) (VP (VBN produced) (PP (IN by) (NP-LGS (NP (JJ altered) (NN activity)) (PP (IN of) (NP (JJ various) (JJ endogenous) (NN host) (NN transcription) (NNS factors)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ particular))) (, ,) (NP-SBJ-13 (NN Tax)) (VP (VBZ is) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG modulating) (NP (NP (DT the) (NP-COOD (NP (NN expression)) (CC or) (NP (NN activity)))) (PP (IN of) (NP (NP (JJ various) (NN host) (NN transcription) (NNS factors)) (, ,) (PP (VBG including) (NP (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN NF-kappa) (NN B/Rel)) (CC and) (NP (NN CREB/ATF))) (NNS families)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (JJ cellular) (NNS factors) (NP-COOD (NP (NN HEB-1)) (CC and) (NP (NN p67SRF)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (JJ additional) (JJ distinguishing) (NN characteristic)) (PP (IN of) (NP (NN HTLV-I) (NN infection)))) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ profound) (NN state)) (PP (IN of) (NP (NP (JJ viral) (NN latency)) (SBAR (WHNP-14 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (JJ present) (PP (IN in) (NP (VBG circulating) (JJ primary) (JJ leukemic) (NN T) (NNS cells))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NN HTLV-I) (NN Tax)) (VP (MD can) (VP (ADVP (RB physically)) (VB associate) (PP (IN with) (NP (NP (NN p100)) (, ,) (NP (NP (DT the) (NN product)) (PP (IN of) (NP (DT the) (JJ Rel-related) (NN NF-kappa) (NN B2) (NN gene)))) (, ,))) (PP-COOD (CC both) (PP (IN in) (NP (VBN transfected) (NNS cells))) (CC and) (PP (IN in) (NP (JJ HTLV-I-infected) (JJ leukemic) (NN T-cell) (NNS lines))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (DT the) (JJ physical) (NN interaction)) (PP (IN of) (NP (NN Tax))) (PP (IN with) (NP (NN p100)))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (JJ Tax-induced) (NN activation)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN HTLV-I)) (CC and) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1))) (JJ long) (JJ terminal) (NNS repeats))))))) (, ,) (S (VP (VBG reflecting) (NP (NP (JJ p100-mediated) (JJ cytoplasmic) (NN sequestration)) (PP (IN of) (NP (DT the) (ADJP (ADVP (RB normally)) (RB nuclearly) (VBN expressed)) (NN Tax) (NN protein))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (DT a) (NN mutant)) (PP (IN of) (NP (NN Tax))) (SBAR (WHNP-18 (WDT that)) (S (ADVP (RB selectively)) (VP (VBZ fails) (S (VP (TO to) (VP (VB activate) (NP (JJ nuclear) (NN NF-kappa) (NN B) (NN expression))))))))) (VP (VBZ does) (RB not) (VP (VB associate) (PP (IN with) (NP (NN p100))))) (. .)))
(TOP (S (-LRB- -LRB-) (NP-SBJ-20 (NN ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (DT the) (NN BZLF1) (NN promoter)) (PP (IN of) (NP (JJ Epstein-Barr) (NN virus))))) (PP (IN by) (NP (JJ second) (NNS messengers))) (PP (IN in) (NP (JJ anti-immunoglobulin-treated) (NN B) (NNS cells))) (. .)))
(TOP (S (NP-SBJ (NP (NN Initiation)) (PP (IN of) (NP (DT the) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (JJ lytic) (NN cycle)))) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (DT the) (NN BZLF1) (NN gene))))))) (. .)))
(TOP (S (NP-SBJ-10 (NP (DT The) (NN BZLF1) (NN gene) (NN promoter)) (PRN (-LRB- -LRB-) (NP (NN Zp)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN activated) (PP (IN by) (NP-LGS (NP (NN crosslinking)) (PP (IN of) (NP (NN cell) (NN surface) (NP (NP (NN immunoglobulin)) (PRN (-LRB- -LRB-) (NP (NN Ig)) (-RRB- -RRB-))))) (PP (IN with) (NP (JJ anti-Ig) (NN antibody))))) (PP (IN in) (NP (NN B) (NNS cells))) (, ,) (PP (RB even) (IN in) (DT the) (NN absence) (IN of) (NP (JJ other) (JJ viral) (NNS genes))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD identified) (NP (NP (JJ several) (JJ anti-Ig) (NN response) (NNS elements)) (PP (IN within) (NP (NN Zp))) (, ,) (SBAR (WHNP-11 (WDT which)) (S (VP (VBD were) (VP (ADVP (RB originally)) (VBN defined) (PP (IN as) (NP (NP (NP (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))) (NN response) (NNS elements) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN ZI) (NNS repeats)) (CC and) (NP (NP (NN ZII)) (, ,) (NP (DT an) (JJ AP-1-like) (NN domain)))) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (JJ anti-Ig) (NN crosslinking)) (VP (VBZ leads) (PP (TO to) (NP-COOD (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ intracellular) (NN calcium) (NN level))))))))) (, ,) (NP-SBJ-13 (NN Zp)) (VP (VBD was) (VP (VBN tested) (PP (IN for) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (DT these) (JJ cellular) (NNS factors))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN with) (NP (NN calcium) (NN ionophore) (NN A23187)))) (VP (VBD increased) (NP (NN Zp) (NN activity))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-14 (WRB When)) (S (NP-SBJ-15 (DT the) (NN calcium) (NN ionophore)) (VP (VBD was) (VP (VBN used) (PP (IN in) (NN conjunction) (IN with) (NP (NP (NN TPA)) (, ,) (NP (DT a) (NN PKC) (NN activator)))))))) (, ,) (NP-SBJ-16 (DT the) (NN Zp) (NN induction)) (VP (VBD was) (ADVP (RB synergistically)) (VP (VBN enhanced))) (. .)))
(TOP (S (NP-SBJ (JJ Retinoic) (NN acid)) (VP (VBZ downmodulates) (NP (NP-COOD (NP (JJ erythroid) (NN differentiation)) (CC and) (NP (NN GATA1) (NN expression))) (PP (IN in) (NP (VBN purified) (JJ adult-progenitor) (NN culture))))) (. .)))
(TOP (S (NP-SBJ-1 (JJ All-trans) (NP (NP (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-)))) (VP-COOD (VP (VBZ is) (NP-PRD (NP (NP (DT an) (JJ important) (NN morphogen)) (PP (IN in) (NP (NN vertebrate) (NN development)))) (, ,) (NP (NP (DT a) (JJ normal) (NN constituent)) (PP (IN in) (NP (JJ human) (JJ adult) (NN blood)))))) (CC and) (VP (VBZ is) (VP (ADVP (RB also)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN cell) (NP-COOD (NP (NN growth)) (CC and) (NP (NN differentiation)))) (PP (IN in) (NP (JJ acute) (JJ promyelocytic) (NN leukemia))))))))))) (. .)))
(TOP (S (NP-SBJ-2 (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN RA))) (PP (IN on) (NP (JJ normal) (NN hematopoiesis)))) (PP (IN by) (S (VP (VBG using) (NP (NP (JJ early) (NP (NP (JJ hematopoietic) (NN progenitor) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN HPC)) (-RRB- -RRB-)))) (VP (ADVP (RB stringently)) (VBN purified) (PP (IN from) (NP (JJ adult) (JJ peripheral) (NN blood)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ clonogenetic) (ADJP-COOD (ADJP (ADJP (JJ fetal) (NN calf) (JJ serum-supplemented)) (PRN (-LRB- -LRB-) (ADJP (JJ FCS+)) (-RRB- -RRB-))) (CC or) (ADJP (ADJP (JJ -nonsupplemented)) (PRN (-LRB- -LRB-) (ADJP (JJ FCS-)) (-RRB- -RRB-)))) (NN culture)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ saturating) (NNS levels)) (PP (IN of) (NP-COOD (NP (NP (NP (NN interleukin-3)) (PRN (-LRB- -LRB-) (NP (NN IL-3)) (-RRB- -RRB-))) (NP (NP (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-)))) (CC and) (NP (NP (NP (NN erythropoietin)) (PRN (-LRB- -LRB-) (NP (NN Ep)) (-RRB- -RRB-))) (-LRB- -LRB-) (PP (VBN combined) (PP (IN with) (NP (NP (NN c-kit) (NN ligand)) (PP (IN in) (NP (JJ FCS-LRB---RRB--culture) (NNS conditions)))))) (-RRB- -RRB-))))))))) (, ,) (NP-SBJ (NN RA)) (VP (VBZ induces) (NP (NP (DT a) (JJ dramatic) (JJ dose-dependent) (NN shift)) (PP (IN from) (NP (JJ erythroid))) (PP (TO to) (NP (JJ granulomonocytic))) (NP-3 (NN colony) (NN formation))) (, ,) (S (NP-SBJ-4 (DT the) (JJ latter) (NNS colonies)) (VP (VBG being) (VP (ADVP (RB essentially)) (VBN represented) (PP (IN by) (NP-LGS (JJ granulocytic) (NNS clones))))))) (. .)))
(TOP (S (NP-SBJ-5 (DT This) (NN shift)) (VP (VBZ is) (ADVP (RB apparently)) (RB not) (VP (VBN caused) (PP (IN by) (NP-LGS (DT a) (NN recruitment) (NN phenomenon))) (, ,) (SBAR (IN because) (S (PP (IN in) (NP (JJ FCS+) (NN culture))) (, ,) (NP-SBJ-6 (NP (DT the) (JJ total) (NN number)) (PP (IN of) (NP (NNS colonies)))) (VP (VBZ is) (RB not) (VP (ADVP (RB significantly)) (VBN modified) (PP (IN by) (NP-LGS (NN RA) (NN addition))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (NP (JJ FCS-) (NN liquid-suspension) (NN culture)) (VP (VBN supplemented) (PP (IN with) (NP-COOD (NP (JJ saturating) (NN Ep) (NN level)) (CC and) (NP (JJ low-dose) (NN IL-3/GM-CSF))))))) (, ,) (NP-SBJ (JJ adult) (NN HPC)) (VP (VBP undergo) (NP (JJ unilineage) (JJ erythropoietic) (NN differentiation))) (: :)) (S (ADVP (RB Here)) (ADVP-TMP (RB again)) (, ,) (NP-SBJ (NP (NN treatment)) (PP (IN with) (NP (JJ high-dose) (NN RA)))) (VP (VBZ induces) (NP (NP (DT a) (NN shift)) (PP (IN from) (NP (DT the) (ADJP-COOD (ADJP (JJ erythroid)) (TO to) (ADJP (JJ granulocytic))) (NN differentiation) (NN pathway))))) (. .))))
(TOP (S (NP-SBJ-7 (NP (NNS Studies)) (PP (IN on) (NP (NP (NN RA) (UCP-COOD (ADJP (JJ time-response)) (CC or) (NP (NN pulse))) (NN treatment)) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ semisolid)) (CC or) (ADJP (JJ liquid))) (NN culture)))))) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (JJ early) (NN RA) (NN addition)) (VP (VBZ is) (ADJP-PRD (RBS most) (JJ effective))))) (, ,) (S (ADVP (RB thus)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (ADJP-COOD (ADJP (JJ early)) (CC but) (ADJP (RB not) (JJ late))) (NN HPC)) (VP (VBP are) (ADJP-PRD (JJ sensitive) (PP (TO to) (NP (PRP$ its) (NN action)))))))))) (. .)))
(TOP (S (S (NP-SBJ (PRP We)) (ADVP-TMP (RB then)) (VP (VBD analyzed) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (NN master) (NN GATA1) (NN gene)) (, ,) (SBAR (WHNP-8 (WDT which)) (S (VP (VBZ encodes) (NP (NP (DT a) (NN finger) (NN transcription) (NN factor)) (VP (VBN required) (PP (IN for) (NP (JJ normal) (JJ erythroid) (NN development)))))))))))) (: ;)) (S (NP-SBJ (NP (NN addition)) (PP (IN of) (NP (NN RA))) (PP (TO to) (NP (NP (NN HPC)) (VP (VBN stimulated) (PP (IN into) (NP (JJ unilineage) (JJ erythropoietic) (NN differentiation))) (PP (IN in) (NP (JJ liquid) (NN culture))))))) (VP (VBD caused) (NP (NP (DT a) (ADJP (RB virtually) (JJ complete)) (NN inhibition)) (PP (IN of) (NP (NN GATA1) (NN mRNA) (NN induction))))) (. .))))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN RA)) (ADVP (RB directly)) (VP-COOD (VP (VBZ inhibits) (NP (DT the) (JJ erythroid) (NN differentiation) (NN program)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ early) (JJ adult) (NN HPC)))))) (, ,) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (NN shift)) (PP (IN from) (NP (DT the) (ADJP-COOD (ADJP (JJ erythroid)) (TO to) (ADJP (JJ granulocytic))) (NN differentiation) (NN pathway))))))))))) (. .)))
(TOP (S (NP-SBJ-9 (DT This) (NN phenomenon)) (VP (VBZ is) (VP (VBN correlated) (PP (IN with) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN GATA1) (NN induction))) (PP (IN in) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (JJ erythropoietic) (NN differentiation))))))))) (. .)))
(TOP (NP (NP (NNS Effects)) (PP (IN of) (NP (NN CD45))) (PP (IN on) (NP (NN NF-kappa) (NN B))) (. .)))
(TOP (NP (NP (NNS Implications)) (PP (IN for) (NP (NP (NN replication)) (PP (IN of) (NP (NN HIV-1))))) (. .)))
(TOP (S (NP-SBJ-10 (NP (VBN Increased) (NNS levels)) (PP (IN of) (NP (NP (NN replication)) (PP (IN of) (NP (DT the) (NN HIV) (NN type) (CD 1)))))) (VP (VBP are) (VP (VBN observed) (PP-TMP (IN after) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ infected) (NN T) (NNS cells))) (PP (IN through) (NP (DT the) (NN TCR))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (JJ anti-CD45) (NNS antibodies)) (VP (VBP inhibit) (NP (NP (DT these) (NNS effects)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (JJ infected) (NNS individuals))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (NNS interrelationships)) (PP (IN between) (NP-COOD (NP (NN CD45)) (CC and) (NP (NN HIV-1))))) (ADVP (RB further))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD measured) (NP (NP (NNS effects)) (PP (IN on) (NP (DT the) (NN HIV-1) (NN LTR))) (PP-COOD (PP (IN in) (NP (NP (NN T) (NN cell) (NNS lines)) (SBAR (WHNP-11 (WDT that)) (S (VP (VBD were) (VP (VBN stimulated) (PP (IN with) (NP (NP (NNS antibodies)) (PP (IN against) (NP (NN CD45))))))))))) (CC and) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP-13 (WDT that)) (S (VP (VBD lacked) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN CD45))) (PP (IN on) (NP (PRP$ their) (NNS surfaces)))))))))))) (. .)))
(TOP (S (ADVP (RB First)) (, ,) (NP-SBJ (JJ anti-CD45) (NNS antibodies)) (VP (VP-COOD (VP (VBD did) (RB not) (VP (VB affect) (NP (JJ basal)))) (CC but) (VP (VBD decreased) (NP (JJ activated)))) (NP-100 (NP (NNS levels)) (PP (IN of) (NP (NP (NN expression)) (PP (IN from) (NP (DT the) (NN HIV-1) (NN LTR))))))) (. .)))
(TOP (S (ADVP (RB Second)) (, ,) (NP-SBJ (NP (NN T) (NNS cells)) (, ,) (SBAR (WHNP-14 (WDT which)) (S (VP-COOD (VP (VBP lack) (NP (NN CD45))) (CC and) (VP (MD can) (RB not) (VP (VB signal) (PP (IN via) (NP (DT the) (NN TCR)))))))) (, ,)) (VP (VBD supported) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP-COOD (NP (JJ viral) (NN replication)) (CC and) (NP (NN gene) (NN expression)))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBD was) (PP-PRD (JJ due) (TO to) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ active) (NN NF-kappa) (NN B) (NNS complexes))) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (JJ CD45-) (NN T) (NNS cells)))))))) (. .)))
(TOP (S (ADVP (RB Additionally)) (, ,) (NP-SBJ (JJ infected) (NN T) (NNS cells)) (VP (VBD displayed) (NP (NP (JJR lower) (NNS levels)) (PP (IN of) (NP (NN CD45)))) (PP (IN on) (NP (PRP$ their) (NNS surfaces)))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NN CD45)) (VP (VBZ plays) (NP (DT an) (JJ active) (NN role)) (PP-COOD (PP (IN in) (NP (NP (DT the) (NN physiology)) (PP (IN of) (NP (NN T) (NNS cells))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN replication)) (PP (IN of) (NP (NN HIV-1))))))) (. .)))
(TOP (NP (NP (NN Induction)) (PP (IN of) (NP-COOD (NP (NN phosphatidylinositol) (NN turnover)) (CC and) (NP (NN EGR-1) (NN mRNA) (NN expression)))) (PP (IN by) (NP (NP (VBG crosslinking)) (PP (IN of) (NP (NP (NN surface) (NP-COOD (NP (NN IgM)) (CC and) (NP (NN IgD)))) (PP (IN in) (NP (DT the) (JJ human) (NN B) (NN cell) (NN line) (NN B104))))))) (. .)))
(TOP (S (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN shown) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NP (DT a) (JJ human) (NN B) (NN lymphoma) (NN cell) (NN line)) (, ,) (NP (NN B104)) (, ,)) (VP (VBD expressed) (NP-COOD (NP (NP (NN surface) (NN IgM)) (PRN (-LRB- -LRB-) (NP (NN sIgM)) (-RRB- -RRB-))) (CC and) (NP (NP (NN surface) (NN IgD)) (PRN (-LRB- -LRB-) (NP (NN sIgD)) (-RRB- -RRB-))))))) (, ,) (CC and) (SBAR (IN that) (S-COOD (S (NP-SBJ (NP (VBG crosslinking)) (PP (IN of) (NP-COOD (NP (NN sIgM)) (CC and) (NP (NN sIgD)))) (PP (IN by) (NP-COOD (NP (JJ anti-IgM) (NP (NP (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN Ab)) (-RRB- -RRB-)))) (CC and) (NP (JJ anti-IgD) (NN Ab))))) (, ,) (ADVP (RB respectively)) (, ,) (VP (VBD induced) (NP (NN Ca2+) (NN influx)) (PP (TO to) (NP (ADJP (RB almost) (DT the) (JJ same)) (NN degree))))) (, ,) (IN whereas) (S (NP-SBJ (RB only) (NN sIgM-crosslinking)) (VP (VBD caused) (NP (NN B104) (NN cell) (NN death)))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP-SBJ-10 (PRP we)) (VP (VBD investigated) (NP (NP-COOD (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NP (JJ cyclic) (NN AMP)) (PRN (-LRB- -LRB-) (NP (NN cAMP)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (NN hydrolysis)) (PP (IN of) (NP (NN inositol) (NNS phosphates)))) (, ,) (NP (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NN activity)) (CC and) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP-COOD (NP (NN Egr-1)) (CC and) (NP (NN c-fos))) (NN mRNA) (NN expression))))) (PP (IN by) (NP-COOD (NP (NN sIgM-)) (CC and) (NP (NN sIgD-crosslinking))))) (S (VP (TO to) (VP (VB examine) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (DT the) (NNS signals)) (VP (VBN mediated) (PP (IN through) (NP-COOD (NP (NN sIgM)) (CC and) (NP (NN sIgD)))) (PP (IN in) (NP (NN B104) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (CC Both) (NP (NN sIgM-)) (CC and) (NP (NN sIgD-crosslinking))) (PP (IN with) (NP (NNS antibodies)))) (VP (VBD induced) (NP-COOD (NP (NP (NN elevation)) (PP (IN of) (NP (NN cAMP) (NNS levels)))) (, ,) (NP (NN phosphatidylinositol) (NN turnover)) (, ,) (NP (NN PKC) (NN activation)) (CC and) (NP (NP (NN expression)) (PP (IN of) (NP (NP-COOD (NP (NN Egr-1)) (CC and) (NP (NN c-fos))) (NN mRNA))))) (, ,) (SBAR (IN although) (S (NP-SBJ (NN sIgM-crosslinking)) (VP (VBD was) (ADJP-PRD (ADJP (RBR more) (JJ effective)) (PP (IN than) (NP (NN sIgD-crosslinking)))) (, ,) (PP (ADVP (RB presumably)) (JJ due) (TO to) (NP (NP (NP (DT the) (JJR higher) (NN expression)) (PP (IN of) (NP (NN sIgM)))) (PP (IN than) (FRAG (PP (IN of) (NP (NN sIgD))))))))))) (. .)))
(TOP (S (NP-SBJ-11 (NP (NN Egr-1) (NN mRNA) (NN expression)) (VP (VBN induced) (PP (IN by) (NP-LGS-COOD (NP (NN sIgM-)) (CC and) (NP (NN sIgD-crosslinking)))))) (VP (VBD was) (VP (VBN inhibited) (PP-COOD (PP (IN by) (NP-LGS-COOD (NP (NN H7)) (, ,) (NP (NN erbstatin)) (CC and) (NP (NN genistein)))) (, ,) (CC but) (PP (RB not) (IN by) (NP-LGS (NN HA1004)))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP-SBJ (NN Erbstatin)) (CC and) (NP (NN genistein))) (VP (VBD inhibited) (NP (NP (DT the) (JJ sIg-crosslinking-induced) (NN Egr-1) (NN mRNA) (NN expression))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (ADJP-12 (JJ parallel) (PP (TO to) (NP (NP (WDT that)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (JJ sIg-crosslinking-induced) (NN protein) (NN tyrosine) (NN phosphorylation)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN Phorbol) (NN myristate) (NN acetate)) (VP (VBD induced) (NP (NN Egr-1) (NN mRNA) (NN expression)))) (CC but) (S (NP-SBJ-COOD (NP (NN forskolin)) (CC and) (NP (NN dibutyryl) (JJ cyclic) (NN AMP))) (VP (VBD did) (RB not))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN Egr-1) (NN mRNA) (NN activating) (NNS signals)) (PP (IN through) (NP-COOD (NP (NN sIgM)) (CC and) (NP (NN sIgD))))) (VP (VBP are) (ADJP-PRD-COOD (ADJP-COOD (ADJP (NP (NN protein) (NN tyrosine) (NN kinase-))) (CC and) (ADJP (JJ PKC-dependent))) (, ,) (CC but) (ADJP (NN protein) (NN kinase) (JJ A-independent))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (NN Cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))) (CC and) (NP (NN FK506))) (VP (VP-COOD (VP (VBD rescued) (NP (NN B104) (NNS cells)) (PP (IN from) (NP (NP (NN death)) (VP (VBN induced) (PP (IN by) (NP-LGS (JJ anti-IgM) (NN Ab))))))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP-COOD (NP (NN Egr-1)) (CC and) (NP (NN c-fos))) (NN mRNA))))))) (, ,) (S (VP (VBG showing) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN CsA)) (CC and) (NP (NN FK506))) (VP (VBP affect) (NP (NN signal) (NNS transducers)) (ADVP (RB differently)) (UCP (UCP-COOD (PP (IN from)) (CC or) (ADVP (RB downstream) (PP (TO to)))) (NP-14 (DT these) (NNS molecules))))))))) (. .)))
(TOP (S (NP-SBJ-15 (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (NNS signals)) (VP (VBN transduced) (PP (IN through) (NP-COOD (NP (NN sIgM)) (CC and) (NP (NN sIgD)))) (PP (IN in) (NP (NN B104) (NNS cells))))))) (VP (VBZ is) (VP (VBN discussed))) (. .)))
(TOP (S (NP-SBJ (NP (NN G-LRB-Anh-RRB-MTetra)) (, ,) (NP (DT a) (JJ natural) (JJ bacterial) (NN cell) (NN wall) (NN breakdown) (NN product)) (, ,)) (VP (VBZ induces) (NP (NP (NP-COOD (NP (NN interleukin-1) (NN beta)) (CC and) (NP (NN interleukin-6))) (NN expression)) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (. .)))
(TOP (NP (NP (DT A) (NN study)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (JJ inflammatory) (NN cytokine) (NN expression)))))) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP J) (NNP Biol) (NNP Chem)) (NP-TMP (CD 1994) (NNP Jun) (CD 17)) (: ;) (NP (CD 269) (-LRB- -LRB-) (CD 24) (-RRB- -RRB-)) (: :) (NP (CD 16983)))))) (-RRB- -RCB-))))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN believed) (SBAR (IN that) (S (NP-SBJ (NP (NN induction)) (PP (IN of) (NP (NN cytokine) (NN expression))) (PP (IN by) (NP (JJ bacterial) (NN cell) (NN wall) (NNS components)))) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN development)) (CC and) (NP (NN course)))) (PP (IN of) (NP (NN sepsis)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-1 (JJS most) (NN attention)) (VP (VBZ has) (VP (VBN been) (VP (VBN focused) (PP (IN on) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (NP (NN N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutamyl-m-diaminopimelyl-D-alanine)) (PRN (-LRB- -LRB-) (NP (NN G-LRB-Anh-RRB-MTetra)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (ADJP (RB naturally) (VBG occurring)) (NN breakdown) (NN product)) (PP (IN of) (NP (NN peptidoglycan))) (SBAR (WHNP-2 (WDT that)) (S (VP (VBZ is) (VP (VBN produced) (PP (IN by) (NP-LGS (NP (JJ soluble) (JJ lytic) (NN transglycosylase)) (PP (IN of) (NP (FW Escherichia) (FW coli)))))))))) (, ,))) (S-4 (VP (TO to) (VP (VB induce) (NP (NP (NN cytokine) (NN expression)) (PP (IN in) (NP (JJ human) (NNS monocytes))))))))) (. .)))
(TOP (S (NP-SBJ-5 (NN G-LRB-Anh-RRB-MTetra)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (ADVP (RB strongly)) (VP (VP-COOD (VP (VB induce) (NP-100 (NP-COOD (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -1) (NN beta)) (CC and) (NP (NN IL-6))) (NN mRNA) (NN expression)) (PP-TMP-101 (IN after) (NP (NP (CD 2) (NN h))))) (CC and) (VP (NP=100 (NP-COOD (NP (NN IL-1) (NN beta)) (CC and) (NP (NN IL-6))) (NN protein) (NN secretion)) (PP-TMP=101 (IN after) (NP (NP (CD 48) (NN h)))))) (PP-102 (IN of) (NP (NN activation)))))))) (. .)))
(TOP (S (NP-SBJ-6 (NP (DT The) (NN increase)) (PP (IN in) (NP (NN mRNA) (NN accumulation)))) (VP-COOD (VP (VBD was) (PP-PRD (ADVP (ADVP (IN at) (JJS least)) (RB partly)) (JJ due) (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN transcription) (NNS rates)) (PP (IN of) (NP (DT the) (JJ respective) (NNS genes)))))))) (CC and) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NP (DT a) (JJ strong) (NN induction)) (PP (IN of) (NP (NP-COOD (NP (JJ nuclear) (NN factor-kappa) (NN B)) (CC and) (NP (NN activator) (NN protein-1) (NN transcription) (NN factor))) (NN expression)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Experiments)) (VP (VBG using) (NP (NP (NNS inhibitors)) (PP (IN of) (NP-COOD (NP (NN protein) (NN kinase) (NN C)) (, ,) (NP (NN protein) (NN kinase) (NN A)) (, ,) (CC and) (NP (ADJP (NN tyrosine) (JJ kinase-dependent)) (NNS pathways))))))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (JJ G-LRB-Anh-RRB-MTetra-induced) (NP-COOD (NP (NN IL-1) (NN beta)) (CC and) (NP (NN IL-6))) (NN mRNA) (NN expression)) (VP (VBZ involves) (NP (NP (NN activation)) (PP (IN of) (NP (DT an) (JJ H7-inhibitable) (NN pathway)))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG using) (NP (DT the) (NN protein) (NN synthesis) (NN inhibitor) (NN cycloheximide))))) (, ,) (S (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S-COOD (S (NP-SBJ (JJ G-LRB-Anh-RRB-MTetra-induced) (NN IL-6) (NN mRNA) (NN expression)) (VP (VBZ depends) (PP (IN on) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (JJ new) (NN protein))))))) (, ,) (IN whereas) (S (NP-SBJ (JJ G-LRB-Anh-RRB-MTetra-induced) (NN IL-1) (NN beta) (NN mRNA) (NN accumulation)) (VP (VBZ does) (RB not)))))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-7 (WRB When)) (S (NP-SBJ-8 (NP (NNS responses)) (PP (TO to) (NP (NN G-LRB-Anh-RRB-MTetra)))) (VP (VBD were) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (TO to) (NP-COOD (NP (NN LPS)) (CC and) (NP (NP (NN muramyldipeptide)) (PRN (-LRB- -LRB-) (NP (NN MDP)) (-RRB- -RRB-))))))))))) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ optimal) (NN response)) (PP (TO to) (NP (NN G-LRB-Anh-RRB-MTetra) (NN induction)))) (VP (VBD was) (ADJP-PRD-COOD (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NN LPS)))))) (CC but) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN MDP)))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-9 (JJ maximal) (JJ G-LRB-Anh-RRB-MTetra-induced) (NP-COOD (NP (NN IL-1) (NN beta)) (CC and) (NP (NN IL-6))) (NN mRNA) (NN expression)) (VP (MD could) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP-LGS (NP (NN co-stimulation)) (PP (IN with) (NP-COOD (NP (NN LPS)) (CC or) (NP (NN MDP)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ-11 (JJ different) (NP-COOD (NP (NNS receptors)) (CC and/or) (NP (NN transduction) (NNS pathways)))) (VP (VBD were) (VP (VBN involved)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN G-LRB-Anh-RRB-MTetra)) (VP (VBZ induces) (NP (NP (NP-COOD (NP (NN IL-1) (NN beta)) (CC and) (NP (NN IL-6))) (NN expression)) (PP (IN in) (NP (JJ human) (NNS monocytes)))) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ possible) (NN role)) (PP (IN for) (NP (NN G-LRB-Anh-RRB-MTetra))) (PP (IN in) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNS cytokines))) (PP-TMP (IN during) (NP (NN sepsis)))))))))))) (. .)))
(TOP (NP (JJ Human) (NN interferon) (JJ regulatory) (NN factor) (CD 2) (NN gene) (. .)))
(TOP (NP (NP-COOD (NP (JJ Intron-exon) (NN organization)) (CC and) (NP (JJ functional) (NN analysis))) (PP (IN of) (NP (JJ 5'-flanking) (NN region))) (. .)))
(TOP (S (NP-SBJ (NP (NN Interferon) (JJ regulatory) (NN factor) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IRF-2)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ transcriptional) (JJ regulatory) (NN protein)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBZ terminates) (NP (NP (NN interferon) (NN beta) (NN expression)) (VP (VBN initiated) (PP (IN by) (NP-LGS (NN interferon) (JJ regulatory) (NN factor) (CD 1)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP-COOD (VP (VBD isolated) (NP (NP (DT the) (JJ genomic) (NN DNA)) (PP (IN for) (NP (JJ human) (NN IRF-2) (NN gene))))) (, ,) (VP (VBD determined) (NP (NP (DT the) (JJ intron-exon) (NN structure)) (PP (IN of) (NP (DT the) (JJ human) (NN IRF-2) (NN gene))))) (, ,) (VP (VBD mapped) (NP (DT the) (JJ major) (NN transcription) (NN initiation) (NN site))) (, ,) (VP (VBD identified) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (JJ potential) (JJ regulatory) (NNS elements)) (PP (IN in) (NP (DT the) (JJ 5'-flanking) (NN region))))))) (, ,) (CC and) (VP (VBD localized) (NP (NP (DT the) (NN IRF-2) (NN gene)) (PP (IN on) (NP (JJ human) (NN chromosome) (CD 4)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN IRF-2) (NN promoter) (NN region)) (VP (VBZ contains) (NP (NP (DT a) (NN CpG) (NN island)) (, ,) (PP (IN with) (NP-COOD (NP (JJ several) (NN GC) (NNS boxes)) (, ,) (NP (DT a) (JJ putative) (ADJP (NN NF-kappa) (JJ B-binding)) (NN site)) (, ,) (CC and) (NP (DT a) (NN CAAT) (NN box)) (, ,) (CC but) (NP (DT no) (NN TATA) (NN box)))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-2 (WRB When)) (S (NP-SBJ-3 (DT the) (NN promoter) (NN region)) (VP (VBD was) (VP (VBN linked) (PP (IN with) (NP (DT a) (JJ heterologous) (NN reporter) (NN gene))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (DT the) (NN promoter) (NN region)) (VP (VBZ is) (ADJP-PRD (JJ inducible) (PP (IN by) (NP-COOD (CC both) (NP (NP (NNS interferons)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN interferon-alpha)) (CC and) (NP (NN -gamma))) (-RRB- -RRB-))) (CC and) (NP (NN interferon) (JJ regulatory) (NN factor) (CD 1))))))))) (. .)))
(TOP (S (NP-SBJ-4 (NP (DT The) (NN region)) (SBAR (WHNP-5 (WDT which)) (S (VP (VBD induced) (NP (DT these) (NNS inductions)))))) (VP (VBD was) (VP (VBN identified) (PP (IN as) (S (VP (VBG being) (VP (VBN confined) (PP (TO to) (NP (CD 40) (NNS nucleotides)) (PP (NP (JJ 5')) (TO to) (NP (DT the) (JJ major) (JJ transcriptional) (NN initiation) (NN site)))))))) (PP (IN by) (S-LGS (VP (VBG testing) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NNS clones)))) (PP (IN with) (NP (NP (VBN truncated) (NN promoter)) (PP (IN of) (NP (NN IRF-2)))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN region)) (VP (VBZ contains) (NP (NP (NNS elements)) (SBAR (WHNP-8 (WDT which)) (S (VP (VBP are) (VP (VBN shared) (PP (IN with) (NP (NP (DT the) (JJ transcriptional) (NNS enhancers)) (PP (IN of) (NP (JJ other) (NNS genes))) (PP (VBG including) (NP-COOD (NP (NN interferon) (JJ regulatory) (NN factor) (CD 1)) (, ,) (NP (NN interferon) (NN beta)) (, ,) (CC and) (NP (JJ interferon-inducible) (NNS genes)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-10 (NN interferon) (JJ regulatory) (NN factor) (CD 1)) (VP-COOD (CONJP (RB not) (RB only)) (VP (VBZ triggers) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NN interferon) (NN signal) (NN transduction) (NN pathway))))) (, ,) (CONJP (CC but) (RB also)) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG limiting) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (DT this) (NN response)))) (PP (IN by) (S (VP (VBG activating) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN IRF-2)))))))))))))))) (. .)))
(TOP (S (NP-SBJ-1 (NN rel)) (VP (VBZ Is) (VP (ADVP-TMP (RB rapidly)) (JJ tyrosine-phosphorylated) (PP-TMP (VBG following) (NP (NP (JJ granulocyte-colony) (NN stimulating) (NN factor) (NN treatment)) (PP (IN of) (NP (JJ human) (NNS neutrophils))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (NNS neutrophils))) (PP (IN with) (NP (NP (JJ granulocyte-colony) (NN stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN G-CSF)) (-RRB- -RRB-))))) (VP (VBZ results) (PP (IN in) (NP-COOD (NP (DT an) (VBN enhanced) (JJ respiratory) (NN burst)) (, ,) (NP (JJ prolonged) (NN survival)) (, ,) (CC and) (NP (VBN increased) (NN tumor) (NN cell) (NN killing))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN G-CSF)))) (VP (VBP are) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (VBG binding)) (PP (TO to) (NP (UCP-COOD (ADJP (JJ specific)) (, ,) (NP (JJ high) (NN affinity))) (NNS receptors))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN G-CSF) (NNS receptors)) (VP (VBP lack) (NP (JJ intrinsic) (NN tyrosine) (NN kinase) (NN activity)))) (, ,) (CC but) (S (NP-SBJ (NP (NN activation)) (PP (IN of) (NP (DT the) (NN receptor)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (JJ rapid) (NN induction)) (PP (IN of) (NP (NN tyrosine) (NN kinase) (NN activity))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Antiphosphotyrosine) (NNS immunoblots)) (PP (IN of) (NP (NP (JJ whole) (NN cell) (NNS lysates)) (VP (VBN prepared) (PP (IN from) (NP (NNS neutrophils))))))) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (DT the) (NN G-CSF)) (ADVP-TMP (RB rapidly)) (VP (VBZ induces) (NP (NP (JJ prominent) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (DT a) (NN protein)) (PP (IN of) (NP (NP (DT a) (JJ relative) (JJ molecular) (NN mass)) (PP (IN of) (NP (CD 80) (NN kDa)))))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ monospecific) (NNS antibodies)))) (, ,) (NP-SBJ-3 (DT the) (JJ 80-kDa) (JJ tyrosine-phosphorylated) (NN protein)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP-PRD (NP (NN p80c-rel)) (, ,) (NP (NP (DT a) (NN proto-oncogene)) (VP (VBG belonging) (PP (TO to) (NP (NP (DT a) (NN family)) (PP (IN of) (NP (NP (JJ transcriptional) (NNS regulators)) (SBAR (WHNP-4 (WDT which)) (S (VP (VBP include) (NP (NN NF-kB)))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN induction)) (PP (IN of) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN p80c-rel)))))) (VP (VBD was) (ADJP-PRD (JJ unique) (PP (TO to) (NP (NN G-CSF)))) (SBAR (IN in) (IN that) (S (NP-SBJ (NP (JJ granulocyte-macrophage) (NN colony) (NN stimulating) (NN factor)) (SBAR (WHNP-5 (WDT which)) (S (ADVP (RB also)) (VP-COOD (VP (VBZ stimulates) (NP (NNS neutrophils))) (CC and) (VP (VBZ induces) (NP (NN tyrosine) (NN phosphorylation))))))) (VP (VBZ does) (RB not) (VP (VB result) (PP (IN in) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN p80c-rel)))))))))) (. .)))
(TOP (S (S (NP-SBJ-6 (NP (DT The) (NNS consequences)) (PP (IN of) (NP (NN p80c-rel) (NN tyrosine) (NN phosphorylation)))) (VP (VBP are) (RB not) (ADVP-TMP (RB yet)) (VP (VBN known))) (: ;)) (S-COOD (S (ADVP (RB however)) (, ,) (NP-SBJ-100 (JJ tyrosine-phosphorylated) (NN p80c-rel)) (VP (VBZ is) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG binding) (PP (TO to) (NP (NN DNA))))))))) (, ,) (CC and) (S (NP-SBJ (NN G-CSF) (NN stimulation)) (VP (VBZ results) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NN p80c-rel)) (SBAR (WHNP-7 (WDT which)) (S (VP (VBZ binds) (PP (TO to) (NP (NN DNA)))))))))))))) (. .))))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ first) (JJ biochemical) (NNS events))) (SBAR (WHNP-8 (WDT which)) (S (VP (VBZ occurs) (PP (IN in) (NP (NNS neutrophils))) (PP-TMP (VBG following) (NP (NN G-CSF) (NN stimulation))))))) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (DT a) (NN tyrosine) (NN kinase)))) (, ,)) (VP (VBZ leads) (ADVP (RB directly)) (PP (TO to) (NP (NP (DT the) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN p80c-rel))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-9 (NP (DT the) (NN tyrosine) (NN kinase)) (VP (VBN activated) (PP (IN by) (NP-LGS (NN G-CSF))))) (VP (VBZ appears) (S (VP (TO to) (VP (ADVP (RB directly)) (VB transduce) (NP (DT a) (NN signal)) (PP (TO to) (NP (NP (DT a) (NN protein)) (SBAR (WHNP-10 (WDT which)) (S (VP (VBZ functions) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN regulator)))))))))))) (. .)))
(TOP (NP (NP (NN Autoregulation)) (PP (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN transactivator) (NP (NP (NN RelA)) (PRN (-LRB- -LRB-) (NP (NN p65)) (-RRB- -RRB-))))) (PP (IN by) (NP (NP (JJ multiple) (JJ cytoplasmic) (NNS inhibitors)) (VP (VBG containing) (NP (NN ankyrin) (NNS motifs))))) (. .)))
(TOP (S (NP-SBJ (NP (NN RelA)) (PRN (-LRB- -LRB-) (NP (NN p65)) (-RRB- -RRB-))) (VP-COOD (VP (VBZ functions) (PP (IN as) (NP (NP (DT the) (JJ critical) (VBG transactivating) (NN component)) (PP (IN of) (NP (DT the) (JJ heterodimeric) (NN p50-p65) (NN NF-kappa) (NN B) (NN complex)))))) (CC and) (VP (VBZ contains) (NP (NP (DT a) (JJ high-affinity) (VBG binding) (NN site)) (PP (IN for) (NP (NP (PRP$ its) (JJ cytoplasmic) (NN inhibitor)) (, ,) (NP (NN I) (NN kappa) (NN B) (NN alpha))))))) (. .)))
(TOP (S (PP-TMP (IN After) (NP (JJ cellular) (NN activation))) (, ,) (NP-SBJ-1 (NN I) (NN kappa) (NN B) (NN alpha)) (VP (VBZ is) (VP (ADVP-TMP (RB rapidly)) (VBN degraded) (PP (IN in) (NN concert) (IN with) (NP (NP (DT the) (VBN induced) (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ present) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP-SBJ-2 (NP (ADJP (NN tumor) (NN necrosis) (NN factor) (JJ alpha-induced)) (NN degradation)) (PP (IN of) (NP (NN I) (NN kappa) (NN B) (NN alpha))) (PP (IN in) (NP (JJ human) (NN T) (NNS cells)))) (VP (VBZ is) (VP (VBN preceded) (PP (IN by) (NP-LGS (NP (PRP$ its) (JJ rapid) (NN phosphorylation)) (ADVP (FW in) (FW vivo))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT these) (NNS effects)) (PP (IN on) (NP (NN I) (NN kappa) (NN B) (NN alpha)))) (VP (VBP result) (PP (IN in) (NP (NP (JJ nuclear) (NN mobilization)) (PP (IN of) (NP (NP (RB only) (DT a) (NN fraction)) (PP (IN of) (NP (NP (DT the) (JJ entire) (JJ cytoplasmic) (NN pool)) (PP (IN of) (NP (NN RelA)))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Subsequent) (NNS studies)) (VP (VBP have) (VP (VBN revealed) (SBAR (IN that) (S-COOD (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP-SBJ-3 (JJ cytoplasmic) (NN RelA)) (VP (VBZ is) (VP (ADVP (RB stably)) (VBN associated) (PP-COOD (CONJP (RB not) (RB only)) (PP (IN with) (NP (NN I) (NN kappa) (NN B) (NN alpha))) (CONJP (CC but) (RB also)) (PP (IN with) (NP (NP (JJ other) (NN ankyrin) (JJ motif-rich) (NNS proteins)) (PP (VBG including) (NP (NP (DT the) (NNS products)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NP (NN NF-kappa) (NN B2)) (PRN (-LRB- -LRB-) (NP (NN p100)) (-RRB- -RRB-))) (CC and) (NP (NP (NN NF-kappa) (NN B1)) (PRN (-LRB- -LRB-) (NP (NN p105)) (-RRB- -RRB-)))) (NNS genes))))))))))) (: ;) (S (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (PP (IN in) (NN contrast) (TO to) (NP (NN RelA-I) (NN kappa) (NN B) (NN alpha))) (, ,) (NP-SBJ-4 (NN RelA-p100) (JJ cytoplasmic) (NNS complexes)) (VP (VBP are) (RB not) (VP (VBN dissociated) (PP-TMP (VBG following) (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha) (NN activation)))))) (: ;) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NP-SBJ (NN p100)) (VP (VBZ functions) (PP (IN as) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NP (JJ RelA-mediated) (NN transcription)) (ADVP (FW in) (FW vivo)))))))) (: ;) (S (LST (-LRB- -LRB-) (LS iv) (-RRB- -RRB-)) (NP-SBJ (NP (DT the) (NN interaction)) (PP (IN of) (NP-COOD (NP (NN RelA)) (CC and) (NP (NN p100))))) (VP (VBZ involves) (NP-COOD (NP (NP (DT the) (VBN conserved) (NN Rel) (NN homology) (NN domain)) (PP (IN of) (NP (DT both) (NNS proteins)))) (CONJP (CC but) (RB not)) (NP (NP (DT the) (JJ nuclear) (NN localization) (NN signal)) (PP (IN of) (NP (NN RelA))) (, ,) (SBAR (WHNP-5 (WDT which)) (S (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NN I) (NN kappa) (NN B) (NN alpha) (NN binding))))))))))) (: ;) (S (LST (-LRB- -LRB-) (LS v) (-RRB- -RRB-)) (NP-SBJ (NP (NN p100) (NN inhibition)) (PP (IN of) (NP (NN RelA) (NN function)))) (VP (VBZ requires) (NP (NP (DT the) (JJ C-terminal) (NN ankyrin) (NN motif) (NN domain)) (, ,) (SBAR (WHNP-7 (WDT which)) (S (VP (VBZ mediates) (NP (NP (JJ cytoplasmic) (NN retention)) (PP (IN of) (NP (NN RelA)))))))))) (: ;) (CC and) (S (LST (-LRB- -LRB-) (LS vi) (-RRB- -RRB-)) (SBAR (IN as) (S (VP (VBN observed) (PP (IN with) (NP (PRP I) (NN kappa) (NN B) (NN alpha)))))) (, ,) (NP-SBJ (JJ nuclear) (NN RelA)) (VP (VBZ stimulates) (NP (NN p100) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))) (NN expression)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (ADVP (RB thus)) (VP (VBP reveal) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT a) (JJ second) (JJ inducible) (JJ autoregulated) (JJ inhibitory) (NN pathway)) (SBAR (WHNP-9 (WDT that)) (S (VP (VBZ helps) (S (VP (VB ensure) (NP (NP (DT the) (ADJP-TMP-COOD (ADJP (JJ rapid)) (CC but) (ADJP (JJ transient))) (NN action)) (PP (IN of) (NP (JJ nuclear) (NN NF-kappa) (NN B))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Direct) (NN exposure)) (PP (TO to) (NP (NP (NN 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (PRN (-LRB- -LRB-) (NP (NN TCDD)) (-RRB- -RRB-))))) (VP (VBZ increases) (NP (NP (NN infectivity)) (PP (IN of) (NP (JJ human) (NNS erythrocytes))) (PP (TO to) (NP (DT a) (JJ malarial) (NN parasite))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Direct) (NN exposure)) (PP (TO to) (NP (ADJP (CD 10) (NN nM)) (NN 2,3,7,8-TCDD)))) (VP (VBD caused) (NP (NP-COOD (NP (DT a) (CD 75) (NN %) (NN increase)) (CC and) (NP (DT a) (QP (JJ 2-fold)) (NN increase))) (PP (IN in) (NP (NP (DT the) (NN infectivity)) (PP (IN of) (NP (VBN isolated) (JJ human) (NNS erythrocytes))) (PP (TO to) (NP (FW P.) (FW falciparum)))))) (PP-TMP (IN after) (NP (NP (CD 48) (NNS hours)) (SBAR (WHADVP-16 (WRB when)) (S (NP-SBJ (DT the) (NNS parasites)) (VP (VBD were) (PP-PRD (IN in) (NP (NP (DT an) (ADJP-COOD (ADJP (JJ unsynchronized)) (CC or) (ADJP (JJ synchronized))) (NN state)) (PP (IN of) (NP (NN growth))))) (, ,) (ADVP (RB respectively)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (JJ human) (NNS erythrocytes))) (PP (IN with) (NP (NP (ADJP (CD 10) (NN microM)) (NP (NP (NN sodium) (NN orthovanadate)) (PRN (-LRB- -LRB-) (NP (NN NaOV)) (-RRB- -RRB-)))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP-COOD (NP (NN plasma) (NN membrane) (NN Ca-ATPase)) (CC and) (NP (NN phosphotyrosine) (NN phosphatase))))) (, ,)))) (VP (VBD decreased) (NP (NN parasitemia)) (PP (IN by) (NP (CD 30) (NN %)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Co-treatment)) (PP (IN of) (NP (NNS RBCs))) (PP (IN with) (NP-COOD (NP (NN TCDD)) (CC and) (NP (NN NaOV))))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (DT the) (JJ TCDD-induced) (NN increase)) (PP (IN in) (NP (NN parasitemia))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP-SBJ-17 (NNS erythrocytes)) (VP (VBP are) (VP (JJ anucleated))))) (, ,) (NP-SBJ-18 (DT these) (NNS results)) (VP (VBP are) (VP (VBN discussed) (PP (IN as) (NP (NP (NN evidence)) (PP (IN for) (NP (NP (JJ biochemical) (NNS changes)) (PP (IN by) (NP (NN TCDD))) (PP (IN without) (S (VP (VBG requiring) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN gene) (NNS products))))))))))))) (. .)))
(TOP (NP (NP (JJ Comparative) (NN mapping)) (PP (IN of) (NP (NN SRY))) (PP (IN in) (NP (DT the) (JJ great) (NNS apes))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Cytogenetic) (NNS studies)) (PP (IN of) (NP (DT the) (JJ primate) (NN Y) (NNS chromosomes)))) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (JJ extensive) (NNS rearrangements)) (VP (VBP have) (VP (VBN occurred) (PP-TMP (IN during) (NP (NP (NN evolution)) (PP (IN of) (NP (DT the) (JJ great) (NNS apes))))))))))) (. .)))
(TOP (S (NP-SBJ-12 (PRP We)) (VP (VBP have) (VP (VBN used) (NP (ADJP (FW in) (FW situ)) (NN hybridization)) (S (VP (TO to) (VP (VB define) (NP (DT these) (NNS rearrangements)) (PP (IN at) (NP (DT the) (JJ molecular) (NN level)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN pHU-14)) (, ,) (NP (NP (DT a) (NN probe)) (PP (VBG including) (NP (NP (NNS sequences)) (PP (IN from) (NP (DT the) (NN sex) (JJ determining) (NN gene) (NN SRY)))))) (, ,)) (VP (VBZ hybridizes) (ADVP (RB close) (PP (TO to) (NP (NP (DT the) (JJ early) (VBG replicating) (JJ pseudoautosomal) (NN segment)) (PP (IN in) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ telomeric)) (CC or) (ADJP (JJ subtelomeric))) (NN position)) (PP (IN of) (NP (NP (DT the) (NN Y) (NNS chromosomes)) (PP (IN of) (NP (DT all) (JJ great) (NNS apes))))))))))) (. .)))
(TOP (S (NP-SBJ-13 (NP (DT The) (JJ low) (NN copy) (NN repeat)) (VP (VBN detected) (PP (IN by) (NP-LGS (DT the) (NN probe) (NN Fr35-II))))) (VP (VBZ is) (ADVP (RB obviously)) (VP (VBN included) (PP (IN in) (NP (NP (NN Y) (NN chromosomal) (NNS rearrangements)) (PP-TMP (IN during) (NP (NN hominid) (NN evolution))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT These) (NNS results)) (, ,) (VP (VBN combined) (PP (IN with) (NP (JJ previous) (NNS studies)))) (, ,)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN Y) (NN chromosome)) (PP (IN in) (NP (JJ great) (NNS apes)))) (VP (VBZ has) (NP (NP (DT a) (VBN conserved) (NN region)) (PP (VBG including) (NP-COOD (NP (DT the) (JJ pseudoautosomal) (NN region)) (CC and) (NP (DT the) (JJ testis-determining) (NN region))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN rest)) (PP (IN of) (NP (DT the) (NN Y) (NN chromosome)))) (VP (VBZ has) (VP (VBN undergone) (NP (JJ several) (NNS rearrangements)) (PP (IN in) (NP (DT the) (JJ different) (JJ great) (NNS apes))))) (. .)))
(TOP (NP (NP (NP (NN Detection)) (PP (IN of) (NP (NP (JJ minimal) (JJ residual) (NN disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ acute) (JJ promyelocytic) (NN leukemia))))))) (PP (IN by) (NP (NN RT-PCR))) (: :)) (NP (NP (NN necessity)) (PP (IN of) (NP (NP (NN chemotherapy)) (PP-TMP (VBG following) (NP (NN ATRA) (NN therapy))))) (. .))))
(TOP (S (NP-SBJ (NP (DT The) (NN PML/RAR) (NN alpha) (NN fusion) (NN gene)) (VP (VBG resulting) (PP (IN from) (NP (DT the) (SYM t) (NN -LRB-15;17-RRB-) (NN translocation))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ specific) (NN marker)) (PP (IN for) (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ-6 (PRP We)) (VP (VBD examined) (NP (NN bone) (NN marrow) (NNS cells)) (PP (IN by) (NP (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB detect) (NP (NP (JJ residual) (ADJP (NN PML/RAR) (NN alpha) (JJ mRNA-containing)) (NNS cells)) (PP-TMP (VBG following) (NP-COOD (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ all-trans) (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN ATRA)) (-RRB- -RRB-))))) (CC and) (NP (JJ cytotoxic) (NN chemotherapy))))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NN APL))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN RT-PCR) (NN assay)) (VP (MD can) (VP (VB detect) (NP (CD one) (JJ leukemic) (NN cell)) (PP (IN in) (NP (CD 10-LRB-2-RRB-) (JJ normal) (NNS cells))) (ADVP (FW in) (FW vitro)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN PML/RAR) (NN alpha) (NN mRNA)) (VP-COOD (VP (VBD was) (ADVP (RB still)) (ADJP-PRD-101 (JJ detectable)) (PP-102 (IN despite) (NP (NP (JJ clinical) (NN remission)) (PP-TMP (VBG following) (NP (NN ATRA) (NN treatment)))))) (, ,) (CC but) (VP (ADJP-PRD=101 (JJ undetectable)) (PP-TMP (VBG following) (NP (NP (NN consolidation)) (PP (IN with) (NP (NN chemotherapy)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (DT this) (NN technique)) (VP (VBZ is) (ADJP-PRD (JJ useful) (PP (IN for) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (JJ minimal) (JJ residual) (NN disease)) (PP (NN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN APL))))))))))))) (CC and) (SBAR (IN that) (S (NP-SBJ-7 (NP (JJ cytotoxic) (NN chemotherapy)) (PP-TMP (VBG following) (NP (NN ATRA) (NN therapy)))) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NN APL) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ-22 (NP (NNS Genes)) (VP (VBG encoding) (NP (NP (JJ general) (NN initiation) (NNS factors)) (PP (IN for) (NP (NN RNA) (NN polymerase) (CD II) (NN transcription)))))) (VP (VBP are) (VP (VBN dispersed) (PP (IN in) (NP (DT the) (JJ human) (NN genome))))) (. .)))
(TOP (S (NP-SBJ-23 (JJ General) (NN transcription) (NNS factors)) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP (JJ accurate) (NN initiation)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN by) (NP (NN RNA) (NN polymerase) (CD II))))))))) (. .)))
(TOP (S (NP-SBJ-24 (NP (JJ Human) (NNS cDNAs)) (VP (VBG encoding) (NP (NP (NNS subunits)) (PP (IN of) (NP (DT these) (NNS factors)))))) (VP (VBP have) (VP (VBN been) (VP-COOD (VP (VBN cloned)) (CC and) (VP (VBN sequenced))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (NP (NN fluorescence) (ADJP (FW in) (FW situ)) (NN hybridization)) (PRN (-LRB- -LRB-) (NP (NN FISH)) (-RRB- -RRB-))))) (, ,) (NP-SBJ-26 (PRP we)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP-COOD (NP (NP (DT the) (NN TATA-box) (NN binding) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN TBP)) (-RRB- -RRB-))) (, ,) (NP (NN TFIIB)) (, ,) (NP (NN TFIIE) (NN alpha)) (, ,) (NP (NN TFIIE) (NN beta)) (, ,) (NP (NN RAP30)) (, ,) (NP (NN RAP74)) (CC and) (NP (NP (DT the) (ADJP (CD 62) (NN kDa)) (NN subunit)) (, ,) (PP (IN of) (NP (NN TFIIH))))))) (VP (VBP are) (ADJP-PRD (JJ located) (PP (IN at) (NP (NP (DT the) (JJ human) (JJ chromosomal) (NNS bands) (NP-COOD (NP (NN 6q26-27)) (, ,) (NP (NN 1p21-22)) (, ,) (NP (NN 3q21-24)) (, ,) (NP (NN 8p12)) (, ,) (NP (NN 13q14)) (, ,) (NP (NN 19p13.3)) (CC and) (NP (NN 11p14-15.1)))) (, ,) (ADVP (RB respectively))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT This) (JJ dispersed) (NN localization)) (PP (IN of) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (ADJP (RB functionally) (JJ related)) (NN gene)))))) (VP (VBZ provides) (NP (NP (NNS insights)) (PP (IN into) (NP-COOD (NP (NP (DT the) (JJ molecular) (NN mechanism)) (PP (IN of) (NP (JJ human) (NN genome) (NN evolution)))) (CC and) (NP (NP (PRP$ their) (JJ possible) (NN involvement)) (PP (IN in) (NP (JJ human) (NNS diseases)))))))) (. .)))
(TOP (NP (NP-COOD (NP (NP (NN Patterns)) (PP (IN of) (NP (NN Pan) (NN expression)))) (CC and) (NP (NP (NN role)) (PP (IN of) (NP (NN Pan) (NNS proteins))))) (PP (IN in) (NP (ADJP (NN endocrine) (NN cell) (JJ type-specific)) (JJ complex) (NN formation))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN Pan) (NN gene)) (VP (VBZ encodes) (NP (NP (QP (IN at) (JJS least) (CD two)) (JJ distinct) (NNS transcripts)) (, ,) (NP (NP-COOD (NP (NN Pan-1)) (CC and) (NP (NN Pan-2))) (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NP-COOD (NP (NN E47)) (CC and) (NP (NN E12))) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-) (, ,))) (PP (IN by) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (JJ alternative) (NN RNA) (NN splicing)))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (JJ Northern) (NN blot) (NNS analyses)) (VP (VBN performed) (PP (IN on) (NP (NP-COOD (NP (NN rat)) (CC and) (NP (NN mouse))) (NNS tissues))))) (VP (VBP have) (VP (VBN detected) (NP (ADJP (RB ubiquitously) (VBN expressed)) (NN Pan) (NNS transcripts))))) (, ,) (CC but) (S (NP-SBJ-11 (NP (DT the) (NP-COOD (NP (NN abundance)) (, ,) (NP (NN distribution)) (, ,) (CC and) (NP (NN form)))) (PP (IN of) (NP (NN Pan) (NNS proteins)))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB clearly)) (VP (VBN defined))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Studies)) (PP (IN of) (NP (NP (NN cell) (NNS lines)) (VP (VBG representing) (NP (UCP (ADJP (NN endocrine)) (, ,) (NP (NN fibroblast)) (, ,) (CC and) (ADJP (JJ lymphoid))) (NNS lineages))))) (VP (VBG using) (NP (JJ polyclonal) (NNS antisera)) (S (VP (TO to) (VP (VB detect) (NP (NN E2A) (NNS proteins))))))) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ-12 (JJ significant) (NN E2A) (NN protein) (NN expression)) (VP (VBZ is) (VP (JJ restricted) (PP (TO to) (NP (NNS B-lymphocytes))))))))) (. .)))
(TOP (S (NP-SBJ-13 (PRP We)) (VP-COOD (VP (VBP have) (VP (VBN developed) (NP (NP (NP (DT a) (JJ monoclonal) (NN antibody)) (, ,) (NP (NN Yae)) (, ,)) (SBAR (WHNP-14 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ specific) (PP (IN for) (NP (NN Pan/E2A) (NNS proteins)))))))))) (, ,) (CC and) (VP (VBP have) (VP (VBN used) (NP (DT the) (NN Yae) (NN antibody)) (S (VP (TO to) (VP (VB examine) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ endocrine)) (CC and) (ADJP (JJ nonendocrine))) (NN cell) (NNS lineages)))) (PP (IN for) (NP (NP (NNS differences)) (PP (IN in) (NP-COOD (NP (NN Pan/E2A) (NN protein) (NN expression)) (, ,) (NP (JJ subcellular) (NN localization)) (, ,) (CC and) (NP (JJ heteromeric) (JJ complex) (NN formation)))))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NP (JJ previous) (NNS results)) (VP (VBN obtained) (S (VP (VBG using) (NP (JJ polyclonal) (NN antiseras)) (S (VP (TO to) (VP (VB detect) (NP (NN Pan/E2A) (NNS proteins)))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP report) (NP (NP (JJ comparable) (NNS levels)) (PP (IN of) (NP (NN Pan) (NNS proteins))) (PP (IN in) (NP (ADJP-COOD (ADJP (NP (NN GH/PRL-))) (CC and) (ADJP (JJ insulin-producing))) (, ,) (NP-COOD (NP (NN B-)) (CC and) (NP (NN T-lymphocyte))) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (NN IEF-1)) (, ,) (NP (NP (DT a) (ADJP (JJ pancreatic) (NN beta-cell) (JJ type-specific)) (NN complex)) (VP (VBN believed) (S (VP (TO to) (VP (VB regulate) (NP (NN insulin) (NN expression))))))) (, ,)) (VP (VBZ is) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB consist) (PP (IN of) (NP (NP (QP (IN at) (JJS least) (CD two)) (JJ distinct) (NNS species)) (, ,) (SBAR (WHNP-18 (NP (CD one)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ does) (RB not) (VP (VB contain) (NP (NN Pan) (NNS molecules))))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN postulated) (SBAR (IN that) (S (NP-SBJ-COOD (NP (JJ pituitary) (JJ endocrine) (NNS cells)) (CC and) (NP (JJ pancreatic) (NN endocrine) (NNS beta-cells))) (VP (VBP share) (NP (JJ identical) (NN Pan/E2A) (NNS complexes)))))))))) (, ,) (NP-SBJ (NP (JJ native-Western) (NNS analyses)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ pituitary)) (CC and) (ADJP (JJ endocrine))) (NNS beta-cells)))) (VP (VBP detect) (NP (NN Pan) (NNS proteins)) (PP (IN in) (NP (JJ distinct) (ADJP (NN cell) (JJ type-specific)) (NNS complexes)))) (. .)))
(TOP (S (NP-SBJ (NN Interferon) (NN alpha)) (ADVP (RB selectively)) (VP (VBZ affects) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ human) (JJ myeloid) (NN cell) (JJ nuclear) (NN differentiation) (NN antigen))) (PP (IN in) (NP (NP (JJ late) (NN stage) (NNS cells)) (PP (IN in) (NP (NP-COOD (NP (DT the) (JJ monocytic)) (CONJP (CC but) (RB not)) (NP (DT the) (JJ granulocytic))) (NP-12 (NN lineage)))))))) (. .)))
(TOP (S (NP-SBJ-13 (DT The) (JJ human) (NP (NP (JJ myeloid) (NN cell) (JJ nuclear) (NN differentiation) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NN MNDA)) (-RRB- -RRB-)))) (VP (VBZ is) (VP (VBN expressed) (ADVP (RB constitutively)) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ myeloid) (NN lineage))))) (, ,) (S (VP-COOD (VP (VBG appearing) (PP (IN in) (NP (NP (JJ myeloblast) (NNS cells)) (PP (IN in) (NP (NP (DT some) (NNS cases)) (PP (IN of) (NP (JJ acute) (JJ myeloid) (NN leukemia)))))))) (CC and) (VP (ADVP-TMP (RB consistently)) (VBG being) (VP (VBN detected) (PP-COOD (PP (IN in) (NP (JJ promyelocyte) (NN stage) (NNS cells))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT all) (JJR later) (NN stage) (NNS cells)) (PP (VBG including) (NP-COOD (NP (JJ peripheral) (NN blood) (NNS monocytes)) (CC and) (NP (NNS granulocytes))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ human) (JJ myeloid) (NN leukemia) (NN cell) (NNS lines)) (, ,) (NP-COOD (NP (NN HL-60)) (, ,) (NP (NN U937)) (, ,) (CC and) (NP (NN THP-1))) (, ,)) (VP (VBP express) (NP (NP (JJ similar) (NNS levels)) (PP (IN of) (NP (ADJP (RB immunochemically) (JJ detectable)) (NN MNDA))))) (. .)))
(TOP (S (SBAR (IN Although) (, ,) (S (NP-SBJ (NP (DT the) (NN level)) (PP (IN of) (NP (NN MNDA) (NN mRNA))) (PP (IN in) (NP (JJ primary) (NNS monocytes)))) (VP (VBZ is) (ADJP-PRD (RB very) (JJ low))))) (NP-SBJ-16 (PRP it)) (VP (VBD was) (VP (VBN up-regulated) (PP-TMP (IN at) (NP (NP (CD 6) (NN h)) (PP-TMP (VBG following) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN interferon) (NN alpha))))))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (DT The) (NN effect)) (PP (IN of) (NP (NN interferon) (NN alpha))) (PP (IN on) (NP (DT the) (NN MNDA) (NN mRNA)))) (VP (VBZ is) (VP (ADVP (RB also)) (VBN observed) (PP (IN in) (NP (DT the) (NN cell) (NNS lines) (NP-COOD (NP (NN HL-60)) (, ,) (NP (NN U937)) (, ,) (CC and) (NP (NN THP-1))))))) (. .)))
(TOP (S (NP-SBJ-18 (NP (DT The) (NN MNDA) (NN mRNA) (NN level)) (PP (IN in) (NP (JJ primary) (NNS granulocytes)))) (VP (VBD was) (VP (JJ unaffected) (PP (IN by) (NP-LGS (NP (NN addition)) (PP (IN of) (NP-COOD (NP (NN interferon) (NN alpha)) (CC and) (NP (NP (JJ other) (NNS agents)) (PP (VBG including) (NP-COOD (NP (NN interferon) (NN gamma)) (, ,) (NP (NN endotoxin)) (, ,) (NP (NN poly-LRB-I-RRB-.poly-LRB-C-RRB-)) (, ,) (CC and) (NP (NN FMLP))))))))))) (. .)))
(TOP (S (NP-SBJ-19 (NP (DT The) (NN MNDA) (NN mRNA) (NN level)) (PP (IN in) (NP (DT the) (JJ myeloid) (NN cell) (NNS lines)))) (VP (VBD was) (VP (ADVP (RB also)) (JJ unaffected) (PP (IN by) (NP-LGS (DT the) (JJ latter) (CD four) (NNS agents))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Induction)) (PP (IN of) (NP (NN differentiation))) (PP (IN in) (NP (DT the) (JJ myeloid) (NN cell) (NNS lines))) (PP (IN with) (NP (NN phorbol) (NN ester)))) (VP (VBZ induces) (NP (NP (NN monocyte) (NN differentiation)) (SBAR (WHNP-20 (WDT which)) (S (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN MNDA) (NN mRNA) (NN level))))))))))) (. .)))
(TOP (S (NP-SBJ-22 (NP (DT This) (JJ reduced) (NN level)) (PP (IN of) (NP (NN mRNA)))) (VP (MD could) (ADVP-TMP (RB then)) (VP (VB be) (VP (JJ elevated) (PP (IN with) (NP (JJ subsequent) (NN interferon) (NN alpha) (NN treatment)))))) (. .)))
(TOP (S (NP-SBJ-23 (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN phorbol) (NN ester))) (PP (IN on) (NP (NN MNDA) (NN mRNA)))) (VP (VBD appeared) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (VBN induced) (NN differentiation))))))) (SBAR (IN since) (S-COOD (S (S-SBJ (VP (VBG inhibiting) (NP (NN cell) (NN proliferation)))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN MNDA) (NN mRNA))))))) (CC and) (S (NP-SBJ-25 (NP (NN cell) (NN cycle) (NN variation)) (PP (IN in) (NP (NN MNDA) (NN mRNA) (NNS levels)))) (VP (VBD were) (RB not) (VP (VBN observed))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN ability)) (PP (IN of) (NP (NN interferon) (NN alpha))) (S-26 (VP (TO to) (VP (VB up-regulate) (NP (NN MNDA) (NN mRNA)) (PP (IN in) (NP (ADJP (NP (NN phorbol) (NN ester)) (JJ treated)) (JJ myeloid) (NN cell) (NNS lines))))))) (VP (VBZ is) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (DT the) (NNS observations)) (VP (VBN made) (PP (IN in) (NP (JJ primary) (NNS monocytes)))))))) (. .)))
(TOP (S (-LRB- -LRB-) (NP-SBJ-100 (NN ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-)))
(TOP (S (S (NP-SBJ (NN Calcineurin)) (VP (VBZ potentiates) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor) (NN gene))) (PP (IN in) (NP (NN T) (NNS cells))))) (: :)) (NP (NP (NN involvement)) (PP (IN of) (NP (DT the) (VBN conserved) (NN lymphokine) (NN element) (CD 0))) (. .))))
(TOP (S (NP-SBJ-COOD-15 (NP (NP (JJ Granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (CC and) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-)))) (VP (VBP are) (VP (VBN produced) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN with) (NP-COOD (NP (NP (NN phorbol-12-myristate) (NN acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (CC and) (NP (NP (NN calcium) (NN ionophore)) (PRN (-LRB- -LRB-) (NP (NN A23187)) (-RRB- -RRB-))))) (PP (IN in) (NP (JJ human) (NN T) (NN cell) (NN leukemia) (NN Jurkat) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-16 (NP (DT The) (NN expression)) (PP (IN of) (NP-COOD (NP (NN GM-CSF)) (CC and) (NP (NN IL-2))))) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP-LGS (NP (JJ immunosuppressive) (NNS drugs)) (PP (JJ such) (IN as) (NP-COOD (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))) (CC and) (NP (NN FK506)))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJR Earlier) (NNS studies)) (PP (IN on) (NP (DT the) (NN IL-2) (NN gene) (NN expression)))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (NN overexpression)) (PP (IN of) (NP (NP (NP (NN calcineurin)) (PRN (-LRB- -LRB-) (NP (NN CN)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ Ca2+/calmodulin-dependent) (NN protein) (NN phosphatase)) (, ,)))) (VP (MD can) (VP (VB stimulate) (NP (NP (NN transcription)) (PP (IN from) (NP (DT the) (NN IL-2) (NN promoter)))) (PP (IN through) (NP (DT the) (JJ NF-AT-binding) (NN site)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD obtained) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ (NP (NN transfection)) (PP (IN of) (NP (NP (DT the) (NNS cDNAs)) (PP (IN for) (NP (NP-COOD (NP (NP (NN CN) (NN A)) (PRN (-LRB- -LRB-) (ADJP (JJ catalytic)) (-RRB- -RRB-))) (CC and) (NP (NP (NN CN) (NN B)) (PRN (-LRB- -LRB-) (ADJP (JJ regulatory)) (-RRB- -RRB-)))) (NNS subunits)))))) (ADVP (RB also)) (VP-COOD (VP (VBZ augments) (NP (NP (NN transcription)) (PP (IN from) (NP (DT the) (NN GM-CSF) (NN promoter))))) (CC and) (VP (VBZ recovers) (NP (NP (DT the) (NN transcription)) (VP (VBN inhibited) (PP (IN by) (NP-LGS (NN CsA))))))))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (DT The) (ADJP (RB constitutively) (JJ active)) (NN type)) (PP (IN of) (NP (DT the) (NN CN) (NN A) (NN subunit))) (, ,) (SBAR (WHNP-18 (WDT which)) (S (VP (VBZ lacks) (NP (DT the) (ADJP-COOD (ADJP (JJ auto-inhibitory)) (CC and) (ADJP (JJ calmodulin-binding))) (NNS domains))))) (, ,)) (VP (VBZ acts) (PP (IN in) (NP (NP (NN synergy)) (PP (IN with) (NP (NN PMA))))) (S (VP (TO to) (VP (VB activate) (NP (NP (NN transcription)) (PP (IN from) (NP (DT the) (NN GM-CSF) (NN promoter)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-19 (DT the) (JJ active) (NN CN)) (ADVP (RB partially)) (VP (VBZ replaces) (NP (NN calcium) (NN ionophore)) (PP (IN in) (NP (NP (NN synergy)) (PP (IN with) (NP (NN PMA))))) (S (VP (TO to) (VP (VB induce) (NP (NP (NN expression)) (PP (IN of) (NP (JJ endogenous) (NP-COOD (NP (NN GM-CSF)) (CC and) (NP (NN IL-2))))))))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG multimerizing) (NP (NP (DT the) (JJ regulatory) (NNS elements)) (PP (IN of) (NP (DT the) (NN GM-CSF) (NN promoter))))))) (, ,) (NP-SBJ-20 (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NN target) (NNS sites)) (PP (IN for) (NP (DT the) (NN CN) (NN action)))))) (VP (VBZ is) (NP-PRD (NP (NP (DT the) (VBN conserved) (NN lymphokine) (NN element) (CD 0)) (PRN (-LRB- -LRB-) (NP (NN CLE0)) (-RRB- -RRB-))) (, ,) (ADJP (JJ located) (PP (IN at) (NP (NP (NNS positions)) (PP (IN between) (NP-COOD (NP (CD -54)) (CC and) (NP (CD -40)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Mobility) (NN shift) (NNS assays)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-21 (DT the) (NN CLE0) (NN sequence)) (VP-COOD (VP (VBZ has) (NP (DT an) (JJ AP1-binding) (NN site))) (CC and) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ NF-AT-like) (NN factor)) (, ,) (VP (VBN termed) (S (NP-PRD (NN NF-CLE0) (NN gamma)))))))))))) (. .)))
(TOP (S (NP-SBJ-22 (NN NF-CLE0) (NN gamma) (NN binding)) (VP-COOD (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP-LGS (NN PMA/A23187))))) (CC and) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP-LGS (NP (NN treatment)) (PP (IN with) (NP (NN CsA)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-24 (NN CN)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (VBN coordinated) (NN induction)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN GM-CSF)) (CC and) (NP (NN IL-2))) (NNS genes))))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN CLE0) (NN sequence)) (PP (IN of) (NP (DT the) (NN GM-CSF) (NN gene)))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ functional) (NN analogue)) (PP (IN of) (NP (NP (DT the) (JJ NF-AT-binding) (NN site)) (PP (IN in) (NP (DT the) (NN IL-2) (NN promoter))))) (, ,) (SBAR (WHNP-25 (WDT which)) (S (VP (VBZ mediates) (NP (NP (NNS signals)) (ADJP (RB downstream) (PP (IN of) (NP (NN T) (NN cell) (NN activation)))))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Novel) (NN aldosterone) (NNS receptors)) (: :) (NP (NP (JJ specificity-conferring) (NN mechanism)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (DT the) (NN cell) (NN membrane))))) (. .)))))
(TOP (S (NP-SBJ (NP (JJ Functional) (NNS studies)) (PP (IN in) (NP (NP (ADJP-COOD (ADJP (JJ extra-renal)) (, ,) (ADJP (JJ nonepithelial))) (NNS cells)) (PP (JJ such) (IN as) (NP-COOD (NP (JJ smooth) (NN muscle) (NNS cells)) (CC and) (NP (ADVP-TMP (RBR more) (RB recently)) (NP (VBG circulating) (JJ human) (NNS lymphocytes)))))))) (VP (VBP have) (VP (VBN provided) (NP (VBG increasing) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NN aldosterone)) (VP (VBZ produces) (NP (NP-COOD (CONJP (RB not) (RB only)) (NP (JJ classical) (JJ genomic) (NNS effects)) (, ,) (CONJP (CC but) (RB also)) (NP (JJ rapid) (JJ non-genomic) (NNS effects))) (PP (IN on) (NP (NN transmembrane) (NN electrolyte) (NNS movements)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These)) (VP (VBP involve) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (NN sodium/proton-exchanger)) (PP (IN of) (NP (DT the) (NN cell) (NN membrane))))) (PP (IN at) (NP (NP (ADJP-COOD (ADJP (RB very) (JJ low)) (, ,) (ADJP (JJ physiological))) (NNS concentrations)) (PP (IN of) (NP (NN aldosterone))))) (PP (IN with) (NP (NP (DT an) (JJ acute) (NN onset)) (PP-TMP (IN within) (NP (QP (CD 1-2)) (NNS minutes))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ second) (NN messenger) (NN cascade)) (VP (VBN involved))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN inositol-1,4,5-trisphosphate/calcium) (NN pathway)) (SBAR (WHNP-5 (WDT which)) (S (VP (VBZ responds) (PP-TMP (IN over) (NP (DT the) (JJ same) (JJ rapid) (NN time) (NN course)))))))) (. .)))
(TOP (S (NP-SBJ-6 (JJ Such) (NNS changes)) (ADVP (RB clearly)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP-LGS (NP (JJ genomic) (NNS mechanisms)) (, ,) (SBAR (WHNP-7 (WDT which)) (S (VP (VBP are) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (JJ later) (NNS effects)) (PP (IN than) (NP (DT the) (JJ membrane-related) (JJ rapid) (NNS responses)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (PRP$ its) (JJ rapid) (NN time) (NN course))) (NP-SBJ (NP (DT the) (JJ unique) (NNS characteristics)) (PP (IN of) (NP (NP (DT this) (JJ new) (NN pathway)) (PP (IN for) (NP (NN steroid) (NN action)))))) (VP (VBP include) (NP-COOD (NP (NP (DT a) (JJ 10000-fold) (NN selectivity)) (PP (IN for) (NP (NN aldosterone))) (PP (IN over) (NP (NN cortisol)))) (CC and) (NP (NP (DT the) (NN ineffectiveness)) (PP (IN of) (NP (NP (NNS spironolactones)) (, ,) (NP (JJ classical) (NN mineralocorticoid) (NNS antagonists)) (, ,))) (PP (IN as) (NP (NP (NNS antagonists)) (PP (IN of) (NP (DT the) (NN response)))))))) (. .)))
(TOP (S (NP-SBJ-8 (NP (ADJP (RB Subsequently) (VBG binding)) (NNS sites))) (VP (VBP have) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN membrane)) (PP (IN of) (NP (JJ human) (NNS lymphocytes))))) (SBAR-9 (WHNP-10 (WDT which)) (S (VP (VBP show) (NP (NP (NP-COOD (NP (NP (JJ pharmacological)) (PRN (-LRB- -LRB-) (NP (NN aldosterone) (NN specificity)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ kinetic)) (PRN (-LRB- -LRB-) (NP (JJ high) (NN turnover)) (-RRB- -RRB-)))) (NP-11 (NNS properties))) (ADJP (JJ identical) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ rapid) (NN aldosterone) (NNS effects)) (PP (IN in) (NP (DT the) (JJ same) (NNS cells))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN SDS-PAGE) (NN analysis)) (PP (IN of) (NP (DT the) (NN receptor) (NN protein)))) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT a) (JJ molecular) (NN weight)) (PP (IN of) (NP (QP (RB approximately) (CD 50)) (NN kD)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ present) (NN paper)) (VP (VBZ reviews) (NP (NP (DT the) (NNS data)) (VP (VBG supporting) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ new)) (, ,) (ADJP (JJ two-step))) (NN model)) (PP (IN for) (NP (ADJP-COOD (ADJP (JJ non-genomic)) (CC and) (ADJP (JJ genomic))) (NN aldosterone) (NNS effects))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (ADVP (RB also)) (VP (VBZ suggests) (NP (NP (DT a) (JJ novel) (JJ specificity-conferring) (NN mechanism)) (PP (IN for) (NP (NP (NN mineralocorticoid) (NN action)) (PP (IN at) (NP (DT the) (NN membrane) (NN level))))))) (. .)))
(TOP (NP (NP (JJ Glucocorticoid-mediated) (NN inhibition)) (PP (IN of) (NP (NP (NN interleukin-2) (NN receptor) (NP-COOD (NP (NN alpha)) (CC and) (NP (NN -beta))) (NN subunit) (NN expression)) (PP (IN by) (NP (JJ human) (NN T) (NNS cells))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (ADJP (NN glucocorticoid) (-LRB- -LRB-) (NN GC) (-RRB- -RRB-) (JJ -mediated)) (NN inhibition)) (PP (IN of) (NP (NN T) (NN cell) (NNS functions))))))))) (, ,) (NP-SBJ-8 (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NN DM)) (-RRB- -RRB-)))) (PP (IN on) (NP-COOD (NP (NN T) (NN cell) (NN proliferation)) (CC and) (NP (NP (NP (NN interleukin-2) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IL-2R)) (-RRB- -RRB-))) (NN generation))))) (VP (VBD were) (VP (VBN studied))) (. .)))
(TOP (S (NP-SBJ (NN Dexamethasone)) (VP (VBD inhibited) (NP (JJ IL-2-induced) (NN T) (NN cell) (NN proliferation)) (PP (IN by) (NP (CD 30) (NN %) (TO -) (CD 88) (NN %))) (, ,) (PP (JJ relative) (TO to) (NP (NP (PRP$ its) (NN concentration)) (PP (IN within) (NP (DT the) (NNS cultures)))))) (. .)))
(TOP (S (NP-SBJ-9 (NP (DT The) (NN effect)) (PP (IN of) (NP (NN DM))) (PP (IN on) (NP (NP (NN expression)) (PP (IN of) (NP (NP-COOD (NP (NP (NN IL-2R) (NN alpha)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Tac)) (, ,) (NP (NN p55)) (, ,) (NP (NN CD25))) (-RRB- -RRB-))) (CC and) (NP (NP (NN beta)) (PRN (-LRB- -LRB-) (NP (NN p75)) (-RRB- -RRB-)))) (NNS genes))) (PP (IN in) (NP (VBN activated) (NN T) (NNS cells)))))) (VP (VBD was) (VP (VBN examined) (ADVP-TMP (RB next)))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NN T) (NNS cells)) (VP (VBN stimulated) (PP (IN with) (NP-COOD (NP (NP (VBN purified) (NN phytohemagglutinin)) (PRN (-LRB- -LRB-) (NP (NN PHA-p)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 4) (NN beta-phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-)))))))) (NP-SBJ-10 (NP (NN addition)) (PP (IN of) (NP (NN DM))) (PP (TO to) (NP (DT the) (NNS cultures)))) (VP (VBD resulted) (PP (IN in) (NP-COOD (NP (NP (DT a) (CD 60) (NN %) (NN reduction)) (PP (IN in) (NP (NN IL-2R) (NN alpha)))) (CC and) (NP (NP (DT a) (CD 30) (NN %) (NN reduction)) (PP (IN in) (NP (NN IL-2R) (NN beta) (NN membrane) (NN expression)))))) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN T) (NNS cells)) (VP (VBN cultured) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN DM))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Inhibition)) (PP (IN of) (NP (NN membrane) (NP-COOD (NP (NN IL-2R) (NN alpha)) (CC and) (NP (NN IL-2R) (NN beta))) (NN expression))) (PP (IN by) (NP (ADJP (CD 10-LRB--6-RRB-) (NN M)) (NN DM)))) (VP (VBD was) (ADJP-PRD (RB partially) (JJ reversible) (PP (IN by) (NP (NP (JJ recombinant) (JJ human) (NN IL-2)) (PRN (-LRB- -LRB-) (NP (NN rhIL-2)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (PP (IN By) (NP (JJ Northern) (NN blot) (NN analysis))) (, ,) (NP-SBJ (NN DM)) (VP (VBD caused) (NP (NP (DT a) (JJ comparable) (NN decrease)) (PP (PP-COOD (PP (IN in) (NP (NN IL-2R) (NN alpha))) (CC and) (PP (IN in) (NP (NN IL-2R) (NN beta)))) (NP-12 (NN mRNA) (NNS levels)))) (PP (TO to) (NP (NP (NN membrane) (NN receptor) (NN expression)) (PP (IN in) (NP (JJ mitogen-stimulated) (NN T) (NNS cells)))))) (. .)))
(TOP (S (PP (IN By) (NP (ADJP (FW in) (FW vitro)) (NN transcription) (NNS assays))) (, ,) (NP-SBJ (NN DM)) (VP (VBD regulated) (NP (NP (NN IL-2R) (NN alpha) (NN gene) (NN expression)) (PP (IN at) (NP (DT a) (JJ transcriptional) (NN level)))) (SBAR (IN while) (S (NP-SBJ-13 (NP (NN transcription)) (PP (IN of) (NP (NN IL-2R) (NN beta) (NN gene)))) (VP (VBD was) (VP (VBN unaffected) (PP (IN by) (NP-LGS (NN DM)))))))) (. .)))
(TOP (S (NP-SBJ-14 (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN DM))) (PP (IN on) (NP (NN IL-2R) (NN alpha) (NN transcription)))))) (VP (VBD was) (VP (VBN examined) (PP (IN by) (S (VP (VBG determining) (NP (NP (DT the) (NN mRNA) (NNS levels)) (PP (IN of) (NP (NP (DT the) (NN p50) (NN subunit)) (PP (IN of) (NP (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN transcription) (NN factor)) (SBAR (WHNP-15 (WDT that)) (S (VP (VBZ stimulates) (NP (NN IL-2R) (NN alpha) (NN gene) (NN expression)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-16 (ADJP (CD 10-LRB--6-RRB-) (NN M)) (NN DM)) (VP (VBD increased) (NP (NN T) (NN cell) (NN p50) (NN NF-kappa) (NN B) (NN mRNA) (NNS levels)) (PP (IN by) (NP (JJ four-fold))) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (NNS levels)) (VP (VBN obtained) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN DM)))))))))))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (NP-SBJ (NP (DT the) (NN level)) (PP (IN of) (NP (NP (JJ nuclear) (NNS proteins)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG binding) (PP (TO to) (NP (DT the) (NN NF-kappa) (NN B) (NNS sites))) (PP (IN in) (NP (VBN activated) (NN T) (NNS cells)))))))))) (VP (VBD increased) (PP (IN in) (NN response) (TO to) (NP (NN DM)))) (. .)))
(TOP (S (PP (IN In) (NP (NN sum))) (, ,) (NP-SBJ (NN DM)) (VP (VBZ regulates) (NP (NP (NN T) (NN cell) (NN membrane) (NN expression)) (PP (IN of) (NP (NN IL-2R)))) (PP (IN by) (NP (QP (JJR more) (IN than) (CD one)) (JJ molecular) (NN mechanism)))) (. .)))
(TOP (NP (NP (NN Pentoxifylline)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN infection)) (PP (IN with) (NP (JJ human) (NN immunodeficiency) (NN virus))))))) (. .)))
(TOP (S (NP-SBJ-1 (NP (NN Cytokine) (NN dysregulation)) (PP (IN in) (NP (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))) (NN infection)))) (VP-COOD (VP (VBZ has) (VP (VBN been) (VP (VBN documented) (PP (IN in) (NP (JJ numerous) (NNS studies)))))) (CC and) (VP (VBZ has) (VP (VBN been) (VP (VBN cited) (PP (IN as) (NP (NP (DT an) (JJ important) (NN component)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT this) (JJ retroviral) (NN infection))))))))))) (. .)))
(TOP (S (NP-SBJ-3 (NP (JJ Pharmacological) (NN modification)) (PP (IN of) (NP (NN cytokine) (NN dysregulation)))) (, ,) (ADVP (RB therefore)) (, ,) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN modality)) (PP (IN for) (NP (NN HIV-1) (NN infection)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNP Dr.) (NNP Dezube)) (PP (IN of) (NP (NP (NNP Beth) (NNP Israel) (NNP Hospital)) (PRN (-LRB- -LRB-) (NP (NNP Boston)) (-RRB- -RRB-))))) (ADVP (RB concisely)) (VP (VBZ reviews) (NP (NP (DT the) (NN state)) (PP (IN of) (NP (NP (PRP$ our) (NN knowledge)) (PP (VBG regarding) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN pentoxifylline))) (PP (IN on) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (, ,) (NP (NP (DT a) (NN cytokine)) (VP (VBN known) (S (VP-COOD (VP (TO to) (VP (VB influence) (NP (NN HIV-1) (NN replication)))) (CC and) (VP (TO to) (VP (VB play) (NP (DT a) (JJ possible) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NNS manifestations)) (PP (IN of) (NP (NP (JJ advanced) (NN infection)) (PP (IN with) (NP (DT this) (NN virus))))))))))))))))))))))) (. .)))
(TOP (S (NP-SBJ-4 (NP (NN Pentoxifylline)) (, ,) (NP (DT a) (JJ trisubstituted) (NN xanthine) (NN derivative)) (, ,)) (VP-COOD (VP (VBZ has) (VP (VBN been) (VP (VBN used) (S (VP (TO to) (VP (VB decrease) (NP (NN blood) (NN viscosity)))))))) (CC and) (VP (VBZ is) (VP (ADVP (RB reasonably) (RB well)) (VBN tolerated) (PP (IN by) (NP-LGS (NP (JJS most) (NNS recipients)) (PP (IN of) (NP (DT the) (NN drug)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Results)) (PP (IN of) (NP (NP (JJ preliminary) (NNS studies)) (, ,) (SBAR (WHNP-7 (NP (JJ many)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBD were) (VP (VBN conducted) (PP (IN by) (NP-LGS (NNP Dr.))))))) (NNP Dezube)))) (VP (, ,) (SBAR (VBP suggest) (S (NP-SBJ (NP (IN that)) (PP (NN use) (NP (IN of) (DT this))) (PP (NN agent) (NP (NP (IN in)) (PP (NN combination) (NP (IN with) (JJ antiretroviral)))))) (VP (NNS compounds) (VP (MD may) (ADJP-PRD (VB prove) (PP (JJ useful) (NP (NP (IN in) (DT the)) (PP (NN treatment) (NP (NP (IN of)) (PP (NNS patients) (NP (IN with) (NN HIV-1))))))))))))) (NN infection)))
(TOP (NP (NP (VBN Increased) (NN interleukin) (CD 2) (NN transcription)) (PP (IN in) (NP (JJ murine) (NNS lymphocytes))) (PP (IN by) (NP (NN ciprofloxacin))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ fluoroquinolone) (JJ antibiotic)) (, ,) (NP (NP (NN ciprofloxacin)) (PRN (-LRB- -LRB-) (NP (NN cipro)) (-RRB- -RRB-))) (, ,)) (VP (VBZ induces) (NP (NP (NN hyperproduction)) (PP (IN of) (NP-COOD (NP (NP (NN interleukin) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-))))) (PP (IN in) (NP (VBN stimulated) (JJ human) (JJ peripheral) (NN blood) (NNS lymphocytes))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN investigation))) (NP-SBJ-1 (DT an) (ADJP-COOD (ADJP (VBN enhanced)) (CC and) (ADJP (JJ prolonged))) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-2) (NN mRNA))) (NN response)) (VP (VBD was) (VP (ADVP (RB also)) (VBN detected) (PP-COOD (PP (IN in) (CC both) (NP (ADJP (VBN stimulated) (-LRB- -LRB-) (NP-2 (NN T) (NN cell) (NP-COOD (NP (NNS mitogens)) (CC or) (NP (NNS alloantigens)))) (-RRB- -RRB-)) (JJ murine) (NNS splenocytes))) (CC and) (PP (IN in) (NP (DT the) (VBN stimulated) (JJ murine) (NN T) (NN cell) (NN line) (NN EL-4)))) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NP (NN ciprofloxacin)) (PRN (-LRB- -LRB-) (NP (QP (CD 5-80)) (NN micrograms/ml)) (-RRB- -RRB-)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN control) (NNS cells)) (PP (IN without) (NP (NNS antibiotics)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (PP (IN in) (NN contrast) (TO to) (NP (JJ human) (NNS lymphocytes))) (, ,) (S-COOD (S (NP-SBJ-3 (NN IFN-gamma) (NN production)) (VP (VBD was) (VP (VBN inhibited)))) (CC and) (S (NP-SBJ-4 (NN IFN-gamma) (NN mRNA) (NNS levels)) (VP (VBD were) (VP (VP-COOD (VP (JJ unaffected) (PP-TMP (IN at) (NP (NP (CD 24) (NN h))))) (CC and) (VP (ADVP (RB only) (RB slightly)) (VBN upregulated) (PP-TMP (IN at) (NP (NP (QP (CD 48) (CC and) (CD 72)) (NN h)))))) (PP-101 (IN of) (NP (NN culture))) (PP (IN in) (NP (NP (JJ murine) (NNS splenocytes)) (VP (VBN incubated) (PP (IN with) (NP (NP (NN cipro)) (PRN (-LRB- -LRB-) (NP (CD 20) (NNS micrograms/ml)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ-5 (NN EL-4) (NNS cells)) (VP (VBD were) (VP (VBN transfected) (PP (IN with) (NP (NP (DT a) (NN plasmid)) (VP (VBG containing) (NP (NP (DT the) (NN IL-2) (NP-COOD (NP (NN promoter)) (CC and) (NP (NN enhancer))) (NN region)) (VP (VBN linked) (PP (TO to) (NP (DT the) (NP (NP (NN chloramphenicol) (NN acetyltransferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (NN reporter) (NN gene)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NN CAT) (NN activity)))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (NN cipro)) (VP (VBD enhanced) (NP (NN IL-2) (NN gene) (NN induction)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-7 (NP (NN EL-4) (NNS cells)) (VP (VBN incubated) (PP (IN with) (NP (NN ciprofloxacin))))) (VP (VBD showed) (NP-COOD (NP (DT an) (JJ early) (NN peak)) (CC and) (NP (ADJP (RBR more) (VBN activated)) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NFAT-1)) (-RRB- -RRB-))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN control) (NNS cells)) (PP (IN without) (NP (NNS antibiotics))))))))) (. .)))
(TOP (S (NP-SBJ (NN Cipro)) (VP (VBD did) (RB not) (VP (VB affect) (NP (DT the) (JJ nuclear) (NN transcription) (NNS factors) (NP-COOD (NP (NN AP-1)) (CC or) (NP (NN NFIL-2A)))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-10 (NN cipro)) (VP-COOD (VP (VBD inhibited) (NP (NN IFN-gamma) (NN synthesis))) (, ,) (CC but) (VP (VBD enhanced) (NP (NP (NN IL-2) (NN production)) (PP (IN in) (NP (JJ murine) (NNS lymphocytes)))) (PP (IN by) (NNS means) (IN of) (S (VP-COOD (VP (VBG influencing) (NP (NN NFAT-1))) (CC and) (VP (VBG causing) (NP (DT an) (VBN increased) (NN IL-2) (NN transcription)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Multiple) (JJ prolactin-responsive) (NNS elements)) (VP (VBP mediate) (NP (NP (NP-COOD (NP (NN G1)) (CC and) (NP (NN S))) (NN phase) (NN expression)) (PP (IN of) (NP (DT the) (NN interferon) (JJ regulatory) (NN factor-1) (NN gene))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NP (NP (NN interferon) (JJ regulatory) (NN factor-1)) (PRN (-LRB- -LRB-) (NP (NN IRF-1)) (-RRB- -RRB-))) (NN gene)) (VP (VBZ is) (NP-PRD (NP-COOD (CC both) (NP (DT an) (JJ immediate-early) (NN G1) (NN phase) (NN gene)) (CC and) (NP (DT an) (NN S) (NN phase) (NN gene))) (ADJP (JJ inducible) (PP (IN by) (NP (NN PRL))) (PP (IN in) (NP (NN rat) (NN Nb2) (NN T) (NNS lymphocytes)))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP-2 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NN PRL)) (VP (VBZ regulates) (NP (NP (DT the) (JJ biphasic) (NN expression)) (PP (IN of) (NP (NN IRF-1))))))))))) (, ,) (NP-SBJ-1 (PRP we)) (VP-COOD (VP (VBD cloned) (NP (DT the) (NN rat) (NN IRF-1) (NN gene))) (CC and) (VP (ADVP (RB functionally)) (VBD characterized) (NP (DT the) (NN IRF-1) (NN promoter)))) (. .)))
(TOP (S (PP-TMP (IN Upon) (NP (NP (NN transfection)) (PP (IN into) (NP (NN Nb2) (NN T) (NNS cells))))) (, ,) (NP-SBJ (NP (CD 1.7) (NP (NP (NNS kilobases)) (PRN (-LRB- -LRB-) (NP (NN kb)) (-RRB- -RRB-)))) (PP (IN of) (NP (NP (NN IRF-1) (JJ 5'-flanking) (NN DNA)) (VP (VBN linked) (PP (TO to) (NP (DT a) (NP (NP (NN chloramphenicol) (JJ acetyl) (NN transferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (NN reporter) (NN gene))))))) (VP (VBD mediated) (NP (NP (DT a) (JJ 30-fold) (NN induction)) (PP (IN of) (NP (NN CAT) (NN enzyme) (NN activity)))) (PP (IN in) (NN response) (TO to) (NP (NP (CD 24) (NN h)) (PP (IN of) (NP (NN PRL) (NN stimulation)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Deletion) (NNS mutants)) (VP (VBG containing) (NP (ADJP (QP (CD 1.3) (, ,) (CD 0.6) (, ,) (CC and) (CD 0.2)) (NN kb)) (JJ 5'-flanking) (NN DNA)))) (VP (VBD were) (ADJP-PRD (ADVP (RB incrementally) (ADVP (RBR less) (RB transcriptionally))) (JJ active)) (, ,) (SBAR (IN although) (S (NP-SBJ (CD 0.2) (NN kb)) (ADVP (RB still)) (VP (VBD mediated) (NP (NP (DT a) (JJ 12-fold) (NN induction)) (PP (IN by) (NP (NN PRL)))))))) (. .)))
(TOP (S (NP-SBJ-3 (NP (DT The) (NN sequence)) (PP (IN between) (NP (QP (CD -1.7) (CC and) (CD -0.2)) (NN kb))) (VP (VBN linked) (PP (TO to) (NP (DT a) (JJ heterologous) (NN thymidine) (NN kinase) (NN promoter))))) (VP (VBD failed) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NN PRL) (NN stimulation)))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN activity)) (PP (IN of) (NP (JJ upstream) (NN PRL) (NN response) (NNS elements)))) (VP (MD may) (VP (VB require) (NP (NP (DT an) (NN interaction)) (PP (IN with) (NP (JJ promoter-proximal) (NNS elements))))))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG assaying) (NP (NP (NN CAT) (NN enzyme) (NN activity)) (PP (IN across) (NP (DT a) (JJ 24-h) (NN PRL) (NN induction) (NN time) (NN course))))))) (, ,) (NP-SBJ-5 (PRP we)) (VP (VBD were) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB assign) (NP (NP (NP-COOD (NP (NN G1)) (CC vs.) (NP (NN S))) (NN phase) (NN PRL) (NNS responses)) (PP (IN of) (NP (DT the) (NN IRF-1) (NN gene)))) (PP (TO to) (NP (NP (JJ different) (NNS regions)) (PP (IN of) (NP (DT the) (NN IRF-1) (UCP-COOD (ADJP (JJ 5'-flanking)) (CC and) (NP (NN promoter))) (NN DNA)))))))))) (. .)))
(TOP (S (NP-SBJ-7 (DT The) (JJ 0.2-kb) (NN IRF-CAT) (NN construct)) (VP (VBD was) (VP (VBN induced) (PP (IN by) (NP-LGS (NN PRL) (NN stimulation))) (PP-TMP (IN during) (NP (NP (DT the) (NN G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (DT the) (JJ 1.7-kb) (NN IRF-CAT) (NN construct)) (VP (VBD was) (ADJP-PRD (JJ inducible) (PP (IN by) (NP (NN PRL)))) (PP-TMP (IN during) (NP (NP-LGS (NP-COOD (CC both) (NP (NN G1)) (CC and) (NP (NN S))) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle)))))) (. .)))
(TOP (S (S (ADVP (RB Hence)) (, ,) (NP-SBJ-8 (NP (DT the) (JJ PRL-induced) (JJ biphasic) (NN expression)) (PP (IN of) (NP (DT the) (NN IRF-1) (NN gene)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN controlled) (PP (IN by) (NP-LGS (JJ separate) (JJ PRL-responsive) (NNS elements)))))))) (: :)) (S-COOD (S (NP-SBJ (NP (NNS elements)) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 0.2) (NN kb)) (PP (IN of) (NP (DT the) (NN IRF-1) (NN promoter) (NN region)))))) (VP (VBP act) (PP-TMP (IN during) (NP (JJ early) (NN activation))))) (, ,) (CC and) (S (NP-SBJ (NP (NNS elements)) (PP (IN between) (NP (QP (CD 0.2) (CC and) (CD 1.7)) (NN kb)))) (VP (VBP act) (PP (IN in) (NN concert) (IN with) (NP (DT the) (JJ proximal) (JJ 0.2-kb) (NN region))) (PP-TMP (IN during) (NP (NN S) (NN phase) (NN progression)))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Description)) (CC and) (NP (JJ functional) (NNS implications))) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN mutation)) (PP (IN in) (NP (DT the) (JJ sex-determining) (NN gene) (NN SRY))))) (. .)))
(TOP (S (NP-SBJ-28 (DT The) (JJ sex-determining) (NN gene) (NN SRY)) (VP (VBD was) (VP (VBN screened) (PP (IN for) (NP (NP (JJ molecular) (NN alteration)) (PP (IN in) (NP (DT an) (ADJP (NN XY) (JJ sex-reversed)) (NN female))))) (PP (IN by) (NP (NP (NP (JJ single-strand) (NN conformation) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SSCP)) (-RRB- -RRB-))) (NN technique))))) (. .)))
(TOP (S (NP-SBJ-29 (NP (DT An) (JJ A-to-G) (NN transition))) (VP (VBD was) (VP (VBN detected) (SBAR-30 (WHNP-31 (WDT which)) (S (VP (VBZ leads) (PP (TO to) (NP (NP (DT an) (NN exchange)) (PP (IN of) (NP (DT a) (NN tyrosine))) (PP (IN by) (NP (DT a) (NN cysteine))) (PP (IN in) (NP (DT the) (NN SRY) (NN protein)))))))))) (. .)))
(TOP (S (NP-SBJ-32 (NP (DT The) (VBN affected) (NN tyrosine) (NN residue)) (ADJP (JJ located) (PP (IN at) (NP (NP (DT the) (NN C) (NN terminus)) (PP (IN of) (NP (DT the) (NN DNA) (NN binding) (NN protein))))))) (VP (VBZ is) (VP (ADVP (RB evolutionarily) (RB strongly)) (VBN conserved) (PP (IN among) (NP (NP (DT the) (NNS members)) (PP (IN of) (NP (DT the) (ADJP (NN HMG) (NN box) (VBG containing)) (NNS proteins))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP-COOD (NP (NN gel) (NN shift) (NN assay)) (CC and) (NP (NN peptide) (NN synthesis))))) (NP-SBJ-33 (PDT such) (DT a) (NN mutation)) (VP (VBZ is) (VP (VBN shown) (S (VP (TO to) (VP (VB abolish) (NP (DT the) (NN SRY) (NN protein) (NN DNA) (NN binding) (NN ability))))))) (. .)))
(TOP (S (NP-SBJ-34 (NP (DT The) (NN involvement)) (PP (IN of) (NP (DT this) (JJ particular) (NN amino) (NN acid))) (PP (IN in) (NP (DT the) (NN binding) (NN specificity)))) (VP (VBZ is) (VP (ADVP (RB also)) (VBN discussed))) (. .)))
(TOP (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (DT a) (JJ trans-acting) (NN activator) (NN function)) (VP (VBG regulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (JJ human) (NN CD5) (NN antigen))))))) (. .)))
(TOP (S (NP-SBJ-19 (JJ Interspecies) (JJ somatic) (NN cell) (NNS hybrids)) (VP (VBD were) (VP (VBN generated) (PP (IN by) (S (VP (VBG fusing) (NP (NP (DT the) (NN mouse) (NN T-lymphoma) (NN cell) (NN line)) (, ,) (NP (NN BW5147)) (, ,)) (PP (IN with) (NP (JJ normal) (JJ human) (NN T) (NNS lymphocytes))) (PP (IN at) (NP (NP (JJ different) (NNS stages)) (PP (IN of) (NP (NN differentiation)))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-20 (NP (NNS Thymocytes)) (, ,) (NP (VBN activated) (JJ peripheral) (NN T) (NNS lymphocytes)) (, ,) (CC or) (NP (DT an) (VBN activated) (NN T-cell) (NN clone))) (VP (VBD were) (VP (VBN used) (PP (IN as) (NP (JJ human) (NNS partners))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN in) (NP (CD three) (JJ independent) (NNS fusions))))) (. .)))
(TOP (S (PP (JJ Irrespective) (IN of) (NP (NP (DT the) (JJ human) (NN cell) (NN partner)) (VP (VBN used) (PP (IN for) (NP (NN fusion)))))) (, ,) (NP-SBJ (NP (DT a) (JJ certain) (NN number)) (PP (IN of) (NP (NNS hybrids)))) (VP (VBD lost) (NP (NN CD5) (NN surface) (NN expression)) (PP-TMP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NN time))) (PP (IN in) (NP (NN culture)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN at) (NP (DT the) (UCP-COOD (NP (NN phenotype)) (CC and) (ADJP (JJ genetic))) (NN level)))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (NN lack)) (PP (IN of) (NP (NN CD5) (NN expression)))) (VP (VBD was) (PP-PRD (JJ due) (PP-COOD (CC neither) (PP (TO to) (NP (NP (NN segregation)) (PP (IN of) (NP (NP (JJ human) (NN autosome) (CD 11)) (, ,) (SBAR (WHPP-21 (IN on) (WHNP (WDT which))) (S (NP-SBJ-22 (DT the) (NN CD5) (NN gene)) (VP (VBZ has) (VP (VBN been) (VP (VBN mapped)))))) (, ,))))) (CC nor) (PP (TO to) (NP (NP (NN deletion)) (PP (IN of) (NP (DT the) (NN CD5) (JJ structural) (NN gene))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (NN loss)) (PP (IN of) (NP (NN CD5) (NN surface) (NN expression)))) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ specific) (NN mRNA)))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (DT these) (NNS hybrids)) (ADVP (RB preferentially)) (VP (VBP segregate) (NP (JJ human) (NNS chromosomes))))) (, ,) (NP-SBJ (DT these) (NNS results)) (VP (VBP indicate) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (JJ non-syntenic) (JJ trans-active) (NP-COOD (NP (NN locus)) (, ,) (CC or) (NP (NNS loci)) (, ,))) (VP (ADVP (RB positively)) (VBG controlling) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (JJ human) (NN CD5) (NN gene))))))))) (. .)))
(TOP (NP (NP (NN Prevalence)) (PP (IN of) (NP (NP-COOD (NP (NN aneuploidy)) (, ,) (NP (JJ overexpressed) (NN ER)) (, ,) (CC and) (NP (JJ overexpressed) (NN EGFR))) (PP (IN in) (NP (NP (JJ random) (NN breast) (NNS aspirates)) (PP (IN of) (NP (NP (NNS women)) (PP (IN at) (NP (NP (ADJP-COOD (ADJP (JJ high)) (CC and) (ADJP (JJ low))) (NN risk)) (PP (IN for) (NP (NN breast) (NN cancer))))))))))) (. .)))
(TOP (S (NP-SBJ-27 (NP (NN Breast) (NN tissue) (NNS biomarkers)) (SBAR (WHNP-28 (WDT which)) (S (ADVP (RB accurately)) (VP (VBP predict) (NP (NP (NN breast) (NN cancer) (NN development)) (PP-TMP (IN within) (NP (DT a) (ADJP (CD 10) (NN year)) (NN period))) (PP (IN in) (NP (ADJP (JJ high) (NN risk)) (NNS women)))))))) (VP (VBP are) (UCP-COOD (VP (VBN needed)) (CC but) (ADJP-PRD (ADVP-TMP (RB currently)) (RB not) (JJ available)))) (. .)))
(TOP (S (NP-SBJ-29 (PRP We)) (VP (VBD initiated) (NP (DT this) (NN study)) (S (VP (TO to) (VP (VB determine) (UCP-COOD (NP (LST (LS 1) (-RRB- -RRB-)) (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (QP (CD one) (CC or) (JJR more)) (NN breast) (NN tissue) (NNS abnormalities)) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS women)) (PP (IN at) (NP (NP (JJ high) (NN risk)) (PP (IN for) (NP (NN breast) (NN cancer)))))))))))) (, ,) (CC and) (SBAR (LST (LS 2) (-RRB- -RRB-)) (IN if) (S (NP-SBJ (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NN biomarker) (NNS abnormalities)))) (VP (VBZ is) (ADJP-PRD (ADJP (JJR greater))) (PP (IN in) (NP (JJ high) (NN risk))) (PP-106 (IN than) (FRAG (PP (IN in) (NP (JJ low) (NN risk) (NNS women))))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Eligible) (JJ high) (NN risk) (NNS women)) (VP (VBD were) (NP-PRD (NP (DT those)) (PP (IN with) (NP (NP (DT a) (ADJP (JJ first) (NN degree)) (NN relative)) (PP (IN with) (NP-COOD (NP (NN breast) (NN cancer)) (, ,) (NP (JJ prior) (NN breast) (NN cancer)) (, ,) (CC or) (NP (JJ precancerous) (NN mastopathy)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Low) (NN risk) (NNS women)) (VP (VBD were) (NP-PRD (NP (DT those)) (PP (IN without) (NP-COOD (NP (DT these)) (CC or) (NP (JJ other) (JJ major) (JJ identifiable) (NN risk) (NNS factors)))))) (. .)))
(TOP (S (NP-SBJ-30 (JJ Ductal) (NNS cells)) (VP (VBD were) (VP-COOD (VP (VBN obtained) (PP (IN via) (NP (JJ random) (JJ fine) (NN needle) (NNS aspirations)))) (CC and) (VP (ADVP (RB cytologically)) (VBN classified)))) (. .)))
(TOP (S (NP-SBJ (NNS Biomarkers)) (VP (VBD included) (NP-COOD (NP (NN DNA) (NN ploidy)) (, ,) (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-32 (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NN DNA) (NN aneuploidy)))) (VP (VBD was) (NP-PRD-33 (CD 30) (NN %)))) (, ,) (S (NP-SBJ=32 (NP (NN overexpression)) (PP (IN of) (NP (NN ER)))) (NP-PRD=33 (CD 10) (NN %))) (, ,) (CC and) (S (NP-SBJ=32 (NP (NN overexpression)) (PP (IN of) (NP (NN EGFR)))) (NP-PRD=33 (CD 35) (NN %)))) (, ,) (PP (IN in) (NP (NP (DT the) (CD 206) (JJ high) (NN risk) (NNS women)) (SBAR (WHNP-34 (NP (WP$ whose) (JJ median) (ADJP (CD 10) (NN year)) (NN Gail) (NP (NP (NN risk)) (PRN (-LRB- -LRB-) (NP (VBN projected) (NN probability)) (-RRB- -RRB-)))) (PP (IN of) (S (VP (VBG developing) (NP (NN breast) (NN cancer)))))) (S (VP (VBD was) (NP-PRD (CD 4.5) (NN %))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN prevalence)) (PP (IN of) (NP-COOD (NP (NN aneuploidy)) (CC and) (NP (JJ overexpressed) (NN EGFR))))) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR higher))) (PP (IN in) (NP (DT the) (JJ high) (NN risk) (NNS women))) (PP-107 (IN than) (FRAG (PP (IN in) (NP (NP (NP (DT the) (CD 25) (JJ low) (NN risk) (NNS controls)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.002)))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP-35 (WP$ whose) (JJ median) (ADJP (CD 10) (NN year)) (NN Gail) (NN risk)) (S (VP (VBD was) (NP-PRD (CD 0.7) (NN %)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NN ER) (NN overexpression))))) (PP (IN between) (NP (ADJP-COOD (ADJP (JJ high)) (CC and) (ADJP (JJ low))) (NN risk) (NNS groups)))) (VP (VBD was) (RB not) (ADVP (RB statistically)) (ADJP-PRD (JJ significant)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (VP (JJ =) (NP-PRD (CD 0.095)))) (-RRB- -RRB-))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP-COOD (NP (NP (DT the) (JJ low) (NN prevalence)) (PP (IN of) (NP (JJ overexpressed) (NN ER)))) (CC and) (NP (NP (DT the) (JJ small) (NN number)) (PP (IN of) (NP (NNS controls)))))))) (. .)))
(TOP (S (NP-SBJ-36 (DT A) (JJ significant) (NN difference)) (VP (VBD was) (VP (VBN noted) (PP (IN in) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (QP (CD one) (CC or) (JJR more)) (JJ abnormal) (NNS biomarkers))))) (PP (IN between) (NP (DT the) (NP-COOD (NP (JJ high) (NN risk)) (CC and) (NP (JJ low) (NN risk))) (NNS women))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.001)))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ-37 (DT A) (JJ large) (JJ prospective) (NN trial)) (VP (VBZ is) (VP (VBN needed) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP-SBJ (NP (QP (CD one) (CC or) (JJR more))) (PP (IN of) (NP (DT these) (NNS biomarkers)))) (, ,) (VP (VBZ is) (ADJP-PRD (JJ predictive) (PP (IN of) (NP (NN breast) (NN cancer) (NN development)))))))))))) (. .)))
(TOP (NP (-LRB- -LCB-) (NP (DT The) (NNS changes)) (PP (IN in) (NP (NP (NN glucocorticoid) (NNS receptors)) (PP (IN in) (NP (NP (JJ peripheral) (NNS leukocytes)) (PP (IN in) (NP (JJ asthmatic) (NNS subjects))))))) (-RRB- -RCB-)))
(TOP (S (NP-SBJ-1 (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN GCR)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ peripheral) (NNS leukocytes)))))) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP (JJ radioligand-binding) (NN assay))) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ extrinsic)) (CC and) (ADJP (JJ intrinsic))) (NNS asthmatics))))) (. .)))
(TOP (S (NP-SBJ-2 (PRP$ Their) (JJ corresponding) (NN plasma) (NN cortisol) (NNS levels)) (VP (VBD were) (VP (VBN assessed))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S-COOD (S (NP-SBJ (NP (DT the) (JJ average) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (NNS asthmatics)))))) (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP-SBJ (EX there)) (VP (VBD was) (NP-PRD (NP (DT a) (JJ linear) (NN correlation)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN GCR)))) (CC and) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (NN asthma)))))))))))) (. .)))
(TOP (S (ADVP (RB Besides)) (, ,) (NP-SBJ (EX there)) (VP (VBD was) (ADVP (RB also)) (NP-PRD (NP (DT a) (JJ linear) (NN correlation)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NN GCR)))) (CC and) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (NP (DT the) (JJ initial) (NN attack)) (PP (IN of) (NP (NN asthma)))))))))) (. .)))
(TOP (S (NP-SBJ-3 (NP (DT No) (NN difference)) (PP (IN in) (NP (NN plasma) (NN cortisol) (NN level)))) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP-COOD (NP (NNS asthmatics)) (CC and) (NP (JJ healthy) (NNS subjects)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S-COOD (S (NP-SBJ (EX there)) (VP (VBZ is) (NP-PRD (NP (DT no) (ADJP-COOD (ADJP (JJ primary)) (CC and) (ADJP (JJ general))) (NN impairment)) (PP (IN of) (NP (NN glucocorticoid) (NN metabolism)))) (PP (IN in) (NP (DT the) (NNS asthmatics))))) (, ,) (CC but) (S (NP-SBJ (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS asthmatics)))))) (VP (VBZ is) (ADJP-PRD (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS controls))))))))))) (. .)))
(TOP (S-4 (NP-SBJ (NP (DT The) (NN decrease)) (PP (IN of) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (NNS asthmatics)))))))) (PRN (, ,) (S (NP-SBJ (PRP we)) (VP (VBP think))) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ related) (PP (TO to) (NP-COOD (NP (NN heredity)) (CC and) (NP (NP (VBN repeated) (NNS attacks)) (PP (IN of) (NP (NN asthma)))))))) (. .)))
(TOP (NP (NP (NP (JJ Alternate) (JJ immune) (NN system) (VBZ targets)) (PP (IN for) (NP (NN TCDD))) (: :)) (NP-COOD (NP (NN lymphocyte) (NN stem) (NNS cells)) (CC and) (NP (JJ extrathymic) (NN T-cell) (NN development)) (. .))))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB here)) (VP (VBP summarize) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ-26 (NP (JJ thymic) (NN atrophy)) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (NN 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (PRN (-LRB- -LRB-) (NP (NN TCDD)) (-RRB- -RRB-)))))) (VP (MD can) (VP (VB be) (VP (VBN mediated) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN by) (NP-LGS (NP (NN damage)) (PP (TO to) (NP (NP (JJ extrathymic) (NN T-cell) (NNS precursors)) (PP (IN in) (NP-COOD (NP (NN bone) (NN marrow)) (CC and) (NP (JJ fetal) (NN liver))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN atrophy) (NN induction)) (VP (VBZ does) (RB not) (VP (VB involve) (NP (NP (JJ apoptotic) (NNS mechanisms)) (PP (IN in) (NP (NP (NNS thymocytes)) (VP (VBN affected) (PP (IN by) (NP-LGS (DT the) (NN bcl-2) (NN proto-oncogene))))))))) (. .)))
(TOP (S (NP-SBJ (NN TCDD)) (VP (VBZ mediates) (NP (NN atrophy) (NN induction)) (PP-COOD (PP (IN through) (NP (NP (PRP$ its) (JJ specific) (NN receptor)) (PRN (-LRB- -LRB-) (NP (DT the) (NN AhR)) (-RRB- -RRB-)))) (CC and) (PP (RB not) (IN through) (NP (NP (NNS effects)) (PP (IN on) (NP (DT the) (NN estrogen) (NN receptor))))))) (. .)))
(TOP (S (NP-SBJ-COOD (CC Both) (NP (NN TCDD)) (CC and) (NP (NN estradiol))) (VP (VBP induce) (NP (NP (JJ extrathymic) (NN T-cell) (NN differentiation)) (PP (IN in) (NP (DT the) (NN liver))))) (. .)))
(TOP (S (NP-SBJ (DT These) (JJ extrathymic) (NN T-cell) (NNS populations)) (VP (VBP include) (NP (NP (NNS cells)) (VP (VBG expressing) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NP (NN V) (NN beta) (NN T-cell) (NNS receptors)) (SBAR (WHNP-27 (WDT that)) (S (VP (VBP are) (VP (ADVP (RB normally)) (VBN deleted) (PP (IN in) (NP (JJ thymic) (NN development))))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NP (NN Alteration)) (PP (IN of) (NP (NP (JJ structural) (NN order)) (PP (IN of) (NP (JJ human) (NN erythrocyte) (NN ghost) (NN membrane))))) (PP (IN by) (NP (NNS glucocorticoids)))) (CC and) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (DT the) (NN glucocorticoid) (NN receptor) (NN antagonist) (NN RU) (CD 486))))) (. .)))
(TOP (S (NP-SBJ-18 (JJ High-dose) (NN pulse) (NN glucocorticoid) (NN therapy)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB successfully)) (PP (IN in) (NP (DT the) (NN clinic))) (PP (IN in) (NP (JJ severe) (JJ pathological) (NNS conditions))) (PP-TMP (IN for) (NP (QP (RB about) (CD 20)) (NNS years)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN mode)) (PP (IN of) (NP (NN glucocorticoid) (NN action))) (PP-TMP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (JJ such) (NNS megadoses)))))) (VP (VBZ is) (ADJP-PRD (JJ inexplicable)) (PP-TMP (RP up) (TO to) (NP (RB now)))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN supposed) (SBAR (IN that) (S (NP-SBJ (DT some) (NNS effects)) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (NN membrane) (NNS alterations))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (ADJP (FW in-vitro)) (NNS experiments))) (NP-SBJ-19 (NP (DT the) (NN effect)) (PP-COOD (PP (IN of) (NP (NN dexamethasone))) (, ,) (PP (IN of) (NP (JJ further) (NNS glucocorticoids))) (, ,) (CC and) (PP (IN of) (NP (DT the) (NN glucocorticoid) (NN receptor) (NN antagonist) (NN RU) (CD 486)))) (, ,) (PP (IN on) (NP (NP (JJ structural) (NN order)) (PP (IN of) (NP (JJ human) (NN erythrocyte) (NN ghost) (NNS membranes)))))) (VP (VBD was) (VP (VBN investigated) (PP (IN by) (S (VP (VBG determining) (NP (NP (DT the) (JJ steady-state) (NN fluorescence) (NN anisotropy)) (PP (IN of) (NP (NP (NN diphenylhexatriene)) (PRN (-LRB- -LRB-) (NP (NN DPH)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ-20 (NN Dexamethasone)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB induce) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NN membrane) (JJ structural) (NN order)))) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (QP (RB about) (CD 10-LRB--6-RRB-)) (NN M))))) (PP (IN in) (NP (DT a) (JJ concentration-dependent) (NN manner)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD found) (NP (NP (DT a) (NN correlation)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN uptake)) (PP (IN of) (NP (NN dexamethasone))) (PP (IN by) (NP (DT the) (NN ghost) (NNS membranes)))) (CC and) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (DT the) (JJ structural) (NN order)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (DT The) (JJ other) (NNS glucocorticoids)) (VP (VBN tested))) (, ,) (NP-COOD (NP (NN methylprednisolone)) (CC and) (NP (NN corticosterone))) (, ,)) (VP (VBD were) (ADVP (RB also)) (ADJP-PRD (JJ effective)) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (CD 10-LRB--5-RRB-) (NN M) (QP (CC or) (JJR greater))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD observed) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NN membrane) (JJ structural) (NN order))) (PP (IN with) (NP (NP (NN RU) (CD 486)) (PP (IN up) (TO to) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (CD 10-LRB--4-RRB-) (NN M))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (JJ simultaneous) (NN incubation)) (PP (IN of) (NP (NN RU) (CD 486))) (PP (IN with) (NP (NN dexamethasone)))) (VP (VBD caused) (NP (NP (DT a) (JJ distinct) (NN interference)) (PP (IN of) (NP (NN RU) (CD 486))) (PP (IN with) (NP (NN dexamethasone))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-COOD (NP (DT the) (JJ glucocorticoid-induced) (NN membrane) (NN perturbation)) (, ,) (NP (DT the) (NN possibility) (S (VP (TO to) (VP (VB inhibit) (NP (PRP it)) (PP (IN by) (NP (NN RU) (CD 486))))))) (, ,) (CC and) (NP (NP (DT the) (NN inactivity)) (PP (IN of) (NP (DT the) (ADJP (RB structurally) (JJ related)) (NN progesterone)))) (, ,)) (VP (VBP refer) (PP (TO to) (NP (NP (ADJP (RB relatively) (JJ specific)) (VBG binding) (NNS sites)) (PP (IN for) (NP (DT the) (NNS glucocorticoids))) (PP (IN in) (NP (NP (DT the) (NN membrane)) (PP (IN of) (NP (NN erythrocyte) (NNS ghosts)))))))) (. .)))
(TOP (NP (NP (NP-COOD (NP (NN Cloning)) (CC and) (NP (NN characterization))) (PP (IN of) (NP-COOD (NP (NN NF-ATc)) (CC and) (NP (NN NF-ATp)))) (: :)) (NP (NP (DT the) (JJ cytoplasmic) (NNS components)) (PP (IN of) (NP (NN NF-AT))) (. .))))
(TOP (S (NP-SBJ (JJ Present) (NN evidence)) (VP (VBZ indicates) (NP (NP (DT a) (NN pathway)) (PP (IN of) (NP (NN signal) (NN transmission))) (PP (IN in) (NP (NN T) (NNS cells))) (SBAR (WHNP-34 (WDT that)) (S (VP (VBZ is) (VP (VBN outlined) (PP (IN in) (NP (NN figure) (CD 1))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN elevation)) (PP (IN in) (NP (JJ intracellular) (NN calcium))) (SBAR (WHNP-36 (WDT that)) (S (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (NNS interactions)) (PP (IN at) (NP (DT the) (NN antigen) (NN receptor)))))))))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (JJ calcium-dependent) (NN phosphatase) (NN calcineurin)))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (PP (IN in) (NP (NN turn))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT the) (JJ nuclear) (NN association)) (PP (IN of) (NP (NP (DT the) (JJ cytosolic) (NN component)) (PP (IN of) (NP (NN NF-ATc)))))))) (. .)))
(TOP (S (NP-SBJ-COOD-38 (NP (NP (DT The) (NN activation)) (PP (IN of) (NP (NN calcineurin)))) (CC and) (NP (NP (DT the) (JJ nuclear) (NN import)) (PP (IN of) (NP (NN NF-ATc))))) (VP (MD can) (ADVP (DT both)) (VP (VB be) (VP (VBN blocked) (PP (IN by) (NP (NP-LGS-COOD (NP (NN cyclosporin) (NN A)) (CC or) (NP (NN FK506))) (PP (IN in) (NP (NP (NN complex)) (PP (IN with) (NP (PRP$ their) (JJ respective) (NNS immunophilins)))))))))) (. .)))
(TOP (S (SBAR (RB Once) (S (PP-PRD (IN in) (NP (DT the) (NN nucleus))))) (, ,) (NP-SBJ-39 (NN NF-ATc)) (VP (VBZ interacts) (PP (IN with) (NP (NN NF-ATn))) (S (VP (TO to) (VP (VB form) (NP (DT an) (JJ active) (JJ transcriptional) (NN complex)))))) (. .)))
(TOP (S (NP-SBJ-40 (NN NF-ATn)) (VP-COOD (VP (VBZ is) (NP-PRD (DT a) (JJ ubiquitous) (NN protein))) (, ,) (VP (MD can) (VP (VB be) (VP (VBN synthesized) (PP (IN in) (NN response) (TO to) (NP (NN PMA)))))) (, ,) (CC and) (VP (VBZ has) (NP (NP (JJ many) (NNS similarities)) (PP (TO to) (NP (NN AP-1)))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (NN mechanism)) (SBAR (WHPP-41 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NN NF-ATc)) (VP (VBZ enters) (NP (DT the) (NN nucleus)))))) (VP (VBZ is) (ADJP-PRD (JJ unknown)))) (, ,) (CC and) (S (SBAR (IN although) (S (NP-SBJ-42 (PRP it)) (VP (VBZ appears) (S (VP (TO to) (VP (VB require) (NP (NN calcineurin)))))))) (, ,) (NP-SBJ-43 (NN NF-ATc)) (VP (VBZ has) (RB not) (ADVP-TMP (RB yet)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (NP-PRD (NP (DT an) (ADJP (FW in) (FW vivo)) (NN substrate)) (PP (IN of) (NP (NN calcineurin))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Alternative) (NNS mechanisms)) (VP (VBP include) (NP (DT the) (NN possibility) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NN NF-ATc)) (VP (VBZ operates) (PP (IN on) (NP (DT some) (JJ cytoplasmic) (NN anchor)))))) (CC or) (SBAR (IN that) (S (NP-SBJ (NP (JJ other) (NNS proteins)) (SBAR (WHNP-44 (WDT that)) (S (VP (VBP are) (VP (VBN controlled) (PP (IN by) (NP-LGS (NN calcineurin)))))))) (VP (VBP carry) (PRT (RP out)) (NP (NP (DT the) (JJ nuclear) (NN import)) (PP (IN of) (NP (NN NF-ATc)))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NN NF-ATp)) (VP (VBZ copurifies) (PP (IN with) (NP (NN NF-ATc)))))) (, ,) (NP-SBJ (EX there)) (VP (VBZ is) (ADVP-TMP (RB as) (RB yet)) (NP-PRD (NP (DT no) (NN understanding)) (PP (IN of) (SBAR (WHADVP-46 (WRB how)) (S (NP-SBJ (NN NF-ATp)) (VP (VBZ is) (VP (VBG functioning) (ADVP (FW in) (FW vivo))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Now) (SBAR (IN that) (S (NP-SBJ-47 (DT these) (NNS proteins)) (VP (VBP are) (VP-COOD (VP (VBN purified)) (CC and) (VP (VBN cloned))))))) (, ,) (NP-SBJ (DT the) (JJ major) (NNS goals)) (VP (MD will) (VP (VB be) (S-PRD (VP (TO to) (VP (VB understand) (NP (NP-COOD (NP (PRP$ their) (NN role)) (CC and) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (JJ other) (NN family) (NNS members))))) (PP (IN in) (NP (JJ thymic) (NN development))))))))) (. .)))
(TOP (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NP (NN triiodothyronine)) (PRN (-LRB- -LRB-) (NP (NN T3)) (-RRB- -RRB-))) (JJ mononuclear) (NN leukocyte) (NN receptor) (NNS kinetics))) (PP-TMP (IN after) (NP-COOD (NP (NN T3) (NN administration)) (CC and) (NP (JJ multiple) (JJ cold-air) (NNS exposures)))) (. .)))
(TOP (S (NP-SBJ (VBN Repeated) (JJ cold-air) (NNS exposures)) (VP (VBP increase) (NP (JJ human) (NP (NP (NN triiodothyronine)) (PRN (-LRB- -LRB-) (NP (CD T3)) (-RRB- -RRB-))) (NN plasma) (NN clearance) (NNS rates))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NN T3) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN NT3R)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT this) (NN condition))))))) (, ,) (NP-SBJ-36 (VBG binding) (NNS characteristics)) (VP (VBD were) (VP (VBN analyzed) (PP (IN in) (NP (JJ human) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NN MNL)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-37 (PRP we)) (VP (VBD supplemented) (NP (NP (CD one) (NN group)) (PP (IN of) (NP (NNS individuals)))) (PP (IN with) (NP (NP (DT a) (RB daily) (JJ oral) (NN replacement) (NN dose)) (PP (IN of) (NP (NN T3))))) (S (VP (TO to) (VP (VB isolate) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP-COOD (NP (NP (NN serum) (NN thyroxine)) (PRN (-LRB- -LRB-) (NP (NN T4)) (-RRB- -RRB-))) (CC and) (NP (NP (NN thyrotropin)) (PRN (-LRB- -LRB-) (NP (NN TSH)) (-RRB- -RRB-)))) (NNS levels))) (PP (IN on) (NP (NN receptor) (NNS kinetics)))))))) (. .)))
(TOP (S (NP-SBJ-38 (DT The) (NNS subjects)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ cold) (NN air)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS degrees) (NN C)) (-RRB- -RRB-)))) (ADVP (RB twice/d)) (, ,) (NP-TMP (CD 30) (NN min/exposure)) (, ,) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 80) (NNS exposures))))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (DT The) (JJ T3-) (NNS subjects)) (VP (VBD received) (NP (NP (NN placebo)) (PRN (-LRB- -LCB-) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 8)))) (-RRB- -RCB-))))) (CC and) (S (NP-SBJ (DT the) (ADJP (JJ T3+)) (NNS subjects)) (VP (VBD received) (NP (NP (CD T3)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN micrograms/d)) (-RRB- -RRB-)) (PRN (-LRB- -LCB-) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 8)))) (-RRB- -RCB-)))))) (PP (IN in) (NP (DT a) (JJ double-blind) (NN fashion))) (. .)))
(TOP (S (NP-SBJ-40 (JJ Mononuclear) (NNS leukocytes)) (VP (VBD were) (VP-COOD (VP (VBN isolated) (PP (IN from) (NP (JJ peripheral) (NN blood))) (SBAR-TMP-101 (IN before) (S (NP-SBJ-COOD (NP (DT the) (JJ cold) (NN exposure)) (CC and) (NP (NN drug) (NNS regimen))) (VP (VBD began))))) (, ,) (CC and) (RB then) (VP (PP-TMP=101 (IN after) (NP (QP (DT every) (CD 20)) (NNS exposures)))))) (. .)))
(TOP (S (NP-SBJ-41 (NP (DT The) (NP-COOD (NP (NP (NN dissociation) (NN constant)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-))) (CC and) (NP (NP (NN maximum) (NN binding) (NN capacity)) (PRN (-LRB- -LRB-) (NP (NN MBC)) (-RRB- -RRB-))))) (PP (IN of) (NP (DT the) (NN NT3R) (NNS values)))) (VP (VBD were) (VP (NN log) (VBN transformed) (S (VP (TO to) (VP (VB minimize) (NP (JJ between-subject) (NN variability))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ T3+) (NN group))) (, ,) (NP-SBJ-COOD (NP (NP (NN serum) (VBP total) (NN thyroxine)) (PRN (-LRB- -LRB-) (NP (NN TT4)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ free) (NN T4)) (PRN (-LRB- -LRB-) (NP (NN FT4)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN TSH))) (VP (VBD were) (ADJP-PRD (ADJP (NP (QP (RB approx) (CD 50)) (NN %)) (JJR lower)) (PP (IN than) (NP-COOD (CC both) (NP (JJ basal)) (CC and) (NP (NNS T3-values)))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (DT The) (NN log10Kd)) (VP (VBD increased) (NP (QP (CD 0.304) (CC +/-) (CD 0.139))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.04)))) (-RRB- -RRB-)))) (CC and) (S (NP-SBJ (DT the) (NN log10MBC)) (VP (VBD increased) (NP (QP (CD 0.49) (CC +/-) (CD 0.10))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.001)))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (JJ T3+) (NNS subjects))) (PP (VBN compared) (PP (TO to) (NP (NN baseline)))) (. .)))
(TOP (S (NP-SBJ (NP (DT This) (NN change)) (PP (IN in) (NP (NN MBC)))) (VP (VBZ represents) (NP-COOD (NP (NP (DT a) (CD 311) (NN %) (NN increase)) (PP (IN in) (NP (DT the) (NN MBC))) (PP (IN over) (NP (NN baseline)))) (CC and) (NP (NP (DT a) (JJ fivefold) (NN increase)) (PP (IN over) (NP (JJ placebo-treated) (NNS subjects)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ T3-) (NN group)) (VP (VBD showed) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NN MBC)))) (PP (IN over) (NP (DT the) (NN study)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP describe) (PP-TMP (IN for) (NP (DT the) (JJ first) (NN time))) (NP (NP (DT the) (JJ rapid) (NN modulation)) (PP (IN of) (NP (DT the) (NN NT3R))) (PP (IN in) (NN response) (TO to) (NP (NP (DT the) (JJ combined) (NN influence)) (PP (IN of) (NP-COOD (NP (JJ cold) (NN exposure)) (CC and) (NP (VBN reduced) (VBG circulating) (NP-COOD (NP (NN T4)) (CC and) (NP (NN TSH)))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NN BCL-6)) (CC and) (NP (NP (DT the) (JJ molecular) (NN pathogenesis)) (PP (IN of) (NP (NN B-cell) (NN lymphoma))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS results)) (VP (VBN presented))) (VP (VBP identify) (NP (NP (DT the) (JJ first) (JJ genetic) (NN lesion)) (VP (VBN associated) (PP (IN with) (NP (NP (NN DLCL)) (, ,) (NP (NP (DT the) (ADJP (RBS most) (RB clinically) (JJ relevant)) (NN form)) (PP (IN of) (NP (NN NHL))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (DT no) (NN proof))) (ADVP-TMP (RB yet)) (VP (VBZ exists) (PP-65 (IN of) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT these) (NNS lesions))) (PP (IN in) (NP (NN DLCL) (NN pathogenesis)))))))) (, ,) (NP-SBJ-COOD (NP (NP (DT the) (NN feature)) (PP (IN of) (NP (DT the) (NN BCL-6) (NN gene) (NN product)))) (, ,) (NP (NP (PRP$ its) (JJ specific) (NN pattern)) (PP (IN of) (NP (NN expression))) (PP (IN in) (NP (NN B) (NNS cells)))) (, ,) (CC and) (NP (NP (DT the) (NN clustering)) (PP (IN of) (NP (NNS lesions))) (VP (VBG disrupting) (NP (PRP$ its) (JJ regulatory) (NN domain))))) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NN deregulation)) (PP (IN of) (NP (NN BCL-6) (NN expression)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NN DLCL) (NN development)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (ADJP (RBR more) (JJ precise)) (NN definition)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN BCL-6))) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ normal)) (CC and) (ADJP (JJ neoplastic))) (NN B-cell) (NN development)))))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN goal)) (PP (IN of) (NP (NP (JJ ongoing) (NN study)) (PP (IN of) (NP (NP (JJ transgenic) (NNS mice)) (VP (VBN engineered) (S (VP-COOD (CC either) (VP (TO to) (VP (VB express) (NP (NN BCL-6)) (PP (IN under) (NP (JJ heterologous) (NNS promoters))))) (CC or) (VP (VBG lacking) (NP (NN BCL-6) (NN function)) (PP (JJ due) (TO to) (NP (VBN targeted) (NNS deletions))))))))))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (S (VP (VBG contributing) (PP (TO to) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NN DLCL) (NN pathogenesis)))))))) (, ,) (NP-SBJ-28 (NP (DT the) (NN identification)) (PP (IN of) (NP (NN BCL-6) (NNS lesions)))) (VP (MD may) (VP (VB have) (NP (JJ relevant) (JJ clinical) (NNS implications)))) (. .)))
(TOP (S (NP-SBJ (NN DLCL)) (VP (VBP represent) (NP (NP (DT a) (JJ heterogeneous) (NN group)) (PP (IN of) (NP (NP (NNS neoplasms)) (SBAR (WHNP-29 (WDT which)) (S (VP (VBP are) (VP (VBN treated) (ADVP (RB homogeneously)) (PP (IN despite) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (NP (QP (RB only) (CD 50)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBP experience) (NP (JJ long-term) (JJ disease-free) (NN survival)))))))))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Schneider)) (ADVP (FW et) (FW al.))) (NP-TMP (CD 1990))) (-RRB- -RRB-))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN fact) (SBAR (IN that) (S (NP-SBJ (NN BCL-6) (NNS rearrangements)) (VP (VBP identify) (NP (NP (ADJP (ADVP-COOD (ADVP (RB biologically)) (CC and) (ADVP (RB clinically))) (JJ distinct)) (NNS subsets)) (PP (IN of) (NP (NN DLCL)))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (DT these) (NNS lesions)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ useful)) (PP (IN as) (NP (NNS markers))) (PP (IN in) (NP (NP (NN selection)) (PP (IN of) (NP (JJ differential) (JJ therapeutic) (NNS strategies))) (PP (VBN based) (PP (IN on) (NP (JJ different) (NN risk) (NNS groups))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-31 (DT the) (NN BCL-6) (NNS rearrangements)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VP-COOD (VP (VB identify)) (CC and) (VP (VB monitor))) (NP-33 (DT the) (JJ malignant) (NN clone)) (PP (IN with) (NP (JJ sensitive) (JJ PCR-based) (NNS techniques))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ-35 (JJ clinical) (NN remission)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN fraction)) (PP (IN of) (NP (NN DLCL) (NNS cases)))))))))) (, ,) (NP-SBJ (DT these) (NNS markers)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (JJ critical) (NNS tools)) (PP (IN for) (NP-COOD (NP (NP (JJ sensitive) (NN monitoring)) (PP (IN of) (NP (JJ minimal) (JJ residual) (NN disease)))) (CC and) (NP (NP (JJ early) (NN diagnosis)) (PP (IN of) (NP (NN relapse)))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Gribben)) (ADVP (FW et) (FW al.))) (NP-TMP (CD 1993))) (-RRB- -RRB-)))) (. .)))
(TOP (NP (NP (JJ Selective) (NNS effects)) (PP (IN of) (NP (NN DNA) (NN damaging) (NNS agents))) (PP (IN on) (NP (NP (NN HIV) (JJ long) (JJ terminal) (NN repeat) (NN activation)) (CC and) (NP (NP (NN virus) (NN replication)) (ADVP (FW in) (FW vitro))))) (. .)))
(TOP (S (NP-SBJ (JJ Much) (NN attention)) (VP (VBZ has) (ADVP-TMP (RB recently)) (VP (VBN focused) (PP (IN on) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP-SBJ (NN UV) (NN light)) (VP (MD can) (VP (VB activate) (NP (NP (NP (DT the) (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN LTR) (NN activation)))) (VP (VBZ remains) (ADJP-PRD (JJ obscure))))) (, ,) (NP-SBJ (NP (JJ several) (NNS lines)) (PP (IN of) (NP (NN investigation)))) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN transcription) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))) (PP-TMP (VBG following) (NP (NP (NN signaling) (NNS events)) (ADJP (JJ related) (PP (TO to) (NP (VBN generalized) (NN DNA) (NN damage)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP present) (NP (NP (NNS data)) (VP (NN demonstrating) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NN HIV) (NN LTR) (NN activation)) (VP (VBZ is) (NP-PRD-COOD (RB not) (NP (NP (DT a) (JJ general) (NN consequence)) (PP (IN of) (NP (JJ cellular) (NN DNA) (NN damage)))) (, ,) (CONJP (CC but) (RB rather)) (NP (NP (DT a) (NN process)) (ADJP (JJ unique) (PP (TO to) (NP (JJ specific) (JJ genotoxic) (NNS stimuli))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (VBZ does) (ADVP (RB not) (RB necessarily)) (VP (VB depend) (PP (IN on) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (JJ several)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (MD can) (ADVP (RB significantly)) (VP (VP-COOD (VP (VB increase) (NP (NN HIV) (NN replication))) (CC and) (VP (VB accelerate) (NP (JJ CD4-positive) (NN lymphocyte) (NN cytotoxicity)))) (ADVP (FW in) (FW vitro))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (VP (VB have) (NP (JJ clinical) (NN significance)) (PP (TO to) (NP (NP (NN AIDS) (NNS patients)) (PP (IN with) (NP (NNS malignancies))) (SBAR (WHNP-81 (WP who)) (S (VP (VBP are) (VP (VBG undergoing) (NP-COOD (NP (NN radiotherapy)) (CC and) (NP (NN chemotherapy))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Characterization)) (CC and) (NP (NN purification))) (PP (IN of) (NP (NP (DT a) (NN protein) (NN kinase) (NN C) (NN substrate)) (PP (IN in) (NP (JJ human) (NN B) (NNS cells))))) (. .)))
(TOP (NP (NP (NN Identification)) (PP (IN as) (NP (NP (JJ lymphocyte-specific) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN LSP1)) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Incubation)) (PP (IN of) (NP (NP (NP (JJ B-chronic) (JJ lymphocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN B-CLL)) (-RRB- -RRB-))) (NNS cells))) (PP (IN with) (NP (NN phorbol) (NNS esters)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN phosphorylation)) (PP-COOD (PP (IN of) (NP (NP (CD two) (JJ major) (NN PKC) (NNS substrates)) (, ,) (NP-COOD (NP (NP (NN MARCKS)) (PRN (-LRB- -LRB-) (NP (ADJP-COOD (ADJP (VBN myristoylated)) (, ,) (ADJP (JJ alanine-rich))) (NN C) (NN kinase) (NN substrate)) (-RRB- -RRB-))) (CC and) (NP (NP (NN MRP)) (PRN (-LRB- -LRB-) (NP (JJ MARCKS-related) (NN protein)) (-RRB- -RRB-)))) (, ,))) (CC and) (PP (IN of) (NP (NP (DT a) (JJ third) (NN protein)) (, ,) (PP (IN with) (NP (NP (DT an) (JJ apparent) (NN m.w.)) (PP (IN of) (NP (CD 60,000))))) (SBAR (WHNP-69 (WDT that)) (S (VP (VBD was) (NP-PRD (DT the) (ADJP (RBS most) (JJ prominent)) (NN protein) (NN kinase) (NN C) (NN substrate)) (PP (IN in) (NP (DT these) (NNS cells)))))))))))) (. .)))
(TOP (S (NP-SBJ-70 (NN p60) (NN phosphorylation)) (VP-COOD (VP (VBD was) (ADJP-PRD (NP-COOD (NP (NN time)) (CC and) (NP (NN PMA) (NN dose))) (JJ dependent))) (, ,) (CC and) (VP (VBD was) (VP (VBN induced) (PP-COOD (PP (IN by) (NP-LGS (JJ cell-permeable) (NN diacylglycerol))) (, ,) (CC but) (PP (RB not) (IN by) (NP-LGS (JJ inactive) (NN phorbol) (NNS esters))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Two-dimensional) (JJ electrophoretic) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN protein) (NN phosphorylation) (NN pattern)) (PP (IN from) (NP (DT the) (NN B) (NN cell) (NN line) (NN CESS)))))) (VP (VBD demonstrated) (NP (NP (DT the) (NN identity)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN p60) (NN protein)) (VP (VBN expressed) (PP (IN in) (NP (DT this) (NN cell) (NN line))))) (CC and) (NP (NP (DT that)) (VP (VBN expressed) (PP (IN in) (NP (NN B-CLL) (NNS cells))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-71 (NN p60)) (VP (VBD was) (VP (VBN purified) (PP (IN from) (NP (NN CESS) (NNS cells)))))) (CC and) (S (NP-SBJ (NP (NN peptide) (NN microsequencing)) (PP (IN of) (NP (DT this) (NN protein)))) (VP (VBD revealed) (SBAR (IN that) (S-CLF (NP-SBJ (PRP it)) (VP (VBD was) (NP-PRD (NP (JJ lymphocyte-specific) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN LSP1)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP-72 (WDT that)) (S (VP (VBZ is) (ADVP (RB here)) (VP (VBN characterized) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ prominent)) (NN protein) (NN kinase) (NN C) (JJ substrate)) (PP (IN in) (NP (NN B) (NNS cells)))))))))))))) (. .)))
(TOP (NP (NP (JJ Differential) (NN regulation)) (PP (IN of) (NP (NN IL-6) (NN gene) (NP-COOD (NP (NN transcription)) (CC and) (NP (NN expression))))) (PP (IN by) (NP-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-10)))) (PP (IN in) (NP (JJ human) (JJ monocytic) (NN cell) (NNS lines))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-10))) (VP (VBP inhibit) (NP (NP (DT the) (NP-COOD (NP (NN cytokine) (NN production)) (CC and) (NP (NN mRNA) (NN expression)))) (PP (IN by) (NP (NNS monocytes/macrophages))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (JJ molecular) (NN mechanism)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (ADJP-COOD (ADJP (JJ transcriptional)) (CC or) (ADJP (JJ post-transcriptional))) (NN regulation)) (PP (IN of) (NP (NN IL-6) (NN gene) (NN expression))))) (PP (IN by) (NP-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-10)))))))))) (, ,) (NP-SBJ-45 (PRP we)) (VP (VBD studied) (NP (NP-COOD (NP (NN IL-6) (NN production)) (, ,) (NP (NP (NN expression) (NN level)) (PP (IN of) (NP (NN IL-6) (NN mRNA)))) (, ,) (NP (NN IL-6) (NN promoter) (NN activity)) (, ,) (NP (NP (JJ transcriptional) (NN activity)) (PP (IN of) (NP-COOD (NP (NN NF-kappaB)) (CC and) (NP (NN NF-IL-6))))) (, ,) (CC and) (NP (NN IL-6) (NN mRNA) (NN stability))) (PP (IN in) (NP (NP (NP (JJ human) (JJ monocytic) (NN cell) (NNS lines)) (, ,) (NP-COOD (NP (NN THP-1)) (CC and) (NP (NN U937))) (, ,)) (VP (VBN stimulated) (PP (IN by) (NP-LGS-COOD (NP (NN PMA)) (CC and) (NP (NN LPS)))) (PP (IN in) (NP (NP-COOD (NP (DT the) (NN absence)) (CC or) (NP (DT the) (NN presence))) (PP (IN of) (NP-COOD (NP (NN IL-4)) (CC or) (NP (NN IL-10))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-46 (CC Both) (NP (NN IL-4)) (CC and) (NP (NN IL-10))) (VP (VBD were) (VP (VBN seen) (S (VP (TO to) (VP (VB inhibit) (NP-COOD (NP (NN IL-6) (NN production)) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN IL-6) (NN mRNA))))) (PP (IN in) (NP (NP (DT both) (JJ monocytic) (NN cell) (NNS lines)) (VP (VBN studied))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN chloramphenicol) (NN acetyltransferase) (NNS assays))) (, ,) (S (VP (VBG utilizing) (NP (NP (DT the) (JJ transient) (NN transfection)) (PP (IN of) (NP (NP (DT a) (NN chloramphenicol) (NN acetyltransferase) (NN reporter) (NN plasmid)) (VP (VBG containing) (NP (DT the) (NN IL-6) (NN gene) (NN promoter)))))))) (, ,) (NP-SBJ-COOD (NP (NN IL-4)) (, ,) (CONJP (CC but) (RB not)) (NP (NN IL-10)) (, ,)) (VP (VBD suppressed) (NP (NP (DT the) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN IL-6) (NN gene) (NN promoter)) (VP (VBN stimulated) (PP (IN by) (NP-LGS-COOD (NP (NN PMA)) (CC and) (NP (NN LPS))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD showed) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN IL-4)) (, ,) (CONJP (CC but) (RB not)) (NP (NN IL-10)) (, ,)) (VP (VBD inhibited) (NP (JJ nuclear) (NN NF-kappaB) (NN activity))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-10))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NN NF-IL-6) (NN activity)))))))) (. .)))
(TOP (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP-SBJ (NN IL-10)) (VP (VBD enhanced) (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (NN IL-6) (NN mRNA)))) (PP (IN in) (NP (DT a) (NN mRNA) (NN stability) (NN assay)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-47 (NN IL-4)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (DT the) (NN IL-6) (NN gene)))) (PP (IN by) (S (VP (VBG affecting) (NP (NN NF-kappaB) (NN binding) (NN activity))))) (, ,) (SBAR (IN while) (S (NP-SBJ-48 (NN IL-10)) (VP (MD may) (VP (VB inhibit) (NP (DT the) (NN IL-6) (NN mRNA) (NNS levels)) (ADVP-TMP (RB post-transcriptionally)) (, ,) (PP (IN without) (S (VP (VBG suppressing) (NP (NN promoter) (NN activity)))))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-10))) (VP (VBP inhibit) (NP (NN IL-6) (NN production)) (PP (IN by) (NP (JJ different) (NNS mechanisms))) (PP (IN in) (NP (JJ human) (JJ monocytic) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (S (NP-SBJ (NN IL-13)) (VP (VBZ induces) (NP (NP-COOD (NP (NN phosphorylation)) (CC and) (NP (NN activation))) (PP (IN of) (NP (NN JAK2) (NN Janus) (NN kinase)))) (PP (IN in) (NP (JJ human) (NN colon) (NN carcinoma) (NN cell) (NNS lines)))) (: :)) (NP (NP (NNS similarities)) (PP (IN between) (NP (NP-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-13))) (NN signaling))) (. .))))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB recently)) (VP (VBN reported) (SBAR (IN that) (S (NP-SBJ (NN IL-13R)) (VP (MD may) (VP (VB share) (NP (DT a) (NN component)) (PP (IN with) (NP (NN IL-4R))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ-COOD (CC both) (NP (NN IL-4)) (CC and) (NP (NN IL-13))) (VP (VBP share) (NP (NP (NN signaling) (NNS events)) (PP (IN in) (NP (NP (JJ human) (NN colon) (NN carcinoma) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN HT-29)) (CC and) (NP (NN WiDr))) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (NN IL-13)) (VP (VBD caused) (NP (NP (JJ rapid) (NN phosphorylation)) (PP (IN of) (NP (NP (DT the) (QP (CD three) (IN out) (IN of) (CD four)) (NNS members)) (PP (IN of) (NP (DT the) (JJ known) (NP (NP (NP (NN Janus) (NN family)) (PP (IN of) (NP (NNS kinases)))) (PRN (-LRB- -LRB-) (NP (NNS JAKs)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-40 (NN JAK2) (NN kinase)) (VP (VBZ is) (ADVP-TMP (RB rapidly)) (VP (VP-COOD (VP (VBN phosphorylated)) (CC and) (VP (VBN activated))) (PP (IN in) (NN response) (TO to) (NP (NN IL-13)))))))) (. .)))
(TOP (S (PP-TPC-TMP-42 (IN Within) (NP (NP (CD 1) (NN min)) (PP (IN of) (NP (NN activation))))) (, ,) (NP-SBJ-41 (NN JAK2)) (VP-COOD (VP (VBD was) (VP (VBN phosphorylated))) (, ,) (CC and) (VP (VBD peaked) (PP-TMP (IN in) (NP (CD 10) (NN min))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NN IL-13)) (VP (VBD phosphorylated) (NP-COOD (NP-COOD (NP (NN insulin) (NN response) (NN substrate-1)) (, ,) (NP (NN IL-4R) (NN p140)) (, ,) (NP (NN JAK1)) (, ,) (CC and) (NP (NN Tyk2))) (, ,) (CONJP (CC but) (RB not)) (NP (NN JAK3) (NN kinase)))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN IL-4)) (ADVP (RB also)) (VP (VBD stimulated) (NP (QP (DT all) (CD three)) (NP-COOD (NP (NNS kinases)) (CC and) (NP (NNS substrates)))))) (, ,) (CC but) (S (PP (IN unlike) (FRAG (PP (IN in) (NP (JJ immune) (NNS cells))))) (, ,) (NP-SBJ (NN IL-4)) (VP (VBD did) (RB not) (VP (VB involve) (NP (NN JAK3) (NN activation)) (PP (IN for) (NP (NP (PRP$ its) (NN signaling)) (PP (IN in) (NP (NN colon) (NN cancer) (NN cell) (NNS lines)))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NN JAK2)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NN IL-4R) (NN p140))) (PP-TMP (PP-COOD (PP (IN before)) (CC and) (PP (IN after))) (NP-44 (NP (NN stimulation)) (PP (IN with) (NP (NN IL-13)))))) (. .)))
(TOP (S (NP-SBJ-COOD (CC Both) (NP (NN IL-13)) (CC and) (NP (NN IL-4))) (VP (VBD induced) (NP (NP (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NP (NN IL-4) (NN STAT)) (PRN (-LRB- -LRB-) (NP (NN STAT6)) (-RRB- -RRB-))) (CONJP (CC but) (RB not)) (NP-COOD (NP (NN STAT1)) (, ,) (NP (NN STAT3)) (, ,) (CC or) (NP (NN STAT5))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN 125I-IL-13)) (VP (VBD did) (RB not) (VP (VB bind) (PP (TO to) (NP (NN colon) (NN cancer) (NN cell) (NNS lines)))))) (, ,) (CC but) (S (NP-SBJ (JJ unlabeled) (NN IL-13)) (VP (VBD competed) (PP (IN for) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NN 125I-IL-4))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S-COOD (S (NP-SBJ (NN IL-13)) (VP (VBZ utilizes) (NP-COOD (NP (NN IL-4R)) (CC and) (NP (PRP$ its) (NN signaling) (NN pathway))))) (, ,) (CC and) (S (NP-SBJ (NN JAK2)) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN function)) (PP (IN of) (NP-COOD (NP (NN IL-4R)) (CC and) (NP (NN IL-13R)))) (PP (IN in) (NP (NN colon) (NN cancer) (NNS cells))))))))))) (. .)))
(TOP (NP (NP (NNS Effects)) (PP (IN of) (NP (NN interleukin-10))) (PP (IN on) (NP (NP (JJ human) (JJ peripheral) (NN blood) (JJ mononuclear) (NN cell) (NNS responses)) (PP (TO to) (NP-COOD (NP (NN Cryptococcus) (NNS neoformans)) (, ,) (NP (NN Candida) (NNS albicans)) (, ,) (CC and) (NP (NN lipopolysaccharide)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Deactivation)) (PP (IN of) (NP (JJ mononuclear) (NNS phagocytes)))) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ critical)) (S (VP (TO to) (VP (VB limit) (NP (DT the) (JJ inflammatory) (NN response)))))) (CC but) (VP (MD can) (VP (VB be) (ADJP-PRD (JJ detrimental)) (PP (IN in) (NP (NP (DT the) (NN face)) (PP (IN of) (NP (JJ progressive) (NN infection)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (VBG deactivating) (NN cytokine) (NP (NP (NN interleukin) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN IL-10)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (JJ human) (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NN cell)) (PRN (-LRB- -LRB-) (NP (NN PBMC)) (-RRB- -RRB-))) (NNS responses)) (PP (TO to) (NP-COOD (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))) (, ,) (NP (NN Cryptococcus) (NNS neoformans)) (, ,) (CC and) (NP (NN Candida) (NNS albicans)))))))) (. .)))
(TOP (S (NP-SBJ (NN IL-10)) (VP (VBD effected) (NP (NP (JJ dose-dependent) (NN inhibition)) (PP (IN of) (NP (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (NN release)) (PP (IN in) (NP (NP (NN PBMC)) (VP (VBN stimulated) (PP (IN by) (NP-LGS-COOD (NP (NN LPS)) (CC and) (NP (FW C.) (FW neoformans)))))))))) (, ,) (SBAR (IN with) (S-COOD (S (NP-SBJ-57 (JJ significant) (NN inhibition)) (VP (VBN seen) (PP (IN with) (NP (CD 0.1) (NN U/ml))))) (CC and) (S (NP-SBJ-58 (NP (QP (JJR greater) (IN than) (CD 90)) (NN %)) (NP (NN inhibition))) (VP (VBN noted) (PP (IN with) (NP (CD 10) (NN U/ml)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (RB even) (IN at) (NP (NNS doses) (NP (QP (RB as) (JJ high) (IN as) (CD 100)) (NN U/ml)))) (, ,) (NP-SBJ (NN IL-10)) (VP (VBD inhibited) (NP (NN TNF-alpha) (NN release)) (PP (IN in) (NN response) (TO to) (NP (FW C.) (FW albicans))) (NP (IN by) (NP (QP (RB only) (CD 50)) (NN %)))) (. .)))
(TOP (S (NP-SBJ (NN IL-10)) (ADVP (RB profoundly)) (VP (VBD inhibited) (NP (NP (NN release)) (PP (IN of) (NP (NN IL-1beta))) (PP (IN from) (NP (NP (NN PBMC)) (VP (VBN stimulated) (PP (IN by) (NP-LGS (QP (DT all) (CD three)) (NNS stimuli)))))))) (. .)))
(TOP (S (NP-SBJ-59 (NN TNF-alpha) (NN mRNA) (CC and) (NN release)) (VP (VBD was) (VP (VBN inhibited) (SBAR (RB even) (IN if) (S (NP-SBJ-60 (NN IL-10)) (VP (VBD was) (VP (VBN added) (PP-TMP (NP (QP (RP up) (TO to) (CD 8)) (NN h)) (IN after) (NP (JJ cryptococcal) (NN stimulation))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN inhibition)) (PP (IN of) (NP (NN IL-1) (NN beta) (NN mRNA)))) (VP-COOD (VP (VBD was) (PP-PRD (IN of) (NP (JJR lesser) (NN magnitude)))) (CC and) (VP (VBD occurred) (SBAR-TMP (WHADVP-61 (RB only) (WRB when)) (S (NP-SBJ-62 (NN IL-10)) (VP (VBD was) (VP (VBN added) (PP-TMP (IN within) (NP (NP (CD 2) (NN h)) (PP (IN of) (NP (JJ cryptococcal) (NN stimulation))))))))))) (. .)))
(TOP (S (NP-SBJ (NN IL-10)) (VP (VBD inhibited) (NP (NP (NN translocation)) (PP (IN of) (NP (NN NF-kappaB)))) (PP (IN in) (NN response) (TO to) (NP-COOD (NP (NN LPS)) (CONJP (CC but) (RB not)) (NP (DT the) (JJ fungal) (NNS stimuli))))) (. .)))
(TOP (S (NP-SBJ (DT All) (CD three) (NNS stimuli)) (VP (VBD induced) (NP (NP (NN IL-10) (NN production)) (PP (IN in) (NP (NN PBMC)))) (, ,) (SBAR (IN although) (S (NP-SBJ-63 (QP (IN over) (RB 10-fold) (JJR less)) (NN IL-10)) (VP (VBD was) (VP (VBN released) (PP (IN in) (NN response) (TO to) (NP (FW C.) (FW neoformans))) (PP (VBN compared) (PP (IN with) (NP-COOD (NP (NN LPS)) (CC and) (NP (NN C.) (NNS albicans)))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (SBAR (IN while) (S (NP-SBJ (NN IL-10)) (VP (VBZ has) (NP (VBG deactivating) (NNS effects)) (PP (IN on) (NP (NP (NN PBMC) (NNS responses)) (PP (TO to) (NP (QP (DT all) (CD three)) (NNS stimuli)))))))) (, ,) (NP-SBJ-64 (NP (JJ disparate) (ADJP-COOD (ADJP (NP (NN stimulus-))) (CC and) (ADJP (JJ response-specific))) (NNS patterns)) (PP (IN of) (NP (NN deactivation)))) (VP (VBP are) (VP (VBN seen))) (. .)))
(TOP (S (NP-SBJ-65 (NP (NN Inhibition)) (PP (IN by) (NP (NN IL-10))) (PP (IN of) (NP (JJ proinflammatory) (NN cytokine) (NN release)))) (VP (VBZ appears) (S (VP (TO to) (VP-COOD (VP (VB occur) (PP-TMP-66 (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN gene) (NN transcription))))) (PP-67 (IN for) (NP (NN TNF-alpha)))) (CC and) (VP (ADVP-TMP-COOD=66 (CC both) (ADVP (RB transcriptionally)) (CC and) (ADVP (RB posttranscriptionally))) (PP=67 (IN for) (NP (NN IL-1beta)))))))) (. .)))
(TOP (NP (NP (NN Activation)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))) (PP (IN in) (NP (DT a) (ADJP (NN cyclosporin) (JJ A-resistant)) (NN pathway))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (DT the) (JJ immunosuppressive) (NN drug) (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-)))))))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN inactivation)) (PP (IN of) (NP (DT the) (JJ Ca2+/calmodulin-dependent) (NN serine-threonine) (NN phosphatase) (NN calcineurin))) (PP (IN by) (NP (DT the) (JJ drug-immunophilin) (NN complex))))) (. .)))
(TOP (S (NP-SBJ-49 (JJ Inactive) (NN calcineurin)) (VP (VBZ is) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB activate) (NP (NP (NP (NP (DT the) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NFAT)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN transcription) (NN factor)) (VP (VBN required) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NP (NP (NN interleukin) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN gene))))))))))))) (. .)))
(TOP (S (NP-SBJ-50 (NP (NN IL-2) (NN production)) (PP (IN by) (NP (JJ CsA-treated) (NNS cells)))) (VP (VBZ is) (ADVP (RB therefore)) (VP (ADVP (RB dramatically)) (VBN reduced))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (ADVP (RB here)) (, ,) (ADVP (RB however)) (, ,) (SBAR (IN that) (S (S-COOD (S (NP-SBJ-51 (NN NFAT)) (VP (MD can) (VP (VB be) (VP (VBN activated))))) (, ,) (CC and) (S (NP-SBJ-52 (NP (JJ significant) (NNS levels)) (PP (IN of) (NP (NN IL-2)))) (VP (MD can) (VP (VB be) (VP (VBN produced)))))) (PP (IN by) (NP-LGS (DT the) (JJ CsA-resistant) (JJ CD28-signaling) (NN pathway)))))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (JJ transient) (NN transfection) (NNS assays))) (, ,) (NP-SBJ-53 (NP-COOD (CC both) (NP (JJ multicopy) (NN NFAT-)) (CC and) (NP (NN IL-2) (NN promoter-beta-galactosidase) (NN reporter) (NN gene))) (NP-54 (NNS constructs))) (VP (MD could) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP-LGS (NN phorbol) (NN 12-myristate) (NN 13-acetate) (-LRB- -LRB-) (NN PMA) (-RRB- -RRB-) (NN /alpha-CD28) (NN stimulation))))))) (, ,) (CC and) (S (NP-SBJ (DT this) (NN activation)) (VP (VBD was) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (NN CsA)))))) (. .)))
(TOP (S (NP-SBJ (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay)) (VP (VBD showed) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (DT a) (JJ CsA-resistant) (NN NFAT) (NN complex))) (PP (IN in) (NP (NP (DT the) (JJ nuclear) (NNS extracts)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NN T) (NNS cells)) (VP (VBN stimulated) (PP (IN with) (NP-COOD (NP (NN PMA)) (CC plus) (NP (NN alphaCD28))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Peripheral) (NN blood) (NN T) (NNS cells)) (VP (VBN stimulated) (PP (IN with) (NP (NN PMA/alphaCD28))))) (VP (VBD produced) (NP (NN IL-2)) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NN CsA)))) (. .)))
(TOP (S (ADVP (RB Collectively)) (, ,) (NP-SBJ (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (S-COOD (S (NP-SBJ-55 (NN NFAT)) (VP (MD can) (VP (VB be) (VP (VBN activated))))) (CC and) (S (NP-SBJ-56 (NN IL-2)) (VP (MD can) (VP (VB be) (VP (VBN produced)))))) (PP (IN in) (NP (DT a) (ADJP (NN calcineurin) (JJ independent)) (NN manner)))))) (. .)))
(TOP (S (NP-SBJ-28 (NP (JJ Age-related) (NNS decreases)) (PP (IN in) (NP (NP (NN IL-2) (NN production)) (PP (IN by) (NP (JJ human) (NN T) (NNS cells)))))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ impaired) (NN activation)) (PP (IN of) (NP (JJ nuclear) (JJ transcriptional) (NNS factors) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-AT))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-COOD (NP (JJ transcriptional) (NNS factors) (NN AP-1)) (CC and) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-)))) (VP (VBP are) (ADJP-PRD (JJ important)) (PP (IN for) (NP (NP (DT the) (JJ normal) (NN induction)) (PP (IN of) (NP (NN IL-2)))))))) (, ,) (NP-SBJ (NP (PRP it))) (VP (VBZ is) (ADJP-PRD (JJ unknown)) (SBAR-30 (IN if) (S (NP-SBJ-29 (NP (DT the) (JJ age-related) (NN decline)) (PP (IN in) (NP (NP (NN IL-2) (NN production)) (PP (IN by) (NP (VBN activated) (JJ human) (NN T) (NNS cells)))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NNS aberrancies)) (PP (IN in) (NP (JJ transcriptional) (JJ regulatory) (NNS proteins))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ current) (NNS studies))) (, ,) (NP-SBJ-31 (NP (NN IL-2) (NN production)) (PP (IN by) (NP (NP (NN T) (NNS cells)) (PP (IN from) (NP (ADJP-COOD (ADJP (JJ elderly) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN mean)) (NP-PRD (CD 78) (NNS years))) (-RRB- -RRB-))) (CC and) (ADJP (JJ young) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN mean)) (NP-PRD (CD 37) (NNS years))) (-RRB- -RRB-)))) (NNS humans)))))) (VP (VBD was) (VP (VBN measured) (PP (IN in) (NP (NP (NNS cultures)) (VP (VBN stimulated) (PP (IN with) (NP-COOD (NP (NN PHA)) (, ,) (NP-COOD (NP (NN PHA)) (CC plus) (NP (NN PMA))) (, ,) (NP-COOD (NP (VBN crosslinked) (JJ anti-CD3) (NN mAB) (NN OKT3)) (CC plus) (NP (NN PMA))) (, ,) (CC or) (NP-COOD (NP (NN PMA)) (CC plus) (NP (NN ionomycin)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-33 (NP (JJ Substantial) (NNS decreases)) (PP (IN of) (NP (NN IL-2) (NN production)))) (VP (VBD were) (VP (VBN observed) (PP (IN for) (NP (NP (NN cell) (NNS cultures)) (PP (IN from) (NP (QP (CD 7) (IN of) (CD 12)) (JJ elderly) (NNS individuals))))) (PP (IN in) (NN response) (TO to) (NP (DT the) (JJ different) (NNS stimuli)))))) (, ,) (IN whereas) (S (NP-SBJ (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NN IL-2)) (VP (VBN produced) (PP (IN by) (NP-LGS (NP (VBN stimulated) (NN T) (NNS cells)) (PP (IN from) (NP (JJ other) (JJ elderly) (NNS individuals))))))))) (VP (VBD were) (ADJP-PRD (JJ equivalent) (PP (TO to) (NP (NP (DT those)) (VP (VBN observed) (PP (IN for) (NP (NP (VBN stimulated) (NN T) (NNS cells)) (PP (IN of) (NP (JJ young) (NNS subjects))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Analyses)) (PP (IN of) (NP (JJ nuclear) (NNS extracts))) (PP (IN by) (NP (JJ electrophoretic) (NN DNA) (NN mobility) (NN shift) (NNS assays)))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-35 (NP (VBN decreased) (NN IL-2) (NN production)) (PP (IN by) (NP (NP (VBN stimulated) (NN T) (NNS cells)) (PP (IN of) (NP (JJ elderly) (NNS individuals)))))) (VP (VBD was) (ADVP (RB closely)) (VP (VBN associated) (PP (IN with) (NP (NP (NNS impairments)) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP-COOD (CC both) (NP (NN AP-1)) (CC and) (NP (NN NF-AT))))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN T) (NNS cells)) (PP (IN from) (NP (NP (JJ elderly) (NNS subjects)) (PP (IN with) (NP (NP (JJ normal) (NNS levels)) (PP (IN of) (NP (NN IL-2) (NN production)))))))) (VP (VBD exhibited) (NP (NP (JJ normal) (NN activation)) (PP (IN of) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-AT)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (NN competition) (NNS experiments)) (VP (VBG analyzing) (NP (NP (DT the) (JJ normal) (NNS components)) (PP (IN of) (NP (NN NF-AT)))))))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ age-related) (NNS reductions)) (PP (IN in) (NP (JJ stimulus-dependent) (NN NF-AT) (NNS complexes)))) (VP (VBD corresponded) (PP (TO to) (NP (NP (DT the) (ADJP (JJ slow) (VBG migrating)) (NNS complexes)) (SBAR (WHNP-36 (WDT that)) (S (VP (VBD were) (VP (VBN composed) (PP (IN of) (NP (NN c-Fos/c-Jun) (NN AP-1))))))))))))) (. .)))
(TOP (S (S (NP-SBJ-38 (NP (DT The) (ADJP-COOD (ADJP (JJ resting)) (CC and) (ADJP (JJ stimulated))) (NNS levels)) (PP (IN of) (NP (NN NF) (NN kappa) (NN B)))) (VP (VBD were) (VP (VBN reduced) (PP (IN in) (NP (NP (NN T) (NNS cells)) (PP (IN from) (NP (JJ certain) (JJ elderly) (NNS individuals))))))) (: ;)) (S (ADVP (RB however)) (, ,) (NP-SBJ (NP (NNS alterations)) (PP (IN of) (NP (NN NF) (NN kappa) (NN B)))) (VP (VBD did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NNS changes)) (PP (IN in) (NP (NN IL-2) (NN expression))))))) (. .))))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (DT these) (NNS results)) (VP-COOD (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-39 (NP (JJ age-related) (NNS impairments)) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-AT))))))) (VP (VBP are) (ADVP (RB closely)) (VP (VBN associated) (PP (IN with) (NP (NP (VBN decreased) (NN expression)) (PP (IN of) (NP (NN IL-2)))))))))) (CC and) (VP (ADVP (RB further)) (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NNS aberrancies)) (PP (IN in) (NP (DT the) (NN signaling) (NNS pathways))) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (ADJP (RB transcriptionally) (JJ active)) (NN c-Fos/c-Jun) (NN AP-1))))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ impaired) (NN activation)) (PP (IN of) (NP (NN NF-AT))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NP (NN Transcription) (NNS factors)) (PP (IN of) (NP (NP-COOD (NP (NN T)) (CC and) (NP (NN B))) (NNS lymphocytes)))) (: --) (NP (NP-COOD (NP (JJ basic) (NN research)) (CC and) (NP (JJ clinical) (NNS perspectives))) (PP (IN for) (NP (NN gastroenterology))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (NN Tissue) (JJ specific)) (NN regulation)) (PP (IN of) (NP (NN gene) (NN expression))) (PP (IN by) (NP (NN transcription) (NNS factors)))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ fascinating) (JJ new) (NN field)) (PP (IN in) (NP (JJ molecular) (NN immunology))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN review)) (VP (VBZ summarizes) (NP (NP (NNS data)) (PP (IN on) (NP (NP (JJ specific) (NN regulation)) (PP (IN of) (NP-COOD (NP (NNS promoters)) (CC and) (NP (NNS enhancers)))) (PP (IN by) (NP (NP (JJ nuclear) (JJ trans-acting) (NNS factors)) (PP (IN in) (NP (NNS lymphocytes))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-74 (NP (DT The) (JJ structural) (NNS classes)) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBP are) (VP (VBN described)))) (CC and) (S (NP-SBJ-75 (NP (JJ basic) (NNS methods)) (PP (IN for) (NP (NP-COOD (NP (NN detection)) (CC and) (NP (NN analysis))) (PP (IN of) (NP (NN transcription) (NNS factors)))))) (VP (VBP are) (VP (VBN detailed)))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-COOD-77 (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (JJ trans-acting) (NNS factors)) (PP (IN of) (NP (NP (NP-COOD (NP (NN T)) (CC and) (NP (NN B))) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (NP-COOD (NP (NN NF-kB)) (, ,) (NP (NN NF-AT)) (CC and) (NP (NN STAT))) (NNS families)) (-RRB- -RRB-))))) (CC and) (NP (PRP$ their) (JJ functional) (NN importance))) (VP (VBP are) (VP (VBN described))) (. .)))
(TOP (S (NP-SBJ-78 (NP (JJ Several) (NNS methods)) (PP (IN for) (NP (NP (JJ specific) (NN down-regulation)) (PP (IN of) (NP (NN transcription) (NNS factors)))))) (VP (VBP are) (VP (VBN shown) (NP (SBAR (WHNP-79 (IN that)) (S (VP (MD may) (VP (VB be) (ADJP-PRD (JJ relevant) (PP (TO to) (NP (NP (NN treatment)) (PP (IN of) (NP (JJ human) (NN disease))))))))))))) (. .)))
(TOP (S (NP-SBJ-80 (DT The) (NNS data)) (VP (VBP are) (VP (VBN discussed) (PP (IN with) (NN regard) (TO to) (NP (NP (PRP$ their) (JJ potential) (JJ clinical) (NN relevance)) (PP (IN for) (NP (NN gastroenterology))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Modulation)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN IFN-gamma) (NN receptor) (NN beta-chain)))))) (VP (VBZ controls) (NP (NP (NN responsiveness)) (PP (TO to) (NP (NN IFN-gamma))) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NN IFN-gamma)) (VP (VBZ has) (NP (NP (JJ potent) (ADJP-COOD (ADJP (JJ antiproliferative)) (CC and) (ADJP (JJ apoptotic))) (NNS effects))) (PP (IN in) (NP (NN T) (NNS cells))) (SBAR-14 (WHNP-15 (WDT that)) (S (VP (VBP are) (ADJP-PRD (JJ important)) (PP (IN in) (S (VP (VBG determining) (NP (NN T) (NN cell) (NP-COOD (NP (NN development)) (CC and) (NP (VBN polarized) (NN differentiation))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (NP (DT any) (NN event)) (SBAR (WHNP-16 (WDT that)) (S (VP (VBZ enables) (S (NP-SBJ (NN T) (NNS cells)) (VP (TO to) (VP (VB become) (ADJP-PRD (RBR less) (JJ responsive) (PP (TO to) (NP (SYM IFN-) (NN gamma))))))))))) (VP (MD may) (ADVP (RB potentially)) (VP (VB alter) (NP (NP (JJ immune) (NN responsiveness)) (PP (TO to) (NP (NN Ag)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN work))) (, ,) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS cells)) (SBAR (WHNP-17 (WDT that)) (S (VP (VBP are) (VP-COOD (VP (VBN stimulated) (PP (IN through) (NP (DT the) (NN TCR)))) (CC and) (VP (VBN expanded) (PP (IN with) (NP (NN IL-2))))))))) (VP (VBP are) (ADJP-PRD (JJ unresponsive) (PP (TO to) (NP (NN IFN-gamma)))) (, ,) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP-COOD (NP (NP (NN activation)) (PP (IN of) (NP-COOD (NP (NN jak) (NNS kinases)) (CC and) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN STAT1-LRB-alpha-RRB-)))))) (, ,) (NP (DT a) (NN signal) (NN transducer)) (CC and) (NP (NP (NN activator)) (PP (IN of) (NP (NN transcription))))))))))))))) (. .)))
(TOP (S (NP-SBJ-20 (DT This) (NN nonresponsiveness)) (VP (VBZ occurs) (PP (IN because) (IN of) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NP (DT the) (SYM beta-) (NN chain)) (PRN (-LRB- -LRB-) (NP (JJ accessory) (NN factor)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN IFN-gamma) (NN receptor))))))))) (, ,) (SBAR (IN while) (S (PP-TMP (IN at) (VP (DT the) (JJ same) (NN time))) (VP (VBG maintaining) (NP (NN IFN-gamma) (NN receptor) (NN alpha-chain) (NN expression)))))) (. .)))
(TOP (S (NP-SBJ-21 (NP (NN Expression)) (PP (IN of) (NP (DT the) (NN beta-chain)))) (VP (MD can) (VP (VB be) (VP (VBN restored) (PP (IN by) (NP-LGS-COOD (NP (JJ secondary) (NN TCR) (NN ligation)) (CC or) (NP (NN PMA) (NN treatment))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN T) (NN cell) (NNS blasts)) (VP (VBN treated) (PP (IN with) (NP (NNS PMA))))) (VP (VBP are) (ADVP-TMP (RB now)) (ADJP-PRD (JJ responsive) (PP (TO to) (NP (NN IFN-gamma))))) (. .)))
(TOP (S (S (SBAR-TMP (WHADVP-24 (WRB When)) (S (ADVP (RB freshly)) (VP (VBN isolated)))) (, ,) (NP-SBJ-22 (ADJP (ADJP (RB highly) (VBN enriched)) (PRN (-LRB- -LRB-) (NP (QP (JJR &gt;) (CD 98)) (NN %)) (-RRB- -RRB-))) (NN T) (NNS cells)) (VP (VBP are) (VP (VBN examined) (PP (IN for) (NP (NN IFN-gamma) (NN responsiveness))))) (: ;)) (S (NP-SBJ (DT these) (NNS cells)) (VP (MD can) (VP-COOD (VP (VB respond) (PP (TO to) (NP (NN IFN-gamma)))) (CC and) (VP (VB express) (NP (NN beta-chain))))) (. .))))
(TOP (S (ADVP (RB Therefore)) (, ,) (SBAR (IN as) (S (NP-SBJ (NN T) (NNS cells)) (VP (VBP progress) (PP (IN from) (NP (JJ primary) (NN TCR) (NN activation))) (PP (IN through) (NP (JJ IL-2-dependent) (NN proliferation))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (JJ secondary) (NN TCR) (NN stimulation)))))))) (, ,) (S-COOD (S (NP-SBJ (NP (PRP$ their) (NN responsiveness)) (PP (TO to) (NP (NN IFN-gamma)))) (VP (VBZ varies))) (, ,) (CC and) (S (NP-SBJ (DT this)) (VP (MD may) (VP (VB affect) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB participate) (PP (IN in) (NP (DT an) (JJ ongoing) (JJ immune) (NN response))))))))))) (. .)))
(TOP (S (NP-SBJ-73 (NP (JJ Recombinant) (NN NFAT1)) (PRN (-LRB- -LRB-) (NP (NN NFATp)) (-RRB- -RRB-))) (VP-COOD (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS (NN calcineurin))) (PP (IN in) (NP (NN T) (NNS cells))))) (CC and) (VP (VBZ mediates) (NP (NP (NN transcription)) (PP (IN of) (NP (JJ several) (NN cytokine) (NNS genes)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Transcription) (NNS factors)) (PP (IN of) (NP (DT the) (NN NFAT) (NN family)))) (VP (VBP play) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP-COOD (NP (NN cytokine) (NNS genes)) (CC and) (NP (JJ other) (NNS genes)))))) (PP-TMP (IN during) (NP (DT the) (JJ immune) (NN response)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN identified) (NP (NP (CD two) (JJ new) (NNS isoforms)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN factor) (NN NFAT1)) (-LRB- -LRB-) (VP (ADVP-TMP (RB previously)) (VBN termed) (S (NP-PRD (NN NFATp)))) (-RRB- -RRB-))) (SBAR (WHNP-74 (WDT that)) (S (VP (VBP are) (NP-PRD (NP (DT the) (JJ predominant) (NNS isoforms)) (VP (VBN expressed) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ murine)) (CC and) (ADJP (JJ human))) (NN T) (NNS cells))))))))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-75 (WRB When)) (S (VP (VBN expressed) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS cells)))))) (, ,) (S-COOD (S (NP-SBJ-76 (JJ recombinant) (NN NFAT1)) (VP (VBZ is) (VP (VBN regulated) (, ,) (SBAR (IN as) (S (VP (VBN expected)))) (, ,) (PP (IN by) (NP-LGS (DT the) (JJ calmodulin-dependent) (NN phosphatase) (NN calcineurin)))))) (, ,) (CC and) (S (NP-SBJ-81 (PRP$ its) (NN function)) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP-LGS (DT the) (JJ immunosuppressive) (NN agent) (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (S (NP-SBJ (NP (NN Transactivation)) (PP (IN by) (NP (JJ recombinant) (NN NFAT1))) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS cells)))) (VP (VBZ requires) (NP (NP (JJ dual) (NN stimulation)) (PP (IN with) (NP-COOD (NP (NN ionomycin)) (CC and) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)))))) (: ;)) (S (NP-SBJ-82 (DT this) (NN activity)) (VP-COOD (VP (VBZ is) (VP (VBN potentiated) (PP (IN by) (NP-LGS (NP (NN coexpression)) (PP (IN of) (NP (ADJP (RB constitutively) (JJ active)) (NN calcineurin))))))) (CC and) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP-LGS (NN CsA)))))) (. .))))
(TOP (S (NP-SBJ (JJ Immunocytochemical) (NN analysis)) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ (JJ recombinant) (NN NFAT1)) (VP-COOD (VP (VBZ localizes) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (ADJP (RB transiently) (VBN transfected)) (NN T) (NNS cells)))))) (CC and) (VP (VBZ translocates) (PP (IN into) (NP (DT the) (NN nucleus))) (PP (IN in) (NP (DT a) (JJ CsA-sensitive) (NN manner))) (PP-TMP (VBG following) (NP (NN ionomycin) (NN stimulation)))))))) (. .)))
(TOP (S (S (SBAR-TMP (WHADVP-84 (WRB When)) (S (VP (VBN expressed) (PP (IN in) (NP (NN COS) (NNS cells)))))) (, ,) (ADVP (RB however)) (, ,) (S-COOD (S (NP-SBJ-85 (NN NFAT1)) (VP (VBZ is) (ADJP-PRD (JJ capable) (PP (IN of) (NP (NN transactivation)))))) (, ,) (CC but) (S (NP-SBJ-87 (PRP it)) (VP (VBZ is) (RB not) (VP (VBN regulated) (ADVP (RB correctly)))))) (: :)) (S (NP-SBJ-88 (PRP$ its) (NP-COOD (NP (JJ subcellular) (NN localization)) (CC and) (NP (JJ transcriptional) (NN function)))) (VP (VBP are) (RB not) (VP (VBN affected) (PP (IN by) (NP-LGS (NP (NN stimulation)) (PP (IN of) (NP (DT the) (NN COS) (NNS cells))) (PP (IN with) (NP-COOD (NP (NN ionomycin)) (CC and) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)))))))) (. .))))
(TOP (S (NP-SBJ (JJ Recombinant) (NN NFAT1)) (VP (MD can) (VP (VB mediate) (NP (NP (NN transcription)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN interleukin-2)) (, ,) (NP (NN interleukin-4)) (, ,) (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (, ,) (CC and) (NP (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor))) (NNS promoters))) (PP (IN in) (NP (NN T) (NNS cells)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN NFAT1)) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ CsA-sensitive) (NN transcription)) (PP (IN of) (NP (DT these) (NNS genes))) (PP-TMP (IN during) (NP (DT the) (JJ immune) (NN response)))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ Epstein-Barr) (NN virus) (JJ nuclear) (NN antigen) (CD 2)) (CC and) (NP (JJ latent) (NN membrane) (NN protein))) (ADVP (RB independently)) (VP (VBP transactivate) (NP (NN p53)) (PP (IN through) (NP (NP (NN induction)) (PP (IN of) (NP (NN NF-kappaB) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN B-cell) (NN immortalization)) (PP (IN by) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NP (JJ permanent) (NN control)) (PP (IN of) (NP (NP (DT the) (JJ cellular) (NNS processes)) (SBAR (WHNP-61 (WDT which)) (S (VP (ADVP (RB normally)) (VB regulate) (NP (NP (NN cell) (NP-COOD (NP (NN division)) (CC and) (NP (NN apoptosis)))) (, ,) (NP (NP (NNS functions)) (VP (VBN possessed) (PP (IN by) (NP-LGS (NN p53))) (PP (IN in) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ normal) (NN cell) (NNS types))))))))))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (NP (NNS studies)) (VP (VBN initiated) (S (VP (TO to) (VP (VB evaluate) (NP (NP (NNS relationships)) (PP (IN between) (NP-COOD (NP (NN EBV) (JJ latent) (NNS genes)) (CC and) (NP (NN p53))))))))))) (, ,) (NP-SBJ-62 (NN p53) (NNS levels)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB increase) (ADVP (RB approximately) (RB 10-fold)) (PP-TMP (NP (QP (CD 4) (TO to) (CD 5)) (NNS days)) (IN after) (NP (NP (NN EBV) (NN infection)) (PP (IN of) (NP (VBN purified) (VBG resting) (JJ human) (NN B) (NNS cells)))))))))) (: ;)) (S (NP-SBJ (DT the) (VBN induced) (NN p53)) (VP (VBD was) (ADVP (RB transcriptionally)) (ADJP-PRD (JJ active))) (. .))))
(TOP (S (S-COOD (S (NP-SBJ (JJ Latent) (NN membrane) (NN protein) (CD 1))) (CC and) (S (, ,) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))) (, ,) (NP-SBJ (NN EBV) (JJ nuclear) (NN antigen) (CD 2)))) (VP-102 (VBD mediated) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN p53) (NNS levels)))) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN NF-kappaB) (NN transcription) (NN factor)))))) (. .)))
(TOP (NP (NP (JJ Differential) (NN utilization)) (PP (IN of) (NP (NP (ADJP (NN Janus) (JJ kinase-signal) (NN transducer)) (NN activator)) (PP (IN of) (NP (NP (NN transcription) (NN signaling) (NNS pathways)) (PP (IN in) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (JJ human) (JJ natural) (NN killer) (NNS cells))) (PP (IN by) (NP-COOD (NP (NN IL-2)) (, ,) (NP (NN IL-12)) (, ,) (CC and) (NP (NN IFN-alpha)))))))))) (. .)))
(TOP (S (NP-SBJ-73 (ADJP-COOD (ADJP (NP (NN IL-2-))) (, ,) (ADJP (NP (NN IL-12-))) (, ,) (CC and) (ADJP (JJ IFN-alpha-mediated))) (NN signaling) (NNS pathways)) (VP (VBD were) (VP (VBN analyzed) (PP-COOD (PP (IN in) (NP (JJ primary) (NN NK) (NNS cells))) (CC and) (PP (IN in) (NP (DT the) (NN NK3.3) (NN cell) (NN line)))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NN Gel) (NN mobility) (NN shift)) (CC and) (NP (NN immunoprecipitation))) (NNS analyses)) (VP (VBD revealed) (SBAR (IN that) (S (PP (IN in) (NN addition) (TO to) (S (VP (VBG activating) (NP-COOD (NP (NP (NN STAT3)) (PRN (-LRB- -LRB-) (NP (NP-COOD (NP (NN signal) (NN transducer)) (CC and) (NP (NN activator))) (PP (IN of) (NP (NN transcription-3)))) (-RRB- -RRB-))) (CC and) (NP (NN STAT5)))))) (, ,) (NP-SBJ-74 (NN IL-2)) (VP (VBD induced) (NP (NP (NP-COOD (NP (NN tyrosine)) (CC and) (NP (NN serine))) (NN phosphorylation)) (PP (IN of) (NP (NN STAT1) (NN alpha))) (, ,) (SBAR (WHNP-75 (WDT which)) (S (VP (VBD formed) (NP (JJ IFN-gamma-activated) (NN sequence-binding) (NNS complexes)) (PP-COOD (PP (IN by) (NP (PRP itself))) (CC and) (PP (IN with) (NP (NN STAT3)))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-COOD (NP (NN IL-2)) (CC and) (NP (NN IFN-alpha))) (VP (VBD activated) (NP-COOD (NP (NN STAT1) (NN alpha)) (CC and) (NP (NN STAT5)))))) (, ,) (NP-SBJ (NN IL-2)) (ADVP (RB predominantly)) (VP (VBN activated) (NP (NN STAT5)) (, ,) (SBAR (IN while) (S (NP-SBJ (NN IFN-alpha)) (ADVP (RB predominantly)) (VP (VBD activated) (NP (NN STAT1) (NN alpha)))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (NN IL-2)) (VP (VBD induced) (NP (RBR less) (NN STAT1) (NN alpha) (NN activation)))) (CC and) (S (NP-SBJ (NN IFN-alpha)) (VP (VBD induced) (NP (NP (JJR greater) (NN STAT5) (NN activation)))))) (PP (IN in) (NP (NN NK3.3) (NNS cells))) (PP (VBN compared) (PP (IN with) (NP (JJ preactivated) (JJ primary) (NN NK) (NNS cells)))) (. .)))
(TOP (S (PP (IN In) (NP (NN NK3.3) (NNS cells))) (, ,) (NP-SBJ (NN IL-2)) (VP (VBD induced) (NP (NP (JJ comparable) (NN formation)) (PP (IN of) (NP (NP (ADJP (NN c-fos) (NN promoter) (JJ sis-inducible) (NN element) (JJ IFN-gamma-activated) (NN sequence-binding)) (NNS complexes)) (VP (VBG containing) (NP (NP (NN STAT3)) (ADVP (RB alone)))))) (PP (IN with) (NP (NP (NNS complexes)) (VP (VBG containing) (NP-COOD (NP (NN STAT3)) (CC and) (NP (NN STAT1) (NN alpha))))))) (, ,) (SBAR (IN while) (S (PP (IN in) (NP (JJ preactivated) (JJ primary) (NN NK) (NNS cells))) (, ,) (NP-SBJ (PRP it)) (ADVP (RB preferentially)) (VP (VBD induced) (NP (NP (NNS complexes)) (VP (VBG containing) (NP-COOD (NP (NN STAT3)) (CC and) (NP (NN STAT1) (NN alpha))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (NN signaling)) (PP (IN in) (NP (NN NK3.3) (NNS cells)))) (VP (VBZ is) (RB not) (ADVP-TMP (RB always)) (ADJP-PRD (JJ identical) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (JJ primary) (NN NK) (NNS cells))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IFN-alpha)))) (, ,) (NP-SBJ (NN IL-12)) (VP (VBD induced) (NP-COOD (NP (NP (JJ strong) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN STAT4)))) (CC and) (NP (NP (JJ variable) (JJ weak) (NN phosphorylation)) (PP (IN of) (NP (NN STAT3)))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (NN supershift) (NNS analyses)) (VP (VBG using) (NP (DT the) (NN c-fos) (NN promoter) (JJ sis-inducible) (NN element) (NN probe)))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NN IL-12)) (VP (VP-COOD (VP (VBD activated) (NP-COOD (NP (NN STAT4)) (, ,) (NP (NN STAT1) (NN alpha)) (, ,) (CC and) (NP (NN STAT3)))) (, ,) (CC and) (VP (VBD induced) (NP (NP (NNS complexes)) (VP (VBG containing) (NP (NP (NP (NN STAT4)) (ADVP (RB only))) (, ,) (NP (NP (NN STAT4)) (PP (IN with) (NP (NN STAT1) (NN alpha)))) (, ,) (NP (NP (NN STAT3)) (PP (IN with) (NP (NN STAT1) (NN alpha)))) (, ,) (CC or) (NP (NP (NN STAT1) (NN alpha)) (ADVP (RB only)))))))) (PP (IN in) (NP (JJ preactivated) (JJ primary) (NN NK) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN STAT1) (NN alpha) (NN activation)) (PP (IN by) (NP (NN IL-12)))) (VP (VBD correlated) (PP (IN with) (NP (NP (VBN increased) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN serine)) (, ,) (CONJP (CC but) (RB not)) (NP (NN tyrosine))))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (NN IL-2)) (VP (VBD induced) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN JAK1)) (CC and) (NP (NN JAK3))))) (, ,) (SBAR (IN while) (S (NP-SBJ (NN IL-12)) (VP (VBD induced) (NP (NP (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN JAK2)) (CC and) (NP (NN TYK2)))))) (PP-101 (IN in) (NP (NP-COOD (CC both) (NP (JJ preactivated) (JJ primary) (NN NK)) (CC and) (NP (NN NK3.3))) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (JJ Differential) (NN phosphorylation)) (CC and) (NP (JJ consequent) (JJ differential) (NN activation))) (PP (IN of) (NP (ADJP-COOD (CC both) (ADJP (JJ separate)) (CC and) (ADJP (JJ overlapping))) (NN STAT) (NNS proteins))) (PP (IN by) (NP-COOD (NP (NN IL-2)) (, ,) (NP (NN IL-12)) (, ,) (CC and) (NP (NN IFN-alpha))))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ molecular) (NN basis)) (PP (IN for) (NP (NP (DT the) (NP-COOD (NP (NNS similarities)) (CC and) (NP (NNS differences)))) (PP (IN in) (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (DT these) (NNS cytokines))) (PP (IN on) (NP (NN NK) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Sublethal) (NNS levels)) (PP (IN of) (NP (JJ oxidative) (NN stress)))) (VP-COOD (VP (VBP stimulate) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NN c-jun))))) (CC and) (VP (VBP suppress) (NP (NP (NN IL-2) (NN promoter) (NN activation)) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS cells)))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-79 (NP (JJ Sublethal) (NNS levels)) (PP (IN of) (NP (JJ oxidative) (NN stress)))) (VP (VBP are) (VP (ADVP (RB well)) (VBN known) (S (VP (TO to) (VP (VB alter) (NP (NN T) (NN cell) (JJ functional) (NNS responses)))))))) (, ,) (CC but) (S (NP-SBJ (DT the) (JJ underlying) (NNS mechanisms)) (VP (VBP are) (ADJP-PRD (JJ unknown))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ current) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oxidative) (NN stress))) (PP (IN on) (NP (NP (JJ transcriptional) (NNS activities)) (VP (VBN mediated) (PP (IN by) (NP-LGS-COOD (NP (NN c-Fos/c-Jun) (NN AP-1)) (CC and) (NP (NP (NP (DT the) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ present) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NN Jurkat) (NN T) (NNS cells)) (VP (ADVP (RB acutely)) (VBN exposed) (PP (TO to) (NP (NP (JJ micromolar) (NNS concentrations)) (PP (IN of) (NP (NN H2O2))))))) (VP (VBP exhibit) (NP-COOD (NP (NP (JJ substantial) (NNS increases)) (PP (IN in) (NP (NN AP-1) (NN binding) (NN activity)))) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP-COOD (NP (NN c-jun)) (CONJP (CC but) (RB not)) (NP (NN c-fos))) (NN mRNA))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (JJ preferential) (NN induction)) (PP (IN of) (NP (NN c-jun))) (PP (IN by) (NP (NN H2O2)))) (VP (VBD did) (RB not) (VP (VB represent) (NP (NP (NN redox) (NN stabilization)) (PP (IN of) (NP (NN mRNA) (NNS transcripts))))))) (, ,) (CC and) (S (NP-SBJ-103 (JJ oxidative) (NNS signals)) (ADVP (RB closely)) (VP (VBD resembled) (NP (NN PHA/PMA) (NN stimulation)) (PP (IN by) (S (VP (ADVP (RB effectively)) (VBG transactivating) (NP (DT the) (JJ full) (NN length) (NN c-jun) (NN promoter)) (PP (IN via) (NP (DT the) (JJ proximal) (NN jun1) (ADJP (NP (ADJP (NN tumor) (JJ promoter-responsive)) (NN element)) (-LRB- -LRB-) (NN TRE) (-RRB- -RRB-) (JJ -like)) (NN promoter) (NN element)))))))) (. .)))
(TOP (S (ADVP (RB Similarly)) (, ,) (NP-SBJ-80 (NP (DT the) (NNS complexes)) (VP (VBG binding) (NP (NP-COOD (NP (DT the) (NN consensus) (NN AP-1) (NN TRE)) (CC and) (NP (NN jun) (JJ TRE-like) (NNS motifs))) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN exposed) (PP (TO to) (NP-COOD (NP (JJ oxidative) (NNS signals)) (CC or) (NP (NN PHA/PMA)))))))))) (VP (VBD were) (ADJP-PRD (JJ indistinguishable)) (, ,) (S (VP (VBG being) (VP (VBN composed) (PP (IN of) (NP-COOD (NP (NN c-Fos)) (, ,) (NP (NN c-Jun)) (, ,) (CC and) (NP (NN JunD)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (UCP-COOD (NP (NN PHA/PMA)) (CC but) (ADJP (RB not) (JJ oxidative))) (NNS signals)) (VP (VBD induced) (NP (DT the) (NP-COOD (NP (NP (JJ coordinate) (NN activation)) (PP (IN of) (NP (NP (NN reporter) (NNS constructs)) (VP (VBG containing) (NP (DT the) (NP-COOD (NP (NN AP-1-TRE)) (, ,) (NP (NN NF-AT)) (, ,) (CC and) (NP (NN IL-2))) (NN promoter) (NNS regions)))))) (CONJP (IN along) (IN with)) (NP (NN IL-2) (NN mRNA) (NN expression))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (JJ sublethal) (NNS levels)) (PP (IN of) (NP (NN H2O2)))) (ADVP (RB actively)) (VP (VBD suppressed) (NP-COOD (NP (NP (DT the) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NP-COOD (NP (NN NF-AT)) (CC and) (NP (NN IL-2))) (NNS reporters)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN IL-2) (NN mRNA))) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN stimulated) (PP (IN with) (NP (NN PHA/PMA))))))))) (. .)))
(TOP (S (NP-SBJ (NN Gel) (NN shift) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (NP (JJ oxidative) (NN suppression)) (PP (IN of) (NP (NN NF-AT)))) (VP (VBD represented) (NP (NP (NN inhibition)) (PP (IN in) (NP-COOD (NP (NP (DT the) (JJ early) (NN generation)) (PP (IN of) (NP (NN NFAT) (NNS complexes)))) (CONJP (RB rather) (IN than)) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (JJ preformed) (NN NF-AT) (NNS complexes))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (JJ oxidative) (NNS signals)) (VP (MD can) (ADVP-COOD (ADVP (RB positively)) (CC and) (ADVP (RB negatively))) (VP (VB regulate) (NP (NN T) (NN cell) (JJ transcriptional) (NNS events)))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NP (NNS changes)) (PP (IN in) (NP (JJ cellular) (NN redox)))) (VP (MD can) (VP (VB uncouple) (NP (NP (NN AP-1) (NN regulation)) (PP (IN of) (NP (NN c-jun)))) (PP (IN from) (NP (NP (JJ transcriptional) (NN up-regulation)) (PP (IN of) (NP (NN IL-2))) (PP (IN via) (NP (NN NF-AT))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NNS Glucocorticoids)) (CC and) (NP (NN interferon-alpha))) (PP (IN in) (NP (DT the) (VBN acquired) (NN immunodeficiency) (NN syndrome))) (. .)))
(TOP (S (NP-SBJ (NP (DT Some) (NNS patients)) (PP (IN with) (NP (NP (VBN acquired) (NN immunodeficiency) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN AIDS)) (-RRB- -RRB-))))) (VP (VBP develop) (NP (NP (NN glucocorticoid) (NN resistance)) (VP (VBN characterized) (PP (IN by) (NP-LGS-COOD (NP (NP (JJ low) (NP (NP (NN receptor) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-)))) (PP (IN for) (NP (NNS glucocorticoids))) (PP (IN in) (NP (JJ mononuclear) (, ,) (NNS cells)))) (CC and) (NP (NP (JJ high) (NNS values)) (PP (IN of) (NP-COOD (NP (NN ACTH)) (CC and) (NP (NN cortisol)))))))))) (. .)))
(TOP (S (SBAR (IN As) (S (NP-SBJ (NNS glucocorticoids)) (VP (VBP regulate) (NP (NP (NP (NN interferon-alpha)) (PRN (-LRB- -LRB-) (NP (NN IFN) (NN alpha)) (-RRB- -RRB-))) (NN production))))) (, ,) (NP-SBJ-54 (PRP we)) (VP (VBD hypothesized) (SBAR (IN that) (S (NP-SBJ-55 (NP (NN IFN) (NN alpha)) (, ,) (NP (NP (DT a) (NN cytokine)) (VP (VBN produced) (PP (RB predominantly) (IN by) (NP-LGS (NNS monocytes))) (PP (IN in) (NP (NN AIDS))))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN increased) (PP (IN in) (NP (JJ cortisol-resistant) (NN AIDS)))))))) (, ,) (S (VP (VBG attributing) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NN cortisol) (NN inhibition)))) (PP (TO to) (NP (NN IFN) (NN alpha) (NN production)))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP-COOD (VP (VBD examined) (NP (NP (NN glucocorticoid) (NN receptor) (NNS characteristics)) (PP (IN on) (NP (NNS monocytes)))) (PP (IN by) (NP (NN -LCB-3H-RCB-dexamethasone) (NN binding)))) (CC and) (VP (VBD measured) (NP (NP-COOD (NP (NN IFN) (NN alpha)) (, ,) (NP (NN cortisol)) (, ,) (CC and) (NP (NN ACTH))) (PP (IN in) (NP-COOD (NP (NP-COOD (NP (NP (NP (NN AIDS) (NNS patients)) (PP-57 (IN with))) (PRN-58 (-LRB- -LRB-) (NP (NN AIDS-GR)) (-RRB- -RRB-))) (CC or) (NP (PP=57 (IN without)))) (NP-56 (NN glucocorticoid) (NN resistance)) (PRN-59 (-LRB- -LRB-) (NP (NN AIDS-C)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN C)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Monocytes)) (PP (IN of) (NP (NN AIDS-GR) (NNS patients)))) (VP (VBD had) (NP (NP (DT a) (NN receptor) (NN Kd)) (PP (IN of) (NP (QP (CD 10.5) (CC +/-) (CD 4.2)) (NN nmol/L))) (SBAR (WHNP-60 (WDT that)) (S (VP (VBD was) (ADJP-PRD (ADJP (JJR higher)) (PP (IN than) (NP (NP-COOD (NP (NP (NP (DT that)) (PP (IN in) (NP-62 (DT the) (NN AIDS-C) (NN group)))) (-LRB- -LRB-) (NP-65 (QP (CD 2.9) (CC +/-) (CD 0.8)) (NN nmol/L)) (-RRB- -RRB-)) (CC and) (NP (NP=62 (JJ normal) (NNS subjects)) (-LRB- -LRB-) (NP=65 (QP (CD 2.0) (CC +/-) (CD 0.8)) (NN nmol/L)))) (: ;) (PRN (S (NP-SBJ (NN P)) (ADJP-PRD (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ-64 (NN IFN) (NN alpha) (NNS levels)) (VP (VBD were) (VP (VBN increased) (PP (IN in) (NP (DT the) (NN AIDS-GR) (NN group))) (PRN (-LRB- -LRB-) (NP-COOD (NP (QP (CD 17) (CC +/-) (CD 6))) (CC vs.) (NP-COOD (NP (NP (QP (CD 4) (CC +/-) (CD 1)) (NN U/mL)) (PP (IN in) (NP (DT the) (NN AIDS-C) (NN group)))) (CC and) (NP (NP (QP (CD 2) (CC +/-) (CD 0.5)) (NN U/mL)) (PP (IN in) (NP (DT the) (NN C) (NN group)))))) (: ;) (S (NP-SBJ (NN P)) (ADJP-PRD (JJR &lt;) (CD 0.01))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ-63 (NNS Correlations)) (VP (VBD were) (VP (VBN found) (PP-COOD (PP (IN between) (NP (NP-COOD (NP (NN plasma) (NN IFN) (NN alpha)) (CC and) (NP (NN receptor) (NN Kd))) (PP (IN on) (NP (NP (NNS monocytes)) (PP (IN of) (NP (NN AIDS-GR))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.77)))) (-RRB- -RRB-)))) (CC and) (PP (IN between) (NP (NP-COOD (NP (NN IFN) (NN alpha)) (CC and) (NP (NN plasma) (NN cortisol))) (PP (IN in) (NP (DT the) (JJ same) (NN group))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN r)) (VP (JJ =) (NP-PRD (CD 0.74)))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (S (NP-SBJ-66 (NP (DT The) (JJ poly-LRB-I-RRB--poly-LRB-C-RRB--induced) (NN IFN) (NN alpha) (NN production)) (PP (IN by) (NP (NNS monocytes)))) (VP (VBD was) (VP (VP (VBN inhibited) (PP (IN by) (NP-LGS (NNS glucocorticoids))) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN C)) (CC and) (NP (NN AIDS-C))) (NNS groups)))) (-LRB- -LRB-) (NP (NP (NP (QP (RB approximately) (CD 80)) (NN %)) (NP (NN inhibition))) (PP (IN in) (NP (DT both) (NNS groups)))) (-RRB- -RRB-))) (: ;)) (S (NP-SBJ-67 (DT the) (NN effect)) (VP (VBD was) (VP (VBN reversed) (PP (IN by) (NP-LGS (DT the) (NN receptor) (NN antagonist) (NN RU-38486))))) (. .))))
(TOP (S (PP (IN By) (NP (NN contrast))) (, ,) (NP-SBJ-68 (NNS glucocorticoids)) (VP (VBD failed) (S (VP (TO to) (VP (VP (VB inhibit) (NP (NP (NN IFNalpha) (NN production)) (PP (IN from) (NP (NN AIDS-GR) (NNS monocytes))))) (-LRB- -LRB-) (NP (NP (QP (RB approximately) (CD 20)) (NN %)) (NP (NN inhibition))) (-RRB- -RRB-))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP-SBJ (NP (JJ elevated) (NN IFN) (NN alpha) (NNS levels)) (PP (IN in) (NP (NN AIDS-GR)))) (VP (MD may) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NN cortisol))) (PP (IN on) (NP (NN IFN) (NN alpha) (NN production))))) (PP (IN due) (TO to) (NP (NP (JJ cortisol) (NN resistance)) (PP (IN in) (NP (NNS monocytes))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Cooperation)) (PP (IN between) (NP-COOD (NP (NN core) (NN binding) (NN factor)) (CC and) (NP (JJ adjacent) (NN promoter) (NNS elements))))) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ tissue-specific) (NN expression)) (PP (IN of) (NP (NN interleukin-3)))))) (. .)))
(TOP (S (NP-SBJ-1 (NP (JJ Tissue-specific) (NN expression)) (PP (IN of) (NP (NP (NN interleukin-3)) (PRN (-LRB- -LRB-) (NP (NN IL-3)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN mediated) (PP (IN via) (NP (NP (JJ cis-acting) (NNS elements)) (ADJP (JJ located) (PP (IN within) (NP (NP (CD 315) (NN base) (NNS pairs)) (PP (IN of) (NP (DT the) (NN transcription) (NN start)))))))))) (. .)))
(TOP (S (NP-SBJ-2 (DT This)) (VP (VBZ is) (VP (VBN achieved) (PP (PP (IN in) (NP (NN part))) (IN through) (NP (NP (DT the) (JJ positive) (NNS activities)) (PP (IN of) (NP (NP (DT the) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN Elf-1))) (NNS sites)) (PP (IN in) (NP (DT the) (NN IL-3) (NN promoter))))))))) (. .)))
(TOP (S (NP-SBJ-3 (NP (DT The) (NN contribution)) (PP (TO to) (NP (ADJP (NN T) (JJ cell-specific)) (NN expression))) (PP (IN by) (NP (JJ other) (NN promoter) (NNS sites)))) (VP (VBD was) (VP (VBN assessed) (PP (IN in) (NP (NP (DT a) (JJ transient) (NN expression) (NN assay)) (PP (IN with) (NP (NP (NN IL-3) (NN promoter) (NNS constructs)) (VP (VBN linked) (PP (TO to) (NP (DT a) (NN luciferase) (NN gene)))))))) (, ,) (S (VP (VBG focusing) (ADVP-TMP (RB initially)) (PP (IN on) (NP (NP (DT the) (NP (NP (NN core) (NN binding) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN CBF)) (-RRB- -RRB-))) (NN site)) (, ,) (SBAR (WHNP-5 (WDT which)) (S (VP (VBZ is) (VP (JJ footprinted) (ADVP (FW in) (FW vivo)) (PP-TMP (IN upon) (NP (NN T) (NN cell) (NN activation))))))))))))) (. .)))
(TOP (S (NP-SBJ-6 (NP (NN Activity)) (PP (IN of) (NP (DT the) (NN CBF) (NN site)))) (VP (VBZ is) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (RB critically) (JJ dependent) (PP (IN on) (NP (DT the) (JJ adjacent) (NN activator) (NN site) (CD Act-1))))))))) (. .)))
(TOP (S (ADVP (RB Together)) (NP-SBJ (DT the) (NP-COOD (NP (NN Act-1)) (CC and) (NP (NN CBF))) (NNS sites)) (VP (VBP form) (NP (NP (NP (DT a) (JJ functional) (NN unit)) (PRN (-LRB- -LRB-) (NP (NN AC) (NN unit)) (-RRB- -RRB-))) (PP (IN with) (NP (JJ dual) (NN activity))))) (. .)))
(TOP (S (NP-SBJ-7 (DT The) (NN AC) (NN unit)) (VP (VBZ is) (VP (VBN demonstrated) (S (VP (TO to) (NP (VB enhance) (NP (NP (JJ basal) (NN activity)) (PP (IN of) (NP (NNS promoters))) (PP (ADVP (CC both)) (IN in) (NP-COOD (NP (NNS fibroblasts)) (CC and) (NP (NN T) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN activity)) (VP (VBZ is) (ADJP-PRD (RB further) (JJ inducible)) (PP-COOD (PP (IN in) (NP (VBN activated) (NN T) (NNS cells))) (, ,) (CC but) (PP (RB not) (IN in) (NP (NNS fibroblasts))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (DT the) (ADJP (RB already) (VBN identified)) (NN NIP) (NN repressor) (NN site))) (, ,) (NP-SBJ-8 (NN evidence)) (VP (VBZ is) (VP (VBN presented) (PP (IN for) (NP (NP (DT a) (JJ second) (NN repressor) (NN region)) (SBAR (WHNP-9 (WDT that)) (S (VP (VBZ restricts) (NP (NP (NN promoter) (NN activity)) (PP (IN in) (NP (NNS fibroblasts))))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ-10 (DT a) (JJ novel) (JJ positive) (JJ regulatory) (NN element)) (VP (VBZ has) (VP (VBN been) (VP (VBN mapped) (PP (IN in) (NP (NP (DT the) (NN IL-3) (NN promoter)) (PP (IN between) (NP (NN nucleotide) (NP-COOD (NP (CD -180)) (CC and) (NP (CD -210))))) (SBAR (WHNP-11 (WDT that)) (S (VP (VBZ leads) (PP (TO to) (NP (NP (VBN increased) (NN expression)) (PP (IN in) (NP (NN T) (NNS cells))))))))))))) (. .)))
(TOP (S (ADVP (RB Together)) (NP-SBJ (DT these) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-12 (NP (NN T) (NN cell) (NN expression)) (PP (IN of) (NP (NN IL-3)))) (VP-COOD (VP (VBZ is) (RB not) (VP (VBN specified) (PP (IN by) (NP-LGS (NP (DT the) (NN activity)) (PP (IN of) (NP (DT a) (JJ single) (JJ tissue-specific) (NN element))))))) (, ,) (CC but) (RB instead) (VP (VBZ involves) (NP (NP (JJ multiple) (VBG interacting) (NNS elements)) (SBAR (WHNP-13 (WDT that)) (S (VP (VBP provide) (NP-COOD (CC both) (NP (NP (JJ specific) (JJ positive) (NN regulation)) (PP (IN in) (NP (NN T) (NNS cells)))) (CC and) (NP (NP (JJ specific) (JJ negative) (NN regulation)) (PP (IN in) (NP (NNS fibroblasts)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (NP-COOD (NP (JJ 3')) (TO --&gt;) (NP (JJ 5'))) (NN XPB) (NN helicase) (NN defect)) (PP (IN in) (NP (NP (NN repair/transcription) (NN factor) (NN TFIIH)) (PP (IN of) (NP (NN xeroderma) (NN pigmentosum) (NN group) (NN B)))))) (VP (VBZ affects) (NP (CC both) (NN DNA) (NP-COOD (NP (NN repair)) (CC and) (NP (NN transcription))))) (. .)))
(TOP (S (NP-SBJ (NN XPB)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN subunit)) (PP (IN of) (NP (DT the) (JJ basal) (NN transcription) (NN factor) (NN TFIIH))) (, ,) (SBAR (WHNP-53 (WDT which)) (S (VP (VBZ is) (ADVP (RB also)) (VP-COOD (VP (VBN involved) (PP-55 (IN in) (NP (NP (NN nucleotide) (NN excision) (NN repair)) (PRN (-LRB- -LRB-) (NP (NN NER)) (-RRB- -RRB-))))) (CC and) (VP (ADVP (RB potentially)) (PP=55 (IN in) (NP (NN cell) (NN cycle) (NN regulation)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (NN frameshift) (NN mutation)) (PP (IN in) (NP (NP (DT the) (NN 3'-end)) (PP (IN of) (NP (DT the) (NN XPB) (NN gene)))))) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (DT a) (NN concurrence)) (PP (IN of) (NP (NP (CD two) (NNS disorders)) (: :) (NP-COOD (NP (NP (NN xeroderma) (NN pigmentosum)) (PRN (-LRB- -LRB-) (NP (NN XP)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN Cockayne) (POS 's)) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN CS)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ-56 (PRP We)) (VP (VBP have) (VP (VBN isolated) (NP (NN TFIIH)) (PP (IN from) (NP-COOD (NP (NP (NP (NNS cells)) (VP (VBN derived) (PP-58 (IN from) (NP (NP (NP (DT a) (NN patient)) (PRN (-LRB- -LRB-) (NP (NN XP11BE)) (-RRB- -RRB-))) (SBAR (WHNP-60 (WP who)) (S (VP (VBZ carries) (NP (DT this) (NN frameshift) (NN mutation))))))))) (PRN-59 (-LRB- -LRB-) (NP (NN TFIIHmut)) (-RRB- -RRB-))) (CC and) (NP (PP=58 (IN from) (NP (NP (DT the) (NN mother)) (PP (IN of) (NP (DT this) (NN patient))))) (PRN=59 (-LRB- -LRB-) (NP (NN TFIIHwt)) (-RRB- -RRB-))))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ biochemical) (NNS consequences)) (PP (IN of) (NP (DT the) (NN mutation))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (ADJP-PRD (JJ identical) (PP (IN in) (NP-COOD (NP (NN composition)) (CC and) (NP (NN stoichiometry)))) (PP (TO to) (NP (NN TFIIHwt)))))) (, ,) (NP-SBJ-61 (NN TFIIHmut)) (VP (VBZ shows) (NP (DT a) (VBN reduced) (NP-COOD (NP (JJ 3')) (TO --&gt;) (NP (JJ 5'))) (NN XPB) (NN helicase) (NN activity))) (. .)))
(TOP (S (NP-SBJ-64 (NP (DT A) (NN decrease)) (PP (IN in) (NP (NP-COOD (NP (NN helicase)) (CC and) (NP (JJ DNA-dependent) (NN ATPase))) (NNS activities)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed) (PP (IN with) (NP (DT the) (VBN mutated) (JJ recombinant) (NN XPB) (NN protein))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN XPB) (NN mutation)) (VP (VBZ causes) (VP (DT a) (JJ severe) (NN NER) (NN defect))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (PRP we)) (VP (VBP provide) (NP (NP (NN evidence)) (PP (IN for) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ basal) (NN transcription) (NN activity)) (ADVP (FW in) (FW vitro)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ latter) (NN defect)) (VP (MD may) (VP (VB provide) (NP (NP (DT an) (NN explanation)) (PP (IN for) (NP (NP (JJ many)) (PP (IN of) (NP (NP (DT the) (NP-COOD (NP (NN XP)) (CC and) (NP (NN CS))) (NNS symptoms)) (SBAR (WHNP-65 (WDT that)) (S (VP (VBP are) (ADJP-PRD (JJ difficult) (SBAR (S (VP (TO to) (VP (VB rationalize) (PP (VBN based) (PP (RB solely) (IN on) (NP (DT an) (NN NER) (NN defect))))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (DT this) (NN work)) (VP-COOD (VP (VBZ presents) (NP (NP (DT the) (JJ first) (JJ detailed) (NN analysis)) (PP (IN of) (NP (NP (DT a) (ADJP (RB naturally) (VBG occurring)) (NN mutation)) (PP (IN in) (NP (DT a) (JJ basal) (NN transcription) (NN factor))))))) (CC and) (VP (VBZ supports) (NP (DT the) (NN concept) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ combined) (NN XP/CS) (JJ clinical) (NN entity)) (VP (VBZ is) (ADVP (RB actually)) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (DT a) (JJ combined) (NN transcription/repair) (NN deficiency)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Signals)) (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN transcription) (NN factor))))))) (VP (VBP are) (ADJP-PRD (ADJP (JJR stronger))) (PP (IN in) (NP (JJ neonatal))) (PP-101 (IN than) (NP (JJ adult) (NN T) (NNS lymphocytes)))) (. .)))
(TOP (S (NP-SBJ-48 (NP (DT The) (JJ molecular) (NN background)) (PP (IN of) (NP (NP (DT the) (NNS defects)) (PP (IN in) (NP (NP (DT the) (JJ immune) (NN reactivity)) (PP (IN of) (NP (JJ human) (NNS neonates)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN elucidated)))) (. .)))
(TOP (S (SBAR (IN As) (S (NP-SBJ (DT the) (NN NF-kappa) (NN B) (NN transcription) (NN factor)) (VP (VBZ has) (NP (DT a) (JJ central) (NN role)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (JJ several) (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ immune)) (CC and) (ADJP (JJ inflammatory))) (NNS responses))))))))))))) (, ,) (NP-SBJ (DT the) (NNS authors)) (VP (VBP have) (VP (VBN analysed) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (JJ human) (JJ umbilical) (NN cord) (NN T) (NNS lymphocytes)))))) (. .)))
(TOP (S (NP-SBJ-49 (DT The) (NN activity)) (VP (VBD was) (VP (VBN tested) (PP (IN by) (S (VP (VP (VBG quantitating) (NP (NP (DT the) (JJ nuclear) (NNS proteins)) (VP (VBG binding) (PP (TO to) (NP (NP (DT an) (NN oligonucleotide)) (VP (VBG containing) (NP (DT the) (NN consensus) (NN kappa) (NN B) (NN binding) (NN sequence)))))))) (PRN (-LRB- -LRB-) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS data)) (VP (VBN obtained))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NP (NN phorbol) (NN dibutyrate/calcium) (NN ionophore) (NN A23187)) (PRN (-LRB- -LRB-) (NP (NN PDBu/iono)) (-RRB- -RRB-))) (NN combination)) (VP (VBD induced) (NP (NP (NP (DT a) (ADJP (RB clearly) (JJR higher)) (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (JJ neonatal)))) (PP (IN than) (NP (JJ adult) (NN T) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-50 (DT This) (JJR higher) (NN NF-kappa) (NN B) (NN activity)) (VP (VBD was) (VP (JJ restricted) (PP (TO to) (NP (DT the) (JJ CD4+) (NN T-cell) (NN subset))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NNS extracts)) (PP (IN with) (NP (NP (NNS antibodies)) (VP (VBN directed) (PP (IN against) (NP (NP (DT the) (JJ major) (NNS components) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (DT the) (NP-COOD (NP (NN p50)) (CC and) (NP (NN RelA) (PRN (-LRB- -LRB-) (NP (NN p65)) (-RRB- -RRB-)))) (NNS proteins) (, ,))))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN composition)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBD was) (ADJP-PRD (JJ similar)) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ neonatal)) (CC and) (ADJP (JJ adult))) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-51 (JJ neonatal) (NN T) (NNS cells)) (VP-COOD (VP (VBP are) (VP (VBN exposed) (PP (TO to) (NP (ADJP (JJ oxidative) (JJ stress-inducing)) (NNS signals))) (PP-TMP (IN during) (NP (NN delivery))))) (CC and/or) (VP (VBP are) (ADVP (RB inherently)) (ADJP-PRD (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (NN NF-kappa) (NN B) (NN activating) (NNS signals)))) (PP (IN than) (NP (JJ adult) (NN T) (NNS cells))))))))) (. .)))
(TOP (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (JJ Grb2-binding) (NNS proteins)) (PP (IN in) (NP (NP (JJ human) (NNS platelets)) (VP (VBN activated) (PP (IN by) (NP-LGS (NN Fc) (NN gamma) (NN RIIA) (NN cross-linking)))))))) (. .)))
(TOP (S (NP-SBJ-68 (ADJP (NN Glutathione-S-transferase) (-LRB- -LRB-) (NN GST) (-RRB- -RRB-) (NN -Grb2)) (NN fusion) (NNS proteins)) (VP (VBP have) (VP (VBN been) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (JJ Grb2-binding) (NNS proteins))) (PP (IN in) (NP (NP (NN platelet) (NN activation)) (PP (IN by) (NP (NP (DT the) (NN platelet) (NN low-affinity) (NN IgG) (NN receptor)) (, ,) (NP (NN Fc) (NN gamma) (NN RIIA))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD Two) (NN tyrosine) (NNS phosphoproteins)) (PP (IN of) (NP (QP (CD 38) (CC and) (CD 63)) (NN kD)))) (VP (VBP bind) (PP (TO to) (NP (NP (DT the) (NN SH2) (NN domain)) (PP (IN of) (NP (NN Grb2))))) (PP-TMP (VBG following) (NP (NP (NN Fc) (NN gamma) (NN RIIA) (NN stimulation)) (PP (IN of) (NP (NNS platelets)))))) (. .)))
(TOP (S (NP-SBJ-69 (DT Both)) (VP-COOD (VP (VBP are) (ADJP-PRD (JJ located) (PP (IN in) (NP (DT the) (JJ particulate) (NN fraction)))) (PP-TMP (VBG following) (NP (NN platelet) (NN activation)))) (CC and) (VP (VBP are) (ADVP (RB also)) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB bind) (PP (TO to) (NP (NP (DT a) (NN GST-construct)) (VP (VBG containing) (NP (NP (DT the) (NP-COOD (NP (NN SH2)) (CC and) (NP (NN SH3))) (NNS domains)) (PP (IN of) (NP (NN phospholipase) (NN C) (NN gamma) (CD 1))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN p38)) (VP-COOD (VP (ADVP (RB also)) (VBZ forms) (NP (DT a) (NN complex)) (PP (IN with) (NP (DT the) (NN tyrosine) (NN kinase) (NN csk))) (PP (IN in) (NP (VBN stimulated) (NNS cells)))) (CC and) (VP (VBZ is) (NP-PRD (NP (DT a) (NN substrate)) (PP (IN for) (NP (DT the) (NN kinase)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN SH3) (NNS domains)) (PP (IN of) (NP (NN Grb2)))) (VP (VBP form) (NP (DT a) (JJ stable) (NN complex)) (PP (IN with) (NP-COOD (NP (NN SOS1)) (CC and) (NP (NP (CD two) (NNS proteins)) (PP (IN of) (NP-COOD (NP (CD 75) (NN kD)) (CC and) (NP (CD 120) (NN kD)))) (, ,) (SBAR (WHNP-71 (WDT which)) (S (VP (VBP undergo) (NP (NN tyrosine) (NN phosphorylation)) (PP (IN in) (NP (ADJP (NP (NN Fc) (NN gamma) (NN RIIA)) (JJ stimulated)) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ-74 (DT The) (JJ 75-kD) (NN protein)) (VP (VBZ is) (VP-COOD (VP (VBN recognized) (PP (IN by) (NP-LGS (NP (NNS antibodies)) (PP (TO to) (NP (NP (NN SLP-76)) (, ,) (SBAR (WHNP-75 (WDT which)) (S (VP (VBZ has) (ADVP-TMP (RB recently)) (VP (VBN been) (VP (VBN isolated) (PP (IN from) (NP (NN T) (NNS cells))))))))))))) (CC and) (VP (VBN sequenced)))) (. .)))
(TOP (S (NP-SBJ-77 (NP (NN Tyrosine) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN p38)) (CC and) (NP (NN p63))))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS platelets)) (VP (VBN stimulated) (PP-COOD (PP (IN by) (NP-LGS (DT the) (ADJP (NN tyrosine) (JJ kinase-linked)) (NN receptor) (NN agonist) (NN collagen))) (CC and) (PP (IN by) (NP-LGS (DT the) (ADJP (NN G) (JJ protein-coupled)) (NN receptor) (NN agonist) (NN thrombin))))))) (, ,) (SBAR (IN although) (S (NP-SBJ-78 (NP (NN phosphorylation)) (PP (IN of) (NP (NN SLP-76)))) (VP (VBZ is) (ADVP (RB only)) (VP (VBN observed) (PP (IN in) (NP (JJ collagen-stimulated) (NNS platelets))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-79 (NP (NN p38)) (CC and) (NP (NN p63))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (NN docking) (NN site)) (PP (IN for) (NP (NN Grb2)))) (, ,) (S (ADVP (RB thereby)) (VP (VBG linking) (NP (NN Grb2) (JJ SH3-binding) (NNS proteins) (NP-COOD (NP (NN SOS1)) (, ,) (NP (NN SLP-76)) (, ,) (CC and) (NP (NN p120)))) (PP (TO to) (NP (JJ downstream) (NN signalling) (NNS events))))))) (. .)))
(TOP (S (NP-SBJ (JJ Retinoic) (NN acid)) (VP (VBZ activates) (NP (NP (NN interferon) (JJ regulatory) (JJ factor-1) (NN gene) (NN expression)) (PP (IN in) (NP (JJ myeloid) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ All-trans-retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN ATRA)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN drug)) (PP (IN of) (NP (NN choice)))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ (NN ATRA)) (VP (VBZ induces) (NP (NP (NP (ADJP-COOD (CC both) (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NN differentiation)) (PP (IN of) (NP (NN APL) (NNS cells)))) (PP (IN into) (NP (JJ mature) (NNS granulocytes))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-63 (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (JJ ATRA-dependent) (NP-COOD (NP (NN growth) (NN inhibition)) (CC and) (NP (JJ cellular) (NN differentiation))))))) (VP (VBP are) (RB not) (ADVP-TMP (RB presently)) (VP (VBN understood))) (. .)))
(TOP (S (NP-SBJ-64 (NP (DT The) (NN NB4) (NN cell) (NN line)) (, ,) (SBAR (WHNP-65 (WDT which)) (S (VP (VBZ is) (VP (VBN derived) (PP (IN from) (NP (NP (DT the) (NN bone) (NN marrow)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NN APL))))))) (PP-TMP (IN during) (NP (NN relapse))))))) (, ,)) (VP (MD can) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ model) (NN system)) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NP-COOD (NP (NN growth)) (CC and) (NP (NN differentiation)))) (PP (IN of) (NP (NN APL) (NNS cells))))))))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP-SBJ-COOD (NP (NP (NP (NP (NN interferon)) (PRN (-LRB- -LRB-) (NP (NN IFN)) (-RRB- -RRB-))) (JJ regulatory) (NNS factors)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN IRF-1)) (CC and) (NP (NN IRF-2))) (-RRB- -RRB-))) (CC and) (NP (JJ other) (JJ IFN-inducible) (NN gene) (NNS products))) (VP (VBP regulate) (NP (NN cell) (NN growth))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN ATRA))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT these) (NNS genes))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN ATRA)) (ADVP (RB directly)) (VP (VBZ activates) (NP (NN IRF-1) (NN gene) (NN expression)) (, ,) (S (VP (VBN followed) (PP (IN by) (NP-LGS (NP (NN activation)) (PP (IN of) (NP (NP-COOD (NP (NN IRF-2)) (CC and) (NP (JJ 2'-5') (NP (NP (NN oligoadenylate) (NN synthetase)) (PRN (-LRB- -LRB-) (NP (NN OAS)) (-RRB- -RRB-))))) (NN gene) (NN expression))) (PP (IN with) (NP (JJR slower) (NNS kinetics))))))))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (NN NB4) (NNS cells))) (, ,) (NP-SBJ (NN ATRA)) (ADVP (RB also)) (VP (VBD activated) (NP (NP (NN IRF-1) (NN gene) (NN expression)) (PP (IN in) (NP (NP (NP-COOD (NP (NN HL-60)) (, ,) (NP (NN U937)) (, ,) (CC and) (NP (NN THP-1))) (NNS cells)) (, ,) (SBAR (WHNP-69 (WDT which)) (S (NP-SBJ (NP (DT all))) (VP (VBP respond) (PP (TO to) (NP (NN ATRA))) (PP (IN by) (NP (NN growth) (NN inhibition)))))))))) (. .)))
(TOP (S (NP-SBJ-70 (NP (DT A) (ADJP (ADJP (JJR more)) (PP (IN than) (ADJP (JJ additive)))) (NN increase)) (PP (IN in) (NP (NN IRF-1) (NN gene) (NN expression)))) (VP (VBD was) (VP (VBN seen) (PP (IN with) (NP-COOD (NP (NN ATRA)) (CC and) (NP (NN IFN-gamma)))) (PP (IN in) (NP (NN NB4) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NN ATRA)) (VP (VBD did) (RB not) (VP (VB activate) (NP-COOD (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (CC or) (NP (NP (NP (NP-COOD (NP (NN signal) (NN transducer)) (CC and) (NP (NN activator))) (PP (IN of) (NP (NN transcription)))) (PRN (-LRB- -LRB-) (NP (NN STAT)) (-RRB- -RRB-))) (NN activation) (NNS pathways))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ-72 (DT an) (JJ alternate) (NN mechanism)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NN IRF-1) (NN gene) (NN activation))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ ATRA-induced) (NN expression)) (PP (IN of) (NP (NP (NN IRF-1)) (, ,) (NP (DT an) (NP-COOD (NP (NP (NN activator)) (PP (IN of) (NP (NN transcription)))) (CC and) (NP (NP (NN repressor)) (PP (IN of) (NP (NN transformation)))))) (, ,)))) (VP (MD may) (VP (VB be) (NP-PRD-COOD (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (JJ ATRA-induced) (NN growth) (NN inhibition)))))) (, ,) (CC and) (NP (NP (DT the) (NN basis)) (PP (IN for) (NP (NP (DT the) (JJ synergistic) (NNS actions)) (PP (IN of) (NP-COOD (NP (NN ATRA)) (CC and) (NP (NN IFNs)))) (PP (IN in) (NP (JJ myeloid) (NN leukemia) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN c-Jun) (NN delta-domain)) (VP (VBZ inhibits) (NP (NN neuroendocrine) (NN promoter) (NN activity)) (PP (IN in) (NP (DT a) (ADJP-COOD (ADJP (NP (NN DNA) (NN sequence-))) (CC and) (ADJP (JJ pituitary-specific))) (NN manner)))) (. .)))
(TOP (S (NP-SBJ-58 (NP (DT The) (NP-COOD (NP (NN transcription)) (CC and) (NP (NN transformation))) (NN activity)) (PP (IN of) (NP (NN c-Jun)))) (VP (VBZ is) (VP (VBN governed) (PP (IN by) (NP-LGS (NP (DT a) (JJ 27-amino) (NN acid) (JJ regulatory) (NN motif)) (, ,) (VP (VBN labeled) (S (NP-PRD (DT the) (NN delta-domain)))) (, ,) (SBAR (WHNP-59 (WDT which)) (S (VP (VBZ is) (VP (VBN deleted) (PP (IN in) (NP (NN v-Jun))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NN c-Jun)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN rat) (NN prolactin)) (PRN (-LRB- -LRB-) (NP (NN rPRL)) (-RRB- -RRB-))) (NN promoter) (NN activity)) (VP (VBN induced) (PP (IN by) (NP-LGS-COOD (DT either) (NP (JJ oncogenic) (NN Ras)) (CC or) (NP (NN phorbol) (NNS esters))))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (S-COOD (S (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN characterized) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ structural)) (CC and) (ADJP (JJ cell-specific))) (NNS requirements)) (PP (IN for) (NP (DT this) (NN c-Jun) (JJ inhibitory) (NN response))))))) (, ,) (CC and) (S (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (DT this) (NN c-Jun) (JJ inhibitory) (NN response)) (VP (VBD mapped) (PP (TO to) (NP (DT the) (NN rPRL) (NN footprint) (CD II) (NN repressor) (NN site))))) (, ,) (VP-COOD (VP (VBD was) (ADJP-PRD (JJ pituitary-specific))) (CC and) (VP (VBD required) (NP (DT the) (NN c-Jun) (NN delta-domain))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ (NP (NN alteration)) (PP (IN of) (NP (NP (DT any) (CD one)) (PP (IN of) (NP (NP (DT these) (NNS features)) (PRN (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NP-COOD (NP (NN cis-element)) (, ,) (NP (NN trans-factor)) (, ,) (CC or) (NP (JJ cell-specific) (NN background)))) (-RRB- -RRB-))))))) (VP (VBD switched) (NP (NN c-Jun)) (PP (TO to) (NP (NP (DT a) (JJ transcriptional) (NN activator)) (PP (IN of) (NP (DT the) (NN rPRL) (NN promoter)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN HeLa) (JJ nonpituitary) (NNS cells))) (, ,) (NP-SBJ (NP (NN c-Jun)) (ADVP (RB alone))) (VP-COOD (VP (VBD activated) (NP (DT the) (NN rPRL) (NN promoter)) (PP (IN via) (NP (NP (DT the) (ADJP (RBS most) (JJ proximal)) (NN GHF-1/Pit-1) (NN binding) (NN site)) (, ,) (NP (NN footprint) (NN I))))) (, ,) (CC and) (VP (VBD synergized) (PP (IN with) (NP (NN GHF-1))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (JJ recombinant) (NN GHF-1)) (VP (VBD interacted) (ADVP (RB directly)) (PP (IN with) (NP (NP-COOD (NP (NN c-Jun)) (CONJP (CC but) (RB not)) (NP (NN c-Fos))) (NNS proteins)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP-COOD (VP (VBP provide) (NP (NP (JJ important) (JJ fundamental) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN molecular) (NNS mechanisms)) (SBAR (WHPP-61 (IN by) (WHNP (WDT which))) (S (NP-SBJ (DT the) (NN c-Jun) (NN delta-domain)) (VP (VBZ functions) (PP (IN as) (NP (DT a) (JJ modulatory) (NN switch)))))))))) (CC and) (VP (ADVP (RB further)) (VBP imply) (SBAR (IN that) (S (NP-SBJ-62 (NP (DT the) (JJ functional) (NN role)) (PP (IN of) (NP (NN c-Jun)))) (VP (VBZ is) (VP (VBN dictated) (PP (IN by) (NP-LGS-COOD (NP (JJ cell-specific) (NNS influences)) (CC and) (NP (DT the) (JJ delta-domain) (NN motif)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN BCL-6)) (, ,) (NP (DT a) (NN POZ/zinc-finger) (NN protein)) (, ,)) (VP (VBZ is) (NP-PRD (DT a) (JJ sequence-specific) (JJ transcriptional) (NN repressor))) (. .)))
(TOP (S (NP-SBJ-43 (NP (QP (RB Approximately) (CD 40)) (NN %)) (PP (IN of) (NP (JJ diffuse) (JJ large) (NN cell) (NN lymphoma)))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (JJ chromosomal) (NNS translocations)) (SBAR (WHNP-44 (WDT that)) (S (VP (VBP deregulate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN BCL6) (NN gene)))) (PP (IN by) (S (VP (VBG juxtaposing) (NP (JJ heterologous) (NNS promoters)) (PP (TO to) (NP (DT the) (NN BCL-6) (NN coding) (NN domain))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN BCL6) (NN gene)) (VP (VBZ encodes) (NP-COOD (NP (NP (DT a) (JJ 95-kDa) (NN protein)) (VP (VBG containing) (NP (CD six) (JJ C-terminal) (NN zinc-finger) (NNS motifs)))) (CC and) (NP (DT an) (JJ N-terminal) (NN POZ) (NN domain))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (MD may) (VP (VB function) (PP (IN as) (NP (DT a) (NN transcription) (NN factor)))))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG using) (NP (NP (DT a) (NN DNA) (NN sequence)) (VP (VBN selected) (PP (IN for) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB bind) (NP (JJ recombinant) (NN BCL-6)) (ADVP (FW in) (FW vitro)))))))))))) (, ,) (NP-SBJ-47 (PRP we)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (NP-SBJ (NN BCL-6)) (VP (VBZ is) (ADJP-PRD (JJ present) (PP (IN in) (NP (NP (JJ DNA-binding) (NNS complexes)) (PP (IN in) (NP (NP (JJ nuclear) (NNS extracts)) (PP (IN from) (NP (JJ various) (NN B-cell) (NNS lines)))))))))))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (JJ transient) (NN transfectin) (NNS experiments))) (, ,) (NP-SBJ (NN BCL6)) (VP (MD can) (VP (VB repress) (NP (NP (NN transcription)) (PP (IN from) (NP (NP (NNS promoters)) (VP (VBN linked) (PP (TO to) (NP (PRP$ its) (NN DNA) (NN target) (NN sequence)))))))))) (CC and) (S (NP-SBJ (DT this) (NN activity)) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN upon) (NP-COOD (NP (JJ specific) (NN DNA-binding)) (CC and) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT an) (JJ intact) (JJ N-terminal) (NN half)) (PP (IN of) (NP (DT the) (NN protein))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NP (DT this) (NN part)) (PP (IN of) (NP (DT the) (NN BCL6) (NN molecule)))) (VP (VBZ contains) (NP (DT an) (JJ autonomous) (NN transrepressor) (NN domain))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NP (CD two) (JJ noncontiguous) (NNS regions)) (, ,) (PP (VBG including) (NP (DT the) (NN POZ) (NN motif))) (, ,)) (VP (VBP mediate) (NP (JJ maximum) (JJ transrepressive) (NN activity))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP-COOD (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (DT the) (NN BCL-6) (NN protein)) (VP (MD can) (VP (VB function) (PP (IN as) (NP (DT a) (JJ sequence-specific) (JJ transcriptional) (NN repressor)))))))) (CC and) (VP (VBP have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN BCL6))) (PP (IN in) (NP-COOD (NP (JJ normal) (JJ lymphoid) (NN development)) (CC and) (NP (NN lymphomagenesis))))))))) (. .)))
(TOP (NP (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP (JJ specific) (NN interferon) (NNS isotypes))) (PP-COOD (PP (IN in) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN from) (NP (JJ normal) (NNS individuals))))) (CC and) (PP (IN in) (NP (JJ promonocytic) (NN U937) (NNS cells)))) (. .)))
(TOP (S (NP-SBJ-80 (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP-COOD (NP (NN IFN-alpha5)) (CC and) (NP (NN IFN-beta))))) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (NP (JJ different) (JJ lymphoid) (NNS cells)) (PP (VBG including) (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (PP (IN from) (NP (JJ normal) (NNS individuals))))))) (PP-TMP (VBG following) (NP-COOD (NP (NP (NN amplification)) (PP (IN of) (NP (NN IFN) (NN mRNA))) (PP (IN by) (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)))) (CC and) (NP (NP (JJ direct) (NN sequencing)) (PP (IN of) (NP (DT the) (VBN amplified) (NN product)))))))) (. .)))
(TOP (S (NP-SBJ-81 (NP (DT The) (JJ activated) (NN form)) (PP (IN of) (NP (DT the) (JJ interferon-induced) (NN transcription) (NN factor) (NN complex) (NN ISGF3)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN detected) (PP (IN in) (NP (NP (JJ nuclear) (NNS extracts)) (PP (IN from) (NP (JJ uninduced) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-82 (NP (NN Culture) (NNS supernatants)) (PP (IN from) (NP (JJ uninduced) (NN U937) (NNS cells)))) (VP (VBD were) (ADVP (RB also)) (VP (VBN found) (S (VP (TO to) (VP (VB activate) (NP (NP (DT an) (NN ISRE)) (VP (VBN cloned) (ADVP (RB upstream) (PP (IN of) (NP (DT the) (NN luciferase) (NN reporter) (NN gene)))))) (, ,) (S (VP (VBG indicating) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ endogenous) (NN IFN) (NN activity)) (ADJP (JJ equivalent) (PP (TO to) (NP (QP (RB approximately) (CD 0.3) (TO to) (CD 0.5)) (NN IU/mL)))))))))))))) (. .)))
(TOP (S (NP-SBJ-84 (DT This) (JJ endogenous) (NN IFN)) (VP (VBD was) (ADVP (RB also)) (VP (VBN shown) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG maintaining) (NP (NP (DT the) (JJ basal) (NN level)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ major) (NN histocompatibility) (NN class) (CD I) (NNS genes))) (PP (IN in) (NP (JJ lymphoid) (NNS cells)))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-COOD-88 (NP (NN IFN-alpha5)) (CC and) (NP (NN IFN-beta))) (VP-COOD (VP (VBP are) (VP (VBN produced) (PP (IN at) (NP (JJ low) (NNS levels))) (PP (IN in) (NP (JJ normal) (NNS tissues))))) (CC and) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP-COOD (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN cell) (NN function))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NN homeostasis))))))))))) (. .)))
(TOP (NP (NP (NNS Mechanisms)) (PP (IN of) (NP (NP (NN transactivation)) (PP (IN by) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells-1))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (JJ Nuclear) (NN factor) (PP (IN of) (NP (VBN activated) (NN T) (NN cells-family)))) (NNS proteins)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN NFAT1/NFATp)) (, ,) (NP (NN NFATc)) (, ,) (NP (NN NFAT3)) (, ,) (CC and) (NP (NN NFAT4/NFATx/NFATc3))) (-RRB- -RRB-))) (VP (VBP play) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP-COOD (NP (NN cytokine) (NNS genes)) (CC and) (NP (JJ other) (NNS genes)))))) (PP-TMP (IN during) (NP (DT the) (JJ immune) (NN response)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN defined) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NP (NN transactivation)) (PP (IN by) (NP (NN NFAT1)))))))) (. .)))
(TOP (S (NP (NNP NFAT1)) (VP (VBZ possesses) (NP-COOD (NP (NP (CD two) (NN transactivation) (NNS domains)) (SBAR (WHNP-57 (WP$ whose) (NNS sequences)) (S (VP (VBP are) (RB not) (VP (VBN conserved) (PP (IN in) (NP (DT the) (JJ other) (NN NFAT-family) (NNS proteins)))))))) (, ,) (CC and) (NP (NP (DT a) (VBN conserved) (JJ DNA-binding) (NN domain)) (SBAR (WHNP-59 (WDT that)) (S (VP (VBZ mediates) (NP (NP (DT the) (NN recruitment)) (PP (IN of) (NP (VBG cooperating) (JJ nuclear) (NN transcription) (NNS factors))))))))) (SBAR-TMP (WHADVP-60 (RB even) (WRB when)) (S (NP-SBJ-61 (PRP it)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NP (JJ other) (NNS regions)) (PP (IN of) (NP (DT the) (NN protein)))))))))) (. .)))
(TOP (S (NP-SBJ-62 (NP (DT The) (NN activity)) (PP (IN of) (NP (DT the) (JJ NH2-terminal) (NN transactivation) (NN domain)))) (VP (VBZ is) (VP (VBN modulated) (PP (IN by) (NP-LGS (NP (DT an) (JJ adjacent) (JJ regulatory) (NN region)) (SBAR (WHNP-63 (WDT that)) (S (VP (VBZ contains) (NP (NP (JJ several) (VBN conserved) (NN sequence) (NNS motifs)) (VP (VBN represented) (PP (RB only) (IN in) (NP (DT the) (NN NFAT) (NN family)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP-COOD (VP (VBP emphasize) (NP (NP (DT the) (JJ multiple) (NNS levels)) (SBAR (WHPP-64 (IN at) (WHNP (WDT which))) (S (NP-SBJ-65 (JJ NFAT-dependent) (NN transactivation)) (VP (VBZ is) (VP (VBN regulated))))))) (, ,) (CC and) (VP (VBP predict) (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN architecture)) (PP (IN of) (NP (NP (JJ cooperative) (NN transcription) (NNS complexes)) (VP (VBG containing) (NP (JJ different) (NN NFAT-family) (NNS proteins)))))))))) (. .)))
(TOP (S (NP-SBJ-67 (DT The) (NN Ets) (NN protein) (NN Spi-B)) (VP (VBZ is) (VP (VBN expressed) (PP (RB exclusively) (IN in) (NP-COOD (NP (NN B) (NNS cells)) (CC and) (NP (NN T) (NNS cells)))) (PP-TMP (IN during) (NP (NN development))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN Spi-B)) (CC and) (NP (NN PU.1))) (VP (VBP are) (NP-PRD (NP (JJ hematopoietic-specific) (NN transcription) (NNS factors)) (SBAR (WHNP-68 (WDT that)) (S (VP (VBP constitute) (NP (NP (DT a) (NN subfamily)) (PP (IN of) (NP (NP (DT the) (NN Ets) (NN family)) (PP (IN of) (NP (JJ DNA-binding) (NNS proteins))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (PP (JJ contrary) (TO to) (NP (JJ previous) (NNS reports))) (, ,) (NP-SBJ-COOD (NP (NN PU.1)) (CC and) (NP (NN Spi-B))) (VP (VBP have) (NP (ADJP (RB very) (JJ different)) (NN expression) (NNS patterns)))))) (. .)))
(TOP (S (NP-SBJ-69 (NN PU.1)) (VP (VBZ is) (VP-COOD (VP (VBN expressed) (PP-70 (IN at) (NP (JJ high) (NNS levels))) (PP-71 (IN in) (NP-COOD (NP (NN B) (NNS cells)) (, ,) (NP (NN mast) (NNS cells)) (, ,) (NP (NNS megakaryocytes)) (, ,) (NP (NNS macrophages)) (, ,) (NP (NNS neutrophils)) (, ,) (CC and) (NP (JJ immature) (JJ erythroid) (NNS cells))))) (CC and) (VP (PP=70 (IN at) (NP (JJR lower) (NNS levels))) (PP=71 (IN in) (NP (JJ mature) (NNS erythrocytes)))))) (. .)))
(TOP (S (NP-SBJ (NN PU.1)) (VP (VBZ is) (ADJP-PRD (RB completely) (JJ absent) (PP (IN from) (NP-COOD (NP (JJ peripheral) (NN T) (NNS cells)) (CC and) (NP (JJS most) (JJ T) (NN cell) (NNS lines))))) (PP (VBN based) (PP (IN on) (NP (JJ sensitive) (NN RT-PCR) (NNS assays))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-72 (NN Spi-B)) (VP-COOD (VP (VBZ is) (VP (VBN expressed) (ADVP (RB exclusively)) (PP (IN in) (NP (JJ lymphoid) (NNS cells))))) (CC and) (VP (MD can) (VP (VB be) (VP (VBN detected) (PP (IN in) (NP (JJ early) (JJ fetal) (NP-COOD (NP (NN thymus)) (CC and) (NP (NN spleen))))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (FW In) (FW situ)) (NNS hybridizations)) (PP (IN of) (NP (JJ adult) (JJ murine) (NNS tissues)))) (VP (VBP demonstrate) (NP (NN Spi-B) (NN mRNA)) (PP (IN in) (NP-COOD (NP (NP (DT the) (NN medulla)) (PP (IN of) (NP (DT the) (NN thymus)))) (, ,) (NP (NP (DT the) (JJ white) (NN pulp)) (PP (IN of) (NP (DT the) (NN spleen)))) (, ,) (CC and) (NP (NP (DT the) (JJ germinal) (NNS centers)) (PP (IN of) (NP (NN lymph) (NNS nodes))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (JJ Spi-B) (NN expression)) (VP (VBZ is) (ADJP-PRD (RB very) (JJ abundant)) (PP (IN in) (NP (NN B) (NNS cells))))) (CC and) (S (NP-SBJ-75 (CC both) (NN Spi-B) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein)))) (VP (VBP are) (VP (VBN detected) (PP (IN in) (NP (DT some) (NN T) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (ADJP (FW In) (FW situ)) (NN hybridization)) (CC and) (NP (NN Northern) (NN blot) (NN analysis))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN Spi-B) (NN gene) (NN expression)) (VP-COOD (VP (VBZ increases) (PP-TMP (IN during) (NP (NN B) (NN cell) (NN maturation)))) (CC and) (VP (VBZ decreases) (PP-TMP (IN during) (NP (NN T) (NN cell) (NN maturation)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Gel-retardation) (NNS experiments)) (VP-COOD (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN Spi-B)) (VP (MD can) (VP (VB bind) (PP (TO to) (NP (DT all) (JJ putative) (NN PU.1) (NN binding) (NNS sites)))))))) (, ,) (CC but) (VP (VBP do) (RB not) (VP (VB reveal) (NP (DT any) (JJ preferred) (NN Spi-B) (NN binding) (NN site))))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ-COOD-76 (CC both) (NP (NN PU.1)) (CC and) (NP (NN Spi-B))) (VP (VBP function) (PP (IN as) (NP (NP (JJ transcriptional) (NNS activators)) (PP (IN of) (NP (DT the) (JJ immunoglobulin) (NN light-chain) (NN enhancer) (NN E) (NN lambda) (CD 2.4))))) (SBAR-TMP (WHADVP-77 (WRB when)) (S (VP (VBN coexpressed) (PP (IN with) (NP (NP (NN Pip)) (PRN (-LRB- -LRB-) (NP (JJ PU.1-interaction) (NN partner)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN NIH-3T3) (NNS cells))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-79 (DT these) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NNS differences)) (PP (IN in) (NP (NP (NNS patterns)) (PP (IN of) (NP (NN expression))))) (PP (IN between) (NP-COOD (NP (NN Spi-B)) (CC and) (NP (NN PU.1))))) (VP (VBP distinguish) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT each) (NN protein))) (PP-TMP (IN during) (NP (NP (NN development)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))))))))) (. .)))
(TOP (NP (NP (JJ Precise) (NN alignment)) (PP (IN of) (NP (NNS sites))) (VP (VBN required) (PP (IN for) (NP (NP (NN mu) (NN enhancer) (NN activation)) (PP (IN in) (NP (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ-44 (DT The) (JJ lymphocyte-specific) (NN immunoglobulin) (NN mu) (JJ heavy-chain) (NN gene) (JJ intronic) (NN enhancer)) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS (JJ multiple) (JJ nuclear) (NNS factors))))) (. .)))
(TOP (S (NP-SBJ-45 (NP (DT The) (ADJP (RB previously) (VBN defined)) (JJ minimal) (NN enhancer)) (VP (VBG containing) (NP (DT the) (NP-COOD (NP (NN muA)) (, ,) (NP (NN muE3)) (, ,) (CC and) (NP (NN muB))) (NNS sites)))) (VP (VBZ is) (VP (VBN transactivated) (PP (IN by) (NP-LGS (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (DT the) (NN ETS-domain) (NNS proteins) (NP-COOD (NP (NN PU.1)) (CC and) (NP (NN Ets-1)))) (PP (IN in) (NP (JJ nonlymphoid) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ-46 (NP (DT The) (NN core) (NNS GGAAs)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN muA)) (CC and) (NP (NN muB))) (NNS sites)))) (VP (VBP are) (VP (VBN separated) (PP (IN by) (NP-LGS (CD 30) (NNS nucleotides))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NNS ETS) (NNS proteins)) (VP (VBP bind) (PP (TO to) (NP (NP (DT these) (NNS sites)) (PP (IN from) (NP (NP (DT these) (JJ same) (NN side)) (PP (IN of) (NP (DT the) (NN DNA) (NN helix)))))))))))))) (. .)))
(TOP (S (NP-SBJ-48 (PRP We)) (VP (VBD tested) (NP (NP (DT the) (NN necessity)) (PP (IN for) (NP (NP (JJ appropriate) (JJ spatial) (NN alignment)) (PP (IN of) (NP (DT these) (NNS elements)))))) (PP (IN by) (S (VP (VBG using) (NP (NP (VBN mutated) (NNS enhancers)) (PP (IN with) (NP (JJ altered) (NNS spacings)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (ADJP-COOD (ADJP (NP (CD 4-))) (CC or) (ADJP (JJ 10-bp))) (NN insertion)) (PP (IN between) (NP-COOD (NP (NN muE3)) (CC and) (NP (NN muB))))) (VP-COOD (VP (VBD inactivated) (NP (DT the) (NN mu) (NN enhancer)) (PP (IN in) (NP (NN S194) (NN plasma) (NNS cells)))) (CC but) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (ADJP (FW in) (FW vitro)) (NN binding)) (PP (IN of) (NP-COOD (NP (NN Ets-1)) (, ,) (NP (NN PU.1)) (, ,) (CC or) (NP (DT the) (JJ muE3-binding) (NN protein) (NN TFE3))))) (, ,) (UCP-COOD (ADVP (RB alone)) (CC or) (PP (IN in) (NP (JJ pairwise) (NNS combinations))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (JJ Circular) (NN permutation)) (CC and) (NP (NN phasing))) (NNS analyses)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN PU.1) (NN binding)) (CONJP (CC but) (RB not)) (NP-COOD (NP (NN TFE3)) (CC or) (NP (NN Ets-1)))) (VP (VBZ bends) (NP (NN mu) (NN enhancer) (NN DNA)) (PP (IN toward) (NP (DT the) (JJ major) (NN groove))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN requirement)) (PP (IN for) (NP (NP (JJ precise) (NN spacing)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN muA)) (CC and) (NP (NN muB))) (NNS elements)))))) (VP (VBZ is) (PP-PRD (JJ due) (PP (IN in) (NP (NN part))) (TO to) (NP (NP (DT a) (JJ directed) (NN DNA) (NN bend)) (VP (VBN induced) (PP (IN by) (NP-LGS (NN PU.1)))))))))) (. .)))
(TOP (S (NP-SBJ-53 (NN C/EBP) (NNS activators)) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP-COOD (NP (NN HIV-1) (NN replication)) (CC and) (NP (JJ proviral) (NN induction))) (PP (IN in) (NP (JJ monocytic) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (NP-SBJ (JJ Previous) (NN work)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN C/EBP) (NNS sites)) (CC and) (NP (NN C/EBP) (JJ transcriptional) (NNS activators))) (VP (VBP are) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (NP (NN HIV-1) (NN LTR) (NN activity)) (PP (IN in) (NP (NNS monocytes/macrophages))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN role)) (SBAR (WHNP-54 (WDT that)) (S (NP-SBJ (NN C/EBP) (NNS proteins)) (VP (VBP play) (PP (IN in) (NP (NP-COOD (NP (NN induction)) (CC and) (NP (NN replication))) (PP (IN of) (NP (NN HIV-1))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Ectopic) (NN expression)) (PP (IN of) (NP (DT the) (JJ dominant) (JJ negative) (NN C/EBP) (NN protein) (NN LIP)))) (VP (VBD inhibited) (NP (NP-COOD (NP (NN HIV-1) (NN mRNA)) (CC and) (NP (NN virus) (NN production))) (PP (IN in) (NP (VBN activated) (NN U1) (NNS cells)))) (, ,) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP-SBJ-56 (NN C/EBP) (NNS proteins)) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NN provirus) (NN induction)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN U1) (NNS lines)) (VP (VBG overexpressing) (NP (NN C/EBP) (NN activator) (NN NF-IL-6)))) (VP (VBD produced) (NP (NP (JJR more) (NP-COOD (NP (JJ viral) (NN mRNA)) (CC and) (NP (NN virus) (NNS particles))))) (PP-TMP (VBG following) (NP (JJ cellular) (NN activation))) (PP-101 (IN than) (NP (NN control) (NNS lines))) (, ,) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP (NN C/EBP) (NNS proteins)) (VP (VBP are) (ADJP-PRD (VBG limiting)) (PP (IN for) (NP (NN virus) (NN transcription))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN HIV-1) (NN harboring) (NNS mutations)) (PP (IN within) (NP (CD two) (NN C/EBP) (NNS sites)))) (VP (VBD were) (ADJP-PRD (VBN crippled)) (PP (IN in) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB replicate) (PP (IN in) (NP (NN U937) (JJ promonocytic) (NNS cells)))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-60 (DT these) (NNS sites)) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NN replication)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP identify) (NP (NN C/EBP) (NNS proteins)) (PP (IN as) (NP (NP (NNS regulators)) (PP (IN of) (NP (NP (NN HIV-1) (NN expression)) (PP (IN in) (NP (NNS monocytes/macrophages)))))))) (. .)))
(TOP (NP (NP (NN Reversal)) (PP (IN of) (NP (NN apoptosis))) (PP (IN by) (NP (DT the) (JJ leukaemia-associated) (NN E2A-HLF) (JJ chimaeric) (NN transcription) (NN factor))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (NP (NP (DT The) (NN E2A-HLF) (-LRB- -LRB-) (PP (IN for) (NP (JJ hepatic) (NN leukaemia) (NN factor))) (-RRB- -RRB-)) (NN fusion) (NN gene)) (, ,) (VP (VBN formed) (PP (IN by) (NP-LGS (NP (NN action)) (PP (IN of) (NP (DT the) (NN t-LRB-17;19-RRB-) (NN -LRB-q22;p13-RRB-) (JJ chromosomal) (NN translocation)))))) (, ,)) (VP (VBZ drives) (NP (NP (DT the) (JJ leukaemic) (NN transformation)) (PP (IN of) (NP (JJ early) (NN B-cell) (NNS precursors)))))) (, ,) (CC but) (S (NP-SBJ (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT this) (NN activity)))) (VP (VBZ remains) (ADJP-PRD (JJ unknown))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ-37 (NP (JJ human) (NN leukaemia) (NNS cells)) (VP (VBG carrying) (NP (DT the) (NN translocation) (NN t-LRB-17;19-RRB-)))) (ADVP-TMP (RB rapidly)) (VP (VBD died) (PP (IN by) (NP (NN apoptosis))) (SBAR-TMP (WHADVP-38 (WRB when)) (S (VP (VBN programmed) (S (VP (TO to) (VP (VB express) (NP (NP (DT a) (JJ dominant-negative) (NN suppressor)) (PP (IN of) (NP (DT the) (NN fusion) (NN protein) (NN E2A-HLF)))))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ chimaeric) (NN oncoprotein)) (ADVP (RB probably)) (VP (VBZ affects) (NP-COOD (NP (NN cell) (NN survival)) (CONJP (RB rather) (IN than)) (NP (NN cell) (NN growth)))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (SBAR-TMP (WHADVP-42 (WRB when)) (S (VP (VBN introduced) (PP (IN into) (NP (JJ murine) (JJ pro-B) (NNS lymphocytes)))))) (, ,) (NP-SBJ-40 (DT the) (JJ oncogenic) (NN E2A-HLF) (NN fusion) (NN protein)) (VP (VBD reversed) (NP (ADJP-COOD (CC both) (ADJP (JJ interleukin-3-dependent)) (CC and) (ADJP (JJ p53-mediated))) (NN apoptosis))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ close) (NN homology)) (PP (IN of) (NP (NP (DT the) (NP (NP (JJ basic) (NN region/leucine) (NN zipper)) (PRN (-LRB- -LRB-) (NP (NN bZIP)) (-RRB- -RRB-))) (UCP-COOD (ADJP (JJ DNA-binding)) (CC and) (NP (NN dimerization))) (NN domain)) (PP (IN of) (NP (NN HLF))))) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (NN CES-2) (NN cell-death) (NN specification) (NN protein)) (PP (IN of) (NP (NN Caenorhabditis) (NNS elegans)))))))) (VP (VBZ suggests) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NN leukaemogenesis))) (SBAR (WHPP-43 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NN E2A-HLF)) (VP (VBZ blocks) (NP (NP (DT an) (JJ early) (NN step)) (PP (IN within) (NP (DT an) (ADJP (RB evolutionarily) (VBN conserved)) (NN cell-death) (NN pathway))))))))) (. .)))
(TOP (NP (NP (NNS Effects)) (PP (IN of) (NP-COOD (NP (NN IL-10)) (CC and) (NP (NN IL-4)))) (PP (IN on) (NP (NP (NP (JJ LPS-induced) (NN transcription) (NNS factors)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN AP-1)) (, ,) (NP (NN NF-IL6)) (CC and) (NP (NN NF-kappa) (NN B))) (-RRB- -RRB-))) (SBAR (WHNP-49 (WDT which)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NN IL-6) (NN regulation))))))))) (. .)))
(TOP (S (NP-SBJ-51 (NP (NN Interleukin-10)) (PRN (-LRB- -LRB-) (NP (NN IL-10)) (-RRB- -RRB-))) (, ,) (PP-TPC-102 (IN like) (NP (NN IL-4))) (, ,) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN cytokine) (NN expression)) (PP (IN in) (NP (VBN activated) (JJ human) (NNS monocytes))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-COOD-52 (CC both) (NP (NN IL-10)) (CC and) (NP (NN IL-4))) (VP (VBP inhibit) (NP (JJ LPS-induced) (NN IL-6) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))) (NN expression)) (PP (IN by) (S (VP (VBG inhibiting) (NP (NP (DT the) (NN transcription) (NN rate)) (PP (IN of) (NP (DT the) (NN IL-6) (NN gene))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ strong) (NN inhibition)) (PP (IN of) (NP (DT the) (NN IL-6) (NN transcription) (NN rate)))) (VP (VBD prompted) (S (NP-SBJ (PRP us)) (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP-COOD (NP (NN IL-10)) (CC and) (NP (NN IL-4)))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN transcription) (NNS factors)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD questioned) (SBAR (IN whether) (CC or) (RB not) (S (NP-SBJ-COOD (NP (NN IL-10)) (CC and) (NP (NN IL-4))) (VP (VBD affected) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (NN transcription) (NNS factors)) (SBAR (WHNP-53 (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT the) (NN IL-6) (NN transcription) (NN rate)))))))))))))) (, ,) (RB namely) (NP-COOD (NP (NP (NN activator) (NN protein-1)) (PRN (-LRB- -LRB-) (NP (NN AP-1)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ nuclear) (NN factor) (NN IL-6)) (PRN (-LRB- -LRB-) (NP (NN NF-IL6)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)) (PRN (-LRB- -LRB-) (NP (NNS EMSAs)) (-RRB- -RRB-)))) (NP-SBJ (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN IL-10)) (CC and) (NP (NN IL-4))) (VP (VBD inhibited) (NP (JJ LPS-induced) (NN AP-1) (NN binding) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ inhibiting) (NN effect)) (PP (IN of) (NP (NN IL-4)))) (VP (VBD was) (ADJP-PRD (ADJP (ADVP (RB slightly) (RBR more)) (JJ pronounced)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NN IL-10))))))) (. .)))
(TOP (S (NP-SBJ-56 (NP (NN Downregulation)) (PP (IN of) (NP (JJ LPS-induced) (NN AP-1)))) (VP (VBD was) (VP (VP-COOD (VP (VBN accompanied)) (, ,) (CC and) (RB thus) (VP (ADVP (RB possibly)) (VBN explained))) (, ,) (PP-58 (IN by) (NP-LGS (NP (DT a) (VBN reduced) (NN expression)) (PP (IN at) (NP (NN mRNA) (NN level))) (PP (IN of) (NP (NP (NP (DT the) (CD two) (JJ major) (NNS components)) (PP (IN of) (NP (DT the) (NN AP-1) (NN complex)))) (, ,) (RB namely) (NP (NP-COOD (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN Northern) (NNS experiments))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-60 (NP (NN Binding) (NN activity)) (PP (IN of) (NP (NN NF-IL6)))) (VP (VBD was) (ADVP (RB also)) (VP (ADVP (RB strongly)) (VBN inhibited) (PP (IN by) (NP-LGS (NN IL-4)))))) (IN whereas) (S (NP-SBJ (NN IL-10)) (VP (VBD showed) (NP (DT no) (NN effect)))) (. .)))
(TOP (S (NP-SBJ-61 (NN NF-IL6) (NN mRNA) (NNS levels)) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP-LGS-COOD (NP (NN IL-10)) (CC or) (NP (NN IL-4)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN IL-4)) (VP (VBZ affects) (NP (NP (NN binding) (NN activity)) (PP (IN of) (NP (VBG preexisting) (NN NF-IL6))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (CC Neither) (NP (NN IL-10)) (CC nor) (NP (NN IL-4))) (VP (VBD inhibited) (NP (JJ LPS-induced) (NN NF-kappa) (NN B) (NN binding) (NN activity))) (. .)))
(TOP (S (PP (IN In) (NN agreement) (IN with) (NP (DT this) (NN finding))) (, ,) (NP-SBJ (NP (NN Northern) (NNS experiments)) (SBAR (WHADVP-63 (WRB where)) (S (NP-SBJ-64 (NP-COOD (NP (NN p65)) (CC and) (NP (NN p105))) (NN mRNA) (NNS levels)) (VP (VBD were) (VP (VBN determined)))))) (, ,) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-65 (NP (NN expression)) (PP (IN of) (NP (NP (DT these) (NNS components)) (PP (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN transcription) (NN factor)))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP-LGS-COOD (NP (NN IL-10)) (CC or) (NP (NN IL-4))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-COOD (CC neither) (NP (NN IL-10)) (CC nor) (NP (NN IL-4))) (VP (VBD showed) (NP (NP (DT any) (NN effect)) (PP (IN on) (NP (NN I-kappa) (NN B) (NN mRNA) (NN expression)))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN Northern) (NNS experiments))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-COOD (NP (NN IL-10)) (CC and) (NP (NN IL-4))) (ADVP (RB similarly)) (VP (VBP affect) (NP (NN IL-6) (NN expression))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (PP (IN for) (NP (NN IL-4))) (NP-SBJ-67 (DT this)) (VP (VBD was) (VP (VBN accompanied) (PP (IN with) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-IL6))) (NN binding) (NN activity))))) (SBAR (IN whereas) (S (NP-SBJ (NN IL-10)) (ADVP (RB only)) (VP (VBD inhibited) (NP (NN AP-1) (NN binding) (NN activity))))))) (. .)))
(TOP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN transcription) (NN factor) (NN Stat1) (NN activity))) (PP (IN in) (NP-COOD (NP (JJ mononuclear) (NN cell) (NNS cultures)) (CC and) (NP (NN T) (NNS cells)))) (PP (IN by) (NP (DT the) (JJ cyclic) (NN AMP) (NN signaling) (NN pathway))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (NN T) (NNS cells)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (NN cascade)) (PP (IN of) (NP-COOD (NP (NN gene) (NN activation)) (CC and) (NP (JJ subsequent) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NP (NN differentiation)) (PP (IN into) (NP (NN effector) (NNS phenotypes))))))))))) (. .)))
(TOP (S (NP-SBJ-38 (NP (DT The) (NN regulation)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (VBG belonging) (PP (TO to) (NP (DT the) (NP (NP-COOD (NP (NN signal) (NN transducer)) (CC and) (NP (NP (NN activator)) (PP (IN of) (NP (NN transcription))))) (PRN (-LRB- -LRB-) (NP (NN STAT)) (-RRB- -RRB-))) (NN family))))))) (VP (VBD was) (VP (VBN analyzed) (PP-COOD (PP (IN in) (NP (JJ PHA-activated) (JJ mononuclear) (NNS cells))) (CC and) (PP (IN in) (NP (NP (VBN purified) (NN T) (NNS cells)) (VP (VBN activated) (PP (IN by) (NP (JJ cross-linking) (NN cell) (NN surface) (NN CD3))))))))) (. .)))
(TOP (S (NP-SBJ (NN Cell) (NN activation)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (VBN delayed) (NN induction)) (PP (IN of) (NP (NN STAT) (JJ DNA-binding) (NN activity))) (, ,) (SBAR (WHNP-39 (WDT which)) (S (VP-COOD (VP (VBD was) (VP (JJ sustained) (PP-TMP (IN for) (NP (JJ several) (NNS days))))) (, ,) (VP (VBD was) (VP (VBN composed) (ADVP (RB predominantly)) (PP (IN of) (NP-COOD (NP (NN Stat1)) (CC and) (NP (NN Stat3)))))) (, ,) (CC and) (VP (VBD was) (VP (VBN blocked) (PP (IN by) (NP-LGS-COOD (NP (NN cycloheximide)) (CC and) (NP (NN actinomycin) (NN D)))))))))))) (. .)))
(TOP (S (NP-SBJ-43 (VBN Increased) (NP-COOD (NP (NN Stat1)) (CC and) (NP (NN Stat3))) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))) (NNS levels)) (VP (VBD were) (VP (VBN detected) (, ,) (PP-TMP (ADVP (RB respectively)) (NP (QP (CD 4) (CC and) (CD 24)) (NN h)) (IN after) (NP (NN activation))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (DT the) (NN cAMP) (NN signal) (NN transduction) (NN pathway))) (, ,) (SBAR (WHNP-44 (WDT which)) (S (VP (VBZ skews) (NP (NN cytokine) (NN production)) (PP (IN toward) (NP (DT a) (NN Th2) (NN pattern)))))) (, ,)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (JJ preferential) (NN suppression)) (PP (IN of) (NP (NN Stat1) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ (NN cAMP)) (VP-COOD (VP (VBD inhibited) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (NN IL-2) (NN receptor) (NNS components))))))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB inhibit) (NP-COOD (NP (NP-COOD (NP (NN IL-4) (NN receptor) (NN alpha-chain)) (CC and) (NP (NN CD69))) (NN expression)) (CC or) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN activator) (NN protein) (CD 1) (NN transcription) (NNS factors)))))))) (. .)))
(TOP (S (NP-SBJ (NN cAMP) (NN signaling)) (VP (VBD inhibited) (NP (NN Stat1)) (PP (IN at) (NP (NP (JJ several) (JJ different) (NNS levels)) (, ,) (PP (VBG including) (NP (NP-COOD (NP (NP (NN suppression)) (PP (IN of) (NP (NN DNA) (NN binding)))) (CC and) (NP (NP (NN down-regulation)) (PP (IN of) (NP (NN Stat1) (NP-COOD (NP (NN protein)) (CC and) (NP (NN mRNA))))))) (NNS levels)))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN STAT) (NN activity))) (PP (IN by) (NP (NP (DT a) (NN signaling) (NN pathway)) (SBAR (WHNP-45 (WDT that)) (S (VP-COOD (VP (VBZ regulates) (NP (DT the) (NN T) (NN cell) (JJ functional) (NN phenotype))) (CC and) (VP (VBZ is) (ADJP-PRD (JJ distinct) (PP (IN from) (NP (DT the) (JJ cytokine-activated) (NN Janus) (NN kinase-STAT) (NN signaling) (NN pathway)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN oriP)) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (NN EBNA) (NN gene) (NN promoter) (NN activity)) (PP (IN in) (NP (ADJP (JJ Epstein-Barr) (JJ virus-immortalized)) (JJ lymphoblastoid) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (PP-TMP (IN During) (NP (NP (JJ Epstein-Barr) (NN virus) (JJ latent) (NN infection)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (ADVP (FW in) (FW vitro)))) (, ,) (NP-SBJ-31 (NP (CD six) (JJ viral) (JJ nuclear) (NNS antigens)) (PRN (-LRB- -LRB-) (NP (NN EBNAs)) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN expressed) (PP (IN from) (NP (NP (CD one)) (PP (IN of) (NP (NP (NP (CD two) (NNS promoters)) (, ,) (NP-COOD (NP (NN Cp)) (CC or) (NP (NN Wp))) (, ,)) (SBAR (WHNP-32 (WP$ whose) (NNS activities)) (S (VP (VBP are) (ADJP-PRD (RB mutually) (JJ exclusive))))))))))) (. .)))
(TOP (S (PP-TMP (IN Upon) (NP (NN infection))) (, ,) (NP-SBJ-33 (NN Wp)) (VP (VBZ is) (ADVP-TMP (RB initially)) (ADJP-PRD (JJ active)) (, ,) (S (VP (VBN followed) (PP (IN by) (NP-LGS (NP (DT a) (NN switch)) (PP (TO to) (NP (NN Cp))) (PP-TMP (IN for) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN latency)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ-35 (NP (DT the) (NN region)) (ADVP (JJ upstream) (PP (IN of) (NP (NN Cp))))) (VP (VBD was) (VP (VBN analyzed) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN cis) (NNS elements)) (VP (VBN involved) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (DT the) (NN EBNA) (NN gene) (NNS promoters)))))))))) (PP (IN in) (NP (JJ established) (ADJP (FW in) (FW vitro)) (VBN immortalized) (NP (NP (JJ lymphoblastoid) (NN cell) (NNS lines)) (PRN (-LRB- -LRB-) (NP (NNS LCLs)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBD was) (VP (VBN determined) (SBAR (IN that) (S (NP-SBJ (NP (NN oriP)) (, ,) (NP (NP (DT the) (NN origin)) (PP (IN for) (NP (NP (JJ episomal) (NN maintenance)) (PP-TMP (IN during) (NP (NN latency)))))) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (JJ efficient) (NN transcription) (NN initiation)) (PP (IN from) (NP-COOD (CC either) (NP (NN Cp)) (CC or) (NP (NN Wp)))) (PP-COOD (PP (IN in) (NP (NN LCLs))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (DT some) (NP (NN Burkitt) (POS 's)) (NN lymphoma) (NN cell) (NNS lines)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Deletion)) (PP (IN of) (NP (NP (DT the) (JJ EBNA2-dependent) (NN enhancer)) (ADJP (JJ located) (ADVP (RB upstream) (PP (IN of) (NP (NN Cp)))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (QP (FW ca.) (CD two-) (TO to) (JJ fivefold)) (NN reduction)) (PP (IN in) (NP (NP (NN Cp) (NN activity)) (PP (IN in) (NP (NP (DT the) (NNS LCLs)) (VP (VBN assayed))))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (RBR More) (JJ extensive)) (NN deletion)) (PP (IN of) (NP (NP (NNS sequences)) (ADVP (JJ upstream) (PP (IN of) (NP (NN Cp)))) (, ,) (PP (VBG including) (NP (DT the) (JJ EBNA2-dependent) (NN enhancer))) (, ,)))) (VP (VBD resulted) (PP (IN in) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN loss)) (PP (IN of) (NP (NN Cp) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ-36 (NP (DT This) (NN loss)) (PP (IN of) (NP (NN activity)))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB correlate) (PP (IN with) (NP (NP (NN deletion)) (PP (IN of) (NP (NP (CD two) (NN CCAAT) (NNS boxes)) (, ,) (NP-COOD (NP (NP (DT a) (JJ proximal) (NN CCAAT) (NN box)) (ADJP (JJ located) (PP (IN at) (NP (NN bp) (NP-COOD (NP (CD -61)) (TO to) (NP (CD -65))))))) (CC and) (NP (NP (DT a) (JJ distal) (NN CCAAT) (NN box)) (ADJP (JJ located) (UCP-COOD (PP (IN at) (NP (NN bp) (NP-COOD (NP (CD -253)) (TO to) (NP (CD -257))))) (, ,) (ADVP (RB upstream) (PP (IN of) (NP (NN Cp))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Site-directed) (NN mutagenesis)) (PP (IN of) (NP (DT these) (NN cis) (NNS elements)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NN Cp) (NN activity)) (VP (VBZ is) (ADJP-PRD (RB highly) (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (ADJP (RB properly) (VBN positioned)) (NN CCAAT) (NN box)))))) (, ,) (PP (IN with) (NP (NP (DT the) (NN dependence)) (PP (IN on) (NP (NP (DT the) (JJ distal) (NN CCAAT) (NN box)) (ADJP (JJ apparent) (SBAR-TMP (WHADVP-37 (RB only) (WRB when)) (S (NP-SBJ-38 (DT the) (JJ proximal) (NN CCAAT) (NN box)) (VP (VBD was) (VP-COOD (VP (VBN deleted)) (CC or) (VP (VBN mutated))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Deletion)) (PP (IN of) (NP (NP (DT the) (NN glucocorticoid) (NN response) (NNS elements)) (ADJP (JJ located) (PP (IN at) (ADVP (NP (FW ca.) (NN bp) (CD -850)) (RB upstream) (PP (IN of) (NP (NN Cp))))))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN loss)) (PP (IN in) (NP (NN activity))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ general))) (, ,) (NP-SBJ (NP (NNS deletions)) (SBAR (WHNP-40 (WDT which)) (S (VP (VBD diminished) (NP (JJ Cp) (NN activity)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN induction)) (PP (IN of) (NP (JJ Wp) (NN activity))))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ Wp) (NN activity))) (PP (IN by) (NP (NP (JJ transcriptional) (NN interference)) (PP (IN from) (NP (NN Cp))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN identification)) (PP (IN of) (NP-COOD (NP (NN oriP)) (CC and) (NP (DT the) (JJ EBNA2-dependent) (NN enhancer)))) (PP (IN as) (NP (NP (DT the) (JJ major) (JJ positive) (NN cis) (NNS elements)) (VP (VBN involved) (PP (IN in) (S (VP (VBG regulating) (NP (NP (JJ Cp) (NN activity)) (PP (IN in) (NP (NN LCL))))))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ-41 (NN EBNA) (NN gene) (NN transcription)) (VP (VBZ is) (ADVP (RB largely)) (VP (VBN autoregulated) (PP (IN by) (NP-LGS-COOD (NP (NN EBNA) (CD 1)) (CC and) (NP (NN EBNA) (CD 2))))))))) (. .)))
(TOP (NP (NP (JJ Various) (NNS modes)) (PP (IN of) (NP (NP (ADJP (JJ basic) (JJ helix-loop-helix) (JJ protein-mediated)) (NN regulation)) (PP (IN of) (NP (NP (JJ murine) (NN leukemia) (NN virus) (NN transcription)) (PP (IN in) (NP (JJ lymphoid) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (ADJP (RB transcriptionally) (JJ regulatory)) (NNS regions)) (PP (IN of) (NP (DT the) (JJ lymphomagenic) (NP-COOD (NP (NN Akv)) (CC and) (NP (NN SL3-3))) (NP (NP (JJ murine) (NN leukemia) (NNS retroviruses)) (PRN (-LRB- -LRB-) (NP (NNS MLVs)) (-RRB- -RRB-)))))) (VP (VBP contain) (NP (NP (NP (CD two) (NNS types)) (PP (IN of) (NP (NN E-box) (NN consensus) (NNS motifs)))) (, ,) (NP (NN CAGATG)))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (CD One) (NN type)) (, ,) (NP (NN EA/S)) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ located) (PP (IN in) (NP (DT the) (JJ upstream) (NN promoter) (NN region)))))) (, ,) (CC and) (S (NP-SBJ (NP (DT the) (JJ other)) (, ,) (NP (NN E-LRB-gre-RRB-)) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ located) (PP (IN in) (NP (NP (DT a) (JJ tandem) (NN repeat)) (PP (IN with) (NP (NN enhancer) (NNS properties)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NNS requirements)) (PP (IN of) (NP (DT the) (JJ individual) (NNS E-boxes))) (PP (IN in) (NP (NN MLV) (JJ transcriptional) (NN regulation)))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ lymphoid) (NN cell) (NNS lines)) (ADVP (RB only)))) (, ,) (NP-SBJ (DT the) (JJ E-LRB-gre-RRB--binding) (NN protein) (NNS complexes)) (VP (VBD included) (NP (NP-COOD (NP-COOD (NP (NN ALF1)) (CC or) (NP (NN HEB))) (CC and) (NP (NN E2A))) (JJ basic) (JJ helix-loop-helix) (NNS proteins))) (. .)))
(TOP (S (NP-SBJ-35 (JJ Ectopic) (NP-COOD (NP (NN ALF1)) (CC and) (NP (NN E2A))) (NNS proteins)) (VP (VBD required) (NP (JJ intact) (NN E-LRB-gre-RRB-) (NNS motifs)) (PP (IN for) (S (VP (VBG mediating) (NP (JJ transcriptional) (NN activation)))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NNP ALF1)) (VP (VBD transactivated) (NP (NP (NN transcription)) (PP (IN of) (NP (NN Akv) (NN MLV)))) (PP (IN through) (NP (DT the) (CD two) (NN E-LRB-gre-RRB-) (NNS motifs))) (ADVP (RB equally)))) (, ,) (IN whereas) (S (NP-SBJ (NN E2A) (NN protein)) (VP (VBD required) (NP (DT the) (JJ promoter-proximal) (NN E-LRB-gre-RRB-) (NN motif)))) (. .)))
(TOP (S (PP (IN In) (NP (NP-COOD (NP (NN T-)) (CC and) (NP (NN B-cell))) (NNS lines))) (, ,) (NP-SBJ (DT the) (NN E-LRB-gre-RRB-) (NNS motifs)) (VP (VBD were) (PP-PRD (IN of) (NP (JJ major) (NN importance))) (PP (IN for) (NP (NN Akv) (NN MLV) (JJ transcriptional) (NN activity))) (, ,) (SBAR (IN while) (S (NP-SBJ (DT the) (NN EA/S) (NN motif)) (VP (VBD had) (NP (DT some) (NN effect)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP-COOD (CC neither) (NP (NN E-LRB-gre-RRB-)) (CC nor) (NP (NN EA/S))) (NNS motifs)) (VP (VBD contributed) (ADVP (RB pronouncedly)) (PP (TO to) (NP (NP (NN Akv) (NN MLV) (NN transcription)) (PP (IN in) (NP (NP (NN NIH) (NN 3T3) (NNS cells)) (VP (VBG lacking) (NP (JJ DNA-binding) (NP-COOD (NP-COOD (NP (NN ALF1)) (CC or) (NP (NN HEB))) (CC and) (NP (NN E2A))) (NNS proteins)))))))) (. .)))
(TOP (S (NP-SBJ-36 (DT The) (NN Id1) (NN protein)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB repress) (NP (NN ALF1) (NN activity)) (ADVP-COOD (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ (JJ ectopic) (NN Id1)) (VP (VBD repressed) (NP (NP (ADJP-COOD (ADJP (JJ E-LRB-gre-RRB--directed)) (CONJP (CC but) (RB not)) (ADJP (JJ EA/S-directed))) (NN MLV) (NN transcription)) (PP (IN in) (NP (JJ lymphoid) (NN cell) (NNS lines))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP-SBJ-COOD (NP (NN E-LRB-gre-RRB-) (NNS motifs)) (CC and) (NP (VBG interacting) (JJ basic) (JJ helix-loop-helix) (NNS proteins))) (VP (VBP are) (NP-PRD (NP (JJ important) (NNS determinants)) (PP (IN for) (NP (NP (NN MLV) (JJ transcriptional) (NN activity)) (PP (IN in) (NP (JJ lymphocytic) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD 1) (JJ posttranscriptional) (NN trans-activator) (NN Rex)) (VP (VBZ contains) (NP (DT a) (JJ nuclear) (NN export) (NN signal))) (. .)))
(TOP (S (NP-SBJ-31 (NP (DT The) (NN Rex) (NN protein)) (PP (IN of) (NP (JJ human) (NN T-cell) (NN leukemia) (NN virus) (NN type) (CD 1)))) (VP (VBZ is) (VP (VBN required) (PP-COOD (PP (IN for) (NP (NP (DT the) (JJ nuclear) (NN export)) (PP (IN of) (NP (JJ unspliced) (JJ viral) (NN mRNA))))) (CC and) (, ,) (RB therefore) (, ,) (PP (IN for) (NP (NN virus) (NN replication)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN manuscript))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NN Rex)) (VP (VBZ shuttles) (PP (IN between) (NP-COOD (NP (DT the) (NN nucleus)) (CC and) (NP (DT the) (NN cytoplasm))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (PRP$ its) (NN activation) (NN domain)) (VP (VBZ constitutes) (NP (NP (DT a) (JJ nuclear) (NN export) (NN signal)) (SBAR (WHNP-32 (WDT that)) (S (VP (VBZ specifies) (NP (NP (JJ efficient) (NN transport)) (PP (TO to) (NP (DT the) (NN cytoplasm))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP are) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (NP (DT a) (NN model)) (PP (IN for) (NP (JJ Rex-mediated) (NN trans-activation))) (SBAR (WHPP-33 (IN in) (WHNP (WDT which))) (S (NP-SBJ-34 (JJ Rex-viral) (NN mRNA) (NNS complexes)) (VP (VBP are) (VP (VBN targeted) (PP (IN for) (NP (NP (JJ nuclear) (NN export)) (PP (IN by) (NP (NP (DT the) (JJ direct) (NN action)) (PP (IN of) (NP (DT the) (NN activation) (NN domain))))))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Multiple) (NN p21ras) (NN effector) (NNS pathways)) (VP (VBP regulate) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ-66 (NP (DT The) (NN transcription) (NN factor)) (, ,) (NP (NP (JJ Nuclear) (NN Factor) (IN of) (VBN Activated) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN NFAT)) (-RRB- -RRB-)))) (VP-COOD (VP (VBZ is) (NP-PRD (NP (DT a) (JJ major) (NN target)) (PP (IN for) (NP (NP (NP-COOD (NP (NN p21ras)) (CC and) (NP (NN calcium))) (NN signalling) (NNS pathways)) (PP (IN in) (NP (DT the) (NN IL-2) (NN gene))))))) (CC and) (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (NN p21ras) (NNS signals)) (VP (VBG acting) (PP (IN in) (NP (NP (NN synergy)) (PP (IN with) (NP (NN calcium/calcineurin) (NNS signals))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (CD One) (NN p21ras) (NN effector) (NN pathway)) (VP (VBZ involves) (NP (DT the) (NN MAP) (NN kinase) (NN ERK-2)))) (, ,) (CC and) (S (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN examined) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (NN NFAT) (NN regulation))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (JJ dominant) (JJ negative) (NN MAPKK-1)))) (VP (VBZ prevents) (NP (NN NFAT) (NN induction))) (. .)))
(TOP (S (NP-SBJ-67 (ADJP (RB Constitutively) (JJ active)) (NN MAPKK-1)) (ADVP (RB fully)) (VP-COOD (VP (VBZ activates) (NP-COOD (NP (NN ERK-2)) (CC and) (NP (DT the) (NN transcription) (NN factor) (NN Elk-1)))) (, ,) (CC but) (VP (VBZ does) (RB not) (VP-COOD (VP (VB substitute) (PP (IN for) (NP (VBN activated) (NN p21ras)))) (CC and) (VP (VBP synergize) (PP (IN with) (NP (NN calcium/calcineurin) (NNS signals))) (S (VP (TO to) (VP (VB induce) (NP (NN NFAT))))))))) (. .)))
(TOP (S (NP-SBJ-68 (NP (NN Expression)) (PP (IN of) (NP (JJ dominant) (JJ negative) (NN N17Rac)))) (ADVP (RB also)) (VP (VBZ prevents) (NP (NP (NP-COOD (NP (NN TCR)) (CC and) (NP (NN p21ras))) (NN activation)) (PP (IN of) (NP (NN NFAT)))) (, ,) (CC but) (PP (IN without) (S (VP (VBG interfering) (PP (IN with) (NP (DT the) (NN ERK-2) (NN pathway))))))) (. .)))
(TOP (S (NP-SBJ-69 (NP (DT The) (JJ transcriptional) (NN activity)) (PP (IN of) (NP (DT the) (NN NFAT) (NN binding) (NN site)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT a) (NN complex)) (VP (VBG comprising) (NP-COOD (NP (NP (DT a) (NN member)) (PP (IN of) (NP (DT the) (NN NFAT) (NN group)))) (CC and) (NP (NN AP-1) (NN family) (NNS proteins)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN induction)) (PP (IN of) (NP (NN AP-1))) (PP (IN by) (NP (NN p21ras)))) (ADVP (RB also)) (VP (VBZ requires) (NP (NN Rac-1) (NN function))) (. .)))
(TOP (S (NP-SBJ-70 (VBN Activated) (NN Rac-1)) (VP (MD could) (VP (VB mimic) (NP (VBN activated) (NN p21ras)) (S (VP-COOD (VP (TO to) (VP (VB induce) (NP (NN AP-1)))) (CC but) (VP (RB not) (TO to) (VP (VB induce) (NP (NN NFAT)))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-71 (NP (DT the) (NN combination)) (PP (IN of) (NP (VBN activated) (NP-COOD (NP (NN MAPKK-1)) (CC and) (NP (NN Rac-1)))))) (VP (MD could) (RB not) (VP-COOD (VP (VB substitute) (PP (IN for) (NP (VBN activated) (NN p21ras)))) (CC and) (VP (VB synergize) (PP (IN with) (NP (NN calcium) (NNS signals))) (S (VP (TO to) (VP (VB induce) (NP (NN NFAT)))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (NN p21ras) (NN regulation)) (PP (IN of) (NP (NN NFAT))) (PP (IN in) (NP (NN T) (NNS cells)))) (VP (VBZ requires) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (JJ multiple) (NN effector) (NNS pathways)) (PP (VBG including) (NP (NP (DT those)) (VP (VBN regulated) (PP (IN by) (NP-LGS-COOD (NP (NN MAPKK-1/ERK-2)) (CC and) (NP (NN Rac-1))))))))))) (. .)))
(TOP (S (NP-SBJ-42 (JJ Protein-tyrosine) (NN kinase) (NN activation)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP-COOD (NP (NP (NN lipopolysaccharide) (NN induction)) (PP (IN of) (NP (NN interleukin) (NN 1beta)))) (CC and) (NP (NN NFkappaB) (NN activation)) (, ,) (CONJP (CC but) (RB not)) (NP (NN NFkappaB) (JJ nuclear) (NN translocation)))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ human) (NNS monocytes))) (, ,) (NP-SBJ-COOD-43 (NP (NN interleukin) (NN 1beta) (NN protein) (NN production)) (CC and) (NP (JJ steady) (NN state) (NN mRNA) (NNS levels))) (VP (VBP are) (VP (VBN increased) (PP (IN in) (NN response) (TO to) (NP (NN lipopolysaccharide))) (, ,) (PP (ADVP (RB predominantly)) (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (VBN increased) (NN transcription)) (PP (IN of) (NP (DT the) (NN interleukin) (NN 1beta) (NN gene))))))))) (. .)))
(TOP (S (NP-SBJ-44 (NP (NN Expression)) (PP (IN of) (NP-COOD (NP (NN interleukin) (NN 1beta)) (CC and) (NP (NP (JJ other) (NNS cytokines)) (, ,) (PP (JJ such) (IN as) (NP-COOD (NP (NN interleukin) (CD 6)) (CC and) (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)))) (, ,))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN NFkappaB))))))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (JJ recent) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-45 (JJ lipopolysaccharide-induced) (NN tyrosine) (NN kinase) (NN activation)) (VP (VBZ is) (RB not) (VP (VBN required) (PP (IN for) (NP (NN NFkappaB) (JJ nuclear) (NN translocation))))))))))) (, ,) (NP-SBJ-46 (PRP we)) (VP (VBD sought) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ-47 (NP (NN NFkappaB)) (VP (VBN translocated) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN tyrosine) (NN kinase) (NN activity))))) (VP (VBD was) (ADJP-PRD (JJ active)) (PP (IN in) (S (VP (VBG stimulating) (NP (NN transcription)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN found) (SBAR (IN that) (, ,) (S (PP (IN in) (NP (NP (DT the) (JJ human) (JJ pro-monocytic) (NN cell) (NN line)) (, ,) (NP (NN THP-1)))) (, ,) (NP-SBJ (NP (DT the) (JJ lipopolysaccharide-induced) (NN expression)) (PP (IN of) (NP (NN interleukin) (NN 1beta)))) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NN tyrosine) (NN kinase) (NN activation))))))))) (. .)))
(TOP (S (NP-SBJ-48 (NN Tyrosine) (NNS kinases)) (VP (VBP are) (RB not) (VP (VBN required) (PP (IN for) (NP (NP (JJ lipopolysaccharide-mediated) (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NN NFkappaB))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN tyrosine) (NN kinase) (NN activity))) (, ,) (NP-SBJ (NP (DT the) (NN ability)) (PP (IN of) (NP (NN NFkappaB))) (S-50 (VP (TO to) (VP (VB stimulate) (NP (NN transcription)))))) (VP (VBZ is) (ADJP-PRD (JJ impaired))) (. .)))
(TOP (S (S (NP-SBJ (NP (DT This) (NN inhibition)) (PP (IN of) (NP (NN transcription)))) (VP (VBZ is) (ADJP-PRD (JJ specific) (PP (IN for) (NP (NN NFkappaB))))) (: ;)) (S (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN tyrosine) (NN kinase) (NN activity))) (, ,) (NP-SBJ-51 (JJ AP-1-dependent) (NN transcription)) (VP (VBZ is) (VP (VBN enhanced))) (. .))))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (SBAR (, ,) (S (NP-SBJ (NP (IN while) (JJ lipopolysaccharide-induced)) (PP (NN expression) (NP (IN of) (JJ inflammatory)))) (VP (NNS mediators) (NP (VBZ requires) (NN tyrosine) (NN kinase))))) (NN activity) (NP-SBJ (, ,) (NN tyrosine) (NN kinase)) (VP (NN activity) (VBZ is) (ADJP-PRD (RB not) (PP (JJ obligatory) (NP (IN for) (NN lipopolysaccharide) (NN signal)))))))) (NN transduction)))
(TOP (S (NP-SBJ (JJ Granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (ADVP (RB preferentially)) (VP (VBZ activates) (NP (NP-COOD (NP (DT the) (JJ 94-kD) (NN STAT5A)) (CC and) (NP (DT an) (JJ 80-kD) (NN STAT5A) (NN isoform))) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NNS monocytes))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (VP (VBZ induces) (NP (JJ immediate) (NNS effects)) (PP (IN in) (NP (NNS monocytes))) (PP (IN by) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NP (NN Janus) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN JAK2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN STAT) (NN transcription) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN STAT5)) (-RRB- -RRB-)))) (NN pathway)))))) (. .)))
(TOP (S (NP-SBJ (JJ Recent) (NNS studies)) (VP (VBP have) (VP (VBN identified) (NP-COOD (NP (NP (NNS homologues)) (PP (IN of) (NP-COOD (NP (NN STAT5)) (, ,) (NP (NN STAT5A)) (, ,) (CC and) (NP (NN STAT5B))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJR lower) (JJ molecular) (NN weight) (NNS variants)) (PP (IN of) (NP (NN STAT5))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB define) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NN STAT5) (NP-COOD (NP (NNS homologues)) (CC and) (NP (JJR lower) (JJ molecular) (NN weight) (NN variant))))) (PP (IN in) (NP-COOD (NP (JJ human) (NNS monocytes)) (CC and) (NP (NP (NNS monocytes)) (VP (VBN differentiated) (PP (IN into) (NP (NNS macrophages))) (PP (IN by) (NP-LGS (NP (NN culture)) (PP (IN in) (NP (NP (NN macrophage-CSF)) (PRN (-LRB- -LRB-) (NP (NN M-CSF)) (-RRB- -RRB-)))))))))))))) (, ,) (NP-SBJ-35 (PRP we)) (VP (VBD measured) (NP (NP (DT the) (ADJP (NN GM-CSF) (JJ induced)) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN STAT5A)) (, ,) (NP (NN STAT5B)) (, ,) (CC and) (NP (DT any) (JJR lower) (JJ molecular) (NN weight) (NN STAT5) (NNS isoforms)))))) (. .)))
(TOP (S (NP-SBJ (ADJP (RB Freshly) (VBN isolated)) (NNS monocytes)) (VP (VBD expressed) (NP-COOD (NP (JJ 94-kD) (NN STAT5A)) (, ,) (NP (JJ 92-kD) (NN STAT5B)) (, ,) (CC and) (NP (DT an) (JJ 80-kD) (NN STAT5A) (NN molecule)))) (. .)))
(TOP (S (SBAR (IN Whereas) (S (NP-SBJ-100 (JJ 94-kD) (NN STAT5A)) (VP (VBD was) (ADVP (RB clearly)) (VP-COOD (VP (NN tyrosine) (JJ phosphorylated)) (CC and) (VP (VBD bound) (PP (TO to) (NP (DT the) (NN enhancer) (NN element)))))))) (, ,) (NP-SBJ (NP (NP (DT the) (NN gamma) (NN response) (NN region)) (PRN (-LRB- -LRB-) (NP (NN GRR)) (-RRB- -RRB-))) (, ,) (PP (IN of) (NP (DT the) (NN Fc) (NN gamma) (NN RI) (NN gene))) (, ,)) (VP (ADVP (RB substantially) (JJR less)) (NN tyrosine) (JJ phosphorylated) (NP (NP (NN STAT5B)) (VP (VBD bound) (PP (TO to) (NP (DT the) (JJ immobilized) (NN GRR) (NN element)))))) (. .)))
(TOP (S (NP-SBJ (NNS Macrophages)) (VP-COOD (VP (VBD lost) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB express) (NP (DT the) (JJ 80-kD) (NN STAT5A) (NN protein))))))) (, ,) (CC but) (VP (VBD retained) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB activate) (NP (NN STAT5A)))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ STAT5A-STAT5A) (NNS homodimers)) (CC and) (NP (NN STAT5A-STAT5B) (NNS heterodimers))) (VP (VBD formed) (PP (IN in) (NN response) (TO to) (NP (NN GM-CSF)))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ-36 (NP (NN activation)) (PP (IN of) (NP (NN STAT5A)))) (VP (VBZ predominates) (PP (VBN compared) (PP (TO to) (NP (NN STAT5B)))) (SBAR-TMP (WHADVP-40 (WRB when)) (S (VP (VBN assayed) (PP-COOD (PP (IN by) (NP (JJ direct) (NN immunoprecipitation))) (CC and) (PP (IN by) (NP (NP (NN evaluation)) (PP (IN of) (NP (NP (VBN bound) (NNS STATs)) (PP (TO to) (NP (JJ immobilized) (NN GRR)))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (JJ Selective) (NN activation)) (PP (IN of) (NP (NN STAT5) (NNS homologues)))) (CONJP (IN in) (NN addition) (TO to)) (NP (NP (NN generation)) (PP (IN of) (NP (JJR lower) (JJ molecular) (NNS isoforms))))) (VP (MD may) (VP (VB provide) (NP-COOD (NP (NN specificity)) (CC and) (NP (NN control))) (PP-DTV (TO to) (NP (NP (NNS genes)) (VP (VBN expressed) (PP (IN in) (NN response) (TO to) (NP (NP (NNS cytokines)) (PP (JJ such) (IN as) (NP (NN GM-CSF)))))))))) (. .)))
(TOP (NP (NP (NP (JJ LYSP100-associated) (JJ nuclear) (NNS domains)) (PRN (-LRB- -LRB-) (NP (NNS LANDs)) (-RRB- -RRB-)) (: :)) (NP-COOD (NP (NP (NN description)) (PP (IN of) (NP (NP (DT a) (JJ new) (NN class)) (PP (IN of) (NP (JJ subnuclear) (NNS structures)))))) (CC and) (NP (NP (PRP$ their) (NN relationship)) (PP (TO to) (NP (NN PML) (JJ nuclear) (NNS bodies)))) (. .))))
(TOP (S (NP-SBJ-37 (DT The) (NN PML) (NN gene)) (VP (VBZ is) (VP (VBN fused) (PP (TO to) (NP (NP (DT the) (NP (NP (JJ retinoic) (NN acid) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN RAR) (NN alpha)) (-RRB- -RRB-))) (NN gene)) (PP (IN in) (NP (NN t-LRB-15;17-RRB-) (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))))))) (, ,) (S (VP (VBG creating) (NP (DT a) (NN PML-RAR) (NN alpha) (NN fusion) (NN oncoprotein)))))) (. .)))
(TOP (S (NP-SBJ-39 (DT The) (NN PML) (NN gene) (NN product)) (VP (VBZ has) (VP (VBN been) (VP (JJ localized) (PP (TO to) (NP (NP (JJ subnuclear) (JJ dot-like) (NNS structures)) (VP (ADVP (RB variously)) (VBN termed) (S (NP-PRD-COOD (NP (NNS PODs)) (, ,) (NP (NNS ND10s)) (, ,) (NP (NN Kr) (NNS bodies)) (, ,) (CC or) (NP (NP (NN PML) (JJ nuclear) (NNS bodies)) (PRN (-LRB- -LRB-) (NP (NN PML) (NNS NBs)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ present) (NN study)) (VP (VBZ describes) (NP (NP (DT the) (NN cloning)) (PP (IN of) (NP (NP (NP (DT a) (JJ lymphoid-restricted) (NN gene)) (, ,) (NP (NN LYSP100)) (, ,)) (SBAR (WHNP-40 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (JJ homologous) (PP (TO to) (NP (NP (DT another) (NN protein)) (SBAR (WHNP-41 (WDT that)) (S (VP (VBZ localizes) (PP (TO to) (NP-COOD (NP (NN PML) (NNS NBs)) (, ,) (NP (NN SP100))))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (NN SP100) (NN homology) (NNS regions))) (, ,) (NP-SBJ (CD one) (NN LYSP100) (NN cDNA) (NN isoform)) (VP (VBZ contains) (NP (NP-COOD (NP (DT a) (NN bromodomain)) (CC and) (NP (DT a) (NN PHD/TTC) (NN domain))) (, ,) (SBAR (WHNP-42 (WDT which)) (S (VP (VBP are) (ADJP-PRD (JJ present) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ transcriptional) (JJ regulatory) (NNS proteins))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NN immunofluorescence))) (, ,) (NP-SBJ-43 (NN LYSP100)) (VP (VBD was) (VP (JJ localized) (PP (TO to) (NP (NP (JJ nuclear) (NNS dots)) (SBAR (WHNP-44 (WDT that)) (S (VP (VBD were) (ADVP (RB surprisingly)) (ADJP-PRD (RB largely) (JJ nonoverlapping) (PP (IN with) (NP (NN PML) (NNS NBs))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT a) (NN minority)) (PP (IN of) (NP (NN LYSP100) (JJ nuclear) (NNS dots)))) (ADVP (RB exactly)) (VP (VBD colocalized) (PP (IN with) (NP-COOD (NP (NN PML)) (CC and) (NP (NN SP100))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP term) (S (NP-SBJ (DT the) (NN LYSP100) (NNS structures)) (`` ") (NP-PRD (NNS LANDs))) (, ,) ('' ") (PP (IN for) (NP (JJ LYSP100-associated) (JJ nuclear) (NNS domains)))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-45 (NN LYSP100)) (VP (VBZ is) (VP (VBN expressed) (PP (RB only) (IN in) (NP (JJ lymphoid) (NNS cells))))))) (, ,) (NP-SBJ-46 (NNS LANDs)) (VP (MD could) (VP (VB be) (VP (VBN visualized) (PP (IN in) (NP (NN HeLa) (NNS cells))) (PP (IN by) (NP-LGS (NP (NN transfection)) (PP (IN of) (NP (DT a) (NN LYSP100) (NN cDNA)))))))) (. .)))
(TOP (S (NP-SBJ (NN Immunoelectron) (NN microscopy)) (VP (VBD revealed) (S (NP-SBJ (NNS LANDs)) (VP (TO to) (VP (VB be) (NP-PRD (NP (ADJP-COOD (ADJP (JJ globular)) (, ,) (ADJP (JJ electron-dense))) (NNS structures)) (ADJP (RB morphologically) (JJ distinct) (PP (IN from) (NP (NP (DT the) (JJ annular) (NNS structures)) (ADJP (JJ characteristic) (PP (IN of) (NP (NN PML) (NNS NBs)))))))))))) (. .)))
(TOP (S (NP-SBJ-48 (NNS LANDs)) (VP (VP-COOD (VP (VBD were) (ADVP-TMP (RBS most) (RB often)) (VP (VBN found) (PP (IN in) (NP (DT the) (NN nucleoplasm))))) (, ,) (CC but) (VP (VBD were) (ADVP (RB also)) (VP (VBN found) (PP-COOD (PP (IN at) (NP (DT the) (JJ nuclear) (NN membrane))) (CC and) (PP (IN in) (NP (DT the) (NN cytoplasm))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (DT these) (NNS structures)) (VP (MD may) (VP (VBP traffic) (PP (IN between) (NP-COOD (NP (DT the) (NN cytoplasm)) (CC and) (NP (DT the) (NN nucleus))))))))))) (. .)))
(TOP (S (PP (IN By) (NP (NP (JJ double-immunogold) (NN labeling)) (PP (IN of) (NP-COOD (NP (NN PML)) (CC and) (NP (NN LYSP100)))))) (, ,) (NP-SBJ-51 (DT some) (NNS LANDs)) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB contain) (NP-COOD (CC both) (NP (NN PML)) (CC and) (NP (NN LYSP100)))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-52 (NN PML)) (VP (VBZ is) (VP (JJ localized) (NP (TO to) (NP (NP (DT a) (JJ second) (JJ subnuclear) (NN domain)) (SBAR (WHNP-53 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (ADVP-COOD (ADVP (RB morphologically)) (CC and) (ADVP (RB biochemically))) (JJ distinct) (PP (IN from) (NP (NN PML) (NNS NBs))))))))))) (. .)))
(TOP (NP (NP (NNS Abnormalities)) (PP (IN of) (NP (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC and) (NP (NN CDK4))) (NNS genes))) (PP (IN in) (NP (JJ recurrent) (JJ malignant) (NNS astrocytomas))) (. .)))
(TOP (S (NP-SBJ-38 (NP (NNS Abnormalities)) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC and) (NP (NN CDK4))) (NNS genes)) (SBAR (WHNP-39 (WDT that)) (S (VP (VBP regulate) (NP (NP (NN transition)) (PP (IN through) (NP (NP (DT the) (NN G1) (NN phase)) (PP (IN of) (NP (DT the) (NN cell) (NN cycle)))))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (JJ malignant) (NN progression)) (PP (IN of) (NP (NNS astrocytomas)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN dysfunction)) (PP (IN of) (NP (DT these) (NNS genes)))) (ADVP (RB also)) (VP (VBZ occurs) (PP-TMP (IN during) (NP (NP (NN recurrence)) (PP (IN of) (NP (NP (JJ glial) (NNS tumors)) (SBAR (WHNP-40 (WDT that)) (S (VP (VBD were) (ADJP-PRD (RB highly) (JJ malignant)) (PP (IN at) (NP (JJ first) (NN presentation)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (CD 10) (VBN matched) (NNS pairs)) (PP (IN of) (NP-COOD (NP (JJ high) (NN grade) (JJ malignant) (NNS astrocytomas)) (CC and) (NP (PRP$ their) (JJ subsequent) (NNS recurrences))))))) (VP (VBD identified) (NP (CD three) (JJ distinct) (NNS groups))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (ADJP-COOD (ADJP (JJ primary)) (CC and) (ADJP (JJ recurrent))) (NNS tumors)) (PP (IN in) (NP (NN Group) (NN A)))) (VP (VBD did) (RB not) (VP (VB show) (NP (NP (JJ structural) (NNS alterations)) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC or) (NP (NN CDK4))) (NNS genes))))))) (, ,) (IN whereas) (S (NP-SBJ-41 (NP (JJ homozygous) (NN codeletion)) (PP (IN of) (NP-COOD (NP (NN p16)) (CC and) (NP (NN p15))))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (ADJP-COOD (CC both) (ADJP (JJ primary)) (CC and) (ADJP (JJ recurrent))) (NNS tumors)) (PP (IN in) (NP (NN Group) (NN B)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ primary) (NNS tumors)) (PP (IN in) (NP (NN Group) (NN C)))) (VP (VBD had) (NP (NP (DT a) (JJ normal) (NN profile)) (PP (IN of) (NP-COOD (NP (NN p16)) (, ,) (NP (NN p15)) (CC and) (NP (NN CDK4))))) (PP (IN at) (NP (NN presentation)))) (. .)))
(TOP (S (PP-TMP (IN Upon) (NP (NN recurrence))) (, ,) (ADVP (RB however)) (, ,) (NP-SBJ (DT the) (NNS tumors)) (VP (VBD sustained) (NP-COOD (CC either) (NP (NP (NN deletion)) (PP (IN of) (NP (NP (NN p16)) (ADVP (RB alone))))) (CC or) (NP (NP (NN codeletion)) (PP (IN of) (NP-COOD (CC both) (NP (NN p16)) (CC and) (NP (NN p15))))) (CC or) (NP (NP (NN amplification)) (PP (IN of) (NP (NN CDK4)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS differences)) (PP (IN between) (NP-COOD (NP (JJ primary) (JJ anaplastic) (NNS astrocytomas/glioblastomas)) (CC and) (NP (PRP$ their) (JJ subsequent) (NNS recurrences)))) (, ,) (SBAR (WHNP-42 (WDT which)) (S (VP (VBP are) (ADVP (RB clinically)) (ADJP-PRD (JJ indistinguishable))))) (, ,)))) (VP (MD may) (VP (VB provide) (NP (NP (JJR better) (JJ therapeutic) (NNS options)) (PP (IN for) (NP (NN treatment)))))) (. .)))
(TOP (NP (NP (NN CTL) (NN recognition)) (PP (IN of) (NP (DT an) (JJ altered) (NN peptide))) (VP (VBN associated) (PP (IN with) (NP (NN asparagine) (NN bond) (NN rearrangement)))) (. .)))
(TOP (NP (NP (NNS Implications)) (PP (IN for) (NP-COOD (NP (NN immunity)) (CC and) (NP (NN vaccine) (NN design)))) (. .)))
(TOP (S (NP-SBJ-46 (NP (DT The) (NN extent)) (SBAR (WHPP-47 (TO to) (WHNP (WDT which))) (S (NP-SBJ-48 (NP (NNS peptides)) (VP (VBG containing) (NP (ADJP (ADVP-COOD (ADVP (RB chemically)) (CC and) (ADVP-TMP (RB post-translationally))) (VBN modified)) (NN amino) (NN acid) (JJ side) (NNS chains)))) (VP (VBP are) (VP (VBN recognized) (PP (IN by) (NP-LGS (JJ primed) (NN CTL)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB clearly)) (VP (VBN defined)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT the) (NN CTL) (NN recognition)) (PP (IN of) (NP (NP (DT a) (ADJP (NN MHC) (NN class) (JJ I-restricted)) (NN peptide)) (VP (VBG containing) (NP (DT a) (NP (NP (JJ cyclized) (NN asparagine)) (PRN (-LRB- -LRB-) (NP (NN succinimide)) (-RRB- -RRB-))) (NN residue)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT This) (NN modification)) (PP (IN of) (NP (DT the) (NN asparagine) (JJ side) (NN chain)))) (VP-COOD (VP (VBZ is) (NP-PRD (NP (DT a) (JJ common) (JJ intermediate) (NN structure)) (PP-TMP (IN during) (NP (NP-COOD (NP (NN deamidation)) (, ,) (NP (NN isomerization)) (, ,) (CC and) (NP (NN bond) (NNS rearrangements))) (PP (IN of) (NP (JJ amide-containing) (NN amino) (NNS acids))))))) (CC and) (RB also) (VP (VBZ occurs) (PP (IN as) (NP (NP (DT a) (JJ side) (NN reaction)) (PP (IN in) (NP (NN peptide) (NN synthesis))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN CTL)) (ADVP (RB specifically)) (VP (VBD recognized) (NP (NP (DT the) (JJ succinimide-containing) (NN peptide)) (VP (VBG showing) (NP (ADJP (RB only) (JJ weak)) (NN cross-reactivity)) (PP (IN at) (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NP (DT the) (NN parent) (NN peptide)) (VP (VBG containing) (NP (JJ unmodified) (NN asparagine)))))))))) (. .)))
(TOP (S (ADVP (RB Similarly)) (, ,) (NP-SBJ (NP (NN CTL)) (VP (VBN raised) (PP (IN against) (NP (DT the) (NN parent) (NN peptide))))) (VP (VBD did) (RB not) (VP (VB recognize) (NP (NP (DT the) (JJ succinimide) (NN derivative)) (PP (IN of) (NP (DT this) (NN peptide)))))) (. .)))
(TOP (S (NP-SBJ-49 (NP (ADJP (RB Naturally) (VBN processed)) (NNS forms)) (PP (IN of) (NP (DT these) (NNS structures)))) (VP (VBP are) (ADJP-PRD (JJ likely) (S (VP (TO to) (VP (VB occur))))) (PP (VBN given) (NP (NP (DT the) (NP-COOD (NP (NN importance)) (CC and) (NP (NN frequency)))) (PP (IN of) (NP (NN deamidation))) (ADVP-COOD (CC both) (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (SBAR (IN since) (S (NP-SBJ (NP (NN succinimide) (NNS intermediates)) (PP (IN of) (NP (VBN deamidated) (NNS peptides)))) (VP (MD can) (ADVP-TMP (RB occasionally)) (VP (VB be) (ADJP-PRD (RB very) (JJ stable)))))) (, ,) (NP-SBJ (DT these) (NNS peptides)) (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB act) (PP (IN as) (NP (NP (JJ altered) (NNS self-Ags)) (PP (IN with) (NP (NP (JJ significant) (NNS implications)) (PP (IN for) (NP (NN autoimmunity)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-50 (ADJP-COOD (ADJP (JJ unwanted)) (CC and) (ADJP (RB potentially) (JJ hazardous))) (NNS specificities)) (VP (MD may) (VP (VB be) (VP (VBN elicited) (SBAR-TMP (WHADVP-51 (WRB when)) (S (VP (VBG using) (NP (JJ synthetic) (NNS peptides)) (PP (IN in) (NP (NP (NN subunit) (NNS vaccines)) (SBAR (WHPP-52 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NN succinimide) (NNS residues)) (VP (MD may) (VP (VB form) (ADVP (RB spontaneously)) (PP-TMP (IN during) (NP-COOD (NP (NN storage)) (CC or) (NP (JJ chemical) (NN synthesis)))))))))))))))) (. .)))
(TOP (NP (-LRB- -LCB-) (NP (NN NGFI-B/nur77) (NN family)) (VP (VBN involved) (PP (IN in) (NP (NN T-cell) (NN apoptosis)))) (-RRB- -RCB-)))
(TOP (S (NP-SBJ (NN NGFI-B/nur77)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN member)) (PP (IN of) (NP (DT the) (NN steroid) (NN receptor) (NN superfamily))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-COOD (NP (NN NGFI-B/nur77)) (CC and) (NP (PRP$ its) (JJ related) (NNS genes))) (VP (VBP constitute) (NP (DT a) (NN family)))) (CC and) (S (NP-SBJ (DT the) (NN NGFI-B/nur77) (NN family)) (VP (VBZ consists) (PP (IN of) (NP (NP (CD three) (NNS subtypes)) (, ,) (VP (VBN named) (S (NP-PRD-COOD (NP (NN nur77) (NN alpha)) (, ,) (NP (NN nur77) (NN beta)) (, ,) (NP (NN nur77) (NN gamma))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD cloned) (NP (NP (JJ human) (NN nur77) (NN beta) (NN cDNA)) (, ,) (VP (VBN called) (S (NP-PRD (NN TINUR)))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NN NGFI-B/nur77)) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (JJ TCR-mediated) (NN apoptosis)) (PP (IN in) (NP (NN T-cell) (NNS hybridomas))))))))) (, ,) (NP-SBJ (NP (DT the) (NNS reports)) (PP (IN on) (NP-COOD (NP (NN nur77) (JJ knock-out) (NNS mice)) (CC and) (NP (NN nur77) (JJ dominant) (JJ negative) (JJ transgenic) (NNS mice))))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (EX there)) (VP (VBZ is) (NP-PRD (DT a) (JJ functional) (NN redundancy)) (PP (IN among) (NP (NN NGFI-B/nur77) (NN family))))))) (. .)))
(TOP (S (NP-SBJ (NN NGFI-B/nur77)) (VP (VBZ binds) (PP (TO to) (NP (DT the) (NN response) (NN element))) (PP (IN by) (NP-COOD (NP (NN monomer)) (CC or) (NP (NP (NN heterodimer)) (PP (IN with) (NP (NP (NN retinoid) (NN X) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN RXR)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (PP (VBG Assuming) (SBAR (IN that) (S (NP-SBJ (NP (JJ 9-cis-retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN 9-cis-RA)) (-RRB- -RRB-))) (VP (VBZ inhibits) (NP (JJ TCR-mediated) (NN apoptosis)))))) (, ,) (NP-SBJ (NNS nur77)) (VP-COOD (VP (MD may) (VP (VB cause) (NP (NN apoptosis)) (PP (IN by) (NP (NN monomer))) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN 9-cis-RA))))) (CC and) (VP (MD may) (VP (VB inhibit) (NP (NN apoptosis)) (PP (IN by) (NP (NP (NN heterodimer)) (PP (IN with) (NP (NN RXR))))) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NN 9-cis-RA)))))) (. .)))
(TOP (NP (NP (NN Interaction)) (PP (IN of) (NP (DT the) (JJ human) (NN T-cell) (JJ lymphotropic) (NN virus) (NN type) (CD 1) (NN tax) (NN transactivator))) (PP (IN with) (NP (NN transcription) (NN factor) (NN IIA))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN Tax) (NN protein)) (PP (IN of) (NP (NP (JJ human) (NN T-cell) (NN lymphotropic) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HTLV-1)) (-RRB- -RRB-))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ 40-kDa) (JJ transcriptional) (NN activator)) (SBAR (WHNP-31 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (IN for) (NP-COOD (NP (NN HTLV-1) (NN gene) (NN regulation)) (CC and) (NP (JJ virus-induced) (JJ cellular) (NN transformation)))))))))) (. .)))
(TOP (S (NP-SBJ-32 (NN Tax)) (VP (VBZ is) (VP (JJ localized) (PP (TO to) (NP (DT the) (NN DNA))) (PP (IN through) (NP (NP (PRP$ its) (NN interaction)) (PP (IN with) (NP (DT the) (JJ site-specific) (NNS activators) (NP-COOD (NP (ADJP (JJ cyclic) (JJ AMP-responsive) (JJ element-binding)) (NN protein)) (, ,) (NP (NN NF-kappaB)) (, ,) (CC and) (NP (NN serum) (NN response) (NN factor))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN recruitment)) (PP (IN of) (NP (NN Tax))) (PP (TO to) (NP (DT the) (NN DNA)))) (VP (VBZ positions) (NP (NN Tax)) (PP (IN for) (NP (NP (NN interaction)) (PP (IN with) (NP (DT the) (JJ basal) (JJ transcriptional) (NN machinery))))))))))) (. .)))
(TOP (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (JJ several) (JJ independent) (NNS assays))) (, ,) (NP-SBJ (PRP we)) (ADVP-TMP (RB now)) (VP (VBP report) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ physical)) (CC and) (ADJP (JJ functional))) (NN interaction)) (PP (IN between) (NP-COOD (NP (NN Tax)) (CC and) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN TFIIA))))))) (. .)))
(TOP (S (ADVP (RB First)) (, ,) (NP-SBJ-33 (NN Tax)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (ADJP (JJ 35-kDa) (PRN (-LRB- -LRB-) (NP (NN alpha)) (-RRB- -RRB-))) (NN subunit)) (PP (IN of) (NP (NN TFIIA))))) (PP (IN in) (NP (DT the) (NN yeast) (JJ two-hybrid) (NN interaction) (NN system)))))))) (. .)))
(TOP (S (ADVP (RB Importantly)) (, ,) (NP-SBJ-34 (NP (CD two) (ADJP (RB previously) (VBN characterized)) (NNS mutants)) (PP (IN with) (NP (NN point) (NNS mutations))) (PP (IN in) (NP-COOD (NP (NN Tax)) (, ,) (NP (NP (NN M32)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Y196A)) (, ,) (NP (NN K197S))) (-RRB- -RRB-))) (CC and) (NP (NP (NN M41)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN H287A)) (, ,) (NP (NN P288S))) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP-35 (WDT which)) (S (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (JJ Tax-activated) (NN transcription))))))))))) (VP (VBD were) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NN TFIIA))) (PP (IN in) (NP (DT this) (NN assay)))))))) (. .)))
(TOP (S (ADVP (RB Second)) (, ,) (NP-SBJ (DT a) (NP (NP (NN glutathione-S-transferase)) (PRN (-LRB- -LRB-) (NP (NN GST)) (-RRB- -RRB-))) (JJ affinity-binding) (NN assay)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN holo-TFIIA))) (PP (IN with) (NP (NN GST-Tax)))) (VP (VBD was) (ADJP-PRD (ADJP (RB 20-fold) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN observed) (PP (IN with) (NP-COOD (CC either) (NP (DT the) (NN GST-Tax) (NN M32) (NN activation) (NN mutant)) (CC or) (NP (DT the) (NN GST) (NN control)))))))))))) (. .)))
(TOP (S (ADVP (RB Third)) (, ,) (NP-SBJ (DT a) (NN coimmunoprecipitation) (NN assay)) (VP (VBD showed) (SBAR (IN that) (S (PP (IN in) (NP (JJ HTLV-1-infected) (JJ human) (NN T) (NNS lymphocytes))) (, ,) (NP-SBJ-COOD-37 (NP (NN Tax)) (CC and) (NP (NN TFIIA))) (VP (VBD were) (VP (VBN associated)))))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP-SBJ (NN TFIIA)) (VP (NNS facilitates) (NP (NN Tax) (NN transactivation)) (ADVP-COOD (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)))) (. .)))
(TOP (S (NP-SBJ (ADJP (FW In) (FW vitro)) (NN transcription) (NNS studies)) (VP (VBD showed) (NP (NP (VBN reduced) (NNS levels)) (PP (IN of) (NP (JJ Tax-activated) (NN transcription))) (PP (IN in) (NP (NP (NN cell) (NNS extracts)) (VP (VBN depleted) (PP (IN of) (NP (NN TFIIA)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (NN transfection)) (PP (IN of) (NP (JJ human) (NN T) (NNS lymphocytes))) (PP (IN with) (NP (NN TFIIA) (NN expression) (NNS vectors)))) (VP (VBD enhanced) (NP (NP (JJ Tax-activated) (NN transcription)) (PP (IN of) (NP (DT an) (ADJP (NN HTLV-1) (JJ long) (JJ terminal) (NN repeat-chloramphenicol) (NN acetyltransferase) (NN reporter)) (NN construct))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN interaction)) (PP (IN of) (NP (NN Tax))) (PP (IN with) (NP (DT the) (NN transcription) (NN factor) (NN TFIIA)))) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (JJ Tax-mediated) (JJ transcriptional) (NN activation)))))))) (. .)))
(TOP (S (NP-SBJ (NN Peptide) (NN vaccination)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (VBN enhanced) (NN tumor) (NN growth))) (PP (IN through) (NP (JJ specific) (NN T-cell) (NN tolerance) (NN induction))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Vaccination)) (PP (IN with) (NP (NP (JJ synthetic) (NNS peptides)) (VP (VBG representing) (NP (NP (NP (JJ cytotoxic) (NN T) (NN lymphocyte)) (PRN (-LRB- -LRB-) (NP (NN CTL)) (-RRB- -RRB-))) (NNS epitopes)))))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ protective) (JJ CTL-mediated) (NN immunity)) (PP (IN against) (NP-COOD (NP (NNS tumors)) (CC or) (NP (NNS viruses)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NP (NN vaccination)) (PP (IN with) (NP (NP (DT a) (NN CTL) (NN epitope)) (VP (VBN derived) (PP (IN from) (NP (NP (DT the) (JJ human) (NN adenovirus) (NN type) (CD 5) (NN E1A-region)) (PRN (-LRB- -LRB-) (NP (NN Ad5E1A234-243)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP-49 (WDT which)) (S (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN target)) (PP (IN for) (NP (JJ tumor-eradicating) (NN CTL))))))))) (, ,)))) (VP (VP-COOD (VP (VBZ enhances)) (CONJP (RB rather) (IN than)) (VP (VBZ inhibits))) (NP-50 (NP (DT the) (NN growth)) (PP (IN of) (NP (JJ Ad5E1A-expressing) (NNS tumors)))))))) (. .)))
(TOP (S (NP-SBJ-51 (NP (DT This) (JJ adverse) (NN effect)) (PP (IN of) (NP (NN peptide) (NN vaccination)))) (VP-COOD (VP (VBD was) (ADVP-TMP (RB rapidly)) (VP (VBN evoked))) (, ,) (VP (VBD required) (NP (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NN peptide)))) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS micrograms)) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBD was) (VP (VBN achieved) (PP (IN by) (NP-LGS (NP (DT a) (NN mode)) (PP (IN of) (NP (NN peptide) (NN delivery))) (SBAR (WHNP-52 (WDT that)) (S (VP (VBZ induces) (NP (JJ protective) (JJ T-cell-mediated) (NN immunity)) (PP (IN in) (NP (JJ other) (NNS models))))))))))) (. .)))
(TOP (S (NP-SBJ-53 (JJ Ad5E1A-specific) (NN CTL) (NN activity)) (VP (MD could) (ADVP-TMP (RB no) (RB longer)) (VP (VB be) (VP (VBN isolated) (PP (IN from) (NP (NNS mice))) (PP-TMP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NN Ad5E1A-peptide))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (NN tolerization)) (PP (IN of) (NP (JJ Ad5E1A-specific) (NN CTL) (NN activity)))) (VP (VBZ causes) (NP (DT the) (VBN enhanced) (NN tumor) (NN outgrowth)))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NN peptide) (NN vaccination))) (, ,) (NP-SBJ (NP (NN immunization)) (PP (IN with) (NP (NP (NN adenovirus)) (, ,) (VP (VBG expressing) (NP (NN Ad5E1A))) (, ,)))) (VP-COOD (VP (VBD induced) (NP (JJ Ad5E1A-specific) (NN immunity))) (CC and) (VP (VBD prevented) (NP (NP (DT the) (NN outgrowth)) (PP (IN of) (NP (JJ Ad5E1A-expressing) (NNS tumors)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NN immunization)) (PP (IN with) (NP (JJ synthetic) (NNS peptides)))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (JJ anti-tumor) (NN CTL) (NNS responses)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP are) (ADJP-PRD (JJ important) (PP (IN for) (NP (NP (DT the) (NN design)) (PP (IN of) (NP (NP (JJ safe) (JJ peptide-based) (NNS vaccines)) (PP (IN against) (NP-COOD (NP (NNS tumors)) (, ,) (NP (JJ allogeneic) (NN organ) (NNS transplants)) (, ,) (CC and) (NP (JJ T-cell-mediated) (JJ autoimmune) (NNS diseases)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Transgenic) (NN expression)) (PP (IN of) (NP (NN PML/RARalpha)))) (VP (VBZ impairs) (NP (NN myelopoiesis))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN translocation)) (VP (VBN found) (PP (IN in) (NP (JJ acute) (JJ promyelocytic) (NN leukemia))))) (VP (VBZ rearranges) (NP (NP (NP (DT the) (JJ promyelocytic) (NN leukemia) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN PML)) (-RRB- -RRB-))) (PP (IN on) (NP (NN chromosome) (CD 15)))) (PP (IN with) (NP (NP (NP (DT the) (JJ retinoic) (NN acid) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN RARalpha)) (-RRB- -RRB-))) (PP (IN on) (NP (NN chromosome) (CD 17)))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBZ yields) (NP (NP (DT a) (NN fusion) (NN transcript)) (, ,) (NP (NN PML/RARalpha)) (, ,) (NP (NP (DT a) (NN transcription) (NN factor)) (PP (IN with) (NP (NP (VBN reported) (JJ dominant) (JJ negative) (NNS functions)) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN hormone)))))))) (. .)))
(TOP (S (NP-SBJ-44 (NP (JJ Clinical) (NNS remissions)) (VP (VBN induced) (PP (IN with) (NP (JJ all-trans) (NP (NP (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (NN treatment))) (PP (IN in) (NP (JJ acute) (JJ promyelocytic) (NN leukemia))))) (VP (VBP are) (VP (VBN linked) (PP (TO to) (NP (NP (NN PML/RARalpha) (NN expression)) (PP (IN in) (NP (JJ leukemic) (NNS cells))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN PML/RARalpha) (NN role)) (PP (IN in) (NP (NN myelopoiesis))))))) (, ,) (NP-SBJ-45 (NP (JJ transgenic) (NNS mice)) (VP (VBG expressing) (NP (NN PML/RARalpha)))) (VP (VBD were) (VP (VBN engineered))) (. .)))
(TOP (S (NP-SBJ-46 (NP (DT A) (JJ full-length) (NN PML/RARalpha) (NN cDNA)) (VP (VBN driven) (PP (IN by) (NP-LGS (DT the) (NN CD11b) (NN promoter))))) (VP (VBD was) (VP (VBN expressed) (PP (IN in) (NP (JJ transgenic) (NNS mice))))) (. .)))
(TOP (S (NP-SBJ-47 (NN Expression)) (VP (VBD was) (VP (VBN confirmed) (PP (IN in) (NP (DT the) (NN bone) (NN marrow))) (PP (IN with) (NP (DT a) (JJ reverse) (NN transcription) (NN PCR) (NN assay))))) (. .)))
(TOP (S (NP-SBJ (JJ Basal) (JJ total) (NP-COOD (NP (JJ white) (NN blood) (NN cell)) (CC and) (NP (NN granulocyte))) (NNS counts)) (VP (VBD did) (RB not) (ADVP (RB appreciably)) (VP (VB differ) (PP (IN between) (NP (UCP-COOD (ADJP (NN PML/RARalpha) (JJ transgenic)) (CC and) (NP (NN control))) (NNS mice))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Cell) (NN sorter) (NN analysis)) (PP (IN of) (NP (JJ CD11b+) (NN bone) (NN marrow) (NNS cells)))) (VP (VBD revealed) (NP (JJ similar) (JJ CD11b+) (NNS populations)) (PP (IN in) (NP (UCP-COOD (ADJP (JJ transgenic)) (CC and) (NP (NN control))) (NNS mice)))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (ADJP (FW in) (FW vitro)) (JJ clonal) (NN growth) (NNS assays)) (VP (VBN performed) (PP (IN on) (NP (NP (JJ peripheral) (NN blood)) (PP (IN from) (NP (UCP-COOD (ADJP (JJ transgenic)) (CC versus) (NP (NN control))) (NNS mice))))))) (VP (VBD revealed) (NP (NP (DT a) (JJ marked) (NN reduction)) (PP (IN of) (NP (JJ myeloid) (NNS progenitors))) (, ,) (PP (RB especially) (IN in) (NP (NP (DT those)) (VP (VBG responding) (PP (TO to) (NP (NN granulocyte) (NN macrophage) (JJ colony-stimulating) (NN factor)))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN Granulocyte/macrophage) (JJ colony-stimulating) (NN factor)) (CC and) (NP (NN kit) (NN ligand) (NN cotreatment))) (VP (VBD did) (RB not) (VP (VB overcome) (NP (DT this) (NN inhibition)))) (. .)))
(TOP (S (NP-SBJ-48 (NP (JJ Impaired) (NN myelopoiesis)) (ADVP (FW in) (FW vivo))) (VP (VBD was) (VP (VBN shown) (PP (IN by) (S (VP (VBG stressing) (NP (DT these) (NNS mice)) (PP (IN with) (NP (JJ sublethal) (NN irradiation)))))))) (. .)))
(TOP (S (PP-TMP (VBG Following) (NP (NN irradiation))) (, ,) (NP-SBJ-49 (ADJP (NN PML/RARalpha) (JJ transgenic)) (NNS mice)) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NNS controls)))))) (, ,) (ADVP-TMP (RBR more) (RB rapidly)) (VP (VBD depressed) (NP (NP-COOD (NP (JJ peripheral) (JJ white) (NN blood) (NN cell)) (CC and) (NP (NN granulocyte))) (NNS counts))) (. .)))
(TOP (S (SBAR (IN As) (S (VP (VBN expected)))) (, ,) (S-COOD (S (NP-SBJ (NP (QP (RB nearly) (DT all)) (NN control) (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD 94.4) (NN %)) (-RRB- -RRB-))) (VP (VBD survived) (NP (NN irradiation)))) (, ,) (CC yet) (S (NP-SBJ (DT this) (NN irradiation)) (VP (VBD was) (ADJP-PRD (JJ lethal) (PP (TO to) (NP (NP (CD 45.8) (NN %)) (PP (IN of) (NP (ADJP (NN PML/RARalpha) (JJ transgenic)) (NNS mice))))))))) (. .)))
(TOP (S (NP-SBJ-52 (NN Lethality)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (ADJP (RBR more) (JJ severe)) (NN leukopenia))) (PP (IN in) (NP (UCP-COOD (ADJP (JJ transgenic)) (CC versus) (NP (NN control))) (NNS mice))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Retinoic) (NN acid) (NN treatment)) (PP (IN of) (NP (JJ irradiated) (NN PML/RARalpha) (NNS mice)))) (VP (VBD enhanced) (NP (NN granulocyte) (NN recovery))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (JJ abnormal) (NN myelopoiesis)) (PP (IN due) (TO to) (NP (NN PML/RARalpha) (NN expression)))) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ early) (NN event)) (PP (IN in) (NP (JJ oncogenic) (NN transformation)))))))) (. .)))
(TOP (S (NP-SBJ-27 (NP (JJ Defective) (NN transcription)) (PP (IN of) (NP (DT the) (NN IL-2) (NN gene)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ impaired) (NN expression)) (PP (IN of) (NP-COOD (NP (NN c-Fos)) (, ,) (NP (NN FosB)) (, ,) (CC and) (NP (NN JunB)))) (PP (IN in) (NP (JJ anergic) (NN T) (NN helper) (CD 1) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-28 (JJ Anergic) (JJ CD4+) (NN Th) (NNS cells)) (VP (VBP do) (RB not) (VP (VB produce) (NP (NN IL-2)) (SBAR-TMP (WHADVP-30 (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (JJ Ag-pulsed) (JJ accessory) (NNS cells))) (PP (IN because) (IN of) (NP (DT a) (JJ transcriptional) (NN defect)))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN work))) (, ,) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (DT these) (JJ anergic) (NN T) (NNS cells)) (VP (VBP are) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB up-regulate) (NP (NP-COOD (NP (NN protein) (NN binding)) (CC and) (NP (NN transactivation))) (PP (IN at) (NP (NP (CD two) (JJ critical) (NN IL-2) (NN DNA) (NN enhancer) (NNS elements)) (: :) (NP (NP (NP (NN NF-AT)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (: ;) (NP (NP (DT a) (NN sequence)) (SBAR (WHNP-31 (WDT that)) (S (VP (VBZ binds) (NP (DT a) (JJ heterotrimeric) (NP-COOD (NP (NN NFATp)) (, ,) (NP (NN Fos)) (, ,) (CC and) (NP (NN Jun))) (NN protein) (NN complex))))))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN Activator) (NN Protein-1)) (PRN (-LRB- -LRB-) (NP (NN AP-1)) (-RRB- -RRB-))) (-LRB- -LRB-) (SBAR (WHNP-32 (WDT that)) (S (VP (VBZ binds) (NP (NP-COOD (NP (NN Fos)) (CC and) (NP (NN Jun))) (NNS heterodimers))))) (-RRB- -RRB-))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Western) (NN blot) (NN analysis)) (PP (IN of) (NP (JJ nuclear) (NNS extracts)))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-33 (NP (DT the) (JJ impaired) (NN DNA-protein) (NNS interactions)) (PP (IN in) (NP (JJ anergic) (NN T) (NNS cells)))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (JJ poor) (NN expression)) (PP (IN of) (NP (DT the) (JJ inducible) (NN AP-1) (NN family) (NNS members) (NP-COOD (NP (NN c-Fos)) (, ,) (NP (NN FosB)) (, ,) (CC and) (NP (NN JunB)))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (VBN reduced) (NN expression)) (PP (IN of) (NP (DT these) (NNS proteins)))) (VP (VBD was) (RB not) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (DT a) (JJ global) (JJ TCR/CD3-signaling) (NN defect)))) (SBAR (IN because) (S (NP-SBJ (NN CD3) (NN cross-linking)) (VP (VBD induced) (NP-COOD (NP (NP (DT an) (JJ equivalent) (NN increase)) (PP (IN in) (NP (JJ intracellular-free) (NN calcium) (NNS ions)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP-COOD (NP (NN NFATp) (NN dephosphorylation)) (, ,) (NP (NP (NN translocation)) (PP (TO to) (NP (DT the) (NN nucleus)))) (, ,) (CC and) (NP (NN DNA) (NN binding)))) (PP (IN in) (NP (ADJP-COOD (CC both) (ADJP (JJ normal)) (CC and) (ADJP (JJ anergic))) (NN T) (NNS cells))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-34 (JJ defective) (NN IL-2) (NN gene) (NN transcription)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (PP-PRD (JJ due) (PP (ADVP (, ,) (IN at)) (JJS least) (NP (IN in))) (NN part) (, ,) (NP (NP (TO to) (DT a) (JJ selective)) (PP (NN block) (NP (NP (IN in) (DT the)) (PP (NN expression) (NP (IN of) (DT the) (NP-COOD (NP (NN AP-1)) (NN Fos) (NP (CC and))) (NN Jun) (NN family))) (PP (NNS members) (NP (IN in) (JJ anergic) (NN T))))))))))) (NNS cells)))
(TOP (S (NP-SBJ (JJ Elevated) (JJ cyclic) (NN AMP)) (VP (VBZ inhibits) (NP (NP (JJ NF-kappaB-mediated) (NN transcription)) (PP (IN in) (NP (JJ human) (NP-COOD (NP (JJ monocytic) (NNS cells)) (CC and) (NP (JJ endothelial) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN NF-kappaB/Rel) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors)))) (VP (VBZ regulates) (NP (NP (DT the) (JJ inducible) (NN expression)) (PP (IN of) (NP (JJ many) (NNS genes))) (PP (IN in) (NP (VBN activated) (JJ human) (NP-COOD (NP (NNS monocytes)) (CC and) (NP (JJ endothelial) (NNS cells))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ molecular) (NN mechanism)) (SBAR (WHPP-22 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NP (NNS agents)) (SBAR (WHNP-23 (WDT that)) (S (VP (VBP elevate) (NP (JJ intracellular) (NN cAMP)))))) (VP (VBP inhibit) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNFalpha)) (-RRB- -RRB-))) (, ,) (NP (NN tissue) (NN factor)) (, ,) (NP (JJ endothelial) (NN leukocyte) (NN adhesion) (NN molecule-1)) (, ,) (CC and) (NP (JJ vascular) (NN cell) (NN adhesion) (NN molecule-1))) (NNS genes))))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (CC Both) (NP (NN forskolin)) (CC and) (NP (NN dibutyryl) (NN cAMP))) (, ,) (SBAR (WHNP-24 (WDT which)) (S (VP (VBP elevate) (NP (JJ intracellular) (NN cAMP)) (PP (IN by) (NP (JJ independent) (NNS mechanisms)))))) (, ,)) (VP (VBD inhibited) (NP (NP-COOD (NP (NN TNFalpha)) (CC and) (NP (NN tissue) (NN factor))) (NN expression)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN transcription)))))) (. .)))
(TOP (S (NP-SBJ-25 (NP (NN Induction)) (PP (IN of) (NP (JJ NF-kappaB-dependent) (NN gene) (NN expression))) (PP (IN in) (NP (ADJP (RB transiently) (VBN transfected)) (NP-COOD (NP (JJ human) (JJ monocytic) (NN THP-1) (NNS cells)) (CC and) (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)))))) (VP (VBD was) (VP (VBN inhibited) (PP-COOD (PP (IN by) (NP-LGS (JJ elevated) (NN cAMP))) (CC and) (PP (IN by) (NP-LGS (NP (NN overexpression)) (PP (IN of) (NP (NP (DT the) (JJ catalytic) (NN subunit)) (PP (IN of) (NP (NP (NN protein) (NN kinase) (NN A)) (PRN (-LRB- -LRB-) (NP (NN PKA)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Elevated) (NN cAMP)) (VP (VBD did) (RB not) (VP-COOD (VP (VB prevent) (NP (NP (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NP-COOD (NP (NN p50/p65)) (CC and) (NP (NN c-Rel/p65))) (NNS heterodimers))))) (, ,) (VP (VB decrease) (NP (NP (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NN p65))))) (, ,) (CC or) (VP (ADVP (RB significantly)) (VB modify) (NP (NP (JJ TNFalpha-induced) (NN phosphorylation)) (PP (IN of) (NP (NN p65))))))) (. .)))
(TOP (S (NP-SBJ (JJ Functional) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-26 (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NP (DT a) (NN plasmid)) (VP (VBG containing) (NP (JJ multimerized) (NN kappaB) (NNS sites))))) (PP (IN by) (NP (NN p65)))) (VP (VBD was) (VP (VBN inhibited) (PP-COOD (PP (IN by) (NP-LGS (NP (NNS agents)) (SBAR (WHNP-27 (IN that)) (S (VP (VBP elevate) (NP (NN cAMP))))))) (CC and) (PP (IN by) (NP-LGS (NP (NN overexpression)) (PP (IN of) (NP (NP (DT the) (JJ catalytic) (NN subunit)) (PP (IN of) (NP (NN PKA))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN study)) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ-28 (NP (NN activation)) (PP (IN of) (NP (NN PKA)))) (VP (VBZ reduces) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT a) (JJ distinct) (NN set)) (PP (IN of) (NP (NNS genes))))) (PP (IN in) (NP-COOD (NP (NNS monocytes)) (CC and) (NP (JJ endothelial) (NNS cells))))) (PP (IN by) (S (VP (VBG inhibiting) (NP (JJ NF-kappaB-mediated) (NN transcription))))))))) (. .)))
(TOP (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (DT a) (JJ new) (NN isoform) (PP (IN of) (NP (DT the) (NP (NP (NN NFAT)) (PRN (-LRB- -LRB-) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (-RRB- -RRB-))) (NN gene) (NN family) (NN member)))) (NN NFATc))) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP J) (NNP Biol) (NNP Chem)) (NP-TMP (CD 1996) (NNP Dec) (CD 27)) (: ;) (NP (CD 271) (-LRB- -LRB-) (CD 52) (-RRB- -RRB-)) (: :) (NP (CD 33705)))))) (-RRB- -RCB-))))
(TOP (S (NP-SBJ (DT The) (ADJP (NN cyclosporin) (NN A) (-LRB- -LRB-) (NN CsA) (-RRB- -RRB-) (JJ /FK506-sensitive)) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NFAT)) (-RRB- -RRB-)))) (VP (VBZ plays) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ inducible) (NN expression)) (PP (IN of) (NP (NN cytokine) (NNS genes))) (PP (IN in) (NP (NN T) (NNS cells)))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-51 (NN NFAT)) (VP (VBZ has) (VP (VBN been) (ADVP-TMP (RB recently)) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ inducible)) (PP (IN in) (NP (JJ several) (ADJP (JJ non-T) (JJ immune)) (NNS cells))))))))))) (, ,) (NP-SBJ-50 (NP (DT the) (NN NFAT) (NN gene) (NN family) (NNS members)) (VP (VBN characterized) (PP-TMP (TO to) (NP (NN date))))) (VP (VBP have) (VP (VBN been) (VP (VBN isolated) (PP (RB only) (IN from) (NP (NN T) (NNS cells)))))) (. .)))
(TOP (S (S (VP-COOD (VP (TO To) (ADVP (RBR further)) (VP (VB characterize) (NP (NP (NN NFAT) (NN function)) (PP (IN in) (NP (JJ human) (NN B) (NNS cells)))))) (CC and) (VP (TO to) (VP (VB demonstrate) (NP (NP (NN cytokine) (NN gene) (NN specificity)) (PP (IN of) (NP (NN NFAT) (NNS proteins)))))))) (, ,) (NP-SBJ-52 (PRP we)) (VP (VBP report) (ADVP (RB here)) (NP (NP (DT the) (NP-COOD (NP (NN isolation)) (CC and) (NP (NN characterization)))) (PP (IN of) (NP (NP (DT a) (NN cDNA) (NN clone)) (PP (IN from) (NP (DT the) (NN Raji) (NN B) (NN cell) (NN line))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN cDNA) (NN clone)) (VP (VBZ encodes) (NP (NP (NP (DT a) (JJ new) (NN isoform)) (, ,) (NP (NN NFATc.beta)) (, ,)) (PP (IN of) (NP (NP (DT the) (NN NFAT) (NN gene) (NN family) (NN member) (NN NFATc)) (-LRB- -LRB-) (VP (VBN designated) (ADVP (RB here)) (S (NP-PRD (NN NFATc.alpha)))) (-RRB- -RRB-))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN amino) (NN acid) (NN sequence)) (PP (IN of) (NP (NN NFATc.beta)))) (VP-COOD (VP (VBZ differs) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (NN NFATc.alpha))) (PP (IN in) (NP (DT the) (JJ first) (JJ NH2-terminal) (CD 29) (NNS residues)))))) (CC and) (VP (VBZ contains) (NP (NP (DT an) (JJ additional) (NN region)) (PP (IN of) (NP (CD 142) (NNS residues)))) (PP (IN at) (NP (DT the) (NN COOH) (NN terminus))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Northern) (NN analysis)) (VP (VBG using) (NP (NP (VBG a) (NN probe)) (VP (VBG encompassing) (NP (NP (DT a) (JJ common) (NN region)) (PP (IN of) (NP (DT both) (NNS isoforms)))))))) (VP (VBD showed) (NP (NP (CD two) (NN mRNA) (NNS species)) (PP (IN of) (NP (ADJP (QP (CD 2.7) (CC and) (CD 4.5)) (NN kilobase)) (NNS pairs)))) (, ,) (SBAR (IN while) (S (NP-SBJ (DT an) (JJ NFATc.beta-specific) (NN probe)) (VP (VBD detected) (NP (NP (RB only) (DT the) (NN 4.5-kilobase) (NN pair) (NN mRNA)) (SBAR (WHNP-53 (WDT which)) (S (VP (VBD was) (ADVP (RB preferentially)) (VP (VBN expressed) (PP (IN in) (NP (DT the) (NN spleen)))))))))))) (. .)))
(TOP (S (NP-SBJ-55 (NP (JJ Transient) (NN expression)) (PP (IN of) (NP (NN NFATc.beta)))) (VP (VBD was) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG activating) (NP (NP (DT an) (NN interleukin-2) (JJ NFAT-driven) (NN reporter) (NN gene)) (PP (IN in) (NP (VBN stimulated) (NN Jurkat) (NNS cells)))) (PP (IN in) (NP (DT a) (JJ CsA-sensitive) (NN manner)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NN NFATc.beta)) (VP (VP-COOD (CC neither) (VP (VBD bound) (PP (TO to) (NP (NP (NP (DT the) (NN kappa3) (NN element)) (PRN (-LRB- -LRB-) (NP (DT an) (JJ NFAT-binding) (NN site)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN tumor) (NN necrosis) (NN factor-alpha) (NN promoter)))))) (CC nor) (VP (VBD activated) (NP (DT the) (NN tumor) (NN necrosis) (NN factor-alpha) (NN promoter)))) (PP (IN in) (NP (NN cotransfection) (NN assays)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (JJ different) (NP-COOD (NP (NNS members)) (CC or) (NP (NNS isoforms)))) (PP (IN of) (NP (NN NFAT) (NN gene) (NN family)))) (VP (MD may) (VP (VB regulate) (NP (NP (JJ inducible) (NN expression)) (PP (IN of) (NP (JJ different) (NN cytokine) (NNS genes))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (JJ human) (JJ monocytic) (NNS cells))) (PP (IN by) (NP-COOD (NP (NP-COOD (NP (FW Treponema) (FW pallidum)) (CC and) (NP (FW Borrelia) (FW burgdorferi))) (NNS lipoproteins)) (CC and) (NP (JJ synthetic) (NNS lipopeptides))))) (VP-COOD (VP (VBZ proceeds) (PP (IN via) (NP (NP (DT a) (NN pathway)) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (NN lipopolysaccharide))))))))) (CC but) (VP (VBZ involves) (NP (DT the) (JJ transcriptional) (NN activator) (NN NF-kappa) (NN B)))) (. .)))
(TOP (S (NP-SBJ (EX There)) (VP (VBZ is) (NP-PRD (VBG increasing) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NP (NNS lipoproteins)) (PP (IN of) (NP-COOD (NP (FW Treponema) (FW pallidum)) (CC and) (NP (FW Borrelia) (FW burgdorferi))))) (VP (VBP are) (NP-PRD (JJ key) (JJ inflammatory) (NNS mediators)) (PP-TMP (IN during) (NP-COOD (NP (NN syphilis)) (CC and) (NP (NN Lyme) (NN disease))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ principal) (NN objective)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBD was) (S-PRD (VP (TO to) (VP (VB identify) (ADVP (RBR more) (RB precisely)) (NP (NP-COOD (NP (NNS similarities)) (CC and) (NP (NNS divergences))) (PP (IN among) (NP (ADJP-COOD (ADJP (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-)) (: -))) (CC and) (ADJP (JJ lipoprotein-lipopeptide-induced))) (JJ immune) (NN cell) (NN signaling) (NNS events)))))))) (. .)))
(TOP (S (PP (IN Like) (NP (NN LPS))) (, ,) (NP-SBJ (NP-COOD (NP (VBN purified) (JJ native) (FW B.) (FW burgdorferi) (NN OspA)) (CC and) (NP (NP (JJ synthetic) (NNS analogs)) (PP (IN of) (NP-COOD (NP (NN OspA)) (, ,) (NP (NN OspB)) (, ,) (CC and) (NP (NP (CD two) (FW T.) (FW pallidum) (NNS lipoproteins)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Tpp47)) (CC and) (NP (NN Tpp17))) (-RRB- -RRB-))))))) (NP (DT all))) (VP (VBD induced) (NP (NP (NN NF-kappa) (NN B) (NN translocation)) (PP (IN in) (NP (NN THP-1) (JJ human) (NN monocytoid) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Acylation)) (PP (IN of) (NP-COOD (NP (NN OspA)) (CC and) (NP (DT the) (JJ synthetic) (NNS peptides))))) (VP (VBD was) (ADJP-PRD (JJ requisite) (PP (IN for) (NP (NN cell) (NN activation))))) (. .)))
(TOP (S (NP-SBJ (NN Polymyxin) (NN B)) (VP (VBD abrogated) (NP (NP (RB only) (DT the) (NN response)) (PP (TO to) (NP (NN LPS))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG using) (NP (NP (JJ 70Z/3-derived) (NN pre-B-cell) (NNS lines)) (VP (VP-COOD (CC either) (VP (VBG lacking)) (CC or) (VP (VBG expressing))) (NP-32 (NP (JJ human) (NN CD14)) (PRN (-LRB- -LRB-) (NP (DT the) (NN LPS) (NN receptor)) (-RRB- -RRB-)))))))) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN observed) (SBAR (IN that) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (JJ human) (NN CD14)))) (VP (VBD imparted) (NP (NP (NN responsiveness)) (PP-COOD (PP (TO to) (NP (NN LPS))) (CC but) (PP (RB not) (TO to) (NP-COOD (NP (NN OspA)) (CC or) (NP (JJ spirochetal) (NNS lipopeptides)))))) (PRN (-LRB- -LRB-) (S (VP (VBN assessed) (PP (IN by) (NP-COOD (NP (NP (NN induction)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (CC and) (NP (NP (NN expression)) (PP (IN of) (NP (NN surface) (NN immunoglobulin) (NN M)))))))) (-RRB- -RRB-))))))) (. .)))
(TOP (S (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ-33 (NP (DT the) (JJ biological) (NN relevance)) (PP (IN of) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP-SBJ (FW T.) (FW pallidum) (NNS lipoproteins-lipopeptides)) (VP (VBP induce) (NP (NP (NP-COOD (CC both) (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN cytokine))) (NN production)) (PP (IN in) (NP (NNS monocytes)))))))))) (VP (VBD was) (VP (VBN supported) (PP (IN by) (NP-LGS (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (JJ synthetic) (NNS analogs))) (S-34 (VP (TO to) (VP (VB promote) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN replication)) (PP (IN in) (NP (ADJP (RB chronically) (JJ infected)) (NN U1) (NN monocytoid) (NNS cells)))))))))) (: ;)) (S (NP-SBJ (DT these) (NNS observations)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (DT a) (JJ potential) (NN mechanism)) (SBAR (WHADVP-35 (WRB whereby)) (S (NP-SBJ (DT a) (JJ syphilitic) (NN chancre)) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN cofactor)) (PP (IN for) (NP (JJ human) (NN immunodeficiency) (NN virus) (NN transmission))))))))))) (. .))))
(TOP (S (NP-SBJ (DT The) (JJ combined) (NNS data)) (VP (VBP lend) (NP (JJ additional) (NN support)) (PP (TO to) (NP (DT the) (NN proposal) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-COOD (NP (JJ spirochetal) (NNS lipoproteins)) (CC and) (NP (NN LPS))) (VP (VBP initiate) (NP (NN monocyte) (NN activation)) (PP (IN via) (NP (JJ different) (NN cell) (NN surface) (NNS events)))))) (CC but) (SBAR (IN that) (S (NP-SBJ-36 (DT the) (NN signaling) (NNS pathways)) (ADVP (RB ultimately)) (VP (VBP converge) (S (VP (TO to) (VP (VB produce) (NP (ADJP (RB qualitatively) (JJ similar)) (JJ cellular) (NNS responses)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Chronic) (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1) (NN infection)) (PP (IN of) (NP (JJ myeloid) (NNS cells)))) (VP (VBZ disrupts) (NP (NP (DT the) (JJ autoregulatory) (NN control)) (PP (IN of) (NP (DT the) (NN NF-kappaB/Rel) (NN pathway)))) (PP (IN via) (NP (VBN enhanced) (NN IkappaBalpha) (NN degradation)))) (. .)))
(TOP (S (NP-SBJ (JJ Productive) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HIV-1)) (-RRB- -RRB-))) (NN infection)) (VP (VBZ causes) (NP (JJ sustained) (NN NF-kappaB) (JJ DNA-binding) (NN activity)) (PP (IN in) (NP (ADJP (RB chronically) (VBN infected)) (JJ monocytic) (NNS cells)))) (. .)))
(TOP (S (NP-SBJ (DT A) (JJ direct) (JJ temporal) (NN correlation)) (VP (VBZ exists) (PP (IN between) (NP-COOD (NP (NN HIV) (NN infection)) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NN NF-kappaB) (JJ DNA-binding) (NN activity))) (PP (IN in) (NP (JJ myelomonoblastic) (NN PLB-985) (NNS cells))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (JJ molecular) (NN basis)) (PP (IN of) (NP (NP (JJ constitutive) (NN NF-kappaB) (JJ DNA-binding) (NN activity)) (PP (IN in) (NP (SYM HIV1) (JJ -infected) (NNS cells))))))))) (, ,) (NP-SBJ-52 (PRP we)) (VP (VBD analyzed) (NP (NP-COOD (NP (NP (DT the) (NP-COOD (NP (NN phosphorylation)) (CC and) (NP (NN turnover)))) (PP (IN of) (NP (NN IkappaBalpha) (NN protein)))) (, ,) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ double-stranded) (NP (NP (JJ RNA-dependent) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN PKR)) (-RRB- -RRB-)))))) (CC and) (NP (NP (DT the) (JJ intracellular) (NNS levels)) (PP (IN of) (NP (NN NF-kappaB) (NNS subunits))))) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN PLB-985)) (CC and) (NP (NN U937))) (JJ myeloid) (NN cell) (NNS models))))) (. .)))
(TOP (S (NP-SBJ (NN HIV-1) (NN infection)) (VP (VBD resulted) (PP (IN in) (NP (NP (ADJP-COOD (ADJP (JJ constitutive)) (, ,) (ADJP (JJ low-level))) (NN expression)) (PP (IN of) (NP (NN type) (CD 1) (NP (NP (NN interferon)) (PRN (-LRB- -LRB-) (NP (NN IFN)) (-RRB- -RRB-))))) (PP (IN at) (NP (DT the) (NN mRNA) (NN level)))))) (. .)))
(TOP (S (NP-SBJ-53 (JJ Constitutive) (NN PKR) (NN activity)) (VP (VBD was) (ADVP (RB also)) (VP (VBN detected) (PP (IN in) (NP (JJ HIV-1-infected) (NNS cells))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (JJ low-level) (NN IFN) (NN production))))) (, ,) (SBAR (IN since) (S (NP-SBJ (NP (DT the) (NN addition)) (PP (IN of) (NP (JJ anti-IFN-alpha/beta) (NN antibody))) (PP (TO to) (NP (DT the) (NNS cells)))) (VP (VBD decreased) (NP (NN PKR) (NN expression))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (DT the) (NN analysis)) (PP (IN of) (NP (NN IkappaBalpha) (NN turnover)))) (VP (VBD demonstrated) (NP (NP (DT an) (VBN increased) (NN degradation)) (PP (IN of) (NP (NN IkappaBalpha))) (PP (IN in) (NP (JJ HIV-1-infected) (NNS cells))) (SBAR (WHNP-54 (WDT that)) (S (VP (MD may) (VP (VB account) (PP (IN for) (NP (DT the) (JJ constitutive) (NN DNA) (NN binding) (NN activity))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-COOD-55 (NP (NP (DT A) (JJ dramatic) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ intracellular) (NNS levels)) (PP (IN of) (NP (NN NF-kappaB) (NNS subunits) (NP-COOD (NP (NN c-Rel)) (CC and) (NP (NN NF-kappaB2) (NN p100)))))))) (CC and) (NP (NP (DT a) (JJ moderate) (NN increase)) (PP (IN in) (NP-COOD (NP (NN NF-kappaB2) (NN p52)) (CC and) (NP (NN RelA-LRB-p65-RRB-)))))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (JJ HIV-1-infected) (NNS cells)))))) (, ,) (IN whereas) (S (NP-SBJ-56 (NN NF-kappaB1) (NN p105/p50) (NNS levels)) (VP (VBD were) (RB not) (VP (VBN altered) (PP (JJ relative) (TO to) (NP (NP (DT the) (NNS levels)) (PP (IN in) (NP (JJ uninfected) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NN HIV-1) (NN infection)) (PP (IN of) (NP (JJ myeloid) (NNS cells)))) (VP (VBZ induces) (NP (NP-COOD (NP (NN IFN) (NN production)) (CC and) (NP (NN PKR) (NN activity))) (, ,) (SBAR (WHNP-57 (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBP contribute) (PP (TO to) (NP-COOD (NP (VBN enhanced) (NN IkappaBalpha) (NN phosphorylation)) (CC and) (NP (JJ subsequent) (NN degradation)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Nuclear) (NN translocation)) (PP (IN of) (NP (NN NF-kappaB) (NNS subunits)))) (VP (MD may) (ADVP (RB ultimately)) (VP (VB increase) (NP (NP (DT the) (JJ intracellular) (NN pool)) (PP (IN of) (NP (NN NF-kappaB/IkappaBalpha)))) (PP (IN by) (NP (DT an) (JJ autoregulatory) (NN mechanism))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (VBN Enhanced) (NN turnover)) (PP (IN of) (NP (NN IkappaBalpha)))) (CC and) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NN NF-kappaB/Rel) (NNS proteins))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (ADJP (RB chronically) (JJ activated)) (NN state)) (PP (IN of) (NP (JJ HIV-1-infected) (NNS cells))))))) (. .)))
(TOP (NP (NP (JJ Sequence-specific) (NN DNA) (NN binding)) (PP (IN of) (NP (DT the) (JJ B-cell-specific) (NN coactivator) (NN OCA-B))) (. .)))
(TOP (S (NP-SBJ-36 (NP (JJ B-cell-specific) (NN transcription)) (PP (IN of) (NP (NN immunoglobulin) (NNS genes)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (DT a) (NN POU) (NN domain)) (VP (VBG containing) (NP (NN transcription) (NN factor) (NP-COOD (NP (NN Oct-1)) (CC or) (NP (NN Oct-2))))))) (, ,) (PP (IN with) (NP-COOD (NP (NP (DT the) (JJ B-cell-specific) (NN coactivator) (NN OCA-B)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Bob-1)) (, ,) (NP (NN OBF-1))) (-RRB- -RRB-))) (CC and) (NP (DT a) (NN prototype) (NN octamer) (NN element)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP-SBJ-37 (NN OCA-B)) (VP (VBZ binds) (NP (NN DNA)) (ADVP (RB directly)) (PP (IN in) (NP (NP (DT the) (JJ major) (NN groove)) (PP (IN between) (NP (NP (DT the) (CD two) (NNS subdomains)) (PP (IN of) (NP (DT the) (NN POU) (NN domain))))))) (, ,) (S (VP (VBG requiring) (NP-COOD (CC both) (NP (NP (DT an) (NN A)) (PP (IN at) (NP (NP (DT the) (JJ fifth) (NN position)) (PP (IN of) (NP (DT the) (NN octamer) (NN element)))))) (CC and) (NP (NP (NN contact)) (PP (IN with) (NP (DT the) (NN POU) (NN domain))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (JJ amino-terminal) (NN fragment)) (PP (IN of) (NP (NN OCA-B)))) (VP (VBZ binds) (NP (DT the) (NN octamer) (NN site)) (PP (IN in) (DT the) (NN absence) (IN of) (NP (DT a) (NN POU) (NN domain))) (PP (IN with) (NP (DT the) (JJ same) (NN sequence) (NN specificity)))) (. .)))
(TOP (S (NP-SBJ-38 (NN Coactivator) (NN OCA-B)) (VP (MD may) (VP (VB undergo) (NP (NP (DT a) (JJ POU-dependent) (JJ conformational) (NN change)) (SBAR (WHNP-39 (WDT that)) (S (VP (VBZ exposes) (NP (PRP$ its) (NN amino) (NN terminus)))))) (, ,) (S (VP (VBG allowing) (S (NP-SBJ (PRP it)) (VP (TO to) (VP (VB recognize) (NP (NP (JJ specific) (NN DNA) (NNS sequences)) (PP (IN in) (NP (NP (DT the) (JJ major) (NN groove)) (PP (IN within) (NP (NP (DT the) (VBG binding) (NN site)) (PP (IN for) (NP-COOD (NP (NN Oct-1)) (CC or) (NP (NN Oct-2)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN recognition)) (PP (IN of) (NP-COOD (CC both) (NP (DT the) (NN POU) (NN domain)) (CC and) (NP (DT the) (NN octamer) (NN sequence)))) (PP (IN by) (NP (NN OCA-B)))) (VP (VBZ provides) (NP (NP (DT a) (NN mechanism)) (PP (IN for) (NP (NP (JJ differential) (NN regulation)) (PP (IN of) (NP (NP (NN octamer) (NNS sites)) (VP (VBG containing) (NP (NNS genes))))) (PP (IN by) (NP (DT the) (JJ ubiquitous) (NN factor) (NN Oct-1))))))) (. .)))
(TOP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (JJ early) (NN growth) (NN response) (NN gene) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN egr-1)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (DT the) (JJ immune) (NN response))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN induction)) (PP (IN of) (NP (JJ immediate) (JJ early) (NNS genes))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))))) (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (TO to) (S (VP (VBG determining) (NP (NP (DT the) (JJ ultimate) (NN outcome)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (NN antigen))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN importance)) (PP (IN of) (NP (NP (JJ many)) (PP (IN of) (NP (DT these) (NNS genes)))))) (VP (VBZ relates) (PP (TO to) (NP (NP (DT the) (NN role)) (SBAR (S (NP-SBJ-45 (PRP$ their) (NN transcription) (NN factor) (NNS products)) (VP (VBP play) (PP (IN in) (S (VP (VBG dictating) (NP (NP (NNS patterns)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ downstream)) (, ,) (ADJP (JJ function-related))) (NNS genes))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Evidence)) (PP (IN from) (NP (JJ several) (NNS systems)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ immediate) (JJ early) (NN gene)) (, ,) (NP (NN egr-1))) (VP (MD may) (VP (VB be) (PP-PRD (IN of) (NP (JJ particular) (NN importance))) (PP (IN in) (NP (DT the) (JJ immune) (NN system)))))))) (. .)))
(TOP (S (ADVP-TMP (RB Recently)) (, ,) (NP-SBJ-46 (DT the) (NN egr-1) (NN promoter)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (RB highly) (JJ responsive) (PP (TO to) (NP (NP (DT the) (JJ diverse) (JJ biochemical) (NNS signals)) (VP (VBN generated) (PP (IN by) (NP-LGS (NP-COOD (NP (NN antigen)) (CC and) (NP (NNS cytokines))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ immune) (NN system))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-47 (NP (DT an) (JJ important) (NN role)) (PP (IN for) (NP (NN egr-1))) (PP (IN in) (S (VP (VBG determining) (NP (NP (DT the) (NN differentiation) (NN pathway)) (PP (IN of) (NP (JJ myeloid) (NN cell) (NNS precursors)))))))) (VP (VBZ has) (VP (VBN been) (ADVP-TMP (RB recently)) (VP (VBN elaborated)))) (. .)))
(TOP (S (ADVP-TMP (RB Finally)) (, ,) (NP-SBJ (NP (JJ potential) (NNS targets)) (PP (IN of) (NP (NP (NN regulation)) (PP (IN by) (NP (NP (DT the) (NN zinc-finger) (NN transcription) (NN factor)) (VP (VBN encoded) (PP (IN by) (NP-LGS (NN egr-1))))))))) (VP (VBP include) (NP (DT the) (NP-COOD (NP (NN interleukin-2)) (, ,) (NP (NN CD44)) (, ,) (NP (NN ICAM-1)) (, ,) (CC and) (NP (NN tumor) (NN necrosis) (NN factor) (NNS genes))))) (. .)))
(TOP (S (NP-SBJ-48 (NP (DT The) (NN role)) (PP (IN of) (NP (NN egr-1))) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (DT the) (JJ immune) (NN response)))))) (VP (MD will) (VP (VB be) (VP (VBN discussed) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (DT these) (JJ recent) (NNS studies)))))))) (. .)))
(TOP (NP (NP (NP (NN Cross) (NN talk)) (PP (IN between) (NP-COOD (NP (NN cell) (NN death)) (CC and) (NP (NN cell) (NN cycle) (NN progression)))) (: :)) (S (NP-SBJ (NN BCL-2)) (VP (VBZ regulates) (NP (JJ NFAT-mediated) (NN activation))) (. .))))
(TOP (S (NP-SBJ (JJ BCL-2-deficient) (NN T) (NNS cells)) (VP (VBP demonstrate) (NP-COOD (NP (VBN accelerated) (NN cell) (NN cycle) (NN progression)) (CC and) (NP (NP (VBN increased) (NN apoptosis)) (PP-TMP (VBG following) (NP (NN activation)))))) (. .)))
(TOP (S (S-SBJ (VP (VBG Increasing) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN BCL-2)))))) (VP-COOD (VP (VBD retarded) (NP (DT the) (ADJP (NN G0) (TO --&gt;) (NN S)) (NN transition))) (, ,) (VP (VBD sustained) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN p27Kip1))))) (, ,) (CC and) (VP (VBD repressed) (NP (NN postactivation) (NN death)))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ Proximal) (NN signal) (NN transduction) (NNS events)) (CC and) (NP (JJ immediate) (JJ early) (NN gene) (NN transcription))) (VP (VBD were) (ADJP-PRD (JJ unaffected))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-27 (NP (DT the) (NP-COOD (NP (NN transcription)) (CC and) (NP (NN synthesis)))) (PP (IN of) (NP-COOD (NP (NN interleukin) (CD 2)) (CC and) (NP (JJ other) (VBN delayed) (JJ early) (NNS cytokines))))) (VP (VBD were) (VP (ADVP (RB markedly)) (VBN attenuated) (PP (IN by) (NP-LGS (NN BCL-2))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (DT a) (NN cysteine) (NN protease) (NN inhibitor)) (SBAR (WHNP-28 (WDT that)) (S (VP (ADVP (RB also)) (VBZ blocks) (NP (NN apoptosis)))))) (VP (VBD had) (NP (DT no) (JJ substantial) (NN affect)) (PP (IN upon) (NP (NN cytokine) (NN production)))) (. .)))
(TOP (S (NP-SBJ (NN InterleUkin) (CD 2) (NN expression)) (VP (VBZ requires) (NP (NP (JJ several) (NN transcription) (NNS factors)) (SBAR (WHPP-29 (IN of) (WHNP (WDT which))) (S (NP-SBJ-30 (NP-COOD (NP (NP (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NP (NN NFAT)) (PRN (-LRB- -LRB-) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (-RRB- -RRB-))))) (CC and) (NP (JJ NFAT-mediated) (NN transactivation)))) (VP (VBD were) (VP (VBN impaired) (PP (IN by) (NP-LGS (NN BCL-2))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NP (JJ select) (JJ genetic) (NNS aberrations)) (PP (IN in) (NP (DT the) (JJ apoptotic) (NN pathway)))) (VP (VBP reveal) (NP (NP (DT a) (NN cell) (JJ autonomous) (NN coregulation)) (PP (IN of) (NP (NN activation))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (NN Stat) (NN 5b))) (PP (IN in) (NP (JJ erythroid) (NNS progenitors)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN ErbB))) (S-19 (VP (TO to) (VP (VB induce) (NP (JJ sustained) (NN cell) (NN proliferation)))))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-20 (NP (NN Self) (NN renewal)) (PP (IN of) (NP (JJ normal) (JJ erythroid) (NNS progenitors)))) (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP-LGS (DT the) (NN receptor) (NN tyrosine) (NN kinase) (NN c-ErbB)))))) (, ,) (IN whereas) (S (NP-SBJ (NP (JJ other) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS c-Kit/Epo-R)) (-RRB- -RRB-))) (VP (VBP regulate) (NP (JJ erythroid) (NN differentiation))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB address) (NP (NP (JJ possible) (NNS mechanisms)) (SBAR (WHNP-22 (WDT that)) (S (VP (MD could) (VP (VB explain) (NP (NP (DT this) (JJ selective) (NN activity)) (PP (IN of) (NP (NN c-ErbB)))))))))))) (, ,) (NP-SBJ-21 (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT these) (NNS receptors))) (S-23 (VP (TO to) (VP (VB activate) (NP (NP (DT the) (JJ different) (NNS members)) (PP (IN of) (NP (DT the) (NN Stat) (NN transcription) (NN factor) (NN family))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Ligand) (NN activation)) (PP (IN of) (NP (NN c-ErbB)))) (VP (VBD induced) (NP (NP (DT the) (NP-COOD (NP (NN tyrosine) (NN phosphorylation)) (, ,) (NP (NN DNA-binding)) (, ,) (CC and) (NP (NN reporter) (NN gene) (NN transcription)))) (PP (IN of) (NP (NN Stat) (NN 5b)))) (PP (IN in) (NP (NNS erythroblasts)))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-24 (NP (NN ligand) (NN activation)) (PP (IN of) (NP (NN c-Kit)))) (VP (VBD was) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB induce) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS effects)))) (PP (IN in) (NP (DT the) (JJ same) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ-25 (NP (NN Activation)) (PP (IN of) (NP (DT the) (NN erythropoietin) (NN receptor)))) (VP-COOD (VP (VBD caused) (NP (NP (JJ specific) (NN DNA-binding)) (PP (IN of) (NP (NN Stat) (NN 5b))))) (, ,) (CC but) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (NN reporter) (NN gene) (NN transcription))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (JJ biochemical) (NNS findings)) (VP (VBP correlate) (ADVP (RB perfectly)) (PP (IN with) (NP (NP (DT the) (JJ selective) (NN ability)) (PP (IN of) (NP (NN c-ErbB))) (S-26 (VP (TO to) (VP (VB cause) (NP (JJ sustained) (NN self) (NN renewal)) (PP (IN in) (NP (JJ erythroid) (NNS progenitors))))))))) (. .)))
(TOP (S (NP-SBJ (NN Calcineurin) (NNS mutants)) (VP (VBP render) (S (NP-SBJ (NN T) (NNS lymphocytes)) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (NN cyclosporin) (NN A)))))) (. .)))
(TOP (S (NP-SBJ-29 (DT The) (NNS immunosuppressants) (NP-COOD (NP (NP (NN cyclosporin) (NN A)) (PRN (-LRB- -LRB-) (NP (NN CsA)) (-RRB- -RRB-))) (CC and) (NP (NN FK506)))) (VP (VBP have) (VP (VBN been) (ADVP (RB widely)) (VP (VBN used) (S (VP (TO to) (VP (VP-COOD (VP (VB prevent)) (CC and) (VP (VB treat))) (NP-31 (NP (NN graft) (NN rejection)) (PP-TMP (IN after) (NP (JJ human) (NP-COOD (NP (NN organ)) (CC and) (NP (NN tissue))) (NNS transplantations)))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-32 (NP (NN CsA)) (CC and) (NP (NN FK506))) (VP (VBP associate) (PP (IN with) (NP (NP (JJ intracellular) (VBG binding) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (ADVP (FW i.e.)) (, ,) (NP-COOD (NP (NP (NN CsA)) (PP (IN with) (NP (NN cyclophilin) (NN A)))) (CC and) (NP (NP (NN FK506)) (PP (IN with) (NP (NN FKBP12)))))) (-RRB- -RRB-)))) (S (VP (TO to) (VP (VB form) (NP (NP (NN protein/drug) (NNS complexes)) (SBAR (WHNP-33 (WDT that)) (S (VP (VBP suppress) (NP (DT the) (JJ immune) (NN system)) (PP (IN by) (S (VP (VBG preventing) (NP (NP (NN activation)) (PP (IN of) (NP (NN T) (NNS cells))) (PP (IN in) (NN response) (TO to) (NP (NN antigen) (NN presentation))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ common) (NN target)) (PP (IN of) (NP-COOD (NP (NN CsA)) (CC and) (NP (NN FK506))))) (VP (VBZ is) (NP-PRD (NP (NN calcineurin)) (, ,) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ Ca2+/calmodulin-regulated)) (, ,) (ADJP (JJ serine/threonine-specific))) (NN protein) (NN phosphatase)) (SBAR (WHNP-35 (WDT that)) (S (VP (VBZ regulates) (NP (NP (DT the) (JJ nuclear) (NN import)) (PP (IN of) (NP (NP (NP (DT a) (NN transcription) (NN factor)) (, ,) (NP (NN NF-AT)) (, ,)) (VP (VBN required) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (NN T) (NN cell) (NN activation) (NNS genes))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ previous) (NNS studies))) (, ,) (NP-SBJ (PRP we)) (VP (VBD identified) (NP (NP (NN calcineurin) (NNS mutations)) (SBAR (WHNP-36 (WDT that)) (S (VP-COOD (VP (VBP block) (NP (NP (NN binding)) (PP (IN by) (NP (DT the) (ADJP-COOD (ADJP (NN cyclophilin) (NN A/CsA)) (CC or) (ADJP (NN FKBP12/FK506))) (NNS complexes))))) (CC and) (RB thereby) (VP (VBP render) (S (NP-SBJ (NN yeast) (NNS cells)) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (NP (DT the) (JJ antifungal) (NNS effects)) (PP (IN of) (NP-COOD (NP (NN CsA)) (CC or) (NP (NN FK506)))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ corresponding) (NNS mutations)) (PP (IN in) (NP (JJ murine) (NN calcineurin)))) (VP (VBP render) (S (NP-SBJ (DT the) (NN T) (NN cell) (NN receptor) (NN signal) (NN transduction) (NN cascade) (NN CsA)) (ADJP-PRD (JJ resistant) (PP (IN in) (NP (JJ human) (NN Jurkat) (NN T) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS findings)) (VP-COOD (VP (VBP support) (NP (DT the) (ADJP (RB recently) (VBN determined)) (NN calcineurin) (NN X-ray) (NN crystal) (NN structure))) (, ,) (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ (NN calcineurin)) (VP (VBZ is) (NP-PRD (NP (DT the) (RB only) (JJ CsA-sensitive) (NN component)) (VP (VBG limiting) (NP (NP (NN signaling)) (PP (IN from) (NP (DT the) (NN T) (NN cell) (NN receptor))) (PP (TO to) (NP (DT the) (NN nucleus))))))))))) (, ,) (CC and) (VP (VBP suggest) (NP (NP (DT a) (NN means)) (SBAR (S (VP (TO to) (VP (VB render) (S (NP-SBJ-COOD (NP (NNS cells)) (CC and) (NP (NNS tissues))) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (NP (DT the) (JJ toxic) (JJ side) (NNS effects)) (PP (IN of) (NP-COOD (NP (NN CsA)) (CC and) (NP (NN FK506))))))))))))))) (. .)))
(TOP (NP (NP (NN Retinoid) (NN differentiation) (NN therapy)) (PP (IN in) (NP (JJ promyelocytic) (NN leukemia))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ specific) (NN type)) (PP (IN of) (NP (JJ acute) (JJ myeloid) (NN leukemia))) (VP (VBN characterized) (PP (IN by) (NP-LGS-COOD (NP (NP (DT the) (NN morphology)) (PP (IN of) (NP (DT the) (NN blast) (NNS cells)))) (, ,) (NP (DT a) (JJ specific) (NN t-LRB-15;17-RRB-) (NN translocation)) (, ,) (CC and) (NP (NP (NNS risks)) (PP (IN of) (NP (JJ definite) (NN coagulopathy))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Recently)) (NP-SBJ-72 (DT this) (NN leukemia)) (VP (VBD was) (VP (ADVP (RB further)) (VBN characterized) (PP (IN by) (NP-LGS-COOD (NP (NP (DT an) (JJ exquisite) (NN sensitivity)) (PP (TO to) (NP (NP (JJ all-trans) (JJ retinoic) (NN acid) (POS 's)) (NN differentiation) (NN effect)))) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (DT a) (NN fusion) (NN gene)) (VP (VBG altering) (NP-COOD (NP (NP (DT the) (NN gene)) (PP (IN of) (NP (NN RARalpha)))) (CC and) (NP (DT a) (JJ novel) (NN gene) (NN PML))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (FW In) (FW vivo)) (NN differentiation) (NN therapy)) (PP (IN with) (NP (NNS retinoids))) (PP (IN in) (NP (NN APL) (NNS patients)))) (VP (VBZ follows) (NP (NP (JJ strict) (NNS guidelines)) (ADJP (JJ related) (PP (CC both) (TO to) (NP-COOD (NP (DT the) (NN APL) (NN cell)) (CC and) (NP (NP (DT the) (NN biodisposal)) (PP (IN of) (NP (JJ all-trans) (JJ retinoic) (NN acid))))))))) (. .)))
(TOP (S (NP-SBJ-38 (JJ Epstein-Barr) (JJ viral) (NN latency)) (VP (VBZ is) (VP (VBN disrupted) (PP (IN by) (NP-LGS (DT the) (JJ immediate-early) (NN BRLF1) (NN protein))) (PP (IN through) (NP (DT a) (JJ cell-specific) (NN mechanism))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (JJ causative) (NN agent)) (PP (IN of) (NP (JJ infectious) (NN mononucleosis)))) (, ,)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ human) (NN herpesvirus)) (VP (VBN associated) (PP (IN with) (NP-COOD (NP (NP (JJ epithelial) (NN cell) (NNS malignancies)) (PRN (-LRB- -LRB-) (NP (JJ nasopharyngeal) (NN carcinoma)) (-RRB- -RRB-))) (CONJP (RB as) (RB well) (IN as)) (NP (NN B-cell) (NNS malignancies))))))) (. .)))
(TOP (S (S-SBJ (VP (VBG Understanding) (SBAR (WHADVP-39 (WRB how)) (S (NP-SBJ-40 (JJ viral) (NN latency)) (VP (VBZ is) (VP (VBN disrupted))))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ central) (NN issue)) (PP (IN in) (NP (JJ herpesvirus) (NN biology))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (JJ Epithelial) (NNS cells)) (VP (VBP are) (NP-PRD (NP (DT the) (JJ major) (NN site)) (PP (IN of) (NP (NP (JJ lytic) (NN EBV) (NN replication)) (PP (IN within) (NP (DT the) (JJ human) (NN host)))))))) (, ,) (CC and) (S (NP-SBJ (JJ viral) (NN reactivation)) (VP (VBZ occurs) (PP (IN in) (NP (JJ EBV-associated) (JJ nasopharyngeal) (NNS carcinomas))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN known) (SBAR (IN that) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ viral) (JJ immediate-early) (NN protein)) (, ,) (NP (NN BZLF1)) (, ,)))) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (S (VP (TO to) (VP (VB initiate) (NP (NP (DT the) (NN switch)) (PP (IN from) (NP (JJ latent))) (PP (TO to) (NP (JJ lytic))) (NP-41 (NN infection)) (PP (IN in) (NP (NN B) (NNS cells))))))))))))) (. .)))
(TOP (S (NP-SBJ-42 (NP (JJ Cellular) (NN regulation)) (PP (IN of) (NP (NN BZLF1) (NN transcription)))) (VP (VBZ is) (ADVP (RB therefore)) (VP (VBN thought) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (NN stringency)) (PP (IN of) (NP (JJ viral) (NN latency)))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (, ,) (S (ADVP (RB unexpectedly)) (, ,) (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (NP (DT another) (JJ viral) (JJ immediate-early) (NN protein)) (, ,) (NP (NN BRLF1)) (, ,)))) (VP (MD can) (VP (VB disrupt) (NP (JJ viral) (NN latency)) (PP (IN in) (NP (DT an) (ADJP (JJ epithelial) (JJ cell-specific)) (NN fashion)))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ-44 (NP (DT the) (NNS mechanisms)) (VP (VBG leading) (PP (TO to) (NP (NP (NN disruption)) (PP (IN of) (NP (NN EBV) (NN latency))))))) (VP (VBP appear) (S (VP (TO to) (VP (VB be) (ADJP-PRD (NN cell-type) (JJ specific)))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NN IL4)) (CC and) (NP (NN IL13))) (NNS receptors)) (VP (VP-COOD (VP (VBP share) (NP (DT the) (NN gamma) (NN c) (NN chain))) (CC and) (VP (VBP activate) (NP (NP-COOD (NP (NN STAT6)) (, ,) (NP (NN STAT3)) (CC and) (NP (NN STAT5))) (NNS proteins)))) (PP (IN in) (NP (JJ normal) (JJ human) (NN B) (NNS cells)))) (. .)))
(TOP (S (NP-SBJ (NN IL13)) (VP (VBZ induces) (NP (NP (DT the) (JJ same) (JJ biological) (NNS effects)) (PP (IN as) (NP (NN IL4)))) (PP (IN in) (NP (JJ normal) (JJ human) (NN B) (NNS cells)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (S (PP (IN as) (FRAG (PP (IN in) (NP (DT the) (NN IL4R) (NN complex))))) (, ,) (NP-SBJ-COOD (CC both) (NP (NN IL4R) (NN alpha)) (CC and) (NP (NN IL2R) (NN gamma) (NN c))) (VP (VBP are) (NP-PRD (NP (NNS components)) (PP (IN of) (NP (DT the) (NN IL13R))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (DT both) (NNS cytokines)) (VP (VBD induced) (NP (NP (NP-COOD (NP (NN STAT6)) (, ,) (NP (NN STAT3)) (CC and) (NP (NN STAT5))) (NN activation)) (PP (IN in) (NP (NN B) (NNS cells))))))))) (. .)))
(TOP (S (S (PP (IN In) (NN spite) (IN of) (NP (DT this) (JJ similar) (JJ downstream) (NN signalling))) (, ,) (NP-SBJ-COOD (NP (NN IL4)) (CC and) (NP (NN IL13))) (VP (VBD used) (NP (NP (DT a) (JJ different) (NN set)) (PP (IN of) (NP (NN Janus) (NNS kinases))))) (: :)) (S (NP-SBJ-28 (NN IL13)) (VP (VBZ is) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB activate) (NP-COOD (NP (NN JAK1)) (CC and) (NP (NN JAK3)))))))) (. .))))
(TOP (NP (NP (VBN Attenuated) (NN function)) (PP (IN of) (NP (NP (NP (NP (DT a) (JJ variant) (NN form)) (PP (IN of) (NP (DT the) (JJ helix-loop-helix) (NN protein)))) (, ,) (NP (NN Id-3)) (, ,)) (VP (VBN generated) (PP (IN by) (NP (DT an) (JJ alternative) (NN splicing) (NN mechanism)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN Id) (NN family)) (PP (IN of) (NP (JJ helix-loop-helix) (NNS proteins)))) (VP (VBP function) (PP (IN as) (NP (NP (JJ negative) (NNS regulators)) (NP (IN of) (NP (ADJP-COOD (ADJP (NN DNA) (NN binding)) (, ,) (ADJP (JJ basic) (JJ helix-loop-helix))) (NNS proteins))))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN cell) (NP-COOD (NP (NN growth)) (CC and) (NP (NN differentiation)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP report) (ADVP (RB here)) (PP (IN on) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (DT a) (ADJP (CD 17) (NN kDa)) (NN variant)) (PP (IN of) (NP (DT the) (ADJP (CD 14) (NN kDa)) (NN Id-3) (NN protein))) (VP (VBN termed) (S (NP-PRD (NP (NN Id-3L)) (PRN (-LRB- -LRB-) (NP (JJ long) (NN version)) (-RRB- -RRB-))))) (SBAR (WHNP-18 (WDT which)) (S (VP (VBZ possesses) (NP (NP (DT a) (JJ unique) (CD 60) (NN amino) (NN acid) (NN carboxy-terminus)) (VP (VBN generated) (PP (IN by) (NP-COOD (NP (NP (VBN read) (IN through)) (PP (IN of) (NP (DT a) (`` ') (VBG coding) (NN intron) ('' ')))) (CC and) (NP (JJ alternative) (NN splicing)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Northern) (NN analysis)) (VP (VBD revealed) (NP (NP (NN expression)) (PP (IN of) (NP-COOD (NP (DT a) (JJ minor) (ADJP (CD 1.1) (NN kb)) (NN Id-3L) (NN transcript)) (CONJP (RB together) (IN with)) (NP (DT the) (JJ predominant) (ADJP (CD 0.95) (NN kb)) (NN Id-3) (NN transcript)))) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NP (JJ adult) (JJ human) (NNS tissues)) (VP (VBN analysed)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ variant) (NN Id-3L) (NN protein)) (VP (VBZ is) (ADJP-PRD (RB functionally) (JJ distinguishable) (PP (IN from) (NP (JJ conventional) (NN Id-3)))) (SBAR (IN since) (S (PP (IN in) (NP (ADJP (FW in) (FW vitro)) (NN DNA) (NN mobility) (NN shift) (NNS assays))) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (ADJP-PRD (RB greatly) (JJ impaired)) (PP (IN in) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB abrogate) (NP (NP (NN binding)) (PP (IN of) (NP (NP (DT the) (ADJP (JJ basic) (JJ helix-loop-helix)) (NN protein)) (, ,) (NP (NN E47)) (, ,))) (PP (TO to) (NP (DT an) (NN E) (NN box) (NN recognition) (NN sequence))))))))))))) (. .)))
(TOP (NP (NP (JJ Multifactor) (JJ cis-dominant) (JJ negative) (NN regulation)) (PP (IN of) (NP (NN IL-2) (NN gene) (NN expression))) (PP (IN in) (NP (VBN anergized) (NN T) (NNS cells))) (. .)))
(TOP (S (NP-SBJ-10 (NP (DT The) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (NP (NP (NN IL-2) (JJ transcriptional) (NN blockade)) (PP (IN in) (NP (JJ anergic) (NN T) (NN cell) (NNS clones)))))) (VP (VBZ is) (RB not) (ADVP (RB fully)) (VP (VBN understood))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (SBAR (IN whether) (S (NP-SBJ (DT an) (JJ active) (ADJP (JJ negative) (JJ regulatory)) (NN process)) (VP (VBZ occurs))))))) (, ,) (NP-SBJ-11 (PRP we)) (VP (VBD created) (NP (NP (DT a) (NN reporter) (NN construct)) (VP (VBG containing) (PP (IN as) (NP (DT an) (NN enhancer))) (NP (NP-COOD (NP (NP (CD four) (NNS copies)) (PP (IN of) (NP (DT the) (NN NF-AT) (NN site)))) (CC and) (NP (NP (CD one) (NN copy)) (PP (IN of) (NP (DT the) (NN octamer) (NN site))))) (PRN (-LRB- -LRB-) (NP (NN 4X) (NN NF-AT-Oct)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ-12 (DT This) (NN construct)) (VP (VBD was) (ADVP (ADVP (RB only) (RB slightly))) (VP (VBN reduced) (PRN-101 (-LRB- -LRB-) (ADVP (RB 1.3-fold)) (-RRB- -RRB-)) (PP (IN in) (NP (PRP$ its) (NN expression))) (SBAR-TMP (WHADVP-15 (WRB when)) (S (VP (VBN stimulated) (PP (IN under) (NP (JJ anergic) (NNS conditions)))))) (, ,) (SBAR (IN while) (S (NP-SBJ (DT a) (JJ whole) (NN mouse) (NN IL-2) (NN enhancer) (NN construct)) (VP (VBD showed) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ 4.3-fold))))))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (NP (NN Addition)) (PP (IN of) (NP (DT the) (NP-COOD (NP (CD -176)) (TO to) (NP (CD -96))) (NN sequence))) (PP (TO to) (NP (DT the) (NN 4X) (NN NF-AT-Oct) (NN construct)))) (VP (VBD did) (RB not) (VP (VB impart) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP-LGS (NN anergy))))))))))) (, ,) (CC but) (S (NP-SBJ (NP (NN addition)) (PP (IN of) (NP (DT the) (NP-COOD (NP (CD -236)) (TO to) (NP (CD -96))) (NN sequence)))) (VP (VBD did)))) (, ,) (S (VP (VBG demonstrating) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NN anergy)) (VP (VBZ is) (NP-PRD (DT an) (JJ active) (JJ inhibitory) (NN process))))) (CC and) (SBAR (IN that) (S (NP-SBJ-17 (NP (JJR more)) (PP (IN than) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT the) (CD -150) (NN AP-1) (NN binding) (NN site)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD -152)) (TO to) (NP (CD -147))) (-RRB- -RRB-))))))) (VP (VBZ is) (VP (VBN required) (S (VP (TO to) (VP (VB mediate) (NP (DT the) (NN effect)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Mutational) (NNS studies)) (PP (IN of) (NP (DT the) (NP-COOD (NP (CD -236)) (TO to) (NP (CD -96))) (NN sequence)))) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN presence)) (PP (IN of) (NP-COOD (CC both) (NP (DT the) (NP (NP (CD -130) (JJ AP-1-like) (NN site)) (PRN (-LRB- -LRB-) (NP-COOD (NP (CD -187)) (TO to) (NP (CD -181))) (-RRB- -RRB-)))) (CC and) (NP (DT the) (CD -150) (JJ proximal) (NN AP-1) (NN site))))) (VP (VBD were) (ADJP-PRD (JJ necessary) (S (VP (TO to) (VP (VB observe) (NP (NN anergy)))))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP-SBJ-18 (DT the) (CD -180) (NN site)) (VP (VBZ is) (RB not) (VP (VBN required) (PP (IN for) (NP (NN trans-activation))))))) (, ,) (NP-SBJ (NP (PRP it))) (VP (VBD was) (ADJP-PRD (JJ possible)) (S-19 (VP (TO to) (VP (VB confirm) (PP (IN by) (NP (NP (NN mutation)) (PP (IN in) (NP (DT the) (JJ normal) (NN mouse) (NN IL-2) (NN enhancer))))) (SBAR (IN that) (S (NP-SBJ (DT this) (NN site)) (VP (VBZ is) (ADJP-PRD (RB absolutely) (JJ essential) (PP (IN for) (NP (NN anergy) (NN induction))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJS simplest) (NN model)) (SBAR (S (VP (TO to) (VP (VB explain) (NP (DT these) (NNS results))))))) (VP (VBZ is) (SBAR-PRD (IN that) (S (NP-SBJ-21 (NN anergy)) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT a) (NN complex)) (PP (IN of) (NP (NP (JJ multiple) (NN transcription) (NNS factors)) (SBAR (WHNP-22 (WDT that)) (S (VP (VBP exert) (NP (DT a) (JJ cis-acting) (JJ dominant) (JJ negative) (JJ regulatory) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN trans-activation)) (PP (IN of) (NP (DT the) (NN IL-2) (NN gene))))))))))))))))) (. .)))
(TOP (NP (NP (NN Characterization)) (PP (IN of) (NP (DT the) (JJ human) (JJ myeloid) (NN cell) (JJ nuclear) (NN differentiation) (NN antigen) (NN gene) (NN promoter))) (. .)))
(TOP (S (NP-SBJ (NP (NN MNDA)) (PRN (-LRB- -LRB-) (NP (JJ myeloid) (NN cell) (JJ nuclear) (NN differentiation) (NN antigen)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT an) (ADJP (NP (NN interferon) (NN alpha)) (VBN regulated)) (JJ nuclear) (NN protein)) (VP (VBN expressed) (PP (RB only) (IN in) (NP (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ human) (JJ myelomonocytic) (NN lineage)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB identify) (NP (NP (NNS mechanisms)) (ADJP (JJ responsible) (PP (IN for) (NP (DT this) (ADJP-COOD (ADJP (JJ lineage-specific)) (CC and) (ADJP (JJ interferon-regulated))) (NN expression)))))))) (, ,) (NP-SBJ-34 (NP (DT the) (JJ 5') (JJ flanking) (NN sequence)) (PP (IN of) (NP (DT the) (NN gene)))) (VP (VBZ has) (VP (VBN been) (VP (VBN characterized)))) (. .)))
(TOP (S (NP-SBJ (CD Two) (NP (NP (JJ interferon-stimulated) (NN response) (NNS elements)) (PRN (-LRB- -LRB-) (NP (NN ISRE)) (-RRB- -RRB-)))) (VP (VBP flank) (NP (NP (DT a) (JJ multiple) (NN transcription) (NN start) (NN site) (NN region)) (VP (VBG identifying) (NP (NN MNDA)) (PP (IN as) (NP (DT a) (JJ TATA-less) (JJ interferon-regulated) (NN gene)))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Other) (NN DNA) (NNS elements)) (ADJP (JJ present))) (VP (VBP include) (NP (NP-COOD (NP (NP (DT a) (NN cluster)) (PP (IN of) (NP (NN Myb) (NNS sites)))) (, ,) (NP (JJ several) (NNS Ets)) (, ,) (NP (DT an) (ADJP (NN Ets) (JJ related)) (NN PU.1) (NN site)) (CC and) (NP (DT an) (NN Sp1) (NN site))) (ADJP (JJ located) (PP (IN within) (NP (NP (CD 600) (NN bp)) (PP (IN of) (NP (DT the) (NN transcription) (NN start) (NNS sites)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-35 (NN DNA) (NN methylation)) (VP (VBD was) (VP (VBN revealed) (PP (IN as) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ possible) (NNS factors))) (PP (IN in) (S (VP (VBG establishing) (NP (NN MNDA) (NN expression))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ 5') (JJ flanking) (NN sequence)) (VP (VBZ has) (NP (NP (NN promoter) (NN activity)) (SBAR (WHNP-37 (WDT which)) (S (VP (VBZ is) (VP (VBN elevated) (PP (IN by) (NP-LGS (NN interferon) (NN alpha))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-39 (NN MNDA) (NN expression)) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS (NP (NNS mechanisms)) (ADJP (JJ similar) (PP (TO to) (NP-COOD (NP (JJ other) (ADJP (NP (JJ myelomonocytic) (NN cell)) (JJ specific)) (NNS genes)) (CC and) (NP (NP (NNS genes)) (VP (VBN up-regulated) (PP (IN by) (NP-LGS (NN interferon) (NN alpha))))))))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (NN GM-CSF) (NN gene) (NN transcription))) (PP (IN by) (NP (JJ core-binding) (NN factor))) (. .)))
(TOP (S (NP-SBJ-68 (NP (NN GM-CSF) (NN gene) (NN activation)) (PP (IN in) (NP (NN T) (NNS cells)))) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB involve) (NP (DT the) (NN transcription) (NNS factors) (NP-COOD (NP (JJ nuclear) (NN factor-kappa) (NN B)) (, ,) (NP (NN AP-1)) (, ,) (NP (NN NFAT)) (, ,) (CC and) (NP (NN Sp1))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ human) (NN GM-CSF) (NP-COOD (NP (NN promoter)) (CC and) (NP (NN enhancer)))) (ADVP (RB also)) (VP (VBP encompass) (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (JJ core-binding) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN CBF)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (ADVP (RB Significantly)) (, ,) (NP-SBJ-69 (DT the) (NN CBF) (NNS sites)) (VP (VBP are) (PP (IN in) (NP (DT each) (NN case))) (VP (VBN contained) (PP (IN within) (NP (NP (DT the) (JJ minimum) (JJ essential) (NN core) (NNS regions)) (VP (VBN required) (PP (IN for) (NP (NP (JJ inducible) (NN activation)) (PP (IN of) (NP (NN transcription)))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (DT these) (NN core) (NNS regions)) (PP (IN of) (NP (NP (DT the) (NP-COOD (NP (NN enhancer)) (CC and) (NP (NN promoter)))) (NP (DT each))))) (VP (VBP encompass) (NP (NP (ADJP (RB closely) (VBN linked)) (VBG binding) (NNS sites)) (PP (IN for) (NP-COOD (NP (NN CBF)) (, ,) (NP (NN AP-1)) (, ,) (CC and) (NP (NN NFATp)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN GM-CSF) (NN promoter) (NN CBF) (NN site) (NN TGTGGTCA)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ located) (ADVP (ADJP (CD 51) (NN bp)) (RB upstream) (PP (IN of) (NP (DT the) (NN transcription) (NN start) (NN site)))))) (CC and) (RB also) (VP (VBZ overlaps) (NP (DT a) (NN YY-1) (NN binding) (NN site)))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ 2-bp) (NN mutation)) (PP (IN within) (NP (DT the) (NN CBF) (NN site)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ 2-3-fold) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP-COOD (CC both) (NP (DT a) (JJ 69-bp) (JJ proximal) (NN promoter) (NN fragment)) (CC and) (NP (DT a) (JJ 627-bp) (NN full-length) (NN promoter) (NN fragment))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Stepwise) (NNS deletions)) (PP (IN into) (NP (DT the) (JJ proximal) (NN promoter)))) (ADVP (RB also)) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ-COOD-71 (NP (DT the) (NN CBF) (NN site)) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (NN YY-1) (NN site)) (, ,)) (VP (VBD was) (VP (VBN required) (PP (IN for) (NP (NP (JJ efficient) (NN induction)) (PP (IN of) (NP (JJ transcriptional) (NN activation)))))))))) (. .)))
(TOP (S (NP-SBJ-72 (NP (DT The) (NP-COOD (NP (NN AML1)) (CC and) (NP (NN CBF) (NN beta))) (NNS genes)) (SBAR (WHNP-73 (WDT that)) (S (VP (VBP encode) (NP (NN CBF))))) (NP (DT each))) (VP-COOD (VP (VBP have) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB influence) (NP (NN cell) (NP-COOD (NP (NN growth)) (CC and) (NP (NN differentiation))))))))) (CC and) (VP (VBP have) (NP (VBN been) (VP (VBN implicated) (PP (IN as) (NP (NNS proto-oncogenes))) (PP (IN in) (NP (JJ acute) (JJ myeloid) (NN leukemia))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN study)) (VP (VBZ adds) (NP (NN GM-CSF)) (PP (TO to) (NP (NP (DT a) (VBG growing) (NN list)) (PP (IN of) (NP (NP-COOD (NP (NNS cytokines)) (CC and) (NP (NNS receptors))) (SBAR-COOD (SBAR (WHNP-74 (WDT that)) (S (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP-LGS (NN CBF))))))) (CC and) (SBAR (WHNP-76 (WDT which)) (S (VP (VBP control) (NP (NP (DT the) (NP-COOD (NP (NN growth)) (, ,) (NP (NN differentiation)) (, ,) (CC and) (NP (NN activation)))) (PP (IN of) (NP (JJ hemopoietic) (NNS cells))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN GM-CSF) (NN locus)) (VP (MD may) (VP (VB represent) (NP (NP (CD one)) (PP (IN of) (NP (NP (JJ several) (NN target) (NNS genes)) (SBAR (WHNP-77 (WDT that)) (S (VP (VBP are) (VP (VBN dysregulated) (PP (IN in) (NP (JJ acute) (JJ myeloid) (NN leukemia)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Tyloxapol)) (VP-COOD (VP (VBZ inhibits) (NP (NP-COOD (NP (NN NF-kappa) (NN B)) (CC and) (NP (NN cytokine))) (NN release))) (, ,) (VP (VBZ scavenges) (NP (NN HOCI))) (, ,) (CC and) (VP (VBZ reduces) (NP (NP (NN viscosity)) (PP (IN of) (NP (JJ cystic) (NN fibrosis) (NN sputum)))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (JJ Cystic) (NN fibrosis)) (PRN (-LRB- -LRB-) (NP (NN CF)) (-RRB- -RRB-))) (NNS patients)) (VP (VB develop) (NP (NP (JJ progressive) (JJ cytokine-mediated) (JJ inflammatory) (NN lung) (NN disease)) (, ,) (PP (IN with) (NP (NP (JJ abundant) (NN production)) (PP (IN of) (NP (NP (ADJP-COOD (ADJP (JJ thick)) (, ,) (ADJP (JJ tenacious)) (, ,) (ADJP-COOD (ADJP (NP (NN protease-))) (CC and) (ADJP (JJ oxidant-rich)))) (JJ purulent) (NN airway) (NNS secretions)) (SBAR (WHNP-20 (WDT that)) (S (VP (VBP are) (ADJP-PRD (JJ difficult) (SBAR (S (VP (TO to) (VP (VB clear) (PP (RB even) (IN with) (NP (NN physiotherapy))))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT the) (NN search)) (PP (IN for) (NP (DT a) (JJ potential) (NN treatment))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN tested) (NP (NP (NN tyloxapol)) (, ,) (NP (NP (DT an) (NN alkylaryl) (JJ polyether) (NN alcohol) (NN polymer) (NN detergent)) (VP (ADVP-TMP (RB previously)) (VBN used) (PP (IN as) (NP (DT a) (JJ mucolytic) (NN agent))) (PP (IN in) (NP (JJ adult) (JJ chronic) (NN bronchitis)))))))) (. .)))
(TOP (S (NP-SBJ (NN Tyloxapol)) (VP-COOD (VP (VBZ inhibits) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NP (NP (JJ nuclear) (NN factor-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NK-kappa) (NN B)) (-RRB- -RRB-))))))) (, ,) (VP (VBZ reduces) (NP (NP (VBG resting) (NN secretion)) (PP (IN of) (NP (NP (DT the) (NN cytokine) (NP (NP (NN interleukin-8)) (PRN (-LRB- -LRB-) (NP (NN IL-8)) (-RRB- -RRB-)))) (PP (IN in) (NP (VBN cultured) (JJ human) (NNS monocytes))))))) (, ,) (CC and) (VP (VBZ inhibits) (NP (NP (ADJP (NN lipopolysaccharide) (-LRB- -LRB-) (NN LPS) (-RRB- -RRB-) (JJ -stimulated)) (NN release)) (PP (IN of) (NP-COOD (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (, ,) (NP (NN IL-1) (NN beta)) (, ,) (NP (NN IL-6)) (, ,) (NP (NN IL-8)) (, ,) (NP (NP (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (, ,) (CC and) (NP (DT the) (NNS eiconsanoids) (NP-COOD (NP (NN thromboxane) (NN A2)) (CC and) (NP (NP (NN leukotriene) (NN B4)) (PRN (-LRB- -LRB-) (NP (NN LTB4)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NN tyloxapol)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ potent) (NN antioxidant)) (PP (IN for) (NP (NP (NN hydroxyl) (NNS radicals)) (PRN (-LRB- -LRB-) (NP (NN OH)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Tyloxapol)) (PRN (-LRB- -LRB-) (NP (ADJP (QP (CD 0.05) (TO to) (CD 0.1)) (NN %)) (NN wt/vol)) (-RRB- -RRB-))) (ADVP (RB effectively)) (VP-COOD (VP (VBZ scavenges) (NP (NP (DT the) (JJ oxidant) (JJ hypochlorous) (NN acid)) (PRN (-LRB- -LRB-) (NP (NP (NN HOCl)) (: ;) (NP (QP (CD 1) (TO to) (CD 7.5)) (NN mM))) (-RRB- -RRB-))) (ADVP (FW in) (FW vitro))) (, ,) (CC and) (VP (VBZ protects) (PP (IN from) (NP (JJ HOCl-mediated) (NN lung) (NN injury))) (PP (IN in) (NP (NNS rats))))) (. .)))
(TOP (S (NP-SBJ (NN Tyloxapol)) (ADVP (RB also)) (VP (VBZ reduces) (NP (NP (DT the) (NN viscosity)) (PP (IN of) (NP (NN CF) (NN sputum)))) (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 463) (CC +/-) (CD 133)))) (PP (TO to) (NP (QP (CD 128) (CC +/-) (CD 52)))) (NP-100 (NN centipoise)) (-RRB- -RRB-)) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP-SBJ (NN tyloxapol)) (VP-COOD (VP (VBZ is) (ADVP (RB potentially)) (ADJP-PRD (JJ useful) (PP (IN as) (NP (NP (DT a) (JJ new) (JJ antiinflammatory) (NN therapy)) (PP (IN for) (NP (NN CF) (NN lung) (NN disease))))))) (, ,) (CC and) (VP (MD could) (ADVP (RB possibly)) (VP (VB promote) (NP (NP (NN clearance)) (PP (IN of) (NP (NNS secretions))) (PP (IN in) (NP (DT the) (NN CF) (NN airway)))))))))) (. .)))
(TOP (NP (NP (NN Abnormality)) (PP (IN of) (NP (NP (NN Oct-1) (NN DNA) (NN binding)) (PP (IN in) (NP (NP (NN T) (NNS cells)) (PP (IN from) (NP (NP (NN Sjogren) (POS 's)) (NN syndrome) (NNS patients))))))) (. .)))
(TOP (S (NP-SBJ (JJ Primary) (NP (NP (NP (NN Sjogren) (POS 's)) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN SS)) (-RRB- -RRB-)))) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ autoimmune) (JJ rheumatic) (NN disease)) (VP (VBN characterized) (PP (IN by) (NP-LGS (NN T) (NN cell) (NN hypoactivity)))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB understand) (NP (NP (DT the) (VBN diminished) (NN T) (NN cell) (NN response)) (PP (TO to) (NP (NN activation) (NNS signals))))))) (, ,) (NP-SBJ-40 (PRP we)) (VP (VBD measured) (NP (NP (NN nucleoprotein) (JJ DNA-binding) (NNS activities)) (VP (VBG regulating) (NP (NN gene) (NN expression)) (PP-TMP (IN during) (NP (NN T) (NN cell) (NN activation))))) (S (VP (VBG using) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))))) (. .)))
(TOP (S (NP-SBJ-42 (NP (JJ Peripheral) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (CD 9/19) (NN SS) (NNS patients)))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ defective)) (PP (IN in) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB bind) (NP (NP (DT an) (NN october) (NN sequence)) (PRN (-LRB- -LRB-) (NP (NN Oct-1)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ Oct-1-binding) (NN phenotype)) (VP (VBD remained) (ADJP-PRD (JJ stable)) (PP (IN in) (NP (NN culture))) (PP-TMP (IN for) (NP (NP (QP (IN up) (TO to) (CD 3)) (NNS days)) (PP-TMP (RB prior) (TO to) (NP (NN activation)))))) (. .)))
(TOP (S (NP-SBJ-43 (DT This) (NN abnormality)) (VP (VBD was) (RB not) (VP (VBN seen) (PP (IN in) (NP (NP-COOD (NP (VBG resting) (NN T) (NNS cells)) (CC nor) (NP (NN T) (NNS cells))) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP-COOD (NP (JJ systemic) (NN lupus) (NN erythematosus)) (, ,) (NP (NP (JJ rheumatoid) (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN SS)) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NN RA))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN SS) (NN Oct-1) (JJ DNA-binding) (NN abnormality)) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (NP (DT an) (NN inability)) (PP (IN of) (NP (NNS cells))) (S-45 (VP (TO to) (VP (VB exit) (NP (DT the) (NN Gzero/G1) (NN cell) (NN cycle) (NN phase)) (SBAR-TMP (WHADVP-46 (WRB when)) (S (VP (VBN stimulated) (ADVP (FW in) (FW vitro))))))))))) (. .)))
(TOP (S (ADVP (RB Importantly)) (, ,) (NP-SBJ (NP (NN nucleoprotein) (NNS extracts)) (VP (VBG showing) (NP (VBN decreased) (JJ DNA-binding) (NN activity)))) (VP (VBD had) (NP (NP (JJ normal) (NNS amounts)) (PP (IN of) (NP (NN Oct-1) (NNS proteins))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP-LGS (NN immunoprecipitation))))))) (, ,) (S (VP (VBG implying) (NP (NP (DT a) (JJ functional) (NN defect)) (PP (IN in) (NP (DT the) (NN Oct-1) (NN protein))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-49 (JJ defective) (NN DNA) (NN binding)) (VP (VBD was) (VP (VBN corrected) (PP (IN by) (NP-LGS (NP (NN treatment)) (PP (IN with) (NP (NN acid) (NN phosphatase))))))) (. .)))
(TOP (NP (NP (JJ Severe) (JJ combined) (NN immunodeficiency)) (PP (IN due) (TO to) (NP (NP (JJ defective) (NN binding)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NN factor)) (PP (IN of) (NP (NP (VBN activated) (NN T) (NNS cells)) (PP (IN in) (NP (NP (NN T) (NNS lymphocytes)) (PP (IN of) (NP (CD two) (JJ male) (NNS siblings))))))))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NP (JJ Peripheral) (NN blood) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (NN PBL)) (-RRB- -RRB-))) (CC and) (NP (JJ alloreactive) (NN T) (NN cell) (NNS lines))) (PP (IN of) (NP (NP (CD two) (JJ male) (NNS infants)) (VP-COOD (VP (VBN born) (PP (TO to) (NP (JJ consanguinous) (NNS parents)))) (CC and) (VP (VBG presenting) (PP (IN with) (NP (NP (JJ severe) (JJ combined) (NN immunodeficiency)) (PRN (-LRB- -LRB-) (NP (NN SCID)) (-RRB- -RRB-))))))))) (VP (VBD showed) (NP (NP (DT a) (JJ pronounced) (NN deficiency)) (PP (IN in) (NP (NN T) (NN cell) (NN activation))))) (. .)))
(TOP (S (SBAR (IN Although) (FRAG (ADJP (RB phenotypically) (JJ normal)))) (, ,) (NP-SBJ-23 (NP (DT the) (JJ proliferative) (NN response)) (PP (IN of) (NP (NP (DT the) (NNS childrens) (POS ')) (NN T) (NNS cells)))) (VP (VP-COOD (VP (VBD was) (ADVP (RB strongly)) (VP (VBN reduced))) (CC but) (VP (MD could) (VP (VB be) (VP (VBN improved))))) (PP (IN by) (NP-LGS (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (NP-SBJ-25 (NP (DT both) (NNS childrens) (POS ')) (NN T) (NNS cells)) (VP (VBD were) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB produce) (NP (DT the) (NNS cytokines) (NP-COOD (NP (NN IL-2)) (, ,) (NP (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-))) (, ,) (NP (NN IL-4)) (CC and) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ-26 (DT This) (JJ multiple) (NN cytokine) (NN production) (NN deficiency)) (VP (MD could) (RB not) (VP (VB be) (VP (VBN restored) (PP (IN by) (NP-LGS (NP (UCP-COOD (NP (NN IL-2)) (CC or) (ADJP (JJ co-stimulatory))) (NNS signals)) (VP (VBN provided) (PP (IN by) (NP-LGS (NP (JJ antigen-presenting) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-27 (NP (NN mRNA)) (PP (IN for) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IFN-gamma))))) (VP (MD could) (RB not) (VP (VB be) (VP (VBN detected)))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ activation-dependent) (NN cell) (NN surface) (NNS markers) (NP-COOD (NP (NN CD25)) (CC and) (NP (NN CD69)))))) (VP (VBD was) (PP-PRD (IN within) (NP (JJ normal) (NNS limits)))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ (NP (DT the) (JJ functional) (NN defect)) (PP (IN of) (NP (NP (DT the) (NNS patients) (POS ')) (NN T) (NNS cells)))) (VP (VBD was) (PP-PRD (JJ due) (TO to) (NP (NP (DT the) (NP-COOD (NP (NN absence)) (CC or) (NP (JJ abnormal) (NN binding)))) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NN cytokine) (NN gene) (NN expression)))))))))))))) (, ,) (NP-SBJ-28 (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN DNA) (NN binding)) (PP (IN of) (NP-COOD (NP (NN AP-1)) (, ,) (NP (NN Oct)) (, ,) (NP (NN CREB)) (, ,) (NP (NN SP1)) (, ,) (NP (NN NF-kappa) (NN B)) (CC and) (NP (NP (NP (DT the) (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))))) (PP (TO to) (NP (NP (PRP$ their) (JJ respective) (NN response) (NNS elements)) (PP (IN in) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (DT the) (NN IL-2) (NN gene))))))))))))) (. .)))
(TOP (S (SBAR (IN Whereas) (S (NP-SBJ-COOD (NP (NN AP-1)) (, ,) (NP (NN NF-kappa) (NN B)) (, ,) (NP (NN Oct)) (, ,) (NP (NN CREB)) (CC and) (NP (NN SP1))) (VP (VBD displayed) (NP (NP (JJ normal) (NN binding) (NNS activities)) (PP (IN in) (NP (JJ nuclear) (NNS extracts))))))) (, ,) (NP-SBJ (NP (DT the) (NN binding)) (PP (IN of) (NP (NN NF-AT))) (PP (TO to) (NP (PRP$ its) (NN IL-2) (NN promoter) (NN response) (NN element)))) (VP (VBD was) (ADJP-PRD (RB barely) (JJ detectable)) (PP-TMP (PP-COOD (CC both) (PP (IN before)) (CC and) (PP (IN after))) (NP-30 (NN T) (NN cell) (NN stimulation)))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (DT this) (NN NF-AT/DNA) (NN binding) (NN defect)) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP-COOD (NP (DT the) (JJ multiple) (NN cytokine) (NN deficiency)) (CC and) (NP (DT the) (NN SCID) (NN phenotype))) (VP (VBN observed) (PP (IN in) (NP (DT the) (CD two) (JJ infant) (NNS brothers))))))))))) (. .)))
(TOP (NP (NP (NNS Requirements)) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (ADJP (NN vitamin) (JJ D-mediated)) (NN gene) (NN regulation))) (PP (IN in) (NP (JJ normal) (JJ human) (NN B) (NNS lymphocytes))))) (. .)))
(TOP (S (NP-SBJ (JJ Mature) (JJ human) (NNS lymphocytes)) (VP (VBP are) (NP-PRD (NP (JJ unique) (NNS targets)) (PP (IN of) (NP (NP (CD 1) (NN alpha,25-dihydroxyvitamin) (NN D3)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3)) (-RRB- -RRB-))))) (PP (IN in) (SBAR (IN that) (S-COOD (S (NP-SBJ-16 (NP (NN vitamin) (NN D) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN VDR)) (-RRB- -RRB-))) (VP (VBP are) (RB not) (VP (ADVP (RB constitutively)) (VBN expressed)))) (, ,) (CC and) (S (NP-SBJ-17 (JJ specific) (JJ cellular) (NN activation) (NNS signals)) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (DT both) (DT the) (NP-COOD (NP (NP (NN up-regulation)) (PP (IN of) (NP (NN VDR)))) (CC and) (NP (NP (NN establishment)) (PP (IN of) (NP (NP (NN reactivity)) (PP (TO to) (NP (DT the) (JJ lipophilic) (NN ligand)))))))))))))))) (. .)))
(TOP (S (NP-SBJ-18 (NP (NN Treatment)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN with) (NP (NP (DT the) (NN cytokine) (NN IL-4)) (PRN (-LRB- -LRB-) (NP (NN IL-4)) (-RRB- -RRB-))))) (, ,) (PP (IN in) (DT the) (NN absence) (IN of) (NP (JJ prior) (NN activation))) (, ,) (VP-COOD (VP (VBZ induces) (NP (NP (DT a) (JJ weak) (NN up-regulation)) (PP (IN of) (NP (NN VDR) (NN expression))))) (CC but) (VP (VBZ fails) (S (VP-COOD (VP (TO to) (VP (VB generate) (NP (ADJP (NP (ADJP (NN vitamin) (JJ D-responsive)) (NN element)) (-LRB- -LRB-) (NN VDRE) (-RRB- -RRB-) (JJ -reactive)) (JJ nuclear) (NN protein) (NNS complexes)))) (CC or) (VP (TO to) (VP (VB initiate) (NP (NP (DT the) (JJ genomic) (NN transcription)) (PP (IN of) (NP (NN 25-hydroxyvitamin) (NN D3) (NN 24-hydroxylase)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN by) (UCP-COOD (CC either) (NP (NP (NN ligation)) (PP (IN of) (NP (NN CD40) (NN Ag)))) (CC or) (S (VP (VBG cross-linking) (NP (DT the) (NN Ig) (NN receptor))))))) (VP (VBZ is) (ADVP (RB also)) (ADJP-PRD (JJ insufficient) (S (VP (TO to) (VP (VB render) (S (NP-SBJ (NN B) (NNS lymphocytes)) (ADJP-PRD (JJ responsive) (PP (TO to) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-20 (NP (DT this) (JJ apparent) (NN lack)) (PP (IN of) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN secosterol)))))) (VP (MD can) (VP (VB be) (VP (VBN overcome) (PP (IN by) (NP-LGS (NP (NN stimulation)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (DT these) (JJ cellular) (NN activation) (NNS signals)) (, ,) (SBAR (WHNP-21 (WDT which)) (S (VP (VBP are) (ADJP-PRD (JJ sufficient) (S (VP (TO to) (VP (VB lead) (PP (TO to) (NP (NN G1) (NN cell) (NN cycle) (NN progression))))))))))))))))))) (. .)))
(TOP (S (PP (IN In) (DT the) (NN presence) (IN of) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3))) (, ,) (NP-SBJ-23 (NP (JJ cellular) (NN activation)) (VP (VBN associated) (PP (IN with) (NP (NP (NN stimulation)) (PP (IN of) (NP (PDT such) (DT a) (NN progression))))))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP-PRD-COOD (ADJP (JJ sufficient) (PP (IN for) (NP (NP (DT the) (NN up-regulation)) (PP (IN of) (NP-COOD (NP (NN VDR) (NN message)) (CC and) (NP (NN protein))))))) (CC and) (ADJP (JJ necessary) (PP (IN for) (NP-COOD (NP (NP (DT the) (NN establishment)) (PP (IN of) (NP (NN VDRE) (NN binding) (NNS complexes)))) (CC and) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN 24-hydroxylase) (NN message)))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-24 (JJ biologic) (NNS functions)) (VP (VBP are) (VP (VP (VBN modulated)) (, ,) (SBAR (WHPP-101 (IN in) (WHNP (IN that))) (S (NP-SBJ (DT the) (NN hormone)) (VP (VBZ inhibits) (NP (NP (NN proliferation)) (PP (IN in) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (DT the) (VBN activated) (NN B) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-25 (NP (NN reactivity)) (PP (TO to) (NP (CD 1) (NN alpha,25-LRB-OH-RRB-2D3)))) (VP (VBZ is) (VP (ADVP (RB tightly)) (VBN regulated) (PP (IN in) (NP (NN B) (NNS lymphocytes))) (, ,) (S (VP (VBG requiring) (NP (JJ specific) (NNS signals)) (PP (IN for) (NP (PRP$ its) (NN initiation)))))))))) (. .)))
(TOP (NP (NP (JJ Cell-type-specific) (NN regulation)) (PP (IN of) (NP (NP (DT the) (JJ human) (NN tumor) (NN necrosis) (NN factor) (NN alpha) (NN gene)) (PP (IN in) (NP-COOD (NP (NN B) (NNS cells)) (CC and) (NP (NN T) (NNS cells)))))) (PP (IN by) (NP-COOD (NP (NN NFATp)) (CC and) (NP (NN ATF-2/JUN)))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ human) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (NN gene)) (VP (VBZ is) (NP-PRD (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJS earliest) (NNS genes)) (VP (VBN transcribed) (PP-TMP (IN after) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (DT a) (NN B) (NN cell))) (PP-COOD (PP (IN through) (NP (PRP$ its) (NN antigen) (NN receptor))) (CC or) (PP (IN via) (NP (DT the) (NN CD-40) (NN pathway))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT both) (NNS cases))) (, ,) (NP-SBJ-12 (NP (NN induction)) (PP (IN of) (NP (NN TNF-alpha) (NN gene) (NN transcription)))) (VP (MD can) (VP (VB be) (VP (VP (VBN blocked) (PP (IN by) (NP-LGS (DT the) (NNS immunosuppressants) (NP-COOD (NP (NN cyclosporin) (NN A)) (CC and) (NP (NN FK506)))))) (, ,) (SBAR (WHNP-13 (WDT which)) (S (VP (VBD suggested) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (DT the) (NN NFAT) (NN family)) (PP (IN of) (NP (NNS proteins))))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (DT the) (NN gene))) (PP (IN in) (NP (NN B) (NNS cells)))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (PP (IN in) (NP (NN T) (NNS cells))) (, ,) (NP-SBJ (NP (CD two) (NNS molecules)) (PP (IN of) (NP (NN NFATp)))) (VP (VBP bind) (PP (TO to) (NP (DT the) (NN TNF-alpha) (NN promoter) (NN element) (NN kappa) (CD 3))) (PP (NN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (NP-COOD (NP (NN ATF-2)) (CC and) (NP (NN Jun))) (NNS proteins)) (VP (VBN bound) (PP (TO to) (NP (DT an) (ADJP (RB immediately) (JJ adjacent)) (NP (NP (JJ cyclic) (NN AMP) (NN response) (NN element)) (PRN (-LRB- -LRB-) (NP (NN CRE)) (-RRB- -RRB-))) (NN site))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (S (VP (VBG using) (NP (DT the) (JJ murine) (NN B-cell) (NN lymphoma) (NN cell) (NN line) (NN A20)))) (, ,) (NP-SBJ-14 (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-15 (DT the) (NN TNF-alpha) (NN gene)) (VP (VBZ is) (VP (VBN regulated) (PP (IN in) (NP (DT a) (JJ cell-type-specific) (NN manner)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN A20) (NN B) (NNS cells))) (, ,) (NP-SBJ-16 (DT the) (NN TNF-alpha) (NN gene)) (VP (VBZ is) (RB not) (VP (VBN regulated) (PP (IN by) (NP-LGS (NP (NN NFATp)) (VP (VBN bound) (PP (TO to) (NP (DT the) (NN kappa) (CD 3) (NN element)))))))) (. .)))
(TOP (S (ADVP (RB Instead)) (, ,) (S-COOD (S (NP-SBJ (NP-COOD (NP (NN ATF-2)) (CC and) (NP (NN Jun))) (NNS proteins)) (VP (VBP bind) (PP (TO to) (NP (DT the) (JJ composite) (NN kappa) (NN 3/CRE) (NN site))))) (CC and) (S (NP-SBJ (NN NFATp)) (VP (VBZ binds) (PP (TO to) (NP (NP (DT a) (ADJP (RB newly) (VBN identified)) (JJ second) (NN NFAT) (NN site)) (VP (JJ centered) (PP (IN at) (NP (CD -76) (NNS nucleotides))) (PP (JJ relative) (TO to) (NP (DT the) (NN TNF-alpha) (NN transcription) (NN start) (NN site))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ new) (NN site)) (VP (VBZ plays) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (NP (NP (DT the) (ADJP-COOD (ADJP (JJ calcium-mediated)) (, ,) (ADJP (NN cyclosporin) (JJ A-sensitive))) (NN induction)) (PP (IN of) (NP (NN TNF-alpha)))) (PP (IN in) (NP-COOD (CC both) (NP (NN A20) (NN B) (NNS cells)) (CC and) (NP (NN Ar-5) (NNS cells))))))) (. .)))
(TOP (S (ADJP (JJ Consistent) (PP (IN with) (NP (DT these) (NNS results)))) (, ,) (NP-SBJ (NP (JJ quantitative) (NN DNase) (NN footprinting)) (PP (IN of) (NP (DT the) (NN TNF-alpha) (NN promoter))) (VP (VBG using) (NP (NP (VBG increasing) (NNS amounts)) (PP (IN of) (NP (JJ recombinant) (NN NFATp)))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (DT the) (CD -76) (NN site)) (VP (VBZ binds) (PP (TO to) (NP (NN NFATp))) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN affinity)) (PP (IN than) (NP (DT the) (NN kappa) (CD 3) (NN site))))))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (CD Two) (JJ other) (ADJP (RB previously) (JJ unrecognized)) (JJ NFATp-binding) (NNS sites)) (PP (IN in) (NP (DT the) (JJ proximal) (NN TNF-alpha) (NN promoter)))) (VP (VBD were) (ADVP (RB also)) (VP (VBN identified) (PP (IN by) (NP-LGS (DT this) (NN analysis))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (PP (IN through) (NP (NP (DT the) (JJ differential) (NN use)) (PP (IN of) (NP (NP (DT the) (JJ same) (NN promoter) (NN element)) (, ,) (NP (DT the) (JJ composite) (NN kappa) (NN 3/CRE) (NN site)))))) (, ,) (NP-SBJ-18 (DT the) (NN TNF-alpha) (NN gene)) (VP (VBZ is) (VP (VBN regulated) (PP (IN in) (NP (DT a) (JJ cell-type-specific) (NN manner))) (PP (IN in) (NN response) (TO to) (NP (DT the) (JJ same) (JJ extracellular) (NN signal))))) (. .)))
(TOP (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ ligand-binding) (NN domain)) (PP (IN of) (NP (JJ human) (JJ retinoic) (NN acid) (NN receptor) (NN alpha))))) (PP (IN by) (NP (JJ site-directed) (NN mutagenesis))) (. .)))
(TOP (S (NP-SBJ-23 (NP (CD Three) (NNS subtypes)) (PP (IN of) (NP (NP (JJ retinoic) (NN acid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN RAR)) (-RRB- -RRB-)))) (, ,) (VP (VBN termed) (S (NP-PRD-COOD (NP (NN RAR) (NN alpha)) (, ,) (NP (NN RAR) (NN beta)) (, ,) (CC and) (NP (NN RAR) (NN gamma))))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN described)))) (. .)))
(TOP (S (NP-SBJ-24 (PRP They)) (VP (VBP are) (VP (VBN composed) (PP (IN of) (NP (NP (JJ different) (JJ structural) (NNS domains)) (, ,) (PP (VBG including) (NP (NP (JJ distinct) (NNS domains)) (PP (IN for) (NP (NP-COOD (NP (NN DNA)) (CC and) (NP (NN ligand))) (NN binding))))))))) (. .)))
(TOP (S (NP-SBJ (NNS RARs)) (ADVP (RB specifically)) (VP (VBP bind) (NP-COOD (NP (NP (JJ all-trans-retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (, ,) (NP (NN 9-cis-RA)) (, ,) (CC and) (NP (JJ retinoid) (NNS analogs)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ functional) (NN role)) (PP (IN of) (NP (NP (NP-COOD (NP (NN cysteine)) (CC and) (NP (NN arginine))) (NNS residues)) (PP (IN in) (NP (NP (NP (DT the) (JJ ligand-binding) (NN domain)) (PP (IN of) (NP (NN hRAR) (NN alpha)))) (PRN (-LRB- -LRB-) (NP (NP (NN hRAR) (NN alpha-LBD)) (, ,) (NP (NN amino) (NNS acids) (NP-COOD (NP (CD 154)) (TO to) (NP (CD 462))))) (-RRB- -RRB-)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-25 (NP (DT All) (VBN conserved) (NP-COOD (NP (NN cysteine)) (CC and) (NP (NN arginine))) (NNS residues)) (PP (IN in) (NP (DT this) (NN domain)))) (VP (VBD were) (VP (VBN mutated) (PP (IN by) (NP-LGS (JJ site-directed) (NN mutagenesis)))))) (, ,) (CC and) (S (NP-SBJ-26 (DT the) (JJ mutant) (NNS proteins)) (VP (VBD were) (VP (VBN characterized) (PP (IN by) (NP-LGS-COOD (NP (VBG blocking) (NNS reactions)) (, ,) (NP (JJ ligand-binding) (NNS experiments)) (, ,) (NP (NN transactivation) (NNS assays)) (, ,) (CC and) (NP (NN protease) (NN mapping))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Changes)) (PP (IN of) (NP (NP (DT any) (JJ cysteine) (NN residue)) (PP (IN of) (NP (DT the) (NN hRAR) (NN alpha-LBD)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP-COOD (NP (JJ all-trans) (NN RA)) (CC or) (NP (JJ 9-cis) (NN RA))))))) (. .)))
(TOP (S (NP (RB Interestingly)) (, ,) (NP-SBJ (JJ residue) (NN C-235)) (VP (VBZ is) (ADVP (RB specifically)) (ADJP-PRD (JJ important)) (PP (IN in) (NP (NN antagonist) (NN binding)))) (. .)))
(TOP (S (PP (IN With) (NN respect) (TO to) (NP (NN arginine) (NNS residues))) (, ,) (NP-SBJ (NP (RB only) (DT the) (CD two) (JJ single) (NNS mutations)) (PP (IN of) (NP-COOD (NP (NN R-276)) (CC and) (NP (NN R-394)))) (PP (TO to) (NP (NN alanine)))) (VP (VBD showed) (NP (NP (DT a) (JJ dramatic) (NN decrease)) (PP (IN of) (NP (NP-COOD (NP (NN agonist)) (CC and) (NP (NN antagonist))) (NN binding)))) (SBAR (IN whereas) (S (NP-SBJ (DT the) (NN R272A) (NN mutation)) (VP (VBD showed) (NP (RB only) (DT a) (JJ slight) (NN effect)))))) (. .)))
(TOP (S (PP (IN For) (NP (DT all) (JJ other) (NN arginine) (NNS mutations))) (, ,) (NP-SBJ (NP (DT no) (NNS differences)) (PP (IN in) (NP (NN affinity)))) (VP (VBD were) (ADJP-PRD (JJ detectable))) (. .)))
(TOP (S (NP-SBJ (DT The) (CD two) (NNS mutations) (NP-COOD (NP (NN R217A)) (CC and) (NP (NN R294A)))) (VP (VBD caused) (NP-COOD (NP (NP (DT an) (VBN increased) (NN binding) (NN efficiency)) (PP (IN for) (NP (NNS antagonists)))) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NN agonist) (NN binding)))))) (. .)))
(TOP (S (PP (IN From) (NP (DT these) (NNS results))) (, ,) (NP-SBJ (PRP we)) (VP (MD can) (VP (VB conclude) (SBAR (IN that) (S (NP-SBJ (NP (JJ electrostatic) (NNS interactions)) (PP (IN of) (NP (NNS retinoids))) (PP (IN with) (NP (DT the) (NN RAR) (NN alpha-LBD)))) (VP (VBP play) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (NP (NN ligand) (NN binding)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NNS antagonists)) (VP (VBP show) (NP (NP (ADJP (RB distinctly) (JJ different)) (NNS requirements)) (PP (IN for) (NP (JJ efficient) (NN binding))) (, ,) (SBAR (WHNP-27 (WDT which)) (S (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (PRP$ their) (NN interference)) (PP (IN in) (NP (NP (DT the) (JJ ligand-inducible) (NN transactivation) (NN function)) (PP (IN of) (NP (NN RAR) (NN alpha))))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NP-COOD (NP (NN Cloning)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (NP (DT the) (NN beta) (NN subunit)) (PP (IN of) (NP (ADJP (JJ human) (JJ proximal) (NN sequence) (JJ element-binding)) (NN transcription) (NN factor)))))) (CC and) (NP (NP (PRP$ its) (NN involvement)) (PP (IN in) (NP (NP (NN transcription)) (PP (IN of) (NP (JJ small) (JJ nuclear) (NN RNA) (NNS genes))) (PP (IN by) (NP (NN RNA) (NNS polymerases) (NP-COOD (NP (CD II)) (CC and) (NP (CD III))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (DT The) (ADJP (NP (JJ proximal) (NN sequence) (NN element)) (-LRB- -LRB-) (NN PSE) (-RRB- -RRB-) (JJ -binding)) (NN transcription) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN PTF)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP-13 (WDT which)) (S (VP (VBZ binds) (NP (NP (DT the) (NN PSE)) (PP (IN of) (NP (ADJP-COOD (CC both) (ADJP (NP (NN RNA) (NN polymerase) (NN II-))) (CC and) (ADJP (NN RNA) (NN polymerase) (JJ III-transcribed))) (JJ mammalian) (NP (NP (JJ small) (JJ nuclear) (NN RNA)) (PRN (-LRB- -LRB-) (NP (NN snRNA)) (-RRB- -RRB-))) (NNS genes))))))) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (PRP$ their) (NN transcription))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB previously)) (VP (VBD reported) (NP-COOD (NP (NP (DT the) (NN purification)) (PP (IN of) (NP (NP (JJ human) (NN PTF)) (, ,) (NP (NP (DT a) (NN complex)) (PP (IN of) (NP (CD four) (NNS subunits))))))) (, ,) (CC and) (NP (NP (DT the) (NP-COOD (NP (JJ molecular) (NN cloning)) (CC and) (NP (NN characterization)))) (PP (IN of) (NP (NN PTF) (NP-COOD (NP (NN gamma)) (CC and) (NP (NN delta))) (NNS subunits)))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP describe) (NP-COOD (NP (NP (DT the) (NP-COOD (NP (NN isolation)) (CC and) (NP (NN expression)))) (PP (IN of) (NP (NP (DT a) (NN cDNA)) (VP (VBG encoding) (NP (NN PTF) (NN beta)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ functional) (NNS studies)) (VP (VBG using) (NP (ADJP (JJ anti-PTF) (NN beta)) (NNS antibodies)))))) (. .)))
(TOP (S (NP-SBJ-14 (NP (JJ Native) (NN PTF) (NN beta)) (, ,) (PP (IN in) (NP-COOD (CC either) (NP (NN protein) (NNS fractions)) (CC or) (NP (DT a) (NN PTF-Oct-1-DNA) (NN complex)))) (, ,)) (VP (MD can) (VP (VB be) (VP (VBN recognized) (PP (IN by) (NP-LGS (NP (JJ polyclonal) (NNS antibodies)) (VP (VBN raised) (PP (IN against) (NP (JJ recombinant) (NN PTF) (NN beta))))))))) (. .)))
(TOP (S (NP-SBJ (NN Immunodepletion) (NNS studies)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-15 (NN PTF) (NN beta)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT both) (NNS classes)) (PP (IN of) (NP (NN snRNA) (NNS genes))))) (ADVP (FW in) (FW vitro))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NN immunoprecipitation) (NNS analyses)) (VP (VBP demonstrate) (SBAR (IN that) (S-COOD (S (NP-SBJ (NP (ADJP-COOD (ADJP (JJ substantial)) (CC and) (ADJP (JJ similar))) (JJ molar) (NNS amounts)) (PP (IN of) (NP-COOD (NP (NP (JJ TATA-binding) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN TBP)) (-RRB- -RRB-))) (CC and) (NP (NN TFIIIB90))))) (VP (MD can) (ADVP (RB weakly)) (VP (VBP associate) (PP (IN with) (NP (NN PTF))) (PP (IN at) (NP (JJ low) (NN salt) (NNS conditions)))))) (, ,) (CC but) (S (NP-SBJ-16 (DT this) (NN association)) (VP (VBZ is) (ADVP (RB dramatically)) (VP (VBN reduced) (PP (IN at) (NP (JJ high) (NN salt) (NNS concentrations))))))))) (. .)))
(TOP (S (PP (IN Along) (IN with) (NP (NP (PRP$ our) (JJ previous) (NN demonstration)) (PP (IN of) (NP-COOD (NP (NP (DT both) (JJ physical) (NNS interactions)) (PP (IN between) (NP-COOD (NP-COOD (NP (NN PTF) (NN gamma)) (: /) (NP (NN PTF) (NN delta))) (CC and) (NP (NN TBP))))) (CC and) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NN TFIIIB90))) (PP (IN in) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN class) (CD III) (NN snRNA) (NNS genes)))))))))) (, ,) (NP-SBJ (DT these) (NNS results)) (VP (VBP are) (ADJP-PRD (JJ consistent) (PP (IN with) (NP (DT the) (NN notion) (SBAR (IN that) (S (NP-SBJ-17 (NP (DT a) (JJ TBP-containing) (NN complex)) (ADJP (JJ related) (PP (TO to) (NP (NN TFIIIB))))) (VP-COOD (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN class) (CD III) (NN snRNA) (NNS genes))))))) (, ,) (CC and) (VP (VBZ acts) (PP (IN through) (NP (NP (JJ weak) (NN interaction)) (PP (IN with) (NP (DT the) (JJ four-subunit) (NN PTF))))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NP (NN Induction)) (PP (IN of) (NP (NN bcl-2) (NN expression))) (PP (IN by) (NP (VBN phosphorylated) (NN CREB) (NNS proteins))) (PP-TMP (IN during) (NP (NN B-cell) (NN activation)))) (CC and) (NP (NP (NN rescue)) (PP (IN from) (NP (NN apoptosis))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Engagement)) (PP (IN of) (NP (NP (NN surface) (NN immunoglobulin)) (PP (IN on) (NP (JJ mature) (NN B) (NNS cells)))))) (VP (VBZ leads) (PP-COOD (PP (TO to) (NP (NP (NN rescue)) (PP (IN from) (NP (NN apoptosis))))) (CC and) (PP (TO to) (NP (NN proliferation))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Levels)) (PP (IN of) (NP (NN bcl-2) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein)))))) (VP (VBP increase) (PP (IN with) (NP (NP (NN cross-linking)) (PP (IN of) (NP (NN surface) (NN immunoglobulin)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (JJ located) (NP (NP (DT the) (JJ major) (JJ positive) (JJ regulatory) (NN region)) (PP (IN for) (NP (NP (NN control)) (PP (IN of) (NP (NP (NN bcl-2) (NN expression)) (PP (IN in) (NP (NN B) (NNS cells)))))))) (PP (IN in) (NP (DT the) (JJ 5'-flanking) (NN region))))) (. .)))
(TOP (S (NP-SBJ-21 (DT The) (JJ positive) (NN region)) (VP (MD can) (VP (VB be) (VP (VBN divided) (PP (IN into) (NP (NP-COOD (NP (DT an) (JJ upstream)) (CC and) (NP (DT a) (JJ downstream))) (NP-22 (JJ regulatory) (NN region))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ downstream) (JJ regulatory) (NN region)) (VP (VBZ contains) (NP (NP (DT a) (ADJP (JJ cyclic) (JJ AMP-responsive)) (NN element)) (PRN (-LRB- -LRB-) (NP (NN CRE)) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (PP (IN by) (NP (NP-COOD (NP (NN antibody) (NN supershift) (NNS experiments)) (CC and) (NP (NN UV) (NN cross-linking))) (VP (VBN followed) (PP (IN by) (NP-LGS (VBG denaturing) (NN polyacrylamide) (NN gel) (NN electrophoresis)))))) (SBAR (IN that) (S (NP-SBJ (NP-COOD (CC both) (NP (NN CREB)) (CC and) (NP (NN ATF))) (NN family) (NNS members)) (VP (VBP bind) (PP (TO to) (NP (DT this) (NN region))) (ADVP (FW in) (FW vitro)))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Mutations)) (PP (IN of) (NP (DT the) (NN CRE) (NN site))) (SBAR (WHNP-23 (WDT that)) (S (VP (VBP result) (PP (IN in) (NP (NP (NN loss)) (PP (IN of) (NP (NN CREB) (NN binding))))))))) (ADVP (RB also)) (VP (VBP lead) (PP (TO to) (NP (NP (NN loss)) (PP (IN of) (NP (NP (JJ functional) (NN activity)) (PP (IN of) (NP (DT the) (NN bcl-2) (NN promoter))))))) (PP (IN in) (NP (NN transient-transfection) (NNS assays)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN presence)) (PP (IN of) (NP (DT an) (JJ active) (NN CRE) (NN site))) (PP (IN in) (NP (DT the) (NN bcl-2) (NN promoter)))) (VP (VBZ implies) (SBAR (IN that) (S (NP-SBJ-24 (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN bcl-2) (NN expression)))) (VP (VBZ is) (VP (VBN linked) (PP (TO to) (NP (NP (DT a) (NN signal) (NN transduction) (NN pathway)) (PP (IN in) (NP (NN B) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (DT the) (JJ mature) (NN B-cell) (NN line) (NN BAL-17))) (PP (IN with) (NP-COOD (CC either) (NP (JJ anti-immunoglobulin) (NN M)) (CC or) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate))))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN bcl-2) (NN expression)) (SBAR (WHNP-25 (WDT that)) (S (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (DT the) (NN CRE) (NN site)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (NP (DT the) (ADJP (RBR more) (JJ immature)) (NN B-cell) (NN line)) (, ,) (NP (NN Ramos)) (, ,))) (PP (IN with) (NP (NN phorbol) (NNS esters)))) (VP (VBZ rescues) (NP (DT the) (NNS cells)) (PP (IN from) (NP (JJ calcium-dependent) (NN apoptosis)))) (. .)))
(TOP (S-COOD (S (NP-SBJ-27 (NN bcl-2) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP-TMP (VBG following) (NP (NN phorbol) (NN ester) (NN treatment)))))) (, ,) (CC and) (S (NP-SBJ (DT the) (VBN increased) (NN expression)) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (DT the) (NN CRE) (NN site)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS stimuli)) (VP (VBP result) (PP (IN in) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN CREB))) (PP (IN at) (NP (NN serine) (CD 133)))))) (. .)))
(TOP (S (NP-SBJ-28 (NP (DT The) (NN phosphorylation)) (PP (IN of) (NP (NN CREB))) (SBAR (WHNP-29 (WDT that)) (S (VP (VBZ results) (PP (IN in) (NP (NN activation))))))) (VP (VBZ is) (VP (VBN mediated) (PP-COOD (PP (IN by) (NP-LGS (NN protein) (NN kinase) (NN C))) (CONJP (RB rather) (IN than)) (PP (IN by) (NP-LGS (NN protein) (NN kinase) (NN A)))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (DT the) (NN CRE) (NN site)) (VP (VBZ is) (ADJP-PRD (JJ necessary))))) (, ,) (NP-SBJ (NP (JJ optimal) (NN induction)) (PP (IN of) (NP (NN bcl-2) (NN expression)))) (VP (VBZ requires) (NP (NP (NN participation)) (PP (IN of) (NP (DT the) (JJ upstream) (JJ regulatory) (NN element)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (NN phosphorylation)) (PP (IN of) (NP (NN CREB)))) (VP (VBZ alters) (NP (NP (PRP$ its) (NN interaction)) (PP (IN with) (NP (DT the) (JJ upstream) (JJ regulatory) (NN element)))))))))) (. .)))
(TOP (S (NP-SBJ-30 (NP (DT The) (NN CRE) (NN site)) (PP (IN in) (NP (DT the) (NN bcl-2) (NN promoter)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN bcl-2) (NN expression))))) (PP-TMP-COOD (PP (IN during) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ mature) (NN B) (NNS cells))))) (CC and) (PP (IN during) (NP (NP (DT the) (NN rescue)) (PP (IN of) (NP (JJ immature) (NN B) (NNS cells))) (PP (IN from) (NP (NN apoptosis)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (PRP It))) (VP (VBZ is) (ADJP-PRD (JJ possible)) (SBAR-31 (IN that) (S (NP-SBJ (DT the) (NN CRE) (NN site)) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN bcl-2) (NN expression)) (PP (IN in) (NP (NP (JJ other) (NN cell) (NNS types)) (, ,) (NP (NP (RB particularly) (DT those)) (SBAR (WHPP-32 (IN in) (WHNP (WDT which))) (S (NP-SBJ-33 (NN protein) (NN kinase) (NN C)) (VP (VBZ is) (VP (VBN involved))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Interleukin-6)) (VP (VBZ promotes) (NP (JJ multiple) (NN myeloma) (NN cell) (NN growth)) (PP (IN via) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN retinoblastoma) (NN protein)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Interleukin-6)) (PRN (-LRB- -LRB-) (NP (NN IL-6)) (-RRB- -RRB-))) (VP-COOD (VP (VBZ mediates) (NP (NP (ADJP-COOD (ADJP (NN autocrine)) (CC and) (ADJP (NN paracrine))) (NN growth)) (PP (IN of) (NP (NP (NP (JJ multiple) (NN myeloma)) (PRN (-LRB- -LRB-) (NP (NN MM)) (-RRB- -RRB-))) (NNS cells))))) (CC and) (VP (VBZ inhibits) (NP (NN tumor) (NN cell) (NN apoptosis)))) (. .)))
(TOP (S (NP-SBJ-COOD-18 (NP (NP (NNS Abnormalities)) (PP (IN of) (NP (NP (NN retinoblastoma) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN pRB)) (-RRB- -RRB-))))) (CC and) (NP (NP (NNS mutations)) (PP (IN of) (NP (NN RB) (NN gene))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP-COOD (NP (NP (QP (IN up) (TO to) (CD 70)) (NN %)) (PP (IN of) (NP (NN MM) (NNS patients)))) (CC and) (NP (NP (CD 80) (NN %)) (PP (IN of) (NP (JJ MM-derived) (NN cell) (NNS lines))))))))) (. .)))
(TOP (S (SBAR (IN Because) (S-COOD (S (NP-SBJ (ADJP (ADJP (VBN dephosphorylated)) (PRN (-LRB- -LRB-) (ADJP (VBN activated)) (-RRB- -RRB-))) (NN pRB)) (VP (VBZ blocks) (NP (NP (NN transition)) (PP (IN from) (NP (NP (NN G1)))) (PP (TO to) (NP (NP (NN S)))) (NP-19 (NN phase)) (PP-20 (IN of) (NP (DT the) (NN cell) (NN cycle)))))) (IN whereas) (S (NP-SBJ (ADJP (ADJP (VBN phosphorylated)) (PRN (-LRB- -LRB-) (ADJP (VBN inactivated)) (-RRB- -RRB-))) (NN pRB)) (VP (VBZ releases) (NP (DT this) (NN growth) (NN arrest)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD characterized) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN pRB))) (PP (IN in) (NP (JJ IL-6-mediated) (NN MM) (NN cell) (NN growth))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-22 (ADJP-COOD (CC Both) (ADJP (VBN phosphorylated)) (CC and) (ADJP (VBN dephosphorylated))) (NN pRB)) (VP (VBD were) (VP (VBN expressed) (PP (IN in) (NP (DT all) (NP-COOD (NP (JJ serum-starved) (NN MM) (NN patient) (NNS cells)) (CC and) (NP (JJ MM-derived) (NN cell) (NNS lines)))))))) (, ,) (CC but) (S (NP-SBJ (NN pRB)) (VP (VBD was) (ADVP (RB predominantly)) (PP-PRD (IN in) (NP (PRP$ its) (JJ phosphorylated) (NN form))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NN MM) (NNS cells)) (SBAR (WHNP-23 (WDT that)) (S (VP (VBD proliferated) (PP (IN in) (NN response) (TO to) (NP (NN IL-6)))))))) (, ,) (NP-SBJ (JJ exogenous) (NN IL-6)) (VP-COOD (VP (VBD downregulated) (NP (VBN dephosphorylated) (NN pRB))) (CC and) (VP (VBD decreased) (NP (VBN dephosphorylated) (NN pRB-E2F) (NNS complexes)))) (. .)))
(TOP (S (S (ADVP (RB Importantly)) (, ,) (NP-SBJ (NP (NN culture)) (PP (IN of) (NP (NP (NN MM) (NNS cells)) (PP (IN with) (NP (ADJP-COOD (ADJP (NN RB) (JJ antisense)) (, ,) (CC but) (ADJP (RB not) (NN RB) (NN sense)) (, ,)) (NP (NP (NN oligonucleotide)) (PRN (-LRB- -LRB-) (NP (NN ODN)) (-RRB- -RRB-)))))))) (VP (VBD triggered) (NP (NP (NN IL-6) (NP-COOD (NP (NN secretion)) (CC and) (NP (NN proliferation)))) (PP (IN in) (NP (NN MM) (NNS cells))))) (: ;)) (S (ADVP (RB however)) (, ,) (NP-SBJ-24 (NN proliferation)) (VP (VBD was) (ADVP (RB only) (RB partially)) (VP (VBN inhibited) (PP (IN by) (S-LGS (VP (VBG neutralizing) (NP (JJ anti-IL-6) (NP (NP (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN MoAb)) (-RRB- -RRB-))))))))) (. .))))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NN MM) (NNS cells))) (, ,) (NP-SBJ (JJ normal) (JJ splenic) (NN B) (NNS cells)) (VP (VBP express) (NP (VBN dephosphorylated) (NN pRB))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (NN CD40) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN CD40L)) (-RRB- -RRB-))) (VP (VBZ triggers) (NP-COOD (NP (NP (DT a) (NN shift)) (PP (IN from) (NP (VBN dephosphorylated))) (PP (TO to) (NP (VBN phosphorylated))) (NP-25 (NN pRB))) (CC and) (NP (NP (NN proliferation)) (PP (IN of) (NP (NN B) (NNS cells)))))))) (, ,) (NP-SBJ (NP (DT the) (NN addition)) (PP (IN of) (NP (JJ exogenous) (NN IL-6))) (PP (TO to) (NP (JJ CD40L-treated) (NN B) (NNS cells)))) (VP (VBZ does) (RB not) (VP (VB alter) (NP-COOD (CC either) (NP (NN pRB)) (CC or) (NP (NN proliferation))) (, ,) (SBAR (IN as) (S (VP (VBN observed) (PP (IN in) (NP (NN MM) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-27 (VBN phosphorylated) (NN pRB)) (VP (VBZ is) (ADVP (RB constitutively)) (VP (VBN expressed) (PP (IN in) (NP (JJ MM) (NNS cells))))))) (CC and) (SBAR (IN that) (S (NP-SBJ-29 (NN IL-6)) (ADVP (RB further)) (VP (VBZ shifts) (NP (NN pRB)) (PP (IN from) (NP (PRP$ its) (JJ dephosphorylated))) (PP (TO to) (NP (PRP$ its) (JJ phosphorylated))) (NP-28 (NN form)) (, ,) (S (ADVP (RB thereby)) (VP (VBG promoting) (NP (NN MM) (NN cell) (NN growth)) (PP (IN via) (NP (NP (CD two) (NNS mechanisms)) (: ;) (PP-COOD (PP (IN by) (S (VP (VBG decreasing) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NN E2F)) (VP (VBN bound) (PP (IN by) (NP-LGS (VBN dephosphorylated) (NN pRB))))))) (PP (IN due) (TO to) (NP (VBN reduced) (VBN dephosphorylated) (NN pRB))) (, ,) (S (ADVP (RB thereby)) (VP (VBG releasing) (NP (NN growth) (NN arrest))))))) (: ;) (CC and) (PP (IN by) (S (VP (VBG upregulating) (NP-COOD (NP (NP (NN IL-6) (NN secretion)) (PP (IN by) (NP (NN MM) (NNS cells)))) (CC and) (NP (JJ related) (JJ IL-6-mediated) (JJ autocrine) (NN tumor) (NN cell) (NN growth)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN JNK)) (PRN (-LRB- -LRB-) (NP (NN c-Jun) (JJ NH2-terminal) (NN kinase)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN target)) (PP (IN for) (NP (NNS antioxidants)))) (PP (IN in) (NP (NN T) (NNS lymphocytes)))) (. .)))
(TOP (S (NP-SBJ-1 (NN AP-1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB behave) (PP (IN as) (NP (NP (DT a) (JJ redox-sensitive) (NN transcription) (NN factor)) (SBAR (WHNP-2 (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP-LGS (ADJP-COOD (CC both) (ADJP (JJ oxidant)) (CC and) (ADJP (JJ antioxidant))) (NNS stimuli)))))))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN AP-1))) (PP (IN by) (NP (NNS antioxidants))))))) (VP (VBP are) (ADJP-PRD (RB largely) (JJ unknown))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (DT the) (ADJP (RB structurally) (JJ unrelated)) (JJ antioxidant) (NNS agents) (NP-COOD (NP (NP (NN pyrrolidine) (NN dithiocarbamate)) (PRN (-LRB- -LRB-) (NP (NN PDTC)) (-RRB- -RRB-))) (, ,) (NP (VBN butylated) (NN hydroxyanisole)) (, ,) (CC and) (NP (NN Nacetylcysteine)))) (VP (VBD activated) (NP (NP (NN JNK)) (PRN (-LRB- -LRB-) (NP (NN c-Jun) (JJ NH2-terminal) (NN kinase)) (-RRB- -RRB-))) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN activation)) (VP (VBD differed) (ADVP (RB substantially)) (PP (IN from) (NP (NP (DT that)) (VP-COOD (VP (VBN mediated) (PP (IN by) (NP-LGS-COOD (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (CC and) (NP (NN Ca2+) (NN ionophore))))) (CC or) (VP (VBN produced) (PP (IN by) (NP (NP (NN costimulation)) (PP (IN with) (NP (NP (NNS antibodies)) (PP (IN against) (NP (DT the) (NP-COOD (NP (ADJP (NN T) (NN cell) (NN receptor-CD3)) (NN complex)) (CC and) (TO to) (NP (NN CD28)))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (NN activation)) (PP (IN of) (NP (NN JNK))) (PP (IN by) (NP (JJ classical) (NN T) (NN cell) (NNS stimuli)))) (VP (VBD was) (ADJP-PRD (JJ transient)))) (, ,) (IN whereas) (S (NP-SBJ (NP (DT that)) (VP (VBN mediated) (PP (IN by) (NP-LGS-COOD (NP (NN PDTC)) (CC and) (NP (VBN butylated) (NN hydroxyanisole)) (-LRB- -LRB-) (CONJP (CC but) (RB not)) (NP (NN N-acetylcysteine)) (-RRB- -RRB-))))) (VP (VBD was) (ADJP-PRD (JJ sustained)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS kinetics)) (PP (IN of) (NP (NN JNK) (NN activation)))) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN c-jun))) (SBAR (WHNP-4 (WDT which)) (S (VP-COOD (VP (VBD was) (ADJP-PRD-6 (JJ transient)) (PP-TMP-100 (IN after) (NP (NP (NN stimulation)) (PP (IN with) (NP-COOD (NP (NN PMA)) (CC plus) (NP (NN ionophore))))))) (CC and) (VP (VP=6 (VBD prolonged) (PP=100 (IN in) (NN response) (TO to) (NP (NN PDTC)))))))) (, ,) (SBAR (WHNP-7 (WDT which)) (S (ADVP (RB also)) (VP (ADVP-TMP (RB transiently)) (VBD induced) (NP (NN c-fos)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP (NN JNK) (NN activation)) (PP (IN by) (NP-COOD (NP (NN PMA)) (CC plus) (NP (NN ionophore))))) (VP (VBD was) (ADJP-PRD (JJ sensitive) (PP (TO to) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (NP (NN signaling) (NNS pathways)) (VP (VBG involving) (NP (NP-COOD (NP (NN Ca2+)) (, ,) (NP (NN protein) (NN kinase) (NN C)) (, ,) (CC and) (NP (NN tyrosine))) (NN phosphorylation))))) (, ,) (SBAR (WHNP-8 (WDT which)) (S (VP (VBD failed) (S (VP (TO to) (VP (VB inhibit) (NP (NP (DT the) (NN activation)) (VP (VBN mediated) (PP (IN by) (NP-LGS (NN PDTC))))))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (NN Transfection)) (PP (IN of) (NP-COOD (NP (NP (JJ trans-dominant) (JJ negative) (NN expression) (NNS vectors)) (PP (IN of) (NP-COOD (NP (NN ras)) (CC and) (NP (NN raf))))) (, ,) (CONJP (RB together) (IN with)) (NP (JJ AP-1-dependent) (NN reporter) (NNS constructs))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN Western) (NN blot) (NN analysis)) (VP (VBG using) (NP (ADJP (JJ anti-ERK) (PRN (-LRB- -LRB-) (NP (JJ extracellular) (JJ signal-regulated) (NN kinase)) (-RRB- -RRB-))) (NNS antibodies)))) (, ,)) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ-10 (DT the) (NN Ras/Raf/ERK) (NN pathway)) (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB mediate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NN antioxidant)))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (JJ combined) (NN treatment)) (PP (IN with) (NP (NP-COOD (NP (NN PDTC)) (CC and) (NP (NN PMA))) (, ,) (NP (NP (CD two) (NNS agents)) (SBAR (WHNP-11 (WDT that)) (S (VP (VBP synergize) (PP-TMP (IN on) (NP (NN AP-1) (NN activation))))))) (, ,)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (JJ persistent) (NN phosphorylation)) (PP (IN of) (NP (NN ERK-2)))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP-SBJ (PRP$ our) (NNS results)) (VP (VBP identify) (NP (NN JNK)) (PP (IN as) (NP (NP (DT a) (NN target)) (PP (IN of) (NP (JJ antioxidant) (NNS agents))) (SBAR (WHNP-12 (WDT which)) (S (VP (MD can) (VP (VB be) (VP (VBN regulated) (ADVP (RB differentially)) (PP (IN under) (NP (ADJP-COOD (ADJP (JJ oxidant)) (CC and) (ADJP (JJ antioxidant))) (NNS conditions))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Cytomegalovirus)) (VP (VBZ modulates) (NP (NN interleukin-6) (NN gene) (NN expression))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Complications)) (PP-TMP (IN after) (NP (NN lung) (NN transplantation)))) (VP (VBP include) (NP-COOD (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN rejection)))) (CC and) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (NN infection)) (, ,) (PP (RB particularly) (IN with) (NP (NP (NN cytomegalovirus)) (PRN (-LRB- -LRB-) (NP (NN CMV)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Several) (JJ recent) (NNS studies)) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ-20 (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -6)) (VP (MD may) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB detect) (NP (NP-COOD (CC both) (NP (NN infection)) (CC and) (NP (NN rejection))) (PP-TMP (IN after) (NP (NN lung) (NN transplantation)))))))))))))) (. .)))
(TOP (S (IN In) (NP (NN addition)) (, ,) (NP-SBJ (NN IL-6)) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN bronchiolitis) (NNS obliterans))) (PP-TMP (IN after) (NP (NN transplantation))))))) (. .)))
(TOP (S (SBAR (IN Because) (S (NP-SBJ-22 (NN CMV)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN bronchiolitis) (NNS obliterans))) (PP-TMP (IN after) (NP (NN transplantation))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD determined) (SBAR (IN whether) (S (NP-SBJ (NN CMV)) (VP (VBZ induces) (NP (NN IL-6) (NN gene) (NN expression)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NN CMV) (NN infection)) (VP (VBD increased) (NP (NP-COOD (CC both) (NP (NN IL-6) (NN protein)) (CC and) (NP (NN mRNA))) (PP (IN in) (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (DT the) (NN CMV) (JJ immediate) (JJ early) (CD 1) (NN gene) (NN product)) (VP (VBD increased) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN IL-6) (NN promoter)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT This) (NN effect)) (PP (IN of) (NP (DT the) (NN CMV) (JJ immediate) (JJ early) (CD 1) (NN gene) (NN product)))) (VP (VBD was) (ADJP-PRD (JJ dependent) (PP (IN upon) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ specific) (NN transcription) (NN factor) (NN binding) (NNS sites))) (PP (IN in) (NP (DT the) (NN IL-6) (NN promoter))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS studies)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NN CMV)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (NN cofactor)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP-COOD (NP (NN rejection)) (CC and) (NP (NN infection)))) (PP-TMP (IN after) (NP (NN transplantation))) (PP (IN through) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (NN IL-6))))))))))))) (. .)))
(TOP (NP (NP (NN E3)) (, ,) (NP (NP (DT a) (JJ hematopoietic-specific) (NN transcript)) (VP (ADVP (RB directly)) (VBN regulated) (PP (IN by) (NP-LGS (DT the) (JJ retinoic) (NN acid) (NN receptor) (NN alpha))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (ADJP (JJ Retinoic) (NN acid) (-LRB- -LRB-) (NN RA) (-RRB- -RRB-) (JJ -induced)) (NN maturation)) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT the) (JJ retinoic) (NN acid) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN RAR) (NN alpha)) (-RRB- -RRB-)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (JJ myeloid) (NN development)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN used) (NP-3 (NP (JJ differential) (NN hybridization) (NN analysis)) (PP (IN of) (NP (NP (DT a) (NN cDNA) (NN library)) (VP (VBN constructed) (PP (IN from) (NP (DT the) (JJ murine) (JJ RA-inducible) (NN MPRO) (NN promyelocyte) (NN cell) (NN line))))))) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ immediate-early) (NNS genes)) (VP (VBN induced) (PP (IN by) (NP-LGS (NN RA))) (PP-TMP (IN during) (NP (JJ granulocytic) (NN differentiation)))))))))) (. .)))
(TOP (S (NP-SBJ-4 (NP (NN E3)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD nine) (NNS sequences)) (VP (VBN identified))))) (, ,)) (VP (VBD was) (VP (VBN upregulated) (PP (IN in) (NP (DT an) (JJ immediate-early) (NN manner))) (, ,) (PP (IN with) (S (NP-SBJ (NN transcript) (NNS levels)) (VP (VBG peaking) (PP-TMP (IN after) (NP (NP (NP (CD 60) (NNS minutes)) (NP (NN exposure))) (PP (TO to) (NP (NN RA)))))))))) (. .)))
(TOP (S (NP-SBJ (NN E3) (NNS transcripts)) (VP-COOD (VP (VBD were) (ADJP-PRD (JJ RA-inducible)) (PP-100 (IN in) (NP (NN HL60) (NNS cells)))) (, ,) (CC but) (VP (PP=100 (RB not) (IN in) (NP (NP (NP (DT an) (JJ RA-resistant) (NN subclone)) (, ,) (NP (NN HL60R)) (, ,)) (SBAR (WHNP-5 (WDT that)) (VP (VBZ harbors) (NP (DT a) (VBN mutated) (NN RAR) (NN alpha) (NN gene)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (SBAR-TMP (WHADVP-6 (WRB when)) (S (NP-SBJ-7 (NN HL60R) (NNS cells)) (VP (VBD were) (VP (VBN transduced) (PP (IN with) (NP (NP (DT a) (JJ functional) (NN copy)) (PP (IN of) (NP (DT the) (NN RAR) (NN alpha) (NN gene))))))))) (, ,) (NP-SBJ (NN RA)) (VP (VBD induced) (NP (NP (DT a) (JJ 10-fold) (NN increase)) (PP (IN in) (NP (NN E3) (NN mRNA) (NNS levels))))) (. .)))
(TOP (S (NP-SBJ (NN E3) (NNS transcripts)) (VP-COOD (VP (VBP are) (ADJP-PRD-COOD (ADJP (JJ present) (PP (IN in) (NP (DT the) (ADJP-COOD (ADJP (JJ myeloid)) (, ,) (ADJP (JJ B-lymphoid)) (, ,) (CC and) (ADJP (JJ erythroid))) (NNS lineages)))) (, ,) (ADJP (JJ absent) (PP (IN in) (NP (JJ nonhematopoietic) (NNS cells)))))) (, ,) (CC and) (VP (VBP encode) (NP (NP (DT a) (ADJP-COOD (ADJP (RB highly) (JJ hydrophobic)) (, ,) (ADJP (RB potentially) (VBN phosphorylated))) (NN polypeptide)) (PP (IN of) (NP (JJ unknown) (NN function))) (PP (IN with) (NP (NP (JJ significant) (NN homology)) (PP (TO to) (NP (NP (DT a) (JJ putative) (NN protein)) (VP (VBN expressed) (PP (IN in) (NP (JJ myeloid) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ murine) (NN E3) (NN promoter)) (VP (VBZ harbors) (NP (NP (DT a) (JJ single) (JJ bipartite) (JJ retinoic) (NN acid) (NN response) (NN element)) (SBAR (WHNP-8 (WDT which)) (S (PP (IN in) (NP (NN transient) (NN transfection) (NNS assays))) (VP (VBD conferred) (NP (NN RA) (NN sensitivity))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN E3)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ hematopoietic-specific) (NN gene)) (SBAR (WHNP-9 (WDT that)) (S (VP (VBZ is) (NP-PRD (NP (DT an) (JJ immediate) (NN target)) (PP (IN for) (NP (DT the) (VBN activated) (NN RAR) (NN alpha))) (PP-TMP (IN during) (NP (NN myelopoiesis)))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Interstitial) (NN deletion)) (VP (VBZ constitutes) (NP (NP (DT the) (JJ major) (NN mechanism)) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NP (NN heterozygosity)) (PP (IN on) (NP (NN chromosome) (NN 20q))))) (PP (IN in) (NP (NN polycythemia) (NN vera))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (VBN acquired) (NN deletion)) (PP (IN of) (NP (NP (DT the) (JJ long) (NN arm)) (PP (IN of) (NP (NN chromosome) (CD 20)))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ recurrent) (NN abnormality)) (PP (IN in) (NP (NP (JJ myeloproliferative) (NNS disorders)) (, ,) (NP (RB particularly) (NP (UCP-COOD (NP (NN polycythemia) (NN vera)) (CC and) (ADJP (JJ myelodysplastic))) (NNS syndromes))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN association)) (PP (IN of) (NP (NN 20q) (NNS deletions))) (PP (IN with) (NP (JJ myeloid) (`` ") (NN stem) (NN cell) ('' ") (NNS disorders)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (DT the) (NNS deletions)) (VP (VBP mark) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (QP (CD one) (CC or) (JJR more)) (NNS genes))) (, ,) (SBAR (WHNP-5 (NP-COOD (NP (NN loss)) (CC or) (NP (NN inactivation))) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ normal) (JJ hematopoietic) (NNS progenitors))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (ADVP-TMP (RB recently)) (VP-COOD (VP (VBN performed) (NP (NP (DT a) (JJ detailed) (JJ molecular) (NN analysis)) (PP (IN of) (NP (NP (JJ 20q) (NNS deletions)) (PP (IN in) (NP (NP (NP (JJ peripheral) (NN blood)) (PRN (-LRB- -LRB-) (NP (NN PB)) (-RRB- -RRB-))) (NNS granulocytes))))))) (CC and) (VP (VBN defined) (NP (NP (DT a) (ADJP (RB commonly) (VBN deleted)) (NN region)) (PP (IN of) (NP (QP (CD 16) (TO to) (CD 21)) (NP (NP (NN centimorgan)) (PRN (-LRB- -LRB-) (NP (NN cM)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (S (VP (TO To) (ADVP (RBR further)) (VP (VB reduce) (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (JJ common) (VBN deleted) (NN region))))))) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN searched) (PP (IN for) (NP (NP-COOD (NP (JJ small) (NNS deletions)) (CC or) (NP (JJ mitotic) (NN recombination) (NNS events))) (, ,) (SBAR (WHNP-6 (NP (DT neither)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (MD would) (VP (VB be) (VP (VBN detected) (PP (IN by) (NP (JJ conventional) (NNS cytogenetics)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN studied) (NP-COOD (NP (NP (CD 48) (NNS patients)) (PP (IN with) (NP (NN polycythemia) (NN vera)))) (CC and) (NP (NP (CD four) (NNS patients)) (PP (IN with) (NP (JJ idiopathic) (NN myelofibrosis))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT each) (NN case))) (, ,) (NP-SBJ (JJ cytogenetic) (NN analysis)) (VP-COOD (VP (VBD had) (RB either) (VP (VBN failed))) (CC or) (VP (VBD had) (VP (VBN shown) (NP (NP (DT no) (NNS abnormalities)) (PP (IN of) (NP (NN chromosome) (CD 20))))))) (. .)))
(TOP (S (NP-SBJ-8 (NP (CD Seventeen) (NN microsatellite) (NNS markers)) (SBAR (WHNP-9 (WDT that)) (S (VP (VBP span) (NP (DT the) (JJ common) (VBN deleted) (NN region)))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB search) (PP (IN for) (NP (NP (NN loss)) (PP (IN of) (NP (NN heterozygosity))) (PP (IN in) (NP (NN granulocyte) (NN DNA)))))))))) (. .)))
(TOP (S (NP-SBJ-10 (NP (DT No) (NN instance)) (PP (IN of) (NP (NN microsatellite) (NN instability)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 880) (NNS comparisons)) (PP (IN of) (NP (NP-COOD (NP (NN granulocyte)) (CC and) (NP (NN T-cell))) (NN DNA))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Granulocyte) (NN DNA)) (PP (IN from) (NP (CD four) (NNS patients)))) (VP (VBD exhibited) (NP (NP (NN allele) (NN loss)) (PP (IN on) (NP (NN 20q))))) (. .)))
(TOP (S (PP (IN In) (NP (DT each) (NN case))) (NP-SBJ-11 (DT the) (NN allele) (NN loss)) (VP (VBD was) (VP (VBN caused) (PP (IN by) (NP-LGS (DT an) (JJ interstitial) (NN deletion))) (SBAR-COOD (SBAR (IN because) (S (NP-SBJ-12 (NP (NN heterozygosity)) (PP (IN at) (NP (JJ distal) (NNS markers)))) (VP (VBD was) (VP (VBN retained))))) (CC and) (SBAR (IN because) (S (NP-SBJ (JJ quantitative) (NN Southern) (NN blotting)) (VP (VBD demonstrated) (NP (NN hemizygosity)))))))) (. .)))
(TOP (S (NP-SBJ-13 (NP (NN Loss)) (PP (IN of) (NP (NN heterozygosity))) (PP (IN in) (NP (NN PB) (NNS granulocytes)))) (VP (MD would) (VP (VB be) (VP (VBN masked) (PP (IN by) (NP-LGS (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ significant) (NNS numbers)) (PP (IN of) (NP (NP (JJ normal) (NNS granulocytes)) (VP (RB not) (VBN derived) (PP (IN from) (NP (DT the) (JJ malignant) (NN clone))))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ-14 (NP (DT the) (JJ human) (NN androgen) (NN receptor) (NN assay)) (PRN (-LRB- -LRB-) (NP (NN HUMARA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NN granulocyte) (NN clonality))))))) (. .)))
(TOP (S (PP (IN In) (NP (QP (CD 21) (IN of) (CD 27)) (JJ informative) (NN female) (NNS patients))) (NP-SBJ (NP (DT the) (NN majority)) (PP (IN of) (NP (DT the) (NNS granulocytes)))) (VP (VBD were) (ADJP-PRD (RB clonally) (VBN derived))) (. .)))
(TOP (S-COOD (S (PP (IN In) (NP (CD 5) (NNS patients))) (NP-SBJ (DT the) (NNS granulocytes)) (VP (VBD appeared) (ADJP-PRD (JJ polyclonal)))) (CC and) (S (PP (IN in) (NP (CD 1) (NN patient))) (NP-SBJ-17 (JJ unilateral) (NN X) (NN inactivation)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP-COOD (CC both) (NP (NNS granulocytes)) (CC and) (NP (JJ T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP show) (SBAR (IN that) (, ,) (S (PP (IN in) (NP (NP (DT the) (JJ vast) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN presented) (ADVP (RB here))))))) (, ,) (NP-SBJ-16 (DT the) (NN failure) (S (VP (TO to) (VP (VB detect) (NP (NP (NN loss)) (PP (IN of) (NP (NN heterozygosity)))))))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ normal) (JJ polyclonal) (NNS granulocytes))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (ADVP (RB therefore)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NP (NN allele) (NN loss)) (PP (IN on) (NP (NN chromosome) (NN 20q))) (PP (IN in) (NP (NN polycythemia) (NN vera)))) (VP (VBZ does) (RB not) (ADVP (RB commonly)) (VP (VB involve) (NP-COOD (NP (JJ mitotic) (NN recombination)) (CC or) (NP (NN chromosome) (NN loss))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NN microsatellite) (NN instability)) (VP (VBZ is) (NP-PRD (DT a) (JJ rare) (NN event)) (PP (IN in) (NP (DT this) (NN disorder)))))))) (. .)))
(TOP (NP (NP (JJ Transcriptional) (NN control)) (PP (IN of) (NP (NP (JJ steroid-regulated) (NN apoptosis)) (PP (IN in) (NP (JJ murine) (NN thymoma) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Early) (NNS studies)) (PP (IN in) (NP (JJ murine) (NN T) (NN cell) (NNS lines)))) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ-54 (NP (JJ transcriptional) (NN transactivation) (NNS functions)) (VP (VBN encoded) (PP (IN in) (NP (DT the) (NP (NP (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (JJ N-terminal) (NN domain))))) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (JJ glucocorticoid-mediated) (NN apoptosis)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (ADJP-TMP (RBR more) (JJ recent)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN T) (NN cell) (NNS lines)))) (VP (VBP have) (VP (VBN suggested) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (DT the) (JJ N-terminal) (NN domain)) (VP (VBZ is) (RB not) (ADJP-PRD (JJ necessary) (PP (IN for) (NP (JJ steroid-regulated) (NN apoptosis))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (JJ GR-mediated) (NN transrepression)) (VP (MD may) (VP (VB be) (NP-PRD (DT the) (ADJP (RBR more) (JJ critical)) (NN mechanism))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (ADVP (RBR better)) (VB understand) (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (DT the) (NN GR) (JJ N-terminal) (NN transactivation) (NN domain))) (PP (IN in) (S (VP (VBG mediating) (NP (JJ murine) (NN thymocyte) (NN apoptosis))))))))) (, ,) (NP-SBJ-55 (PRP we)) (ADVP (RB stably)) (VP (VBD transfected) (NP-COOD (NP (NN GR)) (, ,) (NP (NN GR) (NNS variants)) (, ,) (CC and) (NP (NP (DT the) (NN androgen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN AR)) (-RRB- -RRB-)))) (PP (IN into) (NP (JJ receptor-negative) (NN S49) (JJ murine) (NN thymoma) (NNS cells)))) (. .)))
(TOP (S-COOD (S (NP-SBJ-57 (NN GR) (NN expression) (NNS levels)) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ rate-limiting)) (PP (IN for) (S (VP (VBG initiating) (NP (DT the) (JJ apoptotic) (NN pathway))))))))))) (, ,) (CC and) (S (NP-SBJ-59 (NP (DT a) (JJ positive) (NN correlation)) (PP (IN between) (NP (NP-COOD (NP (NN steroid) (NN sensitivity)) (CC and) (NP (JJ GR-mediated) (NN induction))) (PP (IN of) (NP (DT an) (VBN integrated) (NP (NP (NN mouse) (JJ mammary) (NN tumor) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN MMTV)) (-RRB- -RRB-))) (NN LTR) (NN reporter) (NN gene)))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (NN GR) (JJ chimeric) (NNS receptors)) (VP (VBG containing) (NP (DT the) (JJ potent) (NP-COOD (NP (NN VP16)) (CC and) (NP (NN E1A))) (JJ viral) (NN transactivation) (NNS domains)) (PP (IN in) (NN place) (IN of) (NP (DT the) (NN GR) (NN N) (NN terminus))))))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ-60 (NP (RB even) (JJ low) (NN level) (NN expression)) (PP (IN of) (NP (DT these) (NNS receptors)))) (VP (VBD resulted) (PP (IN in) (NP-COOD (CC both) (NP (VBN enhanced) (NN steroid) (NN sensitivity)) (CC and) (NP (NN MMTV) (NN induction)))) (, ,) (S (VP (ADVP (RB thus)) (VBG supporting) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NP (NN transactivation)) (PP (IN in) (NP (NN apoptosis)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NN AR)) (VP (MD can) (VP (VB initiate) (NP (NP (NN apoptosis)) (PP (IN in) (NP (NN S49) (NNS cells)))) (PP-TMP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (CD 5) (NN alpha-dihydrotestosterone))))) (, ,) (PP (IN despite) (NP (PRP$ its) (JJ relative) (NN inability) (S (VP (TO to) (VP (VB induce) (NP (NP (JJ high) (NN level) (NN expression)) (PP (IN of) (NP (NN MMTV)))))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB investigate) (NP (DT this)) (ADVP (RBR further))))) (, ,) (NP-SBJ-61 (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ steroid-regulated) (NN expression)) (PP (IN of) (NP (NP (DT an) (JJ endogenous) (JJ thymocyte-specific) (NN gene)) (VP (VBN called) (S (NP-PRD (NN GIG18)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ-62 (NN GIG18)) (VP (VBD was) (VP (ADVP-TMP (RB rapidly)) (VBN induced) (PP (TO to) (NP (JJ comparable) (NNS levels))) (PP (IN by) (NP-LGS-COOD (CC both) (NP (NN AR)) (CC and) (NP (NN GR)))) (, ,) (S (VP (VBG demonstrating) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NN AR)) (VP (MD can) (VP (ADVP (RB indeed)) (VB function) (PP (IN as) (NP (NP (DT a) (JJ transcriptional) (NN activator)) (PP (IN in) (NP (NN S49) (NNS cells))))))))) (CC and) (, ,) (RB moreover) (, ,) (SBAR (IN that) (S (NP-SBJ (NN GIG18) (NN induction)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ early) (JJ apoptotic) (NNS events))) (PP (IN in) (NP (JJ steroid-treated) (NNS cells)))))))))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-102 (DT these) (NNS results)) (VP (VBP support) (NP (PRP$ our) (NN conclusion) (SBAR (IN that) (S (NP-SBJ (JJ transcriptional) (NN transactivation)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ necessary) (NN signaling) (NN component)) (PP (IN of) (NP (NN S49) (NN cell) (NN apoptosis)))))))) (, ,) (SBAR (IN although) (S (NP-SBJ-65 (NP (DT an) (JJ additional) (NN role)) (PP (IN for) (NP (JJ GR-mediated) (NN transrepression)))) (VP (MD can) (VP (RB not) (VP (VB be))))))) (VBN excluded)))
(TOP (S (NP-SBJ (NP (NN Suppression)) (PP (IN of) (NP (NN c-jun))) (PP (IN by) (NP (JJ antisense) (NNS oligonucleotides)))) (VP (VBZ inhibits) (NP-COOD (NP (NN cell) (NN adhesion)) (CONJP (CC but) (RB not)) (NP (JJ respiratory) (NN burst))) (PP-TMP (IN during) (NP (NP (ADJP (NN phorbol) (JJ ester-induced)) (NN differentiation)) (PP (IN of) (NP (NN U937) (JJ human) (JJ monoblastic) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ-46 (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (JJ immediate) (JJ early) (NN gene) (NN c-jun))) (PP (IN in) (NP (NP-COOD (NP (NN cell) (NN proliferation)) (CC and) (NP (ADJP (NN phorbol) (NN 12-myristate) (NN 13-acetate) (-LRB- -LRB-) (NN PMA) (-RRB- -RRB-) (JJ -induced)) (NN differentiation))) (PP (IN in) (NP (NN U937) (JJ human) (JJ monoblastic) (NNS cells)))))) (, ,) (S (VP (VBG using) (NP (JJ c-jun-specific) (ADJP (ADJP (JJ antisense)) (PRN (-LRB- -LRB-) (ADJP (JJ AS)) (-RRB- -RRB-))) (NN phosphorothioate) (NNS oligonucleotides))))) (. .)))
(TOP (S (PP (IN In) (S (VP (VBG selecting) (NP (DT the) (ADJP (RBS most) (ADJP-COOD (ADJP (JJ specific)) (CC and) (ADJP (JJ potent)))) (JJ oligonucleotide) (NN sequence))))) (, ,) (NP-SBJ-47 (PRP we)) (VP (VBD performed) (NP (NP (JJ extensive) (NNS analyses)) (PP (IN for) (NP (NP (DT the) (NN binding) (NN specificity)) (PP (IN between) (NP-COOD (NP (NP (DT all) (NNS candidates)) (PP (IN of) (NP (NN c-jun) (JJ AS) (NNS oligonucleotides)))) (CC and) (NP (NP (DT the) (JJ whole) (NNS sequences)) (PP (IN in) (NP (NN GenBank) (NN database))))))))) (, ,) (S (VP (VBG using) (NP (DT a) (NN computer) (NN program))))) (. .)))
(TOP (S (PP (IN Among) (NP (DT the) (CD 20) (VBN selected) (NNS oligonucleotides))) (, ,) (NP-SBJ (NP (CD two) (JJ potent) (JJ 15-mer) (JJ AS) (NNS oligonucleotides)) (PRN (-LRB- -LRB-) (NP (NN C-JUN) (JJ AS) (NNS oligonucleotides)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (JJ significant) (NN inhibition)) (PP (IN of) (NP (NN cell) (NN growth)))) (PP (IN in) (NP (NP (DT a) (JJ dose-dependent) (NN manner)) (NP (QP (IN between) (CD 2) (CC and) (CD 10)) (NN microM))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ Reverse) (NN transcription-PCR)) (CC and) (NP (NN Western) (NN blot) (NN analysis))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (CD 10) (NN microM)) (PP (IN of) (NP (NN C-JUN) (JJ AS) (NNS oligonucleotides)))) (VP (VBD reduced) (NP (NN c-jun) (NN expression)) (PP (IN at) (NP (CC both) (DT the) (NP-COOD (NP (NN mRNA)) (CC and) (NP (NN protein))) (NNS levels))))))) (. .)))
(TOP (S (S (ADVP (RBR More) (RB importantly)) (, ,) (NP-SBJ (NN C-JUN) (JJ AS) (NNS oligonucleotides)) (VP (VBD showed) (NP (NP (JJ distinct) (NNS effects)) (PP (IN on) (NP (NP (CD two) (NNS markers)) (PP (IN of) (NP (JJ PMA-induced) (NN differentiation))))))) (: ;)) (S-COOD (S (NP-SBJ (DT the) (NN C-JUN) (JJ AS) (NNS oligonucleotides)) (VP (VBD inhibited) (NP (NN cell) (NN adhesion)))) (, ,) (IN whereas) (S (NP-SBJ (PRP they)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (NP (NP (DT another) (NN marker)) (PP (IN of) (NP (NN differentiation)))) (, ,) (NP (JJ respiratory) (NN burst))) (-LRB- -LRB-) (VP (VBN measured) (PP (IN by) (NP (NN nitro) (JJ blue) (NN tetrazolium) (NN reduction) (NN assay)))) (-RRB- -RRB-))))) (. .))))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN of) (NP (NN c-jun))) (PP-COOD (PP (IN in) (NP-COOD (CC both) (NP (NN cell) (NN proliferation)) (CC and) (NP (JJ PMA-induced) (NN cell) (NN adhesion)))) (CC but) (PP (RB not) (IN in) (NP (NP (JJ PMA-induced) (JJ respiratory) (NN burst)) (PP (IN in) (NP (NN U937) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Human) (NN TAFII) (CD 105)) (VP (VBZ is) (NP-PRD (NP (DT a) (ADJP (NN cell) (JJ type-specific)) (NN TFIID) (NN subunit)) (ADJP (JJ related) (PP (TO to) (NP (NN hTAFII130)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB previously)) (VP (VBD characterized) (NP (NP (NP-COOD (NP (NN Drosophila)) (CC and) (NP (JJ human) (NN TAF))) (NNS subunits)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBP make) (PRT (RP up)) (NP (NP (DT the) (NN core) (NN TFIID) (NN complex)) (VP (VBN found) (PP (IN in) (NP (DT all) (NNS cells)))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (VBN differentiated) (NN B) (NNS cells)) (VP (VBP contain) (NP (NP (DT a) (JJ novel) (JJ substoichiometric) (NN TAF)) (PP (IN of) (NP (CD 105) (NN kDa))) (VP (RB not) (VBN found) (S (VP (VBN associated) (PP (IN with) (NP (NP (NN TFIID)) (VP (VBN isolated) (PP (IN from) (NP (JJ other) (NN cell) (NNS types)))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN cDNA) (NN encoding) (NN hTAFII105)) (VP (VBZ reveals) (NP (NP (DT a) (ADJP (RB highly) (VBN conserved)) (JJ C-terminal) (NN domain)) (VP (VBN shared) (PP (IN by) (NP-LGS-COOD (NP (NN hTAFII130)) (CC and) (NP (NN oTAFII110)))))) (, ,) (SBAR (IN while) (S (NP-SBJ (DT the) (JJ N-terminal) (NN coactivator) (NN domain)) (VP (VBZ has) (VP (VBN diverged) (ADVP (RB significantly))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT All) (NNS cells)) (VP (VBN tested))) (VP (VBP express) (NP (NN TAFII105) (NN mRNA)))) (, ,) (CC but) (S (NP-SBJ (RB only) (NN B) (NNS cells)) (VP (VBP contain) (NP (NP (JJ significant) (NNS levels)) (PP (IN of) (NP (NP (NN protein)) (VP (VBN associated) (PP (IN with) (NP (NN TFIID))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Transient) (NN overexpression)) (PP (IN of) (NP (NN hTAFII105)))) (ADVP (RB selectively)) (VP (VBZ squelches) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (DT some) (NNS genes))) (PP (IN in) (NP (NN B) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS properties)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN TAFII105)) (VP (VBZ is) (NP-PRD (NP (DT a) (ADJP (NN cell) (JJ type-specific)) (NN subunit)) (PP (IN of) (NP (NN TFIID))) (SBAR (WHNP-3 (WDT that)) (S (VP (MD may) (VP (VB be) (ADJP-PRD (JJ responsible) (PP (IN for) (S (VP (VBG mediating) (NP (NN transcription)) (PP (IN by) (NP (NP (DT a) (NN subset)) (PP (IN of) (NP (NNS activators))) (PP (IN in) (NP (NN B) (NNS cells)))))))))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NP (JJ Uneven) (NN X) (NN inactivation)) (PP (IN in) (NP (NP (DT a) (JJ female) (JJ monozygotic) (JJ twin) (NN pair)) (PP (IN with) (NP (NN Fabry) (NN disease)))))) (CC and) (NP (NP (JJ discordant) (NN expression)) (PP (IN of) (NP (DT a) (JJ novel) (NN mutation))) (PP (IN in) (NP (DT the) (NN alpha-galactosidase) (NN A) (NN gene))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP describe) (NP (NP (CD two) (JJ female) (ADJP (ADJP (JJ monozygotic)) (PRN (-LRB- -LRB-) (ADJP (JJ MZ)) (-RRB- -RRB-))) (NNS twins)) (ADJP (JJ heterozygous) (PP (IN for) (NP (NP (NN Fabry) (NN disease)) (, ,) (NP (NP (DT an) (ADJP (NN X) (VBN linked)) (NN disorder)) (VP (VBG resulting) (PP (IN from) (NP (NP (DT the) (JJ deficient) (NN activity)) (PP (IN of) (NP (NN alpha-galactosidase) (NN A)))))))))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP-SBJ (NP (CD one)) (PP (IN of) (NP (DT the) (NNS twins)))) (VP (VBD was) (ADVP (RB clinically)) (ADJP-PRD (VBN affected))))) (, ,) (NP-SBJ (DT the) (JJ other)) (VP (VBD was) (ADJP-PRD (JJ asymptomatic))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Enzymatic) (NN assay)) (PP (IN of) (NP (NP (NN alpha-galactosidase)) (PP (IN in) (NP (NP-COOD (NP (NN blood) (NNS leucocytes)) (, ,) (NP (NN skin) (NNS fibroblasts)) (, ,) (NP (ADJP (NP (JJ Epstein-Barr) (NN virus)) (VBD transformed)) (JJ lymphoid) (NN cell) (NNS lines)) (, ,) (CC and) (NP (NN hair) (NNS follicles))) (PP (IN of) (NP (NP (DT the) (NNS twins)) (CC and) (NP (PRP$ their) (NNS parents))))))))) (VP-COOD (VP (VBD confirmed) (NP (NP (DT the) (JJ heterozygous) (NN status)) (PP (IN of) (NP (DT the) (NNS twins))))) (CC and) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ (NN Fabry) (NN disease)) (VP (VBD had) (VP (VBN occurred) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (DT a) (ADJP (FW de) (FW novo)) (NN mutation))))))))))) (. .)))
(TOP (S (NP-SBJ-40 (NP (DT The) (NN son)) (PP (IN of) (NP (DT the) (JJ unaffected) (NN twin) (NN sister)))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ hemizygous))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Molecular) (NN analysis)) (PP (IN of) (NP (DT the) (NN alpha-galactosidase) (NN A) (NN gene)))) (VP (VBD permitted) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (NP (DT an) (ADJP (ADVP (RB as) (RB yet)) (JJ undescribed)) (NN point) (NN mutation)) (PP (IN at) (NP (NP (NN position) (CD 10182)) (PP (IN of) (NP (NN exon) (CD 5))))) (SBAR (WHNP-41 (WDT which)) (S (VP (VBZ causes) (NP (NP (DT an) (NP-COOD (NP (NN Asp)) (TO to) (NP (NN Asn))) (NN substitution)) (PP (IN at) (NP (NN codon) (CD 231))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Single) (NN strand) (NN conformation) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SSCP)) (-RRB- -RRB-)) (NN analysis)) (ADVP-TMP (RB again)) (VP (VBD showed) (NP-COOD (NP (NP (DT the) (JJ heterozygous) (NN status)) (PP (IN of) (NP (DT the) (NNS twins)))) (CC and) (NP (NP (DT a) (JJ normal) (NN pattern)) (PP (IN in) (NP (PRP$ their) (NNS parents)))))) (. .)))
(TOP (S (NP-SBJ-42 (NP (DT The) (NN basis)) (PP (IN for) (NP (NP (DT the) (JJ discordant) (NN expression)) (PP (IN of) (NP (NP (DT this) (ADJP (FW d) (FW novo)) (NN mutation)) (PP (IN in) (NP (DT the) (NNS twins)))))))) (VP (VBD was) (VP (VBN investigated) (PP (IN by) (S (VP (VBG studying) (NP (PRP$ their) (NN X) (NN inactivation) (NN status))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (ADJP (NP (JJ inactive) (NN X)) (JJ specific)) (NN methylation)) (PP (IN at) (NP (DT the) (NN androgen) (NN receptor) (NN gene)))))) (VP (VBD showed) (NP (NP (JJ unbalanced) (NN inactivation)) (PP-COOD (PP (IN in) (NP (NP (DT the) (NNS twins) (POS ')) (NNS fibroblasts))) (CC and) (PP (IN in) (NP (JJ opposite) (NNS directions)))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP-SBJ (DT the) (ADJP (RB maternally) (VBN derived)) (NN X) (NN chromosome)) (VP (VBD was) (ADJP-PRD (RB preferentially) (JJ active)) (PP (IN in) (NP (DT the) (JJ asymptomatic) (NN twin)))))) (, ,) (NP-SBJ-43 (DT the) (JJ paternal) (NN X) (NN chromosome)) (VP-COOD (VP (VBD was) (ADJP-PRD (JJ active)) (PP (IN in) (NP (DT the) (ADJP-COOD (ADJP (JJ other)) (, ,) (ADJP (VBN affected))) (NN twin)))) (CC and) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (PRP$ her) (JJ hemizygotic) (NN nephew)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (DT the) (JJ paternal) (NN X) (NN chromosome)) (VP (VBZ carries) (NP (DT the) (ADJP (FW de) (FW novo)) (NN alpha-galactosidase) (NN A) (NN mutation))))) (CC and) (SBAR (IN that) (S (NP-SBJ (JJ uneven) (NN X) (NN inactivation)) (VP (VBZ is) (NP-PRD (NP (DT the) (VBG underlying) (NN mechanism)) (PP (IN for) (NP (NP (NN disease) (NN expression)) (PP (IN in) (NP (DT this) (JJ novel) (NN female) (JJ MZ) (NN twin) (NN pair))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ first) (VBN documented) (NN case)) (PP (IN of) (NP (NP (JJ female) (NNS twins)) (ADJP (JJ discordant) (PP (IN for) (NP (NN Fabry) (NN disease)))))))) (. .)))
(TOP (NP (NP (NP (NP (NN Signaling)) (PP (IN by) (NP-COOD (NP (NN IL-2)) (CC and) (NP (JJ related) (NNS cytokines))))) (: :)) (NP-COOD (NP (NNS JAKs)) (, ,) (NP (NNS STATs)) (, ,) (CC and) (NP (NP (NN relationship)) (PP (TO to) (NP (NN immunodeficiency)))) (. .))))
(TOP (S (NP-SBJ (NP (NNS Cytokines)) (SBAR (WHNP-14 (WDT that)) (S (VP (VBP bind) (PP (TO to) (NP (NP (DT the) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN receptor) (JJ common) (NP (NP (NN gamma) (NN chain)) (PRN (-LRB- -LRB-) (NP (NN gamma) (NN c)) (-RRB- -RRB-)))) (, ,) (PP (VBG including) (NP-COOD (NP (NN IL-2)) (, ,) (NP (NN IL-4)) (, ,) (NP (NN IL-7)) (, ,) (NP (NN IL-9)) (, ,) (CC and) (NP (NN IL-15)))) (, ,))))))) (VP (VBP are) (ADJP-PRD (JJ important) (PP (IN for) (NP (NP (DT the) (NP-COOD (NP (NN growth)) (CC and) (NP (NN differentiation)))) (PP (IN of) (NP-COOD (NP (NP-COOD (NP (NN T)) (CC and) (NP (NN B))) (NNS lymphocytes)) (, ,) (NP (JJ natural) (NN killer) (NNS cells)) (, ,) (NP (NNS macrophages)) (, ,) (CC and) (NP (NNS monoctyes)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS cytokines)) (VP (VBP have) (NP (NP (VBG overlapping) (JJ biological) (NNS effects)) (SBAR (WHNP-15 (WDT that)) (S (VP (PP (IN in) (NP (NN part))) (VBP result) (PP (IN from) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (VBN shared) (NN receptor) (NN subunit) (NN gamma) (NN c)))))))))) (. .)))
(TOP (S (ADVP-TMP (RB Recently)) (NP-SBJ (NP (PRP it))) (VP (VBZ has) (VP (VBN become) (ADJP-PRD (JJ clear)) (SBAR-16 (IN that) (S (NP-SBJ (DT these) (NNS cytokines)) (VP (VBP activate) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (JJ important) (JJ intracellular) (VBG signaling) (NNS molecules)) (, ,) (PP (VBG including) (NP-COOD (NP (DT the) (NN Janus) (NNS kinases) (NP-COOD (NP (NN JAK1)) (CC and) (NP (NN JAK3)))) (CC and) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN factor) (NN family)) (PP (IN of) (NP (NP (NP (NN signal) (NP-COOD (NP (NNS transducers)) (CC and) (NP (NNS activators)))) (PP (IN of) (NP (NN transcription)))) (PRN (-LRB- -LRB-) (NP (NNS STATs)) (-RRB- -RRB-))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN discovery)) (PP (IN of) (NP (DT these) (NN signaling) (NNS pathways)))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (JJ important) (JJ new) (NNS insights)) (PP (IN into) (NP (NP (PRP$ their) (NN role)) (PP (IN in) (NP (NN lymphocyte) (NN maturation))))))) (, ,) (SBAR (IN as) (S (NP-SBJ (NP (PRP it))) (VP (VBZ has) (VP (VBN emerged) (SBAR-17 (IN that) (S (NP-SBJ (NP (NNS mutations)) (PP (IN in) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP-COOD (CC both) (NP (NN gamma) (NN c)) (CC and) (NP (NN JAK3))))))) (VP (VBP result) (PP (IN in) (NP (NP (JJ similar) (NNS forms)) (PP (IN of) (NP (NP (JJ severe) (JJ combined) (NN immunodeficiency)) (PRN (-LRB- -LRB-) (NP (NN SCID)) (-RRB- -RRB-))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN review))) (NP-SBJ (PRP we)) (VP (VBP examine) (NP-COOD (NP (NP (DT the) (NP-COOD (NP (NN structure)) (CC and) (NP (NN function)))) (PP (IN of) (NP (NN cytokine) (NNS receptors)))) (CC and) (NP (NP (DT the) (NN signaling) (NNS pathways)) (VP (VBN involved) (PP (IN in) (NP (NP (PRP$ their) (NN regulation)) (PP (IN of) (NP (NN gene) (NN expression))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP discuss) (NP (NP (JJ recent) (NNS advances)) (SBAR (WHNP-18 (WDT that)) (S (VP (VBP have) (VP (VBN led) (PP (TO to) (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (SBAR (WHADVP-19 (WRB how)) (S (NP-SBJ (NNS cytokines)) (VP (VBP elicit) (NP (JJ intracellular) (NNS responses)) (, ,) (PP (RB as) (RB well) (IN as) (NP (NP (PRP$ their) (NN role)) (PP (IN in) (NP (JJ normal) (JJ lymphoid) (NN development))))))))))))))))) (. .)))
(TOP (NP (NP (NN Eosinophil) (NN priming)) (PP (IN by) (NP (NNS cytokines))) (: :) (PP-COOD (PP (IN from) (NP (JJ cellular) (NN signal))) (PP (TO to) (NP (ADJP (FW in) (FW vivo)) (NN modulation)))) (. .)))
(TOP (S (NP-SBJ (NNS Eosinophils)) (VP (VBP play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN effector) (NN phase)) (PP (IN of) (NP (JJ allergic) (NN inflammation)))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN review)) (VP (MD will) (VP (VB focus) (PP (IN on) (NP (NP (NP (DT the) (NN conversion)) (PP (IN of) (NP (NP (DT the) (JJ unprimed) (NN eosinophil) (NN phenotype)) (PP (IN in) (NP (NP (DT the) (JJ peripheral) (NN blood)) (PP (IN of) (NP (JJ normal) (NNS individuals))))))) (PP (TO to) (NP (NP (DT the) (JJ primed) (NN phenotype)) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (JJ peripheral) (NP-COOD (NP (NN blood)) (CC and) (NP (NNS tissues)))) (PP (IN of) (NP (JJ allergic) (NNS patients))))))))) (, ,) (NP (NP (DT a) (NN phenomenon)) (VP (VBN called) (S (NP-PRD (NN priming))))))))) (. .)))
(TOP (S (NP-SBJ-45 (NP (JJ Recent) (NNS data)) (PP (IN on) (NP (NP (DT the) (NNS signals)) (VP (VBN initiated) (PP-TMP (IN after) (NP (NP (NN cytokine) (NN receptor) (NN activation)) (PP (IN on) (NP (NNS eosinophils))))))))) (VP (MD will) (VP (VB be) (VP (VBN reviewed)))) (. .)))
(TOP (NP (NP (NP (JJ Molecular) (NNS mechanisms)) (PP (IN of) (NP (NN steroid) (NN action))) (: :)) (NP (NP (DT a) (JJ novel) (NN type)) (PP (IN of) (NP (NP (NN cross-talk)) (PP (IN between) (NP-COOD (NP (NNS glucocorticoids)) (CC and) (NP (NN NF-kappa) (NN B) (NN transcription) (NNS factors)))))) (. .))))
(TOP (S (PP (IN Despite) (NP (NP (DT the) (JJ widespread) (NN use)) (PP (IN of) (NP (NNS glucocorticoids))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS diseases)) (VP (VBN characterized) (PP (IN by) (NP-LGS (NN inflammation)))))))))) (, ,) (NP-SBJ-29 (NP (DT the) (JJ molecular) (NN mechanism) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (SBAR (WHPP-30 (IN by) (WHNP (WDT which))) (S (NP-SBJ (DT these) (NNS hormones)) (VP (VBP exert) (NP (DT this) (JJ beneficial) (NN effect)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN asthma))))))))) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN elucidated)))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN ICAM-1)) (-RRB- -RRB-))))) (SBAR (IN as) (S (NP-SBJ-32 (NN adhesion) (NNS molecules)) (VP (VBP are) (ADJP-PRD (JJ likely) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ causal) (NN role)) (PP (IN in) (NP (NN inflammation))) (PP (IN in) (S (VP (VBG promoting) (NP (ADJP-COOD (ADJP (JJ cell-cell)) (CC and) (ADJP (JJ cell-matrix))) (NNS interactions)))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD observed) (SBAR (IN that) (S (PP (IN in) (NP (NP-COOD (NP (DT a) (ADJP (ADJP (JJ monocytic)) (PRN (-LRB- -LRB-) (NP (NN U937)) (-RRB- -RRB-)))) (CC and) (NP (DT a) (ADJP (ADJP (JJ bronchial) (NN epithelial)) (PRN (-LRB- -LRB-) (NP (NN H292)) (-RRB- -RRB-))))) (NP-34 (JJ cell-line)))) (NP-SBJ (NN dexamethasone)) (ADVP (RB strongly)) (VP (VBD suppressed) (NP (ADJP-COOD (ADJP (JJ basal)) (CC and) (ADJP (VBN induced))) (NN ICAM-1) (NN expression)))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Subsequent) (NN analysis)) (PP (IN of) (NP (DT the) (JJ human) (NN ICAM-1) (NN promoter)))) (VP (VBZ has) (VP (VBN revealed) (SBAR (IN that) (S (NP-SBJ-COOD (CC both) (NP (NP (NN 12-O-tetradecanoylphorbol) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))) (CC and) (NP (NP (NN tumour) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-)))) (VP (VBP upregulate) (NP (NN ICAM-1) (NN expression)) (PP (IN through) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT a) (NP (NP (JJ nuclear) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (NN target) (NN sequence)) (PRN (-LRB- -LRB-) (NP (NN TGGAAATTCC)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT No) (NN glucocorticoid) (NN recognition) (NNS sequences)) (VP (VBP are) (ADJP-PRD (JJ present) (PP (IN in) (NP (DT this) (NN promoter) (NN region)))))) (CC and) (S (NP-SBJ-35 (NN dexamethasone)) (VP (VBZ is) (ADVP (RB still)) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB repress) (NP (NN transcription)))))) (SBAR-TMP (WHADVP-36 (WRB when)) (S (NP-SBJ-37 (DT the) (JJ multimerized) (NN NF-kappa) (NN B) (NN sequence)) (VP (VBZ is) (VP (VBN transactivated) (PP (IN by) (NP (NN TNF-alpha))) (PP-TMP (IN upon) (NP (NP (NN transfection)) (PP (IN in) (NP (CD 293) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (NP (JJ direct) (NN interaction)) (PP (IN between) (NP-COOD (NP (DT the) (NN glucocorticoid) (NN receptor)) (CC and) (NP (JJ nuclear) (NN factor-kappa) (NN B) (NNS factors))))) (VP (VBZ is) (ADVP (IN at) (JJS least)) (NP-PRD (NP (DT a) (JJ partial) (NN explanation)) (PP (IN for) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT this) (NN hormone))) (PP (IN in) (NP (JJ inflammatory) (NNS diseases)))))))))) (. .)))
(TOP (S (NP-SBJ-1 (NP (DT The) (NN suppression)) (PP (IN of) (NP-COOD (NP (NN T) (NN cell) (NN function)) (CC and) (NP (NN NF-LRB-kappa-RRB-B) (NN expression)))) (PP (IN by) (NP (NN serine) (NN protease) (NNS inhibitors)))) (VP (VBZ is) (VP (VBN blocked) (PP (IN by) (NP-LGS (NN N-acetylcysteine))))) (. .)))
(TOP (S (NP-SBJ-2 (JJ Direct) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NP (NN N-acetylcysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-))) (VP (VBZ enhances) (NP (NP (DT the) (JJ immune) (NN response)) (PP (IN of) (NP (JJ peripheral) (NN blood) (NN T) (NNS cells))) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN NF-LRB-kappa-RRB-B)))))))))) (VP (VBZ is) (VP (VBN presented))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NN NAC)) (VP (VBZ blocks) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP-COOD (NP (NN T) (NN cell) (NN mitogenesis)) (CC and) (NP (NN cytokine) (NN production))))) (PP (IN by) (NP (NP (NN protease) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NN N-tosylphenylalanine) (NN chloromethyl) (NN ketone)) (PRN (-LRB- -LRB-) (NP (NN TPCK)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ-3 (NP (DT The) (JJ proliferative) (NNS responses)) (PP (IN of) (NP (VBN purified) (ADJP-COOD (ADJP (JJ CD4+)) (CC or) (ADJP (JJ CD8+))) (NN T) (NNS cells)))) (VP (VBP are) (VP (VBN suppressed) (ADVP (RBR more) (RB strongly)) (PP (IN by) (NP-LGS (NN TPCK))) (SBAR-TMP (WHADVP-4 (WRB when)) (S (NP-SBJ-COOD-5 (NP (NN anti-CD28)) (CONJP (RB rather) (IN than)) (NP (DT the) (NN phorbol) (NN ester) (NN PMA))) (VP (VBZ is) (VP (VBN used) (PP (IN as) (NP (DT the) (JJ mitogenic) (NN coactivator))))))))) (. .)))
(TOP (S (NP-SBJ-6 (NP (NP (NN Cytokine)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN IL-2)) (, ,) (NP (NN IL-6)) (, ,) (NP (NN INF-gamma))) (-RRB- -RRB-))) (NN production)) (VP (VBZ is) (VP (VBN inhibited) (NP (QP (CD 95-100)) (NN %)) (PP (IN by) (NP-LGS (NP (NNS concentrations)) (PP (IN of) (NP (NP (NN TPCK)) (SBAR (WHNP-7 (WDT that)) (S (VP (ADVP (RB totally)) (VB suppress) (NP (NP (DT the) (NN mitogenesis)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ CD4+)) (CC or) (ADJP (JJ CD8+))) (NNS cells))))))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))) (, ,) (NP-SBJ-8 (PRP we)) (VP (VBP find) (SBAR (IN that) (S (NP-SBJ (NN TPCK)) (ADVP (RB virtually)) (VP (VBZ abolishes) (-LRB- -LRB-) (PP (TO to) (NP (QP (JJR less) (IN than) (CD 1)) (NN %))) (-RRB- -RRB-) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP-COOD (NP (NN NF-LRB-kappa-RRB-B)) (-LRB- -LRB-) (CONJP (CC but) (RB not)) (NP (NN Oct-1)) (-RRB- -RRB-)) (VP (VBN found) (PP (IN in) (NP (NP (UCP-COOD (ADJP (JJ nuclear)) (CC and) (NP (JJ whole) (NN cell))) (NNS extracts)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))))))))))) (. .)))
(TOP (S (ADVP (RB Strikingly)) (, ,) (NP-SBJ-9 (NP (DT the) (JJ immunosuppressive) (NNS effects)) (PP (IN of) (NP (NN TPCK)))) (VP (VBP are) (VP (VBN blocked) (SBAR-TMP (WHADVP-10 (WRB when)) (S (NP-SBJ-11 (NN T) (NNS cells)) (VP (VBP are) (VP (VBN pretreated) (PP-TMP (IN for) (NP (CD 15) (NN min))) (PP (IN with) (NP (ADJP (CD 5) (NN mM)) (NN NAC))))))))) (. .)))
(TOP (S (NP-SBJ (NN NAC)) (VP-COOD (CONJP (RB not) (RB only)) (VP (VBZ blocks) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN TPCK))))) (CC but) (VP (VBZ enhances) (NP-COOD (NP (NN mitogenesis)) (CC and) (NP (NN cytokine) (NN production))) (PRN (-LRB- -LRB-) (FRAG (ADVP (JJR &gt;) (RB 2.5-fold)) (PP (IN in) (NP (DT some) (NNS cases)))) (-RRB- -RRB-)) (PP-TMP (IN upon) (NP (NP (NN activation)) (PP (IN of) (NP (JJ unsuppressed) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP support) (NP (DT the) (NN notion) (SBAR (IN that) (S (NP-SBJ (NP-COOD (NP (NN NF)) (-LRB- -LRB-) (NP (NN kappa))) (-RRB- -RRB-)) (VP (VP (NN B) (NP (CC and) (NN I)) (PP (-LRB- -LRB-) (NP-COOD (NP (NN kappa) (-RRB- -RRB-) (NN B)) (NNS proteases) (NP (VBP play))))) (JJ obligate) (NP (NP (NNS roles)) (SBAR (WHNP-12 (IN in)) (S (VP (NN T) (VP (NN cell) (ADVP (NN activation)) (PP (CC and) (NP-LGS (NN mitogenesis))))))))))))) (, ,)))
(TOP (S (NP-SBJ (NP (JJ IL-12-induced) (NN activation)) (PP (IN of) (NP (NP-COOD (NP (NN NK)) (CC and) (NP (NN T))) (NNS cells)))) (VP (VBZ occurs) (PP (IN in) (DT the) (NN absence) (IN of) (NP (JJ immediate-early) (NN activation) (NN gene) (NN expression)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS responses)) (PP (IN of) (NP (NNS lymphocytes))) (PP (TO to) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-12)))) (, ,) (VP (VBG involving) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN differentiation)) (, ,) (CC and) (NP (NN cytokine) (NN production)))) (, ,)) (VP-COOD (VP (VBP are) (ADVP (RB only) (RB partially)) (VP (VBG overlapping))) (, ,) (CC and) (VP (MD may) (VP (VB depend) (PP (IN on) (NP (NP (VBN induced) (JJ differential) (NN expression)) (PP (IN of) (NP (NP (JJ specific) (NNS sets)) (PP (IN of) (NP (NNS genes)))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ reverse-transcription) (NN PCR) (JJ differential) (NN display)))) (, ,) (NP-SBJ-1 (PRP we)) (VP (VBD isolated) (NP (NP (DT an) (NN mRNA) (NNS species)) (VP (VBN expressed) (PP (IN in) (NP (ADJP-COOD (ADJP (NP (NN IL-2-))) (CC but) (ADJP (RB not) (JJ IL-12-stimulated))) (NN NK) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ-2 (DT This)) (VP (VBD was) (VP (VBN identified) (PP (IN as) (NP (NP (DT the) (NN mRNA)) (VP (VBG encoding) (NP (DT the) (NN transcription) (NN factor) (NN egr-1))) (, ,) (SBAR (WHNP-3 (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (PP (IN with) (NP (JJ fast) (NNS kinetics))) (PP (IN in) (NP (NP-COOD (NP (NN T)) (CC and) (NP (NN NK))) (NNS cells))) (PP-TMP (IN upon) (NP (NP-COOD (NP (NN IL-2)) (, ,) (CONJP (CC but) (RB not)) (NP (NN IL-12)) (, ,)) (NN stimulation))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NP (JJ mRNA-encoding) (NNS members)) (PP (IN of) (NP (DT the) (NN AP-1) (NN transcription) (NN factor) (NN family)))))))) (VP (VBD demonstrated) (SBAR (IN that) (S-COOD (S (NP-SBJ-COOD-5 (NP (NN c-fos)) (CC and) (NP (NN junB))) (VP (VBP are) (ADVP (RB also)) (VP (VBN expressed) (PP-TMP (IN upon) (NP (NP (NN stimulation)) (PP (IN of) (NP (NP-COOD (NP (NN NK)) (CC and) (NP (NN T))) (NNS cells))) (PP (IN with) (NP-COOD (NP (NN IL-2)) (, ,) (CONJP (CC but) (RB not)) (NP (NN IL-12))))))))) (, ,) (IN whereas) (S (NP-SBJ-6 (NP (NN expression)) (PP (IN of) (NP-COOD (NP (NN c-jun)) (CC and) (NP (NN junD))))) (VP (VBZ is) (RB not) (VP (VBN modified) (PP (IN by) (NP-LGS (DT either) (NN cytokine))))))))) (. .)))
(TOP (S (ADVP (RB Accordingly)) (, ,) (NP-SBJ-COOD-7 (NP (VBN increased) (NN AP-1) (JJ DNA-binding) (NN activity)) (CC and) (NP (JJ AP-1-dependent) (JJ transcriptional) (NN activity))) (VP (VBD were) (VP (VBN detected) (ADVP (RB exclusively)) (PP (IN in) (NP (JJ IL-2-stimulated) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN reported) (S (VP (TO to) (VP (VB regulate) (NP (JJ cytokine-induced) (NN proliferation))))))))))) (VP (VBD demonstrated) (SBAR (IN that) (S-COOD (S (NP-SBJ-COOD (CC both) (NP (NN IL-2)) (CC and) (NP (NN IL-12))) (VP (VBP induce) (NP (NN c-myc) (NN mRNA) (NN accumulation)) (PP (IN in) (NP (NP-COOD (NP (NN NK)) (CC and) (NP (NN T))) (NNS cells))))) (, ,) (IN whereas) (S (NP-SBJ (RB only) (NN IL-2)) (VP (VBZ induces) (NP (NN bcl-2) (NN expression))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP provide) (NP (DT the) (JJ first) (NN demonstration) (SBAR (IN that) (S (NP-SBJ (NP (JJ IL-12-mediated) (NN activation)) (PP (IN of) (NP (NP-COOD (NP (NN T)) (CC and) (NP (NN NK))) (NNS cells)))) (VP (VBZ does) (RB not) (VP (VB involve) (NP-COOD (NP (NP (NN expression)) (PP (IN of) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (JJ immediate-early) (NN activation) (NNS genes) (NN family)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN egr-1)) (, ,) (NP (NN c-fos)) (, ,) (CC and) (NP (NN junB))) (-RRB- -RRB-))))))) (, ,) (NP (NN AP-1) (JJ transcriptional) (NN activity)) (, ,) (CC or) (NP (NN bcl-2) (NN expression))))))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ (NP (JJ functional) (NNS differences)) (VP (VBN observed) (PP (IN in) (NP (ADJP-COOD (ADJP (NP (NN IL-2-))) (CC and) (ADJP (JJ IL-12-stimulated))) (NNS cells))))) (VP (MD may) (VP (VB depend) (PP (ADVP (, ,) (IN at)) (JJS least) (NP (IN in))) (NN part) (PP (, ,) (NP (IN on) (JJ differential) (NN gene)))))))) (NN regulation)))
(TOP (NP (NP (DT A) (JJ critical) (NN role)) (PP (IN of) (NP (ADJP-COOD (ADJP (NP (NN Sp1-))) (CC and) (ADJP (JJ Ets-related))) (NN transcription) (NNS factors))) (PP (IN in) (S (VP (VBG maintaining) (NP (NP (JJ CTL-specific) (NN expression)) (PP (IN of) (NP (DT the) (NN mouse) (NN perforin) (NN gene))))))) (. .)))
(TOP (S (NP-SBJ-1 (DT This) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ potential) (NNS cis-elements)) (VP (VBN involved) (PP (IN in) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT the) (NN mouse) (NN perforin) (NN gene)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (NN DNase) (CD I) (JJ hypersensitive) (NN site)) (PRN (-LRB- -LRB-) (NP (NN DHS)) (-RRB- -RRB-))) (NN mapping)) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (DT the) (NN perforin) (NN locus)) (VP-COOD (VP (VBD contained) (NP-100 (CD six) (NN DHS)) (PP-101 (IN within) (NP (NP (CD 7.0) (NN kb)) (PP (IN of) (NP (NP (DT the) (ADJP (JJ 5') (JJ upstream)) (NN sequence)) (PRN (-LRB- -LRB-) (NP (CD -7.0) (NN kb)) (-RRB- -RRB-))))))) (CC and) (VP (NP=100 (CD two) (NN DHS)) (PP=101 (IN in) (NP (NN intron) (CD 2)))))))) (. .)))
(TOP (S (NP-SBJ-3 (DT The) (NP-COOD (NP (CD six) (ADJP (JJ 5') (JJ upstream))) (CC and) (NP (CD one) (JJ intronic))) (NP-102 (NN DHS))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (RB only) (JJ perforin-expressing) (NNS lymphocytes))))) (. .)))
(TOP (S (NP-SBJ-4 (NP (NP (NP (NN Chloramphenicol) (NN acetyltransferase)) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-))) (NNS activities)) (VP (VBN directed) (PP (IN by) (NP-LGS (ADJP (JJ 5') (JJ upstream)) (NN promoter))))) (VP (VBD were) (VP (VBN detected) (ADVP (RB preferentially)) (PP (IN in) (NP (JJ perforin-expressing) (NN cell) (NNS lines))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT A) (NN construct)) (VP (VBN termed) (S (NP-PRD (NN PFP5a)))) (VP (VBG containing) (NP (CD -795) (NN bp)))) (VP (VBD exhibited) (NP (DT the) (JJS highest) (NN CAT) (NN activity)))) (, ,) (CC and) (S (NP-SBJ (NP (NN PFP9a20)) (VP (VBG containing) (NP (RB only) (CD -73) (NN bp)))) (ADVP (RB also)) (VP (VBD produced) (NP (ADJP (RB significantly) (JJ high)) (NN CAT) (NN activity)) (PP (IN in) (NP (NN CTLL-R8) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ proximal) (NN region)) (PP (IN in) (NP (NN PFP9a20)))) (VP (VBD contained) (NP-COOD (NP (NP (CD two) (JJ potential) (NN Sp1) (NN binding) (NNS sites)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN GC) (NN box)) (CC and) (NP (NN GT) (NN box))) (-RRB- -RRB-))) (CC and) (NP (NP (CD one) (NN Ets) (NN binding) (NN site)) (PRN (-LRB- -LRB-) (NP (NN EBS)) (-RRB- -RRB-))))) (. .)))
(TOP (S (NP-SBJ (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (DT each)) (PP (IN of) (NP (DT the) (NNS cis-elements)))) (VP (VBD bound) (NP (JJ specific) (NN protein) (NNS factors)))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-5 (WRB When)) (S (NP-SBJ-6 (JJ single-point) (NN mutation)) (VP (VBD was) (VP (VBN introduced) (PP (TO to) (NP (NP (DT each) (NP-COOD (NP (NN GC) (NN box)) (, ,) (NP (NN EBS)) (, ,) (CC and) (NP (NN GT) (NN box)))) (PP (IN in) (NP (NN PFP9a20))))))))) (, ,) (NP-SBJ-7 (ADJP (QP (IN at) (JJS least) (RB 3-fold)) (JJR less)) (NN CAT) (NN activity)) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NN CTLL-R8) (NNS cells))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB confirm) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT the) (CD three) (JJ cis-acting) (NNS elements))) (PP (IN in) (NP (DT the) (NN perforin) (NN gene) (NN expression))))))) (, ,) (NP-SBJ-8 (NN point) (NN mutation)) (VP (VBD was) (VP (VBN introduced) (ADVP-TMP (RB again)) (PP (TO to) (NP (NP (DT each) (JJ proximal) (NP-COOD (NP (NN GC) (NN box)) (, ,) (NP (NN EBS)) (, ,) (CC and) (NP (NN GT) (NN box)))) (PP (IN of) (NP (NN PFP5a))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN point) (NNS mutations)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (QP (CD 2.5-) (TO to) (JJ 3-fold)) (NN reduction)) (PP (IN of) (NP (NN CAT) (NN activity)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (NN combination)) (PP (IN of) (NP (DT the) (CD three) (JJ proximal) (JJ cis-acting) (NNS elements)))) (VP (MD may) (VP (VB constitute) (NP (NP (DT a) (JJ minimal) (NN region)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ CTL-specific) (NN expression)) (PP (IN of) (NP (NN perforin)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Soluble) (NNS factors)) (VP (VBN secreted) (PP (IN by) (NP-LGS (VBN activated) (NNS T-lymphocytes))))) (VP (VBP modulate) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ immunosuppressive) (NN cytokine) (NN TGF-beta) (CD 2)) (PP (IN in) (NP (JJ glial) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-31 (NP (NN Coordination)) (PP (IN of) (NP (NP (DT the) (JJ immune) (NN response)) (PP (TO to) (NP (NP-COOD (NP (NN injury)) (CC or) (NP (NN disease))) (PP (IN in) (NP (DT the) (NN brain)))))))) (VP (VBZ is) (VP (VBN postulated) (S (VP (TO to) (VP (VB involve) (NP (NP (JJ bi-directional) (NN discourse)) (PP (IN between) (NP-COOD (NP (DT the) (JJ immune) (NN system)) (CC and) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (JJ cross) (NN communication)) (VP (VBZ involves) (NP-COOD (NP (NP (JJ soluble) (NNS mediators)) (, ,) (PP (VBG including) (NP (JJ various) (NN growth) (NNS factors)))) (, ,) (NP (NNS cytokines)) (, ,) (CC and) (NP (NNS neuropeptides)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-32 (NP (DT the) (NN supernatant)) (PP (IN from) (NP (VBN activated) (NNS T-lymphocytes)))) (VP (VBZ is) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB induce) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NP (NP (DT a) (JJ potent) (NN cytokine)) (, ,) (NP (NN TGF-beta) (CD 2))) (PP (IN in) (NP (JJ glial) (NNS cells)))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (VBG activating) (NN stimulus)) (VP (VBZ invokes) (NP (NP (NN signaling) (NNS mechanisms)) (ADJP (JJ distinct) (PP (IN from) (NP (JJ known) (NP-COOD (NP (NN kinase)) (CC or) (NP (NN protease))) (NNS pathways)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (NN TGF-beta) (CD 2) (NN transcription)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (NP (NN binding) (NN activity)) (PP (IN for) (NP (NP (DT an) (CD 80) (NN kDA) (JJ glial) (NN labile) (NN repressor) (NN protein)) (, ,) (NP (NN GLRP)) (, ,))) (PP (TO to) (NP (NP (DT a) (JJ responsive) (NN region)) (PP (IN within) (NP (DT the) (NN TFG-beta) (CD 2) (NN promoter)))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NN GLRP)) (VP (VBZ shares) (NP (DT some) (NNS characteristics)) (PP (IN with) (NP (DT the) (JJ inducible) (NN transcription) (NN factor) (NN AP-1)))))) (, ,) (NP-SBJ-33 (PRP it)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ distinct) (PP (IN from) (NP (JJ known) (NN AP-1) (NN family) (NNS members)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT These) (NNS data)) (PP (IN along) (IN with) (NP (NP (JJ previous) (NNS observations)) (VP (VBG demonstrating) (NP (NP (DT the) (JJ potent) (JJ immunosuppressive) (NN activity)) (PP (IN of) (NP (NN TGF-beta) (CD 2)))))))) (, ,) (VP (VBP support) (NP (NP (DT a) (NN model)) (PP (IN for) (NP (NP (DT a) (NN feedback) (NN mechanism)) (PP (IN between) (NP (DT the) (VBN activated) (NP-COOD (NP (NNS T-lymphocytes)) (CC and) (NP (NNS astrocytes))))) (PP (IN via) (NP (NN TGF-beta) (CD 2))) (SBAR (S (VP (TO to) (VP (VB regulate) (NP (DT the) (JJ immune) (NN response)))))))))) (. .)))
(TOP (NP (NP (ADJP-COOD (ADJP (NP (NN Vitamin) (NN D3-))) (CC and) (ADJP (JJ retinoic) (JJ acid-induced))) (JJ monocytic) (NN differentiation)) (: :) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (DT the) (NP-COOD (NP (JJ endogenous) (NN vitamin) (NN D3) (NN receptor)) (, ,) (NP (JJ retinoic) (NN acid) (NNS receptors)) (, ,) (CC and) (NP (NN retinoid) (NN X) (NNS receptors)))) (PP (IN in) (NP (NN U-937) (NNS cells))))) (. .))))
(TOP (S (NP-SBJ-COOD (NP (NP (JJ Retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 1,25) (NN alpha-dihydroxycholecalciferol)) (PRN (-LRB- -LRB-) (NP (NN VitD3)) (-RRB- -RRB-)))) (VP (VBP are) (NP-PRD (NP (JJ potent) (NNS regulators)) (PP (IN of) (NP (JJ hematopoletic) (NN differentiation))))) (. .)))
(TOP (S (RB Yet) (, ,) (NP-SBJ-23 (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN as) (TO to) (SBAR-COOD (SBAR (WHADVP-24 (WRB how)) (S (NP-SBJ (DT the) (NP-COOD (NP (NN RA)) (CC and) (NP (NN VitD3))) (NN receptor) (NN network)) (VP (VBZ operates) (PP (IN in) (NP (JJ hematopoietic) (NNS cells)))))) (, ,) (CC and) (SBAR (IN whether) (S (NP-SBJ (NN receptor) (NNS interactions)) (VP (MD can) (VP (VB explain) (NP (NP (DT the) (NN interplay)) (PP (IN between) (NP (DT the) (ADJP-COOD (ADJP (NP (NN RA-))) (CC and) (ADJP (JJ VitD3-signaling))) (NNS pathways))) (PP-TMP (IN during) (NP (NN differentiation)))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NP-COOD (NP (NN expression)) (, ,) (NP (NN DNA) (NN binding)) (, ,) (CC and) (NP (JJ transcriptional) (NN activity)))) (PP (IN of) (NP (NP (DT the) (JJ endogenous) (NP-COOD (NP (NN RA)) (CC and) (NP (NN VitD3))) (NNS receptors)) (PRN (-LRB- -LCB-) (NP-COOD (NP (NP (JJ retinoic) (NN acid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS RARs)) (-RRB- -RRB-))) (, ,) (NP (NP (NN retinoid) (NN X) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNS RXRs)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN VitD3) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN VDR)) (-RRB- -RRB-)))) (-RRB- -RCB-)))) (PP (IN in) (NP (NP (DT the) (NN U-937) (NN cell) (NN line)) (, ,) (SBAR (WHPP-25 (IN in) (WHNP (WDT which))) (S (NP-SBJ-COOD (NP (NN RA)) (CC and) (NP (NN VitD3))) (VP (VBP induce) (NP (JJ distinct) (JJ monocytic) (NN differentiation) (NNS pathways))))))))) (. .)))
(TOP (S (NP-SBJ (NN VitD3) (NN induction)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NN VDR/RXR) (JJ DNA-binding) (NNS complexes))) (PP (IN on) (NP-COOD (CC both) (NP (NN VitD3) (NN response) (NNS elements)) (CC and) (NP (NP (NN RA) (NN response) (NNS elements)) (PRN (-LRB- -LRB-) (NP (NNS RAREs)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-26 (JJ transcriptional) (NN activation)) (VP (VBD was) (VP (ADVP (RB only)) (VBN observed) (PP (IN from) (NP (DT a) (ADJP (NN VitD3) (NN response) (JJ element-driven)) (NN reporter) (NN construct))))) (. .)))
(TOP (S (NP-SBJ-27 (JJ Several) (JJ DNA-binding) (NNS complexes)) (VP (VBD were) (VP (VBN detected) (PP (IN on) (NP (NP (NNS RAREs)) (PP (IN in) (NP (JJ undifferentiated) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Stimulation)) (PP (IN by) (NP (NN RA)))) (VP (VBD resulted) (PP (IN in) (NP-COOD (NP (VBN increased) (ADJP (NN RAR) (NN beta/RXR)) (NN DNA) (NN binding)) (, ,) (NP (VBN activated) (JJ RARE-dependent) (NN transcription)) (, ,) (CC and) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NN RAR-beta))))))) (. .)))
(TOP (S (NP-SBJ-28 (NP (JJ Concomitant) (NN stimulation)) (PP (IN by) (NP (NN VitD3)))) (VP (VBD inhibited) (NP (NP (DT the) (JJ RA-stimulated) (NN formation)) (PP (IN of) (NP (ADJP (NN RAR) (NN beta/RXR)) (NNS heterodimers)))) (, ,) (S (VP (VBG favoring) (NP (NP (NN VDR/RXR) (NN binding)) (PP (TO to) (NP (DT the) (NN RARE))))))) (. .)))
(TOP (S (ADVP (RB Also)) (, ,) (NP-SBJ (NN VitD3)) (VP (VBD inhibited) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP-COOD (NP (NN CD23)) (CC and) (NP (NN CD49f))) (, ,) (NP (NP (JJ characteristic) (NNS markers)) (PP (IN of) (NP (JJ retinoid-induced) (NN U-937) (NN cell) (NN differentiation)))))))) (. .)))
(TOP (S (IN In) (NP (NN contrast)) (, ,) (NP-SBJ-COOD-29 (CC neither) (NP (DT the) (ADJP-COOD (ADJP (JJ RA-stimulated)) (, ,) (ADJP (JJ RARE-mediated))) (NN transcription)) (CC nor) (NP (DT the) (VBN induced) (NN RAR-beta) (NN expression))) (VP (VBD was) (VP (VBN suppressed) (PP (IN by) (NP-LGS (NN VitD3))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN VitD3)) (ADVP (RB selectively)) (VP (VBD inhibited) (NP-COOD (NP (DT the) (JJ retinoid-induced) (NN differentiation) (NN program)) (CONJP (CC but) (RB not)) (NP (DT the) (JJ RARE-mediated) (NN signal)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP-COOD (VP (VBP demonstrate) (NP (NP (DT a) (JJ complex) (NN role)) (PP (IN for) (NP (NN VitD3))) (PP (IN in) (S (VP (VBG modifying) (NP (DT the) (NN retinoid) (NN differentiation) (NN pathway))))))) (CC and) (VP (MD may) (VP (VB have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (JJ differentiation-inducing) (NN therapy)) (PP (IN of) (NP (JJ hematopoietic) (NNS tumors))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Inorganic) (NN lead)) (VP (VBZ activates) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (JJ primary) (JJ human) (JJ CD4+) (NN T) (NNS lymphocytes))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Inorganic) (NN lead)) (PRN (-LRB- -LRB-) (NP (NN Pb)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ ubiquitous) (JJ environmental) (NN contaminant)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBZ produces) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN on) (NP (ADJP-COOD (ADJP (JJ humoral)) (CC and) (ADJP (NN cell) (JJ mediated))) (JJ immune) (NNS responses))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (VBG underlying) (JJ molecular) (NN mechanism)) (PP (IN for) (NP (NP (NP (NN Pb) (POS 's)) (JJ complex) (NNS effects)) (PP (IN on) (NP (DT the) (JJ immune) (NN system)))))) (VP (VBP remain) (ADJP-PRD (JJ obscure))) (. .)))
(TOP (S (NP-SBJ-2 (NP (JJ Many)) (PP (IN of) (NP (NP (NP (NN Pb) (POS 's)) (NNS effects)) (PP (IN on) (NP (DT the) (JJ immune) (NN system)))))) (VP (MD could) (VP (VB be) (VP (VBN explained) (PP (IN through) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NN factor)) (, ,) (NP (NN NF-kappa) (NN B))))))))) (. .)))
(TOP (S (NP-SBJ (NN NF-kappa) (NN B)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (IN for) (NP (NN T) (NN lymphocyte) (NN function))))) (CC and) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ strong) (NN inducer)) (PP (IN of) (NP (NN HIV-LTR) (NN activation)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN Pb)) (PP (IN at) (NP (ADJP (RB physiologically) (JJ relevant)) (NNS concentrations)))) (VP (VBZ activates) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (JJ primary) (JJ human) (JJ CD4+) (NN T) (NNS lymphocytes)))))))) (. .)))
(TOP (S (NP-SBJ-3 (NP (JJ Pb-induced) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ is) (VP (VBN blocked) (PP (IN by) (NP-LGS (NP (NNS antibodies)) (PP (IN for) (NP-COOD (NP (NP-COOD (NP (NN p65)) (CC and) (NP (NN p50))) (NNS subunits)) (CONJP (CC but) (RB not)) (NP (NN cRel)))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-5 (NP (DT the) (NN p65:p50) (NN heterodimer)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN involved))))))))) (. .)))
(TOP (S (NP-SBJ-6 (NP (JJ Functional) (NN activation)) (PP (IN of) (NP (NN gene) (NN expression))) (PP (IN by) (NP (NN Pb)))) (VP (VBD was) (VP (VBN confirmed) (S (VP (VBG using) (NP (NP (JJ primary) (JJ CD4+) (NN T) (NNS cells)) (VP (VBN transfected) (PP (IN with) (NP (DT an) (ADJP (NP (NN NF-kappa) (NN B)) (JJ dependent)) (NN reporter) (NN gene) (NN construct))))))))) (. .)))
(TOP (S (NP-SBJ (NN Pb)) (VP (VBD did) (RB not) (VP (VB activate) (NP (NP (NN NF-kappa) (NN B)) (PP (IN in) (NP (CD 4) (JJ different) (NN T) (NN cell) (NNS lines)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (JJ lymphoid) (NN cell) (NNS lines)) (VP (MD may) (RB not) (VP (VB be) (NP-PRD (NP (JJ reliable) (NNS surrogates)) (PP (IN for) (NP (NP (DT the) (NN study)) (PP (IN of) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN in) (NP (JJ human) (NN T) (NNS cells)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (JJ molecular) (NN mediator)) (PP (IN of) (NP (JJ Pb-induced) (NN immunotoxicity))))))))) (. .)))
(TOP (S (NP-SBJ-90 (NP (JJ Calcium-dependent) (JJ immediate-early) (NN gene) (NN induction)) (PP (IN in) (NP (NNS lymphocytes)))) (VP (VBZ is) (VP (ADVP (RB negatively)) (VBN regulated) (PP (IN by) (NP-LGS (NN p21Ha-ras))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN induction)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ immediate-early)) (PRN (-LRB- -LRB-) (ADJP (JJ IE)) (-RRB- -RRB-))) (NN response) (NNS genes)) (, ,) (PP (JJ such) (IN as) (NP-COOD (NP (NN egr-1)) (, ,) (NP (NN c-fos)) (, ,) (CC and) (NP (NN c-jun)))) (, ,)))) (VP (VBZ occurs) (ADVP-TMP (RB rapidly)) (PP-TMP (IN after) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN T) (NNS lymphocytes)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN process)) (PP (IN of) (NP (NN activation)))) (VP (VBZ involves) (NP-COOD (NP (NN calcium) (NN mobilization)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN tyrosine) (NNS kinases)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN p21-LRB-ras-RRB-)) (, ,) (NP (DT a) (NN guanine) (NN nucleotide) (NN binding) (NN factor)) (, ,)) (VP (VBZ mediates) (NP (NN T-cell) (NN signal) (NN transduction)) (PP (IN through) (NP (ADJP-COOD (ADJP (JJ PKC-dependent)) (CC and) (ADJP (JJ PKC-independent))) (NNS pathways)))) (. .)))
(TOP (S (NP-SBJ-91 (NP (DT The) (NN involvement)) (PP (IN of) (NP (NN p21-LRB-ras-RRB-))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ calcium-dependent) (NNS signals)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN suggested) (PP (IN through) (NP (NP (NN analysis)) (PP (IN of) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-AT)))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP-COOD (NP (NP (DT the) (NNS inductions)) (PP (IN of) (NP (DT the) (JJ IE) (NNS genes))) (PP (IN in) (NN response) (TO to) (NP (NN calcium) (NNS signals))) (PP (IN in) (NP (NN Jurkat) (NNS cells))) (-LRB- -LRB-) (PP (IN in) (DT the) (NN presence) (IN of) (NP (VBN activated) (NN p21-LRB-ras-RRB-))) (-RRB- -RRB-)) (CC and) (NP (PRP$ their) (VBN correlated) (NNS consequences))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN expression)) (PP (IN of) (NP (VBN activated) (NN p21-LRB-ras-RRB-)))) (ADVP (RB negatively)) (VP (VBD regulated) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ IE) (NNS genes))) (PP (IN by) (NP (NN calcium) (NN ionophore))))) (. .)))
(TOP (S (NP-SBJ-92 (NP (DT This) (NN inhibition)) (PP (IN of) (NP (JJ calcium-activated) (JJ IE) (NN gene) (NN induction)))) (VP (VBD was) (VP (VBN reversed) (PP (IN by) (NP-LGS (NP (NN treatment)) (PP (IN with) (NP (NN cyclosporin) (NN A)))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NN calcineurin))) (PP (IN in) (NP (DT this) (NN regulation))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ later) (NN result)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (DT this) (NN activation) (NN pathway))) (PP (IN by) (NP (NN p21-LRB-ras-RRB-)))))) (VP (VBD was) (NP-PRD-COOD (NP (NP (NN down-regulation)) (PP (IN of) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN AP-1)))))) (CC and) (NP (NP (JJ subsequent) (JJ coordinate) (NNS reductions)) (PP (IN in) (NP-COOD (NP (NN IL-2) (NN gene) (NN expression)) (CC and) (NP (NN protein) (NN production))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN p2l-LRB-ras-RRB-)) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ essential) (NN mediator)) (PP (IN in) (S (VP (VBG generating) (NP (NP (ADJP-COOD (CONJP (RB not) (RB only)) (ADJP (JJ positive)) (CONJP (CC but) (RB also)) (ADJP (JJ negative))) (JJ modulatory) (NNS mechanisms)) (VP (VBG controlling) (NP (NP (DT the) (NN competence)) (PP (IN of) (NP (NN T) (NNS cells)))) (PP (IN in) (NN response) (TO to) (NP (JJ inductive) (NNS stimulations))))))))))))) (. .)))
(TOP (NP (NP (JJ CD14-mediated) (NN signal) (NN pathway)) (PP (IN of) (NP (NN Porphyromonas) (NN gingivalis) (NN lipopolysaccharide))) (PP (IN in) (NP (JJ human) (JJ gingival) (NNS fibroblasts))) (. .)))
(TOP (S (NP-SBJ (NP (NN Lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))) (VP (VBZ induces) (NP (NP (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS cytokines))) (PP (IN in) (NP (NNS monocytes/macrophages)))) (PP (IN via) (NP (NP (NN CD14)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NN LPS) (NNS receptors)))) (, ,) (SBAR (WHNP-74 (WDT which)) (S (VP (VBZ is) (VP (VBN expressed) (ADVP (RB predominantly)) (PP (IN in) (NP (DT these) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (SBAR (IN that) (S (NP-SBJ-76 (NP (NN Porphyromonas) (NN gingivalis) (NN LPS)) (PRN (-LRB- -LRB-) (NP (NN P-LPS)) (-RRB- -RRB-))) (ADVP (RB also)) (VP (VBZ is) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB induce) (NP (JJ inflammatory) (NNS cytokines)) (PP (IN in) (NP (JJ human) (JJ gingival) (NNS fibroblasts))))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (NP (PRP it))) (VP (VBZ is) (ADJP-PRD (JJ important)) (S-77 (VP-COOD (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP-SBJ-78 (NN CD14)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (JJ gingival) (NNS fibroblasts))))))))) (CC and) (VP (TO to) (VP (VB define) (NP (NP (DT the) (JJ P-LPS-mediated) (JJ signal-transducing) (NN mechanism)) (PP (IN in) (NP (DT the) (NNS cells))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD observed) (ADVP (RB unexpectedly)) (PP (IN by) (NP (UCP-COOD (ADJP (JJ immunohistochemical)) (, ,) (NP (NP (JJ Western) (NN blotting)) (PRN (-LRB- -LRB-) (NP (NN immunoblotting)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN Northern) (-LRB- -LRB-) (NN RNA) (-RRB- -RRB-) (NN blotting))) (NNS assays))) (SBAR (IN that) (S (NP-SBJ-79 (NN CD14)) (VP (VBZ is) (VP (VBN expressed) (PP (IN at) (NP (JJ high) (NN density))) (PP (IN in) (NP (JJ human) (JJ gingival) (NNS fibroblasts)))))))) (. .)))
(TOP (S (NP-SBJ-80 (NP (JJ P-LPS-induced) (NN expression)) (PP (IN of) (NP (DT the) (NP (NP (NN monocyte) (NN chemoattractant) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN MCP-1)) (-RRB- -RRB-))) (NN gene))) (PP (IN in) (NP (DT the) (NNS cells)))) (VP-COOD (VP (VBD was) (VP (VBN inhibited) (ADVP (RB markedly)) (PP (IN by) (NP-LGS (NP (NN treatment)) (PP (IN with) (NP (JJ anti-human) (NN CD14) (NN antibody))))))) (CC and) (VP (VBD was) (VP (ADVP (RB completely)) (VBN inhibited) (PP (IN by) (NP-LGS (NP (NN herbimycin) (NN A)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN tyrosine) (NN kinase))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN inhibitor)) (ADVP (RB also)) (VP (ADVP (RB dramatically)) (VBD inhibited) (NP (NP-COOD (NP (NP (NN monocyte) (JJ chemotactic) (NN activity)) (PP (IN of))) (CC and) (NP (NP (NN MCP-1) (NN production)) (PP (IN by)))) (NP-104 (DT the) (NNS cells)))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-82 (NP (JJ P-LPS-induced) (NN expression)) (PP (IN of) (NP (DT the) (JJ MCP-1) (NN gene))) (PP (IN in) (NP (DT the) (NNS cells)))) (ADVP (RB also)) (VP (VBD was) (VP (VBN blocked) (PP (IN by) (NP-LGS (NP (NNS inhibitors)) (PP (IN of) (NP (NP (CD two) (NN transcription) (NNS factors)) (, ,) (NP (ADVP (FW i.e.)) (, ,) (NP-COOD (NP (NP (NN curcumin)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN AP-1)))) (, ,)) (CC and) (NP (NP (NN pyrolidine) (NN dithiocarbamate)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN NF-kappaB))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (NNS inhibitors)) (VP (VBD inhibited) (NP (NN monocyte) (JJ chemotactic) (NN activity)) (PP (IN in) (NP (NP (DT the) (NN culture) (JJ supernatant)) (PP (IN of) (NP (JJ P-LPS-treated) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (NN Gel) (NN shift) (NN mobility) (NN assay)) (VP (VBD showed) (NP (NP (NN stimulation)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN NF-kappaB))) (NNS contents))) (PP (IN in) (NP (JJ P-LPS-treated) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN study)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ first)) (SBAR (S (VP-COOD (VP (TO to) (VP (VB demonstrate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN CD14))) (PP (IN in) (NP (JJ human) (JJ gingival) (NNS fibroblasts)))))) (CC and) (VP (TO to) (VP (VB show) (SBAR (IN that) (S (NP-SBJ-84 (NP (DT the) (JJ signal-transducing) (NN pathway)) (PP (IN of) (NP (NN P-LPS))) (PP (IN in) (NP (DT the) (NNS cells)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NN CD14)))))))))))))) (. .)))
(TOP (S (NP-SBJ-69 (NP (NNS Tyrosines) (NP-COOD (NP (CD 113)) (, ,) (NP (CD 128)) (, ,) (CC and) (NP (CD 145)))) (PP (IN of) (NP (NN SLP-76)))) (VP (VBP are) (VP (VBN required) (PP (IN for) (NP (NP (JJ optimal) (NN augmentation)) (PP (IN of) (NP (NN NFAT) (NN promoter) (NN activity))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN SLP-76)) (PRN (-LRB- -LRB-) (NP (NP (NN SH2) (NN domain) (NN leukocyte) (NN protein)) (PP (IN of) (NP (CD 76) (NN kDa)))) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (ADJP (RB recently) (VBN identified)) (NN substrate)) (PP (IN of) (NP (DT the) (JJ TCR-stimulated) (NN protein) (NN tyrosine) (NNS kinases))) (SBAR (WHNP-70 (WDT that)) (S (VP (VBZ functions) (PP (IN in) (NP (NP (DT the) (NN signal) (NN transduction) (NN cascade)) (VP (VBG linking) (NP (DT the) (NN TCR)) (PP (IN with) (NP (NN IL-2) (NN gene) (NN expression))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (NN engagement)) (PP (IN of) (NP (DT the) (NN TCR)))) (VP (VBZ results) (PP (IN in) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN SLP-76))) (PP (IN in) (NP (PRP$ its) (JJ amino-terminal) (JJ acidic) (NN region))))))))) (. .)))
(TOP (S (NP-SBJ-72 (NP (CD Two) (NNS tyrosines)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Y113)) (CC and) (NP (NN Y128))) (-RRB- -RRB-))) (VP-COOD (VP (VBP fall) (PP (IN within) (NP (DT an) (JJ identical) (CD five) (JJ amino-acid) (NN motif)))) (CC and) (VP (VBP are) (VP (VBN shown) (VP (VP (TO to) (VP (VB be) (VP (VBN phosphorylated) (PP-TMP (IN upon) (NP (NN TCR) (NN ligation)))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (NN mutation)) (PP (IN of) (NP-COOD (CC either) (NP (NN Y113)) (CC and) (NP (NN Y128))))) (VP (VBZ has) (NP (DT a) (JJ minimal) (NN effect)) (PP (IN on) (NP (NN SLP-76) (NN function)))))) (, ,) (NP-SBJ (NP (NN mutation)) (PP (IN of) (NP (DT both) (NNS residues)))) (VP (VBZ decreases) (ADVP (RB significantly)) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NN SLP-76))) (S-74 (VP (TO to) (VP (VB promote) (NP (NN T) (NN cell) (NN activation))))))) (. .)))
(TOP (S (NP-SBJ-75 (NP (NP (DT A) (JJ third) (NN tyrosine)) (PP (IN within) (NP (DT the) (JJ amino-terminal) (NN region)))) (PRN (-LRB- -LRB-) (NP (NN Y145)) (-RRB- -RRB-))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP-PRD (DT the) (ADJP (RBS most) (JJ important))) (PP (IN for) (NP (JJ optimal) (NN SLP-76) (NN function))) (, ,) (SBAR (IN as) (S (S-SBJ (VP (VBG altering) (NP (NP (PRP it)) (ADVP (RB alone))) (PP (TO to) (NP (NN phenylalanine))))) (VP (VBZ has) (NP (DT a) (JJ potent) (NN impact)) (PP (IN on) (NP (NP (NN SLP-76) (NN augmentation)) (PP (IN of) (NP (NN NFAT) (NN promoter) (NN activity)))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD-79 (NP (NP (DT The) (JJ catalytic) (NN domain)) (PP (IN of) (NP (NN pp56-LRB-lck-RRB-)))) (, ,) (CONJP (CC but) (RB not)) (NP (PRP$ its) (JJ regulatory) (NN domain)) (, ,)) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (PP (IN for) (S (VP (VBG inducing) (NP (NN IL-2) (NN production))))))) (. .)))
(TOP (S (NP-SBJ-80 (DT The) (JJ lymphoid) (NN src) (NN kinase) (NN pp56-LRB-lck-RRB-)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (JJ different) (NN T) (NN lymphocyte) (NNS responses)) (, ,) (PP (VBG including) (NP-COOD (NP (NP (JJ CD4-mediated) (NN enhancement)) (PP (IN of) (NP (JJ Ag-induced) (NN T) (NN cell) (NN activation)))) (, ,) (NP (JJ early) (NN T) (NN cell) (NN differentiation)) (, ,) (NP (NP (NN induction)) (PP (IN of) (NP (NN IL-2) (NN production)))) (, ,) (CC and) (NP (NN cytotoxicity))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (VP (VBN assumed) (SBAR (IN that) (S (NP-SBJ-81 (NN pp56-LRB-lck-RRB-)) (VP (VBZ acts) (PP (IN on) (NP (DT these) (NNS processes))) (PP (IN by) (S (VP (VBG phosphorylating) (NP (NNS substrates)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (PRP it)) (VP (VBZ has) (VP (VBN been) (ADVP-TMP (RB recently)) (VP (VBN reported) (SBAR (IN that) (S (NP-SBJ (DT the) (NN NH2) (JJ regulatory) (NN domain)) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (S (VP (TO to) (VP (VB mediate) (NP (NN CD4) (JJ accessory) (NN function)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (NP-SBJ (PRP we)) (VP (VBP address) (NP (NP (NP (DT the) (NN contribution)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ regulatory)) (CC and) (ADJP (JJ catalytic))) (NNS domains)) (PP (IN of) (NP (NN pp56-LRB-lck-RRB-))))) (PP (TO to) (NP (NP (DT another) (NN function)) (PP (IN of) (NP (DT this) (NN enzyme))) (ADJP (JJ independent) (PP (IN of) (NP (NN CD4))))))) (: :) (NP (JJ TCR-induced) (NN IL-2) (NN production)))) (. .)))
(TOP (S-COOD (S (NP-SBJ-83 (NP (CD Two) (NN pp56-LRB-lck-RRB-) (NNS mutants)) (VP (VBG lacking) (NP-COOD (CC either) (NP (DT the) (JJ entire) (JJ catalytic) (NN domain)) (CC or) (NP (DT the) (JJ entire) (NN NH2) (JJ regulatory) (NN domain))))) (VP (VBD were) (VP (VBN generated)))) (, ,) (CC and) (S (NP-SBJ-84 (PRP$ their) (NNS abilities) (S (VP (TO to) (VP (VB trigger) (NP (NP (NN transactivation)) (PP (IN of) (NP (NP (DT the) (JJ TCR-regulated) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NF-AT)) (-RRB- -RRB-))) (NN region)) (PP (IN of) (NP (DT the) (NN IL-2) (NN promoter)))))))))) (VP (VBD were) (VP (VBN compared)))) (. .)))
(TOP (S (NP-SBJ-85 (NP (RB Only) (NP-COOD (NP (DT the) (JJ catalytic)) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (NN NH2) (JJ regulatory)) (, ,)) (NP-87 (NN domain))) (PP (IN of) (NP (NN pp56-LRB-lck-RRB-)))) (VP (VBD was) (ADJP-PRD (JJ able) (S (VP-COOD (VP (TO to) (VP (VB induce) (NP (NN NF-AT) (NN region) (NN transactivation)) (PP (IN on) (NP (PRP$ its) (JJ own))))) (CC and) (VP (TO to) (VP (VB cooperate) (PP (IN with) (NP (JJ other) (JJ intracellular) (NNS signals))) (S (VP (TO to) (VP (VB trigger) (NP (DT this) (NN response))))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-88 (NP (DT the) (JJ catalytic) (NN domain)) (PP (IN of) (NP (NN pp56-LRB-lck-RRB-)))) (VP (VBD was) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB induce) (NP (NN IL-2) (NN cytokine) (NN production)) (PP (TO to) (NP (NP (DT an) (NN extent)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (JJ wild-type) (NN pp56-LRB-lck-RRB-))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP-SBJ-89 (NP (JJ different) (NNS domains)) (PP (IN of) (NP (DT the) (NN pp56-LRB-lck-RRB-) (NN molecule)))) (VP (VBP contribute) (S (VP (TO to) (VP (VB regulate) (NP (JJ distinct) (JJ biologic) (NNS functions))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN fact))) (, ,) (SBAR (IN while) (S (NP-SBJ (DT the) (NN NH2) (JJ regulatory) (NN domain)) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (S (VP (TO to) (VP (VB mediate) (NP (NN CD4) (JJ accessory) (NN function))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (NP-SBJ-91 (NP (DT the) (JJ catalytic) (NN domain)) (PP (IN of) (NP (NN pp56-LRB-lck-RRB-)))) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN IL-2) (NN production))))))) (, ,) (S (VP (VBG mimicking) (NP (NN TCR) (NN ligation))))))) (. .)))
(TOP (NP (NP (NP-COOD (NP (NN Isolation)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (JJ murine) (NN fra-1))) (: :)) (S (NP-SBJ (NP (NN induction)) (VP (VBN mediated) (PP (IN by) (NP-LGS-COOD (NP (NN CD40)) (CC and) (NP (NN surface) (NN Ig)))))) (VP (VBZ is) (ADJP-PRD (NP (NN protein) (NN kinase) (NN C)) (JJ dependent))) (. .))))
(TOP (S (NP-SBJ-92 (NP (DT The) (JJ murine) (NN fra-1) (NN gene)) (, ,) (VP (VBG encoding) (NP (JJ Fos-related) (NN Ag) (CD 1))) (, ,)) (VP (VBD was) (VP-COOD (VP (VBN isolated) (PP (IN from) (NP (DT a) (JJ splenic) (NN cDNA) (NN library)))) (CC and) (VP (VBN sequenced)))) (. .)))
(TOP (S (NP-SBJ (JJ Murine) (NN fra-1)) (VP (VBD was) (ADJP-PRD (RB highly) (JJ homologous) (PP (TO to) (NP (UCP-COOD (NP (NN rat)) (CC and) (ADJP (JJ human))) (NN fra-1))))) (. .)))
(TOP (S (NP-SBJ-93 (NP (NN Oligonucleotide) (NNS primers)) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ murine) (NN sequence))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB construct) (NP (NP (DT a) (JJ quantitative) (NN reverse) (NN transcription-PCR) (NN assay)) (PP (IN for) (NP (NN gene) (NN expression))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN B) (NN lymphocyte) (NN stimulation)) (PP (IN via) (NP (NP-COOD (CC both) (NP (NN CD40)) (CC and) (NP (NP (NN surface) (NN Ig)) (PRN (-LRB- -LRB-) (NP (NN sIg)) (-RRB- -RRB-)))) (NNS receptors)))) (ADVP (RB substantially)) (VP (VBD induced) (NP (NN fra-1) (NN expression)))) (, ,) (CC and) (S (PP (IN for) (NP (DT both) (NNS receptors))) (, ,) (NP-SBJ (NN induction)) (VP (VBD was) (ADJP-PRD (NP (NP (NN protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (JJ dependent)))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBZ contrasts) (PP (IN with) (NP (NP (NN induction)) (PP (IN of) (NP (NN c-fos))) (PP (IN by) (NP-COOD (CC both) (NP (NN CD40)) (CC and) (NP (NN sIg)))) (, ,) (SBAR (WHNP-96 (WDT which)) (S (VP-COOD (VP (VBZ is) (ADJP-PRD (NN PKC) (JJ independent))) (CC and) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ-97 (NN CD40)) (VP (VBZ is) (ADJP-PRD (JJ capable) (PP (IN of) (S (VP (VBG signaling) (PP (IN through) (NP-COOD (NP (NN PKC)) (CC or) (NP (DT a) (ADJP (RB closely) (JJ related)) (NN kinase)))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Induction)) (PP (IN of) (NP (NN fra-1))) (PP-TMP (VBG following) (NP (NP (NN engagement)) (PP (IN of) (NP (NN CD40)))))) (VP (VBD did) (RB not) (VP (VB require) (NP (NN protein) (NN synthesis)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ PKC-dependent) (NN linkage)) (PP (IN between) (NP-COOD (NP (NN CD40)) (CC and) (NP (NN fra-1))))) (VP (VBZ is) (ADJP-PRD (JJ direct))))))))) (. .)))
(TOP (S (NP-SBJ (JJ CD40-mediated) (NN fra-1) (NN induction)) (VP (VBD did) (VP (VB require) (NP (NN tyrosine) (NN kinase) (NN activity)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-100 (NN CD40)) (, ,) (PP (IN like) (NP (NN sIg))) (, ,) (VP (MD may) (VP (VB employ) (NP (NN PKC)) (PP (IN in) (S (VP (VBG producing) (NP (JJ select) (NNS outcomes))))))))) (, ,) (SBAR (IN that) (S (NP-SBJ (JJ individual) (NN B) (NN cell) (NNS receptors)) (VP (MD may) (VP (VB signal) (NP (JJ downstream) (NNS events)) (PP (IN via) (NP (ADJP-COOD (CC both) (ADJP (JJ PKC-dependent)) (CC and) (ADJP (JJ PKC-independent))) (NNS pathways))))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ-98 (JJ multiple) (NN signal) (NN transduction) (NNS pathways)) (VP (MD may) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB activate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (ADJP (RB closely) (JJ related)) (NNS genes)))))))))))))) (. .)))
(TOP (NP (NP (NP (NN Apoptosis) (NN signaling) (NNS pathways)) (PP (IN in) (NP (JJ normal) (NN T) (NNS cells))) (: :)) (NP (NP (JJ differential) (NN activity)) (PP (IN of) (NP-COOD (NP (NN Bcl-2)) (CC and) (NP (JJ IL-1beta-converting) (NN enzyme) (NN family) (NN protease) (NNS inhibitors)))) (PP (IN on) (NP (ADJP-COOD (ADJP (NP (NN glucocorticoid-))) (CC and) (ADJP (JJ Fas-mediated))) (NN cytotoxicity))) (. .))))
(TOP (S (NP-SBJ-78 (JJ Fas-mediated) (NN apoptosis)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (DT the) (JJ immune) (NN response)) (PP (IN in) (NP (JJ peripheral) (NN T) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Restimulation)) (PP (IN of) (NP (NN T) (NN cell) (NNS blasts)))) (VP (VBZ up-regulates) (NP-COOD (NP (NN Fas)) (CC and) (NP (NN Fas) (NN ligand) (NN expression))) (, ,) (PP (IN with) (S (NP-SBJ (JJ subsequent) (NN interaction)) (VP (VBG leading) (PP (TO to) (NP (NN cell) (NN death))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Overexpression)) (PP (IN of) (NP (NN Bcl-2))) (PP (IN in) (NP (NN tumor) (NNS cells)))) (VP (VBZ blocks) (NP (NP (NN apoptosis)) (VP (VBN induced) (PP (IN by) (NP-LGS (JJ many) (NNS stimuli))))))) (, ,) (CC but) (S (NP-SBJ-79 (NP (NN inhibition)) (PP (IN of) (NP (JJ Fas-mediated) (NN killing)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (ADVP-TMP (RB consistently)) (VBN observed))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN behavior)) (PP (IN of) (NP (NN Bcl-2))) (PP (IN in) (NP (JJ normal) (NNS cells))))))) (, ,) (NP-SBJ-80 (NN T) (NN cell) (NNS blasts)) (VP (VBD were) (VP (ADVP-TMP (RB transiently)) (VBN transfected) (PP (IN with) (NP-COOD (NP (NN Bcl-2)) (CC and) (NP (JJ related) (NN gene) (NNS products)))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (JJ apoptotic) (NN signaling))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (JJ Transient) (NN overexpression)) (PP (IN of) (NP (NN Bcl-2))) (PP (IN in) (NP (UCP-COOD (NP (NN mouse)) (CC and) (ADJP (JJ human))) (NN T) (NN cell) (NNS blasts)))) (VP (VBD did) (RB not) (VP (VB block) (NP (JJ Fas-mediated) (NN apoptosis))))) (, ,) (IN whereas) (S (NP-SBJ-81 (ADJP-COOD (ADJP (NP (NN etoposide-))) (CC and) (ADJP (JJ glucocorticoid-induced))) (NN cytotoxicity)) (VP (VBD was) (VP (ADVP (RB potently)) (VBN inhibited)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP-COOD (NP (NN Bcl-xL)) (CC and) (NP (NN adenovirus) (NN E1B) (NN 19K))))) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (JJ anti-Fas) (NN killing))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (JJ interleukin-1beta-converting) (NN enzyme) (NN family) (NN protease) (NNS inhibitors) (NP-COOD (NP (NN Ac-DEVD-CHO)) (CC and) (NP (NN CrmA)))) (VP (VBD blocked) (NP (JJ Fas-mediated) (NN apoptosis))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (JJ peripheral) (NN T) (NNS cells)) (VP (VBP use) (NP (NP (JJ distinct) (NN apoptosis) (NN signaling) (NNS pathways)) (PP (IN with) (NP (NP (JJ differential) (NN sensitivity)) (PP (TO to) (NP-COOD (NP (NN Bcl-2)) (CC and) (NP (JJ interleukin-1beta-converting) (NN enzyme) (NN family) (NN protease) (NNS inhibitors))))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (NN T) (NNS cells)) (ADVP (RB normally)) (VP (VBP express) (NP-COOD (NP (NN Bcl-2)) (CC and) (NP (NN Bcl-xL))) (PP-TMP (VBG following) (NP (NN activation)))))) (, ,) (NP-SBJ (PRP$ their) (NN inability) (S (VP (TO to) (VP (VB block) (NP (JJ Fas-mediated) (NN apoptosis)))))) (VP (MD may) (VP (VB allow) (PP (IN for) (NP-COOD (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (JJ self-reactive) (NNS cells)))) (CC and) (NP (NP (DT the) (JJ appropriate) (NN regulation)) (PP (IN of) (NP (JJ immune) (NNS responses)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Comparative) (NN analysis)) (VP (VBZ identifies) (NP (NP (VBN conserved) (ADJP (NN tumor) (NN necrosis) (NN factor) (JJ receptor-associated)) (NN factor) (CD 3) (NN binding) (NNS sites)) (PP (IN in) (NP (DT the) (ADJP-COOD (ADJP (JJ human)) (CC and) (ADJP (JJ simian))) (JJ Epstein-Barr) (NN virus) (NN oncogene) (NN LMP1))))) (. .)))
(TOP (S (NP-SBJ-57 (JJ Nonhuman) (NNS primates)) (VP (VBP are) (VP (ADVP (RB naturally)) (VBN infected) (PP (IN with) (NP (NP (DT a) (JJ B-lymphotropic) (NN herpesvirus)) (ADJP (ADVP (RB closely)) (JJ related) (PP (TO to) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (JJ simian) (NNS EBV)) (VP (VBP share) (NP (JJ considerable) (ADJP-COOD (ADJP (JJ genetic)) (, ,) (ADJP (JJ biologic)) (, ,) (CC and) (ADJP (JJ epidemiologic))) (NNS features)) (PP (IN with) (NP (JJ human) (NN EBV))) (, ,) (PP (VBG including) (NP (JJ virus-induced) (NN tumorigenesis)))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (ADJP-COOD (ADJP (JJ latent)) (, ,) (ADJP (JJ transformation-associated))) (JJ viral) (NNS genes)) (VP (VBP demonstrate) (NP (NP (JJ marked) (NN sequence) (NN divergence)) (PP (IN among) (NP (NNS species)))) (PP (IN despite) (NP (DT the) (VBN conserved) (NNS functions)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN cloned) (NP (DT the) (NP (NP (JJ latent) (NN membrane) (NN protein) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN LMP1)) (-RRB- -RRB-))) (NNS homologs)) (PP (IN from) (NP-COOD (NP (NP (NP (DT the) (JJ simian) (NN EBV)) (VP (ADVP (RB naturally)) (VBG infecting) (NP-101 (NNS baboons)))) (PRN-102 (-LRB- -LRB-) (NP (NP (NN cercopithicine) (NN herpesvirus) (CD 12)) (, ,) (NP (NN herpesvirus) (NN papio))) (-RRB- -RRB-))) (CC and) (NP (NP=101 (NN rhesus) (NNS monkeys)) (PRN=102 (-LRB- -LRB-) (NP (NN cercopithicine) (NN herpesvirus) (CD 15)) (-RRB- -RRB-))))) (PP (IN for) (NP (NP (DT a) (JJ comparative) (NN study)) (PP (IN with) (NP (DT the) (JJ human) (NN EBV) (NN oncogene))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-58 (DT The) (NN transmembrane) (NNS domains)) (VP (VBP are) (VP (ADVP (RB well)) (VBN conserved)))) (, ,) (CC but) (S (NP-SBJ (EX there)) (VP (VBZ is) (NP-PRD (NP (JJ striking) (NN sequence) (NN divergence)) (PP (IN of) (NP (NP (DT the) (JJ carboxy-terminal) (JJ cytoplasmic) (NN domain)) (ADJP (JJ essential) (PP (IN for) (NP-COOD (NP (NN B-cell) (NN immortalization)) (CC and) (NP (NP (NN interaction)) (PP (IN with) (NP (DT the) (NN tumor) (NN necrosis) (NN factor) (NN receptor) (NN signaling) (NN pathway)))))))))))) (. .)))
(TOP (S (ADVP (RB Nevertheless)) (, ,) (NP-SBJ (DT the) (JJ simian) (NN EBV) (NNS LMP1s)) (VP (VBP retain) (NP (NP (JJS most) (NNS functions)) (PP (IN in) (NN common) (IN with) (NP (NN EBV) (NN LMP1))) (, ,) (PP (VBG including) (NP (DT the) (NN ability) (S (VP-COOD (VP (TO to) (VP (VB induce) (NP (NN NF--LRB-kappa-RRB-B) (NN activity)) (PP (IN in) (NP (JJ human) (NNS cells))))) (, ,) (VP (TO to) (VP (VB bind) (NP (NP (DT the) (ADJP (NN tumor) (NN necrosis) (JJ factor-associated)) (NN factor) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN TRAF3)) (-RRB- -RRB-))) (ADVP (FW in) (FW vitro)))) (, ,) (CC and) (VP (TO to) (VP (VB induce) (NP (NP (NN expression)) (PP (IN of) (NP (NP (ADJP (NN tumor) (NN necrosis) (JJ factor-responsive)) (NNS genes)) (, ,) (PP (JJ such) (IN as) (NP (NN ICAM1))) (, ,)))) (PP (IN in) (NP (JJ human) (NN B) (NNS lymphocytes))))))))))) (. .)))
(TOP (S (NP-SBJ-59 (NP (JJ Multiple) (NN TRAF3) (NN binding) (NNS sites)) (VP (VBG containing) (NP (DT a) (NN PXQXT/S) (NN core) (NN sequence)))) (VP (MD can) (VP (VB be) (VP (VBN identified) (PP (IN in) (NP (DT the) (JJ simian) (NN EBV) (NNS LMP1s))) (PP (IN by) (NP-LGS (DT an) (ADJP (FW in) (FW vitro)) (NN binding) (NN assay)))))) (. .)))
(TOP (S (NP-SBJ (DT A) (JJ PXQXT/S-containing) (NN sequence)) (VP-COOD (VP (VBZ is) (ADVP (RB also)) (ADJP-PRD (JJ present) (PP (IN in) (NP (NP (NP (DT the) (JJ cytoplasmic) (NN domain)) (PP (IN of) (NP (DT the) (NP (NN Hodgkin) (POS 's)) (NN disease) (NN marker)))) (, ,) (NP (NN CD30)) (, ,))))) (CC and) (VP (VBZ binds) (NP (NN TRAF3)) (ADVP (FW in) (FW vitro)))) (. .)))
(TOP (S (NP-SBJ-60 (NP (DT The) (JJ last) (CD 13) (NN amino) (NNS acids)) (VP (VBG containing) (NP (DT a) (NN PXQXT/S) (NN sequence)))) (VP (VP-COOD (VP (VBP are) (VP (ADVP (RB highly)) (VBN conserved) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ human)) (CC and) (ADJP (JJ simian))) (NN EBV) (NN LMP1))))) (CC but) (VP (VBP do) (RB not) (VP (VB bind) (NP (NN TRAF3))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ distinct) (NN role)) (PP (IN for) (NP (NP (DT this) (VBN conserved) (NN region)) (PP (IN of) (NP (NN LMP1))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (DT The) (VBN conserved) (NN TRAF3) (NN binding) (NNS sites)) (PP (IN in) (NP (NN LMP1)))) (CC and) (NP (DT the) (NN CD30) (NP (NN Hodgkin) (POS 's)) (NN disease) (NN marker))) (VP (VBZ provides) (NP (JJ further) (NN evidence) (SBAR (IN that) (S (NP-SBJ (DT a) (JJ TRAF3-mediated) (NN signal) (NN transduction) (NN pathway)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ important) (PP (IN in) (NP (JJ malignant) (NN transformation)))))))))) (. .)))
(TOP (NP (NP (JJ Rapid) (NN shuttling)) (PP (IN of) (NP (NN NF-AT))) (PP (IN in) (NP-COOD (NP (NP (NN discrimination)) (PP (IN of) (NP (NN Ca2+) (NNS signals)))) (CC and) (NP (NN immunosuppression)))) (. .)))
(TOP (S (NP-SBJ-61 (NNS Cells)) (VP (VBP need) (S (VP (TO to) (VP (VB distinguish) (PP (IN between) (NP-COOD (NP (NP (JJ transient) (NN Ca2+) (NNS signals)) (SBAR (WHNP-62 (WDT that)) (S (VP (VBP induce) (NP (NP (NNS events)) (PP (JJ such) (IN as) (NP-COOD (NP (NN muscle) (NN contraction)) (, ,) (NP (NN secretion)) (, ,) (NP (NN adhesion)) (CC and) (NP (JJ synaptic) (NN transmission))))))))) (, ,) (CC and) (NP (NP (JJ sustained) (NN Ca2+) (NNS signals)) (SBAR (WHNP-63 (WDT that)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NN cell) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN differentiation)))))))))))))))) (. .)))
(TOP (S (NP-SBJ-65 (NP (DT The) (JJ latter) (NN class)) (PP (IN of) (NP (NNS events)))) (VP (VBZ is) (VP (VBN blocked) (PP (IN in) (NP (NNS lymphocytes))) (PP (IN by) (NP-LGS (NP (DT the) (JJ immunosuppressive) (NNS drugs) (NP-COOD (NP (NN cyclosporin) (NN A)) (CC and) (NP (NN FK506)))) (, ,) (SBAR (WHNP-66 (WDT which)) (S (VP (VBP inhibit) (NP (NP (NN calcineurin)) (, ,) (NP (NP (DT a) (JJ Ca2+-activated) (NN serine/threonine) (NN phosphatase)) (ADJP (JJ necessary) (PP (IN for) (NP (NP (DT the) (JJ nuclear) (NN import)) (PP (IN of) (NP (NN NF-AT) (NN transcription) (NNS factors))))))))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ-COOD-67 (NP (NP (JJ sustained) (JJ high) (NNS concentrations)) (PP (IN of) (NP (NN Ca2+)))) (, ,) (CONJP (CC but) (RB not)) (NP (JJ transient) (NNS pulses)) (, ,)) (VP (VBP are) (VP (VBN required) (S (VP (TO to) (VP (VB maintain) (NP (NP (NN NF-AT) (NN transcription) (NNS factors)) (PP (IN in) (NP (NP (DT the) (NN nucleus)) (, ,) (SBAR (WHADVP-68 (WRB where)) (S (NP-SBJ (PRP they)) (VP (VBP participate) (PP (IN in) (NP (NP (JJ Ca2+-dependent) (NN induction)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN required) (PP (IN for) (NP (NN lymphocyte) (NP-COOD (NP (NN activation)) (CC and) (NP (NN proliferation)))))))))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP-COOD (NP (NN overexpression)) (CC and) (NP (JJ constitutive) (JJ nuclear) (NN localization))) (PP (IN of) (NP (NP-COOD (NP (NN NF-AT)) (, ,) (CONJP (CC but) (RB not)) (NP-COOD (NP (NN Jun)) (, ,) (NP (NN Fos)) (, ,) (NP (NN NF-kappaB)) (, ,) (NP (NN Oct)) (CC or) (NP (NN Ets)))) (NN family) (NNS members))) (, ,)) (VP (VBZ renders) (S (NP-SBJ (NP (DT the) (NN interleukin-2) (NN enhancer)) (PP (IN in) (NP (NN Jurkat) (NN T) (NNS lymphocytes)))) (ADJP-PRD (JJ resistant) (PP (TO to) (NP-COOD (NP (NN FK506)) (CC and) (NP (NN cyclosporin) (NN A))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (NP-SBJ (NP (DT a) (JJ primary) (NN effect)) (PP (IN of) (NP (DT these) (JJ immunosuppressive) (NNS reagents)))) (VP (VBZ is) (S-PRD (VP (TO to) (VP (VB control) (NP (NP (DT the) (JJ subcellular) (NN localization)) (PP (IN of) (NP (NP (DT the) (NN NF-AT) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors)))))))))) (. .)))
(TOP (S (S (NP-SBJ (NNS Interferons)) (VP (VBP induce) (NP (ADJP-COOD (ADJP (JJ normal)) (CC and) (ADJP (JJ aberrant))) (NN retinoic-acid) (NNS receptors) (NN type) (NN alpha)) (PP (IN in) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS cells)))) (: :)) (NP (NP (NN potentiation)) (PP (IN of) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (JJ retinoid-dependent) (NN differentiation) (NNS markers))))) (. .))))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (DT the) (ADJP (ADJP (JJ acute) (JJ promyelocytic)) (PRN (-LRB- -LRB-) (ADJP (NN APL)) (-RRB- -RRB-))) (NN cell) (NN line) (NN NB4))) (PP (IN with) (NP-COOD (NP (NP (NN interferon) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN IFN-LRB-alpha-RRB-)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP-COOD (NP (NN IFN-LRB-beta-RRB-)) (CC and) (NP (NN gamma))) (, ,)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS transcripts)) (VP (VBG coding) (PP (IN for) (NP-COOD (NP (NP (JJ retinoic-acid) (NN receptor) (NN type) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN RAR-LRB-alpha-RRB-)) (-RRB- -RRB-))) (CC and) (NP (DT the) (JJ leukemia-specific) (JJ retinoic) (NN acid) (NN receptor) (NN PML-RAR)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP-SBJ (JJ Transcriptional) (NN induction)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN RAR-LRB-alpha-RRB-)) (CC and) (NP (NN PML-RAR))) (NNS mRNAs)))) (VP (VBZ is) (ADJP-PRD (JJ rapid)))) (CC and) (S (NP-SBJ-19 (PRP it)) (VP (VBZ is) (VP (VBN parallelled) (PP (IN by) (NP-LGS (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ corresponding) (NNS proteins)))))))) (. .)))
(TOP (S (NP-SBJ-20 (NP (NN Up-regulation)) (PP (IN of) (NP (NP-COOD (NP (NN RAR-LRB-alpha-RRB-)) (CC and) (NP (NN PML-RAR))) (NN gene) (NN expression))) (PP (IN by) (NP (NN IFN-LRB-alpha-RRB-)))) (VP (VBZ is) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NP (DT a) (JJ strong) (NN potentiation)) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (CD 2) (JJ retinoid-dependent) (JJ granulocytic) (NNS markers)) (, ,) (FW i.e.) (, ,) (NP-COOD (NP (JJ granulocyte-colony-stimulating) (NN factor) (NN receptor) (NN mRNA)) (CC and) (NP (NN leukocyte) (NN alkaline) (NN phosphatase))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NN IFN-LRB-alpha-RRB-)) (VP (VBZ does) (RB not) (VP (VB have) (NP (DT any) (NNS effects)) (PP (IN on) (NP (NP (DT the) (JJ retinoid-dependent) (NN regulation)) (PP (IN of) (NP (DT the) (JJ myeloid) (NN surface) (NNS markers) (NP-COOD (NP (NN CD11b)) (CC and) (NP (NN CD33))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (DT The) (JJ IFN-dependent) (NN increase)) (PP (IN in) (NP (NN RAR-LRB-alpha-RRB-) (NNS levels)))) (CC and) (NP (NP (DT the) (JJ enhancing) (NN effect)) (PP (IN of) (NP (DT the) (NN cytokine))) (PP (IN on) (NP (JJ retinoid-dependent) (JJ granulocytic) (NNS markers) (NN expression))))) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT a) (NN characteristic)) (PP (IN of) (NP (ADJP (NN PML-RAR) (JJ positive)) (NNS cells)))) (, ,) (SBAR (IN since) (S (NP-SBJ-21 (DT the) (NNS phenomena)) (VP (VBP are) (RB not) (VP (VBN observed) (PP (IN in) (NP (NN HL-60) (NNS promyelocytes))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NNS Interferons)) (CONJP (RB as) (RB well) (IN as)) (NP (NNS retinoids))) (VP (VBP inhibit) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (NN NB4) (NNS cells)))) (, ,) (SBAR (IN although) (S (NP-SBJ (NP (DT the) (CD 2) (NNS classes)) (PP (IN of) (NP (NNS compounds)))) (VP (VBP do) (RB not) (ADVP (RB significantly)) (VP (VBP interact) (PP (IN in) (NNS terms) (IN of) (NP (JJ anti-proliferative) (NN activity)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (NP (NP (DT the) (JJ possible) (NN use)) (PP (IN of) (NP (NP (NNS combinations)) (PP (IN between) (NP-COOD (NP (NNS IFNs)) (CC and) (NP (JJ retinoic) (NN acid)))))) (PP (IN in) (NP (NP (DT the) (JJ cyto-differentiating) (NN treatment)) (PP (IN of) (NP (NN APL) (NNS patients))))))) (. .)))
(TOP (S (NP-SBJ-55 (NP-COOD (NP (NP (NN Susceptibility)) (PP (TO to) (NP (JJ natural) (NN killer) (NNS cells)))) (CC and) (NP (NP (JJ down) (NN regulation)) (PP (IN of) (NP (NN MHC) (NN class) (CD I) (NN expression))))) (PP (IN in) (NP (NN adenovirus) (CD 12) (VBN transformed) (NNS cells)))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP-LGS (JJ different) (NN E1A) (NNS domains))))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (DT All) (JJ human) (NNS adenoviruses)) (VP (VBP transform) (NP (JJ rodent) (NNS cells)) (ADVP (FW in) (FW vitro)))) (, ,) (CC but) (S (NP-SBJ (NP (RB only) (NNS cells)) (VP (VBN transformed) (PP (IN by) (NP-LGS (NP (NNS serotypes)) (VP (VBG belonging) (PP (TO to) (NP (NNS subgroups) (NP-COOD (NP (NP (NN A)) (PRN (-LRB- -LRB-) (NP (NN Ad12)) (-RRB- -RRB-))) (CC and) (NP (NP (NN B)) (PRN (-LRB- -LRB-) (NP (NN Ad3)) (-RRB- -RRB-))))))))))) (VP (VBP are) (ADJP-PRD (JJ tumorigenic)) (PP (IN for) (NP (JJ immunocompetent) (NNS animals)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT these) (NNS cells))) (, ,) (NP-SBJ-56 (NP (DT the) (NN expression)) (PP (IN of) (NP (NN MHC-class) (CD I) (NNS antigens)))) (VP-COOD (VP (VBZ is) (VP (VBN repressed))) (CC and) (VP (MD might) (VP (VB allow) (S (NP-SBJ (PRP them)) (VP-COOD (VP (TO to) (VP (VB escape) (PP (IN from) (NP (NP (NN recognition)) (PP (IN by) (NP (NP (JJ cytotoxic) (NN T) (NNS lymphocytes)) (PRN (-LRB- -LRB-) (NP (NN CTL)) (-RRB- -RRB-)))))))) (CC and) (VP (TO to) (VP (VB develop) (PP (IN in) (NP (NN tumor)))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (DT these) (NN cell) (NNS lines)) (VP (VBP appear) (ADJP-PRD (JJ resistant) (PP (TO to) (NP (NP (NN lysis)) (PP (IN by) (NP (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (NNS cells))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN E1A) (NN domain) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-)) (ADJP (JJ responsible) (PP (IN for) (NP (DT these) (NNS properties)))))))) (NP-SBJ-57 (JJ several) (NN cell) (NNS lines)) (VP (VBD were) (VP (VBN created) (PP (IN by) (S (NP (VBG transforming) (NP (NP (NP (NN baby) (NN rat) (NN kidney)) (PRN (-LRB- -LRB-) (NP (NN BRK)) (-RRB- -RRB-))) (NNS cells)) (PP (IN with) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (NNS plasmids)) (VP (VBG expressing) (NP (JJ different) (NN Ad2/Ad12) (NN hybrid) (NN E1A) (NN gene) (NNS products)))))))))))) (. .)))
(TOP (S (NP-SBJ-58 (DT The) (NN MHC) (NN class) (CD 1) (NN gene) (NN expression)) (VP (VBD was) (VP (VBN inhibited) (PP-COOD (PP (IN in) (NP (NP (NNS cells)) (VP (VBG expressing) (NP (DT the) (NN Ad12) (NN 13S) (NN mRNA) (NN product))))) (CC and) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN transformed) (PP (IN with) (NP (NP (NN Ad2/Ad12) (NN hybrid) (NN E1A) (NN gene) (NN product)) (VP (VBG harboring) (NP (NP (DT the) (JJ C-terminal) (NN part)) (PP (IN of) (NP (NP (DT the) (NP (NP (VBN conserved) (NN region)) (PRN (-LRB- -LRB-) (NP (NN CR)) (-RRB- -RRB-))) (CD 3)) (PP (IN of) (NP (NN Ad12))))))))))))))) (. .)))
(TOP (S (NP-SBJ-59 (NP (NN Susceptibility)) (PP (IN of) (NP (DT these) (VBN transformed) (NN cell) (NNS lines))) (PP (TO to) (NP (NN NK) (NNS cells)))) (VP (VBD was) (VP (VBN determined) (PP (IN by) (NP-LGS (JJ cytolytic) (NNS assays))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS results)) (VP (VBD obtained))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-60 (CD two) (NN Ad12) (NN E1A) (NNS domains)) (VP (VBP are) (VP (VBN required) (S (VP (TO to) (VP (VB induce) (NP (NP (NN resistance)) (PP (IN of) (NP (DT the) (NN cell) (NNS lines))) (PP (TO to) (NP (NN NK) (NNS cells)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT An) (NN IL-2) (NN response) (NN element)) (PP (IN in) (NP (DT the) (JJ human) (NN IL-2) (NN receptor) (NN alpha) (NN chain) (NN promoter)))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ composite) (NN element)) (SBAR (WHNP-1 (WDT that)) (S (VP (VBZ binds) (NP-COOD (NP (NN Stat5)) (, ,) (NP (NN Elf-1)) (, ,) (NP (NN HMG-I-LRB-Y-RRB-)) (CC and) (NP (DT a) (NN GATA) (NN family) (NN protein)))))))) (. .)))
(TOP (S (NP-SBJ-2 (NP (NN Expression)) (PP (IN of) (NP (DT the) (JJ human) (NP (NP (NN interleukin-2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (NN receptor) (NN alpha) (NN chain) (NN gene)))) (VP (VBZ is) (ADVP (RB potently)) (VP (VBN upregulated) (PP (IN by) (NP-LGS (NP (PRP$ its) (JJ own) (NN ligand)) (, ,) (NP (NN IL-2)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBP characterize) (NP-COOD (NP (NP (DT an) (JJ essential) (JJ upstream) (NN IL-2) (NN response) (NN element)) (SBAR (WHNP-3 (WDT that)) (S (VP (VBZ contains) (NP (UCP-COOD (CC both) (NP (NN consensus)) (CC and) (ADJP (JJ non-consensus))) (NN GAS) (NNS motifs)))))) (, ,) (NP (NP (CD two) (JJ putative) (NP (NP (NN Ets) (NN binding) (NNS sites)) (PRN (-LRB- -LRB-) (NP (NN EBS)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP-4 (NP (CD one)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBZ overlaps) (NP (DT the) (NN consensus) (NN GAS) (NN motif)))))) (, ,) (CC and) (NP (NP (DT a) (NN GATA) (NN motif)) (, ,) (SBAR (WHNP-5 (WDT which)) (S (VP (VBZ overlaps) (NP (DT the) (JJ non-consensus) (NN GAS) (NN motif)))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (SBAR (IN although) (S (NP-SBJ (NP (DT the) (JJ individual) (NNS components)) (PP (IN of) (NP (DT this) (NN element)))) (VP (VBP do) (RB not) (VP (VB respond) (PP (TO to) (NP (NN IL-2))))))) (, ,) (ADVP (RB together)) (NP-SBJ (PRP they)) (VP (VBP form) (NP (NP (DT a) (JJ composite) (NN element)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG conferring) (NP (NP (NN IL-2) (NN responsiveness)) (PP (TO to) (NP (DT a) (JJ heterologous) (NN promoter))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (JJ Multiple) (NNS factors)) (PP (VBG including) (NP-COOD (NP (NN Stat5)) (, ,) (NP (NN Elf-1)) (, ,) (NP (NN HMG-I-LRB-Y-RRB-)) (CC and) (NP (NN GATA) (NN family) (NNS proteins))))) (VP (VBP bind) (PP (TO to) (NP (DT the) (NN IL-2) (NN response) (NN element))))) (CC and) (S (NP-SBJ (NP (NN mutation)) (PP (IN of) (NP (NP (DT any) (CD one)) (PP (IN of) (NP (DT these) (VBG binding) (NNS sites)))))) (VP (VBZ diminishes) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT this) (NN element)))))) (. .)))
(TOP (S (NP-SBJ-6 (DT An) (JJ unidentified) (NN Ets) (NN family) (NN protein)) (VP-COOD (VP (VBZ binds) (PP (TO to) (NP (NP (DT the) (NN EBS)) (VP (VBG overlapping) (NP (DT the) (NN consensus) (NN GAS) (NN motif)))))) (CC and) (VP (VBZ appears) (S (VP (TO to) (VP (ADVP (RB negatively)) (VB regulate) (NP (DT the) (JJ human) (NN IL-2R) (NN alpha) (NN promoter))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (JJ IL-2-induced) (NN IL-2R) (NN alpha) (NN promoter) (NN activity)) (VP (VBZ requires) (NP (NP (DT a) (JJ complex) (JJ upstream) (NN element)) (, ,) (SBAR (WHNP-7 (WDT which)) (S (VP (VBZ appears) (S (VP (TO to) (VP (VB contain) (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (ADJP-COOD (CC both) (ADJP (JJ positive)) (CC and) (ADJP (JJ negative))) (JJ regulatory) (NNS factors)))))))))))) (. .)))
(TOP (NP (NP (NP-COOD (NP (NN Tyrosine) (NN kinase)) (CC and) (NP (JJ cAMP-dependent) (NN protein) (NN kinase))) (NNS activities)) (PP (IN in) (NP (JJ CD40-activated) (JJ human) (NN B) (NNS lymphocytes))) (. .)))
(TOP (S (ADVP (FW In) (FW vitro)) (, ,) (NP-SBJ-8 (JJ human) (NN B) (NNS lymphocytes)) (VP (VBP undergo) (NP (JJ long-term) (NN proliferation)) (SBAR-TMP (WHADVP-10 (WRB when)) (S (VP (VBN activated) (PP (IN through) (NP (NP (NN CD40)) (, ,) (NP (NP (DT a) (NN protein)) (VP (VBN expressed) (PP (IN on) (NP (PRP$ their) (NN cell) (NN surface))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN nature)) (PP (IN of) (NP (NP-11 (JJ CD40-dependent) (NNS signals)) (PP (IN in) (NP (VBG proliferating) (JJ fresh) (JJ human) (ADJP (JJ Epstein-Barr) (JJ virus-negative)) (NN B) (NNS lymphocytes)))))) (VP (VBZ is) (ADVP-TMP (RB currently)) (ADJP-PRD (JJ unknown))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ-12 (DT a) (JJ CD40-dependent) (NN B) (NN cell) (NN culture) (NN system)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ different) (NN signal) (NN transduction) (NNS elements))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (NP (NN Protein) (NN kinase) (NN C)) (PRN (-LRB- -LRB-) (NP (NN PKC)) (-RRB- -RRB-))) (NN depletion)) (VP (VBN generated) (PP (IN by) (NP (DT a) (JJ long-term) (NN phorbol) (CD 12) (NN myristate) (NN 13-acetate) (NN treatment))))) (VP (VBD had) (NP (JJ weak) (NNS effects)) (PP (IN on) (NP (NN proliferation)))) (. .)))
(TOP (S (ADVP (RB Rather)) (, ,) (NP-SBJ-14 (NN tyrosine) (NN phosphorylation)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (ADVP (RB directly)) (VBN involved) (PP (IN in) (S (VP (VBG mediating) (NP (JJ CD40-dependent) (NNS signals))))))))))) (. .)))
(TOP (S (NP-SBJ-17 (NP (DT The) (NN use)) (PP (IN of) (NP (DT the) (ADJP (NP (NP (NN protein) (NN tyrosine) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN PTK)) (-RRB- -RRB-))) (JJ -specific)) (NN inhibitor) (NN herbimycin) (NN A)))) (ADVP (RB dramatically)) (VP (VBD decreased) (NP (JJ cellular) (NN proliferation)) (PP (IN without) (S (VP (VBG altering) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus-1) (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN HIV-1) (NN LTR)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN promoter)) (ADJP (RB largely) (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (SYM NF-) (NN kappa) (NN B)) (-RRB- -RRB-))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-18 (DT the) (ADJP (NP (JJ cAMP-dependent) (NN protein) (NN kinase)) (JJ specific)) (NN inhibitor) (NN H-89)) (ADVP (RB totally)) (VP (VBD inhibited) (NP (NN HIV-1) (NN LTR) (NN activity)) (PP (IN at) (NP (NP (DT a) (NN concentration)) (NP (QP (RB as) (JJ low) (IN as) (CD 100)) (NN nM)))) (PP (IN without) (S (VP (VBG affecting) (NP (JJ cellular) (NN proliferation)))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NN assay)) (PRN (-LRB- -LRB-) (NP (NN EMSA)) (-RRB- -RRB-))) (CC and) (NP (NN supershift) (NN assay))) (VP (VBG using) (NP (NP (DT an) (NN NF-kappa) (NN B) (NN binding) (NN sequence)) (PP (IN from) (NP (DT the) (NN kappa) (JJ light) (NN chain)))) (PP (IN as) (NP (DT a) (NN probe))))) (, ,) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ-COOD (CC both) (NP (NP (NNS p65)) (PRN (-LRB- -LRB-) (NP (NN RelA)) (-RRB- -RRB-))) (CC and) (NP (NN c-Rel))) (VP (VBD were) (ADJP-PRD (JJ present) (PP (IN in) (NP (JJ CD40-stimulated) (NN B) (NNS cells)))))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP-SBJ (NN PKC) (NN depletion)) (VP (VBD did) (RB not) (VP (VB alter) (NP (DT the) (NN NF-kappa) (NN B) (NN level)))))) (, ,) (NP-SBJ (NP (NN treatment)) (PP (IN of) (NP (NN B) (NNS lymphocytes))) (PP (IN with) (NP-COOD (NP (NN H-89)) (CC or) (NP (NN herbimycin) (NN A))))) (VP (VBD provoked) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (DT the) (NN NF-kappa) (NN B) (NN level))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS observations)) (VP (VBP establish) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NP (JJ different) (NN signal) (NN transducing) (NNS pathways)) (VP (VBG leading) (PP (TO to) (NP (NP (NN CD40) (NN activation)) (PP (IN of) (NP (NN B) (NNS lymphocytes)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Active) (NN suppression)) (PP (IN of) (NP (DT the) (NN class) (CD II) (JJ transactivator-encoding) (NN AIR-1) (NN locus)))) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (JJ major) (NN histocompatibility) (NN complex) (NN class) (CD II) (NN gene) (NN expression)) (VP (VBN observed) (PP-TMP (IN during) (NP (NP (NN differentiation)) (PP (IN from) (NP (NN B) (NNS cells))) (PP (TO to) (NP (NN plasma) (NNS cells)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ-9 (NP (DT the) (JJ genetic) (NN control)) (PP (IN of) (NP (NP (NP (NP (JJ major) (NN histocompatibility) (NN complex)) (PRN (-LRB- -LRB-) (NP (NN MHC)) (-RRB- -RRB-))) (NN class) (CD II) (NN gene) (NN expression)) (PP-TMP (IN during) (NP (NP (DT the) (NN transition)) (PP (IN from) (NP (NN B) (NN cell))) (PP (TO to) (NP (NN plasma) (NN cell)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN analyzed)))) (. .)))
(TOP (S (NP-SBJ-10 (NN Class) (CD II) (NNS molecules)) (VP (VBP are) (RB not) (VP (VBN expressed) (PP (IN in) (NP (NN plasma) (NNS cells))) (PP (IN because) (IN of) (NP (NP (DT an) (JJ active) (NN suppression)) (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (NN abrogation)) (PP (IN of) (NP (NN class) (CD II) (NN gene) (NN transcription)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (ADJP (NN plasma) (JJ cell-specific)) (NN repressor) (NN function)) (, ,) (VP (VBN designated) (S (NP-PRD (NP (NN SIR)) (PRN (-LRB- -LRB-) (NP (NP (NN suppressor)) (PP (IN of) (NP (JJ immune) (NN response) (NNS genes)))) (-RRB- -RRB-))))) (, ,)) (VP (VBZ does) (RB not) (VP (VB act) (ADVP (RB directly)) (PP-COOD (PP (IN on) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NN class) (CD II) (NNS genes))))) (, ,) (CC but) (RB instead) (PP (IN on) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (NP (DT the) (NN AIR-1) (NN gene)) (, ,) (SBAR (WHNP-100 (WHNP (WP$ whose) (NN product)) (, ,) (NP (NP (DT the) (NN class) (CD II) (NN transactivator)) (PRN (-LRB- -LRB-) (NP (NN CIITA)) (-RRB- -RRB-))) (, ,)) (S (VP (VBZ is) (ADJP-PRD (JJ fundamental)) (PP (IN for) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ constitutive)) (CC and) (ADJP (JJ inducible))) (NN expression)) (PP (IN of) (NP (NN MHC) (NN class) (CD II) (NNS genes)))))))))))))))))))) (. .)))
(TOP (S (NP-SBJ-11 (DT This)) (VP (VBD was) (ADVP (RB unambiguously)) (VP (VBN demonstrated) (PP (IN by) (NP-LGS (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (NP (NP-COOD (NP (NN plasmacytoma)) (NN x) (NP (NN B) (NN cell))) (NNS hybrids)) (VP (VBG carrying) (NP (NP (DT an) (NN AIR-1) (NN locus)) (VP (VBN derived) (PP (IN from) (NP (JJ CIITA-expressing) (NNS cells))))))) (VP (VBP do) (RB not) (VP (VB express) (NP (JJ CIITA-specific) (NNS transcripts)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Transfection)) (PP (IN of) (NP (NP (DT a) (NN cDNA)) (VP (VBG containing) (NP (DT the) (JJ human) (NN CIITA) (NN coding) (NN sequence))))) (PP (IN under) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (DT an) (JJ heterologous) (NN promoter)))))) (VP-COOD (VP (VBZ restores) (NP (NP (NN expression)) (PP (IN of) (NP (JJ human) (NN MHC) (NN class) (CD II) (NNS genes))) (PP (IN in) (NP (DT the) (NNS hybrids))))) (CC and) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (ADJP (FW de) (FW novo)) (NN expression)) (PP (IN of) (NP (NN mouse) (NN MHC) (NN class) (CD II) (NNS genes))) (PP (IN in) (NP-COOD (CC both) (NP (DT the) (NN mouse) (NN plasmacytoma) (NN cell) (NN line)) (CC and) (NP (DT the) (NNS hybrids))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VP-COOD (VP (VBP confirm)) (CC and) (VP (VBP extend))) (NP-12 (NP (DT the) (NN notion)) (PP (IN of) (NP (NP (DT the) (JJ functional) (NN conservation)) (PP (IN of) (NP (DT the) (JJ AIR-1) (NN gene) (NN product))) (PP (IN across) (NP (NNS species) (NNS barriers))))))) (. .)))
(TOP (S (ADVP (RB Interestingly)) (, ,) (PP (IN in) (NP (JJ CIITA-transfected) (NN cell) (NNS hybrids))) (, ,) (NP-SBJ-13 (NP (NN cell) (NN surface) (NN expression)) (PP (IN of) (NP (DT the) (JJ human) (NN HLA-DQ) (NN heterodimer)))) (VP (VBD was) (RB not) (VP (VBN observed))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN result)) (VP (VBD was) (RB not) (ADJP-PRD (JJ attributable) (PP (TO to) (NP (NP (NN lack)) (PP (IN of) (NP (NP-COOD (NP (NN HLA-DQ) (NN alpha)) (CC or) (NP (NP (NN -DQ)) (NN beta))) (NN transcription)))))) (, ,) (SBAR (IN because) (S (NP-SBJ (DT both) (NNS transcripts)) (VP (VBD were) (ADJP-PRD (JJ present) (PP (IN in) (NP (DT the) (JJ CIITA-transfected) (NNS hybrids)))) (, ,) (SBAR (IN although) (FRAG (PP (IN at) (NP (VBN reduced) (NNS levels))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (ADVP (RB further)) (VP (VBP support) (NP (NP (PRP$ our) (JJ previous) (NNS observations)) (PP (IN on) (NP (NP (DT the) (JJ distinct) (NN regulation)) (PP (IN of) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (JJ human) (NN HLA-DQ) (NN class) (CD II) (NN subset))) (, ,) (SBAR (WHNP-14 (WDT which)) (S (VP (MD may) (VP (VB be) (VP (ADVP (RB thus)) (VBN controlled) (PP-TMP (IN at) (NP (DT the) (JJ posttranscriptional) (NN level))) (PP (IN by) (NP-LGS (DT a) (JJ CIITA-independent) (NN mechanism)))))))))))))) (. .)))
(TOP (S (NP-SBJ-62 (NP (NN Chromosome) (CD 1) (NN aneusomy)) (PP (IN with) (NP (NN 1p36) (NN under-representation)))) (VP (VBZ is) (ADJP-PRD (JJ related) (PP (TO to) (NP (NP-COOD (NP (JJ histologic) (NN grade)) (, ,) (NP (NN DNA) (NN aneuploidy)) (, ,) (NP (JJ high) (NN c-erb) (NN B-2)) (CC and) (NP (NP (NN loss)) (PP (IN of) (NP (NN bcl-2) (NN expression))))) (PP (IN in) (NP (JJ ductal) (NN breast) (NN carcinoma))))))) (. .)))
(TOP (S (NP-SBJ-63 (NP (NN Chromosome) (CD 1) (NNS abnormalities)) (PP (IN with) (NP (NP (NN loss)) (PP (IN of) (NP (NN 1p36)))))) (VP (VBP have) (VP (VBN been) (VP (VBN investigated) (PP (IN in) (NP (CD 95) (NN breast-cancer) (NNS samples))) (PP (IN by) (NNS means) (IN of) (NP (NP (DT a) (JJ dual-target) (NP (NP (NN fluorescence) (FW in-situ) (NN hybridization)) (PRN (-LRB- -LRB-) (NP (NN FISH)) (-RRB- -RRB-))) (NN technique)) (VP (VBG using) (NP (NP (DT the) (NP-COOD (NP (NN pUC) (CD 1.77)) (CC and) (NP (NN p1-79))) (NNS probes)) (, ,) (ADJP (JJ specific) (PP (IN for) (NP (DT the) (NP-COOD (NP (NN 1q12)) (CC and) (NP (NN 1p36))) (NNS regions))) (, ,) (ADVP (RB respectively)))))))))) (. .)))
(TOP (S (NP-SBJ-64 (NP (NNS Abnormalities)) (PP (IN for) (NP-COOD (NP (CD one)) (CC or) (NP (DT both) (NNS probes))))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (CD 83/95) (NNS samples))))) (. .)))
(TOP (S (NP-SBJ-65 (JJ Relative) (NN 1p36) (NN under-representation)) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (CD 79/95))))) (. .)))
(TOP (S (NP-SBJ-66 (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT these) (NNS alterations)))) (VP (VBD was) (VP (VBN studied) (PP (IN by) (S (VP (VBG comparing) (NP (DT the) (NN FISH) (NNS results)) (PP (IN with) (NP (NP (JJ several) (NNS parameters)) (VP (ADVP-TMP (RB currently)) (VBN used) (PP (IN in) (NP (JJ breast-cancer) (NN pathology))))))))))) (. .)))
(TOP (S (NP-SBJ-67 (NP (JJ Distinct) (NNS patterns)) (PP (IN of) (NP (NN chromosome) (CD 1) (NNS abnormalities)))) (VP (VBD were) (VP (VBN found) (PP (IN among) (NP (NP (DT the) (JJ histologic) (NNS types)) (PP (IN of) (NP (NN breast) (NN carcinoma))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (ADJP-COOD (ADJP (JJ Lobular)) (CC or) (ADJP (JJ mucinous))) (NNS samples)) (VP (VBD showed) (NP (QP (JJ few) (CC or) (DT no)) (NNS alterations)))) (, ,) (IN whereas) (S (NP-SBJ (JJS most) (JJ ductal) (NNS samples)) (VP (VBD had) (NP (NP (JJ high) (NN chromosome) (CD 1) (NN polysomy)) (PP (IN with) (NP (NP (NN under-representation)) (PP (IN of) (NP (NN 1p36)))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ ductal) (NNS carcinomas))) (, ,) (NP-SBJ (NN chromosome) (CD 1) (NNS alterations)) (VP (VBD increased) (PP (IN with) (NP-COOD (NP (JJ histologic) (NN grade)) (, ,) (NP (NN DNA) (NN aneuploidy)) (, ,) (NP (NP (NN loss)) (PP (IN of) (NP (NN bcl-2)))) (CC and) (NP (JJ high) (NN c-erb) (NN B-2) (NN expression))))) (. .)))
(TOP (S (NP-SBJ-68 (DT These) (NNS associations)) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB statistically)) (ADJP-PRD (JJ significant))))))) (. .)))
(TOP (S (NP-SBJ-69 (NP (DT No) (NN correlation)) (PP (IN between) (NP-COOD (NP (NN chromosome) (CD 1) (NNS alterations)) (CC and) (NP-COOD (NP (JJ nuclear) (NP-COOD (NP (NN grade)) (, ,) (NP (NN age)) (, ,) (NP (NN size)))) (, ,) (NP (JJ lymph-node) (NN involvement)) (, ,) (NP (JJ hormonal) (NN receptor) (NN presence)) (, ,) (NP (NN proliferation) (NN activity)) (CC or) (NP (NN p53) (NN protein) (NN expression)))))) (VP (VBD was) (VP (VBN detected))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (NP (NP (DT the) (NN utility)) (PP (IN of) (NP (DT this) (NN FISH) (NN technique))) (PP (IN for) (NP (NP (DT a) (JJR better) (NN definition)) (PP (IN of) (NP (NP (DT the) (JJ biological) (NNS characteristics)) (PP (IN of) (NP (JJ ductal) (NNS carcinomas))))))))) (. .)))
(TOP (S (NP-SBJ-59 (NP (NN Silencing)) (PP (IN of) (NP (JJ human) (JJ fetal) (NN globin) (NN expression)))) (VP (VBZ is) (VP (JJ impaired) (PP (IN in) (DT the) (NN absence) (IN of) (NP (DT the) (JJ adult) (IN beta-globin) (NN gene) (NN activator) (NN protein) (NN EKLF))))) (. .)))
(TOP (S (NP-SBJ (NN Globin) (NNS genes)) (VP (VBP are) (ADJP-PRD (JJ subject) (PP (TO to) (NP (ADJP-COOD (ADJP (JJ tissue-specific)) (CC and) (ADJP (JJ developmental) (JJ stage-specific))) (NN regulation))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (NN switch)) (PP (IN from) (NP (JJ human) (ADJP (ADJP (JJ fetal)) (PRN (-LRB- -LRB-) (NP (NN gamma)) (-RRB- -RRB-))))) (PP (TO -to) (NP (ADJP (ADJP (JJ adult)) (PRN (-LRB- -LRB-) (NP (NN beta)) (-RRB- -RRB-))))) (NP-103 (NN -globin) (NN expression))) (VP (VBZ occurs) (PP (IN within) (NP (NP (JJ erythroid) (JJ precursor) (NNS cells)) (PP (IN of) (NP (DT the) (JJ adult) (NN lineage)))))) (. .)))
(TOP (S (ADVP-TMP (RB Previously)) (NP-SBJ-COOD (NP (PRP we)) (CC and) (NP (NNS others))) (VP (VBD showed) (PP (IN by) (NP (VBN targeted) (NN gene) (NN disruption))) (SBAR (IN that) (S (NP-SBJ-60 (NP (DT the) (NN zinc) (NN finger) (NN gene)) (, ,) (NP (NP (JJ erythroid) (JJ Kruppel-like) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN EKLF)) (-RRB- -RRB-))) (, ,)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (NP (NN expression)) (PP (IN of) (NP (DT the) (NN beta-globin) (NN gene))) (PP (IN in) (NP (NNS mice))))) (, ,) (PP (RB presumably) (IN through) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (DT a) (JJ high-affinity) (VBG binding) (NN site)) (PP (IN in) (NP (DT the) (JJ proximal) (NN promoter)))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN EKLF))) (PP (IN in) (NP (NP (DT the) (JJ developmental) (NN regulation)) (PP (IN of) (NP (DT the) (JJ human) (NN gamma-globin) (NN gene))))))))) (NP-SBJ-61 (PRP we)) (VP (VBD interbred) (NP (NN EKLF) (NNS heterozygotes) (-LRB- -LRB-) (CC +/-) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NNS mice)) (VP (VBG harboring) (NP (DT a) (JJ human) (NN beta-globin) (NN yeast) (JJ artificial) (NN chromosome) (NN transgene)))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP find) (SBAR (IN that) (S (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN EKLF))) (, ,) (SBAR (IN while) (S (NP-SBJ-62 (JJ human) (NN beta-globin) (NN expression)) (VP (VBZ is) (ADVP (RB dramatically)) (VP (VBN reduced))))) (, ,) (NP-SBJ-63 (NN gamma-globin) (NNS transcripts)) (VP (VBP are) (VP (JJ elevated) (ADVP (RB approximately) (RB 5-fold))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Impaired) (NN silencing)) (PP (IN of) (NP (NN gamma-globin) (NN expression)))) (VP (VBZ identifies) (NP (NN EKLF)) (PP (IN as) (NP (NP (DT the) (JJ first) (NN transcription) (NN factor)) (VP (VBG participating) (ADVP (RB quantitatively)) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN gamma-globin)) (TO to) (NP (NN beta-globin))) (NN switch))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS findings)) (VP (VBP are) (ADJP-PRD (JJ compatible) (PP (IN with) (NP (NP (DT a) (JJ competitive) (NN model)) (PP (IN of) (NP (NN switching))) (SBAR (WHPP-64 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NN EKLF)) (VP (VBZ mediates) (NP (NP (DT an) (JJ adult) (JJ stage-specific) (NN interaction)) (PP (IN between) (NP-COOD (NP (DT the) (NN beta-globin) (NN gene) (NN promoter)) (CC and) (NP (NP (DT the) (NN locus) (NN control) (NN region)) (SBAR (WHNP-65 (WDT that)) (S (VP (VBZ excludes) (NP (DT the) (NN gamma-globin) (NN gene)))))))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Modulatory) (NNS effects)) (PP (IN of) (NP-COOD (NP (NNS glucocorticoids)) (CC and) (NP (NNS catecholamines)))) (PP (IN on) (NP (JJ human) (NP-COOD (NP (NN interleukin-12)) (CC and) (NP (NN interleukin-10))) (NN production))) (: :)) (NP (JJ clinical) (NNS implications)) (. .)))
(TOP (S (S-COOD (S (NP-SBJ (NP (NN Interleukin-12)) (PRN (-LRB- -LRB-) (NP (NN IL-12)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ key) (NN inducer)) (PP (IN of) (NP (NP (NN differentiation)) (PP (IN of) (NP (JJ uncommitted) (NP (NP (NN T) (NN helper)) (PRN (-LRB- -LRB-) (NP (NN TH)) (-RRB- -RRB-))) (NNS cells))) (PP (IN toward) (NP (NP (DT the) (NN TH1) (NN phenotype)) (, ,) (SBAR (WHNP-22 (WDT which)) (S (VP (VBZ regulates) (NP (JJ cellular) (NN immunity)))))))))))) (, ,) (IN whereas) (S (NP-SBJ (NN IL-10)) (VP-COOD (VP (VBZ inhibits) (NP (NN TH1) (NNS functions))) (CC and) (VP (VBZ potentiates) (NP (NP (JJ TH2-regulated) (NNS responses)) (PRN (-LRB- -LRB-) (NP (FW i.e.) (, ,) (JJ humoral) (NN immunity)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (JJ potential) (NNS effects)) (PP (IN of) (NP (NN stress))) (PP (IN on) (NP (NN TH1/TH2) (NN balance))))))) (, ,) (NP-SBJ-23 (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (CD three) (NN prototype) (NN stress) (NNS hormones)) (: -) (NP-COOD (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (DT a) (JJ synthetic) (NN glucocorticoid)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NNS catecholamines) (NP-COOD (NP (NN norepinephrine)) (CC and) (NP (NN epinephrine))))) (: -))) (S-24 (VP (TO to) (VP (VB alter) (NP (NP (DT the) (NN production)) (PP (IN of) (NP-COOD (NP (NP (NN IL-12)) (PRN (-LRB- -LRB-) (NP (NN p70)) (-RRB- -RRB-))) (CC and) (NP (NN IL-10)))) (VP (VBN induced) (PP (IN by) (NP-LGS (NP (JJ bacterial) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ human) (JJ whole) (NN blood)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Dexamethasone)) (VP (VBD inhibited) (NP (JJ LPS-induced) (JJ bioactive) (NN IL-12) (NN production)) (PP-COOD (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN fashion))) (CC and) (PP (IN at) (NP (ADJP (RB physiologically) (JJ relevant)) (NNS concentrations))))) (: ;)))
(TOP (S (NP-SBJ (JJ Nasal) (NP-COOD (NP (NN NK-)) (CC and) (NP (NN T-cell))) (NNS lymphomas)) (VP (VBP share) (NP (NP (DT the) (JJ same) (NN type)) (PP (IN of) (NP (JJ Epstein-Barr) (NN virus) (NN latency))) (PP (IN as) (NP-COOD (NP (JJ nasopharyngeal) (NN carcinoma)) (CC and) (NP (NP (NN Hodgkin) (POS 's)) (NN disease)))))) (. .)))
(TOP (S (NP-SBJ-72 (JJ Nasal) (JJ T/NK-cell) (NNS lymphomas)) (VP (MD can) (VP (VB be) (VP (ADVP (RBR further)) (VBN separated) (PP (IN into) (NP (NP (DT those)) (PP-COOD (PP (IN of) (NP (NP (NP (JJ natural) (NN killer)) (PRN (-LRB- -LRB-) (NP (NN NK)) (-RRB- -RRB-))) (NN cell) (NN lineage))) (CC or) (PP (IN of) (NP (NN T-cell) (NN lineage)))) (, ,) (PP (IN with) (NP (NP (NNS differences)) (PP (IN in) (NP-COOD (NP (JJ cellular) (NN phenotype)) (, ,) (NP (NP (NP (NN T-cell) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TcR)) (-RRB- -RRB-))) (NN gene) (NN rearrangement)) (CC and) (NP (NN TcR) (NN transcript) (NN expression))))))))))) (. .)))
(TOP (S (NP-SBJ-73 (NP-COOD (CC Both) (NP (NN NK-)) (CC and) (NP (NN T-cell))) (NNS subtypes)) (VP (VBP are) (VP (ADVP (RB closely)) (VBN associated) (PP (IN with) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ-74 (NN EBV) (NN gene) (NN expression)) (VP (VBD was) (VP (VBN determined) (PP (IN in) (NP (NP (CD 23) (NNS cases)) (PP (IN of) (NP (NP (JJ nasal) (NN lymphoma)) (PRN (-LRB- -LRB-) (NP (NN NL)) (-RRB- -RRB-)))))) (PP (IN by) (NP-LGS-COOD (NP (NP (ADJP (FW in) (FW situ)) (NN hybridisation)) (PRN (-LRB- -LRB-) (NP (NN ISH)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ reverse) (NN transcriptase-polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (CC and) (NP (NP (NN immunohistochemistry)) (PRN (-LRB- -LRB-) (NP (NN IH)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (PP-TPC-75 (IN Of) (NP (DT the) (CD 23) (NNS cases))) (, ,) (S-COOD (S (NP-SBJ-76 (NP (CD 19))) (VP (VBD were) (VP (VBN classified) (PP-78 (IN as) (NN NK-cell))))) (CC and) (S (NP-SBJ=76 (NP (CD 4))) (PP=78 (IN as) (NP (NN T-cell) (NNS tumours))))) (. .)))
(TOP (S (NP-SBJ (NP (NN ISH)) (PP (IN for) (NP (JJ EBV-encoded) (JJ small) (JJ non-polyadenylated) (NNS RNAs)))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (DT all) (NNS cases)) (, ,) (SBAR (IN whether) (FRAG (NP-COOD (NP (NN NK)) (CC or) (NP (NN T))))) (, ,) (VP (VBD harboured) (NP (NN EBV)) (PP (IN in) (NP (ADJP (RB virtually) (DT all)) (NN tumour) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ (NN RT-PCR)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (NN NL)) (PP (IN of) (NP (DT both) (NNS subtypes)))) (VP (VBD expressed) (NP (NP (NN EBNAI)) (PP (IN of) (NP-COOD (NP (DT the) (NN QUK) (NN splice) (NN pattern)) (, ,) (NP (NP (DT the) (JJ latent) (NN membrane) (NNS proteins)) (, ,) (NP-COOD (NP (NN LMP1)) (CC and) (NP (CD 2)))) (CC and) (NP (DT the) (NN BamHI) (NN A) (JJ rightward) (NNS transcripts))))) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN EBNA2) (NNS mRNAs))) (, ,) (ADJP (JJ compatible) (PP (IN with) (NP (DT the) (NN latency) (NN type) (CD II) (NN pattern)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-79 (NP (NN analysis)) (PP (IN of) (NP (NP (NN EBV) (NN protein) (NN expression)) (PP (IN by) (NP (NN IH)))))) (VP (VBD revealed) (NP (NP (DT a) (JJ heterogeneous) (NN pattern)) (PP (IN of) (NP (NP (NN EBV) (NN gene) (NN expression)) (PP (IN at) (NP (NP (DT the) (NN single-cell) (NN level)) (VP (VBG consisting) (PP (IN of) (NP (ADJP-COOD (CC both) (ADJP (JJ LMP1+)) (CC and) (ADJP (JJ LMP1-))) (NN tumour) (NNS cells))))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (NN mixture)) (PP (IN of) (NP (NN latency) (NP-COOD (NP (CD I)) (CC and) (NP (CD II))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-80 (NP (CD 2) (JJ early) (JJ lytic) (NNS transcripts)) (, ,) (NP-COOD (NP (NN BZLF1)) (CC and) (NP (NN BHRF1))) (, ,)) (VP (VBD were) (VP (ADVP (RB also)) (VBN detected) (PP (IN in) (NP (NP (QP (CD 13) (CC and) (CD 10)) (NNS cases)) (, ,) (ADVP (RB respectively)))))))) (, ,) (NP-SBJ (NP (DT the) (NN lack)) (PP (IN of) (NP (NN ZEBRA) (NN staining))) (PP (IN in) (NP (DT any) (NN case)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP-SBJ-81 (DT these) (JJ lytic) (NNS transcripts)) (VP (VBP are) (VP (ADVP (RBS most) (RB likely)) (VBN expressed) (PP (IN by) (NP-LGS (NP (JJ rare) (NNS cells)) (PP (IN in) (NP (NP (DT the) (NNS biopsies)) (VP (VBG entering) (NP (JJ lytic) (NN cycle)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ viral) (JJ transcriptional) (NN pattern)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP-COOD (NP (JJ nasopharyngeal) (NN carcinoma)) (CC and) (NP (NP (NN Hodgkin) (POS 's)) (NN disease)))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NN EBV)) (VP (MD can) (VP (VB exploit) (NP (NP (JJ common) (JJ regulatory) (NNS mechanisms)) (PP (IN for) (NP (NN gene) (NN transcription))) (PP (IN in) (NP (JJ diverse) (NN host) (NN cell) (NNS types))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Down-regulation)) (PP (IN of) (NP (NP (JJ immunogenic) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (NN EBNA2-EBNA6)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ nasal) (NN lymphoma)))) (VP (MD may) (VP (VB enable) (S (NP-SBJ (NN tumour) (NNS cells)) (VP (TO to) (VP (VB evade) (NP (NN host) (JJ cytotoxic) (NN T-cell) (NN surveillance))))))) (. .)))
(TOP (NP (NP (NN Lack)) (PP (IN of) (NP (NN IL-12) (NN signaling))) (PP (IN in) (NP (JJ human) (JJ allergen-specific) (NN Th2) (NNS cells))) (. .)))
(TOP (S (NP-SBJ-64 (NN IL-12)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ powerful) (NN skewer)) (PP (IN of) (NP (NP (JJ CD4+) (NN T) (NN cell) (NNS responses)) (PP (IN toward) (NP (DT the) (NN Th1) (NN phenotype)))))) (PP (IN by) (S (VP (VBG inducing) (NP (NN IFN-gamma) (NN production)) (PP (IN in) (NP (JJ naive) (NN Th) (NNS cells))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP-SBJ (PRP we)) (VP (VBD addressed) (NP (NP (DT the) (NN question)) (PP (IN of) (SBAR (IN whether) (S (NP-SBJ-65 (NN IL-12)) (VP (MD can) (VP (VB reverse) (NP (JJ established) (NN Th2) (NNS responses)) (PP (IN into) (NP (NN Th1/Th0) (NNS responses))) (PP (IN by) (S (VP (VBG inducing) (NP (NP (NN IFN-gamma) (NN production)) (PP (IN in) (NP (NN memory) (NN Th2) (NNS cells)))))))))))))) (. .)))
(TOP (S-COOD (S (PP (TO To) (NP (DT this) (NN aim))) (, ,) (NP-SBJ-66 (JJ allergen-specific) (JJ CD4+) (NP (NP (NN T) (NN cell) (NNS clones)) (PRN (-LRB- -LRB-) (NP (NN TCC)) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN generated) (PP (IN from) (NP (NP (DT the) (JJ peripheral) (NN blood)) (PP (IN of) (NP (CD three) (JJ atopic) (NNS patients)))))))) (, ,) (CC and) (S (NP-SBJ-67 (PRP$ their) (NN cytokine) (NNS profiles)) (VP (VBD were) (VP (VBN analyzed)))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (NN majority)) (PP (IN of) (NP (DT these) (NN TCC)))) (VP (VBD exhibited) (NP (DT a) (ADJP (RB strongly) (VBN polarized)) (NN Th2) (NN cytokine) (NN profile)))) (, ,) (CC and) (S (NP-SBJ-68 (NP (DT the) (NN production)) (PP (IN of) (NP (NN IFN-gamma)))) (VP (MD could) (RB not) (VP (VB be) (VP (VBN induced) (PP (IN by) (NP-LGS (JJ exogenous) (NN IL-12))))))) (. .)))
(TOP (S (NP-SBJ (NP (RB Only) (DT those) (NN TCC)) (PP (IN with) (NP (NP (JJ low) (NN IFN-gamma) (NNS levels)) (PP (IN in) (DT the) (NN absence) (IN of) (NP (NN IL-12)))))) (VP (VBD responded) (PP (TO to) (NP (NN IL-12))) (PP (IN by) (NP (NP (JJ additional) (NN enhancement)) (PP (IN of) (NP (NN IFN-gamma) (NN production)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN IL-12) (NN nonresponsiveness)) (PP (IN of) (NP (DT the) (NN Th2) (NNS clones)))) (VP (VBD was) (ADJP-PRD (RBR further) (JJ evident)) (PP (IN by) (NP (NP (DT the) (JJ total) (NN lack)) (PP (IN of) (NP (NP (JJ IL-12-induced) (NN phosphorylation)) (PP (IN of) (NP (NP (NP (NN STAT4)) (PRN (-LRB- -LRB-) (NP (NP-COOD (NP (NN signal) (NN transducer)) (CC and) (NP (NN activator))) (PP (IN of) (NP (NN transcription-4)))) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN transcription) (NN factor)) (SBAR (WHNP-69 (WDT that)) (S (VP (VBZ is) (VP (ADVP (RB typically)) (VBN involved) (PP (IN in) (NP (NN IL-12) (NN signaling))))))))))))))) (. .)))
(TOP (S (ADVP (RB Consequently)) (, ,) (NP-SBJ-71 (NN IL-12)) (ADVP (RB also)) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP (NP (DT the) (JJ DNA-binding) (NN activity)) (PP (IN of) (NP (JJ STAT4-containing) (NNS complexes))) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (DT these) (NN Th2) (NNS clones)))))))))) (. .)))
(TOP (S (NP-SBJ (DT All) (NN TCC)) (VP (VBD expressed) (NP (NP (JJ equal) (NNS levels)) (PP (IN of) (NP (DT the) (JJ low-affinity) (NN IL-12R) (NN beta1) (NN subunit))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-72 (NP (JJ human) (JJ allergen-specific) (NN Th) (NNS cells)) (PP (IN with) (NP (ADJP (RB strongly) (VBN polarized)) (NN Th2) (NN cytokine) (NNS profiles)))) (VP-COOD (VP (VBP do) (RB not) (VP (VB respond) (PP (TO to) (NP (NN IL-12))))) (CC and) (, ,) (RB therefore) (, ,) (VP (MD can) (RB not) (VP (VB be) (VP (VBN induced) (S (VP (TO to) (VP (VB produce) (NP (NN IFN-gamma)))))))))))) (. .)))
(TOP (S (NP-SBJ-73 (NP (DT The) (JJ apparent) (JJ high) (NN frequency)) (PP (IN of) (NP (JJ IL-12-nonresponsive) (NN Th) (NNS cells))) (PP (IN within) (NP (NP (DT the) (JJ allergen-specific) (NNS populations)) (PP (IN in) (NP (JJ atopic) (NNS patients)))))) (VP (VBZ predicts) (NP (NP (DT a) (JJ limited) (JJ skewing) (NN potential)) (PP (IN of) (NP (NN IL-12))) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (JJ established) (NN Th2) (NNS responses)))))) (, ,) (CC but) (S (VP (ADVP (RB only)) (VBG affecting) (NP (ADJP (RB newly) (VBN recruited)) (JJ naive) (NN Th) (NNS cells))))) (. .)))
(TOP (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (DT a) (JJ CD43/leukosialin-mediated) (NN pathway)) (PP (IN for) (S (VP (VBG inducing) (NP (NP (NN apoptosis)) (PP (IN in) (NP (JJ human) (JJ T-lymphoblastoid) (NNS cells))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NP (NP (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN mAb)) (-RRB- -RRB-))) (NN J393)) (VP (VBZ induces) (NP (NP (NN apoptosis)) (PP (IN in) (NP (NN Jurkat) (NNS T-cells))))) (. .)))
(TOP (S (NP-SBJ (JJ NH2-terminal) (NN amino) (NN acid) (NN sequence) (NN analysis)) (VP (VBD identified) (NP (NP (DT the) (JJ 140-kDa) (NN surface) (NN antigen)) (PP (IN for) (NP (NN mAb) (NN J393)))) (PP (IN as) (NP (NP (NN CD43/leukosialin)) (, ,) (NP (NP (DT the) (JJ major) (NN sialoglycoprotein)) (PP (IN of) (NP (NNS leukocytes))))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP-SBJ (NN Jurkat) (NNS cells)) (VP (VBD co-expressed) (NP (NP (CD two) (JJ discrete) (JJ cell-surface) (NNS isoforms)) (PP (IN of) (NP (NN CD43))) (, ,) (VP (VBN recognized) (PP (IN by) (NP-LGS (NP-COOD (NP (NN mAb) (NN J393)) (CC and) (NP (NN mAb) (NN G10-2))) (, ,) (ADVP (RB respectively))))))))) (, ,) (NP-SBJ (RB only) (NN J393/CD43)) (VP (VBD signaled) (NP (NN apoptosis))) (. .)))
(TOP (S-COOD (S (NP-SBJ-57 (NN J393/CD43)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN hyposialylated) (, ,) (S (VP (VBG bearing) (NP (ADJP (RB predominantly) (JJ O-linked)) (NN monosaccharide) (NNS glycans))))))))))) (, ,) (IN whereas) (S (NP-SBJ (NN G10-2/CD43)) (VP (VBD bore) (NP (ADJP (JJ complex) (VBN sialylated)) (NP-COOD (NP (JJ tetra-)) (CC and) (NP (NN hexasaccharide))) (NNS chains)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN with) (NP (ADJP-COOD (ADJP (JJ soluble)) (, ,) (ADJP (JJ bivalent))) (NN mAb) (NN J393)))) (VP (VBD killed) (NP (NP (QP (CD 25-50)) (NN %)) (PP (IN of) (NP (DT the) (NN cell) (NN population)))) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (JJ concomitant) (NN engagement)) (PP (IN of) (NP-COOD (CC either) (NP (DT the) (NN CD3.TcR) (NN complex)) (CC or) (NP (DT the) (NNS integrins) (NP-COOD (NP (NN CD18)) (CC and) (NP (NN CD29))))))) (ADVP (RB significantly)) (VP (VBD potentiated) (NP (DT this) (NN effect)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (NN Jurkat) (NNS cells))) (PP (IN with) (NP (NN mAb) (NN J393)))) (VP (VBD induced) (NP (NP (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NP (JJ specific) (NN protein) (NNS substrates)) (SBAR (WHNP-60 (WDT that)) (S (VP (VBD underwent) (NP (NN hyperphosphorylation)) (PP-TMP (IN upon) (NP (NN antigen) (NN receptor) (NN costimulation)))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Tyrosine) (NN kinase) (NN inhibition)) (PP (IN by) (NP (NN herbimycin) (NN A)))) (VP (VBD diminished) (NP (JJ J393/CD43-mediated) (NN apoptosis)))) (, ,) (IN whereas) (S (NP-SBJ (NP (NN inhibition)) (PP (IN of) (NP (NN phosphotyrosine) (NN phosphatase) (NN activity))) (PP (IN by) (NP (NN bis-LRB-maltolato-RRB-oxovanadium-IV)))) (VP (VBD enhanced) (NP (NN cell) (NN death)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Signal) (NN transduction)) (PP (IN through) (NP (NN tyrosine) (NN kinase) (NN activation)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ altered) (NN gene) (NN expression)))) (, ,) (SBAR (IN as) (S (NP-SBJ (NN J393/CD43) (NN ligation)) (VP (VBD prompted) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (DT the) (JJ nuclear) (NN localization)) (PP (IN of) (NP-COOD (NP (DT the) (JJ transcriptional) (JJ regulatory) (NN protein) (NN NF-kappaB)) (CC and) (NP (NP (NNS proteins)) (VP (VBG binding) (NP (DT the) (JJ interferon-inducible) (JJ regulatory) (NN element))))))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (JJ peripheral) (NN blood) (NNS T-lymphocytes)) (VP (VBP express) (NP (NP (JJ cryptic) (NNS epitopes)) (PP (IN for) (NP (NN mAb) (NN J393))))))) (, ,) (NP-SBJ (DT these) (NNS findings)) (VP (VBP demonstrate) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (ADJP (RB tightly) (VBN regulated)) (JJ CD43-mediated) (NN pathway)) (PP (IN for) (S (VP (VBG inducing) (NP (NP (NN apoptosis)) (PP (IN in) (NP (JJ human) (NN T-cell) (NNS lineages))))))))))) (. .)))
(TOP (NP (NP (NN Stat3) (NN recruitment)) (PP (IN by) (NP (NP (CD two) (JJ distinct) (ADJP-COOD (ADJP (JJ ligand-induced)) (, ,) (ADJP (JJ tyrosine-phosphorylated))) (NN docking) (NNS sites)) (PP (IN in) (NP (DT the) (NN interleukin-10) (NN receptor) (JJ intracellular) (NN domain))))) (. .)))
(TOP (S (NP-SBJ (JJ Recent) (NN work)) (VP (VBZ has) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NN IL-10)) (VP (VBZ induces) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN JAK-STAT) (NN signaling) (NN pathway))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB define) (NP (NP (DT the) (NN mechanism)) (VP (VBG underlying) (NP (NP (NP (NP (NP-COOD (NP (NN signal) (NN transducer)) (CC and) (NP (NN activator))) (PP (IN of) (NP (NN transcription)))) (PRN (-LRB- -LRB-) (NP (NN STAT)) (-RRB- -RRB-))) (NN protein) (NN recruitment)) (PP (TO to) (NP (DT the) (NP (NP (NN interleukin) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN IL-10)) (-RRB- -RRB-))) (NN receptor))))))))) (, ,) (NP-SBJ-52 (NP (DT the) (NN STAT) (NNS proteins)) (VP (VBN activated) (PP (IN by) (NP-LGS (NN IL-10))) (PP (IN in) (NP (JJ different) (NN cell) (NNS populations))))) (VP (VBD were) (ADVP-TMP (RB first)) (VP (VBN defined) (S (VP (VBG using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT all) (NNS cells)) (VP (VBN tested)))) (, ,) (NP-SBJ (NN IL-10)) (VP-COOD (VP (VBD activated) (NP-COOD (NP (NN Stat1)) (CC and) (NP (NN Stat3)))) (CC and) (VP (VBD induced) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (CD three) (JJ distinct) (NN DNA) (NN binding) (NNS complexes)) (SBAR (WHNP-53 (WDT that)) (S (VP (VBD contained) (NP (NP (JJ different) (NNS combinations)) (PP (IN of) (NP (DT these) (CD two) (NN transcription) (NNS factors)))))))))))) (. .)))
(TOP (S (NP-SBJ (NN IL-10)) (ADVP (RB also)) (VP (VBD activated) (NP (NN Stat5)) (PP (IN in) (NP (NP (NN Ba/F3) (NNS cells)) (SBAR (WHNP-54 (IN that)) (S (ADVP (RB stably)) (VP (VBD expressed) (NP (DT the) (JJ murine) (NN IL-10) (NN receptor)))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (DT a) (JJ structure-function) (NN mutagenesis) (NN approach)))) (, ,) (NP-SBJ-55 (NP (NP (CD two) (NN tyrosine) (NNS residues)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN Tyr427)) (CC and) (NP (NN Tyr477))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ intracellular) (NN domain)) (PP (IN of) (NP (DT the) (JJ murine) (NN IL-10) (NN receptor)))))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (ADVP (RB redundantly)) (VBN required) (PP-COOD (PP (IN for) (NP (NN receptor) (NN function))) (CC and) (PP (IN for) (NP (NP (NN activation)) (PP-COOD (PP (IN of) (NP (NN Stat3))) (CC but) (PP (RB not) (IN for) (NP-COOD (NP (NN Stat1)) (CC or) (NP (NN Stat5)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (CD Twelve) (NN amino) (NN acid) (NNS peptides)) (VP (VBG encompassing) (NP (NP (DT either)) (PP (IN of) (NP (NP (DT these) (CD two) (NN tyrosine) (NNS residues)) (PP (IN in) (NP (JJ phosphorylated) (NN form)))))))) (VP-COOD (VP (VBD coprecipitated) (NP-COOD (NP (NN Stat3)) (CONJP (CC but) (RB not)) (NP (NN Stat1)))) (CC and) (VP (VBD blocked) (NP (JJ IL-10-induced) (NN Stat3) (NN phosphorylation)) (PP (IN in) (NP (DT a) (JJ cell-free) (NN system))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (JJ tyrosine-phosphorylated) (NNS peptides)) (VP (VBG containing) (NP-COOD (NP (NN Tyr374)) (CC or) (NP (NN Tyr396))))) (VP (VBD did) (RB not) (VP-COOD (VP (VB interact) (PP (IN with) (NP (NN Stat3)))) (CC or) (VP (VB block) (NP (NN Stat3) (NN activation))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-COOD-57 (NP (NN Stat3)) (NP (CC but) (RB not)) (NP-COOD (NP (NN Stat1)) (CC or) (NP (NN Stat5)))) (VP (VBZ is) (VP (ADVP (RB directly)) (VBN recruited) (PP (TO to) (NP (DT the) (JJ ligand-activated) (NN IL-10) (NN receptor))) (PP (IN by) (S (VP (VBG binding) (PP (TO to) (NP (NP (ADJP-COOD (ADJP (JJ specific)) (CC but) (ADJP (JJ redundant))) (NN receptor) (JJ intracellular) (NN domain) (NNS sequences)) (VP (VBG containing) (NP (NN phosphotyrosine))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN study)) (ADVP (RB thus)) (VP (VBZ supports) (NP (DT the) (NN concept) (SBAR (IN that) (S (NP-SBJ (NP (NN utilization)) (PP (IN of) (NP (JJ distinct) (NN STAT) (NNS proteins))) (PP (IN by) (NP (JJ different) (NN cytokine) (NNS receptors)))) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ particular) (ADJP-COOD (ADJP (JJ ligand-activatable)) (, ,) (ADJP (JJ tyrosine-containing))) (NN STAT) (NN docking) (NNS sites)) (PP (IN in) (NP (NN receptor) (JJ intracellular) (NNS domains))))))))))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Identification)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (NP (DT a) (JJ leukocyte-specific) (NN component)) (PP (IN of) (NP (DT the) (JJ nuclear) (NN body))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ nuclear) (NN body)) (PRN (-LRB- -LRB-) (NP (NN NB)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ cellular) (NN organelle)) (SBAR (WHNP-74 (WDT that)) (S (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP-COOD (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (CC and) (NP (JJ viral) (NN infection)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN NB)) (VP (VBZ is) (ADVP (RB also)) (NP-PRD (NP (DT a) (NN target)) (PP (IN of) (NP (NNS antibodies))) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (DT the) (JJ autoimmune) (NN disease) (JJ primary) (JJ biliary) (NN cirrhosis))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ-76 (NP (NN serum)) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ primary) (JJ biliary) (NN cirrhosis)))))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (NP (DT a) (NN cDNA)) (VP (VBG encoding) (NP (NP (NP (DT a) (JJ novel) (NN component)) (PP (IN of) (NP (DT the) (NN NB)))) (, ,) (NP (NP (DT a) (JJ 140-kDa) (NN protein)) (VP (VBN designated) (S (NP-PRD (NN Sp140))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (VBN predicted) (NN amino) (NN acid) (NN sequence)) (PP (IN of) (NP (NP (DT the) (JJ amino-terminal) (NN portion)) (PP (IN of) (NP (NN Sp140)))))) (VP (VBD was) (ADJP-PRD (JJ similar) (PP (TO to) (NP (NP (NN Sp100)) (, ,) (NP (DT a) (ADJP (RB previously) (VBN identified)) (NN NB) (NN protein)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ carboxyl) (NN portion)) (PP (IN of) (NP (NN Sp140)))) (VP (VBD contained) (NP (NP-COOD (NP (DT a) (JJ zinc-finger) (NN domain)) (CC and) (NP (DT a) (NN bromodomain))) (, ,) (NP (NP (NNS motifs)) (SBAR (WHNP-77 (WDT that)) (S (VP (VBP are) (ADJP-PRD (JJ present) (PP (IN in) (NP (NP (NNS proteins)) (VP (VBG regulating) (NP (NN gene) (NN transcription)))))))))))) (. .)))
(TOP (S (NP-SBJ-78 (NP (JJ High) (NNS levels)) (PP (IN of) (NP (NN Sp140) (NN mRNA)))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP-COOD (NP (JJ human) (NP-COOD (NP (NN spleen)) (CC and) (NP (JJ peripheral) (NN blood))) (NNS leukocytes)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ other) (JJ human) (NNS tissues)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN level)) (PP (IN of) (NP (NN SP140) (NN mRNA))) (PP (IN in) (NP (JJ myeloid) (NN precursor) (NN cell) (NNS lines) (NP-COOD (NP (NN HL60)) (CC and) (NP (NN NB4)))))) (ADVP (RB markedly)) (VP (VBD increased) (PP (IN in) (NN response) (TO to) (NP (ADJP (RB chemically) (VBN induced)) (JJ cellular) (NN differentiation)))) (. .)))
(TOP (S (NP-SBJ-79 (JJ Immunohistochemical) (NNS techniques)) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB demonstrate) (SBAR (IN that) (S (NP-SBJ (NN SP140)) (VP (VBD localized) (PP (TO to) (NP (DT the) (NN NB))) (PP (IN in) (NP (VBN differentiated) (NP-COOD (NP (NN HL60)) (CC and) (NP (NN NB4))) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (DT The) (NN location)) (PP (IN of) (NP (NN Sp140))) (PP (IN in) (NP (DT the) (NN NB)))) (, ,) (CC and) (NP (NP (NN expression)) (PP (IN of) (NP (DT this) (NN gene))) (PP (IN in) (NP (NP (NNS cells)) (VP (VBN involved) (PP (IN in) (NP (NN host) (NN defense))))))) (, ,)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-81 (NN Sp140)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP-COOD (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (CC and) (NP (JJ viral) (NN infection)))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ T-cell-directed) (NN TAL-1) (NN expression)) (VP (VBZ induces) (NP (NN T-cell) (NNS malignancies)) (PP (IN in) (NP (JJ transgenic) (NNS mice)))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN TAL-1) (NN gene)) (VP (VBZ specifies) (PP (IN for) (NP (NP (DT a) (JJ basic) (JJ domain-helix-loop-helix) (NN protein)) (, ,) (SBAR (WHNP-63 (WDT which)) (S (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ normal) (NN hematopoiesis)))))))))))) (. .)))
(TOP (S (S (PP (IN In) (NP (JJ human) (NN pathology))) (, ,) (NP-SBJ-65 (DT the) (NN TAL-1) (NN gene) (NN product)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (NP (DT a) (JJ high) (NN percentage)) (PP (IN of) (NP (NN T-cell) (JJ acute) (JJ lymphoblastic) (NNS leukemias))))) (PP (IN in) (NP (DT the) (JJ pediatric) (NN age) (NN range))))) (: ;)) (S (ADVP (RB however)) (, ,) (NP-SBJ (PRP it)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established) (SBAR (IN whether) (S (NP-SBJ (DT the) (NN expression)) (VP (VBZ has) (NP (DT a) (JJ causal) (NN role)) (PP (IN in) (NP (NN oncogenesis))))))))) (. .))))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP describe) (NP (NP (DT the) (NN phenotype)) (PP (IN of) (NP (NN mouse) (JJ transgenic) (NNS lines))) (VP (VBN obtained) (PP (IN by) (S (VP (VBG inducing) (NP (NP (NN tal-1) (NN protein) (NN expression)) (PP (IN in) (NP (JJ lymphoid) (NNS tissues)))) (S (VP (VBG using) (NP (DT the) (NN LCK) (NN promoter)))))))))) (. .)))
(TOP (S (NP-SBJ-106 (NP (DT The) (NN survival) (NN rate)) (PP (IN of) (NP (NN tal-1) (JJ transgenic) (NNS animals)))) (VP (VBD was) (ADJP-PRD (RB much) (JJR lower)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NN control) (NNS mice))))))) (. .)))
(TOP (S (NP-SBJ (JJ Histopathological) (NN analysis)) (VP (VBD revealed) (NP (NP (NNS lymphomas)) (PP (IN of) (NP (NN T-cell) (NN type))) (, ,) (VP (ADVP-TMP (RB often)) (VBG comprising) (NP (DT a) (JJ minor) (NN B-cell) (NN component))))) (. .)))
(TOP (S (NP-SBJ (DT Some) (NNS mice)) (VP (VBD showed) (NP (JJ marked) (JJ splenic) (NN lymphocyte) (NN depletion))) (. .)))
(TOP (S (NP-SBJ (JJ Primary) (NN lymphocyte) (NNS cultures)) (VP-COOD (VP (VBD showed) (NP (NP (JJ partial) (NN independence)) (PP (IN from) (NP (JJ exogenous) (NN growth) (NNS stimuli))))) (CC and) (VP (VBD increased) (NP (NP (NN resistance)) (PP (TO to) (NP (JJ low-serum) (NN apoptosis)))))) (. .)))
(TOP (S (S (S (VP (TO To) (VP (ADVP (RB further)) (VB unravel) (NP (DT the) (NN tal-1) (JJ oncogenic) (NN potential))))) (, ,) (NP-SBJ-68 (NP (DT a) (NN strain)) (PP (IN of) (NP (NN tal-1) (JJ transgenic) (NNS mice)))) (VP (VBD was) (VP (VBN crossbred) (PP (IN with) (NP (JJ p53-/-) (NNS mice))))) (: ;)) (S-COOD (S (NP-SBJ-69 (NP (DT the) (NN survival) (NN rate)) (PP (IN in) (NP (DT these) (NNS animals)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (QP (JJR more) (IN than) (NN one-half)))) (SBAR-TMP (WHADVP-70 (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NN tal-1) (NNS mice))))))))))) (, ,) (CC and) (S (NP-SBJ (JJ histopathological) (NN analysis)) (VP (VBD revealed) (ADVP (RB exclusively)) (NP (NN T-cell) (NNS lymphomas)))) (. .))))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN TAL-1)) (, ,) (VP (VBN expressed) (PP (IN in) (NP (NN T) (NNS cells)))) (, ,)) (VP (VBZ is) (ADVP (FW per) (FW se)) (NP-PRD (NP (DT a) (JJ potent) (NN oncogene)) (, ,) (SBAR (WHNP-71 (WDT which)) (S (VP (MD may) (VP (VB exert) (NP (DT a) (JJ key) (JJ leukemogenetic) (NN role)) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NN T-cell) (JJ acute) (JJ lymphoblastic) (NNS leukemias)))))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Naive) (-LRB- -LRB-) (JJ CD45RA+) (-RRB- -RRB-) (NN T) (NNS lymphocytes)) (VP (VBP are) (ADJP-PRD (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (ADJP (JJ oxidative) (JJ stress-induced)) (NNS signals)))) (PP (IN than) (NP (NN memory) (-LRB- -LRB-) (JJ CD45RO+) (-RRB- -RRB-) (NNS cells))))) (. .)))
(TOP (S (S (NP-SBJ-54 (NP (NN Formation)) (PP (IN of) (NP (NP (JJ reactive) (NN oxygen) (NNS intermediates)) (PRN (-LRB- -LRB-) (NP (NN ROI)) (-RRB- -RRB-)))) (PP-TMP (IN after) (NP (JJ oxidative) (NN stress)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (S (VP (TO to) (VP (VB be) (NP-PRD (NP (DT an) (NN activation) (NN signal)) (PP (IN for) (NP (NN T) (NNS lymphocytes))))))) (, ,) (S (ADVP (FW e.g.)) (, ,) (NP-SBJ-55 (NP (NN expression)) (PP (IN of) (NP-COOD (NP (NN IL-2)) (CC and) (NP (PRP$ its) (NN receptor))))) (VP (VBP are) (VP (VBN induced)))))))) (. .))))
(TOP (S (NP-SBJ-56 (DT These) (JJ ROI-induced) (NNS effects)) (VP (MD can) (, ,) (PP (TO to) (NP (DT a) (JJ large) (NN extent))) (, ,) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (DT the) (NN transcription) (NN factor) (NN NF-kappaB)))))))) (. .)))
(TOP (S (ADVP-TMP (RB Now)) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN examined) (SBAR (IN whether) (S (NP-SBJ (UCP-COOD (ADJP (JJ naive)) (CC and) (NP (NN memory))) (NN T) (NNS lymphocytes)) (VP (VBP differ) (PP (IN in) (NP (NP (PRP$ their) (NN sensitivity)) (PP (TO to) (NP (JJ ROI-mediated) (NNS signals)))))))))) (. .)))
(TOP (S (S-COOD (SBAR-TMP (WHADVP-57 (WRB When)) (S (NP-SBJ-58 (ADJP-COOD (ADJP (ADJP (JJ CD45RA+)) (PRN (-LRB- -LRB-) (ADJP (JJ naive)) (-RRB- -RRB-))) (CC and) (ADJP (ADJP (JJ CD45RO+)) (PRN (-LRB- -LRB-) (NP (NN memory)) (-RRB- -RRB-)))) (NN T) (NNS lymphocytes)) (VP (VBD were) (VP (ADVP (RB directly)) (VBN stimulated) (PP (IN with) (NP (NN H2O2))))))) (, ,) (NP-SBJ (NN NF-kappaB) (JJ nuclear) (NN translocation)) (VP (VBD was) (ADJP-PRD (ADJP (JJR stronger))) (PP (IN in) (NP (JJ naive) (NNS cells))) (PP-109 (IN than) (FRAG (PP (IN in) (NP (NN memory) (NNS cells))))))) (CC and) (S (NP-SBJ-59 (PRP it)) (VP (MD could) (VP (VB be) (VP (VBN induced) (PP (IN with) (NP (JJR lower) (NNS doses))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (DT The) (NN composition)) (PP (IN of) (NP (DT the) (VBN induced) (JJ nuclear) (NN NF-kappaB)))) (PRN (-LRB- -LRB-) (NP (NP (NNS levels)) (PP (IN of) (NP (NP-COOD (NP (NN p50)) (CC and) (NP (NN RelA))) (NNS proteins)))) (-RRB- -RRB-))) (VP (VBD was) (ADJP-PRD (JJ similar)) (PP (IN in) (NP (DT these) (NN cell) (NNS types)))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NP-COOD (NP (NN magnitude)) (CC and) (NP (NNS kinetics)))) (PP (IN of) (NP (JJ intracellular) (NN ROI)))) (VP (VBD were) (ADJP-PRD (JJ similar)) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (EX there)) (VP (VBD were) (NP-PRD (DT no) (NNS differences)) (PP (IN in) (NP-COOD (NP (JJ ROI-forming) (NNS mechanisms)) (CC or) (NP (JJ antioxidative) (NNS capacities)))))))))) (. .)))
(TOP (S (S (NP-SBJ (DT The) (JJ probable) (JJ regulatory) (NN point)) (VP (VBD was) (NP-PRD (DT the) (JJ cytoplasmic) (NN IkappaB) (NN inhibitor))) (: :)) (S (PP (IN in) (NP (JJ CD45RA+) (NNS cells))) (, ,) (NP-SBJ (NN H2O2)) (VP (VBD caused) (NP (NP (DT a) (ADJP (RBR more) (JJ profound)) (NN depression)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN IkappaB) (NN alpha))))))) (. .))))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN T) (NNS cells)) (VP (VBG representing) (NP (JJ different) (NP-COOD (NP (NN activation)) (CC and/or) (NP (NN differentiation))) (NNS stages)))) (VP (MD can) (VP (VB be) (ADJP-PRD (RB differentially) (JJ responsive) (PP (TO to) (NP (JJ ROI-mediated) (NNS signals))))))))) (. .)))
(TOP (NP (NP (JJ Potent) (NN gene) (ADJP-COOD (ADJP (JJ regulatory)) (CC and) (ADJP (JJ antiproliferative))) (NNS activities)) (PP (IN of) (NP (NP (JJ 20-methyl) (NNS analogues)) (PP (IN of) (NP (CD 1,25) (NN dihydroxyvitamin) (NN D3))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (DT The) (JJ biological) (JJ active) (NN form)) (PP (IN of) (NP (NN vitamin) (NN D3)))) (, ,) (NP (NP (NN 1,25-dihydroxyvitamin) (NN D3)) (PRN (-LRB- -LRB-) (NP (NN VD)) (-RRB- -RRB-))) (, ,)) (VP (VBZ regulates) (NP (JJ cellular) (NP-COOD (NP (NN growth)) (CC and) (NP (NN differentiation))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBZ provides) (NP (DT the) (NN hormone)) (PP (IN with) (NP (DT an) (JJ interesting) (JJ therapeutic) (NN potential)))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NN hypercalcemia)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ side) (NN effect)) (, ,) (SBAR (WHNP-82 (WDT which)) (S (VP (VBZ is) (VP (VBN caused) (PP (IN by) (NP-LGS (NP (NP (NN VD) (POS 's)) (JJ classical) (NN action)) (, ,) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN calcium) (NN homeostasis)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBD made) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NN VD) (NNS analogues)) (PP (IN with) (NP (ADJP (RB selectively) (VBN increased)) (NN cell) (JJ regulatory) (NNS properties))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Studies)) (PP (IN with) (NP (JJ 20-epi) (NNS analogues)))) (VP-COOD (VP (VBD pointed) (PRT (RP out)) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT the) (NN carbon-20) (NN position))))) (CC and) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NN 20-methyl) (NNS derivatives)) (PP (IN of) (NP (NN VD))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (NP-SBJ-84 (NP (DT the) (JJ biological) (NNS properties)) (PP (IN of) (NP (NP (DT the) (NNS compounds) (NP-COOD (NP (NN ZK161422)) (CC and) (NP (NN ZK157202)))) (, ,) (SBAR (WHNP-85 (WDT which)) (S (VP (VBP are) (NP-PRD (NP-COOD (NP (NN 20-methyl-)) (CC and) (NP (NN 20-methyl-23-eneanalogues))) (, ,) (ADVP (RB respectively)))))) (, ,)))) (VP (VBP have) (VP (VBN been) (VP (VBN analyzed) (PP (IN in) (NN comparison) (IN with) (NP (NN VD)))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (NNS compounds)) (VP (VBP show) (NP (NP (NP (ADJP (ADVP (IN about) (RB 2-fold)) (JJR lower)) (NN affinity)) (PP (TO to) (NP (NP (DT the) (NN VD) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN VDR)) (-RRB- -RRB-))))) (PP (IN than) (NP (NN VD))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (S (VP (VBN compared) (PP (TO to) (NP (NN VD))))) (, ,) (NP-SBJ-86 (PRP$ their) (JJ antiproliferative) (NN effect)) (VP-COOD (VP (VBZ is) (ADJP-PRD-107 (ADVP (QP (RB up) (TO to) (RB 30-fold))) (JJR higher)) (PP-108 (IN on) (NP (JJ human) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)))) (CC and) (VP (ADJP-PRD=107 (RB even) (ADVP (RB up) (TO to) (RB 300-fold)) (JJR higher)) (PP=108 (IN on) (NP (JJ human) (NN breast) (NN cancer) (NN MCF-7) (NNS cells))))) (. .)))
(TOP (S (SBAR (IN Whereas) (S (NP-SBJ-88 (NP (DT the) (JJ hypercalcemic) (NN effect)) (PP (IN for) (NP (NN ZK157202)))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN increased) (ADVP (RB 10-fold)))))) (, ,) (NP-SBJ (NN ZK161422)) (VP (VBZ has) (NP (NP (DT the) (JJ same) (JJ calcium-mobilizing) (NN potency)) (PP (IN as) (NP (NN VD))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-COOD (NP (NN ZK161422)) (, ,) (CONJP (CC but) (RB not)) (NP (NN ZK157202)) (, ,)) (VP (VBD showed) (NP (NP (NN preference)) (PP-COOD (PP (IN for) (NP (NP (NN gene) (NN activation)) (PP (IN from) (NP (NP (DT a) (NN promoter)) (VP (VBG carrying) (NP (NP (DT a) (NN VD) (NN response) (NN element)) (PP (IN with) (NP (NP (DT a) (JJ palindromic) (NN arrangement)) (PP (IN of) (NP (NP (CD two) (JJ hexameric) (NN receptor) (NN binding) (NNS sites)) (VP (VBN spaced) (PP (IN by) (NP-LGS (NP (CD 9) (NNS nucleotides)) (PRN (-LRB- -LRB-) (NP (NN IP9)) (-RRB- -RRB-))))))))))))))) (CONJP (RB rather) (IN than)) (PP (IN for) (NP (NP (NN activation)) (PP (IN from) (NP (NP (DT a) (NN response) (NN element)) (VP (VBN formed) (PP (IN by) (NP-LGS (NP (NP (DT a) (JJ direct) (NN repeat)) (VP (VBN spaced) (PP (IN by) (NP-LGS (CD 3) (NNS nucleotides))))) (PRN (-LRB- -LRB-) (NP (NN DR3)) (-RRB- -RRB-)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN observation)) (VP (VBZ supports) (NP (NP (DT a) (NN model)) (, ,) (SBAR (WHPP-89 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NN promoter) (NN selectivity)) (VP (VBZ reflects) (NP (NP (DT the) (ADJP (RB selectively) (VBN increased)) (JJ antiproliferative) (NN effect)) (PP (IN of) (NP (NN VD) (NNS analogues))))))))) (. .)))
(TOP (S (NP-SBJ-35 (NN Interferon)) (VP-COOD (VP (VBZ augments) (NP (NP (NP-COOD (NP (NN PML)) (CC and) (NP (NN PML/RAR) (NN alpha))) (NN expression)) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ normal) (JJ myeloid)) (CC and) (ADJP (JJ acute) (JJ promyelocytic))) (NNS cells))))) (CC and) (VP (VBZ cooperates) (PP (IN with) (NP (JJ all-trans) (JJ retinoic) (NN acid))) (S (VP (TO to) (VP (VB induce) (NP (NP (NN maturation)) (PP (IN of) (NP (DT a) (JJ retinoid-resistant) (JJ promyelocytic) (NN cell) (NN line))))))))) (. .)))
(TOP (S (NP-SBJ-36 (DT The) (NN PML) (NN gene)) (VP (VBZ is) (VP (VBN fused) (PP (TO to) (NP (NP (DT the) (JJ retinoic) (NN acid) (NN receptor) (NN alpha) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN RAR) (NN alpha)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (CD 15) (: ;) (CD 17) (NN translocation))))) (. .)))
(TOP (S (NP-SBJ-37 (NN PML)) (VP (VBZ is) (VP-COOD (VP (VBN expressed) (PP (IN in) (NP (JJ diverse) (NP-COOD (NP (NNS tissues)) (CC and) (NP (NN cell) (NNS lines)))))) (CC and) (VP (JJ localized) (PP (IN in) (NP (DT the) (NN nucleus))) (PP (IN with) (NP (DT a) (JJ typical) (JJ speckled) (NN pattern)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (NN bone) (NN marrow))) (, ,) (NP-SBJ-39 (PRP it)) (VP (VBZ is) (VP (ADVP (RB preferentially)) (VBN expressed) (PP (IN in) (NP (JJ myeloid) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ-40 (NN PML)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VP (ADVP (RB transcriptionally)) (VBN regulated) (PP (IN by) (NP-LGS (NN class) (NP-COOD (NP (CD I)) (CC and) (NP (CD II))) (NNS interferons)))) (, ,) (SBAR (WHNP-42 (WDT which)) (S (VP (VBZ raises) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP-SBJ-43 (NNS interferons)) (VP (VBP modulate) (NP (NP (DT the) (NP-COOD (NP (NN function)) (CC and) (NP (NN growth)) (CC and) (NP (NN differentiation))) (NN potential)) (PP (IN of) (NP (JJ normal) (JJ myeloid) (NP-COOD (NP (NNS cells)) (CC and) (NP (NNS precursors)))))) (PP (IN by) (S (VP (VBG activating) (NP (JJ PML-dependent) (NNS pathways))))))))))))))))) (. .)))
(TOP (S (ADVP (RB Similarly)) (, ,) (NP-SBJ (NNS interferons)) (VP (MD could) (VP (VB act) (PP (IN on) (NP (NN APL) (NNS cells))) (, ,) (UCP-COOD (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ all-trans) (NP (NP (JJ retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-)))))))) (, ,) (SBAR (RB especially) (IN if) (S (NP-SBJ-44 (NP (DT the) (NN PML/RAR) (NN alpha) (NN fusion) (NN transcript)) (SBAR (WHNP-45 (WDT that)) (S (VP (VBZ results) (PP (IN from) (NP (DT the) (SYM t-LRB-15;) (NN 17-RRB-))))))) (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP-LGS (NN interferon))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP report) (ADVP (RB here)) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ-46 (NN PML)) (VP-COOD (VP (VBZ is) (VP-COOD (VP (VBN expressed) (PP (IN at) (NP (JJ low) (NNS levels)))) (CC or) (VP (RB not) (VBN expressed) (PP (IN in) (NP (JJ normal) (VBG circulating) (JJ human) (NP-COOD (NP (NNS monocytes)) (, ,) (NP (NNS lymphocytes)) (, ,) (CC and) (NP (JJ polymorphonucleate) (NNS cells)))))))) (, ,) (CC but) (VP (VBZ is) (VP (ADVP (RB markedly)) (VBN induced) (PP (IN by) (NP-LGS (NN interferon)))))))) (: ;) (SBAR (IN that) (S (NP-SBJ-49 (NP (NP (NN PML)) (CC and) (NP (NN PML/RAR) (NN alpha))) (NN expression)) (VP (VBZ is) (VP (VBN augmented) (PP (IN by) (NP-LGS (NN interferon))) (PP-COOD (PP (IN in) (NP (NP (DT the) (NN NB4) (NN APL) (NN cell) (NN line)) (, ,) (SBAR (WHNP-50 (WDT which)) (S (VP (VBZ carries) (NP (DT the) (SYM t-LRB-15;) (NN 17-RRB-))))) (, ,))) (CC and) (PP (IN in) (NP (NP (NN APL) (NNS blasts)) (PP (IN from) (NP (NNS patients)))))))))) (: ;) (SBAR (IN that) (S (NP-SBJ (NN interferon)) (VP (VBZ inhibits) (NP (NP-COOD (NP (NN growth)) (CC and) (NP (NN survival))) (PP (IN of) (NP (NN NB4) (NN APL) (NNS cells)))) (PP (IN in) (NN cooperation) (IN with) (NP (NN RA)))))) (: ;) (SBAR (IN that) (S (NP-SBJ (NP (NNS interferons)) (ADVP (RB alone))) (VP (VBP have) (NP (JJ minimal) (NN maturation) (NN effect)) (PP (IN on) (NP (NN NB4) (NNS cells)))))) (: ;) (CC and) (, ,) (SBAR (ADVP-TMP (RB finally)) (, ,) (IN that) (S (NP-SBJ (NN interferon) (NP-COOD (NP (NN gamma)) (, ,) (CONJP (CC but) (RB not)) (NP-COOD (NP (NN alpha)) (CC or) (NP (NN beta))) (, ,))) (VP-COOD (VP (VBZ induces) (NP (NP-COOD (NP (NN maturation)) (CC and) (NP (NN growth) (NN suppression))) (PP (IN of) (NP (NP (NN NB4) (NNS cells)) (PP (IN with) (NP (ADJP (FW de) (FW novo)) (NN retinoid) (NN resistance))))))) (, ,) (CC and) (VP (ADVP (RB partially)) (VBZ restores) (NP (NN RA) (NN response)))))))) (. .)))
(TOP (NP (NP (NN Generation)) (PP (IN of) (NP-COOD (NP (JJ CD1+RelB+) (JJ dendritic) (NNS cells)) (CC and) (NP (ADJP (JJ tartrate-resistant) (NN acid) (JJ phosphatase-positive)) (JJ osteoclast-like) (JJ multinucleated) (JJ giant) (NNS cells)))) (PP (IN from) (NP (JJ human) (NNS monocytes))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB previously)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NP (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (CC and) (NP (NP (NN macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN M-CSF)) (-RRB- -RRB-)))) (VP (VBP stimulate) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (JJ human) (NNS monocytes))) (PP (IN into) (NP (NP (CD two) (ADJP (RB phenotypically) (JJ distinct)) (NNS types)) (PP (IN of) (NP (NNS macrophages)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (ADVP (FW in) (FW vivo)) (, ,) (NP-SBJ-COOD-48 (CONJP (RB not) (RB only)) (NP (NN CSF)) (CONJP (CC but) (RB also)) (NP (JJ many) (JJ other) (NNS cytokines))) (VP (VBP are) (VP (VBN produced) (PP (IN under) (NP (JJ various) (NNS conditions))))) (. .)))
(TOP (S (NP-SBJ (DT Those) (NNS cytokines)) (VP (MD may) (VP (VB modulate) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NNS monocytes))) (PP (IN by) (NP (NNS CSFs)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD showed) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (JJ CD14+) (JJ adherent) (JJ human) (NNS monocytes)) (VP (MD can) (VP (VB differentiate) (PP (IN into) (NP (JJ CD1+relB+) (NP (NP (JJ dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN DC)) (-RRB- -RRB-))))) (PP (IN by) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP-COOD (NP (NN GM-CSF)) (CC plus) (NP (NP (NN interleukin-4)) (PRN (-LRB- -LRB-) (NP (NN IL-4)) (-RRB- -RRB-))))))))))) (CC and) (SBAR (IN that) (S (NP-SBJ (PRP they)) (VP (VBP differentiate) (PP (IN into) (NP (ADJP (JJ tartrate-resistant) (NN acid) (NN phosphatase) (-LRB- -LRB-) (NN TRAP) (-RRB- -RRB-) (JJ -positive)) (JJ osteoclast-like) (NP (NP (JJ multinucleated) (JJ giant) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN MGC)) (-RRB- -RRB-))))) (PP (IN by) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP-COOD (NP (NN M-CSF)) (CC plus) (NP (NN IL-4))))))))))) (. .)))
(TOP (S (S (ADVP (RB However)) (, ,) (NP-SBJ (DT the) (JJ monocyte-derived) (NN DC)) (VP (VBD were) (RB not) (NP-PRD (ADJP (RB terminally) (VBN differentiated)) (NNS cells))) (: ;)) (S (NP-SBJ (PRP they)) (VP (MD could) (VP (ADVP (RB still)) (VB convert) (PP (TO to) (NP (NNS macrophages))) (PP (IN in) (NN response) (TO to) (NP (NN M-CSF))))) (. .))))
(TOP (S (NP-SBJ-49 (NP (NN Tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))) (VP (VBD stimulated) (NP (NP (DT the) (JJ terminal) (NN differentiation)) (PP (IN of) (NP (DT the) (NN DC)))) (PP (IN by) (S (VP-COOD (VP (VBG downregulating) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT the) (NN M-CSF) (NN receptor)) (, ,) (NP (NN cfms) (NN mRNA)))))) (, ,) (CC and) (VP (VBG aborting) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB convert) (PP (TO to) (NP (NNS macrophages)))))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NN IL-4))) (, ,) (NP-SBJ (NP (NN interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-))) (VP (VBD had) (NP (DT no) (JJ demonstrable) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN differentiation)) (PP (IN of) (NP (NNS monocytes)))))) (. .)))
(TOP (S (ADVP (RB Rather)) (, ,) (NP-SBJ (NN IFN-gamma)) (VP-COOD (VP (VBD antagonized) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN IL-4))))) (CC and) (VP (VBD suppressed) (NP (NP (DT the) (NP-COOD (NP (NN DC)) (CC and) (NP (NN MGC))) (NN formation)) (VP (VBN induced) (PP (IN by) (NP-LGS (NP-COOD (NP-COOD (NP (NN GM-CSF)) (CC +) (NP (NN IL-4))) (CC and) (NP-COOD (NP (NN M-CSF)) (CC +) (NP (NN IL-4)))) (, ,) (ADVP (RB respectively)))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-107 (DT these) (NNS results)) (VP-COOD (VP (VBP provide) (NP (DT a) (JJ new) (NN aspect)) (PP-DTV (TO to) (NP (NP (PRP$ our) (NN knowledge)) (PP (IN of) (NP (NN monocyte) (NN differentiation)))))) (CC and) (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ (JJ human) (NNS monocytes)) (VP-COOD (VP (VBP are) (ADJP-PRD (JJ flexible)) (PP (IN in) (NP (PRP$ their) (NN differentiation) (NN potential)))) (CC and) (VP (VBP are) (NP-PRD (NP (NNS precursors)) (PP-COOD (CONJP (RB not) (RB only)) (PP (IN of) (NP (NNS macrophages))) (CONJP (CC but) (RB also)) (PP (IN of) (NP-COOD (NP (NN CD1+relB+DC)) (CC and) (NP (JJ TRAP-positive) (NN MGC))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (PDT Such) (DT a) (JJ diverse) (NN pathway)) (PP (IN of) (NP (NN monocyte) (NN differentiation)))) (VP (MD may) (VP (VB constitute) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ basic) (NNS mechanisms)) (PP (IN of) (NP (JJ immune) (NN regulation)))))))) (. .)))
(TOP (NP (NP (NN T) (NN cell) (NN response)) (PP (TO to) (NP (JJ Epstein-Barr) (NN virus) (NNS transactivators))) (PP (IN in) (NP (JJ chronic) (JJ rheumatoid) (NN arthritis))) (. .)))
(TOP (S (NP-SBJ (JJ Rheumatoid) (NN arthritis)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ multistep) (NN disorder)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ autoimmune) (NNS features)) (PP (IN of) (NP (ADJP (RB yet) (JJ unknown)) (NN etiology)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-71 (NP (NN Implication)) (PP (IN of) (NP (NP (NNS viruses)) (PP (JJ such) (IN as) (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-)))))) (PP (IN in) (NP (JJ rheumatoid) (NN arthritis) (NN pathogenesis)))) (VP (VBZ has) (VP (VBN been) (VP (VBN suspected) (PP (IN on) (DT the) (NN basis) (IN of) (NP (JJ several) (JJ indirect) (NNS observations))))))) (, ,) (CC but) (S (ADVP-TMP (RB thus) (RB far)) (, ,) (NP-SBJ-72 (NP (DT a) (JJ direct) (NN link)) (PP (IN between) (NP-COOD (NP (NN EBV)) (CC and) (NP (JJ rheumatoid) (NN arthritis))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN provided))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (JJ large) (NN fraction)) (PP (IN of) (NP (NN T) (NNS cells))) (VP (VBG infiltrating) (NP (NP (VBN affected) (NNS joints)) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ chronic) (JJ rheumatoid) (NN arthritis)))))))) (VP (VBZ recognizes) (NP (NP (CD two) (NN EBV) (NNS transactivators)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NN BZLF1)) (CC and) (NP (NN BMLF1))) (-RRB- -RRB-))) (PP (IN in) (NP (DT a) (ADJP (JJ major) (NN histocompatibility) (JJ complex-restricted)) (NN fashion))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Responses)) (PP (TO to) (NP (DT these) (NN EBV) (NNS antigens))) (PP (IN by) (NP (NP (JJ synovial) (NNS lymphocytes)) (PP (IN from) (NP (JJ several) (JJ other) (JJ chronic) (JJ rheumatoid) (NN arthritis) (NNS patients)))))) (VP (VBD were) (ADJP-PRD (RB readily) (JJ detectable))) (. .)))
(TOP (S (ADVP (RB Thus)) (NP-SBJ (DT these) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ direct) (NN contribution)) (PP (IN of) (NP (NN EBV))) (PP (TO to) (NP (JJ chronic) (JJ rheumatoid) (NN arthritis) (NN pathogenesis))))) (. .)))
(TOP (S (NP-SBJ (PRP They)) (ADVP (RB also)) (VP (VBP demonstrate) (PP-TMP (IN for) (NP (DT the) (JJ first) (NN time))) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (NN T) (NN cell) (NNS responses)) (PP (IN against) (NP (NN EBV) (VBG transactivating) (NNS factors))))) (, ,) (SBAR (WHNP-73 (WDT which)) (S (VP (MD might) (VP (VB be) (ADJP-PRD (JJ central)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN virus) (NN reactivation))))))))))) (. .)))
(TOP (NP (NP (JJ Differential) (JJ nuclear) (NN localization)) (PP (IN of) (NP (NP-COOD (NP (NN p50)) (, ,) (NP (NN p52)) (, ,) (CC and) (NP (NN RelB))) (NNS proteins))) (PP (IN in) (NP (NP (JJ human) (JJ accessory) (NNS cells)) (PP (IN of) (NP (NP (DT the) (JJ immune) (NN response)) (ADVP (FW in) (FW situ)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN Rel/NF-kappa) (NN B) (NNS proteins)) (, ,) (NP-COOD (NP (NN p50)) (, ,) (NP (NN p52)) (, ,) (NP (NN p65)) (, ,) (NP (NN c-Rel)) (, ,) (CC and) (NP (NN RelB))) (, ,)) (VP (VBP constitute) (NP (NP (DT a) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors))) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ positive) (NN regulation)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS genes))))) (PP-TMP (IN during) (NP (DT the) (JJ immune) (NN response)))))))) (. .)))
(TOP (S (ADVP-TMP (RB Recently)) (, ,) (NP-SBJ (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ (NN RelB) (JJ knockout) (NNS mice)) (VP (VBP have) (NP (DT no) (NP (NP (JJ dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN DC)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ-58 (NP (DT An) (NN overexpression)) (PP (IN of) (NP (NN p50)))) (VP (VBZ has) (VP (VBN been) (VP (VBN described) (PP (IN in) (NP (NP (JJ follicular) (JJ dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN FDC)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP-SBJ-59 (DT A) (JJ constitutive) (NN NF-kappa) (NN B) (NN activity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (JJ mature) (NNS macrophages)))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBD led) (PP (TO to) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP-SBJ (NP (DT some)) (PP (IN of) (NP (DT the) (NN Rel/NF-kappa) (NN B) (NNS proteins)))) (VP (VBD were) (NP-PRD (NP (JJ key) (JJ nuclear) (NNS factors)) (PP (IN in) (NP (NP (NNS functions)) (PP (IN of) (NP (NP (JJ accessory) (NNS cells)) (PP (IN of) (NP (DT the) (JJ immune) (NN response)))))))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD investigated) (ADVP (FW in) (FW situ)) (NP (NP (DT the) (JJ nuclear) (NN localization)) (PP (IN of) (NP (NN Rel/NF-kappa) (NN B) (NNS proteins))) (PP (IN in) (NP (NP (JJ accessory) (NNS cells)) (PP (IN of) (NP (DT the) (JJ immune) (NN system)))))) (PP (IN by) (NP-COOD (NP (NN immunohistochemistry)) (CC and) (NP (NP (JJ double) (NN labeling)) (PP (IN by) (NP (NN immunofluorescence)))))) (PP-60 (IN from) (NP-COOD (NP (CD five) (JJ normal) (JJ human) (NNS tonsils)) (CC and) (NP (NP (CD five) (NN lymph) (NNS nodes)) (PP (IN with) (NP (JJ follicular) (NN hyperplasia))))))) (. .)))
(TOP (S (NP-SBJ-62 (JJ Nuclear) (NP-COOD (NP (NN p65)) (CC and) (NP (NN c-Rel))) (NNS proteins)) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NP (DT all) (NN cell) (NNS types)) (PP (VBG including) (NP (NNS lymphocytes))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ germinal) (NNS centers) (NN GC))) (, ,) (NP-SBJ-COOD-61 (NP (NN p50)) (, ,) (NP (NN p52)) (, ,) (CC and) (NP (NN RelB))) (VP-COOD (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (NN FDC))) (ADVP (RB only)))))) (CC and) (VP (VBD were) (RB not) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (JJ CD68+) (NNS cells)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN T) (NN cell) (NNS areas))) (, ,) (NP-SBJ-COOD-63 (NP (NN p50)) (, ,) (NP (NN p52)) (, ,) (CC and) (NP (NN RelB))) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN of) (NP (NP (JJ HLA-DR+) (NNS cells)) (PP (IN with) (NP (DT an) (NP (NP (JJ antigen-presenting) (NN cell)) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (NN morphology))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-COOD-64 (NP (NN p52)) (CC and) (NP (NN RelB))) (VP (VBD were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (NNS nuclei)) (PP (IN in) (NP (NP (ADJP-COOD (CC both) (ADJP (JJ CD1a+)) (CC and) (ADJP (JJ CD68+))) (NNS cells)) (PP (IN from) (NP (DT the) (NN T) (NN cell) (NN area)))))))))) (, ,) (IN whereas) (S (NP-SBJ-65 (NN p50)) (VP (VBD was) (VP (VBN found) (PP (RB only) (IN in) (NP (ADJP-COOD (ADJP (JJ CD68-)) (CC and) (ADJP (JJ CD1a-))) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Cells)) (PP (IN with) (NP (JJ nuclear) (NN p50)))) (VP (VBD were) (ADJP-PRD (JJ negative)) (PP (IN for) (NP (DT the) (NP-COOD (NP (NN CD38)) (, ,) (NP (NN CD20)) (CC and) (NP (NN CD2))) (NNS markers)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (, ,) (S (ADVP (RB physiologically)) (, ,) (NP-SBJ-66 (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (JJ nuclear)) (PP (IN of) (NP-COOD (NP (NN p50)) (, ,) (NP (NN p52)) (CC and) (NP (NN RelB))))))) (VP (VBP are) (VP (JJ restricted) (PP (TO to) (NP-COOD (NP (NP (JJ accessory) (NNS cells)) (PP (IN of) (NP (DT the) (JJ immune) (NN system))) (, ,) (SBAR (WHNP-67 (WDT which)) (S (VP (VBP include) (NP (NP (NN FDC)) (PP (IN in) (NP (NN GC))))))) (, ,)) (CC and) (NP (NP-COOD (NP (NN DC)) (CC and) (NP (NNS macrophages))) (PP (IN in) (NP (DT the) (NN T) (NN cell) (NN zone)))))))))) (, ,) (SBAR (IN that) (S-COOD (S (NP-SBJ (NP (VBN specialized) (NN scavenger) (NNS macrophages)) (PP (IN from) (NP (NN GC)))) (VP (VBP do) (RB not) (VP (VB have) (NP (NP (JJ detectable) (NNS levels)) (PP (IN of) (NP-COOD (NP (NN p52)) (CC and) (NP (NN RelB)))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NNS macrophages)) (PP (IN from) (NP (DT the) (NN T) (NN cell) (NN area))) (, ,) (VP (VBN known) (S (VP (TO to) (VP (VB present) (NP (DT the) (NN antigen)) (PP-DTV (TO to) (NP (NN T) (NNS cells))))))) (, ,)) (VP (VBP do) (VP (VB have) (NP (CC both) (JJ nuclear) (NP-COOD (NP (NN p52)) (CC and) (NP (NN RelB))))))))) (, ,) (CC and) (SBAR (IN that) (S (PP (IN in) (NP (DT the) (NN T) (NN cell) (NN zone))) (, ,) (S-COOD (S (NP-SBJ-COOD (NP (NN p52)) (CC and) (NP (NN RelB))) (VP (VBP are) (ADJP-PRD (JJ located) (PP (IN in) (NP (NP (NNS nuclei)) (PP (IN of) (NP (ADJP-COOD (DT both) (ADJP (JJ CD1a+)) (, ,) (ADJP (JJ CD68+)) (CC or) (ADJP (DT both)) (, ,)) (NNS cells) (NN APC)))))))) (, ,) (IN whereas) (S (NP-SBJ-68 (NN p50)) (VP (VBZ is) (VP (JJ restricted) (PP (TO to) (NP (ADJP-COOD (ADJP (NN CD1a-)) (CC and) (ADJP (JJ CD68-))) (NN APC))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ different) (NNS patterns)) (PP (IN of) (NP (NP-COOD (NP (NN p50)) (, ,) (NP (NN p52)) (CC and) (NP (NN RelB))) (NN protein) (JJ nuclear) (NN localization)))) (VP (MD may) (VP (VB provide) (NP (NP (NN insight)) (PP (IN into) (NP (NP (PRP$ their) (JJ different) (NNS roles)) (PP-TMP (IN during) (NP (NP (DT the) (JJ immune) (NN response)) (ADVP (FW in) (FW vivo))))))))) (. .)))
(TOP (NP (NP (NN Signal) (NN transduction)) (PP (IN by) (NP (NP (NN DR3)) (, ,) (NP (NP (DT a) (ADJP (NN death) (JJ domain-containing)) (NN receptor)) (ADJP (JJ related) (PP (TO to) (NP-COOD (NP (NN TNFR-1)) (CC and) (NP (NN CD95)))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NP (NN Tumor) (NN necrosis) (NN factor) (NN receptor-1)) (PRN (-LRB- -LRB-) (NP (NN TNFR-1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN CD95)) (-LRB- -LRB-) (VP (ADVP (RB also)) (VBN called) (S (NP-PRD-COOD (NP (NN Fas)) (CC or) (NP (NN APO-1))))) (-RRB- -RRB-))) (VP (VBP are) (NP-PRD (NP (NN cytokine) (NNS receptors)) (SBAR (WHNP-52 (WDT that)) (S (VP (VBP engage) (NP (NP (DT the) (NN apoptosis) (NN pathway)) (PP (IN through) (NP (NP (DT a) (NN region)) (PP (IN of) (NP (JJ intracellular) (NN homology))))) (, ,) (VP (VBD designated) (S (NP-PRD (DT the) (`` ") (NN death) (NN domain)))))))))) (. .) ('' ")))
(TOP (S (NP-SBJ-53 (NP (NP (DT Another) (ADJP (NN death) (NN domain-containing)) (NN member)) (PP (IN of) (NP (DT the) (NN TNFR) (NN family)))) (, ,) (NP (NP (NN death) (NN receptor) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN DR3)) (-RRB- -RRB-))) (, ,)) (VP-COOD (VP (VBD was) (VP (VBN identified))) (CC and) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (NP-COOD (CC both) (NP (NNS apoptosis)) (CC and) (NP (NN activation))) (PP (IN of) (NP (JJ nuclear) (NN factor) (NN kappaB)))))))))) (. .)))
(TOP (S (NP-SBJ-54 (NP (NN Expression)) (PP (IN of) (NP (NN DR3)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (JJ restricted) (PP (TO to) (NP (NP (NNS tissues)) (VP (VBN enriched) (PP (IN in) (NP (NNS lymphocytes))))))))))) (. .)))
(TOP (S (NP-SBJ-56 (NN DR3) (NN signal) (NN transduction)) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (DT a) (NN complex)) (PP (IN of) (NP (NP (JJ intracellular) (VBG signaling) (NNS molecules)) (PP (VBG including) (NP-COOD (NP (NN TRADD)) (, ,) (NP (NN TRAF2)) (, ,) (NP (NN FADD)) (, ,) (CC and) (NP (NN FLICE)))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-57 (NN DR3)) (ADVP (RB likely)) (VP (VBZ plays) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NN lymphocyte) (NN homeostasis)))))) (. .)))
(TOP (NP (NP (NP-COOD (NP (NN Cloning)) (CC and) (NP (NN expression))) (PP (IN of) (NP (DT the) (ADJP (JJ Epstein-Barr) (JJ virus-encoded)) (NN dUTPase))) (: :)) (S (NP-SBJ (NP (NNS patients)) (PP (IN with) (NP (ADJP-COOD (ADJP (JJ acute)) (, ,) (ADJP (VBN reactivated)) (CC or) (ADJP (JJ chronic))) (NN virus) (NN infection)))) (VP (VBP develop) (NP (NP (NNS antibodies)) (PP (IN against) (NP (DT the) (NN enzyme))))) (. .))))
(TOP (S (NP-SBJ-74 (NP (DT The) (NN gene)) (VP (VBG encoding) (NP (DT the) (ADJP (NP (JJ Epstein-Barr) (NN virus)) (-LRB- -LRB-) (NN EBV) (-RRB- -RRB-) (JJ -specific)) (NN dUTPase)))) (VP (VBD was) (VP (VBN amplified) (PP (IN from) (NP (NN virus) (NN DNA))) (PP (IN by) (NP-LGS (NN PCR))))) (. .)))
(TOP (S (NP-SBJ-75 (DT The) (JJ active) (NN enzyme)) (VP (VBD was) (VP (VBN expressed) (PP-COOD (PP (IN in) (NP (FW Escherichia) (FW coli))) (CC and) (PP (IN in) (NP (NN insect) (NNS cells)))) (PP (IN as) (NP (DT a) (JJ non-fusion) (NN protein))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN protein)) (PP (IN from) (NP (FW E.) (FW coli)))) (ADVP (RB specifically)) (VP-COOD (VP (VBD converted) (NP (NN dUTP)) (PP (TO to) (NP (NN dUMP)))) (CC and) (VP (VBD did) (RB not) (VP (VB react) (PP (IN with) (NP (JJ other) (NP-COOD (NP (NNS dNTPs)) (CC or) (NP (NNS NTPs)))))))) (. .)))
(TOP (S (NP-SBJ (JJ Preliminary) (NNS experiments)) (VP (VBD yielded) (NP (NP (DT a) (NN Km) (NN value)) (PP (IN of) (NP (QP (RB about) (CD 0.8)) (NN microM)))) (PP (IN for) (NP (NN dUTP)))) (. .)))
(TOP (S (NP-SBJ (NP (NNS MAbs)) (PP (IN against) (NP (DT the) (NN dUTPase)))) (VP (VBD reacted) (PP (IN with) (NP (NP (DT a) (NN protein)) (PP (IN of) (NP (QP (RB approximately) (CD 31)) (NN kDa))) (PP (IN in) (NP (NP (ADJP (NP (NN 12-O-tetradecanoyl-phorbol-13-acetate)) (-LRB- -LRB-) (NN TPA) (-RRB- -RRB-) (JJ -stimulated)) (NN B) (NNS cells)) (VP (VBG harbouring) (NP (NP-COOD (CC either) (NP (NN type) (CD 1)) (CC or) (NP (NN type) (CD 2))) (NN EBV)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-76 (DT The) (NN protein)) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (JJ untreated) (NNS cells))) (PP (IN at) (NP (JJ low) (NNS levels)))))) (, ,) (IN whereas) (S (NP-SBJ (NP (NN induction)) (PP (IN of) (NP (DT the) (JJ lytic) (NN replication) (NN cycle))) (PP-COOD (PP (IN by) (NP (NN TPA) (NN treatment))) (CC or) (PP (IN by) (S (VP (VBG providing) (NP (DT the) (JJ immediate) (JJ early) (NN transactivator) (NN BZLF1)))))) (PP (IN in) (NP (NN trans)))) (VP (VBD resulted) (PP (IN in) (NP (VBN increased) (NN expression))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN virus) (NN dUTPase)) (VP (VBN isolated) (PP (IN from) (NP (JJ EBV-infected) (NNS cells))))) (VP (VBZ is) (NP-PRD (DT a) (NN phosphoprotein)))))) (. .)))
(TOP (S (NP-SBJ-77 (NP (DT The) (NN protein)) (VP (VBN expressed) (PP (IN in) (NP (NN insect) (NNS cells))))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB test) (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ specific) (NNS antibodies))) (PP (IN in) (NP (NP (NN sera)) (PP-COOD (PP (IN from) (NP (ADJP-COOD (ADJP (JJ normal)) (, ,) (ADJP (JJ healthy))) (NNS carriers))) (CC and) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ various) (NNS diseases))))))))))))))) (. .)))
(TOP (S (SBAR (IN While) (S (NP-SBJ (NP (DT the) (NN sera)) (PP (IN of) (NP-COOD (NP (NP (JJ EBV-negative) (NNS individuals)) (PRN (-LRB- -LRB-) (NP (CD 0/3)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ healthy) (NNS carriers)) (PRN (-LRB- -LRB-) (NP (CD 0/33)) (-RRB- -RRB-)))))) (VP (VBD did) (RB not) (VP (VB contain) (NP (NP (JJ detectable) (NNS levels)) (PP (IN of) (NP (NNS antibodies)))))))) (, ,) (NP-SBJ (NP (NNS patients)) (PP (IN with) (NP-COOD (NP (NP (NN mononucleosis)) (PRN (-LRB- -LRB-) (NP (CD 5/18)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ chronic) (NN EBV) (NN infection)) (PRN (-LRB- -LRB-) (NP (CD 2/7)) (-RRB- -RRB-))) (, ,) (NP (NP (NN EBV) (NN reactivation)) (PRN (-LRB- -LRB-) (NP (CD 7/20)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ human) (NN immunodeficiency) (NN virus) (NN infection)) (PRN (-LRB- -LRB-) (NP (CD 5/24)) (-RRB- -RRB-)))))) (VP (VBD showed) (NP (NP (JJ elevated) (NN antibody) (NNS titres)) (PP (IN against) (NP (DT the) (NN enzyme))))) (. .)))
(TOP (S (NP-SBJ (DT This)) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ-78 (DT the) (NN dUTPase)) (VP (VBZ is) (VP (VBN expressed) (PP-TMP (IN during) (NP (NN EBV) (NP-COOD (NP (NN replication)) (CC and) (NP (NN reactivation)))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN enzyme)) (VP (MD might) (ADVP (RB therefore)) (VP (VB be) (NP-PRD (NP (DT a) (JJ potential) (NN target)) (PP (IN for) (NP (NN drug) (NN therapy)))) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (JJ active) (NN DNA) (NN replication))))))) (. .)))
(TOP (NP (NP (NN Prostaglandin) (NN E2) (NN induction)) (PP (IN of) (NP (NP (NN binding) (NN activity)) (PP (TO to) (NP (NP-COOD (NP (NN CRE)) (CC and) (NP (NN AP-2))) (NNS elements))))) (PP (IN in) (NP (JJ human) (NN T) (NNS lymphocytes))) (. .)))
(TOP (S (NP-SBJ (NP (NNP Prostaglandins)) (PP (IN of) (NP (DT the) (NN E) (NNS series)))) (VP (VBP are) (NP-PRD (NP (JJ immunomodulatory) (NNS agents)) (SBAR (WHNP-66 (WDT which)) (S (VP (VBP exert) (NP (ADJP-COOD (ADJP (JJ inhibitory)) (CONJP (RB as) (RB well) (IN as)) (ADJP (JJ stimulatory))) (NNS effects)) (PP (IN on) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ immune) (NNS responses)))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (PRP it)) (VP (VBZ is) (VP (VBN known) (SBAR (IN that) (S (NP-SBJ-67 (NN PGE2)) (VP (VBZ is) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB increase) (NP (NN cAMP) (NNS levels))))))))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP-SBJ (PRP it)) (VP (MD can) (VP (VB affect) (NP (NN gene) (NN expression)) (PP (IN through) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (DT the) (NN transcription) (NNS factors)) (SBAR (WHNP-68 (WDT which)) (S (VP (VBP bind) (NP (NP (NN enhancer) (NNS elements)) (PP (IN in) (NP (NP (DT the) (NN promoter) (NNS regions)) (PP (IN of) (NP (JJ cAMP-regulated) (NNS genes)))))))))))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NN assay)))) (, ,) (NP-SBJ-69 (PRP we)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (JJ short) (NN treatment)) (PP (IN of) (NP (JJ human) (NN T) (NNS lymphocytes))) (PP (IN with) (NP (NN PGE2)))) (VP (VBZ induces) (NP (NP (JJ specific) (NN binding) (NN activity)) (PP (TO to) (NP (NP-COOD (NP (NN CRE)) (CC and) (NP-COOD (NP (NN AP-2)) (, ,) (NP (CC but) (RB not)) (NP (NN AP-1)) (, ,))) (NN DNA) (NNS elements)))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (NP (DT the) (JJ okadaic) (NN acid)) (, ,) (NP (DT a) (JJ potent) (NN protein) (NN phosphatase) (NN inhibitor)) (, ,)) (VP (VBZ prolongs) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (DT the) (NN binding) (NN activity))))))) (, ,) (NP-SBJ-70 (NN phosphorylation) (NNS events)) (VP (VBP are) (ADJP-PRD (JJ likely) (S (VP (TO to) (VP (VB occur)))))) (. .)))
(TOP (S (NP-SBJ-71 (DT This) (NN activity)) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (PP-PRD (JJ due) (TO to) (NP (VBN increased) (NN cAMP) (NNS levels))) (SBAR (IN because) (S (NP-SBJ-COOD (NP (NN forskolin)) (CC and) (NP (NN IBMX))) (VP (VBP mimic) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN PGE2))))))))))) (. .)))
(TOP (S (ADVP (RBR More) (RB interestingly)) (, ,) (NP-SBJ (NP (NN transfection) (NNS experiments)) (PP (IN with) (NP (NN CRE-CAT) (NN plasmide)))) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN PGE2)) (VP (VBZ activates) (NP (NP (DT the) (NN transcription)) (PP (IN of) (NP (DT a) (NN CRE-containing) (NN promoter)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP support) (NP (NP (DT the) (JJ positive) (NN role)) (PP (IN for) (NP (NN PGE2))) (PP (IN on) (NP (DT some) (JJ immune) (NNS functions))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP-COOD (NP (NN cytokine)) (CC and) (NP (NN cytokine) (NN receptor))) (NN expression))) (PP (IN by) (NP (NNS glucocorticoids))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Glucocorticoids)) (PRN (-LRB- -LRB-) (NP (NNS GCS)) (-RRB- -RRB-))) (ADVP (RB profoundly)) (VP (VBP inhibit) (NP (NP (JJ several) (NNS aspects)) (PP (IN of) (NP (NN T) (NN cell) (NN immunity)))) (PP (RB largely) (IN through) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN cytokine) (NN expression)) (PP (IN at) (NP (DT the) (ADJP-COOD (ADJP (JJ transcriptional)) (CC and) (ADJP (JJ posttranscriptional))) (NNS levels)))))))) (. .)))
(TOP (S (NP-SBJ-82 (NNS GCS)) (VP (VBD were) (VP (ADVP (RB also)) (VBN reported) (S (VP (TO to) (VP (VB act) (ADVP (RB indirectly)) (PP (IN by) (S (VP (VBG inducing) (NP (NP (VBG transforming) (NN growth) (NN factor-beta) (NN expression)) (, ,) (SBAR (WHNP-84 (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ blocks) (NP (NN T) (NN cell) (NN immunity)))))))))))))) (. .)))
(TOP (S (PP (IN In) (S (VP (VBG exerting) (NP (PRP$ their) (JJ antiproliferative) (NNS effects))))) (, ,) (NP-SBJ-85 (NNS GCS)) (VP (VBP diffuse) (PP (IN into) (NP (NP (NN target) (NNS cells)) (SBAR (WHADVP-86 (WRB where)) (S (NP-SBJ (PRP they)) (VP (VBP bind) (NP (NP (PRP$ their) (JJ cytoplasmic) (NN receptor)) (, ,) (SBAR (WHNP-87 (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ translocates) (PP (TO to) (NP (NP (DT the) (NN nucleus)) (SBAR (WHADVP-88 (WRB where)) (S (NP-SBJ (PRP it)) (VP (VBZ inhibits) (NP (NP (NN transcription)) (PP (IN of) (NP (NN cytokine) (NNS genes)))) (PP-COOD (PP (IN through) (NP (NP (JJ direct) (NN binding)) (PP (TO to) (NP (NP (NP (DT the) (NN glucocorticoid) (NN response) (NNS elements)) (PRN (-LRB- -LRB-) (NP (NN GRE)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP-89 (WDT which)) (S (VP (VBP are) (ADJP-PRD (JJ located) (PP (IN in) (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (NN cytokine) (NNS genes))))))))))))) (CC or) (, ,) (PP (ADVP (RB alternatively)) (, ,) (IN through) (NP (NP (NN antagonism)) (PP (IN of) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (VP (VBN required) (PP (IN for) (NP (JJ optimal) (JJ transcriptional) (NN activation)))))))))))))))))))))))))) (. .)))
(TOP (S (PP (IN In) (NN contrast) (TO to) (NP (NP (PRP$ their) (JJ inhibitory) (NNS effects)) (PP (IN on) (NP (NN cytokine) (NN expression))))) (, ,) (NP-SBJ (NNS GCS)) (VP (VBP up-regulate) (NP (NP (NN cytokine) (NN receptor) (NN expression)) (SBAR (WHNP-90 (WDT that)) (S (VP (VBZ correlates) (PP (IN with) (NP (NP (VBN enhanced) (NN cytokine) (NNS effects)) (PP (IN on) (NP (NN target) (NNS cells)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN review))) (, ,) (NP-SBJ (PRP we)) (VP (VBP summarize) (NP (NP (DT the) (JJ current) (NN state)) (PP (IN of) (NP (NP (NN knowledge)) (PP (IN of) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NNS GCS))) (, ,) (PP (VBG including) (NP (NP (DT the) (NN phenomenon)) (PP (IN of) (NP (JJ steroid-induced) (NN rebound))))) (, ,) (SBAR (WHNP-91 (WDT which)) (S (VP (VBZ ensues) (PP-TMP (IN upon) (NP (NNS GCS) (NN withdrawal)))))))))))))) (. .)))
(TOP (NP (DT The) (NN Oct-2) (NN transcription) (NN factor) (. .)))
(TOP (S (NP-SBJ-9 (DT The) (NN Oct-2) (NN transcription) (NN factor)) (VP-COOD (VP (VBZ is) (NP-PRD (NP (DT a) (NN member)) (PP (IN of) (NP (NP (DT the) (NP (NP (NN POU)) (PRN (-LRB- -LRB-) (NP (NN Pit-Oct-Unc)) (-RRB- -RRB-))) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors))))))) (CC and) (VP (VBZ is) (VP (VBN expressed) (PP-COOD (PP (ADVP (RB only)) (PP-COOD (PP (IN in) (NP (NN B) (NNS lymphocytes))) (CC and) (PP (IN in) (NP (JJ neuronal) (NNS cells))))) (CC but) (PP (RB not) (IN in) (NP (JJ other) (NN cell) (NNS types))))))) (. .)))
(TOP (S (NP-SBJ-103 (NP (DT The) (JJ primary) (NN RNA) (NN transcript)) (PP (IN of) (NP (DT the) (NN gene)))) (VP (VBZ is) (ADJP-PRD (JJ subject) (PP (TO to) (NP (JJ alternative) (NN splicing)))) (S (VP (TO to) (VP (VB yield) (NP (NP (JJ different) (NNS variants)) (SBAR (WHNP-10 (WDT which)) (S (VP (MD can) (VP (VP-COOD (CC either) (VP (VBP activate)) (CC or) (VP (VBP repress))) (NP-11 (NN gene) (NN expression))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (NNS forms)) (VP (VBN produced) (PP (IN in) (NP (NN B) (NNS lymphocytes))))) (VP (VBP have) (NP (DT a) (ADJP (RB predominantly) (JJ activating)) (NN effect)) (PP (IN on) (NP (NN gene) (NN expression))))) (IN whereas) (S (NP-SBJ (NP (DT those)) (VP (VBN produced) (PP (IN in) (NP (JJ neuronal) (NNS cells))))) (VP-COOD (VP (VBP have) (NP (DT a) (ADJP (RB predominantly) (JJ inhibitory)) (NN effect))) (CC and) (VP (MD can) (VP (VB repress) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP-COOD (CC both) (NP (DT the) (NN herpes) (NN simplex) (NN virus) (JJ immediate-early) (NNS genes)) (CC and) (NP (DT the) (JJ cellular) (NN tyrosine) (NN hydroxylase) (NN gene))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (NP-SBJ (NN Oct-2)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP-COOD (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (JJ cellular) (NN gene) (NN expression)) (PP (IN in) (NP-COOD (CC both) (NP (NN B) (NNS cells)) (CC and) (NP (JJ neuronal) (NNS cells)))))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ viral) (NN latency))))))) (. .)))
(TOP (NP (NP (ADJP (NP-COOD (NP (NN Tissue)) (CC and) (NP (JJ cell-type))) (JJ specific)) (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ tuberous) (NN sclerosis) (NN gene)) (, ,) (NP (NN TSC2)) (, ,))) (PP (IN in) (NP (JJ human) (NNS tissues))) (. .)))
(TOP (S (NP-SBJ (NN TSC2)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN gene)) (PP (IN on) (NP (NN chromosome) (NN 16p13.3))) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ autosomal) (JJ dominant) (JJ neurocutaneous) (NN disorder)) (, ,) (NP (NP (JJ tuberous) (NN sclerosis) (NN complex)) (PRN (-LRB- -LRB-) (NP (NN TSC)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG using) (NP-COOD (NP (NP (DT a) (JJ partial) (JJ nucleotide) (NN sequence)) (PP (IN from) (NP (DT the) (VBN cloned) (NN TSC2)))) (CC and) (NP (NN polymerase) (NN chain) (NN reaction) (NN methodology)))))) (, ,) (NP-SBJ-72 (PRP we)) (VP (VBD constructed) (NP (DT a) (JJ digoxigenin-labeled) (JJ complementary) (NN DNA) (NN probe)) (S (VP (TO to) (VP (VB examine) (NP (NP (NN TSC2) (NN gene) (NN expression)) (PP (IN in) (NP (ADJP-COOD (ADJP (NP (NN autopsy-))) (CC or) (ADJP (JJ biopsy-derived))) (JJ human) (NNS tissues)))) (PP (IN by) (NP (ADJP (FW in) (FW situ)) (NN hybridization))))))) (. .)))
(TOP (S (NP-SBJ-74 (NN TSC2) (NN messenger) (NN RNA)) (VP (VBD was) (VP (ADVP (RB widely)) (VBN expressed) (PP (IN in) (NP (NP (JJ various) (NN cell) (NNS types)) (PP (IN throughout) (NP (DT the) (NN body))) (, ,) (PP (VBG including) (NP-COOD (NP (NN epithelia)) (, ,) (NP (NNS lymphocytes)) (, ,) (CC and) (NP (NP (NP (NNS cells)) (PP (IN with) (NP (JJ endocrine) (NNS functions)))) (, ,) (NP (ADVP (FW e.g.)) (, ,) (NP-COOD (NP (JJ adrenal) (NN cortex)) (CC and) (NP (JJ anterior) (NN pituitary))))))))))) (. .)))
(TOP (S (NP-SBJ-75 (PRP It)) (VP (VBD was) (VP (ADVP-COOD (ADVP (RB prominently)) (CC and) (ADVP (RB selectively))) (-LRB- -LRB-) (PP (IN within) (NP (DT the) (JJ central) (JJ nervous) (NN system))) (-RRB- -RRB-) (VBN expressed) (PP (PP (IN in) (NP (NP (JJ pyramidal) (NNS cells)) (PP (IN of) (NP-COOD (NP (DT the) (JJ cerebral) (NN cortex)) (CC and) (NP (JJ other) (NN motor) (NNS neurons)))))) (, ,) (PP (ADVP (FW e.g.)) (, ,) (IN in) (NP-COOD (NP (JJ spinal) (NN cord)) (CC and) (NP (NN brainstem) (NNS nuclei))))))) (. .)))
(TOP (S (S (NP-SBJ (JJ Visceral) (NN TSC2) (NN expression)) (VP (VBD was) (ADJP-PRD (JJ comparable)) (PP (IN in) (NP (NP (NN autopsy) (NNS tissues)) (PP (IN from) (NP (NP (NNS patients)) (PP (PP-COOD (PP (IN with)) (CC and) (PP (IN without))) (NP-76 (NN TSC)))))))) (: ;)) (S (NP-SBJ (NN TSC2) (NN messenger) (NN RNA) (NN expression)) (VP (VBD was) (ADJP-PRD (RBS most) (JJ prominent)) (PP-COOD (PP (IN in) (NP (NP (NP (NP (NNS cells)) (PP (IN with) (NP (DT a) (JJ rapid) (JJ mitotic) (NP-COOD (NP (NN rate)) (CC and) (NP (NN turnover)))))) (, ,) (NP (ADVP (FW e.g.)) (, ,) (NP-COOD (NP (NN epithelia)) (CC and) (NP (NNS lymphocytes)))) (, ,)) (PP (IN with) (S (NP-SBJ (JJ central) (JJ nervous) (NN system) (NP-COOD (NP (JJ pyramidal) (NNS cells)) (CC and) (NP (JJ other) (NNS neurons)))) (VP (VBG being) (NP-PRD (DT an) (JJ obvious) (NN exception))))))) (, ,) (CC and/or) (PP (IN in) (NP (NP (NNS cells)) (PP (IN with) (NP (JJ important) (NN secretory/transport) (NNS functions))))))) (. .))))
(TOP (S (NP-SBJ (NP (DT This) (JJ widespread) (NN expression)) (PP (IN of) (NP (DT the) (NN TSC2) (NN gene)))) (VP (VBZ supports) (NP (DT the) (NN view) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (VBZ encodes) (NP-COOD (NP (NP (DT a) (NN protein)) (ADJP (JJ vital) (PP (TO to) (NP (NN cell) (NP-COOD (NP (NN growth)) (CC and) (NP (NN metabolism))))))) (CC or) (NP (NP (CD one)) (SBAR (WHNP-77 (WDT that)) (S (VP (VBZ functions) (PP (IN as) (NP (DT a) (NN tumor/growth) (NN suppressor))))))))))))) (. .)))
(TOP (S (NP-SBJ-61 (NP (NN Cell) (JJ specific) (NN expression)) (PP (IN of) (NP (JJ human) (NP (NP (NP (NN Bruton) (POS 's)) (NN agammaglobulinemia) (NN tyrosine) (NN kinase) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN Btk)) (-RRB- -RRB-)))))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS-COOD (NP (NN Sp1-)) (CC and) (NP (NN Spi-1/PU.1-family) (NNS members)))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (NN Bruton) (POS 's)) (NN agammaglobulinemia) (NN tyrosine) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN Btk)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ cytoplasmic) (NN tyrosine) (NN kinase)) (VP (VBN involved) (PP (IN in) (NP (DT the) (JJ human) (NN disease) (NP (NP (JJ X-linked) (NN agammaglobulinemia)) (PRN (-LRB- -LRB-) (NP (NN XLA)) (-RRB- -RRB-)))))))) (. .)))
(TOP (S (NP-SBJ-62 (DT The) (NN gene)) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (NP (DT all) (JJ hematopoietic) (NNS cells)) (PP (IN with) (NP (NP (DT the) (NN exception)) (PP (IN of) (NP-COOD (NP (NNS T-cells)) (CC and) (NP (NN plasma) (NNS cells)))))))))) (. .)))
(TOP (S (PP (IN For) (NP (DT this) (NN expression) (NN pattern))) (NP-SBJ-63 (NP (DT the) (JJ first) (CD 280) (NN bp)) (ADJP (JJ upstream) (PP (IN of) (NP (DT the) (JJ major) (JJ transcriptional) (NN start) (NN site))))) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ sufficient)))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (FW In) (FW vitro)) (NN footprinting) (NN analysis)) (PP (IN within) (NP (NP (DT this) (NN part)) (PP (IN of) (NP (DT the) (NN promoter)))))) (VP (VBD revealed) (NP-COOD (NP (CD two) (NN Sp1) (NN binding) (NNS sites)) (CONJP (RB as) (RB well) (IN as)) (NP (DT a) (NN PU-box)))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (DT The) (NN transcription) (NN factor) (NN Spi-1/PU.1)) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (ADJP (RB closely) (JJ related)) (NN factor) (NN Spi-B))) (VP (VBD bound) (PP (TO to) (NP (DT the) (NN PU-box))) (PP (IN in) (NP (NNS B-cells)))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (NN erythroleukemia) (NN cell) (NN line) (NN K562))) (, ,) (PP (IN due) (TO to) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN Spi-B))))) (, ,) (NP-SBJ (RB only) (NN PU.1)) (VP (VBD bound) (PP (TO to) (NP (DT the) (NN Btk) (NN promoter)))) (. .)))
(TOP (S (NP-SBJ (NP (NN Mutation)) (PP (IN of) (NP (DT either) (NN site)))) (VP (VBD reduced) (NP (DT the) (NN expression)) (PP (IN in) (NP (JJ transient) (NN transfection) (NNS experiments)))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (NN mutation)) (PP (IN of) (NP (DT the) (NN PU) (NN box)))) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN in) (NP (NP (DT the) (NN T-cell) (NN line) (NN Jurkat)) (, ,) (SBAR (WHADVP-64 (WRB where)) (S (NP-SBJ-65 (NP (NN none)) (PP (IN of) (NP (DT the) (NN Spi-1) (NN family) (NNS members)))) (VP (VBZ is) (VP (VBN expressed)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (NP-SBJ-COOD-66 (NP (NN Spi-B)) (CONJP (RB as) (RB well) (IN as)) (NP (NN PU.1))) (VP (VBD were) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB transactivate) (NP (NN Btk) (NN expression))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (JJ fetal) (NN liver)) (PP (IN of) (NP (NP (JJ PU.1-/-) (NNS mice)) (, ,) (SBAR (WHNP-67 (WDT which)) (S (VP (VBP lack) (NP (ADJP-COOD (ADJP (JJ lymphoid)) (CC and) (ADJP (JJ myeloid))) (NNS cells))))))))) (, ,) (NP-SBJ-68 (NP (NN expression)) (PP (IN of) (NP (NN Btk)))) (VP (VBD was) (VP-COOD (VP (VBN reduced) (ADVP (ADVP (CD two-)) (TO to) (ADVP (RB threefold)))) (CC but) (VP (RB not) (VBN abolished)))) (. .)))
(TOP (S (ADVP (RB Collectively)) (NP-SBJ (DT this) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP-SBJ-70 (NP (NN expression)) (PP (IN of) (NP (DT the) (NN Btk) (NN gene)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP-LGS (NP (DT the) (JJ combined) (NN action)) (PP (IN of) (NP-COOD (NP (NN Sp1-)) (CC and) (NP (NN PU.1-family) (NNS members))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN Elf-1)) (CC and) (NP (NN Stat5))) (VP (VBP bind) (PP (TO to) (NP (NP (DT a) (JJ critical) (NN element)) (PP (IN in) (NP (NP (DT a) (JJ new) (NN enhancer)) (PP (IN of) (NP (DT the) (JJ human) (NN interleukin-2) (NN receptor) (NN alpha) (NN gene))))))) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP Mol) (NNP Cell) (NNP Biol)) (NP-TMP (CD 1997) (NNP Apr)) (: ;) (NP (CD 17) (-LRB- -LRB-) (CD 4) (-RRB- -RRB-)) (: :) (NP (CD 2351)))))) (-RRB- -RCB-)))))
(TOP (S (NP-SBJ (DT The) (NP (NP (NN interleukin) (CD 2) (NN receptor) (NN alpha-chain)) (PRN (-LRB- -LRB-) (NP (NN IL-2R) (NN alpha)) (-RRB- -RRB-))) (NN gene)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ key) (NN regulator)) (PP (IN of) (NP (NN lymphocyte) (NN proliferation))))) (. .)))
(TOP (S (NP-SBJ-42 (NN IL-2R) (NN alpha)) (VP (VBZ is) (VP (ADVP-COOD (ADVP-TMP (RB rapidly)) (CC and) (ADVP (RB potently))) (VBN induced) (PP (IN in) (NP (NN T) (NNS cells))) (PP (IN in) (NN response) (TO to) (NP (JJ mitogenic) (NNS stimuli))))) (. .)))
(TOP (S (NP-SBJ-43 (NP (NN Interleukin) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN IL-2)) (-RRB- -RRB-))) (VP (VBZ stimulates) (NP (NN IL-2R) (NN alpha.) (NN transcription)) (, ,) (S (ADVP (RB thereby)) (VP (VBG amplifying) (NP (NP (NN expression)) (PP (IN of) (NP (PRP$ its) (JJ own) (NN high-affinity) (NN receptor))))))) (. .)))
(TOP (S (NP-SBJ-44 (NN IL-2R) (NN alpha) (NN transcription)) (VP (VBZ is) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (VP (VBN controlled) (PP (IN by) (NP-LGS (NP (CD two) (JJ positive) (JJ regulatory) (NNS regions)) (, ,) (NP-COOD (NP (NN PRRI)) (CC and) (NP (NN PRRII))))))) (. .)))
(TOP (S (NP-SBJ (NN PRRI)) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ inducible) (JJ proximal) (NN enhancer)) (, ,) (ADJP (JJ located) (PP (IN between) (NP (NNS nucleotides) (NP-COOD (NP (CD -276)) (CC and) (NP (CD -244)))))) (, ,) (SBAR (WHNP-45 (WDT which)) (S (VP (VBZ contains) (NP (NP-COOD (NP (NN NF-kappaB)) (CC and) (NP (NN SRE/CArG))) (NNS motifs))))))) (. .)))
(TOP (S (NP-SBJ (NN PRRII)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ T-cell-specific) (NN enhancer)) (, ,) (ADJP (JJ located) (PP (IN between) (NP (NNS nucleotides) (NP-COOD (NP (CD -137)) (CC and) (NP (CD -64)))))) (, ,) (SBAR (WHNP-46 (WDT which)) (S (VP (VBZ binds) (NP-COOD (NP (DT the) (JJ T-cell-specific) (NN Ets) (NN protein) (NN Elf-1)) (CC and) (NP (NN HMG-I-LRB-Y-RRB-) (NNS proteins)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (NN none)) (PP (IN of) (NP (DT these) (JJ proximal) (NNS regions)))) (VP (VBP account) (PP (IN for) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN IL-2R) (NN alpha) (NN transcription))) (PP (IN by) (NP (NN IL-2)))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB find) (NP (NP (JJ new) (JJ regulatory) (NNS regions)) (PP (IN of) (NP (DT the) (NN IL-2R) (NN alpha) (NN gene))))))) (, ,) (NP-SBJ-47 (NP (CD 8.5) (NN kb)) (PP (IN of) (NP (NP (DT the) (JJ 5') (NN end) (JJ noncoding) (NN sequence)) (PP (IN of) (NP (DT the) (NN IL-2R) (NN alpha) (NN gene)))))) (VP (VBP have) (VP (VBN been) (VP (VBN sequenced)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD identified) (NP (NP (DT an) (JJ 86-nucleotide) (NN fragment)) (SBAR (WHNP-48 (WDT that)) (S (VP (VBZ is) (ADJP-PRD (NP (CD 90) (NN %)) (JJ identical) (PP (TO to) (NP (DT the) (ADJP (RB recently) (VBN characterized)) (NP (NP (JJ murine) (JJ IL-2-responsive) (NN element)) (PRN (-LRB- -LRB-) (NP (NN mIL-2rE)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT This) (JJ putative) (JJ human) (NN IL-2rE)) (, ,) (VP (VBN designated) (S (NP-PRD (NN PRRIII)))) (, ,)) (VP (VBZ confers) (NP (NN IL-2) (NN responsiveness)) (PP (IN on) (NP (DT a) (JJ heterologous) (NN promoter)))) (. .)))
(TOP (S (NP-SBJ (NN PRRIII)) (VP (VBZ contains) (NP (NP (DT a) (NN Stat) (NN protein) (NN binding) (NN site)) (SBAR (WHNP-49 (WDT that)) (S (VP (VBZ overlaps) (PP (IN with) (NP (NP (DT an) (NN EBS) (NN motif)) (PRN (-LRB- -LRB-) (NP (NN GASd/EBSd)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP-SBJ (DT These)) (VP (VBP are) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (NN IL-2) (NN inducibility)) (PP (IN of) (NP (NN PRRIII/CAT) (NN reporter) (NNS constructs))))))) (. .)))
(TOP (S (NP-SBJ (NN IL-2)) (VP (VBD induced) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP-COOD (NP-COOD (NP (NN Stat5a)) (CC and) (NP (NN b))) (NNS proteins))) (PP (TO to) (NP (DT the) (JJ human) (NN GASd) (NN element))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB confirm) (NP (NP (DT the) (JJ physiological) (NN relevance)) (PP (IN of) (NP (DT these) (NNS findings))))))) (, ,) (NP-SBJ-50 (PRP we)) (VP (VBD carried) (PRT (RP out)) (NP (NP (ADJP (FW in) (FW vivo)) (NN footprinting) (NNS experiments)) (SBAR (WHNP-51 (WDT which)) (S (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (NN stimulation)) (PP (IN of) (NP (NN IL-2R) (NN alpha) (NN expression)))) (VP (VBD correlated) (PP (IN with) (NP (NP (NN occupancy)) (PP (IN of) (NP (DT the) (NN GASd) (NN element))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS data)) (VP-COOD (VP (VBP demonstrate) (NP (NP (DT a) (JJ major) (NN role)) (PP (IN of) (NP (DT the) (NN GASd/EBSd) (NN element))) (PP (IN in) (NP (NN IL-2R) (NN alpha) (NN regulation))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ T-cell-specific) (NN Elf-1) (NN factor)) (VP (MD can) (VP (VB serve) (PP (IN as) (NP (DT a) (JJ transcriptional) (NN repressor))))))))) (. .)))
(TOP (NP (NP (NP (NN Association)) (PP (IN of) (NP-COOD (NP (NN TRAF1)) (, ,) (NP (NN TRAF2)) (, ,) (CC and) (NP (NN TRAF3)))) (PP (IN with) (NP (NP (DT an) (JJ Epstein-Barr) (NN virus) (NN LMP1) (NN domain)) (ADJP (JJ important) (PP (IN for) (NP (NN B-lymphocyte) (NN transformation)))))) (: :)) (NP (NP (NN role)) (PP (IN in) (NP (NN NF-kappaB) (NN activation)))) (. .)))
(TOP (S (NP-SBJ-55 (NP (NP (DT The) (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (VBG transforming) (NN protein) (NN LMP1)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP-PRD (DT a) (ADJP (RB constitutively) (VBN activated)) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TNFR)) (-RRB- -RRB-)))) (PP (IN on) (DT the) (NN basis) (IN of) (NP-COOD (NP (DT an) (JJ intrinsic) (NN ability) (S (VP (TO to) (VP (VB aggregate) (PP (IN in) (NP (DT the) (NN plasma) (NN membrane))))))) (CC and) (NP (NP (DT an) (NN association)) (PP (IN of) (NP (PRP$ its) (JJ cytoplasmic) (NP (NP (NN carboxyl) (NN terminus)) (PRN (-LRB- -LRB-) (NP (NN CT)) (-RRB- -RRB-))))) (PP (IN with) (NP (NP (JJ TNFR-associated) (NNS factors)) (PRN (-LRB- -LRB-) (NP (NNS TRAFs)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB now)) (VP (VBP show) (SBAR-COOD (SBAR (IN that) (S (PP (IN in) (NP (JJ EBV-transformed) (NN B) (NNS lymphocytes))) (NP-SBJ-COOD-56 (NP (NP (JJS most)) (PP (IN of) (NP-COOD (NP (NN TRAF1)) (CC or) (NP (NN TRAF3))))) (CC and) (NP (NP (CD 5) (NN %)) (PP (IN of) (NP (NN TRAF2))))) (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NN LMP1))))))) (CC and) (SBAR (IN that) (S (NP-SBJ-57 (NP (JJS most)) (PP (IN of) (NP (NN LMP1)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP-COOD (NP (NN TRAF1)) (CC or) (NP (NN TRAF3)))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN TRAF1)) (, ,) (NP (NN TRAF2)) (, ,) (CC and) (NP (NN TRAF3))) (VP (VBP bind) (PP (TO to) (NP (NP (DT a) (JJ single) (NN site)) (PP (IN in) (NP (NP (DT the) (NN LMP1) (NN CT)) (VP (VBG corresponding) (PP (TO to) (NP (NP (NP (NN amino) (NNS acids)) (PRN (-LRB- -LRB-) (NP (NNS aa)) (-RRB- -RRB-))) (NP-COOD (NP (CD 199)) (TO to) (NP (CD 214)))))))) (, ,) (PP (IN within) (NP (NP (DT a) (NN domain)) (SBAR (WHNP-58 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ important) (PP (IN for) (NP (NN B-lymphocyte) (NN growth) (NN transformation)))))))) (PRN (-LRB- -LRB-) (NP (NNS aa) (NP-COOD (NP (CD 187)) (TO to) (NP (CD 231)))) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ Further) (UCP (ADJP (JJ deletional)) (CC and) (NP (NN alanine) (NN mutagenesis))) (NNS analyses)) (CC and) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NN TRAF) (NN binding) (NNS sequences)) (PP-COOD (PP (IN in) (NP (NN CD40))) (, ,) (PP (IN in) (NP (NN CD30))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (NN LMP1)) (PP (IN of) (NP (JJ other) (NNS lymphycryptoviruses)))))))))) (VP (VBP provide) (NP (DT the) (JJ first) (NN evidence) (SBAR (IN that) (S (NP-SBJ (NN PXQXT/S)) (VP (VBZ is) (NP-PRD (DT a) (NN core) (NN TRAF) (NN binding) (NN motif))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ negative) (NNS effects)) (PP (IN of) (NP (NP (NN point) (NNS mutations)) (PP (IN in) (NP (DT the) (NN LMP1-LRB-1-231-RRB-) (NN core) (NN TRAF) (NN binding) (NN motif))))) (PP (IN on) (NP-COOD (NP (NN TRAF) (NN binding)) (CC and) (NP (NN NF-kappaB) (NN activation))))) (ADVP (RB genetically)) (VP (VBP link) (NP (DT the) (NNS TRAFs)) (PP (TO to) (NP (JJ LMP1-LRB-1-231-RRB--mediated) (NN NF-kappaB) (NN activation)))) (. .)))
(TOP (S-COOD (S (NP-SBJ-59 (NP (NN NF-kappaB) (NN activation)) (PP (IN by) (NP (NN LMP1-LRB-1-231-RRB-)))) (VP (VBZ is) (ADJP-PRD (JJ likely) (S (VP (TO to) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP-LGS (NN TRAF1/TRAF2) (NNS heteroaggregates))) (SBAR (IN since) (S (NP-SBJ-108 (NN TRAF1)) (VP (VBZ is) (ADJP-PRD (JJ unique)) (PP (IN among) (NP (DT the) (NNS TRAFs))) (PP (IN in) (S (VP (VBG coactivating) (NP (NN NF-kappaB)) (PP (IN with) (NP (NN LMP1-LRB-1-231-RRB-)))))))))))))))) (, ,) (S (NP-SBJ (DT a) (NN TRAF2) (JJ dominant-negative) (NN mutant)) (VP (MD can) (VP (VB block) (NP-COOD (NP (JJ LMP1-LRB-1-231-RRB--mediated) (NN NF-kappaB) (NN activation)) (CONJP (RB as) (RB well) (IN as)) (NP (NN TRAF1) (NN coactivation)))))) (, ,) (CC and) (S (NP-SBJ-61 (NP (CD 30) (NN %)) (PP (IN of) (NP (NN TRAF2)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NN TRAF1))) (PP (IN in) (NP (JJ EBV-transformed) (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (NN TRAF3)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ negative) (NN modulator)) (PP (IN of) (NP (JJ LMP1-LRB-1-231-RRB--mediated) (NN NF-kappaB) (NN activation))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (NP-SBJ-COOD (NP (NN TRAF1)) (, ,) (NP (CD -2)) (, ,) (CC or) (NP (CD -3))) (VP (VBZ does) (RB not) (VP (VB interact) (PP (IN with) (NP (NP (DT the) (JJ terminal) (NN LMP1) (NN CT) (NNS aa) (NP-COOD (NP (CD 333)) (TO to) (NP (CD 386)))) (SBAR (WHNP-62 (WDT which)) (S (VP (MD can) (ADVP (RB independently)) (VP (VBP mediate) (NP (NN NF-kappaB) (NN activation)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ constitutive) (NN association)) (PP (IN of) (NP (NNS TRAFs))) (PP (IN with) (NP (NN LMP1))) (PP (IN through) (NP (NP (DT the) (NNS aa) (NP-COOD (NP (CD 187)) (TO to) (NP (CD 231))) (NN domain)) (SBAR (WHNP-63 (WDT which)) (S (VP (VBZ is) (ADJP-PRD (JJ important)) (PP (IN in) (NP-COOD (NP (NN NF-kappaB) (NN activation)) (CC and) (NP (JJ primary) (NN B-lymphocyte) (NN growth) (NN transformation)))))))))) (VP (VBZ implicates) (NP (NP (NN TRAF) (NN aggregation)) (PP (IN in) (NP (NN LMP1) (NN signaling))))) (. .)))
(TOP (S (NP-SBJ (NP (NP-COOD (NP (NN CD40)) (, ,) (CONJP (CC but) (RB not)) (UCP-COOD (NP (NN lipopolysaccharide)) (CC and) (ADJP (JJ anti-IgM)))) (NN stimulation)) (PP (IN of) (NP (JJ primary) (NN B) (NNS lymphocytes))) (, ,)) (VP (VBZ leads) (PP (TO to) (NP (NP (DT a) (JJ persistent) (JJ nuclear) (NN accumulation)) (PP (IN of) (NP (NN RelB)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP-SBJ (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN CD40) (NN stimulation))) (PP (IN on) (NP (NP (DT the) (NP-COOD (NP (NN activity)) (CC and) (NP (JJ nuclear) (NN appearance)))) (PP (IN of) (NP (NP (NP (NP (NN Rel/nuclear) (NN factor) (NN kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-))) (NNS factors)) (PP (IN in) (NP (JJ primary) (JJ murine) (NN B) (NNS lymphocytes))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NN triggering)) (PP (IN of) (NP (NN CD40) (NN signaling) (NN pathway) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))) (PP (IN by) (NP (NP (NN CD40) (NNS ligands)) (VP (VBN expressed) (PP (IN on) (NP (NN L) (NNS cells))))))) (VP (VBD led) (PP (TO to) (NP (NP (JJ strong) (NN activation)) (PP (IN of) (NP (NP (DT an) (JJ NF-kappaB-controlled) (NN beta-globin) (NN reporter) (NN gene)) (PP (IN in) (NP (NP (JJ primary) (NN B) (NNS lymphocytes)) (PP (IN from) (NP (JJ transgenic) (NNS mice))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Analyses)) (PP (IN of) (NP (NP (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NP (JJ individual) (NNS members)) (PP (IN of) (NP (NN Rel) (NNS proteins))))) (PP-TMP (IN after) (NP (NP (NN CD40) (NN induction)) (PP (IN of) (NP (JJ primary) (NN B) (NNS cells)))))))) (VP (VBD showed) (NP-COOD (NP (NP (DT a) (ADJP-COOD-68 (ADJP (JJ strong)) (CC and) (ADJP (JJ long-lasting))) (NN accumulation)) (PP-69 (IN of) (NP (NN RelB)))) (CC and) (NP (, ,) (ADJP=68 (RBR less) (JJ pronounced)) (, ,) (PP=69 (IN of) (NP (NN c-Rel)))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NN LPS) (NN stimulation)) (VP (VBD did) (RB not) (VP (VB give) (NP (NN rise)) (PP-DTV (TO to) (NP (NP (DT a) (JJ persistent) (JJ nuclear) (NN accumulation)) (PP (IN of) (NP-COOD (NP (NN RelB)) (CC and) (NP (NN c-Rel))))))))) (, ,) (IN whereas) (S (NP-SBJ (JJ nuclear) (NP-COOD (NP (NN c-Rel)) (, ,) (CONJP (CC but) (RB not)) (NP (NN RelB)) (, ,))) (VP (VBD accumulated) (PP-TMP (IN after) (NP (NN B) (NN cell) (NN receptor) (NN stimulation))))) (. .)))
(TOP (S (NP-SBJ (NN CD40)) (VP (VBD induced) (NP (NP-COOD (CONJP (RB not) (RB only)) (NP (JJ nuclear) (NN translocation)) (CONJP (CC but) (RB also)) (NP (ADJP (FW de) (FW novo)) (NN synthesis))) (PP (IN of) (NP (NN RelB) (NP-COOD (NP (NN RNA)) (CC and) (NP (NN protein))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN S107) (NN plasmacytoma) (NNS cells)) (, ,) (SBAR (WHNP-71 (WDT which)) (S (VP-COOD (VP (VBP express) (NP (NN CD40))) (CC but) (VP (VBP are) (ADJP-PRD (JJ defective) (PP (IN for) (NP (NP (DT the) (JJ nuclear) (NN appearance)) (PP (IN of) (NP (NN p50/p65-NF-kappaB)))))))))) (, ,)) (VP (VBP do) (RB not) (VP (VB express) (NP (NN RelB)) (PP-TMP (IN after) (NP (NN CD40) (NN stimulation))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NN S107) (NNS cells)) (VP (ADVP (RB stably)) (VBN transfected) (PP (IN with) (NP (NN relB) (NNS genes)))))) (, ,) (NP-SBJ-70 (NP (NN stimulation)) (PP (IN of) (NP (JJ nuclear) (NN RelB) (NN translocation))) (PP (IN by) (NP (NN CD40)))) (VP (VBD was) (VP (VBN observed))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN stimulation)) (PP (IN of) (NP (NN CD40) (NN signaling) (NNS pathways)))) (VP (VBZ exerts) (NP (DT a) (JJ long-lasting) (JJ stimulatory) (NN effect)) (PP (IN on) (NP (NP (CC both) (DT the) (NP-COOD (NP (NN transcription)) (CC and) (NP (JJ nuclear) (NN translocation)))) (PP (IN of) (NP (NN RelB))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ-COOD-72 (NP (NN LPS)) (CC and) (NP (NN anti-IgM))) (VP (VBD were) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB activate) (NP (NN RelB))))))))) (, ,) (NP-SBJ-73 (NN CD40)) (VP (VBZ appears) (S (VP (TO to) (VP (VB trigger) (NP (NP (DT a) (JJ special) (NN program)) (PP (IN of) (NP (NN gene) (NN expression))) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN proliferation)) (CC and/or) (NP (NN differentiation)))) (PP (IN of) (NP (NN B) (NNS lymphocytes))))))))))) (. .)))
(TOP (NP (NP (ADJP (NN Sterol) (JJ dependent)) (NN LDL-receptor) (NN gene) (NN transcription)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (UCP-COOD (ADJP (JJ normal)) (CC and) (NP (NN CML))) (NNS patients))))) (. .)))
(TOP (S (NP-SBJ-61 (NP (NN Sterol) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN SRE)) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN recognized) (S (VP (TO to) (VP (VB regulate) (NP (NP (JJ various) (JJ key) (NNS genes)) (VP (VBG coding) (PP (IN for) (NP (NP-COOD (NP (ADJP (RB especially) (JJ low)) (NN density) (NN lipoprotein) (-LRB- -LRB-) (NN LDL) (-RRB- -RRB-) (NN -receptor)) (, ,) (NP (NP (NN 3-hydroxy-3-methylglutaryl) (NN coenzyme) (NN A)) (PRN (-LRB- -LRB-) (NP (NN HMG-CoA)) (-RRB- -RRB-)) (NN reductase)) (CC and) (NP (NN HMG-CoA) (NN synthase))) (VP (VBN known) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (NP (DT the) (NN cholesterol) (NN feedback) (NN mechanism))))))))))))))))) (. .)))
(TOP (S (NP-SBJ-62 (DT The) (JJ deranged) (NN cholesterol) (NN feedback) (NN mechanism)) (VP (VBZ has) (VP (VBN been) (VP (ADVP (RB widely)) (VBN recognised) (PP (IN in) (NP (NP-COOD (NP (NN initiation)) (CONJP (RB as) (RB well) (IN as)) (NP (NN progression))) (PP (IN of) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NNS cancers))) (PP (VBG including) (NP (NP (JJ chronic) (JJ myeloid) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN CML)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (ADVP (RB Consequently)) (, ,) (NP-SBJ-110 (DT the) (JJ present) (NN study)) (VP-COOD (VP (VBD was) (VP (VBN addressed) (S (VP (TO to) (VP (VB understand) (NP (DT this) (NN phenomenon))))))) (CC and) (VP (VBD revealed) (NP-COOD (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (JJ unique) (ADJP (CD 47) (NN kDa)) (NN protein) (NN factor)) (VP (VBG having) (NP (NP (NN affinity)) (PP (IN for) (NP (DT this) (NN SRE) (NN sequence))))))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ normal) (NNS subjects)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (PRP$ its) (NN absence)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ untreated) (NN CML) (NNS patients))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (DT this) (NN factor)) (VP (VBD appeared) (SBAR-TMP (WHADVP-63 (WRB when)) (S (NP-SBJ (DT the) (NN CML) (NNS patients)) (VP (VBD achieved) (NP (NP (JJ complete) (JJ haematological) (NN remission)) (PRN (-LRB- -LRB-) (NP (NN CHR)) (-RRB- -RRB-))) (PP (IN through) (NP (NN alpha-interferon) (NN therapy))))))) (. .)))
(TOP (S (ADVP (RB Further)) (, ,) (NP-SBJ-64 (DT an) (NN inverse) (NN relationship)) (VP (VBD was) (VP (ADVP (RB also)) (VBN observed) (PP (IN between) (NP-COOD (NP (ADJP (NN sterol) (JJ modulated)) (NN LDL-receptor) (NN gene) (NN transcription)) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PP (IN of) (NP (DT this) (ADJP (CD 47) (NN kDa)) (NN factor))) (PP (TO to) (NP (DT the) (NN SRE) (NN sequence)))))))) (. .)))
(TOP (S (PP (VBN Based) (PP (IN upon) (NP (DT these) (NNS results)))) (NP-SBJ (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (NN alpha-interferon)) (PP (IN through) (NP (PRP$ its) (NN receptor))) (VP (VBZ initiates) (NP (NP (ADJP (NP (JJ phosphatidic) (NN acid)) (JJ dependent)) (NN signalling)) (SBAR (WHNP-66 (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ regulates) (NP-COOD (NP (NP (DT the) (NN affinity)) (PP (IN of) (NP (ADJP (CD 47) (NN kDa)) (NN sterol) (JJ regulatory) (NN element) (NN binding) (NN factor)))) (CONJP (RB as) (RB well) (IN as)) (NP (NN LDL-receptor) (NN gene) (NN transcription)))))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (NN CML) (NNS patients)))))))))) (. .)))
(TOP (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NN Ara-C)) (PP (IN on) (NP (NP-COOD (NP (JJ neutral) (NN sphingomyelinase)) (CC and) (NP (ADJP-COOD (ADJP (NN mitogen-)) (CC and) (ADJP (JJ stress-activated))) (NN protein) (NNS kinases))) (PP (IN in) (NP (NN T-lymphocyte) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (NP-SBJ-51 (JJ Neutral) (NP (NP (NN sphingomyelinase)) (PRN (-LRB- -LRB-) (NP (NN SMase)) (-RRB- -RRB-)))) (VP (MD can) (VP (VB be) (VP (VBN activated) (PP (IN by) (NP-LGS (JJ extracellular) (NNS signals))) (S (VP (TO to) (VP (VB produce) (NP (NP (NN ceramide)) (, ,) (SBAR (WHNP-53 (WDT which)) (S (VP (MD may) (VP (VB affect) (NP (NP (NP (JJ mitogen-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MAPK)) (-RRB- -RRB-))) (NNS activities))))))))))))) (. .)))
(TOP (S (NP-SBJ-54 (JJ Neutral) (NN SMase) (NN activity)) (VP (VBD was) (VP (VBN assessed) (PP (IN in) (NP (NP (NNS membranes)) (PP (IN from) (NP-COOD (NP (NP (NN Jurkat)) (, ,) (NP (DT a) (JJ human) (NN T-cell) (NN line)) (, ,)) (CC and) (NP (NP (NN EL4)) (, ,) (NP (DT a) (JJ murine) (NN T-cell) (NN line))))))))) (. .)))
(TOP (S (NP-SBJ (NN Ara-C)) (VP (VBD activated) (NP (NN SMase)) (PP-TMP (IN with) (NP (CD 10) (NNS minutes))) (PP (IN in) (NP (NP-COOD (CC both) (NP (NN Jurkat)) (CC and) (NP (NN EL4))) (NNS cells))) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (NN phorbol) (NN ester)) (PRN (-LRB- -LRB-) (NP (NN PMA)) (-RRB- -RRB-))) (VP (VBD had) (NP (DT no) (NN effect)))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (NN PMA)) (, ,) (CONJP (CC but) (RB not)) (NP-COOD (NP (NN Ara-C)) (CC or) (NP (NNS ceramides))) (, ,)) (VP (VBD activated) (NP (NN ERK) (NNS MAPKS)) (, ,) (PP (IN in) (NP-COOD (NP (NN Jurkat)) (CC and) (NP (NN EL4))))) (. .)))
(TOP (S (NP-SBJ-55 (NN PMA)) (VP (VBD acted) (ADVP (RB synergistically)) (PP (IN with) (NP (NN ionomycin))) (S (VP (TO to) (VP (VB activate) (NP (NN JNK) (NNS MAPKs)) (PP (IN in) (NP-COOD (NP (NN Jurkat)) (CC and) (NP (NN EL4)))) (PP-TMP (IN within) (NP (CD 10) (NNS minutes))))))) (. .)))
(TOP (S (NP-SBJ (NN Ara-C)) (VP (VBD activated) (NP (NNS JNKs)) (PP-TMP (RB only) (IN after) (NP (NP (JJ prolonged) (NN incubation)) (PRN (-LRB- -LRB-) (NP-TMP (QP (CD 90-120)) (NNS minutes)) (-RRB- -RRB-))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ (NN ceramide)) (VP (VBZ is) (RB not) (NP-PRD (NP (DT a) (JJ positive) (NN signal)) (PP (IN for) (NP (NP (NN ERK) (NN activation)) (PP (IN in) (NP (NN T-cell) (NNS lines))))))) (. .)))
(TOP (S (NP-SBJ-56 (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN Ara-C))) (PP (IN on) (NP (NN JNK) (NN activity)))) (VP (MD may) (VP (VB be) (VP (VBN mediated) (PP (IN through) (NP (JJ secondary) (NN response) (NNS pathways)))))) (. .)))
(TOP (NP (-LRB- -LCB-) (JJ Cortisone-resistant) (JJ bronchial) (NN asthma) (-RRB- -RCB-)))
(TOP (S (S (NP-SBJ (EX There)) (VP (VBZ is) (NP-PRD (NP (JJ general) (NN agreement)) (PP (IN on) (NP (NP (DT the) (JJ inflammatory) (NN pathogenesis)) (PP (IN of) (NP (JJ bronchial) (NN asthma))))))) (: :)) (S (NP-SBJ-COOD-50 (NP (NP (DT an) (NN accumulation)) (PP (IN of) (NP-104 (VBN activated) (NNS eosinophils)))) (, ,) (NP (NP=104 (VBN degranulated) (NN mast) (NNS cells))) (, ,) (NP (NP=104 (NN T) (NNS lymphocytes))) (CC and) (NP (PP (IN in) (NP (ADJP (RB very) (JJ severe)) (NNS forms))) (, ,) (NP=104 (NNS granulocytes)))) (VP (VBZ has) (ADVP-TMP (RB constantly)) (VP (VBN been) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ bronchial) (NN mucosa)))))) (. .))))
(TOP (S (PP (IN In) (NP (JJ allergic) (JJ bronchial) (NN asthma))) (, ,) (NP-SBJ-51 (NN inflammation)) (VP (VBZ seems) (S (VP (TO to) (VP (VB be) (VP (VBN orchestrated) (PP (ADVP (RB predominantly)) (IN by) (NP-LGS (NP (DT a) (NN subset)) (PP (IN of) (NP (NN T) (NNS lymphocytes))) (, ,) (PP (IN with) (NP (NP (DT a) (NN phenotype)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT the) (NN Th2) (NN subset)) (ADJP (JJ able) (S (VP (TO to) (VP (VB produce) (NP-COOD (NP (NN IL-4)) (CC and) (NP (NN IL-5))))))))))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NNS corticosteroids)) (VP (VBP are) (NP-PRD (NP (DT the) (ADJP (RBS most) (JJ potent)) (JJ therapeutic) (NNS agents)) (VP (VBN used) (PP (IN for) (NP (DT this) (NN disease)))))))) (, ,) (NP-SBJ (PRP$ their) (JJ anti-inflammatory) (NN effect)) (VP (VBZ differs) (PP-COOD (PP (IN from) (NP (NN patient))) (PP (TO to) (NP (NN patient))))) (. .)))
(TOP (S (NP-SBJ-53 (NP (DT Some) (NNS criteria)) (SBAR (WHNP-54 (WDT which)) (S (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB define) (NP (JJ steroid-resistant) (JJ bronchial) (NN asthma))))))))))) (VP (VBP are) (VP (VBN listed) (ADVP (RB here)))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN review)) (VP (VBZ analyzes) (NP (NP (JJ various) (JJ molecular) (NNS alterations)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ deficient) (NN response)) (PP (TO to) (NP (NN corticosteroid) (NN treatment))) (VP (VBN observed) (PP (IN in) (NP (ADJP (JJ steroid-resistant) (JJ bronchial) (JJ asthmatic)) (NNS subjects))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ New) (NN knowledge)) (PP (IN on) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN steroid) (NN resistance)))))) (VP (MD may) (VP (VB have) (NP (NP (JJ important) (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP-COOD (NP (JJ chronic) (NN asthma)) (CC and) (NP (JJ other) (NNS diseases))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (NN Egr-1)))) (VP (VBZ correlates) (PP (IN with) (NP (NP-COOD (NP (DT the) (VBN transformed) (NN phenotype)) (CC and) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (JJ viral) (NN latency))))) (PP (IN in) (NP (ADJP (NP (NN EBV) (NN genome)) (JJ positive)) (JJ lymphoid) (NN cell) (NNS lines)))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN paper))) (NP-SBJ-41 (PRP we)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN Egr-1))) (PP (IN in) (NP (NN B) (NN cell) (NN growth) (NN regulation)))) (PP (IN by) (S (VP (VBG examining) (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN in) (NP (NP (DT a) (NN panel)) (PP (IN of) (NP (NP (NN B) (NN cell) (NNS lines)) (, ,) (PP (VBG including) (NP (ADJP-COOD (CC both) (ADJP (NP (NN EBV) (NN genome)) (JJ negative)) (CC and) (ADJP (NN EBV) (VBG carrying))) (NN cell) (NNS lines))))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Egr-1) (NN expression)) (VP (VBZ correlates) (PP (IN with) (NP (NP-COOD (NP (DT the) (JJ cellular) (NN phenotype)) (CC and) (NP (NP (DT the) (JJ specific) (NN pattern)) (PP (IN of) (NP (JJ viral) (NN latency))))) (VP (VBN established) (PP (IN within) (NP (DT the) (JJ individual) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-42 (NP (JJ constitutive) (NN activation)) (PP (IN of) (NP (NN Egr-1) (NN gene)))) (VP (VBZ is) (VP (ADVP (RB invariably)) (VBN associated) (PP (IN with) (NP (NP (JJ unrestricted) (NN expression)) (PP (IN of) (NP (JJ viral) (JJ latent) (NNS genes))) (PP (IN in) (NP (DT all) (NN group) (CD III) (ADJP (NP (NN EBV) (NN genome)) (VBG carrying)) (NN cell) (NNS lines))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-43 (NN Egr-1) (NN expression)) (VP (VBZ is) (VP (VBN abrogated) (PP (IN in) (NP (NN group) (NN I) (NN Burkitt) (NN tumor) (NNS cells))) (, ,) (ADVP (JJ irrespective) (PP (IN of) (NP (DT the) (NN EBV) (NN genome) (NN carrying) (NN status)))))) (. .)))
(TOP (S (NP-SBJ (NP (VBN Activated) (JJ viral) (NN gene) (NN expression)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ phenotypic) (NN conversion)) (PP (IN of) (NP (NN group) (NN I) (NN cell) (NNS lines))) (PP (IN in) (TO to) (NP (NN group) (NP-COOD (NP (CD II)) (CC or) (NP (CD III))))))))) (VP (VBZ restores) (NP (DT the) (NN Egr-1) (NN gene) (NN expression))) (. .)))
(TOP (S-COOD (S (NP-SBJ-44 (NP (JJ Several) (NNS forms)) (PP (IN of) (NP (JJ EGR-1) (NN protein)))) (VP (VBP are) (VP (VBN found) (PP (IN within) (NP (NP (DT the) (JJ different) (NNS groups)) (PP (IN of) (NP (NN cell) (NNS lines)))))))) (, ,) (CC and) (S (NP-SBJ-45 (NP (DT the) (NN binding) (NN activity)) (PP (TO to) (NP (NN DNA) (NN consensus) (NNS sequences)))) (VP (VBD was) (VP (VBN investigated)))) (. .)))
(TOP (S (ADVP (RB Finally)) (, ,) (NP-SBJ (NP (NN time) (NN course) (NN analysis)) (PP (IN of) (NP (NP (NN Egr-1) (NN expression)) (PP-TMP (IN during) (NP (NP (DT the) (JJ early) (NNS steps)) (PP (IN of) (NP (NP (NN EBV) (NN infection)) (ADVP (FW in) (FW vitro))))))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ-46 (NN Egr-1)) (VP (VBZ is) (VP (VBN upregulated) (PP-TMP (IN within) (NP (NP (NNS minutes)) (PP (IN from) (NP (NP (DT the) (JJ initial) (NN interaction)) (PP (IN with) (NP (DT the) (NN B) (NN lymphocyte)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ proximal) (JJ regulatory) (NN element)) (PP (IN of) (NP (DT the) (NN interferon-gamma) (NN promoter)))) (VP (VBZ mediates) (NP (JJ selective) (NN expression)) (PP (IN in) (NP (NN T) (NNS cells)))) (. .)))
(TOP (S (S-COOD (S (NP-SBJ-56 (NP (NN Interferon-gamma)) (PRN (-LRB- -LRB-) (NP (NN IFN-gamma)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN produced) (PP (IN by) (NP-LGS-COOD (NP (JJ natural) (NN killer) (NNS cells)) (CC and) (NP (NP (JJ certain) (NNS subsets)) (PP (IN of) (NP (NN T) (NNS cells))))))))) (, ,) (CC but) (S (NP-SBJ (NP (DT the) (NN basis)) (PP (IN for) (NP (PRP$ its) (JJ selective) (NN expression)))) (VP (VBZ is) (ADJP-PRD (JJ unknown))))) (. .)))
(TOP (SINV (PP-PRD-TPC-57 (IN Within) (NP (NP (DT the) (NN region)) (PP (IN between) (NP (NP (NP-COOD (NP (CD -108)) (CC and) (NP (CD -40))) (NN base) (NNS pairs)) (PP (IN of) (NP (DT the) (NN IFN-gamma) (NN promoter))))))) (VP (VBP are)) (NP-SBJ (NP (CD two) (ADJP-COOD (ADJP (VBN conserved)) (CC and) (ADJP (JJ essential))) (JJ regulatory) (NNS elements)) (, ,) (SBAR (WHNP-58 (WDT which)) (S (VP (VBP confer) (NP (NP (JJ activation-specific) (NN expression)) (PP (IN in) (NP (NN T) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN report)) (VP (VBZ describes) (NP (NP (NNS studies)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (ADJP (RBS most) (JJ proximal))) (PP (IN of) (NP (DT these) (CD two) (JJ regulatory) (NNS elements)))) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (PRP$ its) (JJ restricted) (NN expression)))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ proximal) (NN element)) (VP (VBZ is) (NP (NP (DT a) (JJ composite) (NN site)) (SBAR (WHNP-59 (WDT that)) (S (VP (VBZ binds) (NP (NP (NNS members)) (PP (IN of) (NP (NP (DT the) (NP-COOD (NP (NN CREB/ATF)) (, ,) (NP (NN AP-1)) (, ,) (CC and) (NP (NN octamer))) (NNS families)) (PP (IN of) (NP (NN transcription) (NNS factors))))))))))) (. .)))
(TOP (S (NP-SBJ (NN Jun)) (VP-COOD (VP (VBZ is) (ADJP-PRD (JJ essential) (PP (IN for) (NP (JJ activation-induced) (NN transcription))))) (CC and) (VP (VBZ binds) (ADVP (RB preferably)) (PP (IN as) (NP (DT a) (NN heterodimer))) (PP (IN with) (NP (NN ATF-2))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-60 (NN CREB)) (VP (VBZ appears) (S (VP (TO to) (VP (VB dampen) (NP (NP (NN transcription)) (PP (IN from) (NP (DT this) (NN element)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-61 (NP (DT The) (NN CpG) (NN dinucleotide)) (PP (IN in) (NP (DT this) (NN element)))) (VP (VBZ is) (VP (ADVP (RB selectively)) (VBN methylated) (PP (IN in) (NP-COOD (NP (NN Th2) (NN T) (NNS cells)) (CC and) (NP (NP (JJ other) (NNS cells)) (SBAR (WHNP-62 (WDT that)) (S (VP (VBP do) (RB not) (VP (VB express) (NP (NN IFN-gamma)))))))))))) (, ,) (CC and) (S (NP-SBJ (NN methylation)) (ADVP (RB markedly)) (VP (VBZ reduces) (NP (NN transcription) (NN factor) (NN binding)))) (. .)))
(TOP (S (PP (IN As) (NP (NP (DT a) (NN target)) (PP-COOD (PP (IN for) (NP (NN DNA) (NN methylation))) (CC and) (PP (IN for) (NP (NP (NN binding)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (SBAR (WHNP-65 (WDT that)) (S (VP (VP-COOD (VP (VBP mediate)) (CC or) (VP (VBP impede))) (NP-66 (NN transcription)))))))))))) (, ,) (NP-SBJ-64 (DT this) (NN element)) (VP (VBZ appears) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ central) (NN role)) (PP (IN in) (S (VP (VBG controlling) (NP (NN IFN-gamma) (NN expression))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Activation)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappaB))) (PP (IN via) (NP (NN T) (NN cell) (NN receptor)))) (VP (VBZ requires) (NP (DT a) (NP-COOD (NP (NN Raf) (NN kinase)) (CC and) (NP (NN Ca2+))) (NN influx))) (. .)))
(TOP (NP (NP (JJ Functional) (NN synergy)) (PP (IN between) (NP-COOD (NP (NN Raf)) (CC and) (NP (NN calcineurin)))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Signals)) (VP (VBN transduced) (PP (IN via) (NP (DT the) (NN TCR))))) (VP (VBP activate) (NP (NP (DT the) (NN transcription) (NN factor) (NP (NP (JJ nuclear) (NN factor-kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP-41 (WDT which)) (, ,) (S (PP (IN in) (NP (NN turn))) (, ,) (VP (VBZ is) (ADJP-PRD (JJ critical) (PP (TO to) (NP (NP (DT the) (JJ transcriptional) (NN induction)) (PP (IN of) (NP (NP (JJ many) (NNS genes)) (ADJP (JJ important) (PP (IN for) (NP (NP (DT the) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN expression)))) (PP (IN of) (NP (DT a) (VBN differentiated) (NN phenotype)))))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (NN Treatment)) (PP (IN of) (NP (NN T) (NNS cells))) (PP (IN with) (NP (DT the) (NN protein) (NN kinase) (NN C) (NN activator) (NN PMA))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN Ca2+) (NNS ionophores)))))) (VP (VBZ mimics) (NP (DT this) (NN process)))) (, ,) (CC and) (S (NP-SBJ-42 (DT the) (CD two) (NNS agents)) (VP (VBP are) (VP (ADVP-TMP (RB often)) (VBN substituted) (PP (IN for) (NP (NN TCR) (NN stimulation)))) (, ,) (S (VP (VBG bypassing) (NP (DT the) (NN TCR)))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP identify) (NP (NP (JJ intracellular) (VBG signaling) (NNS components)) (VP (VBN involved) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))) (PP-TMP (VBG following) (NP (NN TCR) (NN stimulation)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-44 (NN TCR) (NN signaling)) (VP (VBD was) (VP (VBN triggered) (PP (IN by) (S-LGS (VP (VBG treating) (NP (NN Jurkat) (NN T) (NNS cells)) (PP (IN with) (NP (UCP (NP (NN PHA)) (CC or) (ADJP (JJ anti-CD3))) (NNS Abs))))))))) (, ,) (CC and) (S (NP-SBJ-45 (NN NF-kappaB) (NN activation)) (VP (VBD was) (VP (VBN monitored) (PP-COOD (PP (IN by) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays))) (CC and/or) (PP (IN by) (NP (JJ kappaB-dependent) (NN reporter) (NNS assays))))))) (. .)))
(TOP (S (PP (JJ Contrary) (TO to) (NP (DT the) (NN idea) (SBAR (IN that) (S (NP-SBJ-46 (NN protein) (NN kinase) (NN C)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (JJ TCR-mediated) (NN activation)) (PP (IN of) (NP (NN NF-kappaB))))))))))) (, ,) (NP-SBJ (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NN staurosporine)))) (VP (VBD did) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappaB))) (PP (IN by) (NP (NN PHA))))) (, ,) (SBAR (IN while) (S (NP-SBJ (NP (DT the) (JJ same) (NN dose)) (PP (IN of) (NP (NN staurosporine)))) (ADVP (RB completely)) (VP (VBD blocked) (NP (NP (NN activation)) (PP (IN by) (NP (NN PMA))))))))) (. .)))
(TOP (S (NP-SBJ-47 (JJ PHA-induced) (JJ kappaB-dependent) (NN reporter) (NN activity)) (VP (VBD was) (, ,) (ADVP (RB however)) (, ,) (VP (ADVP (RB effectively)) (VBN blocked) (PP (IN by) (NP-LGS (NP (DT a) (JJ dominant) (JJ negative) (NN form)) (PP (IN of) (NP (NN Raf-1))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN for) (NP (DT a) (NN Raf) (NN kinase)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ TCR-mediated) (NN activation)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBD was) (ADVP (RB also)) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (DT a) (NN Ca2+) (NN influx)))) (, ,) (SBAR (IN because) (S (NP-SBJ-COOD (NP (NP (DT the) (NN Ca2+) (NN channel) (NN blocker)) (, ,) (NP (NN SK&amp;F) (CD 96365))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ other) (NNS agents)) (SBAR (WHNP-49 (WDT that)) (S (VP (VBD prevented) (NP (DT the) (NN Ca2+) (NN influx)))))) (, ,)) (VP (VBD inhibited) (NP (NN NF-kappaB) (NN activation)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Cotransfection)) (PP (IN of) (NP (NP (DT a) (ADJP (RB constitutively) (JJ active)) (NN form)) (PP (IN of) (NP (NN calcineurin)))))) (VP-COOD (VP (ADVP (RB largely)) (VBD substituted) (PP (IN for) (NP (DT the) (NN Ca2+) (NN requirement)))) (CC and) (VP (VBD reversed) (NP (NP (DT the) (NN blockade)) (PP (IN by) (NP (NN SK&amp;F) (CD 96365)))))) (. .)))
(TOP (S (ADJP (JJ Consistent) (PP (IN with) (NP (DT these) (NNS observations)))) (, ,) (NP-SBJ (NP (NN coexpression)) (PP (IN of) (NP (NP (ADJP (RB constitutively) (JJ active)) (NNS forms)) (PP (IN of) (NP-COOD (NP (NN Raf-1)) (CC and) (NP (NN calcineurin))))))) (ADVP (RB synergistically)) (VP (VBD induced) (NP (JJ kappaB-dependent) (NN reporter) (NN activity)) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (ADJP (RB physiologically) (JJ relevant)) (JJ functional) (NN interaction)) (PP (IN between) (NP-COOD (NP (DT the) (NN kinase)) (CC and) (NP (DT the) (NN phosphatase)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Induction)) (PP (IN of) (NP (DT the) (NN CD11b) (NN gene))) (PP-TMP (IN during) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (JJ monocytic) (NN cell) (NN line) (NN U937)))))) (VP (VBZ requires) (NP (DT a) (JJ novel) (JJ nuclear) (NN factor) (NN MS-2)) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP J) (NNP Immunol)) (NP-TMP (CD 1999) (NNP Jul) (CD 15)) (: ;) (NP (CD 163) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (: :) (NP (CD 1091)))))) (-RRB- -RCB-)))))
(TOP (S (NP-SBJ-23 (NP (DT The) (NN differentiation)) (PP (IN of) (NP (JJ myeloid) (NNS precursors))) (PP (IN into) (NP (JJ mature) (JJ myelomonocytic) (NNS cells)))) (VP (VBZ is) (VP (VBN characterized) (PP (IN by) (NP-LGS (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT the) (NN gene)) (VP (VBG encoding) (NP (DT the) (NN beta2) (NN integrin) (NN CD11b))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT The) (NN transcription) (NNS factors) (NP-COOD (NP (NN Sp1)) (CC and) (NP (NN PU.1)))) (VP (VBP prime) (NP (DT the) (NN CD11b) (NN promoter)))) (, ,) (CC but) (S (NP-SBJ (NP (DT the) (NN nature)) (PP (IN of) (NP (NP (DT the) (NNS factors)) (ADJP (JJ responsible) (PP (IN for) (NP (PRP$ its) (JJ inducible) (NN expression))))))) (VP (VBP are) (ADJP-PRD (JJ unknown)))) (. .)))
(TOP (S (PP (IN In) (NN addition) (TO to) (NP (DT the) (NN CD11b) (NN gene))) (, ,) (NP-SBJ (NP (DT the) (JJ homologous) (NNS genes)) (VP (VBG encoding) (NP-COOD (NP (NN CD11a)) (CC and) (NP (NN CD11c))))) (ADVP (RB also)) (VP (VBP exhibit) (NP (JJ inducible) (NN expression)) (PP-TMP (IN during) (NP (JJ myeloid) (NN differentiation)))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ-24 (PRP we)) (VP (VBD compared) (NP (NP (DT the) (JJ nucleotide) (NNS sequences)) (PP (IN of) (NP (DT the) (NP-COOD (NP (NN CD11a)) (, ,) (NP (NN CD11b)) (, ,) (CC and) (NP (NN CD11c))) (NN gene) (NNS promoters)))) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ common) (NNS elements)) (SBAR (WHNP-25 (WDT that)) (S (VP (MD might) (VP (VB contribute) (PP (TO to) (NP (JJ inducible) (NN expression)))))))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN analysis)) (VP (VBD identified) (NP (NP (CD one) (JJ such) (NN element)) (VP (VBN repeated) (NP (CD four) (NNS times)) (PP (IN within) (NP (DT the) (NN CD11b) (NN promoter)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Mutation)) (PP (IN of) (NP (DT these) (NNS elements)))) (VP (VBD indicated) (SBAR (IN that) (S (NP-SBJ (NP (CD two)) (, ,) (NP-COOD (NP (NN MS-2beta)) (CC and) (NP (NN MS-2gamma))) (, ,)) (VP (VBP are) (ADJP-PRD (JJ critical) (PP (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (DT the) (NN CD11b) (NN gene))) (PP-TMP (IN during) (NP (NP (NN differentiation)) (PP (IN of) (NP (DT the) (JJ pro-monocytic) (NN cell) (NN line) (NN U937)))))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN MS-2beta)) (CC and) (NP (NN MS-2gamma))) (VP (VBP interact) (PP (IN with) (NP (NP (JJ nuclear) (NNS factors)) (SBAR (WHNP-26 (WDT that)) (S (VP (VBP are) (VP (VBN induced) (PP-TMP (IN during) (NP (NN U937) (NN differentiation))))))))))))) (. .)))
(TOP (S (NP-SBJ-28 (DT These) (NNS factors)) (VP (VBP are) (VP (VBN detected) (PP-TMP (IN at) (NP (NP (DT the) (NN time)) (SBAR (S (NP-SBJ-30 (DT the) (NN CD11b) (NN promoter)) (VP (VBZ is) (VP (VBN activated))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (JJ molecular) (NN mass)) (PP (IN of) (NP (DT these) (NNS factors)))) (VP (VBZ is) (NP-PRD (QP (RB approximately) (CD 28)) (NN kDa)))) (, ,) (CC and) (S (NP-SBJ (PRP$ their) (NN DNA) (NN binding) (NNS characteristics)) (VP (VBP are) (ADJP-PRD (JJ indistinguishable) (PP (IN from) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (JJ novel) (JJ nuclear) (NN factor) (NN MS-2)))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP-SBJ-100 (PRP$ our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN MS-2)) (VP (VBZ mediates) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NN CD11b) (NN gene)))) (SBAR (IN as) (S (NP-SBJ (NP (NNS cells)) (PP (IN of) (NP (DT the) (JJ monocytic) (NN lineage)))) (VP (VBP mature)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN presence)) (PP (IN of) (NP (NP (JJ multiple) (JJ potential) (VBG binding) (NNS sites)) (PP (IN for) (NP (NN MS-2))))) (PP (IN in) (NP (NP (DT the) (NN promoter) (NNS regions)) (PP (IN of) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN expressed) (PP (IN in) (NP (JJ mature) (JJ myeloid) (NNS cells))))))))))) (VP (VBZ suggests) (SBAR (S (NP-SBJ (DT this) (NN factor)) (VP (VBZ plays) (NP (DT a) (JJ general) (NN role)) (PP (IN in) (NP (JJ myeloid) (NN differentiation))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN HIV-1) (NN LTR) (NN activity)) (PP (IN in) (NP (JJ human) (JJ CD40-activated) (NN B) (NNS lymphocytes)))) (VP (VBZ is) (ADJP-PRD (JJ dependent) (PP (IN on) (NP (NN NF-kappaB))))) (. .)))
(TOP (S (NP-SBJ (JJ CD40-stimulated) (JJ human) (NN B) (NNS lymphocytes)) (VP (VBP are) (ADJP-PRD (RB highly) (JJ permissive) (PP (TO to) (NP (NP (DT a) (JJ productive) (NN infection)) (PP (IN by) (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus) (NN type) (CD 1))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT these) (NNS cells))) (, ,) (NP-SBJ (NP (JJ nuclear) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (NP (DT the) (NN HIV-1) (NN LTR)) (, ,) (SBAR (WHNP-45 (WDT which)) (S (VP (VBZ contains) (NP (NP (DT the) (JJ transcriptional) (NN control) (NNS elements)) (PP (IN of) (NP (DT the) (NN virus))))))) (, ,))))))) (VP (VBP are) (ADJP-PRD (JJ unknown))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Transient) (NN expression) (NNS assays)) (PP (IN with) (NP (NP (NNS plasmids)) (VP (VBG containing) (NP (NP (VBN deleted) (NNS parts)) (PP (IN of) (NP (NP (DT the) (NN LTR) (NN region)) (VP (VBN linked) (PP (TO to) (NP (DT a) (NN reporter) (NN gene))))))))))) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (DT the) (NN NF-kappaB) (NN binding) (NN site)) (VP (VBD was) (ADJP-PRD (JJ essential) (PP (IN for) (NP (NP (NN HIV-1) (NN LTR) (NN activity)) (PP (IN in) (NP (JJ CD40-stimulated) (NN B) (NNS lymphocytes)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NP-COOD (NP (JJ electrophoretic) (NN mobility) (NN shift)) (CC and) (NP (NN supershift))) (NNS assays)) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (NP (JJ important) (NN NF-kappaB) (NN binding) (NN activity)) (VP (VBN composed) (PP (IN of) (NP (ADVP (IN at) (JJS least)) (NP-COOD (NP (NN p50)) (, ,) (NP (NN p65)) (, ,) (CC and) (NP (NN c-Rel) (NN NF-kappaB))) (NNS subunits))))) (VP (VBD was) (ADJP-PRD (JJ present) (PP (IN in) (NP (NP (NNS nuclei)) (PP (IN of) (NP (JJ CD40-stimulated) (NN B) (NNS cells)))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP-COOD (VP (VBP confirm) (PP (IN at) (NP (DT a) (JJ molecular) (NN level))) (NP-102 (NP (DT the) (NN ability)) (PP (IN of) (NP (NN HIV-1))) (S-46 (VP (TO to) (VP (VB replicate) (PP (IN in) (NP (NN B) (NNS cells)))))))) (CC and) (VP (SBAR=102 (IN that) (S (NP-SBJ-47 (DT this) (NN activity)) (VP (VBZ is) (VP (ADVP (RB strongly)) (VBN associated) (PP (IN with) (NP (NN NF-kappaB))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Mutation)) (PP (IN of) (NP (NNS tyrosines) (CD 492/493))) (PP (IN in) (NP (NP (DT the) (NN kinase) (NN domain)) (PP (IN of) (NP (NN ZAP-70)))))) (VP (VBZ affects) (NP (JJ multiple) (NN T-cell) (NN receptor) (NN signaling) (NNS pathways))) (. .)))
(TOP (S (NP-SBJ-21 (DT The) (JJ protein-tyrosine) (NN kinase) (NN ZAP-70)) (VP (VBZ is) (VP (VBN implicated) (, ,) (PP (RB together) (IN with) (NP (DT the) (NN Src) (NN kinase) (NN p56-LRB-lck-RRB-))) (, ,) (PP (IN in) (S (VP (VBG controlling) (NP (NP (DT the) (JJ early) (NNS steps)) (PP (IN of) (NP (DT the) (NP (NP (NN T-cell) (NN antigen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN TCR)) (-RRB- -RRB-))) (NN signaling) (NN cascade))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB help) (S (VP (VB elucidate) (ADVP (RBR further)) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP-24 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NN ZAP-70)) (VP (VBZ regulates) (NP (DT these) (JJ initial) (NNS events))))))))))) (, ,) (NP-SBJ-23 (PRP we)) (VP (VBD used) (NP (DT a) (JJ dominant-negative) (NN mutant) (NN approach))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD overexpressed) (PP (IN in) (NP (DT the) (NN Jurkat) (NN T-cell) (NN line))) (NP (NP (NN ZAP-70)) (VP (VBN mutated) (PP (IN on) (NP (NP-COOD (NP (NN Tyr-492)) (CC and) (NP (NN Tyr-493))) (PP (IN in) (NP (NP (DT the) (JJ putative) (JJ regulatory) (NN loop)) (PP (IN of) (NP (PRP$ its) (NN kinase) (NN domain)))))))))) (. .)))
(TOP (S (NP-SBJ-25 (DT This) (NN mutant)) (VP (VBD inhibited) (NP (NP (JJ TCR-induced) (NN activation)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))))) (PP (IN by) (S (VP (VBG interfering) (PP (IN with) (NP-COOD (CC both) (NP (JJ intracellular) (NN calcium) (NN increase)) (CC and) (NP (NP (JJ Ras-regulated) (NN activation)) (PP (IN of) (NP (JJ extracellular) (JJ signal-regulated) (NNS kinases)))))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP-SBJ-26 (NP (JJ TCR-induced) (NN phosphorylation)) (PP (IN of) (NP (NN pp36-38))) (, ,) (VP (VBN thought) (S (VP (TO to) (VP (VB play) (NP (DT a) (NN role)) (ADVP (RB upstream) (PP (IN of) (NP (DT these) (NNS pathways)))))))) (, ,)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (VP (VBN reduced))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ (NP (NN overexpression)) (PP (IN of) (NP (JJ wild-type) (NN ZAP-70)))) (VP (VBD induced) (NP (NP (JJ constitutive) (NN activation)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP-SBJ-28 (NP (DT The) (NN ZAP-70) (NN mutant)) (VP (VBN studied) (ADVP (RB here)))) (VP-COOD (VP (MD could) (VP (VB be) (VP (VBN phosphorylated) (PP (IN on) (NP (NN tyrosine))) (SBAR-TMP (WHADVP-32 (WRB when)) (S (VP (VBN associated) (PP (TO to) (NP (DT the) (NN TCR) (NN zeta) (NN chain))))))))) (CC and) (VP (VBD was) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB bind) (NP (NN p56-LRB-lck-RRB-)))))))) (. .)))
(TOP (S (NP-SBJ (DT This) (NN result)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP-SBJ-COOD (NP (NN Tyr-492)) (CC and) (NP (NN Tyr-493))) (VP (VBP are) (RB not) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (NP (DT the) (ADJP (NN Src) (NN homology) (NN domain) (JJ 2-mediated)) (NN association)) (PP (IN of) (NP (NN p56-LRB-lck-RRB-))) (PP (IN with) (NP (NN ZAP-70)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS data)) (VP (VBP are) (ADJP-PRD (RBS most) (JJ consistent) (PP (IN with) (NP (NP (DT a) (NN model)) (SBAR (WHPP-33 (IN in) (WHNP (WDT which))) (S (NP-SBJ (NP (NN recruitment)) (PP (TO to) (NP (DT the) (NN TCR)))) (VP (VBZ allows) (NP (NP (NN ZAP-70) (NP-COOD (NP (NN autophosphorylation)) (CC and) (NP (NP (NN binding)) (PP (TO to) (NP (NN p56-LRB-lck-RRB-)))))) (, ,) (SBAR (WHNP-34 (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ phosphorylates) (NP-COOD (NP (NN Tyr-492)) (CC and/or) (NP (NN Tyr-493))) (PP (IN with) (NP (NP (JJ consequent) (NN up-regulation)) (PP (IN of) (NP (DT the) (NN ZAP-70) (NN kinase) (NN activity)))))))))))))))) (. .)))
(TOP (S (NP-SBJ-35 (NN ZAP-70)) (VP (MD will) (ADVP-TMP (RB then)) (VP (VB be) (ADJP-PRD (JJ able) (S (VP (TO to) (ADVP (RB effectively)) (VP-COOD (VP (VB control) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (PRP$ its) (NNS substrates))))) (CC and) (VP (VB lead) (PP (TO to) (NP (NN gene) (NN activation)))))))))) (. .)))
(TOP (NP (NP (NN Dexamethasone) (NN suppression) (NN test)) (: :) (NP (NP (NN corticosteroid) (NNS receptors) (NN regulation)) (PP (IN in) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ young)) (CC and) (ADJP (JJ aged))) (NNS subjects))))) (. .))))
(TOP (S (NP-SBJ-7 (NP (DT The) (NN dexamethasone) (NN suppression) (NN test)) (PRN (-LRB- -LRB-) (NP (NN DST)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN considered) (S (NP-PRD (NP (DT an) (NN indicator)) (PP (IN of) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT the) (JJ adrenal) (JJ pituitary) (NN axis))))))))) (. .)))
(TOP (S (NP-SBJ-8 (NP (DT The) (NN effect)) (PP (IN of) (NP (DT the) (NN steroid)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (PRP$ its) (NN binding)) (PP (TO to) (NP (NN corticosteroid) (NNS receptors))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB previously)) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN measurement)) (PP (IN of) (NP (NP (NN corticosteroid) (NNS receptors)) (PP (IN in) (NP (NNS lymphocytes)))))) (VP (VBZ is) (NP-PRD (NP (DT an) (NN index)) (PP (IN of) (NP (NP (DT an) (JJ analogous) (NN pattern)) (PP (IN in) (NP (NN brain)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP-SBJ-9 (NP (NN corticosteroid) (NP-COOD (NP (NN Type) (CD I)) (CC and) (NP (NN Type) (CD II))) (NNS receptors)) (PP (IN in) (NP (JJ mononuclear) (NNS leukocytes)))) (VP (VBD were) (VP (VBN measured) (PP-COOD (PP (IN in) (NP (CD 10) (JJ elderly) (NNS subjects))) (CC and) (PP (IN in) (NP (CD 9) (JJ young) (NNS adults)))) (, ,) (PP-TMP (PP-COOD (PP (IN before)) (CC and) (PP (IN after))) (NP-10 (NP (JJ overnight) (NN DST)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mg)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ-11 (NNS Receptors)) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (NN radioreceptor) (NN assay))))) (. .)))
(TOP (S (PP (IN In) (NP (PDT all) (DT the) (NNS subjects))) (, ,) (NP-SBJ-12 (NN dexamethasone)) (VP (VBD was) (ADJP-PRD (JJ able) (S (VP (TO to) (VP (VB suppress) (NP (NN plasma) (NN cortisol))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN number)) (PP (IN of) (NP (NP-COOD (NP (NN Type) (CD I)) (CC and) (NP (NN Type) (CD II))) (NNS receptors))) (PP-TMP (IN before) (NP (DT the) (NN test)))) (VP (VBD was) (ADJP-PRD (ADJP (JJR lower))) (PP (IN in) (NP (JJ elderly) (NNS subjects))) (PP-13 (IN than) (FRAG (PP (IN in) (NP (NNS adults)))))) (. .)))
(TOP (S (S (PP (IN In) (NP (DT the) (NN control) (NN group))) (, ,) (NP-SBJ (NN dexamethasone)) (VP (VBD produced) (NP (NP (DT a) (JJ significant) (NN depression)) (PP (IN of) (NP (NN Type) (CD I) (NNS receptors))) (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 267) (CC +/-) (CD 72)))) (PP (TO to) (NP (QP (CD 169) (CC +/-) (CD 71)))) (NP-14 (NP (NNS receptors)) (PP (IN per) (NP (NN cell)))) (-RRB- -RRB-) (, ,) (SBAR (WHNP-15 (WDT which)) (S (VP (MD can) (VP (VB be) (VP (VBN interpreted) (PP (IN as) (NP (NP (DT a) (JJ primary) (NN involvement)) (PP (IN of) (NP (NN Type) (CD I) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (NN response)) (PP (TO to) (NP (NN dexamethasone)))))))))))))) (: ;)) (S (NP-SBJ (NN Type) (CD II) (NNS receptors)) (VP (VBD decreased) (PP (IN in) (NP (PDT half) (DT the) (NNS subjects))) (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 2849) (CC +/-) (CD 703)))) (PP (TO to) (NP (QP (CD 2345) (CC +/-) (CD 569)))) (NP-17 (NP (NNS receptors)) (PP (IN per) (NP (NN cell)))) (-RRB- -RRB-)) (. .))))
(TOP (S (PP (IN In) (NP (JJ elderly) (JJ healthy) (NNS subjects))) (, ,) (NP-SBJ-18 (NN Type) (CD II) (NNS receptors)) (VP (VBD were) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBN decreased) (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 1796) (CC +/-) (CD 671)))) (PP (TO to) (NP (QP (CD 720) (CC +/-) (CD 345)))) (-RRB- -RRB-))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN in) (NP (JJ young) (NNS subjects))) (NP-SBJ-19 (NN Type) (CD II) (NNS receptors)) (VP (VBP are) (VP-COOD (VP (ADVP-TMP (RB initially)) (VBN up-regulated) (PP (IN by) (NP-LGS (NN dexamethasone)))) (, ,) (CC and) (VP (ADVP-TMP (RB then)) (VBN down-regulated))) (, ,) (SBAR (IN while) (S (PP (RB in) (NP (JJ aged) (NNS subjects))) (NP-SBJ-20 (DT an) (NN up-regulation)) (VP (MD can) (VP (RB not) (VP (VB be) (VBN achieved) (SBAR (, ,) (S (VP (IN as) (PP (VBN suggested) (NP-LGS (NP (IN by) (DT the) (JJR higher)) (PP (NNS values) (NP (IN of) (NN plasma))) (VP (ADVP-TMP (NN cortisol)) (RB usually) (PP (VBN found) (NP (IN in) (VBG aging)))))))))))))))))) (NNS subjects)))
(TOP (S (NP-SBJ (NP (NNS Lymphocytes)) (PP (IN from) (NP (NN CML) (NNS patients)))) (VP (VBP lack) (NP (NP (DT a) (ADJP (CD 47) (NN kDa)) (NN factor)) (VP (VBG having) (NP (NP (NN affinity)) (PP (IN for) (NP (DT a) (JJ genomic) (NN sterol) (JJ regulatory) (NN sequence))))))) (. .)))
(TOP (S (NP-SBJ-9 (VBN Deranged) (JJ cellular) (NN cholesterol) (NN homeostasis)) (VP (VBZ has) (VP (VBN been) (ADVP (RB widely)) (VP (VBN recognized) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN initiation)) (CONJP (RB as) (RB well) (IN as)) (NP (NN progression)))) (PP (IN of) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NNS cancers))) (PP (VBG including) (NP (NP (JJ chronic) (JJ myeloid) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN CML)) (-RRB- -RRB-))))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ-10 (DT the) (JJ human) (JJ genomic) (NP (NP (NN sterol) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN SRE)) (-RRB- -RRB-)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB regulate) (NP (NP (JJ various) (JJ key) (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN phenomenon))))))))))))) (, ,) (NP-SBJ (DT the) (JJ present) (NN study)) (VP (VBD revealed) (NP-COOD (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (JJ unique) (ADJP (CD 47) (NN kDa)) (NN protein) (NN factor)) (VP (VBG having) (NP (NP (NN affinity)) (PP (IN for) (NP (DT this) (JJ SRE) (NN sequence))))))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ normal) (NNS subjects)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (PRP$ its) (NN absence)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ untreated) (NN CML) (NNS patients)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (DT this) (NN factor)) (VP (VBD appeared) (SBAR-TMP (WHADVP-11 (WRB when)) (S (NP-SBJ (DT these) (NN CML) (NNS patients)) (VP (VBD achieved) (NP (NP (JJ complete) (JJ haematological) (NN remission)) (PRN (-LRB- -LRB-) (NP (NN CHR)) (-RRB- -RRB-))) (PP (IN through) (NP (NN alpha-interferon) (NN therapy))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-12 (DT an) (JJ inverse) (NN relationship)) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN LDL) (NN receptor) (NN gene) (NN expression)) (PP (IN at) (NP (DT the) (JJ transcriptional) (NN level)))) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PP (IN of) (NP (DT this) (ADJP (CD 47) (NN kDa)) (NN protein) (NN factor))) (PP (TO to) (NP (DT the) (NN SRE) (NN sequence)))))))) (. .)))
(TOP (S (PP (VBN Based) (PP (IN upon) (NP (DT these) (NNS results)))) (NP-SBJ (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (DT this) (NN factor)) (VP (MD may) (VP (VB have) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (NN pathophysiology)) (PP (IN of) (NP (JJ chronic) (JJ myeloid) (NN leukaemia)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Synergistic) (NNS interactions)) (PP (IN between) (NP-COOD (NP (NP (VBG overlapping) (VBG binding) (NNS sites)) (PP (IN for) (NP (DT the) (NN serum) (NN response) (NN factor)))) (CC and) (NP (NN ELK-1) (NNS proteins))))) (VP (VBP mediate) (NP (NP-COOD (CC both) (NP (JJ basal) (NN enhancement)) (CC and) (NP (NN phorbol) (NN ester) (NN responsiveness))) (PP (IN of) (NP (JJ primate) (NN cytomegalovirus) (JJ major) (JJ immediate-early) (NNS promoters)))) (PP (IN in) (NP (NP-COOD (NP (NN monocyte)) (CC and) (NP (NN T-lymphocyte))) (NN cell) (NNS types)))) (. .)))
(TOP (S (NP-SBJ-51 (NP (NP (NN Cytomegalovirus)) (PRN (-LRB- -LRB-) (NP (NN CMV)) (-RRB- -RRB-))) (NN infection)) (VP-COOD (VP (VBZ is) (ADJP-PRD-COOD (ADJP (JJ nonpermissive)) (CC or) (ADJP (JJ persistent))) (PP (IN in) (NP (JJ many) (ADJP-COOD (ADJP (JJ lymphoid)) (CC and) (ADJP (JJ myeloid))) (NN cell) (NNS types)))) (CC but) (VP (MD can) (VP (VB be) (VP (VBN activated) (PP (IN in) (NP (VBN differentiated) (NNS macrophages))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN shown) (ADVP (RB elsewhere)) (SBAR (IN that) (S (NP-SBJ-52 (CC both) (DT the) (NP-COOD (NP (NP (JJ major) (JJ immediate-early) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN MIE)) (-RRB- -RRB-))) (CC and) (NP (JJ lytic) (NN cycle) (JJ infectious) (NN progeny) (NN virus))) (NN expression)) (VP (MD can) (VP (VB be) (VP (VBN induced) (PP (IN in) (NP (NP (ADJP (ADVP (JJ otherwise)) (JJ nonpermissive)) (JJ monocyte-like) (NN U-937) (NN cell) (NNS cultures)) (VP (VBN infected) (PP (IN with) (NP-COOD (CC either) (NP (NP (JJ human) (NN CMV)) (PRN (-LRB- -LRB-) (NP (NN HCMV)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ simian) (NN CMV)) (PRN (-LRB- -LRB-) (NP (NN SCMV)) (-RRB- -RRB-)))))))) (PP (IN by) (NP-LGS (NP (NN treatment)) (PP (IN with) (NP (NP (DT the) (NN phorbol) (NN ester) (NN 12-O-tetradecanoylphorbol-13-acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (CD Two) (JJ multicopy) (JJ basal) (NN enhancer) (NNS motifs)) (PP (IN within) (NP (DT the) (NN SCMV) (NN MIE) (NN enhancer)))) (, ,) (RB namely) (, ,) (NP (NP-COOD (NP (NP (CD 11) (NNS copies)) (PP (IN of) (NP (DT the) (JJ 16-bp) (NP (NP (JJ cyclic) (NN AMP) (NN response) (NN element)) (PRN (-LRB- -LRB-) (NP (NN CRE)) (-RRB- -RRB-)))))) (CC and) (NP (NP (CD 3) (NNS copies)) (PP (IN of) (NP (JJ novel) (JJ 17-bp) (NP (NP (NN serum) (NN response) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN SRF)) (-RRB- -RRB-))) (NN binding) (NNS sites))))) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP-COOD (NP (NP (DT the) (NN SNE)) (PRN (-LRB- -LRB-) (NP (JJ SRF/NFkappaB-like) (NN element)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (CD four) (JJ classical) (NN NFkappaB) (NNS sites)) (PP (IN within) (NP (DT the) (NN HCMV) (NN version)))) (, ,)))))) (VP (VBP contribute) (PP (TO to) (NP (NP (NN TPA) (NN responsiveness)) (PP (IN in) (NP (JJ transient) (NNS assays))) (PP (IN in) (NP (NP-COOD (NP (NN monocyte)) (CC and) (NP (NN T-cell))) (NNS types)))))) (. .)))
(TOP (S (NP-SBJ-53 (DT The) (NN SCMV) (NN SNE) (NNS sites)) (VP-COOD (VP (VBP contain) (NP (NP (JJ potential) (VBG overlapping) (NN core) (NN recognition) (NN binding) (NNS motifs)) (PP (IN for) (NP (NP-COOD (NP (NN SRF)) (, ,) (NP (NN Rel/NFkappaB)) (, ,) (NP (NN ETS)) (, ,) (CC and) (NP (NN YY1))) (NN class) (NN transcription) (NNS factors))))) (CC but) (VP (VBP fail) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP-COOD (CC either) (NP (NN serum)) (CC or) (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NP (NN TPA) (NN responsiveness)) (PP-COOD (PP (IN of) (NP (DT the) (NN SNE) (NNS motifs))) (CC and) (PP (IN of) (NP (NP (DT a) (JJ related) (JJ 16-bp) (NP (NP (NN SEE)) (PRN (-LRB- -LRB-) (NP (NN SRF/ETS) (NN element)) (-RRB- -RRB-))) (NN motif)) (VP (VBN found) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN HCMV)) (CC and) (NP (NN chimpanzee) (NN CMV))) (NN MIE) (NNS enhancers))))))))))))) (, ,) (NP-SBJ-54 (PRP we)) (VP (VBP have) (VP (VBN examined) (NP (NP (DT the) (NP-COOD (NP (JJ functional) (NNS responses)) (CC and) (NP (NN protein) (NN binding) (NNS properties)))) (PP (IN of) (NP (NP (JJ multimerized) (ADJP-COOD (ADJP (JJ wild-type)) (CC and) (ADJP (JJ mutant))) (NNS elements)) (VP (VBN added) (PP (ADVP (RB upstream)) (TO to) (NP (NP (DT the) (NP-COOD (NP (NN SCMV) (NN MIE)) (CC or) (NP (JJ simian) (NN virus))) (CD 40) (JJ minimal) (NN promoter) (NNS regions)) (PP (IN in) (NP (DT the) (NP-COOD (NP (NN U-937)) (, ,) (NP (NN K-562)) (, ,) (NP (NN HL-60)) (, ,) (NP (NN THP-1)) (, ,) (CC and) (NP (NN Jurkat))) (NN cell) (NNS lines))))))))))) (. .)))
(TOP (S (PP (IN Unlike) (NP (JJ classical) (NN NFkappaB) (NNS sites))) (, ,) (NP-SBJ (NP-COOD (CC neither) (NP (DT the) (NN SNE)) (CC nor) (NP (DT the) (NN SEE))) (NN motif)) (VP (VBD responded) (PP (TO to) (NP (NP (NN phosphatase) (NN inhibition)) (PP (IN by) (NP (JJ okadaic) (NN acid)))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-55 (NP (DT the) (NN TPA) (NN responsiveness)) (PP (IN of) (NP (DT both) (NN CMV) (NNS elements)))) (VP (VBD proved) (S (VP (TO to) (VP (VB involve) (NP (NP (JJ synergistic) (NNS interactions)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN core) (NN SRF) (NN binding) (NN site)) (PRN (-LRB- -LRB-) (NP (NN CCATATATGG)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ adjacent) (VBN inverted) (NN ETS) (NN binding) (NNS motifs)) (PRN (-LRB- -LRB-) (NP (NN TTCC)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP-56 (WDT which)) (S (VP (VBD correlated) (ADVP (RB directly)) (PP (IN with) (NP (NP (NN formation)) (PP (IN of) (NP (NP (DT a) (VBN bound) (JJ tripartite) (NN complex)) (VP (VBG containing) (NP-COOD (CC both) (NP (DT the) (JJ cellular) (NN SRF)) (CC and) (NP (NN ELK-1) (NNS proteins)))))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (DT This) (NN protein) (NN complex)) (VP (VBD was) (ADJP-PRD (ADJP (RBR more) (JJ abundant))) (PP (IN in) (NP (NP-COOD (NP (NN U-937)) (, ,) (NP (NN K-562)) (, ,) (CC and) (NP (NN HeLa))) (NN cell) (NNS extracts))) (PP-103 (IN than) (FRAG (PP (IN in) (NP (NP-COOD (NP (NN Raji)) (, ,) (NP (NN HF)) (, ,) (NP (NN BALB/c) (NN 3T3)) (, ,) (CC or) (NP (NN HL-60))) (NNS cells))))))) (, ,) (CC but) (S (NP-SBJ-57 (DT the) (NN binding) (NN activity)) (VP (VBD was) (VP (VBN altered) (ADVP (RB only) (RB twofold)) (PP-TMP (IN after) (NP (NN TPA) (NN treatment)))))) (. .)))
(TOP (S (NP-SBJ-58 (NP (DT A) (JJ 40-fold) (NN stimulation)) (PP (IN of) (NP (JJ chloramphenicol) (NN acetyltransferase) (NN activity))) (VP (VBN mediated) (PP (IN by) (NP-LGS (NP (CD four) (JJ tandem) (NNS repeats)) (PP (IN of) (NP (DT the) (NN SNE))))))) (VP (MD could) (VP (VB be) (VP (VP-COOD (VP (VBN induced) (PP-TMP-104 (IN within) (NP (CD 2) (NN h)))) (-LRB- -LRB-) (CC and) (VP (ADVP (RB up) (TO to) (JJ 250-fold)) (PP-TMP=104 (IN within) (NP (CD 6) (NN h)))) (-RRB- -RRB-)) (PP-TMP (IN after) (NP (NP (NN addition)) (PP (IN of) (NP (NN TPA))) (PP (IN in) (NP (JJ DNA-transfected) (NN U-937) (NNS cells))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-60 (DT the) (NN stimulation)) (VP (VBD appeared) (ADJP-PRD (JJ likely) (S (VP (TO to) (VP (VB be) (NP-PRD-COOD (NP (DT a) (JJ true) (ADJP (NN protein) (NN kinase) (JJ C-mediated)) (NN signal) (NN transduction) (NN event)) (CONJP (RB rather) (IN than)) (NP (DT a) (NN differentiation) (NN response))))))))))))))) (. .)))
(TOP (S (NP-SBJ-61 (NP (JJ Slight) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN sequence)) (PP (IN of) (NP (DT the) (NN core) (NN SRF) (NN binding) (NN site))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ classical) (NN c-Fos) (NN promoter) (NN serum) (NN response) (NN element)))))) (, ,) (PP (RB together) (IN with) (NP (NP (NNS differences)) (PP (IN in) (NP (DT the) (NN spacing))) (PP (IN between) (NP (DT the) (NP-COOD (NP (NN SRF)) (CC and) (NP (NN ETS))) (NNS motifs))))) (, ,)) (VP (VBP appear) (S (VP (TO to) (VP (VB account) (PP (IN for) (NP (NP (DT the) (NN inability)) (PP (IN of) (NP (DT the) (NN SCMV) (NNS SNEs))) (S-62 (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NN serum) (NN induction)))))))))))) (. .)))
(TOP (S (NP-SBJ-COOD (NP (JJ Acetylsalicylic) (NN acid)) (CC and) (NP (NN sodium) (NN salicylate))) (VP (VBP inhibit) (NP (NP-COOD (NP (JJ LPS-induced) (NN NF-kappa) (NN B/c-Rel) (JJ nuclear) (NN translocation)) (, ,) (CC and) (NP (NP (NN synthesis)) (PP (IN of) (NP-COOD (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TF)) (-RRB- -RRB-))) (CC and) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alfa)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))))) (PP (IN in) (NP (JJ human) (NNS monocytes))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP-COOD (NP (JJ acetylsalicylic) (NN acid)) (CC and) (NP (NN sodium) (NN salicylate)))) (PP (IN on) (NP (NP-COOD (NP (NP (DT the) (JJ LPS-induced) (NN synthesis)) (PP (IN of) (NP-COOD (NP (DT the) (JJ pro-coagulant) (NN protein) (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TF)) (-RRB- -RRB-)))) (CC and) (NP (DT the) (JJ pro-inflammatory) (NN protein) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (DT the) (NN prostaglandin) (NN PGE2))) (PP (IN in) (NP (JJ human) (NNS monocytes)))))))) (. .)))
(TOP (S (NP-SBJ (DT Both) (NNS drugs)) (ADVP (RB dose-dependently)) (VP-COOD (VP (VBD inhibited) (NP (NP (JJ LPS-induced) (NP-COOD (NP (NN TF)) (CC and) (NP (NN TNF-alpha))) (NN synthesis)) (PP (IN at) (NP (NP-COOD (NP (DT the) (NN mRNA)) (CC and) (NP (DT the) (NN protein))) (NP-32 (NN level)))))) (, ,) (CC and) (VP (VBD reduced) (NP (NN PGE2) (NN production)))) (. .)))
(TOP (S (SBAR (IN As) (S (VP (VBN evidenced) (PP (IN by) (NP-LGS-COOD (NP (NP (NN electro) (NN mobility) (NN shift) (NN assay)) (PRN (-LRB- -LRB-) (NP (NN EMSA)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT a) (NN NF-kappa) (NN B) (JJ prototypic) (NN probe))))))))) (, ,) (NP-SBJ (DT these) (NNS drugs)) (ADVP (RB probably)) (VP (VBP exert) (NP (PRP$ their) (JJ inhibitory) (NNS effects)) (PP (IN by) (NP (NP (NN interference)) (PP (IN with) (NP (NP (DT the) (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN B/c-Rel) (NNS proteins)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (MD may) (VP (VB expand) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ anti-thrombotic)) (CC and) (ADJP (JJ anti-inflammatory))) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs))) (SBAR-TMP (WHADVP-34 (WRB when)) (S (NP-SBJ (NP (NN activation)) (PP (IN of) (NP (NNS monocytes)))) (VP (VBZ occurs))))))))) (. .)))
(TOP (NP (NP (ADJP (NN Octamer) (JJ independent)) (NN activation)) (PP (IN of) (NP (NP (NN transcription)) (PP (IN from) (NP (DT the) (NN kappa) (NN immunoglobulin) (NN germline) (NN promoter))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Previous) (NNS analyses)) (PP (IN of) (NP (NN immunoglobulin) (JJ V) (NN region) (NNS promoters)))) (VP (VBZ has) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN discovery)) (PP (IN of) (NP (NP (DT a) (JJ common) (NN octamer) (NN motif)) (SBAR (WHNP-44 (WDT which)) (S (VP (VBZ is) (ADVP (RB functionally)) (ADJP-PRD (JJ important)) (PP (IN in) (NP (NP (DT the) (ADJP-COOD (ADJP (JJ tissue-specific)) (CC and) (ADJP (RB developmentally) (VBN regulated))) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NN immunoglobulin) (NNS genes)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (DT The) (NN germline) (NNS promoters)) (PRN (-LRB- -LRB-) (NP (NN Ko)) (-RRB- -RRB-))) (ADJP (JJ located) (ADVP (RB upstream) (PP (IN of) (NP (NP (DT the) (JJ J) (NN region) (NN gene) (NNS segments)) (PP (IN of) (NP (DT the) (NN kappa) (NN locus)))))))) (ADVP (RB also)) (VP (VBP contain) (NP (NP (DT an) (NN octamer) (NN motif)) (-LRB- -LRB-) (VP-COOD (VP (VBG containing) (NP (DT a) (JJ single) (NN base) (NN pair) (NN mutation))) (CC and) (VP (VBN referred) (PP (TO to)) (PP (IN as) (NP (DT the) (JJ variant) (NN octamer))))) (-RRB- -RRB-) (SBAR (WHNP-45 (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (ADVP-TMP (RB previously)) (S (VP (TO to) (VP (VB bind) (NP (NP-COOD (NP (NN Oct-1)) (CC and) (NP (NN Oct-2))) (NN transcription) (NNS factors)) (ADVP (FW in) (FW vitro)))))))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (ADVP (RB further)) (VB elucidate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT this) (JJ variant) (NN octamer) (NN motif))) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN germline) (NN transcription)) (PP (IN from) (NP (DT the) (JJ unrearranged) (NN kappa) (NN locus))))))))))) (, ,) (NP-SBJ-47 (PRP we)) (VP (VBP have) (VP-COOD (VP (VBN quantitated) (NP (NP (DT the) (JJ relative) (NN binding) (NN affinity)) (PP (IN of) (NP-COOD (NP (NN Oct-1)) (CC and) (NP (NN Oct-2)))) (PP (IN for) (NP (DT the) (JJ variant) (NN octamer) (NN motif))))) (CC and) (VP (VBD determined) (NP (NP (DT the) (JJ functional) (NN role)) (PP (IN of) (NP (DT this) (NN octamer) (NN motif))) (PP (IN in) (NP (JJ transcriptional) (NN activation))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP find) (SBAR (IN that) (, ,) (S (SBAR (IN although) (S (NP-SBJ (DT the) (JJ variant) (NN octamer) (NN motif)) (VP (VBZ binds) (NP-COOD (NP (NN Oct-1)) (CC and) (NP (NN Oct-2))) (ADVP (FW in) (FW vitro)) (PP (IN with) (NP (NP (ADJP (JJ 5-fold) (JJR lower)) (NN affinity)) (PP (IN than) (NP (DT the) (NN consensus) (NN octamer) (NN motif)))))))) (, ,) (NP-SBJ (NP (NN mutation)) (PP (IN of) (NP (DT the) (JJ variant) (NN octamer) (NN motif))) (PP (TO to) (NP (CC either) (DT a) (UCP-COOD (NP (NN consensus) (NN octamer)) (CC or) (ADJP (JJ non-octamer))) (NN motif)))) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN from) (NP (DT the) (NN germline) (NN promoter))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBP find) (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (NN activation)) (PP (IN of) (NP (NP-COOD (NP (NN germline)) (CC and) (NP (JJ V) (NN region))) (NNS promoters))) (PP (IN by) (NP (NN kappa) (NNS enhancers))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (DT the) (NP-COOD (NP (NN germline) (NNS promoters)) (CC and) (NP (JJ V) (NN region) (NNS promoters)))) (VP-COOD (VP (VBP differ) (PP (IN in) (NP (NP (PRP$ their) (NN dependence)) (PP (IN on) (NP (NN octamer))) (PP (IN for) (NP (NN activation)))))) (CC and) (VP (VBP respond) (ADVP (RB differently)) (PP (TO to) (NP (NN enhancer) (NN activation)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP (VBP have) (NP (JJ important) (NNS implications)) (PP (IN in) (NP-COOD (NP (NP (NN regulation)) (PP (IN of) (NP (NN germline) (NN transcription)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ concomitant) (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ V-J) (NN recombination)) (PP (IN of) (NP (DT the) (NN kappa) (JJ light) (NN chain) (NN locus))))))))) (. .)))
(TOP (NP (NP (NN Characterization)) (PP (IN of) (NP (DT the) (JJ murine) (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN gene) (NN p27Kip1))) (. .)))
(TOP (S (NP-SBJ-106 (DT The) (JJ cyclin-dependent) (NN kinase) (NN inhibitor) (NN p27Kip1)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (JJ cell-cycle) (NN progression)))))) (. .)))
(TOP (S (NP-SBJ (NN p27Kip1)) (ADVP (RB directly)) (VP-COOD (VP (VBZ inhibits) (NP (NP (DT the) (JJ catalytic) (NN activity)) (PP (IN of) (NP (NNS cyclin/cdks) (PRN (-LRB- -LRB-) (NP (JJ cyclin-dependent) (NN kinase)) (-RRB- -RRB-)) (NNS complexes))))) (CC and/or) (VP (VBZ interferes) (ADVP (RB physically)) (PP (IN with) (NP (NP (NN cyclin/cdks) (NN activation)) (PP (IN by) (NP (NN CAK))))))) (. .)))
(TOP (S (ADVP (RB Interestingly)) (, ,) (NP-SBJ (NP (DT the) (NN expression) (NN level)) (PP (IN of) (NP (NN p27Kip1) (NN mRNA)))) (VP-COOD (VP (VBD was) (ADJP-PRD (JJ maximal)) (PP (IN in) (NP (VBG resting) (NN Go) (NNS T-cells)))) (CC and) (VP (ADVP-TMP (RB rapidly)) (VBD declined) (PP-TMP (VBG following) (NP (JJ anti-CD3) (NN activation))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP report) (ADVP (RB here)) (NP-COOD (NP (NP (DT the) (NN cloning)) (PP (IN of) (NP (NN p27Kip1) (NN gene))) (PP (IN from) (NP (JJ murine) (JJ genomic) (NN DNA)))) (CC and) (NP (NP (DT the) (JJ functional) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NN promoter)) (PP (IN of) (NP (DT the) (NN p27Kip1) (NN gene)))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN gene)) (VP-COOD (VP (VBZ consists) (PP (IN of) (NP (QP (IN at) (JJS least) (CD three)) (NNS exons)))) (CC and) (VP (NNS spans) (NP (NP (QP (RBR more) (IN than) (CD 5.6)) (NN kb)) (PP (IN of) (NP (NN DNA)))))) (. .)))
(TOP (S (NP-SBJ (NP-COOD (NP (NN Primer) (NN extension)) (CC and) (NP (NN nuclease) (NN S1) (NN protection))) (NN analysis)) (VP (VBD revealed) (NP (CD two) (JJ major) (NN transcription) (NN initiation) (NNS sites))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN promoter) (NN region)) (VP-COOD (VP (VBD lacked) (NP (DT a) (NN TATA) (NN box))) (CC but) (VP (VBD contained) (NP (NP (JJ potential) (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (DT the) (JJ transcriptional) (NNS factors)) (PP (VBG including) (NP-COOD (NP (CD two) (NN Sp1)) (, ,) (NP (NN CRE)) (, ,) (NP (NN Myb)) (CC and) (NP (NN NFkB)))))) (ADJP (JJ located) (PP (IN at) (NP (NP (NNS positions) (NP-COOD (NP (CD -153)) (, ,) (NP (CD -178)) (, ,) (NP (CD -286)) (, ,) (NP (CD -875)) (, ,) (CC and) (NP (CD -1011)))) (, ,) (ADVP (RB respectively)))))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB analyze) (NP (NP (DT the) (JJ regulatory) (NNS mechanisms)) (VP (VBG controlling) (NP (NN p27Kip1) (NN gene) (NN expression))))))) (, ,) (NP-SBJ-40 (PRP we)) (VP (VBD characterized) (NP (NP (DT the) (JJ 5'-flanking) (NN region)) (PP-COOD (PP (IN from) (NP (NN nt) (CD -1609))) (PP (TO to) (NP (CD +178)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (QP (CD -326) (TO to) (CD -615)) (NN region)) (VP (VBD contained) (NP (JJ positive) (JJ regulatory) (NNS elements))) (. .)))
(TOP (NP (NP (JJ Glucocorticoid-mediated) (NN inhibition)) (PP (IN of) (NP (NP (NN RANTES) (NN expression)) (PP (IN in) (NP (JJ human) (NN T) (NNS lymphocytes))))) (. .)))
(TOP (S (NP-SBJ-51 (DT The) (NN chemokine) (NN RANTES)) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ allergic) (JJ inflammatory) (NNS diseases)) (PP (VBG including) (NP (NP-COOD (NP (NN asthma)) (CC and) (NP (NN rhinitis))) (SBAR (WHNP-52 (WDT which)) (S (VP (VBP are) (VP (ADVP-TMP (RB frequently)) (VBN treated) (PP (IN with) (NP (NNS glucocorticoids)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD observed) (SBAR (IN that) (S (NP-SBJ (NN dexamethasone)) (ADVP (RB dramatically)) (VP (VBD inhibited) (NP (NN RANTES) (NN mRNA) (NN expression)) (ADVP (NN dose) (RB dependently)) (PP (IN in) (NP-COOD (NP (ADJP (NN anti-CD3) (JJ activated)) (NN Hut-78) (NN T) (NNS cells)) (CC and) (NP (JJ human) (NNS PBMCs)))))))) (. .)))
(TOP (S (NP-SBJ-54 (NP (NN Inhibition)) (PP (IN of) (NP (NNS RANTES) (NN expression)))) (VP-COOD (VP (VBD did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB be) (ADJP-PRD (JJ secondary) (PP (TO to) (NP (NN IL-2) (NN inhibition))))))))) (CC and) (VP (VBD required) (NP (NP (VBG binding)) (PP (TO to) (NP (DT the) (JJ intracellular) (NN glucocorticoid) (NN receptor)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN down-regulation)) (PP (IN of) (NP (NN RANTES) (NN expression))) (PP (IN by) (NP (NP (NNS glucocorticoids)) (PP (IN in) (NP (NN T) (NNS cells)))))) (VP (MD may) (VP (ADVP (RB directly)) (VB contribute) (PP-COOD (PP (TO to) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT these) (NNS agents))) (PP (IN in) (S (VP (VBG suppressing) (NP (JJ cellular) (NN infiltration))))))) (CC and) (PP (TO to) (NP (PRP$ their) (JJ anti-inflammatory) (NNS properties)))))) (. .)))
(TOP (S (NP-SBJ (NP (DT A) (JJ novel) (NN SP-1) (NN site)) (PP (IN in) (NP (DT the) (JJ human) (NN interleukin-1) (NN beta) (NN promoter)))) (VP (VBZ confers) (NP (NP (JJ preferential) (JJ transcriptional) (NN activity)) (PP (IN in) (NP (NNS keratinocytes))))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB investigate) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (NP (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NP (NN interleukin-1beta)) (PRN (-LRB- -LRB-) (NP (NN IL-1beta)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ non-monocytic) (NNS cells))))))))) (, ,) (NP-SBJ-38 (PRP we)) (VP-COOD (VP (VBD constructed) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NP (NN reporter) (NNS plasmids)) (PP (IN with) (NP (NP (DT the) (JJ bacterial) (NN chloramphenicol) (NN acetyltransferase) (NN gene)) (VP (VBN linked) (PP (TO to) (NP (NP (JJ various) (NNS parts)) (PP (IN of) (NP (DT the) (JJ human) (NN IL-1beta) (NN promoter)))))))))))) (CC and) (VP (VBD performed) (NP (JJ transient) (NN transfection) (NNS experiments)))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBD identified) (NP (NP (DT a) (NN promoter) (NN segment)) (SBAR (WHNP-39 (WDT that)) (S (VP (VBZ activates) (NP (NN transcription)) (ADVP (RBS most) (RB efficiently)) (PP (IN in) (NP (NNS keratinocytes)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (PRN (-LRB- -LRB-) (NP (NN EMSA)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (DT a) (ADJP (NN 43-mer)) (NN oligonucleotide)) (VP (VBN derived) (PP (IN from) (NP (DT the) (ADJP (RB functionally) (VBN identified)) (JJ cis-acting) (NN element))))))) (VP (VBD revealed) (NP (JJ specific) (NNS complexes))) (. .)))
(TOP (S (PP-COOD (PP (IN By) (NP-LGS (NP (NN competition) (NN analysis)) (PP (IN with) (NP (NN transcription) (NN factor) (NN consensus) (NN sequence) (NNS oligonucleotides))))) (CC and) (PP (IN by) (NP-LGS (NN immunosupershift)))) (, ,) (NP-SBJ-COOD-40 (NP (NN transcription) (NN factor) (NN SP-1)) (CC or) (NP (DT a) (ADJP (RB closely) (JJ related)) (NN protein))) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VBP bind) (PP (TO to) (NP (DT this) (JJ regulatory) (NN element)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJS closest) (NN match)) (PP (TO to) (NP (DT the) (VBN known) (NN SP-1) (NN consensus) (NN sequence))) (PP (IN within) (NP (DT the) (JJ respective) (NN region)))) (VP (VBZ is) (NP-PRD (DT a) (NN TCCCCTCCCCT) (NN motif))) (. .)))
(TOP (S (NP-SBJ (NP (NN Mutation)) (PP (IN of) (NP (DT this) (NN motif)))) (VP-COOD (VP (ADVP-COOD (ADVP (RB almost) (RB completely)) (, ,) (CC and) (ADVP (RB specifically)) (, ,)) (VBD abolished) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (CD two) (JJ low-mobility) (NNS complexes))))) (CC and) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (CD 95) (NN %) (NN decrease)) (PP (IN of) (NP (NP (JJ constitutive) (JJ transcriptional) (NN activation)) (PP (IN of) (NP (NP (DT a) (NN reporter) (NN construct) (NN IL-1beta)) (PRN (-LRB- -LRB-) (NP (CD -170/+108)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (ADVP (RB Likewise)) (, ,) (NP-SBJ (NP (NN activation)) (PP (IN of) (NP (DT this) (NN reporter) (NN construct))) (PP (IN by) (NP (NN tumor) (NN necrosis) (NN factor-alpha)))) (VP (VBD depended) (PP (IN on) (NP (DT the) (NN SP-1) (NN site)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (DT a) (JJ so-far-unrecognized) (NN SP-1) (NN site)) (PP (IN in) (NP (DT the) (JJ human) (NN IL-1beta) (NN promoter)))) (VP (MD may) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (DT this) (NN gene))) (PP (IN in) (NP (NNS keratinocytes)))))))))) (. .)))
(TOP (NP (NP (NNS Effects)) (PP (IN of) (NP (NNS glucocorticoids))) (PP (IN on) (NP (NN lymphocyte) (NN activation))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP-COOD (ADJP (JJ steroid-sensitive)) (CC and) (ADJP (JJ steroid-resistant))) (NN asthma))))) (. .)))
(TOP (S (NP (NN BACKGROUND) (: :)) (S (NP-SBJ (NNS Glucocorticoids)) (VP (VBP are) (NP-PRD (NP (JJ important) (NNS medications)) (VP (VBN used) (S (VP (TO to) (VP (VB control) (NP (NP (DT the) (NN airway) (NN inflammation)) (VP (VBN associated) (PP (IN with) (NP (NN asthma))))))))))) (. .))))
(TOP (S (NP-SBJ (JJ Synthetic) (NNS glucocorticoids)) (VP (VBP vary) (PP (IN in) (NP (NP (PRP$ their) (NN binding) (NN affinity)) (PP (IN for) (NP (NP (DT the) (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GCR)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (NP (NNS METHODS) (: :)) (S (NP-SBJ (PRP We)) (VP (VBD compared) (NP (NP-COOD (NP (NN hydrocortisone)) (, ,) (NP (NN beclomethasone) (NN dipropionate)) (, ,) (NP (NN triamcinolone) (NN acetonide)) (, ,) (NP (NN flunisolide)) (, ,) (CC and) (NP (NN budesonide)))) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (PRP$ their) (NN capacity) (S (VP (TO to) (VP (VB inhibit) (NP (JJ phytohemagglutinin-induced) (JJ peripheral) (NN blood) (JJ mononuclear) (NN cell) (NN proliferation))))))))) (PP-104 (IN from) (NP-COOD (NP (NP (CD six) (NNS patients)) (PP (IN with) (NP (JJ steroid-sensitive) (NN asthma)))) (CC and) (NP (NP (CD seven) (NNS patients)) (PP (IN with) (NP (JJ steroid-resistant) (NN asthma))))))) (. .))))
(TOP (S (NP-SBJ-36 (NP (JJ Peripheral) (NN blood) (JJ mononuclear) (NN cell) (NN GCR) (NN binding) (NNS affinities)) (PP (IN for) (NP-COOD (NP (NN dexamethasone)) (CC and) (NP (NN budesonide))))) (VP (VBD were) (VP (ADVP (RB also)) (VBN determined) (PP (IN for) (NP (DT both) (NN patient) (NNS groups))) (PP (IN by) (S (VP (VBG using) (NP-COOD (NP (DT a) (NN radioligand) (NN binding) (NN assay)) (CC and) (NP (NN Scatchard) (NN analysis)))))))) (. .)))
(TOP (S (NP (NNS RESULTS) (: :)) (S (NP-SBJ-37 (JJ Dose-dependent) (NN inhibition)) (VP (VBD was) (VP (VBN demonstrated) (PP (IN for) (NP (DT all) (NNS glucocorticoids))) (PP (IN in) (NP (DT both) (NN patient) (NNS groups))) (, ,) (PP (IN with) (S (NP-SBJ (DT the) (JJ steroid-resistant) (NN group)) (VP (VBG requiring) (NP (QP (RB approximately) (CD 2) (JJ log-fold) (JJR more)) (NNS glucocorticoids)) (PP (IN for) (NP (NP (DT an) (JJ equivalent) (NN degree)) (PP (IN of) (NP (NN inhibition)))))))))) (. .))))
(TOP (S-COOD (S (NP-SBJ (NP (DT The) (NN mean) (NNS concentrations)) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB cause) (NP (NP (NP (CD 50) (NN %) (NN inhibition)) (PP (IN of) (NP (NN lymphocyte) (NN proliferation)))) (PRN (-LRB- -LRB-) (NP (NNS IC50s)) (-RRB- -RRB-))) (PP (IN for) (NP (DT the) (JJ steroid-sensitive) (NN group)))))))) (VP (VBD ranged) (PP-COOD (PP (IN from) (NP (NP (QP (CD 2) (CC x) (CD 10-LRB--10-RRB-)) (NN mol/L)) (PP (IN for) (NP (NN budesonide))))) (PP (TO to) (NP (NP (QP (CD 7) (CC x) (CD 10-LRB--8-RRB-)) (NN mol/L)) (PP (IN for) (NP (NN hydrocortisone)))))))) (, ,) (IN whereas) (S (NP-SBJ (NP (DT the) (NN mean) (NNS IC50s)) (PP (IN for) (NP (DT the) (JJ steroid-resistant) (NN group)))) (VP (VBD ranged) (PP-COOD (PP (IN from) (NP (NP (QP (RB approximately) (CD 2) (CC x) (CD 10-LRB--8-RRB-)) (NN mol/L)) (PP (IN for) (NP (NN budesonide))))) (PP (TO to) (NP (NP (QP (JJR greater) (IN than) (CD 10-LRB--6-RRB-)) (NN mol/L)) (PP (IN for) (NP (NN hydrocortisone)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-38 (DT a) (JJ significant) (NN correlation)) (VP (VBD was) (VP (VBN noted) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NN lymphocyte) (NN proliferation)))) (PRN (-LRB- -LRB-) (NP (NN IC50)) (-RRB- -RRB-))))) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PP (IN of) (NP (NN dexamethasone))) (PP (TO to) (NP (DT the) (NN GCR)))))))) (. .)))
(TOP (S (NP-SBJ-39 (NP (NNS Patients)) (PP (IN with) (NP (JJ steroid-resistant) (NN asthma)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (DT a) (VBN reduced) (NN GCR) (NN binding) (NN affinity)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN GCR) (NN binding) (NN affinity)) (PP (IN for) (NP (NN budesonide)))) (VP (VP (VBD was) (ADJP-PRD (ADJP (RB significantly) (JJR higher))) (PP (IN in) (NP (DT both) (NNS groups)))) (NP (-LRB- -LRB-) (ADVP (FW i.e.)) (, ,) (NP (JJR lower) (NN dissociation) (NN constant)) (-RRB- -RRB-)) (PP-105 (IN than) (NP (NP (DT that)) (VP (VBN obtained) (PP (IN for) (NP (NN dexamethasone))))))) (. .)))
(TOP (S (NP (NN CONCLUSION) (: :)) (S (NP-SBJ (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NNS glucocorticoids)) (PP (JJ such) (IN as) (NP (NN budesonide)))) (, ,) (PP (IN by) (NN virtue) (IN of) (NP (PRP$ their) (NP-COOD (NP (JJ high) (NN GCR) (NN binding) (NNS affinities)) (CC and) (NP (JJR greater) (NN ability) (S (VP (TO to) (VP (VB suppress) (NP (NN lymphocyte) (NN proliferation))))))))) (, ,) (VP (MD may) (ADVP (RB therefore)) (VP (VB be) (ADJP-PRD (JJ beneficial)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ difficult-to-control) (NN asthma)))))))))) (. .))))
(TOP (NP (NP (NN Involvement)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappa) (NN B) (NN activation))) (PP (IN in) (NP (NP (NN IgE) (NN synthesis)) (PP (IN in) (NP (JJ human) (NN B) (NNS cells))))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Nuclear) (NN factor-kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN transcription) (NN factor)) (SBAR (WHNP-62 (WDT that)) (S (VP (VBZ binds) (PP (TO to) (NP (NP (DT the) (NN consensus) (NN DNA) (NN sequence)) (PP (IN in) (NP (NP (DT the) (JJ cis-acting) (NNS elements)) (PP (IN of) (NP (JJ various) (NNS genes)))))))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NN NF-kappa) (NN B)) (VP (VBZ activates) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ many) (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ immune)) (CC and) (ADJP (JJ inflammatory))) (NNS responses)))))))))) (, ,) (NP-SBJ-63 (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activation))) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN IgE) (NN synthesis))) (PP (IN in) (NP (JJ human) (NN B) (NNS cells))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (NP-SBJ (PRP we)) (ADVP-TMP (RB first)) (VP (VBD examined) (NP (NP (DT the) (NN participation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN in) (NP (NP (NN germline) (NN C) (NN epsilon) (NN transcription)) (PP (IN in) (NP (NP (DT a) (JJ human) (NN Burkitt) (NN lymphoma) (NN B) (NN cell) (NN line)) (, ,) (NP (NN DND39)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Stimulation)) (PP (IN of) (NP (NN DND39) (NNS cells))) (PP (IN with) (NP-COOD (NP (NN IL-4)) (CC or) (NP (JJ anti-CD40) (NP (NP (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN mAb)) (-RRB- -RRB-))))))) (VP-COOD (VP (VBD activated) (NP (NN phosphatidylinositol) (NN 3-kinase))) (CC and) (VP (ADVP (RB subsequently)) (VBD induced) (NP (NP (JJ nuclear) (NN expression)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (, ,) (SBAR (WHNP-64 (WDT which)) (S (VP (VBD was) (VP (VBN identified) (PP (IN by) (NP-LGS (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NP (NN n-Acetyl-L-cysteine)) (PRN (-LRB- -LRB-) (NP (NN NAC)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ potent) (NN antioxidant)) (, ,)) (VP (VBD blocked) (NP (NP (NN NF-kappa) (NN B) (NN activation)) (VP (VBN caused) (PP-COOD (PP (IN by) (NP-LGS (NN IL-4))) (CC and) (PP (IN by) (NP-LGS (JJ anti-CD40) (NN mAb))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (NN inhibition)) (PP (IN of) (NP (JJ IL-4-driven) (NN germline) (NN C) (NN epsilon) (NN transcription))) (PP (IN by) (NP (NN NAC)))) (VP (VBD was) (RB not) (ADJP-PRD (JJ sufficient))))) (, ,) (NP-SBJ (DT the) (NN agent)) (ADVP (RB remarkably)) (VP (VBD diminished) (NP (NP (ADJP (JJ anti-CD40) (JJ mAb-mediated)) (NN up-regulation)) (PP (IN of) (NP (NN germline) (NN C) (NN epsilon) (NN transcription))))) (. .)))
(TOP (S (ADVP-TMP (RB Second)) (, ,) (NP-SBJ (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN NAC))) (PP (IN on) (NP (NP (NN IgE) (NN synthesis)) (PP (IN in) (NP (NP (JJ human) (JJ normal) (NN B) (NNS cells)) (VP (VBN costimulated) (PP (IN with) (NP-COOD (NP (NN IL-4)) (CC and) (NP (JJ anti-CD40) (NN mAb))))))))))) (. .)))
(TOP (S (NP-SBJ (NN NAC)) (VP (VBD was) (ADJP-PRD (JJ effective)) (PP (IN in) (S (VP (VBG inhibiting) (NP (NP-COOD (NP (JJ mature) (NN C) (NN epsilon) (NN transcription)) (CC and) (NP (NN IgE) (NN synthesis))) (PP (IN in) (NP (DT the) (ADJP (NN T) (JJ cell-independent)) (NN culture) (NN system)))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (NN NAC)) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (JJ spontaneous) (NN production)) (PP (IN of) (NP (NN IgE))) (PP (IN by) (NP (JJ atopic) (NN B) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP-COOD (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN NF-kappa) (NN B) (NN activity)) (VP (VBZ is) (ADVP (RB commonly)) (ADJP-PRD (JJ inducible)) (PP (IN in) (NP (NN DND39) (NNS cells))) (PP-105 (IN by) (NP-COOD (NP (NN IL-4)) (CC and) (NP (JJ anti-CD40) (NN mAb)))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-106 (NP (NN NF-kappa) (NN B)) (ADJP (JJ sensitive) (PP (TO to) (NP (NN NAC))))) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (NP (NN IgE) (NN synthesis)) (PP (IN in) (NP (NN B) (NNS cells))))))))))))) (. .)))
(TOP (NP (-LRB- -LCB-) (NP (JJ Molecular) (NNS mechanisms)) (PP (IN of) (NP (JJ age-related) (NN lymphocyte) (NN dysfunction))) (-RRB- -RCB-)))
(TOP (S (NP-SBJ-14 (NN Aging)) (VP (VBZ is) (ADVP (RB classically)) (VP (VBN accompanied) (PP (IN by) (NP-LGS (NP (DT a) (NN dysregulation)) (PP (IN of) (NP (DT the) (JJ immunologic) (NN machinery))))))) (. .)))
(TOP (S (PP (IN As) (NP (DT a) (NN consequence))) (, ,) (NP-SBJ (NP (DT the) (JJ immune) (NN response)) (VP (VBN developed) (PP (IN in) (NP (JJ senescent) (NNS organisms))))) (VP-COOD (VP (VBZ is) (ADVP-TMP-15 (RB usually)) (ADJP-PRD-16 (JJ inappropriate))) (, ,) (VP (ADVP-TMP=15 (RB often)) (ADJP-PRD=16 (JJ inefficient))) (, ,) (VP (ADVP-TMP=15 (RB sometimes)) (ADJP-PRD=16 (JJ aberrant))) (, ,) (CC and) (VP (ADVP=15 (RB potentially)) (ADJP-PRD=16 (JJ detrimental)))) (. .)))
(TOP (S (NP-SBJ-17 (DT The) (JJ age-associated) (JJ immune) (NN dysfunction)) (VP-COOD (VP (MD may) (VP (VB be) (VP (VBN implicated) (PP (TO to) (NP (DT some) (NN degree))) (PP (IN in) (NP (NP (DT the) (JJ extreme) (NN susceptibility)) (PP (IN of) (NP (DT the) (JJ elderly))) (PP (TO to) (NP-COOD (NP (NN infection)) (CC and) (NP (NN neoplasia))))))))) (CC and) (VP (MD may) (ADVP (RB even)) (VP (VB participate) (PP (IN in) (NP (NP (JJ various) (NNS aspects)) (PP (IN of) (NP (NN senescence)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ current) (NN understanding)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (NN immunosenescence)))))) (VP (VBZ is) (ADVP (RB still)) (ADJP-PRD (JJ fragmentary))) (. .)))
(TOP (S (NP-SBJ (DT The) (ADJP (ADVP (RBS most) (RB extensively)) (VBN studied)) (NN phenomenon)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ progressive) (NN decline)) (PP (IN in) (NP (NP (DT the) (JJ proliferative) (NNS capacities)) (PP (IN of) (NP (NN T) (NNS lymphocytes))))) (PP (IN with) (NP (NN aging))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN loss)) (PP (IN of) (NP (NP (JJ proliferative) (NN potential)) (PP (IN in) (NN response) (TO to) (NP (JJ antigenic) (NN challenge)))))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ characteristic) (NN feature)) (PP (IN of) (NP (JJ immune) (NN senescence))))) (. .)))
(TOP (S (NP-SBJ-18 (PRP It)) (VP (VBZ is) (ADVP (RB directly)) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (DT the) (JJ age-related) (JJ immune) (NN deficiency))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN review)))) (VP (VBZ is) (S-PRD (VP (TO to) (VP (VB show) (SBAR (WHADVP-19 (WRB how)) (S (NP-SBJ (NP (DT the) (NN accumulation)) (PP (IN of) (NP (JJ various) (JJ biochemical) (NNS lesions))) (PP (IN with) (NP (VBG advancing) (NN age)))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT the) (NN failure)) (PP (IN of) (NP (NP (DT a) (JJ critical) (NN cell) (NN function)) (, ,) (RB namely) (NP (DT the) (JJ activation-induced) (NN lymphocyte) (NN proliferation))))))))))))) (. .)))
(TOP (S (NP-SBJ-20 (NP (DT The) (JJ biochemical) (NNS modifications)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN defect)) (PP (IN in) (NP (NP-COOD (NP (NN transduction)) (CC and) (NP (NN execution))) (PP (IN of) (NP (DT the) (JJ proliferative) (NN signal))))))))) (VP (VBP are) (VP (VBN analyzed) (PP (IN as) (NP (NP (DT a) (NN function)) (PP (IN of) (NP (NN age))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (JJ multiple) (NNS alterations)) (VP (VBN observed) (PP (IN on) (NP (DT the) (JJ various) (JJ biochemical) (NNS pathways))))) (VP (MD may) (VP (VB appear) (PP (IN as) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NP (DT a) (JJ unique) (JJ deleterious) (NN mechanism)) (ADJP (ADVP (RBR more) (RB fundamentally)) (JJ related) (PP (TO to) (NP (NP (DT the) (NN process)) (PP (IN of) (NP (NP (NN senescence)) (PP (JJ such) (IN as) (NP (DT the) (NN inability) (S (VP (TO to) (VP (VB cope) (PP (IN with) (NP (JJ oxidative) (NN stress))))))))))))))))))) (. .)))
(TOP (NP (NP (NN Stimulation)) (PP (IN of) (NP (JJ human) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))) (PP (IN by) (NP-COOD (NP (NN zinc)) (CC and) (NP (JJ related) (NNS cations)))) (. .)))
(TOP (S (NP-SBJ (NN Zinc)) (VP (VBZ is) (NP-PRD (NP (DT an) (JJ important) (NN trace) (NN element)) (PP (IN for) (NP (JJ immune) (NN function))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NN zinc) (NN addition)) (PP (IN in) (NP (DT a) (ADJP-COOD (ADJP (NP (NN serum-))) (CC and) (ADJP (JJ lipopolysaccharide-free))) (NN cell) (NN culture) (NN system)))) (VP (VBZ leads) (PP-COOD (PP (TO to) (NP (NP (ADJP (RB significantly) (JJ enhanced)) (NNS levels)) (PP (IN of) (NP-COOD (NP (NP (NN interleukin) (CD 1) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN IL-1) (NN beta)) (-RRB- -RRB-))) (CC and) (NP (NP (NN tumour) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-alpha)) (-RRB- -RRB-))))))) (CC and) (PP (TO to) (NP (NP (NN expression)) (PP (IN of) (NP (NP (DT the) (JJ corresponding) (NN mRNA)) (PP (IN in) (NP (JJ human) (NP (NP (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN PBMC)) (-RRB- -RRB-)))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (ADJP (RB Structurally) (JJ related)) (JJ divalent) (NNS cations)) (PP (IN like) (NP-COOD (NP (NN cobalt)) (, ,) (NP (NN nickel)) (, ,) (CC and) (NP (NN mercury))))) (ADVP (RB also)) (VP (ADVP (RB partially)) (VBP increase) (NP (NN monokine) (NN secretion)) (CC but) (PP (TO to) (NP (DT a) (ADJP-COOD (ADJP (RB much) (JJR lower)) (CC and) (RB thus) (ADJP (JJ insignificant))) (NN extent)))) (. .)))
(TOP (S (NP-SBJ-1 (PRP They)) (VP (VBP fail) (S (VP (TO to) (VP (VB induce) (NP (NP (NN mRNA)) (PP (IN of) (NP (NN TNF-alpha)))) (PP-TMP (IN after) (NP (NP (CD 3) (NN h)) (PP (IN of) (NP (NN culture))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP-SBJ (NN monokine) (NN induction)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ zinc-specific) (NN effect)) (VP (VBN influenced) (PP (IN by) (NP-LGS (NP (DT the) (JJ physicochemical) (NNS properties)) (PP (IN of) (NP (DT the) (NN ion)))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Confirmation)) (PP (IN of) (NP (NP (DT the) (JJ unique) (NN significance)) (PP (IN of) (NP (NN zinc))) (PP (IN for) (NP (JJ immune) (NN function)))))) (VP (VBZ provides) (NP (NP (DT a) (JJR better) (NN understanding)) (PP (IN of) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (JJ specific) (JJ zinc-mediated) (JJ immune) (NN modulation))))))) (. .)))
(TOP (NP (NP-COOD (NP (NN Sequence) (NN analysis)) (CC and) (NP (NP (NN expression)) (PP (IN in) (NP (VBN cultured) (NNS lymphocytes))))) (PP (IN of) (NP (NP (DT the) (JJ human) (NN FOSB) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN G0S3)) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ (NN G0S3)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN member)) (PP (IN of) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (NP (JJ putative) (NN G0/G1) (NN switch) (JJ regulatory) (NNS genes)) (PRN (-LRB- -LRB-) (NP (NN G0S) (NNS genes)) (-RRB- -RRB-))) (VP (VBN selected) (PP (IN by) (S (VP (VBG screening) (NP (NP (NN cDNA) (NNS libraries)) (VP (VBN prepared) (PP (IN from) (NP (NP (JJ human) (NN blood) (JJ mononuclear) (NNS cells)) (VP (VBN cultured) (PP-TMP (IN for) (NP (CD 2) (NN hr))) (PP (IN with) (NP-COOD (NP (NN lectin)) (CC and) (NP (NN cycloheximide))))))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN sequence)) (VP (VBZ shows) (NP (NP (JJ high) (NN homology)) (PP (IN with) (NP (NP (DT the) (JJ murine) (NN FOSB) (NN gene)) (, ,) (SBAR (WHNP-48 (WDT which)) (S (VP (VBZ encodes) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (DT the) (NN AP1) (JJ transcriptional) (NN regulator))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Comparison)) (PP (IN of) (NP-COOD (NP (NN cDNA)) (CC and) (NP (JJ genomic) (NNS sequences))))) (VP (VBZ reveals) (NP (NP (DT a) (JJ 4-exon) (NN structure) (JJ characteristic)) (PP (IN of) (NP (NP (DT the) (NN FOS) (NN family)) (PP (IN of) (NP (NNS genes))))))) (. .)))
(TOP (S (NP-SBJ (ADJP (RB Freshly) (VBN isolated)) (NNS cells)) (VP (VBP show) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP-COOD (NP (NN FOSB/G0S3)) (CC and) (NP (NN FOS/G0S7))) (NNS mRNAs))) (, ,) (SBAR (WHNP-49 (WDT which)) (S (VP (VBP decline) (ADVP-TMP (RB rapidly)) (PP-TMP (IN during) (NP (NP (NN incubation)) (PP (IN in) (NP (NN culture) (NN medium)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS kinetics)) (PP (IN of) (NP (NN expression)))) (VP-COOD (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-50 (DT the) (JJ high) (JJ initial) (NNS levels)) (VP (VBP are) (VP (VBN caused) (PP (IN by) (NP-LGS (DT the) (NN isolation) (NN procedure)))))))) (, ,) (CC and) (VP (VBP do) (RB not) (VP (VB reflect) (NP (JJ constitutive) (NN expression))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NNS cells)) (VP (VBN preincubated) (PP-TMP (IN for) (NP (DT a) (NN day)))))) (, ,) (NP-SBJ (NP (NNS levels)) (PP (IN of) (NP (NN FOS) (NN mRNA)))) (VP-COOD (VP (VBP reach) (NP (DT a) (NN maximum)) (PP-TMP (NP (CD 20) (NN min)) (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN lectin)))))) (CC and) (VP (VBP decline) (PP (TO to) (NP (NN control) (NNS levels))) (PP-TMP (IN over) (NP (DT the) (JJ next) (CD 3) (NN hr))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Levels)) (PP (IN of) (NP (NN FOSB) (NN mRNA)))) (VP-COOD (VP (VBP reach) (NP (DT a) (JJ maximum)) (PP-TMP (NP (CD 40) (NN min)) (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN lectin)))))) (CC and) (VP (VBP decline) (PP (TO to) (NP (NN control) (NNS levels))) (PP-TMP (IN over) (NP (DT the) (JJ next) (CD 6) (NN hr))))) (. .)))
(TOP (S (PP (IN In) (NP (ADJP (RB freshly) (VBN isolated)) (NNS cells))) (, ,) (NP-SBJ (NP-COOD (CC both) (NP (NNS FOS)) (CC and) (NP (NN FOSB))) (NNS mRNAs)) (VP (VBP increase) (ADVP (RB dramatically)) (PP (IN in) (NN response) (TO to) (NP (DT the) (NN protein) (NN synthesis) (NN inhibitor) (NN cycloheximide)))) (. .)))
(TOP (S (PP (IN In) (NP (JJ preincubated) (NNS cells))) (, ,) (NP-SBJ-51 (DT the) (NN cycloheximide) (NN response)) (VP (VBZ is) (VP (VBN decreased) (, ,) (PP (RB especially) (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NN FOSB))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT These) (NNS differences)) (PP (IN in) (NP (NP (NN expression)) (PP (IN of) (NP-COOD (NP (NN FOS)) (CC and) (NP (NN FOSB))))))) (VP (VBP suggest) (NP (JJ different) (NP-COOD (NP (NNS roles)) (CC and) (NP (NN regulation))))) (. .)))
(TOP (S (NP-SBJ-52 (NP (NNS Regions)) (PP (IN of) (NP (JJ low) (ADJP (NN base) (JJ order-dependent)) (JJ stem-loop) (NN potential))) (PP (IN in) (NP (NP (DT the) (NN region)) (PP (IN of) (NP (DT the) (NN gene)))))) (VP (VBP are) (VP (VBN defined))) (. .)))
(TOP (S (NP-SBJ (DT These)) (VP (VBP indicate) (SBAR (WHADVP-53 (WRB where)) (S (NP-SBJ-54 (NN base) (NN order)) (VP (VBZ has) (VP (VBN been) (VP (VBN adapted) (PP (IN for) (NP (NP (NP (NNS purposes)) (PP (JJ other) (IN than) (NP (JJ stem-loop) (NN stability)))) (PRN (-LRB- -LRB-) (UCP (ADVP (FW e.g.)) (, ,) (UCP-COOD (S (VP (VBG encoding) (NP (NNS proteins)))) (CC or) (NP (NN gene) (NN regulation)))) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP-SBJ (NP (NNS Regions)) (PP (IN of) (NP (JJ low) (NN potential))) (PP (IN in) (NP (NP (DT a) (JJ 68.5-kb) (JJ genomic) (NN segment)) (VP (VBG containing) (NP (DT the) (NN FOSB) (NN gene)))))) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (DT the) (NN potential)) (VP (MD may) (VP (VB help) (S (VP (VB locate) (NP (NP (NNS genes)) (PP (IN in) (NP (JJ uncharted) (NN DNA) (NNS sequences))))))))))) (. .)))
(TOP (NP (NP (NP (NN Signaling)) (PP (IN via) (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4)))) (PP (IN in) (NP (JJ JAK3-deficient) (JJ severe) (JJ combined) (NN immunodeficiency) (NNS lymphocytes))) (: :)) (NP (ADJP-COOD (ADJP (JJ JAK3-dependent)) (CC and) (ADJP (JJ independent))) (NNS pathways)) (. .)))
(TOP (S (NP-SBJ-COOD (CC Both) (NP (NN IL-2)) (CC and) (NP (NN IL-4))) (VP (VBP bind) (PP (TO to) (NP (NP (NNS receptors)) (VP (VBG containing) (NP-COOD (NP (DT the) (JJ common) (NN gamma) (NN chain)) (CC and) (NP (NN JAK3))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ-100 (NN JAK3)) (VP (VBZ is) (VP (VBN required) (PP (IN for) (NP (JJ proper) (JJ lymphoid) (NN development))))))) (, ,) (NP-SBJ-39 (NP (DT the) (JJ precise) (NNS roles)) (PP (IN of) (NP (DT this) (NN kinase))) (PP (IN in) (NP (NP (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))) (NN signaling)) (PP (IN in) (NP (NNS lymphocytes)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN defined)))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN studied) (NP (NP (NP-COOD (NP (NN IL-2)) (CC and) (NP (NN IL-4))) (NN signaling)) (PP (IN in) (NP (NP (NN B) (NN cell) (NNS lines)) (VP (VBG lacking) (NP (NN JAK3)))))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP-SBJ (NP (JJ IL-2-induced) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN IL-2R) (NN beta)) (, ,) (NP (NN JAK1)) (, ,) (CC and) (NP (NN STAT5)))) (ADVP (DT all))) (VP (VBN required) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN JAK3))))))) (, ,) (NP-SBJ (NP (JJ IL-4-mediated) (NN phosphorylation)) (PP (IN of) (NP-COOD (NP (NN JAK1)) (, ,) (NP (NN STAT6)) (, ,) (CC and) (NP (NN insulin) (NN receptor) (NNS substrates) (NP-COOD (NP (CD 1)) (CC and) (NP (CD 2))))))) (VP (VBD did) (RB not)) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-40 (JJ IL-4-induced) (NNS effects)) (VP (VBD were) (VP (ADVP (RB clearly)) (VBN improved) (PP-TMP (VBG following) (NP (NN JAK3) (NN expression))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NN IL-4) (NN signaling)) (VP-COOD (VP (VBZ occurs) (PP (IN in) (DT the) (NN absence) (IN of) (IN of) (NP (NN JAK3)))) (, ,) (CC but) (VP (VBZ is) (ADJP-PRD (RB comparatively) (JJ inefficient))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS findings)) (VP-COOD (VP (MD may) (VP (VB help) (PP (RP in) (S (VP (VBG understanding) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (DT the) (NN immunodeficiency)) (SBAR (WHNP-41 (WDT that)) (S (VP (VBZ occurs) (PP (IN with) (NP (NP (NNS mutations)) (PP (IN of) (NP (NN JAK3)))))))))))))))) (CC and) (VP (MD may) (VP (VB suggest) (NP (NP (DT a) (NN mechanism)) (PP (IN for) (NP (NP (DT the) (JJ pleiotropic) (NNS effects)) (PP (IN of) (NP (NN IL-4))))))))) (. .)))
(TOP (NP (NP (NN Identification)) (PP (IN of) (NP (NP (NN Bcd)) (, ,) (NP (NP (DT a) (JJ novel) (NN proto-oncogene)) (VP (VBN expressed) (PP (IN in) (NP (NNS B-cells))))))) (. .)))
(TOP (S (NP-SBJ-29 (DT A) (JJ novel) (ADJP (ADJP (NN B-cell) (JJ derived)) (PRN (-LRB- -LRB-) (ADJP (NN Bcd)) (-RRB- -RRB-))) (NN oncogene)) (VP (VBZ has) (VP (VBN been) (VP (VBN isolated) (PP (IN from) (NP (NP (DT the) (JJ peripheral) (NN blood) (NNS lymphocytes)) (PP (IN of) (NP (CD one) (NP (NP (NN B-cell) (JJ chronic) (JJ lymphocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN B-CLL)) (-RRB- -RRB-))) (NN patient))))) (S (VP (VBG using) (NP-COOD (NP (NN DNA) (NN transfer)) (CC and) (NP (DT a) (NN mouse) (NN tumorigenicity) (NN assay)))))))) (. .)))
(TOP (S (NP-SBJ-30 (DT The) (NN Bcd) (NN proto-oncogene)) (VP (VBD was) (VP (VBN activated) (PP (IN by) (NP-LGS (NP (DT a) (NN truncation)) (PP (IN in) (NP (DT the) (JJ 5') (NN UTR))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ predicts) (PP (IN for) (NP (CD two) (NP (NP (JJ open) (NN reading) (NNS frames)) (PRN (-LRB- -LRB-) (NP (NNS ORFs)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP-SBJ (NN ORF1)) (VP (VBZ consists) (PP (IN of) (NP (NP (CD 240) (NN bp)) (SBAR (WHNP-31 (WDT that)) (S (VP (MD would) (VP (VB encode) (NP (CD 80) (NN amino) (NNS acids)))))))) (, ,) (SBAR (IN while) (S (NP-SBJ (DT the) (JJ major) (NN ORF2)) (VP (VBZ consists) (PP (IN of) (NP (NP (CD 648) (NN bp)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG coding) (PP (IN for) (NP (CD 216) (NN amino) (NNS acids))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (VBN Predicted) (NN peptide) (NN sequence)) (PP (IN of) (NP (NN ORF2)))) (VP (VBD contained) (NP (NP (DT a) (NN zinc) (NN finger) (NN domain)) (SBAR (WHNP-32 (WDT which)) (S (VP (VBD showed) (NP (NP (JJ significant) (NN homology)) (PP (TO to) (NP (NN GC) (NN box) (NN binding) (NNS proteins) (NP-COOD (NP (NN BTEB2)) (CC and) (NP (NN SP1))))))))))) (. .)))
(TOP (S (NP-SBJ-33 (NP (NN Transfection)) (PP (IN of) (NP (NP (DT an) (NN expression) (NN vector)) (VP (VBG containing) (NP-COOD (NP (NN ORF2)) (CONJP (CC but) (RB not)) (NP (JJ full) (NN length) (NN cDNA))))))) (VP (VBD was) (ADJP-PRD (JJ able) (S (VP (TO to) (VP-COOD (VP (VB transform) (NP (NN NIH3T3) (NNS cells))) (CC and) (VP (VB induce) (NP (NNS tumors)) (PP (IN in) (NP (JJ nude) (NNS mice))))))))) (. .)))
(TOP (S (NP-SBJ-34 (NP (NN Bcd) (NN mRNA) (NNS transcripts)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJR &lt;)) (CC or) (ADJP (JJ =))) (CD 2.6) (NN kb)))) (VP (VBD were) (VP (ADVP (RB selectively)) (VBN expressed) (PP (IN in) (NP (NP-COOD (NP (NN PBL)) (CC and) (NP (NN testis))) (PP (IN of) (NP (JJ healthy) (NNS individuals))))))) (. .)))
(TOP (S (PP (IN Within) (NP (DT the) (NN PBL))) (, ,) (NP-SBJ (NN Bcd) (NN gene) (NN expression)) (VP (VBD was) (ADJP-PRD-COOD (ADJP (JJ restricted) (PP (TO to) (NP (JJ CD19+) (NNS B-cells)))) (CC and) (ADJP (JJ absent) (PP (IN from) (NP-COOD (NP (JJ CD14+) (NNS monocytes)) (CC and) (NP (NNS T-cells))))))) (. .)))
(TOP (S (NP-SBJ-35 (NN Bcd) (NNS transcripts)) (VP (VBD were) (VP (VBN detected) (PP-COOD (PP (IN in) (NP (NP (DT all) (JJ normal) (NN PBL) (NNS samples)) (VP (VBN tested)))) (CC but) (PP (RB not) (IN in) (NP (JJ several) (JJ malignant) (JJ human) (NN B-cell) (NNS lines))) (CC and) (PP (RB not) (IN in) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NP (NNS B-cells)) (PP (IN from) (NP (NN B-CLL) (NNS patients)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-36 (NP (NN stimulation)) (PP (IN of) (NP (NP (NNS B-cells)) (PP (IN from) (NP (NN B-CLL) (NNS patients))))) (PP (IN under) (NP (NP (NNS conditions)) (SBAR (WHNP-37 (WDT which)) (S (VP (VBD induced) (NP (NP (NN differentiation)) (PP (IN into) (NP (NN plasma) (NNS cells)))))))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN induction)) (PP (IN of) (NP (NN Bcd) (NN gene) (NN expression))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NN Bcd) (NN gene)) (VP (MD may) (ADVP (RB therefore)) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NN B-cell) (NP-COOD (NP (NN growth)) (CC and) (NP (NN development))))))) (. .)))
(TOP (NP (NP (JJ Pancreatic) (NP-COOD (NP (NN development)) (CC and) (NP (NN maturation)))) (PP (IN of) (NP (DT the) (NN islet) (NN B) (NN cell))) (. .)))
(TOP (NP (NP (NNS Studies)) (PP (IN of) (NP (JJ pluripotent) (NN islet) (NNS cultures))) (. .)))
(TOP (S (NP-SBJ (NN Pancreas) (NN organogenesis)) (VP (VBZ is) (NP-PRD (NP (DT a) (ADJP (RB highly) (VBN regulated)) (NN process)) (, ,) (SBAR (WHPP-36 (IN in) (WHNP (WDT which))) (S (NP-SBJ (CD two) (NNS anlage)) (VP (VBP evaginate) (PP (IN from) (NP (DT the) (JJ primitive) (NN gut)))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ (PRP They)) (ADVP-TMP (RB later)) (VP (VBP fuse))) (, ,) (CC and) (, ,) (S (PP (IN under) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (DT the) (VBG surrounding) (NN mesenchyme))))) (, ,) (NP-SBJ-37 (DT the) (JJ mature) (NN organ)) (VP (VBZ develops) (, ,) (S (VP (VBG being) (VP (ADVP (RB mainly)) (VBN composed) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ ductal)) (, ,) (ADJP (JJ exocrine)) (CC and) (ADJP (JJ endocrine))) (NNS compartments)))))))) (. .)))
(TOP (S (NP-SBJ-39 (JJ Early) (NNS buds)) (VP (VBP are) (VP (VBN characterized) (PP (IN by) (NP-LGS (NP (DT a) (VBG branching) (NN morphogenesis)) (PP (IN of) (NP (NP (DT the) (JJ ductal) (NN epithelium)) (SBAR (WHPP-40 (IN from) (WHNP (WDT which))) (S (NP-SBJ-104 (ADJP-COOD (ADJP (JJ endocrine)) (CC and) (ADJP (JJ exocrine))) (NN precursor) (NNS cells)) (VP (VBP bud) (S (VP (TO to) (VP (ADVP-TMP (RB eventually)) (VB form) (NP (DT the) (CD two) (JJ other) (NNS compartments)))))))))))))) (. .)))
(TOP (S (NP-SBJ-41 (DT The) (CD three) (NNS compartments)) (VP (VBP are) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (PP-PRD (IN of) (NP (JJ common) (JJ endodermal) (NN origin))) (: ;) (PP (IN in) (NN contrast) (TO to) (NP (NP (JJR earlier) (NNS hypotheses)) (, ,) (SBAR (WHNP-42 (WDT which)) (S (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ endocrine) (NN compartment)) (VP (VBD was) (PP-PRD (IN of) (NP (JJ neuroectodermal) (NN origin)))))))))))))))) (. .)))
(TOP (S (NP-SBJ (PRP It)) (VP (VBZ is) (ADVP (RB thus)) (VP (ADVP (RB generally)) (VBN believed) (SBAR (IN that) (S (NP-SBJ (DT the) (JJ pancreatic) (NN endocrine-lineage)) (VP (VBZ possesses) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB mature) (PP (IN along) (NP (NP (DT a) (NN differentiation) (NN pathway)) (SBAR (WHNP-43 (WDT that)) (S (VP (VBZ shares) (NP (JJ many) (NNS characteristics)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (JJ neuronal) (NN differentiation))))))))))))))))))) (. .)))
(TOP (S (PP-TMP (IN During) (NP (JJ recent) (NNS years))) (, ,) (NP-SBJ (NP (NNS studies)) (PP (IN of) (NP-COOD (NP (JJ insulin-gene) (NN regulation)) (CC and) (, ,) (NP (PP (IN in) (NP (JJ particular))) (, ,) (NP (DT the) (JJ tissue-specific) (JJ transcriptional) (NN control)) (PP (IN of) (NP (JJ insulin-gene) (NN activity))))))) (VP (VBP have) (VP (VBN provided) (NP (NP (NN information)) (PP (IN on) (NP (NN pancreas) (NN development))) (PP (IN in) (NP (JJ general)))))) (. .)))
(TOP (S (NP-SBJ (DT The) (JJ present) (NN review)) (VP (VBZ summarizes) (NP (DT these) (NNS findings)) (, ,) (PP (IN with) (NP (NP (DT a) (JJ special) (NN focus)) (PP (IN on) (NP (NP (PRP$ our) (JJ own) (NNS studies)) (PP (IN on) (NP (NP (JJ pluripotent) (JJ endocrine) (NNS cultures)) (PP (IN of) (NP (NN rat) (NN pancreas)))))))))) (. .)))
(TOP (NP (NP (NN Induction)) (PP (IN of) (NP (JJ vascular) (NN cell) (NN adhesion) (NN molecule-1))) (PP (IN by) (NP (JJ low-density) (NN lipoprotein))) (. .)))
(TOP (S (NP-SBJ (NP (JJ Low-density) (NN lipoprotein)) (PRN (-LRB- -LRB-) (NP (NN LDL)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ well-established) (NN risk) (NN factor)) (PP (IN for) (NP (NN atherosclerosis))))) (. .)))
(TOP (S (SBAR-TMP (WHADVP-49 (WRB When)) (S (NP-SBJ-50 (JJ endothelial) (NNS cells)) (VP (VBP are) (VP (VBN incubated) (PP (IN with) (NP (DT this) (NN lipoprotein))) (PP (IN in) (NP (JJ pathophysiologic) (NNS amounts))))))) (, ,) (NP-SBJ-51 (DT the) (NNS cells)) (VP (VBP are) (VP (VBN activated))) (. .)))
(TOP (SINV (PP-PRD-TPC-103 (IN Among) (NP (NP (DT the) (VBN documented) (JJ cellular) (NNS responses)) (PP (TO to) (NP (NN LDL))))) (VP (VBZ is)) (NP-SBJ (NP (VBN increased) (NN recruitment)) (PP (IN of) (NP (NP (NNS monocytes)) (, ,) (SBAR (WHNP-52 (WDT which)) (S (VP (VBP are) (VP (VBN believed) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (S (VP (VBG promoting) (NP (JJ intimal) (NN plaque) (NN formation))))))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NNS findings)) (VP (VBN presented) (ADVP (RB here)))) (VP (VB link) (NP (NP (DT an) (JJ atheogenic) (NN lipoprotein)) (, ,) (NP (NN LDL)) (, ,)) (PP (IN with) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (DT an) (NN adhesion) (NN molecule)) (ADJP (JJ important) (PP (IN in) (NP (NN atherogenesis)))))))))))
(TOP (S (NP-SBJ (JJ Human) (NN LDL)) (VP (VBZ induces) (NP (NP (DT the) (JJ vascular) (NN cell) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN VCAM-1)) (-RRB- -RRB-))) (ADVP (RB transcriptionally)) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN mRNA) (NNS levels))))) (PP (IN through) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN VCAM) (NN promoter)))))) (. .)))
(TOP (S (NP-SBJ-54 (DT This) (NN effect)) (VP (VBZ is) (VP (VBN blocked) (PP (IN by) (NP-LGS (JJ anti-VCAM) (NNS antibodies))))) (. .)))
(TOP (S (PP-TMP (IN After) (NP (NP (DT a) (JJ 2-day) (NN incubation)) (PP (IN in) (NP (NN LDL))))) (, ,) (NP-SBJ (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B)) (, ,) (SBAR (WHNP-55 (WDT which)) (S (VP (VBZ is) (VP (VBN believed) (S (VP (TO to) (VP (VB be) (NP-PRD (NP (DT a) (JJ key) (JJ oxidative-stress) (NN sensor)) (PP (IN for) (NP (NN VCAM) (NN regulation))))))))))) (, ,)))) (VP (VBZ remains) (PP (IN at) (NP (JJ basal) (NN level)))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP-SBJ-57 (NP (DT the) (NN binding) (NNS activities)) (PP (IN of) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN GATA))))) (, ,) (PP (IN on) (NP (DT the) (JJ other) (NN hand))) (, ,) (VP (VBP are) (VP (VBN increased) (PP (IN by) (NP-LGS (NN LDL))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP-SBJ-58 (NP (DT a) (NN component)) (PP (IN of) (NP (NP (JJ LDL-enhanced) (JJ endothelial) (NN recruitment)) (PP (IN of) (NP (NNS monocytes)))))) (VP (VBZ is) (VP (VBN attributed) (PP (TO to) (NP (NP (JJ VCAM-1) (NN expression)) (, ,) (SBAR (WHNP-59 (WDT which)) (S (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (VP (VBN mediated) (PP (IN through) (NP-COOD (NP (NN AP-1)) (CC and) (NP (NN GATA))))))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS data)) (VP (VBP identify) (NP (NN LDL)) (PP (IN as) (NP (NP (DT a) (NN VCAM-inducer)) (ADJP (ADVP (RB possibly)) (JJ distinct) (PP (IN from) (NP-COOD (NP (NNS cytokines)) (CC and) (NP (NN endotoxin)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN NF-kappa) (NN B) (NN inhibitor)) (, ,) (NP (NN tepoxalin)) (, ,)) (VP (VBZ suppresses) (NP (NP (NN surface) (NN expression)) (PP (IN of) (NP (DT the) (NN cell) (NN adhesion) (NNS molecules) (NP-COOD (NP (NN CD62E)) (, ,) (NP (NN CD11b/CD18)) (CC and) (NP (NN CD106))))))) (. .)))
(TOP (S (NP-SBJ-51 (NP (NN Tepoxalin)) (, ,) (NP (NP (DT a) (JJ dual) (NN enzyme) (NN inhibitor)) (PP (IN of) (NP-COOD (NP (NN cyclooxygenase)) (CC and) (NP (NN 5-lipoxygenase)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NN T-cell) (NN activation)))))))) (. .)))
(TOP (S (NP-SBJ (PRP$ Its) (JJ immunosuppressive) (NN property)) (VP (VBZ is) (ADJP-PRD (JJ distinct) (PP (IN from) (NP (NN cyclosporin)))) (SBAR (IN because) (S (NP-SBJ-COOD (NP (RB only) (NN tepoxalin)) (, ,) (CONJP (CC but) (RB not)) (NP (NN cyclosporin)) (, ,)) (VP (VBZ suppresses) (NP (NN NF-kappa) (NN B) (NN activation)))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP report) (SBAR (IN that) (S (NP-SBJ (NN tepoxalin)) (ADVP (RB selectively)) (VP (VBZ inhibits) (NP (NP (ADJP (NP (JJ intercellular) (NN adhesion) (NN molecule-1) (-LRB- -LRB-) (NN ICAM-1) (, ,) (NN CD54) (-RRB- -RRB-) (NN /MAC-1) (-LRB- -LRB-) (NN CD11b/CD18) (-RRB- -RRB-)) (JJ dependent)) (NN adhesion)) (PP (IN of) (NP (JJ polymorphonuclear) (NNS cells))) (PP (TO to) (NP (ADJP (NN IL-1) (JJ activated)) (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NN inhibition)))) (VP (VBZ is) (ADJP-PRD (JJ related) (PP (TO to) (NP (NP (DT the) (NN surface) (NN expression)) (PP (IN of) (NP (JJ several) (NN cell) (NN adhesion) (NNS molecules))))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Flow) (NN cytometry) (NNS analyses)) (PP (IN on) (NP (NP (VBN cultured) (NNS cells)) (SBAR (WHNP-53 (WDT that)) (S (VP (VBD were) (VP-COOD (VP (VBN treated) (PP (IN with) (NP-COOD (NP (NN tepoxalin)) (CC or) (NP (NP (JJ antisense) (NNS oligonucleotides)) (PP (TO to) (NP (NP (DT the) (NN P65/p50) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))))) (, ,) (CC and) (RB then) (VP (VBN stimulated) (PP (IN with) (NP (NN PMA)))) (, ,)))))))) (VP (VBD revealed) (NP-COOD (NP (NP (DT a) (VBN reduced) (NN expression)) (PP (IN of) (NP-108 (NN CD11b/CD18))) (PP-109 (IN on) (NP (JJ monocytic) (NN HL60) (NNS cells)))) (, ,) (CC and) (NP (NP-COOD=108 (NP (NP (JJ endothelial) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN CD62E)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ vascular) (NN adhesion) (NN molecule-1)) (PRN (-LRB- -LRB-) (NP (NN CD106)) (-RRB- -RRB-)))) (PP=109 (IN on) (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)))))) (. .)))
(TOP (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (NP (JJ other) (NN adhesion) (NNS molecules)) (PP (JJ such) (IN as) (NP-COOD (NP (NP (NN lymphocyte) (NN function) (NN associated-antigen-1)) (PRN (-LRB- -LRB-) (NP (NN CD11a/CD18)) (-RRB- -RRB-))) (CC and) (NP (NN CD54))))))) (VP (VBD were) (ADJP-PRD (JJ unaffected))) (. .)))
(TOP (S (NP-SBJ (NN Tepoxalin)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (DT a) (ADJP (NP (NN NF-kappa) (NN B)) (JJ regulated)) (NN chemokine)) (, ,) (NP (NN IL-8)) (, ,) (NP (NP (DT a) (JJ known) (NN inducer)) (PP (IN of) (NP (NN CD11b/CD18) (NN expression)))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (NP-SBJ (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN CD11b/CD18) (NN expression))) (PP (IN by) (NP (NN tepoxalin)))) (VP (MD may) (VP (VB involve) (NP (NN IL-8)))) (. .)))
(TOP (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR-COOD (SBAR (IN that) (S (PP (IN by) (S-LGS (VP (VBG inhibiting) (NP (NN NF-kappa) (NN B) (NN activation))))) (, ,) (NP-SBJ-56 (NP (NN surface) (NN expression)) (PP (IN of) (NP (JJ several) (NN adhesion) (NNS molecules)))) (VP (MD can) (VP (VB be) (VP (VBN modulated)))))) (CC and) (SBAR (IN that) (S (NP-SBJ (NN tepoxalin)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ useful)) (PP (IN in) (S (VP (VBG treating) (NP (NP (VBN selected) (ADJP (NN adhesion) (JJ mediated)) (NNS events)) (PP (JJ such) (IN as) (NP-COOD (NP (NN leukocyte) (NN migration)) (CC or) (NP (JJ atherosclerotic) (NN plaque) (NN formation)))))))))))))) (. .)))
(TOP (NP (NP (NN Expression)) (PP (IN of) (NP (JJ erythroid-specific) (NNS genes))) (PP (IN in) (NP (JJ megakaryoblastic) (NNS disorders))) (. .)))
(TOP (S (NP-SBJ (ADJP (RB Currently) (JJ available)) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S-COOD (S (NP-SBJ (ADJP-COOD (ADJP (JJ erythroid)) (CC and) (ADJP (JJ megakaryocytic))) (NN differentiation) (NNS pathways)) (VP (VBP are) (ADJP-PRD (RB closely) (JJ related) (PP (TO to) (NP (DT each) (JJ other)))))) (, ,) (CC and) (S (NP-SBJ (EX there)) (VP (MD may) (VP (VB exist) (NP-PRD (NP (NN progenitor) (NNS cells)) (ADJP (JJ common) (PP (TO to) (NP (DT those) (CD two) (NNS lineages))))))) (MD may) (VB exist))))) (. .)))
(TOP (S (NP-SBJ-COOD-49 (NP (NP (JJ Acute) (JJ megakaryoblastic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN AML-M7)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ transient) (JJ myeloproliferative) (NN disorder)) (PP (IN in) (NP (NP (NN Down) (POS 's)) (NN syndrome)))) (PRN (-LRB- -LRB-) (NP (NN TMD)) (-RRB- -RRB-)))) (VP (VBP are) (VP (VBN characterized) (PP (IN by) (NP-LGS (NP (JJ rapid) (NN growth)) (PP (IN of) (NP (NP (JJ abnormal) (NN blast) (NNS cells)) (SBAR (WHNP-50 (WDT which)) (S (VP (VBP express) (NP (JJ megakaryocytic) (NNS markers))))))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NN blast) (NNS cells)) (VP (VP-COOD (VP (VBP express) (NP (NP (JJ lineage-specific) (NN transcription) (NNS factors)) (PP (JJ such) (IN as) (NP (NP (NN GATA-1)) (ADJP (JJ common) (PP (TO to) (NP (DT these) (NNS lineages)))))))) (CC and) (VP (ADVP-TMP (RB frequently)) (VBP express) (NP (NP (JJ erythroid-specific) (NNS mRNAs)) (PP (JJ such) (IN as) (NP-COOD (NP (NN gamma-globin)) (CC and) (NP (NP (JJ erythroid) (NN delta-aminolevulinate) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN ALAS-E)) (-RRB- -RRB-)))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (NNS blasts)) (PP (IN in) (NP (NP-COOD (NP (NN M7)) (CC and) (NP (NN TMD))) (NNS cases)))))) (VP (VBP have) (NP (ADJP-COOD (ADJP (JJ erythroid)) (CC and) (ADJP (JJ megakaryocytic))) (NNS phenotypes)))))))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NNS blasts)) (PP (IN in) (NP-COOD (NP (NN M7)) (CC and) (NP (NN TMD))))) (VP (MD may) (VP (VB correspond) (PP (TO to) (NP (NP (NNS progenitors)) (PP (IN of) (NP (ADJP-COOD (CC both) (ADJP (JJ erythroid)) (CC and) (ADJP (JJ megakaryocytic))) (NNS lineages)))))))))) (. .)))
(TOP (S (NP-SBJ (JJ Nuclear) (NN NF-ATp)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN hallmark)) (PP (IN of) (NP (NP (JJ unstimulated) (NN B) (NNS cells)) (PP (IN from) (NP (NN B-CLL) (NNS patients))))))) (. .)))
(TOP (S (NP-SBJ-41 (NP (NN B) (NNS lymphocytes)) (PP (IN from) (NP (NP (DT the) (JJ peripheral) (NN blood)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ chronic) (JJ lymphocytic) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN CLL)) (-RRB- -RRB-))))))))) (VP (VBD were) (VP (VBN analysed) (PP (IN for) (NP (NP (DT the) (NP-COOD (NP (JJ nuclear) (NN presence)) (CC and) (NP (NN DNA) (NN binding)))) (PP (IN of) (NP (NP (DT a) (NN panel)) (PP (IN of) (NP (NP (NN transcription) (NNS factors)) (SBAR (WHNP-42 (WDT which)) (S (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN gene) (NN control)) (PP (IN of) (NP (JJ lymphoid) (NNS cells))))))))))))))))) (. .)))
(TOP (S (NP-SBJ-44 (NP (DT The) (JJ following) (NN transcription) (NNS factors))) (VP (VBD were) (VP (VBN studied) (: :) (NP-COOD-107 (NP (DT the) (NN Octamer) (NNS factors) (NP-COOD (NP (NN Oct-1)) (CC and) (NP (NN Oct-2)))) (, ,) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NN AP-1) (NN factor) (NN family)))) (, ,) (NP (NP (NN NF-AT) (NNS factors)) (, ,) (NP (PP (IN in) (NP (JJ particular))) (NN NF-ATp))) (, ,) (CC and) (NP (NP (NNS members)) (PP (IN of) (NP (DT the) (NN Rel/NF-kB) (NN family))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ constitutive) (JJ nuclear) (NN translocation)) (PP (IN of) (NP (NP (NN NF-ATp)) (, ,) (NP (NP (DT a) (NN member)) (PP (IN of) (NP (NP (DT the) (VBG growing) (NN family)) (PP (IN of) (NP (NN NF-AT) (NNS factors)))))) (, ,)))) (VP (VBZ is) (NP-PRD (NP (DT a) (NN hallmark)) (PP (IN of) (NP (NP (JJ nonstimulated) (NN B) (NNS cells)) (PP (IN from) (NP (NN CLL) (NNS patients))))) (SBAR (WHNP-45 (WDT that)) (S (VP (VBZ distinguishes) (NP (NN B-CLL) (NNS cells)) (PP (IN from) (NP (`` ') (JJ normal) ('' ') (NN B) (NNS lymphocytes))))))))))) (. .)))
(TOP (S (NP-SBJ-46 (JJ Constitutive) (JJ nuclear) (NN appearance)) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed) (PP (IN for) (NP (NN NF-kB2/p52))))) (. .)))
(TOP (S (NP-SBJ-47 (NP (JJ Constitutive) (NN binding)) (PP (IN of) (NP (NP (JJ further) (NN factor) (NNS proteins)))) (PP (TO to) (NP (NN DNA))) (, ,) (PP-108 (JJ such) (IN as) (NP-COOD (NP (NN JunD)) (, ,) (NP (NN c-Fos)) (CC and) (NP (NN FosB)))) (, ,)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (JJ several) (NNS patients))) (SBAR (IN whereas) (S (NP-SBJ (NP (DT the) (NP-COOD (NP (NN localisation)) (CC and) (NP (NN DNA) (NN binding)))) (PP (IN of) (NP (NP (JJ other) (NNS factors)) (PP (JJ such) (IN as) (NP-COOD (NP (NN c-Jun)) (, ,) (NP (NN RelA/p65)) (CC and) (NP (NN c-Rel))))))) (VP (VBD was) (ADJP-PRD (JJ unaltered))))))) (. .)))
(TOP (S (NP-SBJ (NP (PRP It))) (VP (VBZ is) (ADJP-PRD (JJ remarkable)) (SBAR-48 (IN that) (S (PP (IN in) (NP (JJ B-CLL) (NNS cells))) (NP-SBJ-49 (NP (DT the) (NP-COOD (NP (JJ nuclear) (NN appearance)) (CC and) (NP (NN DNA) (NN binding)))) (PP (IN of) (NP (JJ specific) (NN transcription) (NNS factors)))) (VP (VBZ is) (ADVP (RB dramatically)) (VP (JJ affected) (SBAR (IN whereas) (S (NP-SBJ (NP (JJ other) (NNS members)) (PP (IN of) (NP (DT the) (JJ same) (NN factor) (NN family)))) (VP (VBD remained) (ADJP-PRD (JJ unaltered)) (PP (IN in) (NP (DT these) (JJ leukemic) (NNS cells))))))))))) (. .)))
(TOP (S (NP-SBJ-51 (PRP It)) (VP (VBZ remains) (S (VP (TO to) (VP (VB be) (VP (VBN shown) (SBAR (WHNP-52 (WDT which) (JJ molecular) (NNS events)) (S (VP (VBP lead) (PP (TO to) (NP (NP (NP (DT the) (JJ specific) (`` ') (NN pre-activation) ('' ')) (, ,) (NP (ADVP (FW i.e.)) (NP-COOD (NP (JJ constitutive) (JJ nuclear) (NN translocation)) (CC and) (NP (NN DNA) (NN binding)))) (, ,)) (PP (IN of) (NP (NP (DT these) (NNS members)) (PP (IN of) (NP (NP-COOD (NP (NN NF-AT)) (, ,) (NP (NN NF-kB)) (CC and) (NP (NN AP-1))) (NN factor) (NNS families))))))))))))))) (. .)))
(TOP (NP (-LRB- -LCB-) (NP (DT The) (NN value)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NN test)) (PP (IN of) (NP (NP (NN glucocorticoid) (NNS receptors)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease))))))))))) (-RRB- -RCB-)))
(TOP (S (SBAR (IN In) (NN order) (TO to) (S (VP (VB inquire) (PP (IN into) (NP (NP (DT the) (JJ functional) (NN state)) (PP (IN of) (NP (NP (JJ adrenal) (NN cortex)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pulmonary) (NN heart) (NN disease)))))))))))) (, ,) (S-COOD (S (NP-SBJ-27 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NP (NN glucocorticoid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN GCR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS leukocytes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ pulmonary) (NN heart) (NN disease)))))))))) (VP (VBD was) (VP (VBN determined) (PP (IN with) (NP (JJ radioligand-binding) (NN assay)))))) (CC and) (S (NP-SBJ-28 (DT the) (JJ corresponding) (NN plasma) (NN cortisol) (NNS levels)) (VP (VBD were) (VP (VBN assessed) (PP (IN with) (NP (JJ radioimmune) (NNS assays))))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S-COOD (S (NP-SBJ-29 (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN reduced) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))))) (CC and) (S (NP-SBJ-30 (PRP it)) (VP (VBD was) (VP (VBN increased) (SBAR-TMP (WHADVP-31 (WRB when)) (S (NP-SBJ-32 (PRP$ their) (NN health) (NN state)) (VP (VBD was) (VP (VBN improved))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (ADVP (RB still)) (ADJP-PRD (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-))) (. .)))
(TOP (S (NP-SBJ-33 (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NN GCR)) (PP (IN in) (NP (DT the) (NNS patients)))))) (VP (VBD was) (ADVP (RB greatly)) (VP (VBN increased) (SBAR-TMP (WHADVP-34 (WRB when)) (S (NP-SBJ-35 (DT these) (NNS patients)) (VP (VBD were) (VP (VBN treated) (PP (IN with) (NP (NN oxygen))))))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &lt;) (CD 0.01)))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ-36 (NP (DT No) (NN difference)) (PP (IN in) (NP (NN plasma) (NN cortisol)))) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP-COOD (NP (DT the) (NNS patients)) (CC and) (NP (DT the) (JJ healthy) (NNS subjects)))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN P)) (NP-PRD (QP (JJR &gt;) (CD 0.05)))) (-RRB- -RRB-)))) (. .)))
(TOP (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S-COOD (S (NP-SBJ-37 (NP (DT the) (NN function)) (PP (IN of) (NP (JJ adrenal) (NN cortex)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (PP (IN by) (NP-LGS (NP (DT the) (NN compensation) (NN mechanism)) (PP (IN of) (NP (DT the) (NNS patients))))))))) (, ,) (CC but) (S (NP-SBJ (DT the) (JJR lower) (NN GCR) (NN number)) (VP (VBD was) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (NP (NN lacking)) (PP (IN of) (NP (NN oxygen))) (PP (IN in) (NP (DT the) (NNS patients))))))))))) (. .)))
(TOP (S (NP-SBJ-38 (NP (DT The) (NN number)) (PP (IN of) (NP (NN GCR)))) (VP (MD may) (VP (VB be) (VP (VBN improved) (PP (IN by) (NP-LGS (NP (NN inhalation)) (PP (IN of) (NP (NN oxygen)))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (NP-SBJ (NN oxygen) (NN therapy)) (VP (VBZ is) (ADJP-PRD (JJ helpful)) (PP (IN in) (S (VP-COOD (VP (VBG raising) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN glucocorticoid) (NNS receptors))))) (CC and) (VP (VBG controlling) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (NN disease))))))))) (. .)))
(TOP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B) (NN subunit) (NN p65) (NN mRNA) (NN accumulation)) (PP (IN in) (NP (NP (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NN sodium) (NN salicylate)))))))) (. .)))
(TOP (S (NP-SBJ (NN Lipopolysaccharide)) (VP (VBZ is) (NP-PRD (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ potent)) (NN trigger) (NNS substances)) (PP (IN for) (NP-COOD (NP (NNS monocytes)) (CC and) (NP (NNS macrophages)))) (VP (VBG causing) (NP (NP (NN secretion)) (PP (IN of) (NP (NP (JJ inflammatory) (NNS mediators)) (PP (JJ such) (IN as) (NP-COOD (NP (NN tumor) (NN necrosis) (NN factor)) (CC and) (NP (NN interleukin-1)))))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (NN nature)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NP (NN regulation)) (PP (IN of) (NP (DT these) (NN cytokine) (NNS genes))))))))) (VP (VBZ is) (ADVP-TMP (RB still)) (ADJP-PRD (JJ unknown))) (. .)))
(TOP (S (NP-SBJ-38 (NP (NP (JJ Nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NP (NN NF-kappa) (NN B)) (: ;) (NP (NP (NN heterodimer)) (PP (IN of) (NP-COOD (NP (NN p50)) (CC and) (NP (NN p65)))))) (-RRB- -RRB-))) (NNS proteins)) (VP (VBP have) (VP (VBN been) (VP (VBN suggested) (S (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN gene) (NN transcription)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators))))) (SBAR-TMP (WHADVP-39 (WRB when)) (S (NP-SBJ-40 (NNS monocytes)) (VP (VBP are) (VP (VBN stimulated) (PP (IN with) (NP (NN lipopolysaccharide))))))))))))) (. .)))
(TOP (S-COOD (S (NP-SBJ-41 (NP (JJ Nonsteroidal) (JJ anti-inflammatory) (NNS drugs)) (PP (JJ such) (IN as) (NP (NNS salicylates)))) (VP (VBP have) (VP (VBN been) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN inflammation))))))))))) (, ,) (CC and) (S (NP-SBJ-43 (NP (DT a) (JJ new) (NN mechanism)) (PP (IN of) (NP (NN drug) (NN action)))) (VP (VBD was) (VP (VBN suggested) (ADVP-TMP (RB recently))))) (. .)))
(TOP (S (NP-SBJ-44 (NNS Salicylates)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (JJ lipopolysaccharide-induced) (NN gene) (NN transcription)) (PP (IN via) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activation))))) (PP (IN by) (S (VP-COOD (VP (VBG preventing) (NP (NP (DT the) (NN degradation)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN inhibitor) (`` ") (NN I) (NN kappa) (NN B) ('' "))))) (, ,) (VP (VBG blocking) (NP (NP (DT the) (NN translocation)) (PP (IN of) (NP (NN NF-kappa) (NN B))) (PP (IN into) (NP (DT the) (JJ nuclear) (NN compartment)))))))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP-SBJ-46 (NP (DT the) (NN nature)) (PP (IN of) (NP (NP (DT the) (NN subunit)) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN mechanism))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN defined)))) (. .)))
(TOP (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP-47 (IN by) (WHNP (WDT which))) (S (NP-SBJ (NNS salicylates)) (VP (VBP affect) (NP (NN cytokine) (NN gene) (NN transcription))))))))) (, ,) (NP-SBJ-48 (NP (DT the) (NN amount)) (PP (IN of) (NP-COOD (NP (ADJP-COOD (ADJP (JJ active)) (CC and) (ADJP (JJ inactive))) (NN NF-kappa) (NN B)) (CC and) (NP (NN NF-kappa) (NN B) (NN mRNA)))) (, ,) (PP (IN in) (NP (NN Porphyromonas) (NN gingivalis) (JJ lipopolysaccharide-stimulated) (JJ human) (JJ monocytic) (NNS cells)))) (VP (VBD was) (VP (VBN assessed))) (. .)))
(TOP (S-COOD (S (NP-SBJ (NP (JJ High) (NNS doses)) (PP (IN of) (NP (NN sodium) (NN salicylate)))) (VP (VBD suppressed) (NP (NN NF-kappa) (NN B) (NN p65) (NN mRNA) (NN accumulation)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ total) (NN NF-kappa) (NN B))))))))) (, ,) (S (NP-SBJ (NP (NN p50)) (PP (IN on) (NP (NN tissue) (NN oligonucleotide)))) (VP (VBD had) (NP (DT no) (NNS effects)) (PP (IN on) (NP (JJ lipopolysaccharide-induced) (NN NF-kappa) (NN B) (NN activation))))) (. .)))
(TOP (S (NP-SBJ (DT The) (NNS data)) (VP-COOD (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ-50 (NP (DT the) (NN p65) (NN subunit)) (PP (IN of) (NP (NN NF-kappa) (NN B)))) (VP (VBZ is) (VP (VBN inhibited) (PP (IN by) (NP-LGS (NN salicylate) (NN treatment)))))))) (CC and) (VP (VBP highlight) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN salicylate))) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NP (NN gene) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS mediators)))))))))) (. .)))
(TOP (NP (NP (NN Lack)) (PP (IN of) (NP (NP (JJ T-cell-mediated) (NN recognition)) (PP (IN of) (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN pml/RAR-alpha) (NN hybrid) (NN protein))))) (PP (IN by) (NP (NP (NNS lymphocytes)) (PP (IN of) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS patients))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ previous) (NNS studies))) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-42 (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN pml/RAR-alpha) (NN protein))) (, ,) (VP (VBN expressed) (PP (IN by) (NP-LGS (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (NNS cells)))) (, ,)) (VP (MD can) (VP (VB be) (VP (ADVP (RB specifically)) (VBN recognized) (ADVP (FW in) (FW vitro)) (PP (IN by) (NP-LGS (NP (NP (NN donor)) (PRN (-LRB- -LRB-) (NP (NNP D.) (NNP E.)) (-RRB- -RRB-))) (NN CD4) (NN T) (NNS cells))) (PP (IN in) (NP (DT a) (ADJP (NN HLA) (NN class) (CD II) (JJ DR11-restricted)) (NN fashion)))))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (VP (VBP present) (ADVP (RB here)) (NP (NP (DT the) (NNS results)) (PP (IN on) (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (JJ several) (NN pml/RAR-alpha) (NNS peptides))) (PP (IN by) (NP (NP (NN APL) (NNS patients)) (VP (VBG expressing) (NP (NN HLA) (NN DR11))))))))) (. .)))
(TOP (S (NP-SBJ (NP (DT The) (ADJP (FW in) (FW vitro)) (NN immunization)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (NP (NP (CD four) (NNS patients)) (PP (IN in) (NP (NN remission)))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NNP S.R.)) (, ,) (NP (NNP F.R.)) (, ,) (NP (NNP M.M.)) (, ,) (NP (NNP P.) (NNP G.))) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (NN BCR1/25)) (, ,) (NP (DT a) (NN 25-mer) (NN pml/RAR-alpha)) (, ,)))) (VP (VBD did) (RB not) (VP (VB elicit) (NP (NP (NP-COOD (CC either) (NP (DT a) (JJ polyclonal)) (CC or) (NP (DT a) (JJ clonal))) (NP-43 (JJ immune) (NN response))) (ADJP (JJ specific) (PP (TO to) (NP (DT the) (NN peptide))))))) (. .)))
(TOP (S (NP-SBJ (PRP We)) (ADVP-TMP (RB then)) (VP (VBD generated) (NP (JJ new) (NN donor) (JJ anti-pml/RAR-alpha) (JJ CD4-LRB-+-RRB-) (NN T-cell) (NNS clones))) (. .)))
(TOP (S (NP-SBJ-44 (DT These) (NNS clones)) (VP (VBD were) (VP (VBN tested) (PP (IN for) (NP (NP (PRP$ their) (NN recognition)) (PP (IN of) (NP (NN BCR1/25))))))) (. .)))
(TOP (S (NP-SBJ-45 (NP (CD One) (NN clone)) (PRN (-LRB- -LRB-) (NP (NP (NN C3/5)) (, ,) (ADJP-COOD (ADJP (JJ CD3-LRB-+-RRB-)) (, ,) (ADJP (JJ CD4-LRB-+-RRB-)) (, ,) (ADJP (JJ CD8-LRB---RRB-)))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN selected) (PP (IN for) (NP (JJ further) (NN analysis))))) (. .)))
(TOP (S (NP-SBJ-46 (NN Clone) (NN C3/5)) (VP (VBD showed) (NP (JJ specific) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NP (NP (NN cytokine)) (PRN (-LRB- -LRB-) (NP (UCP-COOD (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (, ,) (ADJP (JJ granulocyte-macrophage) (JJ colony-stimulating))) (NN factor)) (-RRB- -RRB-))) (NN production)))) (SBAR-TMP (WHADVP-48 (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (JJ autologous) (JJ lymphoblastic) (NN cell) (NNS lines)) (VP (VBN pulsed) (PP (IN with) (NP (NN peptide) (NN BCR1/25)))))))))) (. .)))
(TOP (S (NP-SBJ-49 (NN C3/5) (NNS cells)) (VP (VBD developed) (NP (JJ specific) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN cytotoxicity)))) (SBAR-TMP (WHADVP-51 (WRB when)) (S (VP (VBN challenged) (PP (IN with) (NP (NP (JJ peptide-pulsed) (NP-COOD (NP (JJ lymphoblastic) (NN cell) (NNS lines)) (CC and) (NP (JJ peripheral) (NN blood) (NNS lymphocytes)))) (PP (IN from) (NP (DT the) (CD four) (JJ DR11-LRB-+-RRB-) (NN APL) (NNS patients))))))))) (. .)))
(TOP (S (NP-SBJ-52 (NP (NN APL) (NNS blasts)) (, ,) (ADJP (JJ available) (PP (RB only) (IN from) (NP (NNS patients) (NP-COOD (NP (NNP F.R.)) (CC and) (NP (NNP P.G.)))))) (, ,)) (VP-COOD (VP (VBD were) (RB not) (VP (VBN lysed) (PP (IN by) (NP-LGS (NN C3/5))))) (CC and) (VP (VBD were) (ADJP-PRD (JJ unable) (S (VP (TO to) (VP (VB present) (NP (NN peptide) (NN BCR1/25)))))))) (. .)))
(TOP (S (NP-SBJ-53 (NP (NN Incubation)) (PP (IN of) (NP (NN APL) (NNS cells))) (PP (IN with) (NP (NN IFN-gamma)))) (VP (VBD failed) (S (VP (TO to) (VP (VB induce) (NP-COOD (NP (NN HLA) (NN class) (CD II) (NNS molecules)) (CC and) (NP (NP (NN recognition)) (PP (IN by) (NP (DT the) (NN C3/5) (NN clone))))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (NP-SBJ (NN APL) (NNS cells)) (VP (VBP do) (RB not) (VP (VB express) (NP (NN HLA) (NN class) (CD II) (NNS molecules)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD tested) (PP-COOD (PP (IN in) (NP (NP (CD two) (NNS donors)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NNP D.E.)) (CC and) (NP (NNP C.H.R.))) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NNS patients) (NP-COOD (NP (NN S.R.)) (CC and) (NP (NN P.G.)))))) (SBAR (CC whether) (S (NP-SBJ (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN 9-mer) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NN BCR1/9)) (-RRB- -RRB-))))) (VP (MD would) (VP (VB generate) (NP (DT a) (ADJP (NN CD8/HLA) (NN class) (JJ I-restricted)) (NN response))))))) (. .)))
(TOP (S (NP-SBJ-54 (DT No) (JJ peptide-specific) (NN T-cell) (NP-COOD (NP (NN line)) (CC or) (NP (NN clone)))) (VP (MD could) (VP (VB be) (VP (VBN generated) (PP (IN from) (NP-COOD (CC both) (NP (NNS donors)) (CC and) (NP (NNS patients))))))) (. .)))
(TOP (S (NP-SBJ-55 (DT These) (NNS findings)) (VP (VBP are) (VP (VBN discussed) (PP (IN in) (NN relation) (TO to) (NP (NP (JJ possible) (JJ therapeutic) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN immunotherapy)) (PP (IN of) (NP (NN APL))))))))) (. .)))
(TOP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (NN IL-6) (NN synthesis)) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells))))) (PP (IN by) (NP (NP (NN C3a)) (CC and) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-))))) (. .)))
(TOP (S (NP (DT The) (NN anaphylatoxin) (NN C3a)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB have) (NP (NP (JJ immunomodulatory) (NNS effects)) (PP (IN on) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ different) (NN cell) (NNS types)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN C3a)) (CC and) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (NN gene) (NN expression)) (CC and) (NP (NP (NN protein) (NN secretion)) (PP (IN of) (NP (NN IL-6))) (PP (IN in) (NP (JJ human) (NNS PBMCs)))))) (, ,) (UCP (ADVP (DT either) (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN LPS) (CC or) (NN IL-1beta)))))))) (. .)))
(TOP (S (NP (NP (NN C3a)) (CC or) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-)))) (ADVP (RB alone)) (VP (VBD exhibited) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN expression)) (CC or) (NP (NN secretion)) (PP (IN of) (NP (NN IL-6)))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN PBMC)) (VP (VBD were) (VP (VBN stimulated) (PP (IN with) (NP (NN LPS) (CC or) (NN IL-1beta))))))) (, ,) (NP (DT both) (NP (NN C3a)) (CC and) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN found) (S (VP (TO to) (VP (VB enhance) (NP (NP (NN IL-6) (NN release)) (PP (IN by) (NP (NN PBMC)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))))) (. .)))
(TOP (S (SBAR (IN Since) (S (S (NP (NN C3a)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB induce) (NP (NP (NN PGE2) (NN production)) (PP (IN by) (NP (NNS monocytes))))))))))) (, ,) (CC and) (S (NP (NN PGE2)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB influence) (NP (NN cytokine) (NN production))))))))))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (NN PGE2))) (PP (IN in) (NP (NP (JJ C3a-mediated) (NN enhancement)) (PP (IN of) (NP (NN LPS-) (CC and) (JJ IL-1beta-induced) (NN IL-6) (NN production))))))) (. .)))
(TOP (S (S (NP (NN Indomethacin)) (VP (VBD blocked) (NP (NN PGE2) (NN release)))) (, ,) (CC but) (S (VP (VBD had) (NP (DT no) (NN influence)) (PP (IN on) (NP (NP (DT the) (VBN observed) (NNS effects)) (PP (IN of) (NP (NN C3a))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN C3a))) (PP (IN on) (NP (NN IL-6) (NN production)))) (VP (VBP are) (ADJP (JJ independent) (PP (IN of) (NP (NP (NN PGE2) (NN formation)) (PP (IN by) (NP (NNS monocytes))))))))))))) (. .)))
(TOP (S (NP (NN Northern) (NN blot) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN C3a)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-)))) (VP (VBN enhanced) (NP (JJ LPS-induced) (NN mRNA) (NNS levels)) (PP (IN for) (NP (NN IL-6))))))) (. .)))
(TOP (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NP (NNS PBMCs)) (PP (IN with) (NP (NN pertussis) (NN toxin)))))) (VP (VBD blocked) (NP (NP (DT the) (NNS functions)) (PP (IN of) (NP (NP (NN C3a)) (CC and) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-)))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT the) (NNS actions)) (PP (IN of) (NP (DT these) (CD two) (NNS molecules)))) (VP (VBP are) (VP (VBN mediated) (PP (IN by) (NP (DT a) (NN G) (JJ protein-coupled) (NN pathway)))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN C3a)) (CC and) (NP (NP (NN C3a)) (PRN (-LRB- -LRB-) (NP (NN desArg)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (NN induction)) (PP (IN of) (NP (NN NF-kappaB)))) (CC and) (VP (VBG activating) (NP (NN protein-1) (NN binding)))))) (. .)))
(TOP (S (NP (DT Both) (NNS molecules)) (VP (VBN enhanced) (NP (JJ LPS-induced) (NN NF-kappaB)) (CC and) (VP (VBG activating) (NP (NN protein-1) (NN binding) (NN activity)))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (NP (NP (DT the) (NN capacity)) (PP (IN of) (NP (NP (JJ intact) (NN C3a)) (CC and) (NP (PRP$ its) (VBG circulating) (NN des-Arg) (NN form)))) (S (VP (TO to) (VP (VB exert) (NP (JJ immunmodulatory) (NNS effects)) (ADVP (FW in) (FW vitro))))))) (. .)))
(TOP (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (JJ primary) (NN sensitization)) (PP (IN of) (NP (JJ naive) (JJ human) (NN T) (NNS cells))) (PP (TO to) (NP (NN varicella-zoster) (NN virus) (NNS peptides))) (PP (IN by) (NP (NP (JJ dendritic) (NNS cells)) (ADJP (FW in) (FW vitro)))))) (PP (IN with) (NP (NNS responses) (VP (VBN elicited) (ADVP (FW in) (FW vivo)) (PP (IN by) (NP (NN varicella) (NN vaccination)))))) (. .)))
(TOP (S (NP (NP (JJ Dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS DC)) (-RRB- -RRB-))) (VP (VBP are) (NP (JJ potent) (NN APC)) (PP (IN during) (NP (ADJP (JJ primary) (CC and) (JJ secondary)) (JJ immune) (NNS responses)))) (. .)))
(TOP (S (NP (NP (DT The) (JJ first) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (JJ human) (NNS DC)) (VP (VBP mediate) (NP (ADJP (FW in) (FW vitro)) (NP (NN sensitization)) (PP (IN of) (NP (JJ naive) (JJ CD4+) (NN T) (NNS cells))) (PP (TO to) (NP (NP (NNS epitopes)) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (JJ immediate) (JJ early) (CD 62)) (PRN (-LRB- -LRB-) (NN IE62) (-RRB- -RRB-))) (NP (NN protein)) (PP (IN of) (NP (NP (NN varicella) (NN zoster) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN VZV)) (-RRB- -RRB-))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN induction)) (PP (IN of) (NP (NP (JJ CD4+) (NN T) (NN cell) (JJ proliferative) (NNS responses)) (PP (TO to) (NP (NP (CD eight) (JJ synthetic) (NNS peptides)) (VP (VBG representing) (NP (NP (NN amino) (NN acid) (NNS sequences)) (PP (IN of) (NP (DT the) (NN VZV) (NN IE62) (NN protein)))))))))) (VP (VBD was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (NN T) (NNS cells)) (CC and) (NP (NNS DC)) (PP (IN from) (NP (JJ VZV-susceptible) (NNS donors)))))))) (. .)))
(TOP (S (NP (DT The) (JJ second) (NN objective)) (VP (VBD was) (S (VP (TO to) (VP (VB compare) (NP (ADJP (FW in) (FW vitro)) (NP (NNS responses)) (PP (IN of) (NP (JJ naive) (NN T) (NNS cells)))) (PP (IN with) (NP (NP (NNS responses)) (PP (TO to) (NP (NP (NN VZV) (NNS peptides)) (VP (VBN induced) (ADVP (FW in) (FW vivo)) (PP (IN after) (NP (NN immunization) (PP (IN with) (NP (NN varicella) (NN vaccine)))))))))))))) (. .)))
(TOP (S (NP (NN T) (NN cell) (NN proliferation)) (VP (VBD was) (VP (VBN induced) (PP (IN by) (NP (NP (CD three) (NNS peptides)) (, ,) (NP (NN P1) (, ,) (NN P4) (, ,) (CC and) (NN P7)) (, ,))) (PP (IN in) (NP (NP (CD 71-100) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS donors)) (VP (VBN tested) (PP (IN before) (CC and) (IN after) (NP (NP (NN vaccination)) (S (VP (VBG using) (NP (NP (NNS DC)) (PP (IN as) (NP (NN APC))))))))))))))) (. .)))
(TOP (S (NP (NNS Monocytes)) (VP (VBD were) (NP (JJ effective) (NN APC)) (PP (IN for) (NP (NN VZV) (NNS peptides))) (PP (ADVP (RB only)) (IN after) (NP (NN immunization)))) (. .)))
(TOP (S (NP (NP (CD Two) (NNS peptides)) (, ,) (NP (NN P2) (CC and) (NN P8)) (, ,)) (VP (VBD induced) (NP (JJ naive) (NN T) (NN cell) (NN proliferation)) (ADVP (RBR less) (RB effectively)) (CC and) (VP (VBD were) (ADVP (RB also)) (ADJP (RBR less) (JJ immunogenic)) (PP (IN for) (NP (NP (NN T) (NNS cells)) (PP (IN from) (NP (ADJP (ADJP (VBN vaccinated)) (CC or) (ADJP (RB naturally) (JJ immune))) (NNS donors))))))) (. .)))
(TOP (S (S (NP (NP (NN T) (NN cell) (NN recognition)) (PP (IN of) (NP (JJ specific) (NNS peptides)))) (VP (VBD was) (ADJP (JJ concordant) (PP (IN between) (NP (NP (JJ naive) (, ,) (JJ DC-mediated) (NNS responses)) (, ,) (CC and) (NP (JJ postvaccine) (NNS responses)))) (VP (VBG using) (NP (NNS monocytes)) (PP (IN as) (NP (NN APC))) (PP (IN in) (NP (NP (NP (CD 69) (NN %)) (PP (IN of) (NP (NNS comparisons)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.05)))) (: ;) (NP (NN chi2)) (-RRB- -RRB-)))))))) (: ;) (S (NP (NP (DT the) (JJ predictive) (NN value)) (PP (IN of) (NP (NP (DT a) (JJ positive) (NN response)) (PP (TO to) (NP (DT an) (NN IE62) (NN peptide))) (PP (IN before) (NP (NP (NN immunization)) (PP (IN for) (NP (NN T) (NN cell) (NN sensitization) (ADJP (FW in) (FW vivo))))))))) (VP (VBD was) (NP (CD 82) (NN %)))) (. .)))
(TOP (S (NP (DT These) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ primary) (NN T) (NN cell) (NNS responses)) (VP (VBN detected) (ADVP (FW in) (FW vitro)) (VP (VBG using) (NP (NNS DC)) (PP (IN as) (NP (NN APC)))))) (VP (MD may) (VP (VB be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT the) (JJ potential) (NN immunogenicity)) (PP (IN of) (NP (JJ viral) (NN protein) (NNS epitopes) (ADJP (FW in) (FW vivo)))))))))))))) (. .)))
(TOP (S (NP (ADJP (RB Mildly) (VBN oxidized)) (JJ low-density) (NNS lipoproteins)) (VP (VBP decrease) (NP (NP (JJ early) (NN production)) (PP (IN of) (NP (NN interleukin) (CD 2))) (CC and) (NP (NP (JJ nuclear) (NN factor) (NN kappaB) (VBG binding)) (PP (TO to) (NP (NN DNA))) (PP (IN in) (NP (VBN activated) (NN T-) (NNS lymphocytes)))))) (. .)))
(TOP (S (NP (VBN Activated) (NNS T-lymphocytes)) (VP (VBP are) (VP (VBN found) (ADVP (RB early)) (PP (IN in) (NP (NN atherosclerosis) (NNS lesions))))) (, ,) (CC but) (S (NP (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (PRP$ their) (NN role)))))) (. .)))
(TOP (S (NP (NP (VBN Oxidized) (JJ low-density) (NNS lipoproteins)) (PRN (-LRB- -LRB-) (NP (NNS oxLDLs)) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT the) (NNS lesions))))))))))) (, ,) (CC and) (S (NP (PRP we)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NNS oxLDLs)) (VP (VBP inhibit) (NP (CONJP (RB not) (RB only)) (NP (NP (NP (NN interleukin)) (PRN (-LRB- -LRB-) (NP (NN IL)) (-RRB- -RRB-)) (NP (NN -2-receptor) (NN expression))) (PP (IN on) (NP (NP (DT the) (NN surface)) (PP (IN of) (NP (ADJP (FW in) (JJ vitro-activated)) (NNS T-lymphocytes)))))) (CONJP (CC but) (RB also)) (NP (PRP$ their) (NN proliferation))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (ADVP (RB now)) (VP (VBN investigated) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS oxLDLs)))) (PP (PP (IN on) (NP (NN blast) (NN differentiation))) (, ,) (PP (IN on) (NP (NN IL-2) (NN synthesis))) (CC and) (PP (IN on) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NN factor) (NN kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-)) (NP (NN system)))) (PP (IN in) (NP (VBN activated) (NNS lymphocytes))))))))) (. .)))
(TOP (S (NP (NP (RB Mildly) (NNS oxLDLs)) (PRN (-LRB- -LRB-) (NP (CD 50) (CC and) (CD 100) (NN microgram/ml)) (-RRB- -RRB-))) (VP (VBD decreased) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS lymphoblasts)))) (CC and) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN IL-2) (NN concentration)))) (PP (IN in) (NP (DT the) (NN culture) (NNS supernatants))) (PP (IN after) (NP (NP (NN activation)) (PP (IN of) (NP (NNS lymphocytes))) (PP (IN by) (NP (NN phytohaemagglutinin) (CC and) (NN PMA+ionomycin)))))) (. .)))
(TOP (S (NP (NP (DT The) (NN inhibition)) (PP (IN of) (NP (NN IL-2) (NN production)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (DT the) (JJ CD3^+|) (NN T-lymphocyte) (NN cytoplasm))) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (NP (NP (CD 4) (NN h)) (PP (IN after) (NP (NP (NN activation)) (PP (IN by) (NP (NN PMA+ionomycin)))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN study)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NNS oxLDLs)) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NP (JJ activation-induced) (NN p65/p50) (NN NF-kappaB) (NN heterodimer) (NN binding)) (PP (TO to) (NP (NN DNA))))))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (DT the) (JJ constitutive) (JJ nuclear) (NN form)) (PP (IN of) (NP (NN p50) (NN dimer)))))) (VP (VBD was) (ADJP (JJ unchanged))))) (. .)))
(TOP (S (NP (DT This)) (VP (VBD was) (VP (VBN correlated) (PP (IN with) (NP (NP (DT an) (JJ unchanged) (NN level)) (PP (IN of) (NP (NP (DT the) (JJ active) (NN form)) (PP (IN of) (NP (DT the) (JJ cytosolic) (NN inhibitor) (NN protein) (NN IkappaB-alpha))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ immunosuppressive) (NN effect)) (PP (IN of) (NP (NNS oxLDLs)))) (VP (MD might) (VP (VB operate) (PP (IN via) (NP (NP (DT a) (NN dysregulation)) (PP (IN of) (NP (DT the) (NN T-lymphocyte) (NN activation) (NNS mechanisms)))))))))) (. .)))
(TOP (S (S (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (DT the) (NN CCAAT-box) (NN binding) (NN factor) (NN NF-Y)))) (VP (VBZ is) (VP (VBN modulated) (PP (IN through) (NP (NP (DT the) (VBN regulated) (NN expression)) (PP (IN of) (NP (PRP$ its) (NN A) (NN subunit))))) (PP (IN during) (NP (NP (NN monocyte)) (PP (TO to) (NP (NN macrophage))) (NP (NN differentiation))))))) (: :) (NP (NP (NN regulation)) (PP (IN of) (NP (JJ tissue-specific) (NNS genes))) (PP (IN through) (NP (DT a) (JJ ubiquitous) (NN transcription) (NN factor)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD analyzed) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NN NF-Y) (NN expression))) (PP (IN during) (NP (NP (JJ human) (NN monocyte)) (PP (TO to) (NP (NN macrophage) (NN maturation))))))) (. .)))
(TOP (S (NP (NN NF-Y)) (VP (VBZ is) (NP (DT a) (ADJP (ADJP (JJ ubiquitous)) (CC and) (ADJP (RB evolutionarily) (VBN conserved))) (NN transcription) (NN factor) (SBAR (WHNP (WDT that)) (S (VP (VBZ binds) (ADVP (RB specifically)) (PP (TO to) (NP (DT the) (NN CCAAT) (NN motif) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (JJ 5') (NN promoter) (NN region)) (PP (IN of) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NNS genes))))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP show) (ADVP (RB here)) (SBAR (IN that) (S (PP (IN in) (NP (VBG circulating) (NNS monocytes))) (, ,) (NP (NN NF-Y) (NN binding) (NN activity)) (VP (VBZ is) (RB not) (VP (VBN detected) (PP (IN on) (NP (DT the) (NN CCAAT) (NN motif) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (NNS promoters)) (PP (IN of) (NP (NNS genes))) (PP (JJ such) (IN as) (NP (NP (NP (JJ major) (NN histocompatibility) (NN complex)) (PRN (-LRB- -LRB-) (NP (NN MHC)) (-RRB- -RRB-)) (NP (NN class) (CD II))) (, ,) (NP (NN gp91-phox)) (, ,) (NP (NN mig)) (, ,) (CC and) (NP (NN fibronectin)))))))))))) (, ,) (SBAR (IN whereas) (S (PP (IN during) (NP (NN macrophage) (NN differentiation))) (, ,) (NP (NP (DT a) (JJ progressive) (NN increase)) (PP (IN in) (NP (NN NF-Y) (NN binding) (NN activity)))) (VP (VBZ is) (VP (VBN observed) (PP (IN on) (NP (DT these) (NNS promoters))))))))) (. .)))
(TOP (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NN NF-Y) (NN subunit) (NN expression)))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NN NF-Y) (NN activity)) (PP (IN in) (NP (VBG circulating) (NNS monocytes)))))) (VP (VBZ is) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (DT the) (NN A) (NN subunit)))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN addition)) (PP (IN of) (NP (DT the) (JJ recombinant) (NN NF-YA) (NN subunit)))) (VP (VBZ restores) (NP (NN NF-Y) (NN binding))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NN NF-YA) (NN protein)))) (VP (VBZ is) (ADJP (JJ due) (PP (PP (TO to) (NP (JJ posttranscriptional) (NN regulation))) (CC and) (RB not) (PP (TO to) (NP (DT a) (JJ specific) (JJ proteolytic) (NN activity))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN fact))) (, ,) (NP (NN NF-YA) (NN mRNA)) (VP (VBZ is) (ADJP (JJ present) (PP (IN at) (NP (DT the) (JJ same) (NN level))) (PP (IN at) (NP (NP (DT all) (NNS days)) (PP (IN of) (NP (NN monocyte) (NN cultivation))))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (NN protein)) (VP (VP (VBZ is) (ADJP (JJ absent) (PP (IN in) (NP (RB freshly) (VBN isolated) (NNS monocytes))))) (CC but) (VP (VBZ is) (VP (ADVP (RB progressively)) (VBN synthesized) (PP (IN during) (NP (DT the) (NN maturation) (NN process)))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB thus)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (NN NF-YA) (NN subunit)) (VP (VBZ plays) (NP (NP (DT a) (JJ relevant) (NN role)) (PP (IN in) (VP (VBG activating) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (NNS genes)) (ADJP (RB highly) (VBN expressed)) (PP (IN in) (NP (JJ mature) (NNS monocytes))))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NN line)) (PP (IN with) (NP (DT this) (NN conclusion))))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NN cut/CDP) (NN protein)) (, ,) (NP (NP (DT a) (JJ transcriptional) (NN repressor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ inhibits) (NP (JJ gpc91-phox) (NN gene) (NN expression)) (PP (IN by) (S (VP (VBG preventing) (NP (NP (NN NF-Y) (NN binding)) (PP (TO to) (NP (DT the) (NN CAAT) (NN box))))))))))) (, ,)) (VP (VBZ is) (ADJP (JJ absent) (PP (IN in) (NP (NNS monocytes)))))))) (. .)))
(TOP (S (VP (VBG Accessing) (NP (JJ Epstein-Barr) (JJ virus-specific) (NN T-cell) (NN memory)) (PP (IN with) (NP (JJ peptide-loaded) (JJ dendritic) (NNS cells)))) (. .)))
(TOP (S (NP (NP (DT The) (JJ conventional) (NNS means)) (PP (IN of) (S (VP (VBG studying) (NP (ADJP (NP (NP (JJ Epstein-Barr) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN EBV)) (-RRB- -RRB-))) (JJ -induced)) (NP (NP (NP (JJ cytotoxic) (NN T-lymphocyte)) (PRN (-LRB- -LRB-) (NP (NN CTL)) (NP (-RRB- -RRB-)))) (NN memory))) (, ,) (PP (IN by) (NP (NP (ADJP (FW in) (FW vitro)) (NN stimulation)) (PP (IN with) (NP (DT the) (ADJP (RB latently) (JJ infected) (JJ autologous)) (NP (NP (JJ lymphoblastoid) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NN LCL)) (-RRB- -RRB-))))))) (, ,))))) (VP (VBZ has) (NP (JJ important) (NNS limitations))) (. .)))
(TOP (S (S (ADVP (RB First)) (, ,) (NP (PRP it)) (VP (VBZ gives) (NP (NP (DT no) (NN information)) (PP (IN on) (NP (NN memory)))) (PP (TO to) (NP (JJ lytic) (NN cycle) (NNS antigens))))) (: ;) (S (ADVP (JJ second)) (, ,) (NP (PRP it)) (ADVP (RB preferentially)) (VP (VBZ amplifies) (NP (NP (DT the) (JJ dominant) (NNS components)) (PP (IN of) (NP (JJ latent) (JJ antigen-specific) (NN memory))) (PP (IN at) (NP (NP (DT the) (NN expense)) (PP (IN of) (NP (JJ key) (JJ subdominant) (NNS reactivities)))))))) (. .)))
(TOP (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT an) (JJ alternative) (NN approach)) (, ,) (VP (VBN based) (PP (IN on) (NP (NP (ADJP (FW in) (FW vitro)) (NN stimulation)) (PP (IN with) (NP (NP (NN epitope) (JJ peptide-loaded) (JJ dendritic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS DCs)) (-RRB- -RRB-))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ allows) (NP (PRP one)) (VP (TO to) (VP (VB probe) (NP (DT the) (NN CTL) (NN repertoire)) (PP (IN for) (NP (NP (DT any) (JJ individual) (NN reactivity)) (PP (IN of) (NP (NN choice))))))))))))) (: ;) (S (NP (DT this) (NN method)) (VP (VBD proved) (ADJP (ADVP (RB significantly) (RBR more)) (JJ efficient) (PP (IN than) (NP (NN stimulation) (PP (IN with) (NP (NP (NN peptide)) (ADVP (RB alone))))))))) (. .)))
(TOP (S (S (VP (VBG Using) (NP (DT this) (NN approach)))) (NP (PRP we)) (VP (ADVP (RB first)) (VBP show) (SBAR (IN that) (S (NP (NP (NNS reactivities)) (PP (TO to) (NP (NP (DT the) (ADJP (NN immunodominant) (CC and) (NN subdominant)) (NN lytic) (NN cycle) (NNS epitopes)) (VP (VBN identified) (PP (IN by) (NP (NN T) (NNS cells))) (PP (IN during) (NP (JJ primary) (NN EBV) (NN infection))))))) (VP (VBP are) (ADJP (RB regularly) (JJ detectable)) (PP (IN in) (NP (NP (DT the) (NN CTL) (NN memory)) (PP (IN of) (NP (NN virus) (NNS carriers))))))))) (: ;) (S (NP (DT this)) (VP (VBZ implies) (SBAR (IN that) (S (PP (IN in) (NP (JJ such) (NNS carriers))) (NP (JJ chronic) (NN virus) (NN replication)) (VP (VBZ remains) (PP (IN under) (NP (JJ direct) (NN T-cell) (NN control)))))))) (. .)))
(TOP (S (S (NP (PRP We)) (ADVP (RB further)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (JJ subdominant) (JJ latent) (NN cycle) (NNS reactivities)) (PP (TO to) (NP (NP (NNS epitopes)) (PP (IN in) (NP (DT the) (JJ latent) (NN membrane) (NN protein) (NN LMP2))))) (, ,) (SBAR (IN though) (S (ADJP (ADJP (RB rarely) (JJ undetectable)) (PP (IN in) (NP (JJ LCL-stimulated) (NNS populations)))))) (, ,)) (VP (MD can) (VP (VB be) (VP (VP (VBN reactivated) (PP (IN by) (NP (NN DC) (NN stimulation)))) (CC and) (VP (ADVP (RB selectively)) (VBN expanded) (PP (IN as) (NP (JJ polyclonal) (NN CTL) (NNS lines))))))))))) (: ;) (S (NP (NP (DT the) (JJ adoptive) (NN transfer)) (PP (IN of) (NP (JJ such) (NNS preparations)))) (VP (MD may) (VP (VB be) (PP (IN of) (NP (NN value))) (PP (IN in) (VP (VBG targeting) (NP (JJ certain) (JJ EBV-positive) (NNS malignancies))))))) (. .)))
(TOP (NP (NP (NP (JJ Differential) (NN monocyte) (NN adhesion)) (CC and) (NP (NN adhesion) (NN molecule) (NN expression))) (PP (IN in) (NP (ADJP (JJ venous) (CC and) (JJ arterial)) (JJ endothelial) (NNS cells))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD compared) (NP (NP (NN U-937) (NN cell) (NN adhesion)) (CC and) (NP (NN adhesion) (NN molecule) (NN expression))) (PP (IN in) (NP (NP (JJ human) (JJ umbilical) (JJ venous) (PRN (-LRB- -LRB-) (NP (NNS HUVECs)) (-RRB- -RRB-)) (CC and) (JJ arterial) (PRN (-LRB- -LRB-) (NP (NNS HUAECs)) (-RRB- -RRB-)) (JJ endothelial) (NNS cells)) (VP (VBN exposed) (PP (TO to) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (, ,) (NP (NN interleukin-1)) (, ,) (CC and) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NNS LPS)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP (NN TNF) (CC and) (NN LPS)) (VP (VBN stimulated) (NP (NP (JJ vascular) (NN cell) (NN adhesion) (NN molecule) (PRN (-LRB- -LRB-) (NP (NN VCAM)) (-RRB- -RRB-)) (CD -1) (NN surface) (NN expression)) (CC and) (NP (NP (NN adhesion)) (PP (IN of) (NP (NN U-937) (JJ monocyte-like) (NNS cells))) (PP (PP (TO to) (NP (NNS HUVECs))) (CC but) (RB not) (PP (TO to) (NP (NNS HUAECs))))))) (. .)))
(TOP (S (NP (NN Antibody) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (PP (IN in) (NP (NNS HUVECs))) (NP (NP (QP (IN at) (JJS least) (CD 75)) (NN %)) (PP (IN of) (NP (DT the) (NN adhesion) (NN response)))) (VP (VBZ is) (ADJP (NN VCAM-1) (VBN mediated)))))) (. .)))
(TOP (S (NP (NN Interleukin-1)) (VP (VBD stimulated) (NP (NP (NP (NN U-937) (NN cell) (NN adhesion)) (PP (TO to))) (CC and) (NP (NP (NN VCAM-1) (NN surface) (NN expression)) (PP (IN in) (NP (CC both) (NNS HUVECs) (CC and) (NNS HUAECs)))))) (. .)))
(TOP (S (NP (NP (NN Pyrrolidinedithiocarbamate)) (CC and) (NP (DT the) (NN proteasome) (NN inhibitor) (NN MG-132))) (VP (VBD blocked) (NP (NP (ADJP (NN TNF-) (CC and) (JJ LPS-stimulated)) (NN U-937) (NN cell) (NN adhesion)) (PP (TO to) (NP (NNS HUVECs))))) (. .)))
(TOP (S (NP (DT These) (NNS agents)) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBD decreased) (NP (NP (ADJP (NN TNF-) (CC and) (JJ LPS-stimulated)) (NNS increases)) (PP (IN in) (NP (NN HUVEC) (NN surface) (NN VCAM-1))))) (. .)))
(TOP (S (NP (NN TNF)) (VP (VBD increased) (NP (NP (NP (NP (NN VCAM-1) (NN protein)) (CC and) (NP (NN mRNA))) (PP (IN in) (NP (NNS HUVECs)))) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (VP (VBN blocked) (PP (IN by) (NP (NN pyrrolidinedithiocarbamate))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (CC neither) (NN TNF) (CC or) (NN LPS)) (VP (VBD stimulated) (NP (NP (NN VCAM-1) (NN expression)) (PP (IN in) (NP (NNS HUAECs))))) (. .)))
(TOP (S (NP (NN TNF)) (VP (VBD stimulated) (NP (NP (NN expression)) (PP (IN of) (NP (CC both) (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (CC and) (NP (NN E-selectin)))) (PP (IN in) (NP (NNS HUVECs))))) (, ,) (CC but) (S (PP (IN in) (NP (NNS HUAECs))) (, ,) (ADVP (RB only)) (NP (JJ intercellular) (NN adhesion) (NN molecule-1)) (VP (VBD was) (VP (VBN increased)))) (. .)))
(TOP (S (NP (JJ Electrophoretic) (NN mobility) (NN shift) (NNS assays)) (VP (VBD demonstrated) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (JJ TNF-stimulated) (JJ nuclear) (NN factor-kappaB) (NN activation))))) (PP (IN between) (NP (NNS HUVECs) (CC and) (NNS HUAECs))))) (. .)))
(TOP (S (NP (DT These) (NNS studies)) (VP (VP (VBP demonstrate) (NP (NP (DT a) (ADJP (JJ novel) (CC and) (JJ striking)) (NN insensitivity)) (PP (IN of) (NP (JJ arterial) (NN endothelium))) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN TNF) (CC and) (NN LPS))))))) (CC and) (VP (VBP indicate) (NP (NP (DT a) (NN dissociation)) (PP (IN between) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNS HUAECs))) (S (VP (TO to) (VP (VB upregulate) (NP (NP (JJ nuclear) (NN factor-kappaB)) (CC and) (NP (NN VCAM-1))))))))))) (. .)))
(TOP (S (NP (NP (NN Tissue) (NN factor) (NN expression)) (PP (IN of) (NP (JJ human) (NNS monocytes)))) (VP (VBZ is) (VP (VBN suppressed) (PP (IN by) (NP (NN lysophosphatidylcholine))))) (. .)))
(TOP (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NN tissue) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TF)) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (JJ principal) (NN initiator)) (PP (IN of) (NP (NN coagulation)))) (, ,)))) (VP (VBZ is) (VP (VBN increased) (PP (IN during) (NP (NN inflammation) (CC and) (NN atherosclerosis))))) (. .)))
(TOP (S (NP (DT Both) (NNS conditions)) (VP (VBP are) (VP (VBN promoted) (PP (IN by) (NP (NP (NN lysophosphatidylcholine)) (PRN (-LRB- -LRB-) (NP (NN lysoPC)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD observed) (PP (IN in) (NP (NP (DT the) (JJ present) (NN study)) (SBAR (IN that) (S (NP (NP (NN lysoPC)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (TO to) (CD 10)) (NN micromol/L)) (-RRB- -RRB-))) (VP (ADVP (RB dose-dependently)) (VBD reduced) (NP (NP (NN TF) (NN activity)) (PP (IN in) (NP (JJ human) (NNS monocytes))) (, ,) (SBAR (IN as) (S (VP (VBN elicited) (PP (IN by) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-)))))))))))))) (. .)))
(TOP (S (NP (NP (NN Lysophosphatidylethanolamine)) (PRN (-LRB- -LRB-) (NP (NN lysoPE)) (-RRB- -RRB-)) (CC and) (NP (JJ other) (NNS lysophospholipids))) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (JJ LPS-induced) (NN TF) (NN activity)) (PP (IN of) (NP (JJ human) (NNS monocytes)))))) (. .)))
(TOP (S (NP (NN TF) (NN antigen) (NN expression)) (SBAR (IN as) (S (VP (VBN elicited) (PP (IN by) (NP (NN LPS)))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN lowered) (PP (IN by) (NP (NN lysoPC))))) (. .)))
(TOP (S (NP (NN Phospholipid) (NNS analyses)) (VP (VBD indicated) (NP (NP (DT a) (JJ selective) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN lysoPC) (NN content)) (PP (IN of) (NP (DT the) (NNS monocytes))))) (PP (IN after) (NP (NN preincubation) (PP (IN with) (NP (DT the) (NN lysophospholipid))))))) (. .)))
(TOP (S (NP (NN LysoPC)) (VP (VBD inhibited) (NP (NP (DT the) (NN TF) (NN activity)) (PP (IN of) (NP (NN Mono) (NN Mac-6) (NNS cells))) (PP (TO to) (NP (DT a) (JJ similar) (NN extent))) (PP (IN as) (PP (IN in) (NP (DT the) (NNS monocytes)))))) (. .)))
(TOP (S (NP (NP (NP (NN LPS) (NN binding)) (PP (TO to) (NP (NN plasma) (NN membrane) (NNS receptors)))) (CC and) (NP (NP (NN internalization)) (PP (IN of) (NP (NN LPS))) (PP (IN into) (NP (NNS monocytes))))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN lysoPC))))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ LPS-mediated) (JJ nuclear) (NN binding)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappaB/Rel))) (PP (TO to) (NP (DT a) (JJ TF-specific) (NN kappaB) (NN site)))) (VP (VBD was) (VP (VBN inhibited) (PP (IN by) (NP (NN lysoPC))))) (. .)))
(TOP (S (NP (NP (NN Induction)) (PP (IN of) (NP (NN TF) (NN mRNA) (NN expression))) (PP (IN by) (NP (NN LPS)))) (VP (VBD tended) (S (VP (TO to) (VP (VB be) (ADVP (RB partially)) (VP (VBN reduced) (PP (IN by) (NP (DT the) (NN lysophospholipid)))))))) (. .)))
(TOP (S (NP (NP (NN Preincubation)) (PP (IN with) (NP (NN lysoPC)))) (VP (VBD increased) (NP (JJ monocytic) (NN cAMP) (NNS levels))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ adenylyl) (NN cyclase))) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (JJ 2'-deoxy-3'-adenosine) (NN monophosphate)))))) (VP (ADVP (RB partially)) (VBD reversed) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (NN TF) (NN activity)) (VP (VBN promoted) (PP (IN by) (NP (NN lysoPC)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN lysoPC)) (VP (ADVP (RB markedly)) (VBZ decreases) (NP (NP (JJ LPS-mediated) (NN TF) (NN expression)) (PP (IN of) (NP (JJ human) (NNS monocytes))))) (, ,) (S (NP (DT the) (NN effect)) (VP (ADVP (RB probably)) (VBG being) (VP (VBN mediated) (PP (IN by) (NP (CC both) (ADJP (JJ transcriptional) (CC and) (JJ posttranscriptional)) (NNS mechanisms)))))) (. .)))
(TOP (S (NP (NN LysoPC)) (VP (MD may) (ADVP (RB thus)) (VP (VB attenuate) (NP (NP (NN activation)) (PP (IN of) (NP (NN coagulation)))) (PP (IN during) (NP (NN inflammation) (CC and) (NN atherosclerosis))))) (. .)))
(TOP (NP (NP (JJ Intranuclear) (VBN targeted) (NN delivery)) (PP (IN of) (NP (JJ functional) (NN NF-kappaB))) (PP (IN by) (NP (CD 70) (NN kDa) (NN heat) (NN shock) (NN protein))) (. .)))
(TOP (S (NP (NP (DT The) (CD 70) (NN kDa) (NN heat) (NN shock) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN Hsp70)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB highly) (VBN conserved)) (, ,) (JJ ubiquitous) (NN protein)) (VP (VBN involved) (PP (IN in) (S (VP (VBG chaperoning) (NP (NNS proteins)) (PP (TO to) (NP (JJ various) (JJ cellular) (NNS organelles))))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (VP (VBN added) (ADVP (RB exogenously)) (PP (TO to) (NP (NNS cells))))) (, ,) (S (NP (NN Hsp70)) (VP (VBZ is) (VP (ADVP (RB readily)) (VBN imported) (PP (IN into) (NP (CC both) (ADJP (JJ cytoplasmic) (CC and) (JJ nuclear)) (NNS compartments))) (PP (IN in) (NP (DT a) (JJ cell-type-specific) (NN fashion)))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD exploited) (NP (NP (DT this) (NN ability)) (PP (IN of) (NP (NN Hsp70))) (S (VP (TO to) (VP (VB deliver) (NP (NP (NN NF-kappaB)) (, ,) (NP (NP (DT a) (JJ key) (JJ transcriptional) (NN regulator)) (PP (IN of) (NP (JJ inflammatory) (NNS responses)))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT a) (NN fusion) (NN protein)) (VP (VBN composed) (PP (IN of) (NP (NP (DT a) (JJ C-terminal) (NN Hsp70) (NN peptide)) (CC and) (NP (NP (DT the) (NN p50) (NN subunit)) (PP (IN of) (NP (NN NF-kappaB)))))))) (VP (VP (VBD was) (VP (VBN directed) (PP (IN into) (NP (NP (DT the) (NN nucleus)) (PP (IN of) (NP (NNS cells))))))) (, ,) (VP (MD could) (VP (VB bind) (NP (NN DNA)) (ADVP (RB specifically)))) (, ,) (CC and) (VP (VBD activated) (NP (NP (NN Igkappa) (NN expression)) (CC and) (NP (NN TNFalpha) (NN production)))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBP propose) (SBAR (IN that) (S (NP (NN Hsp70)) (VP (MD can) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN vehicle)) (PP (IN for) (NP (NP (ADJP (JJ intracytoplasmic) (CC and) (JJ intranuclear)) (NN delivery)) (PP (IN of) (NP (NNS proteins) (CC or) (NN DNA))))))) (S (VP (TO to) (VP (VB modulate) (NP (NN gene) (NN expression))) (CC and) (ADVP (RB thereby)) (VP (VB control) (NP (JJ immune) (NNS responses))))))))))) (. .)))
(TOP (NP (NN Regulation) (PP (IN of) (NP (NN IL-4) (NN expression))) (PP (IN by) (NP (DT the) (NN transcription) (NN factor) (NN JunB))) (PP (IN during) (NP (NN T) (NN helper) (NN cell) (NN differentiation))) (. .)))
(TOP (S (NP (NP (DT The) (JJ molecular) (NN basis)) (PP (IN for) (NP (NP (JJ restricted) (NN cytokine) (NN expression)) (PP (IN by) (NP (ADJP (NP (NP (NN T) (NN helper) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN Th1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN T) (NN helper) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Th2)) (-RRB- -RRB-)))) (NNS cells)))))) (VP (VBZ is) (ADJP (JJ unclear))) (. .)))
(TOP (S (NP (JJ Previous) (NNS studies)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NN P1)) (, ,) (NP (NP (DT an) (NN element)) (PP (IN of) (NP (ADJP (NP (DT the) (NN interleukin) (CD 4)) (PRN (-LRB- -LRB-) (NP (NN IL-4)) (-RRB- -RRB-))) (NP (NN promoter)) (SBAR (WHNP (WDT that)) (S (VP (VBZ binds) (NP (NN AP-1)))))))) (, ,)) (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (NP (JJ Th2-restricted) (NN IL-4) (NN expression)))))))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN JunB)) (, ,) (CC but) (RB not) (NP (DT the) (JJ other) (NN Jun) (NN family) (NNS members)) (, ,)) (VP (VBD was) (ADVP (RB selectively)) (VP (VBN induced) (PP (PP (IN in) (NP (NN Th2) (NNS cells))) (CC and) (RB not) (PP (IN in) (NP (NN Th1) (NNS cells)))) (PP (IN during) (NP (NN differentiation)))))))) (. .)))
(TOP (S (NP (NN JunB)) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ negative) (NN regulator)) (PP (IN of) (NP (NN transcription)))))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NN JunB)) (VP (VP (VBZ binds) (ADVP (RB directly)) (PP (TO to) (NP (DT the) (NN P1) (NN site)))) (CC and) (VP (VBZ synergizes) (PP (IN with) (NP (NN c-Maf))) (S (VP (TO to) (VP (VB activate) (NP (DT an) (NN IL-4) (NN luciferase) (NN reporter) (NN gene)))))))))) (. .)))
(TOP (S (NP (NP (NN JunB-control)) (PP (IN of) (NP (NN IL-4) (NN expression)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN JunB))) (PP (IN at) (NP (NN Thr102) (CC and) (CD -104))) (PP (IN by) (NP (NN JNK) (NN MAP) (NN kinase))))))) (. .)))
(TOP (S (NP (NP (DT The) (NN synergy)) (PP (IN between) (NP (NN c-Maf) (CC and) (NN JunB)))) (VP (MD can) (VP (VB be) (VP (VBN attributed) (PP (TO to) (NP (NP (JJ cooperative) (NN DNA) (NN binding)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN facilitated) (PP (IN by) (NP (NN JunB) (NN phosphorylation)))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (JJ transgenic) (NNS mice))) (, ,) (NP (JJ elevated) (NN JunB) (NNS levels)) (VP (VBD caused) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (JJ several) (NN Th2) (NNS cytokines))) (PP (IN in) (NP (VBG developing) (NN Th1) (NNS cells))))) (. .)))
(TOP (S (NP (NN JunB)) (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN IL-4) (NN expression)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NN immunization))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (JJ early) (NN increase)) (PP (IN of) (NP (NN JunB) (NN protein))) (PP (IN in) (NP (NN Th2) (NNS cells)))) (VP (VP (MD can) (VP (VB provide) (NP (NP (DT the) (NN specificity)) (PP (IN for) (NP (NN c-Maf))) (PP (IN in) (NP (NN IL-4) (NN expression)))) (PP (IN during) (NP (NN T) (NN cell) (NN development))))) (CC and) (VP (VBZ directs) (ADVP (RB thereby)) (NP (NN Th2) (NN differentiation)))) (. .)))
(TOP (NP (NP (JJ Immunohistochemical) (NN study)) (PP (IN of) (NP (NP (JJ c-fos-positive) (NNS lymphocytes)) (VP (VBN infiltrated) (PP (IN into) (NP (NP (JJ human) (JJ squamous) (NN cell) (NNS carcinomas)) (PP (IN of) (NP (DT the) (NN head) (CC and) (NN neck))))) (PP (IN during) (NP (NP (NN radiation) (NN therapy)) (CC and) (NP (PRP$ its) (JJ clinical) (NN significance))))))) (. .)))
(TOP (S (NP (NN C-fos)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ immediate) (JJ early) (NNS genes)) (PP (IN in) (NP (NN signal) (NN transduction) (NNS systems)))))) (PP (IN after) (NP (NP (JJ many) (NNS kinds)) (PP (IN of) (NP (NNS stresses))) (, ,) (PP (VBG including) (NP (VBG ionizing) (NN radiation))))))))))) (. .)))
(TOP (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NN c-fos) (NN expression)) (VP (VBN induced) (PP (IN by) (NP (NN radiation) (NN therapy))) (PP (IN in) (NP (NN tumor) (NNS tissues))))))) (VP (VBP have) (RB not) (ADVP (RB yet)) (VP (VBN been) (VP (VBN reported)))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN attempted) (VP (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NN c-fos) (NN expression)) (VP (VBZ is) (VP (VBN induced) (PP (IN by) (NP (NN radiotherapy))) (PP (IN in) (NP (NP (JJ human) (JJ squamous) (NN cell) (NNS carcinomas)) (PP (IN of) (NP (DT the) (NN head) (CC and) (NN neck)))))))))))) (CC and) (S (VP (TO to) (VP (VB establish) (NP (NP (DT a) (JJ possible) (NN correlation)) (PP (IN between) (NP (NP (NN c-fos) (NN expression)) (CC and) (NP (NP (DT the) (JJ therapeutic) (NNS effects)) (PP (IN of) (NP (NN radiation) (NN therapy))))))))))))) (. .)))
(TOP (S (NP (NP (CD Twenty-seven) (NNS patients)) (PP (IN with) (NP (NP (NNS tumors)) (PP (IN of) (NP (NP (DT the) (JJ oral) (NN cavity)) (, ,) (NP (NN oropharynx)) (, ,) (CC and) (NP (JJ maxillary) (NN sinus))))))) (VP (VBD were) (VP (VBN examined))) (, ,) (S (WHNP (NP (DT all)) (WHPP (IN of) (WHNP (WDT which)))) (VP (VBD were) (VP (VBN confirmed) (PP (IN as) (NP (JJ squamous) (NN cell) (NNS carcinomas)))))) (. .)))
(TOP (S (PP (IN After) (S (VP (VBG obtaining) (NP (NP (DT the) (NNS patients) (POS ')) (VBN informed) (NN consent))))) (, ,) (NP (NNS biopsies)) (VP (VP (VBD were) (VP (VBN performed) (PP (PP (IN before) (NP (NN treatment))) (CC and) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (QP (CD 4) (, ,) (CD 10) (, ,) (CC and) (CD 20)) (NN Gy)) (PP (IN of) (NP (NN radiotherapy))))))))))) (. .) (CC and) (S (NP (DT the) (NNS specimens)) (VP (VBD were) (VP (VBN preserved) (PP (IN in) (NP (JJ liquid) (NN nitrogen))) (PP (IN for) (NP (JJ further) (NN examination)))))) (, ,)))
(TOP (S (S (NP (NP (JJ Serial) (NN sectioning)) (PP (IN of) (NP (CD 6) (NN micrometer)))) (VP (VBD was) (VP (VBN performed) (S (VP (VBG using) (NP (DT a) (NN cryostat))))))) (, ,) (CC and) (S (NP (NNS samples)) (VP (VBD were) (ADVP (RB immunohistochemically)) (VP (VBN stained) (S (VP (VBG using) (NP (NP (DT the) (JJ streptoavidin-biotin) (NN peroxidase) (NN method)) (CC and) (NP (NP (DT a) (JJ monoclonal) (NN antibody)) (PP (IN against) (NP (NN c-fos)))))))))) (. .)))
(TOP (S (NP (QP (CD Three) (IN of) (DT the) (CD 27)) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ squamous) (NN cell) (NN carcinoma))))) (VP (VBD showed) (NP (NP (JJ slight) (NN expression)) (PP (IN of) (NP (NN c-fos)))) (PP (IN in) (NP (PRP$ their) (NN tumor) (NNS cells))) (PP (PP (IN before)) (CC and/or) (PP (IN at) (NP (NP (QP (CD 4) (CC or) (CD 10)) (NN Gy)) (PP (IN of) (NP (NN radiotherapy))))))) (. .)))
(TOP (S (NP (DT The) (NNS tumors)) (VP (VBD showed) (NP (JJ high) (NN radiosensitivity))) (. .)))
(TOP (S (VP (VBG Concerning) (NP (JJ tumor-infiltrating) (NNS lymphocytes))) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (ADJP (JJ moderate) (CC or) (JJ remarkable)) (NNS grades)) (PP (IN of) (NP (JJ c-fos-positive) (NNS lymphocytes))))) (PP (IN before) (NP (NN radiotherapy))) (CC and) (PP (IN at) (NP (NP (NN radiation) (NNS doses)) (PP (IN of) (NP (QP (CD 4) (, ,) (CD 10) (, ,) (CC and) (CD 20)) (NN Gy)))))) (VP (VBD was) (NP (QP (CD 8.0) (, ,) (CD 29.2) (, ,) (CD 4.8) (, ,) (CC and) (CD 0)) (NN %)) (, ,) (ADVP (RB respectively))) (. .)))
(TOP (S (NP (NP (DT The) (NN relationship)) (PP (IN between) (NP (NP (DT the) (JJ immunohistochemical) (NNS findings)) (CC and) (NP (NP (DT the) (NN antitumor) (NN effect)) (PP (IN at) (NP (NP (DT a) (NN radiation) (NN dose)) (PP (IN of) (NP (CD 20) (NN Gy))))))))) (VP (VBD was) (VP (VBN examined) (PP (IN on) (NP (DT the) (JJ corresponding) (NN H) (CC &) (JJ E-stained) (NNS sections))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (NNS patients)) (SBAR (WHNP (WP$ whose) (NP (NP (NN infiltration)) (PP (IN of) (NP (JJ c-fos-positive) (NNS lymphocytes))) (PP (IN into) (NP (NN tumor) (NNS tissues))))) (S (VP (VBD were) (ADJP (JJ moderate) (CC or) (JJ remarkable)) (PP (IN at) (NP (NP (CD 4) (NN Gy)) (PP (IN of) (NP (NN radiotherapy)))))))))) (, ,) (S (NP (DT the) (NNS tumors)) (VP (VBD responded) (ADVP (RB significantly) (RB well)) (PP (TO to) (NP (NN radiation) (NN therapy))) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.025)))) (, ,) (NP (NN chi2) (NN test)) (-RRB- -RRB-)))) (, ,) (CC and) (S (NP (DT the) (NNS patients)) (VP (VBD took) (NP (DT a) (ADJP (RB significantly) (JJ favorable)) (JJ clinical) (NN course)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.05)))) (, ,) (NP (NN chi2) (NN test)) (-RRB- -RRB-)))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT a) (NN sample)) (PP (IN from) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS patients))))))) (, ,) (NP (JJ c-fos-positive) (NNS lymphocytes)) (VP (VBD were) (VP (VBN identified) (PP (IN as) (NP (NP (NN CD4) (JJ positive)) (CC and) (NP (NN CD8) (JJ negative)))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (JJ high) (NN radiosensitivity)) (PP (IN of) (NP (NP (JJ squamous) (NN cell) (NNS carcinomas)) (PP (IN in) (NP (PRP$ our) (NNS samples)))))) (VP (MD could) (VP (VB be) (NP (VBN explained) (PP (IN by) (NP (NP (DT an) (NN overexpression)) (PP (IN of) (NP (NN c-fos))) (PP (IN in) (NP (NP (DT the) (JJ tumor-infiltrating) (NNS lymphocytes)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ small) (NNS doses)) (PP (IN of) (NP (NN radiation) (NN therapy))))))))))))) (, ,) (CC and) (S (NP (DT these) (VBN activated) (NNS lymphocytes)) (VP (VBD exerted) (NP (DT a) (JJ cytotoxic) (NN effect)) (PP (IN against) (NP (DT the) (NN cancer) (NNS cells))))) (. .)))
(TOP (S (NP (NN CD2) (NN signalling)) (VP (VBZ induces) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN CREB)))) (PP (IN in) (NP (JJ primary) (NNS lymphocytes)))) (. .)))
(TOP (S (NP (NP (NN Promoter) (NNS sequences)) (ADJP (JJ responsive) (PP (TO to) (NP (NP (JJ cyclic) (NN AMP)) (PRN (-LRB- -LRB-) (NP (NN cAMP)) (-RRB- -RRB-)))))) (VP (VP (VBP are) (VP (VBN found) (PP (IN in) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ cellular) (NNS genes))))))) (, ,) (CC and) (VP (VBP bind) (NP (NP (NN transcription) (NNS factors)) (PP (IN of) (NP (NP (NP (DT the) (NN cAMP) (NN response) (NN element) (NN binding) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN CREB)) (-RRB- -RRB-))) (: /) (NP (NP (JJ activating) (NN transcription) (NN factor-1)) (PRN (-LRB- -LRB-) (NP (NN ATF-1)) (-RRB- -RRB-)) (NP (NN family)))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN used) (NP (NP (DT a) (JJ human) (JJ T-lymphotropic) (NN virus) (NN type) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN HTLV-1)) (-RRB- -RRB-)) (NP (NP (NN model)) (PP (IN of) (NP (NP (NN cAMP) (NN response) (NN element)) (PRN (-LRB- -LRB-) (NP (NN CRE)) (-RRB- -RRB-)) (NP (NN transcription)))) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NN lymphocyte) (NN activation))) (PP (IN on) (NP (NP (NN transcription)) (PP (IN from) (NP (NP (JJ homologous) (NNS regions)) (PP (IN in) (NP (DT the) (JJ viral) (NN promoter)))))))))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD demonstrated) (VP (VBN increased) (NP (NP (NN HTLV-1) (NN transcription)) (VP (VBG following) (NP (NN CD2)))) (CONJP (CC but) (RB not)) (NP (NN CD3) (NN receptor) (NN cross-linking)))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (IN that) (S (NP (DT this) (VBN increased) (JJ viral) (NN transcription)) (VP (VBD was) (VP (VBN mediated) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (IN through) (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN CREB)))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (NN CD2) (CC and) (NN CD3) (JJ receptor-mediated) (NN signalling)) (PP (IN in) (NP (NP (JJ primary) (JJ human) (JJ peripheral) (NN blood) (JJ mononuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS PBMC)) (-RRB- -RRB-)))))) (. .)))
(TOP (S (NP (NP (NN CD2)) (, ,) (CONJP (CC but) (RB not)) (NP (NN CD3)) (, ,) (NP (NN cross-linking))) (VP (VBD increased) (NP (NP (NN cAMP)) (VP (VBN detected) (PP (IN by) (NP (NP (ADJP (JJ competitive) (JJ enzyme-linked) (JJ immunosorbent)) (NN assay)) (PRN (-LRB- -LRB-) (NP (NN ELISA)) (-RRB- -RRB-)))))) (ADVP (RB approximately) (QP (RB fourfold)))) (. .)))
(TOP (S (NP (NN CD2) (NN cross-linking)) (ADVP (RB concurrently)) (VP (VBD increased) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN CREB))) (VP (VBN detected) (PP (IN by) (NP (NN immunoblot) (NN assay))))) (QP (RB eightfold))) (. .)))
(TOP (S (ADJP (JJ Consistent) (PP (IN with) (NP (JJ post-translational) (NN regulation)))) (, ,) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (JJ total) (NN level)) (PP (IN of) (NP (NN CREB) (NN protein)))))) (VP (VBD was) (VP (VBN observed))) (. .)))
(TOP (S (NP (NP (NN Phosphorylation)) (PP (IN of) (NP (NN CREB)))) (VP (VBD occurred) (PP (IN through) (NP (DT a) (NN herbimycin) (NN A) (CC and) (JJ Rp-cAMP-sensitive) (NN pathway)))) (, ,) (S (VP (VBG suggesting) (S (NP (NN phosphorylation)) (VP (VBD required) (NP (NP (JJ antecedent) (NN activation)) (PP (IN of) (NP (CC both) (NP (NP (NN protein) (NN tyrosine) (NNS kinases)) (PRN (-LRB- -LRB-) (NP (NNS PTK)) (-RRB- -RRB-))) (CC and) (NP (NP (NN protein) (NN kinase) (NN A)) (PRN (-LRB- -LRB-) (NP (NN PKA)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (NP (CC Both) (NN CD2) (CC and) (NN CD3) (NN cross-linking)) (VP (VBD increased) (NP (NP (NN binding)) (PP (IN of) (NP (JJ nuclear) (NNS proteins))) (PP (TO to) (NP (DT a) (JJ radiolabelled) (NN CRE) (NN oligonucleotide) (NN probe))) (PP (IN in) (NP (JJ electrophoretic) (NN mobility) (NN shift) (NNS assays))))) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN lymphocyte) (NN activation)) (VP (VBZ enhances) (NP (NN binding)) (ADVP (RB independently) (PP (IN of) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NN CREB))) (PP (IN at) (NP (NN serine) (CD 133))))))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VP (VBP indicate) (NP (NP (JJ specific) (NN modulation)) (PP (IN of) (NP (NP (DT the) (NN CREB/ATF-1) (NN family)) (PP (IN of) (NP (NN transcription) (NNS factors))))) (PP (IN by) (NP (DT the) (NN CD2) (NN signalling) (NN pathway))))) (CC and) (VP (VBP suggest) (NP (NP (NP (NN CD2) (NN receptor) (NN modulation)) (PP (IN of) (NP (JJ CRE-mediated) (NN transcription))) (VP (VBG following) (NP (NN ligand) (NN engagement)))) (PRN (-LRB- -LRB-) (FW e.g.) (NP (JJ cell-to-cell) (NN contact)) (-RRB- -RRB-))))) (. .)))
(TOP (NP (NP (NP (JJ Protective) (NNS effects)) (PP (IN of) (NP (NN notch-1))) (PP (IN on) (NP (JJ TCR-induced) (NN apoptosis)))) (. .)))
(TOP (S (NP (DT The) (NN Notch) (NN receptor) (NN protein)) (VP (VP (VBD was) (ADVP (RB originally)) (VP (VBN identified) (PP (IN in) (NP (NN Drosophila))))) (CC and) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VP (VB mediate) (NP (ADJP (NN cell) (TO to) (NN cell)) (NN communication))) (CC and) (VP (VB influence) (NP (NN cell) (NN fate) (NNS decisions))))))))) (. .)))
(TOP (S (NP (NP (NNS Members)) (PP (IN of) (NP (DT this) (NN family)))) (VP (VBP have) (VP (VBN been) (VP (VBN isolated) (PP (IN from) (NP (NP (NNS invertebrates)) (CONJP (RB as) (RB well) (IN as)) (NP (NNS vertebrates))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD isolated) (NP (NN mouse) (NN Notch-1)) (PP (IN in) (NP (DT a) (NN yeast) (JJ two-hybrid) (NN screen))) (PP (IN with) (NP (NP (NN Nur77)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (DT a) (NN protein)) (SBAR (WDT that) (S (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (ADVP (RB previously)) (S (VP (TO to) (VP (VB be) (VP (VBN required) (PP (IN for) (NP (NP (NN apoptosis)) (PP (IN in) (NP (NN T) (NN cell) (NNS lines))))))))))))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (NNS data)) (VP (VBN presented) (PP (IN below)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN Notch-1) (NN expression)) (VP (VBZ provides) (NP (JJ significant) (NN protection)) (PP (TO to) (NP (NN T) (NN cell) (NNS lines))) (PP (IN from) (NP (JJ TCR-mediated) (NN apoptosis))))))) (. .)))
(TOP (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (NP (NP (DT a) (JJ new) (JJ antiapoptotic) (NN role)) (PP (IN for) (NP (NN Notch-1))))) (, ,) (S (VP (VBG providing) (NP (NP (NN evidence)) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (S (VP (VBG regulating) (NP (NN cell) (NN fate) (NNS decisions))))))) (, ,) (NP (NN Notch-1)) (VP (MD can) (VP (VB play) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG controlling) (NP (NNS levels) (PP (IN of) (NP (NN cell) (NN death))) (PP (IN in) (NP (NN T) (NNS cells))))))))))))))) (. .)))
(TOP (S (NP (NN T) (NN cell) (NN priming)) (VP (VBZ enhances) (NP (NN IL-4) (NN gene) (NN expression)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ repetitive) (NN activation)) (PP (IN of) (NP (NN T) (NNS cells))) (PRN (-LRB- -LRB-) (NP (NN priming)) (-RRB- -RRB-))) (VP (VBZ enhances) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (JJ many) (NNS cytokines)) (, ,) (PP (JJ such) (IN as) (NP (NN IL-4))) (, ,)) (CONJP (CC but) (RB not)) (NP (NP (NNS others)) (, ,) (PP (JJ such) (IN as) (NP (NN IL-2)))))))) (. .)))
(TOP (S (NP (NP (JJ Molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (JJ selective) (NN expression)) (PP (IN of) (NP (NNS cytokines))) (PP (IN by) (NP (NN T) (NNS cells)))))) (VP (VBP remain) (ADJP (RB poorly) (VBN understood))) (. .)))
(TOP (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN priming)) (PP (IN of) (NP (NN CD4) (NN T) (NNS cells))) (ADVP (RB selectively))) (VP (VBZ enhances) (NP (NP (NN IL-4) (NN expression)) (ADVP (JJ relative) (PP (TO to) (NP (NN IL-2) (NN expression))))) (PP (IN by) (NP (NP (DT a) (JJ transcriptional) (NN mechanism)) (VP (VBG involving) (NP (NP (NP (JJ nuclear) (NN factor)) (PP (IN of) (NP (VBN activated) (NN T) (NNS cells)))) (PRN (-LRB- -LRB-) (NP (NN NFAT)) (-RRB- -RRB-)) (NP (NNS proteins)))))))))) (. .)))
(TOP (S (PP (IN As) (VP (VBN detected) (PP (IN by) (NP (ADJP (FW in) (FW vivo)) (NN footprinting))))) (, ,) (S (VP (NN priming))) (VP (ADVP (RB markedly)) (VBZ increases) (NP (NP (DT the) (JJ activation-dependent) (NN engagement)) (PP (IN of) (NP (NP (DT the) (NN P0) (CC and) (NN P1) (JJ NFAT-binding) (NNS elements)) (PP (IN of) (NP (DT the) (NN IL-4) (NN promoter))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (DT each) (JJ proximal) (NN P) (NN element)) (VP (VBZ is) (ADJP (JJ essential) (PP (IN for) (NP (JJ optimal) (NN IL-4) (NN promoter) (NN activity))))) (. .)))
(TOP (S (NP (ADJP (VBN Activated) (VBN primed)) (NN CD4) (NN T) (NNS cells)) (VP (VP (VBP contain) (ADJP (JJR more) (NP (NN NFAT1)))) (CC and) (VP (VBP support) (ADJP (JJR greater) (NP (JJ NFAT-directed) (NN transcription)))) (PP (IN than) (NP (JJ unprimed) (NN CD4) (NN T) (NNS cells)))) (, ,) (SBAR (IN while) (S (NP (NP (NN activator) (NN protein) (CD 1) (NN binding)) (CC and) (NP (NN activator) (NN protein) (JJ 1-mediated) (NN transcription)) (PP (IN by) (NP (DT both) (NN cell) (NNS types)))) (VP (VBZ is) (ADJP (JJ similar))))) (. .)))
(TOP (S (NP (NP (VBN Increased) (NN expression)) (PP (IN of) (NP (JJ wild-type) (NN NFAT1)))) (VP (ADVP (RB substantially)) (VBZ increases) (NP (NN IL-4) (NN promoter) (NN activity)) (PP (IN in) (NP (JJ unprimed) (NN CD4) (NN T) (NNS cells)))) (, ,) (S (VP (VBG suggesting) (S (NP (NN NFAT1)) (VP (MD may) (VP (VB be) (VP (VBG limiting) (PP (IN for) (NP (NP (NN IL-4) (NN gene) (NN expression)) (PP (IN in) (NP (DT this) (NN cell) (NN type))))))))))) (. .)))
(TOP (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT a) (JJ truncated) (NN form)) (PP (IN of) (NP (NN NFAT1)))) (VP (VBZ acts) (PP (IN as) (NP (DT a) (JJ dominant-negative))) (, ,) (S (VP (VP (VBG reducing) (NP (NN IL-4) (NN promoter) (NN activity)) (PP (IN in) (NP (VBN primed) (NN CD4) (NN T) (NNS cells)))) (CC and) (VP (VBG confirming) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (JJ endogenous) (NN NFAT))) (PP (TO to) (NP (NP (VBN increased) (NN IL-4) (NN gene) (NN expression)) (PP (IN by) (NP (NN effector) (NN T) (NNS cells)))))))))) (. .)))
(TOP (S (NP (NN NFAT1)) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (JJ major) (NN NFAT) (NN family) (NN member)) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ initial) (VBN increased) (NN expression)) (PP (IN of) (NP (NN IL-4))) (PP (IN by) (NP (VBN primed) (NN CD4) (NN T) (NNS cells))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Anoxia/reoxygenation-induced) (NN tolerance)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (JJ polymorphonuclear) (NN leukocyte) (NN adhesion)) (PP (TO to) (NP (VBN cultured) (JJ endothelial) (NNS cells)))))))) (. .)))
(TOP (NP (NP (DT A) (JJ nuclear) (JJ factor-kappaB-mediated) (NN phenomenon)) (. .)))
(TOP (S (S (VP (VBG Exposing) (NP (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NNS HUVECs)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (NN anoxia/reoxygenation)) (PRN (-LRB- -LRB-) (NP (NN A/R)) (-RRB- -RRB-)))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NP (JJ polymorphonuclear) (NN leukocyte)) (PRN (-LRB- -LRB-) (NP (NN PMN)) (-RRB- -RRB-)) (NP (NN adhesion))) (PP (TO to) (NP (NNS HUVECs)))))))) (. .)))
(TOP (S (NP (DT This) (JJ A/R-induced) (NN hyperadhesion)) (VP (VBZ is) (ADVP (RB completely)) (VP (VBN prevented) (PP (IN by) (NP (NP (NP (DT a) (JJ previous)) (PRN (-LRB- -LRB-) (ADVP (NP (CD 24) (NNS hours)) (RBR earlier)) (-RRB- -RRB-)) (NP (NN exposure))) (PP (IN of) (NP (NNS HUVECs))) (PP (TO to) (NP (NN A/R))))))) (. .)))
(TOP (S (NP (DT This) (NN phenomenon)) (VP (VBZ has) (VP (VBN been) (VP (VBN termed) (`` ") (NP (NN A/R) (NN tolerance))))) (. .) ('' ")))
(TOP (S (S (VP (VBG Exposing) (NP (NNS HUVECs)) (PP (TO to) (NP (NN A/R))))) (VP (VBZ induces) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ nuclear) (NN factor) (NN kappaB)) (PRN (-LRB- -LRB-) (NP (NN NF-kappaB)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN HUVEC) (NNS nuclei)))) (PP (IN within) (NP (CD 4) (NNS hours)))) (. .)))
(TOP (S (S (VP (VBG Interfering) (PP (IN with) (NP (NP (CC either) (NN NF-kappaB) (NN activation)) (PRN (-LRB- -LRB-) (NP (NN proteasome) (NN inhibitor)) (-RRB- -RRB-)) (CC or) (NP (NN translocation)) (PRN (-LRB- -LRB-) (NP (NP (JJ double-stranded) (NNS oligonucleotides)) (VP (VBG containing) (NP (NN NF-kappaB) (NN binding) (NN sequence)))) (-RRB- -RRB-)))))) (VP (VBZ prevents) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN A/R) (NN tolerance))))) (PRN (-LRB- -LRB-) (FW ie) (, ,) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (JJ A/R-induced) (NN PMN) (NN adhesion)) (PP (TO to) (NP (NNS HUVECs)))))) (VP (VBZ is) (NP (NP (DT the) (JJ same)) (PP (IN after) (NP (DT the) (ADJP (JJ first) (CC and) (JJ second)) (NN A/R) (NNS challenges)))))) (-RRB- -RRB-)) (. .)))
(TOP (S (NP (NP (NN NO) (NN production)) (PP (IN by) (NP (NNS HUVECs)))) (VP (VBZ is) (VP (VBN increased) (PP (IN after) (NP (DT the) (JJ second) (NN A/R) (NN challenge))) (, ,) (CONJP (CC but) (RB not)) (PP (IN after) (NP (DT the) (JJ first) (NN A/R) (NN challenge))))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (DT NO) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN NOS)) (-RRB- -RRB-)))) (PP (IN during) (NP (DT the) (JJ second) (NN A/R) (NN challenge)))) (VP (VBZ prevents) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN A/R) (NN tolerance)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NN PMN) (NN adhesion)))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (SBAR (IN while) (S (NP (NNS HUVECs)) (VP (VBD contained) (NP (JJ endothelial) (NN NOS) (NN protein))))) (, ,) (NP (DT no) (JJ inducible) (NN NOS)) (VP (VBD was) (VP (VBN detected) (PP (IN in) (NP (CC either) (ADJP (JJ tolerant) (CC or) (JJ nontolerant)) (NNS cells))))) (. .)))
(TOP (S (NP (JJ Further) (NNS studies)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (NN GTP-cyclohydrolase) (CD I)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN enzyme)) (VP (VBN involved) (PP (IN in) (NP (NP (ADJP (FW de) (FW novo)) (NN synthesis)) (PP (IN of) (NP (NP (DT an) (JJ important) (NN cofactor)) (PP (IN for) (NP (NN NOS) (NN activity))) (, ,) (NP (NN tetrahydrobiopterin)))))))) (-RRB- -RRB-))))) (VP (VBD prevented) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NN NO))) (PP (IN in) (NP (JJ A/R-tolerant) (NNS cells)))))))) (. .)))
(TOP (S (NP (NP (JJ Extracellular) (NN generation)) (PP (IN of) (NP (NP (NN NO)) (PRN (-LRB- -LRB-) (NP (NN NO) (NN donor)) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (VP (VB effect) (NP (NP (DT the) (NN hyperadhesion) (NN response)) (VP (VBN induced) (PP (IN by) (NP (DT the) (JJ initial) (NN A/R) (NN challenge))))))) (. .)))
(TOP (S (NP (NN A/R)) (ADVP (RB also)) (VP (VBD induced) (NP (DT an) (JJ oxidant) (NN stress)) (PP (PP (IN in) (NP (JJ naive) (NNS HUVECs))) (, ,) (CONJP (CC but) (RB not)) (PP (IN in) (NP (JJ A/R-tolerant) (NNS HUVECs))))) (. .)))
(TOP (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN NOS))) (PP (IN during) (NP (DT the) (JJ second) (NN A/R) (NN insult)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN generation)) (PP (IN of) (NP (NP (DT an) (JJ oxidant) (NN stress)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN observed) (PP (IN after) (NP (DT the) (JJ first) (NN A/R) (NN challenge)))))))))))) (. .)))
(TOP (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (NP (DT the) (NNS findings)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBP are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN NF-kappaB))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN A/R) (NN tolerance))) (PRN (-LRB- -LRB-) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NN PMN) (NN adhesion))))) (-RRB- -RRB-)) (, ,) (ADVP (RB perhaps)) (PP (IN by) (NP (NP (JJ transcriptional) (NN regulation)) (PP (IN of) (NP (NN GTP-cyclohydrolase))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (VBN increased) (NN NO) (NN production)) (PP (IN during) (NP (DT the) (JJ second) (NN A/R) (NN insult)))) (VP (VBZ reduces) (NP (NN PMN) (NN adhesion)) (ADVP (RBS most) (RB likely)) (PP (IN by) (S (VP (VBG reducing) (NP (NP (DT the) (JJ intracellular) (JJ oxidant) (NN stress)) (VP (VBN induced) (PP (IN by) (NP (NN A/R))))))))) (. .)))
(TOP (NP (NP (NP (NN Involvement)) (PP (IN of) (NP (JJ mitogen-activated) (NN protein) (NN kinase) (NNS pathways))) (PP (IN in) (NP (NP (NN interleukin-8) (NN production)) (PP (IN by) (NP (NP (JJ human) (NNS monocytes)) (CC and) (NP (NP (JJ polymorphonuclear) (NNS cells)) (VP (VBN stimulated) (PP (IN with) (NP (NP (NN lipopolysaccharide)) (CC or) (NP (NN Mycoplasma) (NNS fermentans) (NN membrane) (NNS lipoproteins))))))))))) (. .)))
(TOP (S (NP (NP (NN Interleukin-8)) (PRN (-LRB- -LRB-) (NP (NN IL-8)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (NN chemokine)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ belongs) (PP (TO to) (NP (DT the) (NN alpha-chemokine) (CC or) (NN CXC) (NN subfamily)))) (CC and) (VP (VBZ is) (VP (VBN produced) (PP (IN by) (NP (NP (DT a) (JJ wide) (NN variety)) (PP (IN of) (NP (NP (JJ human) (NNS cells)) (, ,) (S (VP (VBG including) (NP (NP (NNS monocytes)) (CC and) (NP (NP (JJ polymorphonuclear) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN PMN)) (-RRB- -RRB-))))))))))))))))) (. .)))
(TOP (S (NP (NN IL-8)) (VP (VBZ is) (VP (VBN secreted) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ inflammatory) (NNS stimuli)) (, ,) (NP (ADVP (RB notably)) (NP (JJ bacterial) (NNS products)) (PP (JJ such) (IN as) (NP (NP (NN lipopolysaccharide)) (PRN (-LRB- -LRB-) (NP (NN LPS)) (-RRB- -RRB-))))) (, ,))))))) (CC but) (S (NP (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (NNS mechanisms)) (PP (IN by) (SBAR (WHNP (WDT which)) (S (NP (DT these) (NNS agents)) (VP (VBP mediate) (NP (NN IL-8) (NN induction))))))))))) (. .)))
(TOP (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN Mycoplasma) (NNS fermentans) (JJ lipid-associated) (NN membrane) (NNS proteins)) (PRN (-LRB- -LRB-) (NP (NN LAMPf)) (-RRB- -RRB-))) (VP (VBP induce) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN IL-8))))) (PP (IN by) (NP (NP (NP (NN THP-1)) (PRN (-LRB- -LRB-) (NP (JJ human) (NN monocyte)) (-RRB- -RRB-)) (NP (NNS cells))) (CC and) (NP (NN PMN))))) (PP (IN at) (NP (NP (DT the) (JJ same) (NN extent)) (PP (IN as) (NP (NN LPS))))))))) (. .)))
(TOP (S (NP (PRP It)) (VP (VBD was) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN stimulation)) (PP (IN of) (NP (JJ monocytic) (NNS cells))) (PP (IN with) (NP (CC either) (NN LPS) (CC or) (NN LAMPf)))) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (NP (JJ common) (JJ downstream) (NN signaling) (NNS events)) (, ,) (S (VP (VBG including) (NP (NP (DT the) (NN activation)) (PP (PP (IN of) (NP (NN protein) (NN tyrosine) (NN kinase))) (CC and) (PP (IN of) (NP (JJ mitogen-activated) (NN protein) (NN kinase) (NNS cascades)))))))))))))))) (. .)))
(TOP (S (PP (IN By) (S (VP (VBG using) (NP (NP (NN PD-98059)) (CC and) (NP (NN SB203580)) (, ,) (NP (NP (CD two) (ADJP (JJ potent) (CC and) (JJ selective)) (NNS inhibitors)) (PP (IN of) (NP (NP (NP (NN MEK1)) (PRN (-LRB- -LRB-) (NP (DT a) (NN kinase) (ADVP (RB upstream) (PP (IN of) (NP (NN ERK1/2))))) (-RRB- -RRB-))) (CC and) (NP (NN p38))))) (, ,) (ADVP (RB respectively)) (, ,))))) (NP (PRP we)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (CC both) (NN ERK1/2) (CC and) (NN p38) (NNS cascades)) (VP (VBP play) (NP (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NN IL-8))) (PP (IN by) (NP (NP (NNS monocytes) (CC and) (NN PMN)) (VP (VBN stimulated) (PP (IN with) (NP (JJ bacterial) (NNS fractions)))))))))))))) (. .)))
(TOP (S (NP (NN CD80) (CC and) (NN CD86)) (VP (VBP are) (RB not) (ADJP (JJ equivalent) (PP (IN in) (NP (NP (PRP$ their) (NN ability)) (S (VP (TO to) (VP (VB induce) (NP (NP (DT the) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN CD28))))))))))) (. .)))
(TOP (S (NP (NP (NN Ligation)) (PP (IN of) (NP (CC either) (NP (NP (NN CD80)) (PRN (-LRB- -LRB-) (NP (NN B7-1)) (-RRB- -RRB-))) (CC or) (NP (NP (NN CD86)) (PRN (-LRB- -LRB-) (NP (NN B7-2)) (-RRB- -RRB-))) (, ,) (NP (NP (CD two) (JJ principal) (NNS ligands)) (PP (IN for) (NP (NN CD28)))) (, ,)))) (VP (VBZ is) (VP (VBN thought) (S (VP (TO to) (VP (VB skew) (NP (NP (DT the) (JJ immune) (NN response)) (PP (IN toward) (NP (NN Th1) (CC or) (NN Th2) (NN differentiation))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBP have) (VP (VBN examined) (NP (NP (JJ early) (NN signal) (NN transduction) (NNS pathways)) (VP (VBN recruited) (PP (VBG following) (NP (NP (NN T) (NN cell) (NN stimulation)) (PP (IN with) (NP (CC either) (NN CD80) (CC or) (NN CD86))))))))) (. .)))
(TOP (S (NP (VBN Purified) (JJ human) (JJ peripheral) (NN T) (NNS cells) (CC or) (NN Jurkat) (NN T) (NNS cells)) (VP (VBD were) (VP (VBN stimulated) (PP (PP (IN with) (NP (NP (NP (JJ Chinese) (NN hamster) (NN ovary)) (PP (-LRB- -LRB-) (NP (NN CHO)) (-RRB- -RRB-)) (NP (NNS cells))) (VP (VBG expressing) (NP (NP (CC either) (JJ human) (NN CD80)) (PRN (-LRB- -LRB-) (NP (NN CHO-CD80)) (-RRB- -RRB-)) (CC or) (NP (JJ human) (NN CD86)) (PRN (-LRB- -LRB-) (NP (NN CHO-CD86)) (-RRB- -RRB-)))))) (CC or) (PP (IN with) (NP (NP (JJ anti-CD28) (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN mAb)) (-RRB- -RRB-))))))) (. .)))
(TOP (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate))))) (, ,) (NP (CC both) (NN CHO-CD80) (CC and) (NN CHO-CD86)) (, ,) (PP (IN like) (NP (JJ anti-CD28) (NN mAb))) (, ,) (VP (VBD were) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG stimulating) (NP (NN cytokine) (NN production)) (PP (IN from) (NP (NP (CC both) (JJ human) (JJ peripheral) (NN T) (NNS cells)) (CC and) (NP (NN Jurkat) (NN T) (NNS cells))))))))) (. .)))
(TOP (S (NP (NP (CC Both) (NN CHO-CD80) (CC and) (NN CHO-CD86)) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ anti-CD3) (NN mAb))))) (, ,)) (VP (VBD costimulated) (NP (JJ NFAT-dependent) (JJ transcriptional) (NN activation))) (. .)))
(TOP (S (NP (NP (JJ Several) (JJ intracellular) (VBG signaling) (NNS proteins)) (, ,) (PP (JJ such) (IN as) (NP (NN CBL) (CC and) (NN VAV))) (, ,)) (VP (VBD were) (VP (VBN phosphorylated) (PP (IN on) (NP (NN tyrosine))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (NN CD80)) (, ,) (NP (NN CD86)) (, ,) (CC and) (NP (JJ anti-CD28) (NN mAb)))))))) (. .)))
(TOP (S (ADVP (RB Surprisingly)) (, ,) (SBAR (IN although) (S (NP (NP (NN stimulation)) (PP (IN of) (NP (NN Jurkat) (NN T) (NNS cells))) (PP (IN with) (NP (CC either) (NN CHO-CD80) (CC or) (JJ anti-CD28) (NN mAb)))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ robust) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN CD28) (PRP itself)))))))) (, ,) (NP (NP (NN ligation)) (PP (IN with) (NP (NN CHO-CD86)))) (VP (VBD was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB induce) (NP (JJ detectable) (NN CD28) (NN tyrosyl) (NN phosphorylation)) (PP (IN over) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NN stimulation) (NNS conditions)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN phosphoinositide) (NN 3-kinase))) (PP (IN with) (NP (NN CD28)))) (CC and) (NP (NP (VBN enhanced) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN phospholipase) (NN Cgamma))))) (VP (VBD were) (VP (VBN seen) (PP (IN after) (NP (JJ anti-CD28) (NN mAb) (CC and) (NN CHO-CD80) (NN stimulation))) (CC but) (PP (TO to) (NP (DT a) (ADJP (RB much) (JJR lesser)) (NN extent))) (PP (IN after) (NP (NN CHO-CD86) (NN stimulation))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (NP (NN ligation)) (PP (IN of) (NP (NN CD28))) (PP (IN with) (NP (CC either) (NN CD80) (CC or) (NN CD86)))) (VP (VBZ leads) (PP (PP (TO to) (NP (NP (JJ shared) (JJ early) (NN signal) (NN transduction) (NNS events)) (PP (JJ such) (IN as) (NP (NP (DT the) (NN tyrosine) (NN phosphorylation)) (NP (IN of) (NP (NN CBL) (CC and) (NN VAV))))))) (, ,) (PP (TO to) (NP (JJ NFAT-mediated) (JJ transcriptional) (NN activation))) (, ,) (CC and) (PP (TO to) (NP (NP (DT the) (NN costimulation)) (PP (IN of) (NP (NN interleukin-2) (CC and) (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor) (NN production))))))) (. .)))
(TOP (S (ADVP (RB However)) (, ,) (NP (NN CD80) (CC and) (NN CD86)) (ADVP (RB also)) (VP (VBP induce) (NP (NP (JJ distinct) (NN signal) (NN transduction) (NNS pathways)) (VP (VBG including) (NP (NP (NP (DT the) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (NN CD28) (CC and) (NN phospholipase) (NN Cgamma1)))) (CC and) (NP (NP (DT the) (JJ SH2-dependent) (NN association)) (PP (IN of) (NP (NN phosphoinositide) (NN 3-kinase))) (PP (IN with) (NP (NN CD28)))))))) (. .)))
(TOP (S (NP (NP (DT These) (ADJP (JJ quantitative) (, ,) (CONJP (IN if) (RB not)) (JJ qualitative) (, ,)) (NNS differences)) (PP (IN between) (S (VP (NN signaling) (VP (VBN initiated) (PP (IN by) (NP (DT these) (CD two) (NNS ligands))) (PP (IN for) (NP (NN CD28)))))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (JJ functional) (NNS differences)) (PRN (-LRB- -LRB-) (FW e.g.) (NP (NN Th1) (CC or) (NN Th2) (NN differentiation)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN T) (NN cell) (NNS responses))))) (. .)))
(TOP (NP (NP (NP (NN Role)) (PP (IN of) (NP (NN Egr-2))) (PP (IN in) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NN Fas) (NN ligand))) (PP (IN in) (NP (NP (JJ normal) (NN T) (NNS cells)) (CC and) (NP (JJ aberrant) (JJ double-negative) (NN lpr) (CC and) (NN gld) (NN T) (NNS cells))))))) (. .)))
(TOP (S (NP (PRP We)) (ADVP (RB previously)) (VP (VP (VBD identified) (NP (NP (NP (DT a) (NN Fas) (NN ligand) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN FLRE)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (NN Fas) (NN ligand)) (PRN (-LRB- -LRB-) (NP (NN fasL)) (-RRB- -RRB-)) (NP (NN promoter)))) (SBAR (IN that) (S (VP (VBZ binds) (NP (NN Egr) (NN family) (NNS proteins))))))) (CC and) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NP (NN Egr-3)) (PRN (-LRB- -LRB-) (NP (NN PILOT)) (-RRB- -RRB-))) (CONJP (CC but) (RB not)) (NP (NP (NN Egr-1)) (PRN (-LRB- -LRB-) (NP (NP (NN NGFI-A)) (, ,) (NP (NN Krox-24)) (, ,) (NP (NN Tis-8)) (, ,) (CC and) (NP (NN Zif-268))) (-RRB- -RRB-)))) (VP (VBZ induces) (NP (NP (NN transcription)) (PP (IN of) (NP (NN fasL))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ aberrant) (JJ CD4^-|) (JJ CD8^-|) (NN T) (NNS cells)) (PP (IN from) (NP (NN lpr/lpr) (CC and) (NN gld/gld) (NNS mice))) (, ,) (SBAR (WHNP (WDT which)) (VP (VBP have) (NP (NP (NNS mutations)) (PP (IN in) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NN Fas) (CC and) (NN FasL) (, ,) (ADVP (RB respectively))))))))) (, ,)) (VP (VP (VBP have) (NP (DT an) (VBN activated) (NN phenotype))) (CC and) (ADVP (RB constitutively)) (VP (VBP express) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN fasL) (NN mRNA)))))) (, ,) (S (VP (VBG prompting) (NP (PRP us)) (VP (TO to) (VP (VB ask) (SBAR (WHNP (WP what) (NN role) (PP (IN if) (NP (DT any)))) (S (NP (DT the) (NN FLRE) (CC and) (NN Egr) (NN family) (NNS proteins)) (VP (VBP have) (PP (IN in) (NP (NP (DT this) (JJ aberrant) (NN expression)) (PP (IN of) (NP (NN fasL)))))))))))) (. .)))
(TOP (S (NP (JJ Unstimulated) (NN MRL-lpr/lpr) (CC and) (JJ C3H-gld/gld) (JJ CD4^-|) (JJ CD8^-|) (NN T) (NNS cells)) (ADVP (RB constitutively)) (VP (VBD contained) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NP (CD two) (NNS proteins)) (SBAR (WDT that) (S (VP (VBD bound) (PP (TO to) (NP (DT the) (NN FLRE)))))))))) (. .)))
(TOP (S (NP (NN Supershift) (NN analysis)) (VP (VBD revealed) (NP (DT these) (NNS proteins)) (VP (TO to) (VP (VB be) (NP (NP (NN Egr-1) (CC and) (NN Egr-2)) (PRN (-LRB- -LRB-) (NP (NN Krox-20)) (-RRB- -RRB-)))))) (: ;) (S (NP (NN Egr-3)) (VP (VBD was) (RB not) (VP (VBN detected)))) (. .)))
(TOP (S (NP (NP (NN Activation)) (PP (IN of) (NP (JJ normal) (NN lymph) (NN node) (NNS cells)))) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NP (NN Egr-1)) (, ,) (NP (CD -2)) (, ,) (CC and) (NP (CD -3))))))) (. .)))
(TOP (S (PP (IN As) (IN with) (NP (NN egr-3))) (, ,) (NP (NP (NN expression)) (PP (IN of) (NP (NN egr-2)))) (VP (VBD was) (VP (VBN blocked) (PP (IN by) (NP (NN cyclosporin) (NN A))))) (. .)))
(TOP (S (SBAR (IN Although) (S (NP (VBN overexpressed) (NN Egr-1)) (VP (VBD was) (ADJP (JJ ineffective))))) (, ,) (NP (VBN overexpressed) (NN Egr-2)) (VP (VBD was) (ADJP (ADJP (RB as) (JJ potent)) (PP (IN as) (NP (NN Egr-3))) (PP (IN in) (S (VP (VBG inducing) (NP (NN fasL) (JJ promoter-dependent) (NN reporter) (NNS constructs)) (PP (IN in) (NP (NP (NN T) (NN cell) (NNS hybridomas)) (CC and) (NP (NN HeLa) (NNS cells))))))))) (, ,) (SBAR (CC and) (S (NP (DT both)) (VP (VBN up-regulated) (NP (JJ endogenous) (NN fasL) (NN mRNA)) (PP (IN in) (NP (NN HeLa) (NNS cells)))))) (. .)))
(TOP (S (S (NP (NP (JJ FasL-dependent) (NN reporter) (NNS constructs)) (PP (IN in) (NP (JJ MRL-lpr/lpr) (CC and) (JJ C3H-gld/gld) (JJ CD4^-|) (JJ CD8^-|) (NN T) (NNS cells)))) (VP (VBD were) (ADJP (RB constitutively) (JJ active)))) (, ,) (CC and) (S (NP (DT this) (NN activity)) (VP (VBD was) (ADVP (RB largely)) (VP (VBN prevented) (PP (IN by) (NP (NP (NN mutation)) (PP (IN of) (NP (DT the) (JJ critical) (NN Egr) (NN family) (NN binding) (NN element)))))))) (. .)))
(TOP (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NN Egr-2)) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NN Egr-3))))) (, ,)) (VP (VBZ regulates) (NP (NP (NN FasL) (NN expression)) (PP (IN in) (NP (VBN activated) (JJ normal) (NN T) (NNS cells)))))) (, ,) (CC and) (S (NP (NN Egr-2)) (VP (VBZ is) (ADJP (JJ likely) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ direct) (NN role)) (PP (IN in) (NP (NP (NN aberrant) (NN fasL) (NN up-regulation)) (PP (IN in) (NP (NN lpr/lpr) (CC and) (NN gld/gld) (JJ CD4^-|) (JJ CD8^-|) (NN T) (NNS cells))))))))))) (. .)))
(TOP (NP (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN NF-kappa) (NN B) (NN activation) (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo)))))) (: :) (NP (NP (NN role)) (PP (IN of) (NP (NN 26S) (NN proteasome)))) (. .)))
(TOP (S (NP (PRP It)) (VP (VBZ is) (VP (VBG becoming) (ADJP (ADJP (RB increasingly) (JJ apparent)) (SBAR (IN that) (S (NP (NN NF-kappa) (NN B)) (VP (VBZ plays) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG regulating) (NP (DT the) (JJ inflammatory) (NN response)))))))))))) (. .)))
(TOP (S (NP (NP (NNS Data)) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS studies)) (PP (IN in) (NP (PRP$ our) (NNS laboratories))))))) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT the) (NN proteasome)) (VP (VBZ plays) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT the) (JJ inflammatory) (NN cascade))) (PP (IN by) (S (VP (VBG regulating) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B)))))))))))) (. .)))
(TOP (S (ADVP (RB Indeed)) (, ,) (NP (NP (DT the) (NN availability)) (PP (IN of) (NP (ADJP (ADJP (JJ selective)) (CC and) (ADJP (RB orally) (JJ active))) (NN proteasome) (NNS inhibitors)))) (VP (MD should) (VP (VB prove) (ADJP (JJ useful)) (PP (IN in) (S (VP (VBG delineating) (NP (NP (DT the) (NNS roles)) (PP (IN of) (NP (NP (DT the) (NN proteasome)) (CC and) (NP (NN NF-kappa) (NN B)))) (PP (IN in) (NP (NP (JJ other) (JJ pathophysiological) (NNS conditions)) (PP (JJ such) (IN as) (NP (NP (NN cancer)) (CC and) (NP (NN heart) (NN disease)))))))))))) (. .)))
(TOP (NP (NP (NP (NN Requirement)) (PP (IN of) (NP (NP (NN GATA-1)) (CC and) (NP (NP (NN p45) (NN NF-E2) (NN expression)) (PP (IN in) (NP (JJ butyric) (JJ acid-induced) (JJ erythroid) (NN differentiation))))))) (. .)))
(TOP (S (NP (NP (JJ Butyric) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BA)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB induce) (NP (NP (NN overexpression)) (PP (IN of) (NP (NP (JJ fetal) (NN hemoglobin)) (CC and) (ADVP (RB then)) (NP (JJ erythroid) (NN differentiation)))))))))) (. .)))
(TOP (S (ADVP (RB Therefore)) (, ,) (NP (NN BA)) (VP (VBZ is) (ADVP (RB currently)) (PP (IN under) (NP (NP (JJ clinical) (NN investigation)) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN therapy)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ sickle) (NN cell) (NN disease)) (CC and) (NP (NN cancer))))))))))) (. .)))
(TOP (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBN involved) (PP (IN in) (NP (JJ BA-induced) (NN differentiation))))) (VP (VBP remain) (ADJP (RB largely) (JJ unknown))) (. .)))
(TOP (S (NP (JJ Previous) (NNS reports)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (JJ BA-induced) (NN overexpression)) (PP (IN of) (NP (JJ erythroid) (NNS genes)))) (VP (VBD occurred) (PP (IN at) (NP (DT the) (JJ transcriptional) (NN level)))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (JJ erythroid) (NN transcription) (NNS factors)))))) (. .)))
(TOP (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP intend) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT the) (NN requirement)) (PP (IN of) (NP (NN GATA-1) (CC and) (NN NF-E2) (NN transcription) (NNS factors))) (PP (IN in) (NP (NP (DT the) (JJ BA-induced) (JJ erythroid) (NN differentiation)) (PP (IN of) (NP (JJ human) (JJ leukemic) (NN K562) (NNS cells)))))))))) (. .)))
(TOP (S (NP (JJ Time-course) (NNS experiments)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ nuclear) (NNS levels)) (PP (IN of) (NP (NN GATA-1) (CC and) (NN p45) (NN NF-E2) (NNS proteins)))) (VP (VBD increased) (PP (IN during) (NP (NN BA) (NN treatment))))))) (. .)))
(TOP (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ antisense) (NNS oligodeoxynucleotides)) (VP (VBG targeting) (NP (CC either) (NN GATA-1) (CC or) (NN p45) (NN NF-E2) (NNS proteins)))) (VP (VBD inhibited) (NP (CC both) (NN protein) (NN expression) (CC and) (JJ BA-induced) (NN differentiation))) (. .)))
(TOP (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ BA-induced) (NN cell) (NN growth) (NN inhibition)) (VP (VBD was) (RB not) (VP (VBN affected))) (. .)))
(TOP (S (NP (DT These) (NNS results)) (VP (VBP provide) (NP (NP (DT the) (JJ first) (JJ direct) (NN evidence)) (PP (IN for) (NP (NP (DT the) (NN requirement)) (PP (IN of) (NP (NN GATA-1) (CC and) (NN NF-E2))) (PP (IN in) (NP (JJ BA-induced) (NN differentiation) (NN process))))))) (. .)))
(TOP (S (NP (NP (DT A) (JJ novel) (JJ growth-factor-dependent) (JJ myeloid) (NN cell) (NN line)) (VP (VBN derived) (PP (IN from) (NP (NN mouse) (NN bone) (NN marrow) (NNS cells))))) (VP (VBZ contains) (NP (NP (NNS progenitors)) (ADJP (JJ endowed) (PP (IN with) (NP (JJ high) (JJ proliferative) (NN potential)))))) (. .)))
(TOP (S (NP (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP (NP (JJ human) (JJ colony-stimulating) (NN factor-1) (NN receptor)) (PP (-LRB- -LRB-) (NP (NN CSF-1R)) (-RRB- -RRB-))))) (VP (VBZ confers) (NP (NP (JJ long-lasting) (JJ CSF-1-dependent) (NN proliferation)) (PP (TO to) (NP (NN mouse) (JJ myeloid) (NN cell) (NNS lines))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD developed) (NP (NP (NNS mice)) (ADJP (JJ transgenic) (PP (IN for) (NP (JJ human) (NN CSF-1R))))) (SBAR (IN because) (S (NP (NN mouse) (NN CSF-1)) (VP (MD can) (RB not) (VP (VB activate) (NP (JJ human) (NN CSF-1R))))))) (. .)))
(TOP (S (ADVP (RB Then)) (NP (NP (NN bone) (NN marrow) (NNS cells)) (PP (IN from) (NP (JJ transgenic) (NNS mice)))) (VP (VBD were) (VP (VBN plated) (PP (IN onto) (NP (NP (NN MS-5) (JJ stromal) (NNS cells)) (VP (VBG expressing) (NP (NP (DT the) (NN membrane) (NN form)) (PP (IN of) (NP (NP (JJ human) (NN CSF-1)) (PRN (-LRB- -LRB-) (NP (NN 2M-1) (NNS cells)) (-RRB- -RRB-)))))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB combine) (NP (NP (NP (DT the) (JJ hematopoietic) (NN supporting) (NNS properties)) (PP (IN of) (NP (JJ stromal) (NNS cells)))) (CC and) (NP (NP (DT the) (JJ proliferative) (NNS effects)) (PP (IN of) (NP (NN CSF-1))))))))))) (. .)))
(TOP (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBD were) (ADJP (JJ able)) (S (VP (TO to) (VP (VB derive) (NP (NP (DT a) (JJ hematopoietic) (NN cell) (NN line)) (, ,) (VP (VBN called) (NP (CD 47.10))) (, ,) (SBAR (WDT that) (S (VP (VBD grew) (ADVP (RB indefinitely)) (PP (IN under) (NP (DT these) (NNS conditions))))))))))) (, ,) (SBAR (IN whereas) (S (NP (DT no) (NN cell) (NN line)) (VP (MD could) (VP (VB be) (VP (VBN developed) (PP (IN from) (NP (JJ nontransgenic) (NNS mice)))))))) (. .)))
(TOP (S (NP (NP (NN Proliferation)) (PP (IN of) (NP (CD 47.10) (NNS cells)))) (VP (VBZ is) (ADVP (RB severely)) (VP (VBN affected) (PP (IN by) (S (VP (VBG neutralizing) (NP (JJ anti-CSF-1R) (JJ monoclonal) (NNS antibodies))))))) (. .)))
(TOP (S (NP (JJ Morphologic) (CC and) (NN cytofluorometry) (NN analysis)) (VP (VBD established) (SBAR (IN that) (S (NP (JJS most) (CD 47.10) (NNS cells)) (VP (VBP are) (NP (JJ immature) (JJ myelomonocytic) (NNS cells)))))) (. .)))
(TOP (S (ADJP (JJ Consistent) (PP (IN with) (NP (DT this) (NN phenotype)))) (, ,) (NP (NP (DT the) (JJ myeloid) (NN transcription) (NN factor) (NN PU.1)) (PRN (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (JJ erythroid) (NN transcription) (NN factor) (NN GATA-1)) (, ,))) (VP (VBZ is) (VP (VBN expressed) (PP (IN in) (NP (CD 47.10) (NNS cells))))) (. .)))
(TOP (S (S (NP (NP (DT A) (JJ few) (CD 47.10) (NNS cells)) (PRN (-LRB- -LRB-) (NP (CD 3-5) (NN %)) (-RRB- -RRB-))) (VP (VBP do) (RB not) (VP (VB express) (NP (NN lineage) (JJ specific) (NNS markers))))) (: ;) (S (NP (PRP they)) (VP (VBP differentiate) (ADVP (RB spontaneously)) (PP (TO to) (NP (JJ lineage-positive) (NNS cells))) (PP (IN after) (S (VP (VBG replating) (PP (IN on) (NP (NN 2M-1) (NNS cells)))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN agar) (NNS cultures))) (, ,) (NP (CD 47.10) (NNS cells)) (VP (VBP form) (NP (NP (ADJP (CD 7-) (CC and) (JJ 14-day)) (NNS colonies)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT a) (NN cocktail)) (PP (IN of) (NP (NP (NP (NN granulocyte/macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN ng/mL)) (-RRB- -RRB-))) (, ,) (NP (NP (NN interleukin-3)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN ng/mL)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN mouse) (NN CSF-1)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN ng/mL)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (PP (IN Under) (NP (DT these) (NNS conditions))) (, ,) (NP (NP (QP (RB about) (CD 0.5)) (NN %)) (PP (IN of) (NP (CD 47.10) (NNS cells)))) (VP (VBD formed) (NP (NP (JJ large) (JJ 14-day) (NNS colonies)) (PRN (-LRB- -LRB-) (NP (QP (JJR >) (CD 1)) (NN mm)) (-RRB- -RRB-)) (VP (VBN composed) (PP (IN of) (NP (JJ mature) (NNS monocytes) (CC and) (NNS granulocytes)))))) (, ,) (S (VP (VBG reflecting) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNS progenitors)) (ADJP (JJ endowed) (PP (IN with) (NP (NP (JJ high) (JJ proliferative) (NN potential)) (PRN (-LRB- -LRB-) (NP (CD HPP-47.10) (NNS cells)) (-RRB- -RRB-)))))))))) (. .)))
(TOP (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN characterized) (NP (NP (DT a) (ADJP (JJ novel) (JJ continuous) (JJ myeloid)) (NN cell) (NN line)) (S (VP (VBG presenting) (NP (NP (DT a) (JJ hierarchical) (NN structure)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NN bone) (NN marrow) (NN progenitor) (NN cell) (NN compartment)))))))))))) (. .)))
(TOP (NP (NP (NP (JJ Imbalanced) (NN expression)) (PP (IN of) (NP (NP (DT the) (NN glucocorticoid) (NN receptor) (NNS isoforms)) (PP (IN in) (NP (NP (VBN cultured) (NNS lymphocytes)) (PP (IN from) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (JJ systemic) (NN glucocorticoid) (NN resistance)) (CC and) (NP (JJ chronic) (JJ lymphocytic) (NN leukemia))))))))))) (. .)))
(TOP (S (NP (NP (DT The) (JJ human) (NN glucocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GR)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN expressed) (PP (IN as) (NP (NP (CD two) (ADJP (RB alternatively) (VBN spliced)) (NNS isoforms)) (, ,) (NP (NN GRalpha)) (CC and) (NP (NN GRbeta)))))) (. .)))
(TOP (S (SBAR (IN Whereas) (S (NP (NN GRalpha)) (VP (VBZ is) (NP (DT a) (JJ hormone-activated) (NN transcription) (NN factor))))) (, ,) (NP (NN GRbeta)) (VP (VP (VBZ does) (RB not) (VP (VB bind) (NP (NP (NNS glucocorticoids)) (PRN (-LRB- -LRB-) (NP (NNS GCs)) (-RRB- -RRB-))))) (, ,) (VP (VBZ is) (ADJP (RB transcriptionally) (JJ inactive))) (, ,) (CC and) (VP (VBZ is) (NP (NP (DT a) (JJ potential) (NN inhibitor)) (PP (IN of) (NP (VBN activated) (NN GRalpha)))))) (. .)))
(TOP (S (NP (NP (JJ Differential) (NN expression)) (PP (IN of) (NP (NN GR) (NNS isoforms)))) (VP (MD may) (VP (VB play) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (ADJP (VBN generalized) (CC or) (JJ tissue-specific)) (NN GC) (NN resistance)))))) (. .)))
(TOP (S (NP (NNS GCs)) (VP (VBP induce) (NP (NP (NN apoptosis)) (PP (IN in) (NP (JJ neoplastic) (JJ lymphoid) (NNS cells))))) (: ;) (CC and) (, ,) (S (NP (JJ defective) (NN apoptosis)) (VP (VBZ is) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN genesis)) (PP (IN of) (NP (NP (JJ chronic) (JJ lymphocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN CLL)) (-RRB- -RRB-))))))))) (. .)))
(TOP (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (VBN generalized) (NN GC) (NN resistance)) (CC and) (NP (NN CLL)))))) (. .)))
(TOP (S (NP (NP (NN GR) (NN number)) (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (VBN transformed) (NNS lymphocytes)))) (VP (VBD was) (NP (NP (QP (RB approximately) (CD one) (NN half)) (DT that)) (PP (IN of) (NP (JJ control) (NNS cells)))) (PP (IN with) (NP (NP (DT a) (QP (RB approximately) (JJ 10-fold)) (NN reduction)) (PP (IN in) (NP (NP (NN binding) (NN affinity)) (PP (IN for) (NP (NN dexamethasone)))))))) (. .)))
(TOP (S (NP (NP (ADJP (FW In) (FW vitro)) (NN apoptosis) (NN induction)) (PP (IN in) (NP (NN CLL) (NNS cells)))) (VP (VBD was) (VP (VBN delayed) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS GCs))) (, ,) (CONJP (CC but) (RB not)) (PP (TO to) (NP (JJ other) (NN apoptosis) (NNS inducers))))))) (. .)))
(TOP (S (NP (NP (NN Sequencing)) (PP (IN of) (NP (NP (DT the) (NN GR) (NN cDNA) (CC and) (NN gene)) (VP (VBG including) (NP (NP (DT the) (JJ 2.3-kb) (NN coding) (NN region)) (, ,) (NP (DT the) (NN intron/exon) (NNS junctions)) (, ,) (NP (DT the) (JJ known) (JJ 5'-regulatory) (NN region)) (, ,) (CC and) (NP (NP (QP (RB approximately) (CD 300)) (NN bp)) (PP (IN of) (NP (DT the) (NN 3'-region))))))))) (VP (VBD revealed) (NP (DT no) (NNS alterations))) (. .)))
(TOP (S (NP (NP (NN Western) (NN blot)) (PP (IN with) (NP (DT an) (JJ N-terminal) (NN antibody)))) (VP (VBD showed) (NP (NP (JJ normal) (NNS levels)) (PP (IN of) (NP (JJ immunoreactive) (NN GR))))) (, ,) (SBAR (CC but) (S (NP (NP (JJ quantitative) (NN analysis)) (PP (IN with) (NP (JJ isoform-specific) (JJ C-terminal) (NNS antibodies)))) (VP (VBD revealed) (NP (NP (DT a) (ADJP (RB markedly) (VBN reduced)) (NN GRalpha) (NN expression)) (, ,) (CC and) (NP (JJ high) (NN GRbeta) (NN expression)))))) (. .)))
(TOP (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ imbalanced) (NN expression)) (PP (IN of) (NP (DT the) (NN GR) (NNS isoforms)))) (VP (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN mechanism)) (PP (IN of) (NP (NN GC) (NN resistance)))))) (, ,) (CC and) (VP (MD may) (VP (VB have) (NP (NP (NNS implications)) (PP (IN for) (NP (NN tumorigenesis))))) (PP (IN by) (S (VP (VBG enhancing) (NP (NN cell) (NN survival)))))))))) (. .)))
(TOP (FRAG (NP (NN Copyright) (CD 1999) (NNP Academic) (NNP Press)) (. .)))
